assay_tissue,tid,relationship_type,confidence_score,assay_test_type,assay_strain,assay_subcellular_fraction,doc_id,assay_category,description,src_id,assay_organism,curated_by,variant_id,cell_id,src_assay_id,assay_tax_id,assay_cell_type,tissue_id,assay_type,bao_format,chembl_id,assay_id
,12052,H,8,,,,11087,,The compound was tested for the in vitro inhibition of platelet 12-lipoxygenase at a concentration of 30 uM,1,,Autocuration,,,,,,,B,BAO_0000019,CHEMBL615117,1
,22226,U,0,,,,684,,Compound was evaluated for its ability to mobilize calcium in 1321NI cells,1,,Autocuration,,,,,,,F,BAO_0000219,CHEMBL615118,2
,22226,U,0,,,,15453,,,1,,Autocuration,,,,,,,B,BAO_0000019,CHEMBL615119,3
,104729,H,4,,,,17841,,Binding affinity against A2 adenosine receptor in bovine striatal membranes using [3H]CGS-21680,1,Bos taurus,Autocuration,,,,9913.0,,,B,BAO_0000249,CHEMBL615120,4
,80001,N,1,,,,17430,,In vitro cell cytotoxicity against 143-B cell lines (Human osteosarcoma cell line),1,Homo sapiens,Intermediate,,163.0,,9606.0,143B,,F,BAO_0000219,CHEMBL615121,5
,80001,N,1,,,,17430,,In vitro cell cytotoxicity against 143-B cell lines (Human osteosarcoma cell line),1,Homo sapiens,Intermediate,,163.0,,9606.0,143B,,F,BAO_0000219,CHEMBL615122,6
,80001,N,1,,,,13799,,Cytotoxic Activity was evaluated against 143B (TK-) tumor cells,1,Mus musculus,Intermediate,,163.0,,10090.0,143B,,F,BAO_0000219,CHEMBL615123,7
,80001,N,1,,,,17774,,In vitro cell cytotoxicity was determined against 143B cell line,1,Homo sapiens,Expert,,163.0,,9606.0,143B,,F,BAO_0000219,CHEMBL615124,8
,80001,N,1,,,,3801,,Inhibitory activity against tumor osteosarcoma cell line 143B after 72 hr continuous exposure to compound,1,Homo sapiens,Intermediate,,163.0,,9606.0,143B,,F,BAO_0000219,CHEMBL615125,9
,80001,N,1,,,,17430,,In vitro cell cytotoxicity against 143B-LTK cell lines expressed in HSV-1 TK,1,Homo sapiens,Intermediate,,163.0,,9606.0,143B,,F,BAO_0000219,CHEMBL615126,10
,80001,N,1,,,,17430,,In vitro cell cytotoxicity against 143B-LTK cell lines expressed in HSV-1 TK,1,Homo sapiens,Intermediate,,163.0,,9606.0,143B,,F,BAO_0000219,CHEMBL615127,11
,80001,N,1,,,,17774,,In vitro cell cytotoxicity was determined against 143B-LTK cell line,1,Homo sapiens,Expert,,163.0,,9606.0,143B,,F,BAO_0000219,CHEMBL615128,12
,50185,N,1,,,,11324,,"The compound was tested for minimum inhibitory concentration in Staphylococcus aureus,147N penicillin sensitive Staphylococcus aureus",1,Staphylococcus aureus,Intermediate,,,,1280.0,,,F,BAO_0000218,CHEMBL857900,13
,50185,N,1,,,,11324,,"The compound was tested for minimum inhibitory concentration in Staphylococcus aureus,147N penicillin sensitive Staphylococcus aureus",1,Staphylococcus aureus,Intermediate,,,,1280.0,,,F,BAO_0000218,CHEMBL615129,14
,50185,N,1,,,,11324,,"The compound was tested for minimum inhibitory concentration in Staphylococcus aureus,147N penicillin sensitive Staphylococcus aureus",1,Staphylococcus aureus,Intermediate,,,,1280.0,,,F,BAO_0000218,CHEMBL615130,15
,50185,N,1,,,,11324,,"The compound was tested for minimum inhibitory concentration in Staphylococcus aureus,147N penicillin sensitive Staphylococcus aureus",1,Staphylococcus aureus,Intermediate,,,,1280.0,,,F,BAO_0000218,CHEMBL615131,16
,100122,D,9,,,,11347,,Inhibition of cytochrome P450 progesterone 15-alpha hydroxylase,1,Rattus norvegicus,Expert,,,,10116.0,,,A,BAO_0000357,CHEMBL884521,17
,12054,H,8,,,,16474,,Concentration that cause 50% activation of human reticulocyte 15-lipoxygenase (15-HLO),1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL615132,18
,12054,H,8,,,,10091,,Inhibition of partially purified 15-lipoxygenase from human leukocytes,1,,Autocuration,,,,,,,B,BAO_0000019,CHEMBL615133,19
,12054,H,8,,,,16474,,Inhibitory activity against human reticulocyte 15-lipoxygenase (15-HLO),1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL615134,20
,12054,H,8,,,,16474,,Compound was evaluated for the percent increase in activation concentration of human reticulocyte 15-lipoxygenase (15-HLO),1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL615135,21
,12054,H,8,,,,16474,,Inhibitory activity against human reticulocyte 15-lipoxygenase (15-HLO),1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL615136,22
,12054,H,8,,,,16474,,Inhibitory activity against human reticulocyte 15-lipoxygenase (15-HLO); NI is no inhibition,1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL615137,23
,12054,H,8,,,,16474,,Inhibitory activity against human reticulocyte 15-lipoxygenase (15-HLO); NI is no inhibition,1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL615138,24
,22226,U,0,,,,14352,,"Inhibitory concentration against 15-lipoxygenase, by inhibiting 15-HETE production by human umbilical vein endothelial cells (HUVEC) stimulated by calcium ionophore A 23187 at concentration of 10e-5 M.",1,,Autocuration,,,,,,,B,BAO_0000219,CHEMBL836324,25
,12054,H,8,,,,5646,,In vitro inhibitory activity of compound on rabbit reticulocyte 15-lipoxygenase,1,Oryctolagus cuniculus,Autocuration,,,,9986.0,,,B,BAO_0000357,CHEMBL615139,26
,12054,H,8,,,,5646,,Inhibition of rabbit reticulocyte 15-lipoxygenase by compound (30 uM),1,Oryctolagus cuniculus,Autocuration,,,,9986.0,,,B,BAO_0000357,CHEMBL615140,27
,12426,H,8,,,,10997,,Inhibitory activity against 15-lipoxygenase in rat polymorphonuclear leukocytes,1,,Autocuration,,,,,,,B,BAO_0000219,CHEMBL615141,28
,12054,H,8,,,,6309,,Inhibitory activity against 15-lipoxygenase was determined obtained from soya bean,1,soya bean,Autocuration,,,,3847.0,,,B,BAO_0000357,CHEMBL615142,29
,12054,H,8,,,,167,,Inhibitory activity against soybean 15-lipoxygenase was evaluated,1,Glycine max,Autocuration,,,,3847.0,,,B,BAO_0000357,CHEMBL615143,30
,12054,H,8,,,,167,,Inhibitory activity against soybean 15-lipoxygenase was evaluated at 100 uM,1,Glycine max,Autocuration,,,,3847.0,,,B,BAO_0000357,CHEMBL615144,31
,12054,H,8,,,,11087,,The compound was tested for the in vitro inhibition of 15-lipoxygenase of soybean at a concentration of 10 uM,1,Glycine max,Autocuration,,,,3847.0,,,B,BAO_0000357,CHEMBL872867,32
,12054,H,8,,,,11087,,The compound was tested for the in vitro inhibition of 15-lipoxygenase of soybean at a concentration of 100 uM,1,Glycine max,Autocuration,,,,3847.0,,,B,BAO_0000357,CHEMBL615145,33
,12054,H,8,,,,13622,,Compound was tested in vitro for inhibition of 15-lipoxygenase soybean,1,Glycine max,Autocuration,,,,3847.0,,,B,BAO_0000357,CHEMBL615146,34
,12054,H,8,,,,13622,,Compound at 100 uM was tested in vitro for inhibition of 15-lipoxygenase soybean,1,Glycine max,Autocuration,,,,3847.0,,,B,BAO_0000357,CHEMBL615147,35
,22226,U,0,,,,11347,,Inhibition of cytochrome P450 progesterone 16-alpha hydroxylase,1,Rattus norvegicus,Autocuration,,,,10116.0,,,A,BAO_0000019,CHEMBL615148,36
,22226,U,0,,,,5926,,Binding affinity against bacterial 16S rRNA using mass spectrometry based assay,1,Escherichia coli,Autocuration,,,,562.0,,,B,BAO_0000019,CHEMBL615149,37
,22226,U,0,,,,4567,,Dissociation constant with dimeric 16S rRNA RNA construct B,1,,Autocuration,,,,,,,B,BAO_0000019,CHEMBL615150,38
,22222,M,3,,,,3782,,Dissociation constant towards 16S rRNA construct A,1,,Intermediate,,,,,,,B,BAO_0000225,CHEMBL615151,39
,22222,M,3,,,,3782,,Dissociation constant towards 16S rRNA construct B,1,,Intermediate,,,,,,,B,BAO_0000225,CHEMBL615152,40
,100263,M,3,,,,4466,,Binding affinity of aminoglycoside to 16S ribosomal RNA A-site in Escherichia coli,1,Escherichia coli,Expert,,,,562.0,,,B,BAO_0000225,CHEMBL615153,41
,100263,M,3,,,,6592,,Binding affinity for the 16S ribosomal RNA A-site of Escherichia coli,1,Escherichia coli,Expert,,,,562.0,,,B,BAO_0000225,CHEMBL615154,42
,13053,H,8,,,,898,,Inhibitory activity against human placenta 17-beta-hydroxysteroid dehydrogenase type 2 (17-beta-HSD type 2),1,,Autocuration,,,,,,,B,BAO_0000019,CHEMBL615155,43
,13053,H,8,,,,898,,Inhibitory constant against human placenta 17-beta-hydroxysteroid dehydrogenase type 2 (17-beta-HSD type 2),1,,Autocuration,,,,,,,B,BAO_0000019,CHEMBL615156,44
,20001,H,8,,,,13163,,The compound was tested at a concentration of 1 uM for inhibitory activity against 17 beta-hydroxysteroid dehydrogenase from human placental microsomes,1,Homo sapiens,Autocuration,,,,9606.0,,,B,BAO_0000019,CHEMBL615157,45
,20001,H,8,,,,13163,,The compound was tested at a concentration of 1 uM for inhibitory activity against 17 beta-hydroxysteroid dehydrogenase from human placental microsomes,1,Homo sapiens,Autocuration,,,,9606.0,,,B,BAO_0000019,CHEMBL615158,46
,12971,D,9,,,,10691,,"Inhibition of 17-alpha-hydroxylase/17,20 lyase from rat testes microsomal preparation",1,Rattus norvegicus,Expert,,,,10116.0,,,B,BAO_0000019,CHEMBL615159,47
,12971,D,9,,,,10691,,"Inhibition of 17-alpha-hydroxylase/17,20 lyase from rat testes microsomal preparation",1,Rattus norvegicus,Expert,,,,10116.0,,,B,BAO_0000019,CHEMBL615172,48
,12971,D,9,,,,10691,,"Percent inhibition of 17-alpha-hydroxylase/17,20 lyase of rat testes microsomes at 100 uM",1,Rattus norvegicus,Expert,,,,10116.0,,,B,BAO_0000019,CHEMBL615173,49
,12971,D,9,,,,10691,,"Percent inhibition of Steroid 17-alpha-hydroxylase/17,20 lyase of rat testes microsomes at 100 uM",1,Rattus norvegicus,Expert,,,,10116.0,,,B,BAO_0000019,CHEMBL615174,50
,13053,H,8,,,,898,,Inhibitory activity against human placenta 17-beta-hydroxysteroid dehydrogenase type 2 (17-beta-HSD type 2),1,,Autocuration,,,,,,,B,BAO_0000019,CHEMBL884518,51
,11512,H,8,,,,912,,Compound was tested for the inhibition of 17-beta-hydroxysteroid dehydrogenase type 1(17-beta-HSD type 1),1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL615175,52
,11512,H,8,,,,912,,Compound was tested for the inhibition of 17-beta-hydroxysteroid dehydrogenase type 1(17-beta-HSD type 1) at 1 uM concentration,1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL615176,53
,11512,H,8,,,,912,,Compound was tested for the inhibition of 17-beta-hydroxysteroid dehydrogenase type 1(17-beta-HSD type 1) at 10 uM concentration,1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL615177,54
,104740,D,5,,,Membranes,15103,,Selectivity ratio of binding affinity towards mu to delta receptors of rat brain membranes,1,Rattus norvegicus,Autocuration,,,,10116.0,,,B,BAO_0000249,CHEMBL615178,55
,80002,N,1,,,,5116,,Cytotoxicity against ovarian cancer cell line (1A-9) of humans was determined,1,Homo sapiens,Intermediate,,506.0,,9606.0,1A9,,F,BAO_0000219,CHEMBL615179,56
,104835,D,7,,,,14578,,Functional antagonism by electrical assays in Xenopus oocytes expressing 1A/2A NMDA receptor subtype,1,Rattus norvegicus,Autocuration,,,,10116.0,Oocytes,,F,BAO_0000219,CHEMBL615180,57
,104821,D,7,,,,14578,,Functional antagonism by electrical assays in Xenopus oocytes expressing the 1A/2B NMDA receptor,1,Rattus norvegicus,Autocuration,,,,10116.0,Oocytes,,F,BAO_0000219,CHEMBL615181,58
,104848,D,7,,,,14578,,Functional antagonism by electrical assays in Xenopus oocytes expressing the 1A/2C NMDA receptor,1,Rattus norvegicus,Autocuration,,,,10116.0,Oocytes,,F,BAO_0000219,CHEMBL615182,59
,80002,N,1,,,,4787,,In vitro effective concentration required to reduce the number of human ovarian cancer (1A9) after 3-day incubation,1,Homo sapiens,Expert,,506.0,,9606.0,1A9,,F,BAO_0000219,CHEMBL615183,60
,80002,N,1,,,,4787,,In vitro effective concentration required to reduce the number of human ovarian cancer cells (1A9) after 3-day incubation,1,Homo sapiens,Intermediate,,506.0,,9606.0,1A9,,F,BAO_0000219,CHEMBL615184,61
,80002,N,1,,,,3547,,Cytotoxic activity against human ovarian cancer (1A9) cell line,1,Homo sapiens,Intermediate,,506.0,,9606.0,1A9,,F,BAO_0000219,CHEMBL615185,62
,80002,N,1,,,,3547,,Cytotoxic activity against human ovarian cancer (1A9) cell line; ND=Not determined,1,Homo sapiens,Intermediate,,506.0,,9606.0,1A9,,F,BAO_0000219,CHEMBL615186,63
,80002,N,1,,,,6726,,Effective dose of compound against replication of 1A9 cell line was evaluated,1,Homo sapiens,Intermediate,,506.0,,9606.0,1A9,,F,BAO_0000219,CHEMBL615187,64
,80002,N,1,,,,3455,,In vitro cytotoxic activity was determined against ovarian cancer (1A9) cell line,1,Homo sapiens,Expert,,506.0,,9606.0,1A9,,F,BAO_0000219,CHEMBL885343,65
,80002,N,1,,,,5726,,In vitro cytotoxicity evaluated against human ovarian cancer (1A9 cell line),1,Homo sapiens,Intermediate,,506.0,,9606.0,1A9,,F,BAO_0000219,CHEMBL615188,66
,80002,N,1,,,,5726,,In vitro cytotoxicity evaluated against human ovarian cancer (1A9 cell line); NA is not active,1,Homo sapiens,Intermediate,,506.0,,9606.0,1A9,,F,BAO_0000219,CHEMBL615189,67
,80002,N,1,,,,5726,,In vitro percent inhibition evaluated against human ovarian cancer (1A9 cell line) at >20 ug/mL,1,Homo sapiens,Intermediate,,506.0,,9606.0,1A9,,F,BAO_0000219,CHEMBL615190,68
,80002,N,1,,,,3395,,Inhibitory activity against Taxol resistant 1A9 cell lines,1,Homo sapiens,Intermediate,,506.0,,9606.0,1A9,,F,BAO_0000219,CHEMBL615191,69
,80002,N,1,,,,3415,,Cytotoxicity against human ovarian cancer (1A9) cell lines.,1,Homo sapiens,Expert,,506.0,,9606.0,1A9,,F,BAO_0000219,CHEMBL615192,70
,80002,N,1,,,,3415,,Percentage inhibition of human ovarian cancer (1A9) cell lines.,1,Homo sapiens,Expert,,506.0,,9606.0,1A9,,F,BAO_0000219,CHEMBL827083,71
,80002,N,1,,,,17099,,Effective dose required for inhibitory activity against 1A9 human tumor cell line.,1,Homo sapiens,Expert,,506.0,,9606.0,1A9,,F,BAO_0000219,CHEMBL615193,72
,80002,N,1,,,,17099,,Percent inhibition against 1A9 human tumor cell line at 0.10 ug/mL,1,Homo sapiens,Intermediate,,506.0,,9606.0,1A9,,F,BAO_0000219,CHEMBL615194,73
,80002,N,1,,,,17099,,Percent inhibition against 1A9 human tumor cell line at <0.00008 ug/mL,1,Homo sapiens,Intermediate,,506.0,,9606.0,1A9,,F,BAO_0000219,CHEMBL615195,74
,80002,N,1,,,,17099,,Percent inhibition against 1A9 human tumor cell line at >10 ug/mL,1,Homo sapiens,Intermediate,,506.0,,9606.0,1A9,,F,BAO_0000219,CHEMBL615196,75
,81072,N,1,,,,17721,,Inhibitory concentration against Jurkat cells,1,Homo sapiens,Intermediate,,503.0,,9606.0,Jurkat,,F,BAO_0000219,CHEMBL615197,76
,22226,U,0,,,,1229,,In vitro anticancer activity against 2 NCI SCLC cell lines; inactive,1,,Intermediate,,,,,,,F,BAO_0000019,CHEMBL615198,77
,100121,D,9,,,,11347,,Inhibition of cytochrome P450 progesterone 2-alpha-hydroxylase,1,Rattus norvegicus,Expert,,,,10116.0,,,A,BAO_0000357,CHEMBL615199,78
,11231,H,8,,,,17117,,"In vitro inhibition of human 2,3-oxidosqualene cyclase.",1,,Expert,,,,,,,B,BAO_0000357,CHEMBL615200,79
,11231,H,8,,,,17117,,"In vitro inhibition of human 2,3-oxidosqualene cyclase.",1,,Expert,,,,,,,B,BAO_0000357,CHEMBL615201,80
,11231,H,8,,,,17117,,"In vitro inhibition of human 2,3-oxidosqualene cyclase at 100 nM.",1,,Expert,,,,,,,B,BAO_0000357,CHEMBL615202,81
,11231,H,8,,,Microsomes,11375,,"Compound was evaluated for the inhibition of microsomal 2,3-oxidosqualene cyclase in Candida albicans microsomes",1,Candida albicans,Autocuration,,,,5476.0,,,B,BAO_0000251,CHEMBL615203,82
,11231,H,8,,,Microsomes,11375,,"Compound was evaluated for the inhibition of microsomal 2,3-oxidosqualene-lanosterol cyclase in Candida albicans microsomes",1,Candida albicans,Autocuration,,,,5476.0,,,B,BAO_0000251,CHEMBL615204,83
,11231,H,8,,,Microsomes,11375,,"Compound was evaluated for the inhibition of microsomal 2,3-oxidosqualene cyclase in Saccharomyces cerevisiae microsomes",1,Saccharomyces cerevisiae,Autocuration,,,,4932.0,,,B,BAO_0000251,CHEMBL615205,84
,11231,H,8,,,Microsomes,11375,,"Compound was evaluated for the inhibition of microsomal 2,3-oxidosqualene-lanosterol cyclase in Saccharomyces cerevisiae microsomes",1,Saccharomyces cerevisiae,Autocuration,,,,4932.0,,,B,BAO_0000251,CHEMBL615206,85
Liver,12083,H,8,,,Microsomes,11375,,"Compound was evaluated for the inhibition of microsomal 2,3-oxidosqualene-lanosterol cyclase in pig liver microsomes",1,Sus scrofa,Autocuration,,,,9823.0,,2107.0,B,BAO_0000251,CHEMBL615207,86
,11231,H,8,,,,791,,"Concentration required to inhibit rat liver 2,3-oxidosqualene-lanosterol cyclase",1,Rattus norvegicus,Autocuration,,,,10116.0,,,B,BAO_0000019,CHEMBL827084,87
,11231,H,8,,,,791,,"Concentration required to inhibit rat liver 2,3-oxidosqualene-lanosterol cyclase (OSC)",1,Rattus norvegicus,Autocuration,,,,10116.0,,,B,BAO_0000019,CHEMBL615208,88
,11231,H,8,,,,791,,"Evaluated for its activity to inhibit rat liver 2,3-oxidosqualene-lanosterol cyclase, activity expressed as Ki",1,Rattus norvegicus,Autocuration,,,,10116.0,,,B,BAO_0000019,CHEMBL615209,89
Liver,12083,D,9,,,Microsomes,11375,,"Compound was evaluated for the inhibition of microsomal 2,3-oxidosqualene cyclase in rat liver microsomes",1,Rattus norvegicus,Autocuration,,,,10116.0,,2107.0,B,BAO_0000251,CHEMBL615210,90
Liver,12083,D,9,,,Microsomes,11375,,"Compound was evaluated for the inhibition of microsomal 2,3-oxidosqualene-lanosterol cyclase in rat liver microsomes",1,Rattus norvegicus,Autocuration,,,,10116.0,,2107.0,B,BAO_0000251,CHEMBL615211,91
Liver,12083,D,9,,,Microsomes,153,,"Compound was evaluated for inhibitory activity against 2,3-oxidosqualene-lanosterol cyclase in rat liver microsomes",1,Rattus norvegicus,Autocuration,,,,10116.0,,2107.0,B,BAO_0000251,CHEMBL615212,92
,11377,H,8,,,,8269,,Molar concentration needed to give 50% prevention of 2-5A (Adenosine dependent endoribonuclease),1,,Expert,,,,,,,B,BAO_0000357,CHEMBL615213,93
,11377,H,8,,,,8269,,Molar concentration required to displace 50% of the radiolabeled probe from 2-5A (Adenosine dependent endoribonuclease) in endonuclease-nitrocellulose complex,1,,Expert,,,,,,,B,BAO_0000357,CHEMBL615273,94
,81020,N,1,,,,17653,,In vitro cytotoxic concentration required to inhibit hepatitisB virus (HBV) replication in 2.2.15 cell line,1,Homo sapiens,Expert,,726.0,,9606.0,HepG2,,F,BAO_0000219,CHEMBL615274,95
,81020,N,1,,,,14277,,50% Effective concentration of compound required for inhibiting intracellular viral replicative intermediate DNA in HBV-transfected 2.2.15 cell line.,1,Homo sapiens,Intermediate,,726.0,,9606.0,HepG2,,F,BAO_0000219,CHEMBL615275,96
,81020,N,1,,,,1717,,Antiviral activity against Hepatitis B virus in 2.2.15 cell line,1,Homo sapiens,Intermediate,,726.0,,9606.0,HepG2,,F,BAO_0000219,CHEMBL615276,97
,81020,N,1,,,,14091,,In vitro effective concentration against hepatitis B virus was determined in 2.2.15 cells,1,Homo sapiens,Intermediate,,726.0,,9606.0,HepG2,,F,BAO_0000219,CHEMBL615277,98
,81020,N,1,,,,14091,,In vitro effective concentration against hepatitis B virus was determined in 2.2.15 cells; Not determined,1,Homo sapiens,Intermediate,,726.0,,9606.0,HepG2,,F,BAO_0000219,CHEMBL615326,99
,50606,N,1,,,,17653,,In vitro effective concentration required to inhibit hepatitisB virus (HBV) replication in 2.2.15 cell line,1,Hepatitis B virus,Expert,,,,10407.0,,,F,BAO_0000218,CHEMBL883130,100
,81020,N,1,,,,13105,,Ability to inhibit the episomal HBV-DNA in 2.2.15 cells.,1,Homo sapiens,Intermediate,,726.0,,9606.0,HepG2,,F,BAO_0000219,CHEMBL884519,101
,81020,N,1,,,,1717,,Concentration required to inhibit 50% of 2.2.15 cell line,1,Homo sapiens,Intermediate,,726.0,,9606.0,HepG2,,F,BAO_0000219,CHEMBL615327,102
,81020,N,1,,,,13105,,Anti viral activity against 2.2.15 cells (concentration required to reduce the log phase cell growth by 50%).,1,Homo sapiens,Intermediate,,726.0,,9606.0,HepG2,,A,BAO_0000219,CHEMBL615328,103
,50587,N,1,,,,13600,,Cytotoxic activity of compound against uninfected 2.2.15 cells.,1,Homo sapiens,Intermediate,,,,9606.0,2.2.15,,F,BAO_0000218,CHEMBL615329,104
,50587,N,1,,,,13467,,Anti hepatitis-B virus activity was evaluated in 2.2.15 cells.,1,Homo sapiens,Intermediate,,,,9606.0,2.2.15,,F,BAO_0000218,CHEMBL615330,105
,50606,N,1,,,,17477,,"Inhibition of the replication of HBV in 2.2.15 cells, by DNA hybridization assay",1,Hepatitis B virus,Expert,,,,10407.0,2.2.15,,F,BAO_0000218,CHEMBL615331,106
,50587,N,1,,,,1593,,In vitro anti-HBV activity in 2.2.15 cells,1,Homo sapiens,Intermediate,,,,9606.0,2.2.15,,F,BAO_0000218,CHEMBL615332,107
,50587,N,1,,,,1593,,In vitro anti-HBV activity in 2.2.15 cells; Not determined,1,Homo sapiens,Intermediate,,,,9606.0,2.2.15,,F,BAO_0000218,CHEMBL615333,108
,50587,N,1,,,,15089,,The compound was tested in vitro for the anti-HBV activity against 2.2.15 cells,1,Homo sapiens,Intermediate,,,,9606.0,2.2.15,,F,BAO_0000218,CHEMBL615334,109
,50587,N,1,,,,15089,,The compound was tested in vitro for the anti-HBV activity in 2.2.15 cells,1,Homo sapiens,Intermediate,,,,9606.0,2.2.15,,F,BAO_0000218,CHEMBL615335,110
,50587,N,1,,,,1593,,Cytotoxicity in 2.2.15 cells,1,Homo sapiens,Intermediate,,,,9606.0,2.2.15,,F,BAO_0000218,CHEMBL615336,111
,50587,N,1,,,,1593,,Cytotoxicity in 2.2.15 cells; Not determined,1,Homo sapiens,Intermediate,,,,9606.0,2.2.15,,F,BAO_0000218,CHEMBL615337,112
,50587,N,1,,,,13600,,Inhibitory activity of compound against hepatitis B virus (HBV) in growing cultures of 2.2.15 cells,1,Homo sapiens,Intermediate,,,,9606.0,2.2.15,,F,BAO_0000218,CHEMBL615338,113
,50587,N,1,,,,13467,,The growth inhibition activity for the compound was evaluated in 2.2.15 cells.,1,Homo sapiens,Intermediate,,,,9606.0,2.2.15,,F,BAO_0000218,CHEMBL615339,114
,50587,N,1,,,,13467,,Selectivity index was determined from the ratio of IC50 to the EC50 values evaluated in 2.2.15 cells.,1,Homo sapiens,Intermediate,,,,9606.0,2.2.15,,F,BAO_0000218,CHEMBL615340,115
,81020,N,1,,,,14764,,Antiviral activity against HBV was determined in 2.215 cell line,1,Homo sapiens,Intermediate,,726.0,,9606.0,HepG2,,F,BAO_0000219,CHEMBL615341,116
,22226,U,0,,,Microsomes,6531,,Inhibition of 20-HETE synthesis in human renal microsomes,1,Homo sapiens,Autocuration,,,,9606.0,,,B,BAO_0000251,CHEMBL615342,117
,22226,U,0,,,,17322,,Inhibitory activity against 20-HETE production from arachidonic acid using human renal microsome 20-HETE synthase.,1,,Autocuration,,,,,,,B,BAO_0000019,CHEMBL615343,118
,80612,N,1,,,,17072,,Inhibitory concentration against 2008 (ovarian) cells,1,Homo sapiens,Intermediate,,388.0,,9606.0,2008,,F,BAO_0000219,CHEMBL615344,119
,80612,N,1,,,,16936,,50% Growth inhibitory concentration( GI 50 ) by using 2008 human ovarian carcinoma cell lines.,1,Homo sapiens,Intermediate,,388.0,,9606.0,2008,,F,BAO_0000219,CHEMBL615345,120
,80612,N,1,,,,16936,,Compound was tested for 50% growth inhibitory concentration by using human ovarian carcinoma cell lines (2008),1,Homo sapiens,Intermediate,,388.0,,9606.0,2008,,F,BAO_0000219,CHEMBL615346,121
,80612,N,1,,,,17146,,Direct cytotoxicity against the selected tumor cell line 2008 was determined especially on ovarian adenocarcinoma derived cells,1,Homo sapiens,Intermediate,,388.0,,9606.0,2008,,F,BAO_0000219,CHEMBL615347,122
,80612,N,1,,,,17146,,Direct cytotoxicity against the selected tumor cell line 2008 was determined especially on ovarian adenocarcinoma derived cells; not detected,1,Homo sapiens,Intermediate,,388.0,,9606.0,2008,,F,BAO_0000219,CHEMBL615348,123
,80613,N,1,,,,10797,,In vitro inhibition of 2008/R ovarian cancer cell line,1,Homo sapiens,Intermediate,,561.0,,9606.0,2008/R,,F,BAO_0000219,CHEMBL827085,124
,80613,N,1,,,,10797,,In vitro inhibition of 2008/R ovarian cancer cell line; NA= Not achievable,1,Homo sapiens,Intermediate,,561.0,,9606.0,2008/R,,F,BAO_0000219,CHEMBL615349,125
,80614,N,1,,,,10797,,In vitro inhibition of 2008/S ovarian cancer cell line,1,Homo sapiens,Intermediate,,389.0,,9606.0,2008/S,,F,BAO_0000219,CHEMBL615350,126
,80614,N,1,,,,10797,,In vitro inhibition of 2008/S ovarian cancer cell line; NA= Not achievable,1,Homo sapiens,Intermediate,,389.0,,9606.0,2008/S,,F,BAO_0000219,CHEMBL615351,127
,100256,S,2,,,,4823,,Tested in vitro for inhibition of chymotrypsin like activity of purified human 20S proteasome,1,Homo sapiens,Expert,,,,9606.0,,,B,BAO_0000220,CHEMBL615352,128
,100256,S,2,,,,12912,,Compound was evaluated for inhibitory activity against 20S proteasome from human liver and brain,1,Homo sapiens,Intermediate,,,,9606.0,,,B,BAO_0000220,CHEMBL615353,129
,100256,S,2,,,,2957,,Inhibition of chymotrypsin-like activity of 20S proteasome,1,,Expert,,,,,,,B,BAO_0000220,CHEMBL615354,130
,100256,S,2,,,,2957,,Inhibition of chymotrypsin-like activity of 20S proteasome; value ranges from 10-20 uM,1,,Expert,,,,,,,B,BAO_0000220,CHEMBL615355,131
,100256,S,2,,,,3260,,Inhibitory activity against 20S proteosome,1,,Intermediate,,,,,,,B,BAO_0000220,CHEMBL615356,132
,22226,U,0,,,,3451,,Compound was tested for inhibitory activity against tryptase,1,Homo sapiens,Autocuration,,,,9606.0,,,B,BAO_0000019,CHEMBL615357,133
,81020,N,1,,,,13885,,Concentration required to inhibit 50% of extracellular circular replication of HBV DNA using 2215 cell line,1,Homo sapiens,Intermediate,,726.0,,9606.0,HepG2,,F,BAO_0000219,CHEMBL615358,134
,81020,N,1,,,,13885,,Concentration required to inhibit 50% of intracellular circular replication of HBV DNA using 2215 cell line,1,Homo sapiens,Intermediate,,726.0,,9606.0,HepG2,,F,BAO_0000219,CHEMBL827086,135
,22226,U,0,,,,3676,,Compound was tested for the inhibition of Alpha-glucosidase,1,,Autocuration,,,,,,,B,BAO_0000019,CHEMBL615359,136
,235,H,8,,,,6043,,Inhibitory concentration against human neutrophil elastase (HNE),1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL615360,137
Heart,22226,U,0,,,,11140,,Change in heart rate was expressed in percent at at a dose 0.002 mg/kg iv in anesthetized rat,1,Rattus norvegicus,Autocuration,,,,10116.0,,948.0,F,BAO_0000218,CHEMBL615361,138
,19640,H,8,,,,10543,,90% inhibition of the 20 Mycobacterium avium complex (MAC) clinical isolates,1,,Autocuration,,,,,,,F,BAO_0000019,CHEMBL615362,139
,19640,H,8,,,,10543,,Minimum inhibitory concentration of compound against 20 Mycobacterium avium complex (MAC) clinical isolates,1,,Expert,,,,,,,F,BAO_0000019,CHEMBL615363,140
,19640,H,8,,,,10543,,Minimum inhibitory concentration of compound against 20 Mycobacterium avium complex (MAC) clinical isolates,1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL615364,141
,19640,H,8,,,,10543,,90% inhibition of the 20 Mycobacterium avium complex (MAC) clinical isolates,1,,Expert,,,,,,,F,BAO_0000019,CHEMBL615365,142
,80360,N,1,,,,11365,,In Vitro evaluation for the growth inhibition of Subline (P388/AMSA) Leukemia cell lines,1,Mus musculus,Intermediate,,524.0,,10090.0,P338,,F,BAO_0000219,CHEMBL615366,143
,80360,N,1,,,,11365,,In Vitro evaluation for the growth inhibition of Subline (P388/CP) Leukemia cell lines,1,Mus musculus,Intermediate,,524.0,,10090.0,P338,,F,BAO_0000219,CHEMBL615367,144
,80384,N,1,,,,11803,,Compound was evaluated for the inhibition of cell replication human peripheral blood lymphocytes (PBL's).,1,Homo sapiens,Intermediate,,554.0,,9606.0,PBL,,F,BAO_0000219,CHEMBL615368,145
,22226,U,0,,,,11803,,Compound was evaluated for the inhibition of cell replication sheep choroid plexus (SCP) cells,1,Ovis aries,Autocuration,,,,9940.0,,,F,BAO_0000019,CHEMBL615369,146
,22226,U,0,,,,11803,,Compound was evaluated for the inhibition of cell replication sheep choroid plexus (SCP) cells.,1,Ovis aries,Autocuration,,,,9940.0,,,F,BAO_0000019,CHEMBL615370,147
,191,H,8,,,,12278,,Compound is evaluated in vitro for the inhibition single mutant of HIV-1 RT (Y181C),1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL615673,148
,22226,U,0,,,,8249,,Compound was evaluated for its inhibitory effect on thymidine [3H]dThd) incorporation into DNA of CEM/MTX cells in culture at conc. 10e-5,1,Homo sapiens,Autocuration,,,,9606.0,,,F,BAO_0000019,CHEMBL615674,149
,22226,U,0,,,,8249,,Compound was evaluated for its inhibitory effect on thymidine [3H]-dThd) incorporation into DNA of CEM/MTX cells in culture at conc. 10e-6,1,Homo sapiens,Autocuration,,,,9606.0,,,F,BAO_0000019,CHEMBL615675,150
,22226,U,0,,,,8249,,Compound was evaluated for its inhibitory effect on thymidine ([3H]dThd) incorporation into DNA of CEM cells in at conc. 10e-7,1,Homo sapiens,Autocuration,,635.0,,9606.0,CCRF-CEM,,F,BAO_0000219,CHEMBL615676,151
,22226,U,0,,,,8249,,Compound was evaluated for its inhibitory effect on thymidine ([3H]-dThd) incorporation into DNA of CEM cells in culture at conc. 10e-4,1,Homo sapiens,Autocuration,,635.0,,9606.0,CCRF-CEM,,F,BAO_0000219,CHEMBL615677,152
,22226,U,0,,,,8249,,Compound was evaluated for its inhibitory effect on thymidine ([3H]dThd) incorporation into DNA of CEM cells in culture at conc. 10e-5,1,Homo sapiens,Autocuration,,635.0,,9606.0,CCRF-CEM,,F,BAO_0000219,CHEMBL615678,153
,22226,U,0,,,,8249,,Compound was evaluated for its inhibitory effect on thymidine ([3H]dThd) incorporation into DNA of CEM cells in culture at conc. 10e-6,1,Homo sapiens,Autocuration,,635.0,,9606.0,CCRF-CEM,,F,BAO_0000219,CHEMBL615679,154
,22226,U,0,,,,8249,,Compound was evaluated for its inhibitory effect on thymidine ([3H]-dThd) incorporation into DNA of CEM/MTX cells in at conc. 10e-7.,1,Homo sapiens,Autocuration,,,,9606.0,,,F,BAO_0000019,CHEMBL615680,155
,22226,U,0,,,,8249,,Compound was evaluated for its inhibitory effect on thymidine ([3H]dThd) incorporation into DNA of CEM/MTX cells in culture at conc. 10e-4,1,Homo sapiens,Autocuration,,,,9606.0,,,F,BAO_0000019,CHEMBL615681,156
,104290,H,6,,,,16992,,In vitro binding affinity towards (alpha-4)2(beta-2)3 neuronal nicotinic acetylcholine receptor in P2 membrane fractions of rat forebrain,1,,Autocuration,,,,,,,B,BAO_0000249,CHEMBL857972,157
,50264,N,1,,,,10543,,Minimum inhibitory concentration of compound against Streptococcus pyogenus septicemia in the mouse,1,Streptococcus pyogenes,Intermediate,,,,1314.0,,,F,BAO_0000218,CHEMBL857899,158
,50527,N,1,,,,17833,,Antiviral activity against 07/1 strain of thymidine kinase negative (TK-) Varicella-Zoster Virus (VZV),1,Human herpesvirus 3,Intermediate,,,,10335.0,,,F,BAO_0000218,CHEMBL615371,159
,50527,N,1,,,,17290,,Antiviral activity against 07/1 strain of VZV in HEL (human erythroleukemia) cells.,1,vericilla zoster virus,Expert,,468.0,,10335.0,HEL,,F,BAO_0000218,CHEMBL615372,160
,50527,N,1,,,,17290,,Antiviral activity against 07/1 strain of VZV; ND: No data,1,vericilla zoster virus,Intermediate,,,,10335.0,,,F,BAO_0000218,CHEMBL615373,161
,50527,N,1,,,,17290,,Antiviral activity against 07/1 strain of VZV; ND=No data,1,vericilla zoster virus,Intermediate,,,,10335.0,,,F,BAO_0000218,CHEMBL615374,162
,50145,N,1,,,,10932,,"Antibacterial activity was determined against gram negative organism, Enterobacter cloacae (MA2646)",1,escherichia cloac,Intermediate,,,,561.0,,,F,BAO_0000218,CHEMBL615375,163
,22226,U,0,,,,9707,,Ratio of Ki at A2 to Ki at A1 receptors,1,,Autocuration,,,,,,,B,BAO_0000019,CHEMBL615376,164
,11143,H,8,,,,2346,,"In vitro inhibition of 1,3-beta-glucan synthase in Candida albicans membrane assay.",1,Candida albicans,Expert,,,,5476.0,,,B,BAO_0000249,CHEMBL615377,165
,18077,H,8,,,,2205,,"Inhibition of 1,3-beta-glucan synthase",1,Candida glabrata CBS 138,Expert,,,,284593.0,,,B,BAO_0000357,CHEMBL615378,166
,80609,N,1,,,,11900,,Inhibition of growth of 1-87 human tumor cell line,1,Homo sapiens,Intermediate,,832.0,,9606.0,1-87 tumor cell line,,F,BAO_0000219,CHEMBL615379,167
,12166,D,9,,,,14864,,Inhibition of 1-lipoxygenase (LOX)in RBL cells,1,Rattus norvegicus,Expert,,,,10116.0,,,B,BAO_0000219,CHEMBL615380,168
,100171,D,9,,,,16474,,Inhibitory activity against soybean 1-lipoxygenase (SLO),1,Glycine max,Autocuration,,,,3847.0,,,B,BAO_0000357,CHEMBL615381,169
,100171,D,9,,,,16474,,Inhibitory activity against soybean 1-lipoxygenase (SLO); no effect,1,Glycine max,Autocuration,,,,3847.0,,,B,BAO_0000357,CHEMBL615382,170
,100171,D,9,,,,16474,,% inhibition against soybean 1-lipoxygenase (SLO),1,Glycine max,Autocuration,,,,3847.0,,,B,BAO_0000357,CHEMBL615383,171
,100171,D,9,,,,16474,,percent inhibition against soybean 1-lipoxygenase (SLO);NI is no inhibition,1,Glycine max,Autocuration,,,,3847.0,,,B,BAO_0000357,CHEMBL615384,172
,100171,D,9,,,,3094,,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 10:90,1,Glycine max,Autocuration,,,,3847.0,,,B,BAO_0000357,CHEMBL615385,173
,100171,D,9,,,,3094,,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 1:99,1,Glycine max,Autocuration,,,,3847.0,,,B,BAO_0000357,CHEMBL615386,174
,100171,D,9,,,,3094,,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 25:75,1,Glycine max,Autocuration,,,,3847.0,,,B,BAO_0000357,CHEMBL615387,175
,100171,D,9,,,,3094,,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 35:65,1,Glycine max,Autocuration,,,,3847.0,,,B,BAO_0000357,CHEMBL615388,176
,100171,D,9,,,,3094,,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 50:50,1,Glycine max,Autocuration,,,,3847.0,,,B,BAO_0000357,CHEMBL615214,177
,100171,D,9,,,,3094,,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 76:24,1,Glycine max,Autocuration,,,,3847.0,,,B,BAO_0000357,CHEMBL827087,178
,100171,D,9,,,,3094,,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 87:13,1,Glycine max,Autocuration,,,,3847.0,,,B,BAO_0000357,CHEMBL615215,179
,100171,D,9,,,,3094,,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 89:11,1,Glycine max,Autocuration,,,,3847.0,,,B,BAO_0000357,CHEMBL615216,180
,100171,D,9,,,,3094,,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 95:5,1,Glycine max,Autocuration,,,,3847.0,,,B,BAO_0000357,CHEMBL615217,181
,100171,D,9,,,,3094,,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 97:3,1,Glycine max,Autocuration,,,,3847.0,,,B,BAO_0000357,CHEMBL615218,182
,100171,D,9,,,,3094,,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 99:1,1,Glycine max,Autocuration,,,,3847.0,,,B,BAO_0000357,CHEMBL615219,183
,22226,U,0,,,,10413,,Evaluated for inhibitory activity on 10-formyltetrahydrofolate synthetase(L cell) at folate substrate concentration of 100 uM,1,Mus musculus,Autocuration,,,,10090.0,,,B,BAO_0000019,CHEMBL615220,184
,80049,N,1,,,,16929,,Cells were harvested and were assayed for luciferase and -galactosidase activities (Transcriptional activity),1,Mus musculus,Intermediate,,294.0,,10090.0,C3H 10T1/2,,F,BAO_0000219,CHEMBL615221,185
,22226,U,0,,,,1229,,In vitro anticancer activity against 11 NCI NSCLC cell lines; inactive,1,,Intermediate,,,,,,,F,BAO_0000019,CHEMBL615222,186
,11489,H,8,,,,16587,,In vitro inhibitory activity against human 11 beta hydroxysteroid dehydrogenase type 1 using scintillation proximity assay (SPA),1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL615223,187
,11862,H,8,,,,16587,,In vitro inhibitory activity against mouse 11 beta hydroxysteroid dehydrogenase type 1 using scintillation proximity assay (SPA),1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL615224,188
,11862,H,8,,,,16587,,In vitro inhibitory activity against mouse 11 beta hydroxysteroid dehydrogenase type 1 using scintillation proximity assay (SPA).,1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL615225,189
,11489,H,8,,,,16587,,Ability to convert [3H]cortisol to the tritium labeled cortisone in the presence of human 11 beta hydroxysteroid dehydrogenase type 2,1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL615226,190
,11862,H,8,,,,16587,,Inhibitory activity against mouse 11 beta hydroxysteroid dehydrogenase type 2 at a concentration of 0.2 mM; NI means no inhibition,1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL615227,191
,12347,D,9,,,,8058,,Evaluated for inhibition of bovine adrenal cortical mitochondrial 11 beta-hydroxylase,1,Bos taurus,Expert,,,,9913.0,,,F,BAO_0000019,CHEMBL615228,192
,100120,D,9,,,,9065,,Effect on adrenal 11-beta-hydroxylase activity at 10e-4 M; No significant effect,1,Rattus norvegicus,Expert,,,,10116.0,,,B,BAO_0000357,CHEMBL615229,193
Adrenal gland,100120,D,9,,,,8865,,Inhibition of 11 beta-hydroxylase from rat adrenal gland,1,Rattus norvegicus,Expert,,,,10116.0,,2369.0,B,BAO_0000357,CHEMBL615230,194
,100120,D,9,,,,9066,,Inhibition of rat adrenal 11-beta-hydroxylase,1,Rattus norvegicus,Expert,,,,10116.0,,,B,BAO_0000357,CHEMBL615231,195
,100120,D,9,,,,8394,,Inhibition of rat adrenal 11-beta-hydroxylase,1,Rattus norvegicus,Expert,,,,10116.0,,,B,BAO_0000357,CHEMBL884520,196
,100120,D,9,,,,8394,,Inhibition of rat adrenal 11-beta-hydroxylase at 10e-5 M,1,Rattus norvegicus,Expert,,,,10116.0,,,B,BAO_0000357,CHEMBL615232,197
,10328,H,8,,,,6431,,Percent inhibition against 11-beta-hydroxysteroid dehydrogenase 1 of wistar rat liver cytosol at 10 uM was determined using [3H]cortisone,1,,Autocuration,,,,,,,B,BAO_0000019,CHEMBL615233,198
,11490,H,8,,,,6431,,Percent inhibition against 11-beta-hydroxysteroid dehydrogenase 2 of wistar rat kidney at 10 uM was determined using [3H]cortisol,1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL827088,199
,11490,H,8,,,,6431,,Percent inhibition against 11-beta-hydroxysteroid dehydrogenase 2 of wistar rat kidney at 10 uM was determined using [3H]cortisol,1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL615234,200
,11134,H,8,,,,9295,,Compound was tested for the percent of inhibition against 12-LO at 10 uM,1,,Autocuration,,,,,,,F,BAO_0000019,CHEMBL615235,201
,12052,H,8,,,,10193,,In vitro inhibitory activity against rat platelet 12-lipoxygenase at 10 uM,1,,Autocuration,,,,,,,B,BAO_0000019,CHEMBL615236,202
,11134,H,8,,,,13622,,Compound was tested in vitro for inhibition of 12-LO human platelet,1,,Autocuration,,,,,,,B,BAO_0000019,CHEMBL615237,203
,11134,H,8,,,,12079,,Inhibitory concentration against human platelet 12-lipoxygenase,1,,Autocuration,,,,,,,F,BAO_0000019,CHEMBL615238,204
,11134,H,8,,,,13622,,Compound at 100 uM was tested in vitro for inhibition of 12-LO human platelet,1,,Autocuration,,,,,,,B,BAO_0000019,CHEMBL615239,205
,11134,D,9,,,,12079,,Inhibitory concentration against human platelet 12-lipoxygenase,1,Homo sapiens,Autocuration,,,,9606.0,,,F,BAO_0000019,CHEMBL615240,206
,11835,H,8,,,,13500,,Tested for inhibition of 12-LO (12-lipoxygenase) as an inhibitor of 12(S)-HETE biosynthesis in mouse epidermal homogenates,1,,Expert,,,,,,,B,BAO_0000019,CHEMBL615241,207
,11601,H,8,,,,13723,,Inhibitory activity against conversion of [1-14C]arachidonic acid to 12-HPETE and its reduction product 12-HETE by porcine leukocyte type 12-lipoxygenase,1,,Expert,,,,,,,B,BAO_0000357,CHEMBL615242,208
,11134,H,8,,,,16474,,Inhibitory activity against human platelet 12-lipoxygenase (12-HLO),1,,Autocuration,,,,,,,B,BAO_0000019,CHEMBL615243,209
,11134,H,8,,,,1630,,Inhibitory activity against human platelet 12-lipoxygenase,1,,Autocuration,,,,,,,B,BAO_0000019,CHEMBL615244,210
,11134,H,8,,,,167,,Inhibitory activity against human platelet 12-lipoxygenase was evaluated,1,,Autocuration,,,,,,,B,BAO_0000019,CHEMBL615245,211
,11134,H,8,,,,16474,,% inhibition against human platelet 12-lipoxygenase (12-HLO),1,,Autocuration,,,,,,,B,BAO_0000019,CHEMBL615246,212
,11134,H,8,,,,167,,Inhibitory activity against human platelet 12-lipoxygenase was evaluated at 100 uM,1,,Autocuration,,,,,,,B,BAO_0000019,CHEMBL615247,213
,11134,H,8,,,,16474,,percent inhibition against human platelet 12-lipoxygenase (12-HLO); NI is no inhibition,1,,Autocuration,,,,,,,B,BAO_0000019,CHEMBL615248,214
,11601,H,8,,,,10091,,Inhibitory activity towards porcine 12-lipoxygenase,1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL615249,215
,11601,H,8,,,,11966,,Tested for inhibition against porcine 12-LO,1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL615250,216
,12052,H,8,,,,951,,Inhibition of 12-lipoxygenase was evaluated in rat platelets stimulated by thrombin up to a concentration of 10 uM; NE means No effect,1,,Autocuration,,,,,,,B,BAO_0000019,CHEMBL615251,217
,12052,H,8,,,,10997,,Inhibitory activity against 12-lipoxygenase in rat platelet rich plasma,1,,Autocuration,,,,,,,B,BAO_0000019,CHEMBL615252,218
,12052,H,8,,,,10193,,In vitro inhibition of rat platelet 12-lipoxygenase,1,,Expert,,,,,,,B,BAO_0000019,CHEMBL828340,219
,12052,H,8,,,,10193,,In vitro inhibitory activity against rat platelet 12-lipoxygenase at 10 uM,1,,Autocuration,,,,,,,B,BAO_0000019,CHEMBL615253,220
,12052,H,8,,,,10193,,In vitro inhibitory activity against rat platelet 12-lipoxygenase at 100 uM,1,,Autocuration,,,,,,,B,BAO_0000019,CHEMBL615254,221
,12052,H,8,,,,10193,,In vitro inhibitory activity against rat platelet 12-lipoxygenase at 30 uM,1,,Autocuration,,,,,,,B,BAO_0000019,CHEMBL615255,222
,12052,H,8,,,,10193,,In vitro inhibitory activity against rat platelet 12-lipoxygenase at 10 uM,1,,Autocuration,,,,,,,B,BAO_0000019,CHEMBL615256,223
,12052,H,8,,,,10193,,In vitro inhibitory activity against rat platelet 12-lipoxygenase,1,,Autocuration,,,,,,,B,BAO_0000019,CHEMBL615257,224
,12052,H,8,,,,11087,,The compound was tested for the in vitro inhibition of platelet 12-lipoxygenase at a concentration of 100 uM,1,,Autocuration,,,,,,,B,BAO_0000019,CHEMBL615258,225
,80007,N,1,,,,15569,,Cytotoxic activity in a panel of Human ovarian tumor 41M cell line after 96h of drug exposure,1,Homo sapiens,Intermediate,,621.0,,9606.0,41M,,F,BAO_0000219,CHEMBL615259,226
,80007,N,1,,,,12989,,In vitro antitumor activity against 41M cell line.,1,Homo sapiens,Expert,,621.0,,9606.0,41M,,F,BAO_0000219,CHEMBL615260,227
,80007,N,1,,,,16745,,cytotoxicity against 41M cells incubated for 24 hr in MTT assay.,1,Homo sapiens,Intermediate,,621.0,,9606.0,41M,,F,BAO_0000219,CHEMBL615261,228
,80007,N,1,,,,15569,,Cytotoxic activity in a panel of Human ovarian tumor 41M/CDDP cell line after 96h of drug exposure,1,Homo sapiens,Intermediate,,621.0,,9606.0,41M,,F,BAO_0000219,CHEMBL615262,229
,80007,N,1,,,,12989,,In vitro antitumor activity against 41McisR cell line.,1,Homo sapiens,Expert,,621.0,,9606.0,41M,,F,BAO_0000219,CHEMBL615263,230
,80007,N,1,,,,12989,,Resistant factor was determined between IC50 of cisplatin-resistant human tumor cell lines to that of 41McisR cell line,1,Homo sapiens,Expert,,621.0,,9606.0,41M,,F,BAO_0000219,CHEMBL838393,231
,80007,N,1,,,,16745,,cytotoxicity against 41McisR cells incubated for 24 hr in MTT assay,1,Homo sapiens,Intermediate,,621.0,,9606.0,41M,,F,BAO_0000219,CHEMBL615264,232
,84,D,9,,,,6210,,Inhibition of 5'-inosine monophosphate dehydrogenase type I (IMPDH I),1,Homo sapiens,Expert,,,,9606.0,,,B,BAO_0000357,CHEMBL615265,233
,68,D,9,,,,6210,,Inhibition of 5'-inosine monophosphate dehydrogenase type II (IMPDH II),1,Homo sapiens,Expert,,,,9606.0,,,B,BAO_0000357,CHEMBL615266,234
,68,H,8,,,,6226,,Inhibitory activity against inosine 5'-inosine monophosphate dehydrogenase type II (IMPDH II),1,,Expert,,,,,,,B,BAO_0000357,CHEMBL615267,235
,10201,H,8,,,,17855,,Equilibrium dissociation constant towards human 5'-methylthioadenosine phosphorylase,1,,Expert,,,,,,,B,BAO_0000357,CHEMBL615268,236
,10201,H,8,,,,17855,,Equilibrium dissociation constant towards human 5'-methylthioadenosine phosphorylase; nd = Not determined,1,,Expert,,,,,,,B,BAO_0000357,CHEMBL615269,237
,10201,H,8,,,,17855,,Initial dissociation constant towards human 5'-methylthioadenosine phosphorylase,1,,Expert,,,,,,,B,BAO_0000357,CHEMBL615270,238
,12220,H,8,,,,10413,,"Evaluated for inhibitory activity on 5,10-Methenyl Tetrahydrofolate Cyclohydrolase(L cell) at folate substrate concentration of 100 uM",1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL615271,239
,11303,H,8,,,,10413,,"Inhibitory activity against 5,10-methylenetetrahydrofolate dehydrogenase from Escherichia coli at a concentration of 0.1 mM; NT=Not tested",1,Escherichia coli,Autocuration,,,,562.0,,,B,BAO_0000357,CHEMBL615272,240
,11303,H,8,,,,10413,,"Inhibitory activity against 5,10-Methylene Tetrahydrofolate Cyclohydrolase from Escherichia coli at a concentration of 0.1 mM; NT=Not tested",1,Escherichia coli,Autocuration,,,,562.0,,,B,BAO_0000357,CHEMBL615103,241
,11303,H,8,,,,10413,,"Inhibitory activity against 5,10-Methylene Tetrahydrofolate Cyclohydrolase from Escherichia coli at a concentration of 0.1 mM;NT=Not tested",1,Escherichia coli,Autocuration,,,,562.0,,,B,BAO_0000357,CHEMBL615104,242
,12220,H,8,,,,10413,,"Evaluated for inhibitory activity on 5,10-Methylene Tetrahydrofolate Cyclohydrolase(L cell) at folate substrate concentration of 100 uM",1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL615105,243
,12220,H,8,,,,10413,,"Evaluated for inhibitory activity on 5,10-methylenetetrahydrofolate dehydrogenase(L cell) at folate substrate concentration of 100 uM",1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL872866,244
,11303,H,8,,,,7587,,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (L1210 tumor tissue) enzyme at 10E-6 M inhibitory concentration",1,Sus scrofa,Autocuration,,,,9823.0,,,B,BAO_0000357,CHEMBL615106,245
,11303,H,8,,,,7587,,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (A,porcine liver) enzyme.",1,Sus scrofa,Autocuration,,,,9823.0,,,B,BAO_0000019,CHEMBL615107,246
,11303,H,8,,,,7587,,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (L1210 tumor tissue) enzyme at 10E-4 M inhibitory concentration",1,Sus scrofa,Autocuration,,,,9823.0,,,B,BAO_0000357,CHEMBL615108,247
,11303,H,8,,,,7587,,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (L1210 tumor tissue) enzyme at 10E-5 M inhibitory concentration",1,Sus scrofa,Autocuration,,,,9823.0,,,B,BAO_0000357,CHEMBL615109,248
,11303,H,8,,,,7587,,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (L1210 tumor tissue) enzyme at 10E-6 M inhibitory concentration",1,Sus scrofa,Autocuration,,,,9823.0,,,B,BAO_0000357,CHEMBL615110,249
,11303,H,8,,,,7587,,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (porcine liver) enzyme at 10E-4 M inhibitory concentration",1,Sus scrofa,Autocuration,,,,9823.0,,,B,BAO_0000019,CHEMBL840105,250
,11303,H,8,,,,7587,,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (porcine liver) enzyme at 10E-5 M inhibitory concentration",1,Sus scrofa,Autocuration,,,,9823.0,,,B,BAO_0000019,CHEMBL615111,251
,11303,H,8,,,,7587,,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (porcine liver) enzyme at 10E-6 M inhibitory concentration",1,Sus scrofa,Autocuration,,,,9823.0,,,B,BAO_0000019,CHEMBL615112,252
,11303,H,8,,,,7587,,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (porcine liver) enzyme at 10E-7 M inhibitory concentration",1,Sus scrofa,Autocuration,,,,9823.0,,,B,BAO_0000019,CHEMBL615113,253
,11303,H,8,,,,7587,,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (porcine liver) enzyme.",1,Sus scrofa,Autocuration,,,,9823.0,,,B,BAO_0000019,CHEMBL615114,254
,11303,H,8,,,,7587,,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (L1210 tumor tissue) enzyme at 10E-6 M inhibitory concentration",1,Sus scrofa,Autocuration,,,,9823.0,,,B,BAO_0000357,CHEMBL615115,255
,11303,H,8,,,,7587,,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (porcine liver) enzyme at 10E-4 M inhibitory concentration",1,Sus scrofa,Autocuration,,,,9823.0,,,B,BAO_0000019,CHEMBL615116,256
,11303,H,8,,,,7323,,"Compound was tested for in vitro inhibition of 5,10-Methylene Tetrahydrofolate Cyclohydrolase, competitive against (+)-L-5,10-methenyltetrahydrofolate",1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL615698,257
,22226,U,0,,,,7587,,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Reductase (porcine kidney) enzyme at 10E-4 M inhibitory concentration",1,Sus scrofa,Autocuration,,,,9823.0,,,B,BAO_0000019,CHEMBL615699,258
,22226,U,0,,,,7587,,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Reductase (porcine kidney) enzyme.",1,Sus scrofa,Autocuration,,,,9823.0,,,B,BAO_0000019,CHEMBL615700,259
,100249,H,8,,,,13750,,Inhibition of 5-Desaturase involved in ergosterol biosynthesis,1,Saccharomyces cerevisiae,Expert,,,,4932.0,,,B,BAO_0000357,CHEMBL615701,260
,22226,U,0,,,,7662,,Ability for reversible inhibition of Walker 256 5-Fluoro-2'-deoxyuridine Phosphorylase,1,Rattus norvegicus,Autocuration,,,,10116.0,,,B,BAO_0000019,CHEMBL615702,261
,22226,U,0,,,,7662,,Ability for reversible inhibition of Walker 256 5-Fluoro-2'-deoxyuridine Phosphorylase,1,Rattus norvegicus,Autocuration,,,,10116.0,,,B,BAO_0000019,CHEMBL615703,262
,22226,U,0,,,,7662,,"Irreversible inhibition of Walker 256 FUDR phosphorylase; expressed as Vo/Vi, velocity without inhibitor to that of velocity with inhibitor",1,Rattus norvegicus,Autocuration,,,,10116.0,,,B,BAO_0000019,CHEMBL615704,263
,104698,H,6,,,,12211,,"Tested for 5-HT 3 receptor antagonist potency by ability to inhibit the reflex bradycardia, the Bezold-Jarisch reflex in the rat",1,,Autocuration,,,,,,,F,BAO_0000019,CHEMBL615705,264
,104698,H,6,,,,12211,,"Compound was tested for its 5-HT 3 receptor antagonist potency by their ability to inhibit the reflex bradycardia, the Bezold-Jarisch reflex in the rat",1,,Autocuration,,,,,,,F,BAO_0000019,CHEMBL615706,265
Ileum,20033,D,9,,,,12211,,Relative ability to increase cholinergically mediated contractions in isolated ileum of guinea pig,1,Cavia porcellus,Intermediate,,,,10141.0,,2116.0,F,BAO_0000221,CHEMBL615707,266
,10623,H,8,,,,12211,,Stimulatory activity of intragastric pressure was tested in the rat,1,,Expert,,,,,,,F,BAO_0000019,CHEMBL615708,267
,121,H,8,,,,15453,,% Decrease of 5-HT carrier-receptor -bound radioactivity using paroxetine as a radioligand.,1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL615709,268
,22226,U,0,,,,11884,,Dose to reduce neuronal firing against 5-HT cells in rats (iv),1,Rattus norvegicus,Autocuration,,,,10116.0,,,F,BAO_0000218,CHEMBL615710,269
,12688,H,8,,,,7185,,Antagonistic activity of corresponding methoxy compound against serotonin 5-HT receptor,1,,Autocuration,,,,,,,F,BAO_0000019,CHEMBL615711,270
,121,D,9,,,,6876,,Binding affinity at 5-HT reuptake site labeled with [3H]paroxetine,1,Homo sapiens,Expert,,,,9606.0,,,B,BAO_0000357,CHEMBL615712,271
,121,D,9,,,,6876,,Binding affinity at 5-HT reuptake site labeled with [3H]paroxetine; No data,1,Homo sapiens,Expert,,,,9606.0,,,B,BAO_0000357,CHEMBL836325,272
,12198,H,8,,,,11863,,Inhibition of high affinity 5-HT uptake at concentration of 1 uM,1,,Autocuration,,,,,,,F,BAO_0000019,CHEMBL615713,273
,12198,H,8,,,,11863,,Inhibition constant of high-affinity 5-HT uptake,1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL615714,274
,12198,H,8,,,,11863,,Michaelis-Menten constant was reported for high affinity transport of 5-HT,1,,Autocuration,,,,,,,F,BAO_0000019,CHEMBL615715,275
,12198,H,8,,,,11863,,Maximum rate was determined for high affinity transport of 5-HT,1,,Autocuration,,,,,,,F,BAO_0000019,CHEMBL615716,276
,104714,H,4,,,,4639,,Compound was tested for agonistic activity against 5-HT uptake,1,,Autocuration,,,,,,,F,BAO_0000019,CHEMBL615717,277
,10577,H,8,,,,15796,,Inhibition affinity against 5-HT-1B receptor in rat frontal cortex using radio binding assay,1,,Expert,,,,,,,B,BAO_0000019,CHEMBL881818,278
,105,H,8,,,,15796,,Inhibition affinity against 5-HT-1D receptor in bovine caudate nucleus using radio binding assay,1,Bos taurus,Expert,,,,9913.0,,,B,BAO_0000357,CHEMBL884540,279
,104744,D,5,,,,12801,,Binding affinity towards 5-hydroxytryptamine 1 receptor using [3H]5-HT as radioligand,1,Rattus norvegicus,Autocuration,,,,10116.0,,,B,BAO_0000224,CHEMBL615718,280
,104744,H,4,,,,12801,,The compound was evaluated for the binding affinity towards 5-hydroxytryptamine 1 using [3H]5-HT as radioligand,1,,Autocuration,,,,,,,B,BAO_0000224,CHEMBL615719,281
,104744,H,4,,,Membranes,12120,,Percent inhibition of binding of 3.0 nM [3H]5-HT to 5-hydroxytryptamine 1 receptor in rat caudate membranes at 10 e -5 M,1,,Autocuration,,,,,,,B,BAO_0000249,CHEMBL615720,282
,104744,H,4,,,Membranes,12120,,Percent inhibition of binding of 3.0 nM [3H]5-HT to 5-hydroxytryptamine 1 receptor in rat caudate membranes at 10 e -5 M.,1,,Autocuration,,,,,,,B,BAO_0000249,CHEMBL615721,283
,104744,H,4,,,,11963,,Displacement of binding of [3H]-5-HT to 5-hydroxytryptamine 1 receptor in rat cerebral cortex,1,,Autocuration,,,,,,,B,BAO_0000019,CHEMBL615722,284
,51,H,8,,,,11701,,Dose required to reduce neuronal firing of 5-HT1A cells by 50%,1,,Autocuration,,,,,,,F,BAO_0000019,CHEMBL615723,285
Hippocampus,51,H,8,,,,9995,,In vitro inhibition of [3H]5-HT (2 nM) binding to 5-hydroxytryptamine 1A receptor from bovine hippocampus,1,,Autocuration,,,,,,10000000.0,B,BAO_0000221,CHEMBL615724,286
Hippocampus,51,H,8,,,,9995,,In vitro inhibition of [3H]DPAT (1 nM) binding to 5-HT1A receptor from bovine hippocampus,1,,Autocuration,,,,,,10000000.0,B,BAO_0000221,CHEMBL615725,287
Hippocampus,51,H,8,,,,9995,,In vitro inhibition of [3H]DPAT (1 nM) binding to 5-hydroxytryptamine 1A receptor from bovine hippocampus,1,,Autocuration,,,,,,10000000.0,B,BAO_0000221,CHEMBL615726,288
,10576,H,8,In vivo,,,16394,,Antagonistic activity at postsynaptic 5-HT1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (.26-3.52),1,,Autocuration,,,,,,,F,BAO_0000218,CHEMBL615727,289
,105570,D,9,,,,11574,,Effect on forskolin stimulated adenylate cyclase activity at 5-HT1D receptor of guinea pig substantia nigra.,1,Cavia porcellus,Intermediate,,,,10141.0,,,F,BAO_0000019,CHEMBL615728,290
,279,H,8,,,,15779,,Binding affinity towards 5-HT1F (human cloned receptor) in CHO cells using [3H]5-HT as radioligand.,1,,Autocuration,,449.0,,,CHO,,B,BAO_0000219,CHEMBL857971,291
,107,H,8,,,,15363,,Compound was tested for the displacement of [125I]DOI from clone human 5-hydroxytryptamine 2A receptor,1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL615729,292
,12687,D,9,,,,15363,,Efficacy against 5-hydroxytryptamine 2A receptor,1,Rattus norvegicus,Expert,,,,10116.0,,,F,BAO_0000019,CHEMBL615730,293
,12687,H,8,,,,15329,,Intrinsic activity towards 5-HT2A receptor of rat tail artery,1,,Expert,,,,,,,F,BAO_0000019,CHEMBL615731,294
,12687,H,8,,,,15329,,Relative potency towards 5-HT2A receptor of rat tail artery,1,,Expert,,,,,,,F,BAO_0000019,CHEMBL615732,295
,12687,H,8,,,,15329,,Blocking 5-HT2A receptor-mediated contractions of rat tail artery,1,,Expert,,,,,,,F,BAO_0000019,CHEMBL615733,296
,12687,H,8,,,,15329,,Partial agonism at 5-HT2A receptor was evaluated in presence of ketanserin (3-10 nM) in isolated rat tail artery,1,,Expert,,,,,,,F,BAO_0000019,CHEMBL615734,297
,12687,H,8,,,,15329,,Compound was tested for the intrinsic activity against 5-HT2A receptors of rat tail artery.,1,,Autocuration,,,,,,,F,BAO_0000019,CHEMBL615735,298
,12687,H,8,,,,15329,,Effectiveness in blocking 5-HT2A receptor-mediated contractions of rat tail artery,1,,Expert,,,,,,,F,BAO_0000019,CHEMBL615736,299
Ileum,20033,D,9,,,,273,,Evaluated for the agonistic activity against 5-HT4 receptor in non-electrically stimulated guinea-pig ileum.,1,Cavia porcellus,Intermediate,,,,10141.0,,2116.0,F,BAO_0000221,CHEMBL615737,300
Ileum,20033,D,9,,,,273,,Agonistic activity against Serotonin 5-HT4 receptor in low frequency field stimulation of guinea-pig ileum (FSGPI),1,Cavia porcellus,Intermediate,,,,10141.0,,2116.0,F,BAO_0000221,CHEMBL615738,301
Ileum,20033,D,9,,,,273,,Evaluated for the agonistic activity against Serotonin 5-HT4 receptor in non-electrically stimulated guinea-pig ileum.,1,Cavia porcellus,Intermediate,,,,10141.0,,2116.0,F,BAO_0000221,CHEMBL615739,302
,10623,H,8,,,,12092,,The binding affinity was measured on 5-hydroxytryptamine 4 receptor using [3H]- GR-113808 as radioligand.,1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL615278,303
,10623,D,9,,,,1317,,Antagonist activity against 5-HT4 receptor mediated relaxation of rat carbachol contracted esophageal muscularis mucosae,1,Rattus norvegicus,Expert,,,,10116.0,,,F,BAO_0000019,CHEMBL615279,304
,168,H,8,,,,12409,,Binding affinity against 5-hydroxytryptamine 4 receptor,1,,Expert,,,,,,,B,BAO_0000357,CHEMBL615280,305
,22226,U,0,,,,11126,,Relative competitive index values for binding to 25-OH-D3-1-hydroxylase of chick intestine,1,Gallus gallus,Autocuration,,,,9031.0,,,B,BAO_0000019,CHEMBL615281,306
,22226,U,0,,,,11126,,Inhibitory effect (10e-6 M) on the 25-OH-D3-1-hydroxylase activity,1,Homo sapiens,Autocuration,,,,9606.0,,,F,BAO_0000019,CHEMBL615282,307
,22226,U,0,,,,11126,,25-OH-D3-1-hydroxylase activity (10e-6 M) was measured as %control,1,Homo sapiens,Autocuration,,,,9606.0,,,F,BAO_0000019,CHEMBL615283,308
,80156,N,1,,,,11126,,Relative competitive index values for binding to 25-OH-D3-1-hydroxylase of human HL-60 cells,1,Homo sapiens,Autocuration,,649.0,,9606.0,HL-60,,B,BAO_0000219,CHEMBL615284,309
,22226,U,0,,,,11126,,Inhibitory effect (10e-6 M) on the 25-hydroxyvitamin D3-1-hydroxylase activity,1,Homo sapiens,Autocuration,,,,9606.0,,,B,BAO_0000019,CHEMBL615285,310
,22226,U,0,,,,11126,,25-hydroxyvitamin D3-1-hydroxylase activity (10e-6 M) was measured as %control,1,Homo sapiens,Autocuration,,,,9606.0,,,B,BAO_0000019,CHEMBL615286,311
,104703,D,7,,,,17807,,Displacement of [3H]-Ro- 15-1788 from human GABA-A alpha-1-beta-3-gamma-2 receptor subunits expressed in Xenopus oocytes,1,Homo sapiens,Autocuration,,,,9606.0,Oocytes,,B,BAO_0000219,CHEMBL615287,312
,100256,S,2,,,,16575,,Chymotryptic inhibitory activity against 26S proteasome,1,,Intermediate,,,,,,,F,BAO_0000220,CHEMBL615288,313
,100256,S,2,,,,15407,,Inhibitory activity against 26S proteasome degradation of IkB,1,,Intermediate,,,,,,,B,BAO_0000220,CHEMBL615289,314
,81034,N,1,,,,10797,,In vitro inhibition of 2780/DOX ovarian cancer cell line,1,Homo sapiens,Intermediate,,478.0,,9606.0,A2780,,F,BAO_0000219,CHEMBL615290,315
,81034,N,1,,,,10797,,In vitro inhibition of 2780/S ovarian cancer cell line,1,Homo sapiens,Intermediate,,478.0,,9606.0,A2780,,F,BAO_0000219,CHEMBL884522,316
,22226,U,0,,,,3469,,Relative activity on the cellular accumulation of vincristine in multidrug-resistant (MDR) human ovarian cancer 2780AD cells,1,Homo sapiens,Autocuration,,,,9606.0,,,F,BAO_0000019,CHEMBL615291,317
,22222,M,3,,,,16037,,Association constant for binding to AATT 28-mer AATT hairpin,1,,Intermediate,,,,,,,B,BAO_0000225,CHEMBL615292,318
,22222,M,3,,,,16037,,Kinetically Defined Association Constant for 28-mer AATT hairpin.,1,,Intermediate,,,,,,,B,BAO_0000225,CHEMBL615293,319
,22222,M,3,,,,16037,,Reaction Rate Parameter for 28-mer AATT hairpin,1,,Intermediate,,,,,,,B,BAO_0000225,CHEMBL615294,320
,22222,M,3,,,,16037,,Reaction Rate Parameter for 28-mer AATT hairpin,1,,Intermediate,,,,,,,B,BAO_0000225,CHEMBL615295,321
,22226,U,0,,,,16524,,Antiviral activity against envelope deficient HIV-1 in a single cycle replication assay (experiment 1),1,Homo sapiens,Autocuration,,,,9606.0,,,F,BAO_0000019,CHEMBL825021,322
,22226,U,0,,,,16524,,Antiviral activity against envelope deficient HIV-1 in a single cycle replication assay (experiment 2),1,Homo sapiens,Autocuration,,,,9606.0,,,F,BAO_0000019,CHEMBL615296,323
,22226,U,0,,,,16524,,Inhibitory concentration by single cycle replication assay using envelope deficient HIV-1,1,Homo sapiens,Autocuration,,,,9606.0,,,F,BAO_0000019,CHEMBL615297,324
,22226,U,0,,,,16758,,Cytotoxicity against cell line 2SC/20 determined by MTT test,1,Cricetulus griseus,Autocuration,,,,10029.0,,,F,BAO_0000019,CHEMBL615298,325
,22226,U,0,,,,16758,,Cytotoxicity against cell line 2SC/20 of hamster determined by MTT test,1,Cricetulus griseus,Autocuration,,,,10029.0,,,F,BAO_0000019,CHEMBL615299,326
,22226,U,0,,,,16758,,Inhibitory concentration against the growth of 2SC/20 cell line after 72 hr of drug exposure by MTT test,1,Cricetulus griseus,Autocuration,,,,10029.0,,,F,BAO_0000019,CHEMBL615300,327
,241,H,8,,,,14360,,Binding affinity on 3 beta-hydroxysteroid dehydrogenase,1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL615301,328
,241,D,9,,,,14360,,Binding affinity for 3-beta-hydroxysteroid dehydrogenase,1,Homo sapiens,Expert,,,,9606.0,,,B,BAO_0000357,CHEMBL615302,329
,22226,U,0,,,,9964,,Selectivity ratio of ID50 in liver and heart,1,Rattus norvegicus,Autocuration,,,,10116.0,,,B,BAO_0000019,CHEMBL615303,330
,12132,H,8,,,,9964,,"Selectivity, ratio of relative ID50 in liver and heart",1,,Autocuration,,,,,,,B,BAO_0000019,CHEMBL615304,331
,12132,H,8,,,,9964,,Binding affinity to the receptor was determined in isolated nuclei of heart(In vitro) relative to T3,1,,Autocuration,,,,,,,B,BAO_0000019,CHEMBL615305,332
,12132,H,8,,,,9964,,"Binding affinity to the receptor was determined in nuclei of heart In vivo 1 hour after intravenous administration relative to 3,5,3' triiodothyronine receptor",1,,Autocuration,,,,,,,B,BAO_0000218,CHEMBL615306,333
,12132,H,8,,,,9964,,"Binding affinity to the receptor was determined in nuclei of liver In vivo 1 hour after intravenous administration relative to 3,5,3' triiodothyronine receptor",1,,Autocuration,,,,,,,B,BAO_0000218,CHEMBL615307,334
,12132,H,8,In vivo,,,9964,,"Binding affinity to the receptor was determined in nuclei of liver in vivo 1 hour after intravenous administration relative to 3,5,3' triiodothyronine receptor",1,,Autocuration,,,,,,,B,BAO_0000218,CHEMBL615308,335
,12132,H,8,In vivo,,,9964,,"Binding affinity to the receptor was determined in nuclei of liver in vivo 1 hour after intravenous administration relative to 3,5,3' triiodothyronine receptor",1,,Autocuration,,,,,,,F,BAO_0000218,CHEMBL615309,336
,22226,U,0,,,,9964,,"Binding affinity to the thyroid hormone receptor was determined in vitro in isolated nuclei of rat liver relative to 3,5,3' triiodothyronine",1,,Autocuration,,,,,,,B,BAO_0000019,CHEMBL615310,337
,12132,H,8,,,,9964,,Binding affinity to the receptor was determined in vitro in isolated nuclei of rat liver relative to T3,1,,Autocuration,,,,,,,B,BAO_0000019,CHEMBL615311,338
,22226,U,0,,,,9964,,"Binding affinity to thyroid hormone receptor beta, relative to 3,5,3' triiodothyronine receptor, in isolated nuclei of heart",1,Homo sapiens,Autocuration,,,,9606.0,,,B,BAO_0000019,CHEMBL615312,339
,12132,H,8,,,,9964,,In vitro binding affinity to the receptor was determined in isolated nuclei of heart relative to T3,1,,Autocuration,,,,,,,B,BAO_0000019,CHEMBL615313,340
,12132,H,8,,,,9964,,In vitro binding affinity to the receptor was determined in isolated nuclei of heart relative to T3,1,,Autocuration,,,,,,,F,BAO_0000019,CHEMBL615314,341
,12132,H,8,,,,9964,,"Binding affinity to the receptor was determined in isolated nuclei of heart(In vitro) relative to 3,5,3' triiodothyronine receptor",1,,Autocuration,,,,,,,B,BAO_0000019,CHEMBL615315,342
,22226,U,0,,,,9964,,"In vivo binding affinity for 3,5,3'' triiodothyronine receptor of heart nuclei 1 hr after intravenous administration",1,Rattus norvegicus,Autocuration,,,,10116.0,,,B,BAO_0000218,CHEMBL615316,343
,12132,H,8,In vivo,,,9964,,Binding affinity to the receptor was determined in nuclei of heart in vivo 1 hour after intravenous administration relative to T3,1,,Autocuration,,,,,,,B,BAO_0000218,CHEMBL615317,344
,12132,H,8,,,,9964,,"Binding affinity to the receptor was determined in nuclei of liver In vivo 1 hour after intravenous administration relative to 3,5,3' triiodothyronine receptor",1,,Autocuration,,,,,,,B,BAO_0000218,CHEMBL615318,345
,22226,U,0,,,,9964,,"In vivo binding affinity for 3,5,3' triiodothyronine receptor of liver nuclei 1 hour after intravenous administration",1,Rattus norvegicus,Autocuration,,,,10116.0,,,B,BAO_0000218,CHEMBL615319,346
,12132,H,8,,,,9964,,"In vitro binding affinity to the receptor was determined in isolated nuclei of heart relative to 3,5,3' triiodothyronine receptor",1,,Autocuration,,,,,,,B,BAO_0000019,CHEMBL615320,347
,12132,H,8,,,,9964,,"In vitro binding affinity to the receptor was determined in isolated nuclei of heart relative to 3,5,3' triiodothyronine receptor",1,,Autocuration,,,,,,,F,BAO_0000019,CHEMBL615321,348
,22226,U,0,,,,3796,,"Inhibition of [125I]L-T3 binding to rat hepatic 3,5,3''-triiodo-L-thyronine receptor",1,Rattus norvegicus,Autocuration,,,,10116.0,,,B,BAO_0000019,CHEMBL615322,349
,19690,H,8,,,,4251,,Inhibition constant for binding to Co2+ form of 3-dehydroquinate synthase (DHQ) purified from Escherichia coli,1,Escherichia coli,Autocuration,,,,562.0,,,B,BAO_0000357,CHEMBL615323,350
,19690,H,8,,,,4251,,Inhibition constant for binding to Zn2+ form of 3-dehydroquinate synthase (DHQ) purified from Escherichia coli,1,Escherichia coli,Autocuration,,,,562.0,,,B,BAO_0000357,CHEMBL615407,351
,19690,H,8,,,,4251,,Kinetics expressed as Michaelis-Menten constant against Co2+ form of 3-dehydroquinate synthase purified from Escherichia coli,1,Escherichia coli,Autocuration,,,,562.0,,,B,BAO_0000357,CHEMBL857267,352
,19690,H,8,,,,4251,,Kinetics expressed as Michaelis-Menten constant against Zn2+ form of 3-dehydroquinate synthase purified from Escherichia coli,1,Escherichia coli,Autocuration,,,,562.0,,,B,BAO_0000357,CHEMBL615408,353
,19690,H,8,,,,166,,Type of inhibition of 3-dehydroquinate synthase was determined; R - Slowly reversible,1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL615409,354
,19690,H,8,,,,17861,,Compound was evaluated for its inhibitory constant against 3-dehydroquinate synthase,1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL615410,355
,19690,H,8,,,,166,,Inhibition constant against 3-dehydroquinate synthase,1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL615411,356
,19690,H,8,,,,166,,Association rate constant against 3-dehydroquinate synthase,1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL615412,357
,19690,H,8,,,,166,,Rate constant against 3-dehydroquinate synthase,1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL615413,358
,22226,U,0,,,,3548,,Inhibitory activity against fuc-TVII,1,,Autocuration,,,,,,,B,BAO_0000019,CHEMBL615414,359
Liver,12236,D,9,,,Microsomes,9877,,Ability of compound (2.5 uM) to inhibit the activity of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) using [14C]mevalonate in rat liver microsomes,1,Rattus norvegicus,Autocuration,,,,10116.0,,2107.0,B,BAO_0000251,CHEMBL615415,360
Liver,12236,D,9,,,Microsomes,9877,,Ability of compound (2500 uM) to inhibit the activity of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) using [14C]mevalonate in rat liver microsomes,1,Rattus norvegicus,Autocuration,,,,10116.0,,2107.0,B,BAO_0000251,CHEMBL615416,361
Liver,12236,D,9,,,Microsomes,9877,,Ability of compound (250 uM) to inhibit the activity of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) using [14C]mevalonate in rat liver microsomes,1,Rattus norvegicus,Autocuration,,,,10116.0,,2107.0,B,BAO_0000251,CHEMBL615417,362
Liver,12236,D,9,,,Microsomes,9877,,Ability of compound (25 uM) to inhibit the activity of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) using [14C]mevalonate in rat liver microsomes,1,Rattus norvegicus,Autocuration,,,,10116.0,,2107.0,B,BAO_0000251,CHEMBL615418,363
Liver,12236,D,9,,,Microsomes,9877,,Ability of compound at 0 uM to inhibit the activity of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) using [14C]mevalonate in rat liver microsomes,1,Rattus norvegicus,Autocuration,,,,10116.0,,2107.0,B,BAO_0000251,CHEMBL615419,364
Liver,12236,D,9,,,Microsomes,9877,,Ability of compound to inhibit the activity of 3-hydroxy-3-methylglutarylcoenzyme A(HMGR) reductase in rat liver microsomes,1,Rattus norvegicus,Autocuration,,,,10116.0,,2107.0,B,BAO_0000251,CHEMBL615420,365
Liver,12236,D,9,,,Microsomes,9877,,Percentage inhibition of 3-hydroxy-3-methyl glutaryl coenzyme A reductase in rat liver microsomes at 250 uM,1,Rattus norvegicus,Autocuration,,,,10116.0,,2107.0,B,BAO_0000251,CHEMBL615421,366
Liver,12236,D,9,,,Microsomes,9877,,Percentage inhibition of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) in rat liver microsomes at 0 uM,1,Rattus norvegicus,Autocuration,,,,10116.0,,2107.0,B,BAO_0000251,CHEMBL615422,367
Liver,12236,D,9,,,Microsomes,9877,,Percentage inhibition of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) in rat liver microsomes at 2.5 uM,1,Rattus norvegicus,Autocuration,,,,10116.0,,2107.0,B,BAO_0000251,CHEMBL615423,368
Liver,12236,D,9,,,Microsomes,9877,,Percentage inhibition of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) in rat liver microsomes at 2500 uM,1,Rattus norvegicus,Autocuration,,,,10116.0,,2107.0,B,BAO_0000251,CHEMBL872868,369
Liver,12236,D,9,,,Microsomes,9877,,Percentage inhibition of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) in rat liver microsomes at 25 uM,1,Rattus norvegicus,Autocuration,,,,10116.0,,2107.0,B,BAO_0000251,CHEMBL615424,370
,104832,H,4,,,,3003,,Inhibitory activity against 3-phosphoglycerate kinase.,1,,Autocuration,,,,,,,B,BAO_0000224,CHEMBL825022,371
,104832,H,4,,,,3003,,Binding affinity was evaluated towards 3-phosphoglycerate kinase at 37 degrees Celsius in 0.1 m NaCl pH 7.1,1,,Autocuration,,,,,,,B,BAO_0000224,CHEMBL615425,372
,104832,H,4,,,,3003,,"Michaelis-Menten constant with 1,3-bisphosphoglyceric acid (1,3-BPG) against 3-phosphoglycerate kinase",1,,Autocuration,,,,,,,B,BAO_0000224,CHEMBL615426,373
,10612,D,9,,,,17185,,Inhibition of human 3-phosphoinositide-dependent protein kinase 1 at 10 uM,1,Homo sapiens,Expert,,,,9606.0,,,B,BAO_0000357,CHEMBL615427,374
,80616,N,1,,,,6072,,Cytotoxicity on 3677 melanoma cells,1,Homo sapiens,Intermediate,,844.0,,9606.0,3677 melanoma cell line,,F,BAO_0000219,CHEMBL615428,375
,80616,N,1,,,,6072,,Cytotoxicity on 3677 melanoma cells in combination with L-49-sFv-bL,1,Homo sapiens,Intermediate,,844.0,,9606.0,3677 melanoma cell line,,F,BAO_0000219,CHEMBL615429,376
,80617,N,1,,,,5018,,Antitumor activity against Mouse colon 38 at 500 ug/disk in disk diffusion assay,1,Mus musculus,Intermediate,,700.0,,10090.0,MC-38,,F,BAO_0000219,CHEMBL615430,377
,22226,U,0,,,,2852,,Compound was evaluated for inhibition of tumor cell growth using sulforhodamine-B assay in 38 human cell lines,1,Homo sapiens,Intermediate,,,,9606.0,,,F,BAO_0000019,CHEMBL615431,378
,22226,U,0,,,,8663,,In vivo antitumor activity against 3B131 intraperitoneally implanted B16 melanoma cells; NT= Not tested,1,,Autocuration,,798.0,,,B16,,F,BAO_0000218,CHEMBL615432,379
,22226,U,0,,,,8663,,In vivo antitumor activity against 3B131 intraperitoneally implanted B16 melanoma cells; reproducible significant activity.,1,,Autocuration,,798.0,,,B16,,F,BAO_0000218,CHEMBL615433,380
,12464,D,9,,,,3245,,Inhibitory activity against Human RhinoVirus serotype-14 3C Protease,1,Human rhinovirus 14,Expert,,,,12131.0,,,F,BAO_0000019,CHEMBL615434,381
,50085,N,1,,,,3245,,Inhibitory activity against Human RhinoVirus serotype-14 3C Protease; NI means No inhibition to 50 uM,1,Human rhinovirus sp.,Intermediate,,,,169066.0,,,F,BAO_0000218,CHEMBL615435,382
,50679,N,1,,,,3877,,Compound was evaluated for the inactivation of HRV 14 3C protease activity expressed as KI,1,human rhinovirus type 14,Intermediate,,,,169066.0,,,F,BAO_0000218,CHEMBL615436,383
,50679,N,1,,,,3877,,Compound was evaluated for the inactivation of HRV 14 3C protease activity expressed as kinact,1,human rhinovirus type 14,Intermediate,,,,169066.0,,,F,BAO_0000218,CHEMBL615437,384
,12464,D,9,,,,5861,,Antiviral activity against human rhinovirus-14 (HRV-14) 3C protease using enzyme assay,1,Human rhinovirus 14,Expert,,,,12131.0,,,F,BAO_0000019,CHEMBL615438,385
,12464,D,9,,,,5861,,Antiviral activity against human rhinovirus-14 (HRV-14) 3C protease using enzyme assay,1,Human rhinovirus 14,Expert,,,,12131.0,,,F,BAO_0000019,CHEMBL615439,386
,12464,D,9,,,,5861,,Antiviral activity against human rhinovirus-14 (HRV-14) 3C protease using enzyme assay,1,Human rhinovirus 14,Expert,,,,12131.0,,,F,BAO_0000019,CHEMBL615440,387
,12464,D,9,,,,5861,,Antiviral activity against human rhinovirus-14 (HRV-14) 3C protease using enzyme assay; inactive,1,Human rhinovirus 14,Expert,,,,12131.0,,,F,BAO_0000019,CHEMBL615441,388
,50665,N,1,,,,13748,,Compound was tested for the inhibitory activity of compound towards human rhinovirus 3C protease,1,Enterovirus,Intermediate,,,,12059.0,,,F,BAO_0000218,CHEMBL615641,389
,50665,N,1,,,,13748,,Compound was tested for the inhibitory activity of compound towards human rhinovirus-16 3C protease,1,Enterovirus,Intermediate,,,,12059.0,,,F,BAO_0000218,CHEMBL872065,390
,50665,N,1,,,,13748,,Compound was tested for the inhibitory activity of compound towards human rhinovirus-2 3C protease,1,Enterovirus,Intermediate,,,,12059.0,,,F,BAO_0000218,CHEMBL825023,391
,50665,N,1,,,,13748,,Compound was tested for the inhibitory activity of compound towards human rhinovirus-89 3C protease,1,Enterovirus,Intermediate,,,,12059.0,,,F,BAO_0000218,CHEMBL615642,392
,12464,H,8,,,,13748,,Inhibition of human rhinovirus 3C protease,1,Human rhinovirus B,Expert,,,,147712.0,,,B,BAO_0000357,CHEMBL615643,393
,22226,U,0,,,,17699,,Compound was tested for inhibition of a proteinase 3CL pro of human coronavirus; Inhibited,1,Homo sapiens,Autocuration,,,,9606.0,,,B,BAO_0000019,CHEMBL615644,394
,80619,N,1,,,,7145,,Compound tested for activity against 3EM 37 mouse ependymoblastoma after single ip injection on day 1 at optimal dose of 100 mg/kg (Dose range 200-12.5),1,Mus musculus,Intermediate,,833.0,,10090.0,3EM 37,,F,BAO_0000218,CHEMBL615645,395
,80619,N,1,,,,7145,,Compound tested for activity against 3EM 37 mouse ependymoblastoma after single ip injection on day 1 at optimal dose of 128 mg/kg (Dose range 256-16),1,Mus musculus,Intermediate,,833.0,,10090.0,3EM 37,,F,BAO_0000218,CHEMBL615646,396
,80619,N,1,,,,7145,,Compound tested for toxicity against 3EM 37 Mouse Ependymoblastoma after single ip injection on day 1 at optimal dose (OD) of 100 mg/kg on the 5th day after the injection of the compound; (10/10),1,Mus musculus,Intermediate,,833.0,,10090.0,3EM 37,,F,BAO_0000218,CHEMBL615647,397
,80619,N,1,,,,7145,,Compound tested for toxicity against 3EM 37 mouse ependymoblastoma after single ip injection on day 1 at optimal dose (OD) of 100 mg/kg on the 5th day after the injection of the compound; (6/6),1,Mus musculus,Intermediate,,833.0,,10090.0,3EM 37,,F,BAO_0000218,CHEMBL615648,398
,80619,N,1,,,,7145,,Effect of compound on 3EM 37 mouse ependymoblastoma after single ip injection on day 1 recorded as animal weight difference of the treated and the control (T-C) at OD of 100 mg/kg,1,Mus musculus,Intermediate,,833.0,,10090.0,3EM 37,,F,BAO_0000218,CHEMBL615649,399
,80619,N,1,,,,7145,,Effect of compound on 3EM 37 mouse ependymoblastoma after single ip injection on day 1 recorded as percentage of cured animals at OD of 100 mg/kg,1,Mus musculus,Intermediate,,833.0,,10090.0,3EM 37,,F,BAO_0000218,CHEMBL615650,400
,80620,N,1,,,,5325,,In vivo anti-tumor and anti-metastatic activity was measured after oral dosing 15 mg/kg b.i.d. to B6D2F1 mice bearing metastatic 3LL Lewis lung tumor,1,Mus musculus,Intermediate,,847.0,,10090.0,3LL cell line,,F,BAO_0000218,CHEMBL615651,401
,80620,N,1,,,,5325,,In vivo anti-tumor and anti-metastatic activity was measured after oral dosing b.i.d. to B6D2F1 mice bearing metastatic 3LL Lewis lung tumor,1,Mus musculus,Intermediate,,847.0,,10090.0,3LL cell line,,F,BAO_0000218,CHEMBL615652,402
,80620,N,1,,,,5325,,In vivo anti-tumor and anti-metastatic activity following p.o. administration b.i.d. to B6D2F1 mice bearing metastatic 3LL Lewis lung tumor; Not tested.,1,Mus musculus,Expert,,847.0,,10090.0,3LL cell line,,F,BAO_0000218,CHEMBL615653,403
,80620,N,1,,,,16169,,accumulation of compound in 3LL cells was measured with DFMO by HPLC at 1 uM dose,1,Mus musculus,Intermediate,,847.0,,10090.0,3LL cell line,,F,BAO_0000219,CHEMBL615654,404
,80620,N,1,,,,16169,,accumulation of compound in 3LL cells was measured with DFMO by HPLC at 10 uM dose,1,Mus musculus,Intermediate,,847.0,,10090.0,3LL cell line,,F,BAO_0000219,CHEMBL615655,405
,80620,N,1,,,,16169,,accumulation of compound in 3LL cells was measured with DFMO by HPLC at 250 uM dose,1,Mus musculus,Intermediate,,847.0,,10090.0,3LL cell line,,F,BAO_0000219,CHEMBL825024,406
,80620,N,1,,,,16169,,accumulation of compound in 3LL cells was measured with DFMO by HPLC at 50 uM dose,1,Mus musculus,Intermediate,,847.0,,10090.0,3LL cell line,,F,BAO_0000219,CHEMBL615656,407
,80620,N,1,,,,16169,,accumulation of compound in 3LL cells was measured with DFMO by ICP-AES at 50 uM dose,1,Mus musculus,Intermediate,,847.0,,10090.0,3LL cell line,,F,BAO_0000219,CHEMBL615657,408
,80620,N,1,,,,16169,,accumulation of compound in 3LL cells was measured without DFMO by HPLC at 1 uM dose,1,Mus musculus,Intermediate,,847.0,,10090.0,3LL cell line,,F,BAO_0000219,CHEMBL615658,409
,80620,N,1,,,,16169,,accumulation of compound in 3LL cells was measured without DFMO by HPLC at 10 uM dose,1,Mus musculus,Intermediate,,847.0,,10090.0,3LL cell line,,F,BAO_0000219,CHEMBL615659,410
,80620,N,1,,,,16169,,accumulation of compound in 3LL cells was measured without DFMO by HPLC at 250 uM dose,1,Mus musculus,Intermediate,,847.0,,10090.0,3LL cell line,,F,BAO_0000219,CHEMBL615660,411
,80620,N,1,,,,16169,,accumulation of compound in 3LL cells was measured without DFMO by HPLC at 50 uM dose,1,Mus musculus,Intermediate,,847.0,,10090.0,3LL cell line,,F,BAO_0000219,CHEMBL615661,412
,80620,N,1,,,,16169,,accumulation of compound in 3LL cells was measured without DFMO by ICP-AES at 50 uM dose,1,Mus musculus,Intermediate,,847.0,,10090.0,3LL cell line,,F,BAO_0000219,CHEMBL615662,413
,80620,N,1,,,,16169,,Effect on the growth of 3LL cells by DFMO pretreatment at 48 hr incubation,1,Mus musculus,Intermediate,,847.0,,10090.0,3LL cell line,,F,BAO_0000219,CHEMBL615663,414
,80620,N,1,,,,16169,,Effect on the growth of 3LL cells was evaluated using an MTT assay at 48 hour incubation,1,Mus musculus,Intermediate,,847.0,,10090.0,3LL cell line,,F,BAO_0000219,CHEMBL615664,415
,80620,N,1,,,,16169,,Effect on the growth of 3LL cells was evaluated using an MTT assay at 72 hour incubation,1,Mus musculus,Intermediate,,847.0,,10090.0,3LL cell line,,F,BAO_0000219,CHEMBL615665,416
,80620,N,1,,,,16169,,accumulation of compound in 3LL cells was measured without DFMO by HPLC at 50 uM dose,1,Mus musculus,Intermediate,,847.0,,10090.0,3LL cell line,,F,BAO_0000219,CHEMBL615666,417
,80620,N,1,,,,16169,,putrescine levels in 3LL cells after the treatment of 1 uM of Compound,1,Mus musculus,Intermediate,,847.0,,10090.0,3LL cell line,,F,BAO_0000219,CHEMBL615667,418
,80620,N,1,,,,16169,,putrescine levels in 3LL cells after the treatment of 10 uM of Compound,1,Mus musculus,Intermediate,,847.0,,10090.0,3LL cell line,,F,BAO_0000219,CHEMBL615668,419
,80620,N,1,,,,16169,,putrescine levels in 3LL cells after the treatment of 250 uM of Compound,1,Mus musculus,Intermediate,,847.0,,10090.0,3LL cell line,,F,BAO_0000219,CHEMBL615669,420
,80620,N,1,,,,16169,,putrescine levels in 3LL cells after the treatment of 50 uM of Compound,1,Mus musculus,Intermediate,,847.0,,10090.0,3LL cell line,,F,BAO_0000219,CHEMBL615670,421
,80620,N,1,,,,16169,,spermidine levels in 3LL cells after the treatment of 1 uM of Compound,1,Mus musculus,Intermediate,,847.0,,10090.0,3LL cell line,,F,BAO_0000219,CHEMBL836739,422
,80620,N,1,,,,16169,,spermidine levels in 3LL cells after the treatment of 10 uM of Compound,1,Mus musculus,Intermediate,,847.0,,10090.0,3LL cell line,,F,BAO_0000219,CHEMBL615671,423
,80620,N,1,,,,16169,,spermidine levels in 3LL cells after the treatment of 250 uM of Compound,1,Mus musculus,Intermediate,,847.0,,10090.0,3LL cell line,,F,BAO_0000219,CHEMBL615672,424
,80620,N,1,,,,16169,,spermidine levels in 3LL cells after the treatment of 50 uM of Compound,1,Mus musculus,Intermediate,,847.0,,10090.0,3LL cell line,,F,BAO_0000219,CHEMBL615791,425
,80620,N,1,,,,16169,,spermine levels in 3LL cells after the treatment of 1 uM of Compound,1,Mus musculus,Intermediate,,847.0,,10090.0,3LL cell line,,F,BAO_0000219,CHEMBL615792,426
,80620,N,1,,,,16169,,spermine levels in 3LL cells after the treatment of 10 uM of Compound,1,Mus musculus,Intermediate,,847.0,,10090.0,3LL cell line,,F,BAO_0000219,CHEMBL615793,427
,80620,N,1,,,,16169,,spermine levels in 3LL cells after the treatment of 250 uM of Compound,1,Mus musculus,Intermediate,,847.0,,10090.0,3LL cell line,,F,BAO_0000219,CHEMBL615794,428
,80620,N,1,,,,16169,,spermine levels in 3LL cells after the treatment of 50 uM of Compound,1,Mus musculus,Intermediate,,847.0,,10090.0,3LL cell line,,F,BAO_0000219,CHEMBL615795,429
,80621,N,1,,,,15547,,Concentration required to inhibit the colony formation of lung carcinoma (3LLD122) cell lines by 50%,1,Homo sapiens,Intermediate,,971.0,,9606.0,3LLD122,,F,BAO_0000219,CHEMBL615590,430
,22226,U,0,,,,8663,,In vivo antitumor activity against 3M531 is the sarcoma M5076; reproducible minimal activity,1,,Autocuration,,,,,,,F,BAO_0000218,CHEMBL615591,431
,22226,U,0,,,,8663,,In vivo antitumor activity against 3M531 is the sarcoma M5076; reproducible significant activity.,1,,Autocuration,,,,,,,F,BAO_0000218,CHEMBL615592,432
,22226,U,0,,,,8663,,In vivo antitumor activity against 3MBG5 subrenal capsule mammary carcinoma MX-1 xenograft; NT= Not tested,1,,Autocuration,,,,,,,F,BAO_0000218,CHEMBL615593,433
,22226,U,0,,,,8663,,In vivo antitumor activity against 3MBG5 subrenal capsule mammary carcinoma MX-1 xenograft; reproducible significant activity.,1,,Autocuration,,,,,,,F,BAO_0000218,CHEMBL615594,434
,80951,N,1,,,,4504,,Effective dose required against Trypanosoma cruzi amastigotes in 3T3 Fibroblasts,1,Mus musculus,Intermediate,,723.0,,10090.0,NIH3T3,,F,BAO_0000219,CHEMBL615595,435
,80951,N,1,,,,4504,,Effective dose required against Trypanosoma cruzi amastigotes in 3T3 Fibroblasts,1,Mus musculus,Intermediate,,723.0,,10090.0,NIH3T3,,F,BAO_0000219,CHEMBL615596,436
,11169,H,8,,,,12695,,Inhibition of 6 nM bombesin induced [3H]thymidine incorporation measured in swiss 3T3 cells using a mitogenicity assay,1,,Expert,,723.0,,,NIH3T3,,F,BAO_0000219,CHEMBL615597,437
,80951,N,1,,,,12695,,Ability of the peptide to inhibit 6 nM bombesin induced [3H]thymidine incorporation was measured in swiss 3T3 cells using mitogenicity assay; na=Not active,1,Mus musculus,Intermediate,,723.0,,10090.0,NIH3T3,,F,BAO_0000219,CHEMBL615598,438
,80951,N,1,,,,12695,,Ability of the peptide to inhibit 6 nM bombesin induced [3H]thymidine incorporation was measured in swiss 3T3 cells using mitogenicity assay; nt=Not tested,1,Mus musculus,Intermediate,,723.0,,10090.0,NIH3T3,,F,BAO_0000219,CHEMBL615599,439
,80951,N,1,,,,17642,,Effective dose against murine 3T3 fibroblasts cells,1,Mus musculus,Expert,,723.0,,10090.0,NIH3T3,,F,BAO_0000219,CHEMBL615600,440
,80951,N,1,,,,17642,,Dose required against murine 3T3 fibroblasts cells; 1-10 uM,1,Mus musculus,Expert,,723.0,,10090.0,NIH3T3,,F,BAO_0000219,CHEMBL615601,441
,80951,N,1,,,,12340,,Cytotoxic effect on 3T3 cells,1,Mus musculus,Expert,,723.0,,10090.0,NIH3T3,,F,BAO_0000219,CHEMBL615602,442
,80951,N,1,,,,12340,,Cytotoxic effect on 3T3 cells,1,Mus musculus,Expert,,723.0,,10090.0,NIH3T3,,F,BAO_0000219,CHEMBL615603,443
,80951,N,1,,,,12716,,Compound was tested for the concentration necessary to inhibit swiss 3T3 Mouse Fibroblast cell growth rate by 50%.,1,Mus musculus,Intermediate,,723.0,,10090.0,NIH3T3,,F,BAO_0000219,CHEMBL615604,444
,80951,N,1,,,,6277,,Concentration of NO in supernatant generated by mouse fibroblasts (3T3) cell line in the presence of compound was determined using NR coloration,1,Mus musculus,Intermediate,,723.0,,10090.0,NIH3T3,,F,BAO_0000219,CHEMBL615605,445
,80951,N,1,,,,6277,,Concentration of NO in supernatant generated by mouse fibroblasts (3T3) cell line in the presence of compound was determined using NR coloration; nd=No data,1,Mus musculus,Intermediate,,723.0,,10090.0,NIH3T3,,F,BAO_0000219,CHEMBL615606,446
,80951,N,1,,,,6277,,In vitro cytotoxic concentration against mouse fibroblasts (3T3) cell line using MTT coloration,1,Mus musculus,Expert,,723.0,,10090.0,NIH3T3,,F,BAO_0000219,CHEMBL884526,447
,80951,N,1,,,,6277,,In vitro cytotoxic concentration against mouse fibroblasts (3T3) cell line using MTT coloration; n.d.=no data,1,Mus musculus,Expert,,723.0,,10090.0,NIH3T3,,F,BAO_0000219,CHEMBL615607,448
,80951,N,1,,,,6277,,In vitro cytotoxic concentration against mouse fibroblasts (3T3) cell line using MTT coloration; n.t.=not tested,1,Mus musculus,Intermediate,,723.0,,10090.0,NIH3T3,,F,BAO_0000219,CHEMBL615608,449
,80951,N,1,,,,6277,,In vitro inhibitory activity against mouse fibroblasts (3T3) cell line using CV coloration,1,Mus musculus,Expert,,723.0,,10090.0,NIH3T3,,F,BAO_0000219,CHEMBL615609,450
,80951,N,1,,,,6277,,In vitro inhibitory activity against mouse fibroblasts (3T3) cell line using CV coloration; n.d.=no data,1,Mus musculus,Expert,,723.0,,10090.0,NIH3T3,,F,BAO_0000219,CHEMBL615682,451
,80951,N,1,,,,6277,,In vitro inhibitory activity against mouse fibroblasts (3T3) cell line using CV coloration; n.t.=not tested,1,Mus musculus,Intermediate,,723.0,,10090.0,NIH3T3,,F,BAO_0000219,CHEMBL615683,452
,80951,N,1,,,,17780,,In vivo inhibition of H-ras-transformed 3T3 fibroblasts in nude mouse tumor models,1,Mus musculus,Expert,,723.0,,10090.0,NIH3T3,,F,BAO_0000218,CHEMBL615684,453
,104860,D,7,,,,12751,,Inhibition of PDGF-dependent autophosphorylation of PDGF-R in mouse BALB/c3T3 cells,1,Mus musculus,Autocuration,,,,10090.0,,,F,BAO_0000219,CHEMBL615685,454
,80951,N,1,,,,12380,,Inhibition of Swiss 3T3 Mouse fibroblast proliferation,1,Mus musculus,Expert,,723.0,,10090.0,NIH3T3,,F,BAO_0000219,CHEMBL615686,455
,80951,N,1,,,,14892,,Inhibitory activity against 3T3 cell line,1,Mus musculus,Intermediate,,723.0,,10090.0,NIH3T3,,F,BAO_0000219,CHEMBL615687,456
,80951,N,1,,,,12695,,The ability of the peptide to inhibit the binding of 10 pM [125I]gastrin releasing peptide to S-3T3 cell membrane was measured,1,Mus musculus,Intermediate,,723.0,,10090.0,NIH3T3,,F,BAO_0000219,CHEMBL884523,457
,11169,H,8,,,,12695,,Ability of peptide to inhibit binding of 10 pM [125I]gastrin releasing peptide to S-3T3 cell membrane.,1,,Expert,,,,,,,F,BAO_0000019,CHEMBL615688,458
,80951,N,1,,,,12695,,The ability of the peptide to inhibit the binding of 10 pM [125I]gastrin releasing peptide to S-3T3 cell membrane was measured; nt=Not tested,1,Mus musculus,Intermediate,,723.0,,10090.0,NIH3T3,,F,BAO_0000219,CHEMBL615689,459
,80951,N,1,,,,12695,,The ability of the peptide to inhibit the binding of 50 pM [125I]gastrin releasing peptide to intact S-3T3 cells was measured,1,Mus musculus,Intermediate,,723.0,,10090.0,NIH3T3,,F,BAO_0000219,CHEMBL615690,460
,11169,H,8,,,,12695,,The ability of the peptide to inhibit the binding of 50 pM [125I]gastrin releasing peptide to intact S-3T3 cells,1,,Expert,,,,,,,F,BAO_0000019,CHEMBL615691,461
,11169,H,8,,,,12695,,The ability of the peptide to inhibit the binding of 50 pM [125I]gastrin releasing peptide to intact S-3T3 cells; nt=Not tested,1,,Expert,,,,,,,F,BAO_0000019,CHEMBL615692,462
,80951,N,1,,,,6277,,Concentration of NO in supernatant generated by mouse fibroblasts (3T3) cell line in the presence of compound was determined using NR coloration,1,Mus musculus,Intermediate,,723.0,,10090.0,NIH3T3,,F,BAO_0000219,CHEMBL615693,463
,80951,N,1,,,,6277,,Concentration of NO in supernatant generated by mouse fibroblasts (3T3) cell line was determined using NR coloration; n.d.=no data,1,Mus musculus,Expert,,723.0,,10090.0,NIH3T3,,F,BAO_0000219,CHEMBL615324,464
,9,D,9,,,,4959,,Inhibition of ligand-induced proliferation in human EGF-R Kinase expressing 3T3 cells,1,Homo sapiens,Expert,,723.0,,9606.0,NIH3T3,,F,BAO_0000219,CHEMBL615325,465
,9,D,9,,,,4959,,Inhibition of ligand-induced proliferation in human EGF-R Kinase expressing 3T3 cells (Not tested),1,Homo sapiens,Expert,,723.0,,9606.0,NIH3T3,,F,BAO_0000219,CHEMBL615490,466
,188,D,9,,,,4959,,Inhibition of ligand induced proliferation in human Her-2 (p185erbB) tyrosine kinase expressing 3T3 cells,1,Homo sapiens,Expert,,723.0,,9606.0,NIH3T3,,F,BAO_0000219,CHEMBL615491,467
,188,D,9,,,,4959,,Inhibition of ligand-induced proliferation in human Her-2 (p185erbB) tyrosine kinase expressing 3T3 cells (Not tested),1,Homo sapiens,Expert,,723.0,,9606.0,NIH3T3,,F,BAO_0000219,CHEMBL615492,468
,80951,N,1,,,,12082,,Inhibitory concentration of compound rwas calculated on 3T3 cells by [3H]Thd incorporation,1,Mus musculus,Intermediate,,723.0,,10090.0,NIH3T3,,F,BAO_0000219,CHEMBL615493,469
,80951,N,1,,,,12082,,Inhibitory concentration of compound was calculated on 3T3 cells by [14C]Leu incorporation,1,Mus musculus,Intermediate,,723.0,,10090.0,NIH3T3,,F,BAO_0000219,CHEMBL615494,470
,80951,N,1,,,,12082,,Inhibitory concentration of compound was calculated on 3T3 cells by using clonal assay,1,Mus musculus,Intermediate,,723.0,,10090.0,NIH3T3,,F,BAO_0000219,CHEMBL615495,471
,80951,N,1,,,,12082,,Inhibitory concentration was calculated on 3T3 cells by using growth assay,1,Mus musculus,Intermediate,,723.0,,10090.0,NIH3T3,,F,BAO_0000219,CHEMBL615496,472
,80951,N,1,,,,2643,,In vitro cytotoxicity was evaluated in mouse embryo BALB/c 3T3 cells,1,Mus musculus,Intermediate,,723.0,,10090.0,NIH3T3,,F,BAO_0000219,CHEMBL615497,473
,80951,N,1,,,,11926,,Inhibition of Swiss 3T3 mouse fibroblast proliferation,1,Mus musculus,Expert,,723.0,,10090.0,NIH3T3,,F,BAO_0000219,CHEMBL615498,474
,80951,N,1,,,,15204,,The compound was tested for cytotoxicity against 3T3 fibroblast murine cell line.,1,Mus musculus,Intermediate,,723.0,,10090.0,NIH3T3,,A,BAO_0000219,CHEMBL615499,475
,80951,N,1,,,,15992,,Effective concentration required to inhibit the growth of murine 3T3 fibroblasts,1,Mus musculus,Expert,,723.0,,10090.0,NIH3T3,,F,BAO_0000219,CHEMBL835522,476
,80951,N,1,,,,16279,,Cytotoxicity on 3T3 fibroblasts (3T3F) murine cell line (O.D.=0.131+/-0.014); Not tested,1,Mus musculus,Intermediate,,723.0,,10090.0,NIH3T3,,F,BAO_0000219,CHEMBL615500,477
,80951,N,1,,,,16279,,Cytotoxicity against 3T3 fibroblasts (3T3F) murine cell line (O.D.=0.131+/-0.014),1,Mus musculus,Intermediate,,723.0,,10090.0,NIH3T3,,F,BAO_0000219,CHEMBL615501,478
,80951,N,1,,,,16279,,Cytotoxicity on 3T3 fibroblasts (3T3F) murine cell line (O.D.=0.131+/-0.014),1,Mus musculus,Intermediate,,723.0,,10090.0,NIH3T3,,F,BAO_0000219,CHEMBL615502,479
,80951,N,1,,,,16279,,cytotoxicity on 3T3 fibroblasts (3T3F) murine cell line (O.D.=0.131+/-0.014),1,Mus musculus,Intermediate,,723.0,,10090.0,NIH3T3,,F,BAO_0000219,CHEMBL615503,480
,80951,N,1,,,,16279,,Cytotoxicity on 3T3 fibroblasts (3T3F) murine cell line (O.D.=0.131+/-0.014),1,Mus musculus,Intermediate,,723.0,,10090.0,NIH3T3,,F,BAO_0000219,CHEMBL615504,481
,80951,N,1,,,,16279,,Cytotoxicity against 3T3 fibroblasts (3T3F) murine cell line (O.D.=0.131+/-0.014),1,Mus musculus,Intermediate,,723.0,,10090.0,NIH3T3,,F,BAO_0000219,CHEMBL615505,482
,80951,N,1,,,,12831,,Inhibition of swiss 3T3 mouse fibroblast proliferation,1,Mus musculus,Expert,,723.0,,10090.0,NIH3T3,,F,BAO_0000219,CHEMBL615506,483
,80951,N,1,,,,13497,,Compound was tested for sublethal concentrations in 3T3 mouse fibroblast lysis.,1,Mus musculus,Intermediate,,723.0,,10090.0,NIH3T3,,F,BAO_0000219,CHEMBL615507,484
,80006,N,1,,,,13715,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 30 uM dose.,1,,Intermediate,,620.0,,,3T3-L1,,F,BAO_0000218,CHEMBL615508,485
,80006,N,1,,,,13618,,Concentration required to stimulate glucose uptake in 3T3-L1 adipocytes after 48 hr incubation,1,Mus musculus,Intermediate,,620.0,,10090.0,3T3-L1,,F,BAO_0000219,CHEMBL615509,486
,80006,N,1,,,,11902,,Effect on GLUT 1 glucose transporter expression in 3T3-L1 adipocytes at dose of 0.3 uM,1,Mus musculus,Intermediate,,620.0,,10090.0,3T3-L1,,F,BAO_0000219,CHEMBL615510,487
,80006,N,1,,,,11902,,Effect on GLUT 1 glucose transporter expression in 3T3-L1 adipocytes at dose of 3 uM,1,Mus musculus,Intermediate,,620.0,,10090.0,3T3-L1,,F,BAO_0000219,CHEMBL615511,488
,80006,N,1,,,,11902,,Effect on GLUT 1 glucose transporter expression in 3T3-L1 adipocytes at dose of 30 uM,1,Mus musculus,Intermediate,,620.0,,10090.0,3T3-L1,,F,BAO_0000219,CHEMBL615512,489
,80006,N,1,,,,14840,,"In vitro ability to stimulate glucose transport in 3T3-L1 adipocytes, given at 100 mg/kg in mouse, after 24 hr",1,Mus musculus,Intermediate,,620.0,,10090.0,3T3-L1,,F,BAO_0000218,CHEMBL615513,490
,80006,N,1,,,,14840,,"In vitro ability to stimulate glucose transport in 3T3-L1 adipocytes, given at 100 mg/kg in mouse, after 3 hr",1,Mus musculus,Intermediate,,620.0,,10090.0,3T3-L1,,F,BAO_0000218,CHEMBL615514,491
,80006,N,1,,,,13715,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes,1,,Intermediate,,620.0,,,3T3-L1,,F,BAO_0000219,CHEMBL615515,492
,80006,N,1,,,,13715,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at concentration of 10 micro M,1,,Intermediate,,620.0,,,3T3-L1,,F,BAO_0000219,CHEMBL615516,493
,80006,N,1,,,,13715,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at concentration of 3 micro M,1,,Intermediate,,620.0,,,3T3-L1,,F,BAO_0000219,CHEMBL615517,494
,80006,N,1,,,,13715,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at concentration of 30 micro M,1,,Intermediate,,620.0,,,3T3-L1,,F,BAO_0000219,CHEMBL615518,495
,80006,N,1,,,,13715,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at concentration of 3 micro M,1,,Intermediate,,620.0,,,3T3-L1,,F,BAO_0000219,CHEMBL615519,496
,80006,N,1,,,,13715,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 0.3 uM dose.,1,,Intermediate,,620.0,,,3T3-L1,,F,BAO_0000218,CHEMBL615520,497
,80006,N,1,,,,13715,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 0.5 uM dose.,1,,Intermediate,,620.0,,,3T3-L1,,F,BAO_0000218,CHEMBL615521,498
,80006,N,1,,,,13715,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 1 uM dose.,1,,Intermediate,,620.0,,,3T3-L1,,F,BAO_0000218,CHEMBL615522,499
,80006,N,1,,,,13715,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 10 uM dose.,1,,Intermediate,,620.0,,,3T3-L1,,F,BAO_0000218,CHEMBL615523,500
,80006,N,1,,,,13715,,In vitro measurements 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 100 uM dose.,1,,Expert,,620.0,,,3T3-L1,,F,BAO_0000218,CHEMBL615524,501
,80006,N,1,,,,13715,,Acute effects in vitro by measuring 2-deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 10 uM dose.,1,,Expert,,620.0,,,3T3-L1,,F,BAO_0000218,CHEMBL615525,502
,80006,N,1,,,,13715,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 1 uM dose.,1,,Intermediate,,620.0,,,3T3-L1,,F,BAO_0000218,CHEMBL615526,503
,80006,N,1,,,,13715,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 3 uM dose.,1,,Intermediate,,620.0,,,3T3-L1,,F,BAO_0000218,CHEMBL615527,504
,80006,N,1,,,,13715,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 300 uM dose.,1,,Intermediate,,620.0,,,3T3-L1,,F,BAO_0000218,CHEMBL615528,505
,80006,N,1,,,,13715,,Acute effects in vitro by measuring 2-deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 30 uM dose.,1,,Expert,,620.0,,,3T3-L1,,F,BAO_0000218,CHEMBL615529,506
,80006,N,1,,,,13715,,In vitro by measurements of 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 3 uM dose.,1,,Expert,,620.0,,,3T3-L1,,F,BAO_0000218,CHEMBL615530,507
,80006,N,1,,,,13715,,In vitro measurements of 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 60 uM dose.,1,,Expert,,620.0,,,3T3-L1,,F,BAO_0000218,CHEMBL615531,508
,80006,N,1,,,,13715,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at concentration of 10 micro M,1,,Intermediate,,620.0,,,3T3-L1,,F,BAO_0000219,CHEMBL615532,509
,80006,N,1,,,,13715,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at concentration of 3 micro M,1,,Intermediate,,620.0,,,3T3-L1,,F,BAO_0000219,CHEMBL615533,510
,80006,N,1,,,,13715,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at concentration of 30 micro M,1,,Intermediate,,620.0,,,3T3-L1,,F,BAO_0000219,CHEMBL615534,511
,80006,N,1,,,,13715,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 100 uM dose.,1,,Intermediate,,620.0,,,3T3-L1,,F,BAO_0000218,CHEMBL615535,512
,80006,N,1,,,,13715,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 10 uM dose.,1,,Intermediate,,620.0,,,3T3-L1,,F,BAO_0000218,CHEMBL615536,513
,80006,N,1,,,,13715,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 30 uM dose.,1,,Intermediate,,620.0,,,3T3-L1,,F,BAO_0000218,CHEMBL615537,514
,80006,N,1,,,,13715,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 3 uM dose.,1,,Intermediate,,620.0,,,3T3-L1,,F,BAO_0000218,CHEMBL615538,515
,80006,N,1,,,,13715,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 60 uM dose.,1,,Intermediate,,620.0,,,3T3-L1,,F,BAO_0000218,CHEMBL836166,516
,11214,H,8,,,,6411,,Inhibition of forskolin-stimulated lipolysis in differentiated 3T3-L1 cells,1,,Expert,,620.0,,,3T3-L1,,F,BAO_0000219,CHEMBL615539,517
,80006,N,1,,,,6411,,Evaluated for the inhibition of forskolin-stimulated lipolysis in differentiated 3T3-L1 cells; ND = No data,1,Mus musculus,Intermediate,,620.0,,10090.0,3T3-L1,,F,BAO_0000219,CHEMBL615540,518
,11214,H,8,,,,6411,,Evaluated for the inhibition of forskolin-stimulated lipolysis in differentiated 3T3-L1 cells; Na = Not active,1,,Expert,,620.0,,,3T3-L1,,F,BAO_0000219,CHEMBL615541,519
,80006,N,1,,,,3966,,Insulin-sensitizing activity; triglyceride accumulation from insulin regulated differentiation of 3T3-L1 cells at 1 uM expressed as percent activity of pioglitazone,1,Mus musculus,Expert,,620.0,,10090.0,3T3-L1,,F,BAO_0000219,CHEMBL615542,520
,80006,N,1,,,,3966,,Compound was tested for insulin-sensitizing activity by measuring triglyceride accumulation from insulin regulated differentiation of 3T3-L1 cells at 10 uM expressed as percent activity of pioglitazone,1,Mus musculus,Intermediate,,620.0,,10090.0,3T3-L1,,F,BAO_0000219,CHEMBL615543,521
,80006,N,1,,,,15556,,Stimulation of adipogenesis in 3T3-L1 cells is expressed as concentration equivalent to the [ 1-14C] uptake counts after treatment with 0.2 ug/mL troglitazone,1,Mus musculus,Expert,,620.0,,10090.0,3T3-L1,,F,BAO_0000219,CHEMBL615544,522
,80006,N,1,,,,5845,,Effective concentration for enhancement of insulin-induced triglyceride accumulation in 3T3-L1 cells,1,Mus musculus,Expert,,620.0,,10090.0,3T3-L1,,F,BAO_0000219,CHEMBL615545,523
,80006,N,1,,,,14422,,Effective concentration for 50% enhancement of insulin-induced triglyceride accumulation in 3T3-L1 cells,1,Mus musculus,Expert,,620.0,,10090.0,3T3-L1,,F,BAO_0000219,CHEMBL615546,524
,80006,N,1,,,,5845,,Percentage of rosiglitazone response for insulin-sensitizing activity at 1 uM concentration in 3T3-L1 cells,1,Mus musculus,Expert,,620.0,,10090.0,3T3-L1,,F,BAO_0000219,CHEMBL615547,525
,80006,N,1,,,,14508,,In vitro glucose transport activity in 3T3-LI adipocytes at 10 uM concentration.,1,Mus musculus,Expert,,620.0,,10090.0,3T3-L1,,F,BAO_0000219,CHEMBL615548,526
,80006,N,1,,,,14508,,In vitro glucose transport activity in 3T3-LI adipocytes at 3 uM concentration.,1,Mus musculus,Expert,,620.0,,10090.0,3T3-L1,,F,BAO_0000219,CHEMBL615549,527
,80006,N,1,,,,14508,,In vitro glucose transport activity in 3T3-LI adipocytes at 30 uM concentration.,1,Mus musculus,Expert,,620.0,,10090.0,3T3-L1,,F,BAO_0000219,CHEMBL615550,528
,80622,N,1,,,,6349,,Inhibitory activity against rat fibroblast (3Y1) cell line,1,Rattus norvegicus,Intermediate,,1118.0,,10116.0,3Y1 cell line,,F,BAO_0000219,CHEMBL615551,529
,80622,N,1,,,,15899,,Mean concentration causing inhibition of cell growth in 3Y1 cells.,1,Rattus norvegicus,Expert,,1118.0,,10116.0,3Y1 cell line,,F,BAO_0000219,CHEMBL615552,530
,80622,N,1,,,,15899,,Cytotoxicity in 3Y1 cells.,1,Rattus norvegicus,Expert,,1118.0,,10116.0,3Y1 cell line,,F,BAO_0000219,CHEMBL615553,531
,80622,N,1,,,,15899,,Cytostatic effect in 3Y1 cells.,1,Rattus norvegicus,Expert,,1118.0,,10116.0,3Y1 cell line,,F,BAO_0000219,CHEMBL615554,532
,80622,N,1,,,,15899,,"Mean averaged concentration for total growth inhibition, which signifies cytostatic effect",1,Rattus norvegicus,Intermediate,,1118.0,,10116.0,3Y1 cell line,,F,BAO_0000219,CHEMBL615555,533
,80622,N,1,,,,17038,,Concentration to inhibit growth of normal rat fibroblast cells (3Y1-B cells) after 72 h exposure,1,Rattus norvegicus,Expert,,1118.0,,10116.0,3Y1 cell line,,F,BAO_0000219,CHEMBL615556,534
,22226,U,0,,,,12421,,In vitro inhibitory activity against human adrenal 3-beta hydroxy-delta 5-teroid isomerase,1,,Autocuration,,,,,,,B,BAO_0000019,CHEMBL615557,535
,22226,U,0,,,,12947,,Inhibition of recombinant human adrenal 3-beta-hydroxy-delta-5-steroid dehydrogenase,1,,Autocuration,,,,,,,B,BAO_0000019,CHEMBL615558,536
,22226,U,0,,,,12947,,Inhibition of recombinant rat adrenal 3-beta-hydroxy-delta-5-steroid dehydrogenase,1,,Autocuration,,,,,,,B,BAO_0000019,CHEMBL872066,537
,11607,D,9,,,,4896,,In vitro inhibition against of 4-Hydroxyphenylpyruvate dioxygenase (4-HPPD) from pig liver by the enol borate method,1,Sus scrofa,Expert,,,,9823.0,,,B,BAO_0000019,CHEMBL615559,538
,11607,H,8,,,,6148,,In vitro inhibitory concentration required against 4-hydroxyphenylpyruvate dioxygenase (4-HPPD) taken from pig liver,1,,Autocuration,,,,,,,B,BAO_0000019,CHEMBL615560,539
,11607,H,8,,,,16432,,Inhibition of pig liver 4-Hydroxyphenylpyruvate dioxygenase (4-HPPD) enzyme,1,,Autocuration,,,,,,,B,BAO_0000019,CHEMBL615561,540
,11607,H,8,,,,4978,,Concentration required to achieve 50% inhibition against 4-Hydroxyphenylpyruvate dioxygenase (HPPD) from pig liver,1,,Expert,,,,,,,B,BAO_0000019,CHEMBL857062,541
,11607,H,8,,,,4978,,Concentration required to achieve 50% inhibition against 4-Hydroxyphenylpyruvate dioxygenase (HPPD) from pig liver; (observed value),1,,Expert,,,,,,,B,BAO_0000019,CHEMBL615562,542
,11607,H,8,,,,3723,,In vitro inhibitory activity against HPPD(4-hydroxyphenylpyruvate Dioxygenase) from pig liver using enol borate assay method,1,,Autocuration,,,,,,,B,BAO_0000019,CHEMBL615563,543
,11607,H,8,,,,3518,,Compound was evaluated for complete competitive inhibition of 4-hydroxyphenylpyruvate dioxygenase (HPPD),1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL615564,544
,11607,H,8,,,,4164,,In vitro inhibition of 4-hydroxyphenylpyruvate dioxygenase obtained from purified pig liver by enol-borate method,1,,Autocuration,,,,,,,B,BAO_0000019,CHEMBL615565,545
,11607,H,8,,,,3518,,Inhibitory activity on pig liver 4-hydroxyphenylpyruvate dioxygenase (HPPD) was evaluated,1,,Autocuration,,,,,,,B,BAO_0000019,CHEMBL615566,546
,11607,D,9,,,,4164,,Inhibition of 4-hydroxyphenylpyruvate dioxygenase of purified pig liver by enol-borate method,1,Sus scrofa,Expert,,,,9823.0,,,B,BAO_0000019,CHEMBL615567,547
,11607,H,8,,,,3518,,The inhibitory activity on pig liver 4-hydroxyphenylpyruvate dioxygenase (HPPD) was evaluated.,1,,Autocuration,,,,,,,B,BAO_0000019,CHEMBL615568,548
,11607,H,8,,,,3518,,Compound was evaluated for competitive inhibition of 4-hydroxyphenylpyruvate dioxygenase (HPPD) (complete inhibition was observed at a concentration of 0.5-1.0 mM),1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL615569,549
,11607,H,8,,,,4978,,Concentration required to achieve 50% inhibition against 4-hydroxyphenylpyruvate dioxygenase from pig liver,1,,Autocuration,,,,,,,B,BAO_0000019,CHEMBL615570,550
,11607,H,8,,,,4978,,Concentration required to achieve 50% inhibition against 4-hydroxyphenylpyruvate dioxygenase from pig liver; (observed value),1,,Autocuration,,,,,,,B,BAO_0000019,CHEMBL615571,551
,104733,H,4,,,,6455,,Binding affinity against melatonin (MT1) receptor (pC1),1,,Autocuration,,,,,,,B,BAO_0000224,CHEMBL615572,552
,22226,U,0,,,,2222,,Compound was tested for inhibitory activity against 5-hydroxytryptamine 1 receptor,1,,Autocuration,,,,,,,B,BAO_0000019,CHEMBL615573,553
,22226,U,0,,,,13020,,Inhibition of [3H]- 5-HT binding to 5-hydroxytryptamine 1 receptor at 10e-5 M,1,,Autocuration,,,,,,,B,BAO_0000019,CHEMBL615574,554
,22226,U,0,,,,13021,,Inhibition of [3H]5-HT binding to 5-hydroxytryptamine 1 receptor of central nervous system,1,,Autocuration,,,,,,,B,BAO_0000019,CHEMBL615575,555
,10619,H,8,,,,14532,,Inhibitory activity against 5-hydroxytryptamine 1 receptor using [3H]5-HT as radioligand at 10e-5 M concentration,1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL615576,556
,10619,H,8,,,,14118,,Binding affinity against 5-hydroxytryptamine 1 receptor using [3H]5-HT as radioligand,1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL615577,557
Hippocampus,51,H,8,,,,11884,,Binding affinity at 5-hydroxytryptamine 1A receptor in bovine hippocampal preparation using [3H]8-OH-DPAT,1,,Autocuration,,,,,,10000000.0,B,BAO_0000221,CHEMBL615578,558
,51,H,8,,,,13969,,Binding affinity against 5-hydroxytryptamine 1A receptor was measured using [3H]8-OH-DPAT as radioligand,1,,Expert,,,,,,,B,BAO_0000357,CHEMBL615579,559
,51,H,8,,,,13392,,Binding affinity for 5-hydroxytryptamine 1A receptor,1,,Expert,,,,,,,B,BAO_0000357,CHEMBL615580,560
,51,H,8,,,,14430,,Affinity towards 5-hydroxytryptamine 1A receptor in membranes from bovine hippocampus using [3H]OH-DPAT,1,,Expert,,,,,,,B,BAO_0000019,CHEMBL615581,561
Hippocampus,51,H,8,,,,12248,,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in bovine hippocampus,1,,Autocuration,,,,,,10000000.0,B,BAO_0000221,CHEMBL615582,562
Hippocampus,51,H,8,,,,12249,,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in bovine hippocampus,1,,Autocuration,,,,,,10000000.0,B,BAO_0000221,CHEMBL615583,563
Hippocampus,51,H,8,,,,9995,,In vitro inhibition of [3H]5-HT (2 nM) binding to 5-HT1A receptor from bovine hippocampus,1,,Autocuration,,,,,,10000000.0,B,BAO_0000221,CHEMBL615584,564
Hippocampus,51,H,8,,,,9995,,In vitro inhibition of [3H]5-HT (2 nM) binding to 5-hydroxytryptamine 1A receptor from bovine hippocampus,1,,Autocuration,,,,,,10000000.0,B,BAO_0000221,CHEMBL833691,565
Hippocampus,51,H,8,,,,9995,,In vitro inhibition of azido-[125I]-IPAPP (0.25 nM) binding to 5-HT1A receptor from bovine hippocampus,1,,Autocuration,,,,,,10000000.0,B,BAO_0000221,CHEMBL615585,566
Hippocampus,51,H,8,,,,9995,,In vitro inhibition of [125I]IPAPP (0.25 nM) binding to 5-HT1A receptor from bovine hippocampus,1,,Autocuration,,,,,,10000000.0,B,BAO_0000221,CHEMBL615586,567
Hippocampus,51,H,8,,,,9995,,In vitro inhibition of [125I]IPAPP (2.5 nM) binding to 5-hydroxytryptamine 1A receptor from bovine hippocampus,1,,Autocuration,,,,,,10000000.0,B,BAO_0000221,CHEMBL884524,568
Hippocampus,51,H,8,,,,12249,,Inhibitory concentration against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in bovine hippocampus,1,,Autocuration,,,,,,10000000.0,B,BAO_0000221,CHEMBL615587,569
Hippocampus,51,H,8,,,,11799,,"Compound was tested for binding affinity against 5-hydroxytryptamine 1A receptor from bovine hippocampus, used [3H]8-OH-DPAT as radioligand",1,,Autocuration,,,,,,10000000.0,B,BAO_0000221,CHEMBL615588,570
,10576,D,9,,,Membranes,14331,,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor of rat hippocampal membranes,1,Rattus norvegicus,Expert,,,,10116.0,,,B,BAO_0000249,CHEMBL615589,571
Hippocampus,51,H,8,,,,11884,,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor of bovine hippocampus.,1,Bos taurus,Expert,,,,9913.0,,10000000.0,B,BAO_0000221,CHEMBL615442,572
Hippocampus,51,H,8,,,,14331,,Binding affinity of compound towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT (0.5 nM) ligand in hippocampus + frontal bovine was determined,1,,Autocuration,,,,,,10000000.0,B,BAO_0000221,CHEMBL615443,573
Hippocampus,51,H,8,,,,11701,,Compound was evaluated for its ability to displace [3H]DPAT from 5-HT1A receptor in homogenates of bovine hippocampus,1,,Autocuration,,,,,,10000000.0,B,BAO_0000221,CHEMBL615444,574
Hippocampus,51,H,8,,,,11701,,Ability to displace [3H]-DPAT from 5-hydroxytryptamine 1A receptor in homogenates of bovine hippocampus.,1,,Expert,,,,,,10000000.0,B,BAO_0000221,CHEMBL615445,575
Hippocampus,51,H,8,,,,12248,,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor in bovine hippocampus,1,,Autocuration,,,,,,10000000.0,B,BAO_0000221,CHEMBL615446,576
,51,H,8,,,,12248,,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in CHO cells,1,,Autocuration,,449.0,,,CHO,,B,BAO_0000219,CHEMBL615447,577
Hippocampus,51,H,8,,,,12248,,Binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in bovine hippocampus,1,,Expert,,,,,,10000000.0,B,BAO_0000221,CHEMBL615448,578
Hippocampus,51,H,8,,,,12249,,Binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in bovine hippocampus,1,,Expert,,,,,,10000000.0,B,BAO_0000221,CHEMBL615449,579
,51,H,8,,,,12248,,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in cloned CHO cells,1,,Autocuration,,449.0,,,CHO,,B,BAO_0000219,CHEMBL615450,580
Hippocampus,51,H,8,,,,11799,,"Binding affinity against 5-hydroxytryptamine 1A receptor from bovine hippocampus, used [3H]8-OH-DPAT as radioligand",1,,Expert,,,,,,10000000.0,B,BAO_0000221,CHEMBL615451,581
,51,H,8,,,,634,,Compound was tested for its binding affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT radioligand,1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL615452,582
Hippocampus,51,H,8,,,,9995,,In vitro inhibition of [3H]5-HT (2 nM) binding to 5-HT1A receptor from bovine hippocampus,1,,Autocuration,,,,,,10000000.0,B,BAO_0000221,CHEMBL615453,583
Hippocampus,51,H,8,,,,9995,,In vitro inhibition of [3H]5-HT (2 nM) binding to 5-hydroxytryptamine 1A receptor from bovine hippocampus,1,,Autocuration,,,,,,10000000.0,B,BAO_0000221,CHEMBL615454,584
Hippocampus,51,H,8,,,,9995,,In vitro inhibition of [3H]DPAT (1 nM) binding to 5-HT1A receptor from bovine hippocampus,1,,Autocuration,,,,,,10000000.0,B,BAO_0000221,CHEMBL615455,585
Hippocampus,51,H,8,,,,9995,,In vitro inhibition of [3H]DPAT (1 nM) binding to 5-hydroxytryptamine 1A receptor from bovine hippocampus,1,,Autocuration,,,,,,10000000.0,B,BAO_0000221,CHEMBL615456,586
Hippocampus,51,H,8,,,,9995,,In vitro inhibition of [3H]DPAT (1 nM) binding to 5-HT1A receptor from bovine hippocampus,1,,Autocuration,,,,,,10000000.0,B,BAO_0000221,CHEMBL615457,587
Hippocampus,51,H,8,,,,12210,,In vivo binding affinity towards [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in bovine hippocampus.,1,,Expert,,,,,,10000000.0,B,BAO_0000218,CHEMBL615458,588
Hippocampus,51,H,8,,,,13311,,Tested for activity against 5-hydroxytryptamine 1A receptor from bovine hippocampus,1,,Expert,,,,,,10000000.0,B,BAO_0000221,CHEMBL615459,589
,51,D,9,,,,2331,,"Tested in vitro for the inhibition of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor, expressed in cloned CHO cells.",1,Homo sapiens,Expert,,449.0,,9606.0,CHO,,B,BAO_0000219,CHEMBL615460,590
,51,H,8,,,,1375,,Compound was tested for the inhibition of forskolin-stimulated adenylate cyclase at 5-hydroxytryptamine 1A receptor in guinea pig,1,Cavia porcellus,Autocuration,,,,10141.0,,,F,BAO_0000019,CHEMBL615461,591
,51,H,8,,,,1375,,Compound was tested for the inhibition of forskolin-stimulated adenylate cyclase at 5-hydroxytryptamine 1A receptor in guinea pig; NT means not tested,1,Cavia porcellus,Autocuration,,,,10141.0,,,F,BAO_0000019,CHEMBL615462,592
Hippocampus,51,H,8,,,,11574,,Effect on forskolin stimulated adenylate cyclase activity at 5-hydroxytryptamine 1A receptor of guinea pig hippocampus.,1,Cavia porcellus,Autocuration,,,,10141.0,,10000000.0,F,BAO_0000221,CHEMBL615463,593
Ileum,51,H,8,,,,12867,,Ability to antagonize Acetylcholine induced contractile responses in Guinea pig ileum for 5-HT1A receptor.,1,Cavia porcellus,Autocuration,,,,10141.0,,2116.0,B,BAO_0000221,CHEMBL615464,594
Ileum,51,H,8,,,,12867,,Ability to antagonize Acetylcholine induced contractile responses in Guinea pig ileum for 5-HT1A receptor. Inactive at dose level of 1.0 uM,1,Cavia porcellus,Autocuration,,,,10141.0,,2116.0,B,BAO_0000221,CHEMBL615465,595
Ileum,51,H,8,,,,12867,,Ability to antagonize electrical induced contractile responses in Guinea pig ileum for 5-HT1A receptor.,1,Cavia porcellus,Autocuration,,,,10141.0,,2116.0,B,BAO_0000221,CHEMBL615466,596
Ileum,51,H,8,,,,12867,,Ability to antagonize electrical induced contractile responses in Guinea pig ileum for 5-HT1A receptor. Inactive at dose level of 1.0 uM,1,Cavia porcellus,Autocuration,,,,10141.0,,2116.0,B,BAO_0000221,CHEMBL615467,597
Ileum,51,H,8,,,,12867,,Ability to antagonize electrical induced contractile responses in Guinea pig ileum for 5-HT1A receptor. Inactive at dose level of 1.0 uM,1,Cavia porcellus,Autocuration,,,,10141.0,,2116.0,B,BAO_0000221,CHEMBL615468,598
Ileum,51,H,8,,,,12867,,Ability to antagonize electrical induced contractile responses in Guinea pig ileum for 5-HT1A receptor; Inactive at dose level of 1.0 uM,1,Cavia porcellus,Autocuration,,,,10141.0,,2116.0,B,BAO_0000221,CHEMBL615469,599
,51,H,8,,,,11574,,Binding affinity against 5-hydroxytryptamine 1A receptor,1,Cavia porcellus,Autocuration,,,,10141.0,,,B,BAO_0000357,CHEMBL615470,600
,51,H,8,,,,13114,,Compound is evaluated for in vitro receptor binding affinity against 5-hydroxytryptamine 1A receptor,1,Cavia porcellus,Autocuration,,,,10141.0,,,B,BAO_0000357,CHEMBL615471,601
,51,H,8,,,,13181,,Binding affinity was determined against 5-hydroxytryptamine 1A receptor,1,Cavia porcellus,Autocuration,,,,10141.0,,,B,BAO_0000357,CHEMBL615472,602
Hippocampus,106,H,8,,,,10639,,Inhibition of Forskolin-stimulated adenylate cyclase activity against 5-hydroxytryptamine 1A receptor of guinea pig hippocampus,1,Cavia porcellus,Autocuration,,,,10141.0,,10000000.0,B,BAO_0000221,CHEMBL883242,603
Hippocampus,106,H,8,,,,10639,,Inhibition of Forskolin-stimulated adenylate cyclase activity against 5-hydroxytryptamine 1A receptor of guinea pig hippocampus,1,Cavia porcellus,Autocuration,,,,10141.0,,10000000.0,F,BAO_0000221,CHEMBL615473,604
,11863,H,8,,,,11883,,In vitro binding affinity against 5-hydroxytryptamine 1A receptor using [3H]-8-OH-DPAT as radioligand in CHO cells (sc),1,Cricetulus griseus,Autocuration,,449.0,,10029.0,CHO,,B,BAO_0000218,CHEMBL615474,605
,51,H,8,,,,17785,,Fraction involved in salt bridge interactions with Asp3:11 part of the 5-hydroxytryptamine 1A receptor,1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL615475,606
,51,H,8,,,,1558,,Compound was tested for its ability to inhibit forskolin-stimulated activity of adenylate cyclase coupled to human 5-HT 1A receptor in HeLa cells; value ranges from 85-370,1,,Autocuration,,308.0,,,HeLa,,F,BAO_0000219,CHEMBL615476,607
,51,H,8,,,,1558,,Compound was tested for its ability to inhibit forskolin-stimulated activity of adenylate cyclase coupled to human 5-hydroxytryptamine 1A receptor in HeLa cells; value ranges from 95-320,1,,Autocuration,,308.0,,,HeLa,,F,BAO_0000219,CHEMBL615477,608
,51,H,8,,,,15740,,EC50 for inhibition of 50 uM forskolin-stimulated cAMP accumulation against 5-hydroxytryptamine 1A receptor,1,,Autocuration,,,,,,,F,BAO_0000019,CHEMBL615478,609
,51,H,8,,,,17624,,Effective concentration against binding of radioligand [35S]GTP-gamma-S in CHO cells expressing human 5-hydroxytryptamine 1A receptor,1,,Autocuration,,449.0,,,CHO,,F,BAO_0000219,CHEMBL615160,610
,51,H,8,,,,17624,,Effective concentration against binding of radioligand [35S]GTP-gamma-S in CHO cells expressing human 5-hydroxytryptamine 1A receptor,1,,Expert,,449.0,,,CHO,,F,BAO_0000219,CHEMBL615161,611
,51,H,8,,,,17624,,Effective concentration against binding of radioligand [35S]GTP-gamma-S in CHO cells expressing human 5-hydroxytryptamine 1A receptor; nd=Not determined,1,,Autocuration,,449.0,,,CHO,,F,BAO_0000219,CHEMBL615162,612
,51,H,8,,,,17624,,Effective concentration against binding of radioligand [35S]GTP-gamma-S in CHO cells expressing human 5-hydroxytryptamine 1A receptor; nd=not determined,1,,Autocuration,,449.0,,,CHO,,F,BAO_0000219,CHEMBL615163,613
,51,H,8,,,,17624,,Effective concentration against human 5-hydroxytryptamine 1A receptor using cAMP as radioligand in CHO cells,1,,Expert,,449.0,,,CHO,,B,BAO_0000219,CHEMBL615164,614
,51,H,8,,,,17624,,Effective concentration against human 5-hydroxytryptamine 1A receptor using cAMP as radioligand in CHO cells,1,,Expert,,449.0,,,CHO,,B,BAO_0000219,CHEMBL615165,615
,51,H,8,,,,17624,,Effective concentration against human 5-hydroxytryptamine 1A receptor using cAMP as radioligand in CHO cells; nd=not determined,1,,Autocuration,,449.0,,,CHO,,B,BAO_0000219,CHEMBL615166,616
,51,H,8,,,,14256,,In vitro potency at human 5-hydroxytryptamine 1A receptor in inhibiting forskolin-stimulated accumulation of intracellular cAMP,1,,Autocuration,,,,,,,F,BAO_0000219,CHEMBL615167,617
,51,D,9,,,,3445,,Stimulation of [35S]- GIPyS binding to cloned human 5-hydroxytryptamine 1A receptor stably expressed in HeLa cells,1,Homo sapiens,Expert,,308.0,,9606.0,HeLa,,B,BAO_0000219,CHEMBL615168,618
,51,D,9,,,,3445,,Stimulation of [35S]- GIPyS binding to cloned human 5-hydroxytryptamine 1A receptor stably expressed in HeLa cells; Inverse,1,Homo sapiens,Expert,,308.0,,9606.0,HeLa,,B,BAO_0000219,CHEMBL615169,619
,51,D,9,,,,17200,,Tested for functional response on CHO cells expressing cloned human 5-hydroxytryptamine 1A receptor,1,Homo sapiens,Expert,,449.0,,9606.0,CHO,,B,BAO_0000219,CHEMBL615170,620
,51,D,9,,,,17200,,Tested for functional response on CHO cells expressing cloned human 5-hydroxytryptamine 1A receptor; Not determined,1,Homo sapiens,Expert,,449.0,,9606.0,CHO,,B,BAO_0000219,CHEMBL615171,621
,51,H,8,,,,15180,,Eudisimic ratio(ER) is the antilog of the defference between the pKb and pD2 values against 5-hydroxytryptamine 1A receptor,1,,Autocuration,,,,,,,F,BAO_0000019,CHEMBL615694,622
,51,H,8,,,,15180,,Eudisimic ratio(ER) is the antilog of the difference between the pKb and pD2 values against 5-hydroxytryptamine 1A receptor,1,,Autocuration,,,,,,,F,BAO_0000019,CHEMBL615695,623
,51,H,8,,,,16026,,"Percent of maximum effect on binding of [35S]GTP-gamma-S, to HeLa cell membranes expressing the human 5-hydroxytryptamine 1A receptor",1,,Autocuration,,,,,,,F,BAO_0000019,CHEMBL615696,624
,51,H,8,,,,2759,,Agonistic efficacy was evaluated by adenylyl cyclase assay in CHO cells stably expressing the human 5-HT1A receptor,1,,Autocuration,,449.0,,,CHO,,F,BAO_0000219,CHEMBL615697,625
,51,D,9,,,,2759,,Agonistic efficacy as adenylyl cyclase assay in CHO cells expressing human 5-HT1A receptor (experiment 1),1,Homo sapiens,Expert,,449.0,,9606.0,CHO,,F,BAO_0000219,CHEMBL859410,626
,51,H,8,,,,2759,,Agonistic efficacy was evaluated by adenylyl cyclase assay in CHO cells stably expressing the human 5-HT1A receptor (experiment 2),1,,Autocuration,,449.0,,,CHO,,F,BAO_0000219,CHEMBL615841,627
,51,D,9,,,,2759,,Agonistic efficacy in adenylyl cyclase assay in CHO cells expressing human 5-HT1A receptor (experiment 2),1,Homo sapiens,Expert,,449.0,,9606.0,CHO,,F,BAO_0000219,CHEMBL615842,628
,51,H,8,,,,2759,,Antagonistic efficacy was evaluated by adenylyl cyclase assay in CHO cells stably expressing the human 5-HT1A receptor,1,,Autocuration,,449.0,,,CHO,,F,BAO_0000219,CHEMBL835003,629
,51,H,8,,,,2759,,Antagonistic efficacy was evaluated by adenylyl cyclase assay in CHO cells stably expressing the human 5-HT1A receptor (experiment 1),1,,Autocuration,,449.0,,,CHO,,F,BAO_0000219,CHEMBL615843,630
,51,D,9,,,,2759,,Antagonistic efficacy as adenylyl cyclase assay in CHO cells expressing human 5-HT1A receptor (experiment 1),1,Homo sapiens,Expert,,449.0,,9606.0,CHO,,F,BAO_0000219,CHEMBL615979,631
,51,H,8,,,,2759,,Antagonistic efficacy was evaluated by adenylyl cyclase assay in CHO cells stably expressing the human 5-HT1A receptor (experiment 2),1,,Autocuration,,449.0,,,CHO,,F,BAO_0000219,CHEMBL615980,632
,51,D,9,,,,2759,,Antagonistic efficacy as adenylyl cyclase assay in CHO cells expressing human 5-HT1A receptor (experiment 2),1,Homo sapiens,Expert,,449.0,,9606.0,CHO,,F,BAO_0000219,CHEMBL615981,633
,51,D,9,,,,3445,,Percent efficacy against cloned human 5-hydroxytryptamine 1A receptor normalized to the maximal 5-HT response,1,Homo sapiens,Expert,,,,9606.0,,,F,BAO_0000019,CHEMBL615982,634
,51,D,9,,,,5272,,"Agonist activity at the 5-hydroxytryptamine 1A receptor was determined in vitro using a [35S]GTP-gamma-S,",1,Homo sapiens,Expert,,,,9606.0,,,F,BAO_0000019,CHEMBL615983,635
,51,D,9,,,,5272,,"Agonist activity at the 5-hydroxytryptamine 1A receptor in vitro using a [35S]GTP-gamma-S, No data",1,Homo sapiens,Expert,,,,9606.0,,,F,BAO_0000019,CHEMBL615984,636
,51,D,9,,,,5272,,"Agonist activity at the 5-hydroxytryptamine 1A receptor determined in vitro using a [35S]GTP-gamma-S,",1,Homo sapiens,Expert,,,,9606.0,,,F,BAO_0000019,CHEMBL615985,637
,51,H,8,,,,17624,,Agonistic effect against 5-HT1A receptor using cAMP as radioligand relative to 5-HT in inhibiting forskolin-stimulated adenylate cyclase activity in CHO cells,1,,Autocuration,,449.0,,,CHO,,F,BAO_0000219,CHEMBL615986,638
,51,H,8,,,,17624,,Agonistic effect against 5-hydroxytryptamine 1A receptor using cAMP as radioligand relative to 5-HT in inhibiting forskolin-stimulated adenylate cyclase activity in CHO cells,1,,Autocuration,,449.0,,,CHO,,F,BAO_0000219,CHEMBL615987,639
,51,H,8,,,,17624,,Agonistic effect against 5-hydroxytryptamine 1A receptor using cAMP as radioligand relative to 5-HT in inhibiting forskolin-stimulated adenylate cyclase activity in CHO cells; nd=Not determined,1,,Autocuration,,449.0,,,CHO,,F,BAO_0000219,CHEMBL615988,640
,51,H,8,,,,17624,,Agonistic effect against 5-hydroxytryptamine 1A receptor using cAMP as radioligand relative to 5-HT in inhibiting forskolin-stimulated adenylate cyclase activity in CHO cells,1,,Expert,,449.0,,,CHO,,F,BAO_0000219,CHEMBL615989,641
,51,H,8,,,,17624,,Agonistic effect against 5-hydroxytryptamine 1A receptor using cAMP as radioligand relative to 5-HT in inhibiting forskolin-stimulated adenylate cyclase activity in CHO cells; nd=Not determined,1,,Autocuration,,449.0,,,CHO,,F,BAO_0000219,CHEMBL615990,642
,51,H,8,,,,17624,,Agonistic effect against 5-hydroxytryptamine 1A receptor using cAMP as radioligand relative to 5-HT in inhibiting forskolin-stimulated adenylate cyclase activity in CHO cells; nd=not determined,1,,Autocuration,,449.0,,,CHO,,F,BAO_0000219,CHEMBL615991,643
,51,H,8,,,,17624,,Agonistic effect against 5-HT 1A receptor using [35S]GTP-gamma-S as radioligand in CHO cells relative to 5-HT,1,,Autocuration,,449.0,,,CHO,,F,BAO_0000219,CHEMBL615992,644
,51,H,8,,,,17624,,Agonistic effect against 5-HT 1A receptor using [35S]GTP-gamma-S as radioligand in CHO cells relative to 5-HT; nd=Not determined,1,,Autocuration,,449.0,,,CHO,,F,BAO_0000219,CHEMBL615993,645
,51,H,8,,,,17624,,Agonistic effect against 5-hydroxytryptamine 1A receptor using [35S]GTP-gamma-S as radioligand in CHO cells relative to 5-HT,1,,Expert,,449.0,,,CHO,,F,BAO_0000219,CHEMBL615994,646
,51,H,8,,,,17624,,Agonistic effect against 5-hydroxytryptamine 1A receptor using [35S]GTP-gamma-S as radioligand in CHO cells relative to 5-HT; nd=not determined,1,,Autocuration,,449.0,,,CHO,,F,BAO_0000219,CHEMBL615995,647
,51,H,8,,,,17624,,Agonistic effect against 5-hydroxytryptamine 1A receptor using [35S]GTP-gamma-S as radioligand in CHO cells relative to 5-HT,1,,Autocuration,,449.0,,,CHO,,F,BAO_0000219,CHEMBL615996,648
,51,H,8,,,,17624,,Agonistic effect against 5-hydroxytryptamine 1A receptor using [35]GTPgammaS as radioligand in CHO cells relative to 5-HT; nd=Not determined,1,,Autocuration,,449.0,,,CHO,,F,BAO_0000219,CHEMBL615997,649
,51,H,8,,,,6563,,"Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by [35S]GTP-gamma-S, stimulated cAMP assay",1,,Autocuration,,,,,,,F,BAO_0000019,CHEMBL615998,650
,51,H,8,,,,6563,,"Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by [35S]GTP-gamma-S, stimulated cAMP assay",1,,Autocuration,,,,,,,F,BAO_0000019,CHEMBL615999,651
,51,H,8,,,,6563,,Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by forskolin stimulated cAMP assay,1,,Autocuration,,,,,,,F,BAO_0000019,CHEMBL616000,652
,51,H,8,,,,17296,,Binding affinity against human 5-hydroxytryptamine 1A receptors HEK 293 cell membranes using [35S]GTP gamma-S,1,,Autocuration,,722.0,,,HEK293,,F,BAO_0000219,CHEMBL616001,653
,51,D,9,,,,6876,,"Evaluated for stimulation at 1 uM concentration expressed as percent of the maximal [35S]GTP-gamma-S, binding induced by 5-hydroxytryptamine",1,Homo sapiens,Expert,,,,9606.0,,,F,BAO_0000019,CHEMBL616002,654
,51,H,8,,,,6876,,"Stimulation of percent maximal [35S]GTP-gamma-S, binding induced by 5-hydroxytryptamine at 1 uM; nd = not determined",1,,Expert,,,,,,,F,BAO_0000019,CHEMBL616003,655
,51,D,9,,,,5272,,In vitro agonist activity at the 5-hydroxytryptamine 1A receptor,1,Homo sapiens,Expert,,,,9606.0,,,F,BAO_0000019,CHEMBL616004,656
,51,D,9,,,,5272,,In vitro agonist activity at the 5-hydroxytryptamine 1A receptor; No data,1,Homo sapiens,Expert,,,,9606.0,,,F,BAO_0000019,CHEMBL616005,657
,51,H,8,,,,5548,,"Maximal response as a result of 5-HT1A receptor-mediated stimulation of [35S]GTP-gamma-S, binding; Not determined",1,,Autocuration,,,,,,,F,BAO_0000019,CHEMBL616006,658
,51,H,8,,,,5548,,"Maximal response as a result of 5-hydroxytryptamine 1A receptor-mediated stimulation of [35S]GTP-gamma-S, binding",1,,Expert,,,,,,,F,BAO_0000019,CHEMBL616007,659
,51,H,8,,,,5548,,"Maximal response as a result of 5-hydroxytryptamine 1A receptor-mediated stimulation of [35S]GTP-gamma-S, binding; Not determined",1,,Autocuration,,,,,,,F,BAO_0000019,CHEMBL616008,660
,51,H,8,,,,5548,,"Maximal response as a result of 5-hydroxytryptamine 1A receptor-mediated stimulation of [35S]GTP-gamma-S, binding; Not determined",1,,Autocuration,,,,,,,F,BAO_0000019,CHEMBL616009,661
,51,H,8,,,,5929,,"Maximal stimulation of expressed human 5-hydroxytryptamine 1A receptor assayed by [35S]GTP-gamma-S, binding",1,,Expert,,,,,,,F,BAO_0000019,CHEMBL616010,662
,51,D,9,,,,5929,,"Maximal response towards 5-hydroxytryptamine 1A receptor in human using [35S]GTP-gamma-S, as radioligand; ND means not determined",1,Homo sapiens,Expert,,,,9606.0,,,F,BAO_0000019,CHEMBL616011,663
,51,D,9,,,,5929,,"Maximal response towards 5-hydroxytryptamine 1A receptor in human using [35S]GTP-gamma-S, as radioligand; ND=Not determined",1,Homo sapiens,Expert,,,,9606.0,,,F,BAO_0000019,CHEMBL615740,664
,51,H,8,,,,16245,,"Maximal stimulation was expressed as percentage of the maximal 5-HT response in the [35S]GTP-gamma-S, binding assay on 5-hydroxytryptamine 1A receptor",1,,Autocuration,,,,,,,F,BAO_0000019,CHEMBL615741,665
,51,H,8,,,,5640,,"Inhibition of 5-HT induced [35S]GTP-gamma-S, binding at human cloned 5-HT 1A receptors.",1,,Expert,,,,,,,F,BAO_0000019,CHEMBL615742,666
,51,H,8,,,,5640,,"5-hydroxytryptamine 1A receptor antagonism was evaluated by the ability to inhibit [35S]GTP-gamma-S, binding that was induced by 5-HT; Emin (%): not determined",1,,Autocuration,,,,,,,F,BAO_0000019,CHEMBL615743,667
,51,H,8,,,,14509,,Antagonist activity was measured against CHO cells expressing the human 5-hydroxytryptamine 1A receptor in a forskolin stimulated adenylate cyclase (FSC) assay,1,,Autocuration,,449.0,,,CHO,,F,BAO_0000219,CHEMBL615744,668
,51,H,8,,,,14509,,Antagonist activity against CHO cells expressing the human 5-hydroxytryptamine 1A receptor in a forskolin stimulated adenylate cyclase (FSC) assay.,1,,Expert,,449.0,,,CHO,,F,BAO_0000219,CHEMBL615745,669
,51,H,8,,,,15331,,Affinity of compound towards 5-hydroxytryptamine 1A receptor was evaluated using radioligand binding technique,1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL615746,670
,51,H,8,,,,15331,,Affinity of compound towards 5-hydroxytryptamine 1A receptor was evaluated using radioligand binding technique,1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL615747,671
,51,H,8,,,,6563,,"Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by [35S]GTP-gamma-S, stimulated cAMP assay",1,,Autocuration,,,,,,,F,BAO_0000019,CHEMBL615748,672
,51,H,8,,,,6563,,"Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by [35S]GTP-gamma-S, stimulated cAMP assay; NA indicates not available",1,,Autocuration,,,,,,,F,BAO_0000019,CHEMBL615749,673
,51,H,8,,,,6563,,Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by forskolin stimulated cAMP assay,1,,Autocuration,,,,,,,F,BAO_0000019,CHEMBL615750,674
,51,D,9,,,,6563,,Forskolin stimulated cAMP assessment of agonist activity for 5-hydroxytryptamine 1A receptor,1,Homo sapiens,Expert,,,,9606.0,,,F,BAO_0000019,CHEMBL616259,675
,51,H,8,,,,6563,,"Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by [35S]GTP-gamma-S, stimulated cAMP assay",1,,Autocuration,,,,,,,F,BAO_0000019,CHEMBL616260,676
,51,D,9,,,,5272,,Antagonism of 5-hydroxytryptamine 1A receptor determined in vitro,1,Homo sapiens,Expert,,,,9606.0,,,F,BAO_0000019,CHEMBL616261,677
,51,D,9,,,,5272,,"Antagonism of 5-hydroxytryptamine 1A receptor was determined in vitro using a [35S]GTP-gamma-S,",1,Homo sapiens,Expert,,,,9606.0,,,F,BAO_0000019,CHEMBL616262,678
,51,D,9,,,,5272,,"Antagonism at the 5-hydroxytryptamine 1A receptor determined in vitro using a [35S]GTP-gamma-S, No data",1,Homo sapiens,Expert,,,,9606.0,,,F,BAO_0000019,CHEMBL616263,679
,51,D,9,,,,5272,,Antagonism at the 5-hydroxytryptamine 1A receptor was determined in vitro; No data,1,Homo sapiens,Expert,,,,9606.0,,,F,BAO_0000019,CHEMBL616264,680
,51,D,9,,,,5272,,Antagonism at the 5-hydroxytryptamine 1A receptor in vitro,1,Homo sapiens,Expert,,,,9606.0,,,F,BAO_0000019,CHEMBL616265,681
,51,D,9,,,,5272,,"Antagonism at the 5-hydroxytryptamine 1A receptor was determined in vitro using a [35S]GTP-gamma-S,",1,Homo sapiens,Expert,,,,9606.0,,,F,BAO_0000019,CHEMBL616266,682
,51,D,9,,,,5272,,"Antagonism at the 5-hydroxytryptamine 1A receptor determined in vitro using a [35S]GTP-gamma-S, No data",1,Homo sapiens,Expert,,,,9606.0,,,F,BAO_0000019,CHEMBL616267,683
,51,D,9,,,,5272,,Antagonism at the 5-hydroxytryptamine 1A receptor determined in vitro; No data,1,Homo sapiens,Expert,,,,9606.0,,,F,BAO_0000019,CHEMBL616268,684
,51,D,9,,,,16146,,Inhibition of human 5-hydroxytryptamine 1A receptor,1,Homo sapiens,Expert,,,,9606.0,,,B,BAO_0000357,CHEMBL616269,685
,51,H,8,,,,17624,,Binding affinity against 5-hydroxytryptamine 1A receptor using cAMP as radioligand in CHO cells,1,,Autocuration,,449.0,,,CHO,,B,BAO_0000219,CHEMBL884528,686
,105,D,9,,,,13706,,Displacement of [3H]-5-HT from human 5-hydroxytryptamine 1D receptor alpha expressed in HEK 293 cells,1,,Expert,,722.0,,,HEK293,,B,BAO_0000219,CHEMBL616270,687
,51,H,8,,,,15250,,Compound was tested for the displacement of [3H]5-HT binding to cloned 5-hydroxytryptamine 1A receptor stably expressed in CHO cells,1,,Autocuration,,449.0,,,CHO,,B,BAO_0000219,CHEMBL616271,688
,51,H,8,,,,17624,,Effective concentration against binding of radioligand [35S]GTP-gamma-S in CHO cells expressing 5-hydroxytryptamine 1A receptor,1,,Autocuration,,449.0,,,CHO,,F,BAO_0000219,CHEMBL616272,689
,51,H,8,,,,6861,,In vitro binding affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT in human CYP3A4 assay,1,,Expert,,,,,,,B,BAO_0000357,CHEMBL616273,690
,51,D,9,,,,17200,,In vitro inhibitory concentration required against [3H]8-OH-DPAT binding to cloned human 5-hydroxytryptamine 1A receptor,1,Homo sapiens,Expert,,,,9606.0,,,B,BAO_0000357,CHEMBL616274,691
,51,H,8,,,,17624,,Inhibition concentration against 5-HT 1A receptor using cAMP as radioligand in CHO cells,1,,Autocuration,,449.0,,,CHO,,B,BAO_0000219,CHEMBL616275,692
,51,H,8,,,,17624,,Inhibition concentration against 5-hydroxytryptamine 1A receptor using cAMP as radioligand in CHO cells,1,,Autocuration,,449.0,,,CHO,,B,BAO_0000219,CHEMBL616276,693
,22226,U,0,In vivo,,,12058,,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain hemispheral area by po administration,1,Rattus norvegicus,Autocuration,,,,10116.0,,,F,BAO_0000218,CHEMBL616277,694
,22226,U,0,In vivo,,,12058,,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain hemispheral area by po administration; Inactive,1,Rattus norvegicus,Autocuration,,,,10116.0,,,F,BAO_0000218,CHEMBL616278,695
,22226,U,0,In vivo,,,12058,,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain hemispheral area by sc administration,1,Rattus norvegicus,Autocuration,,,,10116.0,,,F,BAO_0000218,CHEMBL616279,696
,22226,U,0,In vivo,,,12058,,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain hemispheral area by sc administration; Inactive,1,Rattus norvegicus,Autocuration,,,,10116.0,,,F,BAO_0000218,CHEMBL616280,697
,22226,U,0,In vivo,,,12058,,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain hemispheral area by sc administration; Partial response at the highest dose tested,1,Rattus norvegicus,Autocuration,,,,10116.0,,,F,BAO_0000218,CHEMBL616281,698
,22226,U,0,In vivo,,,12058,,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain hemispheral area by sc administration; Inactive,1,Rattus norvegicus,Autocuration,,,,10116.0,,,F,BAO_0000218,CHEMBL616282,699
,22226,U,0,In vivo,,,12058,,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain limbic area by po administration,1,Rattus norvegicus,Autocuration,,,,10116.0,,,F,BAO_0000218,CHEMBL616283,700
,22226,U,0,In vivo,,,12058,,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain limbic area by po administration; Inactive,1,Rattus norvegicus,Autocuration,,,,10116.0,,,F,BAO_0000218,CHEMBL616284,701
,22226,U,0,In vivo,,,12058,,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain limbic area by sc administration,1,Rattus norvegicus,Autocuration,,,,10116.0,,,F,BAO_0000218,CHEMBL616285,702
,22226,U,0,In vivo,,,12058,,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain limbic area by sc administration; Inactive,1,Rattus norvegicus,Autocuration,,,,10116.0,,,F,BAO_0000218,CHEMBL616286,703
,22226,U,0,In vivo,,,12058,,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain limbic area by sc administration; partial response at the highest dose tested,1,Rattus norvegicus,Autocuration,,,,10116.0,,,F,BAO_0000218,CHEMBL616287,704
,22226,U,0,In vivo,,,12058,,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain striatal area by po administration,1,Rattus norvegicus,Autocuration,,,,10116.0,,,F,BAO_0000218,CHEMBL616288,705
,22226,U,0,In vivo,,,12058,,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain striatal area by po administration; Inactive,1,Rattus norvegicus,Autocuration,,,,10116.0,,,F,BAO_0000218,CHEMBL616289,706
,22226,U,0,In vivo,,,12058,,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain striatal area by po administration; Partial response at the highest dose tested,1,Rattus norvegicus,Autocuration,,,,10116.0,,,F,BAO_0000218,CHEMBL615610,707
,22226,U,0,In vivo,,,12058,,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain striatal area by sc administration,1,Rattus norvegicus,Autocuration,,,,10116.0,,,F,BAO_0000218,CHEMBL615611,708
,22226,U,0,In vivo,,,12058,,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain striatal area by sc administration; Inactive,1,Rattus norvegicus,Autocuration,,,,10116.0,,,F,BAO_0000218,CHEMBL615612,709
,22226,U,0,In vivo,,,12058,,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain striatal area by sc administration; Partial response at the highest dose tested,1,Rattus norvegicus,Autocuration,,,,10116.0,,,F,BAO_0000218,CHEMBL615613,710
,22226,U,0,In vivo,,,12058,,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain striatal area by sc administration; partial response at the highest dose tested,1,Rattus norvegicus,Autocuration,,,,10116.0,,,F,BAO_0000218,CHEMBL615614,711
,22226,U,0,In vivo,,,12058,,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain hemispheral area by po administration,1,Rattus norvegicus,Autocuration,,,,10116.0,,,F,BAO_0000218,CHEMBL615615,712
,105093,H,4,,,,11440,,Affinity in displacing [125I](R)-DOI from rat cortical homogenate 5-HT2 receptor.,1,,Autocuration,,,,,,,B,BAO_0000019,CHEMBL615616,713
Hypothalamus,11923,H,8,,,,6238,,Binding affinity towards 5-HT 7 receptor in rat hypothalamus membranes using [3H]5-CT as radioligand,1,,Autocuration,,,,,,1898.0,B,BAO_0000249,CHEMBL615617,714
,10577,H,8,,,,10046,,Inhibitory activity against 5-HT1B receptor of rat striatal membrane homogenate using [3H]5-HT as the radioligand; nd is No Data,1,,Autocuration,,,,,,,B,BAO_0000019,CHEMBL615618,715
,10577,H,8,,,,10046,,Inhibitory activity against 5-hydroxytryptamine 1B receptor of rat striatal membrane homogenate using [3H]5-HT as the radioligand; nd is No Data.,1,,Autocuration,,,,,,,B,BAO_0000019,CHEMBL615619,716
,10577,H,8,,,,10046,,Inhibitory activity against 5-hydroxytryptamine 1B receptor of rat striatal membrane homogenate using [3H]5-HT as the radioligand.,1,,Expert,,,,,,,B,BAO_0000019,CHEMBL615620,717
,55,H,8,,,,167,,"Inhibitory activity against human whole blood, LTB4 5-lipoxygenase was evaluated",1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL615621,718
,55,H,8,,,,167,,"Inhibitory activity against intact human PMNL, LTB4 5-lipoxygenase was evaluated",1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL615622,719
,12166,H,8,,,,11520,,Compound was evaluated for the inhibition of 5-LO (lipoxygenase),1,,Autocuration,,,,,,,F,BAO_0000019,CHEMBL615623,720
,12166,H,8,,,,11520,,Compound was evaluated for the inhibition of 5-LO (5-lipoxygenase).,1,,Autocuration,,,,,,,F,BAO_0000019,CHEMBL615624,721
,12166,H,8,,,,11520,,Compound was evaluated for the inhibition of 5-LO (5-lipoxygenase).,1,,Autocuration,,,,,,,F,BAO_0000019,CHEMBL615625,722
,12166,H,8,,,,11520,,Compound was evaluated for the inhibition of 5-LO (5-lipoxygenase).,1,,Autocuration,,,,,,,F,BAO_0000019,CHEMBL767045,723
,55,H,8,,,,135,,Inhibition of [14C]arachidonic acid conversion to 5-HETE by broken cell 5-LO isolated from guinea pig PMN,1,Cavia porcellus,Autocuration,,,,10141.0,,,F,BAO_0000019,CHEMBL615626,724
,55,H,8,,,,135,,Inhibition of [14C]arachidonic acid conversion to 5-HETE by broken cell 5-LO isolated from guinea pig PMN; not active at the highest concentration (3 ug/mL) tested; No activity,1,Cavia porcellus,Autocuration,,,,10141.0,,,F,BAO_0000019,CHEMBL615627,725
,55,H,8,,,,11311,,The compound was tested for inhibitory activity against 5-Lipoxygenase in guinea pig polymorphonuclear leukocytes,1,Cavia porcellus,Autocuration,,,,10141.0,,,B,BAO_0000019,CHEMBL615628,726
,55,H,8,,,,10193,,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase using guinea pig supernatant at 10 uM,1,Cavia porcellus,Autocuration,,,,10141.0,,,B,BAO_0000357,CHEMBL615629,727
,55,D,9,,,,12281,,Inhibitory concentration against 5-lipoxygenase from human whole blood,1,Homo sapiens,Expert,,,,9606.0,,,B,BAO_0000357,CHEMBL615630,728
,55,H,8,,,,11311,,The compound was tested for inhibitory activity against 5-Lipoxygenase in human polymorphonuclear leukocytes[PMNS],1,,Autocuration,,,,,,,B,BAO_0000219,CHEMBL615631,729
,17087,H,8,,,,12576,,In vivo inhibition of 5-lipoxygenase (LTC4) in the mouse zymosan peritonitis assay at an oral dose of 30 mg/Kg,1,,Autocuration,,,,,,,F,BAO_0000218,CHEMBL615632,730
,17087,H,8,,,,12281,,Inhibitory concentration against 5-lipoxygenase from mouse macrophage,1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL615633,731
,17087,H,8,,,,12576,,In vivo inhibition of 5-lipoxygenase (LTC4) in the mouse zymosan peritonitis assay at an oral dose of 30 mg/Kg,1,,Autocuration,,,,,,,F,BAO_0000218,CHEMBL615634,732
,55,H,8,,,,11089,,Inhibition of arachidonate 5-lipoxygenase purified from porcine leukocytes.,1,Sus scrofa,Expert,,,,9823.0,,,B,BAO_0000019,CHEMBL615635,733
,12166,H,8,,,,11006,,In vitro inhibition of rat 5-Lipoxygenase,1,,Expert,,,,,,,B,BAO_0000357,CHEMBL615636,734
,12166,D,9,,,,11481,,Inhibitory activity against 5-Lipoxygenase,1,Rattus norvegicus,Expert,,,,10116.0,,,B,BAO_0000357,CHEMBL615637,735
,12166,H,8,,,,10864,,Inhibitory activity against 5-lipoxygenase in rat basophilic leukemia cells,1,,Expert,,702.0,,,RBL-1,,B,BAO_0000219,CHEMBL615638,736
,12166,H,8,,,,3595,,Inhibitory activity against 5-lipoxygenase (5-LO) in intact rat barophilic leukemia cells (RBL-1),1,,Autocuration,,702.0,,,RBL-1,,B,BAO_0000219,CHEMBL615639,737
,12166,H,8,,,,11311,,The compound was tested for inhibitory activity against 5-Lipoxygenase in rat RBL-1,1,,Autocuration,,702.0,,,RBL-1,,B,BAO_0000219,CHEMBL615640,738
,12166,H,8,,,,11311,,The compound was tested for inhibitory activity against 5-Lipoxygenase in rat blood,1,,Autocuration,,,,,,,B,BAO_0000019,CHEMBL615796,739
,12166,H,8,,,,11311,,The compound was tested for inhibitory activity against 5-Lipoxygenase receptor in rat polymorphonuclear leukocytes[PMNS],1,,Autocuration,,,,,,,B,BAO_0000219,CHEMBL615845,740
,12166,H,8,,,,11006,,Compound was evaluated for the inhibition of 5-Lipoxygenase (5-LO) in vitro at 1 uM,1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL615846,741
,12166,H,8,,,,3595,,Inhibitory activity against 5-lipoxygenase (5-LO) using broken rat barophilic leukemia cells (RBL-1)at 10 uM,1,,Autocuration,,702.0,,,RBL-1,,B,BAO_0000219,CHEMBL615847,742
,12166,H,8,,,,11311,,The compound was tested for inhibition of isolated 5-Lipoxygenase,1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL615848,743
,22226,U,0,,,,11481,,Ratio of IC50 against 5-LO and COX,1,Rattus norvegicus,Autocuration,,,,10116.0,,,B,BAO_0000019,CHEMBL615849,744
,12166,H,8,,,,11006,,Compound was evaluated for the inhibition of 5-Lipoxygenase (5-LO) in vitro at 1 uM,1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL615850,745
,12166,H,8,,,,11006,,Compound was evaluated for the inhibition of 5-Lipoxygenase (5-LO) in vitro at 1 uM; range is 20-35%,1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL615851,746
,12166,H,8,,,,11311,,The compound was tested for inhibition against 5-Lipoxygenase in rat polymorphonuclear leukocytes at 10 uM concentration,1,,Autocuration,,,,,,,B,BAO_0000219,CHEMBL615852,747
,12166,H,8,,,,11006,,Compound was evaluated for the inhibition of 5-Lipoxygenase (5-LO) ex vivo,1,,Autocuration,,,,,,,F,BAO_0000019,CHEMBL615853,748
Prostate gland,120,H,8,,,,4288,,Compound was tested for the inhibition of type 2 5-alpha-reductase of human prostates,1,,Autocuration,,,,,,2367.0,B,BAO_0000357,CHEMBL884527,749
,22226,U,0,,,,7587,,Percent inhibition was measured against 5-amino-4-imidazolecarboxamide ribotide transformylase(pigeon liver) enzyme at 10E-4 M inhibitory concentration,1,Columba livia,Autocuration,,,,8932.0,,,B,BAO_0000019,CHEMBL872871,750
,22226,U,0,,,,7587,,Percent inhibition was measured against 5-amino-4-imidazolecarboxamide ribotide transformylase(pigeon liver) enzyme at 10E-5 M inhibitory concentration,1,Columba livia,Autocuration,,,,8932.0,,,B,BAO_0000019,CHEMBL615854,751
,22226,U,0,,,,7587,,Percent inhibition was measured against 5-amino-4-imidazolecarboxamide ribotide transformylase(pigeon liver) enzyme.,1,Columba livia,Autocuration,,,,8932.0,,,B,BAO_0000019,CHEMBL767046,752
,10732,H,8,,,,11249,,Compound was evaluated for the inhibition of 5-aminoimidazole-4-carboxamide ribonucleotide transformylase obtained from human at 100 uM,1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL615855,753
,12198,D,9,,,,8003,,Effect on synaptosomal uptake inhibition of 5-hydroxytryptamine (5-HT); NT = Not Tested,1,Rattus norvegicus,Expert,,,,10116.0,,,F,BAO_0000019,CHEMBL615856,754
,12198,D,9,,,,8003,,Effect on synaptosomal uptake inhibition of 5-hydroxytryptamine (5-HT),1,Rattus norvegicus,Expert,,,,10116.0,,,F,BAO_0000019,CHEMBL615857,755
,12198,D,9,,,,8003,,Effect on synaptosomal uptake inhibition of 5-hydroxytryptamine (5-HT),1,Rattus norvegicus,Expert,,,,10116.0,,,F,BAO_0000019,CHEMBL615858,756
Hippocampus,10576,H,8,,,,12416,,In vitro affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand in hippocampus,1,,Expert,,,,,,10000000.0,B,BAO_0000221,CHEMBL615859,757
,51,H,8,,,,16293,,Binding affinity towards human 5-hydroxytryptamine 1 receptor,1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL615860,758
,22226,U,0,,,,13047,,Intrinsic activity against 5-hydroxytryptamine 1 receptor using rabbit saphenous vein assay.,1,Oryctolagus cuniculus,Autocuration,,,,9986.0,,,B,BAO_0000019,CHEMBL615861,759
,22226,U,0,,,,13047,,Binding affinity against 5-hydroxytryptamine 1 receptor using rabbit saphenous vein assay.,1,Oryctolagus cuniculus,Autocuration,,,,9986.0,,,B,BAO_0000019,CHEMBL615862,760
,22226,U,0,,,,13047,,Binding affinity against 5-hydroxytryptamine 1D receptor using rabbit saphenous vein assay.,1,Oryctolagus cuniculus,Autocuration,,,,9986.0,,,B,BAO_0000019,CHEMBL615863,761
,22226,U,0,,,,13047,,Binding affinity against 5-hydroxytryptamine 4 receptor using rabbit saphenous vein assay.,1,Oryctolagus cuniculus,Autocuration,,,,9986.0,,,B,BAO_0000019,CHEMBL615864,762
Hippocampus,104744,H,4,,,,10085,,Ability to bind at 5-hydroxytryptamine 1 receptor of rat hippocampus by displacing [3H]5-HT,1,,Autocuration,,,,,,10000000.0,B,BAO_0000221,CHEMBL615865,763
Hippocampus,104744,H,4,,,,10085,,Ability to bind at 5-hydroxytryptamine 1 receptor of rat hippocampus by displacing [3H]5-HT,1,,Autocuration,,,,,,10000000.0,B,BAO_0000221,CHEMBL615866,764
Hippocampus,104744,H,4,,,,10085,,Ability to bind at serotonin 5-hydroxytryptamine 1 receptor of rat hippocampus by displacing [3H]5-HT,1,,Autocuration,,,,,,10000000.0,B,BAO_0000221,CHEMBL615867,765
,104744,H,4,,,Membranes,9841,,Ability to inhibit binding of titreated serotonin to the 5-hydroxytryptamine 1 receptor in rat brain frontal cortex membranes,1,,Autocuration,,,,,,,B,BAO_0000249,CHEMBL615868,766
,104744,D,5,,,,8822,,Binding affinity towards 5-hydroxytryptamine 1 receptor in brain cortical membranes of rat,1,Rattus norvegicus,Autocuration,,,,10116.0,,,B,BAO_0000249,CHEMBL615869,767
,104744,D,5,,,,9806,,Binding affinity towards 5-hydroxytryptamine 1 receptor in rat frontal cortex homogenates using [3H]5-HT as a radioligand,1,Rattus norvegicus,Autocuration,,,,10116.0,,,B,BAO_0000019,CHEMBL615870,768
,104744,D,5,,,,9806,,Binding affinity towards 5-hydroxytryptamine 1 receptor using [3H]5-HT as a radioligand from rat frontal cortex homogenates,1,Rattus norvegicus,Autocuration,,,,10116.0,,,B,BAO_0000019,CHEMBL615871,769
,104744,H,4,,,,8868,,Binding affinity towards 5-hydroxytryptamine 1 receptor was measured using radioligand ([3H]5-HT) binding assay,1,,Autocuration,,,,,,,B,BAO_0000224,CHEMBL615872,770
Hippocampus,104744,H,4,,,,9036,,Binding affinity towards hippocampus 5-hydroxytryptamine 1 receptor was measured using radioligand [3H]5-HT,1,,Autocuration,,,,,,10000000.0,B,BAO_0000221,CHEMBL833492,771
Hippocampus,104744,H,4,,,,11374,,Compound was evaluated for the inhibition of [3H]5-HT (concentration of 12 nM) specific binding to rat hippocampus,1,,Autocuration,,,,,,10000000.0,B,BAO_0000221,CHEMBL615873,772
,104744,H,4,,,,10881,,Inhibitory activity against 5-hydroxytryptamine 1 receptor by 3H ligand binding experiments.,1,,Autocuration,,,,,,,B,BAO_0000224,CHEMBL615479,773
,104744,H,4,,,,8822,,Tested for its binding affinity towards 5-hydroxytryptamine 1 receptor in rat,1,,Autocuration,,,,,,,B,BAO_0000019,CHEMBL615480,774
,104744,D,5,,,,9806,,Tested for its binding affinity towards 5-hydroxytryptamine 1 receptor in rat cortical membrane homogenates using radioligand ([3H]5-HT) binding assay.,1,Rattus norvegicus,Autocuration,,,,10116.0,,,B,BAO_0000249,CHEMBL615481,775
,104744,H,4,,,,15463,,Compound at 1 uM was tested for the inhibition of radioligand [3H]5-HT binding to 5-hydroxytryptamine 1 receptor in rat cerebral cortex,1,,Autocuration,,,,,,,B,BAO_0000019,CHEMBL872869,776
,104744,H,4,,,,15463,,Compound at 1 uM was tested for the inhibition of radioligand [3H]5-HT binding to 5-hydroxytryptamine 1 receptor in rat cerebral cortex,1,,Autocuration,,,,,,,B,BAO_0000019,CHEMBL615482,777
Brain,104744,H,4,,,,14542,,Compound is evaluated for binding affinity towards 5-hydroxytryptamine 1 receptor using [3H]5-HT in rat brain cortex at 10 uM,1,,Autocuration,,,,,,955.0,B,BAO_0000221,CHEMBL615483,778
Brain,104744,H,4,,,,14542,,Compound is evaluated for binding affinity towards 5-hydroxytryptamine 1 receptor using [3H]5-HT in rat brain cortex at 10 uM,1,,Autocuration,,,,,,955.0,B,BAO_0000221,CHEMBL615484,779
,104744,H,4,,,,8569,,Percent inhibition of 5-hydroxytryptamine 1 receptor from rat cortex membrane using [3H]- serotonin as radioligand at 33 uM,1,,Autocuration,,,,,,,B,BAO_0000019,CHEMBL615485,780
,104744,D,5,,,,10062,,Inhibition of [3H]5-HT radioligand binding against 5-hydroxytryptamine 1 receptor,1,Rattus norvegicus,Autocuration,,,,10116.0,,,B,BAO_0000224,CHEMBL615486,781
,104744,H,4,,,,4771,,Ancillary Binding affinity towards rat 5-hydroxytryptamine 1 receptor,1,,Autocuration,,,,,,,B,BAO_0000224,CHEMBL615487,782
,104744,H,4,,,,10062,,Binding affinity determined in radioreceptor binding assay by using [3H]5-HT radioligand against 5-hydroxytryptamine 1 receptor,1,,Autocuration,,,,,,,B,BAO_0000224,CHEMBL615488,783
,104744,H,4,,,,10062,,Binding affinity in radioreceptor binding assay by using [3H]5-HT radioligand against 5-hydroxytryptamine 1 receptor,1,,Autocuration,,,,,,,B,BAO_0000224,CHEMBL615489,784
,104744,H,4,,,,10062,,Binding affinity in radioreceptor binding assay by using [3H]5-HT radioligand against 5-hydroxytryptamine 1 receptor,1,,Autocuration,,,,,,,B,BAO_0000224,CHEMBL615389,785
,104744,H,4,,,,15463,,Binding affinity towards 5-hydroxytryptamine 1 receptor was determined in rat cerebral cortex using [3H]5-HT as radioligand,1,,Autocuration,,,,,,,B,BAO_0000019,CHEMBL615390,786
,104744,H,4,,,,15463,,Binding affinity towards central 5-hydroxytryptamine 1 receptor was determined in rat cerebral cortex using [3H]5-HT as radioligand,1,,Autocuration,,,,,,,B,BAO_0000019,CHEMBL615391,787
,104744,H,4,,,,9098,,Binding affinity towards 5-hydroxytryptamine 1 receptor was determined,1,,Autocuration,,,,,,,B,BAO_0000224,CHEMBL615392,788
,22226,U,0,,,,3070,,Affinity for 5-hydroxytryptamine 1 receptor,1,Rattus norvegicus,Autocuration,,,,10116.0,,,B,BAO_0000019,CHEMBL615393,789
Brain,104744,H,4,,,,14542,,Compound is evaluated for binding affinity towards 5-hydroxytryptamine 1 receptor using [3H]5-HT in rat brain cortex,1,,Autocuration,,,,,,955.0,B,BAO_0000221,CHEMBL615394,790
Brain,104744,H,4,,,,14542,,Compound is evaluated for binding affinity towards 5-hydroxytryptamine 1 receptor using [3H]5-HT in rat brain cortex at 10 uM,1,,Autocuration,,,,,,955.0,B,BAO_0000221,CHEMBL615395,791
,104744,H,4,,,,6398,,Compound was evaluated for 5-hydroxytryptamine 1 receptor binding,1,,Autocuration,,,,,,,B,BAO_0000224,CHEMBL615396,792
Brain,104744,H,4,,,,1344,,Compound was evaluated for its binding affinity to 5-hydroxytryptamine 1 receptor in rat brain using [3H]HT radioligand assay,1,,Autocuration,,,,,,955.0,B,BAO_0000221,CHEMBL615397,793
,104744,H,4,,,,11963,,Displacement of binding of [3H]5-HT to 5-hydroxytryptamine 1 receptor in rat cerebral cortex,1,,Autocuration,,,,,,,B,BAO_0000019,CHEMBL615398,794
,22226,U,0,,,,8908,,Displacement of [3H]spiperone from 5-hydroxytryptamine 1 receptor of rat cortex,1,Rattus norvegicus,Autocuration,,,,10116.0,,,B,BAO_0000019,CHEMBL615399,795
,104744,H,4,,,,9098,,Evaluated for binding affinity towards rat cortical membranes at 5-hydroxytryptamine 1 receptor binding site by using [3H]-5-HT as a radioligand.,1,,Autocuration,,,,,,,B,BAO_0000019,CHEMBL615400,796
,104744,D,5,,,,8841,,Binding affinity for 5-hydroxytryptamine 1 receptor of rat prefrontal cortex,1,Rattus norvegicus,Autocuration,,,,10116.0,,,B,BAO_0000019,CHEMBL615401,797
,22226,U,0,,,,8814,,Displacement of [3H]5-HT from 5-hydroxytryptamine 1 receptor of rat cortical membrane homogenates,1,Rattus norvegicus,Autocuration,,,,10116.0,,,B,BAO_0000019,CHEMBL615402,798
,104744,H,4,,,,11752,,The ability to inhibit [3H]5-HT binding to 5-hydroxytryptamine 1 receptor in rat cortex,1,,Autocuration,,,,,,,B,BAO_0000019,CHEMBL615403,799
Brain,104744,H,4,,,,11642,,The binding affinity was measured on serotonin 5-hydroxytryptamine 1 receptor in rat brain tissue,1,,Autocuration,,,,,,955.0,B,BAO_0000221,CHEMBL615404,800
,104744,H,4,,,,11642,,The compound was tested for its binding affinity towards 5-hydroxytryptamine 1 receptor by displacing [3H]5-HT radioligand in rat cerebral cortex,1,,Autocuration,,,,,,,B,BAO_0000019,CHEMBL615781,801
Brain,104744,H,4,,,,9231,,Tested for 5-hydroxytryptamine 1 receptor binding ability by displacement of [3H]5-HT from rat brain synaptosomes,1,,Autocuration,,,,,,955.0,B,BAO_0000220,CHEMBL615782,802
Brain,104744,H,4,,,,11351,,Inhibition constant (1 uM) was measured on 5-hydroxytryptamine 1 receptor/uptake using [3H]- serotonin as radioligand in rat brain cortex.,1,,Autocuration,,,,,,955.0,B,BAO_0000221,CHEMBL615783,803
,22226,U,0,,,,4639,,Compound was tested for binding affinity against 5-HT1 receptor,1,,Autocuration,,,,,,,B,BAO_0000019,CHEMBL873481,804
,22226,U,0,,,,1205,,Inhibitory concentration against 5-hydroxytryptamine 1 receptor,1,,Autocuration,,,,,,,B,BAO_0000019,CHEMBL615784,805
,10576,H,8,,,,10025,,Concentration necessary to achieve half maximal inhibition of [3H]8-Hydroxy-2-(di-n-propylamino)tetralin binding to 5-hydroxytryptamine 1A receptor at 1 uM,1,,Expert,,,,,,,B,BAO_0000357,CHEMBL615785,806
,10576,H,8,,,,13241,,"Ability to inhibit 5-HT sensitive,forskolin-stimulated adenylyl cyclase(FSC) activity in rat hippocampal membranes mediated through 5-hydroxytryptamine 1A receptor",1,,Autocuration,,,,,,,F,BAO_0000249,CHEMBL615786,807
,10576,H,8,In vivo,,,16245,,Agonistic activity (induction of forepaw treading in rats)on postsynaptic 5-hydroxytryptamine 1A receptor while iv administration,1,,Autocuration,,,,,,,F,BAO_0000218,CHEMBL615787,808
,10576,H,8,In vivo,,,16245,,Agonistic activity (induction of forepaw treading in rats)on postsynaptic 5-hydroxytryptamine 1A receptor while subcutaneous administration,1,,Autocuration,,,,,,,F,BAO_0000218,CHEMBL615788,809
,10576,H,8,,,,12438,,Inhibition of forskolin stimulated adenylate cyclase at 5-hydroxytryptamine 1A receptor,1,,Autocuration,,,,,,,F,BAO_0000019,CHEMBL767044,810
,10576,H,8,In vivo,,,16245,,Agonistic activity (induction of forepaw treading in rats)on postsynaptic 5-hydroxytryptamine 1A receptor while iv administration,1,,Autocuration,,,,,,,F,BAO_0000218,CHEMBL615789,811
,10576,H,8,In vivo,,,16245,,Agonistic activity (induction of forepaw treading in rats)on postsynaptic 5-hydroxytryptamine 1A receptor while subcutaneous administration,1,,Autocuration,,,,,,,F,BAO_0000218,CHEMBL615790,812
,10576,H,8,,,,15740,,Evaluated for the 5-hydroxytryptamine 1A receptor agonist activity in LY-293284 trained rats,1,,Autocuration,,,,,,,F,BAO_0000019,CHEMBL615813,813
,10576,H,8,,,,15535,,Percent of maximum response by 5-HT when tested for inhibition of vasoactive intestinal polypeptide-induced (VIP-induced) cAMP formation assessed in GH4ZD10 cells at 10 uM concentration,1,,Autocuration,,,,,,,F,BAO_0000219,CHEMBL615814,814
,51,H,8,,,,15535,,Percent inhibition of vasoactive intestinal polypeptide-induced (VIP-induced) cAMP formation in GH4ZD10 cells expressing 5-HT1A receptor at 50 uM relative to 5-HT,1,,Expert,,,,,,,F,BAO_0000219,CHEMBL615815,815
,10576,H,8,,,,15535,,Percent of maximum response by 5-HT when tested for inhibition of vasoactive intestinal polypeptide-induced (VIP-induced) cAMP formation assessed in GH4ZD10 cells at 50 uM concentration; No effect,1,,Autocuration,,,,,,,F,BAO_0000219,CHEMBL615816,816
,10576,H,8,,,,9888,,Binding affinity at [3H]8-OH-DPAT-Labeled 5-hydroxytryptamine 1A receptor sites in rat brain hippocampal membranes expressed as Hill values,1,,Expert,,,,,,,B,BAO_0000249,CHEMBL615817,817
Hippocampus,10576,H,8,,,,10085,,Ability to bind at 5-hydroxytryptamine 1A receptor of rat hippocampus by displacing [3H]8-OH-DPAT,1,,Autocuration,,,,,,10000000.0,B,BAO_0000221,CHEMBL615818,818
Hippocampus,10576,H,8,,,,10085,,Ability to bind at serotonin 5-hydroxytryptamine 1A receptors of rat hippocampus by displacing [3H]8-OH-DPAT,1,,Autocuration,,,,,,10000000.0,B,BAO_0000221,CHEMBL615819,819
,10576,H,8,,,Membranes,17331,,Binding affinity against 5-hydroxytryptamine 1A receptor (5-HT1A) by displacement of [3H]8-OH-DPAT from rat hippocampus membranes,1,,Expert,,,,,,,B,BAO_0000249,CHEMBL615820,820
Hippocampus,10576,D,9,,,,10845,,Binding affinity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue with [3H]8-OH-DPAT,1,Rattus norvegicus,Expert,,,,10116.0,,10000000.0,B,BAO_0000221,CHEMBL615821,821
Hippocampus,10576,D,9,,,,10845,,Binding affinity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue with [3H]5-HT,1,Rattus norvegicus,Expert,,,,10116.0,,10000000.0,B,BAO_0000221,CHEMBL615822,822
Hippocampus,10576,H,8,,,,10845,,Binding affinity against 5-hydroxytryptamine 1A receptor using in rat hippocampal tissue using [3H]8-OH-DPAT as radioligand,1,,Expert,,,,,,10000000.0,B,BAO_0000221,CHEMBL615823,823
Hippocampus,10576,D,9,,,,10845,,Displacement of [3H]8-OH-DPAT from rat hippocampal 5-hydroxytryptamine 1A receptor; IA-Inactive,1,Rattus norvegicus,Expert,,,,10116.0,,10000000.0,B,BAO_0000221,CHEMBL615824,824
Hippocampus,10576,D,9,,,,10845,,Binding affinity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue with [3H]5-HT,1,Rattus norvegicus,Expert,,,,10116.0,,10000000.0,B,BAO_0000221,CHEMBL615825,825
,10576,H,8,,,,13730,,Binding affinity towards rat 5-hydroxytryptamine 1A receptor was evaluated using [3H]8-OH-DPAT as radioligand,1,,Expert,,,,,,,B,BAO_0000357,CHEMBL615826,826
,10576,H,8,,,,13508,,Binding affinity against 5-hydroxytryptamine 1A receptor in rat hippocampus membranes using [3H]8-OH-DPAT as radioligand,1,,Expert,,,,,,,B,BAO_0000249,CHEMBL615827,827
Hippocampus,10576,H,8,,,,13508,,Binding affinity against serotonin 5-hydroxytryptamine 1A receptor in rat hippocampus membrane using [3H]8-OH-DPAT as radioligand,1,,Expert,,,,,,10000000.0,B,BAO_0000249,CHEMBL615828,828
Hippocampus,10576,H,8,,,,12073,,Binding affinity by measuring displacement of [3H]-8-OH-DPAT from 5-hydroxytryptamine 1A receptor in rat hippocampus,1,,Expert,,,,,,10000000.0,B,BAO_0000221,CHEMBL615829,829
Hippocampus,10576,H,8,,,,4671,,Binding affinity to 5-hydroxytryptamine 1A receptor of rat hippocampus with [3H]8-OH-DPAT as radioligand,1,,Autocuration,,,,,,10000000.0,B,BAO_0000221,CHEMBL615830,830
Hippocampus,10576,H,8,,,,13631,,Binding affinity towards serotonin 5-HT1A receptor was determined in rat hippocampus using [3H]8-OH-DPAT as ligand,1,,Expert,,,,,,10000000.0,B,BAO_0000221,CHEMBL615831,831
,10576,H,8,,,,12438,,Binding affinity was measured against serotonin 5-hydroxytryptamine 1A receptor,1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL615832,832
,10576,H,8,,,,10483,,Binding affinity to 5-hydroxytryptamine 1A receptor in rat cortex using [3H]-8-OH- DPAT as radioligand,1,,Autocuration,,,,,,,B,BAO_0000019,CHEMBL615833,833
Hippocampus,10576,H,8,,,,10483,,Binding affinity to 5-hydroxytryptamine 1A receptor in rat hippocampus using [3H]-8-OH- DPAT as radioligand,1,,Autocuration,,,,,,10000000.0,B,BAO_0000221,CHEMBL615834,834
,10576,H,8,,,,12352,,Binding affinity against 5-hydroxytryptamine 1A (5-HT1A) receptor in rat hippocampus membranes,1,,Intermediate,,,,,,,B,BAO_0000249,CHEMBL615835,835
Hippocampus,10576,H,8,,,,14732,,Binding affinity was measured at the serotonin 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand in rat hippocampal membrane.,1,,Autocuration,,,,,,10000000.0,B,BAO_0000249,CHEMBL615836,836
,10576,D,9,,,,11049,,Binding affinity to 5-hydroxytryptamine 1A receptor in the rat brain using [3H]8-hydroxy-2-(di-n-propylamine)tetralin as radioligand.,1,Rattus norvegicus,Expert,,,,10116.0,,,B,BAO_0000019,CHEMBL615837,837
,10576,D,9,,,,11049,,Binding affinity to 5-hydroxytryptamine 1A receptor in the rat brain using [3H]8-hydroxy-2-(di-n-propylamine)tetralin as radioligand; ND-Not determined,1,Rattus norvegicus,Expert,,,,10116.0,,,B,BAO_0000019,CHEMBL615838,838
,10576,H,8,,,,13657,,"Binding affinity to 5-hydroxytryptamine 1A receptor in rat hippocampus membranes,3H-8-OH-DPAT and buspirone for nonspecific binding (NSB)",1,,Expert,,,,,,,B,BAO_0000249,CHEMBL615839,839
,10576,H,8,,,,11473,,Compound was evaluated for binding affinity towards 5-hydroxytryptamine 1A receptor in rat cortex using [3H]-8-OH-DPAT as radioligand,1,,Autocuration,,,,,,,B,BAO_0000019,CHEMBL884525,840
,10576,H,8,,,,2014,,Compound was evaluated for its ability to displace [3H]8-OH-DPAT from serotonin 5-hydroxytryptamine 1A receptor in rat cerebral cortex membranes,1,,Autocuration,,,,,,,B,BAO_0000249,CHEMBL615840,841
Hippocampus,10576,H,8,,,,3086,,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor in rat hippocampus,1,,Expert,,,,,,10000000.0,B,BAO_0000221,CHEMBL615405,842
,10576,H,8,,,,15854,,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat frontal cortex using [125I]iodocyanopindolol as radio-ligand.,1,,Expert,,,,,,,B,BAO_0000019,CHEMBL615406,843
Hippocampus,10576,H,8,,,,10922,,Affinity for 5-hydroxytryptamine 1A receptor labeled with [3H]8-OH-DPAT radioligand in hippocampus tissue,1,,Expert,,,,,,10000000.0,B,BAO_0000221,CHEMBL615900,844
Hippocampus,10576,H,8,,,,13346,,Inhibition of [3H]8-OH-DPAT binding at serotonin 5-hydroxytryptamine 1A receptor from rat hippocampus tissue.,1,,Expert,,,,,,10000000.0,B,BAO_0000221,CHEMBL615901,845
,10576,H,8,,,,15311,,In vitro inhibition of [3H]8-OH-DPAT binding to rat 5-HT 1a receptors.,1,,Expert,,,,,,,B,BAO_0000357,CHEMBL615902,846
Hippocampus,10576,H,8,,,,10922,,Compound was measured for affinity at 5-hydroxytryptamine 1A receptor labeled with [3H]8-OH-DPAT radioligand in hippocampus tissue,1,,Autocuration,,,,,,10000000.0,B,BAO_0000221,CHEMBL615903,847
,10576,H,8,,,,10025,,Concentration necessary to achieve half maximal inhibition of [3H]8-Hydroxy-2-(di-n-propylamino)tetralin binding to 5-hydroxytryptamine 1A receptor<br>at 1 uM,1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL615904,848
,10576,H,8,,,,10025,,Concentration necessary to achieve half maximal inhibition of [3H]8-Hydroxy-2-(di-n-propylamino)tetralin binding to 5-hydroxytryptamine 1A receptor at 1 uM,1,,Expert,,,,,,,B,BAO_0000357,CHEMBL615905,849
,10576,H,8,,,,9742,,In vitro Inhibitory activity tested at 5-hydroxytryptamine 1A receptor binding site in rat,1,,Autocuration,,,,,,,B,BAO_0000019,CHEMBL615906,850
,10576,H,8,,,,9742,,In vitro Inhibitory activity tested at 5-hydroxytryptamine 1A receptor binding site in rat,1,,Autocuration,,,,,,,F,BAO_0000019,CHEMBL615907,851
,10576,H,8,,,,12304,,In vitro ability to inhibit binding of radioligand [3H]8-OH-DPAT to 5-hydroxytryptamine 1A receptor in rat cerebral cortex,1,,Expert,,,,,,,B,BAO_0000019,CHEMBL615908,852
Hippocampus,10576,H,8,,,,15789,,In vitro affinity against 5-hydroxytryptamine 1A receptor using [3H]-8-OH-DPAT in rat hippocampus,1,,Autocuration,,,,,,10000000.0,B,BAO_0000221,CHEMBL615909,853
,10576,H,8,,,,9912,,"In vitro binding activity against 5-hydroxytryptamine 1A receptor from homogenized rat brain, using [3H]-8-OH-DPAT as the radioligand",1,,Autocuration,,,,,,,B,BAO_0000019,CHEMBL615910,854
,10576,H,8,,,,9912,,"In vitro binding activity against 5-hydroxytryptamine 1A receptor from homogenized rat brain, using [3H]8-OH-DPAT as the radioligand.",1,,Autocuration,,,,,,,B,BAO_0000019,CHEMBL615911,855
,10576,H,8,,,,9912,,"In vitro binding activity against 5-hydroxytryptamine 1A receptor from homogenized rat brain, using [3H]8-OH-DPAT as the radioligand",1,,Autocuration,,,,,,,B,BAO_0000019,CHEMBL615912,856
,10576,H,8,,,,16693,,In vitro binding affinity for serotonin 5-hydroxytryptamine 1A receptor fof rat cerebral cortex using [3H]8-OH-DPAT as radioligand,1,,Expert,,,,,,,B,BAO_0000019,CHEMBL615913,857
,10576,H,8,,,,13276,,In vitro binding affinity measured on serotonin 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand.,1,,Expert,,,,,,,B,BAO_0000357,CHEMBL615914,858
Hippocampus,10576,H,8,,,,12678,,In vitro binding affinity to 5-hydroxytryptamine 1A receptor using [125I](R)-(+)-trans-8-OH-PIPAT as radioligand in rat hippocampal homogenate,1,,Autocuration,,,,,,10000000.0,B,BAO_0000221,CHEMBL615915,859
,10576,H,8,,,,11825,,In vitro binding affinity towards the 5-hydroxytryptamine 1A receptor was evaluated,1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL615916,860
,10576,H,8,,,,12443,,In vitro binding affinity was measured on serotonergic 5-hydroxytryptamine 1A receptor by displacement of [3H]- tetralin,1,,Expert,,,,,,,B,BAO_0000357,CHEMBL615917,861
,10576,H,8,,,,13830,,In vitro inhibitory activity against [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor,1,,Expert,,,,,,,B,BAO_0000357,CHEMBL615918,862
Hippocampus,10576,H,8,,,,14286,,In vitro inhibitory concentration against radioligand [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor in rat hippocampal membrane.,1,,Expert,,,,,,10000000.0,B,BAO_0000249,CHEMBL615919,863
Hippocampus,10576,D,9,,,,14356,,In vitro radioligand binding assay on 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT in rat hippocampus,1,Rattus norvegicus,Expert,,,,10116.0,,10000000.0,B,BAO_0000221,CHEMBL615920,864
,10576,H,8,,,,15306,,Inhibition concentration against 5-hydroxytryptamine 1A receptor,1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL615921,865
,10576,H,8,,,,15306,,Inhibitory concentration against 5-hydroxytryptamine 1A receptor (Inactive at >1000 nM concentration),1,,Expert,,,,,,,B,BAO_0000357,CHEMBL615922,866
,10576,D,9,,,,16616,,"Inhibition of (+)-8-OH-DPAT stimulated [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor in hippocampal membranes",1,Rattus norvegicus,Expert,,,,10116.0,,,F,BAO_0000249,CHEMBL881290,867
Hippocampus,10576,H,8,,,,3651,,"Inhibition of [3H]8-hydroxy-2-dipropylamino-1,2,3,4-tetrahydronaphthalene binding to 5-hydroxytryptamine 1A receptor in hippocampus region of rat brain; Residual radioligand binding higher than 50%",1,,Autocuration,,,,,,10000000.0,B,BAO_0000221,CHEMBL615923,868
Hippocampus,10576,H,8,,,,14331,,Inhibition of forskolin-activated adenylate cyclase (cAMP) activity at 5-hydroxytryptamine 1A receptor in rat hippocampus,1,,Autocuration,,,,,,10000000.0,F,BAO_0000221,CHEMBL615924,869
Hippocampus,10576,H,8,,,,14331,,Inhibition of forskolin-activated adenylate cyclase (cAMP) activity at 5-hydroxytryptamine 1A receptor in rat hippocampus,1,,Autocuration,,,,,,10000000.0,F,BAO_0000221,CHEMBL615925,870
,10576,D,9,,,,14178,,Inhibition of radiolabeled [3H]-8-OH-DPAT ligand binding to 5-hydroxytryptamine 1A receptor,1,Rattus norvegicus,Expert,,,,10116.0,,,B,BAO_0000357,CHEMBL615926,871
,10576,D,9,,,,10639,,Displacement of [3H]8-OH-DPAT from rat cortex 5-hydroxytryptamine 1A receptor,1,Rattus norvegicus,Expert,,,,10116.0,,,B,BAO_0000019,CHEMBL615927,872
Hippocampus,10576,H,8,,,,12306,,Inhibitory activity against 5-hydroxytryptamine 1A receptor of rat hippocampal homogenates,1,,Autocuration,,,,,,10000000.0,B,BAO_0000221,CHEMBL615928,873
,10576,D,9,,,,1348,,Inhibitory activity against 5-hydroxytryptamine 1A receptor subtype,1,Rattus norvegicus,Expert,,,,10116.0,,,B,BAO_0000357,CHEMBL615929,874
Hippocampus,10576,H,8,,,,13605,,Inhibitory activity against [3H]DPAT binding to 5-HT1A receptor in rat hippocampus,1,,Autocuration,,,,,,10000000.0,B,BAO_0000221,CHEMBL615930,875
,51,H,8,,,,17624,,Inhibition concentration against 5-hydroxytryptamine 1A receptor using cAMP as radioligand in CHO cells,1,,Autocuration,,449.0,,,CHO,,B,BAO_0000219,CHEMBL615931,876
,51,H,8,,,,17624,,Inhibition concentration against binding of radioligand [35S]GTP-gamma-S in CHO cells expressing 5-hydroxytryptamine 1A receptor,1,,Autocuration,,449.0,,,CHO,,F,BAO_0000219,CHEMBL615932,877
,51,H,8,,,,17624,,Inhibition concentration against binding of radioligand [35S]GTP-gamma-S in CHO cells expressing 5-hydroxytryptamine 1A receptor,1,,Autocuration,,449.0,,,CHO,,F,BAO_0000219,CHEMBL615933,878
,51,H,8,,,,15267,,Inhibition of [3H]- 8-OH-DAPT binding against human recombinant 5-hydroxytryptamine 1A receptor,1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL615934,879
,51,H,8,,,,16532,,The binding affinity at the 5-hydroxytryptamine 1A receptor determined using [3H]5-CT; Not tested,1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL615935,880
,51,H,8,,,,6563,,"Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by [35S]GTP-gamma-S, stimulated cAMP assay",1,,Autocuration,,,,,,,F,BAO_0000019,CHEMBL615936,881
,51,H,8,,,,4751,,Ability to displace [3H]-8-OH-DPAT from CHO cells stably transfected with human 5-hydroxytryptamine 1A receptor at a concentration of 1 uM,1,,Autocuration,,449.0,,,CHO,,B,BAO_0000219,CHEMBL615937,882
,51,H,8,,,,15463,,Compound at 1 uM was tested for the inhibition of radioligand [3H]8-OH-DPAT binding to recombinant human 5-hydroxytryptamine 1A receptor,1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL615938,883
,51,H,8,,,,3805,,In vitro binding affinity against human 5-hydroxytryptamine 1A receptor at a concentration of 100 (nM),1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL615797,884
,51,H,8,,,,5640,,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL615798,885
,51,H,8,,,,6563,,Inhibition of [3H]8-OH-DPAT binding to human 5-hydroxytryptamine 1A receptor at 1000 nM compound concentration,1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL872870,886
,51,H,8,,,,5548,,Inhibitory activity against 5-hydroxytryptamine 1A receptor using [3H]-8-OH-DPAT as radioligand at 100 nM concentration,1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL615799,887
,51,H,8,,,,6347,,Percent binding affinity against 5-hydroxytryptamine 1A receptor,1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL615800,888
,51,H,8,,,,17296,,Intrinsic activity for human 5-hydroxytryptamine 1A receptors HEK 293 cell membranes using [35S]GTP gamma-S,1,,Autocuration,,722.0,,,HEK293,,F,BAO_0000219,CHEMBL615801,889
,51,H,8,,,,13047,,Binding affinity against 5-hydroxytryptamine 1 receptor using rabbit jugular vein assay in the absence of endothelium,1,,Autocuration,,,,,,,B,BAO_0000019,CHEMBL615802,890
,51,H,8,,,,15740,,Dissociation constant against human 5-hydroxytryptamine 1A receptor receptor,1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL615803,891
,51,H,8,,,,5640,,"Inhibition of 5-HT induced [35S]GTP-gamma-S, binding at human cloned 5-HT 1A receptors.",1,,Expert,,,,,,,F,BAO_0000019,CHEMBL835002,892
,51,H,8,,,,5640,,"5-hydroxytryptamine 1A receptor antagonism was evaluated by the ability to inhibit [35S]GTP-gamma-S, binding that was induced by 5-HT; Ki (nM): not determined",1,,Autocuration,,,,,,,F,BAO_0000019,CHEMBL615804,893
,51,H,8,,,,17211,,Ability to displace [3H]5-CT (2.0 nM) from HeLa cells of human 5-hydroxytryptamine 1A receptor,1,,Expert,,308.0,,,HeLa,,B,BAO_0000219,CHEMBL615805,894
,51,H,8,,,,4751,,Ability to displace [3H]8-OH-DPAT from CHO cells stably transfected with human 5-hydroxytryptamine 1A receptor,1,,Autocuration,,449.0,,,CHO,,B,BAO_0000219,CHEMBL615806,895
,51,D,9,,,,6491,,Affinity towards human 5-hydroxytryptamine 1A serotonin receptor,1,Homo sapiens,Expert,,,,9606.0,,,B,BAO_0000357,CHEMBL615807,896
,51,H,8,,,,4707,,Binding affinity towards human 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT-as radioligand,1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL615808,897
,51,D,9,,,,13910,,Binding affinity against 5-hydroxytryptamine 1A receptor,1,Homo sapiens,Expert,,,,9606.0,,,B,BAO_0000357,CHEMBL615809,898
,51,H,8,,,,16190,,Binding affinity against 5-hydroxytryptamine 1A receptor in HeLa cells was determined using [3H]5-HT,1,,Autocuration,,308.0,,,HeLa,,B,BAO_0000219,CHEMBL615810,899
,51,H,8,,,,16633,,Binding affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL615811,900
,51,H,8,,,,11898,,Binding affinity against [3H]- -8-OH-DPAT -labeled 5-hydroxytryptamine 1A sites in cloned CHO cells,1,,Autocuration,,449.0,,,CHO,,B,BAO_0000219,CHEMBL615812,901
,51,H,8,,,,11898,,Binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in cloned CHO cells,1,,Autocuration,,449.0,,,CHO,,B,BAO_0000219,CHEMBL615751,902
,51,H,8,,,,14331,,Binding affinity against human 5-hydroxytryptamine 1A receptor,1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL615752,903
,51,H,8,,,,17624,,Binding affinity against human 5-hydroxytryptamine 1A receptor in CHO cells labeled with [3H]8-OH-DPAT radioligand,1,,Expert,,449.0,,,CHO,,B,BAO_0000219,CHEMBL615753,904
,51,H,8,,,,17624,,Binding affinity against human 5-hydroxytryptamine 1A receptor in CHO cells labeled with [3H]8-OH-DPAT radioligand; nd=not determined,1,,Autocuration,,449.0,,,CHO,,B,BAO_0000219,CHEMBL615754,905
,51,H,8,,,,3307,,Binding affinity of compound to human 5-hydroxytryptamine 1A receptor,1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL615755,906
,51,D,9,,,,6563,,Displacement of [3H]8-OH-DPAT from human 5-hydroxytryptamine 1A receptor expressed in CHO cells,1,Homo sapiens,Expert,,449.0,,9606.0,CHO,,B,BAO_0000219,CHEMBL615756,907
,51,H,8,,,,14165,,Binding affinity for 5-hydroxytryptamine 1A receptor in HeLa transfected cell type using [3H]8-OH-DPAT as radioligand,1,,Autocuration,,,,,,,B,BAO_0000019,CHEMBL615757,908
,51,H,8,,,,5732,,Binding affinity towards cloned human 5-hydroxytryptamine 1A receptor was determined,1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL615758,909
,51,H,8,,,,13366,,In vitro affinity at human cloned 5-hydroxytryptamine 1A receptor by [3H]8-OH-DPAT displacement.,1,,Expert,,,,,,,B,BAO_0000357,CHEMBL615759,910
,51,H,8,,,,17626,,Binding affinity towards human 5-hydroxytryptamine 1A receptor,1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL615760,911
,51,H,8,,,,6588,,Binding affinity towards human 5-hydroxytryptamine 1A receptor by the displacement of [3H]5-HT radioligand from the cloned receptor expressed in HeLa cells,1,,Expert,,308.0,,,HeLa,,B,BAO_0000219,CHEMBL615761,912
,51,H,8,,,,16209,,Binding affinity towards human 5-hydroxytryptamine 1A receptor was determined using [3H]-5-HT as radioligand,1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL872104,913
,51,H,8,,,,15463,,Binding affinity towards recombinant human 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand,1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL615762,914
,51,H,8,,,,15463,,Binding affinity towards recombinant human Compound at 1 uM was tested for the inhibition of radioligand [3H]8-OH-DPAT binding to recombinant human 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand,1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL615763,915
,51,H,8,,,,14770,,Binding affinity for recombinant human 5-hydroxytryptamine 1A receptor using [3H]5-HT as radioligand.,1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL615764,916
,51,H,8,,,,16245,,Binding affinity on human cloned 5-hydroxytryptamine 1A receptor transfected in human cell lines (He La),1,,Autocuration,,1167.0,,,Cell line,,B,BAO_0000219,CHEMBL615765,917
,51,H,8,,,,16245,,Binding affinity on human cloned 5-hydroxytryptamine 1A receptor transfected in human cell lines(He La),1,,Autocuration,,,,,,,B,BAO_0000019,CHEMBL615766,918
,51,H,8,,,,5548,,Binding affinity towards 5-HT1A receptor using [3H]8-OH-DPAT as radioligand,1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL615767,919
,51,H,8,,,,5548,,Binding affinity was determined towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,1,,Expert,,,,,,,B,BAO_0000357,CHEMBL615768,920
,51,H,8,,,,5548,,Binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL615769,921
,51,H,8,,,,6876,,Binding affinity was evaluated at 5-hydroxytryptamine 1A receptor labeled with [3H]-8-OH-DPAT,1,,Expert,,,,,,,B,BAO_0000357,CHEMBL615770,922
,51,H,8,,,,2598,,Binding affinity was evaluated at human recombinant 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL615771,923
,51,H,8,,,,17785,,Binding affinity to human 5-hydroxytryptamine 1A receptor was measured using [3H]-8-hydroxy-2-(di-n-propylamine) tetraline [3H]8-OH-DPAT) as radioligand,1,,Expert,,,,,,,B,BAO_0000357,CHEMBL615772,924
,51,H,8,,,,6013,,Binding affinity towards 5-hydroxytryptamine 1A receptor,1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL615773,925
,51,H,8,,,,5929,,Binding affinity towards 5-hydroxytryptamine 1A receptor in human using [3H]8-OH-DPAT as radioligand,1,,Expert,,,,,,,B,BAO_0000357,CHEMBL615774,926
,51,H,8,,,,16633,,Binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL615775,927
,51,H,8,,,,1558,,Binding affinity towards cloned human 5-hydroxytryptamine 1A receptor was determined,1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL615776,928
,51,H,8,,,,16026,,Binding affinity towards human cloned 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,1,,Expert,,,,,,,B,BAO_0000357,CHEMBL615777,929
,51,H,8,,,,12469,,Binding affinity was measured on 5-hydroxytryptamine 1A receptor in AK cells transfected with human 5-HT1A gene labeled with [3H]-8-OH-DPAT,1,,Autocuration,,,,,,,B,BAO_0000219,CHEMBL615778,930
,51,D,9,,,,15874,,Binding affinity was measured on cloned Human 5-hydroxytryptamine 1A receptor which is labeled by [3H]8-OH-DPAT,1,Homo sapiens,Expert,,,,9606.0,,,B,BAO_0000357,CHEMBL615779,931
,51,H,8,,,,15874,,Binding affinity was measured on cloned human 5-hydroxytryptamine 1A receptor which is labeled by [3H]8-OH-DPAT,1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL615780,932
,51,H,8,,,,3935,,Compound was evaluated for its binding affinity for human 5-hydroxytryptamine 1A receptor,1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL616298,933
,51,H,8,,,,15818,,Compound was evaluated for its binding affinity towards human 5-hydroxytryptamine 1A receptor,1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL616299,934
,51,H,8,,,,13706,,Compound was tested for binding affinity against cloned human 5-hydroxytryptamine 1A receptor expressed in CHO-K1 cells.,1,,Autocuration,,485.0,,,CHO-K1,,B,BAO_0000219,CHEMBL616300,935
,51,H,8,,,,13729,,Ability to inhibit the forskolin-stimulated c-AMP formation mediated by human 5-hydroxytryptamine 1A receptor in CHO-K1 cells,1,,Expert,,485.0,,,CHO-K1,,F,BAO_0000219,CHEMBL616301,936
,51,H,8,,,,15413,,In vitro inhibition of [3H]- 8-OH-DPAT binding to cloned cell line containing human 5-hydroxytryptamine 1A receptor,1,,Autocuration,,,,,,,B,BAO_0000019,CHEMBL616302,937
,51,H,8,,,,15413,,In vitro inhibition of [3H]- 8-OH-DPAT binding to cloned cell line containing human 5-hydroxytryptamine 1A receptor (Experiment 1),1,,Autocuration,,,,,,,B,BAO_0000019,CHEMBL616117,938
,51,H,8,,,,15413,,In vitro inhibition of [3H]- 8-OH-DPAT binding to cloned cell line containing human 5-hydroxytryptamine 1A receptor (Experiment 2),1,,Autocuration,,,,,,,B,BAO_0000019,CHEMBL616118,939
,51,H,8,,,,15413,,In vitro inhibition of [3H]- 8-OH-DPAT binding to cloned cell line containing human 5-hydroxytryptamine 1A receptor by Panlabs assay,1,,Autocuration,,,,,,,B,BAO_0000019,CHEMBL616119,940
,51,D,9,,,,3445,,Displacement of specific [3H]- 5-HT binding to cloned human 5-hydroxytryptamine 1A receptor stably expressed in HeLa cells,1,Homo sapiens,Expert,,308.0,,9606.0,HeLa,,B,BAO_0000219,CHEMBL616120,941
,51,H,8,,,,15740,,Evaluated for the binding constant at [3H]8-OH-DPAT-labeled human 5-hydroxytryptamine 1A receptor,1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL616121,942
,51,H,8,,,,15740,,Evaluated for the binding constant at [3H]8-OH-DPAT-labeled human 5-hydroxytryptamine 1A receptor receptor,1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL616122,943
,51,H,8,,,,17626,,In vitro binding affinity tested on human 5-hydroxytryptamine 1A receptor,1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL616123,944
,51,D,9,,,,4234,,In vitro binding affinity to human 5-hydroxytryptamine 1A receptor,1,Homo sapiens,Expert,,,,9606.0,,,B,BAO_0000357,CHEMBL616124,945
,51,H,8,,,,5640,,In vitro binding affinity at 5-hydroxytryptamine 1A receptor by [3H]8-OH-DPAT displacement.,1,,Expert,,,,,,,B,BAO_0000357,CHEMBL616125,946
,51,H,8,,,,5272,,In vitro binding affinity towards Human 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT,1,Rattus norvegicus,Expert,,,,10116.0,,,B,BAO_0000357,CHEMBL616126,947
,51,H,8,,,,4622,,In vitro binding affinity towards cloned human 5-hydroxytryptamine 1A receptor expressed in Chinese hamster ovary (CHO) cells using [3H]8-OH-DPAT as radioligand,1,,Autocuration,,449.0,,,CHO,,B,BAO_0000219,CHEMBL616127,948
,51,H,8,,,,17085,,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1A receptor,1,,Expert,,,,,,,B,BAO_0000019,CHEMBL616128,949
,51,H,8,,,,3025,,In vitro binding affinity was determined towards cloned human 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT radioligand,1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL616129,950
,51,H,8,,,,15315,,In vitro receptor binding affinity for cloned human 5-hydroxytryptamine 1A receptor,1,,Expert,,,,,,,B,BAO_0000357,CHEMBL616130,951
,51,H,8,,,,15267,,Inhibition of [3H]- OH-DPAT binding against 5-hydroxytryptamine 1A receptor from human recombinant,1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL616131,952
,51,H,8,,,,17158,,Inhibition of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor serotonergic receptor in human HeLa cells,1,,Autocuration,,308.0,,,HeLa,,B,BAO_0000219,CHEMBL616132,953
,51,D,9,,,,14214,,Receptor binding affinity for cloned human 5-hydroxytryptamine 1A receptor in HeLa cells,1,Homo sapiens,Expert,,308.0,,9606.0,HeLa,,B,BAO_0000219,CHEMBL616133,954
,51,H,8,,,,17133,,Tested in vitro for its ability to bind to 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL616134,955
,51,H,8,,,,16532,,The binding affinity at the 5-hydroxytryptamine 1A receptor determined using [3H]5-CT,1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL616135,956
,51,D,9,,,,2391,,Affinity for 5-hydroxytryptamine 1A receptor subtype,1,Homo sapiens,Expert,,,,9606.0,,,B,BAO_0000357,CHEMBL616136,957
,51,H,8,,,,14447,,The compound was tested for CNS binding affinity towards 5-hydroxytryptamine 1A receptor from cloned Human membranes,1,,Autocuration,,,,,,,B,BAO_0000019,CHEMBL616137,958
,51,H,8,,,,14447,,The compound was tested for CNS binding affinity towards 5-hydroxytryptamine 1A receptor from cloned Human membranes.,1,,Autocuration,,,,,,,B,BAO_0000019,CHEMBL872105,959
,51,H,8,,,,15086,,The compound was tested for binding affinity against 5-hydroxytryptamine 1A receptor receptor,1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL616138,960
,51,D,9,,,,13051,,Binding affinity for cloned human 5-hydroxytryptamine 1A receptor,1,Homo sapiens,Expert,,,,9606.0,,,B,BAO_0000357,CHEMBL616139,961
,51,H,8,,,,16026,,"Ability to influence the binding of [35S]GTP-gamma-S, to HeLa cell membranes expressing the human 5-hydroxytryptamine 1A receptor; Not active",1,,Autocuration,,,,,,,F,BAO_0000019,CHEMBL616140,962
,51,H,8,,,,17085,,In vitro binding affinity was determined by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1A receptor; ND means not determined,1,,Expert,,,,,,,B,BAO_0000019,CHEMBL616141,963
,51,H,8,,,,17133,,Tested in vitro for its ability to bind to 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL616142,964
,51,H,8,,,,17133,,Tested in vitro for its ability to bind to 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand; ND means Not determined,1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL616143,965
,51,H,8,,,,17211,,Ability to displace [3H]5-CT (2.0 nM) from HeLa cells of human 5-hydroxytryptamine 1A receptor; NT denotes not tested,1,,Autocuration,,308.0,,,HeLa,,B,BAO_0000219,CHEMBL616144,966
,51,H,8,,,,17211,,Ability to displace [3H]5-CT (2.0 nM) from HeLa cells of human 5-hydroxytryptamine 1A receptor; NT=not tested,1,,Autocuration,,308.0,,,HeLa,,B,BAO_0000219,CHEMBL616145,967
,51,H,8,,,,17211,,Ability to displace [3H]5-CT (2.0 nM) from HeLa cells of human 5-hydroxytryptamine 1A receptor; NT denotes not tested,1,,Autocuration,,308.0,,,HeLa,,B,BAO_0000219,CHEMBL616012,968
,51,H,8,,,,17211,,Ability to displace [3H]5-CT (2.0 nM) from HeLa cells of human 5-hydroxytryptamine 1A receptor; NT denotes not tested,1,,Autocuration,,308.0,,,HeLa,,B,BAO_0000219,CHEMBL616013,969
,51,H,8,,,,16394,,"Agonist efficacy of [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor compared with 5-HT.; NT is not tested",1,,Autocuration,,,,,,,F,BAO_0000019,CHEMBL616014,970
,51,H,8,,,,16394,,"Agonist efficacy of [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor compared with 5-HT.; NT is not tested",1,,Autocuration,,,,,,,F,BAO_0000019,CHEMBL616015,971
,51,H,8,,,,16394,,"Agonist efficacy of [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor compared with 5-HT.; NT is not tested",1,,Autocuration,,,,,,,F,BAO_0000019,CHEMBL616016,972
,51,H,8,In vivo,,,16394,,Antagonist induction of hypothermia by 8-OH-DPAT in 5-hydroxytryptamine 1A receptor after subcutaneous administration; NT is not tested,1,,Autocuration,,,,,,,F,BAO_0000218,CHEMBL616017,973
,51,H,8,,,,16394,,Binding affinity at human 5-hydroxytryptamine 1A receptor by inhibition of [3H]-8-OH-DPAT binding in Chinese hamster ovary cell line; NT is not tested,1,,Autocuration,,,,,,,B,BAO_0000019,CHEMBL616018,974
,51,H,8,,,,15740,,EC50 for inhibition of 50 uM forskolin-stimulated cAMP accumulation against 5-hydroxytryptamine 1A receptor receptor; Not tested,1,,Autocuration,,,,,,,F,BAO_0000019,CHEMBL616019,975
,51,H,8,,,,15740,,EC50 for inhibition of 50 uM forskolin-stimulated cAMP accumulation against 5-hydroxytryptamine 1A receptor; Not tested,1,,Autocuration,,,,,,,F,BAO_0000019,CHEMBL616020,976
,51,H,8,,,,15740,,Evaluated for the binding constant at [3H]8-OH-DPAT-labeled human 5-hydroxytryptamine 1A receptor,1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL858018,977
,51,H,8,,,,17296,,Binding affinity against human 5-hydroxytryptamine 1A receptors HEK 293 cell membranes using [35S]GTP gamma-S,1,,Autocuration,,722.0,,,HEK293,,F,BAO_0000219,CHEMBL616021,978
,51,H,8,,,,5640,,"Stimulation of binding of [35S]GTP-gamma-S, to G protein mediated by human cloned 5-hydroxytryptamine 1A receptor tested in vitro at 1 uM.",1,,Expert,,,,,,,F,BAO_0000019,CHEMBL616022,979
,51,H,8,,,,5640,,"Stimulation of binding of [35S]GTP-gamma-S, to G protein mediated by human cloned 5-hydroxytryptamine 1A receptor tested in vitro at a concentration of 1 uM; ND means Not determined",1,,Autocuration,,,,,,,F,BAO_0000019,CHEMBL616023,980
,51,H,8,,,,5640,,"Stimulation of binding of [35S]GTP-gamma-S, to G protein mediated by human cloned 5-hydroxytryptamine 1A receptor tested in vitro at a concentration of 1 uM; ND means not determined",1,,Autocuration,,,,,,,F,BAO_0000019,CHEMBL616024,981
,51,H,8,,,,5640,,"Stimulation of binding of [35S]GTP-gamma-S, to G protein mediated by human cloned 5-hydroxytryptamine 1A receptor tested in vitro at a concentration of 1 uM; Not determined",1,,Autocuration,,,,,,,F,BAO_0000019,CHEMBL616025,982
,51,H,8,,,,2759,,Antagonistic efficacy was evaluated by adenylyl cyclase assay in CHO cells stably expressing the human 5-HT1A receptor,1,,Autocuration,,449.0,,,CHO,,F,BAO_0000219,CHEMBL616026,983
,51,H,8,,,,16394,,"Agonist efficacy of [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor compared with 5-HT",1,,Autocuration,,,,,,,F,BAO_0000019,CHEMBL616027,984
,51,D,9,,,,16394,,"Agonist efficacy of [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor compared to 5-HT",1,Homo sapiens,Expert,,,,9606.0,,,F,BAO_0000019,CHEMBL616028,985
,51,D,9,,,,3445,,Percent efficacy against human 5-hydroxytryptamine 1A receptor relative to maximal 5-HT response,1,Homo sapiens,Expert,,,,9606.0,,,F,BAO_0000019,CHEMBL616029,986
,51,H,8,,,,4316,,Binding affinity for 5-hydroxytryptamine 1A receptor was determined by incubating human 5-hydroxytryptamine 1A receptor transfected CHO cells with [3H]8-OH-DPAT,1,,Expert,,449.0,,,CHO,,B,BAO_0000219,CHEMBL616030,987
,51,H,8,,,,4316,,In vitro inhibition of [3H]8-OH-DPAT binding to human cloned 5-hydroxytryptamine 1A receptor on CHO cell membranes.,1,,Expert,,,,,,,B,BAO_0000019,CHEMBL616031,988
,51,D,9,,,,15180,,Agonist efficacy on 5-hydroxytryptamine 1A receptor subtype,1,Homo sapiens,Expert,,,,9606.0,,,F,BAO_0000019,CHEMBL616032,989
,51,D,9,,,,15180,,Agonist efficacy on 5-hydroxytryptamine 1A receptor subtype,1,Homo sapiens,Expert,,,,9606.0,,,F,BAO_0000019,CHEMBL616033,990
,51,H,8,,,,15042,,Maximum binding affinity was evaluated as ([35S]GTP binding on 5-hydroxytryptamine 1A serotonergic receptors.,1,,Autocuration,,,,,,,F,BAO_0000019,CHEMBL616034,991
,51,H,8,,,,15042,,Maximum binding affinity was evaluated as ([35S]GTP binding on 5-hydroxytryptamine 1A serotonergic receptors.,1,,Autocuration,,,,,,,F,BAO_0000019,CHEMBL616035,992
,51,H,8,,,,15042,,Maximum binding affinity was evaluated as ([35S]GTP binding on cloned human 5-hydroxytryptamine 1A receptor,1,,Autocuration,,,,,,,F,BAO_0000019,CHEMBL616036,993
,51,H,8,,,,15042,,Agonist efficacy was evaluated as ([35S]GTP binding on 5-hydroxytryptamine 1A serotonergic receptors.,1,,Autocuration,,,,,,,F,BAO_0000019,CHEMBL616037,994
,51,H,8,,,,15042,,Agonist efficacy was evaluated as ([35S]GTP binding on 5-hydroxytryptamine 1A serotonergic receptors.,1,,Autocuration,,,,,,,F,BAO_0000019,CHEMBL616038,995
,51,H,8,,,,15042,,Agonist efficacy was evaluated as ([35S]GTP binding on 5-hydroxytryptamine 1A serotonergic receptors.,1,,Autocuration,,,,,,,F,BAO_0000019,CHEMBL616039,996
,51,H,8,,,,15042,,Agonist efficacy was evaluated as [35S]GTP binding on cloned human 5-hydroxytryptamine 1A receptor,1,,Autocuration,,,,,,,F,BAO_0000019,CHEMBL616040,997
,51,D,9,,,,15180,,Concentration required to obtain 50% maximal stimulation of [35S]GTP gamma-S binding to human cloned 5-HT1A receptors of cell membranes from HeLa cells,1,Homo sapiens,Expert,,308.0,,9606.0,HeLa,,F,BAO_0000219,CHEMBL616041,998
,51,D,9,,,,15180,,Negative logarithm of concentration required to obtain 50% maximal stimulation of [35S]GTP gamma-S binding to human cloned 5-HT1A receptors of cell membranes from HeLa cells,1,Homo sapiens,Expert,,308.0,,9606.0,HeLa,,F,BAO_0000219,CHEMBL616042,999
,51,D,9,,,,15180,,Negative logarithm of concentration required to obtain 50% maximal stimulation of [35S]GTP gamma-S binding to human cloned 5-HT1A receptors of cell membranes from HeLa cells,1,Homo sapiens,Expert,,308.0,,9606.0,HeLa,,F,BAO_0000219,CHEMBL616043,1000
,51,H,8,,,,16245,,"Potency (pD2) for the stimulation of [35S]GTP-gamma-S, binding on 5-hydroxytryptamine 1A receptor",1,,Autocuration,,,,,,,F,BAO_0000019,CHEMBL616044,1001
,51,H,8,,,,16026,,"Ability to influence the binding of [35S]GTP-gamma-S, to HeLa cell membranes expressing the human 5-hydroxytryptamine 1A receptor",1,,Autocuration,,,,,,,F,BAO_0000019,CHEMBL616045,1002
,51,H,8,,,,17296,,Binding affinity against human 5-hydroxytryptamine 1A receptors HEK 293 cell membranes using [35S]GTP gamma-S,1,,Autocuration,,722.0,,,HEK293,,F,BAO_0000219,CHEMBL616046,1003
,51,H,8,,,,2759,,Compound was tested for its potency against 5-hydroxytryptamine 1A receptor expressed in CHO cells (experiment 2),1,,Autocuration,,449.0,,,CHO,,F,BAO_0000219,CHEMBL616047,1004
,51,H,8,,,,2759,,Compound was tested for its potency against human 5-hydroxytryptamine 1A receptor expressed in CHO cells,1,,Autocuration,,449.0,,,CHO,,F,BAO_0000219,CHEMBL616048,1005
,51,D,9,,,,2759,,Potency against human 5-hydroxytryptamine 1A receptor expressed in CHO cells (experiment 1),1,Homo sapiens,Expert,,449.0,,9606.0,CHO,,F,BAO_0000219,CHEMBL616049,1006
,51,H,8,,,,2759,,Compound was tested for its potency against human 5-hydroxytryptamine 1A receptor expressed in CHO cells (experiment 2),1,,Autocuration,,449.0,,,CHO,,F,BAO_0000219,CHEMBL616050,1007
,51,H,8,,,,15419,,In vitro effective concentration required to inhibit forskolin-stimulated cAMP levels in HA7 cells expressing human 5-HT1A receptor,1,,Expert,,,,,,,F,BAO_0000219,CHEMBL616051,1008
,51,H,8,,,,15419,,In vitro effective concentration required to inhibit forskolin-stimulated cAMP levels in HA7 cells expressing human 5-HT1A receptor; Not tested,1,,Autocuration,,,,,,,F,BAO_0000219,CHEMBL616212,1009
,51,H,8,,,,16026,,"ability to influence the binding of [35S]GTP-gamma-S, to HeLa cell membranes expressing the human 5-hydroxytryptamine 1A receptor",1,,Autocuration,,,,,,,F,BAO_0000019,CHEMBL616213,1010
,51,H,8,In vitro,,,1414,,Ability to bind to 5-hydroxytryptamine 1A receptor from cloned human expressed in Ha7 cells,1,,Expert,,,,,,,B,BAO_0000219,CHEMBL616214,1011
,51,H,8,In vitro,,,1414,,Ability to bind to 5-hydroxytryptamine 1A receptor subtype from cloned human expressed in Ha7 cells,1,,Expert,,,,,,,B,BAO_0000219,CHEMBL616215,1012
,51,H,8,,,,12861,,Binding activity radioligand.,1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL616216,1013
,51,H,8,,,,12861,,Binding activity against 5-hydroxytryptamine 3 receptor from rat cortex homogenate using [3H]-Q-ICS 205-930 as radioligand.,1,,Autocuration,,,,,,,B,BAO_0000019,CHEMBL616217,1014
,51,H,8,,,,5104,,Binding affinity for human cloned 5-hydroxytryptamine 1A receptor,1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL616218,1015
,51,H,8,,,,5105,,Binding affinity for human cloned 5-hydroxytryptamine 1A receptor,1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL616219,1016
,51,H,8,,,,16312,,binding affinity towards human recombinant 5-hydroxytryptamine 1A receptor,1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL616220,1017
,51,D,9,,,,15180,,Displacement of [3H]8-hydroxy-2-(di-n-propylamino)tetralin from human 5-hydroxytryptamine 1A receptor,1,Homo sapiens,Expert,,,,9606.0,,,B,BAO_0000357,CHEMBL833493,1018
,51,H,8,,,,5033,,Ability to displace the radioligand [3H]-8-OH-DPAT from human 5-hydroxytryptamine 1A receptor,1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL616221,1019
,51,D,9,,,,16909,,Affinity constant on CHO cells expressing Human recombinant 5-hydroxytryptamine receptor 1A,1,Homo sapiens,Expert,,449.0,,9606.0,CHO,,B,BAO_0000219,CHEMBL616222,1020
,51,H,8,,,,2590,,Antagonistic affinity against cloned human 5-hydroxytryptamine 1A receptor,1,,Autocuration,,,,,,,F,BAO_0000019,CHEMBL616223,1021
,51,H,8,,,,2590,,Antagonistic affinity against cloned human 5-hydroxytryptamine 1A receptor; Not determined,1,,Autocuration,,,,,,,F,BAO_0000019,CHEMBL616224,1022
,51,H,8,,,,16394,,Binding affinity at human 5-hydroxytryptamine 1A receptor by inhibition of [3H]8-OH-DPAT binding in Chinese hamster ovary cell line,1,,Expert,,,,,,,B,BAO_0000019,CHEMBL616225,1023
,51,D,9,,,,4540,,Binding affinity to human cloned 5-hydroxytryptamine 1A receptor in HEK 293 cells using [3H]-8-OH- DPAT as radioligand,1,Homo sapiens,Expert,,722.0,,9606.0,HEK293,,B,BAO_0000219,CHEMBL616226,1024
,51,H,8,,,,17296,,Binding affinity against 5-hydroxytryptamine 1A human cloned receptors in HEK293 cells,1,,Autocuration,,722.0,,,HEK293,,B,BAO_0000219,CHEMBL616227,1025
,51,H,8,,,,17296,,Binding affinity against 5-hydroxytryptamine 1A human cloned receptors in HEK293 cells using [3H]8-OH-DPAT as radioligand,1,,Autocuration,,722.0,,,HEK293,,B,BAO_0000219,CHEMBL616228,1026
,51,H,8,,,,15779,,Binding affinity towards 5-hydroxytryptamine 1A receptor (human cloned receptor) in HEK293 cells using [3H]8-OH-DPAT as radioligand;,1,,Autocuration,,722.0,,,HEK293,,B,BAO_0000219,CHEMBL616229,1027
,51,H,8,,,,15779,,Binding affinity towards 5-hydroxytryptamine 1A receptor (human cloned receptor) in HEK293 cells using [3H]8-OH-DPAT as radioligand; ND means no data,1,,Autocuration,,722.0,,,HEK293,,B,BAO_0000219,CHEMBL616230,1028
,51,H,8,,,,15779,,Binding affinity towards 5-hydroxytryptamine 1A receptor (human cloned receptor) in HEK293 cells using [3H]8-OH-DPAT as radioligand;ND means no data.,1,,Autocuration,,722.0,,,HEK293,,B,BAO_0000219,CHEMBL616231,1029
,51,H,8,,,,6166,,Binding affinity towards 5-hydroxytryptamine 1A receptor in human using [3H]8-OH-DPAT as radioligand,1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL616232,1030
,51,H,8,,,,15779,,Binding affinity towards 5-hydroxytryptamine 1A receptor (human cloned receptor) in HEK293 cells using [3H]8-OH-DPAT as radioligand;,1,,Autocuration,,722.0,,,HEK293,,B,BAO_0000219,CHEMBL616233,1031
,51,H,8,,,,4199,,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 1A receptor in HEK 293 cells using [3H]8-OH-DPAT as the radioligand,1,,Autocuration,,722.0,,,HEK293,,B,BAO_0000219,CHEMBL857973,1032
,51,H,8,,,,15316,,Compound was evaluated for its ability to displace [3H]8-OH-DPAT binding from human 5-hydroxytryptamine 1A receptor in mammalian cells,1,,Autocuration,,,,,,,B,BAO_0000219,CHEMBL616234,1033
,51,H,8,,,,14875,,Compound was tested for binding affinity against human 5-hydroxytryptamine 1A receptor,1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL616235,1034
,51,H,8,,,,14727,,Binding affinity at human cloned 5-hydroxytryptamine 1A receptor expressed in HeLa cells by [3H]8-hydroxy-2-(di-n-propylamino)tetraline displacement.,1,,Expert,,308.0,,,HeLa,,B,BAO_0000219,CHEMBL616236,1035
,51,H,8,,,,14727,,Binding affinity at native 5-hydroxytryptamine 1A receptor in rat by [3H]8-hydroxy-2-(di-n-propylamino)tetraline displacement.,1,,Expert,,,,,,,B,BAO_0000019,CHEMBL616237,1036
,51,H,8,,,,15146,,Compound was tested for its binding affinity against 5-hydroxytryptamine 1A receptor in human cloned receptors in HEK 293 cells using [3H]8-OH-DPAT,1,,Autocuration,,722.0,,,HEK293,,B,BAO_0000219,CHEMBL616238,1037
,51,H,8,,,,5213,,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 1A receptor in HEK 293 using [3H]5-CT as a radioligand,1,,Autocuration,,722.0,,,HEK293,,B,BAO_0000219,CHEMBL616239,1038
,51,H,8,,,,16429,,In vitro binding affinity at human recombinant 5-hydroxytryptamine 1A receptor in mammalian cells using 3[H]8-OH-DPAT as the radioligand,1,,Autocuration,,,,,,,B,BAO_0000219,CHEMBL616240,1039
,51,D,9,,,,15042,,The binding affinity was evaluated on cloned human 5-hydroxytryptamine 1A receptor expressed in HeLa cells by using DPAT as radioligand.,1,Homo sapiens,Expert,,308.0,,9606.0,HeLa,,B,BAO_0000219,CHEMBL616241,1040
,51,H,8,,,,14818,,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 1A receptor in HEK 293 cells using [3H]8-OH-DPAT.,1,,Autocuration,,722.0,,,HEK293,,B,BAO_0000219,CHEMBL616242,1041
,51,H,8,,,,4829,,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 1A receptor in HEK293 cells, using [3H]8-OH-DPAT as radioligand",1,,Autocuration,,722.0,,,HEK293,,B,BAO_0000219,CHEMBL616243,1042
,51,D,9,,,,17200,,In vitro inhibitory concentration required against [3H]8-OH-DPAT binding to cloned human 5-hydroxytryptamine 1A receptor,1,,Expert,,,,,,,B,BAO_0000357,CHEMBL616244,1043
,51,D,9,,,,13051,,The compound was tested for binding affinity against cloned human 5-hydroxytryptamine 1A receptor,1,Homo sapiens,Autocuration,,,,9606.0,,,B,BAO_0000357,CHEMBL616245,1044
,106,H,8,,,,5486,,Binding affinity towards 5-HT1B receptor by the displacement of [3H]-5-CT] in human recombinant receptors in mammalian cell,1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL616246,1045
,105,H,8,,,,5254,,Binding affinity against 5-HT1D receptor,1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL616247,1046
,105,H,8,,,,5254,,Binding affinity against 5-hydroxytryptamine 1A receptor,1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL616248,1047
,107,H,8,,,,15331,,Affinity of compound towards 5-hydroxytryptamine 1A receptor was evaluated using radioligand binding technique,1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL616249,1048
,10576,H,8,,,,13506,,Binding affinity against serotonin 5-hydroxytryptamine 1A receptor using radioligand [3H]8-OH-DPAT binding assay,1,Homo sapiens,Autocuration,,,,9606.0,,,B,BAO_0000357,CHEMBL616250,1049
,51,H,8,,,,15267,,Inhibition of [3H]- 8-OH-DAPT binding against human recombinant 5-hydroxytryptamine 1A receptor,1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL616251,1050
,11863,H,8,In vivo,,,16616,,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice 15 min after administration of the compound,1,,Autocuration,,,,,,,F,BAO_0000218,CHEMBL616252,1051
,11863,H,8,In vivo,,,16616,,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice 30 min after administration of the compound,1,,Autocuration,,,,,,,F,BAO_0000218,CHEMBL616253,1052
,11863,H,8,In vivo,,,16616,,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice 60 min after administration of the compound,1,,Autocuration,,,,,,,F,BAO_0000218,CHEMBL616254,1053
,11863,D,9,,,,16616,,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice at 10 mg/kg after 15 min,1,Mus musculus,Expert,,,,10090.0,,,F,BAO_0000218,CHEMBL616255,1054
,11863,D,9,,,,16616,,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice at 10 mg/kg after 30 min,1,Mus musculus,Expert,,,,10090.0,,,F,BAO_0000218,CHEMBL832872,1055
,11863,D,9,,,,16616,,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice at 10 mg/kg after 60 min,1,Mus musculus,Expert,,,,10090.0,,,F,BAO_0000218,CHEMBL616256,1056
,11863,D,9,,,,16616,,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice at 1 mg/kg after 15 min,1,Mus musculus,Expert,,,,10090.0,,,F,BAO_0000218,CHEMBL616257,1057
,11863,D,9,,,,16616,,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice at 1 mg/kg after 30 min,1,Mus musculus,Expert,,,,10090.0,,,F,BAO_0000218,CHEMBL616258,1058
,11863,D,9,,,,16616,,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice at 1 mg/kg after 60 min,1,Mus musculus,Expert,,,,10090.0,,,F,BAO_0000218,CHEMBL616384,1059
Hippocampus,11863,H,8,,,,10297,,Hill number was determined for inhibition of of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor in mouse hippocampus,1,,Autocuration,,,,,,10000000.0,B,BAO_0000221,CHEMBL616385,1060
,11863,H,8,,,,13704,,Inhibitory activity against serotonin 5-hydroxytryptamine 1A receptor from mice.,1,,Expert,,,,,,,B,BAO_0000357,CHEMBL616386,1061
Hippocampus,11863,D,9,,,,10297,,Inhibitory activity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in mouse hippocampus,1,Mus musculus,Expert,,,,10090.0,,10000000.0,B,BAO_0000221,CHEMBL616387,1062
Hippocampus,11863,H,8,,,,10297,,Binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in mouse hippocampus; Not determined,1,,Autocuration,,,,,,10000000.0,B,BAO_0000221,CHEMBL616388,1063
Hippocampus,11863,D,9,,,,10297,,Binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in mouse hippocampus,1,Mus musculus,Expert,,,,10090.0,,10000000.0,B,BAO_0000221,CHEMBL616389,1064
Hippocampus,11863,H,8,,,,10297,,Binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in mouse hippocampus; Not determined,1,,Autocuration,,,,,,10000000.0,B,BAO_0000221,CHEMBL616390,1065
,11863,H,8,,,,217,,Compound was tested for binding affinity to 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as a radioligand,1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL616391,1066
Hippocampus,11863,D,9,,,,10297,,Hill number was determined for inhibition of of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor in mouse hippocampus,1,Mus musculus,Expert,,,,10090.0,,10000000.0,B,BAO_0000221,CHEMBL616392,1067
,51,H,8,,,,4921,,Ability to displace [3H]8-OH-DPAT radioligand from porcine 5-hydroxytryptamine 1A receptor,1,Sus scrofa,Autocuration,,,,9823.0,,,B,BAO_0000357,CHEMBL616393,1068
,51,H,8,,,,4921,,Ability to displace [3H]8-OH-DPAT radioligand from porcine 5-hydroxytryptamine 1A receptor; ND denotes not determined,1,Sus scrofa,Autocuration,,,,9823.0,,,B,BAO_0000357,CHEMBL616394,1069
,51,H,8,,,,4996,,Binding affinity of compound measured for 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT-labeled porcine brain homogenates,1,Sus scrofa,Autocuration,,,,9823.0,,,B,BAO_0000019,CHEMBL616395,1070
,51,H,8,,,,12918,,Compound was evaluated for the binding affinity at 5- HT1A receptor,1,Sus scrofa,Autocuration,,,,9823.0,,,B,BAO_0000357,CHEMBL616396,1071
,51,H,8,,,,5333,,Compound was tested in vitro for its ability to compete with [3H]8-OH-DPAT at 5-hydroxytryptamine 1A receptor in porcine brain homogenate,1,Sus scrofa,Autocuration,,,,9823.0,,,B,BAO_0000019,CHEMBL872907,1072
,51,H,8,,,,4437,,In vitro for its ability to displace [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor in porcine brain homogenate,1,Sus scrofa,Autocuration,,,,9823.0,,,B,BAO_0000019,CHEMBL616397,1073
,51,H,8,,,,1742,,Compound was tested for its ability to displace [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor in pig cortex,1,Sus scrofa,Autocuration,,,,9823.0,,,B,BAO_0000019,CHEMBL616398,1074
,51,H,8,,,,16688,,Displacement of [3H]- 8-OH-DPAT from porcine 5-hydroxytryptamine 1A receptor,1,Sus scrofa,Expert,,,,9823.0,,,B,BAO_0000357,CHEMBL616399,1075
,51,H,8,,,,12861,,Binding activity radioligand.,1,Sus scrofa,Autocuration,,,,9823.0,,,B,BAO_0000357,CHEMBL857065,1076
,51,H,8,,,,12861,,Binding activity against 5-hydroxytryptamine 1A receptor from pig cortex membrane using [3H]8-OH-DPAT-HT as radioligand.,1,Sus scrofa,Expert,,,,9823.0,,,B,BAO_0000019,CHEMBL616400,1077
,51,H,8,,,,12861,,Binding activity against 5-hydroxytryptamine 1A receptor from pig cortex membrane using [3H]8-OH-DPAT-HT as radioligand.,1,Sus scrofa,Autocuration,,,,9823.0,,,B,BAO_0000019,CHEMBL616401,1078
,10624,H,8,,,,12490,,Displacement of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor from pig cortex,1,,Expert,,,,,,,B,BAO_0000019,CHEMBL616402,1079
,51,H,8,,,,11828,,Displacement of [3H]8-OH-DPAT from pig cortex 5-hydroxytryptamine 1A receptor,1,Sus scrofa,Expert,,,,9823.0,,,B,BAO_0000019,CHEMBL616403,1080
Hippocampus,51,H,8,,,,11866,,Binding affinity for 5-hydroxytryptamine 1A receptor in piglet hippocampus using [3H]8-OH-DPAT,1,Sus scrofa,Autocuration,,,,9823.0,,10000000.0,B,BAO_0000221,CHEMBL616404,1081
,51,H,8,,,,12827,,Binding affinity towards 5-hydroxytryptamine 1A receptor in pig frontal cortex membranes using [8H]-OH-DPAT,1,Sus scrofa,Autocuration,,,,9823.0,,,B,BAO_0000249,CHEMBL616405,1082
,51,H,8,,,,12918,,Binding affinity was evaluated by 5-hydroxytryptamine 1A receptor agonism in the pig cortex by displacing 8-OH-DPAT,1,Sus scrofa,Autocuration,,,,9823.0,,,B,BAO_0000019,CHEMBL616406,1083
,51,H,8,,,,12919,,Agonistic activity against 5-hydroxytryptamine 1A receptor in pig cortex using [3H]8-OH-DPAT,1,Sus scrofa,Expert,,,,9823.0,,,F,BAO_0000019,CHEMBL616407,1084
,51,H,8,,,,13047,,Binding affinity against 5-hydroxytryptamine 1 receptor using rabbit jugular vein assay in the presence of endothelium,1,Oryctolagus cuniculus,Autocuration,,,,9986.0,,,B,BAO_0000019,CHEMBL616408,1085
,10576,D,9,,,,15796,,Inhibition activity against 5-hydroxytryptamine 1A receptor in rat hippocampus membranes using radio binding assays,1,Rattus norvegicus,Expert,,,,10116.0,,,B,BAO_0000249,CHEMBL616409,1086
Hippocampus,10576,D,9,,,,3651,,"Inhibition of [3H]8-hydroxy-2-dipropylamino-1,2,3,4-tetrahydronaphthalene binding to 5-hydroxytryptamine 1A receptor in hippocampus region of rat brain; Less active",1,Rattus norvegicus,Expert,,,,10116.0,,10000000.0,B,BAO_0000221,CHEMBL616410,1087
,10576,H,8,,,,188,,Tested for the effect on binding at 5-hydroxytryptamine 1A receptor; No activity,1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL616411,1088
,10576,D,9,,,Membranes,16616,,"Antagonist activity to stimulate binding of [35S]GTP-gamma-S, to 5-hydroxytryptamine 1A receptor in isolated rat hippocampal membranes",1,Rattus norvegicus,Expert,,,,10116.0,,,F,BAO_0000249,CHEMBL616412,1089
Hippocampus,10576,D,9,,,Membranes,16616,,"Inhibition of (+)-8-OH-DPAT stimulated [35S]GTP-gamma-S, binding in rat hippocampal membranes",1,Rattus norvegicus,Expert,,,,10116.0,,10000000.0,F,BAO_0000249,CHEMBL616413,1090
Hippocampus,10576,H,8,,,,12306,,The binding of [125I]MPPI ligand to 5-hydroxytryptamine 1A receptor of rat hippocampal homogenates,1,,Autocuration,,,,,,10000000.0,B,BAO_0000221,CHEMBL616414,1091
Hippocampus,10576,D,9,,,,17167,,Binding affinity for rat hippocampus 5-hydroxytryptamine 1A receptor by inhibition of [3H]8-OH-DPAT binding,1,Rattus norvegicus,Expert,,,,10116.0,,10000000.0,B,BAO_0000221,CHEMBL616415,1092
,10576,H,8,,,,14776,,Binding affinity measured at the 5-hydroxytryptamine 1A receptor by the inhibition of [3H]8-OH-DPAT binding to rat cortex using unlabeled buspirone for nonspecific binding.,1,,Autocuration,,,,,,,B,BAO_0000019,CHEMBL616416,1093
,10576,H,8,,,,12158,,Binding affinity of 5-hydroxytryptamine 1A receptor using [3H]-8-OH-DPAT as radioligand.,1,,Expert,,,,,,,B,BAO_0000357,CHEMBL616417,1094
,10576,H,8,,,,13481,,Binding affinity of [3H]- -8-OH-DPAT labelled towards Rat Hippocampal 5-hydroxytryptamine 1A receptor using radioligand binding assay,1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL616418,1095
,10576,H,8,In vitro,,,13427,,Binding affinity of [3H]-8-OH-DPAT towards 5-hydroxytryptamine 1A receptor in cloned mammalian receptor expressed in cultured cells or from rat whole brain.,1,,Autocuration,,,,,,,B,BAO_0000219,CHEMBL616419,1096
,10576,H,8,,,,10210,,Binding affinity of compound against 5-hydroxytryptamine 1A receptor binding site using radioligand [3H]8-OH-DPAT,1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL616420,1097
,10576,H,8,,,Membranes,10205,,Binding affinity of compound towards 5-HT 1A receptor by measuring ability to displace [3H]OH-DPAT from 5-hydroxytryptamine 1A receptor in rat striatal membranes,1,,Autocuration,,,,,,,B,BAO_0000249,CHEMBL616421,1098
,10576,H,8,,,Membranes,10205,,Binding affinity of compound towards 5-HT 1A receptor by measuring ability to displace [3H]OH-DPAT from 5-hydroxytryptamine 1A receptor in rat striatal membranes,1,,Autocuration,,,,,,,B,BAO_0000249,CHEMBL616422,1099
,10576,H,8,,,Membranes,10205,,Binding affinity of compound towards 5-hydroxytryptamine 1A receptor in rat striatal membranes by [3H]OH-DPAT displacement.,1,,Expert,,,,,,,B,BAO_0000249,CHEMBL616423,1100
,10576,D,9,,,,12280,,Binding affinity for 5-hydroxytryptamine 1A receptor with [3H]5-HT,1,Rattus norvegicus,Expert,,,,10116.0,,,B,BAO_0000357,CHEMBL616424,1101
,10576,H,8,,,,17386,,Binding affinity to the rat 5-hydroxytryptamine 1A receptor,1,,Expert,,,,,,,B,BAO_0000357,CHEMBL616425,1102
,10576,H,8,,,,13654,,Binding affinity was tested on 5-hydroxytryptamine 1A receptor using radioligand [3H]5-HT binding assay.,1,,Expert,,,,,,,B,BAO_0000357,CHEMBL616426,1103
Hippocampus,10576,H,8,,,,14423,,Binding affinity against 5-hydroxytryptamine 1A receptor from rat hippocampus using [3H]8-OH-DPAT as the radioligand.,1,,Autocuration,,,,,,10000000.0,B,BAO_0000221,CHEMBL616427,1104
Hippocampus,10576,H,8,,,,15412,,Binding affinity against 5-hydroxytryptamine 1A receptor of rat hippocampus tissue.,1,,Autocuration,,,,,,10000000.0,B,BAO_0000221,CHEMBL616428,1105
Hippocampus,10576,H,8,,,,12073,,Binding affinity by measuring displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor in rat hippocampus,1,,Autocuration,,,,,,10000000.0,B,BAO_0000221,CHEMBL616290,1106
,10576,D,9,,,,4101,,Displacement of [3H]8-OH-DPAT from rat striata 5-hydroxytryptamine 1A receptor,1,Rattus norvegicus,Expert,,,,10116.0,,,B,BAO_0000357,CHEMBL616052,1107
,10576,H,8,,,,10062,,Binding affinity in radioreceptor binding assay by using [3H]5-HT radioligand against 5-hydroxytryptamine 1A receptor,1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL616053,1108
,10576,H,8,,,,6238,,Binding affinity towards 5-HT 1A receptor in rat cerebral cortex membranes using [3H]8-OH-DPAT as radioligand,1,,Autocuration,,,,,,,B,BAO_0000249,CHEMBL616054,1109
,10576,H,8,,,,16273,,Binding affinity towards 5-hydroxytryptamine 1A receptor,1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL616055,1110
,10576,H,8,,,,11139,,Binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand in competitive binding assay,1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL616056,1111
,10576,H,8,,,,16796,,Binding affinity towards 5-hydroxytryptamine 1A receptor from rat hippocampal membranes,1,,Expert,,,,,,,B,BAO_0000019,CHEMBL616057,1112
Brain,10576,D,9,,,,9548,,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat brain,1,Rattus norvegicus,Expert,,,,10116.0,,955.0,B,BAO_0000221,CHEMBL616058,1113
Brain,10576,H,8,,,,10381,,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat brain,1,,Autocuration,,,,,,955.0,B,BAO_0000221,CHEMBL616059,1114
,10576,H,8,,,,13408,,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat hypocampus membrane using [3H]8-OH-DPAT as radioligand,1,,Autocuration,,,,,,,B,BAO_0000249,CHEMBL616060,1115
Hippocampus,10576,D,9,,,,13825,,Binding affinity towards 5-hydroxytryptamine 1A receptor in the rat brain (hippocampus) using [3H]8-OH-DPAT,1,Rattus norvegicus,Expert,,,,10116.0,,10000000.0,B,BAO_0000221,CHEMBL616061,1116
Hippocampus,10576,H,8,,,,11147,,Binding affinity towards 5-hydroxytryptamine 1A receptor of rat hippocampus using [3H]-8-hydroxy-2-(di-n-propylamine) tetralin (8-OH-DPAT) as a radioligand,1,,Expert,,,,,,10000000.0,B,BAO_0000221,CHEMBL616062,1117
,10576,H,8,,,,10552,,Binding affinity towards 5-hydroxytryptamine 1A receptor sites in cortical membranes using [3H]8-OH-DPAT as radioligand,1,,Autocuration,,,,,,,B,BAO_0000249,CHEMBL616063,1118
Striatum,10576,H,8,,,,10552,,"Binding affinity towards 5-hydroxytryptamine 1A receptor sites, in rat striatum membranes using [3H]- sandoz 205-501 as radioligand",1,,Autocuration,,,,,,2435.0,B,BAO_0000249,CHEMBL616064,1119
,10576,D,9,,,Membranes,17136,,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor of rat cortex membranes,1,Rattus norvegicus,Expert,,,,10116.0,,,B,BAO_0000249,CHEMBL616065,1120
,10576,D,9,,,Membranes,5778,,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor of rat cerebral cortex membranes,1,Rattus norvegicus,Expert,,,,10116.0,,,B,BAO_0000249,CHEMBL616066,1121
Hippocampus,10576,H,8,,,,13481,,Binding affinity towards rat hippocampal 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,1,,Autocuration,,,,,,10000000.0,B,BAO_0000221,CHEMBL616067,1122
Hippocampus,10576,H,8,,,,13481,,Binding affinity towards rat hippocampal 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand; Not tested,1,,Autocuration,,,,,,10000000.0,B,BAO_0000221,CHEMBL616068,1123
Hippocampus,10576,H,8,,,,13630,,Binding affinity against rat hippocampal 5-hydroxytryptamine 1A (5-HT1A) receptor determined using [3H]8-OH-DPAT as radioligand,1,,Intermediate,,,,,,10000000.0,B,BAO_0000221,CHEMBL616069,1124
,10576,H,8,,,,16245,,Binding was determined on 5-hydroxytryptamine 1A receptor in rat hippocampal membranes,1,,Expert,,,,,,,B,BAO_0000249,CHEMBL616070,1125
Hippocampus,10576,H,8,,,,14509,,Binding affinity was evaluated against 5-hydroxytryptamine 1A receptor on rat hippocampus using [3H]8-OH-DPAT as radioligand,1,,Autocuration,,,,,,10000000.0,B,BAO_0000221,CHEMBL616071,1126
Hippocampus,10576,H,8,,,,14509,,Binding affinity against 5-hydroxytryptamine 1A receptor on rat hippocampus using [3H]8-OH-DPAT as radioligand.,1,,Expert,,,,,,10000000.0,B,BAO_0000221,CHEMBL616072,1127
Hippocampus,10576,H,8,,,,14509,,Binding affinity was evaluated against 5-hydroxytryptamine 1A receptor on rat hippocampus using [3H]8-OH-DPAT as radioligand.; ND = Not determined,1,,Autocuration,,,,,,10000000.0,B,BAO_0000221,CHEMBL616073,1128
Hippocampus,10576,H,8,,,,14509,,Binding affinity was evaluated against 5-hydroxytryptamine 1A receptor on rat hippocampus using [3H]8-OH-DPAT as radioligand; ND = Not determined,1,,Autocuration,,,,,,10000000.0,B,BAO_0000221,CHEMBL616074,1129
,10576,H,8,,,,14256,,Binding affinity was evaluated by determining in vitro displacement of [3H]8-OH-DPAT from the central 5-hydroxytryptamine 1A receptor recognition site in rat frontal cortex homogenate.,1,,Expert,,,,,,,B,BAO_0000019,CHEMBL616075,1130
,10576,H,8,,,,11139,,Binding affinity was evaluated by using [3H]8-OH-DPAT radioligand by using competitive binding assay on 5-hydroxytryptamine 1A receptor,1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL616076,1131
,10576,D,9,,,,11047,,Binding affinity for 5-HT1A measured by displacing [3H]8-OH-DPAT from rat cortical membranes; Not determined,1,Rattus norvegicus,Expert,,,,10116.0,,,B,BAO_0000019,CHEMBL616077,1132
,10576,D,9,,,,11047,,Binding affinity for 5-hydroxytryptamine 1A receptor measured by displacing [3H]8-OH-DPAT from rat cortical membranes,1,Rattus norvegicus,Expert,,,,10116.0,,,B,BAO_0000019,CHEMBL616078,1133
,10576,D,9,,,,11047,,Binding affinity for 5-hydroxytryptamine 1A receptor measured by displacing [3H]8-OH-DPAT from rat cortical membranes;ND-Not determined,1,Rattus norvegicus,Expert,,,,10116.0,,,B,BAO_0000019,CHEMBL616079,1134
,10576,D,9,,,,2395,,Binding affinity against [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor expressed in CHO-K1 cells,1,Rattus norvegicus,Expert,,485.0,,10116.0,CHO-K1,,B,BAO_0000219,CHEMBL616080,1135
,10576,H,8,,,,9699,,Binding affinity towards 5-hydroxytryptamine 1A receptor,1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL616081,1136
Hippocampus,10576,D,9,,,,12028,,Binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [125I]trans-8-OH-PIPAT in membrane homogenates of hippocampal tissue of rat brain,1,Rattus norvegicus,Expert,,,,10116.0,,10000000.0,B,BAO_0000221,CHEMBL616082,1137
Hippocampus,10576,H,8,,,,12028,,Binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in membrane homogenates of hippocampal tissue of rat brain,1,,Autocuration,,,,,,10000000.0,B,BAO_0000221,CHEMBL616083,1138
,10576,H,8,,,,5815,,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat cerebral cortex,1,,Autocuration,,,,,,,B,BAO_0000019,CHEMBL616084,1139
,10576,H,8,,,,16616,,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat frontal cortex homogenates,1,,Expert,,,,,,,B,BAO_0000019,CHEMBL616085,1140
,10576,H,8,,,,5815,,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat cerebral cortex using [3H]-8-OH-DPAT,1,,Autocuration,,,,,,,B,BAO_0000019,CHEMBL616086,1141
Hippocampus,10576,H,8,,,,2761,,"Binding affinity towards 5-hydroxytryptamine 1A receptor using 0.1 nM [3H]-8-OH-DPAT (8-hydroxy-2-(di-n-propylamino)tet-ralin), from rat hippocampal homogenate",1,,Autocuration,,,,,,10000000.0,B,BAO_0000221,CHEMBL616087,1142
,10576,H,8,,,,13133,,Binding affinity was determined against 5-hydroxytryptamine 1A receptor using [3H]WB-4101,1,,Expert,,,,,,,B,BAO_0000357,CHEMBL616088,1143
,10576,H,8,,,,10444,,Binding affinity was determined against 5-hydroxytryptamine 1A receptor was determined in male Sprague-Dawley rat brain.,1,,Autocuration,,,,,,,B,BAO_0000019,CHEMBL616089,1144
,10576,D,9,,,,13278,,Binding affinity was measured against 5-hydroxytryptamine 1A receptor by displacement of [3H]8-OH-DPAT by lysergic acid amides,1,Rattus norvegicus,Expert,,,,10116.0,,,B,BAO_0000357,CHEMBL616090,1145
,10576,H,8,,,,15874,,Binding affinity was measured on cloned rat 5-hydroxytryptamine 1A receptor which is labeled by [3H]8-OH-DPAT,1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL616091,1146
Striatum,10576,H,8,,,Membranes,10552,,"Binding affinity of the compound towards 5-hydroxytryptamine 1A receptor sites, in rat striatum membranes using [3H]- sandoz 205-501 as radioligand",1,,Autocuration,,,,,,2435.0,B,BAO_0000249,CHEMBL616092,1147
,10576,H,8,,,,11130,,Binding constant against 5-hydroxytryptamine 1A receptor (in vitro),1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL616093,1148
,10576,H,8,In vivo,,,11130,,Binding constant against 5-hydroxytryptamine 1A receptor (in vivo),1,,Autocuration,,,,,,,B,BAO_0000218,CHEMBL616094,1149
Brain,10576,H,8,,,,14542,,Compound is evaluated for binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]-8-OH- -DPAT in rat brain cortex,1,,Autocuration,,,,,,955.0,B,BAO_0000221,CHEMBL616095,1150
,10576,D,9,,,,13670,,Inhibition of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor,1,Rattus norvegicus,Expert,,,,10116.0,,,B,BAO_0000357,CHEMBL616096,1151
,10576,H,8,,,,9888,,Binding affinity at [3H]8-OH-DPAT-Labeled 5-hydroxytryptamine 1A receptor sites in rat brain hippocampal membranes,1,,Expert,,,,,,,B,BAO_0000249,CHEMBL616097,1152
,10576,D,9,,,Membranes,3678,,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor of rat hippocampus membranes,1,Rattus norvegicus,Expert,,,,10116.0,,,B,BAO_0000249,CHEMBL616098,1153
Hippocampus,10576,H,8,,,,11332,,Compound was evaluated for in vitro binding affinity towards 5-hydroxytryptamine 1A receptor in rat hippocampus using [3H]8-OH-DPAT as radioligand,1,,Autocuration,,,,,,10000000.0,B,BAO_0000221,CHEMBL616099,1154
Hippocampus,10576,H,8,,,,11332,,Compound was evaluated for in vitro binding affinity towards serotonin 5-hydroxytryptamine 1A receptor receptor in rat hippocampus using [3H]8-OH-DPAT as radioligand,1,,Autocuration,,,,,,10000000.0,B,BAO_0000221,CHEMBL616100,1155
,10576,H,8,,,,1185,,Ability to displace [3H]-8-OH-DPAT from serotonergic 5-hydroxytryptamine 1A receptor,1,,Expert,,,,,,,B,BAO_0000357,CHEMBL616101,1156
,10576,H,8,,,,2014,,Binding affinity at 5-hydroxytryptamine 1A receptor in rat cerebral cortex membranes by [3H]8-OH-DPAT displacement.,1,,Expert,,,,,,,B,BAO_0000249,CHEMBL616102,1157
,10576,H,8,,,,1185,,Compound was evaluated for its ability to displace [3H]8-OH-DPAT from serotonergic 5-hydroxytryptamine 1A receptor,1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL616103,1158
,10576,H,8,,,,14429,,Compound was evaluated for its binding affinity against 5-hydroxytryptamine 1A receptor from rat cerebral cortex,1,,Expert,,,,,,,B,BAO_0000019,CHEMBL616104,1159
,10576,H,8,,,,16288,,"Binding affinity to 5-hydroxytryptamine 1A receptor (5-HT 1A receptor, serotonin receptor) from rat cortex using [3H]8-OH-DPAT as radioligand",1,,Expert,,,,,,,B,BAO_0000019,CHEMBL616105,1160
,10576,D,9,,,,5432,,Displacement of [3H]prazosin from rat cortex membrane 5-hydroxytryptamine 1A receptor,1,Rattus norvegicus,Expert,,,,10116.0,,,B,BAO_0000019,CHEMBL616106,1161
,10576,H,8,,,,14429,,Compound was evaluated for its binding affinity with 5-hydroxytryptamine 1A receptor using membranes prepared from rat cerebral cortex,1,,Autocuration,,,,,,,B,BAO_0000019,CHEMBL616107,1162
,10576,H,8,,,,13672,,Binding affinity towards rat 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT radioligand.,1,,Expert,,,,,,,B,BAO_0000357,CHEMBL616108,1163
Hippocampus,10576,H,8,,,,11296,,In vitro ability to displace [3H]8-hydroxy-2-(di-n-propylamino) tetralin binding from 5-hydroxytryptamine 1A receptor site in rat brain hippocampus,1,,Expert,,,,,,10000000.0,B,BAO_0000221,CHEMBL616109,1164
,10576,H,8,,,,11296,,In vitro ability to displace [3H]8-hydroxy-2-(di-n-propylamino) tetralin binding from 5-hydroxytryptamine 1A receptor site.,1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL616110,1165
,10576,H,8,,,,14749,,Binding affinity against rat 5-hydroxytryptamine 1A receptor in CHO cells.,1,,Expert,,449.0,,,CHO,,B,BAO_0000219,CHEMBL616111,1166
,10576,H,8,,,,15086,,Binding affinity towards 5-hydroxytryptamine 1A receptor from rat brain using [3H]-8-OH-DPAT as radioligand,1,,Expert,,,,,,,B,BAO_0000019,CHEMBL616112,1167
Hippocampus,10576,H,8,,,,13462,,Compound was tested for the Binding affinity against rat hippocampal 5-hydroxytryptamine 1A receptor by Radio ligand [3H]8-OH-DPAT binding assay.,1,,Autocuration,,,,,,10000000.0,B,BAO_0000221,CHEMBL616113,1168
,10576,H,8,,,,15363,,Compound was tested for the displacement of [3H]-8-OH- DPAT from rat brain 5-hydroxytryptamine 1A receptor,1,,Autocuration,,,,,,,B,BAO_0000019,CHEMBL616114,1169
,10576,H,8,,,,15363,,Compound was tested for the displacement of [3H]-8-OH- DPAT from rat brain 5-hydroxytryptamine 1A receptor,1,,Autocuration,,,,,,,B,BAO_0000019,CHEMBL616115,1170
,10576,H,8,,,,10796,,Compound was tested in vitro for binding affinity for 5-hydroxytryptamine 1A receptor,1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL616116,1171
Brain,10576,H,8,,,,12816,,Binding affinity for 5-hydroxytryptamine 1A receptor in rat brain tissue using [3H]8-OH-DPAT as radioligand,1,,Expert,,,,,,955.0,B,BAO_0000221,CHEMBL615844,1172
Hippocampus,10576,H,8,,,,13542,,In vitro displacement of [3H]8-OH-DPAT binding to rat hippocampal 5-hydroxytryptamine 1A receptor,1,,Expert,,,,,,10000000.0,B,BAO_0000221,CHEMBL615939,1173
,10576,H,8,,,,13308,,In vitro ability to displace [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor sites of rat brain cortex.,1,,Expert,,,,,,,B,BAO_0000019,CHEMBL615940,1174
Hippocampus,10576,H,8,,,,13541,,In vitro affinity at 5-hydroxytryptamine 1A receptor of rat hippocampus by [3H]8-OH-DPAT displacement.,1,,Expert,,,,,,10000000.0,B,BAO_0000221,CHEMBL615941,1175
Hippocampus,10576,H,8,,,,10058,,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-HT1A receptor of rat hippocampus and the value ranges from 9 - 12,1,,Autocuration,,,,,,10000000.0,B,BAO_0000221,CHEMBL615942,1176
Hippocampus,10576,H,8,,,,10058,,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus,1,,Autocuration,,,,,,10000000.0,B,BAO_0000221,CHEMBL615943,1177
Hippocampus,10576,H,8,,,,10058,,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus (94%CI) from 12 to 17,1,,Autocuration,,,,,,10000000.0,B,BAO_0000221,CHEMBL615944,1178
Hippocampus,10576,H,8,,,,10058,,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus (94%CI) from 391-841,1,,Autocuration,,,,,,10000000.0,B,BAO_0000221,CHEMBL615945,1179
Hippocampus,10576,H,8,,,,10058,,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and the value ranges from 12 to 17.,1,,Autocuration,,,,,,10000000.0,B,BAO_0000221,CHEMBL615946,1180
Hippocampus,10576,H,8,,,,10058,,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and the value ranges from 12 to 20.,1,,Autocuration,,,,,,10000000.0,B,BAO_0000221,CHEMBL615947,1181
Hippocampus,10576,H,8,,,,10058,,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and the value ranges from 245 to 736,1,,Autocuration,,,,,,10000000.0,B,BAO_0000221,CHEMBL615948,1182
Hippocampus,10576,H,8,,,,10058,,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and the value ranges from 25 - 84,1,,Autocuration,,,,,,10000000.0,B,BAO_0000221,CHEMBL615949,1183
Hippocampus,10576,H,8,,,,10058,,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and the value ranges from 48 to 59,1,,Autocuration,,,,,,10000000.0,B,BAO_0000221,CHEMBL615950,1184
Hippocampus,10576,H,8,,,,10058,,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and the value ranges from 3 -5,1,,Autocuration,,,,,,10000000.0,B,BAO_0000221,CHEMBL615951,1185
Hippocampus,10576,H,8,,,,10058,,In vitro ability to inhibit [3H]-8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and value ranges from 15 - 31,1,,Autocuration,,,,,,10000000.0,B,BAO_0000221,CHEMBL615952,1186
Hippocampus,10576,H,8,,,,10058,,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and value ranges from 27 - 42,1,,Autocuration,,,,,,10000000.0,B,BAO_0000221,CHEMBL615953,1187
Hippocampus,10576,H,8,,,,10058,,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and value ranges from 6 - 13,1,,Autocuration,,,,,,10000000.0,B,BAO_0000221,CHEMBL615954,1188
Hippocampus,10576,D,9,,,,10058,,Inhibition of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus,1,Rattus norvegicus,Expert,,,,10116.0,,10000000.0,B,BAO_0000221,CHEMBL615955,1189
Hippocampus,10576,H,8,,,,10058,,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus.; ND is No Data.,1,,Autocuration,,,,,,10000000.0,B,BAO_0000221,CHEMBL615956,1190
Hippocampus,10576,H,8,,,,10058,,In vitro ability to inhibit [3H]-8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus. and the value ranges from 16 - 27,1,,Autocuration,,,,,,10000000.0,B,BAO_0000221,CHEMBL615957,1191
,10576,H,8,,,,12879,,Displacement of [3H]2-(di-N-propylamino)-8-hydroxytetralin from central 5-hydroxytryptamine 1A receptor recognition sites in rat frontal cortex homogenates.,1,,Expert,,,,,,,B,BAO_0000019,CHEMBL615958,1192
,10576,H,8,,,,11964,,Displacement of radioligand [3H]2-(di-N-propylamino)-8-hydroxytetralin from 5-hydroxytryptamine 1A receptor in rat frontal cortex homogenate,1,,Expert,,,,,,,B,BAO_0000019,CHEMBL615959,1193
,10576,H,8,,,,11964,,Displacement of radioligand [3H]2-(di-N-propylamino)-8-hydroxytetralin from 5-hydroxytryptamine 1A receptor in rat frontal cortex homogenate (experiment 1),1,,Autocuration,,,,,,,B,BAO_0000019,CHEMBL615960,1194
,10576,H,8,,,,11964,,Displacement of radioligand [3H]2-(di-N-propylamino)-8-hydroxytetralin from 5-hydroxytryptamine 1A receptor in rat frontal cortex homogenate (experiment 2),1,,Autocuration,,,,,,,B,BAO_0000019,CHEMBL615961,1195
Brain,10576,H,8,,,,9548,,Evaluated for binding affinity towards 5-hydroxytryptamine 1A receptor in rat brain,1,,Expert,,,,,,955.0,B,BAO_0000221,CHEMBL615962,1196
,10576,H,8,,,,9098,,Evaluated for the binding affinity to hippocampus striatal membranes at 5-hydroxytryptamine 1A receptor binding site by using [3H]-8-OH- DPAT as a radioligand.,1,,Expert,,,,,,,B,BAO_0000019,CHEMBL615963,1197
,10576,H,8,,,,9098,,Evaluated for the binding affinity to hippocampus striatal membranes at 5-hydroxytryptamine 1A receptor binding site by using [3H]-8-OH- DPAT as a radioligand; ND is no data.,1,,Autocuration,,,,,,,B,BAO_0000019,CHEMBL615964,1198
,10576,H,8,,,,9098,,Evaluated for the binding affinity to hippocampus striatal membranes at 5-hydroxytryptamine 1A receptor binding site by using [3H]-8-OH- DPAT as a radioligand;ND means no data,1,,Autocuration,,,,,,,B,BAO_0000019,CHEMBL615965,1199
,10576,H,8,,,,13248,,In vitro displacement of radioactively labeled ligand [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor site in CHO cells,1,,Expert,,449.0,,,CHO,,B,BAO_0000219,CHEMBL615966,1200
,10576,H,8,,,,3147,,In vitro ability to inhibit [3H]-8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor in rat cortical membranes,1,,Expert,,,,,,,B,BAO_0000249,CHEMBL615967,1201
,10576,H,8,,,,13949,,In vitro binding affinity against 5-hydroxytryptamine 1A receptor of rat cerebral cortex using [3H]8-OH-DPAT as radioligand.,1,,Expert,,,,,,,B,BAO_0000019,CHEMBL615968,1202
,10576,H,8,,,,11883,,In vitro binding affinity against 5-hydroxytryptamine 1A receptor using [3H]-8-OH-DPAT as radioligand in CHO cells (sc),1,,Autocuration,,449.0,,,CHO,,B,BAO_0000218,CHEMBL615969,1203
,10576,H,8,,,,11883,,In vitro binding affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT (agonist) as radioligand (sc),1,,Autocuration,,,,,,,B,BAO_0000218,CHEMBL615970,1204
,10576,D,9,,,,11883,,In vitro binding affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT,1,Rattus norvegicus,Expert,,,,10116.0,,,B,BAO_0000357,CHEMBL615971,1205
,10576,H,8,,,Membranes,15535,,In vitro binding affinity at 5-HT1A receptors assayed by displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor in rat hippocampal membranes,1,,Expert,,,,,,,B,BAO_0000249,CHEMBL615972,1206
,10576,H,8,,,,15535,,In vitro binding affinity at 5-HT1A receptor by measuring its ability to displace [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor in rat hippocampal membranes + cortex,1,,Autocuration,,,,,,,B,BAO_0000249,CHEMBL615973,1207
,10576,H,8,,,,15535,,In vitro binding affinity at 5-HT1A receptor by measuring its ability to displace [3H]-8-OH-DPAT from 5-hydroxytryptamine 1A receptor in rat hippocampal membranes+cortex,1,,Autocuration,,,,,,,B,BAO_0000249,CHEMBL615974,1208
,51,D,9,,,,16372,,Displacement of [3H]8-OH-DPAT from human 5-hydroxytryptamine 1A receptor expressed in CHO cells,1,Homo sapiens,Expert,,449.0,,9606.0,CHO,,B,BAO_0000219,CHEMBL615975,1209
,10576,H,8,,,,14608,,In vitro binding affinity for 5-hydroxytryptamine 1A receptor in rat hippocampal membranes by [125I]-labeled agonist displacement.,1,,Expert,,,,,,,B,BAO_0000249,CHEMBL615976,1210
Hippocampus,10576,D,9,,,,4795,,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor of rat hippocampus,1,Rattus norvegicus,Expert,,,,10116.0,,10000000.0,B,BAO_0000221,CHEMBL872106,1211
,10576,H,8,,,,13863,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand,1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL615977,1212
,10576,H,8,,,,13863,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=100-230,1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL615978,1213
,10576,H,8,,,,13863,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=12-14,1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL616166,1214
,10576,H,8,,,,13863,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=16-20,1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL616167,1215
,10576,H,8,,,,13863,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=160-430,1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL616168,1216
,10576,H,8,,,,13863,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=174-224,1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL616169,1217
,10576,H,8,,,,13863,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=184-503,1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL616170,1218
,10576,H,8,,,,13863,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=19-23,1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL616171,1219
,10576,H,8,,,,13863,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]-8-OH-DPAT as radioligand; range=2.2-3.2,1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL616172,1220
,10576,H,8,,,,13863,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=2.7-3.6,1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL616173,1221
,10576,H,8,,,,13863,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=20-23,1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL616174,1222
,10576,H,8,,,,13863,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]-8-OH-DPAT as radioligand; range=21-28,1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL616175,1223
,10576,H,8,,,,13863,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=240-760,1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL616176,1224
,10576,H,8,,,,13863,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]-8-OH-DPAT as radioligand; range=39-87,1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL616177,1225
,10576,H,8,,,,13863,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=4.6-5.2,1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL616178,1226
,10576,H,8,,,,9742,,Inhibitory activity tested in vitro at 5-hydroxytryptamine 1A receptor binding site in rat,1,,Autocuration,,,,,,,B,BAO_0000019,CHEMBL616179,1227
,10576,H,8,,,,12073,,Inhibitory concentration against 5-hydroxytryptamine 1A receptor,1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL616180,1228
,10576,H,8,,,,4101,,Inhibitory concentration against binding of 5-hydroxytryptamine 1A receptor from striata of male Wistar rats by displacement of [3H]8-OH-DPAT,1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL616181,1229
,10576,H,8,,,,15360,,Inhibitory concentration against radioligand [3H]hydroxy-2-(di-n-propylamino)-tetralin binding to 5-hydroxytryptamine 1A receptor in rat,1,,Autocuration,,,,,,,B,BAO_0000019,CHEMBL616182,1230
Hippocampus,10576,H,8,,,,11576,,Inhibitory concentration against radioligand [3H]8-OH-DPAT binding to rat hippocampal 5-hydroxytryptamine 1A receptor,1,,Autocuration,,,,,,10000000.0,B,BAO_0000221,CHEMBL616183,1231
,10576,H,8,,,,5834,,Inhibition of the 5-hydroxytryptamine 1A receptor in rat dorsal raphe,1,,Expert,,,,,,,B,BAO_0000019,CHEMBL615874,1232
,10576,D,9,,,,2395,,Inhibitory concentration against [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor expressed in CHO-K1 cells,1,Rattus norvegicus,Expert,,485.0,,10116.0,CHO-K1,,B,BAO_0000219,CHEMBL615875,1233
,10576,H,8,,,,1375,,Tested in vitro for receptor binding affinity to 5-hydroxytryptamine 1A receptor in rat cortex using [3H]OH-DPAT radioligand,1,,Autocuration,,,,,,,B,BAO_0000019,CHEMBL615876,1234
,10576,H,8,,,,1375,,Tested in vitro for receptor binding affinity to 5-hydroxytryptamine 1A receptor in rat cortex using [3H]OH-DPAT radioligand; NT means not tested,1,,Autocuration,,,,,,,B,BAO_0000019,CHEMBL615877,1235
,10576,H,8,,,,3967,,The compound was evaluated for the ability to displace [3H]- 8-OH -DPAT from 5-hydroxytryptamine 1A receptor ( striata of male wistar rats),1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL615878,1236
,10576,H,8,,,,12884,,Binding affinity towards 5-hydroxytryptamine 1A receptor binding site using [3H]8-OH-DPAT. ,1,,Expert,,,,,,,B,BAO_0000357,CHEMBL615879,1237
,10576,H,8,,,,2343,,Binding affinity towards 5-hydroxytryptamine 1A receptor using receptor binding assay,1,,Expert,,,,,,,B,BAO_0000357,CHEMBL615880,1238
,10576,H,8,,,,11511,,"The compound was tested in vitro for inhibitory activity against 5-HT1A receptor in rats, using [3H]8-OH-DPAT as radioligand",1,,Autocuration,,,,,,,B,BAO_0000019,CHEMBL615881,1239
,10576,D,9,,,,11511,,"Inhibitory activity against 5-hydroxytryptamine 1A receptor in rats, using [3H]8-OH-DPAT as radioligand",1,Rattus norvegicus,Expert,,,,10116.0,,,B,BAO_0000019,CHEMBL615882,1240
,10576,H,8,In vivo,,,16394,,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat,1,,Autocuration,,,,,,,F,BAO_0000218,CHEMBL615883,1241
,10576,H,8,In vivo,,,16394,,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.10-6.20),1,,Autocuration,,,,,,,F,BAO_0000218,CHEMBL615884,1242
,10576,H,8,In vivo,,,16394,,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.20-1.60),1,,Autocuration,,,,,,,F,BAO_0000218,CHEMBL615885,1243
,10576,H,8,In vivo,,,16394,,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.20-1.80),1,,Autocuration,,,,,,,F,BAO_0000218,CHEMBL615886,1244
,10576,H,8,In vivo,,,16394,,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.37-4.27),1,,Autocuration,,,,,,,F,BAO_0000218,CHEMBL615887,1245
,10576,H,8,In vivo,,,16394,,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.40-2.70),1,,Autocuration,,,,,,,F,BAO_0000218,CHEMBL615888,1246
,10576,H,8,In vivo,,,16394,,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.40-4),1,,Autocuration,,,,,,,F,BAO_0000218,CHEMBL615889,1247
,10576,H,8,In vivo,,,16394,,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.45-4.51),1,,Autocuration,,,,,,,F,BAO_0000218,CHEMBL615890,1248
,10576,H,8,In vivo,,,16394,,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.50-5.30),1,,Autocuration,,,,,,,F,BAO_0000218,CHEMBL615891,1249
,10576,H,8,In vivo,,,16394,,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.60-1.60),1,,Autocuration,,,,,,,F,BAO_0000218,CHEMBL615892,1250
,10576,H,8,In vivo,,,16394,,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.72-2.87),1,,Autocuration,,,,,,,F,BAO_0000218,CHEMBL615893,1251
,10576,H,8,In vivo,,,16394,,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.80-5.80),1,,Autocuration,,,,,,,F,BAO_0000218,CHEMBL615894,1252
,10576,H,8,In vivo,,,16394,,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (1.50-16.5),1,,Autocuration,,,,,,,F,BAO_0000218,CHEMBL615895,1253
,10576,H,8,In vivo,,,16394,,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (2.20-30.5),1,,Autocuration,,,,,,,F,BAO_0000218,CHEMBL615896,1254
,10576,H,8,In vivo,,,16394,,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges is not computable,1,,Autocuration,,,,,,,F,BAO_0000218,CHEMBL615897,1255
,10576,D,9,,,Membranes,16616,,"Percent increase of R(+)-8-OH-DPAT stimulated [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor in isolated rat hippocampal membranes",1,Rattus norvegicus,Expert,,,,10116.0,,,F,BAO_0000249,CHEMBL615898,1256
,10576,H,8,,,,16796,,% inhibition towards 5-HT1A receptor from rat hippocampal membranes,1,,Autocuration,,,,,,,B,BAO_0000019,CHEMBL615899,1257
,10576,H,8,,,,16796,,% inhibition towards 5-hydroxytryptamine 1A receptor from rat hippocampal membranes,1,,Autocuration,,,,,,,B,BAO_0000019,CHEMBL616291,1258
,10576,H,8,,,,15629,,Tested in vitro for % inhibition against (serotonin)5-HT 1A receptor.,1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL616292,1259
,10576,H,8,,,,13241,,"Ability to inhibit 5-HT sensitive,forskolin-stimulated adenylyl cyclase(FSC) activity in rat hippocampal membranes mediated through 5-hydroxytryptamine 1A receptor",1,,Autocuration,,,,,,,F,BAO_0000249,CHEMBL616293,1260
Hippocampus,10576,H,8,,,,12073,,Measurement of binding affinity by displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor in rat hippocampus,1,,Expert,,,,,,10000000.0,B,BAO_0000221,CHEMBL616294,1261
Hippocampus,10576,H,8,,,,14286,,Compound at 10E-5 M was tested in vitro for the inhibition of radioligand [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor in rat hippocampal membrane,1,,Autocuration,,,,,,10000000.0,B,BAO_0000249,CHEMBL616295,1262
Brain,10576,H,8,,,,14542,,Compound is evaluated for binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]-8-OH- -DPAT in rat brain cortex at 10 uM,1,,Autocuration,,,,,,955.0,B,BAO_0000221,CHEMBL616296,1263
,10576,H,8,,,,13630,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.1 uM + 10 uM 5-HT.,1,,Autocuration,,,,,,,F,BAO_0000019,CHEMBL616297,1264
,10576,H,8,,,,13630,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0+ 1 uM 5-HT.,1,,Autocuration,,,,,,,F,BAO_0000019,CHEMBL616605,1265
,10576,H,8,,,,13630,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.01 uM+ 1 uM 5-HT.,1,,Autocuration,,,,,,,F,BAO_0000019,CHEMBL616606,1266
,10576,H,8,,,,13630,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.05 uM,1,,Autocuration,,,,,,,F,BAO_0000019,CHEMBL616607,1267
,10576,H,8,,,,13630,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.05 uM,1,,Expert,,,,,,,F,BAO_0000019,CHEMBL616608,1268
,10576,H,8,,,,13630,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.05 uM+ 1 uM 5-HT.,1,,Autocuration,,,,,,,F,BAO_0000019,CHEMBL616609,1269
,10576,D,9,,,,13630,,Effect against 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at 0.1 uM dose,1,Rattus norvegicus,Expert,,,,10116.0,,,F,BAO_0000019,CHEMBL616610,1270
,10576,H,8,,,,13630,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.1 uM + 10 uM 5-HT.,1,,Autocuration,,,,,,,F,BAO_0000019,CHEMBL616611,1271
,10576,H,8,,,,13630,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.1 uM + 1 uM 5-HT.,1,,Expert,,,,,,,F,BAO_0000019,CHEMBL616612,1272
,10576,H,8,,,,13630,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.1 uM + 0.1 uM 5-HT.,1,,Autocuration,,,,,,,F,BAO_0000019,CHEMBL616613,1273
,10576,H,8,,,,13630,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 10 uM,1,,Expert,,,,,,,F,BAO_0000019,CHEMBL616614,1274
,10576,H,8,,,,13630,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 10 uM+ 10 uM 5-HT.,1,,Autocuration,,,,,,,F,BAO_0000019,CHEMBL616615,1275
,10576,H,8,,,,13630,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM,1,,Expert,,,,,,,F,BAO_0000019,CHEMBL616616,1276
,10576,H,8,,,,13630,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM+ 0.1 uM 5-HT.,1,,Autocuration,,,,,,,F,BAO_0000019,CHEMBL616617,1277
,10576,H,8,,,,13630,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM+ 10 uM 5-HT.,1,,Autocuration,,,,,,,F,BAO_0000019,CHEMBL616618,1278
,10576,H,8,,,,13630,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM+ 1 uM 5-HT.,1,,Autocuration,,,,,,,F,BAO_0000019,CHEMBL616619,1279
,10576,H,8,,,,13630,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM+ 3 uM 5-HT.,1,,Expert,,,,,,,F,BAO_0000019,CHEMBL616620,1280
,10576,H,8,,,,13630,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM+ 50 uM 5-HT.,1,,Expert,,,,,,,F,BAO_0000019,CHEMBL616621,1281
,10576,H,8,,,,13630,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 30 uM,1,,Autocuration,,,,,,,F,BAO_0000019,CHEMBL616622,1282
,10576,H,8,,,,13630,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 50 uM,1,,Expert,,,,,,,F,BAO_0000019,CHEMBL616146,1283
,10576,H,8,,,,13630,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 50 uM+ 50 uM 5-HT.,1,,Autocuration,,,,,,,F,BAO_0000019,CHEMBL832873,1284
,10576,H,8,,,,13630,,Effect on 5-hydroxytryptamine 1A receptor-mediated inhibition of VIP-stimulated cAMP production at dose of 0.1 uM,1,,Autocuration,,,,,,,F,BAO_0000019,CHEMBL616147,1285
,10576,H,8,,,,13630,,Effect on 5-hydroxytryptamine 1A receptor-mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM+ 10 uM 5-HT.,1,,Autocuration,,,,,,,F,BAO_0000019,CHEMBL872872,1286
,10576,H,8,,,,13630,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM,1,,Autocuration,,,,,,,F,BAO_0000019,CHEMBL616148,1287
Hippocampus,10576,H,8,,,,9783,,In vitro inhibition of [3H]spiperone binding to 5-hydroxytryptamine 1A receptor from rat hippocampal tissue,1,,Autocuration,,,,,,10000000.0,B,BAO_0000221,CHEMBL616149,1288
Hippocampus,10576,H,8,,,,9783,,In vitro inhibition of [3H]spiperone binding to 5-hydroxytryptamine 1A receptor from rat hippocampal tissue at 1 uM,1,,Expert,,,,,,10000000.0,B,BAO_0000221,CHEMBL616150,1289
,10576,D,9,,,Membranes,14331,,Inhibition of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor in rat hippocampal membranes at 10e-7 M,1,Rattus norvegicus,Expert,,,,10116.0,,,B,BAO_0000249,CHEMBL616151,1290
Hippocampus,10576,H,8,,,,15260,,Inhibitory activity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue at 1 uM,1,,Expert,,,,,,10000000.0,B,BAO_0000221,CHEMBL872873,1291
Hippocampus,10576,H,8,,,,15260,,Inhibitory activity against rat hippocampal tissue 5-hydroxytryptamine 1A receptor at 0.1 uM concentration,1,,Autocuration,,,,,,10000000.0,B,BAO_0000221,CHEMBL616670,1292
Hippocampus,10576,H,8,,,,15260,,Inhibitory activity against rat hippocampal tissue 5-hydroxytryptamine 1A receptor at 1 uM concentration,1,,Autocuration,,,,,,10000000.0,B,BAO_0000221,CHEMBL616671,1293
,10576,D,9,,,,16616,,"Percent inhibition of (+)-8-OH-DPAT stimulated [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor in hippocampal membranes",1,Rattus norvegicus,Expert,,,,10116.0,,,F,BAO_0000249,CHEMBL884861,1294
,10576,H,8,,,,15629,,Tested in vitro for % inhibition against (serotonin)5-HT 1A receptor,1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL616672,1295
,10576,H,8,,,,15086,,The compound was tested binding affinity against 5-hydroxytryptamine 1A receptor from rat brain using [3H]8-OH-DPAT as radioligand at 10e-6 M.,1,,Autocuration,,,,,,,B,BAO_0000019,CHEMBL616673,1296
,10576,H,8,,,,5717,,Antagonistic activity against 5-hydroxytryptamine 1A receptor in rat cerebral cortex using [3H]8-OH-DPAT as radioligand.,1,,Expert,,,,,,,F,BAO_0000019,CHEMBL616674,1297
,10576,H,8,,,,12652,,Binding affinity against the site labelled by the 5-hydroxytryptamine 1A receptor agonist [3H]- 8-OH-DPAT,1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL616675,1298
Hippocampus,10576,H,8,,,,14608,,In vitro binding affinity for 5-hydroxytryptamine 1A receptor was determined by measuring specific inhibition of [125I]-binding to rat hippocampal membrane preparations,1,,Autocuration,,,,,,10000000.0,B,BAO_0000221,CHEMBL616676,1299
Hippocampus,10576,H,8,,,,12306,,Inhibition of binding of [125I]-8-OH-PIPAT ligand to 5-hydroxytryptamine 1A receptor of rat hippocampal homogenates,1,,Autocuration,,,,,,10000000.0,B,BAO_0000221,CHEMBL616677,1300
Hippocampus,10576,H,8,,,,12306,,The binding of [125I]MPPI ligand to 5-hydroxytryptamine 1A receptor of rat hippocampal homogenates,1,,Autocuration,,,,,,10000000.0,B,BAO_0000221,CHEMBL616678,1301
,10576,D,9,,,,15247,,Ability to displace [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor,1,Rattus norvegicus,Expert,,,,10116.0,,,B,BAO_0000357,CHEMBL616679,1302
Hippocampus,10576,H,8,,,,17529,,Ability to bind to central serotonin 5-hydroxytryptamine 1A receptor in vitro in hippocampus of the rat brain using [3H]8-OH-DPAT radioligand,1,,Expert,,,,,,10000000.0,B,BAO_0000221,CHEMBL616680,1303
Hippocampus,10576,H,8,,,,14826,,Ability to displace [3H]- -OH-DPAT bound to 5-hydroxytryptamine 1A receptor in rat hippocampus,1,,Autocuration,,,,,,10000000.0,B,BAO_0000221,CHEMBL616681,1304
Hippocampus,10576,H,8,,,,14826,,Ability to displace [3H]- -(OH)-DPAT bound to 5-hydroxytryptamine 1A receptor in rat hippocampus,1,,Autocuration,,,,,,10000000.0,B,BAO_0000221,CHEMBL616682,1305
Hippocampus,10576,H,8,,,,13241,,Ability to displace [3H]8-OH-DPAT binding to rat hippocampal 5-hydroxytryptamine 1A receptor,1,,Autocuration,,,,,,10000000.0,B,BAO_0000221,CHEMBL616683,1306
Hippocampus,10576,H,8,,,,14093,,Ability to displace [3H]-8-OH-DPAT from rat hippocampal homogenate 5-hydroxytryptamine 1A receptor,1,,Autocuration,,,,,,10000000.0,B,BAO_0000221,CHEMBL616684,1307
Hippocampus,10576,H,8,,,,14093,,Ability to displace [3H]-8-OH-DPAT from rat hippocampal homogenate 5-hydroxytryptamine 1A receptor; Not tested,1,,Autocuration,,,,,,10000000.0,B,BAO_0000221,CHEMBL616685,1308
Brain,10576,H,8,,,,14442,,Affinity at [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor in rat brain homogenate was determined,1,,Autocuration,,,,,,955.0,B,BAO_0000221,CHEMBL616686,1309
,10576,H,8,,,,9919,,Affinity for 5-hydroxytryptamine 1A receptor site,1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL616687,1310
,10576,H,8,,,,9919,,Affinity for 5-hydroxytryptamine 1A receptor site,1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL616688,1311
Hippocampus,10576,H,8,,,,11440,,Affinity in displacing [3H]8-OH-DPAT from rat hippocampal 5-HT1A receptor.,1,,Autocuration,,,,,,10000000.0,B,BAO_0000221,CHEMBL616689,1312
,10576,H,8,,,,11257,,Affinity on 5-hydroxytryptamine 1A receptor labeled by [3H]8-OH-DPAT,1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL616690,1313
,10576,H,8,,,,10330,,Binding affinity against 5-hydroxytryptamine 1A receptor using [3H]-8-OH-DPAT as radioligand,1,,Expert,,,,,,,B,BAO_0000357,CHEMBL616691,1314
Hippocampus,10576,D,9,,,,17331,,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor of rat hippocampus mambranes,1,Rattus norvegicus,Expert,,,,10116.0,,10000000.0,B,BAO_0000221,CHEMBL616692,1315
,10576,H,8,,,,16567,,Binding affinity against 5-hydroxytryptamine 1A receptor by displacing [3H]8-OH-DPAT radioligand in rat cortex membrane,1,,Expert,,,,,,,B,BAO_0000249,CHEMBL616693,1316
,10576,D,9,,,,12058,,"Binding affinity against 5-hydroxytryptamine 1A receptor in homogenated rat brain tissue, using by [3H]8-OH-DPAT as radioligand",1,Rattus norvegicus,Expert,,,,10116.0,,,B,BAO_0000019,CHEMBL616694,1317
Hippocampus,10576,H,8,,,,9699,,Binding affinity against 5-hydroxytryptamine 1A receptor in rat hippocampal tissue,1,,Autocuration,,,,,,10000000.0,B,BAO_0000221,CHEMBL616695,1318
,10576,H,8,,,,9547,,Binding affinity against 5-hydroxytryptamine 1A receptor of rat was determined using [3H]8-OH-DPAT in binding assay,1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL616696,1319
,10576,H,8,,,,10330,,Binding affinity against 5-hydroxytryptamine 1A receptor using [3H]DOB as radioligand,1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL616697,1320
,10576,H,8,,,,14331,,Binding affinity against rat 5-hydroxytryptamine 1A receptor,1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL616698,1321
,10576,D,9,,,,14060,,Binding affinity against rat brain 5-hydroxytryptamine 1A receptor,1,Rattus norvegicus,Expert,,,,10116.0,,,B,BAO_0000019,CHEMBL616949,1322
Hippocampus,10576,H,8,,,,14744,,Binding affinity against the 5-hydroxytryptamine 1A receptor labelled with [3H]8-OH-DPAT in rat hippocampal homogenates,1,,Autocuration,,,,,,10000000.0,B,BAO_0000221,CHEMBL616950,1323
,10576,H,8,,,,13506,,Binding affinity against serotonin 5-hydroxytryptamine 1A receptor using radioligand [3H]8-OH-DPAT binding assay,1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL832875,1324
Brain,10576,H,8,,,,10862,,Binding affinity at 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in rat brain.,1,,Expert,,,,,,955.0,B,BAO_0000221,CHEMBL616951,1325
Brain,10576,H,8,,,,10862,,Binding affinity at 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in rat brain.,1,,Expert,,,,,,955.0,B,BAO_0000221,CHEMBL616952,1326
,10576,H,8,,,,10062,,Binding affinity at rat 5-hydroxytryptamine 1A receptor by [3H]WB-4101 displacement.,1,,Expert,,,,,,,B,BAO_0000357,CHEMBL616953,1327
,10576,H,8,,,,12073,,Binding affinity for 5-hydroxytryptamine 1A receptor by use of [3H]8-OH-DPAT in male rat,1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL616954,1328
,106,H,8,,,,14875,,GTPgammaS radioligand binding assay,1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL616955,1329
,106,H,8,,,,2391,,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor; Not determined,1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL616956,1330
,106,H,8,,,,2391,,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor; Partial agonist,1,,Autocuration,,,,,,,F,BAO_0000019,CHEMBL616957,1331
,106,H,8,,,,2391,,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor; Slient antagonist,1,,Autocuration,,,,,,,F,BAO_0000019,CHEMBL616958,1332
,106,H,8,,,,2391,,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor,1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL616959,1333
,106,H,8,,,,2391,,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor; Not determined,1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL616960,1334
,106,H,8,,,,2391,,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor; silent antagonist,1,,Autocuration,,,,,,,F,BAO_0000019,CHEMBL616961,1335
,106,H,8,,,,17211,,Ability to displace [3H]5-CT (1.5 nM) from HeLa cells of human 5-hydroxytryptamine 1B receptor,1,,Expert,,308.0,,,HeLa,,B,BAO_0000219,CHEMBL616962,1336
,106,H,8,,,,17211,,Ability to displace [3H]5-CT (1.5 nM) from HeLa cells of human 5-hydroxytryptamine 1B receptor receptor,1,,Autocuration,,308.0,,,HeLa,,B,BAO_0000219,CHEMBL616963,1337
,106,D,9,,,,6491,,Affinity towards human 5-hydroxytryptamine 1B serotonin receptor,1,Homo sapiens,Expert,,,,9606.0,,,B,BAO_0000357,CHEMBL616524,1338
,106,H,8,,,,16190,,Binding affinity against 5-hydroxytryptamine 1B receptor in CHO cells using [3H]5-HT as radioligand,1,,Autocuration,,449.0,,,CHO,,B,BAO_0000219,CHEMBL616525,1339
,106,H,8,,,,14165,,Binding affinity for 5-hydroxytryptamine 1B receptor in C6-glial transfected cell type using [3H]5-CT as radioligand,1,,Autocuration,,,,,,,B,BAO_0000019,CHEMBL872908,1340
,106,H,8,,,,14165,,Binding affinity for 5-hydroxytryptamine 1B receptor in C6-glial transfected cell type using [3H]GR-125743 as radioligand,1,,Autocuration,,,,,,,B,BAO_0000019,CHEMBL616526,1341
,106,D,9,,,,4234,,Binding affinity to cloned human 5-hydroxytryptamine 1B receptor,1,Homo sapiens,Expert,,,,9606.0,,,B,BAO_0000357,CHEMBL616527,1342
,106,H,8,,,,6328,,Binding affinity towards human 5-hydroxytryptamine 1B receptor in L-M(tk-) cells using [3H]GR-125743 as radioligand,1,,Expert,,,,,,,B,BAO_0000219,CHEMBL616528,1343
,106,H,8,,,,14770,,Binding affinity for recombinant human 5-hydroxytryptamine 1B receptor using [3H]5-HT as radioligand.,1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL616529,1344
,106,H,8,,,,2598,,Binding affinity was evaluated at human recombinant 5-hydroxytryptamine 1B receptor using [3H]5-CT as radioligand,1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL616530,1345
,106,H,8,,,,6897,,Binding affinity was evaluated at the cloned human 5-hydroxytryptamine 1B receptor,1,,Expert,,,,,,,B,BAO_0000357,CHEMBL616531,1346
,106,H,8,,,,6897,,Binding affinity was evaluated at the cloned human 5-hydroxytryptamine 1B receptor,1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL616532,1347
,106,H,8,,,,6013,,Binding affinity towards 5-hydroxytryptamine 1B receptor,1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL616533,1348
,106,H,8,,,,5843,,Binding affinity towards cloned human 5-hydroxytryptamine 1B receptor,1,,Expert,,,,,,,B,BAO_0000357,CHEMBL616534,1349
,106,H,8,,,,14454,,Binding affinity towards human 5-hydroxytryptamine 1B receptor using [3H]5-HT trifluoroacetate as radioligand,1,,Expert,,,,,,,B,BAO_0000357,CHEMBL616535,1350
,106,H,8,,,,16209,,Binding affinity towards human 5-hydroxytryptamine 1B receptor using [3H]5-HT radioligand,1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL616536,1351
,106,H,8,,,,3935,,Compound was evaluated for its binding affinity for human 5-hydroxytryptamine 1B receptor,1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL616537,1352
,106,H,8,,,,13729,,Ability to inhibit the forskolin-stimulated c-AMP formation mediated by human 5-hydroxytryptamine 1B receptor in CHO-K1 cells,1,,Expert,,485.0,,,CHO-K1,,F,BAO_0000219,CHEMBL616538,1353
,106,H,8,,,,14251,,Agonist activity to the human recombinant 5-hydroxytryptamine 1B receptor,1,,Expert,,,,,,,F,BAO_0000019,CHEMBL616539,1354
,106,H,8,,,,17085,,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1B receptor,1,,Expert,,,,,,,B,BAO_0000019,CHEMBL616540,1355
,106,H,8,,,,3025,,In vitro binding affinity was determined towards cloned human 5-hydroxytryptamine 1B receptor using [3H]5-CT radioligand,1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL616429,1356
,106,H,8,,,,15315,,In vitro receptor binding affinity for cloned human 5-hydroxytryptamine 1B receptor,1,,Expert,,,,,,,B,BAO_0000357,CHEMBL616430,1357
,106,D,9,,,,14214,,Receptor binding affinity for cloned human 5-hydroxytryptamine 1B receptor in Cos-7 cells,1,Homo sapiens,Expert,,,,9606.0,,,B,BAO_0000219,CHEMBL616431,1358
,106,D,9,,,,3804,,Binding affinity towards cloned human 5-hydroxytryptamine 1B receptor,1,Homo sapiens,Expert,,,,9606.0,,,B,BAO_0000357,CHEMBL616432,1359
,106,D,9,,,,2391,,Affinity for 5-hydroxytryptamine 1B receptor subtype,1,Homo sapiens,Expert,,,,9606.0,,,B,BAO_0000357,CHEMBL616433,1360
,106,D,9,,,,4175,,Binding affinity for human 5-hydroxytryptamine 1B receptor,1,Homo sapiens,Expert,,,,9606.0,,,B,BAO_0000357,CHEMBL616434,1361
,106,H,8,,,,17296,,Binding affinity against cloned human 5-hydroxytryptamine 1B receptor in CHO cells using [3H]5-CT as radioligand; Not determined,1,,Autocuration,,449.0,,,CHO,,B,BAO_0000219,CHEMBL616435,1362
,106,H,8,,,,17085,,In vitro binding affinity was determined by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1B receptor; ND means not determined,1,,Expert,,,,,,,B,BAO_0000019,CHEMBL616436,1363
,106,H,8,,,,17211,,Ability to displace [3H]5-CT (1.5 nM) from HeLa cells of human 5-hydroxytryptamine 1B receptor; NT denotes not tested,1,,Autocuration,,308.0,,,HeLa,,B,BAO_0000219,CHEMBL616437,1364
,106,H,8,,,,17211,,Ability to displace [3H]5-CT (1.5 nM) from HeLa cells of human 5-hydroxytryptamine 1B receptor; NT=not tested,1,,Autocuration,,308.0,,,HeLa,,B,BAO_0000219,CHEMBL616438,1365
,106,H,8,,,,17211,,Ability to displace [3H]-5-CT (1.5 nM) from HeLa cells of human 5-hydroxytryptamine 1B receptor; NT denotes not tested,1,,Autocuration,,308.0,,,HeLa,,B,BAO_0000219,CHEMBL616439,1366
,106,D,9,,,,15926,,Binding activity against human 5-hydroxytryptamine 1B receptor; NT means not tested,1,Homo sapiens,Expert,,,,9606.0,,,B,BAO_0000357,CHEMBL616440,1367
,106,H,8,,,,16312,,Binding affinity in CHO-K1 cells transfected with human recombinant 5-hydroxytryptamine 1B receptor; not tested,1,,Autocuration,,485.0,,,CHO-K1,,B,BAO_0000219,CHEMBL616441,1368
,106,H,8,,,,5843,,Selectivity ratio against cloned human 5-HT1B receptor to that of h5-HT1D receptor,1,,Expert,,,,,,,B,BAO_0000357,CHEMBL616442,1369
,106,H,8,,,,5843,,Selectivity ratio against cloned human 5-hydroxytryptamine 1B receptor to that of human 5-hydroxytryptamine 1D receptor,1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL616443,1370
,106,H,8,,,,16312,,Binding affinity in CHO-K1 cells transfected with human recombinant 5-hydroxytryptamine 1B receptor,1,,Expert,,485.0,,,CHO-K1,,B,BAO_0000219,CHEMBL616444,1371
,106,D,9,,,,15926,,Binding activity against human 5-hydroxytryptamine 1B receptor,1,Homo sapiens,Expert,,,,9606.0,,,B,BAO_0000357,CHEMBL616445,1372
,106,D,9,,,,15926,,Binding activity against human 5-hydroxytryptamine 1B receptor,1,Homo sapiens,Expert,,,,9606.0,,,B,BAO_0000357,CHEMBL616446,1373
,106,D,9,,,,4540,,Binding affinity to human cloned 5-hydroxytryptamine 1B receptor in CHO cells using [3H]5-HT as radioligand,1,Homo sapiens,Expert,,449.0,,9606.0,CHO,,B,BAO_0000219,CHEMBL616447,1374
,106,H,8,,,,6166,,Binding affinity towards cloned human 5-hydroxytryptamine 1B receptor was determined,1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL616448,1375
,106,H,8,,,,17296,,Binding affinity against cloned human 5-hydroxytryptamine 1B receptor in CHO cells using [3H]5-CT as radioligand,1,,Autocuration,,449.0,,,CHO,,B,BAO_0000219,CHEMBL616449,1376
,106,H,8,,,,17296,,Binding affinity against human 5-hydroxytryptamine 1B receptor cloned receptors in CHO cells,1,,Autocuration,,449.0,,,CHO,,B,BAO_0000219,CHEMBL616450,1377
,106,H,8,,,,17296,,Binding affinity against human 5-hydroxytryptamine 1B receptor cloned receptors in CHO cells using [3H]5-CT as radioligand,1,,Autocuration,,449.0,,,CHO,,B,BAO_0000219,CHEMBL857974,1378
,106,H,8,,,,15779,,Binding affinity towards 5-hydroxytryptamine 1B (human cloned receptor) in CHO cells using [3H]5-HT as radioligand,1,,Autocuration,,449.0,,,CHO,,B,BAO_0000219,CHEMBL616451,1379
,106,H,8,,,,15779,,Binding affinity towards 5-hydroxytryptamine 1B receptor (human cloned receptor) in CHO cells using [3H]5-HT as radioligand,1,,Autocuration,,449.0,,,CHO,,B,BAO_0000219,CHEMBL616452,1380
,106,H,8,,,,15779,,Binding affinity towards 5-hydroxytryptamine 1B receptor (human cloned receptor) in CHO cells using [3H]5-HT as radioligand;ND means no data.,1,,Autocuration,,449.0,,,CHO,,B,BAO_0000219,CHEMBL616453,1381
,106,H,8,,,,4199,,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 1B receptor in CHO cells using [3H]5-HT as the radioligand,1,,Autocuration,,449.0,,,CHO,,B,BAO_0000219,CHEMBL616454,1382
,106,D,9,,,,14875,,Binding affinity for human 5-hydroxytryptamine 1B receptor,1,Homo sapiens,Expert,,,,9606.0,,,B,BAO_0000357,CHEMBL616455,1383
,106,H,8,,,,15146,,Compound was tested for its binding affinity against human cloned 5-hydroxytryptamine 1B receptor in CHO cells using [3H]5-HT,1,,Autocuration,,449.0,,,CHO,,B,BAO_0000219,CHEMBL616456,1384
,106,H,8,,,,5213,,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 1B receptor in CHO using [3H]5-HT as a radioligand,1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL616457,1385
,106,H,8,,,,14818,,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 1B receptor in CHO cells using [3H]5-HT,1,,Autocuration,,449.0,,,CHO,,B,BAO_0000219,CHEMBL616458,1386
,106,H,8,,,,4829,,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 1B receptor in CHO cells, using [3H]5-HT as radioligand",1,,Autocuration,,449.0,,,CHO,,B,BAO_0000219,CHEMBL616459,1387
,106,H,8,,,,14454,,Adenyl cyclase activity was expressed as percent forskolin response against 5-hydroxytryptamine 1B receptor at concentration 1 uM,1,,Expert,,,,,,,F,BAO_0000019,CHEMBL616460,1388
,106,H,8,,,,14454,,Adenyl cyclase activity was expressed as percent forskolin response against 5-hydroxytryptamine 1B receptor at concentration 10 uM,1,,Expert,,,,,,,F,BAO_0000019,CHEMBL616461,1389
,106,H,8,,,,14875,,"Effect of compound on [35S]GTP-gamma-S, radioligand binding CHO cells expressing human 5-hydroxytryptamine 1B receptor",1,,Autocuration,,449.0,,,CHO,,F,BAO_0000219,CHEMBL616462,1390
,106,H,8,,,,14875,,"Effect of compound on [35S]GTP-gamma-S, radioligand binding in CHO cells expressing human 5-hydroxytryptamine 1B receptor",1,,Autocuration,,449.0,,,CHO,,F,BAO_0000219,CHEMBL616463,1391
,105,H,8,,,,15250,,"Compound was tested for maximum stimulation of [35S]GTP-gamma-S, binding expressed relative to the maximal effect produced by 5-HT.",1,,Autocuration,,,,,,,F,BAO_0000019,CHEMBL616464,1392
,105,H,8,,,,15250,,Compound was tested for the displacement of [3H]5-HT binding to cloned 5-hydroxytryptamine 1D receptor stably expressed in CHO cells.,1,,Autocuration,,449.0,,,CHO,,B,BAO_0000219,CHEMBL616465,1393
,17105,H,8,,,,15086,,The compound was tested for binding affinity against 5-hydroxytryptamine 1B receptor,1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL832874,1394
,106,H,8,,,,3025,,5-hydroxytryptamine 1B receptor agonist potency determined in rabbit saphenous vein contraction model,1,Oryctolagus cuniculus,Autocuration,,,,9986.0,,,F,BAO_0000019,CHEMBL616184,1395
,106,H,8,,,,14998,,The vascular 5-hydroxytryptamine 1B receptor affinity was assessed using ring preparations of rabbit saphenous vein (RbSV).,1,Oryctolagus cuniculus,Autocuration,,,,9986.0,,,B,BAO_0000019,CHEMBL616185,1396
,106,H,8,,,,14998,,"Binding affinity against vascular 5-hydroxytryptamine 1B receptor, measured using ring preparations of rabbit saphenous vein (RbSV)",1,Oryctolagus cuniculus,Intermediate,,,,9986.0,,,B,BAO_0000019,CHEMBL616186,1397
,106,H,8,,,,14998,,The vascular 5-hydroxytryptamine 1B receptor affinity was assessed using ring preparations of rabbit saphenous vein(RbSV).,1,Oryctolagus cuniculus,Autocuration,,,,9986.0,,,B,BAO_0000019,CHEMBL616187,1398
,10577,H,8,,,,13969,,Binding affinity towards 5-hydroxytryptamine 1B receptor was measured using [3H]5-HT as radioligand,1,,Expert,,,,,,,B,BAO_0000357,CHEMBL616188,1399
,10577,D,9,,,,13392,,Binding affinity for 5-hydroxytryptamine 1B receptor,1,,Intermediate,,,,,,,B,BAO_0000357,CHEMBL873475,1400
Striatum,10577,D,9,,,,3651,,Inhibition of [3H]5-HT binding to 5-hydroxytryptamine 1B receptor in rat striatum; Less active,1,Rattus norvegicus,Expert,,,,10116.0,,2435.0,B,BAO_0000019,CHEMBL616189,1401
,10577,H,8,,,,10025,,Concentration necessary to achieve half maximal inhibition of [125I]- Iodocyanopindolol binding to 5-hydroxytryptamine 1B receptor at 1 uM,1,,Expert,,,,,,,B,BAO_0000357,CHEMBL616190,1402
,10576,H,8,,,,13863,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]-8-OH-DPAT as radioligand; range=48-77,1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL616191,1403
,10576,H,8,,,,13863,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=63-95,1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL616192,1404
,10576,H,8,,,,13863,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=710-980,1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL616193,1405
,10576,H,8,,,,13863,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=78-140,1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL616194,1406
,10576,H,8,,,,13863,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=85-130,1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL616195,1407
,10576,H,8,,,,13863,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=89-280,1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL616196,1408
Hippocampus,10576,H,8,,,,4622,,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand in rat hippocampus membrane.,1,,Autocuration,,,,,,10000000.0,B,BAO_0000249,CHEMBL616197,1409
,10576,H,8,,,,14911,,Binding affinity at 5-hydroxytryptamine 1A (5-HT1A) receptor in rat cerebral cortex using [3H]8-OH-DPAT as radioligand,1,,Intermediate,,,,,,,B,BAO_0000019,CHEMBL616198,1410
Hippocampus,10576,H,8,,,,12678,,In vitro binding affinity to 5-hydroxytryptamine 1A receptor using [125I](R)-(+)-trans-8-OH-PIPAT as radioligand in rat hippocampal homogenate,1,,Autocuration,,,,,,10000000.0,B,BAO_0000221,CHEMBL616199,1411
Hippocampus,10576,H,8,,,,12678,,In vitro binding affinity to 5-hydroxytryptamine 1A receptor in rat hippocampal homogenate by [125I](R)-(+)-trans-8-OH-PIPAT displacement.,1,,Expert,,,,,,10000000.0,B,BAO_0000221,CHEMBL616200,1412
Hippocampus,10576,H,8,,,,14235,,In vitro binding affinity to rat hippocampal 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand,1,,Expert,,,,,,10000000.0,B,BAO_0000221,CHEMBL616201,1413
Hippocampus,10576,H,8,,,,14949,,In vitro binding affinity towards 5-hydroxytryptamine 1A r receptor by the displacement of [3H]8-OH-DPAT radioligand in rat hippocampal homogenates,1,,Expert,,,,,,10000000.0,B,BAO_0000221,CHEMBL616202,1414
Hippocampus,10576,H,8,,,,14949,,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT radioligand in rat hippocampal homogenates,1,,Expert,,,,,,10000000.0,B,BAO_0000221,CHEMBL616203,1415
Hippocampus,10576,H,8,,,,14949,,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT radioligand in rat hippocampal homogenates; ND=not determined,1,,Expert,,,,,,10000000.0,B,BAO_0000221,CHEMBL616204,1416
Hippocampus,10576,H,8,,,,14949,,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT radioligand in rat hippocampal homogenates; Not determined,1,,Expert,,,,,,10000000.0,B,BAO_0000221,CHEMBL616205,1417
Hippocampus,10576,H,8,,,,14949,,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT radioligand in rat hippocampal homogenates; not determined,1,,Expert,,,,,,10000000.0,B,BAO_0000221,CHEMBL616206,1418
,10576,H,8,,,,16118,,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor in rat cerebral cortex membranes,1,,Expert,,,,,,,B,BAO_0000249,CHEMBL616207,1419
,10576,H,8,,,,3268,,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand in rat cerebral cortex membranes,1,,Autocuration,,,,,,,B,BAO_0000249,CHEMBL616208,1420
,10576,H,8,,,,3268,,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand in rat cerebral cortex membranes; Inactive,1,,Autocuration,,,,,,,B,BAO_0000249,CHEMBL616209,1421
,10576,H,8,,,,16117,,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor was determined using radioligand [3H]-8-OH-DPAT,1,,Expert,,,,,,,B,BAO_0000357,CHEMBL616210,1422
Hippocampus,10576,H,8,,,,9783,,In vitro inhibition of [3H]spiperone binding to 5-hydroxytryptamine 1A receptor from rat hippocampal tissue.,1,,Expert,,,,,,10000000.0,B,BAO_0000221,CHEMBL616211,1423
Hippocampus,10576,H,8,,,,9783,,In vitro inhibition of [3H]spiperone binding to 5-hydroxytryptamine 1A receptor from rat hippocampal tissue; NT=Not tested,1,,Autocuration,,,,,,10000000.0,B,BAO_0000221,CHEMBL616504,1424
Hippocampus,10576,D,9,,,,14356,,Displacement of [3H]8-OH-DPAT from rat hippocampal 5-hydroxytryptamine 1A receptor,1,Rattus norvegicus,Expert,,,,10116.0,,10000000.0,B,BAO_0000221,CHEMBL616505,1425
,10576,H,8,,,,15740,,Inhibition constant of 50 uM forskolin-stimulated cAMP accumulation against 5-hydroxytryptamine 1A receptor,1,,Autocuration,,,,,,,F,BAO_0000019,CHEMBL616506,1426
Hippocampus,10576,H,8,,,,12306,,Inhibition of binding of [125I]8-OH-PIPAT ligand to 5-hydroxytryptamine 1A receptor of rat hippocampal homogenates,1,,Autocuration,,,,,,10000000.0,B,BAO_0000221,CHEMBL872107,1427
Hippocampus,10576,D,9,,,,13348,,Displacement of [3H]5-HT from rat hippocampal 5-hydroxytryptamine 1A receptor with 10e-6 M ketanserin,1,Rattus norvegicus,Expert,,,,10116.0,,10000000.0,B,BAO_0000221,CHEMBL616507,1428
,10576,H,8,,,,10394,,Inhibitory activity against 5-hydroxytryptamine 1A receptor in rat cortical membranes using [3H]8-OH-DPAT as a radioligand,1,,Autocuration,,,,,,,B,BAO_0000249,CHEMBL616303,1429
Hippocampus,10576,H,8,,,,15260,,Inhibitory activity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue,1,,Autocuration,,,,,,10000000.0,B,BAO_0000221,CHEMBL616304,1430
Hippocampus,10576,H,8,,,,10046,,Inhibitory activity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue using [3H]OH-DPAT as radioligand.,1,,Expert,,,,,,10000000.0,B,BAO_0000221,CHEMBL616305,1431
Hippocampus,10576,H,8,,,,15260,,Antagonist activity against rat hippocampal tissue 5-hydroxytryptamine 1A receptor,1,,Intermediate,,,,,,10000000.0,F,BAO_0000221,CHEMBL616306,1432
,10576,H,8,,,,12851,,Inhibitory affinity constant against 5-hydroxytryptamine 1A receptor,1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL616307,1433
Hippocampus,10576,D,9,,,,2148,,Displacement of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat brain hippocampus,1,Rattus norvegicus,Expert,,,,10116.0,,10000000.0,B,BAO_0000221,CHEMBL881829,1434
,10576,H,8,,,,13134,,Affinity against the 5-hydroxytryptamine receptor 1A using [3H]WB-4101.,1,,Expert,,,,,,,B,BAO_0000357,CHEMBL616308,1435
,10576,H,8,,,,12462,,Tested for affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT in homogenized rat brain,1,,Autocuration,,,,,,,B,BAO_0000019,CHEMBL616309,1436
,10576,H,8,,,,12462,,Tested for affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT in homogenized rat brain tissue,1,,Expert,,,,,,,B,BAO_0000019,CHEMBL616310,1437
,10576,H,8,,,,12462,,Tested for affinity against 5-hydroxytryptamine 1A receptors using [3H]8-OH-DPAT in homogenized rat cloned CHO cells,1,,Autocuration,,449.0,,,CHO,,B,BAO_0000219,CHEMBL616311,1438
,10576,H,8,,,,11933,,Tested for binding affinity against 5-hydroxytryptamine 1A receptor from rat frontal cortical regions using [3H]8-OH-DPAT as radioligand,1,,Expert,,,,,,,B,BAO_0000357,CHEMBL616312,1439
,10576,H,8,,,,11933,,Tested for binding affinity against 5-hydroxytryptamine 1A receptor from rat frontal cortical regions using [3H]8-OH-DPAT as radioligand; ND is Not Determined,1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL616313,1440
Hippocampus,10576,D,9,,,,403,,Displacement of [3H]8-OH-DPAT from rat hippocampal 5-hydroxytryptamine 1A receptor,1,Rattus norvegicus,Expert,,,,10116.0,,10000000.0,B,BAO_0000221,CHEMBL616314,1441
Hippocampus,10576,H,8,,,,15538,,Tested for binding affinity by measuring displacement of [3H]8-OH-DPAT from rat serotonin 5-hydroxytryptamine 1A receptor in rat hippocampus,1,,Autocuration,,,,,,10000000.0,B,BAO_0000221,CHEMBL616315,1442
Hippocampus,10576,H,8,,,,15538,,Tested for binding affinity by measuring displacement of [3H]8-OH-DPAT from rat serotonin 5-hydroxytryptamine 1A receptor in rat hippocampus; NA means Not Active,1,,Autocuration,,,,,,10000000.0,B,BAO_0000221,CHEMBL616567,1443
Hippocampus,10576,H,8,,,,15538,,Tested for binding affinity by measuring displacement of [3H]-8-OH-DPAT from rat serotonin 5-hydroxytryptamine 1A receptor in rat hippocampus; ND means Not Determined,1,,Autocuration,,,,,,10000000.0,B,BAO_0000221,CHEMBL616568,1444
,10576,H,8,,,,12464,,Binding affinity to displace [3H]2-(di-N-propylamino)-8-hydroxy-tetralin from 5-hydroxytryptamine 1A (5-HT1A) receptor in rat frontal cortex homogenates,1,,Intermediate,,,,,,,B,BAO_0000019,CHEMBL616569,1445
,10576,H,8,,,,1455,,Binding affinity to 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT radioligand assay.,1,,Expert,,,,,,,B,BAO_0000357,CHEMBL616570,1446
,10576,H,8,,,,12652,,Tested for the binding affinity against the site labelled by the 5-hydroxytryptamine 1A receptor agonist [3H]- 8-OH-DPAT,1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL616571,1447
Hippocampus,10576,H,8,,,,12639,,Tested for the inhibitory activity against 5-hydroxytryptamine 1A receptor in rat hippocampal,1,,Autocuration,,,,,,10000000.0,B,BAO_0000221,CHEMBL616572,1448
,10576,H,8,,,,13949,,Tested in vitro for binding affinity by measuring its ability to inhibit [3H]8-OH-DPAT binding at 5-hydroxytryptamine 1A receptor in rat cerebral cortex membranes.,1,,Expert,,,,,,,B,BAO_0000249,CHEMBL616573,1449
,10576,D,9,,,,12463,,Tested in vitro for receptor binding affinity against 5-hydroxytryptamine 1A receptor using radioligand [3H]8-OH-DPAT,1,Rattus norvegicus,Expert,,,,10116.0,,,B,BAO_0000357,CHEMBL616574,1450
Hippocampus,10576,H,8,,,,14829,,The binding affinity by measuring its ability to displace [3H]8-OH-DPAT radioligand in 5-hydroxytryptamine 1A receptor on rat hippocampal preparation,1,,Expert,,,,,,10000000.0,B,BAO_0000221,CHEMBL616575,1451
Hippocampus,10576,H,8,,,,14829,,The binding affinity by measuring its ability to displace [3H]8-OH-DPAT radioligand in 5-hydroxytryptamine 1A receptor on rat hippocampal preparation; ND=not determined,1,,Autocuration,,,,,,10000000.0,B,BAO_0000221,CHEMBL872108,1452
,10576,H,8,,,,12092,,The binding affinity was measured on 5-hydroxytryptamine 1A receptor using [3H]- 8-OH-DPAT as radioligand.,1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL616576,1453
,10576,H,8,,,,403,,The compound was evaluated for binding affinity against 5-hydroxytryptamine 1A receptor in rat hippocampal membranes using [3H]8-OH-DPAT as radioligand in the presence of 1 mM of MnCl2,1,,Autocuration,,,,,,,B,BAO_0000249,CHEMBL616577,1454
,10576,H,8,,,,403,,The compound was evaluated for binding affinity against 5-hydroxytryptamine 1A receptor in rat hippocampal membranes using [3H]8-OH-DPAT as radioligand in the presence of 3*10e-5 M GTP gamma S,1,,Autocuration,,,,,,,B,BAO_0000249,CHEMBL616578,1455
,10576,H,8,,,,3967,,Binding affinity at 5-hydroxytryptamine 1A receptor from striata of wistar rats by [3H]- 8-OH -DPAT displacement.,1,,Expert,,,,,,,B,BAO_0000357,CHEMBL616579,1456
,10576,D,9,,,,12771,,Binding affinity towards 5-hydroxytryptamine 1A receptor of rat brain synaptosomal preparations,1,Rattus norvegicus,Expert,,,,10116.0,,,B,BAO_0000019,CHEMBL616580,1457
,10576,H,8,,,,15086,,The compound was tested binding affinity against 5-hydroxytryptamine 1A receptor from rat brain using [3H]8-OH-DPAT as radioligand at 10e-6 M.,1,,Autocuration,,,,,,,B,BAO_0000019,CHEMBL616581,1458
Hippocampus,10576,H,8,,,,14909,,The compound was tested for binding affinity on [3H]8-OH-DPAT as specific ligand on 5-hydroxytryptamine 1A receptor in rat hippocampus,1,,Autocuration,,,,,,10000000.0,B,BAO_0000221,CHEMBL616582,1459
Hippocampus,10576,H,8,,,,14949,,The compound was tested for binding affinity on [3H]8-OH-DPAT as specific ligand on 5-hydroxytryptamine 1A receptor in rat hippocampus,1,,Expert,,,,,,10000000.0,B,BAO_0000221,CHEMBL616583,1460
Hippocampus,10576,D,9,,,,2309,,Binding affinity against 5-hydroxytryptamine 1A receptor of rat hippocampus using [3H]8-OH-DPAT,1,Rattus norvegicus,Expert,,,,10116.0,,10000000.0,B,BAO_0000221,CHEMBL616584,1461
,10576,H,8,,,,4170,,Binding affinity towards 5-hydroxytryptamine 1A receptor,1,,Expert,,,,,,,B,BAO_0000357,CHEMBL616585,1462
Hippocampus,10576,D,9,,,,11642,,Binding affinity towards 5-hydroxytryptamine 1A receptor by displacing [3H]WB-4101 from rat hippocampus,1,Rattus norvegicus,Expert,,,,10116.0,,10000000.0,B,BAO_0000221,CHEMBL616586,1463
Hippocampus,10576,H,8,,,,11642,,The compound was tested for its binding affinity towards 5-hydroxytryptamine 1A receptor by displacing [3H]WB-4101 radioligand in rat hippocampus,1,,Autocuration,,,,,,10000000.0,B,BAO_0000221,CHEMBL616587,1464
Hippocampus,10576,H,8,,,,12953,,The compound was tested for their binding affinity towards 5-hydroxytryptamine 1A receptor from rat hippocampus using [3H]-8-OH-DPAT as radioligand,1,,Autocuration,,,,,,10000000.0,B,BAO_0000221,CHEMBL616588,1465
Hippocampus,10576,H,8,,,,12953,,The compound was tested for their binding affinity towards 5-hydroxytryptamine 1A receptor from rat hippocampus using [3H]8-OH-DPAT as radioligand.,1,,Autocuration,,,,,,10000000.0,B,BAO_0000221,CHEMBL616589,1466
Hippocampus,10576,H,8,,,,12953,,Binding affinity for 5-hydroxytryptamine 1A receptor from rat hippocampus using [3H]8-OH-DPAT as radioligand,1,,Expert,,,,,,10000000.0,B,BAO_0000221,CHEMBL616590,1467
,10576,H,8,,,,12903,,"In vitro binding affinity against cloned mammalian 5-hydroxytryptamine 1A receptor expressed in CHO cells, by using [3H]8-OH-DPAT as radioligand.",1,,Expert,,449.0,,,CHO,,B,BAO_0000219,CHEMBL616591,1468
,10576,H,8,,,,12536,,Displacement of the radioligand [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor,1,,Expert,,,,,,,B,BAO_0000357,CHEMBL616592,1469
,10576,H,8,,,,10058,,The inhibition activity of 5-HT1A at 1 uM,1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL616593,1470
,10576,H,8,,,,12902,,"Binding affinity against 5-hydroxytryptamine 1A receptor from CHO-K1 cells, using [3H]8-OH-DPAT as the radioligand.",1,,Expert,,485.0,,,CHO-K1,,B,BAO_0000219,CHEMBL616594,1471
,10576,H,8,,,,14057,,Binding affinities against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand in rat cerebral cortex membrane,1,,Expert,,,,,,,B,BAO_0000249,CHEMBL616595,1472
,10576,H,8,,,,11296,,Compound was evaluated for its ability to displace the protonated form of [3H]8-hydroxy-2-(di-n-propylamino)tetralin binding from labeled 5-HT 1A receptor site.,1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL616596,1473
Hippocampus,10576,H,8,,,,11296,,Compound was evaluated for its ability to displace the protonated form of [3H]8-hydroxy-2-(di-n-propylamino)tetralin binding from labeled 5-hydroxytryptamine 1A receptor site in rat brain hippocampus,1,,Autocuration,,,,,,10000000.0,B,BAO_0000221,CHEMBL616597,1474
Hippocampus,10576,H,8,,,,11296,,Ability to displace the protonated form of [3H]8-hydroxy-2-(di-n-propylamino)tetralin binding from labeled 5-hydroxytryptamine 1A receptor site in rat brain hippocampus,1,,Expert,,,,,,10000000.0,B,BAO_0000221,CHEMBL616598,1475
,10576,D,9,,,Membranes,16616,,Antagonist activity to stimulate binding of [35S]-GTP-gamma S binding to 5-hydroxytryptamine 1A receptor in isolated rat hippocampal membranes,1,Rattus norvegicus,Expert,,,,10116.0,,,F,BAO_0000249,CHEMBL616599,1476
Hippocampus,10576,D,9,,,Membranes,16616,,"Inhibition of (+)-8-OH-DPAT stimulated [35S]GTP-gamma-S, binding in rat hippocampal membranes",1,Rattus norvegicus,Expert,,,,10116.0,,10000000.0,F,BAO_0000249,CHEMBL616600,1477
,10576,H,8,,,,16567,,Binding affinity against 5-hydroxytryptamine 1A receptor by displacing [3H]8-OH-DPAT radioligand in rat cortex membrane;ND is defined as not -determined.,1,,Autocuration,,,,,,,B,BAO_0000019,CHEMBL616601,1478
,10576,H,8,,,,16567,,Binding affinity against 5-hydroxytryptamine 1A receptor by displacing [3H]8-OH-DPAT radioligand in rat cortex membrane;ND is defined as not defined.,1,,Autocuration,,,,,,,B,BAO_0000019,CHEMBL616602,1479
,10576,H,8,,,,16567,,Binding affinity against 5-hydroxytryptamine 1A receptor by displacing [3H]8-OH-DPAT radioligand in rat cortex membrane;ND is defined as not determined.,1,,Autocuration,,,,,,,B,BAO_0000019,CHEMBL616603,1480
,10576,H,8,,,,16567,,Binding affinity against 5-hydroxytryptamine 1A receptor by displacing [3H]8-OH-DPAT radioligand in rat cortex membrane;ND means not determined.,1,,Autocuration,,,,,,,B,BAO_0000019,CHEMBL616604,1481
,10576,H,8,,,,17136,,Binding affinity towards 5-hydroxytryptamine 1A receptor was determined in rat cortex membranes using [3H]8-OH-DPAT as radioligand; No data,1,,Autocuration,,,,,,,B,BAO_0000249,CHEMBL616316,1482
,10576,H,8,,,,17136,,Binding affinity towards 5-hydroxytryptamine 1A receptor was determined in rat cortex membranes using [3H]8-OH-DPAT as radioligand; Not determined,1,,Autocuration,,,,,,,B,BAO_0000249,CHEMBL616317,1483
,10576,D,9,,,,16616,,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat frontal cortex homogenates; ND means No data,1,Rattus norvegicus,Expert,,,,10116.0,,,B,BAO_0000019,CHEMBL616318,1484
Hippocampus,10576,H,8,,,,17331,,Binding affinity against 5-hydroxytryptamine 1A receptor by displacement of [3H]8-OH-DPAT from rat hippocampus mambranes,1,,Autocuration,,,,,,10000000.0,B,BAO_0000221,CHEMBL616319,1485
Hippocampus,10576,H,8,,,,17331,,Binding affinity against 5-hydroxytryptamine 1A receptor by displacement of [3H]8-OH-DPAT from rat hippocampus mambranes; Not tested,1,,Autocuration,,,,,,10000000.0,B,BAO_0000221,CHEMBL616320,1486
Hippocampus,10576,D,9,,,,17167,,Binding affinity for rat hippocampus 5-hydroxytryptamine 1A receptor by inhibition of [3H]8-OH-DPAT binding; Not tested,1,Rattus norvegicus,Expert,,,,10116.0,,10000000.0,B,BAO_0000221,CHEMBL616321,1487
,10576,H,8,,,,15740,,Evaluated for the 5-hydroxytryptamine 1A receptor agonist activity in LY-293284 trained rats; Not tested,1,,Autocuration,,,,,,,F,BAO_0000019,CHEMBL616322,1488
,10576,H,8,,,,15740,,Evaluated for the 5-hydroxytryptamine 1A receptor agonist activity in LY-293284 trained rats; not tested,1,,Autocuration,,,,,,,F,BAO_0000019,CHEMBL616323,1489
,10576,H,8,,,,4671,,Ratio of binding affinity to 5-HT 1A and D2 receptor,1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL616324,1490
Hippocampus,10576,H,8,,,,10058,,In vitro ability to inhibit [3H]-8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus at 1 uM,1,,Autocuration,,,,,,10000000.0,B,BAO_0000221,CHEMBL616325,1491
Hippocampus,10576,H,8,,,,10058,,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus at 1 uM,1,,Autocuration,,,,,,10000000.0,B,BAO_0000221,CHEMBL616326,1492
Hippocampus,10576,H,8,,,,10058,,In vitro ability to inhibit [3H]-8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus.,1,,Autocuration,,,,,,10000000.0,B,BAO_0000221,CHEMBL616327,1493
,10576,H,8,,,,12073,,Percentage inhibition against 5-hydroxytryptamine 1A receptor,1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL616328,1494
,10576,H,8,,,,2759,,Compound was tested for its potency against 5-hydroxytryptamine 1A receptor in rat frontal cortex membranes (experiment 1),1,,Autocuration,,,,,,,B,BAO_0000249,CHEMBL858110,1495
,10576,H,8,,,,2759,,Compound was tested for its potency against 5-hydroxytryptamine 1A receptor in rat frontal cortex membranes (experiment 1),1,,Autocuration,,,,,,,F,BAO_0000249,CHEMBL616329,1496
,10576,H,8,,,,2759,,Compound was tested for its potency against 5-hydroxytryptamine 1A receptor in rat frontal cortex membranes (experiment 2),1,,Autocuration,,,,,,,B,BAO_0000249,CHEMBL616330,1497
,10576,H,8,,,,2759,,Compound was tested for its potency against 5-hydroxytryptamine 1A receptor in rat frontal cortex membranes (experiment 2),1,,Autocuration,,,,,,,F,BAO_0000249,CHEMBL616331,1498
,10576,H,8,,,,2759,,Compound was tested for its potency against 5-hydroxytryptamine 1A receptor in rat frontal cortex membranes.,1,,Autocuration,,,,,,,F,BAO_0000249,CHEMBL616332,1499
Brain,10576,H,8,,,,9737,,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat brain membrane using [3H]8-OH-DPAT as a selective ligand.,1,,Autocuration,,,,,,955.0,B,BAO_0000249,CHEMBL857063,1500
,10576,H,8,,,,9737,,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat frontal cortex using [3H]8-OH-DPAT as a radioligand,1,,Autocuration,,,,,,,B,BAO_0000019,CHEMBL616333,1501
,10576,H,8,,,,5717,,Antagonistic activity against 5-hydroxytryptamine 1A receptor in rat cerebral cortex using [3H]-8-OH-DPAT as radioligand.,1,,Expert,,,,,,,F,BAO_0000019,CHEMBL616334,1502
Hippocampus,10576,H,8,,,,12253,,Binding affinity of 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT in rat hippocampus,1,,Autocuration,,,,,,10000000.0,B,BAO_0000221,CHEMBL616335,1503
,10576,H,8,,,,14025,,Affinity pKi for 5-hydroxytryptamine 1A receptor was measured in rat cortex homogenates.,1,,Autocuration,,,,,,,B,BAO_0000019,CHEMBL616336,1504
,10576,H,8,,,,10425,,Binding affinity against 5-hydroxytryptamine 1A receptor in rat cerebral cortical membrane using [3H]-8-OH-DPAT as radioligand.,1,,Expert,,,,,,,B,BAO_0000249,CHEMBL616337,1505
,10576,H,8,,,,14998,,Binding affinity against 5-hydroxytryptamine 1A receptor in rat cortex homogenates.,1,,Autocuration,,,,,,,B,BAO_0000019,CHEMBL616338,1506
Hippocampus,10576,H,8,,,,13694,,Binding affinity against native 5-HT1A-receptors from rat hippocampus using radioligand ([3H]- 8-hydri\oxy-2-(di-n-propylamino)tetraline) binding assay,1,,Autocuration,,,,,,10000000.0,B,BAO_0000221,CHEMBL616339,1507
Hippocampus,10576,H,8,,,,13694,,Binding affinity against native 5-HT1A-receptors from rat hippocampus using radioligand ([3H]8-hydroxy-2-(di-n-propylamino)-tetraline) binding assay,1,,Autocuration,,,,,,10000000.0,B,BAO_0000221,CHEMBL616340,1508
,10576,H,8,,,,4342,,Binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined,1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL616341,1509
,10576,D,9,,,,12936,,Binding affinity against rat 5-hydroxytryptamine 1A receptor,1,Rattus norvegicus,Expert,,,,10116.0,,,B,BAO_0000357,CHEMBL616342,1510
,10576,D,9,,,,13144,,Inhibition of [3H]2-(di-N-propylamino)-8-hydroxytetralin binding to 5-HT1A receptor of rat frontal cortex homogenates,1,Rattus norvegicus,Expert,,,,10116.0,,,B,BAO_0000019,CHEMBL616343,1511
,10576,H,8,,,,13343,,Binding affinity of a compound to rat brain 5-hydroxytryptamine 1A (serotonin) receptor assayed by radiolabeled [3H]-8-OH-DPAT ligand displacement,1,,Expert,,,,,,,B,BAO_0000019,CHEMBL616344,1512
,10576,H,8,,,,12132,,Binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand.,1,,Expert,,,,,,,B,BAO_0000357,CHEMBL616345,1513
,10576,H,8,,,,15419,,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat cortex using [3H]8-OH-DPAT as a radioligand,1,,Expert,,,,,,,B,BAO_0000019,CHEMBL616346,1514
Hippocampus,10576,H,8,,,,1479,,Binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT in rat hippocampus,1,,Autocuration,,,,,,10000000.0,B,BAO_0000221,CHEMBL616347,1515
,10576,H,8,,,,14287,,In vitro by displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor on rat cortical membrane,1,,Expert,,,,,,,B,BAO_0000019,CHEMBL616348,1516
,10576,H,8,,,,13116,,Binding affinity at 5-hydroxytryptamine 1A receptor,1,,Expert,,,,,,,B,BAO_0000357,CHEMBL616349,1517
,10576,D,9,,,Membranes,2759,,Inhibition of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat frontal cortex membranes,1,Rattus norvegicus,Expert,,,,10116.0,,,B,BAO_0000249,CHEMBL616152,1518
,10576,H,8,,,,2759,,Compound was tested for inhibition constant against 5-hydroxytryptamine 1A receptor in rat frontal cortex membranes.,1,,Autocuration,,,,,,,B,BAO_0000249,CHEMBL616153,1519
,10576,H,8,,,,14748,,"Binding affinity for rat cortex 5-hydroxytryptamine 1A receptor, by displacement of 0.2 nM [3H]8-OH-DPAT radioligand",1,,Expert,,,,,,,B,BAO_0000019,CHEMBL616154,1520
,10576,H,8,,,,12304,,In vitro ability to inhibit binding of radioligand [3H]8-OH-DPAT to 5-hydroxytryptamine 1A receptor in rat cerebral cortex,1,,Autocuration,,,,,,,B,BAO_0000019,CHEMBL616155,1521
Hippocampus,10576,D,9,,,,12409,,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat hippocampus using [3H]8-OH-DPAT,1,Rattus norvegicus,Expert,,,,10116.0,,10000000.0,B,BAO_0000221,CHEMBL616156,1522
Hippocampus,10576,D,9,,,,12409,,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat hippocampus with [3H]8-OH-DPAT,1,Rattus norvegicus,Expert,,,,10116.0,,10000000.0,B,BAO_0000221,CHEMBL616157,1523
Hippocampus,10576,H,8,,,,13267,,The binding affinity (pKi) was measured against 5-hydroxytryptamine 4 receptor of piglet hippocampus using [125I]-SB 207710 as radioligand,1,,Autocuration,,,,,,10000000.0,B,BAO_0000221,CHEMBL616158,1524
,10576,H,8,,,,15194,,The compound was tested for the binding affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand.,1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL616159,1525
,10576,H,8,,,,14256,,pKi value against rat 5-hydroxytryptamine 1A receptor.,1,,Expert,,,,,,,B,BAO_0000357,CHEMBL616160,1526
,10576,H,8,,,,16567,,Binding affinity against 5-hydroxytryptamine 1A receptor by displacing [3H]8-OH-DPAT radioligand in rat cortex membrane;ND is define as non-determined.,1,,Autocuration,,,,,,,B,BAO_0000019,CHEMBL616161,1527
,10576,H,8,,,,15740,,Evaluated for the 5-hydroxytryptamine 1A receptor agonist activity in LY-293284 trained rats; Not tested,1,,Autocuration,,,,,,,F,BAO_0000019,CHEMBL616162,1528
,12687,D,9,,,,13278,,Binding affinity was measured against 5-hydroxytryptamine 2A receptor by displacement of [3H]- ketanserin by lysergic acid amides,1,Rattus norvegicus,Expert,,,,10116.0,,,B,BAO_0000357,CHEMBL616163,1529
,10626,H,8,,,Membranes,1970,,Inhibition of specific [3H]OH-DPAT binding at 5-hydroxytryptamine 1A receptor in rat hippocampal membranes,1,,Expert,,,,,,,B,BAO_0000249,CHEMBL616164,1530
Brain,10576,H,8,,,,10034,,Concentration of compound required to inhibit cortical 5-hydroxytryptamine 1A receptor binding sites in rat brain was evaluated,1,,Autocuration,,,,,,955.0,B,BAO_0000221,CHEMBL616165,1531
,51,H,8,,,,13348,,Inhibitory activity against 5-hydroxytryptamine 1A receptor isolated from rat hippocampus membranes membrane using [3H]5-HT as radioligand in the presence of 10e-6 M ketanserin as 5-HT2 blocker,1,Rattus norvegicus,Autocuration,,,,10116.0,,,B,BAO_0000019,CHEMBL616355,1532
,10576,H,8,,,,13630,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM+ 50 uM 5-HT.,1,,Autocuration,,,,,,,F,BAO_0000019,CHEMBL616356,1533
Brain,10576,H,8,,,,10862,,Binding affinity at 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in rat brain.,1,,Autocuration,,,,,,955.0,B,BAO_0000221,CHEMBL616357,1534
,10576,H,8,,,,12058,,"Binding affinity against 5-hydroxytryptamine 1A receptor in homogenated rat brain tissue, using by [3H]8-OH-DPAT as radioligand",1,,Autocuration,,,,,,,B,BAO_0000019,CHEMBL616358,1535
,51,H,8,,,,4639,,Compound was tested for binding affinity against 5-hydroxytryptamine 1A receptor,1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL616359,1536
,51,H,8,,,,15453,,Percent decrease in 5-hydroxytryptamine 1A receptor binding using 8-OH-DPAT,1,,Expert,,,,,,,B,BAO_0000357,CHEMBL616360,1537
,51,H,8,,,,4820,,Binding affinity towards 5-hydroxytryptamine 1A receptor,1,,Expert,,,,,,,B,BAO_0000357,CHEMBL616361,1538
,51,H,8,,,,1089,,Tested for binding affinity for 5-hydroxytryptamine 1A receptor,1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL616362,1539
,51,H,8,,,Brain membranes,386,,The compound was evaluated for its ability to displace [3H]-8-OH-DPAT from 5-hydroxytryptamine 1A receptor in cellular brain membranes,1,,Autocuration,,,,,,,B,BAO_0000249,CHEMBL616363,1540
,51,H,8,,,,6011,,Inhibition of binding towards 5-hydroxytryptamine 1A receptor at 100 nM concentration,1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL616364,1541
,51,H,8,,,,5014,,Percent inhibition (at 1 uM) against 5-hydroxytryptamine 1A receptor,1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL616365,1542
,51,H,8,,,,4402,,Binding affinity for 5-hydroxytryptamine 1A receptor determined using [3H]8-OH-DPAT as radioligand,1,,Expert,,,,,,,B,BAO_0000357,CHEMBL616366,1543
,51,H,8,,,,17066,,Binding affinity towards 5-hydroxytryptamine 1A receptor,1,,Expert,,,,,,,B,BAO_0000357,CHEMBL872906,1544
,51,H,8,,,,17515,,Binding affinity of compound towards serotonin 5-hydroxytryptamine 1A receptor; inactive at 10 uM,1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL616367,1545
,51,H,8,,,,2474,,Binding affinity against 5-hydroxytryptamine 1A receptor,1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL616368,1546
,51,H,8,,,,4775,,Binding affinity to 5-hydroxytryptamine 1A receptor was determined,1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL616369,1547
,51,D,9,,,,14294,,Binding affinity towards Serotonin 5-hydroxytryptamine 1A receptor by displacement of [3H]-(+)-8-OH-DPAT.,1,Homo sapiens,Expert,,,,9606.0,,,B,BAO_0000357,CHEMBL616370,1548
,51,D,9,,,,14294,,Binding affinity towards Serotonin 5-hydroxytryptamine 1A receptor by displacement of [3H](+)-8-OH-DPAT; inactive,1,Homo sapiens,Expert,,,,9606.0,,,B,BAO_0000357,CHEMBL616371,1549
,51,H,8,,,,12249,,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in cloned CHO cells,1,,Autocuration,,449.0,,,CHO,,B,BAO_0000219,CHEMBL616372,1550
,51,H,8,,,,11376,,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor expressed in CHO cell membranes,1,,Expert,,,,,,,B,BAO_0000219,CHEMBL616373,1551
,51,H,8,In vivo,,,2474,,Compound was measured in vivo for its binding affinity at 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,1,,Autocuration,,,,,,,B,BAO_0000218,CHEMBL616374,1552
Hippocampus,51,H,8,,,,13311,,Tested for activity against 5-hydroxytryptamine 1A receptor from bovine hippocampus,1,,Autocuration,,,,,,10000000.0,B,BAO_0000221,CHEMBL616375,1553
,51,H,8,,,,4373,,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 1A receptor was determined,1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL616376,1554
,51,H,8,,,,1633,,Binding affinity towards 5-hydroxytryptamine 1A receptor by displacement of [3H]8-OH-DPAT.,1,,Expert,,,,,,,B,BAO_0000357,CHEMBL857064,1555
,51,H,8,,,,11866,,Binding affinity for 5-hydroxytryptamine 1A receptor was determined,1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL616377,1556
,51,H,8,,,,4373,,Binding affinity for 5-hydroxytryptamine 1A receptor was determined,1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL616378,1557
,51,H,8,,,,4687,,Evaluated for the binding affinity to 5-hydroxytryptamine 1A receptor,1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL616379,1558
,11863,H,8,,,,16946,,Ability to displace [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor,1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL616380,1559
,11863,H,8,,,,13291,,Binding affinity against 5-hydroxytryptamine 1A receptor was determined using [3H]-8-OH-DPAT radioligand,1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL616381,1560
,11863,H,8,,,,14159,,Compound was evaluated for the affinity at 5-hydroxytryptamine 1A receptor,1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL616382,1561
,11863,H,8,,,,10812,,Compound was tested for the binding affinity against 5-hydroxytryptamine 1A receptor by using [3H]DPAT as radioligand,1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL616383,1562
,11863,D,9,,,,3032,,In vitro binding affinity against 5-hydroxytryptamine 1A receptor in CHO cells,1,Mus musculus,Expert,,449.0,,10090.0,CHO,,B,BAO_0000219,CHEMBL616350,1563
,11863,H,8,,,,16655,,Inhibition of 5-OH-DPAT binding to 5-hydroxytryptamine 1A receptor,1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL616351,1564
,11863,H,8,,,,14532,,Inhibitory activity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand at 10e-5 M concentration,1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL616352,1565
,11863,H,8,,,,13944,,Binding affinity against 5-hydroxytryptamine 1A receptor,1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL616353,1566
,11863,H,8,,,,13033,,Binding affinity against serotonergic 5-HT1a receptor,1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL616354,1567
,11863,H,8,,,,10321,,Binding affinity for 5-hydroxytryptamine 1A receptor was determined by using [3H]8-OH-DPAT as radioligand,1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL616508,1568
,11863,D,9,,,,2968,,Binding affinity for 5-hydroxytryptamine 1A receptor,1,Mus musculus,Expert,,,,10090.0,,,B,BAO_0000357,CHEMBL616559,1569
,11863,H,8,,,,13964,,Binding affinity at 5-hydroxytryptamine 1A receptor,1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL616560,1570
,11863,H,8,,,,15527,,"Binding affinity towards 5-hydroxytryptamine 1A receptor receptor, using [3H]5-HT as radioligand.",1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL616561,1571
,11863,H,8,,,,12248,,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in cloned CHO cells,1,,Autocuration,,449.0,,,CHO,,B,BAO_0000219,CHEMBL616562,1572
,11863,H,8,,,,12249,,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in cloned CHO cells,1,,Autocuration,,449.0,,,CHO,,B,BAO_0000219,CHEMBL616563,1573
,11863,H,8,,,,15120,,Compound was tested for binding affinity using [3H]8-OH-DPAT against 5-hydroxytryptamine 1A receptor,1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL616564,1574
,11863,H,8,,,,13313,,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor by using [3H]-8-OH-DPAT as radioligand,1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL616565,1575
,11863,H,8,,,,2613,,In vivo binding affinity was evaluated against 5-hydroxytryptamine 1A receptor,1,,Autocuration,,,,,,,B,BAO_0000218,CHEMBL616566,1576
,11863,H,8,,,,16700,,The binding affinity towards 5-hydroxytryptamine 1A receptor; No affinity,1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL616989,1577
,11863,H,8,,,,2201,,Ability to displace [125I]iodosulpiride from 5-hydroxytryptamine 1A receptor,1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL857975,1578
,11863,D,9,,,,1274,,Binding affinity against 5-hydroxytryptamine 1A receptor,1,Mus musculus,Expert,,,,10090.0,,,B,BAO_0000357,CHEMBL616990,1579
,11863,H,8,,,,1317,,Compound was evaluated for binding affinity against 5-hydroxytryptamine 1A receptor using radioligand binding assay,1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL616991,1580
,11863,H,8,,,,12146,,Tested against 5-hydroxytryptamine 1A receptor,1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL616992,1581
,11863,H,8,,,,14059,,The compound's binding affinity against 5-hydroxytryptamine 1A receptor,1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL616993,1582
,106,H,8,,,,14025,,Dissociation equilibrium constant against the vascular 5-hydroxytryptamine 1B like receptor in the rabbit saphenous vein,1,Oryctolagus cuniculus,Expert,,,,9986.0,,,B,BAO_0000019,CHEMBL616994,1583
,106,H,8,,,,14025,,The dissociation equilibrium constant (pKB=-log KB) of compound was determined against the vascular 5-hydroxytryptamine 1B like receptor in the rabbit saphenous vein(RbSV); NS=non surmountable,1,Oryctolagus cuniculus,Autocuration,,,,9986.0,,,B,BAO_0000019,CHEMBL616995,1584
,105571,D,9,,,,14447,,The compound was tested for CNS binding affinity towards 5-hydroxytryptamine 1B receptor from cloned gorilla membranes expressed in cultured HEK 293 cells,1,Gorilla gorilla,Intermediate,,722.0,,9593.0,HEK293,,B,BAO_0000219,CHEMBL616996,1585
,106,H,8,In vivo,,,3025,,5-HT1B agonist potency was evaluated as effective dose that induced hypothermia in the guinea-pig upon intraperitoneal administration,1,Cavia porcellus,Autocuration,,,,10141.0,,,F,BAO_0000218,CHEMBL616997,1586
,106,H,8,In vivo,,,3025,,5-hydroxytryptamine 1B receptor agonist potency was evaluated as effective dose that induced hypothermia in the guinea-pig upon intraperitoneal administration,1,Cavia porcellus,Autocuration,,,,10141.0,,,F,BAO_0000218,CHEMBL616998,1587
,106,H,8,,,,15329,,Affinity of compound towards 5-hydroxytryptamine 1B receptor in isolated guinea-pig iliac artery,1,Cavia porcellus,Autocuration,,,,10141.0,,,F,BAO_0000019,CHEMBL616999,1588
,106,H,8,,,,15329,,Affinity of compound towards 5-hydroxytryptamine 1B receptor in isolated guinea-pig iliac artery; n.d. indicates Not determined,1,Cavia porcellus,Autocuration,,,,10141.0,,,F,BAO_0000019,CHEMBL617000,1589
,106,H,8,,,,15847,,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 1B receptor of guinea pig,1,Cavia porcellus,Autocuration,,,,10141.0,,,F,BAO_0000019,CHEMBL617001,1590
,106,H,8,,,,15847,,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 1B receptor of guinea pig; ND means not done,1,Cavia porcellus,Autocuration,,,,10141.0,,,F,BAO_0000019,CHEMBL858111,1591
,106,H,8,,,,14165,,Intrinsic activity for Antagonism of 5-hydroxytryptamine 1B receptor-mediated stimulation of [35S]GTP gamma S binding,1,,Autocuration,,,,,,,F,BAO_0000019,CHEMBL617002,1592
,106,H,8,,,,14214,,Antagonism tested at 1 uM against the agonist-induced inhibitory effect of 10 nM 5-carbamoyltryptamine (5-CT),1,,Autocuration,,,,,,,F,BAO_0000019,CHEMBL617003,1593
,106,H,8,,,,14214,,Antagonism tested at 1 uM against the agonist-induced inhibitory effect of 10 nM 5-carbamoyltryptamine(5-CT),1,,Autocuration,,,,,,,F,BAO_0000019,CHEMBL617004,1594
,106,D,9,,,,14214,,Agonist activity at 5-hydroxytryptamine 1B receptor by measuring the inhibition of forskolin-stimulated cAMP formation,1,Homo sapiens,Expert,,,,9606.0,,,F,BAO_0000019,CHEMBL617005,1595
,106,D,9,,,,13729,,Inhibition of forskolin-stimulated c-AMP formation by human 5-hydroxytryptamine 1B receptor expressed in CHO-K1 cells,1,Homo sapiens,Expert,,485.0,,9606.0,CHO-K1,,F,BAO_0000219,CHEMBL616623,1596
,106,H,8,,,,3025,,Effective concentration determined by measuring inhibition of forskolin-stimulated c-AMP formation at 5-hydroxytryptamine 1B receptor stably transfected in CHO cell lines,1,,Autocuration,,449.0,,,CHO,,F,BAO_0000219,CHEMBL616624,1597
,106,H,8,,,,2391,,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor,1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL883243,1598
,106,H,8,,,,2391,,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor; full agonist,1,,Autocuration,,,,,,,F,BAO_0000019,CHEMBL616625,1599
,106,H,8,,,,14956,,"Agonist-induced [35S]GTP-gamma-S, binding in CHO cells stably transfected with human 5-hydroxytryptamine 1B receptor",1,,Expert,,449.0,,,CHO,,F,BAO_0000219,CHEMBL616626,1600
,106,H,8,,,,2598,,The intrinsic activity was evaluated for its ability to inhibit forskolin-stimulated c-AMP formation mediated by cloned 5-hydroxytryptamine 1B receptor in CHO cell line,1,,Autocuration,,449.0,,,CHO,,F,BAO_0000219,CHEMBL616627,1601
,106,H,8,,,,2598,,The intrinsic activity was evaluated for its ability to inhibit forskolin-stimulated c-AMP formation mediated by cloned 5-hydroxytryptamine 1B receptor in CHO cell line; Antagonist,1,,Autocuration,,449.0,,,CHO,,F,BAO_0000219,CHEMBL616628,1602
,106,H,8,,,,2598,,The intrinsic activity was evaluated for its ability to inhibit forskolin-stimulated c-AMP formation mediated by cloned 5-hydroxytryptamine 1B receptor in CHO cell line; Full Agonist,1,,Autocuration,,449.0,,,CHO,,F,BAO_0000219,CHEMBL616629,1603
,106,H,8,,,,2598,,The intrinsic activity was evaluated for its ability to inhibit forskolin-stimulated c-AMP formation mediated by cloned 5-hydroxytryptamine 1B receptor in CHO cell line; Partial Agonist,1,,Autocuration,,449.0,,,CHO,,F,BAO_0000219,CHEMBL616630,1604
,106,H,8,,,,14956,,"Efficacy was evaluated relative to human 5-HT1B receptor using [35S]GTP-gamma-S, as radioligand",1,,Expert,,,,,,,F,BAO_0000019,CHEMBL616631,1605
,106,H,8,,,,14956,,"Efficacy of compound was evaluated relative to human 5-hydroxytryptamine 1B receptor using [35S]GTP-gamma-S, as radioligand",1,,Autocuration,,,,,,,F,BAO_0000019,CHEMBL616632,1606
,106,D,9,,,,14214,,Percentage Maximal inhibition obtained with 1 uM 5-HT against 5-hydroxytryptamine 1B receptor,1,Homo sapiens,Expert,,,,9606.0,,,B,BAO_0000357,CHEMBL616633,1607
,106,H,8,,,,3463,,Ability to displace [3H]5-HT from recombinant human 5-hydroxytryptamine 1B receptor stably expressed in CHO cells determined in vitro,1,,Expert,,449.0,,,CHO,,B,BAO_0000219,CHEMBL616634,1608
,106,H,8,,,,15331,,Affinity of compound towards 5-hydroxytryptamine 1B receptor was evaluated using radioligand binding technique,1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL616635,1609
,106,D,9,,,,16146,,Binding affinity against 5-hydroxytryptamine 1B receptor,1,Homo sapiens,Expert,,,,9606.0,,,B,BAO_0000357,CHEMBL885358,1610
,106,D,9,,,,14159,,Displacement of [3H]5-HT from human 5-hydroxytryptamine 1B receptor expressed in CHO cells,1,Homo sapiens,Expert,,449.0,,9606.0,CHO,,B,BAO_0000219,CHEMBL616636,1611
,106,H,8,,,,14158,,Binding affinity to human cloned 5-hydroxytryptamine 1B receptor in CHO cells by [3H]5-HT binding displacement.,1,,Expert,,449.0,,,CHO,,B,BAO_0000219,CHEMBL616637,1612
,106,H,8,,,,14159,,Compound was evaluated for the affinity at 5-hydroxytryptamine 1B receptor,1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL616638,1613
,106,H,8,,,,15250,,Displacement of [3H]5-HT binding to cloned 5-hydroxytryptamine 1B receptor stably expressed in CHO cells,1,,Expert,,449.0,,,CHO,,B,BAO_0000219,CHEMBL616639,1614
,106,H,8,,,,15250,,Binding affinity at cloned human 5-hydroxytryptamine 1B receptor stably expressed in CHO cells by [3H]5-HT displacement.,1,,Expert,,449.0,,,CHO,,B,BAO_0000219,CHEMBL616640,1615
,106,H,8,,,,15331,,Displacement of [3H]5-HT binding from the cloned human 5-hydroxytryptamine 1B receptor stably expressed in CHO cells,1,,Expert,,449.0,,,CHO,,B,BAO_0000219,CHEMBL616641,1616
,106,H,8,,,,15332,,Displacement of [3H]5-HT binding from cloned human 5-hydroxytryptamine 1B receptor stably expressed in CHO cells.,1,,Expert,,449.0,,,CHO,,B,BAO_0000219,CHEMBL616642,1617
,106,H,8,,,,14956,,Displacement of specific [3H]5-HT binding to cloned human 5-hydroxytryptamine 1B receptor expressed in CHO cells,1,,Expert,,449.0,,,CHO,,B,BAO_0000219,CHEMBL616643,1618
,106,H,8,,,,3805,,In vitro binding affinity against human 5-hydroxytryptamine 1B receptor at a concentration of 100 (nM),1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL616644,1619
,106,H,8,,,,14875,,Intrinsic activity for each compound is calculated as a percentage of the 5-hydroxytryptamine 1B receptor response,1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL616645,1620
,105,H,8,,,,14454,,Compound was tested for 5-hydroxytryptamine 1D like receptor-mediated vascular effect in rabbit saphenous vein (RSV),1,Oryctolagus cuniculus,Autocuration,,,,9986.0,,,F,BAO_0000019,CHEMBL616646,1621
,105,H,8,,,,14454,,Tested for 5-hydroxytryptamine 1D like receptor-mediated vascular effect in rabbit saphenous vein (RSV),1,Oryctolagus cuniculus,Expert,,,,9986.0,,,F,BAO_0000019,CHEMBL616647,1622
,105,H,8,,,,16288,,Affinity at 5-hydroxytryptamine 1D receptor (For sumatriptan = Ki (nM)-12+/-1.9),1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL616509,1623
,105,H,8,,,,16288,,Affinity at 5-hydroxytryptamine 1D receptor from calf caudate using [3H]5-HT as radioligand (For sumatriptan = Ki(nM)-12+/-1.9),1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL616510,1624
,105,H,8,,,,16312,,Binding affinity against calf caudate 5-hydroxytryptamine 1D receptor,1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL616511,1625
,105,H,8,,,,1348,,Inhibitory activity against 5-hydroxytryptamine 1D receptor subtype,1,Bos taurus,Expert,,,,9913.0,,,B,BAO_0000357,CHEMBL616512,1626
,105,H,8,,,,5834,,Inhibitory concentration required against 5-hydroxytryptamine 1D receptor in bovine caudate using [3H]5-HT,1,Bos taurus,Autocuration,,,,9913.0,,,B,BAO_0000357,CHEMBL616513,1627
Striatum,105,H,8,,,,13366,,Binding affinity towards 5-hydroxytryptamine 1D receptor was determined in calf striatum homogenate,1,Bos taurus,Autocuration,,,,9913.0,,2435.0,B,BAO_0000019,CHEMBL616514,1628
,105,H,8,,,,1414,,Ability to bind to 5-hydroxytryptamine 1D receptor of calf substantia nigra,1,Bos taurus,Expert,,,,9913.0,,,B,BAO_0000357,CHEMBL616515,1629
,105,H,8,,,,14998,,Binding affinity against 5-hydroxytryptamine 1D receptor in calf caudate homogenates.,1,Bos taurus,Autocuration,,,,9913.0,,,B,BAO_0000019,CHEMBL616516,1630
,105,H,8,,,,11473,,Compound was evaluated for binding affinity towards 5-hydroxytryptamine 1D receptor in bovine caudate using [3H]- serotonin as radioligand,1,Bos taurus,Autocuration,,,,9913.0,,,B,BAO_0000357,CHEMBL616517,1631
,105,H,8,,,,11473,,Compound was evaluated for binding affinity towards 5-hydroxytryptamine 1D receptor in bovine caudate using [3H]- serotonin as radioligand,1,Bos taurus,Autocuration,,,,9913.0,,,B,BAO_0000357,CHEMBL616518,1632
,105,H,8,,,,10639,,Compound was evaluated for its inhibitory activity against 5-hydroxytryptamine 1D receptor of bovine caudate using [3H]5-HT as the radioligand,1,Bos taurus,Autocuration,,,,9913.0,,,B,BAO_0000357,CHEMBL616519,1633
,105,H,8,,,,10639,,Inhibitory activity against 5-hydroxytryptamine 1D receptor of bovine caudate using [3H]5-HT as the radioligand,1,Bos taurus,Autocuration,,,,9913.0,,,B,BAO_0000357,CHEMBL616520,1634
,105,H,8,,,,1375,,Tested in vitro for receptor binding affinity to 5-hydroxytryptamine 1D receptor in bovine caudate using [3H]5-HT radioligand,1,Bos taurus,Autocuration,,,,9913.0,,,B,BAO_0000357,CHEMBL616521,1635
,105,H,8,,,,1375,,Tested in vitro for receptor binding affinity to 5-hydroxytryptamine 1D receptor in bovine caudate using [3H]5-HT radioligand; NT means not tested,1,Bos taurus,Autocuration,,,,9913.0,,,B,BAO_0000357,CHEMBL616522,1636
,105,H,8,,,,16532,,The binding affinity at 5-hydroxytryptamine 1D receptor was determined using [3H]5-CT; Not tested,1,Bos taurus,Autocuration,,,,9913.0,,,B,BAO_0000357,CHEMBL884531,1637
,105,H,8,,,,11147,,Binding affinity towards 5-hydroxytryptamine 1D receptor using [3H]5-HT as radioligand,1,Bos taurus,Autocuration,,,,9913.0,,,B,BAO_0000357,CHEMBL616523,1638
Striatum,105,H,8,,,,13366,,Binding affinity towards 5-hydroxytryptamine 1D receptor was determined in calf striatum homogenate,1,Bos taurus,Autocuration,,,,9913.0,,2435.0,B,BAO_0000019,CHEMBL616731,1639
,105,H,8,,,,10444,,Binding affinity was determined against 5-hydroxytryptamine 1D receptor in bovine caudate homogenate,1,Bos taurus,Autocuration,,,,9913.0,,,B,BAO_0000019,CHEMBL616732,1640
,105,H,8,,,,16532,,The binding affinity at 5-hydroxytryptamine 1D receptor was determined using [3H]5-CT,1,Bos taurus,Autocuration,,,,9913.0,,,B,BAO_0000357,CHEMBL616733,1641
,105,H,8,,,,16532,,The binding affinity at 5-hydroxytryptamine 1D receptor was determined using [3H]5-CT; Not tested,1,Bos taurus,Autocuration,,,,9913.0,,,B,BAO_0000357,CHEMBL616734,1642
,105,H,8,,,,12827,,Binding affinity towards 5-hydroxytryptamine 1B receptor in rat frontal cortex membranes using [125]ICYP,1,Bos taurus,Autocuration,,,,9913.0,,,B,BAO_0000249,CHEMBL616735,1643
,105,H,8,,,,12827,,Binding affinity towards 5-hydroxytryptamine 1B receptor in rat frontal cortex membranes using [125]ICYP; Not determined,1,Bos taurus,Autocuration,,,,9913.0,,,B,BAO_0000249,CHEMBL616736,1644
,105,H,8,,,,12919,,Agonistic activity against 5-hydroxytryptamine 1D receptor in calf caudate using [3H]-GTI,1,Bos taurus,Expert,,,,9913.0,,,F,BAO_0000019,CHEMBL616737,1645
,105,H,8,,,,14025,,Affinity pKi for 5-hydroxytryptamine 1D receptor was measured in calf caudate homogenate,1,Bos taurus,Autocuration,,,,9913.0,,,B,BAO_0000019,CHEMBL616738,1646
,105,H,8,,,,12919,,Agonistic activity against 5-hydroxytryptamine 1D receptor in calf caudate using [3H]-GTI,1,Bos taurus,Expert,,,,9913.0,,,F,BAO_0000019,CHEMBL616739,1647
,105,H,8,,,,12919,,Agonistic activity against 5-hydroxytryptamine 1D receptor in calf caudate using [3H]-GTI,1,Bos taurus,Expert,,,,9913.0,,,F,BAO_0000019,CHEMBL616740,1648
,105,H,8,,,,12919,,Agonistic activity against 5-hydroxytryptamine 1D receptor in calf caudate using [3H]-GTI,1,Bos taurus,Expert,,,,9913.0,,,F,BAO_0000019,CHEMBL616741,1649
,105,H,8,,,,14447,,The compound was tested for CNS binding affinity towards 5-hydroxytryptamine 1D receptor from cloned gorilla membranes expressed in cultured HEK 293 cells,1,Gorilla gorilla,Autocuration,,722.0,,9593.0,HEK293,,B,BAO_0000219,CHEMBL616742,1650
,105570,D,9,,,,1375,,Compound was tested for the inhibition of forskolin-stimulated adenylate cyclase at 5-hydroxytryptamine 1D receptor in guinea pig substantia nigra,1,Cavia porcellus,Intermediate,,,,10141.0,,,B,BAO_0000019,CHEMBL616743,1651
,105570,D,9,,,,1375,,Compound was tested for the inhibition of forskolin-stimulated adenylate cyclase at 5-hydroxytryptamine 1D receptor in guinea pig substantia nigra; NT means not tested,1,Cavia porcellus,Intermediate,,,,10141.0,,,B,BAO_0000019,CHEMBL616744,1652
,105570,D,9,,,,12409,,Oral effective dose against hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptor by the agonist GR-46611,1,Cavia porcellus,Intermediate,,,,10141.0,,,F,BAO_0000019,CHEMBL616745,1653
,105570,D,9,,,,12409,,Oral effective dose against hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptors by the agonist GR-46611,1,Cavia porcellus,Intermediate,,,,10141.0,,,F,BAO_0000019,CHEMBL616746,1654
,105570,D,9,,,,12409,,Oral effective dose against hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptors by the agonist GR-46611; range is 2-9,1,Cavia porcellus,Intermediate,,,,10141.0,,,F,BAO_0000019,CHEMBL616747,1655
,105570,D,9,,,,12409,,Oral effective dose against hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptors by the agonist GR-46611;range is 0.2-0.4,1,Cavia porcellus,Intermediate,,,,10141.0,,,F,BAO_0000019,CHEMBL616748,1656
,105570,D,9,,,,12409,,Oral effective dose against hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptors by the agonist GR-46611;range is 0.2-1.2,1,Cavia porcellus,Intermediate,,,,10141.0,,,F,BAO_0000019,CHEMBL616648,1657
,105570,D,9,,,,11574,,Binding affinity against 5-hydroxytryptamine 1D receptor,1,Cavia porcellus,Intermediate,,,,10141.0,,,B,BAO_0000357,CHEMBL616649,1658
,105570,D,9,,,,1558,,Binding affinity towards guinea pig 5-hydroxytryptamine 1D receptor was determined,1,Cavia porcellus,Intermediate,,,,10141.0,,,B,BAO_0000357,CHEMBL616650,1659
,105570,D,9,,,,12409,,Compound at 3 mg/kg was tested for the inhibition of hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptors by the agonist GR-46611,1,Cavia porcellus,Intermediate,,,,10141.0,,,F,BAO_0000218,CHEMBL616651,1660
,105570,D,9,,,,12409,,Compound at 45 mg/kg was tested for the inhibition of hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptors by the agonist GR-46611,1,Cavia porcellus,Intermediate,,,,10141.0,,,F,BAO_0000218,CHEMBL616652,1661
,105570,D,9,,,,12409,,Compound at 50 mg/kg was tested for the inhibition of hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptors by the agonist GR-46611,1,Cavia porcellus,Intermediate,,,,10141.0,,,F,BAO_0000218,CHEMBL616653,1662
,105570,D,9,,,,12409,,Compound at oral dose of 45 mg/kg was tested for percent inhibition against 5-hydroxytryptamine 1D receptor causes hypothermia in guinea pig,1,Cavia porcellus,Intermediate,,,,10141.0,,,F,BAO_0000218,CHEMBL616654,1663
,105570,D,9,,,,12253,,Binding affinity of 5-hydroxytryptamine 1D receptor using [3H]-8-HT in guinea pig cortex,1,Cavia porcellus,Intermediate,,,,10141.0,,,B,BAO_0000019,CHEMBL616655,1664
,105570,D,9,,,,12936,,Binding affinity against guinea pig 5-hydroxytryptamine 1D receptor,1,Cavia porcellus,Intermediate,,,,10141.0,,,B,BAO_0000357,CHEMBL616656,1665
,105,H,8,,,,13181,,Binding affinity was determined against 5-hydroxytryptamine 4 receptor using [125I]SB 207710 as radioligand from piglet hippocampal membranes,1,Cavia porcellus,Autocuration,,,,10141.0,,,B,BAO_0000019,CHEMBL616657,1666
Striatum,105570,D,9,,,,12409,,In vitro binding affinity towards 5-hydroxytryptamine 1D receptor in guinea-pig striatum in presence of BMY-7378 and mesulergine,1,Cavia porcellus,Intermediate,,,,10141.0,,2435.0,B,BAO_0000357,CHEMBL616658,1667
,105570,D,9,,,,10639,,Inhibition of Forskolin-stimulated adenylate cyclase activity against 5-hydroxytryptamine 1D receptor of guinea pig substantia nigra,1,Cavia porcellus,Intermediate,,,,10141.0,,,B,BAO_0000357,CHEMBL616659,1668
,51,H,8,,,,5254,,Binding affinity against 5-hydroxytryptamine 1D receptor,1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL616660,1669
,106,H,8,,,,13051,,The compound was tested for binding affinity against cloned human 5-hydroxytryptamine 1D receptor beta,1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL616661,1670
,105,H,8,,,,3463,,Maximum stimulation of [35S]GTP gamma-S binding expressed relative to the maximal effect produced by 5-hydroxytryptamine 1D receptor,1,,Expert,,,,,,,F,BAO_0000019,CHEMBL616662,1671
,105,H,8,,,,15315,,Ability to inhibit forskolin-stimulated adenylate cyclase in a cell line expressing human 5-hydroxytryptamine 1D receptor,1,,Autocuration,,,,,,,F,BAO_0000019,CHEMBL616663,1672
,105,H,8,,,,6011,,Ability to inhibit forskolin-stimulated adenylate cyclase activity in Chinese hamster ovary (CHO) stable cell lines expressing human 5-hydroxytryptamine 1D receptor,1,,Autocuration,,,,,,,F,BAO_0000019,CHEMBL616664,1673
,105,D,9,,,,14159,,"Stimulation of [35S]GTP-gamma-S, binding in CHO cells expressing 5-hydroxytryptamine 1D receptor",1,Homo sapiens,Expert,,449.0,,9606.0,CHO,,F,BAO_0000219,CHEMBL881820,1674
,105,H,8,,,,14159,,"Compound was evaluated for the stimulation of [35S]GTP-gamma-S, binding in CHO cells expressing the 5-hydroxytryptamine 1D receptor.",1,,Autocuration,,449.0,,,CHO,,F,BAO_0000219,CHEMBL616665,1675
,105,H,8,,,,15250,,Agonist-induced [35S]- GTPgammaS binding in CHO cells stably transfected with 5-hydroxytryptamine 1D receptor,1,,Expert,,449.0,,,CHO,,B,BAO_0000219,CHEMBL616666,1676
,105,H,8,,,,15250,,Compound was tested for measuring agonist-induced [35S]- GTPgammaS binding in CHO cells stably transfected with human 5-hydroxytryptamine 1D receptor,1,,Autocuration,,449.0,,,CHO,,B,BAO_0000219,CHEMBL616667,1677
,105,H,8,,,,15331,,"Stimulation of [35S]GTP-gamma-S, binding in CHO cells expressing the 5-hydroxytryptamine 1D receptor",1,,Expert,,449.0,,,CHO,,F,BAO_0000219,CHEMBL616668,1678
,105,D,9,,,,15332,,"Stimulation of [35S]GTP-gamma-S, binding in CHO cells expressing the 5-hydroxytryptamine 1D receptor",1,Homo sapiens,Expert,,449.0,,9606.0,CHO,,F,BAO_0000219,CHEMBL616669,1679
,105,H,8,,,,15332,,"Stimulation of [35S]GTP-gamma-S, binding in CHO cells expressing the human 5-hydroxytryptamine 1D receptor.",1,,Expert,,449.0,,,CHO,,F,BAO_0000219,CHEMBL617040,1680
,105,H,8,,,,3294,,"Measurement of agonist induced [35S]GTP-gamma-S, binding in CHO cells stably transfected with 5-hydroxytryptamine 1D receptor",1,,Autocuration,,449.0,,,CHO,,F,BAO_0000219,CHEMBL617041,1681
,105,H,8,,,,14158,,"Measurement of agonist induced [35S]GTP-gamma-S, binding in CHO cells stably transfected with 5-hydroxytryptamine 1D receptor.",1,,Expert,,449.0,,,CHO,,F,BAO_0000219,CHEMBL617042,1682
,105,H,8,,,,14956,,"Agonist-induced [35S]GTP-gamma-S, binding in CHO cells stably transfected with human 5-hydroxytryptamine 1D receptor",1,,Expert,,449.0,,,CHO,,F,BAO_0000219,CHEMBL617043,1683
,105,H,8,,,,12469,,Compound was evaluated for its agonistic activity on 5-hydroxytryptamine 1D receptor,1,,Autocuration,,,,,,,F,BAO_0000019,CHEMBL617044,1684
,105,H,8,,,,3463,,Measurement of agonist-induced [35S]-GTP gamma-S binding in CHO cells stably transfected with 5-hydroxytryptamine 1D receptor,1,,Expert,,449.0,,,CHO,,F,BAO_0000219,CHEMBL617045,1685
,105,D,9,,,,15250,,"Maximum stimulation of [35S]GTP-gamma-S, binding in CHO cells expressing human 5-HT-1d relative to 5-HT",1,Homo sapiens,Expert,,449.0,,9606.0,CHO,,F,BAO_0000219,CHEMBL617046,1686
,105,D,9,,,,15250,,"Maximum stimulation of [35S]GTP-gamma-S, binding in CHO cells expressing human 5-HT-1d relative to 5-HT",1,Homo sapiens,Expert,,449.0,,9606.0,CHO,,F,BAO_0000219,CHEMBL617047,1687
,105,H,8,,,,14956,,"Efficacy was evaluated relative to human 5-hydroxytryptamine 1D receptor using [35S]GTP-gamma-S, as radioligand",1,,Expert,,,,,,,F,BAO_0000019,CHEMBL617048,1688
,105,H,8,,,,14159,,"Maximum stimulation of [35S]GTP-gamma-S, binding expressed relative to the maximal effect produced by 5-hydroxytryptamine 1D receptor.",1,,Autocuration,,,,,,,F,BAO_0000019,CHEMBL616897,1689
,105,D,9,,,,14159,,"Maximum stimulation of [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1D receptor relative to 5-HT",1,Homo sapiens,Expert,,,,9606.0,,,F,BAO_0000019,CHEMBL616898,1690
,105,D,9,,,,14499,,Percent efficacy relative to 5-HT treatment of CHO cells expressing 5-HT 1d receptor,1,Homo sapiens,Expert,,449.0,,9606.0,CHO,,F,BAO_0000219,CHEMBL858201,1691
,105,H,8,,,,15315,,Intrinsic activity for 5-hydroxytryptamine 1D receptor,1,,Autocuration,,,,,,,F,BAO_0000019,CHEMBL616899,1692
,105,H,8,In vitro,,,3294,,Ability to displace [3H]- -5-HT binding to cloned 5-hydroxytryptamine 1D receptor stably expressed in chinese hamster cells (CHO cells),1,,Autocuration,,,,,,,B,BAO_0000219,CHEMBL616900,1693
,105,H,8,,,,3463,,Ability to displace [3H]-5-HT from recombinant human 5-hydroxytryptamine 1D receptor stably expressed in CHO cells determined in vitro,1,,Expert,,449.0,,,CHO,,B,BAO_0000219,CHEMBL616901,1694
,105,H,8,,,,15331,,Affinity of compound towards 5-hydroxytryptamine 1D receptor was evaluated using radioligand binding technique,1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL616902,1695
,105,D,9,,,,14159,,Displacement of [3H]5-HT from human 5-hydroxytryptamine 1D receptor expressed in CHO cells,1,Homo sapiens,Expert,,449.0,,9606.0,CHO,,B,BAO_0000219,CHEMBL616903,1696
,105,H,8,,,,14158,,Binding affinity by displacement to human cloned 5-hydroxytryptamine 1D receptor in CHO cells by [3H]5-HT displacement.,1,,Expert,,449.0,,,CHO,,B,BAO_0000219,CHEMBL616904,1697
,105,H,8,,,,14159,,Compound was evaluated for the affinity at 5-hydroxytryptamine 1D receptor,1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL616905,1698
,105,H,8,,,,15250,,Binding affinity at human cloned 5-hydroxytryptamine 1D receptor stably expressed in CHO cells by [3H]5-HT displacement.,1,,Expert,,449.0,,,CHO,,B,BAO_0000219,CHEMBL616906,1699
,105,H,8,,,,15250,,Displacement of [3H]5-HT binding to cloned human 5-hydroxytryptamine 1D receptor stably expressed in CHO cells,1,,Expert,,449.0,,,CHO,,B,BAO_0000219,CHEMBL616907,1700
,105,H,8,,,,15331,,Displacement of [3H]5-HT binding from the cloned human 5-hydroxytryptamine 1D receptor stably expressed in CHO cells,1,,Expert,,449.0,,,CHO,,B,BAO_0000219,CHEMBL616908,1701
,105,D,9,,,,15332,,Displacement of [3H]5-HT binding from human 5-hydroxytryptamine 1D receptor expressed in CHO cells,1,Homo sapiens,Expert,,449.0,,9606.0,CHO,,B,BAO_0000219,CHEMBL616909,1702
,105,D,9,,,,14499,,Displacement of [3H]5-HT from human 5-hydroxytryptamine 1D receptor expressed in CHO cells,1,Homo sapiens,Expert,,449.0,,9606.0,CHO,,B,BAO_0000219,CHEMBL616910,1703
,105,H,8,,,,15332,,Displacement of [3H]5-HT binding to the cloned human 5-hydroxytryptamine 1D receptor stably expressed in CHO cells,1,,Expert,,449.0,,,CHO,,B,BAO_0000219,CHEMBL616911,1704
,105,H,8,,,,14956,,Displacement of specific [3H]5-HT binding to cloned human 5-hydroxytryptamine 1D receptor expressed in CHO cells,1,,Expert,,449.0,,,CHO,,B,BAO_0000219,CHEMBL616912,1705
,105,H,8,,,,3805,,In vitro binding affinity against human 5-hydroxytryptamine 1D receptor at a concentration of 100 (nM),1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL616913,1706
,105,D,9,,,,6011,,Inhibition of [3H]5-HT binding to human 5-hydroxytryptamine 1D receptor expressed in CHO cells at 1 uM,1,Homo sapiens,Expert,,449.0,,9606.0,CHO,,B,BAO_0000219,CHEMBL616914,1707
,105,H,8,,,,16190,,Binding affinity against 5-hydroxytryptamine 1D receptor in CHO cells using [3H]5-HT as radioligand,1,,Autocuration,,449.0,,,CHO,,B,BAO_0000219,CHEMBL616915,1708
,105,H,8,,,,14165,,Binding affinity for 5-hydroxytryptamine 1D receptor in Cos-7 transfected cell type using [3H]5-CT as radioligand,1,,Autocuration,,,,,,,B,BAO_0000019,CHEMBL616916,1709
,105,D,9,,,,4234,,Binding affinity to cloned human 5-hydroxytryptamine 1D receptor,1,Homo sapiens,Expert,,,,9606.0,,,B,BAO_0000357,CHEMBL616917,1710
,105,H,8,,,,15527,,"Binding affinity towards 5-HT1D receptor, using [3H]5-HT as radioligand.",1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL616918,1711
,105,H,8,,,,6328,,Binding affinity towards human 5-hydroxytryptamine 1D receptor in L-M(tk-) cells using [3H]GR-125743 as radioligand,1,,Expert,,,,,,,B,BAO_0000219,CHEMBL616919,1712
,105,H,8,,,,16209,,Binding affinity towards human 5-hydroxytryptamine 1D receptor was determined using [3H]5-HT as radioligand,1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL616920,1713
,105,H,8,,,,14770,,Binding affinity for recombinant human 5-hydroxytryptamine 1D receptor using [3H]5-HT as radioligand.,1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL872914,1714
,105,H,8,,,,2598,,Binding affinity was evaluated at human recombinant 5-hydroxytryptamine 1D receptor using [3H]-5-CT as radioligand,1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL616921,1715
,105,H,8,,,,6897,,Binding affinity was evaluated at the cloned human 5-hydroxytryptamine 1D receptor,1,,Expert,,,,,,,B,BAO_0000357,CHEMBL616922,1716
,105,H,8,,,,6013,,Binding affinity towards 5-hydroxytryptamine 1D receptor,1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL616923,1717
,105,H,8,,,,5843,,Binding affinity towards cloned human 5-hydroxytryptamine 1D receptor,1,,Expert,,,,,,,B,BAO_0000357,CHEMBL616924,1718
,105,H,8,,,,14454,,Binding affinity towards human 5-hydroxytryptamine 1D receptor using [3H]5-HT trifluoroacetate as radioligand,1,,Expert,,,,,,,B,BAO_0000357,CHEMBL875909,1719
,105,H,8,,,,14454,,Binding affinity towards human 5-hydroxytryptamine 1D receptor using [3H]5-HT trifluoroacetate as radioligand; Not determined,1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL616925,1720
,105,H,8,,,,14454,,Binding affinity towards human 5-hydroxytryptamine 1D receptor using [3H]5-HT trifluoroacetate as radioligand; not determined,1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL616926,1721
,105,H,8,,,,15818,,Compound was evaluated for its binding affinity towards human 5-hydroxytryptamine 1D receptor,1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL616927,1722
,105,H,8,,,,13729,,Ability to inhibit the forskolin-stimulated c-AMP formation mediated by human 5-hydroxytryptamine 1D receptor in CHO-K1 cells,1,,Expert,,485.0,,,CHO-K1,,F,BAO_0000219,CHEMBL616928,1723
,105,D,9,In vitro,,,6011,,Displacement of [3H]5-HT from human 5-hydroxytryptamine 1D receptor expressed in Chinese hamster ovary cells (CHO cells),1,Homo sapiens,Expert,,,,9606.0,,,B,BAO_0000219,CHEMBL616929,1724
,105,D,9,,,,4234,,In vitro binding affinity to human 5-hydroxytryptamine 1D receptor,1,Homo sapiens,Expert,,,,9606.0,,,B,BAO_0000357,CHEMBL616930,1725
,105,H,8,,,,17085,,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1D receptor,1,,Expert,,,,,,,B,BAO_0000019,CHEMBL616931,1726
,105,H,8,,,,3025,,In vitro binding affinity was determined towards cloned human 5-hydroxytryptamine 1D receptor using [3H]5-CT radioligand,1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL616932,1727
,105,H,8,,,,15315,,In vitro receptor binding affinity for cloned human 5-hydroxytryptamine 1D receptor,1,,Expert,,,,,,,B,BAO_0000357,CHEMBL616933,1728
,105,D,9,,,,14214,,Receptor binding affinity for cloned human 5-hydroxytryptamine 1D receptor in Cos-7 cells,1,Homo sapiens,Expert,,,,9606.0,,,B,BAO_0000219,CHEMBL616934,1729
,105,D,9,,,,3804,,Binding affinity for human 5-hydroxytryptamine 1D receptor,1,Homo sapiens,Expert,,,,9606.0,,,B,BAO_0000357,CHEMBL616935,1730
,105,H,8,,,,16700,,The binding affinity towards the 5-hydroxytryptamine 1D receptor; No affinity,1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL616936,1731
,105,D,9,,,,2391,,Affinity for 5-hydroxytryptamine 1D receptor subtype,1,Homo sapiens,Expert,,,,9606.0,,,B,BAO_0000357,CHEMBL616937,1732
,105,D,9,,,,4175,,Binding affinity for human 5-hydroxytryptamine 1D receptor,1,Homo sapiens,Expert,,,,9606.0,,,B,BAO_0000357,CHEMBL616938,1733
,105,H,8,,,,17085,,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1D receptor,1,,Autocuration,,,,,,,B,BAO_0000019,CHEMBL616939,1734
,105,H,8,,,,17085,,In vitro binding affinity was determined by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1D receptor; ND means not determined,1,,Expert,,,,,,,B,BAO_0000019,CHEMBL616940,1735
,105,D,9,,,,15926,,Binding activity against human 5-hydroxytryptamine 1D receptor; NT means not tested,1,Homo sapiens,Expert,,,,9606.0,,,B,BAO_0000357,CHEMBL616941,1736
,105,H,8,,,,16312,,Binding affinity in CHO-K1 cells transfected with human 5-hydroxytryptamine 1D receptor; Not tested,1,,Autocuration,,485.0,,,CHO-K1,,B,BAO_0000219,CHEMBL616942,1737
,105,H,8,,,,16312,,Binding affinity in CHO-K1 cells transfected with human 5-hydroxytryptamine 1D receptor; not tested,1,,Autocuration,,485.0,,,CHO-K1,,B,BAO_0000219,CHEMBL616943,1738
,104802,H,4,,,,14956,,Selectivity towards 5-HT1D and to that of 5-HT1B in CHO cells,1,,Autocuration,,449.0,,,CHO,,B,BAO_0000219,CHEMBL616944,1739
,105,H,8,,,,3294,,"Maximum stimulation of [35S]GTP-gamma-S, binding expressed relative to the maximal effect produced by the 5-HT",1,,Autocuration,,,,,,,F,BAO_0000019,CHEMBL616945,1740
,105,H,8,,,,12861,,Binding activity radioligand.,1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL616946,1741
,105,H,8,,,,12861,,Binding activity against 5-hydroxytryptamine 3 receptor from rat cortex homogenate using [3H]-Q-ICS 205-930 as radioligand.,1,,Autocuration,,,,,,,B,BAO_0000019,CHEMBL616947,1742
,105,H,8,,,,16312,,Binding affinity in CHO-K1 cells transfected with human 5-hydroxytryptamine 1D receptor,1,,Expert,,485.0,,,CHO-K1,,B,BAO_0000219,CHEMBL616948,1743
,105,H,8,,,,5104,,Binding affinity for human cloned 5-hydroxytryptamine 1D receptor,1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL616851,1744
,105,H,8,,,,5105,,Binding affinity for human cloned 5-hydroxytryptamine 1D receptor,1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL616852,1745
,105,H,8,,,,14499,,Measured as -log Ka on 5-hydroxytryptamine 1D receptor,1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL616853,1746
,105,D,9,,,,15926,,Binding activity against human 5-hydroxytryptamine 1D receptor,1,Homo sapiens,Expert,,,,9606.0,,,B,BAO_0000357,CHEMBL616854,1747
,105,D,9,,,,4540,,Binding affinity to human cloned 5-hydroxytryptamine 1D receptor in CHO cells using [3H]5-HT as radioligand,1,Homo sapiens,Expert,,449.0,,9606.0,CHO,,B,BAO_0000219,CHEMBL616855,1748
,105,H,8,,,,15779,,Binding affinity towards 5-hydroxytryptamine 1D (human cloned receptor) in CHO cells using [3H]-5-HT as radioligand.,1,,Autocuration,,449.0,,,CHO,,B,BAO_0000219,CHEMBL616856,1749
,105,H,8,,,,15779,,Binding affinity towards 5-hydroxytryptamine 1D (human cloned receptor) in CHO cells using [3H]5-HT as radioligand.,1,,Autocuration,,449.0,,,CHO,,B,BAO_0000219,CHEMBL616857,1750
,105,H,8,,,,6166,,Binding affinity towards cloned human 5-hydroxytryptamine 1D receptor,1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL616858,1751
,105,H,8,,,,15779,,Binding affinity towards human cloned 5-hydroxytryptamine 1D receptor in CHO cells using [3H]5-HT as radioligand.,1,,Autocuration,,449.0,,,CHO,,B,BAO_0000219,CHEMBL616859,1752
,105,H,8,,,,15779,,Binding affinity towards human cloned 5-hydroxytryptamine 1D receptor in CHO cells using [3H]-5-HT as radioligand.;ND means no data.,1,,Autocuration,,449.0,,,CHO,,B,BAO_0000219,CHEMBL616860,1753
,105,H,8,,,,17451,,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 1D receptor expressed in HEK 293 cells using [3H]LSD as radioligand,1,,Autocuration,,722.0,,,HEK293,,B,BAO_0000219,CHEMBL616861,1754
,105,H,8,,,,17451,,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 1D receptor expressed in HEK 293 cells using [3H]LSD as radioligand,1,,Autocuration,,722.0,,,HEK293,,B,BAO_0000219,CHEMBL616541,1755
,105,H,8,,,,17451,,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 1D receptor expressed in HEK 293 cells using [3H]LSD as radioligand; Not determined,1,,Autocuration,,722.0,,,HEK293,,B,BAO_0000219,CHEMBL616542,1756
,105,H,8,,,,4199,,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 1D receptor in CHO cells using [3H]5-HT as the radioligand,1,,Autocuration,,449.0,,,CHO,,B,BAO_0000219,CHEMBL616543,1757
,105,D,9,,,,14875,,Binding affinity for human 5-hydroxytryptamine 1D receptor,1,Homo sapiens,Expert,,,,9606.0,,,B,BAO_0000357,CHEMBL616544,1758
,105,H,8,,,,15146,,Compound was tested for its binding affinity against human cloned 5-hydroxytryptamine 1D receptor in CHO cells using [3H]5-HT,1,,Autocuration,,449.0,,,CHO,,B,BAO_0000219,CHEMBL616545,1759
,105,H,8,,,,5213,,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 1D receptor in CHO using [3H]5-HT as a radioligand,1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL616546,1760
,105,H,8,,,,14818,,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 1D receptor in CHO cells using [3H]5-HT.,1,,Autocuration,,449.0,,,CHO,,B,BAO_0000219,CHEMBL616547,1761
,105,H,8,,,,4829,,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 1D receptor in CHO cells, using [3H]5-HT as radioligand",1,,Autocuration,,449.0,,,CHO,,B,BAO_0000219,CHEMBL616548,1762
,105,H,8,,,,14454,,Adenyl cyclase activity was expressed as percent forskolin response against 5-hydroxytryptamine 1D receptor at concentration 1 uM,1,,Expert,,,,,,,F,BAO_0000019,CHEMBL616549,1763
,105,H,8,,,,14454,,Adenyl cyclase activity was expressed as percent forskolin response against 5-hydroxytryptamine 1D receptor at concentration 10 uM,1,,Expert,,,,,,,F,BAO_0000019,CHEMBL616550,1764
,108,H,8,,,,5254,,Binding affinity against 5-HT2C receptor,1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL857066,1765
,108,H,8,,,,5254,,Binding affinity against 5-hydroxytryptamine 1D receptor,1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL616551,1766
,10577,H,8,,,,10639,,Inhibition of Forskolin-stimulated adenylate cyclase activity against 5-hydroxytryptamine 1B receptor of rat substantia nigra,1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL616552,1767
,10577,H,8,,,,10639,,Inhibition of Forskolin-stimulated adenylate cyclase activity against 5-hydroxytryptamine 1B receptor of rat substantia nigra,1,,Autocuration,,,,,,,F,BAO_0000019,CHEMBL832876,1768
,10577,H,8,,,,12352,,"Binding affinity for 5-hydroxytryptamine 1B receptor in rat cortex, striatum and globus pallidus",1,,Expert,,,,,,,B,BAO_0000019,CHEMBL616553,1769
,10577,H,8,,,,9098,,Binding affinity towards 5-HT1B was determined,1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL616554,1770
,10577,H,8,,,,14430,,Affinity towards 5-hydroxytryptamine 1B receptor in membranes from rat frontal cortex using [3H]5-HT,1,,Expert,,,,,,,B,BAO_0000019,CHEMBL616555,1771
,10577,H,8,,,,13657,,"Binding affinity to 5-HT1B receptors using rat cortex+striatum + globus pallidus,[3H]-5-OH-tryptamine, and serotonin for NSB",1,,Expert,,,,,,,B,BAO_0000019,CHEMBL616556,1772
,10577,H,8,,,,13657,,"Compound was evaluated for binding affinity on 5-HT1B receptors using rat cortex+striatum+ globus pallidus,[ 3H]-5-OH-tryptamine, and serotonin for NSB.",1,,Autocuration,,,,,,,B,BAO_0000019,CHEMBL616557,1773
,10577,H,8,,,,15854,,Binding affinity towards 5-hydroxytryptamine 1B receptor in rat frontal cortex using [125I]iodocyanopindolol as radio-ligand.,1,,Expert,,,,,,,B,BAO_0000019,CHEMBL616558,1774
,10577,D,9,,,,10639,,Inhibitory activity against 5-hydroxytryptamine 1B receptor of rat cortex using [3H]5-HT,1,Rattus norvegicus,Expert,,,,10116.0,,,B,BAO_0000019,CHEMBL616749,1775
,10577,H,8,,,,10025,,Concentration necessary to achieve half maximal inhibition of [125I]- Iodocyanopindolol binding to 5-hydroxytryptamine 1B receptor at 1 uM,1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL616750,1776
,10577,H,8,,,,10025,,"Concentration necessary to achieve half maximal inhibition of [125I]- Iodocyanopindolol, binds to 5-hydroxytryptamine 1B receptor at 1 uM",1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL616751,1777
,10577,H,8,,,,14286,,In vitro inhibitory concentration against radioligand [3H]5-HT binding to 5-hydroxytryptamine 1B receptor in rat striatal membrane,1,,Autocuration,,,,,,,B,BAO_0000249,CHEMBL616752,1778
Striatum,10577,H,8,,,,3651,,Inhibition of [3H]-5-HT binding to 5-hydroxytryptamine 1B receptor in rat striatum; Residual radioligand binding higher than 50%,1,,Autocuration,,,,,,2435.0,B,BAO_0000019,CHEMBL616753,1779
,10577,D,9,,,,14178,,Inhibition of radiolabeled [3H]-5-HT ligand binding to 5-hydroxytryptamine 1B receptor,1,Rattus norvegicus,Expert,,,,10116.0,,,B,BAO_0000357,CHEMBL616754,1780
,10577,H,8,,,,10639,,Inhibitory activity against 5-hydroxytryptamine 1B receptor of rat cortex using [3H]5-HT as the radioligand.,1,,Autocuration,,,,,,,B,BAO_0000019,CHEMBL616755,1781
Striatum,10577,H,8,,,,13605,,Inhibitory activity against [3H]5-HT binding to 5-HT1B receptor in rat striatum,1,,Autocuration,,,,,,2435.0,B,BAO_0000019,CHEMBL616756,1782
Striatum,10577,H,8,,,,5834,,Inhibitory concentration required against 5-hydroxytryptamine 1B receptor in rat striatum using [3H]5-HT,1,,Autocuration,,,,,,2435.0,B,BAO_0000019,CHEMBL616757,1783
Striatum,10577,H,8,,,,10922,,compound was measured for affinity against 5-hydroxytryptamine 1B receptor labelled with [3H]5-HT radioligand in striatum tissue,1,,Autocuration,,,,,,2435.0,B,BAO_0000357,CHEMBL616758,1784
,10577,H,8,,,,14286,,Compound at 10E-5 M was tested in vitro for the inhibition of radioligand [3H]5-HT binding to 5-hydroxytryptamine 1B receptor in rat striatal membrane,1,,Autocuration,,,,,,,B,BAO_0000249,CHEMBL616759,1785
,10577,H,8,,,,11825,,In vitro binding affinity towards the 5-hydroxytryptamine 1B receptor at 10 e-6 M,1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL616760,1786
Striatum,10577,H,8,,,,14826,,Ability to displace [3H]5-HT bound to 5-hydroxytryptamine 1B receptor in rat striatum,1,,Autocuration,,,,,,2435.0,B,BAO_0000019,CHEMBL616761,1787
Striatum,10577,H,8,,,,9699,,Binding affinity against 5-HT1B serotonin receptor in rat striatum,1,,Autocuration,,,,,,2435.0,B,BAO_0000019,CHEMBL616762,1788
,10577,H,8,,,,14423,,Binding affinity against 5-hydroxytryptamine 1B receptor in membranes of Rat cerebral cortex,1,,Autocuration,,,,,,,B,BAO_0000019,CHEMBL616763,1789
,10577,H,8,,,,10062,,Binding affinity at rat 5-hydroxytryptamine 1B receptor by [3H]5-HT displacement.,1,,Expert,,,,,,,B,BAO_0000357,CHEMBL872909,1790
,10577,H,8,,,,10062,,Binding affinity determined in radioreceptor binding assay by using [3H]5-HT radioligand against 5-hydroxytryptamine 1B receptor,1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL616764,1791
,10577,D,9,,,,12280,,Inhibition of [3H]5-HT binding to 5-hydroxytryptamine 1B receptor,1,Rattus norvegicus,Expert,,,,10116.0,,,B,BAO_0000357,CHEMBL616765,1792
Striatum,10577,H,8,,,,15412,,Binding affinity against 5-hydroxytryptamine 1B receptor of rat striatum,1,,Autocuration,,,,,,2435.0,B,BAO_0000357,CHEMBL616766,1793
Striatum,10577,H,8,,,,15412,,Binding affinity against 5-hydroxytryptamine 1B receptor of rat striatum.,1,,Autocuration,,,,,,2435.0,B,BAO_0000357,CHEMBL616767,1794
,10577,H,8,,,,10062,,Binding affinity in radioreceptor binding assay by using [3H]5-HT radioligand against 5-hydroxytryptamine 1B receptor,1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL616768,1795
,10577,H,8,,,,11147,,Binding affinity towards 5-hydroxytryptamine 1B receptor using [3H]5-HT as radioligand,1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL616769,1796
,10577,H,8,,,,9547,,Binding affinity towards 5-hydroxytryptamine 1B receptor in rat was determined using 50 uL of [125I]ICYP in binding assay,1,,Autocuration,,,,,,,B,BAO_0000019,CHEMBL616770,1797
,10577,H,8,,,,10444,,Binding affinity was determined against 5-hydroxytryptamine 1B receptor was determined in male Sprague-Dawley rat brain.,1,,Autocuration,,,,,,,B,BAO_0000019,CHEMBL616771,1798
Striatum,10577,H,8,,,,12469,,Binding affinity was measured on 5-hydroxytryptamine 1B receptor in rat striatum labeled with [3H]5-HT,1,,Autocuration,,,,,,2435.0,B,BAO_0000019,CHEMBL616772,1799
,10577,H,8,,,,9098,,Binding affinity (Ki) to rat cortical membranes at 5-HT1B binding site by using [125 I] ICYP as a radioligand.,1,,Expert,,,,,,,B,BAO_0000019,CHEMBL616773,1800
,10577,H,8,,,,9098,,Compound was evaluated for the binding affinity (Ki) to rat cortical membranes at 5-HT1B binding site by using [125 I] ICYP as a radioligand; ND is no data.,1,,Autocuration,,,,,,,B,BAO_0000019,CHEMBL616774,1801
,10577,H,8,,,,9699,,Evaluated for binding affinity towards 5-hydroxytryptamine 1B receptor,1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL616775,1802
,10577,H,8,,,,10394,,Inhibitory activity against 5-hydroxytryptamine 1B receptor in rat cortical membranes using [3H]5-HT as a radioligand,1,,Autocuration,,,,,,,B,BAO_0000249,CHEMBL616776,1803
,10577,H,8,,,,12092,,The binding affinity was measured on 5-hydroxytryptamine 1B receptor using [3H]- serotonin as radioligand.,1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL616777,1804
,10577,H,8,,,,16700,,The binding affinity towards the receptor rat 5-hydroxytryptamine 1B receptor; No affinity,1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL616778,1805
,10577,D,9,,,,403,,Binding affinity against 5-hydroxytryptamine 1B receptor in rat striatal membranes using [3H]5-HT as radioligand,1,Rattus norvegicus,Expert,,,,10116.0,,,B,BAO_0000249,CHEMBL616779,1806
,10577,D,9,,,,12771,,Binding affinity towards 5-hydroxytryptamine 1B receptor,1,Rattus norvegicus,Expert,,,,10116.0,,,B,BAO_0000357,CHEMBL616780,1807
,10577,H,8,,,,11642,,The compound was tested for its binding affinity towards 5-hydroxytryptamine 1B receptor by displacing [3H]serotonin radioligand in rat cerebral cortex,1,,Autocuration,,,,,,,B,BAO_0000019,CHEMBL616781,1808
,10577,H,8,,,,12953,,The compound was tested for their binding affinity towards 5-hydroxytryptamine 1B receptor from rat striatum using [3H]5-HT as radioligand,1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL616782,1809
,10577,H,8,,,,12953,,The compound was tested for their binding affinity towards 5-hydroxytryptamine 1B receptor from rat striatum using [3H]5-HT as radioligand.,1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL616783,1810
Striatum,10577,H,8,,,,12953,,Binding affinity for 5-hydroxytryptamine 1B receptor in rat striatum using [3H]5-HT as radioligand,1,,Expert,,,,,,2435.0,B,BAO_0000019,CHEMBL616784,1811
,10577,H,8,,,,12953,,The compound was tested for their binding affinity towards 5-hydroxytryptamine 1B receptor from rat striatum using [3H]5-HT as radioligand; Nonactive at 10 uM,1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL616785,1812
Brain,10577,H,8,,,,9737,,Binding affinity against 5-HT1B receptor in rat brain membrane using [3H]8-OH-DPAT as a selective ligand.,1,,Autocuration,,,,,,955.0,B,BAO_0000249,CHEMBL857067,1813
,10577,H,8,,,,9737,,Binding affinity against 5-HT1B receptor in rat frontal cortex using [3H]-5-HT in presence of 0.1 uM [3H]-8-OH-DPAT as a radioligand,1,,Autocuration,,,,,,,B,BAO_0000019,CHEMBL616786,1814
Brain,10577,H,8,,,,9737,,Binding affinity towards 5-HT1B receptor in rat brain membrane using [3H]8-OH-DPAT as a selective ligand.,1,,Autocuration,,,,,,955.0,B,BAO_0000249,CHEMBL616787,1815
,10577,H,8,,,,12827,,Binding affinity towards 5-hydroxytryptamine 2C receptor of porcine choroid plexus using [3H]mesulergine,1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL616788,1816
,10577,H,8,,,,5033,,Ability to displace the radioligand [125I](-)-iodocyanopindolol from rat striatal 5-hydroxytryptamine 1B receptor,1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL616789,1817
,10577,D,9,,,,9786,,Displacement of [3H]5-HT from 5-HT1B receptor of rat frontal cortex homogenate,1,Rattus norvegicus,Expert,,,,10116.0,,,B,BAO_0000019,CHEMBL616790,1818
,10577,H,8,,,,13116,,Binding affinity at 5-hydroxytryptamine 1B receptor,1,,Expert,,,,,,,B,BAO_0000357,CHEMBL616791,1819
,10577,H,8,,,,16429,,In vitro binding affinity at 5-hydroxytryptamine 1B receptor in rat striatal muscles using [125I](-)-iodocyanopindolol as the radioligand,1,,Autocuration,,,,,,,B,BAO_0000019,CHEMBL616792,1820
,10577,D,9,,,,12409,,In vitro binding affinity towards 5-hydroxytryptamine 1B receptor in rat striatal membrane with [125I]- iodocyanopindolol,1,Rattus norvegicus,Expert,,,,10116.0,,,B,BAO_0000249,CHEMBL616793,1821
,10577,H,8,,,,15194,,The compound was tested for the binding affinity against 5-hydroxytryptamine 1B receptor using [3H]5-HT as radioligand,1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL616794,1822
,10577,H,8,,,,15194,,The compound was tested for the binding affinity against 5-hydroxytryptamine 1B receptor using [3H]5-HT as radioligand.,1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL616795,1823
,104686,H,4,,,,5486,,Binding affinity towards 5-HT2 receptor by the displacement of [3H]-ketanserin] in rat cerebral cortex,1,,Autocuration,,,,,,,B,BAO_0000019,CHEMBL616796,1824
,106,H,8,,,,4639,,Compound was tested for binding affinity against 5-hydroxytryptamine 1B receptor,1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL616797,1825
,106,H,8,,,Brain membranes,386,,The compound was evaluated for its ability to displace [3H]5-HT from 5-hydroxytryptamine 1B receptor in cellular brain membranes,1,,Autocuration,,,,,,,B,BAO_0000249,CHEMBL616798,1826
,106,H,8,,,,2474,,Compound was measured for its binding affinity at 5-hydroxytryptamine 1B receptor at a concentration of 100 nM using [125I]CYP as radioligand,1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL616799,1827
,106,H,8,,,,6011,,Inhibition of binding towards 5-hydroxytryptamine 1B receptor at 100 nM concentration,1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL616800,1828
,106,H,8,,,,5014,,Percent inhibition (at 1 uM) against 5-hydroxytryptamine 1B receptor,1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL616801,1829
,106,H,8,,,,17515,,Binding affinity of compound towards serotonin 5-hydroxytryptamine 1B receptor; inactive at 10 uM,1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL616802,1830
,106,H,8,,,,4373,,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 1B receptor was determined,1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL616803,1831
,106,H,8,,,,1633,,Binding affinity towards 5-hydroxytryptamine 1B receptor by displacement of [3H]5-HT.,1,,Expert,,,,,,,B,BAO_0000357,CHEMBL857068,1832
,106,H,8,,,,1633,,Compound was evaluated for the binding affinity towards 5-hydroxytryptamine 1B receptor by displacement of [3H]ketanserin.,1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL616804,1833
,106,H,8,,,,4373,,Binding affinity for 5-hydroxytryptamine 1B receptor was determined,1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL616805,1834
,106,H,8,,,,4687,,Evaluated for the binding affinity to 5-hydroxytryptamine 1B receptor,1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL616806,1835
,106,H,8,,,,11574,,Binding affinity against 5-hydroxytryptamine 1B receptor,1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL616807,1836
,106,H,8,,,,10321,,Binding affinity for 5-hydroxytryptamine 1B receptor was determined by using [3H]5-HT as radioligand,1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL616808,1837
,106,H,8,,,,15527,,Binding affinity towards 5-hydroxytryptamine 1B receptor using [3H]5-HT as radioligand.,1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL616809,1838
,106,H,8,,,,17200,,Inhibitory constant against 5-hydroxytryptamine 1B receptor using with [125I]- cyanopindolol radioligand,1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL616810,1839
,104802,H,4,,,,14423,,Binding affinity against 5-hydroxytryptamine 1B receptor - 5-hydroxytryptamine 1D receptor using [3H]5-HT as the radioligand.,1,,Autocuration,,,,,,,B,BAO_0000224,CHEMBL616811,1840
,108,H,8,,,,5834,,Inhibitory concentration required against 5-hydroxytryptamine 1C receptor in bovine choroid plexus using [3H]mesulergine,1,Bos taurus,Autocuration,,,,9913.0,,,B,BAO_0000357,CHEMBL616812,1841
,108,H,8,,,,11473,,Binding affinity towards 5-hydroxytryptamine 1C receptor using [3H]mesulergine as radioligand,1,Sus scrofa,Autocuration,,,,9823.0,,,B,BAO_0000357,CHEMBL616813,1842
,108,H,8,,,,11473,,Compound was evaluated for binding affinity towards 5-hydroxytryptamine 1C receptor in pig choroid plexus using [3H]mesulergine as radioligand,1,Sus scrofa,Autocuration,,,,9823.0,,,B,BAO_0000357,CHEMBL616814,1843
,108,H,8,,,,10639,,Compound was evaluated for its inhibitory activity against 5-hydroxytryptamine 1C receptor of pig choroid plexus using [3H]mesulergine as the radioligand,1,Sus scrofa,Autocuration,,,,9823.0,,,B,BAO_0000357,CHEMBL616815,1844
,108,H,8,,,,10639,,inhibitory activity against 5-hydroxytryptamine 1C receptor of pig choroid plexus using [3H]mesulergine as the radioligand,1,Sus scrofa,Autocuration,,,,9823.0,,,B,BAO_0000357,CHEMBL616816,1845
,108,H,8,,,,14331,,Binding affinity of compound towards 5-hydroxytryptamine 1C receptor using [3H]mesulergine (1.2 nM) ligand in choroid Plexus pig was determined,1,Sus scrofa,Autocuration,,,,9823.0,,,B,BAO_0000357,CHEMBL616817,1846
,108,H,8,,,,10796,,Compound was tested in vitro for binding affinity for 5-hydroxytryptamine 1C receptor,1,Sus scrofa,Autocuration,,,,9823.0,,,B,BAO_0000357,CHEMBL616818,1847
,108,H,8,,,,9098,,Evaluated for the binding affinity to porcine choroid plexus at 5-hydroxytryptamine 2C receptor binding site by using [3H]-MES as a radioligand.,1,Sus scrofa,Expert,,,,9823.0,,,B,BAO_0000357,CHEMBL616819,1848
,108,H,8,,,,14331,,Inhibition of [3H]mesulergine binding to 5-hydroxytryptamine 1C receptor of pig choroid Plexus,1,Sus scrofa,Expert,,,,9823.0,,,B,BAO_0000357,CHEMBL616820,1849
,108,H,8,,,,11828,,Displacement of [3H]mesulergine from pig cortex 5-hydroxytryptamine 1C receptor,1,Sus scrofa,Expert,,,,9823.0,,,B,BAO_0000019,CHEMBL616821,1850
,108,H,8,,,,11866,,Binding affinity for 5-hydroxytryptamine 1C receptor in piglet choroid plexus using [3H]5-HT,1,Sus scrofa,Autocuration,,,,9823.0,,,B,BAO_0000357,CHEMBL616822,1851
,108,H,8,,,,13047,,Binding affinity against 5-hydroxytryptamine 1D receptor alpha using rabbit saphenous vein assay.,1,Oryctolagus cuniculus,Autocuration,,,,9986.0,,,B,BAO_0000019,CHEMBL616823,1852
,12689,D,9,,,,188,,Tested for the effect on binding at 5-hydroxytryptamine 1C receptor; No activity,1,Rattus norvegicus,Autocuration,,,,10116.0,,,B,BAO_0000357,CHEMBL616824,1853
,12689,D,9,,,,11825,,In vitro binding affinity towards the 5-hydroxytryptamine 1C receptor at 10 e-6 M,1,Rattus norvegicus,Autocuration,,,,10116.0,,,B,BAO_0000357,CHEMBL616825,1854
,12689,D,9,,,,11825,,In vitro binding affinity towards the 5-hydroxytryptamine 1C receptor at 10 e-6 M,1,Rattus norvegicus,Autocuration,,,,10116.0,,,B,BAO_0000357,CHEMBL616826,1855
,12689,D,9,,,,11624,,Binding affinity against 5-hydroxytryptamine 1C receptor in rat using [3H]mesulergine as radioligand,1,Rattus norvegicus,Expert,,,,10116.0,,,B,BAO_0000019,CHEMBL616827,1856
,12689,D,9,,,,11139,,Binding affinity towards 5-hydroxytryptamine 1C receptor using [125 I]-SCH23982 as radioligand in competitive binding assay,1,Rattus norvegicus,Autocuration,,,,10116.0,,,B,BAO_0000357,CHEMBL616828,1857
,12689,D,9,,,,11147,,Binding affinity towards 5-hydroxytryptamine 1C receptor using [3H]mesulergine as radioligand,1,Rattus norvegicus,Autocuration,,,,10116.0,,,B,BAO_0000357,CHEMBL616829,1858
,12689,D,9,,,,10444,,Binding affinity was determined against 5-hydroxytryptamine 1C receptor was determined in male Sprague-Dawley rat brain.,1,Rattus norvegicus,Autocuration,,,,10116.0,,,B,BAO_0000019,CHEMBL616830,1859
,12689,D,9,,,,11624,,Binding affinity against 5-hydroxytryptamine 1C receptor,1,Rattus norvegicus,Expert,,,,10116.0,,,B,BAO_0000357,CHEMBL616831,1860
,12689,D,9,,,,11662,,"Compound was tested for binding affinity towards 5-HT1C (5-HT1C) receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]mesulergine as radioligand",1,Rattus norvegicus,Autocuration,,,,10116.0,,,B,BAO_0000019,CHEMBL616832,1861
,12689,D,9,,,,11662,,"Compound was tested for binding affinity towards 5-hydroxytryptamine 1C receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]mesulergine as radioligand",1,Rattus norvegicus,Autocuration,,,,10116.0,,,B,BAO_0000019,CHEMBL616833,1862
,12689,D,9,,,,11662,,"Binding affinity towards 5-hydroxytryptamine 1C receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]mesulergine as radioligand",1,Rattus norvegicus,Expert,,,,10116.0,,,B,BAO_0000019,CHEMBL616834,1863
,12689,D,9,,,,11662,,"Compound was tested for binding affinity towards 5-hydroxytryptamine 1C receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]mesulergine as radioligand",1,Rattus norvegicus,Autocuration,,,,10116.0,,,B,BAO_0000019,CHEMBL829595,1864
,12689,D,9,,,,9098,,Evaluated for the binding affinity to porcine choroid plexus at 5-hydroxytryptamine 1C receptor binding site by using [3H]- MES as a radioligand.,1,Rattus norvegicus,Autocuration,,,,10116.0,,,B,BAO_0000357,CHEMBL616835,1865
,12689,D,9,,,,10394,,Inhibitory activity against 5-hydroxytryptamine 1C receptor in rat cortical membranes using [3H]mesulergine as a radioligand,1,Rattus norvegicus,Autocuration,,,,10116.0,,,B,BAO_0000249,CHEMBL872910,1866
,12689,H,8,,,,11933,,Tested for binding affinity against 5-hydroxytryptamine 1C receptor from rat frontal cortical regions using [3H]mesulergine as radioligand,1,,Expert,,,,,,,B,BAO_0000357,CHEMBL616836,1867
,12689,D,9,,,,12092,,The binding affinity was measured on 5-hydroxytryptamine 1C receptor using [3H]- serotonin as radioligand.,1,Rattus norvegicus,Autocuration,,,,10116.0,,,B,BAO_0000357,CHEMBL616837,1868
,12689,D,9,,,,12253,,Binding affinity of 5-hydroxytryptamine 1C receptor using [3H]- ketanserin in rat frontal cortex,1,Rattus norvegicus,Autocuration,,,,10116.0,,,B,BAO_0000019,CHEMBL616466,1869
,12689,D,9,,,,12253,,Binding affinity towards rat 5-hydroxytryptamine 1C receptor using [3H]mesulergine as radioligand expressed in 293 cells,1,Rattus norvegicus,Autocuration,,722.0,,10116.0,HEK293,,B,BAO_0000219,CHEMBL616467,1870
,108,H,8,,,,1558,,Compound was tested for its affinity towards 5-hydroxytryptamine 1C receptor,1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL616468,1871
,108,H,8,,,,2474,,Compound was measured for its binding affinity at 5-hydroxytryptamine 1C receptor at a concentration of 100 nM using [3H]mesulergine as radioligand,1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL616469,1872
,108,H,8,,,,2474,,Compound was measured for its binding affinity at 5-hydroxytryptamine 1C receptor at a concentration of 100 nM using [3H]mesulergine as radioligand,1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL616470,1873
,12689,H,8,,,,11574,,Binding affinity against 5-hydroxytryptamine 1C receptor,1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL616471,1874
,12689,H,8,,,,1558,,Compound was tested for its affinity towards 5-hydroxytryptamine 1C receptor,1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL616472,1875
,12689,H,8,,,,13944,,Binding affinity against 5-hydroxytryptamine 1C receptor,1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL616473,1876
,12689,H,8,,,,13033,,Binding affinity against serotonergic 5-HT1c receptor,1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL616474,1877
,12689,H,8,,,,10321,,Binding affinity for 5-hydroxytryptamine 1C receptor was determined by using [3H]- mesulergine as radioligand,1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL616475,1878
,12689,H,8,,,,11866,,Binding affinity for 5-hydroxytryptamine 1C receptor was determined,1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL616476,1879
,105,H,8,,,,14454,,Compound was tested for 5-hydroxytryptamine 1D like receptor-mediated vascular effect in rabbit saphenous vein (RSV),1,Oryctolagus cuniculus,Autocuration,,,,9986.0,,,B,BAO_0000019,CHEMBL616477,1880
,104686,H,4,,,,11574,,Binding affinity against 5-hydroxytryptamine 2 receptor using [125I]DOI as radioligand.,1,,Autocuration,,,,,,,B,BAO_0000224,CHEMBL616478,1881
,104686,H,4,,,,11574,,Binding affinity against 5-hydroxytryptamine 2 receptor using [3H]ket as radioligand.,1,,Autocuration,,,,,,,B,BAO_0000224,CHEMBL616479,1882
,104686,H,4,,,,13631,,Binding affinity towards serotonin 5-HT2 receptor was determined in rat cortex using [3H]spiperone as ligand,1,,Autocuration,,,,,,,B,BAO_0000019,CHEMBL616480,1883
,104686,D,5,,,,9630,,Binding affinity towards 5-hydroxytryptamine 2 receptor as antagonism of serotonin-induced contractions in rat jugular vein,1,Rattus norvegicus,Autocuration,,,,10116.0,,,B,BAO_0000019,CHEMBL616481,1884
,104686,D,5,,,,8822,,Binding affinity towards 5-hydroxytryptamine 2 receptor in rat brain cortical membranes,1,Rattus norvegicus,Autocuration,,,,10116.0,,,B,BAO_0000249,CHEMBL616482,1885
Brain,104686,D,5,,,,9064,,Binding affinity towards 5-hydroxytryptamine 2 receptor in rat brain using [3H]spiroperidol,1,Rattus norvegicus,Autocuration,,,,10116.0,,955.0,B,BAO_0000221,CHEMBL884713,1886
,104686,H,4,,,,8868,,Binding affinity towards 5-hydroxytryptamine 2 receptor measured using radioligand ([3H]spiperone) binding assay,1,,Autocuration,,,,,,,B,BAO_0000224,CHEMBL616483,1887
,104686,H,4,,,,9064,,Binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]- spiroperidol,1,,Autocuration,,,,,,,B,BAO_0000224,CHEMBL616484,1888
,104686,H,4,,,,9806,,Binding affinity at 5-hydroxytryptamine 2 receptor from rat frontal cortex homogenates by [3H]-spiperone displacement.,1,,Autocuration,,,,,,,B,BAO_0000019,CHEMBL616485,1889
,104686,H,4,,,,9098,,Binding affinity towards 5-hydroxytryptamine 2 receptor was determined,1,,Autocuration,,,,,,,B,BAO_0000224,CHEMBL616486,1890
,104686,H,4,,,,8868,,Binding affinity towards 5-hydroxytryptamine 2 receptor was measured using radioligand ([3H]spiperone) binding assay,1,,Autocuration,,,,,,,B,BAO_0000224,CHEMBL616487,1891
,104686,H,4,,,,12765,,Binding affinity at serotonin 5-hydroxytryptamine 2 receptor by [3H]ketanserin displacement.,1,,Autocuration,,,,,,,B,BAO_0000224,CHEMBL616488,1892
,104686,H,4,,,,11049,,Compound was evaluated In vitro for its activity by binding to 5-hydroxytryptamine 2 receptor in the rat brain using [3H]ketanserin as radioligand.,1,,Autocuration,,,,,,,B,BAO_0000019,CHEMBL616489,1893
,104686,H,4,,,,11049,,Compound was evaluated In vitro for its activity by binding to 5-hydroxytryptamine 2 receptor in the rat brain using [3H]ketanserin as radioligand.,1,,Autocuration,,,,,,,B,BAO_0000019,CHEMBL616490,1894
,104686,H,4,,,,11049,,Compound was evaluated In vitro for its activity by binding to 5-hydroxytryptamine 2 receptor in the rat brain using [3H]-Ketanserin as radioligand; not determined,1,,Autocuration,,,,,,,B,BAO_0000019,CHEMBL616491,1895
,104686,H,4,,,,11049,,Compound was evaluated In vitro for its activity by binding to 5-hydroxytryptamine 2 receptor in the rat brain using [3H]ketanserin as radioligand; ND-Not determined,1,,Autocuration,,,,,,,B,BAO_0000019,CHEMBL616492,1896
,104686,H,4,,,,11049,,Compound was evaluated In vitro for its activity by binding to 5-hydroxytryptamine 2 receptor in the rat brain using [3H]ketanserin as radioligand.,1,,Autocuration,,,,,,,B,BAO_0000019,CHEMBL616493,1897
,104686,H,4,,,,11473,,Compound was evaluated for binding affinity towards 5-hydroxytryptamine 2 receptor in rat anterior cortex using [125I]DOI as radioligand,1,,Autocuration,,,,,,,B,BAO_0000019,CHEMBL616494,1898
,104686,H,4,,,,11473,,Compound was evaluated for binding affinity towards 5-hydroxytryptamine 2 receptor in rat anterior cortex using [3H]ketanserin as radioligand,1,,Autocuration,,,,,,,B,BAO_0000019,CHEMBL616495,1899
,104686,H,4,,,,3086,,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor in rat pre frontal cortex,1,,Autocuration,,,,,,,B,BAO_0000019,CHEMBL616496,1900
,104686,H,4,,,,11049,,Compound was evaluated for its activity by binding to 5-hydroxytryptamine 2 receptor in the rat brain using [3H]ketanserin as radioligand.,1,,Autocuration,,,,,,,B,BAO_0000019,CHEMBL616497,1901
,104686,H,4,,,,11049,,Compound was evaluated for its activity by binding to 5-hydroxytryptamine 2 receptor in the rat brain using [3H]ketanserin as radioligand.,1,,Autocuration,,,,,,,B,BAO_0000019,CHEMBL616498,1902
,104686,H,4,,,,10639,,Compound was evaluated for its inhibitory activity against 5-hydroxytryptamine 2 receptor of rat anterior cortex using [3H]ketanserin as the radioligand,1,,Autocuration,,,,,,,B,BAO_0000019,CHEMBL616499,1903
,104686,H,4,,,,10922,,Compound was measured for affinity at 5-hydroxytryptamine 2 receptor in rat cortical by [3H]spiroperidol displacement.,1,,Autocuration,,,,,,,B,BAO_0000019,CHEMBL616500,1904
Brain,104686,D,5,,,,9064,,Binding affinity against serotonin-2 receptor in rat brain using [3H]spiroperidol,1,Rattus norvegicus,Autocuration,,,,10116.0,,955.0,B,BAO_0000221,CHEMBL616501,1905
Brain,104686,H,4,,,,10748,,Compound was tested for its inhibitory effect on the binding profile in 5-hydroxytryptamine 2 receptor using [3H]spiroperidol in rat brain.,1,,Autocuration,,,,,,955.0,B,BAO_0000221,CHEMBL616502,1906
,104686,H,4,,,Membranes,11614,,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor from rat cortical membranes.,1,,Autocuration,,,,,,,B,BAO_0000249,CHEMBL884529,1907
,104686,H,4,,,Membranes,11615,,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor in rat cortical membranes,1,,Autocuration,,,,,,,B,BAO_0000249,CHEMBL616503,1908
,104686,H,4,,,,11615,,Compound was tested for the displacement of [3H]ketanserin from serotonin 5-hydroxytryptamine 2 receptor,1,,Autocuration,,,,,,,B,BAO_0000224,CHEMBL616964,1909
,104686,H,4,,,Membranes,11614,,Compound was tested for the displacement of [3H]ketanserin from serotonin 5-hydroxytryptamine 2 receptor from rat cortical membranes.,1,,Autocuration,,,,,,,B,BAO_0000249,CHEMBL616965,1910
,104686,H,4,,,,11702,,Inhibition of [3H]ketanserin binding to rat 5-hydroxytryptamine 2 receptors.,1,,Autocuration,,,,,,,B,BAO_0000224,CHEMBL616966,1911
,104686,H,4,,,,11702,,Compound was tested for the inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor; NT=Not tested,1,,Autocuration,,,,,,,B,BAO_0000224,CHEMBL616967,1912
,104686,D,5,,,,11702,,Inhibition of [3H]ketanserin binding to dopamine 5-hydroxytryptamine 2 receptor,1,Rattus norvegicus,Autocuration,,,,10116.0,,,B,BAO_0000224,CHEMBL616968,1913
,104686,H,4,,,,11702,,Compound was tested for the inhibition of [3H]ketanserin binding to dopamine 5-hydroxytryptamine 2 receptor; NT=Not tested,1,,Autocuration,,,,,,,B,BAO_0000224,CHEMBL616969,1914
,104686,H,4,,,,13346,,Inhibition of [3H]ketanserin binding at 5-hydroxytryptamine 2 receptor from rat frontal cortex.,1,,Autocuration,,,,,,,B,BAO_0000019,CHEMBL884530,1915
,104686,H,4,,,,10025,,Concentration necessary to achieve half maximal inhibition of [3H]-ketanserin binding to 5-hydroxytryptamine 2 receptor,1,,Autocuration,,,,,,,B,BAO_0000224,CHEMBL616970,1916
,104686,H,4,,,,10025,,Concentration necessary to achieve half maximal inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor at 1 uM,1,,Autocuration,,,,,,,B,BAO_0000224,CHEMBL616971,1917
,104686,H,4,,,,10025,,"Concentration necessary to achieve half maximal inhibition of [3H]ketanserin, binds to 5-hydroxytryptamine 2 receptor at 1 uM",1,,Autocuration,,,,,,,B,BAO_0000224,CHEMBL616972,1918
,104686,H,4,,,,9036,,Evaluated for binding affinity towards 5-hydroxytryptamine 2 receptor using radioligand [3H]-spiperone,1,,Autocuration,,,,,,,B,BAO_0000224,CHEMBL616973,1919
,104686,H,4,,,,9036,,Evaluated for binding affinity towards 5-hydroxytryptamine 2 receptor using radioligand [3H]spiperone; IA=Inactive,1,,Autocuration,,,,,,,B,BAO_0000224,CHEMBL616974,1920
,104686,H,4,,,,9161,,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue.,1,,Autocuration,,,,,,,B,BAO_0000019,CHEMBL616975,1921
,104686,H,4,,,,12304,,Inhibition of binding of radioligand [3H]ketanserin to 5-hydroxytryptamine 2 receptor in rat cerebral cortex,1,,Autocuration,,,,,,,B,BAO_0000019,CHEMBL616976,1922
,104686,H,4,,,,13276,,In vitro binding affinity measured on serotonin 5-hydroxytryptamine 2 receptor using [3H]ketanserin as radioligand.,1,,Autocuration,,,,,,,B,BAO_0000224,CHEMBL616977,1923
,104686,H,4,,,,11825,,In vitro binding affinity towards the 5-hydroxytryptamine 2 receptor at 10 e-6 M,1,,Autocuration,,,,,,,B,BAO_0000224,CHEMBL616978,1924
,104686,H,4,,,,12443,,In vitro binding affinity was measured on serotonergic 5-hydroxytryptamine 2 receptor by displacement of [3H]- ketanserin,1,,Autocuration,,,,,,,B,BAO_0000224,CHEMBL616979,1925
,104686,H,4,,,,13830,,In vitro inhibitory activity against [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor,1,,Autocuration,,,,,,,B,BAO_0000224,CHEMBL616980,1926
,104686,H,4,,,Membranes,9592,,Inhibition of [3H]spiperone binding to 5-hydroxytryptamine 2 receptor from rat cortical membranes,1,,Autocuration,,,,,,,B,BAO_0000249,CHEMBL616981,1927
,104686,H,4,,,Membranes,9592,,Inhibition of [3H]spiperone binding to 5-hydroxytryptamine 2 receptor from rat cortical membranes; Not tested,1,,Autocuration,,,,,,,B,BAO_0000249,CHEMBL616982,1928
,104686,H,4,,,,10881,,Inhibitory activity against 5-hydroxytryptamine 2 receptor by 3H ligand binding experiments.,1,,Autocuration,,,,,,,B,BAO_0000224,CHEMBL616983,1929
,104686,H,4,,,,13605,,Inhibitory activity against [3H]spiroperidol binding to 5-HT2 receptor in rat cortex,1,,Autocuration,,,,,,,B,BAO_0000019,CHEMBL616984,1930
,104686,D,5,,,,11624,,Inhibitory activity against 5-hydroxytryptamine 2 receptor,1,Rattus norvegicus,Autocuration,,,,10116.0,,,B,BAO_0000224,CHEMBL616985,1931
,104686,H,4,,,,4101,,Inhibitory concentration against 5-hydroxytryptamine 2 receptor from striata of male Wistar rats by displacement of [3H]-ketanserin,1,,Autocuration,,,,,,,B,BAO_0000224,CHEMBL616986,1932
,104686,H,4,,,,4101,,Inhibitory concentration against binding of 5-hydroxytryptamine 2 receptor from striata of male Wistar rats by displacement of [3H]-ketanserin,1,,Autocuration,,,,,,,B,BAO_0000224,CHEMBL616987,1933
,104686,H,4,,,,15360,,Inhibitory concentration against radioligand [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor in rat,1,,Autocuration,,,,,,,B,BAO_0000019,CHEMBL616988,1934
,104686,H,4,,,,11576,,Inhibitory concentration against radioligand [3H]spiperone binding to 5-hydroxytryptamine 2 receptor in rat cortex,1,,Autocuration,,,,,,,B,BAO_0000019,CHEMBL617243,1935
,104686,H,4,,,,5834,,Inhibitory concentration required against 5-hydroxytryptamine 2 receptor in rat cortex using [3H]spiperone,1,,Autocuration,,,,,,,B,BAO_0000019,CHEMBL617244,1936
,104686,D,5,,,,2395,,Inhibitory concentration against [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor expressed in CHO-K1 cells,1,Rattus norvegicus,Autocuration,,485.0,,10116.0,CHO-K1,,B,BAO_0000219,CHEMBL617245,1937
,104686,H,4,,,Membranes,11965,,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor in rat cortical membranes,1,,Autocuration,,,,,,,B,BAO_0000249,CHEMBL617246,1938
,104686,H,4,,,,3967,,The compound was evaluated for the ability to displace [3H]ketanserin from 5-hydroxytryptamine 2 receptor ( striata of male wistar rats),1,,Autocuration,,,,,,,B,BAO_0000224,CHEMBL617546,1939
,104686,H,4,,,Brain membranes,11130,,The concentration required to inhibit [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor in rat brain membranes (in vitro),1,,Autocuration,,,,,,,B,BAO_0000249,CHEMBL617547,1940
,104686,H,4,In vitro,,,13427,,Binding affinity of [3H]ketanserin towards 5-hydroxytryptamine 2 receptor in cloned mammalian receptor expressed in cultured cells or from rat whole brain.,1,,Autocuration,,,,,,,B,BAO_0000219,CHEMBL617548,1941
,104686,H,4,,,,9443,,Binding affinity towards 5-hydroxytryptamine 2 receptor,1,,Autocuration,,,,,,,B,BAO_0000224,CHEMBL617549,1942
,104686,H,4,,,,9443,,Binding affinity towards 5-hydroxytryptamine 2 receptor at 1.0 uM concentration,1,,Autocuration,,,,,,,B,BAO_0000224,CHEMBL617550,1943
,104686,H,4,,,,11825,,In vitro binding affinity towards the 5-hydroxytryptamine 2 receptor at 10 e-6 M,1,,Autocuration,,,,,,,B,BAO_0000224,CHEMBL617551,1944
,104686,H,4,,,Membranes,12120,,Percent inhibition of binding of 1.0 nM [3H]ketanserin to 5-hydroxytryptamine 2 receptor in rat cortical membranes at 10 e -5 M,1,,Autocuration,,,,,,,B,BAO_0000249,CHEMBL617552,1945
,104686,H,4,,,Membranes,12120,,Percent inhibition of binding of 1.0 nM [3H]-ketanserin to 5-hydroxytryptamine 2 receptor in rat cortical membranes at 10 e-5 M.,1,,Autocuration,,,,,,,B,BAO_0000249,CHEMBL617553,1946
Thoracic aorta,104686,H,4,,,,11963,,Tested for antagonistic activity against 5-hydroxytryptamine 2 receptor from rat thoracic aorta,1,,Autocuration,,,,,,1515.0,F,BAO_0000019,CHEMBL617554,1947
,104686,H,4,,,,9069,,Binding affinity for membrane-bound 5-hydroxytryptamine 2 receptor,1,,Autocuration,,,,,,,B,BAO_0000019,CHEMBL617555,1948
,104686,H,4,,,,8868,,Compound was tested for its effect on 5-hydroxytryptamine 2 receptor saturation analysis,1,,Autocuration,,,,,,,B,BAO_0000224,CHEMBL617556,1949
,10624,H,8,,,,17200,,Inhibitory constant against human 5-hydroxytryptamine 1B receptor using [3H]5-CT radioligand,1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL617557,1950
,10624,H,8,,,,17200,,Inhibitory constant against human 5-hydroxytryptamine 1D receptor using [3H]5-CT radioligand,1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL617558,1951
,17106,H,8,,,,13969,,Binding affinity against 5-hydroxytryptamine 1D receptor was measured using [3H]5-HT as radioligand,1,,Expert,,,,,,,B,BAO_0000357,CHEMBL617559,1952
,17106,D,9,,,,13392,,Binding affinity for 5-hydroxytryptamine 1D receptor,1,,Expert,,,,,,,B,BAO_0000357,CHEMBL617560,1953
,17106,H,8,,,,1742,,Compound was tested for its ability to displace [125I]GTI binding to 5-hydroxytryptamine 1D receptor recognition sites in pig caudate membranes,1,,Autocuration,,,,,,,B,BAO_0000249,CHEMBL617561,1954
,17106,H,8,,,,1742,,Compound was tested for its ability to displace [3H]-5-HT binding to 5-hydroxytryptamine 1D receptor recognition sites in pig caudate membranes,1,,Autocuration,,,,,,,B,BAO_0000249,CHEMBL617562,1955
Striatum,17106,H,8,,,,14331,,Binding affinity against 5-hydroxytryptamine 1D receptor using [3H]5-HT in pig striatum + frontalCortex,1,,Autocuration,,,,,,2435.0,B,BAO_0000357,CHEMBL617563,1956
,17106,H,8,,,,12861,,Relative agonist efficacy against 1 uM 5-hydroxytryptamine 1D receptor,1,,Autocuration,,,,,,,F,BAO_0000019,CHEMBL617564,1957
,17106,H,8,,,,12861,,Binding activity against 5-hydroxytryptamine 1D receptor from pig caudate membrane using [3H]5-HT as radioligand,1,,Expert,,,,,,,B,BAO_0000019,CHEMBL617565,1958
,17106,H,8,,,,12861,,Binding activity radioligand.,1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL856076,1959
,17106,H,8,,,,12861,,Binding activity against 5-hydroxytryptamine 2C receptor from human brain cortex using [3H]mesulergine as radioligand.,1,,Autocuration,,,,,,,B,BAO_0000019,CHEMBL617566,1960
,17106,H,8,,,,12861,,Binding activity against 5-hydroxytryptamine 3 receptor from rat cortex homogenate using [3H]-Q-ICS 205-930 as radioligand.,1,,Expert,,,,,,,B,BAO_0000019,CHEMBL875911,1961
,17106,H,8,,,,12861,,Binding activity against 5-hydroxytryptamine 3 receptor from rat cortex homogenate using [3H]-Q-ICS 205-930 as radioligand; NA Not Available,1,,Autocuration,,,,,,,B,BAO_0000019,CHEMBL617567,1962
,17106,H,8,,,,675,,Compound was tested for the displacement of [3H]-5-HT to 5-hydroxytryptamine 1D receptor recognition sites in pig caudate membranes,1,,Autocuration,,,,,,,B,BAO_0000249,CHEMBL617568,1963
,17106,H,8,,,,12490,,Displacement of [3H]5-HT binding to 5-hydroxytryptamine 1D receptor from pig caudate membrane,1,,Expert,,,,,,,B,BAO_0000019,CHEMBL617569,1964
,17106,H,8,,,,11828,,Displacement of radioligand [3H]5-HT binding to 5-hydroxytryptamine 1D receptor in pig caudate membrane,1,,Expert,,,,,,,B,BAO_0000249,CHEMBL617570,1965
,17106,H,8,,,,11866,,Binding affinity for 5-hydroxytryptamine 1D receptor in piglet caudate using [3H]5-HT,1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL617571,1966
,105,H,8,,,,773,,In Vitro Binding affinity againist 5-hydroxytryptamine 1D receptor by displacing [125I]GTI from pig caudate,1,Sus scrofa,Autocuration,,,,9823.0,,,B,BAO_0000357,CHEMBL617572,1967
,105,H,8,,,,13047,,The compound was tested for intrinsic activity against 5-HT1D receptor,1,Oryctolagus cuniculus,Expert,,,,9986.0,,,B,BAO_0000357,CHEMBL617573,1968
,105,H,8,,,,13047,,Intrinsic activity against 5-hydroxytryptamine 1 receptor using rabbit saphenous vein assay.,1,Oryctolagus cuniculus,Autocuration,,,,9986.0,,,B,BAO_0000019,CHEMBL617574,1969
,105,H,8,,,,13047,,The compound was tested for binding affinity against 5-HT1D receptor,1,Oryctolagus cuniculus,Expert,,,,9986.0,,,B,BAO_0000357,CHEMBL617575,1970
,10578,H,8,,,,188,,Tested for the effect on binding at 5-hydroxytryptamine 1D receptor; No activity,1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL617576,1971
,10578,H,8,,,,10639,,Inhibition of Forskolin-stimulated adenylate cyclase activity against 5-hydroxytryptamine 1D receptor of rat substantia nigra,1,,Autocuration,,,,,,,F,BAO_0000019,CHEMBL617577,1972
,10578,H,8,,,,12438,,Inhibition of forskolin stimulated adenylate cyclase at 5-hydroxytryptamine 1D receptor,1,,Autocuration,,,,,,,F,BAO_0000019,CHEMBL617578,1973
,10578,H,8,,,,12438,,Binding affinity was measured against serotonin 5-hydroxytryptamine 1D receptor,1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL617579,1974
,10578,H,8,,,,15854,,Binding affinity towards 5-hydroxytryptamine 1D receptor in rat frontal cortex using [125I]iodocyanopindolol as radio-ligand.,1,,Expert,,,,,,,B,BAO_0000019,CHEMBL617580,1975
,10578,H,8,,,,10394,,Inhibitory activity against 5-hydroxytryptamine 1D receptor in rat cortical membranes using [3H]5-HT as a radioligand,1,,Autocuration,,,,,,,B,BAO_0000249,CHEMBL617581,1976
,10578,H,8,,,,12092,,The binding affinity was measured on 5-hydroxytryptamine 1D receptor using [3H]- serotonin as radioligand.,1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL617582,1977
,10578,H,8,,,,3389,,Binding affinity to 5-hydroxytryptamine 1D receptor in the rat forebrain by [3H]- SB-204269 displacement.,1,,Expert,,,,,,,B,BAO_0000019,CHEMBL617583,1978
,105,H,8,,,,6011,,Inhibition of binding towards 5-hydroxytryptamine 1D receptor at 100 nM concentration,1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL617584,1979
,105,H,8,,,,4639,,Compound was tested for binding affinity against 5-hydroxytryptamine 1D receptor,1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL617585,1980
,105,H,8,,,,2474,,Compound was measured for its binding affinity at 5-hydroxytryptamine 1D receptor at a concentration of 10 uM using [3H]5-HT as radioligand,1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL875912,1981
,105,H,8,,,,5014,,Percent inhibition (at 1 uM) against 5-hydroxytryptamine 1D receptor,1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL617586,1982
,105,H,8,,,,17515,,Binding affinity of compound towards serotonin 5-hydroxytryptamine 1D receptor; inactive at 10 uM,1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL617587,1983
,105,H,8,,,,11866,,Binding affinity for 5-hydroxytryptamine 1D receptor was determined,1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL617588,1984
,105,H,8,,,,4687,,Evaluated for the binding affinity against 5-hydroxytryptamine 1D receptor,1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL857980,1985
,105,H,8,,,,12146,,Tested against 5-hydroxytryptamine 1D receptor,1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL617589,1986
,105,H,8,,,,10321,,Binding affinity for 5-hydroxytryptamine 1D receptor was determined by using [3H]5-HT as radioligand,1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL617590,1987
,105,H,8,,,,13267,,Antagonistic binding affinity measured against 5-hydroxytryptamine 2A receptor (human clone expressed in 293 cells) using [3H]ketanserin as radioligand,1,,Autocuration,,722.0,,,HEK293,,B,BAO_0000219,CHEMBL617591,1988
,105,D,9,,,,1274,,Binding affinity against 5-Hydroxytryptamine 1D receptor,1,Homo sapiens,Expert,,,,9606.0,,,B,BAO_0000357,CHEMBL617592,1989
,105,H,8,,,,15250,,,1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL617593,1990
,106,H,8,,,,13706,,Compound was tested for binding affinity against cloned human 5-hydroxytryptamine 1D receptor alpha expressed in CHO-K1 cells.,1,,Autocuration,,485.0,,,CHO-K1,,B,BAO_0000219,CHEMBL617594,1991
,105,H,8,,,,13706,,Compound was tested for binding affinity against cloned human 5-hydroxytryptamine 1D receptor alpha expressed in CHO-K1 cells.,1,,Autocuration,,485.0,,,CHO-K1,,B,BAO_0000219,CHEMBL617595,1992
,105,H,8,,,,13706,,Compound was tested for binding affinity against human 5-hydroxytryptamine 1D receptor alpha clones expressed in human embryonic kidney (HEK 293) cells line.,1,,Autocuration,,722.0,,,HEK293,,B,BAO_0000219,CHEMBL617596,1993
,105,H,8,,,,13706,,Compound was tested for binding affinity against human 5-hydroxytryptamine 1D receptor alpha clones expressed in human embryonic kidney (HEK 293) cells line; NT= not tested,1,,Autocuration,,722.0,,,HEK293,,B,BAO_0000219,CHEMBL617597,1994
,105,H,8,,,,13047,,Binding affinity against 5-hydroxytryptamine 1D receptor beta using rabbit saphenous vein assay.,1,,Autocuration,,,,,,,B,BAO_0000019,CHEMBL617598,1995
,105,H,8,,,,13366,,Binding affinity of compound against 5-HT1Dalpha Binding affinity of compound against 5-HT1D alpha receptors in human,1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL872916,1996
,105,H,8,,,,13366,,In vitro affinity human cloned 5-hydroxytryptamine 1D receptor alpha by [3H]5-HT displacement.,1,,Expert,,,,,,,B,BAO_0000357,CHEMBL617599,1997
,105,H,8,,,,1558,,Binding affinity towards cloned human 5-hydroxytryptamine 1D receptor alpha was determined,1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL617091,1998
,105,H,8,,,,12902,,"Binding affinity against 5-hydroxytryptamine 1D receptor alpha expressed in CHO-K1 cells, using [3H]-5-HT as the radioligand.",1,,Expert,,485.0,,,CHO-K1,,B,BAO_0000219,CHEMBL617092,1999
,105,H,8,,,,13706,,Compound was tested for binding affinity against cloned human 5-hydroxytryptamine 1D receptor alpha expressed in CHO-K1 cells.,1,,Autocuration,,485.0,,,CHO-K1,,B,BAO_0000219,CHEMBL617093,2000
,105,H,8,,,,13706,,Compound was tested for intrinsic efficacy against human 5-hydroxytryptamine 1D receptor alpha measured as the reduction of forskolin-stimulated cAMP.,1,,Autocuration,,,,,,,F,BAO_0000019,CHEMBL617094,2001
,105,H,8,,,,13706,,Compound was tested for intrinsic efficacy against human 5-hydroxytryptamine 1D receptor beta measured as the reduction of forskolin-stimulated cAMP.,1,,Autocuration,,,,,,,F,BAO_0000019,CHEMBL617095,2002
,105,H,8,,,,14251,,Compound was tested for its agonist activity against human 5-hydroxytryptamine 1D receptor alpha for comparison purpose.,1,,Autocuration,,,,,,,F,BAO_0000019,CHEMBL617096,2003
,105,H,8,,,,14251,,Compound was tested for its agonist activity against human recombinant 5-hydroxytryptamine 1D receptor alpha for comparison purpose.,1,,Autocuration,,,,,,,F,BAO_0000019,CHEMBL617097,2004
,105,H,8,,,,14251,,Compound was tested for its agonist activity against human recombinant 5-hydroxytryptamine 1D receptor alpha for comparison purpose.,1,,Autocuration,,,,,,,F,BAO_0000019,CHEMBL617098,2005
,105,H,8,,,,13313,,In vitro binding affinity towards 5-HT1D alpha receptor by using [3H]5-HT as radioligand,1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL617301,2006
,105,H,8,,,,13313,,In vitro binding affinity towards 5-hydroxytryptamine 1D receptor alpha by using [3H]5-HT as radioligand,1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL617302,2007
,105,H,8,,,,13366,,Selectivity towards 5-hydroxytryptamine 1D receptor beta to that of 5-hydroxytryptamine 1D receptor alpha,1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL617303,2008
,105,H,8,,,,13051,,Binding affinity to recombinant human 5-hydroxytryptamine 1D receptor alpha,1,,Expert,,,,,,,B,BAO_0000357,CHEMBL617304,2009
,105,H,8,,,,12903,,"In vitro binding affinity against cloned mammalian 5-hydroxytryptamine 1D receptor alpha expressed in CHO cells, by using [3H]5-HT as radioligand",1,,Expert,,449.0,,,CHO,,B,BAO_0000219,CHEMBL617305,2010
,105,D,9,,,,12469,,Binding affinity was measured on 5-hydroxytryptamine 1D receptor alpha in COS cells transfected with human 5-HT1D alpha gene labeled with [3H]5-HT,1,Homo sapiens,Autocuration,,,,9606.0,,,B,BAO_0000219,CHEMBL617306,2011
,17106,H,8,,,,5619,,Binding affinity (in vitro) against 5-hydroxytryptamine 1D receptor alpha using radio-ligand binding assay,1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL617307,2012
,105,H,8,,,,13047,,Binding affinity against 5-hydroxytryptamine 4 receptor using rabbit saphenous vein assay.,1,Oryctolagus cuniculus,Autocuration,,,,9986.0,,,B,BAO_0000019,CHEMBL617308,2013
,105,H,8,,,,16633,,Binding affinities against 5-hydroxytryptamine 1D receptor alpha,1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL617309,2014
,105,H,8,,,,16633,,Binding affinities towards 5-hydroxytryptamine 1D receptor alpha,1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL617310,2015
,105,H,8,,,,16633,,Binding affinities towards 5-hydroxytryptamine 1D receptor alpha,1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL617311,2016
,105,H,8,,,,16633,,Binding affinity towards 5-hydroxytryptamine 1D receptor alpha using [3H]8-OH-DPAT as radioligand,1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL617312,2017
,105,H,8,,,,3269,,Affinity against 5-hydroxytryptamine 1D receptor alpha,1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL617313,2018
,105,H,8,,,,12409,,Binding affinity against 5-hydroxytryptamine 1D receptor alpha,1,,Expert,,,,,,,B,BAO_0000357,CHEMBL617314,2019
,106,H,8,,,,13706,,Compound was tested for intrinsic efficacy against human 5-hydroxytryptamine 1D receptor beta measured as the reduction of forskolin-stimulated cAMP.,1,,Autocuration,,,,,,,F,BAO_0000019,CHEMBL617315,2020
,106,H,8,,,,13706,,Compound was tested for binding affinity against human 5-hydroxytryptamine 1D receptor beta clones expressed in human embryonic kidney (HEK 293) cells line.,1,,Autocuration,,722.0,,,HEK293,,B,BAO_0000219,CHEMBL617316,2021
,106,H,8,,,,13706,,Compound was tested for binding affinity against human 5-hydroxytryptamine 1D receptor beta clones expressed in human embryonic kidney (HEK 293) cells line; NT= not tested,1,,Autocuration,,722.0,,,HEK293,,B,BAO_0000219,CHEMBL617317,2022
,106,H,8,,,,12903,,"The compound was tested in vitro for binding affinity against cloned mammalian 5-hydroxytryptamine 1D receptor beta expressed in CHO cells, by using [3H]5-HT as radioligand",1,,Autocuration,,449.0,,,CHO,,B,BAO_0000219,CHEMBL617318,2023
,106,H,8,,,,13047,,Binding affinity against 5-hydroxytryptamine 1D receptor beta using rabbit saphenous vein assay.,1,,Autocuration,,,,,,,B,BAO_0000019,CHEMBL617319,2024
,106,D,9,,,,13366,,Displacement of [3H]-5-HT from human 5-hydroxytryptamine 1D receptor beta,1,,Expert,,,,,,,B,BAO_0000357,CHEMBL617320,2025
,106,D,9,,,,13366,,Displacement of [3H]-5-HT from human 5-hydroxytryptamine 1D receptor beta,1,,Expert,,,,,,,B,BAO_0000357,CHEMBL617321,2026
,106,D,9,,,,13366,,Displacement of [3H]-5-HT from human 5-hydroxytryptamine 1D receptor beta,1,,Expert,,,,,,,B,BAO_0000357,CHEMBL617322,2027
,106,H,8,,,,13366,,Binding affinity towards cloned human 5-hydroxytryptamine 1D receptor beta was determined using [3H]8-OH-DPAT as radioligand,1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL616862,2028
,106,H,8,,,,13366,,Binding affinity towards cloned human 5-hydroxytryptamine 1D receptor was determined using [3H]8-OH-DPAT as radioligand,1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL616863,2029
,106,H,8,,,,12469,,Binding affinity was measured on 5-hydroxytryptamine 1D receptor beta in CHO cells transfected with human 5-HT1D beta gene labeled with [3H]5-HT,1,,Autocuration,,449.0,,,CHO,,B,BAO_0000219,CHEMBL616864,2030
,106,H,8,,,,13706,,Compound was tested for binding affinity against cloned human 5-HT1D beta receptor expressed in CHO-K1 cells.,1,,Autocuration,,485.0,,,CHO-K1,,B,BAO_0000219,CHEMBL616865,2031
,106,H,8,,,,13706,,Compound was tested for binding affinity against cloned human 5-hydroxytryptamine 1D receptor beta expressed in CHO-K1 cells.,1,,Autocuration,,485.0,,,CHO-K1,,B,BAO_0000219,CHEMBL616866,2032
,106,H,8,,,,13706,,Compound was tested for intrinsic efficacy against human 5-hydroxytryptamine 1D receptor beta measured as the reduction of forskolin-stimulated cAMP.,1,,Autocuration,,,,,,,F,BAO_0000019,CHEMBL616867,2033
,106,H,8,,,,12902,,"Binding affinity against 5-hydroxytryptamine 1D receptor beta expressed in CHO-K1 cells, using [3H]5-HT as the radioligand.",1,,Expert,,485.0,,,CHO-K1,,B,BAO_0000219,CHEMBL616868,2034
,105,H,8,,,,13051,,Binding affinity for cloned human 5-hydroxytryptamine 1D receptor beta,1,,Expert,,,,,,,B,BAO_0000357,CHEMBL616869,2035
,106,H,8,,,,12903,,"In vitro binding affinity against cloned mammalian 5-hydroxytryptamine 1D receptor beta expressed in CHO cells, by using [3H]5-HT as radioligand",1,,Expert,,449.0,,,CHO,,B,BAO_0000219,CHEMBL616870,2036
,105,H,8,,,,1558,,Compound was tested for its ability inhibit forskolin-stimulated activity of adenylate cyclase coupled to human 5-hydroxytryptamine 1D receptor beta in CHO-K1 cells; value ranges from 0.24-0.55,1,,Autocuration,,485.0,,,CHO-K1,,F,BAO_0000219,CHEMBL616871,2037
,105,H,8,,,,1558,,Compound was tested for its ability inhibit forskolin-stimulated activity of adenylate cyclase coupled to human 5-hydroxytryptamine 1D receptor beta in CHO-K1 cells; value ranges from 0.6-2.0,1,,Autocuration,,485.0,,,CHO-K1,,F,BAO_0000219,CHEMBL616872,2038
,105,H,8,,,,1558,,Compound was tested for its ability inhibit forskolin-stimulated activity of adenylate cyclase coupled to human 5-hydroxytryptamine 1D receptor beta in CHO-K1 cells; value ranges from 2.8-6.5,1,,Autocuration,,485.0,,,CHO-K1,,F,BAO_0000219,CHEMBL616873,2039
,105,H,8,,,,1558,,Compound was tested for its ability inhibit forskolin-stimulated activity of adenylate cyclase coupled to human 5-hydroxytryptamine 1D receptor beta in CHO-K1 cells; value ranges from 30-70,1,,Autocuration,,485.0,,,CHO-K1,,F,BAO_0000219,CHEMBL616838,2040
,105,H,8,,,,1558,,Binding affinity towards cloned human 5-hydroxytryptamine 1D receptor beta was determined,1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL616839,2041
,106,H,8,,,,13047,,Binding affinity against 5-hydroxytryptamine 3 receptor using rabbit saphenous vein assay.,1,Oryctolagus cuniculus,Autocuration,,,,9986.0,,,B,BAO_0000019,CHEMBL616840,2042
,105,H,8,,,,13313,,In vitro binding affinity towards 5-hydroxytryptamine 1D receptor alpha by using [3H]-5-HT as radioligand,1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL616841,2043
,105,H,8,,,,13313,,In vitro binding affinity towards 5-hydroxytryptamine 1D receptor beta by using [3H]5-HT as radioligand,1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL616842,2044
,105,H,8,,,,12409,,Binding affinity against 5-hydroxytryptamine 1D receptor beta,1,,Expert,,,,,,,B,BAO_0000357,CHEMBL857976,2045
,10618,H,8,,,,15250,,Compound was tested for the displacement of [3H]5-HT binding to cloned human 5-hydroxytryptamine 1E receptor stably expressed in CHO cells,1,,Autocuration,,449.0,,,CHO,,B,BAO_0000219,CHEMBL616843,2046
,10618,D,9,,,,1348,,Inhibitory activity against 5-hydroxytryptamine 1E receptor subtype,1,Homo sapiens,Expert,,,,9606.0,,,B,BAO_0000357,CHEMBL616844,2047
,10618,H,8,,,,1348,,Inhibitory activity against 5-hydroxytryptamine 1E receptor subtype; NA denotes data not available,1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL616845,2048
,10618,D,9,,,,4234,,Binding affinity to cloned human 5-hydroxytryptamine 1E receptor,1,Homo sapiens,Expert,,,,9606.0,,,B,BAO_0000357,CHEMBL616846,2049
,10618,H,8,,,,16209,,Binding affinity towards human 5-hydroxytryptamine 1E receptor was determined using [3H]5-HT as radioligand,1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL616847,2050
,10618,H,8,,,,10444,,Binding affinity was determined against 5-hydroxytryptamine 1E receptor in human cortical homogenate,1,,Autocuration,,,,,,,B,BAO_0000019,CHEMBL616848,2051
,10618,H,8,,,,3935,,Compound was evaluated for its binding affinity for human 5-hydroxytryptamine 1E receptor,1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL616849,2052
,10618,H,8,,,,15818,,Compound was evaluated for its binding affinity towards human 5-hydroxytryptamine 1E receptor,1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL872911,2053
,10618,H,8,,,,17085,,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1E receptor,1,,Autocuration,,,,,,,B,BAO_0000019,CHEMBL616850,2054
,10618,D,9,,,,12936,,Binding affinity against human 5-hydroxytryptamine 1E receptor expressed in CHO cells,1,Homo sapiens,Expert,,449.0,,9606.0,CHO,,B,BAO_0000219,CHEMBL616699,2055
,10618,H,8,,,,6166,,Binding affinity towards cloned human 5-hydroxytryptamine 1E receptor was determined,1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL616700,2056
,10618,H,8,,,,15779,,Binding affinity towards 5-hydroxytryptamine 1E receptor (human cloned receptor) in CHO cells using [3H]5-HT as radioligand.,1,,Autocuration,,449.0,,,CHO,,B,BAO_0000219,CHEMBL616701,2057
,10618,H,8,,,,15779,,Binding affinity towards human cloned 5-hydroxytryptamine 1E receptor in CHO cells using [3H]5-HT as radioligand.,1,,Autocuration,,449.0,,,CHO,,B,BAO_0000219,CHEMBL616702,2058
,10618,H,8,,,,15779,,Binding affinity towards human cloned 5-hydroxytryptamine 1E receptor in CHO cells using [3H]5-HT as radioligand;ND means no data.,1,,Autocuration,,449.0,,,CHO,,B,BAO_0000219,CHEMBL616703,2059
,10618,H,8,,,,13181,,Binding affinity was determined against 5-hydroxytryptamine 1D receptor,1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL616704,2060
,10618,H,8,,,,4199,,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 1E receptor in CHO cells using [3H]5-HT as the radioligand,1,,Autocuration,,449.0,,,CHO,,B,BAO_0000219,CHEMBL616705,2061
,10618,H,8,,,,14875,,Compound was tested for binding affinity against human 5-hydroxytryptamine 1E receptor,1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL616706,2062
,10618,H,8,,,,15146,,Compound was tested for its binding affinity against cloned human 5-hydroxytryptamine 1E receptor in CHO cells using [3H]-5-HT,1,,Autocuration,,449.0,,,CHO,,B,BAO_0000219,CHEMBL616707,2063
,10618,H,8,,,,5213,,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 1E receptor in CHO using [3H]5-HT as a radioligand,1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL616708,2064
,10618,H,8,,,,12146,,Tested for binding affinity towards cloned human 5-hydroxytryptamine 1E receptor using [3H]5-HT as radioligand,1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL616709,2065
,10618,H,8,,,,13267,,The binding affinity (pKi) measured against 5-hydroxytryptamine 1E receptor (cloned human receptors in CHO cells) using [3H]5-HT1E as radioligand,1,,Autocuration,,449.0,,,CHO,,B,BAO_0000219,CHEMBL616710,2066
,10618,H,8,,,,14818,,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 1E receptor in CHO cells using [3H]5-HT.,1,,Autocuration,,449.0,,,CHO,,B,BAO_0000219,CHEMBL616711,2067
,10618,H,8,,,,4829,,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 1E receptor in CHO cells, using [3H]5-HT as radioligand",1,,Autocuration,,449.0,,,CHO,,B,BAO_0000219,CHEMBL616712,2068
,10618,H,8,,,,4373,,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 1E receptor was determined,1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL616713,2069
,10618,H,8,,,,4373,,Binding affinity for 5-hydroxytryptamine 1E receptor was determined,1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL616714,2070
,10618,H,8,,,,14159,,Compound was evaluated for the affinity at 5-hydroxytryptamine 1E receptor,1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL616715,2071
,10618,H,8,,,,16633,,Binding affinity towards 5-hydroxytryptamine 1E receptor,1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL616716,2072
,279,H,8,,,,17085,,"In vitro effective concentration for stimulation of [35S]GTP-gamma-S, binding in mouse LM(tk-)cells expressing the human 5-HT1F receptor",1,,Autocuration,,,,,,,F,BAO_0000019,CHEMBL616717,2073
,279,H,8,,,,17085,,"In vitro effective concentration for stimulation of [35S]GTP-gamma-S, binding in mouse LM(tk-)cells expressing the human 5-hydroxytryptamine 1F receptor",1,,Expert,,,,,,,F,BAO_0000019,CHEMBL616718,2074
,279,H,8,,,,16209,,In vitro effective concentration for inhibition of skolin-stimulated adenylate cyclase in cell line expressing human 5-hydroxytryptamine 1F receptor,1,,Autocuration,,,,,,,F,BAO_0000019,CHEMBL875905,2075
,279,H,8,,,,16209,,In vitro agonist potency against human 5-hydroxytryptamine 1F receptor,1,,Autocuration,,,,,,,F,BAO_0000019,CHEMBL616719,2076
,279,H,8,,,,17085,,"Maximum stimulation of of [35S]GTP-gamma-S, binding expressed relative to the maximal effect of 5-hydroxytryptamine 1F receptor",1,,Expert,,,,,,,F,BAO_0000019,CHEMBL616720,2077
,279,H,8,,,,14159,,Compound was evaluated for the affinity at 5-hydroxytryptamine 1F receptor,1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL616721,2078
,279,H,8,,,,15250,,Compound was tested for the displacement of [3H]5-HT binding to cloned human 5-hydroxytryptamine 1F receptor stably expressed in CHO cells,1,,Autocuration,,449.0,,,CHO,,B,BAO_0000219,CHEMBL616722,2079
,279,H,8,,,,3805,,In vitro binding affinity against human 5-hydroxytryptamine 1F receptor at a concentration of 100 (nM),1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL616723,2080
,279,H,8,,,,16190,,Binding affinity against 5-hydroxytryptamine 1F receptor in CHO cells using [3H]5-HT radioligand,1,,Autocuration,,449.0,,,CHO,,B,BAO_0000219,CHEMBL616724,2081
,279,H,8,,,,16190,,Binding affinity against 5-hydroxytryptamine 1F receptor in CHO using [3H]5-HT radioligand,1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL616725,2082
,279,H,8,,,,16209,,Binding affinity towards human 5-hydroxytryptamine 1F receptor,1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL616726,2083
,279,H,8,,,,16209,,Binding affinity towards human 5-hydroxytryptamine 1F receptor was determined,1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL616727,2084
,279,H,8,,,,16209,,Binding affinity towards human 5-hydroxytryptamine 1F receptor using [3H]-5-HT radioligand,1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL616728,2085
,279,H,8,,,,6866,,In vitro binding affinity for human 5-hydroxytryptamine 1F receptor,1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL616729,2086
,279,H,8,,,,17085,,In vitro binding affinity was determined by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1F receptor,1,,Expert,,,,,,,B,BAO_0000019,CHEMBL616730,2087
,279,H,8,,,,16312,,Binding affinity towards human recombinant 5-hydroxytryptamine 1F receptor,1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL617125,2088
,279,H,8,,,,6166,,Binding affinity towards cloned human 5-hydroxytryptamine 1F receptor was determined,1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL857977,2089
,279,H,8,,,,15779,,Binding affinity towards 5-hydroxytryptamine 1F receptor (human cloned receptor) in CHO cells using [3H]5-HT as radioligand.,1,,Autocuration,,449.0,,,CHO,,B,BAO_0000219,CHEMBL617126,2090
,279,H,8,,,,4199,,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 1F receptor in CHO cells using [3H]-5-HT as the radioligand,1,,Autocuration,,449.0,,,CHO,,B,BAO_0000219,CHEMBL617127,2091
,279,H,8,,,,14875,,Compound was tested for binding affinity against human 5-hydroxytryptamine 1F receptor,1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL617128,2092
,279,H,8,,,,15146,,Compound was tested for its binding affinity against 5-hydroxytryptamine 1F receptor in human cloned receptors in CHO cells using [3H]5-HT,1,,Autocuration,,449.0,,,CHO,,B,BAO_0000219,CHEMBL617129,2093
,279,H,8,,,,5213,,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 1F receptor in CHO using [3H]5-HT as a radioligand,1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL617130,2094
,279,H,8,,,,14818,,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 1F receptor in CHO cells using [3H]5-HT.,1,,Autocuration,,449.0,,,CHO,,B,BAO_0000219,CHEMBL617131,2095
,279,H,8,,,,4829,,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 1F receptor in CHO cells, using [3H]5-HT as radioligand",1,,Autocuration,,449.0,,,CHO,,B,BAO_0000219,CHEMBL617132,2096
,279,H,8,,,,4829,,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 1F receptor in CHO cells, using [3H]5-HT as radioligand",1,,Autocuration,,449.0,,,CHO,,B,BAO_0000219,CHEMBL617133,2097
,279,H,8,,,,4373,,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 1F receptor was determined,1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL617134,2098
,279,H,8,,,,4373,,Binding affinity for 5-hydroxytryptamine 1F receptor was determined,1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL617135,2099
,279,H,8,,,,5014,,Percent inhibition (at 1 uM) against 5-hydroxytryptamine 1F receptor,1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL617136,2100
,104686,H,4,,,,11662,,"Compound was tested for binding affinity towards 5-hydroxytryptamine 2 (5-hydroxytryptamine-2) receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]-ketanserin as radioligand",1,,Autocuration,,,,,,,B,BAO_0000019,CHEMBL617137,2101
,104686,H,4,,,,11662,,"Compound was tested for binding affinity towards 5-hydroxytryptamine 2 receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]ketanserin as radioligand",1,,Autocuration,,,,,,,B,BAO_0000019,CHEMBL617138,2102
,104686,H,4,,,,11662,,"Compound was tested for binding affinity towards 5-hydroxytryptamine 2 (5-hydroxytryptamine-2) receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]ketanserin as radioligand; Not Determined",1,,Autocuration,,,,,,,B,BAO_0000019,CHEMBL617139,2103
,12687,H,8,,,,14093,,Ability to displace [3H]ketanserin from rat cortical homogenate 5-hydroxytryptamine 2A receptor,1,,Autocuration,,,,,,,B,BAO_0000019,CHEMBL617140,2104
,104686,H,4,In vivo,,,11200,,"In vivo inhibitory activity of 10 mg/kg compound in rats against elevation of BP caused by 5-HT (300 ug/kg, iv) through 5-HT2 receptor 1 hr after oral administration",1,,Autocuration,,,,,,,F,BAO_0000218,CHEMBL617141,2105
,104686,H,4,,,,11200,,In vitro antagonistic activity against the contraction induced by 5-HT through 5-hydroxytryptamine 2 receptor in rat thoracic aortic strips,1,,Autocuration,,,,,,,F,BAO_0000019,CHEMBL858112,2106
,17005,H,8,,,,12352,,Binding affinity towards 5-hydroxytryptamine 2 receptor in calf frontal cortex,1,,Intermediate,,,,,,,B,BAO_0000019,CHEMBL617142,2107
,22226,U,0,,,,13657,,"Binding affinity to 5-hydroxytryptamine 2 receptor using calf frontal cortex, [3H]- ketanserin, and spiperone for NSB",1,Bos taurus,Autocuration,,,,9913.0,,,B,BAO_0000019,CHEMBL617143,2108
,22226,U,0,,,,14331,,Inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor of bovine frontal cortex at 10e-7 M,1,Bos taurus,Autocuration,,,,9913.0,,,B,BAO_0000019,CHEMBL617144,2109
,22226,U,0,,,,14331,,Inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor of bovine frontal cortex,1,Bos taurus,Autocuration,,,,9913.0,,,B,BAO_0000019,CHEMBL617145,2110
,22226,U,0,,,,14331,,Binding affinity of compound towards 5-hydroxytryptamine 2 receptor using [3H]ketanserin (0.8 nM) ligand in frontal cortex bovine was determined,1,,Autocuration,,,,,,,B,BAO_0000019,CHEMBL617146,2111
,104784,H,4,,,,12685,,Binding affinity for serotonin 5-hydroxytryptamine 2 receptor using [3H]ketanserin in guinea pig frontal cortex,1,Cavia porcellus,Autocuration,,,,10141.0,,,B,BAO_0000019,CHEMBL617147,2112
,104784,H,4,,,,14389,,Inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor of guinea pig frontal cortex membranes,1,Cavia porcellus,Autocuration,,,,10141.0,,,B,BAO_0000019,CHEMBL617148,2113
,104784,H,4,,,,14386,,Compound was tested for its binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]ketanserin from guinea pig frontal cortex,1,Cavia porcellus,Autocuration,,,,10141.0,,,B,BAO_0000019,CHEMBL617149,2114
,104784,H,4,,,,5732,,Binding affinity towards cloned human 5-hydroxytryptamine 2 receptor was determined,1,,Autocuration,,,,,,,B,BAO_0000224,CHEMBL617150,2115
,104784,H,4,,,,16293,,Binding affinity towards 5-hydroxytryptamine 2 receptor was determined,1,,Autocuration,,,,,,,B,BAO_0000224,CHEMBL617151,2116
,104784,H,4,,,,2078,,In vitro binding affinity of compound against neuronal 5-hydroxytryptamine 2 receptor,1,,Autocuration,,,,,,,B,BAO_0000224,CHEMBL617201,2117
,10209,H,8,,,,5486,,Binding affinity towards 5-HT7 receptor by the displacement of [3H]-5-CT] in human recombinant receptors in mammalian cell,1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL617202,2118
,104826,H,4,In vivo,,,11820,,Effective dose through peroral route for in vivo inhibition against 5-hydroxytryptamine 2 receptor in male CF-1 mice by using radioligand [3H]ketanserin,1,,Autocuration,,,,,,,B,BAO_0000218,CHEMBL617203,2119
,104826,H,4,,,,10297,,Hill number was determined for inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor in mouse cerebral cortex,1,,Autocuration,,,,,,,B,BAO_0000019,CHEMBL617204,2120
,104826,H,4,,,,13704,,Inhibitory activity against serotonin 5-hydroxytryptamine 2 receptor from mice.,1,,Autocuration,,,,,,,B,BAO_0000224,CHEMBL617205,2121
,104826,D,5,,,,10297,,Inhibitory activity towards 5-hydroxytryptamine 2 receptor by the displacement of [3H]ketanserin in mouse cerebral cortex,1,Mus musculus,Autocuration,,,,10090.0,,,B,BAO_0000019,CHEMBL617206,2122
,104826,H,4,In vivo,,,11820,,Effective dose through peroral route for in vivo inhibition against 5-hydroxytryptamine 2 receptor in male CF-1 mice by using radioligand [3H]ketanserin,1,,Autocuration,,,,,,,B,BAO_0000218,CHEMBL617207,2123
,104826,D,5,,,,10297,,Binding affinity towards 5-hydroxytryptamine 2 receptor by the displacement of [3H]-ketanserin in mouse cerebral cortex,1,Mus musculus,Autocuration,,,,10090.0,,,B,BAO_0000019,CHEMBL617208,2124
,104826,H,4,,,,11555,,The compound was tested in vitro for its binding affinity towards 5-hydroxytryptamine 2 receptor,1,,Autocuration,,,,,,,B,BAO_0000224,CHEMBL617209,2125
,104826,H,4,,,,11555,,In vitro binding affinity for serotonin 5-hydroxytryptamine (5-HT) 2 receptors,1,,Autocuration,,,,,,,B,BAO_0000224,CHEMBL617210,2126
,104826,H,4,,,,11555,,The compound was tested in vitro for its binding affinity towards serotonin 5-hydroxytryptamine 2 receptor; nd = no data,1,,Autocuration,,,,,,,B,BAO_0000224,CHEMBL617211,2127
,104826,D,5,,,,10297,,Hill number was determined for inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor in mouse cerebral cortex,1,Mus musculus,Autocuration,,,,10090.0,,,B,BAO_0000019,CHEMBL617212,2128
,104784,H,4,,,,16688,,Binding affinity for porcine 5-hydroxytryptamine 2 receptor using [3H]- ketanserin,1,Sus scrofa,Autocuration,,,,9823.0,,,B,BAO_0000224,CHEMBL617213,2129
,104784,H,4,,,,16688,,Binding affinity for porcine 5-hydroxytryptamine 2 receptor using [3H]- ketanserin with 10 uM prazosin,1,Sus scrofa,Autocuration,,,,9823.0,,,B,BAO_0000224,CHEMBL617214,2130
,22226,U,0,,,,5333,,Compound was tested in vitro for its ability to compete with [3H]-ketanserin at 5-hydroxytryptamine 2 receptor in porcine brain homogenate,1,,Autocuration,,,,,,,B,BAO_0000221,CHEMBL617215,2131
,22226,U,0,,,,4437,,In vitro for its ability to displace [3H]- ketanserin from 5-hydroxytryptamine 2 receptor in porcine brain homogenate,1,,Autocuration,,,,,,,B,BAO_0000221,CHEMBL617216,2132
,17005,H,8,,,,5033,,Ability to displace the radioligand [3H]mesulergine from pig choroid plexus 5-hydroxytryptamine 2 receptor,1,Sus scrofa,Autocuration,,,,9823.0,,,B,BAO_0000357,CHEMBL617217,2133
,104686,H,4,,,,15267,,Inhibition of [3H]- Ketanserin binding against rat brain 5-hydroxytryptamine 2 receptor,1,,Autocuration,,,,,,,B,BAO_0000019,CHEMBL617218,2134
,104686,H,4,,,,15267,,Inhibition of [3H]- Ketanserin binding against rat brain 5-hydroxytryptamine 2 receptor,1,,Autocuration,,,,,,,B,BAO_0000019,CHEMBL872913,2135
,104826,H,4,,,,11820,,Binding affinity against 5-hydroxytryptamine 2 receptor from rat cortical synaptosomal membrane using radioligand [3H]ketanserin.,1,,Autocuration,,,,,,,B,BAO_0000019,CHEMBL617219,2136
,104686,H,4,,,,9069,,Evaluated for binding activity against [3H]ketanserin as radioligand for 5-hydroxytryptamine 2 receptor,1,,Autocuration,,,,,,,B,BAO_0000224,CHEMBL873482,2137
,104686,D,5,,,,9162,,Affinity towards 5-hydroxytryptamine 2 receptor by measuring its ability to antagonize serotonin-induced contractions in the rat jugular vein; ND means no data,1,Rattus norvegicus,Autocuration,,,,10116.0,,,B,BAO_0000019,CHEMBL617220,2138
,104686,H,4,,,,9162,,Affinity towards 5-hydroxytryptamine 2 receptor by measuring its ability to antagonize serotonin-induced contractions in the rat jugular vein.,1,,Autocuration,,,,,,,B,BAO_0000019,CHEMBL617221,2139
,104686,H,4,,,,9162,,Affinity towards 5-hydroxytryptamine 2 receptor by measuring its ability to antagonize serotonin-induced contractions in the rat jugular vein; no appreciable 5-HT2 receptor affinity,1,,Autocuration,,,,,,,B,BAO_0000019,CHEMBL617222,2140
,104686,H,4,,,,10428,,Antagonistic activity against (5-hydroxytryptamine 2 receptor) serotonin-induced contractions in the rat jugular vein,1,,Autocuration,,,,,,,F,BAO_0000019,CHEMBL875906,2141
,104686,H,4,,,,9628,,Binding affinity to the 5-hydroxytryptamine 2 receptor assayed by antagonism of serotonin-induced contractions in the rat jugular vein,1,,Autocuration,,,,,,,B,BAO_0000019,CHEMBL617223,2142
,104686,H,4,,,,12704,,Binding affinity against serotonin 5-hydroxytryptamine 2 receptor,1,,Autocuration,,,,,,,B,BAO_0000224,CHEMBL617224,2143
,104686,D,5,,,,15453,,Percent decrease in 5-hydroxytryptamine 2 receptor binding using ketanserin,1,Rattus norvegicus,Autocuration,,,,10116.0,,,B,BAO_0000224,CHEMBL617225,2144
,104686,H,4,,,,188,,Tested for the effect on binding at 5-hydroxytryptamine 2 receptor; No activity,1,,Autocuration,,,,,,,B,BAO_0000224,CHEMBL617226,2145
,104686,H,4,,,,10349,,Effect of 2 week administration of compound on 5-hydroxytryptamine 2 receptor binding by using 0.4 nM dose of [3H]- spiperone as a radioligand.,1,,Autocuration,,,,,,,B,BAO_0000224,CHEMBL617227,2146
,104686,H,4,,,,10349,,Effect of 2 week administration of compound on 5-hydroxytryptamine 2 receptor binding by using 0.6 nM dose of [3H]- spiperone as a radioligand.,1,,Autocuration,,,,,,,B,BAO_0000224,CHEMBL617228,2147
,104686,H,4,,,,8868,,Compound was tested for its effect on 5-hydroxytryptamine 2 receptor saturation analysis,1,,Autocuration,,,,,,,B,BAO_0000224,CHEMBL617229,2148
,104686,H,4,,,,10025,,Concentration necessary to achieve half maximal inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor at 1 uM,1,,Autocuration,,,,,,,B,BAO_0000224,CHEMBL617230,2149
,104686,H,4,,,,10025,,"Concentration necessary to achieve half maximal inhibition of [3H]ketanserin, binds to 5-hydroxytryptamine 2 receptor at 1 uM",1,,Autocuration,,,,,,,B,BAO_0000224,CHEMBL617231,2150
,104686,H,4,,,,11702,,Compound was tested for the inhibition of quipazine binding at 5-HT2 receptor,1,,Autocuration,,,,,,,B,BAO_0000224,CHEMBL617232,2151
,104686,H,4,,,,11702,,Compound was tested for the inhibition of quipazine binding at 5-hydroxytryptamine 2 receptor,1,,Autocuration,,,,,,,B,BAO_0000224,CHEMBL617233,2152
,104686,H,4,,,,11702,,Compound was tested for the inhibition of quipazine binding at 5-hydroxytryptamine 2 receptor; NT=Not tested,1,,Autocuration,,,,,,,B,BAO_0000224,CHEMBL617234,2153
,104686,H,4,,,,11702,,Compound was tested for the inhibition of quipazine induced head twitches in rats,1,,Autocuration,,,,,,,F,BAO_0000019,CHEMBL617235,2154
,104686,H,4,,,,11702,,Compound was tested for the inhibition of quipazine induced head twitches in rats; NT=Not tested,1,,Autocuration,,,,,,,F,BAO_0000019,CHEMBL617236,2155
Hippocampus,104686,H,4,,,,10085,,Ability to bind at 5-hydroxytryptamine 2 receptor of rat hippocampus by displacing [3H]spiperone,1,,Autocuration,,,,,,10000000.0,B,BAO_0000221,CHEMBL617237,2156
Hippocampus,104686,H,4,,,,10085,,Ability to bind at serotonin 5-hydroxytryptamine 2 receptors of rat hippocampus by displacing [3H]spiperone,1,,Autocuration,,,,,,10000000.0,B,BAO_0000221,CHEMBL617238,2157
Brain,104686,D,5,,,,9630,,Displacement of [3H]spiroperidol from 5-hydroxytryptamine 2 receptor in rat brain,1,Rattus norvegicus,Autocuration,,,,10116.0,,955.0,B,BAO_0000221,CHEMBL617239,2158
,104686,H,4,,,,11070,,Ability to inhibit binding of [3H]KET to 5-hydroxytryptamine 2 receptor in rat cortex,1,,Autocuration,,,,,,,B,BAO_0000019,CHEMBL617240,2159
,104686,H,4,,,Membranes,9841,,Ability to inhibit binding of titreated spiperone to 5-hydroxytryptamine 2 receptor in rat brain frontal cortex membranes,1,,Autocuration,,,,,,,B,BAO_0000249,CHEMBL617241,2160
,104686,H,4,,,Membranes,9841,,Ability to inhibit binding of titreated spiperone to the 5-hydroxytryptamine 2 receptor in rat brain frontal cortex membranes,1,,Autocuration,,,,,,,B,BAO_0000249,CHEMBL875907,2161
,104686,H,4,,,,13291,,Affinity for 5-hydroxytryptamine 2 receptor binding sites by its ability to displace [3H]spiperone from rat frontal cortex.,1,,Autocuration,,,,,,,B,BAO_0000019,CHEMBL617242,2162
,104686,H,4,,,,10590,,Antagonistic activity against 5-hydroxytryptamine 2 receptor on rat frontal cortex membrane.,1,,Autocuration,,,,,,,F,BAO_0000019,CHEMBL617152,2163
Brain,104686,D,5,,,,9064,,Binding affinity against serotonin-2 receptor in rat brain using [3H]spiroperidol,1,Rattus norvegicus,Autocuration,,,,10116.0,,955.0,B,BAO_0000221,CHEMBL617153,2164
,104686,D,5,,,Membranes,12268,,Binding affinity at 5-hydroxytryptamine 2 receptor by the inhibition of binding to [3H]ketanserin in rat cortical membranes,1,Rattus norvegicus,Autocuration,,,,10116.0,,,B,BAO_0000249,CHEMBL617154,2165
Brain,104686,H,4,,,,13508,,Binding affinity against 5-hydroxytryptamine 2 receptor in rat brain using [3H]ketanserin as radioligand,1,,Autocuration,,,,,,955.0,B,BAO_0000221,CHEMBL617155,2166
,104686,H,4,,,,11279,,5-hydroxytryptamine 2 receptor antagonistic activity on the rat tail artery determined by Schild plot.,1,,Autocuration,,,,,,,F,BAO_0000019,CHEMBL617156,2167
,104686,H,4,,,,11200,,In vitro antagonistic activity against the contraction induced by 5-HT through 5-HT2 receptor in rat thoracic aortic strips,1,,Autocuration,,,,,,,F,BAO_0000019,CHEMBL617157,2168
,104686,H,4,,,,11200,,In vitro antagonistic activity tested against the contraction induced by 5-HT through 5-hydroxytryptamine 2 receptor in rat thoracic aortic strips,1,,Autocuration,,,,,,,F,BAO_0000019,CHEMBL617158,2169
,104686,H,4,,,,11200,,In vitro antagonistic activity against the contraction induced by 5-HT through 5-hydroxytryptamine 2 receptor in rat thoracic aortic strips; NC=non competitive antagonism,1,,Autocuration,,,,,,,F,BAO_0000019,CHEMBL617159,2170
,104686,H,4,,,,11200,,In vitro antagonistic activity against the contraction induced by 5-HT through 5-hydroxytryptamine 2 receptor in rat thoracic aortic strips; NC=non competitive antagonism,1,,Autocuration,,,,,,,F,BAO_0000019,CHEMBL617160,2171
,104686,H,4,,,,11200,,In vitro antagonistic activity against the contraction induced by 5-HT through 5-hydroxytryptamine 2 receptor in rat thoracic aortic strips,1,,Autocuration,,,,,,,F,BAO_0000019,CHEMBL858113,2172
Brain,104686,H,4,,,,9231,,Tested for 5-hydroxytryptamine 2 receptor binding ability by displacement of [3H]spiperone from rat brain frontal cortex synaptosomes,1,,Autocuration,,,,,,955.0,B,BAO_0000220,CHEMBL617247,2173
,104686,H,4,,,,9737,,Binding affinity towards 5-hydroxytryptamine 2 receptor in rat frontal cortex using [3H]ketanserin as radioligand,1,,Autocuration,,,,,,,B,BAO_0000019,CHEMBL617248,2174
Brain,104686,H,4,,,,9737,,Binding affinity towards 5-hydroxytryptamine 2 receptor in rat brain membrane using [3H]8-OH-DPAT as a selective ligand.,1,,Autocuration,,,,,,955.0,B,BAO_0000249,CHEMBL617249,2175
,104686,H,4,,,,9737,,Binding affinity towards 5-hydroxytryptamine 2 receptor in rat frontal cortex,1,,Autocuration,,,,,,,B,BAO_0000019,CHEMBL617250,2176
,104686,H,4,,,,9737,,Binding affinity towards 5-hydroxytryptamine 2 receptor in rat frontal cortex using [3H]ketanserin as radioligand,1,,Autocuration,,,,,,,B,BAO_0000019,CHEMBL617251,2177
,104686,D,5,,,,11828,,isplacement of [3H]DOB from rat cortex homogenate 5-hydroxytryptamine 2 receptor,1,Rattus norvegicus,Autocuration,,,,10116.0,,,B,BAO_0000019,CHEMBL617252,2178
,104686,H,4,,,,12253,,Binding affinity of 5-hydroxytryptamine 2 receptor using [3H]- ketanserin in rat frontal cortex,1,,Autocuration,,,,,,,B,BAO_0000019,CHEMBL617006,2179
,104686,H,4,,,,12253,,Binding affinity against 5-hydroxytryptamine 2 receptor using [3H]ketanserin in rat frontal cortex,1,,Autocuration,,,,,,,B,BAO_0000019,CHEMBL617007,2180
,104686,H,4,,,,11279,,"5-hydroxytryptamine 2 receptor antagonistic activity at concentrations of<br>3,10 and 30 uM on the rat tail artery.",1,,Autocuration,,,,,,,F,BAO_0000019,CHEMBL617008,2181
,104686,H,4,,,,11866,,Binding affinity for 5-hydroxytryptamine 2 receptor in rat cortex using [3H]- ketanserin,1,,Autocuration,,,,,,,B,BAO_0000019,CHEMBL617009,2182
,104686,D,5,,,,14424,,Binding affinity against 5-hydroxytryptamine 2 receptor in serotonin-induced contraction of the rat aorta,1,Rattus norvegicus,Autocuration,,,,10116.0,,,B,BAO_0000224,CHEMBL617010,2183
,104686,D,5,,,,15180,,Displacement of [3H]ketanserin from rat brain 5-hydroxytryptamine 2 receptor,1,Rattus norvegicus,Autocuration,,,,10116.0,,,B,BAO_0000019,CHEMBL857978,2184
,104686,D,5,,,,15180,,Displacement of [3H]ketanserin from rat brain 5-hydroxytryptamine 2 receptor,1,Rattus norvegicus,Autocuration,,,,10116.0,,,B,BAO_0000019,CHEMBL617011,2185
,104686,D,5,,,,9786,,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor of rat frontal cortex homogenate,1,Rattus norvegicus,Autocuration,,,,10116.0,,,B,BAO_0000019,CHEMBL617012,2186
,104686,H,4,,,,12132,,Binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]-ketanserin as radioligand.,1,,Autocuration,,,,,,,B,BAO_0000224,CHEMBL617013,2187
,104686,H,4,,,,5486,,Binding affinity towards 5-hydroxytryptamine 2 receptor by the displacement of [3H]ketanserin in rat cerebral cortex membrane,1,,Autocuration,,,,,,,B,BAO_0000249,CHEMBL617014,2188
,104686,H,4,,,,15316,,Compound was evaluated for its ability to displace [3H]ketanserin binding from cloned rat cerebral cortex membranes 5-hydroxytryptamine 2 receptor,1,,Autocuration,,,,,,,B,BAO_0000019,CHEMBL617015,2189
,104686,H,4,,,,16429,,In vitro binding affinity to 5-hydroxytryptamine 2 receptor of rat cerebral cortex membranes using [3H]ketanserin as the radioligand,1,,Autocuration,,,,,,,B,BAO_0000019,CHEMBL617016,2190
,104686,H,4,,,,14617,,pKi value for 5-hydroxytryptamine 2 receptor binding site,1,,Autocuration,,,,,,,B,BAO_0000224,CHEMBL617017,2191
Brain,104686,H,4,,,,11351,,Inhibitory constant (1 uM) was measured on 5-hydroxytryptamine 2 receptor/uptake using [3H]- ketanserin as radioligand in rat brain cortex.,1,,Autocuration,,,,,,955.0,B,BAO_0000221,CHEMBL617018,2192
,104686,H,4,,,,11279,,5-hydroxytryptamine 2 receptor antagonistic activity on the rat tail artery determined by Schild plot.,1,,Autocuration,,,,,,,F,BAO_0000019,CHEMBL617019,2193
,105075,H,4,,,,9523,,Binding affinity at 5-hydroxytryptamine 2 receptor determined using [125I]- DOI as radioligand in rat frontal cortex,1,,Autocuration,,,,,,,B,BAO_0000019,CHEMBL617020,2194
,105075,H,4,,,,9523,,Binding affinity at 5-hydroxytryptamine 2 receptor was determined using [125I]- DOI as radioligand in rat frontal cortex,1,,Autocuration,,,,,,,B,BAO_0000019,CHEMBL617021,2195
,105075,H,4,,,,9523,,Binding affinity at [3H]DOB labeled sites of 5-hydroxytryptamine 2 receptor determined using [125I]- DOI as radioligand in rat frontal cortex,1,,Autocuration,,,,,,,B,BAO_0000019,CHEMBL617022,2196
,105075,H,4,,,,9523,,Binding affinity at [3H]DOB labeled sites of 5-hydroxytryptamine 2 receptor was determined using [125I]- DOI as radioligand in rat frontal cortex,1,,Autocuration,,,,,,,B,BAO_0000019,CHEMBL617023,2197
,105075,H,4,,,,9523,,Binding affinity at [3H]KET labeled sites of 5-hydroxytryptamine 2 receptor determined using [125I]- DOI as radioligand in rat frontal cortex,1,,Autocuration,,,,,,,B,BAO_0000019,CHEMBL617024,2198
,105075,H,4,,,,9523,,Binding affinity at [3H]KET labeled sites of 5-hydroxytryptamine 2 receptor was determined using [125I]- DOI as radioligand in rat frontal cortex,1,,Autocuration,,,,,,,B,BAO_0000019,CHEMBL617025,2199
,105075,H,4,,,,9523,,Hill coefficient of compound was determined,1,,Autocuration,,,,,,,B,BAO_0000224,CHEMBL617026,2200
,22226,U,0,,,,4771,,Ancillary Binding affinity towards rat 5-hydroxytryptamine 2 receptor,1,,Autocuration,,,,,,,B,BAO_0000019,CHEMBL617027,2201
,104686,D,5,,,,5033,,Ability to displace the radioligand [3H]5-carboximidotryptamine ([3H]-ketanserin) from 5-hydroxytryptamine 2 receptor of rat cerebral cortex membrane,1,Rattus norvegicus,Autocuration,,,,10116.0,,,B,BAO_0000019,CHEMBL617028,2202
,12687,H,8,,,,10845,,Binding affinity against rat 5-hydroxytryptamine 2 receptor in rat cerebral cortex tissue using [3H]spiperone as radioligand,1,,Expert,,,,,,,B,BAO_0000019,CHEMBL617029,2203
,12687,H,8,,,,10845,,Binding affinity against rat 5-hydroxytryptamine 2 receptor in rat cerebral cortex tissue using [3H]spiperone as radioligand; IA-Inactive,1,,Expert,,,,,,,B,BAO_0000019,CHEMBL875908,2204
,12687,H,8,,,,16288,,Affinity at 5-hydroxytryptamine 2 receptor (For ketanserin = Ki(nM)= 0.7+/-0.09),1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL617030,2205
,12687,H,8,,,,16288,,Affinity at 5-hydroxytryptamine 2 receptor from rat frontal cortex using [3H]ketanserin as radioligand (For ketanserin = Ki(nM)=0.7+/-0.09),1,,Autocuration,,,,,,,B,BAO_0000019,CHEMBL617031,2206
,12687,H,8,,,,16190,,Binding affinity for 5-hydroxytryptamine 2 receptor of rat cortical membrane using [3H]DOB radioligand,1,,Autocuration,,,,,,,B,BAO_0000019,CHEMBL617032,2207
,104686,D,5,,,,12463,,Tested in vitro for receptor binding affinity against 5-hydroxytryptamine 2 receptor using radioligand [3H]ketanserin,1,Rattus norvegicus,Autocuration,,,,10116.0,,,B,BAO_0000224,CHEMBL617033,2208
,104686,H,4,,,,9699,,"Binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]- 1-(4-bromo-2,5-dimethoxy-phenyl)-2-aminopropane (D) as radioligand",1,,Autocuration,,,,,,,B,BAO_0000224,CHEMBL617034,2209
,104686,H,4,,,,9699,,Binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]- ketanserin as radioligand,1,,Autocuration,,,,,,,B,BAO_0000224,CHEMBL617035,2210
,104686,H,4,,,,11662,,"Compound was tested for binding affinity towards 5-hydroxytryptamine 2 receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]ketanserin as radioligand; Not Determined",1,,Autocuration,,,,,,,B,BAO_0000019,CHEMBL617036,2211
,104784,H,4,,,,1205,,Inhibitory concentration against 5-hydroxytryptamine 2 receptor,1,,Autocuration,,,,,,,B,BAO_0000224,CHEMBL617037,2212
,22226,U,0,,,,11376,,Compound was evaluated for the binding affinity towards 5-hydroxytryptamine 2 receptor from mammalian clones expressed in CHO cell membranes using [3H]-ketanserin as radioligand,1,,Autocuration,,,,,,,B,BAO_0000219,CHEMBL617038,2213
,104784,H,4,,,,11376,,"Binding affinity towards 5-hydroxytryptamine 2 receptor expressed in CHO cell membranes using [3H]ketanserin (60 Ci/mmol, 1 nM)",1,,Autocuration,,,,,,,B,BAO_0000219,CHEMBL617039,2214
,104784,H,4,,,,4639,,Compound was tested for binding affinity against 5-hydroxytryptamine 2 receptor,1,,Autocuration,,,,,,,B,BAO_0000224,CHEMBL617161,2215
,104784,H,4,,,,2222,,Compound was tested for inhibitory activity against 5-hydroxytryptamine 2 receptor,1,,Autocuration,,,,,,,B,BAO_0000224,CHEMBL617162,2216
,104784,H,4,,,,1558,,Compound was tested for its affinity towards 5-hydroxytryptamine 2 receptor,1,,Autocuration,,,,,,,B,BAO_0000224,CHEMBL617163,2217
,104784,H,4,,,,1089,,Tested for binding affinity for 5-hydroxytryptamine 2 receptor,1,,Autocuration,,,,,,,B,BAO_0000224,CHEMBL617164,2218
,104784,H,4,,,Brain membranes,386,,The compound was evaluated for its ability to displace [3H]ketanserin from 5-hydroxytryptamine 2 receptor in cellular brain membranes,1,,Autocuration,,,,,,,B,BAO_0000249,CHEMBL617165,2219
,104784,H,4,,,,2474,,Compound was measured for its binding affinity at 5-hydroxytryptamine 2 receptor at a concentration of 10 uM using [3H]ketanserin as radioligand,1,,Autocuration,,,,,,,B,BAO_0000224,CHEMBL617166,2220
,104784,H,4,,,,17066,,Binding affinity towards 5-HT2 receptor,1,,Autocuration,,,,,,,B,BAO_0000224,CHEMBL617167,2221
,104784,H,4,,,,959,,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor,1,,Autocuration,,,,,,,B,BAO_0000224,CHEMBL872912,2222
,104784,H,4,,,,6398,,Compound was evaluated for 5-hydroxytryptamine 2 receptor binding,1,,Autocuration,,,,,,,B,BAO_0000224,CHEMBL617168,2223
,104686,H,4,,,,11889,,In vitro binding affinity against rat 5-hydroxytryptamine 2 receptor.,1,,Autocuration,,,,,,,B,BAO_0000224,CHEMBL617169,2224
,104784,H,4,,,,4221,,In vitro binding affinity for 5-hydroxytryptamine 2 receptor,1,,Autocuration,,,,,,,B,BAO_0000224,CHEMBL617170,2225
,104784,H,4,,,,11026,,The compound was tested for binding affinity against 5-hydroxytryptamine 2 receptor using ketanserin as radioligand,1,,Autocuration,,,,,,,B,BAO_0000224,CHEMBL617171,2226
,104784,H,4,,,,11866,,Binding affinity for 5-hydroxytryptamine 2 receptor was determined,1,,Autocuration,,,,,,,B,BAO_0000224,CHEMBL617172,2227
,104784,H,4,,,,4221,,In vitro binding affinity for 5-hydroxytryptamine 2 receptor,1,,Autocuration,,,,,,,B,BAO_0000224,CHEMBL617173,2228
,22226,U,0,,,,13950,,In Vitro binding affinity for 5-hydroxytryptamine 2 receptor,1,,Autocuration,,,,,,,B,BAO_0000019,CHEMBL617174,2229
,104784,H,4,,,,1263,,5-hydroxytryptamine 2 receptor binding affinity,1,,Autocuration,,,,,,,B,BAO_0000224,CHEMBL617175,2230
,17005,H,8,,,,13291,,Binding affinity against 5-hydroxytryptamine 2 receptor was determined using [ [3H]spiperone radioligand,1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL617176,2231
,17005,H,8,,,,10812,,Compound was tested for the binding affinity against 5-hydroxytryptamine 2 receptor by using [3H]ketanserin as radioligand,1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL617177,2232
,104784,H,4,,,,13020,,Inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor at 10e-5 M,1,,Autocuration,,,,,,,B,BAO_0000224,CHEMBL617178,2233
,104784,H,4,,,,13021,,Inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor of central nervous system,1,,Autocuration,,,,,,,B,BAO_0000224,CHEMBL617179,2234
,104784,H,4,,,,13020,,Ketanserin binding to 5-hydroxytryptamine 2 receptor at 10e-5 M,1,,Autocuration,,,,,,,B,BAO_0000224,CHEMBL617180,2235
,17005,H,8,,,,14532,,Inhibitory activity against 5-hydroxytryptamine 2 receptor using [3H]-ketanserin as radioligand at 10e-5 M concentration,1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL617181,2236
,17005,H,8,,,,13944,,Binding affinity against 5-hydroxytryptamine 2 receptor,1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL617182,2237
,17005,H,8,,,,14331,,Binding affinity against 5-hydroxytryptamine 2 receptor,1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL617183,2238
,17005,H,8,,,,14118,,Binding affinity against 5-hydroxytryptamine 2 receptor using [3H]ketanserin as radioligand,1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL617184,2239
,17005,H,8,,,,13033,,Binding affinity against serotonergic 5-HT2 receptor,1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL617185,2240
,17005,H,8,,,,10321,,Binding affinity for 5-hydroxytryptamine 2 receptor was determined by using [3H]ketanserin as radioligand,1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL617186,2241
,17005,H,8,,,,12918,,Compound was evaluated for the binding affinity at 5- HT2 receptor,1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL617187,2242
,17005,H,8,,,,15120,,Compound was tested for binding affinity using [3H]ketanserin against 5-hydroxytryptamine 2 receptor,1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL617188,2243
,17005,H,8,,,,2613,,In vivo binding affinity was evaluated against 5-hydroxytryptamine 2 receptor,1,,Autocuration,,,,,,,B,BAO_0000218,CHEMBL617189,2244
,104784,D,5,,,,13378,,Inhibitory activity against cloned human 5-HT2 receptor,1,Homo sapiens,Autocuration,,,,9606.0,,,B,BAO_0000224,CHEMBL617190,2245
,104784,D,5,,,,2331,,"Tested in vitro for the inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor, expressed in cloned CHO cells",1,Homo sapiens,Autocuration,,449.0,,9606.0,CHO,,B,BAO_0000219,CHEMBL617191,2246
,104784,D,5,,,,2331,,"Tested in vitro for the inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor, expressed in cloned CHO cells.",1,Homo sapiens,Autocuration,,449.0,,9606.0,CHO,,B,BAO_0000219,CHEMBL617192,2247
,104784,D,5,,,,2331,,"Tested in vitro for the inhibition of [3H]-ketanserin binding to 5-hydroxytryptamine 2 receptor, expressed in cloned CHO cells; Inactive",1,Homo sapiens,Autocuration,,449.0,,9606.0,CHO,,B,BAO_0000219,CHEMBL617193,2248
,104784,D,5,,,,2331,,"Tested in vitro for the inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor, expressed in cloned CHO cells; not tested",1,Homo sapiens,Autocuration,,449.0,,9606.0,CHO,,B,BAO_0000219,CHEMBL617194,2249
,104784,H,4,,,,4170,,Binding affinity towards 5-hydroxytryptamine 2 receptor,1,,Autocuration,,,,,,,B,BAO_0000224,CHEMBL617195,2250
,104784,H,4,,,,15453,,Percent decrease in 5-hydroxytryptamine 2 receptor binding using ketanserin,1,,Autocuration,,,,,,,B,BAO_0000224,CHEMBL881830,2251
,17005,H,8,,,,1479,,Binding affinity towards 5-hydroxytryptamine 2 receptor,1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL617196,2252
,104686,H,4,,,,11139,,Binding affinity towards 5-hydroxytryptamine 2- receptor using [3H]ketanserin as radioligand in competitive binding assay,1,,Autocuration,,,,,,,B,BAO_0000224,CHEMBL617197,2253
,17005,H,8,,,,13969,,Binding affinity against 5-hydroxytryptamine 2A receptor was measured using [3H]ketanserin as radioligand,1,,Expert,,,,,,,B,BAO_0000357,CHEMBL617198,2254
,17005,H,8,,,,13392,,Binding affinity towards 5-hydroxytryptamine 2A receptor,1,,Expert,,,,,,,B,BAO_0000357,CHEMBL873476,2255
,17005,H,8,,,,14430,,Affinity towards 5-hydroxytryptamine 2A receptor in membranes from bovine frontal cortex using [3H]ketanserin,1,,Expert,,,,,,,B,BAO_0000019,CHEMBL617199,2256
,107,H,8,,,,13181,,Binding affinity was determined against 5-hydroxytryptamine 2A receptor,1,Cavia porcellus,Autocuration,,,,10141.0,,,B,BAO_0000357,CHEMBL617200,2257
,51,H,8,,,,17200,,Inhibitory constant against cloned human 5-hydroxytryptamine 2A receptor using with [125I]- DOI radioligand,1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL617484,2258
,107,H,8,,,,17200,,Inhibitory constant against cloned human 5-hydroxytryptamine 2A receptor using with [125I]- DOI radioligand,1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL617485,2259
,51,H,8,,,,17200,,Inhibitory constant against cloned human 5-hydroxytryptamine 2A receptor using with [125I]- DOI radioligand,1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL617486,2260
,107,H,8,,,,13463,,Binding affinity analysed on 5-HT 2A human clone using [3H]ketanserin as radioligand,1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL858022,2261
,107,H,8,,,,6347,,Effective concentration against human 5-hydroxytryptamine 2A receptor in CHO cells using 8-OH-DPA radioligand,1,,Autocuration,,449.0,,,CHO,,B,BAO_0000219,CHEMBL617049,2262
,107,D,9,,,,6857,,Functional activity against human 5-hydroxytryptamine 2A receptor expressed in CHO cells using fluorometric imaging plate reader,1,Homo sapiens,Expert,,449.0,,9606.0,CHO,,F,BAO_0000219,CHEMBL617050,2263
,107,H,8,,,,4176,,Functional agonist activity of compound was determined by fluorescence-based assay measuring intracellular calcium mobilization for 5-HT2a receptor cell line,1,,Autocuration,,,,,,,F,BAO_0000219,CHEMBL617051,2264
,107,H,8,,,,4176,,Functional agonist activity of compound was determined by fluorescence-based assay measuring intracellular calcium mobilization for 5-HT2a receptor cell line; no data,1,,Autocuration,,,,,,,F,BAO_0000219,CHEMBL617052,2265
,107,H,8,,,,4176,,Functional antagonist activity of compound was determined by fluorescence-based assay measuring intracellular calcium mobilization for 5-HT2a receptor cell line,1,,Autocuration,,,,,,,F,BAO_0000219,CHEMBL617053,2266
,107,H,8,,,,6347,,"Agonistic binding affinity against human 5-hydroxytryptamine 2A receptor in CHO cells using 8-OH-DPA radioligand, expressed as Emax",1,,Autocuration,,449.0,,,CHO,,B,BAO_0000219,CHEMBL617054,2267
,107,H,8,,,,6347,,"Agonistic binding affinity against human 5-hydroxytryptamine 2A receptor in CHO cells, expressed as Emax",1,,Autocuration,,449.0,,,CHO,,B,BAO_0000219,CHEMBL617055,2268
,107,H,8,,,,15331,,Affinity of compound towards human 5-hydroxytryptamine 2A receptor was evaluated using radioligand binding technique,1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL882924,2269
,107,D,9,,,,16146,,Inhibition of human 5-hydroxytryptamine 2A receptor,1,Homo sapiens,Expert,,,,9606.0,,,B,BAO_0000357,CHEMBL617056,2270
,107,H,8,,,,15250,,Compound was tested for the displacement of [3H]5-HT binding to cloned human 5-hydroxytryptamine 2A receptor stably expressed in CHO cells,1,,Autocuration,,449.0,,,CHO,,B,BAO_0000219,CHEMBL617057,2271
,107,H,8,,,,13631,,Inhibitory concentration against human 5-HT2A receptor in BEK cells,1,,Expert,,,,,,,B,BAO_0000219,CHEMBL617058,2272
,107,H,8,,,,3805,,In vitro binding affinity against human 5-hydroxytryptamine 2A receptor at a concentration of 100 (nM),1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL617059,2273
,107,H,8,,,,4011,,Ability to displace [3H]ketanserin from CHO cells expressing human 5-hydroxytryptamine 2A receptor was determined,1,,Autocuration,,449.0,,,CHO,,B,BAO_0000219,CHEMBL617060,2274
,107,H,8,,,,4012,,Displacement of [3H]ketanserin from CHO cells expressing human 5-hydroxytryptamine 2A receptor.,1,,Expert,,449.0,,,CHO,,B,BAO_0000219,CHEMBL617061,2275
,107,H,8,,,,6366,,Ability to displace [125I]R91150 from human cloned 5-hydroxytryptamine 2A receptor expressed in L929 cells,1,,Expert,,307.0,,,L929,,B,BAO_0000219,CHEMBL617062,2276
,107,H,8,,,,15949,,Ability to displace [3H]ketanserin binding to human 5-hydroxytryptamine 2A receptor stably expressed in CHO cells,1,,Expert,,449.0,,,CHO,,B,BAO_0000219,CHEMBL617063,2277
,107,H,8,,,,14093,,Agonist activity at cloned human 5-hydroxytryptamine 2A receptor using [125I]DOI radioligand,1,,Autocuration,,,,,,,F,BAO_0000019,CHEMBL617064,2278
,107,H,8,,,,13481,,Agonistic activity at cloned human 5-hydroxytryptamine 2A receptor using [125I]DOI as radioligand,1,,Autocuration,,,,,,,F,BAO_0000019,CHEMBL617065,2279
,107,H,8,,,,6347,,Agonistic binding affinity against human 5-hydroxytryptamine 2A receptor in CHO cells using 8-OH-DPA radioligand,1,,Autocuration,,449.0,,,CHO,,B,BAO_0000219,CHEMBL617066,2280
,107,H,8,,,,6347,,Agonistic binding affinity against human 5-hydroxytryptamine 2A receptor in CHO cells using 8-OH-DPA radioligand; Nd means not done,1,,Autocuration,,449.0,,,CHO,,B,BAO_0000219,CHEMBL617067,2281
,107,H,8,,,,14093,,Antagonist activity at cloned human 5-hydroxytryptamine 2A receptor using [3H]-Ketanserin radioligand,1,,Autocuration,,,,,,,F,BAO_0000019,CHEMBL617068,2282
,107,H,8,,,,14093,,Antagonist activity at cloned human 5-hydroxytryptamine 2A receptor using [3H]ketanserin radioligand; Not tested,1,,Autocuration,,,,,,,F,BAO_0000019,CHEMBL617069,2283
,107,H,8,,,,13481,,Antagonistic activity at cloned human 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand,1,,Autocuration,,,,,,,F,BAO_0000019,CHEMBL617070,2284
,107,H,8,,,,14442,,Binding ability of compound at cloned human 5-hydroxytryptamine 2A receptor using [125 I]DOI as radioligand,1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL617071,2285
,107,H,8,,,,14442,,Binding ability of compound at cloned human 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand,1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL872915,2286
,107,H,8,,,,14755,,Binding activity against cloned human 5-hydroxytryptamine 2A receptor using [125I]DOI as the radioligand.,1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL617072,2287
,107,H,8,,,,16441,,Binding affinity against 5-hydroxytryptamine 2A receptor in humans,1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL617073,2288
,107,H,8,,,,14744,,Binding affinity against the cloned human 5-hydroxytryptamine 2A receptor using [125I]DOI as the radioligand,1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL617074,2289
,107,H,8,,,,16659,,Binding affinity for displacement of [3H]ketanserin to human 5-hydroxytryptamine 2A receptor stably expressed in CHO cells,1,,Expert,,449.0,,,CHO,,B,BAO_0000219,CHEMBL617075,2290
,107,H,8,,,,3307,,Binding affinity of compound to human 5-hydroxytryptamine 2A receptor,1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL617076,2291
,107,D,9,,,,6857,,Affinity for human 5-hydroxytryptamine 2A receptor expressed in mammalian cell line,1,Homo sapiens,Expert,,,,9606.0,,,B,BAO_0000019,CHEMBL617077,2292
,107,H,8,,,,5635,,Binding affinity against 5-hydroxytryptamine 2A receptor using [125I]DOI radioligand.,1,,Expert,,,,,,,B,BAO_0000357,CHEMBL617078,2293
,107,D,9,,,,4234,,Binding affinity to cloned human 5-hydroxytryptamine 2A receptor,1,Homo sapiens,Expert,,,,9606.0,,,B,BAO_0000357,CHEMBL617079,2294
,107,H,8,,,,15527,,Binding affinity towards 5-hydroxytryptamine 2A receptor using [3H]5-HT as radioligand.,1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL617080,2295
,107,H,8,,,,6588,,Binding affinity towards human 5-hydroxytryptamine 2A receptor by the displacement of [3H]ketanserin radioligand from the cloned receptor expressed in CHO cells,1,,Expert,,449.0,,,CHO,,B,BAO_0000219,CHEMBL617081,2296
,107,H,8,,,,13631,,Binding affinity towards human 5-HT2A receptor in BEK cells,1,,Expert,,,,,,,B,BAO_0000219,CHEMBL617082,2297
,107,H,8,,,,17723,,Binding affinity towards human serotonin 5-hydroxytryptamine 2A receptor,1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL617083,2298
,107,H,8,,,,14770,,Binding affinity for recombinant human 5-hydroxytryptamine 2A receptor using [3H]5-HT as radioligand.,1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL617084,2299
,107,D,9,,,,16293,,Binding affinity for human 5-hydroxytryptamine 2A receptor,1,Homo sapiens,Expert,,,,9606.0,,,B,BAO_0000357,CHEMBL617085,2300
,107,H,8,,,,16209,,Binding affinity towards human 5-hydroxytryptamine 2A receptor using [125I]DOI as radioligand,1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL617086,2301
,107,H,8,,,,12469,,Binding affinity was measured on 5-hydroxytryptamine 2A receptor in GF6 cells transfected with human 5-HT2A gene labeled with [3H]ketanserin,1,,Autocuration,,,,,,,B,BAO_0000219,CHEMBL617087,2302
,107,H,8,,,,15363,,Compound was tested for the displacement of [125I]-DOI from clone human 5-hydroxytryptamine 2A receptor,1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL617088,2303
,107,H,8,,,,15363,,Compound was tested for the displacement of [125I]DOI from cloned human 5-hydroxytryptamine 2A receptor,1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL617089,2304
,107,H,8,,,,16441,,"Tested on genetically transfected COS7 cell membranes selectively expressing human 5-hydroxytryptamine 2A receptor, using [3H]ketanserin as radioligand",1,,Expert,,,,,,,B,BAO_0000019,CHEMBL617090,2305
,107,H,8,,,,8,,In vitro binding affinity towards 5-hydroxytryptamine 2A receptor in human using [3H]ketanserin as radioligand,1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL617513,2306
,107,H,8,,,,4176,,In vitro binding affinity towards human 5-hydroxytryptamine 2A receptor expressed in HEK293 cells was determined using [3H]ketanserin as radioligand,1,,Autocuration,,722.0,,,HEK293,,B,BAO_0000219,CHEMBL617514,2307
,107,H,8,,,,17085,,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 2A receptor,1,,Autocuration,,,,,,,B,BAO_0000019,CHEMBL617515,2308
,107,H,8,,,,17200,,Inhibitory constant against cloned human 5-hydroxytryptamine 2A receptor using with [125I]- DOI radioligand,1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL617516,2309
,107,D,9,,,,17200,,Inhibitory constant determined against cloned human 5-hydroxytryptamine 2A receptor using with [125I]- DOI radioligand,1,Homo sapiens,Expert,,,,9606.0,,,B,BAO_0000357,CHEMBL617517,2310
,107,D,9,,,,4013,,Displacement of [3H]ketanserin from human 5-hydroxytryptamine 2A receptor expressed in CHO cells,1,Homo sapiens,Expert,,449.0,,9606.0,CHO,,B,BAO_0000219,CHEMBL617518,2311
,107,H,8,,,,5088,,Tested for binding affinity towards 5-hydroxytryptamine 2A receptor,1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL617519,2312
,107,D,9,,,,5088,,Displacement of [3H]DOB from human 5-hydroxytryptamine 2A receptor,1,Homo sapiens,Expert,,,,9606.0,,,B,BAO_0000357,CHEMBL617520,2313
,107,H,8,,,,5088,,Tested for binding affinity towards 5-hydroxytryptamine 2A receptor using [3H]DOB as labeled ligand; binding data not obtained,1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL617521,2314
,107,D,9,,,,5088,,Displacement of [3H]ketanserin from human 5-hydroxytryptamine 2A receptor,1,Homo sapiens,Expert,,,,9606.0,,,B,BAO_0000357,CHEMBL617522,2315
,107,H,8,,,,5088,,Tested for binding affinity towards human 5-hydroxytryptamine 2A receptor using [3H]5-HT as radioligand,1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL617523,2316
,107,H,8,,,,5088,,Tested for binding affinity towards human 5-hydroxytryptamine 2A receptor using [3H]DOB as radioligand,1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL617524,2317
,104686,H,4,,,,9786,,Ability to displace 0.75 nM [3H]ketanserin in 5-hydroxytryptamine 2 receptor from rat frontal cortex homogenate,1,,Autocuration,,,,,,,B,BAO_0000019,CHEMBL617525,2318
,104686,D,5,,,,9205,,Ability to inhibit [3H]spiperone binding to 5-hydroxytryptamine 2 receptor determined in rat,1,Rattus norvegicus,Autocuration,,,,10116.0,,,B,BAO_0000019,CHEMBL617526,2319
,104686,H,4,,,,11257,,Affinity on 5-hydroxytryptamine 2 receptor labeled by [125I]DOI,1,,Autocuration,,,,,,,B,BAO_0000224,CHEMBL617527,2320
,104686,H,4,,,,9362,,Affinity towards [3H]- DOB -labeled 5-hydroxytryptamine 2 receptor sites in rat cortical homogenates,1,,Autocuration,,,,,,,B,BAO_0000019,CHEMBL617528,2321
,104686,H,4,,,,9362,,Affinity towards [3H]- ketanserin-labeled 5-hydroxytryptamine 2 receptor sites in rat cortical homogenates,1,,Autocuration,,,,,,,B,BAO_0000019,CHEMBL617529,2322
,104686,H,4,,,,10590,,Inhibition of 5-hydroxytryptamine 2 induced vasoconstriction of rat caudal artery.,1,,Autocuration,,,,,,,B,BAO_0000224,CHEMBL617530,2323
,104686,H,4,,,,10468,,Binding affinity against 5-hydroxytryptamine 2 receptor of rat frontal cortex using [3H]ketanserin radioligand,1,,Autocuration,,,,,,,B,BAO_0000019,CHEMBL617531,2324
,104686,H,4,,,,13050,,Binding affinity against 5-hydroxytryptamine 2 receptor from rat frontal cortex using [125]-(R)-DOI as radioligand,1,,Autocuration,,,,,,,B,BAO_0000019,CHEMBL617532,2325
,104686,H,4,,,,11624,,Binding affinity against 5-hydroxytryptamine 2 receptor in rat using [3H]ketanserin as radioligand,1,,Autocuration,,,,,,,B,BAO_0000019,CHEMBL617533,2326
,104686,H,4,,,,10468,,Binding affinity against 5-hydroxytryptamine 2 receptor of rat frontal cortex using [3H]ketanserin radioligand,1,,Autocuration,,,,,,,B,BAO_0000019,CHEMBL617534,2327
,104686,H,4,,,,10330,,Binding affinity against 5-hydroxytryptamine 2 receptor using [3H]ketanserin as radioligand,1,,Autocuration,,,,,,,B,BAO_0000224,CHEMBL617535,2328
,104686,H,4,,,,10062,,Binding affinity at rat 5-hydroxytryptamine 2 receptor by [3H]ketanserin displacement.,1,,Autocuration,,,,,,,B,BAO_0000224,CHEMBL617536,2329
,104686,H,4,,,,11642,,Binding affinity determined in radioreceptor binding assay by using [3H]ketanserin radioligand against 5-hydroxytryptamine 2 receptor,1,,Autocuration,,,,,,,B,BAO_0000224,CHEMBL617537,2330
,104686,H,4,,,,10062,,Binding affinity determined in radioreceptor binding assay by using [3H]ketanserin radioligand against 5-hydroxytryptamine 2 receptor,1,,Autocuration,,,,,,,B,BAO_0000224,CHEMBL617538,2331
,104686,H,4,In vitro,,,13427,,Binding affinity of [3H]ketanserin towards 5-hydroxytryptamine 2 receptor in cloned mammalian receptor expressed in cultured cells or from rat whole brain.,1,,Autocuration,,,,,,,B,BAO_0000219,CHEMBL617539,2332
,104686,D,5,,,,12280,,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor,1,Rattus norvegicus,Autocuration,,,,10116.0,,,B,BAO_0000224,CHEMBL617540,2333
,104686,D,5,,,,4101,,Binding affinity for 5-hydroxytryptamine 2 receptor from striata of male Wistar rats by displacement of [3H]ketanserin,1,Rattus norvegicus,Autocuration,,,,10116.0,,,B,BAO_0000224,CHEMBL617541,2334
,104686,H,4,,,,10062,,Binding affinity in radioreceptor binding assay by using [3H]5-HT radioligand against 5-hydroxytryptamine 2 receptor,1,,Autocuration,,,,,,,B,BAO_0000224,CHEMBL617542,2335
,104686,H,4,,,,11147,,Binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]DOB as,1,,Autocuration,,,,,,,B,BAO_0000224,CHEMBL617543,2336
,104686,D,5,,,,2395,,Binding affinity against [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor expressed in CHO-K1 cells,1,Rattus norvegicus,Autocuration,,485.0,,10116.0,CHO-K1,,B,BAO_0000219,CHEMBL617544,2337
,104686,D,5,,,,2395,,Binding affinity against [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor expressed in CHO-K1 cells,1,Rattus norvegicus,Autocuration,,485.0,,10116.0,CHO-K1,,B,BAO_0000219,CHEMBL617545,2338
,104686,D,5,,,,9098,,Binding affinity to rat cortical membranes at 5-hydroxytryptamine 2 receptor binding site by using [3H]- DOB as a radioligand,1,Rattus norvegicus,Autocuration,,,,10116.0,,,B,BAO_0000019,CHEMBL617413,2339
,104686,H,4,,,,9098,,Binding affinity to rat cortical membranes at 5-hydroxytryptamine 2 receptor binding site by using [3H]- DOB as a radioligand.,1,,Autocuration,,,,,,,B,BAO_0000019,CHEMBL617414,2340
,104686,D,5,,,,9098,,Binding affinity to 5-hydroxytryptamine 2 receptor of rat cortical membranes using [3H]- DOB; ND means no data.,1,Rattus norvegicus,Autocuration,,,,10116.0,,,B,BAO_0000019,CHEMBL617415,2341
,104686,H,4,,,,9443,,Binding affinity towards 5-hydroxytryptamine 2 receptor,1,,Autocuration,,,,,,,B,BAO_0000224,CHEMBL617416,2342
,104686,H,4,,,,9443,,Binding affinity towards 5-hydroxytryptamine 2 receptor at 1.0 uM concentration,1,,Autocuration,,,,,,,B,BAO_0000224,CHEMBL617417,2343
,104686,H,4,,,,9699,,"Binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]- 1-(4-bromo-2,5-dimethoxy-phenyl)-2-aminopropane (D) as radioligand in rat frontal cortex",1,,Autocuration,,,,,,,B,BAO_0000019,CHEMBL617418,2344
,104686,H,4,,,,9699,,Binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]- ketanserin as radioligand in rat frontal cortex,1,,Autocuration,,,,,,,B,BAO_0000019,CHEMBL617419,2345
,104686,H,4,,,,9098,,Binding affinity towards 5-hydroxytryptamine 2 receptor was determined,1,,Autocuration,,,,,,,B,BAO_0000224,CHEMBL617420,2346
,104686,D,5,,,,3070,,Affinity for 5-hydroxytryptamine 2 receptor,1,Rattus norvegicus,Autocuration,,,,10116.0,,,B,BAO_0000224,CHEMBL617421,2347
,104686,H,4,,,,9547,,Binding affinity towards serotonin 5-hydroxytryptamine 2 receptor of rat determined using 0.5 nM of [3H]ketanserin in binding assay,1,,Autocuration,,,,,,,B,BAO_0000224,CHEMBL617422,2348
,104686,H,4,,,,10444,,Binding affinity was determined against 5-hydroxytryptamine 2 receptor from male Sprague-Dawley rat brain.,1,,Autocuration,,,,,,,B,BAO_0000019,CHEMBL617423,2349
,104686,H,4,,,,14617,,Binding affinity which represents concentration giving half-maximal inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor from rat tissue homogenate,1,,Autocuration,,,,,,,B,BAO_0000019,CHEMBL617424,2350
,104686,H,4,,,,14617,,Binding affinity which represents concentration giving half-maximal inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor rat tissue homogenate,1,,Autocuration,,,,,,,B,BAO_0000019,CHEMBL617425,2351
,104686,H,4,,,,11130,,Binding constant against 5-hydroxytryptamine 2 receptor (in vitro),1,,Autocuration,,,,,,,B,BAO_0000224,CHEMBL617426,2352
,104686,H,4,In vivo,,,11130,,Binding constant against 5-hydroxytryptamine 2 receptor (in vivo),1,,Autocuration,,,,,,,B,BAO_0000218,CHEMBL617427,2353
Brain,104686,H,4,,,,14542,,Compound is evaluated for binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]ketanserin in rat brain,1,,Autocuration,,,,,,955.0,B,BAO_0000221,CHEMBL617428,2354
,104686,H,4,,,,2797,,Compound was evaluated for binding affinity against 5-hydroxytryptamine 2 receptor from rat,1,,Autocuration,,,,,,,B,BAO_0000224,CHEMBL617429,2355
,104686,H,4,,,,11332,,Compound was evaluated for in vitro binding affinity towards 5-hydroxytryptamine 2 receptor in rat cortex using [3H]- spiperone as radioligand,1,,Autocuration,,,,,,,B,BAO_0000019,CHEMBL617430,2356
,104686,H,4,,,,11332,,Compound was evaluated for in vitro binding affinity towards serotonin 5-hydroxytryptamine 2 receptor in rat cortex using [3H]- spiperone as radioligand,1,,Autocuration,,,,,,,B,BAO_0000019,CHEMBL617431,2357
Frontal cortex,104686,H,4,,,,10752,,Compound was evaluated for its ability to displace 0.25 nM [125I](R)-DOI from binding sites in rat frontal cortex.,1,,Autocuration,,,,,,1870.0,B,BAO_0000019,CHEMBL617432,2358
,104686,H,4,,,,1185,,Ability to displace [3H]ketanserin from serotonergic 5-hydroxytryptamine 2 receptor,1,,Autocuration,,,,,,,B,BAO_0000224,CHEMBL617433,2359
,104686,H,4,,,,1185,,Compound was evaluated for its ability to displace [3H]ketanserin from serotonergic 5-hydroxytryptamine 2 receptor,1,,Autocuration,,,,,,,B,BAO_0000224,CHEMBL617434,2360
,104686,D,5,,,,11624,,Binding affinity against 5-Hydroxy tryptamine 2 (5-hydroxytryptamine 2)receptor,1,Rattus norvegicus,Autocuration,,,,10116.0,,,B,BAO_0000224,CHEMBL617435,2361
,104686,H,4,,,,1344,,Compound was evaluated for its binding affinity to 5-hydroxytryptamine 2 receptor in rat cortex using [3H]ketanserin radioligand assay,1,,Autocuration,,,,,,,B,BAO_0000019,CHEMBL617436,2362
Striatum,104686,D,5,,,,15453,,Binding affinity against 5-hydroxytryptamine 2 receptor in rat striatum using [3H]-RP62203,1,Rattus norvegicus,Autocuration,,,,10116.0,,2435.0,B,BAO_0000019,CHEMBL617437,2363
,104686,H,4,,,,11662,,"Binding affinity towards 5-hydroxytryptamine 2 receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]ketanserin as radioligand",1,,Autocuration,,,,,,,B,BAO_0000019,CHEMBL617438,2364
,104686,H,4,,,,11662,,"Compound was tested for binding affinity towards 5-hydroxytryptamine 2 receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]ketanserin as radioligand; Not Determined",1,,Autocuration,,,,,,,B,BAO_0000019,CHEMBL617439,2365
,104686,H,4,,,,10796,,Compound was tested in vitro for binding affinity for 5-hydroxytryptamine 2 receptor,1,,Autocuration,,,,,,,B,BAO_0000224,CHEMBL617440,2366
,104686,H,4,,,,9069,,Evaluated for binding activity against [3H]ketanserin as radioligand for 5-hydroxytryptamine 2 receptor,1,,Autocuration,,,,,,,B,BAO_0000224,CHEMBL617441,2367
,104686,D,5,,,,8814,,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor of rat cortical membrane homogenates,1,Rattus norvegicus,Autocuration,,,,10116.0,,,B,BAO_0000019,CHEMBL872918,2368
,104686,D,5,,,,8908,,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor of rat cortex,1,Rattus norvegicus,Autocuration,,,,10116.0,,,B,BAO_0000019,CHEMBL617442,2369
,104686,H,4,,,,9098,,Evaluated for the binding affinity to rat cortical membranes at 5-hydroxytryptamine 2 receptor binding site by using [3H]- KET as a radioligand; ND means no data.,1,,Autocuration,,,,,,,B,BAO_0000019,CHEMBL617443,2370
,104686,H,4,,,,9098,,Binding affinity to rat cortical membranes at 5-hydroxytryptamine 2 (5-HT2) receptor using [3H]KET as a radioligand,1,,Autocuration,,,,,,,B,BAO_0000019,CHEMBL617444,2371
,104686,H,4,,,,9098,,Evaluated for the binding affinity to rat cortical membranes at 5-hydroxytryptamine 2 receptor binding site by using [3H]- KET as a radioligand; ND means no data.,1,,Autocuration,,,,,,,B,BAO_0000019,CHEMBL617445,2372
,104686,H,4,,,,9098,,Evaluated for the binding affinity to rat cortical membranes at 5-hydroxytryptamine 2 receptor binding site by using [3H]- KET as a radioligand.,1,,Autocuration,,,,,,,B,BAO_0000019,CHEMBL617446,2373
,104686,H,4,,,,9098,,Binding affinity to 5-hydroxytryptamine 2 receptor in rat frontal cortical membranes by [3H]- KET displacement.,1,,Autocuration,,,,,,,B,BAO_0000249,CHEMBL617447,2374
,104686,H,4,,,,9098,,Evaluated for the binding affinity to rat frontal cortical membranes at 5-hydroxytryptamine 2 receptor binding site by using [3H]- KET as a radioligand.;ND is not determined,1,,Autocuration,,,,,,,B,BAO_0000019,CHEMBL617448,2375
,104686,H,4,,,,9098,,Evaluated for the binding affinity to rat frontal cortical membranes at 5-hydroxytryptamine 2 receptor binding site by using [3H]- KET as a radioligand;ND means no data,1,,Autocuration,,,,,,,B,BAO_0000019,CHEMBL617449,2376
,104686,H,4,,,,9161,,In vitro binding affinity at 5-hydroxytryptamine 2 receptor in rat cortical tissue by [3H]spiperone displacement; No data.,1,,Autocuration,,,,,,,B,BAO_0000019,CHEMBL617450,2377
,104686,H,4,,,,9161,,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue; value may range from 165 to 263,1,,Autocuration,,,,,,,B,BAO_0000019,CHEMBL617451,2378
,104686,H,4,,,,9161,,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue; value may range from 2.4 to 5.3,1,,Autocuration,,,,,,,B,BAO_0000019,CHEMBL617452,2379
,104686,H,4,,,,9161,,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]-Spiperone as the radioligand in rat cortical tissue.,1,,Autocuration,,,,,,,B,BAO_0000019,CHEMBL617453,2380
,104686,H,4,,,,9161,,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue.; value may range from 140 to 980,1,,Autocuration,,,,,,,B,BAO_0000019,CHEMBL617660,2381
,104686,H,4,,,,9161,,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue.; value may range from 76 to 299,1,,Autocuration,,,,,,,B,BAO_0000019,CHEMBL617661,2382
,104686,H,4,,,,9161,,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]-Spiperone as the radioligand in rat cortical tissue; value may range from 12 to 66,1,,Autocuration,,,,,,,B,BAO_0000019,CHEMBL617662,2383
,104686,H,4,,,,9161,,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue; value may range from 136 to 220,1,,Autocuration,,,,,,,B,BAO_0000019,CHEMBL872919,2384
,104686,H,4,,,,9161,,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue; value may range from 197 to 341,1,,Autocuration,,,,,,,B,BAO_0000019,CHEMBL617663,2385
,104686,H,4,,,,9161,,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue; value may range from 23 to 187,1,,Autocuration,,,,,,,B,BAO_0000019,CHEMBL617664,2386
,104686,H,4,,,,9161,,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue; value may range from 29 to 132,1,,Autocuration,,,,,,,B,BAO_0000019,CHEMBL617665,2387
,104686,H,4,,,,9161,,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue; value may range from 6 to 75,1,,Autocuration,,,,,,,B,BAO_0000019,CHEMBL617666,2388
,104686,H,4,,,,12094,,In vitro binding affinity on 5-hydroxytryptamine 2 receptor is inhibition of binding of [125I]- I-LSD to P11 cells,1,,Autocuration,,,,,,,B,BAO_0000019,CHEMBL617667,2389
,104686,H,4,,,,12018,,In vitro binding affinity towards 5-hydroxytryptamine 2 receptor in rat striatal membranes by [3H]ketanserin displacement.,1,,Autocuration,,,,,,,B,BAO_0000249,CHEMBL617668,2390
,104686,H,4,,,,10394,,Inhibitory activity against 5-hydroxytryptamine 2 receptor in rat cortical membranes using [3H]ketanserin as a radioligand,1,,Autocuration,,,,,,,B,BAO_0000249,CHEMBL617669,2391
,104686,H,4,,,,15260,,Inhibitory activity against rat cortical 5-hydroxytryptamine 2 receptor,1,,Autocuration,,,,,,,B,BAO_0000224,CHEMBL617670,2392
,104686,D,5,,,,11624,,Inhibitory constant against 5-hydroxytryptamine 2 receptor,1,Rattus norvegicus,Autocuration,,,,10116.0,,,B,BAO_0000224,CHEMBL617671,2393
,104686,H,4,,,,13654,,Percentage specific displacement of radioligand [3H]-ketanserin from 5-hydroxytryptamine 2 receptor,1,,Autocuration,,,,,,,B,BAO_0000224,CHEMBL617672,2394
,104686,H,4,,,,9541,,Potency to displace [3H]- Spiperone from 5-hydroxytryptamine 2 receptor in rat striatum,1,,Autocuration,,,,,,,B,BAO_0000019,CHEMBL617673,2395
,104686,H,4,,,,11933,,Tested for binding affinity against 5-hydroxytryptamine 2 receptor from rat frontal cortical regions using [3H]ketanserin as radioligand,1,,Autocuration,,,,,,,B,BAO_0000224,CHEMBL617674,2396
,104686,H,4,,,,15538,,Tested for binding affinity by measuring displacement of [3H]ketanserin from rat serotonin 5-hydroxytryptamine 2 receptor in rat cortex,1,,Autocuration,,,,,,,B,BAO_0000019,CHEMBL617675,2397
,104686,H,4,,,,15538,,Tested for binding affinity by measuring displacement of [3H]ketanserin from rat serotonin 5-hydroxytryptamine 2 receptor in rat cortex; NA means Not Active,1,,Autocuration,,,,,,,B,BAO_0000019,CHEMBL617676,2398
,104686,H,4,,,,15538,,Tested for binding affinity by measuring displacement of [3H]ketanserin from rat serotonin 5-hydroxytryptamine 2 receptor in rat cortex; not determined,1,,Autocuration,,,,,,,B,BAO_0000019,CHEMBL617677,2399
,104686,D,5,,,,8841,,Displacement of [3H]ketanserin from rat prefrontal cortex 5-hydroxytryptamine 2 receptor,1,,Autocuration,,,,,,,B,BAO_0000019,CHEMBL617678,2400
,104686,H,4,,,,1455,,Binding affinity to 5-hydroxytryptamine 2 receptor using [3H]ketanserin radioligand assay.,1,,Autocuration,,,,,,,B,BAO_0000224,CHEMBL617679,2401
,104686,H,4,,,,1455,,Tested for its binding affinity to Tested for its binding affinity to 5-hydroxytryptamine 2 receptor using [3H]-ketanserin radioligand assay using [3H]-ketanserin radioligand assay,1,,Autocuration,,,,,,,B,BAO_0000224,CHEMBL617680,2402
,104686,H,4,,,,11752,,The ability to inhibit [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor in rat whole brain,1,,Autocuration,,,,,,,B,BAO_0000019,CHEMBL617681,2403
Brain,104686,H,4,,,,11642,,The binding affinity was measured on 5-hydroxytryptamine 2 receptor in rat brain tissue,1,,Autocuration,,,,,,955.0,B,BAO_0000221,CHEMBL617682,2404
,104686,H,4,,,,12092,,The binding affinity was measured on 5-hydroxytryptamine 2 receptor using [3H]- spiperone as radioligand.,1,,Autocuration,,,,,,,B,BAO_0000224,CHEMBL617683,2405
,104686,H,4,,,,3967,,Binding affinity at 5-hydroxytryptamine 2 receptor from striata wistar rats by [3H]ketanserin displacement.,1,,Autocuration,,,,,,,B,BAO_0000224,CHEMBL617684,2406
,104686,D,5,,,,12771,,Binding affinity towards 5-hydroxytryptamine 2 receptor,1,Rattus norvegicus,Autocuration,,,,10116.0,,,B,BAO_0000224,CHEMBL617685,2407
,104686,H,4,,,,11642,,The compound was tested for its binding affinity towards 5-hydroxytryptamine 2 receptor by displacing [3H]ketanserin radioligand in rat cerebral cortex,1,,Autocuration,,,,,,,B,BAO_0000019,CHEMBL617686,2408
,104686,H,4,,,,11628,,The compound was tested in vitro for binding affinity towards 5-hydroxytryptamine 2 receptor by displacing [125]I-LSD radioligand,1,,Autocuration,,,,,,,B,BAO_0000224,CHEMBL617687,2409
,104686,H,4,,,,13654,,Percentage specific displacement of radioligand [3H]ketanserin from 5-hydroxytryptamine 2 receptor,1,,Autocuration,,,,,,,B,BAO_0000224,CHEMBL617688,2410
,104686,H,4,,,,11200,,In vitro antagonistic activity against the contraction induced by 5-HT through 5-hydroxytryptamine 2 receptor in rat thoracic aortic strips,1,,Autocuration,,,,,,,F,BAO_0000019,CHEMBL617689,2411
,104686,H,4,,,,11200,,In vitro antagonistic activity against the contraction induced by 5-HT through 5-hydroxytryptamine 2 receptor in rat thoracic aortic strips,1,,Autocuration,,,,,,,F,BAO_0000019,CHEMBL617690,2412
,104686,H,4,In vivo,,,11200,,"In vivo inhibitory activity of 10 mg/kg compound in rats against elevation of BP caused by 5-HT (300 ug/kg, iv) through 5-hydroxytryptamine 2 receptor 1 hr after oral administration",1,,Autocuration,,,,,,,F,BAO_0000218,CHEMBL617691,2413
,104686,H,4,In vivo,,,11200,,"In vivo inhibitory activity of 10 mg/kg compound in rats against elevation of BP caused by 5-HT (300 ug/kg, iv) through 5-hydroxytryptamine 2 receptor 3h after oral administration",1,,Autocuration,,,,,,,F,BAO_0000218,CHEMBL617692,2414
,104686,H,4,In vivo,,,11200,,"In vivo inhibitory activity of 3 mg/kg compound in rats against elevation of BP caused by 5-HT (300 ug/kg, iv) through 5-hydroxytryptamine 2 receptor 1 hr after oral administration",1,,Autocuration,,,,,,,F,BAO_0000218,CHEMBL617693,2415
,104686,H,4,In vivo,,,11200,,"In vivo inhibitory activity of 3 mg/kg compound in rats against elevation of BP caused by 5-HT (300 ug/kg, iv) through 5-hydroxytryptamine 2 receptor 3h after oral administration",1,,Autocuration,,,,,,,F,BAO_0000218,CHEMBL617694,2416
Brain,12687,H,8,,,,15436,,Affinity for 5-hydroxytryptamine 2A receptor in rat brain cortex by ability to displace [3H]ketanserin,1,,Expert,,,,,,955.0,B,BAO_0000221,CHEMBL857985,2417
,12687,D,9,,,,15436,,Affinity at 5-hydroxytryptamine 2A receptor of the rat brain cortex was assessed on the basis of their ability to displace [3H]ketanserin,1,Rattus norvegicus,Expert,,,,10116.0,,,B,BAO_0000019,CHEMBL617695,2418
,12687,H,8,,,,14025,,Affinity pKi for 5-hydroxytryptamine 2A receptor was measured in rat cortex homogenates,1,,Autocuration,,,,,,,B,BAO_0000019,CHEMBL617696,2419
,12687,H,8,,,,4342,,Binding affinity of compound towards serotonin 5-hydroxytryptamine 2A receptor was determined,1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL617697,2420
,12687,D,9,,,,13735,,Displacement of [3H]ketanserin from 5-HT2A receptor of rat frontal cortex,1,Rattus norvegicus,Expert,,,,10116.0,,,B,BAO_0000019,CHEMBL617257,2421
,12687,D,9,,,,5816,,Binding affinity towards 5-hydroxytryptamine 2A receptor using [3H]ketanserin,1,Rattus norvegicus,Expert,,,,10116.0,,,B,BAO_0000357,CHEMBL617258,2422
,12687,H,8,,,,14287,,Binding affinity was evaluated in vitro by displacement of [3H]ketanserin from 5-hydroxytryptamine 2A receptor on rat cortical membrane,1,,Expert,,,,,,,B,BAO_0000019,CHEMBL617259,2423
,12687,H,8,,,,15738,,In vitro affinity against serotonin ( 5-hydroxytryptamine 2A receptor ) receptor,1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL617260,2424
,12687,D,9,,,,15738,,In vitro affinity against serotonin 5-hydroxytryptamine 2A receptor,1,Rattus norvegicus,Expert,,,,10116.0,,,B,BAO_0000357,CHEMBL617261,2425
,12687,H,8,,,,15026,,Compound was tested in vitro for its binding affinity towards 5-hydroxytryptamine 2A receptor from rat frontal cortex using [3H]-ketanserin as radioligand,1,,Autocuration,,,,,,,B,BAO_0000019,CHEMBL617262,2426
,12687,H,8,,,,16647,,Half-maximal inhibition of [3H]- Ketanserin binding to 5-hydroxytryptamine 2A receptor in rat cerebral cortex homogenate,1,,Expert,,,,,,,B,BAO_0000019,CHEMBL617263,2427
,12687,H,8,,,,16647,,Half-maximal inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2A receptor in rat tissue homogenate,1,,Autocuration,,,,,,,B,BAO_0000019,CHEMBL617264,2428
,12687,D,9,,,,13345,,Displacement of [3H]-ketanserin from rat brain 5-hydroxytryptamine 2A receptor,1,Rattus norvegicus,Expert,,,,10116.0,,,B,BAO_0000019,CHEMBL617265,2429
,12687,H,8,,,Membranes,1543,,Inhibition constant for in vitro inhibition of [3H]ketanserin binding to rat frontal cortex membranes 5-hydroxytryptamine 2A receptor,1,,Autocuration,,,,,,,B,BAO_0000249,CHEMBL617266,2430
,12687,H,8,,,,12444,,Inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2A receptor rat frontal cortex membrane,1,,Autocuration,,,,,,,B,BAO_0000019,CHEMBL617267,2431
,12687,H,8,,,,16404,,Inhibitory constant on 5-hydroxytryptamine 2A receptor of Rat frontal cortex,1,,Expert,,,,,,,B,BAO_0000019,CHEMBL617268,2432
,12687,H,8,,,,16404,,Inhibitory constant on human 5-hydroxytryptamine 2A receptor transfected in to CHO cells,1,,Autocuration,,449.0,,,CHO,,B,BAO_0000219,CHEMBL617269,2433
,12687,H,8,,,,15577,,Kinetic inhibition constant evaluated by measuring serotonergic activity,1,,Expert,,,,,,,B,BAO_0000357,CHEMBL617323,2434
,12687,H,8,,,,15577,,Serotonergic activity of the compound.,1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL617324,2435
,12687,H,8,,,,2495,,Tested in vitro for its ability to inhibit [3H]ketanserin binding to 5-hydroxytryptamine 2A receptor in rat frontal cortex membranes,1,,Autocuration,,,,,,,B,BAO_0000249,CHEMBL617325,2436
,12687,D,9,,,,15042,,The binding affinity was evaluated on 5-hydroxytryptamine 2A receptor expressed in rat cortex by using [3H]ketanserin as radioligand.,1,Rattus norvegicus,Expert,,,,10116.0,,,B,BAO_0000019,CHEMBL617326,2437
,12687,H,8,,,,15026,,In vitro ability to displace [3H]ketanserin binding from 5-hydroxytryptamine 2A receptor in rat striatal membrane.,1,,Expert,,,,,,,B,BAO_0000249,CHEMBL617327,2438
,12687,D,9,,,,12919,,Agonistic activity against 5-hydroxytryptamine 2A receptor in rat cortex using [3H]ketanserin,1,Rattus norvegicus,Expert,,,,10116.0,,,F,BAO_0000019,CHEMBL617328,2439
,12687,D,9,,,,12919,,Agonistic activity against 5-hydroxytryptamine 2A receptor in rat cortex using [3H]ketanserin,1,Rattus norvegicus,Expert,,,,10116.0,,,F,BAO_0000019,CHEMBL617329,2440
,12687,D,9,,,,12919,,Agonistic activity against 5-hydroxytryptamine 2A receptor in rat cortex using [3H]ketanserin,1,Rattus norvegicus,Expert,,,,10116.0,,,F,BAO_0000019,CHEMBL617330,2441
,12687,H,8,,,,15194,,The compound was tested for the binding affinity against 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand,1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL617331,2442
,12687,H,8,,,,15194,,The compound was tested for the binding affinity against 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand.,1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL617332,2443
,107,H,8,,,,4820,,Binding affinity towards 5-hydroxytryptamine 2A receptor,1,,Expert,,,,,,,B,BAO_0000357,CHEMBL617333,2444
,107,H,8,,,,6736,,Binding affinity against serotonin 5-hydroxytryptamine 2A receptor was determined using human [125I]-eotaxin,1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL617334,2445
,107,H,8,,,,5163,,Binding affinity towards 5-hydroxytryptamine 2A receptor was determined at a concentration of 0.000001 mol/L,1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL617335,2446
,107,H,8,,,,5163,,Binding affinity towards 5-hydroxytryptamine 2A receptor was determined at a concentration of 0.00001 mol/L,1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL617336,2447
,107,H,8,,,,6011,,Inhibition of binding towards 5-hydroxytryptamine 2A receptor at 100 nM concentration,1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL617337,2448
,107,D,9,,,,14294,,Percent inhibition against 5-hydroxytryptamine 2A receptor using [3H]ketanserin at 1 uM,1,Homo sapiens,Expert,,,,9606.0,,,B,BAO_0000357,CHEMBL617338,2449
,107,H,8,,,,5014,,Percent inhibition (at 1 uM) against 5-hydroxytryptamine 2A receptor,1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL617339,2450
,107,H,8,,,,17066,,Binding affinity towards 5-hydroxytryptamine 2A receptor,1,,Expert,,,,,,,B,BAO_0000357,CHEMBL617340,2451
,107,H,8,,,,17515,,Binding affinity of compound towards serotonin 5-hydroxytryptamine 2A receptor; inactive at 10 uM,1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL617341,2452
,107,H,8,,,,6736,,Inhibition of [125I]-eotaxin binding to serotonin 5-hydroxytryptamine 2A receptor,1,,Expert,,,,,,,B,BAO_0000357,CHEMBL617342,2453
,107,H,8,,,,5163,,Affinity for 5-hydroxytryptamine 2A receptor,1,,Expert,,,,,,,B,BAO_0000357,CHEMBL617343,2454
,107,H,8,,,,16911,,Binding affinity was performed using [3H]ketanserin as the radioligand and stably transfected NIH3T3 cells expressing the 5-hydroxytryptamine 2A receptor (GF-62 cells).,1,,Expert,,723.0,,,NIH3T3,,B,BAO_0000219,CHEMBL617344,2455
,107,H,8,,,,6841,,Binding affinity towards 5-hydroxytryptamine 2A receptor using [3H]ketanserin,1,,Expert,,,,,,,B,BAO_0000357,CHEMBL617345,2456
,107,H,8,,,,6119,,Binding affinity towards 5-hydroxytryptamine 2A receptor using [125I]DOI as radioligand.,1,,Expert,,,,,,,B,BAO_0000357,CHEMBL617346,2457
,107,H,8,,,,3962,,Compound was evaluated for its binding against 5-hydroxytryptamine 2A receptor,1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL617347,2458
,107,H,8,,,,4373,,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 2A receptor was determined,1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL617348,2459
,107,H,8,,,,4373,,Binding affinity relative to indolopiperidine (compound 1)for 5-hydroxytryptamine 2A receptor was determined,1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL617349,2460
,107,H,8,,,,3962,,Compound was evaluated for its inverse agonist activity against 5-hydroxytryptamine 2A receptor,1,,Autocuration,,,,,,,F,BAO_0000019,CHEMBL617350,2461
,107,H,8,,,,1633,,Binding affinity towards 5-hydroxytryptamine 2A receptor by displacement of [3H]ketanserin,1,,Expert,,,,,,,B,BAO_0000357,CHEMBL872339,2462
,107,H,8,,,,4373,,Binding affinity for 5-hydroxytryptamine 2A receptor was determined,1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL617351,2463
,107,H,8,,,,6576,,Binding affinity towards serotonin 5-hydroxytryptamine 2A receptor,1,,Expert,,,,,,,B,BAO_0000357,CHEMBL617352,2464
,107,H,8,,,,4687,,Evaluated for the binding affinity towards 5-hydroxytryptamine 2A receptor,1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL617353,2465
,107,H,8,,,,16946,,Ability to displace [3H]-ketanserin from 5-hydroxytryptamine 2A receptor,1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL617354,2466
,107,H,8,,,,14159,,Compound was evaluated for the affinity at 5-hydroxytryptamine 2A receptor,1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL617355,2467
,107,H,8,,,,3032,,In vitro binding affinity against 5-hydroxytryptamine 2A receptor in CHO cells,1,Mus musculus,Expert,,449.0,,10090.0,CHO,,B,BAO_0000219,CHEMBL617356,2468
,107,H,8,,,,16655,,Inhibition of ketanserin binding to 5-hydroxytryptamine 2A receptor,1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL617357,2469
,107,H,8,,,,13964,,Binding affinity at 5-hydroxytryptamine 2A receptor,1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL617358,2470
,107,H,8,,,,16989,,Binding affinity towards Serotonin 5-hydroxytryptamine 2A receptor,1,,Expert,,,,,,,B,BAO_0000357,CHEMBL617359,2471
,107,H,8,,,,16117,,In vitro binding affinity towards 5-hydroxytryptamine 2A receptor was determined,1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL617360,2472
,107,H,8,,,,16700,,The binding affinity towards 5-hydroxytryptamine 2A receptor; No affinity,1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL875913,2473
,107,H,8,,,,3269,,Affinity against 5-hydroxytryptamine 2A receptor,1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL617361,2474
,107,D,9,,,,1274,,Binding affinity against 5-Hydroxytryptamine 2A receptor,1,Homo sapiens,Expert,,,,9606.0,,,B,BAO_0000357,CHEMBL617362,2475
,107,H,8,,,,1317,,Compound was evaluated for binding affinity against 5-hydroxytryptamine 2A receptor using radioligand binding assay,1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL617363,2476
,107,H,8,,,,12146,,Tested against 5-hydroxytryptamine 2A receptor,1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL617364,2477
,105075,H,4,,,,12652,,Binding affinity against the site labelled by the 5-hydroxytryptamine 2A receptor - 5-hydroxytryptamine 2C receptor antagonist [3H]- ketanserin,1,,Autocuration,,,,,,,B,BAO_0000224,CHEMBL617365,2478
,105075,H,4,,,,12652,,Tested for the binding affinity against the site labelled by the 5-hydroxytryptamine 2A receptor - 5-hydroxytryptamine 2C receptor antagonist [3H] ketanserin,1,,Autocuration,,,,,,,B,BAO_0000224,CHEMBL617366,2479
,105075,H,4,,,,12652,,Tested for the binding affinity against the site labelled by the 5-hydroxytryptamine 2A receptor - 5-hydroxytryptamine 2C receptor agonist [125I]- - (+/-)DOI,1,,Autocuration,,,,,,,B,BAO_0000224,CHEMBL617367,2480
,105075,H,4,,,,12652,,Tested for the binding affinity against the site labelled by the 5-hydroxytryptamine 2A receptor - 5-hydroxytryptamine 2C receptor antagonist [3H]- ketanserin,1,,Autocuration,,,,,,,B,BAO_0000224,CHEMBL617368,2481
,107,H,8,,,,16647,,Selectivity ratio towards 5-hydroxytryptamine 2A receptor to Dopamine receptor D2 (5-HT2A/D2 ),1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL617369,2482
,227,D,9,,,,15851,,Displacement of [3H]ketanserin from human 5-hydroxytryptamine 2B receptor expressed in HEK293 cells; ND means no data,1,Homo sapiens,Expert,,722.0,,9606.0,HEK293,,B,BAO_0000219,CHEMBL617370,2483
,227,D,9,,,,6857,,Functional activity against human 5-hydroxytryptamine 2B receptor expressed in CHO cells using fluorometric imaging plate reader,1,Homo sapiens,Expert,,449.0,,9606.0,CHO,,F,BAO_0000219,CHEMBL617371,2484
,227,H,8,,,,3805,,In vitro binding affinity against human 5-HT2B receptor at a concentration of 100 (nM),1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL617372,2485
,227,D,9,,,,6491,,Affinity towards human 5-hydroxytryptamine 2B serotonin receptor,1,Homo sapiens,Expert,,,,9606.0,,,B,BAO_0000357,CHEMBL617373,2486
,227,H,8,,,,14093,,Agonist activity at cloned human 5-hydroxytryptamine 2B receptor using [3H]5-HT radioligand,1,,Autocuration,,,,,,,F,BAO_0000019,CHEMBL617374,2487
,227,H,8,,,,13481,,Agonistic activity at cloned human 5-hydroxytryptamine 2B receptor using [3H]-5-HT as radioligand,1,,Autocuration,,,,,,,F,BAO_0000019,CHEMBL617375,2488
,227,H,8,,,,14093,,Antagonist activity at cloned human 5-hydroxytryptamine 2B receptor using [3H]- rauwolscine radioligand,1,,Autocuration,,,,,,,F,BAO_0000019,CHEMBL617376,2489
,227,H,8,,,,14093,,Antagonist activity at cloned human 5-hydroxytryptamine 2B receptor using [3H]- rauwolscine radioligand; Not tested,1,,Autocuration,,,,,,,F,BAO_0000019,CHEMBL617377,2490
,227,H,8,,,,14093,,Antagonist activity at cloned human 5-hydroxytryptamine 2B receptor using [3H]rauwolscine radioligand,1,,Autocuration,,,,,,,F,BAO_0000019,CHEMBL617378,2491
,227,H,8,,,,13481,,Antagonistic activity at cloned human 5-hydroxytryptamine 2B receptor using [3H]rauwolscine as radioligand,1,,Autocuration,,,,,,,F,BAO_0000019,CHEMBL617379,2492
,227,H,8,,,,14442,,Binding ability of compound at cloned human 5-hydroxytryptamine 2B receptor using [3H]- rauwolscine as radioligand,1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL617380,2493
,227,H,8,,,,14442,,Binding ability of compound at cloned human 5-hydroxytryptamine 2B receptor using [3H]5-HT 2B as radioligand,1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL617381,2494
,227,H,8,,,,14442,,Binding ability of compound at cloned human 5-hydroxytryptamine 2B receptor using [3H]rauwolscine as radioligand,1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL617382,2495
,107,H,8,,,,12369,,The compound evaluated for its affinity against 5-hydroxytryptamine 2A receptor,1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL617383,2496
,107,H,8,,,,12369,,Affinity against 5-hydroxytryptamine 2A receptor (D) labeled with [125I]DOI.,1,,Expert,,,,,,,B,BAO_0000357,CHEMBL617384,2497
,107,H,8,,,,12369,,Affinity against 5-hydroxytryptamine 2A receptor (K) labeled with [3H]ketanserin.,1,,Expert,,,,,,,B,BAO_0000357,CHEMBL617385,2498
,107,H,8,,,,14447,,The compound was tested for CNS binding affinity towards 5-hydroxytryptamine 2A receptor from cloned Human membranes,1,,Autocuration,,,,,,,B,BAO_0000019,CHEMBL617386,2499
,107,H,8,,,,14447,,The compound was tested for CNS binding affinity towards 5-hydroxytryptamine 2A receptor from cloned Human membranes.,1,,Autocuration,,,,,,,B,BAO_0000019,CHEMBL617387,2500
,107,H,8,,,,17451,,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 2A receptor expressed in 3T3 cells using [3H]5-HT as radioligand; Not determined,1,,Autocuration,,723.0,,,NIH3T3,,B,BAO_0000219,CHEMBL617388,2501
,107,H,8,,,,6857,,Relative efficacy against human 5-hydroxytryptamine 2A receptor expressed in CHO cells using fluorometric imaging plate reader relative to 10 uM 5-HT,1,,Autocuration,,449.0,,,CHO,,F,BAO_0000219,CHEMBL617389,2502
,107,D,9,,,,6857,,Relative efficacy against human 5-hydroxytryptamine 2A receptor expressed in CHO cells using fluorometric imaging plate reader relative to 10 uM 5-HT,1,Homo sapiens,Expert,,449.0,,9606.0,CHO,,F,BAO_0000219,CHEMBL617390,2503
,104817,H,4,,,,5635,,Selectivity ratio of binding affinity of 5-hydroxytryptamine 2A receptor to that of 5-hydroxytryptamine 2C receptor.,1,,Autocuration,,,,,,,B,BAO_0000224,CHEMBL617391,2504
,107,H,8,,,,12861,,Binding activity radioligand.,1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL617392,2505
,107,H,8,,,,12861,,Binding activity against 5-hydroxytryptamine 2C receptor from human brain cortex using [3H]mesulergine as radioligand.,1,,Autocuration,,,,,,,B,BAO_0000019,CHEMBL617393,2506
,107,H,8,,,,5105,,Binding affinity for human cloned 5-HT2A receptor expressed in L929 cells using [125I]R91150 as radioligand,1,,Autocuration,,307.0,,,L929,,B,BAO_0000219,CHEMBL617394,2507
,107,H,8,,,,5104,,Binding affinity for human cloned 5-hydroxytryptamine 2A receptor expressed in L929 cells using [125I]R91150 as radioligand,1,,Expert,,307.0,,,L929,,B,BAO_0000219,CHEMBL617395,2508
,107,H,8,,,,5105,,Binding affinity at human cloned 5-hydroxytryptamine 2A receptor expressed in L929 cells by [125I]R91150 displacement.,1,,Expert,,307.0,,,L929,,B,BAO_0000219,CHEMBL617396,2509
,107,H,8,,,,5105,,Binding affinity for human cloned 5-hydroxytryptamine 2A receptor expressed in L929 cells using [125I]R91150 as radioligand; Not tested,1,,Autocuration,,307.0,,,L929,,B,BAO_0000219,CHEMBL617397,2510
,107,H,8,,,,5254,,Binding affinity against 5-HT2A receptor,1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL617398,2511
,107,H,8,,,,5254,,Binding affinity against 5-hydroxytryptamine 2A receptor,1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL617399,2512
,107,H,8,,,,13267,,Antagonistic binding affinity measured against 5-hydroxytryptamine 2A receptor (human clone expressed in 293 cells) using [3H]ketanserin as radioligand,1,,Autocuration,,722.0,,,HEK293,,B,BAO_0000219,CHEMBL617400,2513
,107,H,8,,,,13267,,Antagonistic binding affinity measured against 5-hydroxytryptamine 2C receptor (human clone expressed in 293 cells) using [3H]mesulergine as radioligand,1,,Autocuration,,722.0,,,HEK293,,B,BAO_0000219,CHEMBL617401,2514
,107,D,9,,,,14157,,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2A receptor expressed in HEK 293 cells,1,Homo sapiens,Expert,,722.0,,9606.0,HEK293,,B,BAO_0000219,CHEMBL617402,2515
,107,D,9,,,,12936,,Binding affinity against human 5-hydroxytryptamine 2A receptor expressed in 293 cells using [3H]ketanserin,1,Homo sapiens,Expert,,722.0,,9606.0,HEK293,,B,BAO_0000219,CHEMBL617403,2516
,107,H,8,,,,14068,,Binding affinity against human 5-hydroxytryptamine 2A receptor using displacement of [3H]5-HT,1,,Expert,,,,,,,B,BAO_0000357,CHEMBL617404,2517
,107,D,9,,,,12936,,Binding affinity against human 5-hydroxytryptamine 2A receptor expressed in 293 cells using [3H]ketanserin,1,Homo sapiens,Expert,,722.0,,9606.0,HEK293,,B,BAO_0000219,CHEMBL857981,2518
,107,D,9,,,,12936,,Binding affinity against human 5-hydroxytryptamine 2A receptor expressed in 293 cells using [3H]ketanserin,1,Homo sapiens,Expert,,722.0,,9606.0,HEK293,,B,BAO_0000219,CHEMBL617405,2519
,107,D,9,,,,4540,,Binding affinity to human cloned 5-hydroxytryptamine 2A receptor in HEK 293 cells using [3H]- ketanserin as radioligand,1,Homo sapiens,Expert,,722.0,,9606.0,HEK293,,B,BAO_0000219,CHEMBL617253,2520
,107,H,8,,,,6166,,Binding affinity at human cloned 5-hydroxytryptamine 2A receptor.,1,,Expert,,,,,,,B,BAO_0000357,CHEMBL617254,2521
,107,H,8,,,,17296,,Binding affinity against 5-hydroxytryptamine 2A receptor human cloned receptors in HEK 293 cells using [3H]ketanserin as radioligand,1,,Autocuration,,722.0,,,HEK293,,B,BAO_0000219,CHEMBL617255,2522
,107,H,8,,,,17296,,Binding affinity against 5-hydroxytryptamine 2A receptor human cloned receptors in HEK 293 cells using [3H]ketanserin as radioligand,1,,Autocuration,,722.0,,,HEK293,,B,BAO_0000219,CHEMBL617256,2523
,107,H,8,,,,17296,,Binding affinity against 5-hydroxytryptamine 2A receptor human cloned receptorswithouteffect in HEK 293 cells using [3H]ketanserin as radioligand,1,,Autocuration,,722.0,,,HEK293,,B,BAO_0000219,CHEMBL616874,2524
,107,D,9,,,,15779,,Binding affinity towards 5-hydroxytryptamine 2A receptor (human cloned receptor) in HEK 293 cells using [3H]ketanserin as radioligand.,1,Homo sapiens,Expert,,722.0,,9606.0,HEK293,,B,BAO_0000219,CHEMBL616875,2525
,107,H,8,,,,14391,,Binding affinity towards human 5-hydroxytryptamine 2A receptor expressed in HEK 293 cells using [3H]ketanserin as radioligand,1,,Expert,,722.0,,,HEK293,,B,BAO_0000219,CHEMBL616876,2526
,107,H,8,,,,15851,,"Binding affinity towards human cloned 5-hydroxytryptamine receptor 2A in HEK293 cells, using [3H]ketanserin as radioligand.",1,,Expert,,722.0,,,HEK293,,B,BAO_0000219,CHEMBL616877,2527
,107,D,9,,,,15851,,Displacement of [3H]ketanserin from human 5-hydroxytryptamine 2A receptor expressed in HEK293 cells; compound is insoluble,1,Homo sapiens,Expert,,722.0,,9606.0,HEK293,,B,BAO_0000219,CHEMBL616878,2528
,107,H,8,,,,3832,,Binding affinity towards human cloned 5-hydroxytryptamine 2A receptor of HEK293 cells by displacement of [3H]ketanserin,1,,Expert,,722.0,,,HEK293,,B,BAO_0000219,CHEMBL616879,2529
,107,H,8,,,,3833,,In vitro binding affinity at human cloned 5-hydroxytryptamine 2A receptor of HEK293 cells by [3H]ketanserin displacement.,1,,Expert,,722.0,,,HEK293,,B,BAO_0000219,CHEMBL616880,2530
,107,D,9,,,,12936,,Binding affinity against human 5-hydroxytryptamine 2A receptor expressed in 293 cells using [3H]ketanserin,1,Homo sapiens,Expert,,722.0,,9606.0,HEK293,,B,BAO_0000219,CHEMBL616881,2531
,107,H,8,,,,17451,,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 2A receptor expressed in 3T3 cells using [3H]5-HT as radioligand,1,,Autocuration,,723.0,,,NIH3T3,,B,BAO_0000219,CHEMBL616882,2532
,107,H,8,,,,17451,,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 2A receptor expressed in 3T3 cells using [3H]5-HT as radioligand; Not determined,1,,Autocuration,,723.0,,,NIH3T3,,B,BAO_0000219,CHEMBL616883,2533
,107,H,8,,,,17451,,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 2A receptor expressed in 3T3 cells using [3H]5-HT as radioligand; Not determined,1,,Autocuration,,723.0,,,NIH3T3,,B,BAO_0000219,CHEMBL616884,2534
,107,H,8,,,,4199,,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 2A receptor in HEK 293 cells using [3H]ketanserin as the radioligand,1,,Autocuration,,722.0,,,HEK293,,B,BAO_0000219,CHEMBL616885,2535
,107,H,8,,,,1883,,Compound was evaluated for displacement of [3H]ketanserin from human cloned 5-hydroxytryptamine 2A receptor in transfected CHO-K1 cells,1,,Autocuration,,485.0,,,CHO-K1,,B,BAO_0000219,CHEMBL616886,2536
,107,H,8,,,,1883,,Displacement of [3H]-ketanserin from human cloned 5-hydroxytryptamine 2A receptor expressed in CHO-K1 cells.,1,,Expert,,485.0,,,CHO-K1,,B,BAO_0000219,CHEMBL616887,2537
,107,D,9,,,,14875,,Binding affinity for human 5-hydroxytryptamine 2A receptor,1,Homo sapiens,Expert,,,,9606.0,,,B,BAO_0000357,CHEMBL616888,2538
,107,H,8,,,,15146,,Compound was tested for its binding affinity against 5-hydroxytryptamine 2A receptor in human cloned receptors in HEK 293 cells using [3H]ketanserin,1,,Autocuration,,722.0,,,HEK293,,B,BAO_0000219,CHEMBL616889,2539
,107,H,8,,,,5213,,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 2A receptor in HEK 293 using [3H]ketanserin as a radioligand,1,,Autocuration,,722.0,,,HEK293,,B,BAO_0000219,CHEMBL616890,2540
,107,D,9,,,,16404,,Inhibitory constant for human 5-hydroxytryptamine 2A receptor transfected in to CHO cells,1,Homo sapiens,Expert,,449.0,,9606.0,CHO,,B,BAO_0000219,CHEMBL616891,2541
,107,H,8,,,,14818,,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 2A receptor in HEK293 cells using [3H]-ketanserin.,1,,Autocuration,,722.0,,,HEK293,,B,BAO_0000219,CHEMBL616892,2542
,107,H,8,,,,4829,,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 2A receptor in HEK293 cells, using [3H]ketanserin as radioligand",1,,Autocuration,,722.0,,,HEK293,,B,BAO_0000219,CHEMBL616893,2543
,10620,H,8,,,,12652,,Percent of maximum stimulation of phosphatidylinositol turnover at cloned 5-hydroxytryptamine 2A receptor in 3T3 cells,1,,Autocuration,,723.0,,,NIH3T3,,F,BAO_0000219,CHEMBL616894,2544
,107,H,8,,,,4682,,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2A receptor expressed NIH3T3 cells,1,,Expert,,723.0,,,NIH3T3,,B,BAO_0000219,CHEMBL616895,2545
,10620,H,8,,,,12652,,The maximum responses of [3H]- inositol monophosphate accumulation in cells expressing the 5-hydroxytryptamine 2A receptor,1,,Autocuration,,,,,,,F,BAO_0000019,CHEMBL616896,2546
,10621,H,8,,,,4921,,Ability to displace [3H]-Ketanserin radioligand from porcine 5-hydroxytryptamine 2A receptor,1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL617099,2547
,10621,H,8,,,,4921,,Ability to displace [3H]ketanserin radioligand from porcine 5-hydroxytryptamine 2A receptor; ND denotes not determined,1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL617100,2548
,107,H,8,,,,16312,,Binding affinity against rabbit aorta 5-HT2A receptor,1,Oryctolagus cuniculus,Autocuration,,,,9986.0,,,B,BAO_0000357,CHEMBL884532,2549
,107,H,8,,,,14998,,Binding affinity for 5-hydroxytryptamine 2A receptor of rabbit aorta ring preparations,1,Oryctolagus cuniculus,Expert,,,,9986.0,,,B,BAO_0000357,CHEMBL617101,2550
,107,H,8,,,,14025,,Dissociation equilibrium constant against the vascular 5-hydroxytryptamine 2A receptor in the rabbit saphenous aorta,1,Oryctolagus cuniculus,Expert,,,,9986.0,,,B,BAO_0000357,CHEMBL617102,2551
,107,H,8,,,,13047,,Binding affinity against 5-hydroxytryptamine 1D receptor alpha using rabbit saphenous vein assay.,1,Oryctolagus cuniculus,Autocuration,,,,9986.0,,,B,BAO_0000019,CHEMBL617103,2552
,107,H,8,,,,13047,,The compound was tested for binding affinity against 5-HT2A receptor,1,Oryctolagus cuniculus,Expert,,,,9986.0,,,B,BAO_0000357,CHEMBL617104,2553
,10576,H,8,,,,1883,,Compound was evaluated for displacement of [3H]ketanserin from cloned rat 5-hydroxytryptamine 2A receptor in transfected CHO-K1 cells.,1,,Autocuration,,485.0,,,CHO-K1,,B,BAO_0000219,CHEMBL857979,2554
,12687,H,8,,,,13463,,Binding affinity analysed towards 5-HT 2A in rat jugular vein,1,,Autocuration,,,,,,,B,BAO_0000019,CHEMBL857502,2555
,12687,H,8,,,,13463,,Binding affinity analysed towards 5-HT 2A in rat jugular vein.,1,,Autocuration,,,,,,,B,BAO_0000019,CHEMBL617105,2556
Stomach,12687,H,8,,,,13463,,Binding affinity analysed on 5-HT 2A in rat stomach fundus.,1,,Autocuration,,,,,,945.0,B,BAO_0000019,CHEMBL858021,2557
Stomach,12687,D,9,,,,13463,,Binding affinity for 5-HT 2A in rat stomach fundus,1,Rattus norvegicus,Expert,,,,10116.0,,945.0,B,BAO_0000019,CHEMBL875910,2558
,12687,H,8,,,,13463,,Binding affinity analysed towards 5-HT 2A in rat jugular vein.,1,,Autocuration,,,,,,,B,BAO_0000019,CHEMBL617106,2559
,12687,H,8,,,,16326,,Ability to stimulate phosphoinositide hydrolysis in NIH3T3 cells expressing the 5-hydroxytryptamine 2A receptor,1,,Expert,,723.0,,,NIH3T3,,B,BAO_0000219,CHEMBL617107,2560
,12687,H,8,,,,14093,,Effect on phosphoinositide hydrolysis in NIH 3T3 fibroblast 5-hydroxytryptamine 2A receptor,1,,Autocuration,,,,,,,F,BAO_0000019,CHEMBL617108,2561
,12687,H,8,,,,14093,,Effect on phosphoinositide hydrolysis in NIH 3T3 fibroblast expressing 5-hydroxytryptamine 2A receptor,1,,Autocuration,,,,,,,F,BAO_0000019,CHEMBL617109,2562
,12687,H,8,,,,15740,,Evaluated for the effective concentration at [125I]-DOI-labeled rat 5-hydroxytryptamine 2A receptor,1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL617110,2563
,12687,H,8,,,,16633,,Functional potency at the rat 5-hydroxytryptamine 2A receptor as effective concentration EC50 for stimulating Phosphoinositide accumulation,1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL617111,2564
,12687,D,9,,,,17200,,In vitro relative agonist activity against 5-hydroxytryptamine 2A using PI assay in rat vascular smooth muscle cells,1,Rattus norvegicus,Expert,,,,10116.0,,,F,BAO_0000019,CHEMBL617112,2565
,12687,H,8,,,,17133,,Tested for its ability to activate phospholipase C by quantification of IP3 at cloned rat 5-hydroxytryptamine 2A receptor,1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL617113,2566
,12687,H,8,,,,17133,,Tested for its ability to activate phospholipase C by quantification of IP3 at cloned rat 5-hydroxytryptamine 2A receptor,1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL617114,2567
,12687,H,8,,,,17133,,Tested for its ability to activate phospholipase c by quantification of IP3 at cloned rat 5-hydroxytryptamine 2A receptor,1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL617115,2568
,12687,H,8,,,,17200,,The receptor (5-hydroxytryptamine 2A ) mediated mobilization of intracellular calcium [Ca2+] was studied in rat smooth muscle cells,1,,Autocuration,,,,,,,F,BAO_0000219,CHEMBL617116,2569
,12687,H,8,,,,15363,,Efficacy at 5-hydroxytryptamine 2A receptor,1,,Autocuration,,,,,,,F,BAO_0000019,CHEMBL617117,2570
,12687,H,8,,,,17200,,In vitro efficacy against rat 5-hydroxytryptamine 2A receptor was determined by using CA+ assay (Emax),1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL617118,2571
,12687,D,9,,,,17200,,In vitro efficacy against rat 5-hydroxytryptamine 2A receptor was determined by using CA+ assay (Emax),1,Rattus norvegicus,Expert,,,,10116.0,,,B,BAO_0000357,CHEMBL617119,2572
,12687,D,9,,,,17200,,In vitro efficacy against rat 5-hydroxytryptamine 2A receptor determined by using PI assay (Emax),1,Rattus norvegicus,Expert,,,,10116.0,,,B,BAO_0000357,CHEMBL617120,2573
,12687,D,9,,,,17200,,The receptor (5-hydroxytryptamine 2A ) mediated mobilization of intracellular calcium [Ca2+] was studied in rat smooth muscle cells,1,Rattus norvegicus,Expert,,,,10116.0,,,F,BAO_0000219,CHEMBL617121,2574
,12687,H,8,,,,17200,,The receptor (5-hydroxytryptamine 2A) mediated mobilization of intracellular calcium [Ca2+] was studied in rat smooth muscle cells,1,,Autocuration,,,,,,,F,BAO_0000219,CHEMBL617122,2575
,12687,H,8,,,,17211,,Ability to displace [3H]ketanserin (0.5 nM) from cerebral cortex of rat 5-hydroxytryptamine 2A receptor,1,,Autocuration,,,,,,,B,BAO_0000019,CHEMBL617123,2576
,12687,H,8,,,,17331,,Binding affinity against 5-hydroxytryptamine 2A receptor by displacement of [3H]-ketanserin from rat prefrontal cerebral cortex mambranes,1,,Expert,,,,,,,B,BAO_0000019,CHEMBL617124,2577
,12687,H,8,,,,13565,,Binding affinity to serotonin 5-hydroxytryptamine 2A receptors using a radioligand [3H]ketanserin binding assay in rat cortical membranes,1,,Expert,,,,,,,B,BAO_0000249,CHEMBL617600,2578
,12687,H,8,,,,13730,,Binding affinity towards rat 5-hydroxytryptamine 2A receptor was evaluated using [3H]- ketanserin as radioligand,1,,Expert,,,,,,,B,BAO_0000357,CHEMBL617601,2579
,12687,H,8,,,,12416,,In vitro affinity towards 5-hydroxytryptamine 2A receptor using [3H]spiroperidol as radioligand in cortex,1,,Expert,,,,,,,B,BAO_0000019,CHEMBL882923,2580
,12687,H,8,,,,15295,,Compound was tested for it's binding affinity towards 5-hydroxytryptamine 2A receptor,1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL617602,2581
,12687,H,8,,,,1742,,Compound was tested for its ability to displace [3H]DOB from 5-hydroxytryptamine 2A receptor in rat cortex homogenates,1,,Autocuration,,,,,,,B,BAO_0000019,CHEMBL617603,2582
,12687,H,8,,,,15295,,Compound was tested for the inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2A receptor,1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL617604,2583
,12687,H,8,,,,14970,,Binding affinity towards 5-hydroxytryptamine 2A receptor from rat frontal cortex using [3H]ketanserin as radioligand,1,,Expert,,,,,,,B,BAO_0000019,CHEMBL617605,2584
,12687,H,8,,,,16693,,In vitro binding affinity for serotonin 5-hydroxytryptamine 2A receptor of rat cerebral cortex using [3H]ketanserin as radioligand,1,,Expert,,,,,,,B,BAO_0000019,CHEMBL617606,2585
,12687,D,9,,,,14776,,Inhibition of [3H]ketanserin binding to rat frontal cortex membrane 5-hydroxytryptamine 2A receptor,1,Rattus norvegicus,Expert,,,,10116.0,,,B,BAO_0000019,CHEMBL617607,2586
,12687,H,8,,,,14286,,In vitro inhibitory concentration against radioligand [3H]ketanserin binding to 5-hydroxytryptamine 2A receptor in rat cortical membrane,1,,Autocuration,,,,,,,B,BAO_0000249,CHEMBL617455,2587
,12687,D,9,,,,17200,,In vitro inhibition of [125I]DOI binding to 5-hydroxytryptamine 2A receptor in rat cerebral cortex,1,Rattus norvegicus,Expert,,,,10116.0,,,B,BAO_0000019,CHEMBL617456,2588
,12687,H,8,,,,15306,,Inhibitory concentration against 5-hydroxytryptamine 2A receptor (Inactive at >1000 nM concentration),1,,Expert,,,,,,,B,BAO_0000357,CHEMBL617457,2589
,12687,D,9,,,,14178,,Inhibition of radiolabeled [3H]-Ketanserin ligand binding to 5-hydroxytryptamine 2A receptor,1,Rattus norvegicus,Expert,,,,10116.0,,,B,BAO_0000357,CHEMBL617458,2590
,12687,D,9,,,,14229,,Inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2A receptor from rat brain,1,Rattus norvegicus,Expert,,,,10116.0,,,B,BAO_0000019,CHEMBL617459,2591
,12687,H,8,,,,12884,,Binding affinity towards 5-hydroxytryptamine 2A receptor binding site using [3H]ketanserin. ,1,,Expert,,,,,,,B,BAO_0000357,CHEMBL617460,2592
,12687,H,8,,,,13149,,"Binding affinity for 5-hydroxytryptamine 2A receptor, activity is expressed as IC50 values.",1,,Expert,,,,,,,B,BAO_0000357,CHEMBL617461,2593
,12687,D,9,,,,15295,,Displacement of [3H]ketanserin from rat cortical membrane 5-hydroxytryptamine 2A receptor at 10e-7 M,1,Rattus norvegicus,Expert,,,,10116.0,,,B,BAO_0000019,CHEMBL617462,2594
,12687,H,8,,,,15740,,Intrinsic activity was determined at 5-hydroxytryptamine 2A receptor which is percentage response given compared with the response produced by 10 uM serotonin.,1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL617463,2595
,12687,H,8,,,,15185,,"Compound was tested for binding affinity at 5-hydroxytryptamine 2A receptor sites in rat cortical homogenate using [125I]-2,5-Dimethoxy -4-iodoamphetamine (DOI).",1,,Autocuration,,,,,,,B,BAO_0000019,CHEMBL617464,2596
,12687,H,8,,,,15185,,"Compound was tested for binding affinity using [3H]MDL-100,907 at 5-hydroxytryptamine 2A receptor sites in rat cortical homogenate.",1,,Autocuration,,,,,,,B,BAO_0000019,CHEMBL617465,2597
,12687,H,8,,,,17529,,Ability to bind to central serotonin 5-hydroxytryptamine 2A receptor in vitro in cortex of the rat brain using [3H]ketanserin radioligand,1,,Expert,,,,,,,B,BAO_0000019,CHEMBL617466,2598
,12687,H,8,,,,14826,,Ability to displace [3H]- ketanserin bound to 5-hydroxytryptamine 2A receptor in rat pre-frontal cortex,1,,Autocuration,,,,,,,B,BAO_0000019,CHEMBL617467,2599
,12687,H,8,,,,17211,,Displacement of [3H]ketanserin (0.5 nM) from rat cerebral cortex 5-hydroxytryptamine 2A receptors,1,,Expert,,,,,,,B,BAO_0000019,CHEMBL617468,2600
,12687,H,8,,,,14826,,Ability to displace [3H]ketanserin bound to 5-hydroxytryptamine 2A receptor in rat pre-frontal cortex,1,,Autocuration,,,,,,,B,BAO_0000019,CHEMBL617469,2601
,12687,H,8,,,,14093,,Ability to displace [3H]ketanserin from rat cortical homogenate 5-hydroxytryptamine 2A receptor,1,,Autocuration,,,,,,,B,BAO_0000019,CHEMBL617470,2602
,12687,H,8,,,,14093,,Ability to displace [3H]ketanserin from rat cortical homogenate 5-hydroxytryptamine 2A receptor; Not tested,1,,Autocuration,,,,,,,B,BAO_0000019,CHEMBL617471,2603
,12687,H,8,,,,13246,,Ability to inhibit the binding of iodine-125-labelled lysergic acid diethylamide([125I]-LSD) to the S-2A serotonin receptor in NIH3T3 cell line membranes,1,,Expert,,723.0,,,NIH3T3,,B,BAO_0000219,CHEMBL617472,2604
,12687,H,8,,,,13246,,Ability to inhibit the binding of iodine-125-labelled lysergic acid diethylamide([125I]-LSD) to the S-2A serotonin receptor.,1,,Expert,,,,,,,B,BAO_0000357,CHEMBL617473,2605
,12687,D,9,,,,15436,,Affinity 5-hydroxytryptamine 2A receptor of the rat brain cortex was assessed on the basis of their ability to displace [3H]ketanserin,1,Rattus norvegicus,Expert,,,,10116.0,,,B,BAO_0000019,CHEMBL617474,2606
,12687,D,9,,,,15436,,Affinity at 5-hydroxytryptamine 2A receptor of the rat brain cortex was assessed on the basis of their ability to displace [3H]ketanserin,1,Rattus norvegicus,Expert,,,,10116.0,,,B,BAO_0000019,CHEMBL617475,2607
Brain,12687,H,8,,,,14442,,Affinity at [3H]ketanserin-labeled 5-hydroxytryptamine 2A receptor in rat brain homogenate was determined,1,,Autocuration,,,,,,955.0,B,BAO_0000221,CHEMBL617476,2608
,12687,H,8,,,,12457,,Affinity was evaluated as inhibition constant for serotonin 5-hydroxytryptamine 2A receptor,1,,Expert,,,,,,,B,BAO_0000357,CHEMBL617477,2609
,12687,H,8,,,,12457,,Affinity was evaluated by inhibition of [125I]LSD binding to NIH 3T3 cells transfected with cloned rat 5-hydroxytryptamine 2A receptor,1,,Expert,,723.0,,,NIH3T3,,B,BAO_0000219,CHEMBL617478,2610
,12687,H,8,,,,14755,,"Antagonistic activity measured for 5-hydroxytryptamine 2A receptor using [3H]-MDL- 100,907 as radioligand in rat cortical homogenates.",1,,Autocuration,,,,,,,F,BAO_0000221,CHEMBL617479,2611
,12687,H,8,,,,4707,,Binding affinity towards rat 5-hydroxytryptamine 2A receptor was determined using [125I]- DOI as radioligand,1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL617480,2612
,12687,H,8,,,,13297,,Binding affinity against 5-hydroxytryptamine 2A receptor,1,,Expert,,,,,,,B,BAO_0000357,CHEMBL617481,2613
,12687,H,8,,,,17331,,Binding affinity against 5-hydroxytryptamine 2A receptor by displacement of [3H]ketanserin from rat prefrontal cerebral cortex mambranes,1,,Expert,,,,,,,B,BAO_0000019,CHEMBL617482,2614
,12687,H,8,,,,4664,,Binding affinity against 5-hydroxytryptamine 2A receptor from rat forebrain using [3H]ketanserin as radioligand,1,,Autocuration,,,,,,,B,BAO_0000019,CHEMBL617483,2615
,12687,H,8,,,,16633,,Binding affinity against 5-hydroxytryptamine 2A receptor using [125I]DOI as radioligand,1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL621528,2616
,12687,D,9,,,,4664,,Binding affinity against 5-hydroxytryptamine 2A receptor expressed NIH3T3 cells using [3H]ketanserin,1,Rattus norvegicus,Expert,,723.0,,10116.0,NIH3T3,,B,BAO_0000219,CHEMBL621529,2617
,12687,H,8,,,,16133,,Binding affinity against rat 5-hydroxytryptamine 2A receptor using [3H]DOB as radioligand,1,,Expert,,,,,,,B,BAO_0000357,CHEMBL621530,2618
,12687,H,8,,,,16133,,Binding affinity against rat 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand,1,,Expert,,,,,,,B,BAO_0000357,CHEMBL621531,2619
,12687,D,9,,,,14060,,Binding affinity against rat brain 5-hydroxytryptamine 2A receptor,1,Rattus norvegicus,Expert,,,,10116.0,,,B,BAO_0000019,CHEMBL621532,2620
,12687,H,8,,,,16326,,Binding affinity at cloned rat 5-hydroxytryptamine 2A receptor using [3H]DOB as radioligand,1,,Expert,,,,,,,B,BAO_0000357,CHEMBL621533,2621
,12687,H,8,,,,16659,,Binding affinity for displacement of [3H]ketanserin to rat 5-hydroxytryptamine 2A receptor stably expressed in CHO cells,1,,Expert,,449.0,,,CHO,,B,BAO_0000219,CHEMBL621534,2622
,12687,H,8,,,,14776,,Binding affinity measured at the 5-hydroxytryptamine 2A receptor by the inhibition of [3H]ketanserin binding to rat cortex using unlabeled mianserin for nonspecific binding.,1,,Autocuration,,,,,,,B,BAO_0000019,CHEMBL621535,2623
,12687,H,8,,,,13481,,Binding affinity of [3H]- ketanserin labelled towards Rat cortical 5-hydroxytryptamine 2A receptor using radioligand binding assay,1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL621536,2624
,12687,H,8,,,,17386,,Binding affinity of compound was tested for 5-hydroxytryptamine 2A receptor,1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL621537,2625
,12687,D,9,,,,6611,,Binding affinity for 5-hydroxytryptamine 2A receptor,1,Rattus norvegicus,Expert,,,,10116.0,,,B,BAO_0000357,CHEMBL621538,2626
,12687,H,8,,,,14423,,Binding affinity against 5-hydroxytryptamine 2A receptor from rat cortex using [3H]ketanserin as the radioligand.,1,,Autocuration,,,,,,,B,BAO_0000019,CHEMBL621539,2627
,12687,H,8,,,,15412,,Binding affinity against 5-hydroxytryptamine 2A receptor of rat pre-frontal cortex,1,,Autocuration,,,,,,,B,BAO_0000019,CHEMBL621540,2628
,12687,H,8,,,,15412,,Binding affinity against 5-hydroxytryptamine 2A receptor of rat pre-frontal cortex.,1,,Autocuration,,,,,,,B,BAO_0000019,CHEMBL621541,2629
,12687,H,8,,,,6238,,Binding affinity towards 5-HT 2A receptor in rat cerebral frontal cortex membranes using [3H]ketanserin as radioligand,1,,Autocuration,,,,,,,B,BAO_0000019,CHEMBL621542,2630
,12687,H,8,,,,6648,,Binding affinity at 5-hydroxytryptamine 2A receptor of rat.,1,,Expert,,,,,,,B,BAO_0000357,CHEMBL621543,2631
,12687,H,8,,,,5667,,Binding affinity towards 5-hydroxytryptamine 2A receptor sites by using [3H]ketanserin as radioligand,1,,Expert,,,,,,,B,BAO_0000357,CHEMBL621544,2632
,12687,D,9,,,,6611,,Binding affinity for 5-hydroxytryptamine 2A serotonin receptor,1,Rattus norvegicus,Expert,,,,10116.0,,,B,BAO_0000357,CHEMBL621545,2633
,12687,H,8,,,,13481,,Binding affinity towards rat cortical 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand,1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL621546,2634
,12687,H,8,,,,13481,,Binding affinity towards rat cortical 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand; Not tested,1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL621547,2635
,12687,H,8,,,,15558,,Displacement of [3H]ketanserin from NIH3T3 cells stably expressing rat 5-hydroxytryptamine 2A receptor,1,,Expert,,723.0,,,NIH3T3,,B,BAO_0000219,CHEMBL618692,2636
,12687,H,8,,,,6013,,Binding affinity towards 5-hydroxytryptamine 2A receptor,1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL618693,2637
,12687,H,8,,,,16633,,Binding affinity towards 5-hydroxytryptamine 2A receptor using [125I]DOI as radioligand,1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL872922,2638
,12687,H,8,,,,6013,,Binding affinity towards cloned rat 5-hydroxytryptamine 2A receptor from fundus tissue was determined using [3H]mesulergine as radioligand,1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL618694,2639
,12687,D,9,,,,6013,,Binding affinity for rat 5-hydroxytryptamine 2A receptor using [3H]DOB,1,Rattus norvegicus,Expert,,,,10116.0,,,B,BAO_0000357,CHEMBL618695,2640
,12687,H,8,,,,6013,,Binding affinity towards cloned rat 5-hydroxytryptamine 2A receptor was determined using [3H]DOB as radioligand; ND=No data,1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL618696,2641
,12687,H,8,,,,6013,,Binding affinity towards cloned rat 5-hydroxytryptamine 2A receptor by [3H]ketanserin displacement.,1,,Expert,,,,,,,B,BAO_0000357,CHEMBL618697,2642
,12687,H,8,,,,6013,,Binding affinity towards cloned rat Inhibition of binding towards 5-hydroxytryptamine 2A receptor at 100 nM concentration was determined using [3H]DOB as radioligand,1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL618892,2643
,12687,H,8,,,,6013,,Binding affinity towards cloned rat Inhibition of binding towards 5-hydroxytryptamine 2A receptor at 100 nM concentration was determined using [3H]ketanserin as radioligand,1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL618893,2644
,12687,H,8,,,,16293,,Binding affinity towards rat 5-hydroxytryptamine 2A receptor,1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL618894,2645
,12687,H,8,,,,17175,,Binding affinity towards rat 5-hydroxytryptamine 2A receptor expressed in NIH3T3 cells using [3H]ketanserin as radioligand,1,,Expert,,723.0,,,NIH3T3,,B,BAO_0000219,CHEMBL618895,2646
,12687,D,9,,,,13278,,Binding affinity was measured against 5-hydroxytryptamine 2A receptor by displacement of [3H]- ketanserin by lysergic acid amides,1,Rattus norvegicus,Expert,,,,10116.0,,,B,BAO_0000357,CHEMBL618896,2647
Caudate-putamen,12687,H,8,,,,3682,,Compound was evaluated for affinity towards cerebral 5-hydroxytryptamine 2A receptor in homogenate of caudate putamen tissue from rat brain,1,,Autocuration,,,,,,5383.0,B,BAO_0000019,CHEMBL618897,2648
,12687,H,8,,,,2014,,Compound was evaluated for binding affinity against 5-hydroxytryptamine 2A receptor using [3H]ketanserin as a radioligand,1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL618898,2649
,12687,H,8,,,,2014,,Compound was evaluated for binding affinity against 5-hydroxytryptamine 2A receptor using [3H]ketanserin as a radioligand; Not determined,1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL618899,2650
,12687,H,8,,,,4932,,Compound was evaluated for its ability to displace (+/-)[125I]-DOI from 5-hydroxytryptamine 2A receptor in cloned rat cell culture,1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL618900,2651
,12687,H,8,,,,4932,,Compound was evaluated for its ability to displace [125I](R)-DOI from 5-hydroxytryptamine 2A receptor in cloned rat prefrontal cortex homogenate,1,,Autocuration,,,,,,,B,BAO_0000019,CHEMBL618901,2652
,12687,H,8,,,,3935,,Compound was evaluated for its binding affinity for rat 5-hydroxytryptamine 2A receptor,1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL618902,2653
Hippocampus,12687,D,9,,,,5432,,Displacement of [3H]8-OH-DPAT from rat hippocampus membrane 5-hydroxytryptamine 2A receptor,1,Rattus norvegicus,Expert,,,,10116.0,,10000000.0,B,BAO_0000221,CHEMBL618903,2654
,12687,H,8,,,,15818,,Compound was evaluated for its binding affinity towards rat 5-hydroxytryptamine 2A receptor,1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL618904,2655
,12687,H,8,,,,13672,,Compound was evaluated for the binding affinity towards 5-hydroxytryptamine 2A receptor using [3H]ketanserin radioligand.,1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL618905,2656
,12687,H,8,,,,13672,,Compound was evaluated for the binding affinity towards 5-hydroxytryptamine 2A receptor using [3H]-ketanserin radioligand.,1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL618906,2657
,12687,H,8,,,,14749,,Binding affinity against rat 5-hydroxytryptamine 2A receptor in NIH3T3 cells.,1,,Expert,,723.0,,,NIH3T3,,B,BAO_0000219,CHEMBL618907,2658
,12687,H,8,,,,13462,,Compound was tested for the Binding affinity against rat frontal cortex 5-hydroxytryptamine 2A receptor by Radio ligand [3H]ketanserin binding assay.,1,,Autocuration,,,,,,,B,BAO_0000019,CHEMBL618908,2659
,12687,H,8,,,,15740,,Evaluated for the binding constant at [125I]-DOI-labeled rat 5-hydroxytryptamine 2A receptor,1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL617909,2660
,12687,H,8,,,,16647,,Half-maximal inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2A receptor in rat cerebral cortex homogenate,1,,Expert,,,,,,,B,BAO_0000019,CHEMBL617910,2661
Brain,12687,H,8,,,,13345,,In vitro ability to displace [3H]ketanserin from 5-hydroxytryptamine 2A receptor in rat brain.,1,,Autocuration,,,,,,955.0,B,BAO_0000221,CHEMBL617911,2662
,12687,H,8,,,,16740,,In vitro binding affinity at 5-hydroxytryptamine 2A receptor in rat cortical membrane,1,,Autocuration,,,,,,,B,BAO_0000249,CHEMBL872923,2663
,12687,H,8,,,,16740,,In vitro binding affinity at 5-hydroxytryptamine 2A receptor in rat cortical membrane,1,,Autocuration,,,,,,,B,BAO_0000249,CHEMBL617912,2664
,12687,D,9,,,,15535,,In vitro binding affinity at 5-hydroxytryptamine 2A receptor by displacement of [3H]ketanserin from rat cortex,1,Rattus norvegicus,Expert,,,,10116.0,,,B,BAO_0000019,CHEMBL617913,2665
,12687,H,8,,,,16740,,In vitro binding affinity at 5-hydroxytryptamine 2A receptor in rat cortical membrane,1,,Expert,,,,,,,B,BAO_0000249,CHEMBL617914,2666
,12687,H,8,,,,16740,,In vitro binding affinity at 5-hydroxytryptamine 2A receptor in rat cortical membrane,1,,Autocuration,,,,,,,B,BAO_0000249,CHEMBL617915,2667
,12687,H,8,,,,16740,,In vitro binding affinity at serotonin 5-hydroxytryptamine 2A receptor in rat cortical membrane,1,,Autocuration,,,,,,,B,BAO_0000249,CHEMBL617916,2668
,12687,D,9,,,,4795,,Displacement of [3H]- Ketanserin from rat cortex 5-hydroxytryptamine 2A receptor,1,Rattus norvegicus,Expert,,,,10116.0,,,B,BAO_0000019,CHEMBL617917,2669
,12687,H,8,,,,8,,In vitro binding affinity towards 5-hydroxytryptamine 2A receptor in rat tissue homogenate using [3H]ketanserin as radioligand,1,,Expert,,,,,,,B,BAO_0000019,CHEMBL617918,2670
,12687,H,8,,,,8,,In vitro binding affinity towards 5-hydroxytryptamine 2A receptor in rat tissue homogenate using [3H]ketanserin as radioligand; Not active at 10-5 M,1,,Autocuration,,,,,,,B,BAO_0000019,CHEMBL617919,2671
,12687,D,9,,,,17200,,In vitro inhibitory constant against [125I]DOI binding to 5-hydroxytryptamine 2A receptor in rat cerebral cortex,1,Rattus norvegicus,Expert,,,,10116.0,,,B,BAO_0000019,CHEMBL617920,2672
,12687,D,9,,,,2148,,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2A receptor of rat brain cortex,1,Rattus norvegicus,Expert,,,,10116.0,,,B,BAO_0000019,CHEMBL617921,2673
,105102,D,5,,,,13345,,"Relative binding affinity for D2 receptor and 5-hydroxytryptamine 2A receptor, ratio of Ki",1,Rattus norvegicus,Expert,,,,10116.0,,,B,BAO_0000224,CHEMBL617922,2674
,12687,H,8,,,,5088,,Tested for binding affinity towards rat 5-hydroxytryptamine 2A receptor using [3H]DOB as radioligand,1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL617923,2675
,12687,H,8,,,,5088,,Tested for binding affinity towards rat 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand,1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL617924,2676
,12687,H,8,,,,17133,,Tested in vitro for its ability to bind to 5-hydroxytryptamine 2A receptor using [125 I]-DOI as radioligand,1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL617925,2677
,12687,D,9,,,,17133,,In vitro binding to 5-hydroxytryptamine 2A receptor using [125 I]-DOI,1,Rattus norvegicus,Expert,,,,10116.0,,,B,BAO_0000357,CHEMBL617926,2678
,12687,H,8,,,,16532,,The binding affinity at 5-hydroxytryptamine 2A receptor was determined using [3H]ketanserin,1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL617927,2679
,12687,H,8,,,,15086,,The compound was tested for binding affinity against 5-hydroxytryptamine 2A receptor,1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL617928,2680
,12687,D,9,,,,2309,,Binding affinity for 5-hydroxytryptamine 2A receptor in rat cortex using [3H]ketanserin,1,Rattus norvegicus,Expert,,,,10116.0,,,B,BAO_0000019,CHEMBL617929,2681
,12687,H,8,,,,12953,,Binding affinity to 5-hydroxytryptamine 2A receptor from rat cortex assayed using [3H]ketanserin as radioligand.,1,,Expert,,,,,,,B,BAO_0000019,CHEMBL617930,2682
,12687,H,8,,,,12953,,The compound was tested for its binding affinity towards 5-hydroxytryptamine 2A receptor from rat cortex using [3H]ketanserin as radioligand.; Nonactive at 10 uM,1,,Autocuration,,,,,,,B,BAO_0000019,CHEMBL617931,2683
,12687,H,8,,,,12953,,The compound was tested for its binding affinity towards 5-hydroxytryptamine 2A receptor from rat cortex using [3H]-ketanserin as radioligand; Nonactive at 10 uM,1,,Autocuration,,,,,,,B,BAO_0000019,CHEMBL617932,2684
,12687,H,8,,,,16659,,Binding affinity for displacement of [3H]ketanserin to rat 5-hydroxytryptamine 2A receptor stably expressed in CHO cells; ND is No Data,1,,Autocuration,,449.0,,,CHO,,B,BAO_0000219,CHEMBL617933,2685
,12687,H,8,,,,16740,,In vitro binding affinity at 5-hydroxytryptamine 2A receptor in rat cortical membrane; ND means no data,1,,Autocuration,,,,,,,B,BAO_0000019,CHEMBL617934,2686
,12687,H,8,,,,16740,,In vitro binding affinity at serotonin 5-hydroxytryptamine 2A receptor in rat cortical membrane; ND means no data,1,,Autocuration,,,,,,,B,BAO_0000019,CHEMBL617935,2687
,12687,H,8,,,,17133,,Tested for its ability to activate phospholipase C by quantification of IP3 at cloned rat 5-hydroxytryptamine 2A receptor; Not determined,1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL617936,2688
,12687,H,8,,,,17211,,Ability to displace [3H]ketanserin (0.5 nM) from cerebral cortex of rat 5-hydroxytryptamine 2A receptor; NT=not tested,1,,Autocuration,,,,,,,B,BAO_0000019,CHEMBL617937,2689
,12687,H,8,,,,17331,,Binding affinity against 5-hydroxytryptamine 2A receptor by displacement of [3H]-ketanserin from rat prefrontal cerebral cortex mambranes; Not tested,1,,Autocuration,,,,,,,B,BAO_0000019,CHEMBL617938,2690
,12687,H,8,,,,16633,,Compound was evaluated for effective dose measured in nmol/kg following a dose of 0.04 mg/kg and 0.093 uM/kg (95%CI); range 32-63,1,,Autocuration,,,,,,,B,BAO_0000218,CHEMBL617939,2691
,12687,H,8,,,,16633,,Compound was evaluated for the percentage of rats disrupted following a dose of 0.04 mg/kg and 0.097 uM/kg,1,,Autocuration,,,,,,,B,BAO_0000218,CHEMBL617940,2692
,12687,H,8,,,,16633,,Compound was evaluated for the percentage of rats disrupted following a dose of 0.08 mg/kg and 0.194 uM/kg,1,,Autocuration,,,,,,,B,BAO_0000218,CHEMBL617941,2693
,12687,H,8,,,,15026,,Ratio of pKi of 5-HT2A to that of 5-HT2C receptor,1,,Expert,,,,,,,B,BAO_0000357,CHEMBL617942,2694
,12687,H,8,,,,15026,,Ratio of pKi of 5-HT2A to that of D2 receptor,1,,Expert,,,,,,,B,BAO_0000357,CHEMBL617943,2695
,105093,H,4,,,,16404,,Selectivity ratio towards KB of 5-hydroxytryptamine 2A receptor to 5-hydroxytryptamine 2B receptor,1,,Expert,,,,,,,B,BAO_0000224,CHEMBL617944,2696
,105093,H,4,,,,16404,,Selectivity ratio towards KB of 5-hydroxytryptamine 2A receptor to 5-hydroxytryptamine 2B receptor,1,,Expert,,,,,,,B,BAO_0000224,CHEMBL617945,2697
,105075,H,4,,,,16404,,Selectivity ratio towards Ki of 5-hydroxytryptamine 2A receptor to 5-hydroxytryptamine 2C receptor,1,,Expert,,,,,,,B,BAO_0000224,CHEMBL617946,2698
,12687,H,8,,,,16404,,Selectivity ratio towards Ki of 5-hydroxytryptamine 2A receptor to 5-hydroxytryptamine 2C receptor; ND is no data,1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL617947,2699
,12687,H,8,,,,16326,,Percent maximal 5-HT stimulation at cloned rat 5-hydroxytryptamine 2A receptor (phosphoinositide hydrolysis study) at a conc of 100 uM,1,,Expert,,,,,,,B,BAO_0000357,CHEMBL617948,2700
,12687,H,8,,,,15847,,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 2A receptor of rat,1,,Autocuration,,,,,,,F,BAO_0000019,CHEMBL858116,2701
,12687,H,8,,,,15847,,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 2A receptor of rat; ND means not done,1,,Autocuration,,,,,,,F,BAO_0000019,CHEMBL617949,2702
,12687,H,8,,,,15329,,Effectiveness of compound in blocking 5-hydroxytryptamine 2A receptor-mediated contractions of rat tail artery,1,,Autocuration,,,,,,,F,BAO_0000019,CHEMBL617950,2703
Thoracic aorta,12687,H,8,,,,16404,,Negative log concentration of antagonist on 5-hydroxytryptamine 2A receptor in rat thoracic aorta,1,,Expert,,,,,,1515.0,F,BAO_0000019,CHEMBL617951,2704
Thoracic aorta,12687,H,8,,,,16404,,Negative log concentration of antagonistic compound was determined on 5-hydroxytryptamine 2A receptor of Rat thoracic aorta,1,,Expert,,,,,,1515.0,F,BAO_0000019,CHEMBL617952,2705
Thoracic aorta,12687,H,8,,,,16404,,Negative log concentration of antagonistic compound was determined on 5-hydroxytryptamine 2A receptor of Rat thoracic aorta; ND is not determined.,1,,Autocuration,,,,,,1515.0,F,BAO_0000019,CHEMBL617953,2706
,12687,H,8,,,,12861,,Binding activity radioligand.,1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL617954,2707
,12687,H,8,,,,12861,,Binding activity against 5-hydroxytryptamine 2C receptor from pig cortex membrane using [3H]mesulergine as radioligand.,1,,Expert,,,,,,,B,BAO_0000019,CHEMBL617955,2708
,12687,H,8,,,,12861,,Binding activity against 5-hydroxytryptamine 2C receptor from pig cortex membrane using [3H]mesulergine as radioligand; NA Not Available,1,,Autocuration,,,,,,,B,BAO_0000019,CHEMBL857071,2709
,12687,H,8,,,,12490,,Displacement of [3H]DOB binding to 5-hydroxytryptamine 2A receptor from rat cortex homogenate,1,,Expert,,,,,,,B,BAO_0000019,CHEMBL617270,2710
,12687,H,8,,,,12827,,Binding affinity towards 5-hydroxytryptamine 3 receptor in membranes of N1E-115 neuroblastoma cells using [3H]-ICS 205-930,1,,Autocuration,,339.0,,,N1E-115,,B,BAO_0000219,CHEMBL617271,2711
,12687,H,8,,,,12827,,Binding affinity towards 5-hydroxytryptamine 3 receptor in membranes of N1E-115 neuroblastoma cells using [3H]-ICS 205-930; Not determined,1,,Autocuration,,339.0,,,N1E-115,,B,BAO_0000219,CHEMBL617272,2712
,12687,H,8,,,,12918,,Binding affinity was evaluated by 5-hydroxytryptamine 2A receptor agonism in the rat cortex by displacing ketanserin,1,,Autocuration,,,,,,,B,BAO_0000019,CHEMBL617273,2713
,12687,D,9,,,,12919,,Agonistic activity against 5-hydroxytryptamine 2A receptor in rat cortex using [3H]-ketanserin,1,Rattus norvegicus,Expert,,,,10116.0,,,F,BAO_0000019,CHEMBL617274,2714
,108,H,8,,,,17723,,Binding affinity towards human serotonin 5-hydroxytryptamine 2C receptor,1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL617275,2715
,108,H,8,,,,6013,,Binding affinity towards 5-hydroxytryptamine 2C receptor,1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL617276,2716
,108,H,8,,,,16293,,Binding affinity towards human 5-hydroxytryptamine 2C receptor,1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL617277,2717
,108,H,8,,,,3857,,Binding affinity using [125I]DOI as radioligand with membranes isolated from a CHO-k cell line expressing the human 5-hydroxytryptamine 2C receptor,1,,Expert,,,,,,,B,BAO_0000019,CHEMBL617278,2718
,108,H,8,,,,3857,,Binding affinity using [125I]DOI as radioligand with membranes isolated from a CHO-k cell line expressing the human 5-hydroxytryptamine 2C receptor; Not determined,1,,Expert,,,,,,,B,BAO_0000019,CHEMBL617279,2719
,108,H,8,,,,3857,,Binding affinity using [3H]mesulergine as radioligand with receptor membranes isolated from a CHO-k cell line expressing the human 5-hydroxytryptamine 2C receptor,1,,Expert,,,,,,,B,BAO_0000019,CHEMBL617280,2720
,108,H,8,,,,15363,,Compound was tested for the displacement of [125I]DOI from cloned human 5-hydroxytryptamine 2C receptor,1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL617281,2721
,108,H,8,,,,15363,,Compound was tested for the displacement of [125I]DOI from cloned human 5-hydroxytryptamine 2C receptor,1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL617282,2722
,108,H,8,,,,16441,,Tested on transfected cell membranes selectively expressing human 5-hydroxytryptamine 2C receptor using [3H]mesulergine,1,,Expert,,,,,,,B,BAO_0000019,CHEMBL617283,2723
,108,H,8,,,,16441,,Tested on transfected cell membranes selectively expressing human 5-hydroxytryptamine 2C receptor using [3H]-mesulergine; ND is No Data.,1,,Expert,,,,,,,B,BAO_0000019,CHEMBL617284,2724
,108,H,8,,,,4176,,In vitro binding affinity towards human 5-hydroxytryptamine 2C receptor expressed in HEK293 cells was determined using [3H]mesulergine as radioligand,1,,Autocuration,,722.0,,,HEK293,,B,BAO_0000219,CHEMBL617285,2725
,108,H,8,,,,17085,,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 2C receptor,1,,Autocuration,,,,,,,B,BAO_0000019,CHEMBL617286,2726
,108,D,9,,,,17200,,Inhibitory constant against cloned human 5-hydroxytryptamine 2C receptor using with [125I]- DOI radioligand,1,Homo sapiens,Expert,,,,9606.0,,,B,BAO_0000357,CHEMBL617287,2727
,108,H,8,,,,5088,,Binding affinity towards human 5-hydroxytryptamine 2C receptor.,1,,Expert,,,,,,,B,BAO_0000357,CHEMBL617288,2728
,108,H,8,,,,5088,,Tested for binding affinity towards human 5-hydroxytryptamine 2C receptor using [3H]DOB as radioligand,1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL617289,2729
,108,H,8,,,,5088,,Tested for binding affinity towards human 5-hydroxytryptamine 2C receptor using [3H]mesulergine as radioligand,1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL872917,2730
,108,H,8,,,,5088,,Tested for binding affinity towards human 5-hydroxytryptamine 2C receptor using [3H]5-HT as radioligand,1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL617290,2731
,108,H,8,,,,16659,,Binding affinity for displacement of [3H]mesulergine to human 5-hydroxytryptamine 2C receptor stably expressed in CHO cells,1,,Autocuration,,449.0,,,CHO,,B,BAO_0000219,CHEMBL617291,2732
,108,H,8,,,,16659,,Binding affinity for displacement of [3H]mesulergine to human 5-hydroxytryptamine 2C receptor stably expressed in CHO cells; ND is no data,1,,Autocuration,,449.0,,,CHO,,B,BAO_0000219,CHEMBL617292,2733
,108,H,8,,,,17451,,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 2C receptor expressed in 3T3 cells using [3H]5-HT as radioligand; Not determined,1,,Autocuration,,723.0,,,NIH3T3,,B,BAO_0000219,CHEMBL617293,2734
,108,D,9,,,,6857,,Relative efficacy against human 5-hydroxytryptamine 2B receptor expressed in CHO cells using fluorometric imaging plate reader relative to 10 uM 5-HT,1,Homo sapiens,Expert,,449.0,,9606.0,CHO,,F,BAO_0000219,CHEMBL617294,2735
,108,H,8,,,,3857,,Inhibitory activity using [3H]mesulergine as radioligand with receptor membranes isolated from a CHO-k cell line expressing the human 5-hydroxytryptamine 2C receptor at a concentration of 1 uM,1,,Expert,,,,,,,B,BAO_0000019,CHEMBL617295,2736
,108,H,8,,,,12861,,Binding activity radioligand.,1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL617296,2737
,108,H,8,,,,12861,,Binding activity against 5-hydroxytryptamine 2C receptor from human brain cortex using [3H]mesulergine as radioligand.,1,,Autocuration,,,,,,,B,BAO_0000019,CHEMBL617297,2738
,108,H,8,,,,5104,,Binding affinity for human cloned 5-hydroxytryptamine 2C receptor expressed in CHO cells using [3H]mesulergine as radioligand,1,,Expert,,449.0,,,CHO,,B,BAO_0000219,CHEMBL617298,2739
,108,H,8,,,,5105,,Binding affinity at human cloned 5-hydroxytryptamine 2C receptor expressed in CHO cells by [3H]mesulergine displacement.,1,,Expert,,449.0,,,CHO,,B,BAO_0000219,CHEMBL617299,2740
,108,H,8,,,,5105,,Binding affinity for human cloned 5-hydroxytryptamine 2C receptor expressed in CHO cells using [3H]mesulergine as radioligand; NT means not tested,1,,Autocuration,,449.0,,,CHO,,B,BAO_0000219,CHEMBL617300,2741
,108,H,8,,,,5254,,Binding affinity against 5-HT2C receptor,1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL617454,2742
,108,H,8,,,,13267,,Antagonistic binding affinity measured against 5-hydroxytryptamine 2C receptor (human clone expressed in 293 cells) using [3H]mesulergine as radioligand,1,,Autocuration,,722.0,,,HEK293,,B,BAO_0000219,CHEMBL617505,2743
,108,D,9,,,,14157,,Displacement of [3H]mesulergine from 5-hydroxytryptamine 2C receptor expressed in HEK 293 cells,1,Homo sapiens,Expert,,722.0,,9606.0,HEK293,,B,BAO_0000219,CHEMBL617506,2744
,108,D,9,,,,12936,,Binding affinity against human 5-hydroxytryptamine 2C receptor expressed in 293 cells using [3H]mesulergine,1,Homo sapiens,Expert,,722.0,,9606.0,HEK293,,B,BAO_0000219,CHEMBL617507,2745
,108,H,8,,,,14068,,Binding affinity against human 5-hydroxytryptamine 2C receptor using displacement of [3H]DOB,1,,Expert,,,,,,,B,BAO_0000357,CHEMBL617508,2746
,108,D,9,,,,12936,,Binding affinity against human 5-hydroxytryptamine 2C receptor expressed in 293 cells using [3H]mesulergine,1,Homo sapiens,Expert,,722.0,,9606.0,HEK293,,B,BAO_0000219,CHEMBL857982,2747
,108,D,9,,,,4540,,Binding affinity to human cloned 5-hydroxytryptamine 2C receptor in HEK 293 cells using [3H]- mesulergine as radioligand,1,Homo sapiens,Expert,,722.0,,9606.0,HEK293,,B,BAO_0000219,CHEMBL617509,2748
,108,D,9,,,,4540,,Binding affinity to human cloned 5-hydroxytryptamine 2C receptor in HEK 293 cells using [3H]- mesulergine as radioligand; Nd means not determined,1,Homo sapiens,Expert,,722.0,,9606.0,HEK293,,B,BAO_0000219,CHEMBL617510,2749
,108,H,8,,,,6166,,Binding affinity towards cloned human 5-hydroxytryptamine 2C receptor was determined,1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL617511,2750
,108,H,8,,,,17296,,Binding affinity against 5-hydroxytryptamine 2C receptor human cloned receptors in HEK 293 cells using [3H]mesulergine as radioligand,1,,Autocuration,,722.0,,,HEK293,,B,BAO_0000219,CHEMBL617512,2751
,108,H,8,,,,17296,,Binding affinity against 5-hydroxytryptamine 2C receptor human cloned receptorswithouteffect in HEK 293 cells using [3H]mesulergine as radioligand,1,,Autocuration,,722.0,,,HEK293,,B,BAO_0000219,CHEMBL617749,2752
,108,H,8,,,,15779,,Binding affinity towards 5-HT2C (human cloned receptor) in HEK 293 cells using [3H]mesulergine as radioligand.,1,,Autocuration,,722.0,,,HEK293,,B,BAO_0000219,CHEMBL617750,2753
,108,H,8,,,,15779,,Binding affinity towards 5-hydroxytryptamine 2C receptor (human cloned receptor) in HEK 293 cells using [3H]mesulergine as radioligand.,1,,Autocuration,,722.0,,,HEK293,,B,BAO_0000219,CHEMBL617751,2754
,108,H,8,,,,14391,,Binding affinity towards cloned human 5-hydroxytryptamine 2C receptor expressed in HEK 293 cells using [3H]mesulergine as radioligand,1,,Expert,,722.0,,,HEK293,,B,BAO_0000219,CHEMBL617752,2755
,108,H,8,,,,15779,,"Binding affinity towards human cloned 5-hydroxytryptamine 2C receptor in HEK293 cells, using [3H]mesulergine as radioligand",1,,Autocuration,,722.0,,,HEK293,,B,BAO_0000219,CHEMBL617753,2756
,108,H,8,,,,15851,,"Binding affinity towards human cloned 5-hydroxytryptamine receptor 2C in HEK293 cells, using [3H]mesulergine as radioligand.",1,,Expert,,722.0,,,HEK293,,B,BAO_0000219,CHEMBL617754,2757
,108,D,9,,,,15851,,Displacement of [3H]mesulergine from human 5-hydroxytryptamine 2C receptor expressed in HEK293 cells; compound insoluble,1,Homo sapiens,Expert,,722.0,,9606.0,HEK293,,B,BAO_0000219,CHEMBL617755,2758
,108,H,8,,,,15779,,"Binding affinity towards human cloned 5-hydroxytryptamine 2C receptor in HEK293 cells, using [3H]mesulergine as radioligand; no data",1,,Autocuration,,722.0,,,HEK293,,B,BAO_0000219,CHEMBL617756,2759
,108,H,8,,,,3832,,Binding affinity towards human cloned 5-hydroxytryptamine 2C receptor of HEK293 cells by displacement of [3H]mesulergine,1,,Expert,,722.0,,,HEK293,,B,BAO_0000219,CHEMBL617757,2760
,108,H,8,,,,3833,,In vitro binding affinity at human cloned 5-hydroxytryptamine 2C receptor of HEK293 cells by [3H]mesulergine displacement.,1,,Expert,,722.0,,,HEK293,,B,BAO_0000219,CHEMBL617758,2761
,108,H,8,,,,17451,,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 2C receptor expressed in 3T3 cells using [3H]5-HT as radioligand,1,,Autocuration,,723.0,,,NIH3T3,,B,BAO_0000219,CHEMBL617759,2762
,108,H,8,,,,4199,,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 2C receptor in HEK 293 cells using [3H]mesulergine as the radioligand,1,,Autocuration,,722.0,,,HEK293,,B,BAO_0000219,CHEMBL617760,2763
,108,H,8,,,,1883,,Displacement of [3H]mesulergine from human cloned 5-hydroxytryptamine 2C receptor expressed in CHO-K1 cells,1,,Expert,,485.0,,,CHO-K1,,B,BAO_0000219,CHEMBL617761,2764
,108,D,9,,,,4321,,Binding affinity against 5-hydroxytryptamine 2C receptor,1,Homo sapiens,Expert,,,,9606.0,,,B,BAO_0000357,CHEMBL617762,2765
,108,H,8,,,,14875,,Compound was tested for binding affinity against human 5-hydroxytryptamine 2C receptor,1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL617763,2766
,108,H,8,,,,15146,,Compound was tested for its binding affinity against human cloned 5-hydroxytryptamine 2C receptor in HEK 293 cells using [3H]mesulergine,1,,Autocuration,,722.0,,,HEK293,,B,BAO_0000219,CHEMBL857983,2767
,108,H,8,,,,5213,,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 2C receptor in HEK 293 using [3H]mesulergine as a radioligand,1,,Autocuration,,722.0,,,HEK293,,B,BAO_0000219,CHEMBL617764,2768
,108,H,8,,,,16404,,Inhibitory constant on human 5-hydroxytryptamine 2C receptor transfected in to HeLa cells,1,,Autocuration,,308.0,,,HeLa,,B,BAO_0000219,CHEMBL617765,2769
,108,H,8,,,,13267,,Selectivity as the ratio of Ki value towards 5-hydroxytryptamine 2C receptor to that of pA2 value towards 5-hydroxytryptamine 2B receptor,1,,Autocuration,,,,,,,F,BAO_0000019,CHEMBL617766,2770
Hippocampus,108,H,8,,,,13267,,The binding affinity (pKi) measured against 5-hydroxytryptamine 3 receptor of rat hippocampus and entorhinal cortex using [3H]granisetron as radioligand,1,,Autocuration,,,,,,10000000.0,F,BAO_0000221,CHEMBL617767,2771
,108,H,8,,,,14818,,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 2C receptor in HEK293 cells using [3H]mesulergine.,1,,Autocuration,,722.0,,,HEK293,,B,BAO_0000219,CHEMBL617768,2772
,108,H,8,,,,4829,,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 2C receptor in HEK293 cells, using [3H]5-mesulergine as radioligand",1,,Autocuration,,722.0,,,HEK293,,B,BAO_0000219,CHEMBL617769,2773
,11864,H,8,,,,13463,,Binding affinity analysed on 5-HT 2C in human clone using [3H]mesulergine as radioligand,1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL858023,2774
Stomach,11864,H,8,,,,13463,,Binding affinity analysed on 5-HT 2C in rat stomach fundus,1,,Autocuration,,,,,,945.0,B,BAO_0000019,CHEMBL617770,2775
Stomach,11864,H,8,,,,13463,,Binding affinity analysed towards 5-HT 2C in rat stomach fundus,1,,Autocuration,,,,,,945.0,B,BAO_0000019,CHEMBL617771,2776
,11864,H,8,,,,12652,,Percent of maximum stimulation of phosphatidylinositol turnover at cloned 5-hydroxytryptamine 2C receptor in A9 cells,1,,Autocuration,,625.0,,,A9,,F,BAO_0000219,CHEMBL617772,2777
,11864,H,8,,,,4682,,Binding affinity to 5-hydroxytryptamine 2C receptor using [3H]Mesulergine as radioligand in stably transfected NIH3T3 cells,1,,Autocuration,,723.0,,,NIH3T3,,B,BAO_0000219,CHEMBL617773,2778
,11864,H,8,,,,4682,,Binding affinity to 5-hydroxytryptamine 2C receptor measured using radioligand [3H]Mesulergine in stably transfected NIH3T3 cells,1,,Autocuration,,723.0,,,NIH3T3,,B,BAO_0000219,CHEMBL617850,2779
,11864,H,8,,,,4682,,Binding affinity to 5-hydroxytryptamine 2C receptor using [3H]Mesulergine as radioligand in stably transfected NIH3T3 cells,1,,Autocuration,,723.0,,,NIH3T3,,B,BAO_0000219,CHEMBL617851,2780
,11864,H,8,,,,12652,,The maximum responses of [3H]- inositol monophosphate accumulation in cells expressing the 5-hydroxytryptamine 2C receptor,1,,Autocuration,,,,,,,F,BAO_0000019,CHEMBL617852,2781
Stomach,12689,H,8,,,,13463,,Binding affinity analysed on 5-HT 2C in rat stomach fundus.,1,Mus musculus,Autocuration,,,,10090.0,,945.0,B,BAO_0000019,CHEMBL858024,2782
Stomach,12689,D,9,,,,13463,,Binding affinity towards 5-HT 2C receptor in rat stomach fundus,1,Rattus norvegicus,Expert,,,,10116.0,,945.0,B,BAO_0000019,CHEMBL617853,2783
,108,H,8,,,,13969,,Binding affinity against 5-Hydroxytryptamine 2C Receptor was measured using [3H]N-methyl-mesulergine as radioligand,1,,Expert,,,,,,,B,BAO_0000357,CHEMBL617854,2784
,108,H,8,,,,13392,,Binding affinity for 5-hydroxytryptamine 2C receptor,1,Sus scrofa,Expert,,,,9823.0,,,B,BAO_0000357,CHEMBL873477,2785
,108,H,8,,,,13392,,Binding affinity towards 5-hydroxytryptamine 2C receptor,1,,Expert,,,,,,,B,BAO_0000357,CHEMBL617855,2786
,108,H,8,,,,14430,,Affinity towards 5-hydroxytryptamine 2C receptor in membranes from pig choroid plexus using [3H]N-methyl-mesulergine,1,,Expert,,,,,,,B,BAO_0000019,CHEMBL617856,2787
,108,H,8,,,,1742,,Compound was tested for its ability to displace [3H]mesulergine from 5-hydroxytryptamine 2C receptor in pig cortex,1,,Autocuration,,,,,,,B,BAO_0000019,CHEMBL617857,2788
,108,H,8,,,,14286,,In vitro inhibitory concentration against radioligand [3H]mesulergine binding to 5-hydroxytryptamine 2C receptor in pig cortical membrane,1,,Autocuration,,,,,,,B,BAO_0000249,CHEMBL617858,2789
,108,H,8,,,,5619,,Binding affinity towards pig 5-hydroxytryptamine 2C receptor,1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL617859,2790
,108,H,8,,,,15086,,The compound was tested for binding affinity against 5-hydroxytryptamine 2C receptor,1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL617860,2791
,108,H,8,,,,12861,,Binding activity radioligand.,1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL617861,2792
,108,H,8,,,,12861,,Binding activity against 5-hydroxytryptamine 2C receptor from pig cortex membrane using [3H]mesulergine as radioligand.,1,,Expert,,,,,,,B,BAO_0000019,CHEMBL617862,2793
,108,H,8,,,,12861,,Binding activity against 5-hydroxytryptamine 3 receptor from pig cortex membrane using [3H]mesulergine as radioligand; NA Not Available,1,,Autocuration,,,,,,,B,BAO_0000019,CHEMBL617863,2794
,108,H,8,,,,12827,,Binding affinity towards 5-hydroxytryptamine 1D receptor in calf caudate membranes using [3H]5-HT,1,,Autocuration,,,,,,,B,BAO_0000249,CHEMBL617864,2795
,108,H,8,,,,12827,,Binding affinity towards 5-hydroxytryptamine 1D receptor in calf caudate membranes using [3H]5-HT; Not determined,1,,Autocuration,,,,,,,B,BAO_0000249,CHEMBL617649,2796
,108,H,8,,,,12919,,Agonistic activity against 5-hydroxytryptamine 2C receptor in pig choroid plexus using [3H]mesulergine,1,Sus scrofa,Expert,,,,9823.0,,,F,BAO_0000019,CHEMBL617650,2797
,108,H,8,,,,12919,,Agonistic activity against 5-hydroxytryptamine 2C receptor in pig choroid plexus using [3H]mesulergine,1,Sus scrofa,Expert,,,,9823.0,,,F,BAO_0000019,CHEMBL617651,2798
,108,H,8,,,,16429,,In vitro binding affinity at 5-hydroxytryptamine 2C receptor in pig choroid plexus using 3[H]mesulergine as the radioligand,1,Sus scrofa,Autocuration,,,,9823.0,,,B,BAO_0000357,CHEMBL617652,2799
,108,H,8,,,,773,,In Vitro Binding affinity againist 5-hydroxytryptamine 2C receptor by displacing [3H]mesulergine from pig cortex,1,Sus scrofa,Autocuration,,,,9823.0,,,B,BAO_0000019,CHEMBL857072,2800
,108,H,8,,,,5033,,Ability to displace the radioligand [3H]mesulergine from pig choroid plexus 5-hydroxytryptamine 2C receptor,1,Sus scrofa,Autocuration,,,,9823.0,,,B,BAO_0000357,CHEMBL617653,2801
,12687,H,8,,,,12861,,Binding activity against 5-hydroxytryptamine 2C receptor from pig cortex membrane using [3H]mesulergine as radioligand.,1,,Autocuration,,,,,,,B,BAO_0000019,CHEMBL617654,2802
,12689,H,8,,,,14093,,Effect on phosphoinositide hydrolysis in NIH 3T3 fibroblast 5-hydroxytryptamine 2C receptor,1,,Autocuration,,,,,,,F,BAO_0000019,CHEMBL617655,2803
,12689,H,8,,,,14970,,Binding affinity towards 5-HT2C receptor from rat using [3H]mesulergine as radioligand,1,,Expert,,,,,,,B,BAO_0000357,CHEMBL617656,2804
,12689,H,8,,,,14970,,Compound was tested in vitro for its binding affinity towards 5-hydroxytryptamine 2C receptor from rat using [3H]mesulergine as radioligand,1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL617657,2805
,12689,H,8,,,,14970,,Compound was tested in vitro for its binding affinity towards 5-hydroxytryptamine 2C receptor from rat using [3H]mesulergine as radioligand; Not tested,1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL617658,2806
,12689,D,9,,,,14178,,Inhibition of radiolabeled [3H]-Ketanserin ligand binding to 5-hydroxytryptamine 2C receptor,1,Rattus norvegicus,Expert,,,,10116.0,,,B,BAO_0000357,CHEMBL617659,2807
,12689,D,9,,,,14178,,Inhibition of radiolabeled [3H]mesulergine ligand binding to 5-hydroxytryptamine 2C receptor,1,Rattus norvegicus,Expert,,,,10116.0,,,B,BAO_0000357,CHEMBL617838,2808
,12689,D,9,,,Brain membranes,14229,,Inhibition of [3H]mesulergine binding to 5-hydroxytryptamine 2C receptor in rat brain membranes,1,Rattus norvegicus,Expert,,,,10116.0,,,B,BAO_0000249,CHEMBL617839,2809
,12689,H,8,,,,16532,,The binding affinity at 5-hydroxytryptamine 2C receptor was determined using [3H]mesulergine; Not tested,1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL617840,2810
,12689,H,8,,,,14826,,Ability to displace [3H]mesulergine bound to 5-hydroxytryptamine 2C receptor in rat cortex,1,,Autocuration,,,,,,,B,BAO_0000019,CHEMBL617841,2811
,12689,H,8,,,,17211,,Ability to displace [3H]mesulergine (0.5 nM) from SR-3T3 cells of rat 5-HT2C receptor,1,,Autocuration,,,,,,,B,BAO_0000019,CHEMBL875915,2812
,12689,H,8,In vitro,,,17211,,Displacement of [3H]mesulergine (0.5 nM) from rat 5-hydroxytryptamine 2C receptor expressed in SR-3T3 cells,1,,Expert,,,,,,,B,BAO_0000219,CHEMBL617842,2813
,12689,H,8,,,,13246,,Ability to inhibit the binding of iodine-125-labelled lysergic acid diethylamide([125I]-LSD) to the S-2C serotonin receptor in NIH3T3 cell line membranes,1,,Expert,,723.0,,,NIH3T3,,B,BAO_0000219,CHEMBL617843,2814
,12689,H,8,,,,13246,,Ability to inhibit the binding of iodine-125-labelled lysergic acid diethylamide([125I]-LSD) to the S-2C serotonin receptor.,1,,Expert,,,,,,,B,BAO_0000357,CHEMBL617844,2815
,12689,H,8,,,,12457,,Affinity was evaluated as inhibition constant for serotonin 5-hydroxytryptamine 2C receptor,1,,Expert,,,,,,,B,BAO_0000357,CHEMBL617845,2816
,12689,H,8,,,,12457,,Affinity was evaluated by inhibition of [125I]LSD binding to NIH 3T3 cells transfected with cloned rat 5-hydroxytryptamine 2C receptor,1,,Expert,,723.0,,,NIH3T3,,B,BAO_0000219,CHEMBL617846,2817
,12689,H,8,,,,4707,,Binding affinity towards rat 5-hydroxytryptamine 2C receptor was determined using [125I]- DOI as radioligand,1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL617847,2818
,12689,H,8,,,,13297,,Binding affinity against 5-hydroxytryptamine 2C receptor,1,,Expert,,,,,,,B,BAO_0000357,CHEMBL617848,2819
,12689,H,8,,,,16633,,Binding affinity against 5-hydroxytryptamine 2C receptor using [125I]DOI as radioligand,1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL617849,2820
,12689,H,8,,,,16133,,Binding affinity against rat 5-hydroxytryptamine 2C receptor using [3H]mesulergine as radioligand,1,,Expert,,,,,,,B,BAO_0000357,CHEMBL621507,2821
,12689,H,8,,,,16326,,Binding affinity at cloned rat 5-hydroxytryptamine 2C receptor using [3H]DOI as radioligand,1,,Expert,,,,,,,B,BAO_0000357,CHEMBL621508,2822
,12689,H,8,,,,14423,,Binding affinity against 5-hydroxytryptamine 2C receptor from rat cortex using [3H]mesulergine as the radioligand.,1,,Autocuration,,,,,,,B,BAO_0000019,CHEMBL621509,2823
,12689,H,8,,,,15412,,Binding affinity against 5-hydroxytryptamine 2C receptor of rat cortex,1,,Autocuration,,,,,,,B,BAO_0000019,CHEMBL621510,2824
,12689,H,8,,,,15412,,Binding affinity against 5-hydroxytryptamine 2C receptor of rat cortex.,1,,Autocuration,,,,,,,B,BAO_0000019,CHEMBL621511,2825
,12689,H,8,,,,15558,,Displacement of [3H]mesulergine from A9 cells stably expressing rat 5-hydroxytryptamine 2C receptor,1,,Expert,,625.0,,,A9,,B,BAO_0000219,CHEMBL621512,2826
,12689,H,8,,,,16633,,Binding affinity towards 5-hydroxytryptamine 2C receptor using [125I]DOI as radioligand,1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL621513,2827
,12689,H,8,,,,6013,,Binding affinity towards cloned rat 5-hydroxytryptamine 2C receptor from fundus tissue by [3H]mesulergine displacement.,1,,Expert,,,,,,,B,BAO_0000357,CHEMBL621514,2828
,12689,H,8,In vitro,,,17175,,Binding affinity towards rat 5-hydroxytryptamine 2C receptor expressed in A-9 cells using [3H]mesulergine as radioligand,1,,Expert,,,,,,,B,BAO_0000219,CHEMBL621515,2829
,12689,H,8,,,,12469,,Binding affinity was measured on 5-hydroxytryptamine 2C receptor in J1 cells transfected with rat 5-HT2C gene labeled with [3H]mesulergine,1,,Autocuration,,,,,,,B,BAO_0000219,CHEMBL621516,2830
Caudate-putamen,12689,H,8,,,,3682,,Compound was evaluated for affinity towards cerebral 5-hydroxytryptamine 2C receptor in homogenate of caudate putamen tissue from rat brain,1,,Autocuration,,,,,,5383.0,B,BAO_0000019,CHEMBL621517,2831
,12689,H,8,,,,4932,,Compound was evaluated for its ability to displace (+/-)[125I]-DOI from 5-hydroxytryptamine 2C receptor in cloned rat cell culture,1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL621518,2832
,12689,H,8,,,,4932,,Compound was evaluated for its ability to displace [125I](R)-DOI from 5-hydroxytryptamine 2C receptor in cloned rat prefrontal cortex homogenate; ND denotes no data,1,,Autocuration,,,,,,,B,BAO_0000019,CHEMBL621519,2833
,12689,H,8,,,,3935,,Compound was evaluated for its binding affinity for rat 5-hydroxytryptamine 2C receptor,1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL621520,2834
,12689,H,8,,,,15818,,Compound was evaluated for its binding affinity towards rat 5-hydroxytryptamine 2C receptor,1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL621521,2835
,12689,H,8,,,,15818,,Compound was evaluated for its binding affinity towards rat r5-hydroxytryptamine 2C receptor,1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL621522,2836
,12689,H,8,,,,14749,,Binding affinity against rat 5-hydroxytryptamine 2C receptor in A-9 cells.,1,,Expert,,,,,,,B,BAO_0000219,CHEMBL621523,2837
,12689,H,8,,,,15740,,Evaluated for the binding constant at [125I]-DOI-labeled rat 5-hydroxytryptamine 2C receptor,1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL621524,2838
,12689,D,9,,,,17133,,In vitro binding to 5-hydroxytryptamine 2C receptor using [125 I]-DOI,1,Rattus norvegicus,Expert,,,,10116.0,,,B,BAO_0000357,CHEMBL621525,2839
,12689,H,8,,,,16532,,The binding affinity at 5-hydroxytryptamine 2C receptor was determined using [3H]mesulergine,1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL872921,2840
,12689,H,8,,,,12369,,The compound evaluated for its affinity against 5-hydroxytryptamine 2C receptor,1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL621526,2841
,12689,H,8,,,,12369,,Affinity against 5-hydroxytryptamine 2C receptor in J1 cells transfected with the rat 5-HT2C gene labeled with [3H]mesulergine.,1,,Expert,,,,,,,B,BAO_0000219,CHEMBL621527,2842
,12689,D,9,,,,2309,,Binding affinity against 5-hydroxytryptamine 2C receptor in rat choroid plexus using [3H]N-methyl-mesulergine,1,Rattus norvegicus,Expert,,,,10116.0,,,B,BAO_0000019,CHEMBL617865,2843
,12689,H,8,,,,12953,,The compound was tested for their binding affinity towards 5-hydroxytryptamine 2C receptor,1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL617866,2844
,12689,H,8,,,,12953,,The compound was tested for their binding affinity towards 5-hydroxytryptamine 2C receptor from rat cortex using [3H]-citalopram as radioligand; Nonactive at 10 uM,1,,Autocuration,,,,,,,B,BAO_0000019,CHEMBL617867,2845
,12689,H,8,,,,12953,,The compound was tested for their binding affinity towards 5-hydroxytryptamine 2C receptor using [3H]mesulergine as radioligand; Nonactive at 10 uM,1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL617487,2846
,12689,H,8,,,,12953,,Binding affinity for 5-hydroxytryptamine 2C receptor,1,,Expert,,,,,,,B,BAO_0000357,CHEMBL617488,2847
,12689,H,8,,,,17133,,Tested in vitro for its ability to bind to 5-hydroxytryptamine 2C receptor using [125 I]-DOI as radioligand; Not determined,1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL617489,2848
,12689,H,8,,,,17211,,Ability to displace [3H]mesulergine (0.5 nM) from SR-3T3 cells of rat 5-hydroxytryptamine 2C receptor; NT denotes not tested,1,,Autocuration,,,,,,,B,BAO_0000019,CHEMBL617490,2849
,12689,H,8,,,,17211,,Ability to displace [3H]mesulergine (0.5 nM) from SR-3T3 cells of rat 5-hydroxytryptamine 2C receptor; NT=not tested,1,,Autocuration,,,,,,,B,BAO_0000019,CHEMBL617491,2850
,12689,H,8,,,,14025,,Affinity pKi for 5-hydroxytryptamine 2C receptor was measured in rat cortex homogenates.,1,,Autocuration,,,,,,,B,BAO_0000019,CHEMBL617492,2851
,12689,H,8,,,,14998,,Binding affinity against 5-hydroxytryptamine 2C receptor in rat cortex homogenates.,1,,Autocuration,,,,,,,B,BAO_0000019,CHEMBL617493,2852
,12689,H,8,,,,4342,,Binding affinity of compound towards serotonin 5-hydroxytryptamine 2C receptor was determined,1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL617494,2853
,12689,D,9,,,,13735,,Displacement of [3H]mesulergine from rat 5-HT2C receptor expressed in HEK293,1,Rattus norvegicus,Expert,,,,10116.0,,,B,BAO_0000019,CHEMBL617495,2854
,12689,H,8,,,,13181,,Binding affinity was determined against cloned human 5-hydroxytryptamine 2C receptor using [3H]5-HT as radioligand,1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL617496,2855
,12689,H,8,,,,1883,,Compound was evaluated for displacement of [3H]mesulergine from cloned rat 5-hydroxytryptamine 2C receptor in transfected CHO-K1 cells.,1,,Autocuration,,485.0,,,CHO-K1,,B,BAO_0000219,CHEMBL617497,2856
,12689,H,8,,,,15194,,The compound was tested for the binding affinity against 5-hydroxytryptamine 2C receptor using [3H]mesulergine as radioligand,1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL617498,2857
,12689,H,8,,,,15194,,The compound was tested for the binding affinity against 5-hydroxytryptamine 2C receptor using [3H]Mesulergine as radioligand.,1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL617499,2858
,12689,H,8,,,,14579,,Compound tested for relative response using 0.1 uM 5-HT as agonist against 5-hydroxytryptamine 2C receptor,1,,Autocuration,,,,,,,F,BAO_0000019,CHEMBL617500,2859
,108,H,8,,,,4639,,Compound was tested for binding affinity against 5-hydroxytryptamine 2C receptor,1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL617501,2860
,108,H,8,,,,4820,,Binding affinity towards 5-hydroxytryptamine 2C receptor,1,,Expert,,,,,,,B,BAO_0000357,CHEMBL617502,2861
,227,H,8,,,,14442,,Binding ability of compound at cloned human 5-hydroxytryptamine 2B receptor using [3H]rauwolscine as radioligand; Not Tested,1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL617503,2862
,227,H,8,,,,14755,,Binding activity against cloned human 5-hydroxytryptamine 2B receptor using [3H]5-HT as the radioligand.,1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL617504,2863
,227,H,8,,,,14744,,Binding affinity against the cloned human 5-hydroxytryptamine 2B receptor using [3H]5-HT as the radioligand,1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL617406,2864
,227,D,9,,,,6857,,Affinity for human 5-hydroxytryptamine 2B receptor expressed in mammalian cell line,1,Homo sapiens,Expert,,,,9606.0,,,B,BAO_0000019,CHEMBL617407,2865
,227,H,8,,,,16209,,Binding affinity towards human 5-hydroxytryptamine 2B receptor using [3H]5-HT as radioligand,1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL617408,2866
,227,H,8,,,,15363,,Compound was tested for the displacement of [3H]5-HT from clone human 5-hydroxytryptamine 2B receptor,1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL617409,2867
,227,H,8,,,,15363,,Compound was tested for the displacement of [3H]5-HT from clone human 5-hydroxytryptamine 2B receptor,1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL617410,2868
,227,H,8,,,,15363,,Compound was tested for the displacement of [3H]5-HT from cloned human 5-hydroxytryptamine 2B receptor,1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL617411,2869
,227,H,8,,,,17085,,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 2B receptor,1,,Autocuration,,,,,,,B,BAO_0000019,CHEMBL617412,2870
,227,D,9,,,,17200,,Inhibitory constant against cloned human 5-hydroxytryptamine 2B receptor using with [125I]- DOI radioligand,1,Homo sapiens,Expert,,,,9606.0,,,B,BAO_0000357,CHEMBL617774,2871
,227,D,9,,,,15851,,Displacement of [3H]5-HT from human 5-hydroxytryptamine 2B receptor expressed in HEK293 cells; ND = no data,1,Homo sapiens,Expert,,722.0,,9606.0,HEK293,,B,BAO_0000219,CHEMBL617775,2872
,227,D,9,,,,15851,,Displacement of [3H]ketanserin from human 5-hydroxytryptamine 2B receptor expressed in HEK293 cells; ND = no data,1,Homo sapiens,Expert,,722.0,,9606.0,HEK293,,B,BAO_0000219,CHEMBL617776,2873
,227,D,9,,,,6857,,Relative efficacy against human 5-hydroxytryptamine 2B receptor expressed in CHO cells using fluorometric imaging plate reader relative to 10 uM 5-HT,1,Homo sapiens,Expert,,449.0,,9606.0,CHO,,F,BAO_0000219,CHEMBL617777,2874
,227,D,9,,,,6857,,Rleative efficacy against human 5-hydroxytryptamine 2B receptor expressed in CHO cells using fluorometric imaging plate reader relative to 10 uM 5-HT,1,Homo sapiens,Expert,,449.0,,9606.0,CHO,,F,BAO_0000219,CHEMBL617778,2875
,227,H,8,,,,15779,,"Binding affinities towards human cloned 5-hydroxytryptamine 2B receptor in HEK293 cells, using [3H]5-HT as radioligand",1,,Autocuration,,722.0,,,HEK293,,B,BAO_0000219,CHEMBL617779,2876
,227,H,8,,,,15851,,Binding affinities towards human cloned 5-hydroxytryptamine 2B receptor in HEK293 cells using [3H]5-HT as radioligand.,1,,Expert,,722.0,,,HEK293,,B,BAO_0000219,CHEMBL617780,2877
,227,H,8,,,,15779,,"Binding affinities towards human cloned 5-hydroxytryptamine 2B receptor in HEK293 cells, using [3H]5-HT as radioligand; no data",1,,Autocuration,,722.0,,,HEK293,,B,BAO_0000219,CHEMBL617781,2878
,227,D,9,,,,14157,,Displacement of [3H]5-HT from 5-hydroxytryptamine 2B receptor expressed in HEK 293 cells,1,Homo sapiens,Expert,,722.0,,9606.0,HEK293,,B,BAO_0000219,CHEMBL617782,2879
,227,D,9,,,,4540,,Binding affinity to human cloned 5-HT2B receptor in HEK 293 cells using [3H]- -5-HT as radioligand,1,Homo sapiens,Expert,,722.0,,9606.0,HEK293,,B,BAO_0000219,CHEMBL617783,2880
,227,H,8,,,,6166,,Binding affinity towards cloned human 5-hydroxytryptamine 2B receptor was determined,1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL617784,2881
,227,H,8,,,,15779,,Binding affinity towards 5-hydroxytryptamine 2B receptor (human cloned receptor) in HEK 293 cells using [3H]5-HT as radioligand.,1,,Autocuration,,722.0,,,HEK293,,B,BAO_0000219,CHEMBL617785,2882
,227,H,8,,,,14391,,Binding affinity towards cloned human 5-hydroxytryptamine 2B receptor expressed in HEK 293 cells using [3H]5-HT as radioligand,1,,Expert,,722.0,,,HEK293,,B,BAO_0000219,CHEMBL857984,2883
,227,H,8,,,,3832,,Binding affinity towards human cloned 5-HT2B receptor of HEK293 cells by displacement of [3H]5-HT,1,,Expert,,722.0,,,HEK293,,B,BAO_0000219,CHEMBL617786,2884
,227,H,8,,,,3833,,In vitro binding affinity at human cloned 5-hydroxytryptamine 2B receptor of HEK293 cells by [3H]5-HT displacement.,1,,Expert,,722.0,,,HEK293,,B,BAO_0000219,CHEMBL617787,2885
,227,D,9,,,,15851,,Displacement of [3H]5-HT from human 5-hydroxytryptamine 2B receptor expressed in HEK293 cells,1,Homo sapiens,Expert,,722.0,,9606.0,HEK293,,B,BAO_0000219,CHEMBL617788,2886
,227,D,9,,,,15851,,Displacement of [3H]5-HT from human 5-hydroxytryptamine 2B receptor expressed in HEK293 cells; compound is insoluble,1,Homo sapiens,Expert,,722.0,,9606.0,HEK293,,B,BAO_0000219,CHEMBL617789,2887
,227,H,8,,,,4199,,Compound was evaluated for binding affinity against human cloned 5-HT2B receptor in HEK 293 cells using [3H]5-HT as the radioligand,1,,Autocuration,,722.0,,,HEK293,,B,BAO_0000219,CHEMBL617790,2888
,227,H,8,,,,1883,,Displacement of [3H]-5-5HT from human cloned 5-hydroxytryptamine 2B receptor expressed in CHO-K1 cells,1,,Expert,,485.0,,,CHO-K1,,B,BAO_0000219,CHEMBL617791,2889
,227,H,8,,,,4321,,Binding affinity against 5-hydroxytryptamine 2B receptor,1,,Expert,,,,,,,B,BAO_0000357,CHEMBL617608,2890
,227,H,8,,,,15146,,Compound was tested for its binding affinity against cloned human 5-hydroxytryptamine 2B receptor in HEK 293 cells using [3H]5-HT,1,,Autocuration,,722.0,,,HEK293,,B,BAO_0000219,CHEMBL617609,2891
,227,H,8,,,,5213,,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 2B receptor in HEK 293 using [3H]ketanserin as a radioligand,1,,Autocuration,,722.0,,,HEK293,,B,BAO_0000219,CHEMBL617610,2892
,227,H,8,,,,14818,,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 2B receptors in HEK293 cells using [3H]5-HT.,1,,Autocuration,,722.0,,,HEK293,,B,BAO_0000219,CHEMBL617611,2893
,227,H,8,,,,4829,,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 2B receptor in HEK293 cells, using [3H]5-HT as radioligand",1,,Autocuration,,722.0,,,HEK293,,B,BAO_0000219,CHEMBL617612,2894
,227,H,8,,,,4829,,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 2B receptor in HEK293 cells, using [3H]5-HT as radioligand",1,,Autocuration,,722.0,,,HEK293,,B,BAO_0000219,CHEMBL617613,2895
,227,H,8,,,,14025,,The dissociation equilibrium constant (pKB=-log KB) of compound was determined against the vascular 5-hydroxytryptamine 2B receptor in the endothelium intact rabbit jugular vein.,1,Oryctolagus cuniculus,Autocuration,,,,9986.0,,,B,BAO_0000019,CHEMBL617614,2896
Stomach,12688,H,8,,,,13463,,Binding affinity analysed for 5-HT 2B receptor in rat stomach fundus,1,,Expert,,,,,,945.0,B,BAO_0000019,CHEMBL617615,2897
Stomach,12688,H,8,,,,7259,,Affinity against 5-hydroxytryptamine 2B receptor in the isolated rat stomach fundus,1,,Expert,,,,,,945.0,B,BAO_0000357,CHEMBL858114,2898
Stomach,12688,H,8,,,,7259,,Affinity against serotonergic receptor in the isolated rat stomach fundus,1,,Autocuration,,,,,,945.0,B,BAO_0000357,CHEMBL617616,2899
Stomach,12688,D,9,,,,7185,,Antagonistic activity against 5-hydroxytryptamine 2B receptor obtained from rat stomach fundus preparation,1,Rattus norvegicus,Expert,,,,10116.0,,945.0,F,BAO_0000019,CHEMBL617617,2900
,12688,D,9,,,,7185,,Antagonistic against 5-hydroxytryptamine 2B receptor,1,Rattus norvegicus,Expert,,,,10116.0,,,F,BAO_0000019,CHEMBL875914,2901
Stomach,12688,H,8,,,,13267,,Antagonistic affinity measured as pA2 value on 5-hydroxytryptamine 2B receptor of the rat stomach fundus,1,,Autocuration,,,,,,945.0,F,BAO_0000019,CHEMBL617618,2902
Stomach,12688,D,9,,,,13735,,Inhibition of 5-HT binding to 5-HT2B receptor of Rat stomach fundus,1,Rattus norvegicus,Expert,,,,10116.0,,945.0,B,BAO_0000357,CHEMBL617619,2903
,12688,H,8,,,,15738,,Compound was evaluated for antagonism against serotonin (5-hydroxytryptamine 2B receptor ) receptor,1,,Autocuration,,,,,,,F,BAO_0000019,CHEMBL617620,2904
,12688,H,8,,,,15738,,Compound was evaluated for antagonism against serotonin (5-hydroxytryptamine 2B receptor ) receptor; No data,1,,Autocuration,,,,,,,F,BAO_0000019,CHEMBL617621,2905
,12688,H,8,,,,15738,,Compound was evaluated for antagonism against serotonin (5-hydroxytryptamine 2B) receptor,1,,Autocuration,,,,,,,F,BAO_0000019,CHEMBL617622,2906
Stomach,12688,D,9,,,,12936,,Inhibitory potency against rat stomach fundus 5-hydroxytryptamine 2B receptor,1,Rattus norvegicus,Expert,,,,10116.0,,945.0,B,BAO_0000357,CHEMBL617623,2907
Stomach,12688,D,9,,,,12936,,Inhibitory potency against rat stomach fundus 5-hydroxytryptamine 2B receptor,1,Rattus norvegicus,Expert,,,,10116.0,,945.0,B,BAO_0000357,CHEMBL617624,2908
Stomach,12688,D,9,,,,12936,,Inhibitory potency against rat stomach fundus 5-hydroxytryptamine 2B receptor,1,Rattus norvegicus,Expert,,,,10116.0,,945.0,B,BAO_0000357,CHEMBL617625,2909
Stomach,12688,D,9,,,,12936,,Inhibitory potency against rat stomach fundus 5-hydroxytryptamine 2B receptor,1,Rattus norvegicus,Expert,,,,10116.0,,945.0,B,BAO_0000357,CHEMBL617626,2910
Stomach,12688,H,8,,,,16404,,Negative log concentration of antagonistic compound was determined on 5-hydroxytryptamine 2B receptor of Rat stomach fundus,1,,Autocuration,,,,,,945.0,F,BAO_0000019,CHEMBL617627,2911
Stomach,12688,H,8,,,,16404,,Negative log concentration of antagonist was determined on 5-hydroxytryptamine 2B receptor of Rat stomach fundus,1,,Expert,,,,,,945.0,F,BAO_0000019,CHEMBL617628,2912
Stomach,12688,H,8,,,,16404,,Negative log concentration of antagonistic compound was determined on 5-hydroxytryptamine 2B receptor of Rat stomach fundus; ND is No Data.,1,,Autocuration,,,,,,945.0,F,BAO_0000019,CHEMBL617629,2913
Stomach,12688,H,8,,,,16404,,Negative log concentration of antagonistic compound was determined on 5-hydroxytryptamine 2B receptor of Rat stomach fundus; ND is not determined.,1,,Autocuration,,,,,,945.0,F,BAO_0000019,CHEMBL858115,2914
Stomach,12688,D,9,,,,16404,,Antagonistic activity on 5-hydroxytryptamine 2B receptor of Rat stomach fundus;ND is not determined,1,Rattus norvegicus,Expert,,,,10116.0,,945.0,F,BAO_0000019,CHEMBL617630,2915
Thoracic aorta,12688,H,8,,,,16404,,Negative log concentration of antagonistic compound was determined on 5-hydroxytryptamine 2B receptor of Rat thoracic aorta; ND is not determined,1,,Autocuration,,,,,,1515.0,F,BAO_0000019,CHEMBL617631,2916
,12688,H,8,,,,7483,,The binding affinity of compound to 5-HT receptor of rat fundus was expressed as pA2 value; Unable to determine valid PA2 value due to slope of Schild plot,1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL617632,2917
,12688,H,8,,,,7483,,The binding affinity to 5-hydroxytryptamine 2B receptor of rat fundus,1,,Expert,,,,,,,B,BAO_0000357,CHEMBL617633,2918
,12688,H,8,,,,7483,,The binding affinity of compound to 5-hydroxytryptamine 2B receptor of rat fundus was expressed as pA2 value; Unable to determine valid PA2 value due to slope of Schild plot,1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL617634,2919
,12688,H,8,,,,7483,,The binding affinity of compound to 5-hydroxytryptamine 2B receptor of rat fundus; Unable to determine valid PA2 value due to slope of Schild plot,1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL617635,2920
Stomach,12688,D,9,,,,16404,,Negative log concentration of antagonistic compound was determined on 5-hydroxytryptamine 2B receptor of Rat stomach fundus,1,Rattus norvegicus,Autocuration,,,,10116.0,,945.0,F,BAO_0000019,CHEMBL617637,2922
,227,H,8,,,,6347,,Binding affinity against 5-hydroxytryptamine 1A receptor,1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL617638,2923
,227,H,8,,,,4373,,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 2B receptor was determined,1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL617639,2924
,227,H,8,,,,4373,,Binding affinity for 5-hydroxytryptamine 2B receptor was determined,1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL617640,2925
,227,H,8,,,,4687,,Evaluated for the binding affinity to 5-HT 2B receptor,1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL617641,2926
,227,H,8,,,,16946,,Ability to displace [3H]5-HT from 5-hydroxytryptamine 2B receptor,1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL617642,2927
,227,H,8,,,,16633,,Binding affinities against 5-hydroxytryptamine 2B receptor,1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL617643,2928
,227,H,8,,,,16633,,Binding affinities towards 5-hydroxytryptamine 2B receptor,1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL617644,2929
,227,H,8,,,,16633,,Binding affinity towards 5-hydroxytryptamine 2B receptor using [125I]DOI as radioligand,1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL617645,2930
,108,H,8,,,,15026,,In vitro ability to displace [3H]mesulergine binding from 5-hydroxytryptamine 2C receptor from bovine choroid plexus.,1,,Expert,,,,,,,B,BAO_0000357,CHEMBL617646,2931
,108,H,8,,,,15738,,In vitro affinity against serotonin (5-hydroxytryptamine 2C) receptor,1,Bos taurus,Autocuration,,,,9913.0,,,B,BAO_0000357,CHEMBL617647,2932
,108,H,8,,,,15738,,In vitro affinity against serotonin (5-hydroxytryptamine 2C) receptor at a concentration of 10E-6 M,1,Bos taurus,Autocuration,,,,9913.0,,,B,BAO_0000357,CHEMBL617648,2933
,108,H,8,,,,15738,,In vitro affinity against serotonin (5-hydroxytryptamine 2C) receptor at a concentration of 10e-6 M,1,Bos taurus,Autocuration,,,,9913.0,,,B,BAO_0000357,CHEMBL617875,2934
,108,H,8,,,,15738,,In vitro affinity against serotonin (5-hydroxytryptamine 2C) receptor at concentration of 10e-6 M,1,Bos taurus,Autocuration,,,,9913.0,,,B,BAO_0000357,CHEMBL617876,2935
,108,H,8,,,,16404,,Inhibitory constant was determined on 5-hydroxytryptamine 2C receptor of Bovine choroid plexus,1,Bos taurus,Expert,,,,9913.0,,,B,BAO_0000357,CHEMBL617877,2936
,108,H,8,,,,15026,,In vitro ability to displace [3H]mesulergine binding from 5-hydroxytryptamine 2C receptor from bovine choroid plexus.,1,Bos taurus,Expert,,,,9913.0,,,B,BAO_0000357,CHEMBL617878,2937
,108,H,8,,,,15738,,In vitro affinity against serotonin (5-hydroxytryptamine 2C) receptor,1,Bos taurus,Autocuration,,,,9913.0,,,B,BAO_0000357,CHEMBL617879,2938
,108,H,8,,,,16312,,Binding affinity against guinea pig cortex 5-HT2C receptor in the presence of [3H]mesulergine,1,Cavia porcellus,Autocuration,,,,10141.0,,,B,BAO_0000019,CHEMBL617880,2939
Striatum,20033,D,9,,,,5486,,Binding affinity towards 5-HT4 receptor by the displacement of [3H]GR-113808 in guinea-pig striatum,1,Cavia porcellus,Intermediate,,,,10141.0,,2435.0,B,BAO_0000357,CHEMBL617881,2940
,51,H,8,,,,5254,,Binding affinity against 5-HT1A receptor,1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL857073,2941
,108,H,8,,,,3857,,Agonistic activity for 5-HT2c (5-HT2C) by measuring [3H]inositol monophosphate fromation in CHO cells in which the human 5-HT2C receptor subtype was stably expressed,1,,Expert,,449.0,,,CHO,,F,BAO_0000219,CHEMBL617882,2942
,108,D,9,,,,6857,,Functional activity against human 5-hydroxytryptamine 2C receptor expressed in CHO cells using fluorometric imaging plate reader,1,Homo sapiens,Expert,,449.0,,9606.0,CHO,,F,BAO_0000219,CHEMBL617883,2943
,108,H,8,,,,4176,,Functional agonist activity of compound was determined by fluorescence-based assay measuring intracellular calcium mobilization for 5-HT2c receptor cell line,1,,Autocuration,,,,,,,F,BAO_0000219,CHEMBL617884,2944
,108,H,8,,,,6347,,Agonistic binding efficacy against human 5-hydroxytryptamine 2C receptor in CHO cells using [125I]- DOI radioligand,1,,Autocuration,,449.0,,,CHO,,B,BAO_0000219,CHEMBL617885,2945
,108,H,8,,,,6347,,"Agonistic binding affinity against human 5-hydroxytryptamine 2C receptor in CHO cells using [125I]- DOI radioligand, expressed as Emax",1,,Autocuration,,449.0,,,CHO,,B,BAO_0000219,CHEMBL617886,2946
,108,D,9,,,,16146,,Inhibition of human 5-hydroxytryptamine 2C receptor,1,Homo sapiens,Expert,,,,9606.0,,,B,BAO_0000357,CHEMBL617887,2947
,108,H,8,,,,3805,,In vitro binding affinity against human 5-hydroxytryptamine 2C receptor at a concentration of 100 (nM),1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL617888,2948
,108,H,8,,,,3857,,Inhibitory activity using [3H]mesulergine as radioligand with receptor membranes isolated from a CHO-k cell line expressing the human 5-hydroxytryptamine 2C receptor at a concentration of 1 uM,1,,Autocuration,,,,,,,B,BAO_0000019,CHEMBL617889,2949
,108,H,8,,,,5635,,Intrinsic efficacy against 5-hydroxytryptamine 2C receptor,1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL617890,2950
,108,H,8,,,,5635,,Intrinsic efficacy against 5-hydroxytryptamine 2C receptor Intrinsic efficacy against 5-hydroxytryptamine 2C receptor; Intrinsic efficacy (%) not determined,1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL617891,2951
,108,H,8,,,,5635,,Intrinsic efficacy against 5-hydroxytryptamine 2C receptor; Intrinsic efficacy (%) not determined,1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL617892,2952
,108,H,8,,,,4012,,Displacement of [H]-mesulergine from CHO cells expressing human 5-hydroxytryptamine 2C receptor.,1,,Expert,,449.0,,,CHO,,B,BAO_0000219,CHEMBL617893,2953
,108,H,8,,,,6366,,Ability to displace [3H]- mesulergine from human cloned 5-hydroxytryptamine 2C receptor expressed in CHO cells,1,,Expert,,449.0,,,CHO,,B,BAO_0000219,CHEMBL617894,2954
,108,H,8,,,,15949,,Ability to displace [3H]mesulergine binding to human 5-hydroxytryptamine 2C receptor stably expressed in CHO cells,1,,Expert,,449.0,,,CHO,,B,BAO_0000219,CHEMBL617895,2955
,108,H,8,,,,17211,,Ability to displace [3H]mesulergine (0.5 nM) from CHO cells of human 5-hydroxytryptamine 2C receptor,1,,Autocuration,,449.0,,,CHO,,B,BAO_0000219,CHEMBL617896,2956
,108,D,9,,,,6491,,Affinity towards human 5-hydroxytryptamine 2C serotonin receptor,1,Homo sapiens,Expert,,,,9606.0,,,B,BAO_0000357,CHEMBL617897,2957
,108,H,8,,,,14093,,Agonist activity at cloned human 5-hydroxytryptamine 2C receptor using [125I]DOI radioligand,1,,Autocuration,,,,,,,F,BAO_0000019,CHEMBL617898,2958
,108,H,8,,,,13481,,Agonistic activity at cloned human 5-hydroxytryptamine 2C receptor using [125I]DOI as radioligand,1,,Autocuration,,,,,,,F,BAO_0000019,CHEMBL617899,2959
,108,H,8,,,,6347,,Agonistic binding affinity against human 5-hydroxytryptamine 2C receptor in CHO cells using [125I]- DOI ,1,Rattus norvegicus,Expert,,449.0,,10116.0,CHO,,B,BAO_0000219,CHEMBL617900,2960
,108,H,8,,,,14093,,Antagonist activity at cloned human 5-hydroxytryptamine 2C receptor using [3H]mesulergine radioligand,1,,Autocuration,,,,,,,F,BAO_0000019,CHEMBL617901,2961
,108,H,8,,,,14093,,Antagonist activity at cloned human 5-hydroxytryptamine 2C receptor using [3H]mesulergine radioligand; Not tested,1,,Autocuration,,,,,,,F,BAO_0000019,CHEMBL617902,2962
,108,H,8,,,,13481,,Antagonistic activity at cloned human 5-hydroxytryptamine 2C receptor using [3H]mesulergine as radioligand,1,,Autocuration,,,,,,,F,BAO_0000019,CHEMBL617903,2963
,108,H,8,,,,14442,,Binding ability of compound at cloned human 5-hydroxytryptamine 2C receptor using [125 I]DOI as radioligand,1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL617904,2964
,108,H,8,,,,14442,,Binding ability of compound at cloned human 5-hydroxytryptamine 2C receptor using [3H]- mesulergine as radioligand,1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL617905,2965
,108,H,8,,,,14442,,Binding ability of compound at cloned human 5-hydroxytryptamine 2C receptor using [3H]- mesulergine as radioligand;not tested,1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL617906,2966
,108,H,8,,,,14755,,Binding activity against cloned human 5-hydroxytryptamine 2C receptor using [125I]DOI as the radioligand.,1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL617907,2967
,108,H,8,,,,14744,,Binding affinity against the cloned human 5-hydroxytryptamine 2C receptor using [125I]DOI as the radioligand,1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL617908,2968
,108,H,8,,,,16659,,Binding affinity for displacement of [3H]mesulergine to human 5-hydroxytryptamine 2C receptor stably expressed in CHO cells,1,,Expert,,449.0,,,CHO,,B,BAO_0000219,CHEMBL620617,2969
,108,D,9,,,,6857,,Affinity for human 5-hydroxytryptamine 2C receptor expressed in mammalian cell line,1,Homo sapiens,Expert,,,,9606.0,,,B,BAO_0000019,CHEMBL620618,2970
,108,H,8,,,,5635,,Binding affinity against 5-hydroxytryptamine 2C receptor using [125I]DOI radioligand.,1,,Expert,,,,,,,B,BAO_0000357,CHEMBL620619,2971
,108,D,9,,,,4234,,Binding affinity to cloned human 5-hydroxytryptamine 2C receptor,1,Homo sapiens,Expert,,,,9606.0,,,B,BAO_0000357,CHEMBL620620,2972
,108,H,8,,,,16209,,Binding affinity towards human 5-HT2C receptor was determined using [125I]- DOI as radioligand,1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL620621,2973
,104698,D,7,,,Membranes,5778,,Binding affinity for 5-HT3 receptor by displacement of [3H]-LY 278584 in rat cerebral cortex membranes,1,Rattus norvegicus,Autocuration,,,,10116.0,,,B,BAO_0000249,CHEMBL872920,2974
,104698,H,6,,,,5094,,Binding affinity towards rat 5-hydroxytryptamine 3 receptor was evaluated,1,,Autocuration,,,,,,,B,BAO_0000223,CHEMBL620622,2975
,104698,D,7,,,,809,,Binding affinity against 5-hydroxytryptamine 3 receptor using [3H]BRL-43694 in rat posterior cortex,1,Rattus norvegicus,Autocuration,,,,10116.0,,,B,BAO_0000019,CHEMBL620623,2976
,104698,H,6,,,,1578,,Binding affinity against 5-hydroxytryptamine 3 receptor using [3H]BRL-43694 as radioligand in rat posterior cortex,1,,Autocuration,,,,,,,B,BAO_0000019,CHEMBL620624,2977
,104698,H,6,,,,809,,Binding affinity against 5-hydroxytryptamine 3 receptor using [3H]BRL-43694 as radioligand in rat posterior cortex; Not tested,1,,Autocuration,,,,,,,B,BAO_0000019,CHEMBL620625,2978
,104698,H,6,,,,12469,,Binding affinity was measured on 5-hydroxytryptamine 3 receptor in NG-108 cells labeled with [3H]GR-65630,1,,Autocuration,,,,,,,B,BAO_0000219,CHEMBL620626,2979
,104698,H,6,,,,14290,,Binding affinity was measured on 5-hydroxytryptamine 3 receptor using [3H]-BRL 43694 as radioligand in rat posterior cortex,1,,Autocuration,,,,,,,B,BAO_0000019,CHEMBL621307,2980
,104698,H,6,,,,14290,,Binding affinity was measured on 5-hydroxytryptamine 3 receptor using [3H]-BRL 43694 as radioligand in rat posterior cortex.,1,,Autocuration,,,,,,,B,BAO_0000019,CHEMBL621308,2981
,104698,H,6,,,,10609,,Binding affinity for central 5-hydroxytryptamine 3 receptor was determined by displacement of [3H]-5-HT,1,,Autocuration,,,,,,,B,BAO_0000223,CHEMBL621309,2982
,104698,H,6,,,,10609,,Binding affinity for central 5-hydroxytryptamine 3 receptor was determined by displacement of [3H]GR-65630,1,,Autocuration,,,,,,,B,BAO_0000223,CHEMBL621310,2983
,104698,H,6,,,,10609,,Binding affinity for central 5-hydroxytryptamine 3 receptor was determined by displacement of [3H]-ketanserin,1,,Autocuration,,,,,,,B,BAO_0000223,CHEMBL621311,2984
,104698,H,6,,,,15253,,"Compound was evaluated for its in vitro affinity at serotonergic 5-hydroxytryptamine 3 receptor by radioligand binding assay, using [3H]-LY 278584 in rat cerebral cortex membranes.",1,,Autocuration,,,,,,,B,BAO_0000249,CHEMBL621502,2985
,104698,H,6,,,,15253,,"In vitro affinity at serotonergic 5-hydroxytryptamine 3 receptor by radioligand binding assay, using [3H]-LY 278584 in rat cerebral cortex membranes.",1,,Autocuration,,,,,,,B,BAO_0000249,CHEMBL621503,2986
,104698,H,6,,,Membranes,11683,,Displacement of the 5-hydroxytryptamine 3 receptor ligand [3H]GR-65630 from rat brain cortical membranes.,1,,Autocuration,,,,,,,B,BAO_0000249,CHEMBL621504,2987
,104698,H,6,,,,12092,,Compound was evaluated for binding affinity against 5-hydroxytryptamine 3 receptor,1,,Autocuration,,,,,,,B,BAO_0000223,CHEMBL621505,2988
,104698,H,6,,,,1946,,Binding affinity at 5-hydroxytryptamine 3 receptor in rat entorhinal cortex by [3H]BRL-43694 displacement.,1,,Autocuration,,,,,,,B,BAO_0000019,CHEMBL621506,2989
,104698,H,6,,,,11623,,Ability to displace [3H]quipazine binding to 5-hydroxytryptamine 3 receptor sites in NG 108-15.,1,,Autocuration,,,,,,,B,BAO_0000223,CHEMBL619781,2990
,104698,H,6,,,,11623,,Compound was evaluated for its ability to displace [3H]quipazine binding to 5-hydroxytryptamine 3 receptor sites in NG 108-15. ,1,,Autocuration,,,,,,,B,BAO_0000223,CHEMBL619782,2991
,104698,H,6,,,,14788,,Compound was evaluated for its binding affinity for 5-hydroxytryptamine 3 receptor by measuring displacement [3H]GR-65630 in rat cerebral cortex,1,,Autocuration,,,,,,,B,BAO_0000019,CHEMBL619783,2992
,104698,D,7,,,,5432,,Displacement of [3H]ketanserin from rat cortex 5-HT3 receptor,1,Rattus norvegicus,Autocuration,,,,10116.0,,,B,BAO_0000019,CHEMBL619784,2993
,104698,H,6,,,,14826,,Ability to displace [3H]granisetron specifically bound to 5-hydroxytryptamine 3 receptor in rat cortical membrane,1,,Autocuration,,,,,,,B,BAO_0000249,CHEMBL619785,2994
,104698,H,6,,,,2222,,Compound was tested for its binding affinity for the 5-hydroxytryptamine 3 receptor,1,,Autocuration,,,,,,,B,BAO_0000223,CHEMBL619786,2995
,104698,H,6,,,,11963,,Displacement of binding of [3H]-BRL 43694 to 5-hydroxytryptamine 3 receptor in rat cerebral cortex,1,,Autocuration,,,,,,,B,BAO_0000019,CHEMBL619787,2996
,104698,H,6,,,,14145,,In vitro affinity for 5-hydroxytryptamine 3 (5-HT3) receptor by displacement of [3H]BRL-43694 from rat entorhinal cortex,1,,Autocuration,,,,,,,B,BAO_0000019,CHEMBL872925,2997
,104698,H,6,,,,17819,,In vitro binding affinity at serotonin 5-hydroxytryptamine 3 receptor in rat cortex by [3H]granisetron displacement.,1,,Autocuration,,,,,,,B,BAO_0000019,CHEMBL619788,2998
,104698,H,6,,,,10394,,Inhibitory activity against 5-hydroxytryptamine 3 receptor in rat cortical membranes using [3H]- 1-Methyl-1H-indazole-3-carboxylic acid (8-methyl-8-aza-bicyclo[3.2.1]oct-3-yl)-amide as a radioligand,1,,Autocuration,,,,,,,B,BAO_0000249,CHEMBL619789,2999
,104698,H,6,,,,10394,,Inhibitory activity against 5-hydroxytryptamine 3 receptor in rat cortical membranes using [3H]-1-Methyl-1H-indazole-3-carboxylic acid (8-methyl-8-aza-bicyclo[3.2.1]oct-3-yl)-amide as a radioligand,1,,Autocuration,,,,,,,B,BAO_0000249,CHEMBL619790,3000
,104698,H,6,,,,15034,,Inhibitory concentration against 5-hydroxytryptamine 3 receptor in rat entorhinal cortex using [3H]-LY 278584 as radioligand,1,,Autocuration,,,,,,,B,BAO_0000019,CHEMBL619791,3001
,104698,H,6,,,,691,,Binding affinity at 5-hydroxytryptamine 3 receptor in rat entorhinal cortex by [3H]BRL-43694 displacement.,1,,Autocuration,,,,,,,B,BAO_0000019,CHEMBL619792,3002
,104698,H,6,,,Membranes,12092,,Displacement of [3H]GR-65630 binding to 5-hydroxytryptamine 3 receptor in rat brain cortical membranes,1,,Autocuration,,,,,,,B,BAO_0000249,CHEMBL619793,3003
,104698,D,7,,,,11752,,Inhibition of [3H]GR-65630 binding to 5-hydroxytryptamine 3 receptor,1,Rattus norvegicus,Autocuration,,,,10116.0,,,B,BAO_0000223,CHEMBL619794,3004
Brain,104698,H,6,,,,11752,,The ability to inhibit [3H]GR-65630 binding to 5-hydroxytryptamine 3 receptor in rat brain cortices,1,,Autocuration,,,,,,955.0,B,BAO_0000221,CHEMBL619795,3005
,104698,H,6,,,,301,,Binding affinity at 5-hydroxytryptamine 3 receptor in rat posterior cortex by [3H]-BRL 43694 displacement.,1,,Autocuration,,,,,,,B,BAO_0000019,CHEMBL619796,3006
,104698,H,6,,,,16532,,The binding affinity at 5-hydroxytryptamine 3 receptor was determined using [3H]LY-278584,1,,Autocuration,,,,,,,B,BAO_0000223,CHEMBL620448,3007
,104698,H,6,,,,16532,,The binding affinity at 5-hydroxytryptamine 3 receptor was determined using [3H]LY-278584; Not tested,1,,Autocuration,,,,,,,B,BAO_0000223,CHEMBL620449,3008
,104698,H,6,,,,12092,,The binding affinity was measured on 5-hydroxytryptamine 3 receptor using [3H]GR-65630 as radioligand.,1,,Autocuration,,,,,,,B,BAO_0000223,CHEMBL620450,3009
,104698,H,6,,,,11684,,The compound was evaluated for the binding affinity towards 5-hydroxytryptamine 3 receptor by displacement of radioligand [3H]GR-65630,1,,Autocuration,,,,,,,B,BAO_0000223,CHEMBL620451,3010
,104698,H,6,,,,11684,,Binding affinity towards 5-hydroxytryptamine 3 receptor by displacement of radioligand [3H]GR-65630.,1,,Autocuration,,,,,,,B,BAO_0000223,CHEMBL620631,3011
,104698,H,6,,,,12953,,Binding affinity for 5-hydroxytryptamine 3 receptor from rat cortex using [3H]BRL-43694 as radioligand,1,,Autocuration,,,,,,,B,BAO_0000019,CHEMBL620632,3012
,104698,H,6,,,,12953,,The compound was tested for its binding affinity towards 5-hydroxytryptamine 3 receptor from rat cortex using [3H]BRL-43694 as radioligand; NA means Not active,1,,Autocuration,,,,,,,B,BAO_0000019,CHEMBL620633,3013
,104698,H,6,,,,12953,,The compound was tested for their binding affinity towards 5-hydroxytryptamine 3 receptor; Nonactive at 10 uM,1,,Autocuration,,,,,,,B,BAO_0000223,CHEMBL620634,3014
,104698,H,6,,,,12861,,Binding activity against 5-hydroxytryptamine 3 receptor from rat cortex homogenate using [3H]-Q-ICS 205-930 as radioligand; NA Not Available,1,,Autocuration,,,,,,,B,BAO_0000019,CHEMBL620635,3015
,104698,H,6,In vivo,,,11454,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg at 0.5 hours in urethane-anesthetized rats,1,,Autocuration,,,,,,,F,BAO_0000218,CHEMBL620636,3016
,104698,H,6,In vivo,,,11454,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg at 1 hour in urethane-anesthetized rats,1,,Autocuration,,,,,,,F,BAO_0000218,CHEMBL620637,3017
,104698,H,6,In vivo,,,11454,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg at 3 hours in urethane-anesthetized rats,1,,Autocuration,,,,,,,F,BAO_0000218,CHEMBL620638,3018
,104698,H,6,In vivo,,,11454,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg at 6 hours in urethane-anesthetized rats,1,,Autocuration,,,,,,,F,BAO_0000218,CHEMBL620639,3019
,104698,H,6,In vivo,,,11454,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.1 mg/kg at 0.5 hours in urethane-anesthetized rats,1,,Autocuration,,,,,,,F,BAO_0000218,CHEMBL620640,3020
,104698,H,6,In vivo,,,11454,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.1 mg/kg at 1 hour in urethane-anesthetized rats,1,,Autocuration,,,,,,,F,BAO_0000218,CHEMBL620641,3021
,104698,H,6,In vivo,,,11454,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.1 mg/kg at 16 hours in urethane-anesthetized rats,1,,Autocuration,,,,,,,F,BAO_0000218,CHEMBL620642,3022
,104698,H,6,In vivo,,,11454,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.1 mg/kg at 3 hours in urethane-anesthetized rats,1,,Autocuration,,,,,,,F,BAO_0000218,CHEMBL620643,3023
,104698,H,6,In vivo,,,11454,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.1 mg/kg at 6 hours in urethane-anesthetized rats,1,,Autocuration,,,,,,,F,BAO_0000218,CHEMBL620644,3024
,104698,H,6,In vivo,,,11454,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.3 mg/kg at 0.5 hours in urethane-anesthetized rats,1,,Autocuration,,,,,,,F,BAO_0000218,CHEMBL620645,3025
,104698,H,6,In vivo,,,11454,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.3 mg/kg at 1 hour in urethane-anesthetized rats,1,,Autocuration,,,,,,,F,BAO_0000218,CHEMBL620646,3026
,104698,H,6,In vivo,,,11454,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.3 mg/kg at 3 hours in urethane-anesthetized rats,1,,Autocuration,,,,,,,F,BAO_0000218,CHEMBL620647,3027
,104698,H,6,In vivo,,,11454,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.3 mg/kg at 6 hours in urethane-anesthetized rats,1,,Autocuration,,,,,,,F,BAO_0000218,CHEMBL620648,3028
,104698,H,6,In vivo,,,11454,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 1 mg/kg at 0.5 hours in urethane-anesthetized rats,1,,Autocuration,,,,,,,F,BAO_0000218,CHEMBL620649,3029
,104698,H,6,In vivo,,,11454,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 1 mg/kg at 3 hours in urethane-anesthetized rats,1,,Autocuration,,,,,,,F,BAO_0000218,CHEMBL620650,3030
,104698,H,6,In vivo,,,11454,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 10 mg/kg at 1 hour in urethane-anesthetized rats,1,,Autocuration,,,,,,,F,BAO_0000218,CHEMBL620651,3031
,104698,H,6,In vivo,,,11454,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 10 mg/kg at 3 hours in urethane-anesthetized rats,1,,Autocuration,,,,,,,F,BAO_0000218,CHEMBL872875,3032
,104698,H,6,In vivo,,,11454,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 1 mg/kg at 1 hour in urethane-anesthetized rats,1,,Autocuration,,,,,,,F,BAO_0000218,CHEMBL620652,3033
,104698,H,6,,,,10609,,5-hydroxytryptamine 3 receptor antagonist activity was confirmed by its ability to antagonize 5-HT evoked tachycardia of rabbit isolated heart,1,,Autocuration,,,,,,,F,BAO_0000019,CHEMBL620653,3034
,104698,H,6,,,,12861,,Binding activity against 5-hydroxytryptamine 2A receptor from rat cortex homogenates using [3H]DOB as radioligand.,1,,Autocuration,,,,,,,B,BAO_0000019,CHEMBL857076,3035
,104698,D,7,,,,12861,,Inhibition of [3H]-Q-ICS 205-930 binding to rat cortex homogenate 5-hydroxytryptamine 3 receptor,1,Rattus norvegicus,Autocuration,,,,10116.0,,,B,BAO_0000019,CHEMBL620654,3036
,104698,H,6,,,,12861,,Binding activity radioligand.,1,,Autocuration,,,,,,,B,BAO_0000223,CHEMBL620655,3037
,104698,H,6,,,Brain membranes,10728,,Compound was evaluated for the displacement of [3H]-Q-ICS 205-930 binding to 5-hydroxytryptamine 3 receptor in rat brain membranes,1,,Autocuration,,,,,,,B,BAO_0000249,CHEMBL620656,3038
,104698,H,6,,,Brain membranes,10728,,Displacement of [3H]-Q-ICS 205-930 binding to 5-hydroxytryptamine 3 receptor recognition sites in rat brain membranes.,1,,Autocuration,,,,,,,B,BAO_0000249,CHEMBL620657,3039
,108,H,8,,,,5163,,Binding affinity towards 5-hydroxytryptamine 2C receptor was determined at a concentration of 0.000001 mol/L,1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL620658,3040
,108,H,8,,,,5163,,Binding affinity towards 5-hydroxytryptamine 2C receptor was determined at a concentration of 0.00001 mol/L,1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL620659,3041
,108,H,8,,,,6011,,Inhibition of binding towards 5-hydroxytryptamine 2C receptor at 100 nM concentration,1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL620660,3042
,108,H,8,,,,5014,,Percent inhibition (at 1 uM) against 5-hydroxytryptamine 2C receptor,1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL620661,3043
,108,H,8,,,,5635,,Binding affinity of compound towards 5-hydroxytryptamine 2C receptor,1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL620662,3044
,108,H,8,,,,5163,,Affinity for 5-hydroxytryptamine 2C receptor,1,,Expert,,,,,,,B,BAO_0000357,CHEMBL620663,3045
,108,H,8,,,,6841,,Binding affinity towards 5-hydroxytryptamine 2C receptor using [3H]mesulergine as radioligand,1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL620664,3046
,108,H,8,,,,6119,,Binding affinity towards 5-hydroxytryptamine 2C receptor using [125I]DOI as radioligand.,1,,Expert,,,,,,,B,BAO_0000357,CHEMBL620665,3047
,108,H,8,,,,4373,,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 2C receptor was determined,1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL620666,3048
,108,H,8,,,,1633,,Compound was evaluated for the binding affinity towards 5-hydroxytryptamine 2C receptor by displacement of [3H]-Ketanserin,1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL620667,3049
,108,H,8,,,,1633,,Binding affinity towards 5-hydroxytryptamine 2C receptor by displacement of [3H]N-methyl-mesulergine,1,,Expert,,,,,,,B,BAO_0000357,CHEMBL620668,3050
,108,H,8,,,,4373,,Binding affinity for 5-hydroxytryptamine 2C receptor was determined,1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL620669,3051
,108,H,8,,,,6576,,Binding affinity towards serotonin 5-hydroxytryptamine 2C receptor,1,,Expert,,,,,,,B,BAO_0000357,CHEMBL620670,3052
,108,H,8,,,,4687,,Evaluated for the binding affinity to 5-hydroxytryptamine 2C receptor,1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL620671,3053
,108,H,8,,,,12146,,Tested agains t5-hydroxytryptamine 2C receptor in experiment 1,1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL620672,3054
,108,H,8,,,,12146,,Tested against 5-hydroxytryptamine 2C receptor in experiment 2,1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL620673,3055
,108,H,8,,,,16946,,Ability to displace [3H]mesulergine from 5-hydroxytryptamine 2C receptor,1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL620674,3056
,108,H,8,,,,14159,,Compound was evaluated for the affinity at 5-hydroxytryptamine 2C receptor,1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL620675,3057
,108,H,8,,,,16700,,The binding affinity towards 5-hydroxytryptamine 2C receptor; No affinity,1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL620676,3058
,108,H,8,,,,3269,,Affinity against 5-hydroxytryptamine 2C receptor,1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL621382,3059
,108,D,9,,,,1274,,Binding affinity against 5-hydroxytryptamine 2C receptor,1,Homo sapiens,Expert,,,,9606.0,,,B,BAO_0000357,CHEMBL621383,3060
,108,H,8,,,,1317,,Compound was evaluated for binding affinity against 5-hydroxytryptamine 2C receptor using radioligand binding assay,1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL621384,3061
,144,H,8,,,,5834,,Inhibitory concentration required against 5-HT3 receptor in bovine area postrema using [3H]GR-65630,1,Bos taurus,Autocuration,,,,9913.0,,,B,BAO_0000357,CHEMBL621385,3062
,144,H,8,,,,11147,,Binding affinity towards 5-hydroxytryptamine 3 receptor using [3H]GR-65630 as radioligand,1,Bos taurus,Autocuration,,,,9913.0,,,B,BAO_0000357,CHEMBL617989,3063
,104714,H,4,,,,14145,,Antagonistic potency against serotonin 5-hydroxytryptamine 3 receptor in GPI assay,1,Cavia porcellus,Expert,,,,10141.0,,,F,BAO_0000019,CHEMBL617990,3064
Ileum,104714,H,4,,,,10561,,Binding affinity to 5-hydroxytryptamine 3 receptor entirely in guinea pig ileum,1,Cavia porcellus,Autocuration,,,,10141.0,,2116.0,B,BAO_0000221,CHEMBL875085,3065
,104714,H,4,,,,15847,,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 3 receptor of guinea pig,1,Cavia porcellus,Autocuration,,,,10141.0,,,F,BAO_0000019,CHEMBL617991,3066
,104714,H,4,,,,15847,,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 3 receptor of guinea pig; ND means not done,1,Cavia porcellus,Autocuration,,,,10141.0,,,F,BAO_0000019,CHEMBL617992,3067
Ileum,104714,H,4,,,,10561,,Potency to 5-hydroxytryptamine 3 receptor entirely in guinea pig ileum,1,Cavia porcellus,Autocuration,,,,10141.0,,2116.0,B,BAO_0000221,CHEMBL617993,3068
Ileum,104714,H,4,,,,11454,,In vitro binding affinity was measured for 5-hydroxytryptamine 3 receptor in the guinea pig ileum.,1,Cavia porcellus,Autocuration,,,,10141.0,,2116.0,B,BAO_0000221,CHEMBL617994,3069
,104714,H,4,,,,4639,,Compound was tested for agonistic activity against 5-hydroxytryptamine 3 receptor on guinea colon at a concentration 0.01 uM,1,Cavia porcellus,Autocuration,,,,10141.0,,,F,BAO_0000019,CHEMBL617995,3070
,104714,H,4,,,,4639,,Percent of control response to 5-HT3 agonistic activity on guinea colon at a concentration 0.1 uM,1,Cavia porcellus,Autocuration,,,,10141.0,,,F,BAO_0000019,CHEMBL617996,3071
,104714,H,4,,,,4639,,Percent of control response to 5-HT3 agonistic activity on guinea colon at a concentration 1 uM,1,Cavia porcellus,Autocuration,,,,10141.0,,,F,BAO_0000019,CHEMBL617997,3072
,104714,H,4,,,,4639,,Percent of control response to 5-HT3 agonistic activity on guinea colon at a concentration 1 uM in the presence of 30 uM MDL 72222,1,Cavia porcellus,Autocuration,,,,10141.0,,,F,BAO_0000019,CHEMBL617998,3073
,104714,H,4,,,,4639,,Percent of control response to 5-HT3 antagonistic activity on guinea colon at a concentration 0.01 uM,1,Cavia porcellus,Autocuration,,,,10141.0,,,F,BAO_0000019,CHEMBL617999,3074
,104714,H,4,,,,4639,,Percent of control response to 5-HT3 antagonistic activity on guinea colon at a concentration 1 uM,1,Cavia porcellus,Autocuration,,,,10141.0,,,F,BAO_0000019,CHEMBL618000,3075
Ileum,104714,H,4,,,,15253,,"Concentration required to produce 50% of maximal contraction induced by 5-HT through 5-HT3 receptors in the presence of the compound, in isolated guinea pig ileum",1,Cavia porcellus,Autocuration,,,,10141.0,,2116.0,F,BAO_0000221,CHEMBL617815,3076
Ileum,104714,H,4,,,,15253,,"Concentration required to produce 50% of maximal contraction induced by 5-HT through 5-HT3 receptors in the presence of the compound, in isolated guinea pig ileum.",1,Cavia porcellus,Autocuration,,,,10141.0,,2116.0,F,BAO_0000221,CHEMBL617816,3077
Ileum,104714,H,4,,,,11963,,Tested for the antagonistic activity against 5-hydroxytryptamine 3 receptor from guinea pig ileum,1,Cavia porcellus,Autocuration,,,,10141.0,,2116.0,F,BAO_0000221,CHEMBL617817,3078
Ileum,104714,H,4,,,,1946,,In vitro 5-hydroxytryptamine 3 receptor activity in guinea pig ileum,1,Cavia porcellus,Autocuration,,,,10141.0,,2116.0,B,BAO_0000221,CHEMBL617818,3079
Ileum,104714,H,4,,,,1946,,In vitro 5-hydroxytryptamine 3 receptor activity in guinea pig ileum; Not tested,1,Cavia porcellus,Autocuration,,,,10141.0,,2116.0,B,BAO_0000221,CHEMBL617819,3080
,104714,H,4,,,,12045,,Binding affinity towards [3H]quipazine labeled 5-hydroxytryptamine 3 receptor sites in HG108-15,1,Cavia porcellus,Autocuration,,,,10141.0,,,B,BAO_0000223,CHEMBL617820,3081
Ileum,104714,H,4,,,,1559,,Binding affinity against 5-hydroxytryptamine 3 receptor of guinea pig ileum,1,Cavia porcellus,Autocuration,,,,10141.0,,2116.0,B,BAO_0000221,CHEMBL617821,3082
Ileum,104714,H,4,,,,273,,Evaluated for the antagonistic activity against 5-hydroxytryptamine 3 receptor in isolated guinea pig ileum (GPI),1,Cavia porcellus,Autocuration,,,,10141.0,,2116.0,F,BAO_0000221,CHEMBL617822,3083
Ileum,104714,H,4,,,,273,,Antagonistic activity against Serotonin 5-hydroxytryptamine 3 receptor of isolated guinea pig ileum (GPI),1,Cavia porcellus,Autocuration,,,,10141.0,,2116.0,F,BAO_0000221,CHEMBL617823,3084
Ileum,104714,H,4,,,,188,,Tested for antagonistic activity on 5-hydroxytryptamine 3 receptor mediated effects of 5-HT in guinea pig isolated ileum,1,Cavia porcellus,Autocuration,,,,10141.0,,2116.0,F,BAO_0000221,CHEMBL617824,3085
Ileum,104714,H,4,,,,12919,,Agonistic activity against 5-hydroxytryptamine 3 receptor in guinea pig ileum assay,1,Cavia porcellus,Autocuration,,,,10141.0,,2116.0,F,BAO_0000221,CHEMBL617825,3086
Ileum,104714,H,4,,,,12918,,5-hydroxytryptamine 3 receptor agonism in the guinea pig ileum by functional 5-HT3 receptor assay,1,Cavia porcellus,Autocuration,,,,10141.0,,2116.0,F,BAO_0000221,CHEMBL617826,3087
Ileum,104714,H,4,,,,1559,,Binding affinity against 5-hydroxytryptamine 3 receptor of guinea pig ileum,1,Cavia porcellus,Autocuration,,,,10141.0,,2116.0,B,BAO_0000221,CHEMBL617827,3088
Ileum,104714,H,4,,,,273,,Evaluated for the antagonistic activity against Serotonin 5-hydroxytryptamine 3 receptor in isolated guinea pig ileum (GPI),1,Cavia porcellus,Autocuration,,,,10141.0,,2116.0,F,BAO_0000221,CHEMBL617828,3089
Ileum,104714,H,4,,,,1559,,Binding affinity against 5-hydroxytryptamine 3 receptor of guinea pig ileum,1,Cavia porcellus,Autocuration,,,,10141.0,,2116.0,B,BAO_0000221,CHEMBL617829,3090
Ileum,104714,H,4,,,,1559,,Binding affinity against 5-hydroxytryptamine 3 receptor of guinea pig ileum; Not determined,1,Cavia porcellus,Autocuration,,,,10141.0,,2116.0,B,BAO_0000221,CHEMBL617830,3091
Ileum,104714,H,4,,,,1559,,Binding affinity towards 5-hydroxytryptamine 3 receptor of guinea pig ileum; not determined,1,Cavia porcellus,Autocuration,,,,10141.0,,2116.0,B,BAO_0000221,CHEMBL617831,3092
Ileum,104714,H,4,,,,14424,,The compound was tested for binding affinity against 5-hydroxytryptamine 3 receptor in guinea pig ileum.,1,Cavia porcellus,Autocuration,,,,10141.0,,2116.0,B,BAO_0000221,CHEMBL617832,3093
,22226,U,0,,,,13181,,Binding affinity was determined against 5-hydroxytryptamine 2A receptor,1,Cavia porcellus,Autocuration,,,,10141.0,,,B,BAO_0000019,CHEMBL617833,3094
,51,H,8,,,,5486,,Binding affinity towards 5-HT1A receptor by the displacement of [3H]-8-OH-DPAT] in human recombinant receptors in mammalian cell,1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL617834,3095
,104714,D,5,,,,6491,,Affinity towards human 5-hydroxytryptamine 3 serotonin receptor,1,Homo sapiens,Expert,,,,9606.0,,,B,BAO_0000223,CHEMBL617835,3096
,104714,H,4,,,,6013,,Binding affinity towards 5-HT3 receptor,1,,Autocuration,,,,,,,B,BAO_0000223,CHEMBL617836,3097
,104714,H,4,,,,12861,,Binding activity radioligand.,1,,Autocuration,,,,,,,B,BAO_0000223,CHEMBL617837,3098
,104714,H,4,,,,12861,,Binding activity against 5-hydroxytryptamine 1A receptor from human brain cortex using [3H]8-OH-DPAT-HT as radioligand.,1,,Autocuration,,,,,,,B,BAO_0000019,CHEMBL620392,3099
,104714,H,4,,,,5104,,Binding affinity for human cloned 5-hydroxytryptamine 3 receptor,1,,Autocuration,,,,,,,B,BAO_0000223,CHEMBL620393,3100
,104714,H,4,,,,5105,,Binding affinity for human cloned 5-hydroxytryptamine 3 receptor,1,,Autocuration,,,,,,,B,BAO_0000223,CHEMBL620394,3101
,104714,H,4,,,,5104,,Binding affinity for human cloned 5-hydroxytryptamine 3 receptor; NT means Not tested,1,,Autocuration,,,,,,,B,BAO_0000223,CHEMBL620395,3102
,22226,U,0,,,,3935,,Compound was evaluated for its binding affinity for human 5-hydroxytryptamine 3 receptor,1,,Autocuration,,,,,,,B,BAO_0000019,CHEMBL620396,3103
,105030,H,4,,,,13657,,Displacement of [3H]-BRC 36694 from 5-hydroxytryptamine 3 receptor in NG108-15 cells,1,,Expert,,433.0,,,NG108-15,,B,BAO_0000219,CHEMBL620582,3104
,105030,H,4,In vivo,,,10369,,"Percent inhibition of [3H]5 binding to 5-hydroxytryptamine 3 receptor was evaluated by injection of compound (75 microCi/kg, 1.32 ug/kg) into the tail vein of mice (in vivo)",1,,Autocuration,,,,,,,B,BAO_0000218,CHEMBL620583,3105
,105030,H,4,,,,10369,,The binding affinity was measured for 5-hydroxytryptamine 3 receptor on NG 108-15 cell line of mouse neuroblastoma-glioma cells in presence of [3H]5 radioligand (in vitro),1,,Autocuration,,,,,,,B,BAO_0000019,CHEMBL620584,3106
,105030,H,4,,,,12918,,Compound was evaluated for the binding affinity at 5- HT3 receptor subtype,1,,Autocuration,,,,,,,B,BAO_0000224,CHEMBL620585,3107
,105030,H,4,,,,12918,,Compound was evaluated for the binding affinity at 5- HT3 receptor,1,,Autocuration,,,,,,,B,BAO_0000224,CHEMBL620586,3108
,105030,H,4,,,,10369,,The binding affinity was measured for 5-hydroxytryptamine 3 receptor on NG 108-15 cell line of mouse neuroblastoma-glioma cells in presence of [3H]5 radioligand (in vitro),1,,Autocuration,,,,,,,B,BAO_0000019,CHEMBL620587,3109
,105030,H,4,,,,773,,In Vitro Binding affinity againist 5-hydroxytryptamine 3 receptor by displacing [3H]-Q-ICS 205-930 from rat cortex homogenates,1,,Autocuration,,,,,,,B,BAO_0000019,CHEMBL620588,3110
,105030,H,4,,,,12918,,5-hydroxytryptamine 3 receptor agonism in mouse,1,,Autocuration,,,,,,,F,BAO_0000218,CHEMBL620589,3111
,105030,H,4,,,,10561,,Binding affinity towards 5-hydroxytryptamine 3 receptor was determined by using [3H]-ICS 205-930 as radioligand in mouse N1E 115 cells,1,,Autocuration,,,,,,,B,BAO_0000219,CHEMBL620590,3112
,105030,H,4,,,,12827,,Binding affinity towards 5-hydroxytryptamine 2A receptor in rat cortex preparations using [3H]ketanserin,1,,Autocuration,,,,,,,B,BAO_0000019,CHEMBL617956,3113
,105030,H,4,,,,12827,,Binding affinity towards 5-hydroxytryptamine 2A receptor in rat cortex preparations using [3H]ketanserin,1,,Autocuration,,,,,,,B,BAO_0000019,CHEMBL617957,3114
,105030,H,4,,,,12918,,Binding affinity was evaluated by 5-hydroxytryptamine 3 receptor agonism in the mouse NIE-115 by displacing tropisetron,1,,Autocuration,,,,,,,B,BAO_0000224,CHEMBL617958,3115
,105030,H,4,,,,273,,Compound was evaluated for binding to 5-hydroxytryptamine 3 receptor in N1E cells using [3H]- -Tropisetron as radioligand,1,,Autocuration,,,,,,,B,BAO_0000219,CHEMBL617959,3116
,105030,H,4,,,,273,,Compound was evaluated for binding to Serotonin 5-hydroxytryptamine 3 receptor in N1E cells using [3H]- -Tropisetron as radioligand,1,,Autocuration,,,,,,,B,BAO_0000219,CHEMBL617960,3117
,105030,H,4,,,,10561,,Potency at neuronal 5-hydroxytryptamine 3 receptor in the rabbit heart,1,,Autocuration,,,,,,,B,BAO_0000224,CHEMBL617961,3118
,105030,H,4,In vitro,,,5033,,Ability to displace the radioligand [3H]GR-65630 from 5-hydroxytryptamine 3 receptor expressed in NIE-115 cells,1,,Autocuration,,,,,,,B,BAO_0000219,CHEMBL617962,3119
,105030,H,4,,,,16429,,In vitro binding affinity at 5-hydroxytryptamine 3 receptor in N1E-115 cells using 3[H]GR-65630 as the radioligand,1,,Autocuration,,339.0,,,N1E-115,,B,BAO_0000219,CHEMBL617963,3120
,11765,H,8,,,,10322,,In vitro binding affinity for the 5-hydroxytryptamine 3 receptor was determined with NG-108-15 mouse neuroblastoma-glioma cells,1,,Autocuration,,,,,,,B,BAO_0000019,CHEMBL617964,3121
,11765,H,8,,,,14331,,Inhibition of [3H]BRL-43694 binding to 5-hydroxytryptamine 3 receptor in NG cells 108-15,1,,Autocuration,,,,,,,B,BAO_0000219,CHEMBL617965,3122
,10630,D,9,,,,13462,,Compound was tested for the Binding affinity against N1e-115 neuroblastoma 5-hydroxytryptamine 3 receptor by Radio ligand [3H]GR-65630 binding assay.,1,Mus musculus,Autocuration,,,,10090.0,,,B,BAO_0000357,CHEMBL617966,3123
,17106,H,8,,,,12861,,Binding activity against 5-hydroxytryptamine 3 receptor from rat cortex homogenate using [3H]-Q-ICS 205-930 as radioligand.,1,,Autocuration,,,,,,,B,BAO_0000019,CHEMBL857074,3124
,144,H,8,,,,15086,,The compound was tested for binding affinity against 5-hydroxytryptamine 3 receptor,1,Sus scrofa,Autocuration,,,,9823.0,,,B,BAO_0000357,CHEMBL617967,3125
,144,H,8,,,,12861,,Binding activity radioligand.,1,Sus scrofa,Autocuration,,,,9823.0,,,B,BAO_0000357,CHEMBL617968,3126
,104714,H,4,,,,10561,,Binding affinity to 5-hydroxytryptamine 3 receptor of neuronal in the afferent rabbit vagus,1,Oryctolagus cuniculus,Autocuration,,,,9986.0,,,B,BAO_0000223,CHEMBL617969,3127
,104714,H,4,,,,10561,,Potency at neuronal 5-hydroxytryptamine 3 receptor in the rabbit heart,1,Oryctolagus cuniculus,Autocuration,,,,9986.0,,,B,BAO_0000223,CHEMBL617970,3128
,104714,H,4,,,,10561,,Potency at neuronal 5-hydroxytryptamine 3 receptors in the rabbit heart,1,Oryctolagus cuniculus,Autocuration,,,,9986.0,,,B,BAO_0000223,CHEMBL617971,3129
,104714,H,4,,,,10561,,Potency to 5-hydroxytryptamine 3 receptor using [3H]GR-65630 as radioligand in rat cortex,1,Oryctolagus cuniculus,Autocuration,,,,9986.0,,,B,BAO_0000019,CHEMBL617972,3130
,104714,H,4,,,,273,,Evaluated for the antagonistic activity against 5-hydroxytryptamine 3 receptor in isolated perfused rabbit heart (RH),1,Oryctolagus cuniculus,Autocuration,,,,9986.0,,,F,BAO_0000019,CHEMBL617973,3131
,104714,H,4,,,,273,,Evaluated for the antagonistic activity against 5-hydroxytryptamine 3 receptor in isolated rabbit vagus nerve (RVN),1,Oryctolagus cuniculus,Autocuration,,,,9986.0,,,F,BAO_0000019,CHEMBL617974,3132
Ileum,104714,H,4,,,,273,,Evaluated for the antagonistic activity against Serotonin 5-hydroxytryptamine 3 receptor in isolated guinea pig ileum (GPI),1,Oryctolagus cuniculus,Autocuration,,,,9986.0,,2116.0,F,BAO_0000221,CHEMBL617975,3133
,104714,H,4,,,,273,,Evaluated for the antagonistic activity against Serotonin 5-hydroxytryptamine 3 receptor in isolated perfused rabbit heart (RH),1,Oryctolagus cuniculus,Autocuration,,,,9986.0,,,F,BAO_0000019,CHEMBL617976,3134
,104714,H,4,,,,273,,Antagonistic activity against Serotonin 5-hydroxytryptamine 3 receptor in isolated rabbit vagus nerve (RVN),1,Oryctolagus cuniculus,Autocuration,,,,9986.0,,,F,BAO_0000019,CHEMBL617977,3135
,104714,H,4,,,,273,,Evaluated for the antagonistic activity against Serotonin 5-hydroxytryptamine 3 receptor in isolated perfused rabbit heart (RH),1,Oryctolagus cuniculus,Autocuration,,,,9986.0,,,F,BAO_0000019,CHEMBL617978,3136
,104714,H,4,,,,273,,Evaluated for the antagonistic activity against Serotonin 5-hydroxytryptamine 3 receptor in isolated rabbit vagus nerve (RVN),1,Oryctolagus cuniculus,Autocuration,,,,9986.0,,,F,BAO_0000019,CHEMBL617979,3137
,104714,H,4,,,,13047,,Binding affinity against 5-hydroxytryptamine 3 receptor in CHO cells using [3H]5-HT as radioligand,1,Oryctolagus cuniculus,Autocuration,,449.0,,9986.0,CHO,,B,BAO_0000219,CHEMBL617980,3138
,104698,D,7,,,,1650,,In vitro displacement of [3H]-LY 278584 from rat cerebral cortex 5-hydroxytryptamine 3 receptor,1,Rattus norvegicus,Autocuration,,,,10116.0,,,B,BAO_0000019,CHEMBL617981,3139
,12020,H,8,,,,16288,,Affinity at 5-hydroxytryptamine 3 receptor from rat frontal cortex using [3H]granisetron as radioligand (For granisetron = Ki(nM)=0.3+/-0.01),1,,Autocuration,,,,,,,B,BAO_0000019,CHEMBL617982,3140
,12020,H,8,,,,16288,,Affinity at 5-hydroxytryptamine 3 receptor (For granisetron = Ki (nM)=0.3+/-0.01),1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL617983,3141
,104698,D,7,,,,10254,,In vitro displacement of [3H]ICS-205-930 from 5-hydroxytryptamine 3 receptor in cultured NG-108-15 rat glioma cells,1,Rattus norvegicus,Autocuration,,,,10116.0,,,B,BAO_0000019,CHEMBL617984,3142
,104698,H,6,,,,14532,,"Binding affinity for 5-hydroxytryptamine 3 receptor in rat cerebral cortex, determined by displacement of [3H]GR-65630",1,,Autocuration,,,,,,,B,BAO_0000019,CHEMBL617985,3143
Heart,104698,H,6,In vivo,,,13392,,"5-Hydroxy tryptamine 3 receptor showing agonist activity (in vivo) in Von Bezold-Jarisch Reflex in rats at 120 (ug/kg), evaluated as change in heart rate",1,,Autocuration,,,,,,948.0,F,BAO_0000218,CHEMBL617986,3144
Heart,104698,H,6,,,,13392,,"Agonistic activity of compound towards 5-hydroxytryptamine 3 receptor in Von Bezold-Jarisch Reflex in rats at 100 (ug/kg), evaluated as change in heart rate",1,,Autocuration,,,,,,948.0,F,BAO_0000019,CHEMBL617987,3145
Heart,104698,H,6,,,,13392,,"Agonistic activity of compound towards 5-hydroxytryptamine 3 receptor in Von Bezold-Jarisch Reflex in rats at 120 (ug/kg), evaluated as change in heart rate",1,,Autocuration,,,,,,948.0,F,BAO_0000019,CHEMBL617988,3146
Heart,104698,H,6,,,,13392,,"Agonistic activity of compound towards 5-hydroxytryptamine 3 receptor in Von Bezold-Jarisch Reflex in rats at 60 (ug/kg), evaluated as change in heart rate",1,,Autocuration,,,,,,948.0,F,BAO_0000019,CHEMBL617792,3147
Heart,104698,H,6,,,,13392,,"Agonistic activity of compound towards 5-hydroxytryptamine 3 receptorr in Von Bezold-Jarisch Reflex in rats at 100 (ug/kg), evaluated as change in heart rate",1,,Autocuration,,,,,,948.0,F,BAO_0000019,CHEMBL617793,3148
,104698,H,6,,,,13392,,"Antagonistic activity of compound towards 5-hydroxytryptamine 3 receptor in Von Bezold-Jarisch Reflex in rats at 100(ug/kg), evaluated as percent inhibition of bradycardia",1,,Autocuration,,,,,,,F,BAO_0000019,CHEMBL617794,3149
,104698,H,6,,,,13392,,"Antagonistic activity of compound towards 5-hydroxytryptamine 3 receptor in Von Bezold-Jarisch Reflex in rats at 60 (ug/kg), evaluated as percent inhibition of bradycardia",1,,Autocuration,,,,,,,F,BAO_0000019,CHEMBL617795,3150
,104698,H,6,,,,13392,,"Antagonistic activity of compound towards 5-hydroxytryptamine 3 receptor in Von Bezold-Jarisch reflex in rats at 60 (ug/kg), evaluated as percent inhibition of bradycardia",1,,Autocuration,,,,,,,F,BAO_0000019,CHEMBL617796,3151
,104698,H,6,,,,13392,,"Antagonistic activity of compound towards 5-hydroxytryptamine 3 receptor in Von Bezold-Jarisch reflex in rats at 60(ug/kg), evaluated as percent inhibition of bradycardia",1,,Autocuration,,,,,,,F,BAO_0000019,CHEMBL617797,3152
,104698,D,7,In vivo,,,1089,,Antagonism of 5-HT-induced Von Bezold-Jarisch reflex in rat after intravenous administration of 30 ug/kg of HT (5-hydroxytryptamine 3 receptor antagonism),1,Rattus norvegicus,Autocuration,,,,10116.0,,,F,BAO_0000218,CHEMBL617798,3153
,104698,H,6,In vivo,,,1089,,Ability to antagonise the 5-HT- induced Von Bezold-Jarisch reflex in the rat after intravenous administration of 30 ug/kg of HT (5-hydroxytryptamine 3 receptor),1,,Autocuration,,,,,,,F,BAO_0000218,CHEMBL617799,3154
,104698,D,7,In vivo,,,11454,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 1000 ug/kg dose in urethane-anesthetized rats,1,Rattus norvegicus,Autocuration,,,,10116.0,,,F,BAO_0000218,CHEMBL617800,3155
,104698,D,7,,,,11454,,Inhibition of 5-HT-induced bradycardia by 5-hydroxytryptamine 3+,1,Rattus norvegicus,Autocuration,,,,10116.0,,,F,BAO_0000019,CHEMBL617801,3156
,104698,D,7,In vivo,,,12205,,In vivo inhibitory concentration after 5 minutes against 5-hydroxytryptamine 3 receptor induced bradycardia [bezold-jarisch (B-J) reflex test] in rat by intravenous administration,1,Rattus norvegicus,Autocuration,,,,10116.0,,,F,BAO_0000218,CHEMBL617802,3157
,104698,D,7,,,,1089,,Inhibition of 5-HT (1 ug/mL) induced depolarization in rat vagus nerve (5-hydroxytryptamine 3 receptor antagonism),1,Rattus norvegicus,Autocuration,,,,10116.0,,,F,BAO_0000019,CHEMBL617803,3158
,104698,H,6,,,,5094,,Binding affinity towards 5-HT3 receptor in rat was evaluated,1,,Autocuration,,,,,,,B,BAO_0000019,CHEMBL617804,3159
,104698,D,7,,,,2622,,Inhibition of [3H]GR-65630 binding to rat cortical membrane 5-hydroxytryptamine 3 receptor,1,Rattus norvegicus,Autocuration,,,,10116.0,,,B,BAO_0000019,CHEMBL617805,3160
,104698,H,6,,,,245,,Binding affinity was evaluated in vitro by displacement of [3H]zacopride radioligand from 5-hydroxytryptamine 3 receptor,1,,Autocuration,,,,,,,B,BAO_0000223,CHEMBL617806,3161
,104698,H,6,,,,14788,,Compound was evaluated for its binding affinity for 5-hydroxytryptamine 3 receptor by measuring displacement [3H]GR-65630 in rat cerebral cortex.,1,,Autocuration,,,,,,,B,BAO_0000019,CHEMBL617807,3162
,104698,H,6,,,,14788,,Compound was evaluated for its binding affinity for 5-hydroxytryptamine 3 receptor by measuring displacement of [3H]granisetron from rat cerebral cortex,1,,Autocuration,,,,,,,B,BAO_0000019,CHEMBL617808,3163
,104698,H,6,,,,3020,,Binding affinity against 5-hydroxytryptamine 3 receptor in rat cortical membrane using [3H]GR-65630 as radioligand,1,,Autocuration,,,,,,,B,BAO_0000249,CHEMBL617809,3164
,104698,H,6,,,,1742,,Compound was tested for its ability to displace [3H]-Q-ICS 205-930 from 5-hydroxytryptamine 3 receptor in rat cortex homogenates,1,,Autocuration,,,,,,,B,BAO_0000019,CHEMBL617810,3165
Brain,104698,H,6,,,,17394,,Concentration of compound required to inhibit the binding of radioligand [3H]GR-65630 to 5-hydroxytryptamine 3 receptor in rat brain cortical membrane,1,,Autocuration,,,,,,955.0,B,BAO_0000249,CHEMBL617811,3166
Brain,104698,H,6,,,,17394,,Concentration required to inhibit the binding of radioligand [3H]GR-65630 to serotonin 5-hydroxytryptamine-3 receptor (5-HT 3 receptor)in rat brain cortical membrane,1,,Autocuration,,,,,,955.0,B,BAO_0000221,CHEMBL617812,3167
,104698,H,6,,,,17394,,Concentration of compound required to inhibit the binding of radioligand [3H]GR-65630 to serotonin 5-hydroxytryptamine 3 receptor in rat cortical membrane,1,,Autocuration,,,,,,,B,BAO_0000249,CHEMBL617813,3168
,104698,H,6,,,,14286,,In vitro inhibitory concentration against radioligand [3H]BRL-43694 binding to 5-hydroxytryptamine 3 receptor in rat cortical membrane,1,,Autocuration,,,,,,,B,BAO_0000249,CHEMBL617814,3169
,104698,H,6,,,,14178,,Inhibition of [3H]BRL-43694 binding to 5-hydroxytryptamine 3 receptor of rat cortical homogenate.,1,,Autocuration,,,,,,,B,BAO_0000019,CHEMBL617698,3170
,104698,D,7,,,,14178,,Inhibition of [3H]BRL-43694 binding to 5-hydroxytryptamine 3 receptor of rat cortical homogenate; Not active at 10000 nm,1,Rattus norvegicus,Autocuration,,,,10116.0,,,B,BAO_0000019,CHEMBL617699,3171
,104698,D,7,,,,14178,,Inhibition of [3H]BRL-43694 binding to 5-hydroxytryptamine 3 receptor of rat cortical homogenate; not active at 10000 nM,1,Rattus norvegicus,Autocuration,,,,10116.0,,,B,BAO_0000019,CHEMBL617700,3172
,104698,D,7,,,,14178,,Inhibition of radiolabeled [3H]-Zacopride ligand binding to 5-hydroxytryptamine 3 receptor,1,Rattus norvegicus,Autocuration,,,,10116.0,,,B,BAO_0000223,CHEMBL617701,3173
,104698,H,6,,,,15034,,Inhibitory concentration against 5-hydroxytryptamine 3 receptor in rat entorhinal cortex using [3H]-LY 278584 as radioligand,1,,Autocuration,,,,,,,B,BAO_0000019,CHEMBL617702,3174
,104698,H,6,,,Membranes,1089,,"Tested for inhibition of binding of [3H]GR-65630 to rat cortical membranes, expressed as IC50",1,,Autocuration,,,,,,,B,BAO_0000249,CHEMBL617703,3175
,104698,D,7,,,,1089,,Inhibition of [3H]GR-65630 binding to rat cortical membrane serotonin 3 receptor,1,Rattus norvegicus,Autocuration,,,,10116.0,,,B,BAO_0000019,CHEMBL617704,3176
,104698,H,6,,,,16532,,The binding affinity at 5-hydroxytryptamine 3 receptor was determined using [3H]LY-278584; Not tested,1,,Autocuration,,,,,,,B,BAO_0000223,CHEMBL617705,3177
,104698,D,7,,,,12801,,Inhibition of [3H]BRL-43694 binding to rat 5-hydroxytryptamine 3 receptor,1,Rattus norvegicus,Autocuration,,,,10116.0,,,B,BAO_0000223,CHEMBL617706,3178
,104698,H,6,,,,15194,,The compound was tested for binding affinity against 5-hydroxytryptamine 3 receptor from NG108-15 cells (using [3H]zacopride as radioligand),1,,Autocuration,,433.0,,,NG108-15,,B,BAO_0000219,CHEMBL617707,3179
,104698,H,6,,,,15194,,The compound was tested for binding affinity against 5-hydroxytryptamine 3 receptor from NG108-15 cells using [3H]zacopride as radioligand,1,,Autocuration,,433.0,,,NG108-15,,B,BAO_0000219,CHEMBL617708,3180
,104698,H,6,,,,15194,,Binding affinity against 5-hydroxytryptamine 3 (5-HT3) receptor from rat cortical homogenate using [3H]zacopride as radioligand,1,,Autocuration,,,,,,,B,BAO_0000019,CHEMBL617709,3181
,104698,H,6,,,,15194,,The compound was tested for binding affinity against 5-hydroxytryptamine 3 receptor from rat cortical homogenate using [3H]zacopride as radioligand; NA= Not active,1,,Autocuration,,,,,,,B,BAO_0000019,CHEMBL617710,3182
,104698,H,6,,,,15194,,The compound was tested for binding affinity against 5-hydroxytryptamine 3 receptor from rat cortical homogenate using [3H]zacopride as radioligand; NA=Not active,1,,Autocuration,,,,,,,B,BAO_0000019,CHEMBL882925,3183
,104698,H,6,,,,15194,,The compound was tested for binding affinity against 5-hydroxytryptamine 3 receptor from rat cortical homogenate using [3H]zacopride as radioligand; not active,1,,Autocuration,,,,,,,B,BAO_0000019,CHEMBL617711,3184
,104698,H,6,,,,10610,,Antagonist potency to 5-hydroxytryptamine 3 receptor was assayed by antagonism of the 5-HT-evoked reflex bradycardia [Bezold-Jarisch(BJ) reflex] in rats,1,,Autocuration,,,,,,,F,BAO_0000019,CHEMBL617712,3185
,104698,D,7,,,,10355,,Antagonistic activity against 5-hydroxytryptamine 3 receptor as inhibition of 5-HT-induced bradycardia (von Bezold-jarisch reflex) in anesthetized rat,1,Rattus norvegicus,Autocuration,,,,10116.0,,,F,BAO_0000019,CHEMBL617713,3186
,104698,H,6,,,,691,,"Compound was tested as a 5-hydroxytryptamine 3 receptor antagonist in the rat by assessment of the inhibition of the Bezold-Jarisch effect, when administered intravenously",1,,Autocuration,,,,,,,F,BAO_0000019,CHEMBL617714,3187
,104698,H,6,,,,10611,,In vivo 5-hydroxytryptamine 3 receptor (5-HT 3 receptor) antagonistic activity expressed as ability to inhibit Bezold-Jarich reflex evoked by 5-HT in rats,1,,Autocuration,,,,,,,F,BAO_0000218,CHEMBL617715,3188
,104698,H,6,In vivo,,,12801,,Inhibition dose for 50 percent antagonism for 5-hydroxytryptamine 3 receptor in vivo in rats,1,,Autocuration,,,,,,,F,BAO_0000218,CHEMBL617716,3189
,104698,H,6,,,,10609,,Inhibition of 5-HT evoked reflex bradycardia in rat.,1,,Autocuration,,,,,,,F,BAO_0000218,CHEMBL617717,3190
,104698,H,6,In vivo,,,11454,,5-HT3 receptor antagonistic activity was measured by the inhibition of 5-HT-induced bradycardia after iv administration of 1000 ug/kg dose in urethane-anesthetized rats,1,,Autocuration,,,,,,,F,BAO_0000218,CHEMBL617718,3191
,104698,H,6,In vivo,,,11454,,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after iv administration of 1 ug/kg dose in urethane-anesthetized rats,1,,Autocuration,,,,,,,F,BAO_0000218,CHEMBL617719,3192
,104698,H,6,In vivo,,,11454,,5-hydroxytryptamine 3 receptor antagonistic activity measured by inhibition of 5-HT-induced bradycardia (iv administration 10 ug/kg dose in urethane-anesthetized rats),1,,Autocuration,,,,,,,F,BAO_0000218,CHEMBL617720,3193
,104698,D,7,In vivo,,,11454,,5-hydroxytryptamine 3 receptor antagonistic activity as inhibition of 5-HT-induced bradycardia after iv administration of 100 ug/kg dose in urethane-anesthetized rats,1,Rattus norvegicus,Autocuration,,,,10116.0,,,F,BAO_0000218,CHEMBL617721,3194
,104698,H,6,In vivo,,,11454,,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after iv administration of 1000 ug/kg dose in urethane-anesthetized rats,1,,Autocuration,,,,,,,F,BAO_0000218,CHEMBL617722,3195
,104698,H,6,In vivo,,,11454,,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after iv administration of 1000 ug/kgetized rats,1,,Autocuration,,,,,,,F,BAO_0000218,CHEMBL617723,3196
,104698,H,6,In vivo,,,11454,,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after iv administration of 3 ug/kg dose in urethane-anesthetized rats,1,,Autocuration,,,,,,,F,BAO_0000218,CHEMBL617724,3197
,104698,H,6,In vivo,,,11454,,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after po administration of 10 ug/kg dose in urethane-anesthetized rats,1,,Autocuration,,,,,,,F,BAO_0000218,CHEMBL617725,3198
,104698,H,6,In vivo,,,11454,,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after po administration of 100 ug/kg dose in urethane-anesthetized rats,1,,Autocuration,,,,,,,F,BAO_0000218,CHEMBL617726,3199
,104698,H,6,In vivo,,,11454,,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after po administration of 1000 ug/kg dose in urethane-anesthetized rats,1,,Autocuration,,,,,,,F,BAO_0000218,CHEMBL617727,3200
,104698,H,6,In vivo,,,11454,,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after po administration of 30 ug/kg dose in urethane-anesthetized rats,1,,Autocuration,,,,,,,F,BAO_0000218,CHEMBL617728,3201
,104698,H,6,In vivo,,,11454,,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after po administration of 300 ug/kg dose in urethane-anesthetized rats,1,,Autocuration,,,,,,,F,BAO_0000218,CHEMBL617729,3202
,104698,H,6,In vivo,,,11454,,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after po administration of 3ug/kg dose in urethane-anesthetized rats,1,,Autocuration,,,,,,,F,BAO_0000218,CHEMBL617730,3203
,104698,H,6,In vivo,,,11454,,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5-HT-induced bradycardia after iv administration of 1000 ug/kg dose in urethane-anesthetized rats,1,,Autocuration,,,,,,,F,BAO_0000218,CHEMBL617731,3204
,104698,H,6,In vivo,,,11454,,Compound was tested for the inhibition of 5-HT-induced bradycardia after intravenous administration of 0.3 ug/kg dose in urethane-anesthetized rats,1,,Autocuration,,,,,,,F,BAO_0000218,CHEMBL617732,3205
,104698,H,6,In vivo,,,11454,,Compound was tested for the inhibition of 5-HT-induced bradycardia after intravenous administration of 1 ug/kg dose in urethane-anesthetized rats,1,,Autocuration,,,,,,,F,BAO_0000218,CHEMBL617733,3206
,104698,H,6,In vivo,,,11454,,Compound was tested for the inhibition of 5-HT-induced bradycardia after intravenous administration of 30 ug/kg dose in urethane-anesthetized rats,1,,Autocuration,,,,,,,F,BAO_0000218,CHEMBL617734,3207
,104698,H,6,In vivo,,,11454,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg dose in urethane-anesthetized rats at 0.05 hour,1,,Autocuration,,,,,,,F,BAO_0000218,CHEMBL872874,3208
,104698,H,6,In vivo,,,11454,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg dose in urethane-anesthetized rats at 1 hour,1,,Autocuration,,,,,,,F,BAO_0000218,CHEMBL617735,3209
,104698,H,6,In vivo,,,11454,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg dose in urethane-anesthetized rats at 16 hour,1,,Autocuration,,,,,,,F,BAO_0000218,CHEMBL617736,3210
,104698,H,6,In vivo,,,11454,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg dose in urethane-anesthetized rats at 3 hour,1,,Autocuration,,,,,,,F,BAO_0000218,CHEMBL617737,3211
,104698,H,6,In vivo,,,11454,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg dose in urethane-anesthetized rats at 6 hour,1,,Autocuration,,,,,,,F,BAO_0000218,CHEMBL617738,3212
,104698,H,6,In vivo,,,11454,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 10 ug/kg dose in urethane-anesthetized rats,1,,Autocuration,,,,,,,F,BAO_0000218,CHEMBL617739,3213
,104698,H,6,In vivo,,,11454,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 100 ug/kg dose in urethane-anesthetized rats,1,,Autocuration,,,,,,,F,BAO_0000218,CHEMBL617740,3214
,104698,H,6,In vivo,,,11454,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 1000 ug/kg dose in urethane-anesthetized rats,1,,Autocuration,,,,,,,F,BAO_0000218,CHEMBL617741,3215
,104698,H,6,In vivo,,,11454,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 10 ug/kg dose in urethane-anesthetized rats,1,,Autocuration,,,,,,,F,BAO_0000218,CHEMBL617742,3216
,104698,H,6,In vivo,,,11454,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 3 ug/kg dose in urethane-anesthetized rats,1,,Autocuration,,,,,,,F,BAO_0000218,CHEMBL617743,3217
,104698,H,6,In vivo,,,11454,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 30 ug/kg dose in urethane-anesthetized rats,1,,Autocuration,,,,,,,F,BAO_0000218,CHEMBL617744,3218
,104698,H,6,In vivo,,,11454,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 300 ug/kg dose in urethane-anesthetized rats,1,,Autocuration,,,,,,,F,BAO_0000218,CHEMBL617745,3219
,104698,H,6,,,,670,,"In vivo 5-hydroxytryptamine 3 receptor antagonist activity by antagonism of the von Bezold-Jarisch (B-J) reflex in anesthetized rats, (i.v.)",1,,Autocuration,,,,,,,F,BAO_0000218,CHEMBL617746,3220
,104698,H,6,,,,670,,"In vivo 5-hydroxytryptamine 3 receptor antagonist activity by antagonism of the von Bezold-Jarisch (B-J) reflex in anesthetized rats, (i.v.); Not tested",1,,Autocuration,,,,,,,F,BAO_0000218,CHEMBL617747,3221
,104698,H,6,In vivo,,,10321,,Serotonin receptor antagonist activity was measured as ability to block the serotonin-induced Bezold-Jarisch reflex in rats after iv administration of 10 ug/Kg,1,,Autocuration,,,,,,,F,BAO_0000218,CHEMBL617748,3222
,104698,H,6,In vivo,,,10321,,Serotonin receptor antagonist activity was measured as ability to block the serotonin-induced Bezold-Jarisch reflex in rats after iv administration of 100 ug/Kg,1,,Autocuration,,,,,,,F,BAO_0000218,CHEMBL618909,3223
,104698,H,6,In vivo,,,10321,,Serotonin receptor antagonist activity was measured as ability to block the serotonin-induced Bezold-Jarisch reflex in rats after iv administration of 2 ug/Kg,1,,Autocuration,,,,,,,F,BAO_0000218,CHEMBL618910,3224
,104698,H,6,In vivo,,,10321,,Serotonin receptor antagonist activity was measured as ability to block the serotonin-induced Bezold-Jarisch reflex in rats after iv administration of 20 ug/Kg,1,,Autocuration,,,,,,,F,BAO_0000218,CHEMBL618911,3225
,104698,H,6,In vivo,,,10321,,Serotonin receptor antagonist activity was measured as ability to block the serotonin-induced Bezold-Jarisch reflex in rats after iv administration of 5 ug/Kg,1,,Autocuration,,,,,,,F,BAO_0000218,CHEMBL618912,3226
,104698,H,6,In vivo,,,10322,,Tested for inhibition of Bezold-Jarisch (B-J) reflex mediated by 5-hydroxytryptamine 3 receptor in rats after intravenous administration (2.0 ug/kg),1,,Autocuration,,,,,,,F,BAO_0000218,CHEMBL618913,3227
,104698,H,6,,,,15412,,Intrinsic efficacy against 5-hydroxytryptamine 3 receptor; A means pure agonist,1,,Autocuration,,,,,,,F,BAO_0000019,CHEMBL618914,3228
,104698,H,6,,,,15412,,Intrinsic efficacy against 5-hydroxytryptamine 3 receptor; A means pure agonist,1,,Autocuration,,,,,,,F,BAO_0000019,CHEMBL618915,3229
,104698,D,7,,,,15412,,Intrinsic efficacy for rat 5-hydroxytryptamine 3 receptor,1,Rattus norvegicus,Autocuration,,,,10116.0,,,B,BAO_0000223,CHEMBL618916,3230
,104698,H,6,,,,15412,,Intrinsic efficacy against 5-hydroxytryptamine 3 receptor; PA means partial agonist,1,,Autocuration,,,,,,,F,BAO_0000019,CHEMBL618917,3231
Hippocampus,104698,D,7,,,,15412,,Inhibition of [3H]granisetron binding to 5-hydroxytryptamine 3 receptor (5-HT 3 receptor) of rat cortex and hippocampus tissue,1,,Intermediate,,,,,,10000000.0,B,BAO_0000221,CHEMBL618918,3232
,104698,D,7,,,,15412,,Inhibition of [3H]granisetron binding to 5-hydroxytryptamine 3 receptor of rat cortical membrane,1,Rattus norvegicus,Autocuration,,,,10116.0,,,B,BAO_0000019,CHEMBL618919,3233
,104698,D,7,,,,17394,,Inhibition of [3H]GR-65630 binding to rat cortical membrane serotonin 5-hydroxytryptamine 3 receptor,1,Rattus norvegicus,Autocuration,,,,10116.0,,,B,BAO_0000019,CHEMBL618920,3234
,104698,H,6,,,,12457,,Affinity was evaluated as inhibition constant for serotonin 5-hydroxytryptamine 3 receptor,1,,Autocuration,,,,,,,B,BAO_0000223,CHEMBL618921,3235
,104698,H,6,,,,12457,,Affinity was evaluated by inhibition of [3H]GR-65630 binding to NG108-15 cell transfected with cloned rat 5-hydroxytryptamine 3 receptor,1,,Autocuration,,,,,,,B,BAO_0000019,CHEMBL618922,3236
,104698,H,6,,,,12205,,Binding affinity against radioligand [3H]quipazine labeled 5-hydroxytryptamine 3 receptor sites in neuroblastoma-glioma (NG108-15) cells.,1,,Autocuration,,,,,,,B,BAO_0000019,CHEMBL618923,3237
,104698,H,6,,,,14532,,Binding affinity for 5-hydroxytryptamine 3 receptor was determined by measuring displacement of [3H]GR-65630 from rat brain cortices,1,,Autocuration,,,,,,,B,BAO_0000019,CHEMBL618924,3238
,104698,H,6,,,,1122,,Binding affinity to 5-hydroxytryptamine 3 receptor in rat entorhinal cortex using [3H]-BRL 43694 as radioligand,1,,Autocuration,,,,,,,B,BAO_0000019,CHEMBL618925,3239
,104698,H,6,,,,5094,,Binding affinity towards 5-HT3 receptor in rat was evaluated,1,,Autocuration,,,,,,,B,BAO_0000019,CHEMBL618926,3240
Ileum,20033,D,9,,,,809,,5-hydroxytryptamine 4 receptor agonist activity as increased response to electrical stimulation in guinea pig ileum,1,Cavia porcellus,Intermediate,,,,10141.0,,2116.0,F,BAO_0000221,CHEMBL618927,3241
Ileum,20033,D,9,,,,809,,5-hydroxytryptamine 4 receptor agonist activity expressed as the concentration which gave a 50% increase in the response to the electrical stimulation in male guinea pig ileum; Not tested,1,Cavia porcellus,Intermediate,,,,10141.0,,2116.0,F,BAO_0000221,CHEMBL618928,3242
Ileum,20033,D,9,,,,14290,,"5-hydroxytryptamine 4 receptor agonist activity, concentration which gave 50% increase in the response to electrically-stimulated myenteric plexus and longitudinal muscle of the guinea pig ileum",1,Cavia porcellus,Intermediate,,,,10141.0,,2116.0,F,BAO_0000221,CHEMBL618929,3243
Ileum,20033,D,9,,,,14290,,"5-hydroxytryptamine 4 receptor agonist activity, concentration which gave 50% increase in the response to electrically-stimulated myenteric plexus and longitudinal muscle of the guinea pig ileum; Inactive up to 10E-5 M",1,Cavia porcellus,Intermediate,,,,10141.0,,2116.0,F,BAO_0000221,CHEMBL618930,3244
Ileum,20033,D,9,,,,14290,,"5-hydroxytryptamine 4 receptor agonist activity, concentration which gave 50% increase in the response to electrically-stimulated myenteric plexus and longitudinal muscle of the guinea pig ileum; Not tested",1,Cavia porcellus,Intermediate,,,,10141.0,,2116.0,F,BAO_0000221,CHEMBL618931,3245
Ileum,20033,D,9,,,,14290,,"5-hydroxytryptamine 4 receptor agonist activity, concentration which gave 50% increase in the response to electrically-stimulated myenteric plexus and longitudinal muscle of the guinea pig ileum; Not tested",1,Cavia porcellus,Intermediate,,,,10141.0,,2116.0,F,BAO_0000221,CHEMBL619594,3246
Ileum,20033,D,9,,,,14290,,"5-hydroxytryptamine 4 receptor antagonist activity, concentration which gave 50% reduction of the 5-HT-induced contractions in the guinea pig ileum; Not capable of evaluation",1,Cavia porcellus,Intermediate,,,,10141.0,,2116.0,F,BAO_0000221,CHEMBL619595,3247
Ileum,20033,D,9,,,,13961,,concentration which gave a 50% increase in the response to electrical stimulation against 5-hydroxytryptamine 4 receptor in the guinea pig ileum.,1,Cavia porcellus,Intermediate,,,,10141.0,,2116.0,F,BAO_0000221,CHEMBL619596,3248
Ileum,20033,D,9,,,,13961,,concentration which gave a 50% increase in the response to electrical stimulation against 5-hydroxytryptamine 4 receptor in the guinea pig ileum. Activity expressed as percent of the maximum 5-HT response given in brackets.,1,Cavia porcellus,Intermediate,,,,10141.0,,2116.0,F,BAO_0000221,CHEMBL619755,3249
Ileum,20033,D,9,,,,809,,5-hydroxytryptamine 4 receptor antagonist activity expressed as the concentration which produced a 50% reduction of 5-HT induced contraction in guinea pig ileum,1,Cavia porcellus,Intermediate,,,,10141.0,,2116.0,F,BAO_0000221,CHEMBL619756,3250
Ileum,20033,D,9,,,,809,,5-hydroxytryptamine 4 receptor antagonist activity expressed as the concentration which produced a 50% reduction of 5-HT induced contraction in guinea pig ileum; Not evaluable,1,Cavia porcellus,Intermediate,,,,10141.0,,2116.0,F,BAO_0000221,CHEMBL619757,3251
Ileum,20033,D,9,,,,809,,5-hydroxytryptamine 4 receptor antagonist activity expressed as the concentration which produced a 50% reduction of 5-HT induced contraction in guinea pig ileum; Not tested,1,Cavia porcellus,Intermediate,,,,10141.0,,2116.0,F,BAO_0000221,CHEMBL619758,3252
Ileum,20033,D,9,,,,14290,,"5-hydroxytryptamine 4 receptor antagonist activity, concentration which gave 50% reduction of the 5-HT-induced contractions in the guinea pig ileum",1,Cavia porcellus,Intermediate,,,,10141.0,,2116.0,F,BAO_0000221,CHEMBL619759,3253
Ileum,20033,D,9,,,,14290,,"5-hydroxytryptamine 4 receptor antagonist activity, concentration which gave 50% reduction of the 5-HT-induced contractions in the guinea pig ileum; Inactive up to 10-5 M",1,Cavia porcellus,Intermediate,,,,10141.0,,2116.0,F,BAO_0000221,CHEMBL619760,3254
Ileum,20033,D,9,,,,14290,,"5-hydroxytryptamine 4 receptor antagonist activity, concentration which gave 50% reduction of the 5-HT-induced contractions in the guinea pig ileum; Inactive up to 10E-5 M",1,Cavia porcellus,Intermediate,,,,10141.0,,2116.0,F,BAO_0000221,CHEMBL619761,3255
Ileum,20033,D,9,,,,14290,,5-hydroxytryptamine 4 receptor antagonist activity as inhibition of 5-HT-induced contractions in guinea pig ileum; Not capable of evaluation.,1,Cavia porcellus,Intermediate,,,,10141.0,,2116.0,F,BAO_0000221,CHEMBL619762,3256
Ileum,20033,D,9,,,,14290,,"5-hydroxytryptamine 4 receptor antagonist activity, concentration which gave 50% reduction of the 5-HT-induced contractions in the guinea pig ileum; Not tested",1,Cavia porcellus,Intermediate,,,,10141.0,,2116.0,F,BAO_0000221,CHEMBL619763,3257
Ileum,20033,D,9,,,,14290,,"5-hydroxytryptamine 4 receptor antagonist activity, concentration which gave 50% reduction of the 5-HT-induced contractions in the guinea pig ileum; Not tested",1,Cavia porcellus,Intermediate,,,,10141.0,,2116.0,F,BAO_0000221,CHEMBL617868,3258
,20033,D,9,,,,15034,,Displacement of [3H]GR-113808 from 5-hydroxytryptamine 4 receptor in guinea pig striatum,1,Cavia porcellus,Intermediate,,,,10141.0,,,B,BAO_0000357,CHEMBL617869,3259
Striatum,20033,D,9,,,,5094,,Binding affinity towards 5-HT4 receptor in striatum membranes of guinea-pig brain was evaluated,1,Cavia porcellus,Intermediate,,,,10141.0,,2435.0,B,BAO_0000249,CHEMBL882926,3260
Striatum,20033,D,9,,,,5094,,Binding affinity towards 5-hydroxytryptamine 4 receptor in striatum membranes of guinea-pig brain was evaluated,1,Cavia porcellus,Intermediate,,,,10141.0,,2435.0,B,BAO_0000249,CHEMBL617870,3261
Striatum,20033,D,9,,,,5399,,Inhibitory activity against 5-hydroxytryptamine 4 receptor of guinea pig striatum using [3H]GR-113808 as radioligand,1,Cavia porcellus,Intermediate,,,,10141.0,,2435.0,B,BAO_0000357,CHEMBL617871,3262
Striatum,20033,D,9,,,,17394,,Concentration of compound required to inhibit the binding of radioligand [3H]GR-113808 to 5-hydroxytryptamine 4 receptor in guinea pig striatum,1,Cavia porcellus,Intermediate,,,,10141.0,,2435.0,B,BAO_0000357,CHEMBL617872,3263
Striatum,20033,D,9,,,,17394,,Concentration of compound required to inhibit the binding of radioligand [3H]GR-113808 to 5-hydroxytryptamine 4 receptor in guinea-pig striatum,1,Cavia porcellus,Intermediate,,,,10141.0,,2435.0,B,BAO_0000357,CHEMBL617873,3264
Striatum,20033,D,9,,,,17394,,Concentration of compound required to inhibit the binding of radioligand [3H]GR-113808 to serotonin 5-hydroxytryptamine 4 receptor in guinea-pig striatum,1,Cavia porcellus,Intermediate,,,,10141.0,,2435.0,B,BAO_0000357,CHEMBL617874,3265
Ileum,20033,D,9,,,,13961,,The antagonist activity was calculated as the concentration which produced a 50% reduction against 5-hydroxytryptamine 4 receptor in guinea pig ileum.,1,Cavia porcellus,Intermediate,,,,10141.0,,2116.0,F,BAO_0000221,CHEMBL619067,3266
Ileum,20033,D,9,,,,13961,,The antagonist activity was calculated as the concentration which produced a 50% reduction against 5-hydroxytryptamine 4 receptor in guinea pig ileum. 95% confidence limits are in brackets.,1,Cavia porcellus,Intermediate,,,,10141.0,,2116.0,F,BAO_0000221,CHEMBL619068,3267
Ileum,20033,D,9,,,,13961,,The antagonist activity was calculated as the concentration which produced a 50% reduction against 5-hydroxytryptamine 4 receptor in guinea pig ileum;ne=not capable of evaluation.,1,Cavia porcellus,Intermediate,,,,10141.0,,2116.0,F,BAO_0000221,CHEMBL619069,3268
,20033,D,9,,,,16946,,Ability to displace [3H]GR-113808 from 5-hydroxytryptamine 4 receptor at concentration of 10e-6 M in guinea pig,1,Cavia porcellus,Intermediate,,,,10141.0,,,B,BAO_0000357,CHEMBL619070,3269
,20033,D,9,,,,16946,,Ability to displace [3H]GR-113808 from 5-hydroxytryptamine 4 receptor at concentration of 10e-8 M in guinea pig,1,Cavia porcellus,Intermediate,,,,10141.0,,,B,BAO_0000357,CHEMBL619071,3270
,20033,D,9,,,,15034,,Agonistic activity against 5-hydroxytryptamine 4 receptor,1,Cavia porcellus,Intermediate,,,,10141.0,,,F,BAO_0000019,CHEMBL619072,3271
,20033,D,9,,,,15034,,Agonistic activity against 5-hydroxytryptamine 4 receptor; not tested,1,Cavia porcellus,Intermediate,,,,10141.0,,,F,BAO_0000019,CHEMBL619073,3272
,20033,D,9,,,,12918,,Compound was evaluated for the relative potency with respect to serotonin against 5-hydroxytryptamine 4 receptor,1,Cavia porcellus,Intermediate,,,,10141.0,,,F,BAO_0000019,CHEMBL619074,3273
,20033,D,9,,,,16946,,Ability to displace [3H]GR-113808 from 5-hydroxytryptamine 4 receptor,1,Cavia porcellus,Intermediate,,,,10141.0,,,B,BAO_0000357,CHEMBL619075,3274
Striatum,20033,D,9,,,,17394,,Inhibition of [3H]GR-113808 binding to guinea pig striatum 5-hydroxytryptamine 4 receptor,1,Cavia porcellus,Intermediate,,,,10141.0,,2435.0,B,BAO_0000357,CHEMBL619076,3275
Striatum,20033,D,9,,,,15034,,Binding affinity against 5-hydroxytryptamine 4 receptor in guinea pig striatum using [3H]GR-113808 as radioligand,1,Cavia porcellus,Intermediate,,,,10141.0,,2435.0,B,BAO_0000357,CHEMBL619077,3276
Striatum,20033,D,9,,,,5094,,Binding affinity towards 5-HT4 receptor in striatum membranes of guinea-pig brain was evaluated,1,Cavia porcellus,Intermediate,,,,10141.0,,2435.0,B,BAO_0000249,CHEMBL619078,3277
Striatum,20033,D,9,,,,5094,,Binding affinity towards 5-hydroxytryptamine 4 receptor in striatum membranes of guinea-pig brain was evaluated,1,Cavia porcellus,Intermediate,,,,10141.0,,2435.0,B,BAO_0000249,CHEMBL619079,3278
Ileum,20033,D,9,,,,17358,,Tested for affinity against 5-hydroxytryptamine 4 receptor in the myenteric plexus of the guinea pig ileum.,1,Cavia porcellus,Intermediate,,,,10141.0,,2116.0,B,BAO_0000221,CHEMBL619080,3279
,20033,D,9,,,,12953,,Displacement of [3H]-GR113808 from 5-HT4 receptor of guinea pig striatum,1,Cavia porcellus,Expert,,,,10141.0,,,B,BAO_0000357,CHEMBL619081,3280
,20033,D,9,,,,12953,,The compound was tested for their binding affinity towards 5-HT4 receptor from guinea pig striatum using [3H]GR-113808 as radioligand; Nonactive at 10 uM,1,Cavia porcellus,Intermediate,,,,10141.0,,,B,BAO_0000357,CHEMBL619082,3281
,20033,D,9,,,,12953,,The compound was tested for their binding affinity towards 5-hydroxytryptamine 4 receptor from guinea pig striatum using [3H]GR-113808 as radioligand.,1,Cavia porcellus,Intermediate,,,,10141.0,,,B,BAO_0000357,CHEMBL619083,3282
,20033,D,9,,,,12953,,The compound was tested for their binding affinity towards 5-hydroxytryptamine 4 receptor from guinea pig striatum using [3H]GR-113808 as radioligand; Nonactive at 10 uM,1,Cavia porcellus,Intermediate,,,,10141.0,,,B,BAO_0000357,CHEMBL619084,3283
Ileum,20033,D,9,,,,273,,Evaluated for the antagonistic activity against Serotonin 5-hydroxytryptamine 4 receptor in non-electrically stimulated guinea-pig ileum.,1,Cavia porcellus,Intermediate,,,,10141.0,,2116.0,F,BAO_0000221,CHEMBL859397,3284
Ileum,20033,D,9,,,,12918,,5-hydroxytryptamine 4 receptor agonist activity in the guinea pig ileum assay,1,Cavia porcellus,Intermediate,,,,10141.0,,2116.0,F,BAO_0000221,CHEMBL619085,3285
Ileum,20033,D,9,,,,12919,,5-hydroxytryptamine 4 receptor agonistic activity was measured by twitch response enhancing activity in electrically stimulated guinea pig ileum preparation,1,Cavia porcellus,Intermediate,,,,10141.0,,2116.0,F,BAO_0000221,CHEMBL619086,3286
Ileum,20033,D,9,,,,273,,Agonistic activity against Serotonin 5-hydroxytryptamine 4 receptor in low frequency field stimulation of guinea-pig ileum (FSGPI).,1,Cavia porcellus,Intermediate,,,,10141.0,,2116.0,F,BAO_0000221,CHEMBL619087,3287
Ileum,20033,D,9,,,,273,,Agonistic activity against Serotonin 5-hydroxytryptamine 4 receptor in non-electrically stimulated guinea-pig ileum.,1,Cavia porcellus,Intermediate,,,,10141.0,,2116.0,F,BAO_0000221,CHEMBL619088,3288
,20033,D,9,,,,13181,,Ability to antagonize 5-HT-evoked contractions mediated through 5-hydroxytryptamine 4 receptor activation in the guinea pig distal colon LMMP,1,Cavia porcellus,Intermediate,,,,10141.0,,,B,BAO_0000357,CHEMBL619089,3289
,168,H,8,,,,13181,,Binding affinity was determined against 5-hydroxytryptamine 3 receptor,1,Cavia porcellus,Autocuration,,,,10141.0,,,B,BAO_0000357,CHEMBL619090,3290
,20033,D,9,,,,15034,,Antagonistic activity against 5-hydroxytryptamine 4 receptor,1,Cavia porcellus,Intermediate,,,,10141.0,,,F,BAO_0000019,CHEMBL619091,3291
,20033,D,9,,,,5033,,Ability to displace the radioligand [3H]GR-113808 from guinea pig striatum 5-hydroxytryptamine 4 receptor,1,Cavia porcellus,Intermediate,,,,10141.0,,,B,BAO_0000357,CHEMBL619092,3292
,20033,D,9,,,,1980,,Binding affinity for 5-hydroxytryptamine 4 receptor by displacement of [3H]GR-113808 from guinea pig brain striatum.,1,Cavia porcellus,Intermediate,,,,10141.0,,,B,BAO_0000019,CHEMBL619093,3293
,168,H,8,,,,13181,,Binding affinity was determined against 5-hydroxytryptamine 2C receptor using cloned rat receptors expressed in 293 cells radiolabeled with [3H]mesulergine,1,Cavia porcellus,Autocuration,,722.0,,10141.0,HEK293,,B,BAO_0000219,CHEMBL619094,3294
,20033,D,9,,,,14287,,In vitro by displacement of [3H]GR-113808 from 5-hydroxytryptamine 4 receptor on guinea pig striatal membrane,1,Cavia porcellus,Intermediate,,,,10141.0,,,B,BAO_0000019,CHEMBL619095,3295
,20033,D,9,,,,1317,,Compound was evaluated for binding affinity against 5-hydroxytryptamine 4 receptor using radioligand binding assay using [3H]GR as radioligand,1,Cavia porcellus,Intermediate,,,,10141.0,,,B,BAO_0000357,CHEMBL857988,3296
,20033,D,9,,,,15316,,Compound was evaluated for its ability to displace [3H]GR-113808 binding from 5-hydroxytryptamine 4 receptor in guinea pig striatum.,1,Cavia porcellus,Intermediate,,,,10141.0,,,B,BAO_0000357,CHEMBL619096,3297
Striatum,20033,D,9,,,,16429,,In vitro binding affinity at 5-hydroxytryptamine 4 receptor in guinea pig striatum using 3[H]GR-113808 as the radioligand,1,Cavia porcellus,Intermediate,,,,10141.0,,2435.0,B,BAO_0000357,CHEMBL619097,3298
Hippocampus,20033,D,9,,,,14818,,The compound was tested for its binding affinity towards 5-hydroxytryptamine 4 receptor in guinea pig hippocampus using [125I]SB-207710.,1,Cavia porcellus,Intermediate,,,,10141.0,,10000000.0,B,BAO_0000221,CHEMBL619098,3299
,20033,D,9,,,,15194,,The compound was tested for the binding affinity against 5-hydroxytryptamine 4 receptor using [3H]GR-113808 as radioligand,1,Cavia porcellus,Intermediate,,,,10141.0,,,B,BAO_0000357,CHEMBL619751,3300
,20033,D,9,,,,15194,,The compound was tested for the binding affinity against 5-hydroxytryptamine 4 receptor using [3H]GR-113808 as radioligand.,1,Cavia porcellus,Intermediate,,,,10141.0,,,B,BAO_0000357,CHEMBL619752,3301
Ileum,20033,D,9,,,,13961,,The antagonist activity was calculated as the concentration which produced a 50% reduction against 5-hydroxytryptamine 4 receptor in guinea pig ileum;ne=not capable of evaluation.,1,Cavia porcellus,Intermediate,,,,10141.0,,2116.0,F,BAO_0000221,CHEMBL875096,3302
,108,H,8,,,,5486,,Binding affinity towards 5-HT2C receptor by the displacement of [3H]mesulergine] in human recombinant receptors in mammalian cell,1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL619004,3303
,168,H,8,,,,16209,,Binding affinity towards human 5-hydroxytryptamine 4 receptor using [3H]5-HT as radioligand,1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL619005,3304
,168,H,8,,,,17085,,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 4 receptor,1,,Autocuration,,,,,,,B,BAO_0000019,CHEMBL619006,3305
,168,H,8,,,,4199,,Compound was evaluated for the binding affinity against human cloned 5-hydroxytryptamine 4 receptor in HeLa cells using [3H]-LSD as the radioligand,1,,Autocuration,,308.0,,,HeLa,,B,BAO_0000219,CHEMBL619007,3306
,168,H,8,,,,15146,,Compound was tested for its binding affinity against 5-hydroxytryptamine 4 receptor,1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL619008,3307
,168,H,8,,,,5213,,Compound was tested for its binding affinity for 5-hydroxytryptamine 4 receptor,1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL619009,3308
,168,H,8,,,,4829,,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 4 receptor in HeLa cells, using [3H]LSD as radioligand",1,,Autocuration,,308.0,,,HeLa,,B,BAO_0000219,CHEMBL619010,3309
,10622,H,8,,,,17358,,Tested for ability to stimulate production of cAMP mediated by 5-hydroxytryptamine 4 receptor in mouse Coliculi neurons,1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL619011,3310
,10622,H,8,,,,17358,,Tested for ability to stimulate production of cAMP mediated by 5-hydroxytryptamine 4 receptor in mouse Coliculi neurons; IA means inactive,1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL619012,3311
,10622,H,8,,,,16946,,Ability to displace [3H]GR-113808 from mouse 5-hydroxytryptamine 4 receptor in COS7 cells,1,,Autocuration,,,,,,,B,BAO_0000219,CHEMBL619013,3312
,10622,H,8,,,,17358,,Tested for ability to stimulate 5-hydroxytryptamine 4 receptors in mouse Coliculi neurons,1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL619014,3313
Cardiac atrium,11249,H,8,,,,268,,Evaluated for the 5-hydroxytryptamine 4 receptor antagonistic activity in piglet atrium model,1,,Autocuration,,,,,,2081.0,F,BAO_0000019,CHEMBL857503,3314
Cardiac atrium,11249,H,8,,,,268,,Evaluated for the 5-hydroxytryptamine 4 receptor antagonistic activity in piglet atrium model; compound found inactive at 1 uM,1,,Autocuration,,,,,,2081.0,F,BAO_0000019,CHEMBL619015,3315
,11249,H,8,,,,15086,,The compound was tested for binding affinity against 5-hydroxytryptamine 4 receptor,1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL619016,3316
Hippocampus,11249,H,8,,,,14875,,Compound was tested for binding affinity against piglet hippocampus 5-hydroxytryptamine 4 receptor,1,,Autocuration,,,,,,10000000.0,B,BAO_0000221,CHEMBL619017,3317
Hippocampus,168,H,8,,,,13267,,The binding affinity (pKi) was measured against 5-hydroxytryptamine 4 receptor of piglet hippocampus using [125I]SB 207710 as radioligand,1,Sus scrofa,Autocuration,,,,9823.0,,10000000.0,B,BAO_0000221,CHEMBL619018,3318
,168,H,8,,,,13047,,Binding affinity against 5-hydroxytryptamine 2A receptor using rabbit saphenous vein assay.,1,Oryctolagus cuniculus,Autocuration,,,,9986.0,,,B,BAO_0000019,CHEMBL619019,3319
,10623,D,9,,,,1650,,Displacement of [3H]GR-113808 from rat striatum 5-hydroxytryptamine 4 receptor,1,Rattus norvegicus,Expert,,,,10116.0,,,B,BAO_0000357,CHEMBL619020,3320
,10623,H,8,,,,567,,Tested for its agonist potency against the 5-hydroxytryptamine 4 receptor located in the rat esophageal tunica muscularis mucosae,1,,Autocuration,,,,,,,F,BAO_0000019,CHEMBL619021,3321
,10623,H,8,,,,17358,,Tested for affinity towards 5-hydroxytryptamine 4 receptor in relaxation of rat oesophagus,1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL619022,3322
,10623,H,8,,,,188,,Tested for the effect on binding at 5-hydroxytryptamine 4 receptor; No activity,1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL619023,3323
,10623,H,8,,,,670,,lntrinsic activity relative to 5-HT receptor,1,,Autocuration,,,,,,,F,BAO_0000019,CHEMBL619024,3324
,10623,H,8,,,,204,,Compound was evaluated for the agonistic activity towards 5-hydroxytryptamine 4 receptor using the rat tunica muscularis mucosae (TMM) esophagus strip assay,1,,Autocuration,,,,,,,F,BAO_0000019,CHEMBL619025,3325
,10623,H,8,,,,1946,,In vitro relaxation of carbachol pre-contracted rat oesophageal TMM.,1,,Expert,,,,,,,F,BAO_0000019,CHEMBL619026,3326
,10623,H,8,,,,6398,,Compound was tested for agonist activity at the 5-hydroxytryptamine 4 receptor in the rat tunica muscularis mucosae (TMM) assay,1,,Autocuration,,,,,,,F,BAO_0000019,CHEMBL619027,3327
,10623,H,8,,,,6398,,Compound was tested for agonist activity at the 5-hydroxytryptamine 4 receptor in the rat tunica muscularis mucosae (TMM) assay; IN = Inactive,1,,Autocuration,,,,,,,F,BAO_0000019,CHEMBL619028,3328
,10623,H,8,,,,17358,,Efficient 5-hydroxytryptamine 4 agonist in the rat tunica muscularis mucosae,1,,Autocuration,,,,,,,F,BAO_0000019,CHEMBL619029,3329
,10623,H,8,,,,6398,,Tested for agonist activity at the 5-hydroxytryptamine 4 receptor in the rat tunica muscularis mucosae (TMM) assay of racemate mixture,1,,Autocuration,,,,,,,F,BAO_0000019,CHEMBL619030,3330
,10623,H,8,,,,11752,,Relaxation of carbachol induced contractions of rat tunica muscularis mucosae,1,,Expert,,,,,,,B,BAO_0000357,CHEMBL619031,3331
,10623,H,8,,,,809,,5-hydroxytryptamine 4 receptor agonist activity was determined by the relaxation of the carbachol-contracted rat esophageal tunica muscularis mucosae,1,,Autocuration,,,,,,,F,BAO_0000019,CHEMBL619032,3332
,10623,D,9,,,,14178,,Inhibition of radiolabeled [3H]GR-113808 ligand binding to 5-hydroxytryptamine 4 receptor,1,Rattus norvegicus,Expert,,,,10116.0,,,B,BAO_0000357,CHEMBL619033,3333
,10623,H,8,,,,567,,Tested for its efficacy against the 5-hydroxytryptamine 4 receptor located in the rat esophageal tunica muscularis mucosae,1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL619034,3334
,10623,H,8,,,,1946,,In vitro 5-hydroxytryptamine 4 receptor activity by using carbachol-precontracted esophageal tunica muscularis mucosae.,1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL619035,3335
,10623,H,8,,,,1946,,In vitro 5-hydroxytryptamine 4 receptor activity by using carbachol-precontracted esophageal tunica muscularis mucosae; No activity up to 104M concentration,1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL619036,3336
,10623,D,9,,,,13961,,Binding affinity (Ki+/-SEM) against 5-hydroxytryptamine 4 receptor from cheng Prusoff equation by using [3H]GR-113808 in rat striatum,1,Rattus norvegicus,Expert,,,,10116.0,,,B,BAO_0000019,CHEMBL619037,3337
Striatum,10623,H,8,,,,6238,,Binding affinity towards 5-HT 4 receptor in rat striatum membranes using [3H]GR-113808 as radioligand,1,,Autocuration,,,,,,2435.0,B,BAO_0000249,CHEMBL619038,3338
,10623,H,8,,,,14290,,Binding affinity towards 5-HT4 receptor was determined in rat striatal membranes using [3H]GR-113808 as radioligand; Not tested,1,,Autocuration,,,,,,,B,BAO_0000249,CHEMBL619039,3339
,10623,H,8,,,,14290,,Binding affinity towards 5-hydroxytryptamine 4 receptor was determined in rat striatal membranes using [3H]GR-113808 as radioligand,1,,Expert,,,,,,,B,BAO_0000249,CHEMBL619040,3340
Striatum,10623,D,9,,,,809,,Binding affinity against 5-hydroxytryptamine 4 receptor using [3H]GR-113808 as radioligand in rat striatum,1,Rattus norvegicus,Expert,,,,10116.0,,2435.0,B,BAO_0000019,CHEMBL619041,3341
Striatum,10623,H,8,,,,1578,,Binding affinity against 5-hydroxytryptamine 4 receptor using [3H]GR-113808 as radioligand in rat striatum,1,,Autocuration,,,,,,2435.0,B,BAO_0000019,CHEMBL619042,3342
Striatum,10623,H,8,,,,16709,,Binding affinity to 5-hydroxytryptamine 4 receptor using [3H]GR-113808 as radioligand in rat striatum membrane,1,,Expert,,,,,,2435.0,B,BAO_0000249,CHEMBL619043,3343
Striatum,10623,H,8,,,,1946,,Binding affinity at 5-hydroxytryptamine 4 receptor in rat striatum by [3H]GR-113808 displacement.,1,,Expert,,,,,,2435.0,B,BAO_0000019,CHEMBL619044,3344
Striatum,10623,H,8,,,,15253,,In vitro affinity at serotonergic 5-hydroxytryptamine 4 receptor by radioligand binding assay using [3H]GR-113808 in rat striatum membranes.,1,,Expert,,,,,,2435.0,B,BAO_0000249,CHEMBL619045,3345
Striatum,10623,H,8,,,,4535,,In vitro binding affinity to 5-hydroxytryptamine 4 receptor in rat striatum membrane,1,,Expert,,,,,,2435.0,B,BAO_0000249,CHEMBL619046,3346
,10623,H,8,,,,13961,,Binding affinity at 5-hydroxytryptamine 4 receptor in rat striatal membranes by [3H]GR-113808 displacement.,1,,Expert,,,,,,,B,BAO_0000249,CHEMBL619047,3347
Brain,10623,H,8,,,,17358,,Tested for potency against 5-hydroxytryptamine 4 receptor agonist in rat brain,1,,Autocuration,,,,,,955.0,F,BAO_0000221,CHEMBL619048,3348
,10623,H,8,,,,15847,,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 4 receptor of rat,1,,Autocuration,,,,,,,F,BAO_0000019,CHEMBL859398,3349
,10623,H,8,,,,15847,,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 4 receptor of rat; ND means not done,1,,Autocuration,,,,,,,F,BAO_0000019,CHEMBL619049,3350
,10623,H,8,,,,670,,5-hydroxytryptamine 4 receptor agonist activity in the rat esophageal muscularis mucosae,1,,Autocuration,,,,,,,F,BAO_0000019,CHEMBL857886,3351
,10623,H,8,,,,670,,5-hydroxytryptamine 4 receptor agonist activity in the rat esophageal muscularis mucosae; Not tested,1,,Autocuration,,,,,,,F,BAO_0000019,CHEMBL619050,3352
,10623,H,8,,,,1317,,Antagonist activity against 5-hydroxytryptamine 4 receptor mediated relaxation of rat carbachol contracted esophageal muscularis mucosae,1,,Autocuration,,,,,,,F,BAO_0000019,CHEMBL620591,3353
,10623,D,9,,,,12936,,Binding affinity against rat 5-hydroxytryptamine 4 receptor,1,Rattus norvegicus,Expert,,,,10116.0,,,B,BAO_0000357,CHEMBL620592,3354
Striatum,10623,H,8,,,,4535,,pKi against 5-hydroxytryptamine 4 receptor in rat striatum membrane,1,,Expert,,,,,,2435.0,B,BAO_0000249,CHEMBL620593,3355
,10623,D,9,,,,14424,,Antagonistic activity evaluated by ability to block serotonin induced relaxation (mediated by activation of 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 10e-5 M.,1,Rattus norvegicus,Expert,,,,10116.0,,,F,BAO_0000019,CHEMBL620594,3356
,10623,H,8,,,,14424,,Antagonistic activity by ability to block serotonin induced relaxation (mediated by activation of 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 10e-6 M.,1,,Expert,,,,,,,F,BAO_0000019,CHEMBL875079,3357
,10623,H,8,,,,14424,,Antagonistic activity by ability to block serotonin induced relaxation (mediated by activation of 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 10e-7 M.,1,,Expert,,,,,,,F,BAO_0000019,CHEMBL620595,3358
,10623,D,9,,,,14424,,Antagonistic activity evaluated by ability to block serotonin induced relaxation (mediated by activation of 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 10e-8 M.,1,Rattus norvegicus,Expert,,,,10116.0,,,F,BAO_0000019,CHEMBL620596,3359
,10623,H,8,,,,14424,,Antagonistic activity of compound was evaluated by ability to block serotonin induced relaxation (mediated by activation of 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 3*10e-7 M.,1,,Autocuration,,,,,,,F,BAO_0000019,CHEMBL620597,3360
,10623,H,8,,,,14424,,Antagonistic activity evaluated by ability to block serotonin induced relaxation (via 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 3*10e-8 M.,1,,Expert,,,,,,,F,BAO_0000019,CHEMBL620598,3361
,10623,H,8,,,,14424,,Antagonistic activity evaluated by ability to block serotonin induced relaxation via 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 0.1 mg/kg (p.o.),1,,Expert,,,,,,,F,BAO_0000218,CHEMBL620599,3362
,10623,H,8,,,,14424,,Antagonistic activity of compound was evaluated by ability to block serotonin induced relaxation (mediated by activation of 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 10e-7 M.,1,,Autocuration,,,,,,,F,BAO_0000019,CHEMBL620600,3363
,168,H,8,,,,1980,,Estimate from relaxation of carbachol-contracted rat esophageal muscularis mucosae,1,Rattus norvegicus,Autocuration,,,,10116.0,,,F,BAO_0000019,CHEMBL620601,3364
,168,H,8,,,,4639,,Compound was tested for agonistic activity against 5-hydroxytryptamine 4 receptor on guinea colon at a concentration 0.1 uM,1,,Autocuration,,,,,,,F,BAO_0000019,CHEMBL620602,3365
,168,H,8,,,,17358,,Tested for affinity towards 5-hydroxytryptamine 4 receptor,1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL620603,3366
,168,H,8,,,,17358,,Tested for affinity towards 5-hydroxytryptamine 4 receptor.,1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL620604,3367
,168,H,8,,,,17358,,Compound was tested for 5-hydroxytryptamine 4 binding affinity,1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL620605,3368
,168,H,8,,,,1558,,Compound was tested for its affinity towards 5-hydroxytryptamine 4 receptor,1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL620606,3369
,168,H,8,,,,17358,,Tested for 5-hydroxytryptamine 4 receptor antagonist activity,1,,Autocuration,,,,,,,F,BAO_0000019,CHEMBL620607,3370
,168,H,8,,,,16117,,In vitro binding affinity towards 5-HT4 receptor was determined,1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL620608,3371
,168,H,8,,,,17358,,Tested for 5-hydroxytryptamine 4 receptor antagonist activity,1,,Autocuration,,,,,,,F,BAO_0000019,CHEMBL620609,3372
,168,H,8,,,,17358,,Tested for agonist activity against 5-hydroxytryptamine 4 receptor,1,,Autocuration,,,,,,,F,BAO_0000019,CHEMBL620610,3373
,168,H,8,,,,17358,,Tested for selectivity for 5-hydroxytryptamine 4 receptor,1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL620611,3374
,168,H,8,,,,17358,,Tested for 5-hydroxytryptamine 4 binding affinity against cisapride,1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL620612,3375
,168,H,8,,,,17358,,Tested for 5-hydroxytryptamine 4 binding affinity against renzapride,1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL620613,3376
,168,H,8,,,,17358,,Tested for 5-hydroxytryptamine 4 binding affinity against zacopride,1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL620614,3377
,168,H,8,,,,1274,,Binding affinity against 5-Hydroxytryptamine 4 receptor,1,,Expert,,,,,,,B,BAO_0000357,CHEMBL620615,3378
,104698,H,6,,,Brain membranes,10728,,Compound was evaluated for the displacement of [3H]-Q-ICS 205-930 binding to 5-hydroxytryptamine 3 recognition sites in rat brain membranes,1,,Autocuration,,,,,,,B,BAO_0000249,CHEMBL857075,3379
,104698,H,6,,,Brain membranes,11695,,Compound was evaluated for the displacement of [3H]Q-ICS-205-930 from 5-HT3 recognition sites in rat brain membranes,1,,Autocuration,,,,,,,B,BAO_0000249,CHEMBL620616,3380
,104698,H,6,,,Brain membranes,11695,,Displacement of [3H]Q-ICS-205-930 from 5-hydroxytryptamine 3 receptor recognition sites in rat brain membranes,1,,Autocuration,,,,,,,B,BAO_0000249,CHEMBL619411,3381
,104698,H,6,,,,12490,,Displacement of [3H]-Q-ICS 205-930 binding to 5-hydroxytryptamine 3 receptor from rat cortex homogenate,1,,Autocuration,,,,,,,B,BAO_0000019,CHEMBL619412,3382
,104698,D,7,,,,11828,,Displacement of [3H]-Q-ICS 205-930 from rat cortex homogenate 5-hydroxytryptamine 3 receptor,1,Rattus norvegicus,Autocuration,,,,10116.0,,,B,BAO_0000019,CHEMBL619413,3383
Hippocampus,104698,H,6,,,,12253,,Binding affinity of 5-hydroxytryptamine 3 receptor using [3H]granisetron in rat hippocampus and entorhinal cortex,1,,Autocuration,,,,,,10000000.0,B,BAO_0000221,CHEMBL619414,3384
,104698,H,6,,,,10561,,Binding affinity to 5-hydroxytryptamine 3 receptor using [3H]GR-65630 as radioligand in rat cortex,1,,Autocuration,,,,,,,B,BAO_0000019,CHEMBL619415,3385
,104698,H,6,,,,10561,,Binding affinity to 5-hydroxytryptamine 3 receptor using [3H]quipazine as radioligand in rat cortex,1,,Autocuration,,,,,,,B,BAO_0000019,CHEMBL619416,3386
,104698,H,6,,,,14432,,Rat 5-hydroxytryptamine 3 receptor (5-HT3) antagonist,1,,Autocuration,,,,,,,F,BAO_0000019,CHEMBL619417,3387
,104698,D,7,,,,12936,,Binding affinity against rat 5-hydroxytryptamine 3 receptor,1,Rattus norvegicus,Autocuration,,,,10116.0,,,B,BAO_0000223,CHEMBL619418,3388
,104698,D,7,,,,1274,,Binding affinity against 5-Hydroxytryptamine 3 receptor,1,Rattus norvegicus,Autocuration,,,,10116.0,,,B,BAO_0000223,CHEMBL619419,3389
,104698,H,6,,,,1980,,Binding affinity for 5-hydroxytryptamine 3 receptor by displacement of racemic [3H]zacopride from rat cortex,1,,Autocuration,,,,,,,B,BAO_0000019,CHEMBL619420,3390
,104698,H,6,,,,670,,Binding affinity to 5-hydroxytryptamine 3 receptor was determined in rat cerebro cortical membranes using [3H]quipazine.,1,,Autocuration,,,,,,,B,BAO_0000249,CHEMBL619421,3391
,104698,D,7,,,,968,,Displacement of [3H]granisetron from 5-hydroxytryptamine 3 receptor of rat cortex,1,Rattus norvegicus,Autocuration,,,,10116.0,,,B,BAO_0000019,CHEMBL619422,3392
,104698,H,6,,,,14287,,In vitro by displacement of [3H]LY-278584 from 5-hydroxytryptamine 3 receptor on rat entorhinal cortex,1,,Autocuration,,,,,,,B,BAO_0000019,CHEMBL619423,3393
,104698,H,6,,,,567,,Tested for its binding affinity by measuring its ability to displace [3H]granisetron from 5-hydroxytryptamine 3 receptor in rat cortex,1,,Autocuration,,,,,,,B,BAO_0000019,CHEMBL875080,3394
,104698,H,6,,,,13267,,The binding affinity (pKi) measured against 5-hydroxytryptamine 1A receptor of rat cortex using [3H]8-OH-DPAT as radioligand,1,,Autocuration,,,,,,,B,BAO_0000019,CHEMBL619424,3395
,104698,H,6,,,,14826,,Binding affinity at 5-hydroxytryptamine 3 receptor in rat cortical membrane by [3H]graniestron displacement.,1,,Autocuration,,,,,,,B,BAO_0000249,CHEMBL619425,3396
,104698,H,6,,,,15194,,The compound was tested for the binding affinity against 5-hydroxytryptamine 3 receptor using [3H]zacopride as radioligand,1,,Autocuration,,,,,,,B,BAO_0000223,CHEMBL619426,3397
,104698,H,6,,,,15194,,The compound was tested for the binding affinity against 5-hydroxytryptamine 3 receptor using [3H]zacopride as radioligand.,1,,Autocuration,,,,,,,B,BAO_0000223,CHEMBL619427,3398
,104698,D,7,,,,10394,,pKi value for inhibition of [3H]LY-278584 binding to 5-hydroxytryptamine 3 receptor,1,Rattus norvegicus,Autocuration,,,,10116.0,,,B,BAO_0000223,CHEMBL619645,3399
,10576,D,9,,,,13657,,"Compound was evaluated for binding affinity on 5-hydroxytryptamine 1A receptor in rat hippocampus membranes,3H-8-OH-DPAT and buspirone for nonspecific binding",1,,Expert,,,,,,,B,BAO_0000249,CHEMBL619646,3400
Brain,12020,H,8,,,,1879,,Compound was tested for its antagonistic activity against 5-hydroxytryptamine 3 receptor in rat brain using [3H]zacopride as the radioligand.,1,,Autocuration,,,,,,955.0,F,BAO_0000221,CHEMBL619647,3401
,12020,H,8,,,,1879,,Compound was tested in vitro for its antagonistic activity against 5-hydroxytryptamine 3 receptor,1,,Autocuration,,,,,,,F,BAO_0000019,CHEMBL619648,3402
,12020,H,8,,,,1879,,Compound was tested in vitro for its antagonistic activity against 5-hydroxytryptamine 3 receptor in rat CNS.,1,,Autocuration,,,,,,,F,BAO_0000019,CHEMBL619165,3403
,12020,H,8,In vivo,,,204,,Compound was evaluated in vivo for the antagonistic activity towards 5-hydroxytryptamine 3 receptor,1,,Autocuration,,,,,,,F,BAO_0000218,CHEMBL620719,3404
,12020,H,8,,,,1879,,Compound was tested for its binding affinity towards 5-HT-3 receptor in whole rat brain using (S)-[125I]-zacopride as the radioligand.,1,,Autocuration,,,,,,,B,BAO_0000019,CHEMBL872924,3405
,12020,H,8,,,,1879,,Compound was tested for its binding affinity towards 5-hydroxytryptamine 3 receptor,1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL620720,3406
,12020,H,8,,,,1879,,Compound was tested for its binding affinity towards 5-hydroxytryptamine 3 receptor in whole rat brain using (S)-[125I]-zacopride as the radioligand.,1,,Autocuration,,,,,,,B,BAO_0000019,CHEMBL620721,3407
,12020,H,8,,,,1879,,Compound was tested for its binding affinity towards 5-hydroxytryptamine 3 receptor in whole rat brain using [125I]DAIZAC as the radioligand.,1,,Autocuration,,,,,,,B,BAO_0000019,CHEMBL620722,3408
,104698,H,6,,,,10641,,"Concentration that inhibits the binding of radioligand, [3H]-ICS 205930, to 5-hydroxytryptamine 3 receptor from rat cortex",1,,Autocuration,,,,,,,B,BAO_0000019,CHEMBL620723,3409
,12020,H,8,,,,773,,In Vitro Binding affinity againist 5-hydroxytryptamine 3 receptor by displacing [3H]-Q-ICS 205-930 from rat cortex homogenates,1,,Autocuration,,,,,,,B,BAO_0000019,CHEMBL620724,3410
,104698,H,6,,,,11952,,Binding affinity against 5-hydroxytryptamine 3 (5-HT3) receptor in rat brain cortical membranes using radioligand [3H]quipazine,1,,Autocuration,,,,,,,B,BAO_0000249,CHEMBL620725,3411
,12020,D,9,,,,14145,,Antagonist activity (100 ug/kg) for the Bezold Jarisch reflex evoked by 30 (ug/Kg) of 5-hydroxytryptamine 3 receptor in ethylurethane anesthetized rats i.v.,1,Rattus norvegicus,Autocuration,,,,10116.0,,,F,BAO_0000019,CHEMBL620726,3412
,144,H,8,,,,17066,,Binding affinity towards 5-hydroxytryptamine 3 receptor,1,,Expert,,,,,,,B,BAO_0000357,CHEMBL620727,3413
,104714,H,4,,,,6398,,Compound was evaluated for 5-hydroxytryptamine 3 receptor binding,1,,Autocuration,,,,,,,B,BAO_0000223,CHEMBL620728,3414
,22226,U,0,,,,10321,,Binding affinity towards 5-hydroxytryptamine 3 receptor by displacement of [3H]2 in Neuroblastoma-Glioma NG-108-15 cells,1,,Autocuration,,,,,,,B,BAO_0000019,CHEMBL620729,3415
,104714,H,4,,,,511,,Tested for 5-hydroxytryptamine 3 receptor antagonist activity by inhibiting the 5-HT evoked Bezold-Jarisch reflex,1,,Autocuration,,,,,,,F,BAO_0000019,CHEMBL858288,3416
,104714,H,4,,,,4639,,Compound was tested for binding affinity towards 5-hydroxytryptamine 3 receptor,1,,Autocuration,,,,,,,B,BAO_0000223,CHEMBL620730,3417
,104714,H,4,,,,4639,,Binding affinity towards 5-hydroxytryptamine 3 receptor,1,,Autocuration,,,,,,,B,BAO_0000223,CHEMBL620731,3418
,104714,H,4,,,,4639,,Compound was tested for antagonistic activity against 5-hydroxytryptamine 3 receptor on guinea pig colon at a concentration of 0.3 uM,1,Cavia porcellus,Autocuration,,,,10141.0,,,F,BAO_0000019,CHEMBL620732,3419
,104714,H,4,,,,4639,,Compound was tested for antagonistic activity against 5-hydroxytryptamine 3 receptor on guinea pig colon at a concentration of 3 uM,1,Cavia porcellus,Autocuration,,,,10141.0,,,F,BAO_0000019,CHEMBL618042,3420
,104714,H,4,,,,4639,,Compound was tested for antagonistic activity against 5-hydroxytryptamine 3 receptor on guinea pig colon at a concentration of 30 uM,1,Cavia porcellus,Autocuration,,,,10141.0,,,F,BAO_0000019,CHEMBL618043,3421
,104714,H,4,,,,1558,,Compound was tested for its affinity towards 5-hydroxytryptamine 3 receptor,1,,Autocuration,,,,,,,B,BAO_0000223,CHEMBL618044,3422
,104714,H,4,,,,268,,Evaluated for the 5-hydroxytryptamine 3 receptor antagonistic activity in Bezold-Jarisch model expressed as inhibition of the reflex bradycardia induced by an intravenous injection,1,,Autocuration,,,,,,,F,BAO_0000019,CHEMBL618045,3423
,104714,H,4,,,,2474,,Compound was measured for its binding affinity at 5-hydroxytryptamine 3 receptor at a concentration of 10 uM using [3H]BRL-43694 as radioligand,1,,Autocuration,,,,,,,B,BAO_0000223,CHEMBL618046,3424
,104714,H,4,,,,5067,,Intrinsic activity towards 5-hydroxytryptamine 3 receptor was determined by Benzold-Jarisch reflex (peripheral assay); A: agonist,1,,Autocuration,,,,,,,F,BAO_0000019,CHEMBL618047,3425
,104714,H,4,,,,5067,,Intrinsic activity towards 5-hydroxytryptamine 3 receptor was determined by Benzold-Jarisch reflex (peripheral assay); ANT: agonist,1,,Autocuration,,,,,,,F,BAO_0000019,CHEMBL875084,3426
,104714,H,4,,,,5067,,Intrinsic activity towards 5-hydroxytryptamine 3 receptor was determined by Benzold-Jarisch reflex (peripheral assay); ANT: antagonist,1,,Autocuration,,,,,,,F,BAO_0000019,CHEMBL618048,3427
,104714,H,4,,,,5067,,Intrinsic activity towards 5-hydroxytryptamine 3 receptor was determined by Benzold-Jarisch reflex (peripheral assay); NA means data not available,1,,Autocuration,,,,,,,B,BAO_0000223,CHEMBL618049,3428
,104714,H,4,,,,5067,,Intrinsic activity towards 5-hydroxytryptamine 3 receptor was determined by Benzold-Jarisch reflex (peripheral assay); PA: Partial agonist,1,,Autocuration,,,,,,,F,BAO_0000019,CHEMBL619764,3429
,104714,H,4,,,,5067,,Intrinsic activity towards CNS 5-hydroxytryptamine 3 receptor was determined; A: agonist,1,,Autocuration,,,,,,,F,BAO_0000019,CHEMBL619765,3430
,104714,H,4,,,,5067,,Intrinsic activity towards CNS 5-hydroxytryptamine 3 receptor was determined; ANT: Antagonist,1,,Autocuration,,,,,,,F,BAO_0000019,CHEMBL619766,3431
,104714,H,4,,,,5067,,Intrinsic activity towards CNS 5-hydroxytryptamine 3 receptor was determined; NA: not active,1,,Autocuration,,,,,,,B,BAO_0000223,CHEMBL619767,3432
,104714,H,4,,,,5067,,Intrinsic activity towards CNS 5-hydroxytryptamine 3 receptor was determined; NA means data not available,1,,Autocuration,,,,,,,B,BAO_0000223,CHEMBL619768,3433
,104714,H,4,,,,5067,,Intrinsic activity towards CNS 5-hydroxytryptamine 3 receptor was determined; PA: Partial agonist,1,,Autocuration,,,,,,,F,BAO_0000019,CHEMBL619769,3434
,104714,H,4,,,,5067,,Intrinsic activity towards CNS 5-hydroxytryptamine 3 receptor was determined; na means data not available,1,,Autocuration,,,,,,,B,BAO_0000223,CHEMBL619770,3435
,104714,H,4,,,,5067,,Binding affinity towards 5-hydroxytryptamine 3 receptor,1,,Autocuration,,,,,,,B,BAO_0000223,CHEMBL619771,3436
,104714,H,4,,,,14331,,Binding affinity of compound towards 5-hydroxytryptamine 3 receptor using [3H]-BRL-43694 (1 nM) ligand in NG cells 108-15 was determined,1,,Autocuration,,,,,,,B,BAO_0000219,CHEMBL619772,3437
,104714,H,4,,,,5067,,Binding affinity of compound towards 5-hydroxytryptamine 3 receptor; NA: not active,1,,Autocuration,,,,,,,B,BAO_0000223,CHEMBL619773,3438
,104714,H,4,,,,6179,,Binding affinity for 5-HT3 receptor of NG108-15 cells using [3H]GR-65630,1,,Autocuration,,433.0,,,NG108-15,,B,BAO_0000219,CHEMBL619774,3439
,104714,H,4,,,,4265,,Binding affinity to 5-HT3 serotonin receptor in NG 108-15 neuroblastoma glioma cells using [3H]GR-65630 radioligand.,1,,Autocuration,,,,,,,B,BAO_0000019,CHEMBL875083,3440
,104714,H,4,,,,4265,,Binding affinity to 5-HT3 serotonin receptor in NG108-15 neuroblastoma glioma cells using [3H]GR-65630 radioligand,1,,Autocuration,,433.0,,,NG108-15,,B,BAO_0000219,CHEMBL620718,3441
,104714,H,4,,,,17358,,Compound was tested for 5-hydroxytryptamine 3 receptor binding affinity,1,,Autocuration,,,,,,,B,BAO_0000223,CHEMBL618127,3442
,104714,H,4,,,,17358,,Compound was tested for selectivity against 5-hydroxytryptamine 3 receptor binding affinity,1,,Autocuration,,,,,,,B,BAO_0000223,CHEMBL618128,3443
,104714,H,4,In vitro,,,13628,,Compound was tested for the inhibition of [3H]GR-65630 binding to 5-hydroxytryptamine 3 receptor expressed in NG 108-15 cells,1,,Autocuration,,,,,,,B,BAO_0000219,CHEMBL618129,3444
,104714,H,4,,,,4612,,In vitro Binding affinity towards 5-hydroxytryptamine 3 receptor was determined,1,,Autocuration,,,,,,,B,BAO_0000223,CHEMBL618130,3445
,104714,H,4,,,,17358,,Tested for 5-hydroxytryptamine 3 receptor antagonist activity,1,,Autocuration,,,,,,,F,BAO_0000019,CHEMBL618131,3446
,104714,H,4,,,,4639,,Compound was tested for agonistic activity against 5-hydroxytryptamine 3 receptor on guinea pig colon at a concentration of 1 uM,1,Cavia porcellus,Autocuration,,,,10141.0,,,F,BAO_0000019,CHEMBL618132,3447
,104714,H,4,,,,4639,,Compound was tested for agonistic activity against 5-hydroxytryptamine 3 receptor on guinea pig colon at a concentration of 10 uM,1,Cavia porcellus,Autocuration,,,,10141.0,,,F,BAO_0000019,CHEMBL618133,3448
,104714,H,4,,,,4639,,Compound was tested for agonistic activity against 5-hydroxytryptamine 3 receptor on guinea pig colon at a concentration of 10 uM in the presence of 30 uM MDL 72222,1,Cavia porcellus,Autocuration,,,,10141.0,,,F,BAO_0000019,CHEMBL618134,3449
,104714,H,4,,,,4639,,Compound was tested for agonistic activity against 5-hydroxytryptamine 3 receptor on guinea pig colon at a concentration of 3 uM,1,Cavia porcellus,Autocuration,,,,10141.0,,,F,BAO_0000019,CHEMBL618135,3450
,104714,H,4,,,,511,,Binding affinity for the 5-hydroxytryptamine 3 receptor was evaluated in vitro by examining its ability to displace [3H]-BRL 43694.,1,,Autocuration,,,,,,,B,BAO_0000223,CHEMBL618136,3451
,104714,H,4,,,,1479,,Binding affinity towards 5-hydroxytryptamine 3 receptor,1,,Autocuration,,,,,,,B,BAO_0000223,CHEMBL618137,3452
,104714,H,4,,,,1317,,Compound was evaluated for binding affinity against 5-hydroxytryptamine 3 receptor using radioligand binding assay,1,,Autocuration,,,,,,,B,BAO_0000223,CHEMBL618138,3453
,104714,H,4,,,,12146,,Tested against 5-hydroxytryptamine 3 receptor in experiment 1,1,,Autocuration,,,,,,,B,BAO_0000223,CHEMBL618139,3454
,104714,H,4,,,,12146,,Tested against 5-hydroxytryptamine 3 receptor in experiment 2,1,,Autocuration,,,,,,,B,BAO_0000223,CHEMBL618140,3455
,104714,H,4,,,,13969,,Binding affinity against 5-hydroxytryptamine 3 receptor was measured using [3H]granisetron as radioligand,1,,Autocuration,,,,,,,B,BAO_0000223,CHEMBL618141,3456
,108,H,8,,,,13392,,Binding affinity for 5-hydroxytryptamine 2C receptor,1,,Expert,,,,,,,B,BAO_0000357,CHEMBL873478,3457
,104698,H,6,,,,13392,,Binding affinity towards 5-hydroxytryptamine 3 receptor,1,,Autocuration,,,,,,,B,BAO_0000223,CHEMBL618142,3458
,144,H,8,,,,14159,,Compound was evaluated for the affinity at 5-hydroxytryptamine 3 receptor,1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL618143,3459
,144,H,8,,,,1558,,Compound was tested for its affinity towards 5-hydroxytryptamine 3 receptor,1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL618144,3460
,144,H,8,,,,16655,,Inhibition of GR-65630 binding to 5-hydroxytryptamine 3 receptor,1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL618145,3461
,104714,H,4,,,,13020,,Inhibition of [3H]- BRL 43 694 binding to 5-hydroxytryptamine 3 receptor at 10e-5 M,1,,Autocuration,,,,,,,B,BAO_0000223,CHEMBL618146,3462
,104714,H,4,,,,13021,,Inhibition of [3H]-BRL 43 694 binding to 5-hydroxytryptamine 3 receptor of central nervous system,1,,Autocuration,,,,,,,B,BAO_0000223,CHEMBL618147,3463
,104714,H,4,,,,13020,,Inhibition of [3H]- BRL 43 694 binding to 5-hydroxytryptamine 3 receptor at 10e-5 M,1,,Autocuration,,,,,,,B,BAO_0000223,CHEMBL618148,3464
,144,H,8,,,,10321,,Binding affinity towards 5-hydroxytryptamine 3 receptor by displacement of [3H]2 in Neuroblastoma-Glioma NG-108-15 cells,1,,Autocuration,,,,,,,B,BAO_0000019,CHEMBL618149,3465
,144,H,8,,,,15818,,Compound was evaluated for its binding affinity towards 5-hydroxytryptamine 3 receptor,1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL872927,3466
,144,H,8,,,,15818,,Compound was evaluated for its binding affinity towards 5-hydroxytryptamine 3 receptor,1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL618150,3467
,144,H,8,,,,17358,,Compound was tested for 5-hydroxytryptamine 3 receptor binding affinity,1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL618151,3468
,144,H,8,,,,2222,,Compound was tested for its binding affinity for the 5-hydroxytryptamine 3 receptor,1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL875094,3469
,144,H,8,,,,10322,,In vitro binding affinity for the 5-hydroxytryptamine 3 receptor was determined with NG-108-15 mouse neuroblastoma-glioma cells,1,,Autocuration,,,,,,,B,BAO_0000019,CHEMBL618152,3470
,144,H,8,,,,16117,,In vitro binding affinity towards 5-hydroxytryptamine 3 receptor was determined,1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL618153,3471
,144,H,8,,,,17200,,Inhibitory constant against 5-hydroxytryptamine 3 receptor using [3H]GR-65630 radioligand,1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL618888,3472
,144,H,8,,,,17358,,Tested for 5-hydroxytryptamine 3 receptor agonist activity,1,,Autocuration,,,,,,,F,BAO_0000019,CHEMBL618889,3473
,144,H,8,,,,16700,,The binding affinity towards 5-hydroxytryptamine 3 receptor; No affinity,1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL618890,3474
,144,H,8,,,,1980,,Binding affinity for 5-hydroxytryptamine 3 receptor by displacement of [3H](R)-zacopride from ondansetron-treated NG-108-15 cell membranes,1,,Autocuration,,,,,,,B,BAO_0000019,CHEMBL618891,3475
,144,H,8,,,,1980,,Binding affinity for 5-hydroxytryptamine 3 receptor by displacement of [3H]-BRL 43694 from NG-108-15 cell membranes,1,,Autocuration,,,,,,,B,BAO_0000019,CHEMBL619054,3476
,104714,H,4,,,,12409,,Binding affinity against the 5-hydroxytryptamine 3 receptor,1,,Autocuration,,,,,,,B,BAO_0000223,CHEMBL619055,3477
,144,H,8,,,,4365,,Binding affinity against human 5-hydroxytryptamine 3A receptor,1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL619056,3478
,144,H,8,,,,4365,,Percent efficacy against 5-hydroxytryptamine 3A receptor,1,,Autocuration,,,,,,,F,BAO_0000019,CHEMBL619057,3479
,144,H,8,,,,4365,,Binding affinity against human 5-hydroxytryptamine 3A receptor,1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL619058,3480
,12020,D,9,,,,6769,,Response at rat 5-hydroxytryptamine 3a receptor expressed in xenopus oocytes,1,Rattus norvegicus,Expert,,,,10116.0,Oocytes,,F,BAO_0000219,CHEMBL619059,3481
,12020,D,9,,,,6769,,Ability to block serotonin (30 uM)-evoked responses at rat 5HT3-alpha receptor expressed in xenopus oocytes,1,Rattus norvegicus,Expert,,,,10116.0,Oocytes,,F,BAO_0000219,CHEMBL619060,3482
,12020,D,9,,,,6769,,Effect on rat 5-hydroxytryptamine 3a receptor expressed in xenopus oocytes at concentration up to 100 uM,1,Rattus norvegicus,Expert,,,,10116.0,Oocytes,,F,BAO_0000219,CHEMBL875095,3483
Ileum,20033,D,9,,,,809,,5-hydroxytryptamine 4 receptor agonist activity as percent maximum 5-HT effect in response to electrical stimulation in male guinea pig ileum,1,Cavia porcellus,Intermediate,,,,10141.0,,2116.0,F,BAO_0000221,CHEMBL619061,3484
Ileum,20033,D,9,,,,809,,5-hydroxytryptamine 4 receptor agonist activity expressed as the concentration which gave a 50% increase in the response to the electrical stimulation in male guinea pig ileum,1,Cavia porcellus,Intermediate,,,,10141.0,,2116.0,F,BAO_0000221,CHEMBL619062,3485
,20033,D,9,,,,14290,,5-hydroxytryptamine 4 receptor agonist activity is expressed as percent of the maximum 5-HT response,1,Cavia porcellus,Intermediate,,,,10141.0,,,F,BAO_0000019,CHEMBL619063,3486
Ileum,20033,D,9,,,,17358,,Tested for affinity towards 5-hydroxytryptamine 4 receptor in electrically stimulated longitudinal muscle preparation of guinea pig ileum,1,Cavia porcellus,Intermediate,,,,10141.0,,2116.0,B,BAO_0000221,CHEMBL619064,3487
,20033,D,9,,,,17358,,Tested for affinity towards 5-hydroxytryptamine 4 receptor in guinea pig distal colon preparation,1,Cavia porcellus,Intermediate,,,,10141.0,,,B,BAO_0000357,CHEMBL619065,3488
Ileum,20033,D,9,,,,17358,,Tested for affinity towards 5-hydroxytryptamine 4 receptor in isolated guinea pig ileum longitudinal muscle preparation,1,Cavia porcellus,Intermediate,,,,10141.0,,2116.0,B,BAO_0000221,CHEMBL619066,3489
Ileum,10209,H,8,,,,17386,,Maximal relaxation effect induced by 3 uM compound on substance P stimulated guinea pig ileum with 5-hydroxytryptamine 7 receptor nondesensitization,1,,Autocuration,,,,,,2116.0,B,BAO_0000221,CHEMBL619775,3490
,10209,H,8,,,,3269,,Affinity against 5-hydroxytryptamine 7 receptor,1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL619776,3491
,104841,H,4,,,,7721,,Ability to displace [3H]5-HT binding from 5-hydroxytryptamine receptor site using 1 uM LSD as masking ligand,1,Cavia porcellus,Autocuration,,,,10141.0,,,B,BAO_0000224,CHEMBL619777,3492
,104841,H,4,,,,7721,,Ability to displace [3H]5-HT binding to 5-hydroxytryptamine receptor site using 1 uM LSD as masking ligand,1,Cavia porcellus,Autocuration,,,,10141.0,,,B,BAO_0000224,CHEMBL619778,3493
Ileum,104841,H,4,,,,9117,,Evaluated for inhibition of 5-hydroxytryptamine receptor on guinea pig ileum at 10 uM; No effect,1,Cavia porcellus,Autocuration,,,,10141.0,,2116.0,B,BAO_0000221,CHEMBL619779,3494
,104841,H,4,,,,7721,,"Ability to displace [3H]5-HT binding to 5-hydroxytryptamine receptor site using 1 uM LSD as masking ligand, activity is expressed as Kd.",1,Cavia porcellus,Autocuration,,,,10141.0,,,B,BAO_0000224,CHEMBL619780,3495
,104841,H,4,,,,7721,,"Ability to displace [3H]5-HT binding to 5-hydroxytryptamine receptor using 1 uM LSD as masking ligand, activity is expressed as Kd.",1,Cavia porcellus,Autocuration,,,,10141.0,,,B,BAO_0000224,CHEMBL619166,3496
,104841,H,4,,,,15796,,5-HT level in K+ induced 5-hydroxytryptamine release in guinea pig cortex.,1,Cavia porcellus,Autocuration,,,,10141.0,,,F,BAO_0000019,CHEMBL619167,3497
,104841,H,4,,,,15796,,5-hydroxytryptamine level in K+ induced 5-hydroxytryptamine release in guinea pig cortex.,1,Cavia porcellus,Autocuration,,,,10141.0,,,F,BAO_0000019,CHEMBL619168,3498
Cardiac atrium,168,D,9,,,,15650,,Concentration required to produce half-maximal response against 5-hydroxytryptamine receptor in the presence of 10 nM compound in isolated human atrial myocytes,1,Homo sapiens,Expert,,,,9606.0,,2081.0,B,BAO_0000219,CHEMBL619169,3499
Cardiac atrium,168,D,9,,,,15650,,Concentration required to produce half-maximal response against 5-hydroxytryptamine receptor on the L-type calcium current (I Ca) in isolated human atrial myocytes,1,Homo sapiens,Expert,,,,9606.0,,2081.0,B,BAO_0000219,CHEMBL619170,3500
,104841,D,5,,,,6866,,"Maximum stimulation of [35S]GTP-gamma-S, binding expressed relative to the maximal effect of 5-hydroxytryptamine",1,Homo sapiens,Autocuration,,,,9606.0,,,F,BAO_0000019,CHEMBL619171,3501
Cardiac atrium,168,D,9,,,,15650,,",Antagonism of stimulation of 5-hydroxytryptamine receptor on the L-type calcium current (I Ca) in isolated human atrial myocytes",1,Homo sapiens,Expert,,,,9606.0,,2081.0,F,BAO_0000219,CHEMBL619172,3502
,22226,U,0,,,,10063,,Ability (10 ug/kg) to inhibit binding of [125I]iododexetimide to 5-hydroxytryptamine receptor in mice,1,Mus musculus,Autocuration,,,,10090.0,,,B,BAO_0000019,CHEMBL619173,3503
,22226,U,0,,,,12665,,Percent inhibition of radioligand [3H]-LSD binding to 5-HT receptor at 10 uM concentration,1,Mus musculus,Autocuration,,,,10090.0,,,B,BAO_0000019,CHEMBL619174,3504
,104705,H,4,,,,7504,,5-hydroxytryptamine receptor binding affinity was determined in rats,1,,Autocuration,,,,,,,B,BAO_0000019,CHEMBL619175,3505
,104705,H,4,,,,7504,,Binding affinity at rat 5-hydroxytryptamine receptor.,1,,Autocuration,,,,,,,B,BAO_0000224,CHEMBL619176,3506
,104705,H,4,,,,7038,,Affinity against 5-hydroxytryptamine receptors in rat fundus model,1,,Autocuration,,,,,,,B,BAO_0000019,CHEMBL619177,3507
,104705,H,4,,,,7626,,Affinity for 5-hydroxytryptamine receptor was determined using male Dawley rat fundus preparation,1,,Autocuration,,,,,,,B,BAO_0000224,CHEMBL619178,3508
,104705,H,4,,,,7626,,Affinity for 5-hydroxytryptamine receptor was determined using male Dawley rat fundus preparation; Not determined,1,,Autocuration,,,,,,,B,BAO_0000224,CHEMBL619179,3509
Stomach,104705,H,4,,,,7185,,Antagonistic activity against serotonin 5-HT receptor obtained from rat stomach fundus preparation,1,,Autocuration,,,,,,945.0,F,BAO_0000019,CHEMBL619180,3510
Stomach,104705,H,4,,,,7185,,Antagonistic activity against serotonin 5-HT receptor obtained from rat stomach fundus preparation (resulted in discoloration in the oxygenated muscle bath to give varying results).,1,,Autocuration,,,,,,945.0,F,BAO_0000019,CHEMBL619181,3511
,104705,H,4,,,,7185,,Antagonistic activity of corresponding methoxy compound against serotonin 5-HT receptor,1,,Autocuration,,,,,,,F,BAO_0000019,CHEMBL619182,3512
,104705,H,4,,,,6960,,Compound was evaluated for binding affinity towards 5-hydroxytryptamine receptor in isolated rat fundus preparation measured as pA2,1,,Autocuration,,,,,,,B,BAO_0000224,CHEMBL619183,3513
,104705,H,4,,,,6960,,"Compound was evaluated for binding affinity towards 5-hydroxytryptamine receptor in isolated rat fundus preparation measured as pA2; Valid pA2, can not be determined because of slope of Schild plot.",1,,Autocuration,,,,,,,B,BAO_0000224,CHEMBL619184,3514
Hippocampus,10576,H,8,,,,12416,,In vitro affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand in hippocampus,1,,Autocuration,,,,,,10000000.0,B,BAO_0000221,CHEMBL619185,3515
,12198,H,8,,,,15753,,Binding affinity for rat 5-hydroxytryptamine transporter.,1,,Expert,,,,,,,B,BAO_0000357,CHEMBL619186,3516
,104705,H,4,,,,8062,,Evaluated for inhibition of specific [3H]5-HT receptor binding in rat cortex.,1,,Autocuration,,,,,,,B,BAO_0000019,CHEMBL619187,3517
,104705,D,5,,,,9036,,Binding affinity at serotonin 5-HT1-type site receptor in rat cortex by displacing [3H]5-HT,1,Rattus norvegicus,Autocuration,,,,10116.0,,,B,BAO_0000019,CHEMBL619188,3518
,104705,D,5,,,,15067,,Compound was tested for its inhibitory activity against 5-hydroxytryptamine receptor,1,Rattus norvegicus,Autocuration,,,,10116.0,,,B,BAO_0000224,CHEMBL619189,3519
Brain,12198,D,9,,,,15753,,Inhibitory activity against [3H]- 5-hydroxytryptamine reuptake in whole rat brain minus cerebellum,1,Rattus norvegicus,Expert,,,,10116.0,,955.0,F,BAO_0000019,CHEMBL619190,3520
Cerebellum,12198,D,9,,,,15753,,Inhibition of [3H]5-HT reuptake in whole rat brain (minus cerebellum) homogenate.,1,Rattus norvegicus,Expert,,,,10116.0,,2037.0,F,BAO_0000221,CHEMBL619191,3521
,104705,D,5,,,,15295,,Displacement of [3H]-citalopram from rat forebrain membrane 5-hydroxytryptamine receptor at 10e-7 M,1,Rattus norvegicus,Autocuration,,,,10116.0,,,B,BAO_0000019,CHEMBL619192,3522
,104705,D,5,,,,6347,,Percent binding affinity against 5-hydroxytryptamine receptor,1,Rattus norvegicus,Autocuration,,,,10116.0,,,B,BAO_0000224,CHEMBL619193,3523
,22226,U,0,,,,6763,,Ability to displace 0.4 nM [3H]paroxetine binding to 5-hydroxytryptamine receptor in rat frontal cortex,1,,Autocuration,,,,,,,B,BAO_0000019,CHEMBL619194,3524
,104705,D,5,,,,12092,,The binding affinity was measured on 5-hydroxytryptamine receptor uptake receptor using [3H]- paroxetine as radioligand.,1,Rattus norvegicus,Autocuration,,,,10116.0,,,B,BAO_0000224,CHEMBL619195,3525
,104705,D,5,,,,1579,,Affinity against 5-hydroxytryptamine receptor was determined,1,Rattus norvegicus,Autocuration,,,,10116.0,,,B,BAO_0000224,CHEMBL619196,3526
Stomach,104705,D,5,,,,1579,,Affinity against 5-hydroxytryptamine receptor was determined in rat stomach fundus strip,1,Rattus norvegicus,Autocuration,,,,10116.0,,945.0,B,BAO_0000019,CHEMBL619197,3527
,121,D,9,In vitro,,,5963,,Inhibition of [3H]5-HT uptake in HEK cells expressing human SERT,1,Homo sapiens,Expert,,,,9606.0,,,B,BAO_0000219,CHEMBL619198,3528
,121,D,9,In vitro,,,5963,,Inhibition of [3H]5-HT uptake in HEK cells expressing human SERT,1,Homo sapiens,Expert,,,,9606.0,,,B,BAO_0000219,CHEMBL875081,3529
,18065,H,8,,,,5030,,Ability to compete with radioactive ligands specific to the Serotonergic 5-HT receptor at 10 uM; NA means compound failed to compete,1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL884712,3530
,121,H,8,,,,15796,,Inhibition of 5-hydroxytryptamine reuptake,1,,Expert,,,,,,,B,BAO_0000357,CHEMBL884710,3531
,18065,H,8,,,,15413,,"Receptor-linked G protein activation at 5-hydroxytryptamine receptor was determined by measuring the stimulation of [35S]GTP-gamma-S, binding",1,,Autocuration,,,,,,,F,BAO_0000019,CHEMBL619199,3532
,18065,H,8,,,,15413,,"Receptor-linked G protein activation at 5-hydroxytryptamine receptor was determined by measuring the stimulation of [35S]GTP-gamma-S, binding (Experiment 1)",1,,Autocuration,,,,,,,F,BAO_0000019,CHEMBL619200,3533
,18065,H,8,,,,15413,,"Receptor-linked G protein activation at 5-hydroxytryptamine receptor was determined by measuring the stimulation of [35S]GTP-gamma-S, binding (Experiment 2)",1,,Autocuration,,,,,,,F,BAO_0000019,CHEMBL619201,3534
,18065,H,8,,,,12409,,Tested for 5-hydroxytryptamine receptor uptake,1,,Autocuration,,,,,,,F,BAO_0000019,CHEMBL619202,3535
,51,D,9,,,,16909,,Affinity constant on CHO cells expressing Human recombinant 5-hydroxytryptamine receptor 1A,1,Homo sapiens,Expert,,449.0,,9606.0,CHO,,B,BAO_0000219,CHEMBL619203,3536
,51,D,9,,,,16909,,Antagonistic affinity tested against isolated human cloned alpha-1d adrenoceptor subtype,1,Homo sapiens,Expert,,,,9606.0,,,F,BAO_0000019,CHEMBL619204,3537
,10576,H,8,,,,15629,,In vitro binding affinity towards 5-hydroxytryptamine receptor 1A receptor by using [3H]8-OH-DPAT in rat hippocampal membranes.,1,Homo sapiens,Autocuration,,,,9606.0,,,B,BAO_0000249,CHEMBL619205,3538
,10576,H,8,,,,15629,,Tested in vitro for % inhibition against 5-hydroxytryptamine receptor 1A,1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL619206,3539
,10576,H,8,,,,15629,,In vitro binding affinity at 5-hydroxytryptamine receptor 1A receptor in rat hippocampal membranes by [3H]8-OH-DPAT displacement.,1,,Expert,,,,,,,B,BAO_0000249,CHEMBL619207,3540
Striatum,10825,H,8,,,,10034,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP in rats corpus striatum at a dosage of 0.10 umol/kg,1,,Autocuration,,,,,,2435.0,F,BAO_0000019,CHEMBL619208,3541
Striatum,10825,H,8,,,,10034,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP in rats corpus striatum at a dosage of 10 umol/kg,1,,Autocuration,,,,,,2435.0,F,BAO_0000019,CHEMBL619209,3542
Striatum,10825,H,8,,,,10034,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP in rats in corpus striatum at a dosage of 0.32 umol/kg,1,,Autocuration,,,,,,2435.0,F,BAO_0000019,CHEMBL619210,3543
Striatum,10825,H,8,,,,10034,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP in rats in corpus striatum at a dosage of 3.2 umol/kg,1,,Autocuration,,,,,,2435.0,F,BAO_0000019,CHEMBL619211,3544
Striatum,10825,H,8,,,,10034,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP in rats in corpus striatum at a dosage of 32 umol/kg,1,,Autocuration,,,,,,2435.0,F,BAO_0000019,CHEMBL619212,3545
Striatum,10825,H,8,,,,10034,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in corpus striatum at a dosage of 0.032 umol/kg,1,,Autocuration,,,,,,2435.0,F,BAO_0000019,CHEMBL620681,3546
Striatum,10825,H,8,,,,10034,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in corpus striatum at a dosage of 1.0 umol/kg,1,,Autocuration,,,,,,2435.0,F,BAO_0000019,CHEMBL620682,3547
Striatum,10825,H,8,,,,10034,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in corpus striatum at a dosage of 10 umol/kg,1,,Autocuration,,,,,,2435.0,F,BAO_0000019,CHEMBL620683,3548
Striatum,10825,H,8,,,,10034,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in corpus striatum at a dosage of 100 umol/kg,1,,Autocuration,,,,,,2435.0,F,BAO_0000019,CHEMBL620684,3549
Striatum,10825,H,8,,,,10034,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in corpus striatum at a dosage of 3.2 umol/kg,1,,Autocuration,,,,,,2435.0,F,BAO_0000019,CHEMBL620685,3550
Striatum,10825,H,8,,,,10034,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in corpus striatum at a dosage of 32 umol/kg,1,,Autocuration,,,,,,2435.0,F,BAO_0000019,CHEMBL620686,3551
Limbic system,10825,H,8,,,,10034,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 0.032 umol/kg,1,,Autocuration,,,,,,349.0,F,BAO_0000019,CHEMBL620687,3552
Limbic system,10825,H,8,,,,10034,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 0.10 umol/kg,1,,Autocuration,,,,,,349.0,F,BAO_0000019,CHEMBL620688,3553
Limbic system,10825,H,8,,,,10034,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 0.32 umol/kg,1,,Autocuration,,,,,,349.0,F,BAO_0000019,CHEMBL620689,3554
Limbic system,10825,H,8,,,,10034,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 1.0 umol/kg,1,,Autocuration,,,,,,349.0,F,BAO_0000019,CHEMBL620690,3555
Limbic system,10825,H,8,,,,10034,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 10 umol/kg,1,,Autocuration,,,,,,349.0,F,BAO_0000019,CHEMBL620691,3556
Limbic system,10825,H,8,,,,10034,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 100 umol/kg,1,,Autocuration,,,,,,349.0,F,BAO_0000019,CHEMBL620692,3557
Limbic system,10825,H,8,,,,10034,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 3.2 umol/kg,1,,Autocuration,,,,,,349.0,F,BAO_0000019,CHEMBL620693,3558
,168,H,8,,,,1274,,Binding affinity against 5-hydroxytryptamine 4 receptor,1,,Expert,,,,,,,B,BAO_0000357,CHEMBL620694,3559
,168,H,8,,,,17358,,Tested for 5-hydroxytryptamine 4 receptor antagonist activity,1,,Autocuration,,,,,,,F,BAO_0000019,CHEMBL857986,3560
,168,H,8,,,,14532,,Inhibitory activity against 5-hydroxytryptamine 4 receptor using [3H]GR-113808 as radioligand at 10e-5 M concentration,1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL620695,3561
,168,H,8,,,,16989,,Binding affinity towards Serotonin 5-hydroxytryptamine 4 receptor,1,,Expert,,,,,,,B,BAO_0000357,CHEMBL620696,3562
,168,H,8,,,,17200,,Inhibitory constant against 5-hydroxytryptamine 4 receptor using [3H]GR-113808 radioligand,1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL620697,3563
,168,H,8,,,,15779,,Binding affinity towards 5-hydroxytryptamine 4 receptor,1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL620698,3564
,168,H,8,,,,15779,,Binding affinity towards 5-hydroxytryptamine 4 receptor; ND means no data.,1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL620699,3565
,168,H,8,,,,15779,,Binding affinity towards 5-hydroxytryptamine 4 receptor; ND means no data.,1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL620700,3566
,168,H,8,,,,15650,,Binding affinity was determined against cloned 5-hydroxytryptamine 4A receptor isoform expressed in COS-7 cells,1,,Autocuration,,643.0,,,COS-7,,B,BAO_0000219,CHEMBL620701,3567
,168,H,8,,,,15650,,Binding affinity was determined against cloned 5-hydroxytryptamine 4B receptor isoform expressed in COS-7 cells,1,,Autocuration,,643.0,,,COS-7,,B,BAO_0000219,CHEMBL875082,3568
,168,H,8,,,,15650,,Binding affinity was determined against cloned 5-hydroxytryptamine 4C receptor isoform expressed in COS-7 cells,1,,Autocuration,,643.0,,,COS-7,,B,BAO_0000219,CHEMBL620702,3569
,168,H,8,,,,15650,,Binding affinity was determined against cloned 5-hydroxytryptamine 4D receptor isoform expressed in COS-7 cells,1,,Autocuration,,643.0,,,COS-7,,B,BAO_0000219,CHEMBL620703,3570
,168,H,8,,,,17046,,Binding affinity of compound towards cloned human 5-hydroxytryptamine 4E receptor expressed in C6 glial cells using [3H]GR-113808 as radioligand,1,,Autocuration,,673.0,,,C6,,B,BAO_0000219,CHEMBL620704,3571
,168,H,8,,,,17046,,Binding affinity towards cloned human 5-hydroxytryptamine 4E receptor expressed in C6 glial cells using [3H]GR-113808 as radioligand,1,,Expert,,673.0,,,C6,,B,BAO_0000219,CHEMBL620705,3572
,168,H,8,,,,15650,,Binding affinity was determined against cloned 5-hydroxytryptamine 4E receptor isoform expressed in C6 glial cells incubated with 0.2 nM [3H]GR-113808,1,,Expert,,673.0,,,C6,,B,BAO_0000219,CHEMBL620706,3573
,168,H,8,,,,17046,,Binding affinity towards cloned human 5-hydroxytryptamine 4E receptor expressed in C6 glial cells using [3H]GR-113808 as radioligand; Not determined,1,,Expert,,673.0,,,C6,,B,BAO_0000219,CHEMBL620707,3574
,10624,H,8,,,,17066,,Binding affinity towards 5-hydroxytryptamine 5 receptor,1,,Expert,,,,,,,B,BAO_0000357,CHEMBL620708,3575
,105,H,8,,,,17200,,Inhibitory constant against human 5-hydroxytryptamine 5A receptor using [3H]LSD radioligand,1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL620709,3576
,10624,D,9,,,,16146,,Binding affinity against 5-hydroxytryptamine 5A receptor,1,Homo sapiens,Expert,,,,9606.0,,,B,BAO_0000357,CHEMBL620710,3577
,10624,H,8,,,,15250,,Compound was tested for the displacement of [3H]5-HT binding to cloned human 5-hydroxytryptamine 5A receptor stably expressed in CHO cells,1,,Autocuration,,449.0,,,CHO,,B,BAO_0000219,CHEMBL620711,3578
,10624,D,9,,,,6491,,Affinity towards human 5-hydroxytryptamine 5A serotonin receptor,1,Homo sapiens,Expert,,,,9606.0,,,B,BAO_0000357,CHEMBL620712,3579
,10624,D,9,,,,17066,,Binding affinity towards human 5-hydroxytryptamine 5A receptor,1,Homo sapiens,Expert,,,,9606.0,,,B,BAO_0000357,CHEMBL620713,3580
,10624,D,9,,,,17066,,Binding affinity towards human 5-hydroxytryptamine 5A receptor was evaluated using [3H]-5-CT as radioligand,1,Homo sapiens,Expert,,,,9606.0,,,B,BAO_0000357,CHEMBL620714,3581
,10624,D,9,,,,4234,,Binding affinity to cloned human 5-hydroxytryptamine 5A receptor,1,Homo sapiens,Expert,,,,9606.0,,,B,BAO_0000357,CHEMBL620715,3582
,10624,H,8,,,,6013,,Binding affinity towards 5-HT5A receptor,1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL620716,3583
,10624,H,8,,,,17175,,Binding affinity towards human 5-hydroxytryptamine 5A receptor using LSD as radioligand,1,,Expert,,,,,,,B,BAO_0000357,CHEMBL620717,3584
,10624,H,8,,,,15818,,Compound was evaluated for its binding affinity towards human 5-hydroxytryptamine 5A receptor,1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL618072,3585
,10624,H,8,,,,6166,,Binding affinity towards cloned human 5-HT5A receptor was determined,1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL857987,3586
,10624,H,8,,,,15779,,Binding affinity towards 5-hydroxytryptamine 5A receptor (human cloned receptor) in HEK 293 cells using [3H]mesulergine as radioligand.,1,,Autocuration,,722.0,,,HEK293,,B,BAO_0000219,CHEMBL618073,3587
,10624,H,8,,,,15779,,Binding affinity towards 5-hydroxytryptamine 5A receptor (human cloned receptor) in HEK 293 cells using [3H]mesulergine as radioligand;ND means no data.,1,,Autocuration,,722.0,,,HEK293,,B,BAO_0000219,CHEMBL618074,3588
,10624,H,8,,,,5213,,Compound was tested for its binding affinity in 5-hydroxytryptamine 5A receptor (using human cloned receptors in HEK 293 and [3H]5-CTas a radioligand ),1,,Autocuration,,722.0,,,HEK293,,B,BAO_0000219,CHEMBL618075,3589
,10625,D,9,,,,17066,,Binding affinity towards mouse 5-hydroxytryptamine 5A receptor,1,Mus musculus,Expert,,,,10090.0,,,B,BAO_0000357,CHEMBL618076,3590
,10625,D,9,,,,17066,,Binding affinity towards mouse 5-hydroxytryptamine 5A receptor was evaluated using [125I]-2-iodo LSD as radioligand,1,Mus musculus,Expert,,,,10090.0,,,B,BAO_0000357,CHEMBL618077,3591
,10625,D,9,,,,17066,,Binding affinity towards mouse 5-hydroxytryptamine 5A receptor was evaluated using [3H]- LSD as radioligand,1,Mus musculus,Expert,,,,10090.0,,,B,BAO_0000357,CHEMBL618078,3592
,10625,D,9,,,,17066,,Binding affinity towards mouse 5-hydroxytryptamine 5A receptor was evaluated using [3H]LSD as radioligand,1,Mus musculus,Expert,,,,10090.0,,,B,BAO_0000357,CHEMBL881821,3593
,10625,D,9,,,,17066,,Binding affinity towards murine 5-hydroxytryptamine 5A receptor,1,Mus musculus,Expert,,,,10090.0,,,B,BAO_0000357,CHEMBL618079,3594
,10625,H,8,,,,17175,,Binding affinity towards mouse 5-hydroxytryptamine 5A receptor using LSD as radioligand,1,,Expert,,,,,,,B,BAO_0000357,CHEMBL618080,3595
,10576,H,8,,,,16190,,Binding affinity against 5-hydroxytryptamine 5A receptor in HEK 293 cells was determined using [3H]LSD as radioligand,1,,Autocuration,,722.0,,,HEK293,,B,BAO_0000219,CHEMBL618081,3596
,10626,H,8,,,,16190,,Binding affinity against 5-hydroxytryptamine 5A receptor in HEK 293 cells was determined using [3H]LSD as radioligand,1,,Autocuration,,722.0,,,HEK293,,B,BAO_0000219,CHEMBL618082,3597
,10624,H,8,,,,4820,,Binding affinity towards 5-HT5a receptor,1,,Expert,,,,,,,B,BAO_0000357,CHEMBL618083,3598
,10624,D,9,,,,17066,,Binding affinity towards 5-hydroxytryptamine 5A receptor,1,Homo sapiens,Expert,,,,9606.0,,,B,BAO_0000357,CHEMBL618084,3599
,10624,H,8,,,,17066,,Binding affinity for rodent 5-hydroxytryptamine 5A receptor,1,,Expert,,,,,,,B,BAO_0000357,CHEMBL618085,3600
,10624,H,8,,,,17175,,Binding affinity towards 5-hydroxytryptamine 5A receptor using lysergic acid diethylamide (LSD) as radioligand,1,,Expert,,,,,,,B,BAO_0000357,CHEMBL618086,3601
,10624,H,8,,,,16633,,Binding affinities against 5-hydroxytryptamine 5A receptor,1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL875092,3602
,10624,H,8,,,,16633,,Binding affinities towards 5-hydroxytryptamine 5A receptor,1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL618087,3603
,10624,H,8,,,,16700,,The binding affinity towards 5-hydroxytryptamine 5A receptor; No affinity,1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL872926,3604
,104714,H,4,,,,4639,,Percent of control response to 5-HT3 agonistic activity on guinea colon at a concentration 0.01 uM,1,Cavia porcellus,Autocuration,,,,10141.0,,,F,BAO_0000019,CHEMBL618088,3605
,104714,H,4,,,,5486,,Binding affinity towards 5-HT3 receptor by the displacement of [3H]GR-65630] in human recombinant receptors in mammalian cell,1,,Autocuration,,,,,,,B,BAO_0000223,CHEMBL618089,3606
,10627,D,9,,,,16146,,Inhibition of human 5-hydroxytryptamine 6 receptor,1,Homo sapiens,Expert,,,,9606.0,,,B,BAO_0000357,CHEMBL618090,3607
,10627,D,9,,,,17273,,Binding affinity towards 5-hydroxytryptamine 6 receptor using [3H]- LSD as radioligand,1,Homo sapiens,Expert,,,,9606.0,,,B,BAO_0000357,CHEMBL618091,3608
,10627,H,8,,,,17687,,Inhibition against human 5-hydroxytryptamine 6 receptor,1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL618092,3609
,10627,D,9,,,,6491,,Affinity towards human 5-hydroxytryptamine 6 serotonin receptor,1,Homo sapiens,Expert,,,,9606.0,,,B,BAO_0000357,CHEMBL618093,3610
,10627,H,8,,,,16190,,Binding affinity as displacement of [3H]5-HT binding to 5-hydroxytryptamine 6 receptor in HeLa cells.,1,,Expert,,308.0,,,HeLa,,B,BAO_0000219,CHEMBL618094,3611
,10627,D,9,,,,17066,,Binding affinity towards [3H]LSD-labeled human 5-hydroxytryptamine 6 receptor,1,Homo sapiens,Expert,,,,9606.0,,,B,BAO_0000357,CHEMBL618095,3612
,10627,D,9,,,,17066,,Binding affinity towards human 5-hydroxytryptamine 6 receptor,1,Homo sapiens,Expert,,,,9606.0,,,B,BAO_0000357,CHEMBL875093,3613
,10627,D,9,,,,17066,,Binding affinity towards human 5-hydroxytryptamine 6 receptor was evaluated using [125I]-2-iodo LSD as radioligand,1,Homo sapiens,Expert,,,,9606.0,,,B,BAO_0000357,CHEMBL618096,3614
,10627,D,9,,,,17066,,Binding affinity towards human 5-hydroxytryptamine 6 receptor was evaluated using [3H]-LSD as radioligand,1,Homo sapiens,Expert,,,,9606.0,,,B,BAO_0000357,CHEMBL618118,3615
,10627,D,9,,,,3555,,Binding affinity against 5-hydroxytryptamine 6 receptor,1,Homo sapiens,Expert,,,,9606.0,,,B,BAO_0000357,CHEMBL618119,3616
,10627,H,8,,,,5808,,Binding affinity towards human 5-hydroxytryptamine 6 receptor,1,,Expert,,,,,,,B,BAO_0000357,CHEMBL618120,3617
,10627,H,8,,,,6013,,Binding affinity towards human 5-hydroxytryptamine 6 receptor,1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL618121,3618
,10627,H,8,,,,15818,,"Binding affinity for human 5-hydroxytryptamine 6 receptor expressed in HEK 293 human embryonic kidney cells, [3H]-lysergic acid diethylamide as radioligand",1,,Expert,,722.0,,,HEK293,,B,BAO_0000219,CHEMBL618122,3619
,10627,H,8,,,,16209,,Binding affinity towards human 5-hydroxytryptamine 6 receptor using [3H]LSD as radioligand,1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL618123,3620
,10627,H,8,,,,3935,,Binding affinity against human 5-hydroxytryptamine 6 receptor stably transfected to HEK 293 human embryonic kidney cells using [3H]-lysergic acid diethylamide as radioligand,1,,Expert,,722.0,,,HEK293,,B,BAO_0000219,CHEMBL618124,3621
,10627,H,8,,,,15818,,Compound was evaluated for its binding affinity towards human 5-hydroxytryptamine 6 receptor,1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL618125,3622
,10627,D,9,,,,3805,,Displacement of [3H]LSD from human 5-hydroxytryptamine 6 receptor expressed in HEK 293 cells,1,Homo sapiens,Expert,,722.0,,9606.0,HEK293,,B,BAO_0000219,CHEMBL618126,3623
,10627,H,8,,,,16441,,Tested on cell membranes from transfected cells selectively expressing human 5-hydroxytryptamine 6 receptor incubated with 1 nM [3H]LSD,1,,Expert,,,,,,,B,BAO_0000019,CHEMBL618236,3624
,10627,H,8,,,,16441,,Tested on cell membranes from transfected cells selectively expressing human 5-hydroxytryptamine 6 receptor incubated with 1 nM [3H]LSD; ND is No Data.,1,,Expert,,,,,,,B,BAO_0000019,CHEMBL618237,3625
,10627,H,8,,,,6786,,Ability to displace [3H]LSD from human 5-hydroxytryptamine 6 receptor transiently expressed in COS-7 cells,1,,Expert,,643.0,,,COS-7,,B,BAO_0000219,CHEMBL618238,3626
,10627,D,9,,,,4234,,In vitro binding affinity to human 5-hydroxytryptamine 6 receptor,1,Homo sapiens,Expert,,,,9606.0,,,B,BAO_0000357,CHEMBL618239,3627
,10627,H,8,,,,17085,,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 6 receptor,1,,Autocuration,,,,,,,B,BAO_0000019,CHEMBL618240,3628
,10627,H,8,,,,17200,,Inhibitory constant against human 5-hydroxytryptamine 6 receptor using [3H]LSD radioligand,1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL618241,3629
,10627,H,8,,,,17451,,Antagonism assessed in a functional cAMP binding assay using 5-CT to stimulate human 5-hydroxytryptamine 6 receptor expressed in HEK 293 cells,1,,Autocuration,,722.0,,,HEK293,,B,BAO_0000219,CHEMBL859399,3630
,10627,H,8,,,,3935,,The compound was tested for antagonist activity by inhibition of human 5-HT6 stimulated adenylate cyclase,1,,Autocuration,,,,,,,F,BAO_0000019,CHEMBL618242,3631
,10627,H,8,,,,5033,,Ability to displace the radioligand [3H]LSD from human 5-hydroxytryptamine 6 receptor,1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL857991,3632
,10627,H,8,,,,4540,,Binding affinity against human 5-hydroxytryptamine 6 receptor,1,,Expert,,,,,,,B,BAO_0000357,CHEMBL619951,3633
,10627,D,9,,,,4540,,Binding affinity to human cloned 5-HT6 receptor in HeLa cells using [3H]- LSD as radioligand,1,Homo sapiens,Expert,,308.0,,9606.0,HeLa,,B,BAO_0000219,CHEMBL619952,3634
,10627,D,9,,,,4540,,Binding affinity to human cloned 5-hydroxytryptamine 6 receptor in HeLa cells using [3H]- LSD as radioligand,1,Homo sapiens,Expert,,308.0,,9606.0,HeLa,,B,BAO_0000219,CHEMBL619953,3635
,10627,H,8,,,,17296,,Binding affinity against 5-hydroxytryptamine 6 human cloned receptors in HeLa cells,1,,Autocuration,,308.0,,,HeLa,,B,BAO_0000219,CHEMBL619954,3636
,10627,H,8,,,,17296,,Binding affinity against 5-hydroxytryptamine 6 human cloned receptors in HeLa cells using [3H]LSD as radioligand,1,,Autocuration,,308.0,,,HeLa,,B,BAO_0000219,CHEMBL619955,3637
,10627,H,8,,,,17296,,Binding affinity against 5-hydroxytryptamine 6 human cloned receptors in HeLa cells using [3H]LSD as radioligand,1,,Autocuration,,308.0,,,HeLa,,B,BAO_0000219,CHEMBL619956,3638
,10627,H,8,,,,15779,,Binding affinity towards 5-hydroxytryptamine 6 receptor (human cloned receptor) in CHO cells using [3H]5-HT as radioligand,1,,Autocuration,,449.0,,,CHO,,B,BAO_0000219,CHEMBL619957,3639
,10627,H,8,,,,15779,,Binding affinity towards 5-hydroxytryptamine 6 receptor (human cloned receptor) in HEK 293 cells using [3H]mesulergine as radioligand.,1,,Autocuration,,722.0,,,HEK293,,B,BAO_0000219,CHEMBL619958,3640
,10627,H,8,,,,15779,,Binding affinity towards 5-hydroxytryptamine 6 receptor (human cloned receptor) in HEK 293 cells using [3H]mesulergine as radioligand; ND means no data.,1,,Autocuration,,722.0,,,HEK293,,B,BAO_0000219,CHEMBL620627,3641
,10627,H,8,,,,15779,,Binding affinity towards 5-hydroxytryptamine 6 receptor (human cloned receptor) in HEK 293 cells using [3H]mesulergine as radioligand;ND means no data.,1,,Autocuration,,722.0,,,HEK293,,B,BAO_0000219,CHEMBL620628,3642
,10627,H,8,,,,15779,,Binding affinity towards 5-hydroxytryptamine 6 receptor (human cloned receptor) in HeLa cells using [3H]LSD as radioligand;ND means no data.,1,,Autocuration,,308.0,,,HeLa,,B,BAO_0000219,CHEMBL620629,3643
,10627,H,8,,,,6166,,Binding affinity towards human 5-hydroxytryptamine 6 receptor,1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL620630,3644
,10627,H,8,,,,17451,,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 6 receptor expressed in HeLa cells using [3H]LSD as radioligand,1,,Autocuration,,308.0,,,HeLa,,B,BAO_0000219,CHEMBL620782,3645
,10627,H,8,,,,15316,,Compound was evaluated for its ability to displace [3H]LSD binding from human recombinant 5-hydroxytryptamine 6 receptor,1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL620783,3646
,10627,H,8,,,,4199,,Binding affinity against human 5-hydroxytryptamine 6 receptor,1,,Expert,,,,,,,B,BAO_0000357,CHEMBL620784,3647
,10627,H,8,,,,15146,,Binding affinity against human cloned 5-hydroxytryptamine 6 receptor in HeLa cells using [3H]LSD,1,,Expert,,308.0,,,HeLa,,B,BAO_0000219,CHEMBL620785,3648
,10627,H,8,,,,5213,,Compound was tested for its binding affinity in 5-hydroxytryptamine 6 receptor (using human cloned receptors in HeLa and [3H]LSD as a radioligand ),1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL857992,3649
,10627,H,8,,,,16429,,In vitro binding affinity at human recombinant 5-hydroxytryptamine 6 receptor in mammalian cells using 3[H]LSD as the radioligand,1,,Autocuration,,,,,,,B,BAO_0000219,CHEMBL620786,3650
,10627,H,8,,,,14818,,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 6 receptor in HeLa cells using [3H]5-LSD.,1,,Autocuration,,308.0,,,HeLa,,B,BAO_0000219,CHEMBL620787,3651
,10627,H,8,,,,4829,,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 6 receptor in HeLa cells, using [3H]5-LSD as radioligand; n=3",1,,Autocuration,,308.0,,,HeLa,,B,BAO_0000219,CHEMBL620788,3652
,10627,H,8,,,,4829,,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 6 receptor in HeLa cells, using [3H]5-LSD as radioligand; n=9",1,,Autocuration,,308.0,,,HeLa,,B,BAO_0000219,CHEMBL620789,3653
,10627,H,8,,,,4829,,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 6 receptor in HeLa cells, using [3H]LSD as radioligand; n=3",1,,Autocuration,,308.0,,,HeLa,,B,BAO_0000219,CHEMBL620790,3654
,10628,H,8,,,,15250,,Compound was tested for the displacement of [3H]5-HT binding to cloned rat 5-hydroxytryptamine 6 receptor stably expressed in CHO cells,1,,Autocuration,,449.0,,,CHO,,B,BAO_0000219,CHEMBL620791,3655
,10628,H,8,,,,14423,,Binding affinity against 5-hydroxytryptamine 6 receptor from CHO cell membranes using [3H]5-HT as the radioligand.,1,,Autocuration,,,,,,,B,BAO_0000019,CHEMBL620792,3656
,10628,H,8,,,,15086,,The compound was tested for binding affinity against 5-hydroxytryptamine 6 receptor,1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL620793,3657
,10628,H,8,,,,4342,,Binding affinity of compound towards serotonin 5-hydroxytryptamine 6 receptor was determined,1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL620794,3658
,10627,D,9,,,,16190,,Binding affinity as displacement of [3H]5-HT binding to 5-hydroxytryptamine 6 receptor in HeLa cells,1,Homo sapiens,Autocuration,,308.0,,9606.0,HeLa,,B,BAO_0000219,CHEMBL620795,3659
,10627,H,8,,,,4820,,Binding affinity towards human 5-hydroxytryptamine 6 receptor,1,,Expert,,,,,,,B,BAO_0000357,CHEMBL620796,3660
,10627,H,8,,,,4639,,Percentage of displacement at 5-hydroxytryptamine 6 receptor at 10e-8 M,1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL620797,3661
,10627,D,9,,,,17066,,Antagonistic activity towards 5-hydroxytryptamine 6 receptor was evaluated in cAMP assay,1,Homo sapiens,Expert,,,,9606.0,,,F,BAO_0000019,CHEMBL620798,3662
,10627,H,8,,,,6011,,Inhibition of binding towards 5-hydroxytryptamine 6 receptor at 100 nM concentration,1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL620799,3663
,10627,H,8,,,,17066,,Binding affinity towards human 5-hydroxytryptamine 6 receptor,1,,Expert,,,,,,,B,BAO_0000357,CHEMBL620800,3664
,10627,H,8,,,,17515,,Binding affinity of compound towards serotonin 5-hydroxytryptamine 6 receptor; inactive at 10 uM,1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL620801,3665
,10627,H,8,,,,5014,,Compound was tested for its binding affinity towards 5-hydroxytryptamine 6 receptor,1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL875100,3666
,10627,H,8,,,,4373,,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 6 receptor was determined,1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL620802,3667
,10627,H,8,,,,17066,,Antagonistic activity towards 5-hydroxytryptamine 6 receptor,1,,Expert,,,,,,,F,BAO_0000019,CHEMBL620803,3668
,10627,H,8,,,,17066,,Antagonistic activity towards 5-hydroxytryptamine 6 receptor was evaluated in cAMP assay,1,,Expert,,,,,,,F,BAO_0000019,CHEMBL620804,3669
,10627,H,8,,,,4373,,Binding affinity for 5-hydroxytryptamine 6 receptor was determined,1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL620805,3670
,10627,H,8,,,,4687,,Evaluated for the binding affinity towards 5-hydroxytryptamine 6 receptor,1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL620806,3671
,10627,H,8,,,,16946,,Ability to displace [125I]LSD 113808 from 5-hydroxytryptamine 6 receptor at concentration of 10e-6 M,1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL620807,3672
,10627,H,8,,,,16946,,Ability to displace [125I]LSD 113808 from 5-hydroxytryptamine 6 receptor at concentration of 10e-8 M,1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL620808,3673
,10627,H,8,,,,16633,,Binding affinities against 5-hydroxytryptamine 6 receptor,1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL620809,3674
,10627,H,8,,,,16633,,Binding affinities towards 5-hydroxytryptamine 6 receptor,1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL620810,3675
,10627,D,9,,,,17066,,Binding affinity towards 5-hydroxytryptamine 6 receptor,1,Homo sapiens,Expert,,,,9606.0,,,B,BAO_0000357,CHEMBL620811,3676
,10627,H,8,,,,16700,,The binding affinity towards 5-hydroxytryptamine 6 receptor; No affinity,1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL620812,3677
,10627,H,8,,,,3269,,Affinity against 5-hydroxytryptamine 6 receptor,1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL620813,3678
,10627,H,8,,,,5486,,Binding affinity towards human recombinant 5-hydroxytryptamine 7 receptor by the displacement of [3H]-5-CT],1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL620814,3679
,10209,D,9,,,,16146,,Inhibition of human 5-hydroxytryptamine 7 receptor,1,Homo sapiens,Expert,,,,9606.0,,,B,BAO_0000357,CHEMBL620815,3680
,10209,H,8,,,,5014,,Compound was tested for its binding affinity towards human 5-hydroxytryptamine 7 receptor from HEK293 cells using radioligand [3H]LSD,1,,Autocuration,,722.0,,,HEK293,,B,BAO_0000219,CHEMBL620816,3681
,10209,H,8,,,,15463,,Compound at 1 uM was tested for the inhibition of radioligand [3H]LSD binding to recombinant human 5-hydroxytryptamine 7 receptor,1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL620817,3682
,10209,H,8,,,,3805,,In vitro binding affinity against human 5-hydroxytryptamine 7 receptor at a concentration of 100 (nM),1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL620818,3683
,10209,H,8,,,,5014,,Inhibition (at 1 uM) of radioligand [3H]LSD binding to human 5-hydroxytryptamine 7 receptor on HEK293 cells,1,,Expert,,722.0,,,HEK293,,B,BAO_0000219,CHEMBL620819,3684
,10209,D,9,,,,6491,,Affinity towards human 5-hydroxytryptamine 7 serotonin receptor,1,Homo sapiens,Expert,,,,9606.0,,,B,BAO_0000357,CHEMBL620820,3685
,10209,H,8,,,,16190,,Binding affinity for 5-hydroxytryptamine 7 receptor human cloned receptors in CHO cells using [3H]5-HT,1,,Autocuration,,449.0,,,CHO,,B,BAO_0000219,CHEMBL620821,3686
,10209,D,9,,,,17066,,Binding affinity towards human 5-hydroxytryptamine 7 receptor,1,Homo sapiens,Expert,,,,9606.0,,,B,BAO_0000357,CHEMBL620822,3687
,10209,D,9,,,,17066,,Displacement of [3H]5-HT from human 5-hydroxytryptamine 7 receptor,1,Homo sapiens,Expert,,,,9606.0,,,B,BAO_0000357,CHEMBL620823,3688
,10209,D,9,,,,3555,,Binding affinity against 5-hydroxytryptamine 7 receptor,1,Homo sapiens,Expert,,,,9606.0,,,B,BAO_0000357,CHEMBL620824,3689
,10209,H,8,,,,6588,,Binding affinity towards human 5-hydroxytryptamine 7 receptor by the displacement of [3H]-5-HT radioligand from the cloned receptor expressed in CHO cells,1,,Expert,,449.0,,,CHO,,B,BAO_0000219,CHEMBL620825,3690
,10209,H,8,,,,15463,,Binding affinity towards recombinant human 5-hydroxytryptamine 7 receptor was determined using [3H]LSD as radioligand,1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL872930,3691
,10209,H,8,,,,6013,,Binding affinity towards 5-hydroxytryptamine 7 receptor,1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL620826,3692
,10209,H,8,,,,16209,,Binding affinity towards human 5-hydroxytryptamine 7 receptor using [3H]5-HT as radioligand,1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL620827,3693
,10209,H,8,,,,3935,,Compound was evaluated for its binding affinity for human 5-hydroxytryptamine 7 receptor,1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL620828,3694
,10209,H,8,,,,15818,,Compound was evaluated for its binding affinity towards human 5-hydroxytryptamine 7 receptor,1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL620829,3695
,10209,H,8,,,,5014,,Binding affinity towards human 5-hydroxytryptamine 7 receptor on HEK293 cells using radioligand [3H]LSD,1,,Expert,,722.0,,,HEK293,,B,BAO_0000219,CHEMBL620830,3696
,10209,H,8,,,,16441,,Tested on cell membranes from transfected cells selectively expressing human 5-hydroxytryptamine 7 receptor incubated with 1 nM [3H]LSD,1,,Expert,,,,,,,B,BAO_0000019,CHEMBL620831,3697
,10209,H,8,,,,16441,,Tested on cell membranes from transfected cells selectively expressing human 5-hydroxytryptamine 7 receptor incubated with 1 nM [3H]LSD; ND is No Data.,1,,Expert,,,,,,,B,BAO_0000019,CHEMBL620832,3698
,10209,D,9,,,,4234,,In vitro binding affinity to human 5-hydroxytryptamine 7 receptor,1,Homo sapiens,Expert,,,,9606.0,,,B,BAO_0000357,CHEMBL621548,3699
,10209,H,8,,,,17085,,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 7 receptor,1,,Autocuration,,,,,,,B,BAO_0000019,CHEMBL621549,3700
,10209,H,8,,,,17200,,Inhibitory constant against human 5-hydroxytryptamine 7 receptor using [3H]LSD radioligand,1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL621550,3701
,10209,H,8,,,,17451,,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 7 receptor expressed in CHO cells using [3H]-LSD as radioligand; Not determined,1,,Autocuration,,449.0,,,CHO,,B,BAO_0000219,CHEMBL621551,3702
,10209,H,8,,,,17085,,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 7 receptor; ND means not determined,1,,Autocuration,,,,,,,B,BAO_0000019,CHEMBL621552,3703
,10209,H,8,,,,5104,,Binding affinity for human cloned 5-hydroxytryptamine 7 receptor,1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL857077,3704
,10209,H,8,,,,5104,,Binding affinity for human cloned 5-hydroxytryptamine 7 receptor; Not tested,1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL618158,3705
,10209,D,9,,,,5033,,Ability to displace the radioligand [3H]5-carboxyamidotryptamine ([3H]5-CT) from human 5-hydroxytryptamine 7 receptor expressed in COS-7 cells,1,Homo sapiens,Expert,,643.0,,9606.0,COS-7,,B,BAO_0000219,CHEMBL618159,3706
,10209,H,8,,,,5486,,Ability to displace the radioligand [3H]5-carboximidotryptamine ([3H]-5-CT) from cloned human 5-hydroxytryptamine 7 receptor expressed in COS-7 cells,1,,Autocuration,,643.0,,,COS-7,,B,BAO_0000219,CHEMBL875101,3707
,10209,D,9,,,,4540,,Binding affinity to human cloned 5-hydroxytryptamine 7 receptor in HEK 293 cells using [3H]-5-CT as radioligand,1,Homo sapiens,Expert,,722.0,,9606.0,HEK293,,B,BAO_0000219,CHEMBL618160,3708
,10209,H,8,,,,6166,,Binding affinity at human cloned 5-hydroxytryptamine 7 receptor.,1,,Expert,,,,,,,B,BAO_0000357,CHEMBL618161,3709
,10209,H,8,,,,17342,,Binding affinity towards cloned human 5-hydroxytryptamine 7 receptor was determined in HEK293 cells using [3H]5-CT as radioligand,1,,Expert,,722.0,,,HEK293,,B,BAO_0000219,CHEMBL618162,3710
,10209,H,8,,,,17342,,Binding affinity towards human recombinant 5-hydroxytryptamine 7 receptor was determined using [3H]5-CT as radioligand,1,,Expert,,,,,,,B,BAO_0000357,CHEMBL618163,3711
,10209,H,8,,,,17296,,Binding affinity against 5-hydroxytryptamine 7 human receptors,1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL618164,3712
,10209,H,8,,,,16429,,Binding affinity to human recombinant 5-hydroxytryptamine 7 receptor in mammalian cells using [3H]5-CT as radioligand,1,,Expert,,,,,,,B,BAO_0000219,CHEMBL618165,3713
,10209,H,8,,,,15779,,Binding affinity toward 5-hydroxytryptamine 7 receptor (human cloned receptor) in HEK 293 cells using [3H]-5-CT as radioligand.,1,,Autocuration,,722.0,,,HEK293,,B,BAO_0000219,CHEMBL618166,3714
,10209,H,8,,,,15779,,Binding affinity towards 5-hydroxytryptamine 7 receptor (a) (human cloned receptor) in HEK 293 cells using [3H]5-CT as radioligand.,1,,Autocuration,,722.0,,,HEK293,,B,BAO_0000219,CHEMBL857989,3715
,10209,H,8,,,,15779,,Binding affinity towards 5-hydroxytryptamine 7 receptor (human cloned receptor) in HEK 293 cells using [3H]5-CT as radioligand.,1,,Autocuration,,722.0,,,HEK293,,B,BAO_0000219,CHEMBL619888,3716
,10209,H,8,,,,15779,,Binding affinity towards 5-hydroxytryptamine 7 receptor (human cloned receptor) in HEK 293 cells using [3H]5-CT as radioligand.,1,,Autocuration,,722.0,,,HEK293,,B,BAO_0000219,CHEMBL619889,3717
,10209,H,8,,,,15779,,Binding affinity towards 5-hydroxytryptamine 7 receptor 7(a) (human cloned receptor in HEK 293 cells using [3H]5-CT as radioligand.,1,,Autocuration,,722.0,,,HEK293,,B,BAO_0000219,CHEMBL619890,3718
,10209,H,8,,,,17451,,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 7 receptor expressed in CHO cells using [3H]LSD as radioligand,1,,Autocuration,,449.0,,,CHO,,B,BAO_0000219,CHEMBL619891,3719
,10209,H,8,,,,4199,,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 7 receptor in HEK 293 cells using [3H]5-CT as the radioligand (n=3),1,,Autocuration,,722.0,,,HEK293,,B,BAO_0000219,CHEMBL619892,3720
,10209,D,9,,,,4199,,Displacement of [3H]-5-CT from human 5-hydroxytryptamine 7 receptor expressed in HEK-293 cells,1,,Expert,,722.0,,,HEK293,,B,BAO_0000219,CHEMBL619893,3721
,10209,H,8,,,,4199,,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 7 receptor in HEK 293 cells using [3H]5-CT as the radioligand(n=6),1,,Autocuration,,722.0,,,HEK293,,B,BAO_0000219,CHEMBL619894,3722
,10209,D,9,,,,3680,,Binding affinity towards cloned human 5-hydroxytryptamine 7 receptor in HEK 293 cells,1,,Intermediate,,722.0,,,HEK293,,B,BAO_0000219,CHEMBL619895,3723
,10209,D,9,,,,3680,,Binding affinity towards human recombinant 5-hydroxytryptamine 7 receptor using [3H]5-CT as radioligand,1,,Intermediate,,,,,,,B,BAO_0000357,CHEMBL619896,3724
,10209,H,8,,,,15316,,Compound was evaluated for its ability to displace [3H]5-CT binding from cloned human 5-hydroxytryptamine 7 receptor expressed in COS-7 cells.,1,,Autocuration,,643.0,,,COS-7,,B,BAO_0000219,CHEMBL619897,3725
,10209,H,8,,,,15146,,Compound was tested for its binding affinity against human cloned 5-hydroxytryptamine 7 receptor in HEK 293 cells using [3H]5-CT,1,,Autocuration,,722.0,,,HEK293,,B,BAO_0000219,CHEMBL619898,3726
,10209,H,8,,,,5213,,Binding affinity for human cloned 5-hydroxytryptamine 7 receptor in HEK 293 using [3H]5-CT as a radioligand,1,,Expert,,722.0,,,HEK293,,B,BAO_0000219,CHEMBL619899,3727
,10209,H,8,,,,5213,,Compound was tested for its binding affinity in 5-hydroxytryptamine 7 receptor (using human cloned receptors in HEK 293 and [3H]5-CT as a radioligand ),1,,Autocuration,,722.0,,,HEK293,,B,BAO_0000219,CHEMBL619900,3728
,10209,D,9,,,,14818,,Binding affinity towards cloned human 5-hydroxytryptamine 7 receptor expressed in HEK 293 cells using [3H]5-CT,1,Homo sapiens,Expert,,722.0,,9606.0,HEK293,,B,BAO_0000219,CHEMBL619901,3729
,10209,H,8,,,,14818,,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 7 receptor expressed in HEK 293 cells using [3H]5-CT. ,1,,Autocuration,,722.0,,,HEK293,,B,BAO_0000219,CHEMBL620580,3730
,10209,H,8,,,,14818,,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 7 receptor in HEK 293 cells using [3H]5-CT.,1,,Autocuration,,722.0,,,HEK293,,B,BAO_0000219,CHEMBL620581,3731
,10209,H,8,,,,4829,,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 7 receptor in HEK293 cells, using [3H]5-CT as radioligand",1,,Autocuration,,722.0,,,HEK293,,B,BAO_0000219,CHEMBL620733,3732
,10209,D,9,,,,17200,,Inhibitory constant against human 5-hydroxytryptamine 7 receptor using [3H]-LSD radioligand; Not determined,1,Homo sapiens,Autocuration,,,,9606.0,,,B,BAO_0000357,CHEMBL620734,3733
,10022,D,9,,,,17066,,Binding affinity towards mouse 5-hydroxytryptamine 7 receptor was evaluated using [3H]5-HT as radioligand,1,Mus musculus,Expert,,,,10090.0,,,B,BAO_0000357,CHEMBL620735,3734
,10209,H,8,,,,14025,,The dissociation equilibrium constant (pKB=-log KB) of compound was determined against the vascular 5-hydroxytryptamine 7 receptor in the endothelium denuded rabbit jugular vein.,1,Oryctolagus cuniculus,Autocuration,,,,9986.0,,,B,BAO_0000019,CHEMBL620736,3735
,11923,H,8,,,,15250,,Compound was tested for the displacement of [3H]5-HT binding to cloned rat 5-hydroxytryptamine 7 receptor stably expressed in CHO cells,1,,Autocuration,,449.0,,,CHO,,B,BAO_0000219,CHEMBL620737,3736
,11923,H,8,,,,16372,,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT 7 receptors at a concentration of 10000 nM,1,,Autocuration,,449.0,,,CHO,,B,BAO_0000219,CHEMBL620738,3737
,11923,H,8,,,,16372,,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT 7 receptors at a concentration of 100 nM,1,,Autocuration,,449.0,,,CHO,,B,BAO_0000219,CHEMBL620739,3738
,11923,H,8,,,,16372,,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT 7 receptors at a concentration of 1 nM,1,,Autocuration,,449.0,,,CHO,,B,BAO_0000219,CHEMBL620740,3739
,11923,H,8,,,,16372,,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT 7 receptors by 10000 nM 5-HT.,1,,Autocuration,,449.0,,,CHO,,B,BAO_0000219,CHEMBL620741,3740
,11923,H,8,,,,16372,,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT 7 receptors by 100 nM 5-HT.,1,,Autocuration,,449.0,,,CHO,,B,BAO_0000219,CHEMBL620742,3741
,11923,H,8,,,,16372,,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT 7 receptors by 1 nM 5-HT,1,,Autocuration,,449.0,,,CHO,,B,BAO_0000219,CHEMBL620743,3742
,11923,H,8,,,,16372,,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors at a concentration of 10000 nM,1,,Autocuration,,449.0,,,CHO,,B,BAO_0000219,CHEMBL620744,3743
,11923,H,8,,,,16372,,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors at a concentration of 100 nM,1,,Autocuration,,449.0,,,CHO,,B,BAO_0000219,CHEMBL620745,3744
,11923,H,8,,,,16372,,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors at a concentration of 1 nM,1,,Autocuration,,449.0,,,CHO,,B,BAO_0000219,CHEMBL620746,3745
,11923,H,8,,,,16372,,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors by 10000 nM 5-HT.,1,,Autocuration,,449.0,,,CHO,,B,BAO_0000219,CHEMBL620747,3746
,11923,H,8,,,,16372,,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors by 100 nM 5-HT.,1,,Autocuration,,449.0,,,CHO,,B,BAO_0000219,CHEMBL620748,3747
,11923,H,8,,,,16372,,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors by 1 nM 5-HT.,1,,Autocuration,,449.0,,,CHO,,B,BAO_0000219,CHEMBL620749,3748
,11923,H,8,,,,17066,,Binding affinity towards rat 5-hydroxytryptamine 7 receptor,1,,Expert,,,,,,,B,BAO_0000357,CHEMBL620750,3749
,11923,D,9,,,,17066,,Binding affinity towards rat 5-hydroxytryptamine 7 receptor was evaluated using [3H]5-HT as radioligand,1,Rattus norvegicus,Expert,,,,10116.0,,,B,BAO_0000357,CHEMBL620751,3750
,11923,H,8,,,,17386,,Binding affinity to the rat 5-hydroxytryptamine 7 receptor,1,,Expert,,,,,,,B,BAO_0000357,CHEMBL620752,3751
,11923,H,8,,,,14423,,Binding affinity against 5-hydroxytryptamine 7 receptor using from CHO cell membranes [3H]5-HT as the radioligand.,1,,Autocuration,,,,,,,B,BAO_0000019,CHEMBL872929,3752
,11923,D,9,,,,15874,,Binding affinity against Rat 5-hydroxytryptamine 7 receptor using [3H]5-HT,1,Rattus norvegicus,Expert,,,,10116.0,,,B,BAO_0000357,CHEMBL620753,3753
,11923,D,9,,,,15874,,Displacement of [3H]5-HT from over-expressed rat 5-hydroxytryptamine 7 receptor,1,Rattus norvegicus,Expert,,,,10116.0,,,B,BAO_0000357,CHEMBL620754,3754
,11923,D,9,,,,16372,,Displacement of [3H]5-HT from rat 5-hydroxytryptamine 7 receptor expressed in CHO cells,1,Rattus norvegicus,Expert,,449.0,,10116.0,CHO,,B,BAO_0000219,CHEMBL620755,3755
,11923,H,8,,,,4622,,In vitro binding affinity towards cloned rat 5-hydroxytryptamine 7 receptor using [3H]5-HT as radioligand,1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL620756,3756
,11923,H,8,,,,15086,,The compound was tested for binding affinity against 5-hydroxytryptamine 7 receptor,1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL620757,3757
,11923,H,8,,,,16372,,"Effect of compound on stimulation of cAMP production in CHO cells expressing rat 5-HT7 receptors at 1, 10, 100 1000 and 10000 nM conc; Not tested",1,,Autocuration,,449.0,,,CHO,,B,BAO_0000219,CHEMBL620758,3758
,11923,H,8,,,,16372,,"Effect of compound on stimulation of cAMP production in CHO cells expressing rat 5-HT7 receptors at 1, 10, 100 1000 and 10000 nM conc; not tested",1,,Autocuration,,449.0,,,CHO,,B,BAO_0000219,CHEMBL620759,3759
,11923,H,8,,,,16372,,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors at a concentration of 1 nM; not tested,1,,Autocuration,,449.0,,,CHO,,B,BAO_0000219,CHEMBL620760,3760
,11923,H,8,,,,16372,,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors by 1 nM 5-HT; Not tested,1,,Autocuration,,449.0,,,CHO,,B,BAO_0000219,CHEMBL620761,3761
Ileum,11923,H,8,,,,17386,,Maximal relaxation effect induced by 3 uM compound on substance P stimulated guinea pig ileum with 5-hydroxytryptamine 7 receptor desensitization,1,,Autocuration,,,,,,2116.0,F,BAO_0000221,CHEMBL620762,3762
Ileum,11923,H,8,,,,17386,,Maximal relaxation effect induced by 3 uM compound on substance P stimulated guinea pig ileum with 5-hydroxytryptamine 7 receptor nondesensitization,1,,Autocuration,,,,,,2116.0,F,BAO_0000221,CHEMBL620763,3763
Ileum,11923,H,8,,,,17386,,Maximal relaxation effect induced by 3 uM compound on substance P stimulated guinea pig ileum with 5-hydroxytryptamine receptor desensitization,1,,Autocuration,,,,,,2116.0,F,BAO_0000221,CHEMBL620764,3764
,11923,D,9,,,Membranes,5831,,Inhibition of [3H]-5-CT binding to 5-hydroxytryptamine 7 receptor of rat cortical membranes,1,Rattus norvegicus,Expert,,,,10116.0,,,B,BAO_0000249,CHEMBL857990,3765
,11923,H,8,,,,4342,,Binding affinity of compound towards serotonin 5-hydroxytryptamine 7 receptor was determined,1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL620765,3766
,11923,H,8,,,,17319,,Binding affinity at rat 5-hydroxytryptamine 7 receptor.,1,,Expert,,,,,,,B,BAO_0000357,CHEMBL620766,3767
Hypothalamus,11923,H,8,,,,17342,,Binding affinity towards 5-hydroxytryptamine receptor 7 on rat hypothalamus membranes using [3H]5-CT as radioligand.,1,,Expert,,,,,,1898.0,B,BAO_0000019,CHEMBL620767,3768
,11923,H,8,,,,17342,,Binding affinity towards cloned rat 5-hydroxytryptamine 7 receptor was determined using [3H]5-HT as radioligand,1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL620768,3769
Hypothalamus,11923,H,8,,,,3680,,Binding affinity against 5-hydroxytryptamine 7 receptor using [3H]-5-CT in rat hypothalamus membranes,1,,Expert,,,,,,1898.0,B,BAO_0000249,CHEMBL619051,3770
,11923,H,8,,,,3680,,Binding affinity towards 5-hydroxytryptamine 7 receptor,1,,Expert,,,,,,,B,BAO_0000357,CHEMBL619052,3771
,11923,D,9,,,,17319,,Agonistic activity against rat 5-HT7 adenyl cyclase expressed by HEK293 cells,1,Rattus norvegicus,Expert,,722.0,,10116.0,HEK293,,F,BAO_0000219,CHEMBL619053,3772
,11923,D,9,,,,17319,,Agonistic activity against rat 5-HT7 adenyl cyclase expressed in HEK293 cells; Active,1,Rattus norvegicus,Expert,,722.0,,10116.0,HEK293,,F,BAO_0000219,CHEMBL619703,3773
,11923,D,9,,,,17319,,Agonistic activity against rat 5-HT7-adenyl cyclase expressed by HEK293 cells; Active,1,Rattus norvegicus,Autocuration,,722.0,,10116.0,HEK293,,F,BAO_0000219,CHEMBL619704,3774
,10209,H,8,,,,4820,,Binding affinity towards 5-hydroxytryptamine 7 receptor,1,,Expert,,,,,,,B,BAO_0000357,CHEMBL619851,3775
,10209,H,8,,,,4639,,Percentage of displacement at 5-hydroxytryptamine 7 receptor at 10e-8 M,1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL619852,3776
,10209,H,8,,,,6011,,Inhibition of binding towards 5-hydroxytryptamine 7 receptor at 100 nM concentration,1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL619853,3777
,10209,D,9,,,,17066,,Binding affinity towards human 5-hydroxytryptamine 7 receptor,1,Homo sapiens,Expert,,,,9606.0,,,B,BAO_0000357,CHEMBL619854,3778
,10209,H,8,,,,17066,,Binding affinity of compound towards rodent 5-hydroxytryptamine 7 receptor,1,,Expert,,,,,,,B,BAO_0000357,CHEMBL619855,3779
,10209,H,8,,,,17515,,Binding affinity of compound towards serotonin 5-hydroxytryptamine 7 receptor; inactive at 10 uM,1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL619856,3780
,10209,H,8,,,,4373,,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 7 receptor was determined,1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL619857,3781
,10209,H,8,,,,17066,,Antagonistic activity towards 5-hydroxytryptamine 7 receptor was evaluated by cAMP assay,1,,Expert,,,,,,,F,BAO_0000019,CHEMBL619858,3782
,10209,H,8,,,,4373,,Binding affinity for 5-hydroxytryptamine 7 receptor was determined,1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL619859,3783
,10209,H,8,,,,4373,,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 7 receptor was determined,1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL619860,3784
,10209,H,8,,,,4687,,Evaluated for the binding affinity to 5-hydroxytryptamine 7 receptor,1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL619861,3785
,10209,H,8,,,,17342,,Non-selective inhibitory activity was determined against 5-hydroxytryptamine 7 receptor,1,,Expert,,,,,,,B,BAO_0000357,CHEMBL619862,3786
,10209,H,8,,,,16946,,Ability to displace [125I]LSD 113808 from 5-hydroxytryptamine 7 receptor at concentration of 10e-6 M,1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL619863,3787
,10209,H,8,,,,16946,,Ability to displace [125I]LSD 113808 from 5-hydroxytryptamine 7 receptor at concentration of 10e-8 M,1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL619864,3788
,10209,H,8,,,,16633,,Binding affinities against 5-hydroxytryptamine 7 receptor,1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL872928,3789
,10209,H,8,,,,16633,,Binding affinities towards 5-hydroxytryptamine 7 receptor,1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL619865,3790
,10209,H,8,,,,17066,,Binding affinity towards rodent 5-hydroxytryptamine 7 receptor,1,,Expert,,,,,,,B,BAO_0000357,CHEMBL619866,3791
,10209,H,8,,,,16700,,The binding affinity towards 5-hydroxytryptamine 7 receptor; No affinity,1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL619867,3792
Ileum,10209,H,8,,,,17386,,Maximal relaxation effect induced by 3 uM compound on substance P stimulated guinea pig ileum with 5-hydroxytryptamine 7 receptor desensitization,1,,Autocuration,,,,,,2116.0,B,BAO_0000221,CHEMBL619868,3793
,55,H,8,,,,14080,,Compound was evaluated for the potency to inhibit oxidation of arachidonic acid by human recombinant 5-Lipoxygenase using a spectrophotometric assay,1,,Autocuration,,,,,,,F,BAO_0000019,CHEMBL619869,3794
,55,D,9,,,,14080,,Inhibition of oxidation of arachidonic acid by human 5-Lipoxygenase using spectrophotometric assay,1,Homo sapiens,Expert,,,,9606.0,,,F,BAO_0000019,CHEMBL619870,3795
,55,H,8,,,,409,,In vitro inhibition of human recombinant 5-lipoxygenase enzyme,1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL619871,3796
,55,H,8,,,,409,,In vitro inhibition of human recombinant lipoxygenase enzyme,1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL619872,3797
,55,H,8,,,,409,,In vitro inhibition of human recombinant lipoxygenase enzyme; No inhibition,1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL619873,3798
Blood,55,H,8,,,,11090,,Inhibition of 5-lipoxygenase in human whole blood.,1,,Expert,,,,,,178.0,B,BAO_0000357,CHEMBL619874,3799
Blood,55,H,8,,,,11090,,Inhibition of 5-lipoxygenase in human whole blood.,1,,Expert,,,,,,178.0,B,BAO_0000357,CHEMBL619875,3800
,55,H,8,,,,948,,Compound was tested for the inhibition of 5-lipoxygenase of human PMN stimulated by calcium ionophore A-23187 for the formation of 5-HETE,1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL619876,3801
,55,H,8,,,,948,,Compound was tested for the inhibition of 5-lipoxygenase of human PMN stimulated by calcium ionophore A-23187 for the formation of leukotriene B4 (LTB4),1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL619877,3802
,55,H,8,,,,13622,,In vitro 5-lipoxygenase inhibitory activity against calcium ionophore (A23187) induced LTB4 formation in human polymorphonuclear leukocytes.,1,,Expert,,,,,,,F,BAO_0000219,CHEMBL619878,3803
Blood,55,H,8,,,,13622,,In vitro 5-lipoxygenase inhibitory activity against calcium ionophore (A23187) induced LTB4 formation in human whole blood,1,,Autocuration,,,,,,178.0,F,BAO_0000019,CHEMBL619879,3804
,55,H,8,,,,9637,,In vitro inhibition of 5-lipoxygenase from human polymorphs,1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL619880,3805
,55,H,8,,,,11320,,In vitro inhibition of leukotriene B4 synthesis in human whole blood by inhibiting 5-LPO (5-lipoxygenase),1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL619881,3806
,55,H,8,,,,11320,,In vitro inhibition of leukotriene B4 synthesis in human whole blood by inhibiting 5-lipoxygenase,1,,Expert,,,,,,,B,BAO_0000357,CHEMBL619882,3807
,55,H,8,,,,6838,,In vitro inhibitory activity against 5-lipoxygenase in a human whole blood assay,1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL619883,3808
Blood,55,D,9,,,,17667,,Inhibition of 5-Lipoxygenase (5-LO) of human whole blood (HWB),1,Homo sapiens,Expert,,,,9606.0,,178.0,B,BAO_0000357,CHEMBL619884,3809
,55,H,8,,,,12703,,In vitro potency against human 5-Lipoxygenase,1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL619885,3810
,55,D,9,,,,14312,,Inhibitory activity against 5-lipoxygenase in Human whole blood (HWBL) stimulated with calcium ionophore (A23187) and LTB4 measured by enzyme immunoassay,1,Homo sapiens,Expert,,,,9606.0,,,F,BAO_0000019,CHEMBL619886,3811
Blood,55,H,8,,,,14312,,Inhibition activity against 5-lipoxygenase in Human whole blood (HWBL) stimulated with calcium ionophore (A23187) and LTB4 measured by enzyme immunoassay; No data,1,,Autocuration,,,,,,178.0,F,BAO_0000019,CHEMBL619887,3812
,55,H,8,,,,5364,,Inhibition of 5-lipoxygenase activity of compound evaluated as determined by the inhibition of calcium ionophore-induced leukotriene B4 production in human blood.,1,,Autocuration,,,,,,,F,BAO_0000019,CHEMBL875097,3813
,55,H,8,,,,951,,Inhibition of 5-lipoxygenase was evaluated in human polymorphonuclear leukocytes stimulated by calcium ionophore A-23187 for formation of 5-HETE,1,,Autocuration,,,,,,,B,BAO_0000219,CHEMBL618001,3814
,55,H,8,,,,951,,Inhibition of 5-lipoxygenase was evaluated in human polymorphonuclear leukocytes stimulated by calcium ionophore A-23187 for formation of 5-HETE; NA means Not active,1,,Autocuration,,,,,,,B,BAO_0000219,CHEMBL618002,3815
,55,H,8,,,,951,,Inhibition of 5-lipoxygenase was evaluated in human polymorphonuclear leukocytes stimulated by calcium ionophore A-23187 for formation of LTB4,1,,Autocuration,,,,,,,B,BAO_0000219,CHEMBL618003,3816
,55,H,8,,,,951,,Inhibition of 5-lipoxygenase was evaluated in human polymorphonuclear leukocytes stimulated by calcium ionophore A-23187 for formation of LTB4; NA means Not active,1,,Autocuration,,,,,,,B,BAO_0000219,CHEMBL618004,3817
,55,H,8,,,,12365,,Inhibition of human 5-lipoxygenase in human cells,1,,Autocuration,,,,,,,B,BAO_0000219,CHEMBL618005,3818
,55,H,8,,,,10603,,Inhibition of human neutrophil 5-lipoxygenase,1,,Expert,,,,,,,B,BAO_0000357,CHEMBL618006,3819
,55,H,8,,,,10501,,Inhibitory activity against 5-lipoxygenase expressed from human polymorphonuclear cells,1,,Autocuration,,,,,,,B,BAO_0000019,CHEMBL875086,3820
Blood,55,H,8,,,,12281,,Inhibition of 5-lipoxygenase from human whole blood,1,,Expert,,,,,,178.0,B,BAO_0000357,CHEMBL618007,3821
,55,H,8,,,,2567,,Inhibitory concentration required against 5-lipoxygenase activity in cytosolic fractions of human neutrophils,1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL618008,3822
,55,H,8,,,,2567,,Inhibitory concentration required against 5-lipoxygenase activity in intact cells of human neutrophils,1,,Autocuration,,,,,,,B,BAO_0000219,CHEMBL618009,3823
,55,H,8,,,,10193,,In vitro inhibition of polymorphonuclear leukocyte derived human 5-lipoxygenase,1,,Expert,,,,,,,B,BAO_0000357,CHEMBL618010,3824
,55,H,8,,,,10193,,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in human cell at 10 uM,1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL618011,3825
,55,H,8,,,,13623,,Potency to inhibit oxidation of arachidonic acid by recombinant human 5-lipoxygenase,1,,Expert,,,,,,,B,BAO_0000357,CHEMBL618012,3826
,55,H,8,,,,12780,,Tested against 5-lipoxygenase,1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL882927,3827
,55,H,8,,,,12780,,Tested for activity against 5-Lipoxygenase (5-LO),1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL618013,3828
,55,H,8,,,,12780,,Tested for activity against 5-lipoxygenase,1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL618014,3829
,55,H,8,,,,11966,,Tested for inhibition of 5-HPETE production by human 5-LO,1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL618015,3830
,55,H,8,,,,5364,,The 5-lipoxygenase activity by the inhibition of calcium ionophore-induced leukotriene B4 production in human blood.,1,,Autocuration,,,,,,,F,BAO_0000019,CHEMBL618016,3831
,55,H,8,,,,13165,,Inhibition of Human 5-lipoxygenase,1,,Expert,,,,,,,B,BAO_0000357,CHEMBL618017,3832
,55,H,8,,,,5364,,The compound was evaluated for its inhibitory activity against 5-lipoxygenase using granulocytes-type cells,1,,Autocuration,,,,,,,B,BAO_0000019,CHEMBL618018,3833
,55,H,8,,,,11311,,The compound was tested for inhibitory activity against 5-lipoxygenase in human polymorphonuclear leukocytes[PMNS],1,,Autocuration,,,,,,,B,BAO_0000219,CHEMBL875087,3834
,55,H,8,,,,11311,,The compound was tested for inhibitory activity against LT synthesis in human polymorphonuclear leukocytes[PMNS],1,,Autocuration,,,,,,,B,BAO_0000219,CHEMBL618019,3835
,55,H,8,,,,14863,,The compound was tested for the concentration (in uM) to inhibit 50% of 5-Lipoxygenase (5-LOX) and is expressed in IC50.,1,,Autocuration,,,,,,,B,BAO_0000019,CHEMBL618020,3836
,55,H,8,,,,14863,,The compound was tested for the concentration (in uM) to inhibit 50% of 5-Lipoxygenase (5-LOX) and is expressed in IC50; Not tested,1,,Autocuration,,,,,,,B,BAO_0000019,CHEMBL618021,3837
Blood,55,H,8,,,,11087,,The compound was tested for the inhibition of 5-lipoxygenase (5-lo) in human whole blood (HWBL),1,,Autocuration,,,,,,178.0,B,BAO_0000357,CHEMBL618022,3838
,55,H,8,,,,455,,The compound was tested in vitro for inhibition against 5-lipoxygenase in intact human neutrophils,1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL618023,3839
,55,H,8,,,,13183,,5-lipoxygenase Inhibitory activity was measured by enzyme immunoassay using human whole blood stimulated with calcium ionophore (A23187) and LTB4 (leukotriene B4),1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL618024,3840
,55,H,8,,,,10319,,In vitro inhibitory activity against 5-lipoxygenase in human polymorphonuclear (PMN) cells,1,,Expert,,,,,,,B,BAO_0000019,CHEMBL873950,3841
,55,H,8,,,,10193,,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in human cell at 10 uM,1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL618025,3842
,55,H,8,,,,951,,Inhibition of 5-lipoxygenase was evaluated in human polymorphonuclear leukocytes stimulated by calcium ionophore A-23187 for formation of 5-HETE at 10 uM,1,,Autocuration,,,,,,,B,BAO_0000219,CHEMBL618026,3843
,55,H,8,,,,951,,Inhibition of 5-lipoxygenase was evaluated in human polymorphonuclear leukocytes stimulated by calcium ionophore A-23187 for formation of 5-HETE at 10 uM; NA means Inactive,1,,Autocuration,,,,,,,B,BAO_0000219,CHEMBL618027,3844
,55,H,8,,,,951,,Inhibition of 5-lipoxygenase was evaluated in human polymorphonuclear leukocytes stimulated by calcium ionophore A-23187 for formation of LTB4 at 10 uM,1,,Autocuration,,,,,,,B,BAO_0000219,CHEMBL618028,3845
,55,H,8,,,,951,,Inhibition of 5-lipoxygenase was evaluated in human polymorphonuclear leukocytes stimulated by calcium ionophore A-23187 for formation of LTB4 at 10 uM; NA means Inactive,1,,Autocuration,,,,,,,B,BAO_0000219,CHEMBL618029,3846
,55,H,8,,,,9859,,Inhibitory activity against 5-lipoxygenase at 10 uM concentration,1,,Expert,,,,,,,B,BAO_0000357,CHEMBL618030,3847
,55,H,8,,,,9859,,Inhibitory activity against 5-lipoxygenase at 1 uM concentration,1,,Expert,,,,,,,B,BAO_0000357,CHEMBL618031,3848
,55,H,8,,,,9859,,Inhibitory activity against lipoxygenase (LO) at 10 uM concentration,1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL618032,3849
,55,H,8,,,,2567,,Inhibitory concentration required against 5-lipoxygenase activity in cytosolic fractions of human neutrophils,1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL618033,3850
,55,H,8,,,,10193,,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in human cell at 1 uM,1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL618034,3851
,55,H,8,,,,10193,,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in human cell at 10 uM,1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL875088,3852
,55,H,8,,,,949,,Tested for the inhibition of 5-lipoxygenase from human polymorphonuclear leukocytes(PMN) at 10 uM concentration of the compound; IA= Inactive,1,,Autocuration,,,,,,,B,BAO_0000019,CHEMBL618035,3853
,55,H,8,,,,949,,Tested for the inhibition of 5-lipoxygenase from human polymorphonuclear leukocytes(PMN) at 10 uM concentration of the compound; value ranges from 70-90,1,,Autocuration,,,,,,,B,BAO_0000019,CHEMBL618036,3854
,55,H,8,,,,10603,,Inhibition of human neutrophil 5-lipoxygenase at the concentration of 0.1 uM,1,,Expert,,,,,,,B,BAO_0000357,CHEMBL618037,3855
,55,H,8,,,,10603,,Inhibition of human neutrophil 5-lipoxygenase at the concentration of 1 uM,1,,Expert,,,,,,,B,BAO_0000357,CHEMBL618038,3856
,55,H,8,,,,10603,,Inhibition of human neutrophil 5-lipoxygenase at the concentration of 1 uM,1,,Autocuration,,,,,,,F,BAO_0000019,CHEMBL618761,3857
,55,H,8,,,,10603,,Inhibition of lipoxygenase at the concentration of 0.1 uM,1,,Expert,,,,,,,B,BAO_0000357,CHEMBL618762,3858
,55,H,8,,,,10603,,Inhibition of lipoxygenase at the concentration of 1 uM,1,,Expert,,,,,,,B,BAO_0000357,CHEMBL618763,3859
,55,H,8,,,,10193,,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in human cell,1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL618764,3860
,55,D,9,,,,14580,,Inhibition of 5-Lipoxygenase (5-LOX),1,Homo sapiens,Expert,,,,9606.0,,,B,BAO_0000357,CHEMBL618765,3861
,17087,H,8,,,,11090,,Inhibition of 5-lipoxygenase in mouse macrophages.,1,,Expert,,,,,,,B,BAO_0000357,CHEMBL618766,3862
,17087,H,8,,,,11090,,Inhibition of 5-lipoxygenase in mouse macrophages.,1,,Expert,,,,,,,B,BAO_0000357,CHEMBL618767,3863
,17087,H,8,,,,6339,,Inhibitory activity against lipoxygenase-2 in mice,1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL619380,3864
,17087,H,8,,,,6339,,Inhibitory activity against murine lipoxygenase-2.,1,,Expert,,,,,,,B,BAO_0000357,CHEMBL619381,3865
,17087,D,9,,,,12281,,Inhibition of 5-lipoxygenase from mouse macrophage,1,Mus musculus,Expert,,,,10090.0,,,B,BAO_0000357,CHEMBL619382,3866
,17087,H,8,,,,11311,,The compound was tested for inhibitory activity against 5-lipoxygenase in mouse macrophages,1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL619383,3867
,55,H,8,,,,11089,,The compound was tested for the inhibition of Arachidonate 5-lipoxygenase purified from porcine leukocytes.,1,Sus scrofa,Autocuration,,,,9823.0,,,B,BAO_0000019,CHEMBL619384,3868
,55,H,8,,,,10091,,Inhibition of 5-lipoxygenase reaction catalyzed by purified enzyme from porcine leukocytes,1,Sus scrofa,Autocuration,,,,9823.0,,,B,BAO_0000019,CHEMBL619385,3869
,55,H,8,,,,14352,,Inhibitory concentration against 5-lipoxygenase from isolated rabbit granulocytes,1,Oryctolagus cuniculus,Autocuration,,,,9986.0,,,B,BAO_0000019,CHEMBL882928,3870
,12166,D,9,,,,13329,,5-lipoxygenase Inhibitory activity against rat polymorphonuclear leucocytes using 5-HETE,1,Rattus norvegicus,Expert,,,,10116.0,,,B,BAO_0000019,CHEMBL619386,3871
,12166,H,8,,,,13329,,"5-lipoxygenase inhibitory activity against rat polymorphonuclear leucocytes from female wistar rat, by using 5-HETE. ",1,,Autocuration,,,,,,,B,BAO_0000019,CHEMBL619387,3872
,12166,H,8,,,,13329,,"5-lipoxygenase inhibitory activity against rat polymorphonuclear leucocytes from female wistar rat, by using 5-HETE.",1,,Autocuration,,,,,,,B,BAO_0000019,CHEMBL619388,3873
,12166,H,8,,,,13329,,"5-lipoxygenase inhibitory activity against rat polymorphonuclear leucocytes from female wistar rat, by using LTB4.",1,,Autocuration,,,,,,,B,BAO_0000019,CHEMBL619389,3874
,12166,H,8,,,,13329,,Inhibition of 5-lipoxygenase pathway in rat polymorphonuclear assay (inhibition of 5-HETE formation),1,,Expert,,,,,,,B,BAO_0000019,CHEMBL619390,3875
,12166,H,8,,,,13329,,"Inhibition of 5-lipoxygenase pathway in rat polymorphonuclear assay, by ability to inhibit formation of LTB4 AT 10 uM",1,,Expert,,,,,,,B,BAO_0000019,CHEMBL619391,3876
,12166,H,8,,,,13329,,Inhibition of 5-lipoxygenase pathway was evaluated in rat polymorphonuclear assay by compound (50 uM) ability to inhibit formation of 5-HETE,1,,Autocuration,,,,,,,B,BAO_0000019,CHEMBL619392,3877
,12166,H,8,,,,11311,,The effective dose for inhibition of 5-lipoxygenase in rat blood leukocyte (ex vivo),1,,Autocuration,,,,,,,B,BAO_0000019,CHEMBL619393,3878
,12166,H,8,,,,11311,,The effective dose for inhibition of 5-lipoxygenase in rat passive Arthus model after oral administration,1,,Autocuration,,,,,,,B,BAO_0000019,CHEMBL619394,3879
,12166,H,8,,,,105,,"In vitro inhibition of 5-lipoxygenase HETE (5-hydroperoxyeicosatetraenoic acid) in RBL-1 macrophage, a cell-free enzyme assay",1,,Autocuration,,702.0,,,RBL-1,,B,BAO_0000219,CHEMBL619395,3880
,12166,H,8,,,,105,,"In vitro inhibition of 5-lipoxygenase HETE (5-hydroperoxyeicosatetraenoic acid) in RBL-1 macrophage, a cell-free enzyme assay",1,,Autocuration,,702.0,,,RBL-1,,B,BAO_0000219,CHEMBL619396,3881
,12166,H,8,,,,9138,,Inhibition of rat neutrophil 5- Lipoxygenase (5-LO),1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL619397,3882
,12166,H,8,,,,9138,,"Inhibition of rat neutrophil 5- Lipoxygenase (5-LO),",1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL619398,3883
,12166,H,8,,,,9138,,"Inhibition of rat neutrophil 5- Lipoxygenase (5-LO), (at a concentration of 0.2 nM ),",1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL619399,3884
,12166,H,8,,,,14427,,5-LO inhibitory activity determined by measuring the conversion of [14C]arachidonic acid to leukotrienes in RBL-2H3 cell using thin-layer chromatography; Not determined,1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL619400,3885
,12166,H,8,,,,13329,,"5-lipoxygenase inhibitory activity against rat polymorphonuclear leucocytes from female wistar rat, by using 5-HETE.",1,,Autocuration,,,,,,,B,BAO_0000019,CHEMBL619401,3886
,12166,H,8,,,,13329,,"5-lipoxygenase inhibitory activity against rat polymorphonuclear leucocytes from female wistar rat, by using LTB4. ",1,,Autocuration,,,,,,,B,BAO_0000019,CHEMBL619402,3887
,12166,D,9,,,,14427,,Inhibition of 5-lipoxygenase mediated conversion of [14C]arachidonic acid to leukotrienes in RBL-2H3 cells,1,Rattus norvegicus,Expert,,663.0,,10116.0,RBL-2H3,,B,BAO_0000219,CHEMBL619403,3888
,12166,H,8,,,,14427,,5-lipoxygenase inhibitory activity determined by measuring the conversion of [14C]arachidonic acid to leukotrienes in RBL-2H3 cell using thin-layer chromatography; Not determined,1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL619404,3889
,12166,H,8,,,,14427,,5-lipoxygenase inhibitory activity determined by measuring the conversion of [14C]arachidonic acid to leukotrienes in RBL-2H3 cell using thin-layer chromatography.,1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL619405,3890
,12166,H,8,,,,10293,,Ability to inhibit 5-lipoxygenase by using a crude preparation of the cytosolic enzyme from the rat basophilic leukemia (RBL-1) cell line,1,,Expert,,702.0,,,RBL-1,,B,BAO_0000219,CHEMBL619406,3891
,12166,D,9,,,,338,,Inhibition of 5-Lipoxygenase of rat basophilic leukemia cells,1,Rattus norvegicus,Expert,,702.0,,10116.0,RBL-1,,B,BAO_0000219,CHEMBL619407,3892
,12166,H,8,,,,303,,Compound was evaluated for its inhibitory activity against 5-LO (5-lipoxygenase),1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL619408,3893
,12166,H,8,,,,303,,Compound was evaluated for its inhibitory activity against 5-LO (5-lipoxygenase) in intact RBL-1 cell line assay,1,,Autocuration,,702.0,,,RBL-1,,B,BAO_0000219,CHEMBL619409,3894
,12166,H,8,,,,9247,,Inhibition of rat basophilic leukemia-1 (RBL-1) 5-lipoxygenase,1,,Expert,,702.0,,,RBL-1,,B,BAO_0000219,CHEMBL619410,3895
,12166,H,8,,,,9247,,Compound was evaluated for the inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 100 uM; NS = no significant activity,1,,Autocuration,,702.0,,,RBL-1,,B,BAO_0000219,CHEMBL619753,3896
,12166,H,8,,,,137,,Compound was evaluated in an intact RBL-1 cell line for inhibition of 5-lipoxygenase,1,,Autocuration,,702.0,,,RBL-1,,B,BAO_0000219,CHEMBL619754,3897
,12166,H,8,,,,11481,,Evaluated in vitro for its inhibitory activity against 5-lipoxygenase,1,,Expert,,,,,,,B,BAO_0000357,CHEMBL619903,3898
,12166,H,8,,,,11481,,"Evaluated in vitro for its inhibitory activity against 5-lipoxygenase; N=Inactive, <50% inhibition at 10 uM concentration",1,,Expert,,,,,,,B,BAO_0000357,CHEMBL619904,3899
,12166,H,8,,,,9029,,Inhibition of rat polymorphonuclear leukocyte (PMN) 5-Lipoxygenase in vitro,1,,Expert,,,,,,,B,BAO_0000357,CHEMBL619905,3900
,12166,H,8,,,,1701,,Compound was tested for inhibition of 5-lipoxygenase activity in a broken cell supernatant rat basophilic leukemia cells,1,,Autocuration,,,,,,,B,BAO_0000019,CHEMBL619906,3901
,12166,H,8,,,,1701,,Compound was tested for inhibition of 5-lipoxygenase activity in a broken cell supernatant rat basophilic leukemia cells at concentration of 32 uM; Not active,1,,Autocuration,,,,,,,B,BAO_0000019,CHEMBL619907,3902
,12166,H,8,,,,1701,,Compound was tested for inhibition of 5-lipoxygenase activity in a broken cell supernatant rat basophilic leukemia cells at concentration of 50 uM; Not active,1,,Autocuration,,,,,,,B,BAO_0000019,CHEMBL619908,3903
,12166,H,8,,,,1701,,Compound was tested for inhibition of 5-lipoxygenase activity in a broken cell supernatant rat basophilic leukemia cells; No data,1,,Autocuration,,,,,,,B,BAO_0000019,CHEMBL619909,3904
,12166,H,8,,,,13358,,Inhibition of 5-lipoxygenase by measuring 5-HETE levels in RBL-1 cell-free supernatant,1,,Expert,,702.0,,,RBL-1,,F,BAO_0000219,CHEMBL619910,3905
,12166,H,8,,,,1175,,Inhibitory activity against 5-lipoxygenase enzyme from RBL-1 cells,1,,Expert,,702.0,,,RBL-1,,B,BAO_0000219,CHEMBL882929,3906
,12166,H,8,,,,8797,,Ability to inhibit 5-lipoxygenase in rat basophilic leukemia cells.,1,,Expert,,702.0,,,RBL-1,,B,BAO_0000219,CHEMBL619911,3907
,12166,H,8,,,,8797,,Compound was tested for its ability to inhibit 5-lipoxygenase in rat basophilic leukemia cells; No data,1,,Autocuration,,,,,,,B,BAO_0000019,CHEMBL619912,3908
,12166,D,9,,,,577,,Inhibition of rat basophilic leukemia cell 5-lipoxygenase,1,Rattus norvegicus,Expert,,,,10116.0,,,B,BAO_0000357,CHEMBL619913,3909
,12166,H,8,,,,9295,,In vitro inhibitory activity against RBL-1 5-LO,1,,Expert,,702.0,,,RBL-1,,B,BAO_0000219,CHEMBL619914,3910
,12166,H,8,,,,9295,,Compound was tested for its in vitro inhibitory activity against RBL-1 5-LO (insoluble above 45 uM),1,,Autocuration,,702.0,,,RBL-1,,B,BAO_0000219,CHEMBL619915,3911
,12166,H,8,,,,9295,,Compound was tested for its in vitro inhibitory activity against RBL-1 5-LO (time dependent),1,,Autocuration,,702.0,,,RBL-1,,B,BAO_0000219,CHEMBL619916,3912
,12166,H,8,,,,9295,,Compound was tested for its inhibition activity against 5-LO of the whole cell in vitro in rat.,1,,Autocuration,,,,,,,B,BAO_0000218,CHEMBL619917,3913
,12166,H,8,,,,9295,,Compound was tested for its inhibition activity against the 5-LO in isolated enzyme,1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL619918,3914
,12166,H,8,,,,216,,Compound was tested for its inhibitory activity against 5-lipoxygenase in rat.,1,,Autocuration,,,,,,,B,BAO_0000218,CHEMBL619919,3915
,12166,H,8,,,,11090,,Compound was tested for the inhibition of 5-lipoxygenase (5-LPO) in rat basophilic leukemia (RBL) cells.,1,,Autocuration,,702.0,,,RBL-1,,B,BAO_0000219,CHEMBL883710,3916
Blood,12166,H,8,,,,11090,,Compound was tested for the inhibition of 5-lipoxygenase (5-Lpo) in rat whole blood.,1,,Autocuration,,,,,,178.0,B,BAO_0000019,CHEMBL619920,3917
,12166,H,8,,,,10091,,Concentration required for 50 % inhibition of arachidonic acid oxidation by rat 5-lipoxygenase,1,,Expert,,,,,,,B,BAO_0000357,CHEMBL619921,3918
,12166,H,8,,,,10274,,Concentration that produces 50% inhibition of A-23187-stimulated radiolabeled 5-HETE and TXB2 synthesis by PMN 5-lipoxygenase.,1,,Autocuration,,,,,,,F,BAO_0000019,CHEMBL619922,3919
,12166,H,8,,,,13622,,In vitro 5-lipoxygenase inhibitory activity against calcium ionophore (A23187) induced LTB4 formation in rat polymorphonuclear leukocytes,1,,Autocuration,,,,,,,F,BAO_0000219,CHEMBL619923,3920
,12166,H,8,,,,12118,,In vitro inhibition against 5-lipoxygenase in RBL-1 cells was determined,1,,Expert,,702.0,,,RBL-1,,B,BAO_0000219,CHEMBL619924,3921
,12166,H,8,,,,12576,,In vitro inhibition of 5-lipoxygenase (5-HETE) derived from the 9000xg supernatant of RBL broken cell assay,1,,Expert,,,,,,,B,BAO_0000357,CHEMBL619925,3922
,12166,H,8,,,,9546,,In vitro inhibition of 5-lipoxygenase from RBL-1 cells,1,,Expert,,702.0,,,RBL-1,,B,BAO_0000219,CHEMBL619926,3923
,12166,H,8,,,,9521,,In vitro inhibition of 5-lipoxygenase in RBL-1 cells,1,,Autocuration,,702.0,,,RBL-1,,B,BAO_0000219,CHEMBL619927,3924
,12166,H,8,,,,10626,,In vitro inhibition of 5-lipoxygenase pathway in rat basophilic leukemia (RBL-1) cells,1,,Expert,,702.0,,,RBL-1,,B,BAO_0000219,CHEMBL619928,3925
,12166,H,8,,,,9225,,In vitro inhibition of RBL-1 5-lipoxygenase,1,,Autocuration,,702.0,,,RBL-1,,B,BAO_0000219,CHEMBL619929,3926
,12166,H,8,,,,9225,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 0.18-0.31,1,,Autocuration,,702.0,,,RBL-1,,B,BAO_0000219,CHEMBL875089,3927
,12166,H,8,,,,9225,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 0.3-1.6,1,,Autocuration,,702.0,,,RBL-1,,B,BAO_0000219,CHEMBL619930,3928
,12166,H,8,,,,9225,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 0.4-2.2,1,,Autocuration,,702.0,,,RBL-1,,B,BAO_0000219,CHEMBL619931,3929
,12166,H,8,,,,9225,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 0.72-1.07,1,,Autocuration,,702.0,,,RBL-1,,B,BAO_0000219,CHEMBL619932,3930
,12166,H,8,,,,9225,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 0.9-4.0,1,,Autocuration,,702.0,,,RBL-1,,B,BAO_0000219,CHEMBL619933,3931
,12166,H,8,,,,9225,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.0-1.5,1,,Autocuration,,702.0,,,RBL-1,,B,BAO_0000219,CHEMBL619934,3932
,12166,H,8,,,,9225,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.0-1.7,1,,Autocuration,,702.0,,,RBL-1,,B,BAO_0000219,CHEMBL619935,3933
,12166,H,8,,,,9225,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.0-2.4,1,,Autocuration,,702.0,,,RBL-1,,B,BAO_0000219,CHEMBL619936,3934
,12166,H,8,,,,9225,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.07-5.54,1,,Autocuration,,702.0,,,RBL-1,,B,BAO_0000219,CHEMBL619937,3935
,12166,H,8,,,,9225,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.1-1.6,1,,Autocuration,,702.0,,,RBL-1,,B,BAO_0000219,CHEMBL619938,3936
,12166,H,8,,,,9225,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.3-2.8,1,,Autocuration,,702.0,,,RBL-1,,B,BAO_0000219,CHEMBL619939,3937
,12166,H,8,,,,9225,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.4-3.2,1,,Autocuration,,702.0,,,RBL-1,,B,BAO_0000219,CHEMBL619940,3938
,12166,H,8,,,,9225,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.7-2.6,1,,Autocuration,,702.0,,,RBL-1,,B,BAO_0000219,CHEMBL875090,3939
,12166,H,8,,,,9225,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.8-2.8,1,,Autocuration,,702.0,,,RBL-1,,B,BAO_0000219,CHEMBL619941,3940
,12166,H,8,,,,9225,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.8-5.7,1,,Autocuration,,702.0,,,RBL-1,,B,BAO_0000219,CHEMBL619942,3941
,12166,H,8,,,,9225,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.9-2.4,1,,Autocuration,,702.0,,,RBL-1,,B,BAO_0000219,CHEMBL883711,3942
,12166,H,8,,,,9225,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 2.3-.8,1,,Autocuration,,702.0,,,RBL-1,,B,BAO_0000219,CHEMBL619943,3943
,12166,H,8,,,,9225,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 2.46-2.63,1,,Autocuration,,702.0,,,RBL-1,,B,BAO_0000219,CHEMBL619944,3944
,12166,H,8,,,,9225,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 3.3-3.5,1,,Autocuration,,702.0,,,RBL-1,,B,BAO_0000219,CHEMBL619945,3945
,12166,H,8,,,,9225,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 3.8-7.1,1,,Autocuration,,702.0,,,RBL-1,,B,BAO_0000219,CHEMBL619946,3946
,12166,H,8,,,,9225,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 4.0-6.4,1,,Autocuration,,702.0,,,RBL-1,,B,BAO_0000219,CHEMBL619947,3947
,12166,H,8,,,,9225,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 4.9-11.6,1,,Autocuration,,702.0,,,RBL-1,,B,BAO_0000219,CHEMBL619948,3948
,12166,H,8,,,,9225,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 7.5-11.8,1,,Autocuration,,702.0,,,RBL-1,,B,BAO_0000219,CHEMBL619949,3949
,12166,H,8,,,,9401,,In vitro inhibitory activity against 5-lipoxygenase from rat basophilic leukemia cells.,1,,Expert,,,,,,,B,BAO_0000019,CHEMBL619950,3950
,12166,H,8,,,,10325,,In vitro inhibitory activity against 5-Lipoxygenase in rat by Peritoneal 5-lipoxygenase assay,1,,Autocuration,,,,,,,B,BAO_0000019,CHEMBL618050,3951
,12166,H,8,,,,1556,,In vitro inhibition of 5-lipoxygenase in RBL-2H3 (Rat basophilic leukemia) cells.,1,,Expert,,663.0,,,RBL-2H3,,F,BAO_0000219,CHEMBL875091,3952
,12166,H,8,,,,1556,,In vitro inhibition of 5-lipoxygenase in RBL-2H3 (Rat basophilic leukemia) cells; Not tested,1,,Expert,,663.0,,,RBL-2H3,,F,BAO_0000219,CHEMBL618051,3953
,12166,D,9,,,,961,,Inhibition of 5-lipoxygenase from rat basophilic leukemia(RBL-1) cells,1,Rattus norvegicus,Expert,,702.0,,10116.0,RBL-1,,B,BAO_0000219,CHEMBL618052,3954
,12166,H,8,,,,6838,,In vitro inhibitory activity against 5-lipoxygenase in an RBL-2H3 cell lysate,1,,Autocuration,,,,,,,B,BAO_0000019,CHEMBL618053,3955
,12166,H,8,,,,10325,,In vitro inhibition of 5-lipoxygenase in rat (peritoneal assay),1,,Expert,,,,,,,B,BAO_0000019,CHEMBL618054,3956
,12166,D,9,,,,9209,,In vitro inhibitory activity against 5-lipoxygenase in rat RBL-1 cells,1,Rattus norvegicus,Expert,,702.0,,10116.0,RBL-1,,B,BAO_0000219,CHEMBL618055,3957
,12166,H,8,,,,11520,,inhibitory activity against 5-lipoxygenase in rat basophilic leukemia cell line.,1,,Expert,,702.0,,,RBL-1,,B,BAO_0000219,CHEMBL618056,3958
,12166,H,8,,,,137,,In vitro inhibitory activity against 5-lipoxygenase was determined,1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL618057,3959
,12166,H,8,,,,4717,,In vitro inhibitory concentration against 5-lipoxygenase in RBL-1 cells,1,,Autocuration,,702.0,,,RBL-1,,B,BAO_0000219,CHEMBL618058,3960
,12166,H,8,,,,10636,,Inhibition of 5-lipoxygenase in intact RBL-1 cell line,1,,Expert,,702.0,,,RBL-1,,B,BAO_0000219,CHEMBL618059,3961
,12166,D,9,,,,14312,,Inhibitory activity against 5-lipoxygenase catalysis (5-LO) in sonicated rat basophilic leukemia cell lysate,1,Rattus norvegicus,Expert,,,,10116.0,,,F,BAO_0000019,CHEMBL618060,3962
,12166,H,8,,,,1203,,Inhibition of 5-Lipoxygenase (5-LO) in rat basophilic leukemia cells,1,,Autocuration,,702.0,,,RBL-1,,B,BAO_0000219,CHEMBL618061,3963
,12166,H,8,,,,1203,,Inhibition of 5-Lipoxygenase (5-LO) in rat basophilic leukemic cells,1,,Autocuration,,,,,,,B,BAO_0000019,CHEMBL618062,3964
,12166,H,8,,,,13622,,Inhibition of 5-lipoxygenase catalysis in rat basophilic leukemia (RBL) cells by measuring 5-HETE product formation,1,,Expert,,702.0,,,RBL-1,,B,BAO_0000219,CHEMBL618063,3965
,12166,H,8,,,,9793,,Inhibition of 5-lipoxygenase from rat peritoneal neutrophils after oral administration,1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL618064,3966
,12166,D,9,,,,1143,,Inhibition of 5-lipoxygenase of rat basophilic leukemia (RBL) cell cytosolic enzymes,1,Rattus norvegicus,Expert,,702.0,,10116.0,RBL-1,,B,BAO_0000219,CHEMBL618065,3967
,12166,D,9,,,,11854,,Inhibition 5-lipoxygenase mediated LTB4 formation in rat basophilic leukemia (RBL-1) cells,1,Rattus norvegicus,Expert,,702.0,,10116.0,RBL-1,,B,BAO_0000219,CHEMBL618066,3968
,12166,H,8,,,,3595,,Inhibitory activity against 5-lipoxygenase (5-LO) in intact rat barophilic leukemia cells (RBL-1),1,,Autocuration,,702.0,,,RBL-1,,B,BAO_0000219,CHEMBL618067,3969
,12166,H,8,,,,3595,,Inhibitory activity against 5-lipoxygenase (5-LO) using broken rat barophilic leukemia cells (RBL-1),1,,Autocuration,,702.0,,,RBL-1,,B,BAO_0000219,CHEMBL618068,3970
,12166,D,9,,,,10501,,Inhibition of 5-lipoxygenase in rat RBL-1 cells,1,Rattus norvegicus,Expert,,702.0,,10116.0,RBL-1,,B,BAO_0000219,CHEMBL618069,3971
,12166,H,8,,,,12526,,Inhibition of 5-lipoxygenase in intact rat basophilic leukemia cells stimulated with the calcium ionophore A-23187,1,,Expert,,702.0,,,RBL-1,,B,BAO_0000219,CHEMBL618070,3972
Limbic system,10825,H,8,,,,10034,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 32 umol/kg,1,,Autocuration,,,,,,349.0,F,BAO_0000019,CHEMBL618071,3973
Limbic system,10825,H,8,,,,10034,,Compound was tested for its effects on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 0.10 umol/kg,1,,Autocuration,,,,,,349.0,F,BAO_0000019,CHEMBL619247,3974
,10825,H,8,,,,10034,,Approximate dose levels for a half maximal reduction of 5-HTP levels,1,,Autocuration,,,,,,,F,BAO_0000019,CHEMBL619248,3975
Hippocampus,10576,H,8,,,,10046,,Inhibitory activity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue using [3H]OH-DPAT as radioligand.,1,,Autocuration,,,,,,10000000.0,B,BAO_0000221,CHEMBL619249,3976
Hippocampus,10576,H,8,,,,10046,,Inhibitory activity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue using [3H]OH-DPAT as radioligand.,1,,Autocuration,,,,,,10000000.0,B,BAO_0000221,CHEMBL619250,3977
,10577,H,8,,,,10046,,Inhibitory activity against 5-hydroxytryptamine 1B receptor of rat striatal membrane homogenate using [3H]5-HT as the radioligand.,1,,Autocuration,,,,,,,B,BAO_0000019,CHEMBL619251,3978
Blood,55,H,8,,,,12079,,Inhibitory concentration against human platelet 5-lipoxygenase in dog whole blood,1,Canis lupus familiaris,Autocuration,,,,9615.0,,178.0,F,BAO_0000019,CHEMBL619252,3979
Blood,55,H,8,,,,12079,,Inhibitory concentration against human platelet 5-lipoxygenase in human whole blood,1,,Autocuration,,,,,,178.0,F,BAO_0000019,CHEMBL619253,3980
,12166,H,8,,,,11311,,The compound was tested for inhibitory activity against 5-Lipoxygenase in rat polymorphonuclear leukocytes[PMNS],1,,Autocuration,,,,,,,B,BAO_0000219,CHEMBL619254,3981
,17140,H,8,,,,12338,,Inhibition of 5-lipoxygenase in bovine polymorphonuclear leukocytes,1,,Expert,,,,,,,B,BAO_0000219,CHEMBL619255,3982
,17140,H,8,,,,12143,,Inhibitory activity against 5-lipoxygenase (inhibition of 5-HETE and LTB4 biosynthesis) in bovine polymorphonuclear leukocytes (PMNL).,1,,Expert,,,,,,,B,BAO_0000219,CHEMBL619256,3983
,17140,H,8,,,,12143,,Inhibitory activity against 5-lipoxygenase (inhibition of 5-HETE and LTB4 biosynthesis) in bovine polymorphonuclear leukocytes (PMNL),1,,Autocuration,,,,,,,B,BAO_0000219,CHEMBL875418,3984
,17140,H,8,,,,12143,,Inhibitory activity against 5-lipoxygenase (inhibition of 5-HETE and LTB4 biosynthesis) in bovine polymorphonuclear leukocytes (PMNL) at 30 uM,1,,Expert,,,,,,,B,BAO_0000219,CHEMBL619257,3985
,17140,H,8,,,,12143,,Inhibitory activity against 5-lipoxygenase (inhibition of 5-HETE and LTB4 biosynthesis) in bovine polymorphonuclear leukocytes (PMNL) at 30 uM,1,,Autocuration,,,,,,,B,BAO_0000219,CHEMBL619258,3986
,17140,H,8,,,,12365,,Inhibition of 5-lipoxygenase in bovine PMNL cell assay.,1,,Expert,,,,,,,B,BAO_0000357,CHEMBL619259,3987
,17140,H,8,,,,13500,,Tested for inhibition of 5-lipoxygenase as inhibition of 5-HETE and LTB4 biosynthesis in bovine PMNL,1,,Expert,,,,,,,B,BAO_0000357,CHEMBL619260,3988
Blood,55,H,8,In vivo,,,12832,,"Ex vivo inhibition of 5-LO was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.08h, following intravenous administration at the dose of 1.0 mg/kg",1,Canis lupus familiaris,Autocuration,,,,9615.0,,178.0,F,BAO_0000218,CHEMBL619261,3989
Blood,55,H,8,In vivo,,,12832,,"Ex vivo inhibition of 5-LO was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.25h, following intravenous administration at the dose of 1.0 mg/kg",1,Canis lupus familiaris,Autocuration,,,,9615.0,,178.0,F,BAO_0000218,CHEMBL619263,3990
Blood,55,H,8,In vivo,,,12832,,"Ex vivo inhibition of 5-LO was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.5h, following intravenous administration at the dose of 1.0 mg/kg",1,Canis lupus familiaris,Autocuration,,,,9615.0,,178.0,F,BAO_0000218,CHEMBL619264,3991
Blood,55,H,8,In vivo,,,12832,,"Ex vivo inhibition of 5-LO was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 1.0h, following intravenous administration at the dose of 1.0 mg/kg",1,Canis lupus familiaris,Autocuration,,,,9615.0,,178.0,F,BAO_0000218,CHEMBL619265,3992
Blood,55,H,8,In vivo,,,12832,,"Ex vivo inhibition of 5-LO was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 24h, following intravenous administration at the dose of 1.0 mg/kg",1,Canis lupus familiaris,Autocuration,,,,9615.0,,178.0,F,BAO_0000218,CHEMBL619266,3993
Blood,55,H,8,In vivo,,,12832,,"Ex vivo inhibition of 5-LO was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 3.0h, following intravenous administration at the dose of 1.0 mg/kg",1,Canis lupus familiaris,Autocuration,,,,9615.0,,178.0,F,BAO_0000218,CHEMBL619902,3994
Blood,55,H,8,In vivo,,,12832,,"Ex vivo inhibition of 5-LO was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 6.0h, following intravenous administration at the dose of 1.0 mg/kg",1,Canis lupus familiaris,Autocuration,,,,9615.0,,178.0,F,BAO_0000218,CHEMBL620058,3995
Blood,55,H,8,In vivo,,,12832,,"Ex vivo inhibition of 5-LO was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 9.0h, following intravenous administration at the dose of 1.0 mg/kg",1,Canis lupus familiaris,Autocuration,,,,9615.0,,178.0,F,BAO_0000218,CHEMBL620059,3996
Blood,55,H,8,In vivo,,,12832,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.08h, following intravenous administration at the dose of 1.0 mg/kg",1,Canis lupus familiaris,Autocuration,,,,9615.0,,178.0,F,BAO_0000218,CHEMBL620060,3997
Blood,55,H,8,In vivo,,,12832,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.25h, following intravenous administration at the dose of 1.0 mg/kg",1,Canis lupus familiaris,Autocuration,,,,9615.0,,178.0,F,BAO_0000218,CHEMBL620061,3998
Blood,55,H,8,In vivo,,,12832,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.25h, following peroral administration at the dose of 0.3 mg/kg",1,Canis lupus familiaris,Autocuration,,,,9615.0,,178.0,F,BAO_0000218,CHEMBL620062,3999
Blood,55,H,8,In vivo,,,12832,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.25h, following peroral administration at the dose of 1.0 mg/kg",1,Canis lupus familiaris,Autocuration,,,,9615.0,,178.0,F,BAO_0000218,CHEMBL620063,4000
Blood,55,H,8,In vivo,,,12832,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.25h, following peroral administration at the dose of 3.0 mg/kg",1,Canis lupus familiaris,Autocuration,,,,9615.0,,178.0,F,BAO_0000218,CHEMBL620064,4001
Blood,55,H,8,In vivo,,,12832,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.5h, following intravenous administration at the dose of 1.0 mg/kg",1,Canis lupus familiaris,Autocuration,,,,9615.0,,178.0,F,BAO_0000218,CHEMBL620065,4002
Blood,55,H,8,In vivo,,,12832,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.5h, following peroral administration at the dose of 0.3 mg/kg",1,Canis lupus familiaris,Autocuration,,,,9615.0,,178.0,F,BAO_0000218,CHEMBL620066,4003
Blood,55,H,8,In vivo,,,12832,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.5h, following peroral administration at the dose of 1.0 mg/kg",1,Canis lupus familiaris,Autocuration,,,,9615.0,,178.0,F,BAO_0000218,CHEMBL620067,4004
Blood,55,H,8,In vivo,,,12832,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.5h, following peroral administration at the dose of 3.0 mg/kg",1,Canis lupus familiaris,Autocuration,,,,9615.0,,178.0,F,BAO_0000218,CHEMBL620068,4005
Blood,55,H,8,In vivo,,,12832,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 1.0h, following intravenous administration at the dose of 1.0 mg/kg",1,Canis lupus familiaris,Autocuration,,,,9615.0,,178.0,F,BAO_0000218,CHEMBL620069,4006
Blood,55,H,8,In vivo,,,12832,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 1.0h, following peroral administration at the dose of 0.3 mg/kg",1,Canis lupus familiaris,Autocuration,,,,9615.0,,178.0,F,BAO_0000218,CHEMBL620070,4007
Blood,55,H,8,In vivo,,,12832,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 1.0h, following peroral administration at the dose of 1.0 mg/kg",1,Canis lupus familiaris,Autocuration,,,,9615.0,,178.0,F,BAO_0000218,CHEMBL620071,4008
Blood,55,H,8,In vivo,,,12832,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 1.0h, following peroral administration at the dose of 3.0 mg/kg",1,Canis lupus familiaris,Autocuration,,,,9615.0,,178.0,F,BAO_0000218,CHEMBL620072,4009
Blood,55,H,8,In vivo,,,12832,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 24h, following intravenous administration at the dose of 1.0 mg/kg",1,Canis lupus familiaris,Autocuration,,,,9615.0,,178.0,F,BAO_0000218,CHEMBL620036,4010
Blood,55,H,8,In vivo,,,12832,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 24h, following peroral administration at the dose of 0.3 mg/kg",1,Canis lupus familiaris,Autocuration,,,,9615.0,,178.0,F,BAO_0000218,CHEMBL857702,4011
Blood,55,H,8,In vivo,,,12832,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 24h, following peroral administration at the dose of 1.0 mg/kg",1,Canis lupus familiaris,Autocuration,,,,9615.0,,178.0,F,BAO_0000218,CHEMBL620037,4012
Blood,55,H,8,In vivo,,,12832,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 24h, following peroral administration at the dose of 3.0 mg/kg",1,Canis lupus familiaris,Autocuration,,,,9615.0,,178.0,F,BAO_0000218,CHEMBL620038,4013
Blood,55,H,8,In vivo,,,12832,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 3.0h, following intravenous administration at the dose of 1.0 mg/kg",1,Canis lupus familiaris,Autocuration,,,,9615.0,,178.0,F,BAO_0000218,CHEMBL620039,4014
Blood,55,H,8,In vivo,,,12832,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 3.0h, following peroral administration at the dose of 0.3 mg/kg",1,Canis lupus familiaris,Autocuration,,,,9615.0,,178.0,F,BAO_0000218,CHEMBL620040,4015
Blood,55,H,8,In vivo,,,12832,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 3.0h, following peroral administration at the dose of 1.0 mg/kg",1,Canis lupus familiaris,Autocuration,,,,9615.0,,178.0,F,BAO_0000218,CHEMBL620041,4016
Blood,55,H,8,In vivo,,,12832,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 3.0h, following peroral administration at the dose of 3.0 mg/kg",1,Canis lupus familiaris,Autocuration,,,,9615.0,,178.0,F,BAO_0000218,CHEMBL620042,4017
Blood,55,H,8,In vivo,,,12832,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 6.0h, following intravenous administration at the dose of 1.0 mg/kg",1,Canis lupus familiaris,Autocuration,,,,9615.0,,178.0,F,BAO_0000218,CHEMBL620043,4018
Blood,55,H,8,In vivo,,,12832,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 6.0h, following peroral administration at the dose of 0.3 mg/kg",1,Canis lupus familiaris,Autocuration,,,,9615.0,,178.0,F,BAO_0000218,CHEMBL620044,4019
Blood,55,H,8,In vivo,,,12832,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 6.0h, following peroral administration at the dose of 1.0 mg/kg",1,Canis lupus familiaris,Autocuration,,,,9615.0,,178.0,F,BAO_0000218,CHEMBL620045,4020
Blood,55,H,8,In vivo,,,12832,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 6.0h, following peroral administration at the dose of 3.0 mg/kg",1,Canis lupus familiaris,Autocuration,,,,9615.0,,178.0,F,BAO_0000218,CHEMBL620046,4021
Blood,55,H,8,In vivo,,,12832,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 9.0h, following intravenous administration at the dose of 1.0 mg/kg",1,Canis lupus familiaris,Autocuration,,,,9615.0,,178.0,F,BAO_0000218,CHEMBL620047,4022
Blood,55,H,8,In vivo,,,12832,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 9.0h, following peroral administration at the dose of 0.3 mg/kg",1,Canis lupus familiaris,Autocuration,,,,9615.0,,178.0,F,BAO_0000218,CHEMBL620048,4023
Blood,55,H,8,In vivo,,,12832,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 9.0h, following peroral administration at the dose of 1.0 mg/kg",1,Canis lupus familiaris,Autocuration,,,,9615.0,,178.0,F,BAO_0000218,CHEMBL857703,4024
Blood,55,H,8,In vivo,,,12832,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 9.0h, following peroral administration at the dose of 3.0 mg/kg",1,Canis lupus familiaris,Autocuration,,,,9615.0,,178.0,F,BAO_0000218,CHEMBL620049,4025
Blood,55,H,8,In vivo,,,12832,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.08h, following intravenous administration at the dose of 1.0 mg/kg",1,Canis lupus familiaris,Autocuration,,,,9615.0,,178.0,F,BAO_0000218,CHEMBL620050,4026
Blood,55,H,8,In vivo,,,12832,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.25h, following intravenous administration at the dose of 1.0 mg/kg",1,Canis lupus familiaris,Autocuration,,,,9615.0,,178.0,F,BAO_0000218,CHEMBL620051,4027
Blood,55,H,8,In vivo,,,12832,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.5h, following intravenous administration at the dose of 1.0 mg/kg",1,Canis lupus familiaris,Autocuration,,,,9615.0,,178.0,F,BAO_0000218,CHEMBL619213,4028
Blood,55,H,8,In vivo,,,12832,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 1.0h, following intravenous administration at the dose of 1.0 mg/kg",1,Canis lupus familiaris,Autocuration,,,,9615.0,,178.0,F,BAO_0000218,CHEMBL619214,4029
Blood,55,H,8,In vivo,,,12832,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 3.0h, following intravenous administration at the dose of 1.0 mg/kg",1,Canis lupus familiaris,Autocuration,,,,9615.0,,178.0,F,BAO_0000218,CHEMBL619804,4030
Blood,55,H,8,In vivo,,,12832,,"Ex vivo inhibition was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.25h, following peroral administration at the dose of 1.0 mg/kg",1,Canis lupus familiaris,Autocuration,,,,9615.0,,178.0,F,BAO_0000218,CHEMBL619805,4031
Blood,55,H,8,In vivo,,,12832,,"Ex vivo inhibition was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 24h, following intravenous administration at the dose of 1.0 mg/kg",1,Canis lupus familiaris,Autocuration,,,,9615.0,,178.0,F,BAO_0000218,CHEMBL619806,4032
Blood,55,H,8,In vivo,,,12832,,"Ex vivo inhibition was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 6.0h, following intravenous administration at the dose of 1.0 mg/kg",1,Canis lupus familiaris,Autocuration,,,,9615.0,,178.0,F,BAO_0000218,CHEMBL619807,4033
Blood,55,H,8,In vivo,,,12832,,"Ex vivo inhibition was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 9.0h, following intravenous administration at the dose of 1.0 mg/kg",1,Canis lupus familiaris,Autocuration,,,,9615.0,,178.0,F,BAO_0000218,CHEMBL619808,4034
,55,H,8,,,,3595,,Inhibitory activity against 5-lipoxygenase (5-LO) in after oral administration of 5 mg/kg at 24 hr r,1,Canis lupus familiaris,Autocuration,,,,9615.0,,,B,BAO_0000218,CHEMBL619809,4035
,55,H,8,,,,3595,,Inhibitory activity against 5-lipoxygenase (5-LO) in after oral administration of 5 mg/kg at 24 hr r to canine,1,Canis lupus familiaris,Autocuration,,,,9615.0,,,B,BAO_0000218,CHEMBL619810,4036
,55,H,8,,,,3595,,Inhibitory activity against 5-lipoxygenase (5-LO) in after oral administration of 5 mg/kg at 2 hr,1,Canis lupus familiaris,Autocuration,,,,9615.0,,,B,BAO_0000218,CHEMBL619811,4037
,55,H,8,,,,3595,,Inhibitory activity against 5-lipoxygenase (5-LO) in after oral administration of 5 mg/kg at 2 hr to canine,1,Canis lupus familiaris,Autocuration,,,,9615.0,,,B,BAO_0000218,CHEMBL620769,4038
,55,H,8,,,,3595,,Inhibitory activity against 5-lipoxygenase (5-LO) in after oral administration of 5 mg/kg at 4 hr,1,Canis lupus familiaris,Autocuration,,,,9615.0,,,B,BAO_0000218,CHEMBL620770,4039
,55,H,8,,,,3595,,Inhibitory activity against 5-lipoxygenase (5-LO) in after oral administration of 5 mg/kg at 4 hr to canine,1,Canis lupus familiaris,Autocuration,,,,9615.0,,,B,BAO_0000218,CHEMBL620771,4040
,55,H,8,,,,3595,,Inhibitory activity against 5-lipoxygenase (5-LO) in after oral administration of 5 mg/kg at 8 hr,1,Canis lupus familiaris,Autocuration,,,,9615.0,,,B,BAO_0000218,CHEMBL620772,4041
,55,H,8,,,,3595,,Inhibitory activity against 5-lipoxygenase (5-LO) in after oral administration of 5 mg/kg at 8 hr to canine,1,Canis lupus familiaris,Autocuration,,,,9615.0,,,B,BAO_0000218,CHEMBL620773,4042
,55,H,8,,,,9203,,Ability to inhibit 5-lipoxygenase in guinea pig,1,Cavia porcellus,Autocuration,,,,10141.0,,,B,BAO_0000357,CHEMBL620774,4043
,55,H,8,,,,82,,Inhibition of [14C]arachidonic acid conversion to 5-HETE by broken cell 5-lipoxygenase in vitro (guinea pig PMN),1,Cavia porcellus,Expert,,,,10141.0,,,B,BAO_0000357,CHEMBL620775,4044
,55,H,8,,,,11090,,Compound was tested for the inhibition of 5-lipoxygenase (5-Lpo) in guinea pig.,1,Cavia porcellus,Autocuration,,,,10141.0,,,B,BAO_0000357,CHEMBL620776,4045
Blood,55,H,8,,,,12832,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 12 h, following intravenous administration at the dose of 1.0 mg/kg",1,Cavia porcellus,Autocuration,,,,10141.0,,178.0,B,BAO_0000218,CHEMBL620777,4046
,55,H,8,,,,1065,,In vitro 5-lipoxygenase inhibition in guinea pig PMNs was determined based on 5-hydroxyeicosapentaenoic acid (5-HETE) production,1,Cavia porcellus,Autocuration,,,,10141.0,,,B,BAO_0000357,CHEMBL620778,4047
,55,H,8,,,,1065,,In vitro 5-lipoxygenase inhibition in guinea pig PMNs was determined based on LTB4 production,1,Cavia porcellus,Autocuration,,,,10141.0,,,B,BAO_0000357,CHEMBL620779,4048
,55,H,8,,,,12832,,In vitro 5-lipoxygenase inhibitory activity against A-23187-stimulated conversion of [14C]-AA to 5-HETE in guinea pig peritoneal polymorphonuclear leukocytes,1,Cavia porcellus,Expert,,,,10141.0,,,B,BAO_0000019,CHEMBL621500,4049
,55,H,8,,,,12832,,In vitro 5-lipoxygenase inhibitory activity against A-23187-stimulated conversion of [14C]AA to LTB4 in guinea pig peritoneal polymorphonuclear leukocytes,1,Cavia porcellus,Expert,,,,10141.0,,,B,BAO_0000019,CHEMBL621501,4050
,55,H,8,,,,12832,,In vitro 5-lipoxygenase inhibitory activity against A-23187-stimulated conversion of [14C]AA to LTB4 in guinea pig peritoneal polymorphonuclear leukocytes,1,Cavia porcellus,Autocuration,,,,10141.0,,,B,BAO_0000019,CHEMBL618098,4051
,55,H,8,,,,10504,,Inhibition against 5-lipoxygenase from guinea pig polymorphonuclear lymphocytes,1,Cavia porcellus,Autocuration,,,,10141.0,,,B,BAO_0000019,CHEMBL618099,4052
,55,H,8,,,,7788,,Inhibitory activity against 5-lipoxygenase,1,Cavia porcellus,Autocuration,,,,10141.0,,,B,BAO_0000357,CHEMBL618100,4053
,55,H,8,,,,10001,,Inhibitory activity against 5-lipoxygenase in guinea pig leukocyte,1,Cavia porcellus,Autocuration,,,,10141.0,,,B,BAO_0000357,CHEMBL618101,4054
,55,H,8,,,,10193,,Inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase using guinea pig supernatant,1,Cavia porcellus,Autocuration,,,,10141.0,,,B,BAO_0000357,CHEMBL618102,4055
,55,H,8,,,,13243,,Inhibitory activity against partially-purified Guinea pig PMN 5-lipoxygenase,1,Cavia porcellus,Autocuration,,,,10141.0,,,B,BAO_0000357,CHEMBL618103,4056
,55,H,8,,,,13243,,Inhibitory activity uM,1,Cavia porcellus,Autocuration,,,,10141.0,,,B,BAO_0000357,CHEMBL618104,4057
,55,H,8,,,,969,,Inhibitory activity against 5-lipoxygenase in guinea pig leukocytes was determined,1,Cavia porcellus,Autocuration,,,,10141.0,,,B,BAO_0000219,CHEMBL883712,4058
,55,H,8,,,,10001,,Inhibitory activity against 5-lipoxygenase at 10 uM,1,Cavia porcellus,Autocuration,,,,10141.0,,,B,BAO_0000357,CHEMBL618105,4059
,55,H,8,,,,7788,,Inhibitory activity against 5-lipoxygenase at a dose of 0.1 mM,1,Cavia porcellus,Autocuration,,,,10141.0,,,B,BAO_0000357,CHEMBL618106,4060
,55,H,8,,,,10001,,Inhibitory activity against 5-lipoxygenase in guinea pig leukocyte at 30 uM,1,Cavia porcellus,Autocuration,,,,10141.0,,,B,BAO_0000357,CHEMBL618107,4061
,55,H,8,,,,10193,,Inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase using guinea pig supernatant at 10 uM,1,Cavia porcellus,Autocuration,,,,10141.0,,,B,BAO_0000357,CHEMBL618108,4062
,55,H,8,,,,13243,,Inhibitory activity uM,1,Cavia porcellus,Autocuration,,,,10141.0,,,B,BAO_0000357,CHEMBL618109,4063
,55,H,8,,,,13243,,Inhibitory activity against partially-purified Guinea pig PMN 5-lipoxygenase at 10 uM,1,Cavia porcellus,Autocuration,,,,10141.0,,,B,BAO_0000357,CHEMBL618110,4064
,55,H,8,,,,13243,,Inhibitory activity uM,1,Cavia porcellus,Expert,,,,10141.0,,,B,BAO_0000357,CHEMBL618111,4065
,55,H,8,,,,13243,,Inhibitory activity uM,1,Cavia porcellus,Autocuration,,,,10141.0,,,F,BAO_0000019,CHEMBL618112,4066
,55,H,8,,,,10504,,Percent inhibition against 5-lipoxygenase from guinea pig polymorphonuclear lymphocytes,1,Cavia porcellus,Autocuration,,,,10141.0,,,B,BAO_0000019,CHEMBL618113,4067
,55,H,8,,,,7788,,Inhibitory activity against 5-lipoxygenase at a dose of 0.1 mM,1,Cavia porcellus,Autocuration,,,,10141.0,,,B,BAO_0000357,CHEMBL618114,4068
Ileum,55,H,8,,,,10546,,Evaluated for inhibition of the formation and release of 5-lipoxygenase in isolated guinea pig ileum,1,Cavia porcellus,Expert,,,,10141.0,,2116.0,F,BAO_0000221,CHEMBL620871,4069
,55,H,8,,,,13183,,5-lipoxygenase Inhibitory activity was measured by enzyme immunoassay using human whole blood stimulated with calcium ionophore (A23187) and LTB4 (leukotriene B4),1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL620872,4070
,55,H,8,,,,13183,,5-lipoxygenase Inhibitory activity was measured by enzyme immunoassay using human whole blood stimulated with calcium ionophore (A23187) and LTB4 (leukotriene B4),1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL620873,4071
,55,H,8,,,,2578,,Compound was evaluated for in vitro inhibition of recombinant human 5-lipoxygenase (5-LO),1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL620874,4072
,55,H,8,,,,12780,,In vitro inhibition of human 5-Lipoxygenase.,1,,Expert,,,,,,,B,BAO_0000357,CHEMBL620875,4073
Liver,22226,U,0,,,Microsomes,7411,,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 75 uM,1,Rattus norvegicus,Autocuration,,,,10116.0,,2107.0,B,BAO_0000251,CHEMBL620876,4074
Liver,22226,U,0,,,Microsomes,7411,,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 1 uM,1,Rattus norvegicus,Autocuration,,,,10116.0,,2107.0,B,BAO_0000251,CHEMBL620877,4075
Liver,22226,U,0,,,Microsomes,7411,,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 10 uM,1,Rattus norvegicus,Autocuration,,,,10116.0,,2107.0,B,BAO_0000251,CHEMBL857854,4076
Liver,22226,U,0,,,Microsomes,7411,,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 10 uM exposed 100 uM,1,Rattus norvegicus,Autocuration,,,,10116.0,,2107.0,B,BAO_0000251,CHEMBL620878,4077
Liver,22226,U,0,,,Microsomes,7411,,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 100 uM,1,Rattus norvegicus,Autocuration,,,,10116.0,,2107.0,B,BAO_0000251,CHEMBL620879,4078
Liver,22226,U,0,,,Microsomes,7411,,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 1000 uM,1,Rattus norvegicus,Autocuration,,,,10116.0,,2107.0,B,BAO_0000251,CHEMBL620880,4079
Liver,22226,U,0,,,Microsomes,7411,,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 1000 uM,1,Rattus norvegicus,Autocuration,,,,10116.0,,2107.0,B,BAO_0000251,CHEMBL620881,4080
Liver,22226,U,0,,,Microsomes,7411,,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 150 uM,1,Rattus norvegicus,Autocuration,,,,10116.0,,2107.0,B,BAO_0000251,CHEMBL620882,4081
Liver,22226,U,0,,,Microsomes,7411,,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 1500 uM,1,Rattus norvegicus,Autocuration,,,,10116.0,,2107.0,B,BAO_0000251,CHEMBL620883,4082
Liver,22226,U,0,,,Microsomes,7411,,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 2.5 uM,1,Rattus norvegicus,Autocuration,,,,10116.0,,2107.0,B,BAO_0000251,CHEMBL620884,4083
Liver,22226,U,0,,,Microsomes,7411,,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 200 uM,1,Rattus norvegicus,Autocuration,,,,10116.0,,2107.0,B,BAO_0000251,CHEMBL620885,4084
Liver,22226,U,0,,,Microsomes,7411,,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 27.5 uM,1,Rattus norvegicus,Autocuration,,,,10116.0,,2107.0,B,BAO_0000251,CHEMBL620886,4085
Liver,22226,U,0,,,Microsomes,7411,,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 5 uM,1,Rattus norvegicus,Autocuration,,,,10116.0,,2107.0,B,BAO_0000251,CHEMBL620887,4086
Liver,22226,U,0,,,Microsomes,7411,,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 50 uM,1,Rattus norvegicus,Autocuration,,,,10116.0,,2107.0,B,BAO_0000251,CHEMBL618039,4087
Liver,22226,U,0,,,Microsomes,7411,,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 500 uM,1,Rattus norvegicus,Autocuration,,,,10116.0,,2107.0,B,BAO_0000251,CHEMBL618040,4088
Liver,22226,U,0,,,Microsomes,7411,,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to exposed to 3-methylcholanthrene at concentration of 200 uM,1,Rattus norvegicus,Autocuration,,,,10116.0,,2107.0,B,BAO_0000251,CHEMBL618041,4089
Liver,22226,U,0,,,Microsomes,7411,,"Compound was evaluated for inhibition constant, in liver microsomes from 3-methylcholanthrene-exposed rats",1,Rattus norvegicus,Autocuration,,,,10116.0,,2107.0,B,BAO_0000251,CHEMBL618216,4090
Liver,22226,U,0,,,Microsomes,7411,,"Compound was evaluated for inhibition constant, in liver microsomes from beta-naphthoflavone-exposed rats",1,Rattus norvegicus,Autocuration,,,,10116.0,,2107.0,B,BAO_0000251,CHEMBL618217,4091
Liver,22226,U,0,,,Microsomes,7411,,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes 3-methylcholanthrene at concentration of 100 uM,1,Rattus norvegicus,Autocuration,,,,10116.0,,2107.0,B,BAO_0000251,CHEMBL618218,4092
Liver,22226,U,0,,,Microsomes,7411,,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes 3-methylcholanthrene at concentration of 200 uM,1,Rattus norvegicus,Autocuration,,,,10116.0,,2107.0,B,BAO_0000251,CHEMBL618219,4093
Liver,22226,U,0,,,Microsomes,7411,,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes 3-methylcholanthrene at concentration of 50 uM,1,Rattus norvegicus,Autocuration,,,,10116.0,,2107.0,B,BAO_0000251,CHEMBL618220,4094
Liver,22226,U,0,,,Microsomes,7411,,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at 5 uM,1,Rattus norvegicus,Autocuration,,,,10116.0,,2107.0,B,BAO_0000251,CHEMBL618221,4095
Liver,22226,U,0,,,Microsomes,7411,,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at 50 uM,1,Rattus norvegicus,Autocuration,,,,10116.0,,2107.0,B,BAO_0000251,CHEMBL618222,4096
Liver,22226,U,0,,,Microsomes,7411,,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at a concentration of 10 uM,1,Rattus norvegicus,Autocuration,,,,10116.0,,2107.0,B,BAO_0000251,CHEMBL618223,4097
Liver,22226,U,0,,,Microsomes,7411,,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 100 uM,1,Rattus norvegicus,Autocuration,,,,10116.0,,2107.0,B,BAO_0000251,CHEMBL618224,4098
Liver,22226,U,0,,,Microsomes,7411,,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 1 uM,1,Rattus norvegicus,Autocuration,,,,10116.0,,2107.0,B,BAO_0000251,CHEMBL618225,4099
Liver,22226,U,0,,,Microsomes,7411,,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 20 uM,1,Rattus norvegicus,Autocuration,,,,10116.0,,2107.0,B,BAO_0000251,CHEMBL618226,4100
Liver,22226,U,0,,,Microsomes,7411,,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 200 uM,1,Rattus norvegicus,Autocuration,,,,10116.0,,2107.0,B,BAO_0000251,CHEMBL618227,4101
Liver,22226,U,0,,,Microsomes,7411,,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 25 uM,1,Rattus norvegicus,Autocuration,,,,10116.0,,2107.0,B,BAO_0000251,CHEMBL618228,4102
Liver,22226,U,0,,,Microsomes,7411,,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 50 uM,1,Rattus norvegicus,Autocuration,,,,10116.0,,2107.0,B,BAO_0000251,CHEMBL618229,4103
Liver,22226,U,0,,,Microsomes,7411,,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 75 uM,1,Rattus norvegicus,Autocuration,,,,10116.0,,2107.0,B,BAO_0000251,CHEMBL618230,4104
Liver,22226,U,0,,,Microsomes,7411,,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 1 uM,1,Rattus norvegicus,Autocuration,,,,10116.0,,2107.0,B,BAO_0000251,CHEMBL618231,4105
Liver,22226,U,0,,,Microsomes,7411,,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 10 uM,1,Rattus norvegicus,Autocuration,,,,10116.0,,2107.0,B,BAO_0000251,CHEMBL618232,4106
Liver,22226,U,0,,,Microsomes,7411,,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 100 uM,1,Rattus norvegicus,Autocuration,,,,10116.0,,2107.0,B,BAO_0000251,CHEMBL618233,4107
Liver,22226,U,0,,,Microsomes,7411,,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 1000 uM,1,Rattus norvegicus,Autocuration,,,,10116.0,,2107.0,B,BAO_0000251,CHEMBL618234,4108
Liver,22226,U,0,,,Microsomes,7411,,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 150 uM,1,Rattus norvegicus,Autocuration,,,,10116.0,,2107.0,B,BAO_0000251,CHEMBL618235,4109
Liver,22226,U,0,,,Microsomes,7411,,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 1500 uM,1,Rattus norvegicus,Autocuration,,,,10116.0,,2107.0,B,BAO_0000251,CHEMBL618115,4110
Liver,22226,U,0,,,Microsomes,7411,,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 2.5 uM,1,Rattus norvegicus,Autocuration,,,,10116.0,,2107.0,B,BAO_0000251,CHEMBL618116,4111
Liver,22226,U,0,,,Microsomes,7411,,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 200 uM,1,Rattus norvegicus,Autocuration,,,,10116.0,,2107.0,B,BAO_0000251,CHEMBL618117,4112
Liver,22226,U,0,,,Microsomes,7411,,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 5 uM,1,Rattus norvegicus,Autocuration,,,,10116.0,,2107.0,B,BAO_0000251,CHEMBL619968,4113
Liver,22226,U,0,,,Microsomes,7411,,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 50 uM,1,Rattus norvegicus,Autocuration,,,,10116.0,,2107.0,B,BAO_0000251,CHEMBL619969,4114
Liver,22226,U,0,,,Microsomes,7411,,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 500 uM,1,Rattus norvegicus,Autocuration,,,,10116.0,,2107.0,B,BAO_0000251,CHEMBL619970,4115
Liver,22226,U,0,,,Microsomes,7411,,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at concentration of 1000 uM,1,Rattus norvegicus,Autocuration,,,,10116.0,,2107.0,B,BAO_0000251,CHEMBL619971,4116
Liver,22226,U,0,,,Microsomes,7411,,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at concentration of 1500 uM,1,Rattus norvegicus,Autocuration,,,,10116.0,,2107.0,B,BAO_0000251,CHEMBL619972,4117
Liver,22226,U,0,,,Microsomes,7411,,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at concentration of 27.5 uM,1,Rattus norvegicus,Autocuration,,,,10116.0,,2107.0,B,BAO_0000251,CHEMBL619973,4118
Liver,22226,U,0,,,Microsomes,7411,,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at concentration of 500 uM,1,Rattus norvegicus,Autocuration,,,,10116.0,,2107.0,B,BAO_0000251,CHEMBL619974,4119
Liver,22226,U,0,,,Microsomes,7411,,Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 50 uM,1,Rattus norvegicus,Autocuration,,,,10116.0,,2107.0,B,BAO_0000251,CHEMBL619975,4120
,22226,U,0,,,Microsomes,7411,,Vmax determined by 7-ethoxycoumarin deethylation in the presence by liver microsomes from rats exposed to 3-methylcholanthrene at concentration of 10 uM,1,Rattus norvegicus,Autocuration,,,,10116.0,,,B,BAO_0000251,CHEMBL619976,4121
Liver,22226,U,0,,,Microsomes,7411,,"Compound was evaluated for alpha -rate constant, in liver microsomes from 3-methylcholanthrene-exposed rats",1,Rattus norvegicus,Autocuration,,,,10116.0,,2107.0,B,BAO_0000251,CHEMBL619977,4122
Liver,22226,U,0,,,Microsomes,7411,,"Compound was evaluated for alpha -rate constant, in liver microsomes from beta-naphthoflavone-exposed rats",1,Rattus norvegicus,Autocuration,,,,10116.0,,2107.0,B,BAO_0000251,CHEMBL619978,4123
Liver,22226,U,0,,,Microsomes,7411,,"Compound was evaluated for alpha -rate constant, in liver microsomes from beta-naphthoflavone-exposed rats; competitive inhibition",1,Rattus norvegicus,Autocuration,,,,10116.0,,2107.0,B,BAO_0000251,CHEMBL619979,4124
Liver,22226,U,0,,,Microsomes,7411,,"Compound was evaluated for alpha inhibition constant, in liver microsomes from 3-methylcholanthrene-exposed rats",1,Rattus norvegicus,Autocuration,,,,10116.0,,2107.0,B,BAO_0000251,CHEMBL619980,4125
Liver,22226,U,0,,,Microsomes,7411,,"Compound was evaluated for alpha inhibition constant, in liver microsomes from beta-naphthoflavone-exposed rats",1,Rattus norvegicus,Autocuration,,,,10116.0,,2107.0,B,BAO_0000251,CHEMBL619981,4126
,80433,N,1,,,,10797,,In vitro inhibition of 7226/S myeloma cancer cell line,1,Homo sapiens,Intermediate,,741.0,,9606.0,RPMI-8226,,F,BAO_0000219,CHEMBL619982,4127
,80698,N,1,,,,6881,,In vitro antitumor activity of compound against 7404 cell line (human liver carcinoma cells),1,Homo sapiens,Intermediate,,993.0,,9606.0,BEL-7404 tumor cell line,,F,BAO_0000219,CHEMBL619983,4128
,80640,N,1,,,,3838,,In vitro growth inhibition of compound was determined against 768-0 cell lines of Renal cancer,1,Homo sapiens,Intermediate,,391.0,,9606.0,786-0,,F,BAO_0000219,CHEMBL620031,4129
,80640,N,1,,,,3838,,In vitro growth inhibition of compound was determined against 768-0 cell lines of Renal cancer,1,Homo sapiens,Intermediate,,391.0,,9606.0,786-0,,F,BAO_0000219,CHEMBL620032,4130
,81264,N,1,,,,12981,,Net accumulation of the [99mTc]Isonitrile complex was measured in 77A cell lines in the presence of Verapamil.,1,Cricetulus griseus,Expert,,505.0,,10029.0,V79,,F,BAO_0000219,CHEMBL620033,4131
,81264,N,1,,,,12981,,Verapamil index represents the ratio of net uptake in the presense of verapamil over control in 77A cell lines.,1,Cricetulus griseus,Expert,,505.0,,10029.0,V79,,F,BAO_0000219,CHEMBL620034,4132
,80635,N,1,,,,7653,,Tested for its cytotoxic effect on the growth of the cell strain 7800C1 (1 x 10e 4 (MEM)) at 10 ug/mL dose,1,Rattus norvegicus,Intermediate,,1119.0,,10116.0,7800C1 cell line,,F,BAO_0000219,CHEMBL620035,4133
,80635,N,1,,,,7653,,Tested for its cytotoxic effect on the growth of the cell strain 7800C1 (1 x 10e 4 (MEM)) at 2 ug/mL dose,1,Rattus norvegicus,Intermediate,,1119.0,,10116.0,7800C1 cell line,,F,BAO_0000219,CHEMBL618318,4134
,80635,N,1,,,,7653,,Tested for its cytotoxic effect on the growth of the cell strain 7800C1 (1 x 10e 4 (MEM)) at 20 ug/mL dose,1,Rattus norvegicus,Intermediate,,1119.0,,10116.0,7800C1 cell line,,F,BAO_0000219,CHEMBL618319,4135
,80635,N,1,,,,7653,,Tested for its cytotoxic effect on the growth of the cell strain 7800C1 (1 x 10e 4 (MEM)) at 5 ug/mL dose,1,Rattus norvegicus,Intermediate,,1119.0,,10116.0,7800C1 cell line,,F,BAO_0000219,CHEMBL618320,4136
,80635,N,1,,,,7653,,Tested for its cytotoxic effect on the growth of the cell strain 7800C1 (1 x 10e 4 (MEM)) at 50 ug/mL dose,1,Rattus norvegicus,Intermediate,,1119.0,,10116.0,7800C1 cell line,,F,BAO_0000219,CHEMBL618321,4137
,80635,N,1,,,,7653,,Tested for its cytotoxic effect on the growth of the cell strain 7800C1 (1 x 10e 4 (MEM)) at 75 ug/mL dose,1,Rattus norvegicus,Intermediate,,1119.0,,10116.0,7800C1 cell line,,F,BAO_0000219,CHEMBL883118,4138
,80640,N,1,,,,17229,,In vitro antitumor activity against renal 786-0 tumor cell lines,1,Homo sapiens,Intermediate,,391.0,,9606.0,786-0,,F,BAO_0000219,CHEMBL883795,4139
,80640,N,1,,,,12858,,Cytotoxic activity against 786-0 Renal cancer cell line,1,Homo sapiens,Intermediate,,391.0,,9606.0,786-0,,F,BAO_0000219,CHEMBL618322,4140
,80640,N,1,,,,16325,,Growth inhibitory activity was determined against 786-0 cancer cell line of Renal cancer,1,Homo sapiens,Intermediate,,391.0,,9606.0,786-0,,F,BAO_0000219,CHEMBL618323,4141
,80640,N,1,,,,16325,,Growth inhibitory activity was determined against 786-0 cancer cell line of renal cancer,1,Homo sapiens,Intermediate,,391.0,,9606.0,786-0,,F,BAO_0000219,CHEMBL618324,4142
,80640,N,1,,,,5858,,In vitro antitumor activity against human renal 786-0 cell line,1,Homo sapiens,Intermediate,,391.0,,9606.0,786-0,,F,BAO_0000219,CHEMBL618325,4143
,80640,N,1,,,,16325,,Inhibition of Renal cancer in 786-0 cancer cell lines,1,Homo sapiens,Intermediate,,391.0,,9606.0,786-0,,F,BAO_0000219,CHEMBL875416,4144
,80640,N,1,,,,14696,,Inhibition of the growth of renal cancer(786-0) cell line. value in parentheses is percent inhibition at 0.01 uM,1,Homo sapiens,Intermediate,,391.0,,9606.0,786-0,,F,BAO_0000219,CHEMBL618326,4145
,80640,N,1,,,,3786,,The compound was tested for its cytotoxic activity against the following renal cancer cell lines 786-0,1,Homo sapiens,Intermediate,,391.0,,9606.0,786-0,,F,BAO_0000219,CHEMBL618327,4146
,80640,N,1,,,,14696,,inhibition of the growth of renal cancer(786-0) cell line,1,Homo sapiens,Intermediate,,391.0,,9606.0,786-0,,F,BAO_0000219,CHEMBL619215,4147
,80640,N,1,,,,14769,,Compound was evaluated for in vitro activity against 786-0 kidney cell lines (Human tumor cells ),1,Homo sapiens,Intermediate,,391.0,,9606.0,786-0,,F,BAO_0000219,CHEMBL619216,4148
,80640,N,1,,,,15354,,Compound was tested for the growth inhibition of 786-0 renal tumor cell line,1,Homo sapiens,Intermediate,,391.0,,9606.0,786-0,,F,BAO_0000219,CHEMBL619217,4149
,80640,N,1,,,,14255,,The IC50 value was measured on 786-0 cell line in ovarian tumor,1,Homo sapiens,Intermediate,,391.0,,9606.0,786-0,,F,BAO_0000219,CHEMBL619218,4150
,80640,N,1,,,,14255,,The IC50 value was measured on 786-0 cell line in ovarian tumor t,1,Homo sapiens,Intermediate,,391.0,,9606.0,786-0,,F,BAO_0000219,CHEMBL619219,4151
,80640,N,1,,,,14255,,The IC50 value was measured on 786-0 cell line in renal tumor type.,1,Homo sapiens,Intermediate,,391.0,,9606.0,786-0,,F,BAO_0000219,CHEMBL619220,4152
,80640,N,1,,,,14696,,Inhibition of the growth of renal cancer(786-0) cell line at 0.01 uM,1,Homo sapiens,Intermediate,,391.0,,9606.0,786-0,,F,BAO_0000219,CHEMBL619221,4153
,80640,N,1,,,,12016,,Tested for cytotoxic activity against renal cancer 786-0 cell line,1,Homo sapiens,Intermediate,,391.0,,9606.0,786-0,,F,BAO_0000219,CHEMBL619222,4154
,80640,N,1,,,,2597,,Compound was tested for growth inhibitory activity against 786-0 cell line,1,Homo sapiens,Intermediate,,391.0,,9606.0,786-0,,F,BAO_0000219,CHEMBL857454,4155
,12166,H,8,,,,12526,,Inhibitory activity against 5-lipoxygenase in intact rat basophilic leukemia cells stimulated with the calcium ionophore A-23187; Inactive(N)= <50% inhibition at 10 uM,1,,Autocuration,,702.0,,,RBL-1,,B,BAO_0000219,CHEMBL619223,4156
,12166,H,8,,,,12526,,Inhibitory activity against 5-lipoxygenase in intact rat basophilic leukemia cells stimulated with the calcium ionophore A-23187; N=Inactive,1,,Autocuration,,702.0,,,RBL-1,,B,BAO_0000219,CHEMBL619224,4157
,12166,H,8,,,,14799,,Inhibitory activity against 5-lipoxygenase obtained from rat basophilic leukemia cells,1,,Autocuration,,,,,,,B,BAO_0000019,CHEMBL619225,4158
,12166,H,8,,,,3595,,Inhibitory activity against 5-lipoxygenase (5-LO) in intact rat barophilic leukemia cells (RBL-1),1,,Expert,,702.0,,,RBL-1,,B,BAO_0000219,CHEMBL619226,4159
,12166,H,8,,,,3595,,Inhibitory activity against 5-lipoxygenase (5-LO) using broken rat barophilic leukemia cells (RBL-1),1,,Expert,,702.0,,,RBL-1,,B,BAO_0000219,CHEMBL619227,4160
,12166,H,8,,,,12767,,Inhibitory activity against rat basophilic leukemia 5-lipoxygenase,1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL619228,4161
,12166,H,8,,,,10997,,Inhibitory activity against 5-lipoxygenase in rat polymorphonuclear leukocytes,1,,Autocuration,,,,,,,B,BAO_0000219,CHEMBL619229,4162
,12166,H,8,,,,11388,,Inhibitory activity against 5-lipoxygenase of RBL-1 cell line,1,,Autocuration,,702.0,,,RBL-1,,B,BAO_0000219,CHEMBL619230,4163
,12166,H,8,,,,167,,Inhibitory activity against RBL broken cell-supematant 5-lipoxygenase was evaluated,1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL619231,4164
,12166,H,8,,,,167,,"Inhibitory activity against intact rat PMNL, LTB4 5-lipoxygenase was evaluated",1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL619232,4165
,12166,H,8,,,,13744,,Inhibitory activity against rat 5-lipoxygenase by using continuous oxygen consumption assay.,1,,Expert,,,,,,,B,BAO_0000357,CHEMBL619233,4166
,12166,H,8,,,,1630,,Inhibitory activity against rat basophilic leukemia cell 5-lipoxygenase,1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL619234,4167
,12166,H,8,,,,1630,,Inhibitory activity against rat basophilic leukemia cell 5-lipoxygenase (5-LO),1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL619235,4168
,12166,D,9,,,,969,,"Inhibitory activity against 5-lipoxygenase in rat neutrophils as inhibition of A 23,187-induced LTB4 production",1,Rattus norvegicus,Expert,,,,10116.0,,,B,BAO_0000019,CHEMBL619236,4169
,12166,H,8,,,,13621,,Inhibitory concentration against 5-lipoxygenase in rat RBL-1 cells,1,,Autocuration,,702.0,,,RBL-1,,B,BAO_0000219,CHEMBL619237,4170
,12166,H,8,,,,10089,,Inhibitory concentration to inhibit 5-lipoxygenase in the rat,1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL619238,4171
,12166,H,8,,,,10193,,In vitro inhibition of rat polymorphonuclear leukocyte 5-lipoxygenase,1,,Expert,,,,,,,B,BAO_0000357,CHEMBL619239,4172
,12166,H,8,,,,11966,,Tested for inhibition of 5-HPETE production by rat 5-LO; value ranges from 16-36 nM,1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL619240,4173
,12166,H,8,,,,12251,,Tested for inhibition of 5-LO by measuring the reduction of leukotriene B4 (LTB4) in intact basophilic rat leukemia cells,1,,Autocuration,,,,,,,B,BAO_0000019,CHEMBL875417,4174
,12166,H,8,,,,211,,Tested for inhibition of 5-Lipoxygenase (ARBL) in calcium-stimulated rat basophilic leukemia cells(RBL-1),1,,Autocuration,,702.0,,,RBL-1,,B,BAO_0000219,CHEMBL619241,4175
,12166,H,8,,,,12251,,Inhibition of 5-lipoxygenase measured by the reduction of leukotriene B4 (LTB4) in intact basophilic rat leukemia cells,1,,Expert,,,,,,,F,BAO_0000019,CHEMBL619242,4176
,12166,H,8,,,,12495,,Tested for inhibitory activity against 5-lipoxygenase in microsome of RBL-1 cells,1,,Autocuration,,702.0,,,RBL-1,,B,BAO_0000219,CHEMBL883796,4177
,12166,H,8,,,,414,,Tested for its inhibitory activity against 5-lipoxygenase,1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL619243,4178
,12166,H,8,,,,414,,Tested for its inhibitory activity against 5-lipoxygenase; Not determined,1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL619244,4179
,12166,H,8,,,,10325,,"Iin vitro inhibition of 5-lipoxygenase activity in rat basophil leukemia type 1(RBL1) cell homogenates, (reduction of [14C]-5-HETE formation)",1,,Expert,,,,,,,B,BAO_0000019,CHEMBL619245,4180
,12166,H,8,,,,11966,,In vitro test for inhibition of 5-lipoxygenase in cell-free preparations from rat PMN leukocytes,1,,Expert,,,,,,,B,BAO_0000019,CHEMBL619246,4181
,12166,H,8,,,,165,,In vitro inhibition of 5-lipoxygenase activity in RBL-1 cells.,1,,Expert,,702.0,,,RBL-1,,B,BAO_0000219,CHEMBL619984,4182
,12166,H,8,,,,165,,The compound was evaluated in vitro for inhibition of 5-lipoxygenase activity in RBL-1 cells; No significant inhibitory activity up to 30 uM,1,,Autocuration,,702.0,,,RBL-1,,B,BAO_0000219,CHEMBL619985,4183
,12166,H,8,,,,165,,The compound was evaluated in vitro for inhibition of 5-lipoxygenase activity in RBL-1 cells.,1,,Autocuration,,702.0,,,RBL-1,,B,BAO_0000219,CHEMBL619986,4184
,12166,H,8,,,,165,,In vitro for inhibition of 5-lipoxygenase activity in RBL-1 cells.,1,,Expert,,702.0,,,RBL-1,,B,BAO_0000219,CHEMBL619987,4185
,12166,H,8,,,,11311,,The compound was tested for inhibitory activity against 5-lipoxygenase in mouse,1,,Autocuration,,,,,,,B,BAO_0000218,CHEMBL619988,4186
,12166,H,8,,,,11311,,The compound was tested for inhibitory activity against 5-lipoxygenase in rat RBL-1,1,,Autocuration,,702.0,,,RBL-1,,B,BAO_0000219,CHEMBL619989,4187
,12166,H,8,,,,11311,,The compound was tested for inhibitory activity against 5-lipoxygenase in rat RBL-1 cells,1,,Autocuration,,702.0,,,RBL-1,,B,BAO_0000219,CHEMBL619990,4188
,12166,H,8,,,,11311,,The compound was tested for inhibitory activity against 5-lipoxygenase in rat polymorphonuclear leukocytes[PMNS],1,,Autocuration,,,,,,,B,BAO_0000219,CHEMBL619991,4189
,12166,H,8,,,,11311,,The compound was tested for inhibitory activity against 5-lipoxygenase in rat polymorphonuclear leukocytes[PMNS] (in vitro),1,,Autocuration,,,,,,,B,BAO_0000219,CHEMBL619992,4190
,12166,H,8,In vivo,,,11311,,The compound was tested for inhibitory activity against 5-lipoxygenase in rat polymorphonuclear leukocytes[PMNS] (in vivo),1,,Autocuration,,,,,,,B,BAO_0000218,CHEMBL619993,4191
,12166,H,8,,,,11311,,The compound was tested for inhibitory activity against 5-lipoxygenase translocation inhibitor in RBL-2H3 cells,1,,Autocuration,,663.0,,,RBL-2H3,,F,BAO_0000219,CHEMBL619994,4192
,12166,H,8,,,,11311,,The compound was tested for inhibitory activity against 5-lipoxygenase translocation inhibitor in rat RBL-2H3 cells,1,,Autocuration,,663.0,,,RBL-2H3,,F,BAO_0000219,CHEMBL619995,4193
,12166,H,8,,,,11311,,The compound was tested for inhibitory activity against 5-lipoxygenase using rat polymorphonuclear leukocytes[PMNS],1,,Autocuration,,,,,,,B,BAO_0000019,CHEMBL619996,4194
,12166,H,8,,,,11732,,The compound was tested for its inhibitory activity against arachidonic acid in rat 5-lipoxygenase,1,,Autocuration,,,,,,,B,BAO_0000019,CHEMBL619997,4195
,12166,H,8,,,,11732,,Tested for its inhibitory activity against arachidonic acid in rat 5-lipoxygenase.,1,,Expert,,,,,,,B,BAO_0000019,CHEMBL619998,4196
,12166,H,8,,,,11087,,In vitro inhibition of 5-lipoxygenase (5-lo) from the 20000 g supernatant of RBI-1 cells,1,,Expert,,,,,,,B,BAO_0000019,CHEMBL619999,4197
,12166,H,8,,,,11087,,The compound was tested for the in vitro inhibition of 5-lipoxygenase from the 20000 g supernatant of RBI-1 cells,1,,Autocuration,,,,,,,B,BAO_0000019,CHEMBL620000,4198
,12166,H,8,,,,11087,,The compound was tested for the inhibition of 5-lipoxygenase (5-lo) in homogenized rat basophilic leukemia (RBL-1) cells,1,,Autocuration,,702.0,,,RBL-1,,B,BAO_0000219,CHEMBL620001,4199
,12166,D,9,,,,11087,,Inhibition of 5-lipoxygenase (5-lo) in intact rat polymorphonuclear leukocyte RPMNL,1,Rattus norvegicus,Expert,,,,10116.0,,,B,BAO_0000357,CHEMBL620002,4200
,12166,H,8,,,,496,,The compound was tested for the inhibition of 5-lipoxygenase in intact basophilic rat leukemia cells,1,,Autocuration,,702.0,,,RBL-1,,B,BAO_0000219,CHEMBL620003,4201
,12166,H,8,,,,13986,,Inhibition of 5-lipoxygenase on rat basophil leukemia cell line lysate (RBL-1 2H3 subline) by measuring 5-HETE production,1,,Expert,,702.0,,,RBL-1,,F,BAO_0000219,CHEMBL620004,4202
,12166,H,8,,,,11520,,Compound was evaluated for the inhibition of 5-lipoxygenase,1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL874063,4203
,12166,H,8,,,,10293,,Ability to inhibit 5-lipoxygenase by using a crude preparation of the cytosolic enzyme from the rat basophilic leukemia (RBL-1) cell line at a concentration of 25 uM,1,,Autocuration,,702.0,,,RBL-1,,B,BAO_0000219,CHEMBL620005,4204
,12166,H,8,,,,303,,Compound was evaluated for its inhibitory activity against 5-LO (5-lipoxygenase) at 10 uM concentration in intact RBL-1 cell line assay,1,,Autocuration,,702.0,,,RBL-1,,B,BAO_0000219,CHEMBL620006,4205
,12166,H,8,,,,303,,Compound was evaluated for its inhibitory activity against 5-LO (5-lipoxygenase) at 10 uM concentration in intact RBL-1 cell line assay; Less than 5% inhibition at 10 uM reported as not active,1,,Autocuration,,702.0,,,RBL-1,,B,BAO_0000219,CHEMBL620007,4206
,12166,H,8,,,,9247,,Compound was evaluated for the inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 10 uM,1,,Autocuration,,702.0,,,RBL-1,,B,BAO_0000219,CHEMBL620008,4207
,12166,D,9,,,,9247,,Inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 100 uM,1,Rattus norvegicus,Expert,,702.0,,10116.0,RBL-1,,B,BAO_0000219,CHEMBL620009,4208
,12166,H,8,,,,9247,,Compound was evaluated for the inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 100 uM; NS = no significant activity,1,,Autocuration,,702.0,,,RBL-1,,B,BAO_0000219,CHEMBL620010,4209
,12166,H,8,,,,9247,,Compound was evaluated for the inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 30 uM,1,,Autocuration,,702.0,,,RBL-1,,B,BAO_0000219,CHEMBL620011,4210
,12166,H,8,,,,9247,,Compound was evaluated for the inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 300 uM,1,,Autocuration,,702.0,,,RBL-1,,B,BAO_0000219,CHEMBL620677,4211
,12166,H,8,,,,9247,,Compound was evaluated for the inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 33 uM,1,,Autocuration,,702.0,,,RBL-1,,B,BAO_0000219,CHEMBL620678,4212
,12166,H,8,,,,9247,,Compound was evaluated for the inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 40 uM,1,,Autocuration,,702.0,,,RBL-1,,B,BAO_0000219,CHEMBL620679,4213
,12166,H,8,,,,9247,,Compound was evaluated for the inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 75 uM,1,,Autocuration,,702.0,,,RBL-1,,B,BAO_0000219,CHEMBL620680,4214
,12166,D,9,,,,11481,,Inhibitory activity against 5-lipoxygenase at 10 uM,1,Rattus norvegicus,Expert,,,,10116.0,,,B,BAO_0000357,CHEMBL620838,4215
,12166,H,8,,,,105,,In vitro inhibition of 5-lipoxygenase; NS means no significant inhibition,1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL620839,4216
,12166,H,8,,,,9029,,In vitro inhibition of rat polymorphonuclear leukocyte (PMN) 5-Lipoxygenase at 10 uM,1,,Expert,,,,,,,B,BAO_0000357,CHEMBL620840,4217
,12166,H,8,,,,1175,,Inhibitory activity against 5-lipoxygenase enzyme from RBL-1 cells at 20 uM,1,,Expert,,702.0,,,RBL-1,,B,BAO_0000219,CHEMBL620841,4218
,12166,H,8,,,,12118,,In vitro inhibition against 5-lipoxygenase in RBL-1 cells was determined at 100 uM,1,,Autocuration,,702.0,,,RBL-1,,B,BAO_0000219,CHEMBL620842,4219
,12166,H,8,,,,12118,,In vitro inhibition against 5-lipoxygenase in RBL-1 cells was determined at 10e-4 M,1,,Autocuration,,702.0,,,RBL-1,,B,BAO_0000219,CHEMBL620843,4220
,12166,H,8,,,,12118,,In vitro inhibition against 5-lipoxygenase in RBL-1 cells was determinedb at 100 uM,1,,Autocuration,,702.0,,,RBL-1,,B,BAO_0000219,CHEMBL620844,4221
,12166,H,8,,,,9225,,In vitro inhibition of RBL-1 5-lipoxygenase at 20 uM,1,,Autocuration,,702.0,,,RBL-1,,B,BAO_0000219,CHEMBL620845,4222
,12166,H,8,,,,9401,,In vitro inhibitory activity against 5-Lipoxygenase from rat basophilic leukemia cells at 30 uM concentration,1,,Autocuration,,,,,,,B,BAO_0000019,CHEMBL620846,4223
,12166,H,8,,,,137,,In vitro inhibitory activity against 5-lipoxygenase was determined at 16 uM,1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL873951,4224
,12166,H,8,,,,137,,In vitro inhibitory activity against 5-lipoxygenase was determined at 16 uM,1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL620847,4225
,12166,H,8,,,,4717,,In vitro percent inhibition against 5-lipoxygenase in RBL-1 cells at 10 uM concentration,1,,Autocuration,,702.0,,,RBL-1,,B,BAO_0000219,CHEMBL620848,4226
,12166,H,8,,,,3595,,Inhibitory activity against 5-lipoxygenase (5-LO) using broken rat barophilic leukemia cells (RBL-1) at 10 uM,1,,Autocuration,,702.0,,,RBL-1,,B,BAO_0000219,CHEMBL620849,4227
,12166,H,8,,,,10501,,Inhibitory activity against 5-lipoxygenase in RBL-1 cells at 40 uM concentration,1,,Autocuration,,702.0,,,RBL-1,,B,BAO_0000219,CHEMBL620850,4228
,12166,H,8,,,,10501,,Inhibitory activity against 5-lipoxygenase in RBL-1 cells at a concentration 40 uM,1,,Autocuration,,702.0,,,RBL-1,,B,BAO_0000219,CHEMBL620851,4229
,12166,H,8,,,,10501,,Inhibitory activity against 5-lipoxygenase in RBL-1 cells at a concentration 40 uM.,1,,Autocuration,,702.0,,,RBL-1,,B,BAO_0000219,CHEMBL620852,4230
,12166,H,8,,,,12526,,Inhibitory activity against 5-lipoxygenase in intact rat basophilic leukemia cells stimulated with the calcium ionophore A-23187,1,,Autocuration,,702.0,,,RBL-1,,B,BAO_0000219,CHEMBL875098,4231
,12166,D,9,,,,14799,,Inhibition of 5-lipoxygenase of rat basophilic leukemia cells at 30 uM,1,Rattus norvegicus,Expert,,702.0,,10116.0,RBL-1,,B,BAO_0000219,CHEMBL620853,4232
,12166,H,8,,,,14799,,Inhibitory activity against 5-lipoxygenase obtained from rat basophilic leukemia cells at 30 uM concentration; NT=Not tested,1,,Autocuration,,,,,,,B,BAO_0000019,CHEMBL620854,4233
,12166,H,8,,,,3595,,Inhibitory activity against 5-lipoxygenase (5-LO) using broken rat barophilic leukemia cells (RBL-1) at 10 uM,1,,Autocuration,,702.0,,,RBL-1,,B,BAO_0000219,CHEMBL620855,4234
,12166,H,8,,,,3595,,Inhibitory activity against 5-lipoxygenase (5-LO) using broken rat barophilic leukemia cells (RBL-1)at 10 uM,1,,Expert,,702.0,,,RBL-1,,B,BAO_0000219,CHEMBL839884,4235
,12166,H,8,,,,12526,,Inhibitory activity at 10 uM against 5-lipoxygenase in intact rat basophilic leukemia cells stimulated with the calcium ionophore A-23187,1,,Autocuration,,702.0,,,RBL-1,,B,BAO_0000219,CHEMBL620856,4236
,12166,H,8,,,,12526,,Inhibitory activity at 1 uM against 5-lipoxygenase in intact rat basophilic leukemia cells stimulated with the calcium ionophore A-23187,1,,Autocuration,,702.0,,,RBL-1,,B,BAO_0000219,CHEMBL620857,4237
,12166,H,8,,,,10193,,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in rat cell at 1 uM,1,,Autocuration,,,,,,,B,BAO_0000019,CHEMBL620858,4238
,12166,H,8,,,,10193,,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in rat cell at 10 uM,1,,Autocuration,,,,,,,B,BAO_0000019,CHEMBL620859,4239
,12166,H,8,,,,10193,,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in rat cell at 1 uM,1,,Autocuration,,,,,,,B,BAO_0000019,CHEMBL620860,4240
,12166,H,8,,,,10193,,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in rat cell at 3 uM,1,,Autocuration,,,,,,,B,BAO_0000019,CHEMBL620861,4241
,12166,H,8,,,,9138,,Percent inhibition of rat neutrophil 5-lipoxygenase (5-LO),1,,Expert,,,,,,,B,BAO_0000357,CHEMBL620862,4242
,12166,H,8,,,,9138,,Percent inhibition of rat neutrophil 5- Lipoxygenase (5-LO) at 100 uM,1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL620863,4243
,12166,H,8,,,,11966,,Tested in vitro for the inhibition of 5-lipoxygenase in cell-free preparations from rat PMN leukocytes,1,,Autocuration,,,,,,,B,BAO_0000019,CHEMBL620864,4244
,12166,H,8,,,,165,,The compound was evaluated in vitro for inhibition of 5-lipoxygenase activity in RBL-1 cells at 100 uM,1,,Autocuration,,702.0,,,RBL-1,,B,BAO_0000219,CHEMBL620865,4245
,12166,H,8,,,,165,,The compound was evaluated in vitro for inhibition of 5-lipoxygenase activity in RBL-1 cells at 30 uM,1,,Autocuration,,702.0,,,RBL-1,,B,BAO_0000219,CHEMBL620866,4246
,12166,H,8,,,,11311,,The compound was tested for inhibition of 5-lipoxygenase in rat RBL-2H3 cells,1,,Autocuration,,663.0,,,RBL-2H3,,B,BAO_0000219,CHEMBL620867,4247
,12166,H,8,,,,11311,,The compound was tested for inhibition of 5-lipoxygenase translocation in SAR in rat RBL-2H3 cells,1,,Autocuration,,663.0,,,RBL-2H3,,B,BAO_0000219,CHEMBL620868,4248
,12166,H,8,,,,11311,,The compound was tested for inhibition of 5-lipoxygenase translocation in SAR in rat RBL-2H3 cells,1,,Autocuration,,663.0,,,RBL-2H3,,F,BAO_0000219,CHEMBL620869,4249
,12166,H,8,,,,11311,,The compound was tested for inhibition of LTB4 synthesis on isolated 5-lipoxygenase,1,,Autocuration,,,,,,,F,BAO_0000019,CHEMBL873952,4250
,12166,H,8,,,,11311,,The compound was tested for inhibition of isolated 5-lipoxygenase,1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL875099,4251
,12166,H,8,,,,11311,,The compound was tested for inhibition of isolated 5-lipoxygenase translocation into rat RBL-2H3 cells,1,,Autocuration,,663.0,,,RBL-2H3,,F,BAO_0000219,CHEMBL620870,4252
,12166,H,8,,,,11087,,The compound was tested for the in vitro inhibition of 5-lipoxygenase (5-lo) from the 20000 g supernatant of RBI-1 cells at a concentration of 30 uM,1,,Autocuration,,,,,,,B,BAO_0000019,CHEMBL618261,4253
,12166,H,8,,,,11087,,The compound was tested for the in vitro inhibition of 5-lipoxygenase (5-lo) from the 20000 g supernatant of RBI-1 cells at a concentration of 32 uM,1,,Autocuration,,,,,,,B,BAO_0000019,CHEMBL618262,4254
,12166,H,8,,,,11087,,The compound was tested for the in vitro inhibition of 5-lipoxygenase (5-lo) from the 20000 g supernatant of RBI-1 cells measured at a concentration of 30 uM,1,,Autocuration,,,,,,,B,BAO_0000019,CHEMBL619428,4255
,12166,H,8,,,,11087,,The compound was tested for the in vitro inhibition of 5-lipoxygenase (5-lo) from the 20000 g supernatant of RBI-1 cells; NS indicates nonsignificant inhibition at 32 uM concentration,1,,Autocuration,,,,,,,B,BAO_0000019,CHEMBL619429,4256
,12166,H,8,,,,11087,,The compound was tested for the in vitro inhibition of 5-lipoxygenase from the 20000 g supernatant of RBI-1 cells; NS indicates nonsignificant inhibition at 32 uM concentration,1,,Autocuration,,,,,,,B,BAO_0000019,CHEMBL619430,4257
,12166,H,8,,,,496,,The compound was tested for the inhibition of 5-lipoxygenase in intact basophilic rat leukemia cells at 1.0 uM,1,,Autocuration,,702.0,,,RBL-1,,B,BAO_0000219,CHEMBL620017,4258
,12166,H,8,,,,496,,The compound was tested for the inhibition of 5-lipoxygenase in intact basophilic rat leukemia cells at 10 uM,1,,Autocuration,,702.0,,,RBL-1,,B,BAO_0000219,CHEMBL620018,4259
,12166,H,8,,,,13986,,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by 5-HETE production at 0.1 uM,1,,Autocuration,,702.0,,,RBL-1,,F,BAO_0000219,CHEMBL620019,4260
,12166,H,8,,,,13986,,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by 5-HETE production at 0.195 uM,1,,Autocuration,,702.0,,,RBL-1,,F,BAO_0000219,CHEMBL620020,4261
,12166,H,8,,,,13986,,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by 5-HETE production at 0.2 at uM,1,,Autocuration,,702.0,,,RBL-1,,F,BAO_0000219,CHEMBL620021,4262
,12166,H,8,,,,13986,,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by 5-HETE production at 0.25 uM,1,,Autocuration,,702.0,,,RBL-1,,F,BAO_0000219,CHEMBL620022,4263
,12166,H,8,,,,13986,,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by 5-HETE production at 0.39,1,,Autocuration,,702.0,,,RBL-1,,F,BAO_0000219,CHEMBL620023,4264
,12166,H,8,,,,13986,,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by 5-HETE production at 0.39 uM,1,,Autocuration,,702.0,,,RBL-1,,F,BAO_0000219,CHEMBL620024,4265
,12166,H,8,,,,13986,,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by measuring 5-HETE production at 0.195 uM,1,,Autocuration,,702.0,,,RBL-1,,F,BAO_0000219,CHEMBL620025,4266
,12166,H,8,,,,13986,,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by measuring 5-HETE production at 0.2 uM,1,,Autocuration,,702.0,,,RBL-1,,F,BAO_0000219,CHEMBL620026,4267
,12166,H,8,,,,13986,,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by measuring 5-HETE production at 0.39 uM,1,,Autocuration,,702.0,,,RBL-1,,F,BAO_0000219,CHEMBL620027,4268
,12166,D,9,,,,13986,,Inhibition of 5-lipoxygenase on rat basophil leukemia cell (RBL-2H3) lysate as 5-HETE production at 32 uM,1,Rattus norvegicus,Expert,,,,10116.0,,,F,BAO_0000019,CHEMBL620028,4269
,12166,H,8,,,,10193,,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase,1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL620029,4270
,12166,H,8,,,,9295,,Compound was tested for the percent of inhibition against 5-LO at 10 uM,1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL620030,4271
,12166,H,8,,,,4717,,In vitro percent inhibition against 5-lipoxygenase in RBL-1 cells at 1 uM concentration,1,,Autocuration,,702.0,,,RBL-1,,B,BAO_0000219,CHEMBL875415,4272
,12166,H,8,,,,4717,,In vitro percent inhibition against 5-lipoxygenase in RBL-1 cells at 10 uM concentration,1,,Autocuration,,702.0,,,RBL-1,,B,BAO_0000219,CHEMBL618256,4273
,12166,H,8,,,,11854,,Inhibition of LTB4 in whole cell 5-lipoxygenase assay in an intact rat basophilic leukemia (RBL-1) cell line,1,,Autocuration,,702.0,,,RBL-1,,B,BAO_0000219,CHEMBL618257,4274
,12166,H,8,,,,11854,,Inhibition of LTB4 in whole cell 5-lipoxygenase assay in an intact rat basophilic leukemia (RBL-1) cell line at 10 uM,1,,Autocuration,,702.0,,,RBL-1,,B,BAO_0000219,CHEMBL618258,4275
,12166,H,8,,,,11854,,Inhibition of LTB4 in whole cell 5-lipoxygenase assay in an intact rat basophilic leukemia (RBL-1) cell line at 16 uM,1,,Autocuration,,702.0,,,RBL-1,,B,BAO_0000219,CHEMBL618259,4276
,12166,H,8,,,,10193,,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in rat cell at 10 uM,1,,Autocuration,,,,,,,B,BAO_0000019,CHEMBL618260,4277
,12166,H,8,,,,9295,,Percent inhibition against RBL-1 5-LO in vitro at 10 uM,1,,Autocuration,,702.0,,,RBL-1,,B,BAO_0000219,CHEMBL618215,4278
,12166,H,8,,,,9295,,Percent inhibition against RBL-1 5-LO in vitro at 100 uM,1,,Autocuration,,702.0,,,RBL-1,,B,BAO_0000219,CHEMBL618390,4279
,12166,H,8,,,,9295,,Percent inhibition against RBL-1 5-LO in vitro at 30 uM,1,,Autocuration,,702.0,,,RBL-1,,B,BAO_0000219,CHEMBL618391,4280
,12166,H,8,,,,9295,,Percent inhibition against RBL-1 5-LO in vitro at 300 uM,1,,Autocuration,,702.0,,,RBL-1,,B,BAO_0000219,CHEMBL618392,4281
,12166,H,8,,,,165,,The compound was evaluated in vitro for inhibition of 5-lipoxygenase activity in RBL-1 cells at 20 uM,1,,Autocuration,,702.0,,,RBL-1,,B,BAO_0000219,CHEMBL618393,4282
,12166,H,8,,,,11311,,The compound was tested for inhibition against 5-lipoxygenase in rat polymorphonuclear leukocytes[PMNS] at 10 uM concentration,1,,Autocuration,,,,,,,B,BAO_0000219,CHEMBL618394,4283
,12166,H,8,,,,10489,,In vitro inhibitory activity against 5-lipoxygenase in rat basophilic leukemia cells(RBL-1),1,Homo sapiens,Expert,,702.0,,9606.0,RBL-1,,B,BAO_0000219,CHEMBL618395,4284
,12166,D,9,,,,10489,,In vitro inhibitory activity against 5-lipoxygenase in rat basophilic leukemia cells(RBL-1),1,Rattus norvegicus,Expert,,702.0,,10116.0,RBL-1,,B,BAO_0000219,CHEMBL618396,4285
,12166,D,9,,,,10489,,Logarithmic value of inhibitory concentration against 5-lipoxygenase in rat basophilic leukemia cells (RBL-1),1,Rattus norvegicus,Expert,,702.0,,10116.0,RBL-1,,B,BAO_0000219,CHEMBL858253,4286
,12166,D,9,,,,14799,,Inhibitory activity against 5-lipoxygenase obtained from rat basophilic leukemia cells,1,Rattus norvegicus,Autocuration,,,,10116.0,,,B,BAO_0000019,CHEMBL618397,4287
,12054,H,8,,,,9295,,Compound was tested for the percent of inhibition against soybean 15-LO (at 100 uM),1,Glycine max,Autocuration,,,,3847.0,,,B,BAO_0000357,CHEMBL618398,4288
,22226,U,0,,,,16811,,"Inhibitory activity against 5-lipoxygenase, by using soybean lipoxygenase spectrophotometric assay",1,,Autocuration,,,,,,,B,BAO_0000019,CHEMBL618399,4289
,55,H,8,,,,168,,In vitro inhibition of 5-Lipoxygenase; Inactive.,1,,Expert,,,,,,,B,BAO_0000357,CHEMBL618400,4290
,55,H,8,,,,6309,,Inhibitory concentration against 5-lipoxygenase was determined; No inhibition,1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL618401,4291
,55,H,8,,,,6309,,Inhibitory concentration against 5-lipoxygenase; No inhibition,1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL618402,4292
,55,H,8,,,,3092,,Evaluated for inhibitory activity against RBL-1 cell 5-lipoxygenase in guinea pig,1,,Autocuration,,702.0,,,RBL-1,,B,BAO_0000219,CHEMBL876400,4293
,55,H,8,,,,168,,Inhibitory activity against 5-lipoxygenase.,1,,Expert,,,,,,,B,BAO_0000357,CHEMBL618403,4294
,55,H,8,,,,168,,Inhibitory Activity against 5-Lipoxygenase was determined; IA=Inactive,1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL618404,4295
,55,H,8,,,,168,,Inhibitory Activity against 5-Lipoxygenase was determined; IA=Inactive at concentrations less than 32 uM,1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL618405,4296
,55,H,8,,,,168,,Inhibitory Activity against 5-Lipoxygenase was determined; NA=No significant inhibitory activity up to 300 uM,1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL618406,4297
,55,H,8,,,,12338,,Inhibitory concentration against arachidonic acid 5-lipoxygenation,1,,Expert,,,,,,,F,BAO_0000019,CHEMBL618407,4298
,55,H,8,,,,4501,,Tested for the inhibitory activity against 5-lipoxygenase,1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL618408,4299
,55,H,8,,,,1132,,Compound was tested for its inhibitory activity against 5-lipoxygenase,1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL618409,4300
,55,H,8,,,,2117,,Compound was tested for inhibition of 5-lipoxygenase at 50 uM; NI means no inhibition was observed,1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL618410,4301
,55,H,8,,,,168,,Inhibitory Activity against 5-Lipoxygenase at 30 uM was determined; Weakly active,1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL618411,4302
,55,H,8,,,,168,,Inhibitory Activity against 5-Lipoxygenase at concentration 32 uM was determined,1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL618412,4303
,12166,H,8,,,,13575,,Concentration required to inhibit RBL-1 supernatant 5-lipoxygenase,1,,Autocuration,,702.0,,,RBL-1,,B,BAO_0000219,CHEMBL618413,4304
,12166,H,8,,,,11089,,,1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL618414,4305
,10102,H,8,,,,216,,Compound was tested for its binding activity towards 5-lipoxygenase activating protein (FLAP),1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL618415,4306
,10102,H,8,,,,13165,,Inhibition of 5-lipoxygenase activating protein using human leukocyte membrane preparations,1,,Autocuration,,,,,,,B,BAO_0000019,CHEMBL618416,4307
,10102,H,8,,,,3278,,Measuring the affinity of leukotriene synthesis inhibitor for 5-Lipoxygenase activating protein (FLAP) by using [125I]L-691831 as radioligand.,1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL876401,4308
,10102,H,8,,,,3278,,Measuring the affinity of leukotriene synthesis inhibitor for 5-lipoxygenase activating protein by using [125I]L-691831 as radioligand.,1,,Expert,,,,,,,B,BAO_0000357,CHEMBL618417,4309
,10102,H,8,,,,11966,,Tested for inhibition of leukotriene biosynthesis by binding to 5-lipoxygenase activating protein,1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL618418,4310
,10102,H,8,,,,175,,"The compound was tested for the inhibition of binding of [125I]- L- 691,831 binding to 5-lipoxygenase activating protein",1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL618419,4311
,10102,H,8,,,,175,,"The compound was tested for the inhibition of binding of [125I]- L- 691,831 binding to 5-lipoxygenase activating protein (FLAP)",1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL618420,4312
,10102,H,8,,,,13449,,Binding affinity of compound for 5-lipoxygenase activating protein protein by FLAP binding assay,1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL618421,4313
,11238,H,8,,,,12014,,Tested for inhibition of 5-phosphatase isolated from human erythrocyte membrane,1,,Autocuration,,,,,,,B,BAO_0000019,CHEMBL618422,4314
,11238,H,8,,,,12014,,Tested for inhibition of 5-phosphatase isolated from human erythrocyte membrane (R metabolically resistant),1,,Autocuration,,,,,,,B,BAO_0000019,CHEMBL618423,4315
,11238,H,8,,,,12014,,Tested for inhibition of 5-phosphatase isolated from human erythrocyte membrane (S substrate),1,,Autocuration,,,,,,,B,BAO_0000019,CHEMBL618424,4316
,100284,S,2,,,,99,,Inhibition of protein biosynthesis at the level of the peptidyl transferase center of the 50 s ribosomal subunit,1,,Intermediate,,,,,,,B,BAO_0000220,CHEMBL618425,4317
,22226,U,0,,,,4349,,The dark toxicity against 543 human galactophore carcinoma cells,1,Homo sapiens,Autocuration,,,,9606.0,,,F,BAO_0000019,CHEMBL618426,4318
,80623,N,1,,,,4071,,Tested in vitro for cytotoxicity against 56 human tumor cell lines,1,Homo sapiens,Expert,,390.0,,9606.0,Panel (56 tumour cell lines),,F,BAO_0000219,CHEMBL618427,4319
,80008,N,1,,,,17589,,Cytotoxic activity against human 5637 cell line at 20 uM expressed as percent growth value,1,Homo sapiens,Expert,,345.0,,9606.0,5637,,F,BAO_0000219,CHEMBL618428,4320
,80008,N,1,,,,15002,,Antitumor activity was evaluated against human bladder carcinoma cell line 5637.,1,Homo sapiens,Intermediate,,345.0,,9606.0,5637,,F,BAO_0000219,CHEMBL618429,4321
,80008,N,1,,,,13958,,"Compound was tested for antiproliferative activity against 5637, human bladder carcinoma cell line",1,Homo sapiens,Intermediate,,345.0,,9606.0,5637,,F,BAO_0000219,CHEMBL618430,4322
,80008,N,1,,,,17589,,Growth inhibition against human 5637 cell lines,1,Homo sapiens,Expert,,345.0,,9606.0,5637,,F,BAO_0000219,CHEMBL618431,4323
,80008,N,1,,,,16748,,Antitumor activity against human bladder carcinoma 5637 cells.,1,Homo sapiens,Expert,,345.0,,9606.0,5637,,F,BAO_0000219,CHEMBL883799,4324
,80008,N,1,,,,16747,,Antitumor activity against human bladder carcinoma 5637 cells,1,Homo sapiens,Intermediate,,345.0,,9606.0,5637,,F,BAO_0000219,CHEMBL618432,4325
,80008,N,1,,,,16747,,Antitumor activity against human bladder carcinoma 5637 cells,1,Homo sapiens,Intermediate,,345.0,,9606.0,5637,,F,BAO_0000219,CHEMBL618433,4326
,10443,D,9,,,,15285,,In vitro inhibition of bovine trypsin(Trp).,1,Bos taurus,Expert,,,,9913.0,,,B,BAO_0000357,CHEMBL618434,4327
,240,H,8,,,,3726,,Transcriptional activation in CV-1 cells expressing retinoic acid gamma receptor,1,Cercopithecidae,Expert,,407.0,,9527.0,CV-1,,B,BAO_0000219,CHEMBL618435,4328
,10577,H,8,,,,5033,,Ability to displace the radioligand [125I](-)-iodocyanopindolol from rat striatal 5-HT1B receptor,1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL876402,4329
,104698,H,6,,,,11756,,In vitro antagonism of the 5-HT-3 receptor determined by inhibition of 5-HT-induced depolarization of the isolated rat vagus nerve.,1,,Autocuration,,,,,,,F,BAO_0000019,CHEMBL618436,4330
,22226,U,0,In vivo,,,11953,,Concentration required to inhibit pressor response to serotonin after 15 min i.v. administration of compound mediated via activation of vascular 5-HT2 receptors in rat,1,,Autocuration,,,,,,,F,BAO_0000218,CHEMBL618437,4331
,20033,D,9,,,,5033,,Ability to displace the radioligand [3H]GR-113808 from guinea pig striatum 5-HT4 receptor,1,Cavia porcellus,Intermediate,,,,10141.0,,,B,BAO_0000357,CHEMBL618438,4332
,17045,H,8,,,Microsomes,11347,,Inhibition of progesterone 6-beta-hydroxylase in rat hepatic microsomes,1,Rattus norvegicus,Expert,,,,10116.0,,,A,BAO_0000251,CHEMBL883800,4333
,17045,H,8,,,Microsomes,11347,,Inhibition of progesterone 6-beta-hydroxylase in rat hepatic microsomes,1,Rattus norvegicus,Expert,,,,10116.0,,,A,BAO_0000251,CHEMBL618439,4334
,22226,U,0,,,,1229,,In vitro anticancer activity against 6 NCI ovarian cancer cell lines; inactive,1,,Intermediate,,,,,,,F,BAO_0000019,CHEMBL618440,4335
,22226,U,0,,,,1229,,In vitro anticancer activity against 6 NCI ovarian cancer cell lines; inactive,1,,Intermediate,,,,,,,F,BAO_0000019,CHEMBL618441,4336
,11938,H,8,,,,17588,,Inhibition constant against 6-phosphogluconate dehydrogenase of Trypanosoma brucei expressed in Escherichia coli,1,Trypanosoma brucei,Expert,,,,5691.0,,,B,BAO_0000019,CHEMBL618442,4337
,11938,H,8,,,,17588,,Inhibition constant against 6-phosphogluconate dehydrogenase of Trypanosoma brucei expressed in Escherichia coli; NI denotes no inhibition,1,Trypanosoma brucei,Autocuration,,,,5691.0,,,B,BAO_0000019,CHEMBL618443,4338
,11938,H,8,,,,17588,,Inhibition constant against 6-phosphogluconate dehydrogenase of sheep liver,1,Ovis aries,Expert,,,,9940.0,,,B,BAO_0000019,CHEMBL619158,4339
,11938,H,8,,,,17588,,Inhibition constant against 6-phosphogluconate dehydrogenase of sheep liver; NI denotes no inhibition,1,Ovis aries,Autocuration,,,,9940.0,,,B,BAO_0000019,CHEMBL620974,4340
,11938,H,8,,,,16485,,log Kd which is the binding affinity against 6-phosphogluconate dehydrogenase,1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL620975,4341
,22226,U,0,,,,4337,,Average inhibitory concentration against 60 human cell lines was reported,1,Homo sapiens,Intermediate,,,,9606.0,,,F,BAO_0000019,CHEMBL620976,4342
,22226,U,0,,,,4112,,Inhibition of proliferation in NCI panel of 60 human tumor cell lines,1,Homo sapiens,Expert,,,,9606.0,,,F,BAO_0000019,CHEMBL620977,4343
,80315,N,1,,,,16160,,Cancer specificity was measured from the +/- value under average log LC50 60-cell line,1,Homo sapiens,Intermediate,,542.0,,9606.0,Panel NCI-60 (60 carcinoma cell lines),,F,BAO_0000219,CHEMBL620978,4344
,80315,N,1,,,,16160,,Cancer specificity was measured from the +/- value under average log LC50 60-cell line. ,1,Homo sapiens,Intermediate,,542.0,,9606.0,Panel NCI-60 (60 carcinoma cell lines),,F,BAO_0000219,CHEMBL620979,4345
,80315,N,1,,,,17376,,In vitro mean growth inhibitory activity against 60-cell panel,1,,Expert,,542.0,,,Panel NCI-60 (60 carcinoma cell lines),,F,BAO_0000219,CHEMBL620980,4346
,80315,N,1,,,,17376,,In vitro mean growth lethal concentration against 60-cell panel,1,,Expert,,542.0,,,Panel NCI-60 (60 carcinoma cell lines),,F,BAO_0000219,CHEMBL620981,4347
,80315,N,1,,,,17376,,In vitro mean growth lethal concentration in colon subpanel against 60-cell panel,1,,Expert,,542.0,,,Panel NCI-60 (60 carcinoma cell lines),,F,BAO_0000219,CHEMBL620982,4348
,80315,N,1,,,,17376,,In vitro mean growth lethal concentration in renal subpanel against 60-cell panel,1,,Expert,,542.0,,,Panel NCI-60 (60 carcinoma cell lines),,F,BAO_0000219,CHEMBL620983,4349
,104775,H,4,,,,3241,,Inhibition of CK-II-mediated 60S acidic ribosomal P protein activity at 10 uM,1,,Autocuration,,,,,,,F,BAO_0000019,CHEMBL620984,4350
,104775,H,4,,,,3241,,Inhibition of CK-II-mediated 60S acidic ribosomal P protein activity at 10 uM,1,,Autocuration,,,,,,,F,BAO_0000019,CHEMBL620985,4351
,275,H,8,,,,3725,,Transcriptional activation in CV-1 expressing retinoid X receptor RXR alpha,1,,Expert,,,,,,,B,BAO_0000357,CHEMBL620986,4352
,50425,N,1,,,,10805,,Inhibitory activity against Plasmodium falciparum 68 neutral proteinase,1,Plasmodium falciparum,Expert,,,,5833.0,,,F,BAO_0000218,CHEMBL620987,4353
,50425,N,1,,,,10805,,In vitro inhibition of Plasmodium falciparum 68 neutral proteinase activity by reinvasion of red blood cells,1,Plasmodium falciparum,Expert,,,,5833.0,,,F,BAO_0000218,CHEMBL620988,4354
,50425,N,1,,,,10805,,Inhibitory activity against Plasmodium falciparum 68 neutral proteinase.,1,Plasmodium falciparum,Expert,,,,5833.0,,,F,BAO_0000218,CHEMBL620989,4355
,50425,N,1,,,,10805,,Substrate affinity for Plasmodium falciparum 68 neutral proteinase.,1,Plasmodium falciparum,Expert,,,,5833.0,,,F,BAO_0000218,CHEMBL620990,4356
,50425,N,1,,,,10805,,Reaction velocity for Plasmodium falciparum 68 neutral proteinase.,1,Plasmodium falciparum,Intermediate,,,,5833.0,,,F,BAO_0000218,CHEMBL620991,4357
,80628,N,1,,,,10144,,Percent inhibition against 6C3HED lymphosarcoma at dose 100 mg/kg in C3H mice,1,Mus musculus,Intermediate,,850.0,,10090.0,6C3HED,,F,BAO_0000218,CHEMBL620992,4358
,80628,N,1,,,,10144,,Percent inhibition against 6C3HED lymphosarcoma at dose 12.5 mg/kg in C3H mice,1,Mus musculus,Intermediate,,850.0,,10090.0,6C3HED,,F,BAO_0000218,CHEMBL620993,4359
,80628,N,1,,,,10144,,Percent inhibition against 6C3HED lymphosarcoma at dose 200 mg/kg in C3H mice,1,Mus musculus,Intermediate,,850.0,,10090.0,6C3HED,,F,BAO_0000218,CHEMBL620994,4360
,80628,N,1,,,,10144,,Percent inhibition against 6C3HED lymphosarcoma at dose 25 mg/kg in C3H mice,1,Mus musculus,Intermediate,,850.0,,10090.0,6C3HED,,F,BAO_0000218,CHEMBL620995,4361
,80628,N,1,,,,10144,,Percent inhibition against 6C3HED lymphosarcoma at dose 50 mg/kg in C3H mice,1,Mus musculus,Intermediate,,850.0,,10090.0,6C3HED,,F,BAO_0000218,CHEMBL620996,4362
,80628,N,1,,,,10144,,Percent inhibition against 6C3HED lymphosarcoma at dose 6 mg/kg in C3H mice,1,Mus musculus,Intermediate,,850.0,,10090.0,6C3HED,,F,BAO_0000218,CHEMBL875581,4363
,22224,U,0,In vivo,,,10685,,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 100 mg/kg,1,Mus musculus,Autocuration,,,,10090.0,,,F,BAO_0000218,CHEMBL620997,4364
,22224,U,0,In vivo,,,10685,,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 150 mg/kg,1,Mus musculus,Autocuration,,,,10090.0,,,F,BAO_0000218,CHEMBL620998,4365
,22224,U,0,In vivo,,,10685,,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 1600 mg/kg (intraperitoneal dosing for 8 days),1,Mus musculus,Autocuration,,,,10090.0,,,F,BAO_0000218,CHEMBL620999,4366
,22224,U,0,In vivo,,,10685,,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 200 mg/kg,1,Mus musculus,Autocuration,,,,10090.0,,,F,BAO_0000218,CHEMBL621000,4367
,22224,U,0,In vivo,,,10685,,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 225 mg/kg,1,Mus musculus,Autocuration,,,,10090.0,,,F,BAO_0000218,CHEMBL621001,4368
,22224,U,0,In vivo,,,10685,,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 270 mg/kg,1,Mus musculus,Autocuration,,,,10090.0,,,F,BAO_0000218,CHEMBL621002,4369
,22224,U,0,In vivo,,,10685,,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 275 mg/kg,1,Mus musculus,Autocuration,,,,10090.0,,,F,BAO_0000218,CHEMBL621003,4370
,22224,U,0,In vivo,,,10685,,"Antitumor activity in vivo against the 6C3HED lymphosarcoma, dosed for 10 days at 300 mg/kg",1,Mus musculus,Autocuration,,,,10090.0,,,F,BAO_0000218,CHEMBL621004,4371
,22224,U,0,In vivo,,,10685,,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 300 mg/kg (intraperitoneal dosing for 8 days),1,Mus musculus,Autocuration,,,,10090.0,,,F,BAO_0000218,CHEMBL621005,4372
,22224,U,0,In vivo,,,10685,,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 300 mg/kg (ip dosing daily for 8 days),1,Mus musculus,Autocuration,,,,10090.0,,,F,BAO_0000218,CHEMBL621006,4373
,22224,U,0,In vivo,,,10685,,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 600 mg/kg,1,Mus musculus,Autocuration,,,,10090.0,,,F,BAO_0000218,CHEMBL621007,4374
,22224,U,0,,,,10144,,Percent inhibition against 6C3HED lymphosarcoma at dose 100 mg/kg in C3H mice,1,Mus musculus,Autocuration,,,,10090.0,,,F,BAO_0000218,CHEMBL621008,4375
,22224,U,0,,,,10144,,Percent inhibition against 6C3HED lymphosarcoma at dose 12.5 mg/kg in C3H mice,1,Mus musculus,Autocuration,,,,10090.0,,,F,BAO_0000218,CHEMBL621009,4376
,22224,U,0,,,,10144,,Percent inhibition against 6C3HED lymphosarcoma at dose 25 mg/kg in C3H mice,1,Mus musculus,Autocuration,,,,10090.0,,,F,BAO_0000218,CHEMBL857705,4377
,22224,U,0,,,,10144,,Percent inhibition against 6C3HED lymphosarcoma at dose 50 mg/kg in C3H mice,1,Mus musculus,Autocuration,,,,10090.0,,,F,BAO_0000218,CHEMBL619828,4378
,22224,U,0,,,,10685,,Tested on 6C3HED lymphosarcoma and percent inhibition was determined at 100 mg/kg dosage administered for 8 days intraperitoneally,1,Mus musculus,Autocuration,,,,10090.0,,,F,BAO_0000218,CHEMBL619829,4379
,22224,U,0,,,,10685,,Tested on 6C3HED lymphosarcoma and percent inhibition was determined at 200 mg/kg dosage administered for 10 days intraperitoneally,1,Mus musculus,Autocuration,,,,10090.0,,,F,BAO_0000218,CHEMBL619830,4380
,22224,U,0,,,,10685,,Tested on 6C3HED lymphosarcoma and percent inhibition was determined at 200 mg/kg dosage administered for 8 days intraperitoneally,1,Mus musculus,Autocuration,,,,10090.0,,,F,BAO_0000218,CHEMBL619831,4381
,22224,U,0,,,,10685,,Tested on 6C3HED lymphosarcoma and percent inhibition was determined at 50 mg/kg dosage administered for 8 days intraperitoneally,1,Mus musculus,Autocuration,,,,10090.0,,,F,BAO_0000218,CHEMBL619832,4382
,22224,U,0,,,,10685,,Tested on 6 C3 HED lymphosarcoma and number of drug related deaths/total animals in treatment group was determined at 100 mg/kg dosage administered for 8 days intraperitoneally; 0/10,1,Mus musculus,Autocuration,,,,10090.0,,,A,BAO_0000218,CHEMBL619833,4383
,22224,U,0,,,,10685,,Tested on 6 C3 HED lymphosarcoma and number of drug related deaths/total animals in treatment group was determined at 200 mg/kg dosage administered for 8 days perorally; 1/10,1,Mus musculus,Autocuration,,,,10090.0,,,A,BAO_0000218,CHEMBL619834,4384
,22224,U,0,,,,10685,,Tested on 6 C3 HED lymphosarcoma and number of drug related deaths/total animals in treatment group was determined at 200 mg/kg dosage administered for 10 days intraperitoneally; 1/10,1,Mus musculus,Autocuration,,,,10090.0,,,A,BAO_0000218,CHEMBL619835,4385
,22224,U,0,,,,10685,,Tested on 6 C3 HED lymphosarcoma and number of drug related deaths/total animals in treatment group was determined at 50 mg/kg dosage administered for 8 days perorally; 3/10,1,Mus musculus,Autocuration,,,,10090.0,,,A,BAO_0000218,CHEMBL619836,4386
,80628,N,1,,,,8831,,"Compound was evaluated for the antitumor activity against 6C3HED lymphosarcoma for ip administration and daily x 8 schedule; Number of toxic deaths over total number of mice per group (T/C), 0/10 at dose of 35 mg/kg",1,Mus musculus,Intermediate,,850.0,,10090.0,6C3HED,,F,BAO_0000218,CHEMBL619837,4387
,22224,U,0,In vivo,,,11704,,In vivo antitumor activity against 6C3HED tumor type after intraperitoneal administration of 400 mg/kg,1,,Autocuration,,,,,,,F,BAO_0000218,CHEMBL619838,4388
,50594,N,1,,,,11704,,In vivo antitumor activity against 6C3HED tumor type was expressed as toxic deaths/total treated mice at 400 mg/kg dose; 2/10,1,Mus musculus,Intermediate,,,,10090.0,,,A,BAO_0000218,CHEMBL619839,4389
,80628,N,1,In vivo,,,10685,,Antitumor activity in vivo expressed as percent of inhibition in 6C3HED-lymphosarcoma tumor cell line,1,Mus musculus,Intermediate,,850.0,,10090.0,6C3HED,,F,BAO_0000218,CHEMBL619840,4390
,80628,N,1,In vivo,,,10685,,Antitumor activity in vivo expressed as percent of inhibition in 6C3HED-lymphosarcoma tumor cell line; 95-100% inhibition,1,Mus musculus,Intermediate,,850.0,,10090.0,6C3HED,,F,BAO_0000218,CHEMBL619841,4391
,80628,N,1,,,,11368,,Inhibition of tumor growth of 6C3HED lymphosarcoma tumor cell line in mice at a dose of 150 mg/kg given orally(daily x 8),1,Mus musculus,Expert,,850.0,,10090.0,6C3HED,,F,BAO_0000218,CHEMBL857704,4392
,80628,N,1,,,,11368,,Inhibition of tumor growth of 6C3HED lymphosarcoma tumor cell line in mice at a dose of 200 mg/kg given orally(daily x 8),1,Mus musculus,Intermediate,,850.0,,10090.0,6C3HED,,F,BAO_0000218,CHEMBL619842,4393
,80628,N,1,,,,11368,,Inhibition of tumor growth of 6C3HED lymphosarcoma tumor cell line in mice at a dose of 300 mg/kg given orally (daily x 8),1,Mus musculus,Expert,,850.0,,10090.0,6C3HED,,F,BAO_0000218,CHEMBL619843,4394
,22226,U,0,,,,17763,,"Inhibition of Staphylococcus aureus 7,8-dihydroneopterin aldolase",1,Staphylococcus aureus,Autocuration,,,,1280.0,,,B,BAO_0000019,CHEMBL619844,4395
Liver,22226,U,0,,,Microsomes,7411,,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes 3-methylcholanthrene at a concentration of 5 uM,1,Rattus norvegicus,Autocuration,,,,10116.0,,2107.0,B,BAO_0000251,CHEMBL857855,4396
Liver,22226,U,0,,,Microsomes,7411,,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at a concentration of 10 uM,1,Rattus norvegicus,Autocuration,,,,10116.0,,2107.0,B,BAO_0000251,CHEMBL619845,4397
Liver,22226,U,0,,,Microsomes,7411,,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at a concentration of 1 uM,1,Rattus norvegicus,Autocuration,,,,10116.0,,2107.0,B,BAO_0000251,CHEMBL619846,4398
Liver,22226,U,0,,,Microsomes,7411,,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at a concentration of 20 uM,1,Rattus norvegicus,Autocuration,,,,10116.0,,2107.0,B,BAO_0000251,CHEMBL619847,4399
Liver,22226,U,0,,,Microsomes,7411,,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at a concentration of 25 uM,1,Rattus norvegicus,Autocuration,,,,10116.0,,2107.0,B,BAO_0000251,CHEMBL619848,4400
Liver,22226,U,0,,,Microsomes,7411,,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at a concentration of 50 uM,1,Rattus norvegicus,Autocuration,,,,10116.0,,2107.0,B,BAO_0000251,CHEMBL620893,4401
Liver,22226,U,0,,,Microsomes,7411,,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at a concentration of 5 uM,1,Rattus norvegicus,Autocuration,,,,10116.0,,2107.0,B,BAO_0000251,CHEMBL620894,4402
Liver,22226,U,0,,,Microsomes,7411,,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 10 uM,1,Rattus norvegicus,Autocuration,,,,10116.0,,2107.0,B,BAO_0000251,CHEMBL620895,4403
Liver,22226,U,0,,,Microsomes,7411,,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 100 uM,1,Rattus norvegicus,Autocuration,,,,10116.0,,2107.0,B,BAO_0000251,CHEMBL620896,4404
Liver,22226,U,0,,,Microsomes,7411,,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 200 uM,1,Rattus norvegicus,Autocuration,,,,10116.0,,2107.0,B,BAO_0000251,CHEMBL620897,4405
Liver,22226,U,0,,,Microsomes,7411,,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 25 uM,1,Rattus norvegicus,Autocuration,,,,10116.0,,2107.0,B,BAO_0000251,CHEMBL620898,4406
Liver,22226,U,0,,,Microsomes,7411,,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 50 uM,1,Rattus norvegicus,Autocuration,,,,10116.0,,2107.0,B,BAO_0000251,CHEMBL620899,4407
Plasma,22224,U,0,In vivo,,,347,,The apparent total plasma clearance in monkey,1,Cercopithecidae,Autocuration,,,,9527.0,,1969.0,A,BAO_0000218,CHEMBL620900,4408
,22224,U,0,In vivo,,,3341,,Compound was evaluated for Hepatic clearance in monkey,1,Cercopithecidae,Autocuration,,,,9527.0,,,A,BAO_0000218,CHEMBL620901,4409
,22224,U,0,In vivo,,,17853,,Lower clearance in monkey (i.v.) at 0.5 mpk,1,Cercopithecidae,Autocuration,,,,9527.0,,,A,BAO_0000218,CHEMBL620902,4410
,22224,U,0,In vivo,,,4514,,Plasma clearance in rhesus monkey,1,Cercopithecidae,Autocuration,,,,9527.0,,,A,BAO_0000218,CHEMBL620903,4411
,22224,U,0,In vivo,,,6062,,Plasma clearance for the compound was measured in monkey after an iv dose of 1 mg/kg,1,Cercopithecidae,Autocuration,,,,9527.0,,,A,BAO_0000218,CHEMBL620904,4412
,22224,U,0,In vivo,,,6821,,Plasma clearance of compound was determined in monkey,1,Cercopithecidae,Autocuration,,,,9527.0,,,A,BAO_0000218,CHEMBL620905,4413
,22224,U,0,In vivo,,,6057,,Plasma clearance was calculated in rhesus monkey,1,Cercopithecidae,Autocuration,,,,9527.0,,,A,BAO_0000218,CHEMBL620906,4414
,22224,U,0,In vivo,,,5145,,Plasma clearance in rhesus monkey,1,Cercopithecidae,Autocuration,,,,9527.0,,,A,BAO_0000218,CHEMBL875420,4415
,22224,U,0,In vivo,,,6641,,Plasma clearance in monkey (dosed at 0.5 mpk iv and 2.0 mpk orally),1,Cercopithecidae,Autocuration,,,,9527.0,,,A,BAO_0000218,CHEMBL620907,4416
,22224,U,0,In vivo,,,5472,,Plasma clearance was evaluated in rhesus,1,Cercopithecidae,Autocuration,,,,9527.0,,,A,BAO_0000218,CHEMBL620908,4417
,22224,U,0,In vivo,,,4257,,Plasma clearance value was determined in monkey after a 3 mg/kg of iv dose,1,Cercopithecidae,Autocuration,,,,9527.0,,,A,BAO_0000218,CHEMBL620909,4418
,22224,U,0,In vivo,,,5546,,Plasma clearance was determined in rhesus monkey at a dose of 1 mg/kg by iv administration,1,Cercopithecidae,Autocuration,,,,9527.0,,,A,BAO_0000218,CHEMBL620910,4419
,22224,U,0,In vivo,,,5334,,Plasma clearance was reported after intravenous administration at a dose of 1 mg/kg in Rhesus monkey (male),1,Cercopithecidae,Autocuration,,,,9527.0,,,A,BAO_0000218,CHEMBL620911,4420
,22224,U,0,In vivo,,,5334,,Plasma clearance was reported after oral administration at a dose of 2 mg/kg in Rhesus monkey (male),1,Cercopithecidae,Autocuration,,,,9527.0,,,A,BAO_0000218,CHEMBL620912,4421
,22224,U,0,In vivo,,,17509,,Cmax 24 hr after 2 mg/kg oral administration in monkeys,1,Cercopithecidae,Autocuration,,,,9527.0,,,A,BAO_0000218,CHEMBL620913,4422
,22224,U,0,In vivo,,,6535,,Cmax in monkey after administration of 1 mg/kg iv,1,Cercopithecidae,Autocuration,,,,9527.0,,,A,BAO_0000218,CHEMBL620914,4423
,22224,U,0,In vivo,,,5668,,Cmax was determine after peroral administration at 10 mpk in Rhesus,1,Cercopithecidae,Autocuration,,,,9527.0,,,A,BAO_0000218,CHEMBL620915,4424
,22224,U,0,In vivo,,,5922,,Cmax in cynomolgus monkey by iv administration,1,Cercopithecidae,Autocuration,,,,9527.0,,,A,BAO_0000218,CHEMBL620916,4425
,22224,U,0,In vivo,,,5922,,Cmax in cynomolgus monkey by po administration,1,Cercopithecidae,Autocuration,,,,9527.0,,,A,BAO_0000218,CHEMBL620917,4426
,22224,U,0,In vivo,,,6078,,Cmax value evaluated in monkey,1,Cercopithecidae,Autocuration,,,,9527.0,,,A,BAO_0000218,CHEMBL620918,4427
,22224,U,0,In vivo,,,2661,,Compound was evaluated for maximum concentration after treatment with oral dose of 2 mgkg to female cynomolgus monkey,1,Cercopithecidae,Autocuration,,,,9527.0,,,A,BAO_0000218,CHEMBL620919,4428
Plasma,22224,U,0,In vivo,,,3249,,Maximal concentration (Cmax) in rhesus monkey plasma at a dose of 5 mg/kg,1,Cercopithecidae,Autocuration,,,,9527.0,,1969.0,A,BAO_0000218,CHEMBL620920,4429
Plasma,22224,U,0,In vivo,,,3249,,Maximal concentration (Cmax) in squirrel monkey plasma at a dose of 5 mg/kg,1,Cercopithecidae,Autocuration,,,,9527.0,,1969.0,A,BAO_0000218,CHEMBL620921,4430
Plasma,22224,U,0,In vivo,,,5553,,Maximal plasma concentration in squirrel monkeys,1,Cercopithecidae,Autocuration,,,,9527.0,,1969.0,A,BAO_0000218,CHEMBL620922,4431
,22224,U,0,In vivo,,,1916,,Maximum concentration was evaluated against Cynomolgus monkey at a dose of 15 mg/kg after po administration,1,Cercopithecidae,Autocuration,,,,9527.0,,,A,BAO_0000218,CHEMBL620923,4432
Plasma,22224,U,0,In vivo,,,6227,,Maximum plasma concentration (Cmax) in rhesus monkey(in vivo) at a dose of 5 mg/kg,1,Cercopithecidae,Autocuration,,,,9527.0,,1969.0,A,BAO_0000218,CHEMBL620924,4433
,22224,U,0,In vivo,,,4809,,Pharmacokinetic parameter Cmax was determined in monkey after (po) administration of a dose of 50 (uM/kg),1,Cercopithecidae,Autocuration,,,,9527.0,,,A,BAO_0000218,CHEMBL620925,4434
,22224,U,0,In vivo,,,5355,,The peak concentration (Cmax) value after intravenous administration in cynomolgus monkeys; NA means Not applicable,1,Cercopithecidae,Autocuration,,,,9527.0,,,A,BAO_0000218,CHEMBL620926,4435
,22224,U,0,In vivo,,,5355,,The peak concentration (Cmax) value after intravenous administration in cynomolgus monkeys; NA means not applicable,1,Cercopithecidae,Autocuration,,,,9527.0,,,A,BAO_0000218,CHEMBL620927,4436
,22224,U,0,In vivo,,,5355,,The peak concentration (Cmax) value after intravenous administration in cynomolgus monkeys;NA means not applicable,1,Cercopithecidae,Autocuration,,,,9527.0,,,A,BAO_0000218,CHEMBL620928,4437
,22224,U,0,In vivo,,,5355,,The peak concentration (Cmax) value after oral administration in cynomolgus monkeys,1,Cercopithecidae,Autocuration,,,,9527.0,,,A,BAO_0000218,CHEMBL620929,4438
Plasma,22224,U,0,In vivo,,,6221,,The peak plasma concentration after 5 hr administration (2.5 mg/kg) in monkey was determined,1,Cercopithecidae,Autocuration,,,,9527.0,,1969.0,A,BAO_0000218,CHEMBL620930,4439
,22224,U,0,,,,167,,Compound was evaluated for Plasma levels upon oral administration at 30 mg/kg in Monkey at maximum of 0.4 hours,1,Cercopithecidae,Autocuration,,,,9527.0,,,A,BAO_0000218,CHEMBL620931,4440
,22224,U,0,,,,167,,Compound was evaluated for Plasma levels upon oral administration at 30 mg/kg in Monkey at maximum of 1.0 hours,1,Cercopithecidae,Autocuration,,,,9527.0,,,A,BAO_0000218,CHEMBL620932,4441
,22224,U,0,In vivo,,,4257,,Absolute bioavailability was evaluated in monkey,1,monkey,Autocuration,,,,9443.0,,,A,BAO_0000218,CHEMBL620933,4442
,22224,U,0,In vivo,,,6221,,Bioavailability after oral administration (2.5 mg/kg) in monkey was determined,1,monkey,Autocuration,,,,9443.0,,,A,BAO_0000218,CHEMBL620934,4443
,22224,U,0,In vivo,,,17667,,Bioavailability of compound at 3 mg/kg in monkey after i.v. administration,1,monkey,Autocuration,,,,9443.0,,,A,BAO_0000218,CHEMBL620935,4444
,22224,U,0,In vivo,,,17267,,Bioavailability of compound was determined in rhesus monkey,1,Macaca mulatta,Autocuration,,,,9544.0,,,A,BAO_0000218,CHEMBL620936,4445
,22224,U,0,In vivo,,,4256,,Bioavailability determined after oral administration in marmoset,1,marmosets,Autocuration,,,,38020.0,,,A,BAO_0000218,CHEMBL620937,4446
,22224,U,0,In vivo,,,4256,,Oral bioavailability in cynomolgus monkey,1,Macaca fascicularis,Autocuration,,,,9541.0,,,A,BAO_0000218,CHEMBL620938,4447
,22224,U,0,In vivo,,,17853,,Bioavailability in monkey (p.o.) at 2.0 mpk,1,monkey,Autocuration,,,,9443.0,,,A,BAO_0000218,CHEMBL620939,4448
,22224,U,0,In vivo,,,16365,,Bioavailability was evaluated after oral administration in monkey,1,monkey,Autocuration,,,,9443.0,,,A,BAO_0000218,CHEMBL620940,4449
,22224,U,0,In vivo,,,1916,,Bioavailability was evaluated against Cynomolgus monkey at a dose of 15 mg/kg after po administration,1,Macaca fascicularis,Autocuration,,,,9541.0,,,A,BAO_0000218,CHEMBL620941,4450
,22224,U,0,In vivo,,,5334,,Bioavailability was reported after intravenous administration at a dose of 1 mg/kg in Rhesus monkey (male),1,Macaca mulatta,Autocuration,,,,9544.0,,,A,BAO_0000218,CHEMBL620942,4451
,22224,U,0,In vivo,,,5334,,Bioavailability was reported after oral administration at a dose of 2 mg/kg in Rhesus monkey (male),1,Macaca mulatta,Autocuration,,,,9544.0,,,A,BAO_0000218,CHEMBL620943,4452
,22224,U,0,In vivo,,,17592,,Bioavailability of the compound was determined in monkey,1,monkey,Autocuration,,,,9443.0,,,A,BAO_0000218,CHEMBL620944,4453
,22224,U,0,In vivo,,,1399,,Bioavailability in squirrel monkey (dose 5 mg/kg),1,Saimiri sciureus,Autocuration,,,,9521.0,,,A,BAO_0000218,CHEMBL620945,4454
,22224,U,0,In vivo,,,4809,,Bioavailability was determined in monkey after (po) administration of a dose of 50 (uM/kg),1,monkey,Autocuration,,,,9443.0,,,A,BAO_0000218,CHEMBL620946,4455
,22224,U,0,In vivo,,,3341,,Oral bioavailability in monkey,1,monkey,Autocuration,,,,9443.0,,,A,BAO_0000218,CHEMBL620947,4456
,22224,U,0,In vivo,,,64,,Compound was tested for bioavailability in squirrel monkey,1,Saimiri sciureus,Autocuration,,,,9521.0,,,A,BAO_0000218,CHEMBL620948,4457
,22224,U,0,In vivo,,,5005,,Oral bioavailability in Rhesus monkey,1,Macaca mulatta,Autocuration,,,,9544.0,,,A,BAO_0000218,CHEMBL620949,4458
,22224,U,0,In vivo,,,5005,,Oral bioavailability in Rhesus monkey (dose of 0.75 mg/kg i.v. and 1.5 mg/kg p.o.),1,Macaca mulatta,Autocuration,,,,9544.0,,,A,BAO_0000218,CHEMBL620950,4459
,22224,U,0,In vivo,,,5237,,Oral bioavailability in cynomolgus monkeys for the compound was determined; Acceptable,1,Macaca fascicularis,Autocuration,,,,9541.0,,,A,BAO_0000218,CHEMBL620951,4460
,22224,U,0,In vivo,,,5237,,Oral bioavailability in cynomolgus monkeys was determined; Acceptable,1,Macaca fascicularis,Autocuration,,,,9541.0,,,A,BAO_0000218,CHEMBL620952,4461
,22224,U,0,In vivo,,,5302,,Oral bioavailability in monkey (dose 5 mg/kg),1,monkey,Autocuration,,,,9443.0,,,A,BAO_0000218,CHEMBL875421,4462
,22224,U,0,In vivo,,,17667,,Oral bioavailability of compound at 5 mg/kg in monkey,1,monkey,Autocuration,,,,9443.0,,,A,BAO_0000218,CHEMBL620953,4463
,50588,N,1,In vivo,,,6161,,Pharmacokinetic profile in terms of half life was determined at a dose of 0.5 mg/kg administered intravenously in dog,1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL873491,4464
,50588,N,1,In vivo,,,6161,,Pharmacokinetic profile in terms of half life was determined at a dose of 5 mg/kg administered intravenously in dog,1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL620954,4465
Plasma,50588,N,1,,,,3854,,Plasma half life determined,1,Canis lupus familiaris,Intermediate,,,,9615.0,,1969.0,A,BAO_0000218,CHEMBL620955,4466
Plasma,50588,N,1,,,,993,,Plasma half life in dog,1,Canis lupus familiaris,Intermediate,,,,9615.0,,1969.0,A,BAO_0000218,CHEMBL618097,4467
Plasma,50588,N,1,,,,4514,,Plasma half-life in Beagle dogs,1,Canis lupus familiaris,Intermediate,,,,9615.0,,1969.0,A,BAO_0000218,CHEMBL618268,4468
Plasma,50588,N,1,In vivo,,,5334,,Plasma half-life period (0-8 h) was reported after intravenous administration at a dose of 1 mg/kg in Beagle dog (male),1,Canis lupus familiaris,Intermediate,,,,9615.0,,1969.0,A,BAO_0000218,CHEMBL618269,4469
Plasma,50588,N,1,In vivo,,,5334,,Plasma half-life period (0-8 h) was reported after oral administration at a dose of 2 mg/kg respectively in Beagle dog (male),1,Canis lupus familiaris,Intermediate,,,,9615.0,,1969.0,A,BAO_0000218,CHEMBL618270,4470
,50588,N,1,In vivo,,,1466,,Tested for t1/2 upon intravenous administration of 5.0 mg/Kg dose in dog,1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL618271,4471
,50588,N,1,In vivo,,,1466,,Tested for t1/2 upon peroral administration of 10.0 mg/Kg dose in dog,1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL873493,4472
,50588,N,1,,,,5313,,Tested for the half life period in dog,1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL621031,4473
,50588,N,1,In vivo,,,5313,,Tested for the half life period in dog at dosage of 10 mpk,1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL621032,4474
,50588,N,1,,,,3880,,The compound was tested for half life in dog,1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL621033,4475
Plasma,50588,N,1,,,,3639,,"The compound was tested for time taken to decrease, half of its initial concentration in dog plasma.",1,Canis lupus familiaris,Intermediate,,,,9615.0,,1969.0,A,BAO_0000218,CHEMBL621034,4476
,50588,N,1,,,,3880,,The half life was determined,1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL621035,4477
Plasma,50588,N,1,,,,3918,,The plasma half-life in dogs,1,Canis lupus familiaris,Intermediate,,,,9615.0,,1969.0,A,BAO_0000218,CHEMBL621036,4478
Plasma,50588,N,1,,,,16452,,suboptimal plasma half-life caused a10% prolongation of QTc interval in dogs at a plasma level of 2.5 M,1,Canis lupus familiaris,Intermediate,,,,9615.0,,1969.0,A,BAO_0000218,CHEMBL621037,4479
,50588,N,1,,,,17796,,Half life in dog,1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL619812,4480
,50588,N,1,In vivo,,,5983,,Pharmacokinetic property (t1/2beta) was measured in dog at the dose of 0.032 mg/kg i.v.,1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL619813,4481
,50588,N,1,In vivo,,,1466,,tmax upon peroral administration of 10.0 mg/Kg dose in dog,1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL873335,4482
,50588,N,1,In vivo,,,16456,,Volume of distribution in Beagle dogs after intravenous administration at a dose of 10 mg/kg,1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL619814,4483
,50506,N,1,In vivo,,,6113,,Cmax in ferrets after 30 mg/kg oral dose,1,Mustela putorius furo,Expert,,,,9669.0,,,A,BAO_0000218,CHEMBL619815,4484
,50506,N,1,In vivo,,,6113,,Emesis in ferrets at 30 mg/kg oral dose,1,Mustela putorius furo,Expert,,,,9669.0,,,F,BAO_0000218,CHEMBL619816,4485
,22224,U,0,In vivo,,,17796,,Bioavailability in cynomolgus monkey,1,Macaca fascicularis,Autocuration,,,,9541.0,,,A,BAO_0000218,CHEMBL619817,4486
,100710,N,1,In vivo,,,17796,,Volume of distribution in cynomolgus,1,Macaca fascicularis,Intermediate,,,,9541.0,,,A,BAO_0000218,CHEMBL619818,4487
Plasma,22224,U,0,,,,5308,,AUC tested in guinea pig when 3 mg/kg dose was given perorally,1,Cavia porcellus,Autocuration,,,,10141.0,,1969.0,A,BAO_0000218,CHEMBL619819,4488
,22224,U,0,,,,4877,,Tested for concentration as Area Under Curve against PDE4 in guinea pig lung eosinophilia orally at 5 mg/kg,1,Cavia porcellus,Autocuration,,,,10141.0,,,A,BAO_0000218,CHEMBL619820,4489
,22224,U,0,,,,4876,,"Tested for the pharmacokinetic parameter in guinea pig, administered orally at 5 mg/kg",1,Cavia porcellus,Autocuration,,,,10141.0,,,A,BAO_0000218,CHEMBL875419,4490
Plasma,22224,U,0,In vivo,,,4878,,AUC in guinea pig after 3mg/kg oral dose,1,Cavia porcellus,Autocuration,,,,10141.0,,1969.0,A,BAO_0000218,CHEMBL619821,4491
,22224,U,0,In vivo,,,5308,,Bioavailability in guinea pig was tested,1,Cavia porcellus,Autocuration,,,,10141.0,,,A,BAO_0000218,CHEMBL619822,4492
,22224,U,0,In vivo,,,4877,,Tested for oral bioavailability in guinea pig at 5 mg/kg,1,Cavia porcellus,Autocuration,,,,10141.0,,,A,BAO_0000218,CHEMBL619823,4493
,22224,U,0,In vivo,,,4876,,Tested for the oral bioavailability of the compound,1,Cavia porcellus,Autocuration,,,,10141.0,,,A,BAO_0000218,CHEMBL619824,4494
,22224,U,0,In vivo,,,4876,,Compound at a dose 5 mg/kg was administered orally to guinea pig and the pharmacokinetic parameter (Cmax) was reported,1,Cavia porcellus,Autocuration,,,,10141.0,,,A,BAO_0000218,CHEMBL619825,4495
,22224,U,0,In vivo,,,5308,,Maximum plsma drug concentration in guinea pig when 3 mg/kg dose was given perorally,1,Cavia porcellus,Autocuration,,,,10141.0,,,A,BAO_0000218,CHEMBL619826,4496
Lung,22224,U,0,In vivo,,,4877,,Tested for maximum concentration against PDE4 in guinea pig lung eosinophilia orally at 5 mg/kg,1,Cavia porcellus,Autocuration,,,,10141.0,,2048.0,A,BAO_0000218,CHEMBL619827,4497
,22224,U,0,In vivo,,,4878,,Cmax in guinea pig after 3mg/kg oral dose,1,Cavia porcellus,Autocuration,,,,10141.0,,,A,BAO_0000218,CHEMBL618167,4498
Blood,22224,U,0,,,,5689,,Distribution in blood expressed as [18F]- organ uptake in % of injected activity/gram,1,Cavia porcellus,Autocuration,,,,10141.0,,178.0,A,BAO_0000019,CHEMBL618168,4499
Brain,22224,U,0,,,,5689,,Distribution in brain expressed as [18F]- organ uptake in % of injected activity/gram,1,Cavia porcellus,Autocuration,,,,10141.0,,955.0,A,BAO_0000019,CHEMBL618169,4500
,22224,U,0,,,,5689,,Distribution in heart expressed as [18F]- organ uptake in % of injected activity/gram,1,Cavia porcellus,Autocuration,,,,10141.0,,,A,BAO_0000019,CHEMBL618170,4501
Intestine,22224,U,0,,,,5689,,Distribution in intestine expressed as [18F]- organ uptake in % of injected activity/gram,1,Cavia porcellus,Autocuration,,,,10141.0,,160.0,A,BAO_0000019,CHEMBL618171,4502
Kidney,22224,U,0,,,,5689,,Distribution in kidney expressed as [18F]- organ uptake in % of injected activity/gram,1,Cavia porcellus,Autocuration,,,,10141.0,,2113.0,A,BAO_0000019,CHEMBL618172,4503
Liver,22224,U,0,,,,5689,,Distribution in liver expressed as [18F]- organ uptake in % of injected activity/gram,1,Cavia porcellus,Autocuration,,,,10141.0,,2107.0,A,BAO_0000019,CHEMBL618173,4504
,22224,U,0,,,,5689,,Distribution in lung expressed as [18F]- organ uptake in % of injected activity/gram,1,Cavia porcellus,Autocuration,,,,10141.0,,,A,BAO_0000019,CHEMBL618174,4505
Spleen,22224,U,0,,,,5689,,Distribution in spleen expressed as [18F]- organ uptake in % of injected activity/gram,1,Cavia porcellus,Autocuration,,,,10141.0,,2106.0,A,BAO_0000019,CHEMBL875408,4506
,22224,U,0,In vivo,,,14465,,Elimination T1/2 in Guinea pig (PO dose),1,Cavia porcellus,Autocuration,,,,10141.0,,,A,BAO_0000218,CHEMBL839827,4507
,22224,U,0,,,,5689,,Partition coefficient was measured as -log (counts per min ),1,Cavia porcellus,Autocuration,,,,10141.0,,,A,BAO_0000019,CHEMBL618175,4508
,22224,U,0,In vivo,,,611,,Biological half life when administered at 0.1 umol/kg intravenously to guinea pig in GR-64349 antagonism,1,Cavia porcellus,Autocuration,,,,10141.0,,,A,BAO_0000218,CHEMBL618176,4509
,22224,U,0,In vivo,,,611,,Biological half life when administered at 5 umol/kg intravenously to guinea pig in GR-64349 antagonism,1,Cavia porcellus,Autocuration,,,,10141.0,,,A,BAO_0000218,CHEMBL618177,4510
,22224,U,0,In vivo,,,14465,,Elimination T1/2 in Guinea pig (PO dose),1,Cavia porcellus,Autocuration,,,,10141.0,,,A,BAO_0000218,CHEMBL618178,4511
,22224,U,0,In vivo,,,4876,,"Tested for the half life period of the compound, intravenously",1,Cavia porcellus,Autocuration,,,,10141.0,,,A,BAO_0000218,CHEMBL618179,4512
,22224,U,0,,,,5689,,Half-life was measured,1,Cavia porcellus,Autocuration,,,,10141.0,,,A,BAO_0000019,CHEMBL873489,4513
,22224,U,0,,,,7515,,The time required for onset of inotropy after addition of a single dose of delta F75,1,Cavia porcellus,Autocuration,,,,10141.0,,,A,BAO_0000019,CHEMBL618180,4514
,22224,U,0,In vivo,,,17667,,Bioavailability of compound at 10 mg/kg in guinea pig after i.v. administration,1,Cavia porcellus,Autocuration,,,,10141.0,,,A,BAO_0000218,CHEMBL618181,4515
,22224,U,0,In vivo,,,17667,,Bioavailability of compound at 3 mg/kg in guinea pig after i.v. administration,1,Cavia porcellus,Autocuration,,,,10141.0,,,A,BAO_0000218,CHEMBL618182,4516
,22224,U,0,In vivo,,,4727,,Plasma clearance was measured in hamster at the dose of 10 mg/kg by peroral administration,1,Cricetulus griseus,Autocuration,,,,10029.0,,,A,BAO_0000218,CHEMBL618183,4517
,50594,N,1,In vivo,,,10107,,Biodistribution of intravenously injected [82Br]-labeled compound in tumor of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,1,Mus musculus,Intermediate,,,,10090.0,,,A,BAO_0000218,CHEMBL618184,4518
,50594,N,1,In vivo,,,10107,,Biodistribution of intravenously injected [82Br]-labeled compound in tumor of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.50 hours,1,Mus musculus,Intermediate,,,,10090.0,,,A,BAO_0000218,CHEMBL618185,4519
,50594,N,1,In vivo,,,10107,,Biodistribution of intravenously injected [82Br]-labeled compound in tumor of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,1,Mus musculus,Intermediate,,,,10090.0,,,A,BAO_0000218,CHEMBL618186,4520
,50594,N,1,In vivo,,,10107,,Biodistribution of intravenously injected [82Br]-labeled compound in tumor of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,1,Mus musculus,Intermediate,,,,10090.0,,,A,BAO_0000218,CHEMBL618187,4521
,50594,N,1,In vivo,,,10107,,Biodistribution of intravenously injected [82Br]-labeled compound in tumor of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hr,1,Mus musculus,Intermediate,,,,10090.0,,,A,BAO_0000218,CHEMBL618188,4522
,50594,N,1,In vivo,,,10107,,Biodistribution of intravenously injected [82Br]-labeled compound in tumor of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,1,Mus musculus,Intermediate,,,,10090.0,,,A,BAO_0000218,CHEMBL875409,4523
,50594,N,1,In vivo,,,10107,,Biodistribution of intravenously injected [82Br]-labeled compound in tumor of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,1,Mus musculus,Intermediate,,,,10090.0,,,A,BAO_0000218,CHEMBL618189,4524
Blood,50594,N,1,In vivo,,,3655,,Biodistribution of the injected compound in blood of female BALB/C mice for 0.5 hours,1,Mus musculus,Intermediate,,,,10090.0,,178.0,A,BAO_0000218,CHEMBL618190,4525
Blood,50594,N,1,In vivo,,,3655,,Biodistribution of the injected compound in blood of female BALB/C mice for 2.5 hours,1,Mus musculus,Intermediate,,,,10090.0,,178.0,A,BAO_0000218,CHEMBL618191,4526
Blood,50594,N,1,In vivo,,,3655,,Biodistribution of the injected compound in blood of female BALB/C mice for 5 hours,1,Mus musculus,Intermediate,,,,10090.0,,178.0,A,BAO_0000218,CHEMBL618192,4527
Bone,50594,N,1,In vivo,,,3655,,Biodistribution of the injected compound in bone of female BALB/C mice for 0.5 hours,1,Mus musculus,Intermediate,,,,10090.0,,10000001.0,A,BAO_0000218,CHEMBL618193,4528
Bone,50594,N,1,In vivo,,,3655,,Biodistribution of the injected compound in bone of female BALB/C mice for 2.5 hours,1,Mus musculus,Intermediate,,,,10090.0,,10000001.0,A,BAO_0000218,CHEMBL618194,4529
Bone,50594,N,1,In vivo,,,3655,,Biodistribution of the injected compound in bone of female BALB/C mice for 5 hours,1,Mus musculus,Intermediate,,,,10090.0,,10000001.0,A,BAO_0000218,CHEMBL618195,4530
Brain,50594,N,1,In vivo,,,3655,,Biodistribution of the injected compound in brain of female BALB/C mice for 0.5 hours,1,Mus musculus,Intermediate,,,,10090.0,,955.0,A,BAO_0000218,CHEMBL618196,4531
Brain,50594,N,1,In vivo,,,3655,,Biodistribution of the injected compound in brain of female BALB/C mice for 2.5 hours,1,Mus musculus,Intermediate,,,,10090.0,,955.0,A,BAO_0000218,CHEMBL618197,4532
Brain,50594,N,1,In vivo,,,3655,,Biodistribution of the injected compound in brain of female BALB/C mice for 5 hours,1,Mus musculus,Intermediate,,,,10090.0,,955.0,A,BAO_0000218,CHEMBL618198,4533
Heart,50594,N,1,In vivo,,,3655,,Biodistribution of the injected compound in heart of female BALB/C mice for 0.5 hours,1,Mus musculus,Intermediate,,,,10090.0,,948.0,A,BAO_0000218,CHEMBL618199,4534
Heart,50594,N,1,In vivo,,,3655,,Biodistribution of the injected compound in heart of female BALB/C mice for 2.5 hours,1,Mus musculus,Intermediate,,,,10090.0,,948.0,A,BAO_0000218,CHEMBL618200,4535
Heart,50594,N,1,In vivo,,,3655,,Biodistribution of the injected compound in heart of female BALB/C mice for 5 hours,1,Mus musculus,Intermediate,,,,10090.0,,948.0,A,BAO_0000218,CHEMBL618201,4536
Intestine,50594,N,1,In vivo,,,3655,,Biodistribution of the injected compound in intestines of female BALB/C mice for 0.5 hours,1,Mus musculus,Intermediate,,,,10090.0,,160.0,A,BAO_0000218,CHEMBL618202,4537
Intestine,50594,N,1,In vivo,,,3655,,Biodistribution of the injected compound in intestines of female BALB/C mice for 2.5 hours,1,Mus musculus,Intermediate,,,,10090.0,,160.0,A,BAO_0000218,CHEMBL618203,4538
Intestine,50594,N,1,In vivo,,,3655,,Biodistribution of the injected compound in intestines of female BALB/C mice for 5 hours,1,Mus musculus,Intermediate,,,,10090.0,,160.0,A,BAO_0000218,CHEMBL618204,4539
Kidney,50594,N,1,In vivo,,,3655,,Biodistribution of the injected compound in kidneys of female BALB/C mice for 0.5 hours,1,Mus musculus,Intermediate,,,,10090.0,,2113.0,A,BAO_0000218,CHEMBL618205,4540
Kidney,50594,N,1,In vivo,,,3655,,Biodistribution of the injected compound in kidneys of female BALB/C mice for 2.5 hours,1,Mus musculus,Intermediate,,,,10090.0,,2113.0,A,BAO_0000218,CHEMBL618206,4541
Kidney,50594,N,1,In vivo,,,3655,,Biodistribution of the injected compound in kidneys of female BALB/C mice for 5 hours,1,Mus musculus,Intermediate,,,,10090.0,,2113.0,A,BAO_0000218,CHEMBL618207,4542
Liver,50594,N,1,In vivo,,,3655,,Biodistribution of the injected compound in liver of female BALB/C mice for 0.5 hours,1,Mus musculus,Intermediate,,,,10090.0,,2107.0,A,BAO_0000218,CHEMBL618208,4543
Liver,50594,N,1,In vivo,,,3655,,Biodistribution of the injected compound in liver of female BALB/C mice for 2.5 hours,1,Mus musculus,Intermediate,,,,10090.0,,2107.0,A,BAO_0000218,CHEMBL618932,4544
Liver,50594,N,1,In vivo,,,3655,,Biodistribution of the injected compound in liver of female BALB/C mice for 5 hours,1,Mus musculus,Intermediate,,,,10090.0,,2107.0,A,BAO_0000218,CHEMBL618933,4545
Lung,50594,N,1,In vivo,,,3655,,Biodistribution of the injected compound in lung of female BALB/C mice for 0.5 hours,1,Mus musculus,Intermediate,,,,10090.0,,2048.0,A,BAO_0000218,CHEMBL618934,4546
Lung,50594,N,1,In vivo,,,3655,,Biodistribution of the injected compound in lung of female BALB/C mice for 2.5 hours,1,Mus musculus,Intermediate,,,,10090.0,,2048.0,A,BAO_0000218,CHEMBL618935,4547
Lung,50594,N,1,In vivo,,,3655,,Biodistribution of the injected compound in lung of female BALB/C mice for 5 hours,1,Mus musculus,Intermediate,,,,10090.0,,2048.0,A,BAO_0000218,CHEMBL618936,4548
Muscle tissue,50594,N,1,In vivo,,,3655,,Biodistribution of the injected compound in muscle of female BALB/C mice for 0.5 hours,1,Mus musculus,Intermediate,,,,10090.0,,2385.0,A,BAO_0000218,CHEMBL618937,4549
Muscle tissue,50594,N,1,In vivo,,,3655,,Biodistribution of the injected compound in muscle of female BALB/C mice for 2.5 hours,1,Mus musculus,Intermediate,,,,10090.0,,2385.0,A,BAO_0000218,CHEMBL618938,4550
Muscle tissue,50594,N,1,In vivo,,,3655,,Biodistribution of the injected compound in muscle of female BALB/C mice for 5 hours,1,Mus musculus,Intermediate,,,,10090.0,,2385.0,A,BAO_0000218,CHEMBL619104,4551
Spleen,50594,N,1,In vivo,,,3655,,Biodistribution of the injected compound in spleen of female BALB/C mice for 0.5 hours,1,Mus musculus,Intermediate,,,,10090.0,,2106.0,A,BAO_0000218,CHEMBL619105,4552
Spleen,50594,N,1,In vivo,,,3655,,Biodistribution of the injected compound in spleen of female BALB/C mice for 2.5 hours,1,Mus musculus,Intermediate,,,,10090.0,,2106.0,A,BAO_0000218,CHEMBL619106,4553
Spleen,50594,N,1,In vivo,,,3655,,Biodistribution of the injected compound in spleen of female BALB/C mice for 5 hours,1,Mus musculus,Intermediate,,,,10090.0,,2106.0,A,BAO_0000218,CHEMBL619107,4554
Stomach,50594,N,1,In vivo,,,3655,,Biodistribution of the injected compound in stomach of female BALB/C mice for 0.5 hours,1,Mus musculus,Intermediate,,,,10090.0,,945.0,A,BAO_0000218,CHEMBL875410,4555
Stomach,50594,N,1,In vivo,,,3655,,Biodistribution of the injected compound in stomach of female BALB/C mice for 2.5 hours,1,Mus musculus,Intermediate,,,,10090.0,,945.0,A,BAO_0000218,CHEMBL619108,4556
Stomach,50594,N,1,In vivo,,,3655,,Biodistribution of the injected compound in stomach of female BALB/C mice for 5 hours,1,Mus musculus,Intermediate,,,,10090.0,,945.0,A,BAO_0000218,CHEMBL619109,4557
,50594,N,1,In vivo,,,16597,,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for MRT,1,Mus musculus,Intermediate,,,,10090.0,,,A,BAO_0000218,CHEMBL619110,4558
,50594,N,1,In vivo,,,16597,,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for MRT,1,Mus musculus,Intermediate,,,,10090.0,,,F,BAO_0000218,CHEMBL619111,4559
,50594,N,1,In vivo,,,16597,,MRT value at a dose of 10 mg/kg intravenous administration in mice.,1,Mus musculus,Intermediate,,,,10090.0,,,A,BAO_0000218,CHEMBL619112,4560
,50594,N,1,In vivo,,,16597,,MRT value at a dose of 10 mg/kg peroral administration in mice.,1,Mus musculus,Intermediate,,,,10090.0,,,A,BAO_0000218,CHEMBL619113,4561
,50594,N,1,In vivo,,,17764,,Mean-residence time of compound after intravenous administration in mice at 24 uM/kg,1,Mus musculus,Intermediate,,,,10090.0,,,A,BAO_0000218,CHEMBL619114,4562
,50594,N,1,In vivo,,,17764,,Mean-residence time was determined for compound after intraperitoneal administration in mice at 18 uM/kg,1,Mus musculus,Intermediate,,,,10090.0,,,F,BAO_0000218,CHEMBL619115,4563
,81034,N,1,,,,3830,,In vitro cytotoxicity of compound was determined against A2780 cell lines (cisplatin resistant) at 37 degree C after 96 hr,1,Homo sapiens,Intermediate,,478.0,,9606.0,A2780,,F,BAO_0000219,CHEMBL619116,4564
,81034,N,1,,,,3829,,In vitro cytotoxicity of compound was determined against A2780 cell lines (cisplatin resistant) at 37 degree C for 96 hr,1,Homo sapiens,Intermediate,,478.0,,9606.0,A2780,,F,BAO_0000219,CHEMBL619117,4565
,81034,N,1,,,,2040,,Compound was evaluated for cytotoxicity against A2780 cell lines.,1,Homo sapiens,Intermediate,,478.0,,9606.0,A2780,,F,BAO_0000219,CHEMBL619118,4566
,81034,N,1,,,,15684,,Potentiation of growth inhibition of A2780 by compound alone in experiment 1,1,Homo sapiens,Intermediate,,478.0,,9606.0,A2780,,F,BAO_0000219,CHEMBL619119,4567
,81034,N,1,,,,15684,,Potentiation of growth inhibition of A2780 cells by compound alone in experiment 2,1,Homo sapiens,Intermediate,,478.0,,9606.0,A2780,,F,BAO_0000219,CHEMBL619120,4568
,81034,N,1,,,,15684,,Potentiation of growth inhibition of A2780 cells along with 10 uM NU1085 in experiment 1,1,Homo sapiens,Intermediate,,478.0,,9606.0,A2780,,F,BAO_0000219,CHEMBL619121,4569
,81034,N,1,,,,15684,,Potentiation of growth inhibition of A2780 cells along with 10 uM NU1085 in experiment 2,1,Homo sapiens,Intermediate,,478.0,,9606.0,A2780,,F,BAO_0000219,CHEMBL619122,4570
,81034,N,1,,,,15684,,Potentiation factor at 50% growth inhibition (IC50 of compound to that of compound along with PARP inhibitor) in experiment 1,1,Homo sapiens,Intermediate,,478.0,,9606.0,A2780,,F,BAO_0000219,CHEMBL619123,4571
,81034,N,1,,,,15684,,Potentiation factor at 50% growth inhibition (IC50 of compound to that of compound along with PARP inhibitor) in experiment 2,1,Homo sapiens,Intermediate,,478.0,,9606.0,A2780,,F,BAO_0000219,CHEMBL619124,4572
,81034,N,1,,,,2859,,Compound was evaluated for cytotoxicity against A2780 cell line,1,Homo sapiens,Intermediate,,478.0,,9606.0,A2780,,F,BAO_0000219,CHEMBL619125,4573
,81034,N,1,,,,5618,,In vitro inhibitory activity against human tumor cell line A2780,1,Homo sapiens,Intermediate,,478.0,,9606.0,A2780,,F,BAO_0000219,CHEMBL875411,4574
,81034,N,1,,,,15684,,Potentiation of growth inhibition of A2780 cells by compound alone in experiment 1,1,Homo sapiens,Intermediate,,478.0,,9606.0,A2780,,F,BAO_0000219,CHEMBL619126,4575
,81034,N,1,,,,15684,,Potentiation of growth inhibition of A2780 cells by compound alone in experiment 2,1,Homo sapiens,Intermediate,,478.0,,9606.0,A2780,,F,BAO_0000219,CHEMBL619127,4576
,81034,N,1,,,,15684,,Potentiation of growth inhibition of A2780 cells along with 10 uM NU1085 in experiment 1,1,Homo sapiens,Intermediate,,478.0,,9606.0,A2780,,F,BAO_0000219,CHEMBL619128,4577
,81034,N,1,,,,15684,,Potentiation of growth inhibition of A2780 cells along with 10 uM NU1085 in experiment 2,1,Homo sapiens,Intermediate,,478.0,,9606.0,A2780,,F,BAO_0000219,CHEMBL619129,4578
,81034,N,1,,,,2113,,The compound was tested for cytotoxic potency against A2780 human tumor cell lines,1,Homo sapiens,Intermediate,,478.0,,9606.0,A2780,,F,BAO_0000219,CHEMBL619130,4579
,81034,N,1,,,,2113,,The compound was tested for cytotoxic potency against A2780 human tumor cell lines.,1,Homo sapiens,Intermediate,,478.0,,9606.0,A2780,,F,BAO_0000219,CHEMBL619131,4580
,81034,N,1,,,,16745,,cytotoxicity against A2780 cells incubated for 24 hr in MTT assay.,1,Homo sapiens,Intermediate,,478.0,,9606.0,A2780,,F,BAO_0000219,CHEMBL619132,4581
,81034,N,1,,,,16597,,In vitro antitumor activity against A2780 human ovarian carcinoma at 7.5 mg/kg i.p. /qd x7,1,Homo sapiens,Expert,,478.0,,9606.0,A2780,,F,BAO_0000218,CHEMBL619133,4582
,81034,N,1,,,,15684,,Potentiation factor at 50% growth inhibition (IC50 of compound to that of compound along with PARP inhibitor) in experiment 1,1,Homo sapiens,Intermediate,,478.0,,9606.0,A2780,,F,BAO_0000219,CHEMBL619134,4583
,81034,N,1,,,,15684,,Potentiation factor at 50% growth inhibition (IC50 of compound to that of compound along with PARP inhibitor) in experiment 2,1,Homo sapiens,Intermediate,,478.0,,9606.0,A2780,,F,BAO_0000219,CHEMBL619135,4584
,81034,N,1,,,,2040,,Compound was evaluated for cytotoxicity against A2780 cis cell lines.,1,Homo sapiens,Intermediate,,478.0,,9606.0,A2780,,F,BAO_0000219,CHEMBL619136,4585
,81034,N,1,,,,2040,,Relative resistance factor in A2780 cisplatin-resistant line,1,Homo sapiens,Intermediate,,478.0,,9606.0,A2780,,F,BAO_0000219,CHEMBL619137,4586
,81034,N,1,,,,16165,,Concentration required to inhibit 50% growth of A2780 human ovarian cancer cells,1,Homo sapiens,Intermediate,,478.0,,9606.0,A2780,,F,BAO_0000219,CHEMBL883713,4587
,81034,N,1,,,,16165,,Concentration required to inhibit 50% growth of A2780 human ovarian cancer cells.,1,Homo sapiens,Intermediate,,478.0,,9606.0,A2780,,F,BAO_0000219,CHEMBL875412,4588
,81034,N,1,,,,16597,,In vitro antitumor activity against A2780 human ovarian carcinoma at 7.5 mg/kg i.p. /qd x7,1,Homo sapiens,Expert,,478.0,,9606.0,A2780,,F,BAO_0000218,CHEMBL619138,4589
,81034,N,1,,,,16597,,In vitro antitumor activity against A2780 human ovarian carcinoma at 7.5 mg/kg i.p. /qd x7,1,Homo sapiens,Expert,,478.0,,9606.0,A2780,,F,BAO_0000218,CHEMBL619262,4590
,81034,N,1,,,,3992,,Cytotoxicity against A2780 ovarian carcinoma cells was evaluated using standard sulforhodamine 96h assay test,1,Homo sapiens,Intermediate,,478.0,,9606.0,A2780,,F,BAO_0000219,CHEMBL619139,4591
,81034,N,1,,,,10553,,In vitro cytotoxicity was determined against A2780 human ovarian cell line using NCI screen,1,Homo sapiens,Intermediate,,478.0,,9606.0,A2780,,F,BAO_0000219,CHEMBL619140,4592
,81034,N,1,,,,15608,,cytotoxic activity toward A2780 ovarian human cell line sensitive (S) to cisplatin,1,Homo sapiens,Intermediate,,478.0,,9606.0,A2780,,F,BAO_0000219,CHEMBL619141,4593
,81034,N,1,,,,15608,,cytotoxic activity toward A2780 ovarian human cell line sensitive (S) to cisplatin in experiment 1,1,Homo sapiens,Intermediate,,478.0,,9606.0,A2780,,F,BAO_0000219,CHEMBL619142,4594
,81034,N,1,,,,15608,,cytotoxic activity toward A2780 ovarian human cell line sensitive (S) to cisplatin in experiment 2,1,Homo sapiens,Intermediate,,478.0,,9606.0,A2780,,F,BAO_0000219,CHEMBL619143,4595
,81034,N,1,,,,15608,,cytotoxic activity toward A2780 ovarian human cell line sensitive (S) to cisplatin in experiment 3,1,Homo sapiens,Intermediate,,478.0,,9606.0,A2780,,F,BAO_0000219,CHEMBL619144,4596
,81034,N,1,,,,15608,,cytotoxic activity toward A2780 ovarian human cell line sensitive (S) to cisplatin in experiment 5,1,Homo sapiens,Intermediate,,478.0,,9606.0,A2780,,F,BAO_0000219,CHEMBL619145,4597
,81034,N,1,,,,15608,,cytotoxic activity toward A2780 ovarian human cell line sensitive (S) to cisplatin in experiment 8,1,Homo sapiens,Intermediate,,478.0,,9606.0,A2780,,F,BAO_0000219,CHEMBL619146,4598
,81034,N,1,,,,15569,,Cytotoxic activity in a panel of Human ovarian tumor A2780/CDDP cell line after 96h of drug exposure,1,Homo sapiens,Intermediate,,478.0,,9606.0,A2780,,F,BAO_0000219,CHEMBL619147,4599
,81034,N,1,,,,17420,,Antiproliferative effect of compound on A2780/DX cell line,1,Homo sapiens,Intermediate,,478.0,,9606.0,A2780,,F,BAO_0000219,CHEMBL619148,4600
,81034,N,1,,,,17420,,Antiproliferative effect of compound on A2780/DX cell line; n.d. indicates not determined,1,Homo sapiens,Intermediate,,478.0,,9606.0,A2780,,F,BAO_0000219,CHEMBL619149,4601
,81034,N,1,,,,15099,,In vitro Cytotoxic activity of compound in comparison with reference compounds in human cell line A2780/DX(RI),1,Homo sapiens,Intermediate,,478.0,,9606.0,A2780,,F,BAO_0000219,CHEMBL619150,4602
,81034,N,1,,,,15099,,In vitro Cytotoxic activity of compound in comparison with reference compounds in human cell line A2780/Dx(RI),1,Homo sapiens,Intermediate,,478.0,,9606.0,A2780,,F,BAO_0000219,CHEMBL619151,4603
,81034,N,1,,,,17672,,Cytotoxicity against ovarian carcinoma A2780/cis tumor cell lines,1,Homo sapiens,Intermediate,,478.0,,9606.0,A2780,,F,BAO_0000219,CHEMBL883794,4604
,81034,N,1,,,,17672,,Cytotoxicity against ovarian carcinoma A2780/cis90 tumor cell lines,1,Homo sapiens,Intermediate,,478.0,,9606.0,A2780,,F,BAO_0000219,CHEMBL619152,4605
,81034,N,1,,,,17270,,In vitro cytotoxicity against A2780ADR cell line,1,Homo sapiens,Intermediate,,478.0,,9606.0,A2780,,F,BAO_0000219,CHEMBL619153,4606
,81034,N,1,,,,17270,,In vitro cytotoxicity against A2780CIS cell line,1,Homo sapiens,Intermediate,,478.0,,9606.0,A2780,,F,BAO_0000219,CHEMBL619154,4607
,81034,N,1,,,,5574,,In vitro cytotoxic activity against human tumor cell line A2780CisR after incubation for 96 hours,1,Homo sapiens,Intermediate,,478.0,,9606.0,A2780,,F,BAO_0000219,CHEMBL619155,4608
,81034,N,1,,,,2113,,The compound was tested for cytotoxic potency against A2780R human tumor cell lines.,1,Homo sapiens,Intermediate,,478.0,,9606.0,A2780,,F,BAO_0000219,CHEMBL619156,4609
,81034,N,1,,,,16913,,"Inhibitory effect of Gold(III) complex, 2,2' bipy on growth of cisplatin-resistant A2780/R human tumor cell lines",1,Homo sapiens,Intermediate,,478.0,,9606.0,A2780,,F,BAO_0000219,CHEMBL619157,4610
,81034,N,1,,,,16913,,"Inhibitory effect of Gold(III) complex, CDDP on growth of cisplatin-resistant A2780/R human tumor cell lines",1,Homo sapiens,Intermediate,,478.0,,9606.0,A2780,,F,BAO_0000219,CHEMBL619797,4611
,22224,U,0,In vivo,,,17839,,Oral bioavailability of compound in rhesus macaques,1,Macaca mulatta,Autocuration,,,,9544.0,,,A,BAO_0000218,CHEMBL619798,4612
,22224,U,0,In vivo,,,6821,,Oral bioavailability in monkey,1,monkey,Autocuration,,,,9443.0,,,A,BAO_0000218,CHEMBL619799,4613
,22224,U,0,In vivo,,,6078,,Oral bioavailability evaluated in monkey,1,monkey,Autocuration,,,,9443.0,,,A,BAO_0000218,CHEMBL619800,4614
,22224,U,0,In vivo,,,6535,,Oral bioavailability in monkey (dose 1 mg/kg p.o.),1,monkey,Autocuration,,,,9443.0,,,A,BAO_0000218,CHEMBL619801,4615
,22224,U,0,In vivo,,,4449,,Oral bioavailability in Rhesus monkey,1,Macaca mulatta,Autocuration,,,,9544.0,,,A,BAO_0000218,CHEMBL619802,4616
,22224,U,0,In vivo,,,6057,,Oral bioavailability was calculated in rhesus monkey,1,Macaca mulatta,Autocuration,,,,9544.0,,,A,BAO_0000218,CHEMBL619803,4617
,22224,U,0,In vivo,,,5922,,Oral bioavailability in cynomolgus monkey,1,Macaca fascicularis,Autocuration,,,,9541.0,,,A,BAO_0000218,CHEMBL619965,4618
,22224,U,0,In vivo,,,5940,,Oral bioavailability in monkey,1,monkey,Autocuration,,,,9443.0,,,A,BAO_0000218,CHEMBL619966,4619
,22224,U,0,In vivo,,,6265,,Oral bioavailability in monkey,1,monkey,Autocuration,,,,9443.0,,,A,BAO_0000218,CHEMBL619967,4620
,22224,U,0,In vivo,,,6265,,Oral bioavailability in monkey (dose 1 mg/kg),1,monkey,Autocuration,,,,9443.0,,,A,BAO_0000218,CHEMBL620073,4621
,22224,U,0,In vivo,,,6265,,Oral bioavailability in monkey (dose 5 mg/kg),1,monkey,Autocuration,,,,9443.0,,,A,BAO_0000218,CHEMBL620074,4622
,22224,U,0,In vivo,,,5940,,Oral bioavailability in monkey,1,monkey,Autocuration,,,,9443.0,,,A,BAO_0000218,CHEMBL620075,4623
,22224,U,0,In vivo,,,5940,,Oral bioavailability in monkey,1,monkey,Autocuration,,,,9443.0,,,A,BAO_0000218,CHEMBL620076,4624
,22224,U,0,In vivo,,,4514,,Oral bioavailability in rhesus monkey,1,Macaca mulatta,Autocuration,,,,9544.0,,,A,BAO_0000218,CHEMBL620077,4625
,22224,U,0,In vivo,,,5546,,Oral bioavailability in rhesus monkey at a dose of 2 mg/kg by po administration,1,Macaca mulatta,Autocuration,,,,9544.0,,,A,BAO_0000218,CHEMBL620078,4626
,22224,U,0,In vivo,,,5553,,Oral bioavailability in squirrel monkey at a dose of 10 mg/kg,1,Saimiri sciureus,Autocuration,,,,9521.0,,,A,BAO_0000218,CHEMBL620079,4627
,22224,U,0,In vivo,,,6641,,Oral bioavailability in monkey (dosed at 0.5 mpk iv and 2.0 mpk orally),1,monkey,Autocuration,,,,9443.0,,,A,BAO_0000218,CHEMBL620080,4628
,22224,U,0,In vivo,,,5472,,Oral bioavailability in Rhesus monkey,1,Macaca mulatta,Autocuration,,,,9544.0,,,A,BAO_0000218,CHEMBL620081,4629
,22224,U,0,In vivo,,,5668,,Oral bioavailability in Rhesus monkey (dose 10 mg/kg p.o.),1,Macaca mulatta,Autocuration,,,,9544.0,,,A,BAO_0000218,CHEMBL620082,4630
,22224,U,0,In vivo,,,5711,,Oral bioavailability in monkey at 10 mg/kg of the compound,1,monkey,Autocuration,,,,9443.0,,,A,BAO_0000218,CHEMBL620083,4631
,22224,U,0,In vivo,,,5145,,Bioavailability in Rhesus monkey,1,Macaca mulatta,Autocuration,,,,9544.0,,,A,BAO_0000218,CHEMBL620084,4632
,22224,U,0,,,,3443,,Glomerular Filtration Rate(GFR) evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,1,Cercopithecidae,Autocuration,,,,9527.0,,,A,BAO_0000218,CHEMBL620085,4633
,22224,U,0,,,,3443,,Glomerular Filtration Rate(GFR)of the compound compared to Cilastatin evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,1,Cercopithecidae,Autocuration,,,,9527.0,,,A,BAO_0000218,CHEMBL874595,4634
,22224,U,0,In vivo,,,3249,,Half life by ''Cr'' assay in rhesus monkey at a dose of 5 mg/kg,1,Cercopithecidae,Autocuration,,,,9527.0,,,A,BAO_0000218,CHEMBL873352,4635
,22224,U,0,In vivo,,,3249,,Half life the of compound was determined by ''Cr'' assay in squirrel monkey at a dose of 5 mg/kg,1,Cercopithecidae,Autocuration,,,,9527.0,,,A,BAO_0000218,CHEMBL620086,4636
,22224,U,0,In vivo,,,5355,,Mean residence time was determined after intravenous administration in cynomolgus monkeys,1,Cercopithecidae,Autocuration,,,,9527.0,,,A,BAO_0000218,CHEMBL620087,4637
,22224,U,0,In vivo,,,5355,,Mean residence time was determined after oral administration in cynomolgus monkeys; NA means Not applicable,1,Cercopithecidae,Autocuration,,,,9527.0,,,A,BAO_0000218,CHEMBL620088,4638
,22224,U,0,In vivo,,,5355,,Mean residence time was determined after oral administration in cynomolgus monkeys; NA means not applicable,1,Cercopithecidae,Autocuration,,,,9527.0,,,A,BAO_0000218,CHEMBL620089,4639
,22224,U,0,In vivo,,,4809,,Pharmacokinetic parameter MRT was determined in monkey after (iv) administration of a dose of 13 (uM/kg),1,Cercopithecidae,Autocuration,,,,9527.0,,,A,BAO_0000218,CHEMBL620090,4640
,22224,U,0,In vivo,,,4809,,Pharmacokinetic parameter MRT was determined in monkey after (po) administration of a dose of 50 (uM/kg),1,Cercopithecidae,Autocuration,,,,9527.0,,,A,BAO_0000218,CHEMBL620091,4641
,22224,U,0,,,Microsomes,14294,,Metabolism of compound in monkey S9 microsomes ('+''indicates <20% largest observed peak),1,Cercopithecidae,Autocuration,,,,9527.0,,,A,BAO_0000251,CHEMBL620092,4642
,22224,U,0,,,Microsomes,14294,,Metabolism of compound in monkey S9 microsomes ('++''indicates 20-50% largest observed peak),1,Cercopithecidae,Autocuration,,,,9527.0,,,A,BAO_0000251,CHEMBL620093,4643
,22224,U,0,,,Microsomes,14294,,Metabolism of compound in monkey S9 microsomes ('+++'indicates 50-80% largest observed peak),1,Cercopithecidae,Autocuration,,,,9527.0,,,A,BAO_0000251,CHEMBL620094,4644
,22224,U,0,,,Microsomes,14294,,Metabolism of compound in monkey S9 microsomes ('++++' indicates largest observed peak),1,Cercopithecidae,Autocuration,,,,9527.0,,,A,BAO_0000251,CHEMBL620095,4645
,22224,U,0,In vivo,,,3443,,Plasma clearance evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,1,Cercopithecidae,Autocuration,,,,9527.0,,,A,BAO_0000218,CHEMBL620096,4646
,22224,U,0,In vivo,,,3443,,Plasma clearance compared to Cilastatin evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,1,Cercopithecidae,Autocuration,,,,9527.0,,,A,BAO_0000218,CHEMBL620097,4647
,22224,U,0,,,,11271,,Clearance from plasma(with matabolite-corrected plasma radioactivity-time integral) at 30 min after administration.,1,Cercopithecidae,Autocuration,,,,9527.0,,,A,BAO_0000019,CHEMBL620098,4648
,22224,U,0,,,,3443,,Renal clearance evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,1,Cercopithecidae,Autocuration,,,,9527.0,,,A,BAO_0000218,CHEMBL620099,4649
,22224,U,0,,,,3443,,Renal clearance compared to Cilastatin evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,1,Cercopithecidae,Autocuration,,,,9527.0,,,A,BAO_0000218,CHEMBL620100,4650
,22224,U,0,,,,6821,,Elimination Half-life of compound was determined in monkey,1,Cercopithecidae,Autocuration,,,,9527.0,,,A,BAO_0000019,CHEMBL620101,4651
,22224,U,0,,,,17267,,Half life of compound was determined in rhesus monkey,1,Cercopithecidae,Autocuration,,,,9527.0,,,A,BAO_0000019,CHEMBL620102,4652
Plasma,22224,U,0,,,,5819,,Half life in monkey plasma,1,Cercopithecidae,Autocuration,,,,9527.0,,1969.0,A,BAO_0000366,CHEMBL620103,4653
Plasma,22224,U,0,,,,5819,,Half life in monkey plasma; Not detected,1,Cercopithecidae,Autocuration,,,,9527.0,,1969.0,A,BAO_0000366,CHEMBL620104,4654
,22224,U,0,In vivo,,,1916,,Half life period was evaluated against Cynomolgus monkey at a dose of 15 mg/kg after po administration,1,Cercopithecidae,Autocuration,,,,9527.0,,,A,BAO_0000218,CHEMBL874596,4655
,22224,U,0,In vivo,,,17509,,Half-life 24 hr after 2 mg/kg iv administration in monkeys,1,Cercopithecidae,Autocuration,,,,9527.0,,,A,BAO_0000218,CHEMBL873490,4656
,22224,U,0,,,,1399,,Terminal half life of the compound.,1,Cercopithecidae,Autocuration,,,,9527.0,,,A,BAO_0000019,CHEMBL620105,4657
,22224,U,0,In vivo,,,1916,,Maximum time was evaluated against Cynomolgus monkey at a dose of 15 mg/kg after po administration,1,Cercopithecidae,Autocuration,,,,9527.0,,,A,BAO_0000218,CHEMBL620780,4658
,22224,U,0,In vivo,,,4809,,Pharmacokinetic parameter Tmax was determined in monkey after (po) administration of a dose of 50 (uM/kg),1,Cercopithecidae,Autocuration,,,,9527.0,,,A,BAO_0000218,CHEMBL620781,4659
,22224,U,0,,,,5546,,Unbound plasma was determined in rhesus monkey at a dose of 1 mg/kg by iv administration,1,Cercopithecidae,Autocuration,,,,9527.0,,,A,BAO_0000218,CHEMBL620956,4660
Urine,22224,U,0,,,,3443,,Urinary recovery evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,1,Cercopithecidae,Autocuration,,,,9527.0,,1088.0,A,BAO_0000218,CHEMBL620957,4661
Urine,22224,U,0,,,,3443,,Urinary recovery compared to Cilastatin evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,1,Cercopithecidae,Autocuration,,,,9527.0,,1088.0,A,BAO_0000218,CHEMBL620958,4662
,22224,U,0,In vivo,,,4257,,Volume of distribution was determined in monkey after a 3 mg/kg of iv dose,1,Cercopithecidae,Autocuration,,,,9527.0,,,A,BAO_0000218,CHEMBL620959,4663
,22224,U,0,In vivo,,,6221,,Volume distribution after oral administration (2.5 mg/kg) in monkey was determined,1,Cercopithecidae,Autocuration,,,,9527.0,,,A,BAO_0000218,CHEMBL620960,4664
,22224,U,0,In vivo,,,5472,,Volume of distribution was evaluated in rhesus,1,Cercopithecidae,Autocuration,,,,9527.0,,,A,BAO_0000218,CHEMBL620961,4665
,22224,U,0,In vivo,,,4727,,Plasma clearance was measured in hamster at the dose of 10 mg/kg by peroral administration,1,Cricetulus griseus,Autocuration,,,,10029.0,,,A,BAO_0000218,CHEMBL620962,4666
,22224,U,0,In vivo,,,4727,,Plasma clearance was measured in hamster at the dose of 3 mg/kg by intravenous administration,1,Cricetulus griseus,Autocuration,,,,10029.0,,,A,BAO_0000218,CHEMBL620963,4667
,22224,U,0,In vivo,,,4727,,Bioavailability in hamster was determined,1,Cricetulus griseus,Autocuration,,,,10029.0,,,A,BAO_0000218,CHEMBL620964,4668
,22224,U,0,In vivo,,,4727,,Bioavailability in hamster at a dose of 3 mg/kg by intravenous administration,1,Cricetulus griseus,Autocuration,,,,10029.0,,,A,BAO_0000218,CHEMBL620965,4669
,22224,U,0,In vivo,,,4727,,Bioavailability in hamster at a dose of 3 mg/kg by oral administration,1,Cricetulus griseus,Autocuration,,,,10029.0,,,A,BAO_0000218,CHEMBL620966,4670
Blood,22224,U,0,,,,4727,,Half life of compound was determined in hamster blood,1,Cricetulus griseus,Autocuration,,,,10029.0,,178.0,A,BAO_0000221,CHEMBL620967,4671
,22224,U,0,,,,1452,,Michaelis-Menten constant of the compound.,1,Sus scrofa,Autocuration,,,,9823.0,,,A,BAO_0000019,CHEMBL620968,4672
,22224,U,0,,,,1452,,Vmax value was measured at 0 uM concentration of silyl ether.,1,Sus scrofa,Autocuration,,,,9823.0,,,A,BAO_0000019,CHEMBL874597,4673
,22224,U,0,,,,1452,,Vmax value was measured at 10 uM concentration of silyl ether.,1,Sus scrofa,Autocuration,,,,9823.0,,,A,BAO_0000019,CHEMBL620969,4674
,22224,U,0,,,,1452,,Vmax value was measured at 5 uM concentration of silyl ether.,1,Sus scrofa,Autocuration,,,,9823.0,,,A,BAO_0000019,CHEMBL620970,4675
,235,D,9,,,,11706,,Inactivation of human leukocyte (neutrophil) elastase(HLE)(HNE) as rate constant,1,Homo sapiens,Expert,,,,9606.0,,,B,BAO_0000357,CHEMBL620971,4676
,22224,U,0,,,,1916,,Area under curve was evaluated against man at a dose of 10 mg/kg after po administration,1,Homo sapiens,Autocuration,,,,9606.0,,,A,BAO_0000218,CHEMBL620972,4677
,22224,U,0,,,,17791,,Compound was evaluated for area under the curve expressed as (h*ug/ml),1,Homo sapiens,Autocuration,,,,9606.0,,,A,BAO_0000019,CHEMBL620973,4678
,22224,U,0,,,,7766,,Active metabolite of ifosfamide determined in humans; A-Active,1,Homo sapiens,Autocuration,,,,9606.0,,,A,BAO_0000019,CHEMBL618243,4679
,22224,U,0,,,,6567,,Amount of tecadenoson present after 30 min in the liver S-9 assay as determined by mass specanalysis,1,Homo sapiens,Autocuration,,,,9606.0,,,A,BAO_0000019,CHEMBL618244,4680
,22224,U,0,,,,6567,,Amount of tecadenoson present after 30 min in the liver S-9 assay as determined by mass specanalysis; -0.5 to 1,1,Homo sapiens,Autocuration,,,,9606.0,,,A,BAO_0000019,CHEMBL618245,4681
,22224,U,0,,,,6567,,Amount of tecadenoson present after 30 min in the liver S-9 assay as determined by mass specanalysis; 1-2,1,Homo sapiens,Autocuration,,,,9606.0,,,A,BAO_0000019,CHEMBL618246,4682
,22224,U,0,,,,6567,,Amount of tecadenoson present after 30 min in the liver S-9 assay as determined by mass specanalysis; trace,1,Homo sapiens,Autocuration,,,,9606.0,,,A,BAO_0000019,CHEMBL618247,4683
,22224,U,0,,,,17791,,Compound was evaluated for oral bioavailability in human,1,Homo sapiens,Autocuration,,,,9606.0,,,A,BAO_0000218,CHEMBL618248,4684
Urine,22224,U,0,,,,7766,,Metabolite of ifosfamide determined in urine; NF-Not found,1,Homo sapiens,Autocuration,,,,9606.0,,1088.0,A,BAO_0000019,CHEMBL618249,4685
,22224,U,0,,,,6852,,Percent of compound in cirrhotic patients of spontaneous ascitic fluid infection (Group A and B),1,Homo sapiens,Autocuration,,,,9606.0,,,A,BAO_0000019,CHEMBL618250,4686
,22224,U,0,,,,6852,,Percent of compound in cirrhotic patients of spontaneous ascitic fluid infection after dosing with normal antibiotics,1,Homo sapiens,Autocuration,,,,9606.0,,,A,BAO_0000019,CHEMBL874598,4687
,22224,U,0,,,,6852,,Percent of compound in cirrhotic patients of spontaneous ascitic fluid infection after dosing with normal antibiotics and lactose,1,Homo sapiens,Autocuration,,,,9606.0,,,A,BAO_0000019,CHEMBL618251,4688
,22224,U,0,,,,6852,,Percent of compound in cirrhotic patients of spontaneous ascitic fluid infection before dosing with normal antibiotics,1,Homo sapiens,Autocuration,,,,9606.0,,,A,BAO_0000019,CHEMBL618252,4689
,22224,U,0,,,,6852,,Percent of compound in cirrhotic patients of spontaneous ascitic fluid infection before dosing with normal antibiotics and lactose,1,Homo sapiens,Autocuration,,,,9606.0,,,A,BAO_0000019,CHEMBL618253,4690
,22224,U,0,,,,6852,,Percent of compound in cirrhotic patients of sterile ascitic fluid (Group C),1,Homo sapiens,Autocuration,,,,9606.0,,,A,BAO_0000019,CHEMBL618254,4691
,22224,U,0,,,,6852,,Percent of compound in healthy individuals (Group D),1,Homo sapiens,Autocuration,,,,9606.0,,,A,BAO_0000019,CHEMBL618255,4692
Liver,22224,U,0,,,Microsomes,4397,,Percent of the parent compound remaining after 20 mins incubation with human liver microsomes,1,Homo sapiens,Autocuration,,,,9606.0,,2107.0,A,BAO_0000251,CHEMBL618983,4693
,22224,U,0,,,,17409,,Binding towards human plasma protein at 10 uM,1,Homo sapiens,Autocuration,,,,9606.0,,,A,BAO_0000019,CHEMBL618984,4694
,22224,U,0,,,,17409,,Binding towards human plasma protein at 100 uM,1,Homo sapiens,Autocuration,,,,9606.0,,,A,BAO_0000019,CHEMBL618985,4695
,22224,U,0,,,,17176,,Human plasma protein binding activity was determined,1,Homo sapiens,Autocuration,,,,9606.0,,,A,BAO_0000019,CHEMBL618986,4696
,22224,U,0,,,,15444,,The ability binding to plasma (Binding classified based on injection of compound at 80 concentration.),1,Homo sapiens,Autocuration,,,,9606.0,,,A,BAO_0000019,CHEMBL618987,4697
,22224,U,0,,,,17267,,Percent binding of compound towards human plasma protein was determined,1,Homo sapiens,Autocuration,,,,9606.0,,,A,BAO_0000019,CHEMBL618988,4698
Liver,22224,U,0,In vitro,,Microsomes,5944,,Plasma clearance in human liver microsomes,1,Homo sapiens,Autocuration,,,,9606.0,,2107.0,A,BAO_0000251,CHEMBL618989,4699
Liver,22224,U,0,In vitro,,Microsomes,5668,,In vitro intrinsic clearance in human liver microsome,1,Homo sapiens,Autocuration,,,,9606.0,,2107.0,A,BAO_0000251,CHEMBL618990,4700
Liver,22224,U,0,In vitro,,Microsomes,5669,,In vitro intrinsic clearance in human liver microsome,1,Homo sapiens,Autocuration,,,,9606.0,,2107.0,A,BAO_0000251,CHEMBL618991,4701
,22224,U,0,In vitro,,Microsomes,5041,,In vitro microsome metabolism clearance in human was determined,1,Homo sapiens,Autocuration,,,,9606.0,,,A,BAO_0000251,CHEMBL876725,4702
,22224,U,0,In vitro,,Microsomes,5041,,In vitro microsome metabolism clearance in human was determined; High,1,Homo sapiens,Autocuration,,,,9606.0,,,A,BAO_0000251,CHEMBL618992,4703
,22224,U,0,In vitro,,Microsomes,5041,,In vitro microsome metabolism clearance in human was determined; ND denotes no data,1,Homo sapiens,Autocuration,,,,9606.0,,,A,BAO_0000251,CHEMBL618993,4704
Liver,22224,U,0,In vitro,,Microsomes,5676,,Pharmacokinetic property (clearance) in human liver microsome,1,Homo sapiens,Autocuration,,,,9606.0,,2107.0,A,BAO_0000251,CHEMBL618994,4705
Liver,22224,U,0,In vitro,,Microsomes,5944,,Plasma clearance in human liver microsomes,1,Homo sapiens,Autocuration,,,,9606.0,,2107.0,A,BAO_0000251,CHEMBL618995,4706
Liver,22224,U,0,In vitro,,Microsomes,17538,,In vitro clearance in human liver microsomes,1,Homo sapiens,Autocuration,,,,9606.0,,2107.0,A,BAO_0000251,CHEMBL618996,4707
Liver,22224,U,0,In vitro,,Microsomes,6331,,Intrinsic clearance in human liver microsomes was determined,1,Homo sapiens,Autocuration,,,,9606.0,,2107.0,A,BAO_0000251,CHEMBL618997,4708
Liver,22224,U,0,In vitro,,Microsomes,5948,,Intrinsic clearance in human liver microsomes was determined,1,Homo sapiens,Autocuration,,,,9606.0,,2107.0,A,BAO_0000251,CHEMBL618998,4709
,22224,U,0,In vivo,,,5965,,Cmax (Tissue distribution) of compound was determined at a dose of 5 mg/kg in human,1,Homo sapiens,Autocuration,,,,9606.0,,,A,BAO_0000218,CHEMBL618999,4710
,22224,U,0,In vivo,,,1916,,Maximum concentration was evaluated against man at a dose of 10 mg/kg after po administration,1,Homo sapiens,Autocuration,,,,9606.0,,,A,BAO_0000218,CHEMBL620223,4711
,22224,U,0,,,,5965,,Cmin (Clearance) of compound was determined at a dose of 5 mg/kg in human,1,Homo sapiens,Autocuration,,,,9606.0,,,A,BAO_0000218,CHEMBL620224,4712
,22224,U,0,,,,1299,,Stability in human plasma 2 hr after incubation expressed as percent concentration,1,Homo sapiens,Autocuration,,,,9606.0,,,A,BAO_0000019,CHEMBL620225,4713
,22224,U,0,,,,1299,,Stability in human plasma 4 hr after incubation expressed as percent concentration,1,Homo sapiens,Autocuration,,,,9606.0,,,A,BAO_0000019,CHEMBL620226,4714
Urine,22224,U,0,,,,7766,,Portion of holoxan excreted in the form of the metabolite from 1200 mL of urine on day 3 was determined in embryonal rhabdomyosarcoma patients treated with ifosfamide,1,Homo sapiens,Autocuration,,,,9606.0,,1088.0,A,BAO_0000019,CHEMBL620227,4715
Urine,22224,U,0,,,,7766,,Portion of holoxan excreted in the form of the metabolite from 1200 mL of urine on day 7 was determined in embryonal rhabdomyosarcoma patients treated with ifosfamide,1,Homo sapiens,Autocuration,,,,9606.0,,1088.0,A,BAO_0000019,CHEMBL876726,4716
Urine,22224,U,0,,,,7766,,Portion of holoxan excreted in the form of the metabolite from 1300 mL of urine on day 6 was determined in embryonal rhabdomyosarcoma patients treated with ifosfamide,1,Homo sapiens,Autocuration,,,,9606.0,,1088.0,A,BAO_0000019,CHEMBL620228,4717
Urine,22224,U,0,,,,7766,,Portion of holoxan excreted in the form of the metabolite from 1300 mL of urine on day 8 was determined in embryonal rhabdomyosarcoma patients treated with ifosfamide,1,Homo sapiens,Autocuration,,,,9606.0,,1088.0,A,BAO_0000019,CHEMBL620229,4718
,50594,N,1,In vivo,,,17764,,Mean-residence time was determined for compound after intraperitoneal administration in mice at 23 uM/kg,1,Mus musculus,Intermediate,,,,10090.0,,,F,BAO_0000218,CHEMBL620230,4719
,50594,N,1,In vivo,,,17764,,Mean-residence time was determined for compound after intraperitoneal administration in mice at 25 uM/kg,1,Mus musculus,Intermediate,,,,10090.0,,,F,BAO_0000218,CHEMBL620231,4720
,50594,N,1,In vivo,,,17764,,Mean-residence time was determined for compound after intraperitoneal administration in mice at 26 uM/kg,1,Mus musculus,Intermediate,,,,10090.0,,,F,BAO_0000218,CHEMBL620232,4721
,50594,N,1,In vivo,,,17764,,Mean-residence time was determined for compound intravenous administration in mice at 23 uM/kg,1,Mus musculus,Intermediate,,,,10090.0,,,F,BAO_0000218,CHEMBL620233,4722
,50594,N,1,,,,14294,,Metabolism of compound in Mouse S9 microsomes ('++++'indicates largest observed peak),1,Mus musculus,Intermediate,,,,10090.0,,,A,BAO_0000218,CHEMBL620234,4723
,50594,N,1,,,,14294,,Metabolism of compound in mouse S9 microsomes ('+''indicates <20% largest observed peak),1,Mus musculus,Intermediate,,,,10090.0,,,A,BAO_0000218,CHEMBL620235,4724
,50594,N,1,,,,14294,,Metabolism of compound in mouse S9 microsomes ('++++' indicates largest observed peak),1,Mus musculus,Intermediate,,,,10090.0,,,A,BAO_0000218,CHEMBL620236,4725
Liver,50594,N,1,,,,6251,,In vitro metabolic potential in mouse liver microsomes,1,Mus musculus,Intermediate,,,,10090.0,,2107.0,A,BAO_0000218,CHEMBL620237,4726
,50594,N,1,,,,17582,,Ability of compound to bind to plasma protein was evaluated in HSA cells,1,Mus musculus,Intermediate,,,,10090.0,,,A,BAO_0000218,CHEMBL620238,4727
Adrenal gland,50594,N,1,,,,17811,,Compound was tested for radioactivity level in mice adrenal glands (Compound is radiolabeled),1,Mus musculus,Intermediate,,,,10090.0,,2369.0,A,BAO_0000218,CHEMBL620239,4728
Brain,50594,N,1,,,,17811,,Compound was tested for radioactivity level in mice brain (Compound is radiolabeled); 2.2-4.9% ID/g,1,Mus musculus,Intermediate,,,,10090.0,,955.0,A,BAO_0000218,CHEMBL620240,4729
Brain,50594,N,1,,,,17811,,Compound was tested for radioactivity level in mice brain (Compound is radiolabeled); 2.6-4.4% ID/g,1,Mus musculus,Intermediate,,,,10090.0,,955.0,A,BAO_0000218,CHEMBL620241,4730
,50594,N,1,,,,17811,,Compound was tested for radioactivity level in mice heart (Compound is radiolabeled),1,Mus musculus,Intermediate,,,,10090.0,,,A,BAO_0000218,CHEMBL876727,4731
Kidney,50594,N,1,,,,17811,,Compound was tested for radioactivity level in mice kidney (Compound is radiolabeled),1,Mus musculus,Intermediate,,,,10090.0,,2113.0,A,BAO_0000218,CHEMBL620242,4732
,50594,N,1,,,,17811,,Compound was tested for radioactivity level in mice lungs (Compound is radiolabeled),1,Mus musculus,Intermediate,,,,10090.0,,,A,BAO_0000218,CHEMBL620243,4733
,50594,N,1,,,,5288,,Tested for urinary recovery in mice after subcutaneous administration of 20 mg/Kg,1,Mus musculus,Intermediate,,,,10090.0,,,A,BAO_0000218,CHEMBL620244,4734
Serum,50594,N,1,,,,2717,,Compound was evaluated for its potency in CDF1 mice and the serum cholesterol levels were determined,1,Mus musculus,Intermediate,,,,10090.0,,1977.0,A,BAO_0000218,CHEMBL620245,4735
Serum,50594,N,1,,,,2717,,Compound was evaluated for its potency in CDF1 mice and the serum metabolite levels were determined,1,Mus musculus,Intermediate,,,,10090.0,,1977.0,A,BAO_0000218,CHEMBL620246,4736
Serum,50594,N,1,,,,2717,,Compound was evaluated for its potency in CDF1 mice and the serum triglyceride levels were determined,1,Mus musculus,Intermediate,,,,10090.0,,1977.0,A,BAO_0000218,CHEMBL620247,4737
Plasma,50594,N,1,In vivo,,,17753,,Half life of compound was determined in plasma of mice at 24 mg/Kg,1,Mus musculus,Intermediate,,,,10090.0,,1969.0,A,BAO_0000218,CHEMBL620248,4738
Plasma,50594,N,1,In vivo,,,17753,,Half life of compound was determined in plasma of mice at 40 mg/Kg,1,Mus musculus,Intermediate,,,,10090.0,,1969.0,A,BAO_0000218,CHEMBL873497,4739
Plasma,50594,N,1,In vivo,,,17753,,Half life of compound was determined in plasma of mice at 5 mg/Kg,1,Mus musculus,Intermediate,,,,10090.0,,1969.0,A,BAO_0000218,CHEMBL620249,4740
,50594,N,1,In vivo,,,17764,,Half life after intraperitoneal administration in mice at 18 uM/kg,1,Mus musculus,Intermediate,,,,10090.0,,,F,BAO_0000218,CHEMBL620250,4741
,50594,N,1,In vivo,,,17764,,Half life after intraperitoneal administration in mice at 23 uM/kg,1,Mus musculus,Intermediate,,,,10090.0,,,F,BAO_0000218,CHEMBL620251,4742
,50594,N,1,In vivo,,,17764,,Half life after intraperitoneal administration in mice at 25 uM/kg,1,Mus musculus,Intermediate,,,,10090.0,,,F,BAO_0000218,CHEMBL620252,4743
,50594,N,1,In vivo,,,17764,,Half life after intraperitoneal administration in mice at 26 uM/kg,1,Mus musculus,Intermediate,,,,10090.0,,,F,BAO_0000218,CHEMBL620253,4744
,50594,N,1,In vivo,,,17764,,Half life after intravenous administration in mice at 23 uM/kg,1,Mus musculus,Intermediate,,,,10090.0,,,F,BAO_0000218,CHEMBL620254,4745
,50594,N,1,In vivo,,,17764,,Half life after intravenous administration in mice at 24 uM/kg,1,Mus musculus,Intermediate,,,,10090.0,,,A,BAO_0000218,CHEMBL620255,4746
,50594,N,1,In vivo,,,16597,,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for T max,1,Mus musculus,Intermediate,,,,10090.0,,,A,BAO_0000218,CHEMBL620256,4747
,50594,N,1,In vivo,,,2675,,Maximum time required to reach Cp max was evaluated in mice after intravenous administration; T max Not determined,1,Mus musculus,Intermediate,,,,10090.0,,,A,BAO_0000218,CHEMBL876728,4748
,50594,N,1,In vivo,,,2675,,Maximum time required to reach Cp max was evaluated in mice after oral administration,1,Mus musculus,Intermediate,,,,10090.0,,,A,BAO_0000218,CHEMBL620257,4749
,50594,N,1,In vivo,,,16597,,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for half life (T1/2),1,Mus musculus,Intermediate,,,,10090.0,,,A,BAO_0000218,CHEMBL620258,4750
,50594,N,1,In vivo,,,4890,,"Compound was evaluated for the pharmacokinetic parameter, Terminal half life period",1,Mus musculus,Intermediate,,,,10090.0,,,A,BAO_0000218,CHEMBL620259,4751
,50594,N,1,In vivo,,,429,,Evaluated for pharmacokinetic parameter half-life in mouse at the dose 20 mg/kg,1,Mus musculus,Intermediate,,,,10090.0,,,A,BAO_0000218,CHEMBL620260,4752
Blood,50594,N,1,In vivo,,,17837,,Half life of compound in mouse blood following i.v. administration of 10 mg/kg,1,Mus musculus,Intermediate,,,,10090.0,,178.0,A,BAO_0000218,CHEMBL620261,4753
,50594,N,1,In vivo,,,16597,,Half life at a dose of 10 mg/kg intravenous administration in mice.,1,Mus musculus,Intermediate,,,,10090.0,,,A,BAO_0000218,CHEMBL620262,4754
,50594,N,1,In vivo,,,16597,,Half life at a dose of 10 mg/kg peroral administration in mice.,1,Mus musculus,Intermediate,,,,10090.0,,,A,BAO_0000218,CHEMBL620263,4755
,50594,N,1,,,,6619,,Half life in ob/ob mice,1,Mus musculus,Intermediate,,,,10090.0,,,A,BAO_0000218,CHEMBL620264,4756
,50594,N,1,In vivo,,,4066,,Half-life at a single subcutaneous administration of 40 mg/kg in mice,1,Mus musculus,Intermediate,,,,10090.0,,,A,BAO_0000218,CHEMBL620265,4757
,50594,N,1,,,,4239,,Half-life was measured in mouse,1,Mus musculus,Intermediate,,,,10090.0,,,A,BAO_0000218,CHEMBL620266,4758
,50594,N,1,In vivo,,,5969,,In vivo half life period was determined in murine septicemia at dose of 50 mg/kg,1,Mus musculus,Intermediate,,,,10090.0,,,A,BAO_0000218,CHEMBL620267,4759
,50594,N,1,,,,8999,,Time for esterases in unfractionated mouse serum to reduce the concentration due to thio ester deacylation,1,Mus musculus,Intermediate,,,,10090.0,,,A,BAO_0000218,CHEMBL619364,4760
,50594,N,1,,,,8999,,Time for esterases in unfractionated mouse serum to reduce the concentration due to thio ester deacylation; 10 % hydrolysis at 60 mins,1,Mus musculus,Intermediate,,,,10090.0,,,A,BAO_0000218,CHEMBL619365,4761
Brain,50594,N,1,,,,17641,,T2 in brain of mice at the oral dose of 50 mg/kg,1,Mus musculus,Intermediate,,,,10090.0,,955.0,A,BAO_0000218,CHEMBL619366,4762
Kidney,50594,N,1,,,,17641,,T2 in kidney of mice at the oral dose of 50 mg/kg,1,Mus musculus,Intermediate,,,,10090.0,,2113.0,A,BAO_0000218,CHEMBL619367,4763
Liver,50594,N,1,,,,17641,,T2 in liver of mice at the oral dose of 50 mg/kg,1,Mus musculus,Intermediate,,,,10090.0,,2107.0,A,BAO_0000218,CHEMBL619368,4764
Lung,50594,N,1,,,,17641,,T2 in lungs of mice at the oral dose of 50 mg/kg,1,Mus musculus,Intermediate,,,,10090.0,,2048.0,A,BAO_0000218,CHEMBL619369,4765
Spleen,50594,N,1,,,,17641,,T2 in spleen of mice at the oral dose of 50 mg/kg,1,Mus musculus,Intermediate,,,,10090.0,,2106.0,A,BAO_0000218,CHEMBL876729,4766
,50594,N,1,In vivo,,,16597,,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for T max,1,Mus musculus,Intermediate,,,,10090.0,,,A,BAO_0000218,CHEMBL619370,4767
,50594,N,1,In vivo,,,4890,,"Compound was evaluated for the pharmacokinetic parameter, maximum time constant",1,Mus musculus,Intermediate,,,,10090.0,,,A,BAO_0000218,CHEMBL619371,4768
,50594,N,1,In vivo,,,429,,Evaluated for pharmacokinetic parameter tmax in mouse at the dose 20 mg/kg,1,Mus musculus,Intermediate,,,,10090.0,,,A,BAO_0000218,CHEMBL619372,4769
,50594,N,1,In vivo,,,429,,Evaluated for pharmacokinetic parameter tmax in mouse at the dose 20 mg/kg was determined,1,Mus musculus,Intermediate,,,,10090.0,,,A,BAO_0000218,CHEMBL620012,4770
,50594,N,1,In vivo,,,5969,,In vivo Tmax was determined in murine septicemia at dose of 100 mg/kg,1,Mus musculus,Intermediate,,,,10090.0,,,A,BAO_0000218,CHEMBL620013,4771
,81034,N,1,,,,16913,,"Inhibitory effect of Gold(III) complex, [Au(bipy)-(OH)2]-[PF6] on growth of cisplatin-resistant A2780/R human tumor cell lines",1,Homo sapiens,Intermediate,,478.0,,9606.0,A2780,,F,BAO_0000219,CHEMBL620014,4772
,81034,N,1,,,,16913,,"Inhibitory effect of Gold(III) complex, [Au(bipy-H)(OH)]-[PF6] on growth of cisplatin-resistant A2780/R human tumor cell lines",1,Homo sapiens,Intermediate,,478.0,,9606.0,A2780,,F,BAO_0000219,CHEMBL620015,4773
,81034,N,1,,,,16913,,"Inhibitory effect of Gold(III) complex, 2,2' bipy on growth of cisplatin-sensitive A2780/S human tumor cell lines",1,Homo sapiens,Intermediate,,478.0,,9606.0,A2780,,F,BAO_0000219,CHEMBL621010,4774
,81034,N,1,,,,16913,,"Inhibitory effect of Gold(III) complex, CDDP on growth of cisplatin-sensitive A2780/S human tumor cell lines",1,Homo sapiens,Intermediate,,478.0,,9606.0,A2780,,F,BAO_0000219,CHEMBL621011,4775
,81034,N,1,,,,16913,,"Inhibitory effect of Gold(III) complex, [Au(bipy)-(OH)2]-[PF6] on growth of cisplatin-sensitive A2780/S human tumor cell lines",1,Homo sapiens,Intermediate,,478.0,,9606.0,A2780,,F,BAO_0000219,CHEMBL621012,4776
,81034,N,1,,,,16913,,"Inhibitory effect of Gold(III) complex, [Au(bipy-H)(OH)]-[PF6] on growth of cisplatin-sensitive A2780/S human tumor cell lines",1,Homo sapiens,Intermediate,,478.0,,9606.0,A2780,,F,BAO_0000219,CHEMBL621013,4777
,81034,N,1,,,,17270,,In vitro cytotoxicity against A2780TAX cell line,1,Homo sapiens,Intermediate,,478.0,,9606.0,A2780,,F,BAO_0000219,CHEMBL621014,4778
,80017,N,1,,,,5618,,In vitro inhibitory activity against human tumor cell line A2780cis,1,Homo sapiens,Intermediate,,481.0,,9606.0,A2780cisR,,F,BAO_0000219,CHEMBL618154,4779
,81034,N,1,,,,17777,,Growth inhibition against A2780 cisplatin resistant wild-type ovarian cell lines,1,Homo sapiens,Expert,,478.0,,9606.0,A2780,,F,BAO_0000219,CHEMBL618155,4780
,80017,N,1,,,,16112,,Antitumor activity of compound for 96-h exposure in A2780cisR (acquired resistance to cisplatin) human ovarian cell line,1,Homo sapiens,Intermediate,,481.0,,9606.0,A2780cisR,,F,BAO_0000219,CHEMBL618156,4781
,80017,N,1,,,,15748,,The compound was tested for cytotoxic activity against A2780cisR cell line(human ovarian carcinoma ),1,Homo sapiens,Intermediate,,481.0,,9606.0,A2780cisR,,F,BAO_0000219,CHEMBL618157,4782
,81034,N,1,,,,6633,,Concentration required to inhibit A2780cisR cell growth when compared with control after incubation for 96 h at 37 C,1,Homo sapiens,Intermediate,,478.0,,9606.0,A2780,,F,BAO_0000219,CHEMBL618328,4783
,81034,N,1,,,,16930,,Compound was evaluated against human Ovarian carcinoma cell line A2780cisR,1,Homo sapiens,Intermediate,,478.0,,9606.0,A2780,,F,BAO_0000219,CHEMBL618329,4784
,81034,N,1,,,,17496,,Cytotoxicity against human ovarian carcinoma A2780cisR cell line,1,Homo sapiens,Intermediate,,478.0,,9606.0,A2780,,F,BAO_0000219,CHEMBL618330,4785
,81034,N,1,,,,12989,,In vitro antitumor activity against A2780cisR cell line.,1,Homo sapiens,Expert,,478.0,,9606.0,A2780,,F,BAO_0000219,CHEMBL618331,4786
,81034,N,1,,,,4840,,Tested for the cytotoxicity in A2780cisR ovarian cell line (cisR denotes resistance to cisplatin),1,Homo sapiens,Intermediate,,478.0,,9606.0,A2780,,F,BAO_0000219,CHEMBL618332,4787
,81034,N,1,,,,12989,,Resistant factor determined between IC50 of resistant line to that of A2780cisR cell line,1,Homo sapiens,Expert,,478.0,,9606.0,A2780,,F,BAO_0000219,CHEMBL618333,4788
,80017,N,1,,,,16745,,cytotoxicity against A2780cisR cells incubated for 24 hr in MTT assay,1,Homo sapiens,Intermediate,,481.0,,9606.0,A2780cisR,,F,BAO_0000219,CHEMBL618334,4789
,81034,N,1,,,,16597,,Inhibition of A2780 / DDP-S human ovarian carcinoma cell proliferation,1,Homo sapiens,Expert,,478.0,,9606.0,A2780,,F,BAO_0000219,CHEMBL618335,4790
,11736,D,9,,,,16547,,Inhibition against A2A-Adenosine Receptor of rat PC12 cell membranes,1,Rattus norvegicus,Expert,,,,10116.0,,,B,BAO_0000019,CHEMBL618336,4791
,11736,H,8,,,,16547,,Inhibition against A2A-Adenosine Receptor of rat PC12 cell membranes (functional antagonist activity),1,,Expert,,,,,,,F,BAO_0000019,CHEMBL618337,4792
,11736,D,9,,,,16547,,Inhibition against A2A-Adenosine Receptor of rat PC12 cell membranes (functional antagonist activity),1,Rattus norvegicus,Expert,,,,10116.0,,,F,BAO_0000019,CHEMBL618338,4793
,278,D,9,,,,15856,,Antagonist activity against human A2B adenosine receptor expressed in HEK293 cells uisng [3H]ZM-241385 or [125I]-IABOPX,1,Homo sapiens,Expert,,722.0,,9606.0,HEK293,,F,BAO_0000219,CHEMBL618339,4794
,278,D,9,,,,15856,,Antagonist activity against human A2B adenosine receptor expressed in HEK293 cells using [3H]ZM-241385 (or) [125 I]IABOPX at 10e-5 M,1,Homo sapiens,Expert,,722.0,,9606.0,HEK293,,F,BAO_0000219,CHEMBL618340,4795
,11831,D,9,,,,16547,,Inhibition against A2B-Adenosine Receptor in mouse NIH 3T3 fibroblast cell membranes,1,Mus musculus,Expert,,,,10090.0,,,B,BAO_0000019,CHEMBL618341,4796
,11831,H,8,,,,16547,,Inhibition against A2B-Adenosine Receptor in mouse NIH 3T3 fibroblast cell membranes (functional antagonist activity),1,,Expert,,,,,,,F,BAO_0000019,CHEMBL618342,4797
,11831,D,9,,,,16547,,Inhibition against A2B-Adenosine Receptor in mouse NIH 3T3 fibroblast cell membranes (functional antagonist activity),1,Mus musculus,Expert,,,,10090.0,,,F,BAO_0000019,CHEMBL618343,4798
,280,H,8,,,,17402,,Ability to displace the binding of [3H]-MRE 3008-F20 to the ligand binding site of CHO:hA3 (human Adenosine receptor) at concentration of 10 uM,1,,Expert,,,,,,,B,BAO_0000357,CHEMBL621038,4799
,22226,U,0,,,,11746,,Compound was tested in vitro for inhibition of cytopathogenicity of LAV(IIIB) in CD4+ T-cells (A3.01),1,Homo sapiens,Autocuration,,574.0,,9606.0,T-cells,,F,BAO_0000219,CHEMBL621039,4800
,22226,U,0,,,,11746,,Compound was tested in vitro for inhibition of cytopathogenicity of LAV(IIIB) in CD4+ T-cells (A3.01); Not active,1,Homo sapiens,Autocuration,,574.0,,9606.0,T-cells,,F,BAO_0000219,CHEMBL621040,4801
,80018,N,1,,,,5455,,Compound was evaluated for cytotoxic activity against human melanoma cell line A375,1,Homo sapiens,Intermediate,,455.0,,9606.0,A-375,,F,BAO_0000219,CHEMBL621041,4802
,80018,N,1,,,,2068,,In vitro antitumor activity against A375 (melanoma) human tumor cell lines.,1,Homo sapiens,Intermediate,,455.0,,9606.0,A-375,,F,BAO_0000219,CHEMBL621042,4803
,80018,N,1,,,,2683,,In vitro antitumor activity against A375cell line extracted form melanoma,1,Homo sapiens,Intermediate,,455.0,,9606.0,A-375,,F,BAO_0000219,CHEMBL621043,4804
,80018,N,1,,,,15313,,Inhibition of cell growth in (A375) melan cell line,1,Homo sapiens,Expert,,455.0,,9606.0,A-375,,F,BAO_0000219,CHEMBL621044,4805
,80018,N,1,,,,13739,,In vitro tumor cell growth inhibitory activity against Human melanoma cell lines A375,1,Homo sapiens,Intermediate,,455.0,,9606.0,A-375,,F,BAO_0000219,CHEMBL621045,4806
,80018,N,1,,,,13739,,In vitro tumor cell growth inhibitory activity against Human melanoma cell lines. A375,1,Homo sapiens,Intermediate,,455.0,,9606.0,A-375,,F,BAO_0000219,CHEMBL621046,4807
,80018,N,1,,,,14750,,Compound was tested in vitro for cytotoxicity against A375 cell lines from melanoma.,1,Homo sapiens,Intermediate,,455.0,,9606.0,A-375,,F,BAO_0000219,CHEMBL621047,4808
,80019,N,1,,,,14777,,Antiproliferative activity measured against A427 human lung carcinoma,1,Homo sapiens,Intermediate,,797.0,,9606.0,A-427,,F,BAO_0000219,CHEMBL621048,4809
,80019,N,1,,,,14777,,Antiproliferative activity measured against A427 human lung carcinoma,1,Homo sapiens,Intermediate,,797.0,,9606.0,A-427,,F,BAO_0000219,CHEMBL883798,4810
,80019,N,1,,,,17672,,Cytotoxicity against lung carcinoma A427 tumor cell lines,1,Homo sapiens,Intermediate,,797.0,,9606.0,A-427,,F,BAO_0000219,CHEMBL621049,4811
,80019,N,1,,,,14368,,Inhibition of large cell lung carcinoma (A427),1,Homo sapiens,Intermediate,,797.0,,9606.0,A-427,,F,BAO_0000219,CHEMBL621050,4812
,80019,N,1,,,,14368,,Inhibition of large cell lung carcinoma (A427) after 48-h treatment,1,Homo sapiens,Intermediate,,797.0,,9606.0,A-427,,F,BAO_0000219,CHEMBL621051,4813
,80019,N,1,,,,13866,,Inhibitory activity against A427 epithelial Cancer cell line at the concentration 0-30 uM for 48 hr,1,Homo sapiens,Intermediate,,797.0,,9606.0,A-427,,F,BAO_0000219,CHEMBL621052,4814
,80019,N,1,,,,2545,,Inhibitory concentration in human lung carcinoma A427 cell line,1,Homo sapiens,Intermediate,,797.0,,9606.0,A-427,,F,BAO_0000219,CHEMBL621053,4815
,80019,N,1,,,,2545,,Inhibitory concentration in human lung carcinoma A427/VCR cell line,1,Homo sapiens,Intermediate,,797.0,,9606.0,A-427,,F,BAO_0000219,CHEMBL621054,4816
,22224,U,0,In vivo,,,6062,,Terminal phase volume of distribution was measured in monkey after an iv dose of 1 mg/kg,1,Cercopithecidae,Autocuration,,,,9527.0,,,A,BAO_0000218,CHEMBL621055,4817
,22224,U,0,In vivo,,,4578,,Tested for volume of distribution upon iv administration to african green monkey,1,Cercopithecidae,Autocuration,,,,9527.0,,,A,BAO_0000218,CHEMBL876398,4818
,22224,U,0,In vivo,,,17592,,Volume of distribution in monkey,1,Cercopithecidae,Autocuration,,,,9527.0,,,A,BAO_0000218,CHEMBL621056,4819
,22224,U,0,In vivo,,,5005,,Compound was tested for its plasma volume distribution in rhesus monkey at a dose of 0.75 mg/kg iv/ 1.5 mg/kg po,1,Macaca mulatta,Autocuration,,,,9544.0,,,A,BAO_0000218,CHEMBL621057,4820
,22224,U,0,In vivo,,,5005,,Compound was tested for its plasma volume distribution in rhesus monkey at a dose of 0.75 mg/kg iv/ 1.5 mg/kg po; ND is not determined.,1,Macaca mulatta,Autocuration,,,,9544.0,,,A,BAO_0000218,CHEMBL621058,4821
,22224,U,0,In vivo,,,5922,,Pharmacokinetic property(Vdss) in cynomolgus monkey,1,Cercopithecidae,Autocuration,,,,9527.0,,,A,BAO_0000218,CHEMBL621059,4822
,22224,U,0,In vivo,,,5355,,The distribution volume after intravenous administration in cynomolgus monkeys,1,Cercopithecidae,Autocuration,,,,9527.0,,,A,BAO_0000218,CHEMBL621060,4823
,22224,U,0,In vivo,,,5355,,The distribution volume after oral administration in cynomolgus monkeys; NA means Not applicable,1,Cercopithecidae,Autocuration,,,,9527.0,,,A,BAO_0000218,CHEMBL621061,4824
,22224,U,0,In vivo,,,5355,,The distribution volume after oral administration in cynomolgus monkeys; NA means not applicable,1,Cercopithecidae,Autocuration,,,,9527.0,,,A,BAO_0000218,CHEMBL621062,4825
,22224,U,0,In vivo,,,6057,,Volume displacement was calculated in rhesus monkey,1,Cercopithecidae,Autocuration,,,,9527.0,,,A,BAO_0000218,CHEMBL621063,4826
,22224,U,0,In vivo,,,5145,,Volume of distribution in steady state was determined in rhesus monkey,1,Cercopithecidae,Autocuration,,,,9527.0,,,A,BAO_0000218,CHEMBL621064,4827
,22224,U,0,In vivo,,,6821,,Volume of distribution of compound was determined in monkey,1,Cercopithecidae,Autocuration,,,,9527.0,,,A,BAO_0000218,CHEMBL621065,4828
,22224,U,0,In vivo,,,5334,,Volume of distribution was reported after intravenous administration at a dose of 1 mg/kg in Rhesus monkey (male),1,Cercopithecidae,Autocuration,,,,9527.0,,,A,BAO_0000218,CHEMBL621066,4829
,22224,U,0,In vivo,,,5334,,Volume of distribution was reported after oral administration at a dose of 2 mg/kg in Rhesus monkey (male),1,Cercopithecidae,Autocuration,,,,9527.0,,,A,BAO_0000218,CHEMBL621067,4830
,22224,U,0,In vivo,,,6641,,Volumes of distribution in monkey (dosed at 0.5 mpk iv and 2.0 mpk orally),1,Cercopithecidae,Autocuration,,,,9527.0,,,A,BAO_0000218,CHEMBL621068,4831
,22224,U,0,In vivo,,,2661,,Compound was evaluated for volume of distribution (steady state) after treatment with iv dose of 1 mgkg to female cynomolgus monkey,1,Cercopithecidae,Autocuration,,,,9527.0,,,A,BAO_0000218,CHEMBL876399,4832
,22224,U,0,In vivo,,,6535,,Volume distribution in monkey after administration of 1 mg/kg iv,1,Cercopithecidae,Autocuration,,,,9527.0,,,A,BAO_0000218,CHEMBL621069,4833
,22224,U,0,In vivo,,,4809,,Volume distribution was determined in monkey after (iv) administration of a dose of 13 (uM/kg),1,Cercopithecidae,Autocuration,,,,9527.0,,,A,BAO_0000218,CHEMBL621070,4834
,22224,U,0,In vivo,,,6062,,Volume of distribution was measured in monkey after an iv dose of 1 mg/kg,1,Cercopithecidae,Autocuration,,,,9527.0,,,A,BAO_0000218,CHEMBL621071,4835
,22224,U,0,In vivo,,,3443,,Half life evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,1,Cercopithecidae,Autocuration,,,,9527.0,,,A,BAO_0000218,CHEMBL621072,4836
,22224,U,0,In vivo,,,4578,,Oral systemic bioavailability upon iv administration to african green monkey,1,Cercopithecidae,Autocuration,,,,9527.0,,,A,BAO_0000218,CHEMBL618209,4837
,22224,U,0,In vivo,,,4809,,Plasma clearance was determined in monkey after (iv) administration of a dose of 13 (uM/kg),1,Cercopithecidae,Autocuration,,,,9527.0,,,A,BAO_0000218,CHEMBL618210,4838
,22224,U,0,,,,11271,,Baboon plasma free fraction. ,1,Cercopithecidae,Autocuration,,,,9527.0,,,A,BAO_0000019,CHEMBL618211,4839
,22224,U,0,,,,6057,,Area under the curve was calculated in rhesus monkey after iv administration,1,Cercopithecidae,Autocuration,,,,9527.0,,,A,BAO_0000218,CHEMBL618212,4840
,22224,U,0,,,,6057,,Area under the curve was calculated in rhesus monkey after peroral administration,1,Cercopithecidae,Autocuration,,,,9527.0,,,A,BAO_0000019,CHEMBL618213,4841
,22224,U,0,,,,17853,,Dose-normalized area under curve in monkey (p.o.) at 2.0 mpk,1,Cercopithecidae,Autocuration,,,,9527.0,,,A,BAO_0000019,CHEMBL618214,4842
,22224,U,0,In vivo,,,5302,,Half life period in monkey after 5 mg/kg dose,1,Cercopithecidae,Autocuration,,,,9527.0,,,A,BAO_0000218,CHEMBL873492,4843
,22224,U,0,In vivo,,,4257,,Half-life was determined in monkey after 3 mg/kg of i.v. dose,1,Cercopithecidae,Autocuration,,,,9527.0,,,A,BAO_0000218,CHEMBL618272,4844
,22224,U,0,In vivo,,,4257,,Half-life was determined in monkey after 3 mg/kg of i.v. dose; Not determined,1,Cercopithecidae,Autocuration,,,,9527.0,,,A,BAO_0000218,CHEMBL618273,4845
Plasma,22224,U,0,In vivo,,,13501,,Apparent Half life was determined from the linear portion of the log plasma concentration-time profile after oral administration of compound 18 at a dose of 1 mg/kg to rhesus monkey,1,Cercopithecidae,Autocuration,,,,9527.0,,1969.0,A,BAO_0000218,CHEMBL618274,4846
,22224,U,0,In vivo,,,5394,,Compound at a dose 3 mg/kg was administered to monkey and was evaluated for half life after administration into monkey at 3 mg/kg,1,Cercopithecidae,Autocuration,,,,9527.0,,,A,BAO_0000218,CHEMBL618275,4847
,22224,U,0,In vivo,,,2661,,Compound was evaluated for half-life after treatment with iv dose of 1 mgkg to female cynomolgus monkey,1,Cercopithecidae,Autocuration,,,,9527.0,,,A,BAO_0000218,CHEMBL618276,4848
,22224,U,0,,,,3341,,Compound was evaluated for terminal half life in monkey,1,Cercopithecidae,Autocuration,,,,9527.0,,,A,BAO_0000019,CHEMBL618277,4849
,22224,U,0,In vivo,,,3045,,Compound was evaluated for the half life period after iv administration in cynomolgus monkey,1,Cercopithecidae,Autocuration,,,,9527.0,,,A,BAO_0000218,CHEMBL618278,4850
Plasma,22224,U,0,In vivo,,,5005,,Compound was tested for its plasma half life in rhesus monkey at a dose of 0.75 mg/kg iv/ 1.5 mg/kg po,1,Macaca mulatta,Autocuration,,,,9544.0,,1969.0,A,BAO_0000218,CHEMBL618279,4851
,22224,U,0,,,,4847,,Half life of compound was determined in squirrel monkey,1,Cercopithecidae,Autocuration,,,,9527.0,,,A,BAO_0000019,CHEMBL618280,4852
,22224,U,0,In vivo,,,4256,,Half life after iv administration in cynomolgus monkey,1,Macaca fascicularis,Autocuration,,,,9541.0,,,A,BAO_0000218,CHEMBL618281,4853
Plasma,22224,U,0,In vivo,,,6535,,Half life in monkey plasma after administration of 1 mg/kg iv,1,Cercopithecidae,Autocuration,,,,9527.0,,1969.0,A,BAO_0000218,CHEMBL618282,4854
,22224,U,0,,,,6057,,Half life was calculated in rhesus monkey,1,Cercopithecidae,Autocuration,,,,9527.0,,,A,BAO_0000019,CHEMBL618283,4855
,22224,U,0,,,,17592,,Half life in monkey,1,Cercopithecidae,Autocuration,,,,9527.0,,,A,BAO_0000019,CHEMBL618284,4856
,22224,U,0,In vivo,,,6641,,Half life in monkey (dosed at 0.5 mpk iv and 2.0 mpk orally),1,Cercopithecidae,Autocuration,,,,9527.0,,,A,BAO_0000218,CHEMBL618285,4857
,22224,U,0,,,,5472,,Half life was evaluated in rhesus,1,Cercopithecidae,Autocuration,,,,9527.0,,,A,BAO_0000019,CHEMBL618286,4858
,22224,U,0,In vivo,,,6221,,Half life period after oral administration (2.5 mg/kg) in monkey was determined,1,Cercopithecidae,Autocuration,,,,9527.0,,,A,BAO_0000218,CHEMBL618287,4859
,22224,U,0,In vivo,,,5668,,Half life period was determine after peroral administration at 10 mpk in Rhesus,1,Cercopithecidae,Autocuration,,,,9527.0,,,A,BAO_0000218,CHEMBL618288,4860
,22224,U,0,In vivo,,,4809,,Half life period was determined in monkey after (iv) administration of a dose of 13 (uM/kg),1,Cercopithecidae,Autocuration,,,,9527.0,,,A,BAO_0000218,CHEMBL876393,4861
,22224,U,0,In vivo,,,5546,,Half life period was determined in rhesus monkey at a dose of 1 mg/kg by iv administration,1,Cercopithecidae,Autocuration,,,,9527.0,,,A,BAO_0000218,CHEMBL618289,4862
,22224,U,0,In vivo,,,5553,,Half life period was determined in squirrel monkey after iv administration at a dose of 5 mg/kg,1,Cercopithecidae,Autocuration,,,,9527.0,,,A,BAO_0000218,CHEMBL618290,4863
,22224,U,0,,,,6078,,Half-life was calculated in monkey,1,Cercopithecidae,Autocuration,,,,9527.0,,,A,BAO_0000019,CHEMBL618291,4864
,22224,U,0,,,,5147,,Half-life in Squirrel monkey,1,Cercopithecidae,Autocuration,,,,9527.0,,,A,BAO_0000019,CHEMBL618292,4865
,22224,U,0,,,,5145,,Half-life in rhesus monkey,1,Cercopithecidae,Autocuration,,,,9527.0,,,A,BAO_0000019,CHEMBL618293,4866
,22224,U,0,In vivo,,,6062,,Half-life was measured in monkey after an iv dose of 1 mg/kg,1,Cercopithecidae,Autocuration,,,,9527.0,,,A,BAO_0000218,CHEMBL618294,4867
,22224,U,0,In vivo,,,5355,,Half-life period after intravenous administration in cynomolgus monkeys,1,Cercopithecidae,Autocuration,,,,9527.0,,,A,BAO_0000218,CHEMBL618295,4868
,22224,U,0,In vivo,,,5355,,Half-life period after oral administration in cynomolgus monkeys,1,Cercopithecidae,Autocuration,,,,9527.0,,,A,BAO_0000218,CHEMBL618296,4869
,22224,U,0,In vivo,,,5355,,Half-life period after oral administration in cynomolgus monkeys; ND meansn Not determined,1,Cercopithecidae,Autocuration,,,,9527.0,,,A,BAO_0000218,CHEMBL618297,4870
Urine,22224,U,0,,,,7766,,Portion of holoxan excreted in the form of the metabolite from 1500 mL of urine on day 9 was determined in embryonal rhabdomyosarcoma patients treated with ifosfamide,1,Homo sapiens,Autocuration,,,,9606.0,,1088.0,A,BAO_0000019,CHEMBL618298,4871
Urine,22224,U,0,,,,7766,,Portion of holoxan excreted in the form of the metabolite from 1600 mL of urine on day 10 was determined in embryonal rhabdomyosarcoma patients treated with ifosfamide,1,Homo sapiens,Autocuration,,,,9606.0,,1088.0,A,BAO_0000019,CHEMBL618299,4872
Urine,22224,U,0,,,,7766,,Portion of holoxan excreted in the form of the metabolite from 1700 mL of urine on day 5 was determined in embryonal rhabdomyosarcoma patients treated with ifosfamide,1,Homo sapiens,Autocuration,,,,9606.0,,1088.0,A,BAO_0000019,CHEMBL618300,4873
Urine,22224,U,0,,,,7766,,Portion of holoxan excreted in the form of the metabolite from 2310 mL of urine on day 4 was determined in embryonal rhabdomyosarcoma patients treated with ifosfamide,1,Homo sapiens,Autocuration,,,,9606.0,,1088.0,A,BAO_0000019,CHEMBL618301,4874
Urine,22224,U,0,,,,7766,,Percent ratio of the enantiomeric form (+)R extracted from the urine of alveolar rhabdomyosarcoma patients was determined,1,Homo sapiens,Autocuration,,,,9606.0,,1088.0,A,BAO_0000019,CHEMBL618302,4875
Urine,22224,U,0,,,,7766,,Percent ratio of the enantiomeric form (+)R extracted from the urine of embryonal rhabdomyosarcoma patients was determined,1,Homo sapiens,Autocuration,,,,9606.0,,1088.0,A,BAO_0000019,CHEMBL876394,4876
Urine,22224,U,0,,,,7766,,Percent ratio of the enantiomeric form (-)S extracted from the urine of alveolar rhabdomyosarcoma patients was determined,1,Homo sapiens,Autocuration,,,,9606.0,,1088.0,A,BAO_0000019,CHEMBL618303,4877
Urine,22224,U,0,,,,7766,,Percent ratio of the enantiomeric form (-)S extracted from the urine of embryonal rhabdomyosarcoma patients was determined,1,Homo sapiens,Autocuration,,,,9606.0,,1088.0,A,BAO_0000019,CHEMBL618304,4878
,22224,U,0,In vivo,,,1916,,Bioavailability was evaluated in man at a dose of 10 mg/kg after po administration; not determined,1,Homo sapiens,Autocuration,,,,9606.0,,,A,BAO_0000218,CHEMBL618305,4879
,22224,U,0,In vivo,,,16643,,Oral bioavailability in human,1,Homo sapiens,Autocuration,,,,9606.0,,,A,BAO_0000218,CHEMBL618306,4880
,22224,U,0,,,,17248,,Compound was tested for human plasma protein binding,1,Homo sapiens,Autocuration,,,,9606.0,,,A,BAO_0000019,CHEMBL618307,4881
,22224,U,0,,,,17248,,Compound was tested for human plasma protein binding; Not determined,1,Homo sapiens,Autocuration,,,,9606.0,,,A,BAO_0000019,CHEMBL618308,4882
,22224,U,0,,,,6241,,Protein binding activity of compound in human plasma; % Free,1,Homo sapiens,Autocuration,,,,9606.0,,,A,BAO_0000019,CHEMBL618309,4883
,22224,U,0,,,,17716,,Unbound fraction (plasma),1,Homo sapiens,Autocuration,,,,9606.0,,,A,BAO_0000019,CHEMBL618310,4884
Plasma,22224,U,0,,,,17605,,Half life for the hydrolysis of compound in human blood serum,1,Homo sapiens,Autocuration,,,,9606.0,,1969.0,A,BAO_0000366,CHEMBL873353,4885
Plasma,22224,U,0,,,,17625,,Half life period in human plasma using phosphate buffer (0.08 M),1,Homo sapiens,Autocuration,,,,9606.0,,1969.0,A,BAO_0000366,CHEMBL618311,4886
Plasma,22224,U,0,,,,17625,,Half life period in human plasma using phosphate buffer (0.1 M),1,Homo sapiens,Autocuration,,,,9606.0,,1969.0,A,BAO_0000366,CHEMBL618312,4887
Plasma,22224,U,0,,,,17747,,Half-life in human plasma was determined,1,Homo sapiens,Autocuration,,,,9606.0,,1969.0,A,BAO_0000366,CHEMBL618313,4888
,22224,U,0,,,,15613,,Concentration required for 50% toxicity in metastatic lung carcinoma (MV522) cells.,1,Homo sapiens,Autocuration,,,,9606.0,,,A,BAO_0000019,CHEMBL618314,4889
,22224,U,0,,,,354,,Effect of compound on gelation time of human serum induced by dithiothreitol (DTT),1,Homo sapiens,Autocuration,,,,9606.0,,,A,BAO_0000019,CHEMBL618315,4890
,22224,U,0,,,,3741,,"Rate constant in chemical and enzymatic hydrolysis to form L-DOPA, in 80% human plasma",1,Homo sapiens,Autocuration,,,,9606.0,,,A,BAO_0000019,CHEMBL618316,4891
,22224,U,0,,,,3741,,"Rate constant in chemical and enzymatic hydrolysis to form another compound (8)*, in 80% human plasma (experiment 1)",1,Homo sapiens,Autocuration,,,,9606.0,,,A,BAO_0000019,CHEMBL618317,4892
,22224,U,0,,,,3741,,"Rate constant in chemical and enzymatic hydrolysis to form another compound (8)*, in 80% human plasma (experiment 2)",1,Homo sapiens,Autocuration,,,,9606.0,,,A,BAO_0000019,CHEMBL620138,4893
,22224,U,0,,,,17599,,Partition coefficient (logP),1,Homo sapiens,Autocuration,,,,9606.0,,,A,BAO_0000019,CHEMBL858280,4894
,22224,U,0,,,,5486,,In vitro metabolic stability in human was measured as pmol/min/mg/protein,1,Homo sapiens,Autocuration,,,,9606.0,,,A,BAO_0000019,CHEMBL620139,4895
,22224,U,0,,,Microsomes,5600,,In vitro metabolic stability determined after 30 min of incubation in human hepatic microsomes,1,Homo sapiens,Autocuration,,,,9606.0,,,A,BAO_0000251,CHEMBL620140,4896
,22224,U,0,,,,14294,,Metabolism of compound in human liver slices (male) ('+''indicates <20% largest observed peak),1,Homo sapiens,Autocuration,,,,9606.0,,,A,BAO_0000019,CHEMBL620141,4897
,22224,U,0,,,,14294,,Metabolism of compound in human liver slices (male) ('++''indicates 20-50% largest observed peak),1,Homo sapiens,Autocuration,,,,9606.0,,,A,BAO_0000019,CHEMBL620142,4898
,22224,U,0,,,,14294,,Metabolism of compound in human liver slices (male) ('++++' indicates largest observed peak),1,Homo sapiens,Autocuration,,,,9606.0,,,A,BAO_0000019,CHEMBL620143,4899
,22224,U,0,,,Microsomes,14294,,Metabolism of compound in human microsomes ('+''indicates <20% largest observed peak),1,Homo sapiens,Autocuration,,,,9606.0,,,A,BAO_0000251,CHEMBL620144,4900
,22224,U,0,,,Microsomes,14294,,Metabolism of compound in human microsomes ('++++' indicates largest observed peak),1,Homo sapiens,Autocuration,,,,9606.0,,,A,BAO_0000251,CHEMBL620145,4901
,22224,U,0,,,Microsomes,14294,,Metabolism of compound in human microsomes; Trace,1,Homo sapiens,Autocuration,,,,9606.0,,,A,BAO_0000251,CHEMBL620146,4902
Liver,22224,U,0,,,Microsomes,6260,,Percent of compound remaining after 120 min of Metabolization upon incubation with human liver microsomes,1,Homo sapiens,Autocuration,,,,9606.0,,2107.0,A,BAO_0000251,CHEMBL620147,4903
,22224,U,0,,,Microsomes,6187,,Percent metabolized in an in vitro human liver microsomal incubation assay after 60 min,1,Homo sapiens,Autocuration,,,,9606.0,,,A,BAO_0000251,CHEMBL620148,4904
Liver,22224,U,0,,,Microsomes,6251,,In vitro metabolic potential in human liver microsomes,1,Homo sapiens,Autocuration,,,,9606.0,,2107.0,A,BAO_0000251,CHEMBL620149,4905
,22224,U,0,,,,3246,,Metabolism by recombinant human NAD(P)H:quinone oxidoreductase (NQO1) was evaluated,1,Homo sapiens,Autocuration,,,,9606.0,,,A,BAO_0000019,CHEMBL876412,4906
,22224,U,0,,,,17313,,Tested for human plasma protein binding of the compound; Not tested,1,Homo sapiens,Autocuration,,,,9606.0,,,A,BAO_0000019,CHEMBL619352,4907
,22224,U,0,,,,6227,,Compound was tested for percent protein binding (PB) in human,1,Homo sapiens,Autocuration,,,,9606.0,,,A,BAO_0000019,CHEMBL619353,4908
Plasma,22224,U,0,,,,5530,,Protein binding in human plasma,1,Homo sapiens,Autocuration,,,,9606.0,,1969.0,A,BAO_0000019,CHEMBL619354,4909
,22224,U,0,,,,6108,,Permeability coefficient (B to A) in Caco-2 cell,1,Homo sapiens,Autocuration,,,,9606.0,,,A,BAO_0000019,CHEMBL619355,4910
,22224,U,0,,,,6108,,Permeability directional ratio (PB-A/PA-B) in Caco-2 cell,1,Homo sapiens,Autocuration,,,,9606.0,,,A,BAO_0000019,CHEMBL619356,4911
,22224,U,0,,,,2774,,Apparent permeability coefficient (Papp) was determined in human Caco-2 cell monolayer (n = 3),1,Homo sapiens,Autocuration,,,,9606.0,,,A,BAO_0000019,CHEMBL619357,4912
,22224,U,0,,,,16643,,In vitro rate of absorption observed as Caco-2 permeability in humans,1,Homo sapiens,Autocuration,,,,9606.0,,,A,BAO_0000019,CHEMBL619358,4913
,22224,U,0,,,,17582,,Cellular permeability of compound was determined in Caco-2 cells; High,1,Homo sapiens,Autocuration,,495.0,,9606.0,Caco-2,,A,BAO_0000219,CHEMBL619359,4914
,22224,U,0,,,,6838,,Permeability in Caco-2 cells of compound,1,Homo sapiens,Autocuration,,495.0,,9606.0,Caco-2,,A,BAO_0000219,CHEMBL619360,4915
,22224,U,0,,,,6108,,Permeability coefficient (A to B) in Caco-2 cell,1,Homo sapiens,Autocuration,,,,9606.0,,,A,BAO_0000019,CHEMBL619361,4916
,22224,U,0,,,,6108,,Permeability coefficient (B to A) in Caco-2 cell,1,Homo sapiens,Autocuration,,,,9606.0,,,A,BAO_0000019,CHEMBL619362,4917
,22224,U,0,,,,6108,,Permeability coefficient (Papp) (Caco-2 cell monolayer),1,Homo sapiens,Autocuration,,,,9606.0,,,A,BAO_0000019,CHEMBL619363,4918
,22224,U,0,,,,2146,,Compound was measured for binding rate for human serum at a carbapenem concentration of 10 ug/mL,1,Homo sapiens,Autocuration,,,,9606.0,,,A,BAO_0000019,CHEMBL618942,4919
,22224,U,0,,,,4514,,Compound was tested for protein binding in human plasma,1,Homo sapiens,Autocuration,,,,9606.0,,,A,BAO_0000019,CHEMBL618943,4920
,22224,U,0,,,,6108,,Transcellular permeability of the [(PA-B+PB-A)/2)] compound was determined in Caco-2 cell,1,Homo sapiens,Autocuration,,,,9606.0,,,A,BAO_0000019,CHEMBL618944,4921
Urine,22224,U,0,,,,7766,,Quantity of the metabolite found in the urine of the embryonal rhabdomyosarcoma patients treated with ifosfamide from 1200 mL of urine tested on day 3,1,Homo sapiens,Autocuration,,,,9606.0,,1088.0,A,BAO_0000019,CHEMBL618945,4922
,50594,N,1,In vivo,,,5969,,In vivo Tmax was determined in murine septicemia at dose of 50 mg/kg,1,Mus musculus,Intermediate,,,,10090.0,,,A,BAO_0000218,CHEMBL618946,4923
,50594,N,1,In vivo,,,3277,,Maximum time was determined in mice at a single subcutaneous administration of 40 mg/kg (n=4),1,Mus musculus,Intermediate,,,,10090.0,,,A,BAO_0000218,CHEMBL876413,4924
,50594,N,1,In vivo,,,3802,,Tested for Tmax value at the dose of 10 mg/kg when administered perorally in mouse,1,Mus musculus,Intermediate,,,,10090.0,,,A,BAO_0000218,CHEMBL618947,4925
Plasma,50594,N,1,In vivo,,,2862,,Time taken to reach maximum concentration in plasma upon oral administration in mouse,1,Mus musculus,Intermediate,,,,10090.0,,1969.0,A,BAO_0000218,CHEMBL618948,4926
Plasma,50594,N,1,In vivo,,,6348,,Time to reach maximum plasma concentration was determined in mouse after 5 mg/kg (i.v.) and 6 mg/kg (p.o.) administration,1,Mus musculus,Intermediate,,,,10090.0,,1969.0,A,BAO_0000218,CHEMBL618949,4927
,50594,N,1,In vivo,,,17764,,Tmax after intraperitoneal administration in mice at 23 uM/kg,1,Mus musculus,Intermediate,,,,10090.0,,,F,BAO_0000218,CHEMBL618950,4928
,50594,N,1,In vivo,,,5781,,Tmax after oral administration at 30 mg/kg in ICR mouse,1,Mus musculus,Intermediate,,,,10090.0,,,A,BAO_0000218,CHEMBL618951,4929
,50594,N,1,In vivo,,,17764,,Tmax after peroral administration in mice at 2.4 uM/kg,1,Mus musculus,Intermediate,,,,10090.0,,,A,BAO_0000218,CHEMBL618952,4930
,50594,N,1,In vivo,,,4066,,Tmax at a single subcutaneous administration of 40 mg/kg in mice,1,Mus musculus,Intermediate,,,,10090.0,,,A,BAO_0000218,CHEMBL618953,4931
Brain,50594,N,1,In vivo,,,17641,,Tmax in brain of mice at the oral dose of 50 mg/kg,1,Mus musculus,Intermediate,,,,10090.0,,955.0,A,BAO_0000218,CHEMBL618954,4932
Kidney,50594,N,1,In vivo,,,17641,,Tmax in kidney of mice at the oral dose of 50 mg/kg,1,Mus musculus,Intermediate,,,,10090.0,,2113.0,A,BAO_0000218,CHEMBL618955,4933
Liver,50594,N,1,In vivo,,,17641,,Tmax in liver of mice at the oral dose of 50 mg/kg,1,Mus musculus,Intermediate,,,,10090.0,,2107.0,A,BAO_0000218,CHEMBL618956,4934
Lung,50594,N,1,In vivo,,,17641,,Tmax in lungs of mice at the oral dose of 50 mg/kg,1,Mus musculus,Intermediate,,,,10090.0,,2048.0,A,BAO_0000218,CHEMBL618957,4935
,50594,N,1,In vivo,,,17764,,Tmax in mice at 18 uM/kg i.p. administration,1,Mus musculus,Intermediate,,,,10090.0,,,F,BAO_0000218,CHEMBL618958,4936
,50594,N,1,In vivo,,,17764,,Tmax in mice at 23 uM/kg i.v. administration,1,Mus musculus,Intermediate,,,,10090.0,,,F,BAO_0000218,CHEMBL618959,4937
,50594,N,1,In vivo,,,17764,,Tmax in mice at 25 uM/kg i.p. administration,1,Mus musculus,Intermediate,,,,10090.0,,,F,BAO_0000218,CHEMBL618960,4938
,50594,N,1,In vivo,,,17764,,Tmax in mice at 26 uM/kg i.p. administration,1,Mus musculus,Intermediate,,,,10090.0,,,F,BAO_0000218,CHEMBL876723,4939
Spleen,50594,N,1,In vivo,,,17641,,Tmax in spleen of mice at the oral dose of 50 mg/kg,1,Mus musculus,Intermediate,,,,10090.0,,2106.0,A,BAO_0000218,CHEMBL618961,4940
,50594,N,1,In vivo,,,16597,,Tmax value at a dose of 10 mg/kg intravenous administration in mice.,1,Mus musculus,Intermediate,,,,10090.0,,,A,BAO_0000218,CHEMBL618962,4941
,50594,N,1,In vivo,,,16597,,Tmax value at a dose of 10 mg/kg peroral administration in mice.,1,Mus musculus,Intermediate,,,,10090.0,,,A,BAO_0000218,CHEMBL618963,4942
,50594,N,1,,,,5951,,Tmax value in IRC mice,1,Mus musculus,Intermediate,,,,10090.0,,,A,BAO_0000218,CHEMBL618964,4943
,50594,N,1,In vivo,,,5506,,Tmax value was determined at a dose of 100 mg/kg (i.p.) in Mice,1,Mus musculus,Intermediate,,,,10090.0,,,A,BAO_0000218,CHEMBL618965,4944
,50594,N,1,In vivo,,,5506,,Tmax value was determined at a dose of 200 mg/kg (i.p.) in Mice,1,Mus musculus,Intermediate,,,,10090.0,,,A,BAO_0000218,CHEMBL618966,4945
Urine,50594,N,1,,,,429,,Evaluated for pharmacokinetic parameter urine recovery in mouse at the dose 20 mg/kg ( 0-24 hr ),1,Mus musculus,Intermediate,,,,10090.0,,1088.0,A,BAO_0000218,CHEMBL618967,4946
Urine,50594,N,1,,,,429,,Evaluated for pharmacokinetic parameter urine recovery in mouse at the dose 20 mg/kg (0-24 hr),1,Mus musculus,Intermediate,,,,10090.0,,1088.0,A,BAO_0000218,CHEMBL618968,4947
Urine,50594,N,1,,,,4066,,Urinary recovery by disk method using Streptococcus pyogenes (0-24 h),1,Mus musculus,Intermediate,,,,10090.0,,1088.0,A,BAO_0000218,CHEMBL618969,4948
,50594,N,1,,,,17734,,The first compartment constitutes the majority of the volume of distribution after intraperitoneal administration of 100 mg/kg in mice,1,Mus musculus,Intermediate,,,,10090.0,,,A,BAO_0000218,CHEMBL618970,4949
,50594,N,1,,,,17734,,The second majority of the volume of distribution after intraperitoneal administration of 100 mg/kg in mice,1,Mus musculus,Intermediate,,,,10090.0,,,A,BAO_0000218,CHEMBL618971,4950
,50594,N,1,In vivo,,,6062,,Terminal phase volume of distribution was measured in mouse after an iv dose of 1 mg/kg,1,Mus musculus,Intermediate,,,,10090.0,,,A,BAO_0000218,CHEMBL618972,4951
,50594,N,1,In vivo,,,5969,,In vivo volume distribution (Vd) was determined in murine septicemia at dose of 100 mg/kg,1,Mus musculus,Intermediate,,,,10090.0,,,A,BAO_0000218,CHEMBL618973,4952
,50594,N,1,In vivo,,,5969,,In vivo volume distribution (Vd) was determined in murine septicemia at dose of 50 mg/kg,1,Mus musculus,Intermediate,,,,10090.0,,,A,BAO_0000218,CHEMBL618974,4953
,50594,N,1,In vivo,,,5969,,In vivo volume distribution (Vd) was determined in murine septicemia at dose of 50 mg/kg;ND=not determined,1,Mus musculus,Intermediate,,,,10090.0,,,A,BAO_0000218,CHEMBL618975,4954
,50594,N,1,In vivo,,,5980,,Vd in mice,1,Mus musculus,Intermediate,,,,10090.0,,,A,BAO_0000218,CHEMBL618976,4955
,50594,N,1,In vivo,,,17592,,Volume of distribution in mouse,1,Mus musculus,Intermediate,,,,10090.0,,,A,BAO_0000218,CHEMBL618977,4956
,50594,N,1,In vivo,,,6348,,Volume of distribution was determined in mouse after 5 mg/kg (i.v.) and 6 mg/kg (p.o.) administration,1,Mus musculus,Intermediate,,,,10090.0,,,A,BAO_0000218,CHEMBL876724,4957
,50594,N,1,In vivo,,,17753,,Volume of distribution of compound in plasma was determined at 24 mg/Kg,1,Mus musculus,Intermediate,,,,10090.0,,,A,BAO_0000218,CHEMBL618978,4958
,50594,N,1,In vivo,,,17753,,Volume of distribution of compound in plasma was determined at 40 mg/Kg,1,Mus musculus,Intermediate,,,,10090.0,,,A,BAO_0000218,CHEMBL618979,4959
,50594,N,1,In vivo,,,17753,,Volume of distribution of compound in plasma was determined at 5 mg/Kg,1,Mus musculus,Intermediate,,,,10090.0,,,A,BAO_0000218,CHEMBL618980,4960
,50594,N,1,In vivo,,,4239,,Pharmacokinetic property (vdss) was measured in mouse,1,Mus musculus,Intermediate,,,,10090.0,,,A,BAO_0000218,CHEMBL618981,4961
,50594,N,1,In vivo,,,2862,,Value distribution upon iv administration in mouse,1,Mus musculus,Intermediate,,,,10090.0,,,A,BAO_0000218,CHEMBL618982,4962
,50594,N,1,In vivo,,,17734,,Volume of distribution after intraperitoneal administration of 100 mg/kg in mice,1,Mus musculus,Intermediate,,,,10090.0,,,A,BAO_0000218,CHEMBL620150,4963
,50594,N,1,In vivo,,,2675,,Volume of distribution was evaluated in mice after intravenous administration,1,Mus musculus,Intermediate,,,,10090.0,,,A,BAO_0000218,CHEMBL620151,4964
,50594,N,1,In vivo,,,2675,,Volume of distribution was evaluated in mice after oral administration,1,Mus musculus,Intermediate,,,,10090.0,,,A,BAO_0000218,CHEMBL620152,4965
,50594,N,1,In vivo,,,17837,,Steady state volume of distribution of compound in mouse blood following i.v. administration of 10 mg/kg,1,Mus musculus,Intermediate,,,,10090.0,,,A,BAO_0000218,CHEMBL620153,4966
,50594,N,1,In vivo,,,5727,,Steady state volume of distribution was determined in mice,1,Mus musculus,Intermediate,,,,10090.0,,,A,BAO_0000218,CHEMBL876395,4967
,50594,N,1,In vivo,,,17852,,Volume distribution (steady state) of compound was determined in mouse,1,Mus musculus,Intermediate,,,,10090.0,,,A,BAO_0000218,CHEMBL620154,4968
,50594,N,1,In vivo,,,17764,,Volume of solubility in solution after intravenous administration in mice at 24 uM/kg,1,Mus musculus,Intermediate,,,,10090.0,,,A,BAO_0000218,CHEMBL620155,4969
,50594,N,1,In vivo,,,16597,,Vss value at a dose of 10 mg/kg intravenous administration in mice.,1,Mus musculus,Intermediate,,,,10090.0,,,A,BAO_0000218,CHEMBL620156,4970
,50594,N,1,In vivo,,,6062,,Volume of distribution was measured in mouse after an iv dose of 1 mg/kg,1,Mus musculus,Intermediate,,,,10090.0,,,A,BAO_0000218,CHEMBL620157,4971
Kidney,50594,N,1,In vivo,,,16438,,Biodistribution of compound (oxidized form) in in kidney tissue,1,Mus musculus,Intermediate,,,,10090.0,,2113.0,A,BAO_0000218,CHEMBL620158,4972
Blood,50594,N,1,In vivo,,,16438,,Biodistribution in mice as total concentration of both oxidized and reduced forms in blood and animals were sacrificed 10 minutes after ip administration in DMSO solution,1,Mus musculus,Intermediate,,,,10090.0,,178.0,A,BAO_0000218,CHEMBL620159,4973
Blood,50594,N,1,In vivo,,,16438,,"Biodistribution in mice as total concentration of both oxidized and reduced forms in blood and animals were sacrificed 10 minutes after ip dosing, in DMSO solution",1,Mus musculus,Intermediate,,,,10090.0,,178.0,A,BAO_0000218,CHEMBL620160,4974
Blood,50594,N,1,In vivo,,,16438,,"Biodistribution in mice as total concentration of both oxidized and reduced forms in blood tissues, animals were sacrificed 60 minutes after dosing, in DMSO sol.",1,Mus musculus,Intermediate,,,,10090.0,,178.0,A,BAO_0000218,CHEMBL620161,4975
,80019,N,1,,,,10708,,Evaluated for the inhibitory concentration required to cause growth inhibition of A427Mer- cell line of lung using the MTT Cytotoxicity Assay,1,Homo sapiens,Intermediate,,797.0,,9606.0,A-427,,F,BAO_0000219,CHEMBL620162,4976
,80852,N,1,,,,16597,,Inhibition of A431 human squamous cell carcinoma cell proliferation,1,Homo sapiens,Expert,,500.0,,9606.0,A-431,,F,BAO_0000219,CHEMBL620163,4977
,80852,N,1,,,,16062,,Inhibition of cell growth of human epidermoid carcinoma xenograft (A431) model using cell based assay,1,Homo sapiens,Expert,,500.0,,9606.0,A-431,,F,BAO_0000219,CHEMBL620833,4978
,80852,N,1,,,,16062,,Inhibition of human epidermoid carcinoma xenograft (A431) tumor growth,1,Homo sapiens,Expert,,500.0,,9606.0,A-431,,F,BAO_0000219,CHEMBL876396,4979
,80852,N,1,,,,16958,,Concentration required to inhibit growth of human carcinoma epidermoid (A431) cell line,1,Homo sapiens,Expert,,500.0,,9606.0,A-431,,F,BAO_0000219,CHEMBL620834,4980
,80852,N,1,,,,6700,,Inhibition of A431 human carcinoma cell proliferation,1,Homo sapiens,Expert,,500.0,,9606.0,A-431,,F,BAO_0000219,CHEMBL620835,4981
,80852,N,1,,,,17226,,In vitro inhibition of A431 (human carcinoma) cell basal growth.,1,Homo sapiens,Expert,,500.0,,9606.0,A-431,,F,BAO_0000219,CHEMBL620836,4982
,80852,N,1,,,,6828,,Inhibitory concentration of compound against growth of human A431 cell line; Resistant,1,Homo sapiens,Intermediate,,500.0,,9606.0,A-431,,F,BAO_0000219,CHEMBL620837,4983
,80852,N,1,,,,12314,,In vitro cytotoxicity against epidermoid carcinoma cell line,1,Homo sapiens,Intermediate,,500.0,,9606.0,A-431,,F,BAO_0000219,CHEMBL621017,4984
,9,D,9,,,,13412,,"In vivo efficacy following oral administration in nude mouse tumor model, xenograft A431 cells expressing EGF-R",1,Homo sapiens,Expert,,500.0,,9606.0,A-431,,F,BAO_0000218,CHEMBL621018,4985
,80852,N,1,,,,13299,,Antiproliferative activity of compound was measured on human tumor cell line A431.,1,Homo sapiens,Intermediate,,500.0,,9606.0,A-431,,F,BAO_0000219,CHEMBL621019,4986
,80852,N,1,,,,17420,,Antiproliferative effect of compound on A431 cell line expressing mutant p53,1,Homo sapiens,Intermediate,,500.0,,9606.0,A-431,,F,BAO_0000219,CHEMBL621020,4987
,80852,N,1,,,,13678,,Compound was evaluated for cell growth inhibition against A 431 cell line by irradiation in the presence of examined compound,1,Homo sapiens,Intermediate,,500.0,,9606.0,A-431,,F,BAO_0000219,CHEMBL621021,4988
,9,H,8,,,,14171,,Inhibition of EGF-stimulated tyrosine phosphorylation in A431 cells.,1,,Expert,,500.0,,,A-431,,F,BAO_0000219,CHEMBL621022,4989
,80852,N,1,,,,6333,,Tested for antiproliferative activity against human A431 cells,1,Homo sapiens,Expert,,500.0,,9606.0,A-431,,F,BAO_0000219,CHEMBL621023,4990
,9,D,9,,,,2356,,Inhibition of epidermal growth factor receptor (EGF-R) autophosphorylation in A431 cells,1,Homo sapiens,Expert,,500.0,,9606.0,A-431,,F,BAO_0000219,CHEMBL621024,4991
,80852,N,1,,,,15578,,Concentration needed to inhibit 50% growth of the human A431 (epidermoid carcinoma) cell lines,1,Homo sapiens,Expert,,500.0,,9606.0,A-431,,F,BAO_0000219,CHEMBL621025,4992
,80852,N,1,,,,5126,,Inhibition of A431 cell proliferation,1,Homo sapiens,Expert,,500.0,,9606.0,A-431,,F,BAO_0000219,CHEMBL621026,4993
,80852,N,1,,,,6844,,Cytotoxic effect on A431 human epidermoid carcinoma cells,1,Homo sapiens,Expert,,500.0,,9606.0,A-431,,F,BAO_0000219,CHEMBL621027,4994
,80852,N,1,,,,6844,,Cytotoxic effect on A431 human epidermoid carcinoma cells (No response to 1 mM),1,Homo sapiens,Expert,,500.0,,9606.0,A-431,,F,BAO_0000219,CHEMBL876397,4995
,80852,N,1,,,,4925,,Cytotoxicity expressed as inhibitory concentration required to reduce the cell growth of A431 human epidermal carcinoma cell line,1,Homo sapiens,Intermediate,,500.0,,9606.0,A-431,,F,BAO_0000219,CHEMBL883797,4996
,80852,N,1,,,,4925,,Cytotoxicity expressed as inhibitory concentration required to reduce the cell growth of A431 human epidermal carcinoma cell line; NT=Not tested,1,Homo sapiens,Intermediate,,500.0,,9606.0,A-431,,F,BAO_0000219,CHEMBL621028,4997
,80852,N,1,,,,13978,,In vitro Growth Inhibitory activity against A431 Human vulva cancer cell line,1,Homo sapiens,Intermediate,,500.0,,9606.0,A-431,,F,BAO_0000219,CHEMBL621029,4998
,80852,N,1,,,,16786,,In vitro cytotoxicity of compound against human A431 (epidermoid) cancer cell line after 72 hr of drug exposure,1,Homo sapiens,Intermediate,,500.0,,9606.0,A-431,,F,BAO_0000219,CHEMBL621030,4999
,9,H,8,,,,13412,,Inhibition of EGF-stimulated tyrosine phosphorylation in A431 cells expressing EGF-R,1,,Expert,,500.0,,,A-431,,F,BAO_0000219,CHEMBL621147,5000
,80852,N,1,,,,17824,,In vivo antiproliferative activity against A431 cell line,1,Homo sapiens,Intermediate,,500.0,,9606.0,A-431,,F,BAO_0000218,CHEMBL621148,5001
,9,D,9,,,,12751,,Inhibition of EGF-dependent autophosphorylation of EGF-R in human A431 cells,1,Homo sapiens,Expert,,500.0,,9606.0,A-431,,F,BAO_0000219,CHEMBL621149,5002
,80852,N,1,,,,12380,,Inhibition of A431 human epidermoid carcinoma cell proliferation,1,Homo sapiens,Expert,,500.0,,9606.0,A-431,,F,BAO_0000219,CHEMBL621150,5003
,9,D,9,,,,4959,,Inhibition of autophosphorylation of human epidermal growth factor-receptor (EGF-R) expressed in A431 cells,1,Homo sapiens,Expert,,500.0,,9606.0,A-431,,F,BAO_0000219,CHEMBL621151,5004
,80852,N,1,,,,6333,,Inhibitory effect on nonphospho-Src after EGF (100 uM) stimulation of A431 cells (control=178),1,Homo sapiens,Intermediate,,500.0,,9606.0,A-431,,F,BAO_0000219,CHEMBL621152,5005
,80852,N,1,,,,6333,,Inhibitory effect on phospho-Src (Tyr416) after EGF (100 uM) stimulation of A431 cells (38),1,Homo sapiens,Intermediate,,500.0,,9606.0,A-431,,F,BAO_0000219,CHEMBL621153,5006
,80852,N,1,,,,6333,,Inhibitory effect on phospho-Src/nonphospho after EGF (100 uM) stimulation of A431 cells (21),1,Homo sapiens,Intermediate,,500.0,,9606.0,A-431,,F,BAO_0000219,CHEMBL884000,5007
,9,D,9,,,,5296,,Inhibition of EGFR overexpressing A431 cell proliferation,1,Homo sapiens,Expert,,,,9606.0,,,F,BAO_0000019,CHEMBL621154,5008
,80852,N,1,,,,12624,,Inhibition of A431 cell proliferation,1,Homo sapiens,Expert,,500.0,,9606.0,A-431,,F,BAO_0000219,CHEMBL621155,5009
,9,D,9,,,,14926,,No inhibition of EGFR phosphorylation in A431 cells 8 hour after washing cells free of the inhibitor,1,Homo sapiens,Expert,,500.0,,9606.0,A-431,,F,BAO_0000219,CHEMBL621156,5010
,9,D,9,,,,14926,,"Partial inhibition of EGFR phosphorylation in A431 cells, 8 hour after washing cells free of the inhibitor",1,Homo sapiens,Expert,,500.0,,9606.0,A-431,,F,BAO_0000219,CHEMBL621157,5011
,9,H,8,,,,14926,,Irreversible inhibition of ATP binding site of EGFR (lack of phosphorylated EGFR) in A431 cells 8 hour after washing cells free of the inhibitor),1,,Expert,,500.0,,,A-431,,F,BAO_0000219,CHEMBL621158,5012
,80852,N,1,,,,15144,,The compound was tested in vitro for antiproliferative activity against A431 tumor cell lines,1,Homo sapiens,Intermediate,,500.0,,9606.0,A-431,,F,BAO_0000219,CHEMBL621159,5013
,80852,N,1,,,,15144,,The compound was tested in vitro for antiproliferative activity against A431 tumor cell lines,1,Homo sapiens,Intermediate,,500.0,,9606.0,A-431,,F,BAO_0000219,CHEMBL621160,5014
,80852,N,1,,,,5245,,Cell viability in A431 cells unstimulated with EGF was tested when incubated with concentration at 2 uM after 48 h; Did not affect the viability,1,Homo sapiens,Intermediate,,500.0,,9606.0,A-431,,F,BAO_0000219,CHEMBL621161,5015
,80852,N,1,,,,5245,,Cell viability in A431 cells unstimulated with EGF was tested when incubated with concentration in the range of 1-10 uM after 48 h; Did not affect the viability,1,Homo sapiens,Intermediate,,500.0,,9606.0,A-431,,F,BAO_0000219,CHEMBL621162,5016
,80852,N,1,,,,5245,,Cell viability in A431 cells unstimulated with EGF was tested when incubated with concentration up to 10 uM after 48 h; Did not affect the viability,1,Homo sapiens,Intermediate,,500.0,,9606.0,A-431,,F,BAO_0000219,CHEMBL621163,5017
,80852,N,1,,,,5245,,Cell viability in A431 cells when stimulated with EGF was tested when incubated with concentration 0.01 uM after 48 h; Cell death,1,Homo sapiens,Intermediate,,500.0,,9606.0,A-431,,F,BAO_0000219,CHEMBL621164,5018
,80852,N,1,,,,5245,,Cell viability in A431 cells when stimulated with EGF was tested when incubated with concentration 2 uM after 48 h; Cell death,1,Homo sapiens,Intermediate,,500.0,,9606.0,A-431,,F,BAO_0000219,CHEMBL621165,5019
,22224,U,0,,,,5922,,Half-life period in cynomolgus monkey,1,Cercopithecidae,Autocuration,,,,9527.0,,,A,BAO_0000019,CHEMBL619159,5020
Plasma,22224,U,0,In vitro,,,1116,,"In vitro half life at 1.5 -5.6ug/mL, 37 degree C in monkey plasma",1,Cercopithecidae,Autocuration,,,,9527.0,,1969.0,A,BAO_0000366,CHEMBL619160,5021
,22224,U,0,In vivo,,,17853,,Longer half-life in monkey (i.v.) at 0.5 mpk,1,Cercopithecidae,Autocuration,,,,9527.0,,,A,BAO_0000218,CHEMBL619161,5022
Plasma,22224,U,0,,,,993,,Plasma half life in monkey,1,Cercopithecidae,Autocuration,,,,9527.0,,1969.0,A,BAO_0000366,CHEMBL619162,5023
Plasma,22224,U,0,,,,4514,,Plasma half-life in rhesus monkey,1,Cercopithecidae,Autocuration,,,,9527.0,,1969.0,A,BAO_0000366,CHEMBL619163,5024
Plasma,22224,U,0,In vivo,,,5334,,Plasma half-life period (0-8 h) was reported after intravenous administration at a dose of 1 mg/kg in Rhesus monkey (male),1,Cercopithecidae,Autocuration,,,,9527.0,,1969.0,A,BAO_0000218,CHEMBL619164,5025
Plasma,22224,U,0,In vivo,,,5334,,Plasma half-life period (0-8 h) was reported after oral administration at a dose of 2 mg/kg in Rhesus monkey (male),1,Cercopithecidae,Autocuration,,,,9527.0,,1969.0,A,BAO_0000218,CHEMBL619320,5026
,22224,U,0,In vivo,,,4578,,Tested for half life upon iv administration to african green monkey,1,Cercopithecidae,Autocuration,,,,9527.0,,,A,BAO_0000218,CHEMBL619321,5027
,22224,U,0,In vivo,,,2661,,Compound was evaluated for maximum time to reach Cmax after treatment with oral dose of 2 mgkg to female cynomolgus monkey,1,Cercopithecidae,Autocuration,,,,9527.0,,,A,BAO_0000218,CHEMBL873336,5028
,22224,U,0,In vivo,,,5355,,The time for peak concentration value after intravenous administration in cynomolgus monkeys; NA means Not applicable,1,Cercopithecidae,Autocuration,,,,9527.0,,,A,BAO_0000218,CHEMBL619322,5029
,22224,U,0,In vivo,,,5355,,The time for peak concentration value after intravenous administration in cynomolgus monkeys; NA means not applicable,1,Cercopithecidae,Autocuration,,,,9527.0,,,A,BAO_0000218,CHEMBL619323,5030
,22224,U,0,In vivo,,,5355,,The time for peak concentration value after oral administration in cynomolgus monkeys,1,Cercopithecidae,Autocuration,,,,9527.0,,,A,BAO_0000218,CHEMBL619324,5031
,22224,U,0,,,,11271,,Percentage of tracer or metabolite (CO2) in baboon plasma at 10 min after injection of the compound,1,Cercopithecidae,Autocuration,,,,9527.0,,,A,BAO_0000019,CHEMBL619325,5032
,22224,U,0,,,,11271,,Percentage of tracer or metabolite (CO2) in baboon plasma at 1 min after injection of the compound,1,Cercopithecidae,Autocuration,,,,9527.0,,,A,BAO_0000019,CHEMBL876411,5033
,22224,U,0,,,,11271,,Percentage of tracer or metabolite (CO2) in baboon plasma at 30 min after injection of the compound,1,Cercopithecidae,Autocuration,,,,9527.0,,,A,BAO_0000019,CHEMBL619326,5034
,22224,U,0,,,,11271,,Percentage of tracer or metabolite (CO2) in baboon plasma at 5 min after injection of the compound,1,Cercopithecidae,Autocuration,,,,9527.0,,,A,BAO_0000019,CHEMBL619327,5035
,22224,U,0,,,,11271,,Percentage of tracer or metabolite(EME) in baboon plasma at 10 min after injection of the compound,1,Cercopithecidae,Autocuration,,,,9527.0,,,A,BAO_0000019,CHEMBL619328,5036
,22224,U,0,,,,11271,,Percentage of tracer or metabolite(EME) in baboon plasma at 1 min after injection of the compound,1,Cercopithecidae,Autocuration,,,,9527.0,,,A,BAO_0000019,CHEMBL619329,5037
,22224,U,0,,,,11271,,Percentage of tracer or metabolite(EME) in baboon plasma at 30 min after injection of the compound,1,Cercopithecidae,Autocuration,,,,9527.0,,,A,BAO_0000019,CHEMBL619330,5038
,22224,U,0,,,,11271,,Percentage of tracer or metabolite(EME) in baboon plasma at 5 min after injection of the compound,1,Cercopithecidae,Autocuration,,,,9527.0,,,A,BAO_0000019,CHEMBL619331,5039
,22224,U,0,,,,11271,,Percentage of tracer or metabolite (acid metabolites) in baboon plasma at 10 min after injection of the compound,1,Cercopithecidae,Autocuration,,,,9527.0,,,A,BAO_0000019,CHEMBL619332,5040
,22224,U,0,,,,11271,,Percentage of tracer or metabolite (acid metabolites) in baboon plasma at 1 min after injection of the compound,1,Cercopithecidae,Autocuration,,,,9527.0,,,A,BAO_0000019,CHEMBL619333,5041
,22224,U,0,,,,11271,,Percentage of tracer or metabolite (acid metabolites) in baboon plasma at 30 min after injection of the compound,1,Cercopithecidae,Autocuration,,,,9527.0,,,A,BAO_0000019,CHEMBL619334,5042
,22224,U,0,,,,11271,,Percentage of tracer or metabolite (acid metabolites) in baboon plasma at 5 min after injection of the compound,1,Cercopithecidae,Autocuration,,,,9527.0,,,A,BAO_0000019,CHEMBL619335,5043
,22224,U,0,,,,11271,,Percentage of tracer or metabolite (unchanged) in baboon plasma at 10 min after injection of the compound,1,Cercopithecidae,Autocuration,,,,9527.0,,,A,BAO_0000019,CHEMBL619336,5044
,22224,U,0,,,,11271,,Percentage of tracer or metabolite (unchanged) in baboon plasma at 1 min after injection of the compound,1,Cercopithecidae,Autocuration,,,,9527.0,,,A,BAO_0000019,CHEMBL619337,5045
,22224,U,0,,,,11271,,Percentage of tracer or metabolite (unchanged) in baboon plasma at 30 min after injection of the compound,1,Cercopithecidae,Autocuration,,,,9527.0,,,A,BAO_0000019,CHEMBL619338,5046
,22224,U,0,,,,11271,,Percentage of tracer or metabolite (unchanged) in baboon plasma at 5 min after injection of the compound,1,Cercopithecidae,Autocuration,,,,9527.0,,,A,BAO_0000019,CHEMBL619339,5047
,50597,N,1,In vivo,,,5809,,Bioavailability in rat (cannulated) (dose 2 mg/kg),1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL619340,5048
Plasma,50597,N,1,In vivo,,,17720,,Half life at a dose of 4 mg/kg in Rat Plasma after iv administration,1,Rattus norvegicus,Intermediate,,,,10116.0,,1969.0,A,BAO_0000218,CHEMBL873496,5049
Plasma,50597,N,1,,,,3546,,AUC value in rat after IV administration at a dose of 10 mg/kg,1,Rattus norvegicus,Intermediate,,,,10116.0,,1969.0,A,BAO_0000218,CHEMBL619341,5050
Plasma,50597,N,1,,,,3546,,AUC value in rat after oral administration at a dose of 10 mg/kg,1,Rattus norvegicus,Intermediate,,,,10116.0,,1969.0,A,BAO_0000218,CHEMBL619342,5051
,50597,N,1,In vivo,,,3546,,Cmax value in rat after oral administration at a dose of 10 mg/kg,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL619343,5052
,50597,N,1,In vivo,,,3546,,Bioavailability in rat after oral administration at a dose of 10 mg/kg,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL619344,5053
,50597,N,1,In vivo,,,3546,,Tmax value in rat after oral administration at a dose of 10 mg/kg,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL619345,5054
,50597,N,1,,,,3546,,Vc value in rat after IV administration at a dose of 10 mg/kg,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL619346,5055
,50597,N,1,In vivo,,,3546,,Half life period in rat after IV administration at a dose of 10 mg/kg,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL619347,5056
,22224,U,0,,,,10625,,The absolute striatal uptake of the carbon-11 labeled compound at 60 min was determined in baboon,1,Papio hamadryas,Autocuration,,,,9557.0,,,A,BAO_0000019,CHEMBL619348,5057
,22224,U,0,,,,10625,,Peak plasma radioactivity for the carbon-11 labeled compound was determined at 0.5 min after injection in baboon; (Range = 0.08-0.11),1,Papio hamadryas,Autocuration,,,,9557.0,,,A,BAO_0000019,CHEMBL619349,5058
,22224,U,0,,,,10625,,Peak plasma radioactivity for the carbon-11 labeled compound was determined at 1.5 min after injection in baboon; (Range = 0.08-0.11),1,Papio hamadryas,Autocuration,,,,9557.0,,,A,BAO_0000019,CHEMBL619350,5059
,22224,U,0,,,,10625,,The amount of unchanged tracer in baboon plasma was determined 1 min after injection of the carbon-11 labeled compound,1,Papio hamadryas,Autocuration,,,,9557.0,,,A,BAO_0000019,CHEMBL619351,5060
,22224,U,0,,,,10625,,The amount of unchanged tracer in baboon plasma was determined 10 min after injection of the carbon-11 labeled compound,1,Papio hamadryas,Autocuration,,,,9557.0,,,A,BAO_0000019,CHEMBL875953,5061
,22224,U,0,,,,10625,,The amount of unchanged tracer in baboon plasma was determined 30 min after injection of the carbon-11 labeled compound,1,Papio hamadryas,Autocuration,,,,9557.0,,,A,BAO_0000019,CHEMBL621716,5062
,22224,U,0,,,,10625,,The amount of unchanged tracer in baboon plasma was determined 60 min after injection of the carbon-11 labeled compound,1,Papio hamadryas,Autocuration,,,,9557.0,,,A,BAO_0000019,CHEMBL621717,5063
,22224,U,0,,,,10625,,The absolute striatal uptake of the carbon-11 labeled compound at 60 min was determined in baboon,1,Papio hamadryas,Autocuration,,,,9557.0,,,A,BAO_0000019,CHEMBL621718,5064
,22224,U,0,,,,3510,,Area under curve after 1 mpk peroral administration to beagles,1,beagle,Autocuration,,,,9615.0,,,A,BAO_0000019,CHEMBL621719,5065
,22224,U,0,,,,3510,,Area under curve after 2 mpk peroral administration to beagles,1,beagle,Autocuration,,,,9615.0,,,A,BAO_0000019,CHEMBL621720,5066
,22224,U,0,In vivo,,,3510,,Cmax value after 1 mpk peroral administration to beagles,1,beagle,Autocuration,,,,9615.0,,,A,BAO_0000218,CHEMBL621721,5067
Urine,22224,U,0,,,,7766,,Quantity of the metabolite found in the urine of the embryonal rhabdomyosarcoma patients treated with ifosfamide from 1200 mL of urine tested on day 7,1,Homo sapiens,Autocuration,,,,9606.0,,1088.0,A,BAO_0000019,CHEMBL621722,5068
Urine,22224,U,0,,,,7766,,Quantity of the metabolite found in the urine of the embryonal rhabdomyosarcoma patients treated with ifosfamide from 1300 mL of urine tested on day 6,1,Homo sapiens,Autocuration,,,,9606.0,,1088.0,A,BAO_0000019,CHEMBL621723,5069
Urine,22224,U,0,,,,7766,,Quantity of the metabolite found in the urine of the embryonal rhabdomyosarcoma patients treated with ifosfamide from 1300 mL of urine tested on day 8,1,Homo sapiens,Autocuration,,,,9606.0,,1088.0,A,BAO_0000019,CHEMBL621724,5070
Urine,22224,U,0,,,,7766,,Quantity of the metabolite found in the urine of the embryonal rhabdomyosarcoma patients treated with ifosfamide from 1500 mL of urine tested on day 9,1,Homo sapiens,Autocuration,,,,9606.0,,1088.0,A,BAO_0000019,CHEMBL623443,5071
Urine,22224,U,0,,,,7766,,Quantity of the metabolite found in the urine of the embryonal rhabdomyosarcoma patients treated with ifosfamide from 1600 mL of urine tested on day 10,1,Homo sapiens,Autocuration,,,,9606.0,,1088.0,A,BAO_0000019,CHEMBL623444,5072
Urine,22224,U,0,,,,7766,,Quantity of the metabolite found in the urine of the embryonal rhabdomyosarcoma patients treated with ifosfamide from 1700 mL of urine tested on day 5,1,Homo sapiens,Autocuration,,,,9606.0,,1088.0,A,BAO_0000019,CHEMBL623445,5073
Urine,22224,U,0,,,,7766,,Quantity of the metabolite found in the urine of the embryonal rhabdomyosarcoma patients treated with ifosfamide from 2310 mL of urine tested on day 4,1,Homo sapiens,Autocuration,,,,9606.0,,1088.0,A,BAO_0000019,CHEMBL623446,5074
Liver,22224,U,0,,,Microsomes,16643,,Metabolic stability observed at 30 min after administration in human liver microsomes,1,Homo sapiens,Autocuration,,,,9606.0,,2107.0,A,BAO_0000251,CHEMBL623447,5075
,22224,U,0,,,,6852,,Percent recovery of 100 ug/mL compound after administration in cirrhotic patients,1,Homo sapiens,Autocuration,,,,9606.0,,,A,BAO_0000019,CHEMBL623448,5076
,22224,U,0,,,,6852,,Percent recovery of 10 ug/mL compound after administration in cirrhotic patients,1,Homo sapiens,Autocuration,,,,9606.0,,,A,BAO_0000019,CHEMBL623449,5077
,22224,U,0,,,,6852,,Percent recovery of 500 ug/mL compound after administration in cirrhotic patients,1,Homo sapiens,Autocuration,,,,9606.0,,,A,BAO_0000019,CHEMBL623450,5078
Liver,22224,U,0,,,Microsomes,6567,,"Compound remaining after incubation with 2 mg/mL of human liver microsomes at 37 degrees C for 30 min in a pH 7.4, 0.05 M phosphate buffer",1,Homo sapiens,Autocuration,,,,9606.0,,2107.0,A,BAO_0000251,CHEMBL623451,5079
,22224,U,0,,,,6570,,Metabolic stability (% remaining at 30 mins) in human S9.,1,Homo sapiens,Autocuration,,,,9606.0,,,A,BAO_0000019,CHEMBL623452,5080
,22224,U,0,,,,6570,,Metabolic stability determined as remaining percent after 30 min of incubation in human isolated liver S9 preparations; N/D= Not determined,1,Homo sapiens,Autocuration,,,,9606.0,,,A,BAO_0000019,CHEMBL623453,5081
Liver,22224,U,0,,,Microsomes,5237,,Percent parent compound remaining after 20 min incubation with human liver microsomes,1,Homo sapiens,Autocuration,,,,9606.0,,2107.0,A,BAO_0000251,CHEMBL623454,5082
Liver,22224,U,0,,,Microsomes,5237,,Percent parent compound remaining after 20 min incubation with human liver microsomes; ND=No data,1,Homo sapiens,Autocuration,,,,9606.0,,2107.0,A,BAO_0000251,CHEMBL623455,5083
Liver,22224,U,0,,,Microsomes,5237,,Percent parent compound remaining after 20 min incubation with human liver microsomes; No data,1,Homo sapiens,Autocuration,,,,9606.0,,2107.0,A,BAO_0000251,CHEMBL624371,5084
,22224,U,0,,,,5202,,First pass metabolism and metabolic bioavailability using human hepatic microsomes,1,Homo sapiens,Autocuration,,,,9606.0,,,A,BAO_0000218,CHEMBL624372,5085
,22224,U,0,,,,5481,,Percent compound remaining in human plasma after incubation for 60 min at 37 C.,1,Homo sapiens,Autocuration,,,,9606.0,,,A,BAO_0000019,CHEMBL624373,5086
,22224,U,0,,,,5481,,Percent remaining in human plasma after incubation for 60 min at 37 C.,1,Homo sapiens,Autocuration,,,,9606.0,,,A,BAO_0000019,CHEMBL624374,5087
,22224,U,0,,,,3956,,The percent remaining in human plasma after 30 min was determined,1,Homo sapiens,Autocuration,,,,9606.0,,,A,BAO_0000019,CHEMBL624556,5088
Plasma,22224,U,0,,,,5074,,Conversion rate of the prodrug in human plasma,1,Homo sapiens,Autocuration,,,,9606.0,,1969.0,A,BAO_0000366,CHEMBL624557,5089
Plasma,22224,U,0,,,,5074,,Conversion rate of the prodrug in human plasma; ND means no data,1,Homo sapiens,Autocuration,,,,9606.0,,1969.0,A,BAO_0000366,CHEMBL624558,5090
Blood,22224,U,0,,,,4727,,Half life of compound was determined in human blood,1,Homo sapiens,Autocuration,,,,9606.0,,178.0,A,BAO_0000221,CHEMBL624559,5091
,22224,U,0,,,,5965,,Half life of compound was determined in man with once daily dosing,1,Homo sapiens,Autocuration,,,,9606.0,,,A,BAO_0000019,CHEMBL624560,5092
,22224,U,0,In vitro,,Microsomes,5732,,Half life in human microsomes,1,Homo sapiens,Autocuration,,,,9606.0,,,A,BAO_0000251,CHEMBL624561,5093
Plasma,22224,U,0,,,,5819,,Half life in human plasma,1,Homo sapiens,Autocuration,,,,9606.0,,1969.0,A,BAO_0000366,CHEMBL624562,5094
Plasma,22224,U,0,,,,5819,,Half life in human plasma; Not detected,1,Homo sapiens,Autocuration,,,,9606.0,,1969.0,A,BAO_0000366,CHEMBL624563,5095
,22224,U,0,In vivo,,,1916,,Half life period was evaluated against man at a dose of 10 mg/kg after po administration,1,Homo sapiens,Autocuration,,,,9606.0,,,A,BAO_0000218,CHEMBL624564,5096
Liver,22224,U,0,In vitro,,Microsomes,6597,,Half-life for oxidative metabolic stability was determined using rat liver microsomes,1,Homo sapiens,Autocuration,,,,9606.0,,2107.0,A,BAO_0000251,CHEMBL624565,5097
Plasma,22224,U,0,,,,5229,,Half-life in human plasma,1,Homo sapiens,Autocuration,,,,9606.0,,1969.0,A,BAO_0000366,CHEMBL875152,5098
Plasma,22224,U,0,,,,5229,,Half-life of the parent prodrug in plasma,1,Homo sapiens,Autocuration,,,,9606.0,,1969.0,A,BAO_0000366,CHEMBL624566,5099
Plasma,22224,U,0,In vitro,,,2192,,In vitro half life in human plasma was determined,1,Homo sapiens,Autocuration,,,,9606.0,,1969.0,A,BAO_0000366,CHEMBL873805,5100
Liver,22224,U,0,In vitro,,Microsomes,3032,,The compound was tested In Vitro for half life in human liver microsomes.,1,Homo sapiens,Autocuration,,,,9606.0,,2107.0,A,BAO_0000251,CHEMBL624567,5101
,22224,U,0,In vivo,,,1916,,Maximum time was evaluated against man at a dose of 10 mg/kg after po administration,1,Homo sapiens,Autocuration,,,,9606.0,,,A,BAO_0000218,CHEMBL624568,5102
,22224,U,0,In vivo,,,17716,,Observed volume of distribution,1,Homo sapiens,Autocuration,,,,9606.0,,,A,BAO_0000218,CHEMBL624569,5103
,22224,U,0,In vivo,,,15778,,Oral bioavailability in human,1,Homo sapiens,Autocuration,,,,9606.0,,,A,BAO_0000218,CHEMBL624570,5104
,22224,U,0,,,,17313,,Tested for human plasma protein binding of the compound,1,Homo sapiens,Autocuration,,,,9606.0,,,A,BAO_0000019,CHEMBL624571,5105
,22224,U,0,,,,4231,,"First order rate constant, k was determined in human plasma",1,Homo sapiens,Autocuration,,,,9606.0,,,A,BAO_0000019,CHEMBL624572,5106
,22224,U,0,,,,4755,,Observed rate constant in 80% human plasma at 37 degree Centigrade,1,Homo sapiens,Autocuration,,,,9606.0,,,A,BAO_0000019,CHEMBL624573,5107
,22224,U,0,,,,4755,,Observed rate constant in 80% human plasma at 37 degree Centigrade,1,Homo sapiens,Autocuration,,,,9606.0,,,A,BAO_0000019,CHEMBL875153,5108
Liver,22224,U,0,,,Microsomes,16907,,Loss of compound (%metabolized) after 30 min exposure to human liver microsomes,1,Homo sapiens,Autocuration,,,,9606.0,,2107.0,A,BAO_0000251,CHEMBL624574,5109
,22224,U,0,,,,10839,,The compound was tested for the plasma binding in human,1,Homo sapiens,Autocuration,,,,9606.0,,,A,BAO_0000019,CHEMBL624575,5110
,22224,U,0,,,,10839,,Plasma protein binding (human),1,Homo sapiens,Autocuration,,,,9606.0,,,A,BAO_0000019,CHEMBL624576,5111
Liver,22224,U,0,In vitro,,Microsomes,3199,,Compound was evaluated for half-life in human liver microsomes,1,Homo sapiens,Autocuration,,,,9606.0,,2107.0,A,BAO_0000251,CHEMBL624577,5112
Blood,22224,U,0,In vitro,,,1345,,Half life measured in vitro for its stability in human blood,1,Homo sapiens,Autocuration,,,,9606.0,,178.0,A,BAO_0000221,CHEMBL624578,5113
Serum,22224,U,0,,,,4297,,Half life in human serum,1,Homo sapiens,Autocuration,,,,9606.0,,1977.0,A,BAO_0000019,CHEMBL622796,5114
Serum,22224,U,0,,,,4297,,Half life in human serum; ND=not determined,1,Homo sapiens,Autocuration,,,,9606.0,,1977.0,A,BAO_0000019,CHEMBL622797,5115
,22224,U,0,,,,4297,,Half life were determined in CEM-SS cell extract in decomposition step 1,1,Homo sapiens,Autocuration,,,,9606.0,,,A,BAO_0000019,CHEMBL622798,5116
,22224,U,0,,,,4297,,Half life were determined in CEM-SS cell extract in decomposition step 2,1,Homo sapiens,Autocuration,,,,9606.0,,,A,BAO_0000019,CHEMBL622799,5117
Plasma,22224,U,0,,,,4231,,Half life of the in human plasma,1,Homo sapiens,Autocuration,,,,9606.0,,1969.0,A,BAO_0000366,CHEMBL622800,5118
,22224,U,0,In vitro,,S9,5633,,Half life period in human hepatic S9 fraction was determined,1,Homo sapiens,Autocuration,,,,9606.0,,,A,BAO_0000220,CHEMBL622801,5119
Liver,22224,U,0,In vitro,,Microsomes,5633,,Half life period in human liver microsome was determined,1,Homo sapiens,Autocuration,,,,9606.0,,2107.0,A,BAO_0000251,CHEMBL622802,5120
,22224,U,0,,,,17791,,Half life period was determined; 6-7,1,Homo sapiens,Autocuration,,,,9606.0,,,A,BAO_0000019,CHEMBL622803,5121
,22224,U,0,,,,17791,,Half life period was evaluated in human,1,Homo sapiens,Autocuration,,,,9606.0,,,A,BAO_0000019,CHEMBL875154,5122
Plasma,22224,U,0,,,,3160,,Half life time in human plasma,1,Homo sapiens,Autocuration,,,,9606.0,,1969.0,A,BAO_0000366,CHEMBL622804,5123
Brain,50594,N,1,In vivo,,,16438,,"Biodistribution in mice as total concentration of both oxidized and reduced forms in brain tissues, animals were sacrificed 60 minutes after dosing, in DMSO sol.",1,Mus musculus,Intermediate,,,,10090.0,,955.0,A,BAO_0000218,CHEMBL622805,5124
Heart,50594,N,1,In vivo,,,16438,,"Biodistribution in mice as total concentration of both oxidized and reduced forms in heart tissues, animals were sacrificed 10 minutes after dosing, in DMSO sol.",1,Mus musculus,Intermediate,,,,10090.0,,948.0,A,BAO_0000218,CHEMBL622611,5125
Heart,50594,N,1,In vivo,,,16438,,"Biodistribution in mice as total concentration of both oxidized and reduced forms in heart tissues, animals were sacrificed 60 minutes after dosing, in DMSO sol.",1,Mus musculus,Intermediate,,,,10090.0,,948.0,A,BAO_0000218,CHEMBL622612,5126
Kidney,50594,N,1,In vivo,,,16438,,"Biodistribution in mice as total concentration of both oxidized and reduced forms in kidney and animals were sacrificed 10 minutes after dosing, in DMSO sol.",1,Mus musculus,Intermediate,,,,10090.0,,2113.0,A,BAO_0000218,CHEMBL875160,5127
Kidney,50594,N,1,In vivo,,,16438,,"Biodistribution in mice as total concentration of both oxidized and reduced forms in kidney and animals were sacrificed 10 minutes after ip dosing, in DMSO solution",1,Mus musculus,Intermediate,,,,10090.0,,2113.0,A,BAO_0000218,CHEMBL622613,5128
Kidney,50594,N,1,In vivo,,,16438,,"Biodistribution in mice as total concentration of both oxidized and reduced forms in kidney tissues, animals were sacrificed 60 minutes after dosing, in DMSO sol.",1,Mus musculus,Intermediate,,,,10090.0,,2113.0,A,BAO_0000218,CHEMBL622614,5129
Liver,50594,N,1,In vivo,,,16438,,"Biodistribution in mice as total concentration of both oxidized and reduced forms in liver and animals were sacrificed 10 minutes after dosing, in DMSO sol.",1,Mus musculus,Intermediate,,,,10090.0,,2107.0,A,BAO_0000218,CHEMBL622615,5130
Liver,50594,N,1,In vivo,,,16438,,Biodistribution in mice as total concentration of both oxidized and reduced forms in liver and animals were sacrificed 10 minutes after ip administration in DMSO solution,1,Mus musculus,Intermediate,,,,10090.0,,2107.0,A,BAO_0000218,CHEMBL622616,5131
Liver,50594,N,1,In vivo,,,16438,,"Biodistribution in mice as total concentration of both oxidized and reduced forms in liver tissues, animals were sacrificed 60 minutes after dosing, in DMSO sol.",1,Mus musculus,Intermediate,,,,10090.0,,2107.0,A,BAO_0000218,CHEMBL622617,5132
Spleen,50594,N,1,In vivo,,,16438,,Biodistribution in mice as total concentration of both oxidized and reduced forms in spleen and animals were sacrificed 10 minutes after ip administration in DMSO solution,1,Mus musculus,Intermediate,,,,10090.0,,2106.0,A,BAO_0000218,CHEMBL622618,5133
Spleen,50594,N,1,In vivo,,,16438,,"Biodistribution in mice as total concentration of both oxidized and reduced forms in spleen and animals were sacrificed 10 minutes after ip dosing, in DMSO solution",1,Mus musculus,Intermediate,,,,10090.0,,2106.0,A,BAO_0000218,CHEMBL622619,5134
Spleen,50594,N,1,In vivo,,,16438,,"Biodistribution in mice as total concentration of both oxidized and reduced forms in spleen tissues, animals were sacrificed 60 minutes after dosing, in DMSO sol.",1,Mus musculus,Intermediate,,,,10090.0,,2106.0,A,BAO_0000218,CHEMBL622620,5135
Brain,50594,N,1,In vivo,,,16438,,"Biodistribution in mice, total concentration of both oxidized and reduced forms in brain tissues, animals were sacrificed 60 minutes after dosing, in DMSO",1,Mus musculus,Intermediate,,,,10090.0,,955.0,A,BAO_0000218,CHEMBL622621,5136
Blood,50594,N,1,In vivo,,,16438,,Biodistribution of compound (oxidized form) in blood tissue,1,Mus musculus,Intermediate,,,,10090.0,,178.0,A,BAO_0000218,CHEMBL622622,5137
Blood,50594,N,1,In vivo,,,16438,,"Biodistribution of compound (oxidized form) in blood tissue, animals were sacrificed 10 minutes after dosing, in DMSO sol.",1,Mus musculus,Intermediate,,,,10090.0,,178.0,A,BAO_0000218,CHEMBL622623,5138
Blood,50594,N,1,In vivo,,,16438,,"Biodistribution of compound (oxidized form) in blood tissue, animals were sacrificed 10 minutes after dosing, in DMSO solution",1,Mus musculus,Intermediate,,,,10090.0,,178.0,A,BAO_0000218,CHEMBL622624,5139
Blood,50594,N,1,In vivo,,,16438,,"Biodistribution of compound (oxidized form) in blood tissues, animals were sacrificed 60 minutes after dosing, in DMSO",1,Mus musculus,Intermediate,,,,10090.0,,178.0,A,BAO_0000218,CHEMBL622625,5140
Blood,50594,N,1,In vivo,,,16438,,"Biodistribution of compound (oxidized form) in blood tissues, animals were sacrificed 60 minutes after dosing, in DMSO sol.",1,Mus musculus,Intermediate,,,,10090.0,,178.0,A,BAO_0000218,CHEMBL622626,5141
Blood,50594,N,1,In vivo,,,16438,,"Biodistribution of compound (oxidized form) in blood tissues, animals were sacrificed 60 minutes after dosing, in DMSO solution",1,Mus musculus,Intermediate,,,,10090.0,,178.0,A,BAO_0000218,CHEMBL622627,5142
Brain,50594,N,1,In vivo,,,16438,,Biodistribution of compound (oxidized form) in brain tissue of mice,1,Mus musculus,Intermediate,,,,10090.0,,955.0,A,BAO_0000218,CHEMBL622628,5143
Brain,50594,N,1,In vivo,,,16438,,"Biodistribution of compound (oxidized form) in brain tissue, animals were sacrificed 10 minutes after dosing, in DMSO sol.",1,Mus musculus,Intermediate,,,,10090.0,,955.0,A,BAO_0000218,CHEMBL622629,5144
Brain,50594,N,1,In vivo,,,16438,,"Biodistribution of compound (oxidized form) in brain tissue, animals were sacrificed 60 minutes after dosing, in DMSO",1,Mus musculus,Intermediate,,,,10090.0,,955.0,A,BAO_0000218,CHEMBL622630,5145
Brain,50594,N,1,In vivo,,,16438,,"Biodistribution of compound (oxidized form) in brain tissue, animals were sacrificed 60 minutes after dosing, in DMSO sol.",1,Mus musculus,Intermediate,,,,10090.0,,955.0,A,BAO_0000218,CHEMBL622631,5146
Brain,50594,N,1,In vivo,,,16438,,"Biodistribution of compound (oxidized form) in brain tissue, animals were sacrificed 60 minutes after dosing, in DMSO solution",1,Mus musculus,Intermediate,,,,10090.0,,955.0,A,BAO_0000218,CHEMBL622632,5147
Brain,50594,N,1,In vivo,,,16438,,"Biodistribution of compound (oxidized form) in brain tissues, animals were sacrificed 10 minutes after dosing, in DMSO solution",1,Mus musculus,Intermediate,,,,10090.0,,955.0,A,BAO_0000218,CHEMBL622633,5148
Heart,50594,N,1,In vivo,,,16438,,Biodistribution of compound (oxidized form) in heart tissue of mice,1,Mus musculus,Intermediate,,,,10090.0,,948.0,A,BAO_0000218,CHEMBL622634,5149
Heart,50594,N,1,In vivo,,,16438,,"Biodistribution of compound (oxidized form) in heart tissue, animals were sacrificed 10 minutes after dosing, in DMSO sol.",1,Mus musculus,Intermediate,,,,10090.0,,948.0,A,BAO_0000218,CHEMBL622635,5150
Heart,50594,N,1,In vivo,,,16438,,"Biodistribution of compound (oxidized form) in heart tissue, animals were sacrificed 10 minutes after dosing, in DMSO sol.",1,Mus musculus,Intermediate,,,,10090.0,,948.0,A,BAO_0000218,CHEMBL875161,5151
Heart,50594,N,1,In vivo,,,16438,,"Biodistribution of compound (oxidized form) in heart tissue, animals were sacrificed 60 minutes after dosing, in DMSO",1,Mus musculus,Intermediate,,,,10090.0,,948.0,A,BAO_0000218,CHEMBL622636,5152
Heart,50594,N,1,In vivo,,,16438,,"Biodistribution of compound (oxidized form) in heart tissue, animals were sacrificed 60 minutes after dosing, in DMSO sol.",1,Mus musculus,Intermediate,,,,10090.0,,948.0,A,BAO_0000218,CHEMBL623335,5153
Heart,50594,N,1,In vivo,,,16438,,"Biodistribution of compound (oxidized form) in heart tissue, animals were sacrificed 60 minutes after dosing, in DMSO solution",1,Mus musculus,Intermediate,,,,10090.0,,948.0,A,BAO_0000218,CHEMBL623336,5154
Kidney,50594,N,1,In vivo,,,16438,,"Biodistribution of compound (oxidized form) in kidney tissue, animals were sacrificed 10 minutes after dosing, in DMSO sol.",1,Mus musculus,Intermediate,,,,10090.0,,2113.0,A,BAO_0000218,CHEMBL623337,5155
Kidney,50594,N,1,In vivo,,,16438,,"Biodistribution of compound (oxidized form) in kidney tissue, animals were sacrificed 10 minutes after dosing, in DMSO solution",1,Mus musculus,Intermediate,,,,10090.0,,2113.0,A,BAO_0000218,CHEMBL623338,5156
Kidney,50594,N,1,In vivo,,,16438,,"Biodistribution of compound (oxidized form) in kidney tissue, animals were sacrificed 60 minutes after dosing, in DMSO",1,Mus musculus,Intermediate,,,,10090.0,,2113.0,A,BAO_0000218,CHEMBL623339,5157
Kidney,50594,N,1,In vivo,,,16438,,"Biodistribution of compound (oxidized form) in kidney tissue, animals were sacrificed 60 minutes after dosing, in DMSO sol.",1,Mus musculus,Intermediate,,,,10090.0,,2113.0,A,BAO_0000218,CHEMBL623524,5158
Kidney,50594,N,1,In vivo,,,16438,,"Biodistribution of compound (oxidized form) in kidney tissue, animals were sacrificed 60 minutes after dosing, in DMSO solution",1,Mus musculus,Intermediate,,,,10090.0,,2113.0,A,BAO_0000218,CHEMBL623525,5159
Liver,50594,N,1,In vivo,,,16438,,Biodistribution of compound (oxidized form) in liver tissue,1,Mus musculus,Intermediate,,,,10090.0,,2107.0,A,BAO_0000218,CHEMBL623526,5160
Liver,50594,N,1,In vivo,,,16438,,"Biodistribution of compound (oxidized form) in liver tissue, animals were sacrificed 10 minutes after dosing, in DMSO sol.",1,Mus musculus,Intermediate,,,,10090.0,,2107.0,A,BAO_0000218,CHEMBL623527,5161
Liver,50594,N,1,In vivo,,,16438,,"Biodistribution of compound (oxidized form) in liver tissues, animals were sacrificed 60 minutes after dosing, in DMSO",1,Mus musculus,Intermediate,,,,10090.0,,2107.0,A,BAO_0000218,CHEMBL623528,5162
,80852,N,1,,,,5245,,Cell viability in A431 cells when stimulated with EGF was tested when incubated with concentration in the range of 1-10 uM of the compound after 48 h; Cell death,1,Homo sapiens,Intermediate,,500.0,,9606.0,A-431,,F,BAO_0000219,CHEMBL624615,5163
,80852,N,1,,,,5245,,Cell viability in A431 cells when stimulated with EGF was tested when incubated with concentration up to 10 uM after 48 h; Did not affect the viability,1,Homo sapiens,Intermediate,,500.0,,9606.0,A-431,,F,BAO_0000219,CHEMBL621672,5164
,80852,N,1,,,,16289,,"In vivo activity in A431 tumor bearing mice, maximum dose (schedule 10-24 days)",1,,Expert,,500.0,,,A-431,,F,BAO_0000218,CHEMBL621673,5165
,80852,N,1,,,,16289,,"In vivo activity in A431 tumor bearing mice, maximum dose (schedule 12-26 days)",1,,Expert,,500.0,,,A-431,,F,BAO_0000218,CHEMBL621674,5166
,9,D,9,,,,16093,,Inhibition of EGF-induced Tyrosine phosphorylation in A431 cells expressing EGF-R,1,Homo sapiens,Expert,,500.0,,9606.0,A-431,,F,BAO_0000219,CHEMBL884002,5167
,80852,N,1,,,,16825,,"Concentration required to inhibit the epidermoid A431 cell growth by 50%, P53 status of cell line used was wild-type. ",1,Homo sapiens,Intermediate,,500.0,,9606.0,A-431,,F,BAO_0000219,CHEMBL621850,5168
,80852,N,1,,,,4848,,Inhibitory activity against proliferation of human epidermoid carcinoma (A431) cells,1,Homo sapiens,Intermediate,,500.0,,9606.0,A-431,,F,BAO_0000219,CHEMBL621851,5169
,9,D,9,,,,14827,,Inhibition of EGF-dependent autophosphorylation of EGF-R in A431 cells,1,Homo sapiens,Expert,,500.0,,9606.0,A-431,,F,BAO_0000219,CHEMBL621852,5170
,9,D,9,,,,14827,,Inhibition of autophosphorylation of epidermal growth factor receptor in A431 cells in culture,1,Homo sapiens,Expert,,500.0,,9606.0,A-431,,F,BAO_0000219,CHEMBL621853,5171
,80852,N,1,,,,16289,,"In vivo activity in A431 tumor bearing mice, relative time required for treated and control tumors to reach 750 mg (schedule 10-24 days)",1,,Expert,,500.0,,,A-431,,F,BAO_0000218,CHEMBL621854,5172
,80852,N,1,,,,16289,,"In vivo activity in A431 tumor bearing mice, relative time required for treated and control tumors to reach 750 mg (schedule 12-26 days)",1,,Expert,,500.0,,,A-431,,F,BAO_0000218,CHEMBL621855,5173
,80852,N,1,,,,16289,,"In vivo activity in A431 tumor bearing mice, relative time required for treated and control tumors to reach 750 mg (schedule 12-26 days)",1,,Expert,,500.0,,,A-431,,F,BAO_0000218,CHEMBL623724,5174
,80852,N,1,,,,16289,,"In vivo activity in A431 tumor bearing mice, ratio of treated and control tumor mass day 24",1,,Expert,,500.0,,,A-431,,F,BAO_0000218,CHEMBL623725,5175
,80852,N,1,,,,16289,,"In vivo activity in A431 tumor bearing mice, ratio of treated and control tumor mass day 26",1,,Expert,,500.0,,,A-431,,F,BAO_0000218,CHEMBL623726,5176
,9,D,9,,,,16289,,"Irreversible inhibition of EGF-R phosphorylation in A431 cells, 8 hr after washing cells free of compound",1,Homo sapiens,Expert,,500.0,,9606.0,A-431,,F,BAO_0000219,CHEMBL623727,5177
,9,H,8,,,,16289,,Irreversible inhibition of formation of phosphorylated EGFR in A431 cells 8 hr after washing cells free of compound,1,,Expert,,500.0,,,A-431,,F,BAO_0000219,CHEMBL623728,5178
,80852,N,1,,,,16289,,"In vivo activity in A431 tumor bearing mice, maximum weight loss days 10-24",1,,Expert,,500.0,,,A-431,,F,BAO_0000218,CHEMBL623729,5179
,80852,N,1,,,,16289,,"In vivo activity in A431 tumor bearing mice, maximum weight loss days 12-26",1,,Expert,,500.0,,,A-431,,F,BAO_0000218,CHEMBL623730,5180
,80852,N,1,,,,16289,,"In vivo activity in A431 tumor bearing mice, maximum weight loss days 12-26",1,,Expert,,500.0,,,A-431,,F,BAO_0000218,CHEMBL623731,5181
,80852,N,1,,,,14555,,"Ratio of treated and control A431 cell tumor mass in mice at 5 mg/kg peroral dose, days 7-21 administration",1,Mus musculus,Expert,,500.0,,10090.0,A-431,,F,BAO_0000218,CHEMBL623732,5182
,80852,N,1,,,,14555,,"Difference in days for treated (T) and control (C) A431 cell tumors to reach 750 mg in mice at 5 mg/kg peroral dose, days 7-21 administration",1,Mus musculus,Expert,,500.0,,10090.0,A-431,,F,BAO_0000218,CHEMBL623733,5183
,80852,N,1,,,,14555,,"Net reduction in tumor burden between first and last treatments of A431 cell tumors in mice at 5 mg/kg peroral dose, days 7-21 administration",1,Mus musculus,Expert,,500.0,,10090.0,A-431,,F,BAO_0000218,CHEMBL623734,5184
,80852,N,1,,,,14555,,"Weight change of A431 cell tumors in mice at 5 mg/kg peroral dose, days 7-21 administration",1,Mus musculus,Expert,,500.0,,10090.0,A-431,,F,BAO_0000218,CHEMBL623735,5185
,80852,N,1,,,,1937,,In vitro antiproliferative effect against A431 human epidermoid carcinoma cells,1,Homo sapiens,Expert,,500.0,,9606.0,A-431,,F,BAO_0000219,CHEMBL623736,5186
,80852,N,1,,,,13739,,In vitro tumor cell growth inhibitory activity against Human leiomyosarcoma A431 cell lines,1,Homo sapiens,Intermediate,,500.0,,9606.0,A-431,,F,BAO_0000219,CHEMBL623737,5187
,80852,N,1,,,,3558,,Cytotoxicity against A437 cells is the dose giving 50% decrease in the formation of formazan dye,1,Homo sapiens,Intermediate,,500.0,,9606.0,A-431,,F,BAO_0000219,CHEMBL623738,5188
,80852,N,1,,,,3558,,Dose giving a 50% decrease in the living cell number (A437 cells),1,Homo sapiens,Intermediate,,500.0,,9606.0,A-431,,F,BAO_0000219,CHEMBL875168,5189
,80682,N,1,,,,17686,,In vitro inhibitory concentration against proliferation of A459 cell line.,1,Homo sapiens,Expert,,646.0,,9606.0,A549,,F,BAO_0000219,CHEMBL623739,5190
,80682,N,1,,,,5305,,Inhibitory concentration of compound for cytotoxicity against A459 human lung cells was determined,1,Homo sapiens,Intermediate,,646.0,,9606.0,A549,,F,BAO_0000219,CHEMBL623740,5191
,80682,N,1,,,,3614,,Inhibition of growth of human NSCL non small cell lung carcinoma cell line (A459) after 72 hr of drug exposure,1,Homo sapiens,Intermediate,,646.0,,9606.0,A549,,F,BAO_0000219,CHEMBL624424,5192
,80021,N,1,,,,17229,,In vitro antitumor activity against renal A498 tumor cell lines,1,Homo sapiens,Intermediate,,624.0,,9606.0,A498,,F,BAO_0000219,CHEMBL624425,5193
,80021,N,1,,,,15935,,"In vitro growth inhibition of human kidney carcinoma cell line, A498 with low levels of folate receptors",1,Homo sapiens,Intermediate,,624.0,,9606.0,A498,,F,BAO_0000219,CHEMBL624426,5194
,80021,N,1,,,,15935,,"In vitro growth inhibition of human kidney carcinoma cell line, A498 with low levels of folate receptors in folate deficient medium",1,Homo sapiens,Intermediate,,624.0,,9606.0,A498,,F,BAO_0000219,CHEMBL624427,5195
,80021,N,1,,,,15560,,Cytotoxicity against A498 Tumor cell line in SRB Cell viability test,1,Homo sapiens,Intermediate,,624.0,,9606.0,A498,,F,BAO_0000219,CHEMBL624428,5196
,80021,N,1,,,,13891,,Cytotoxicity concentration against human kidney carcinoma A-498 cell line,1,Homo sapiens,Intermediate,,624.0,,9606.0,A498,,F,BAO_0000219,CHEMBL624429,5197
,80021,N,1,,,,13891,,Cytotoxicity concentration against human kidney carcinoma A-498 cell line; NT =Not tested,1,Homo sapiens,Intermediate,,624.0,,9606.0,A498,,F,BAO_0000219,CHEMBL624620,5198
,80021,N,1,,,,13788,,Cytotoxicity on kidney carcinoma (A-498) cell line,1,Homo sapiens,Intermediate,,624.0,,9606.0,A498,,F,BAO_0000219,CHEMBL624621,5199
,80021,N,1,,,,15403,,Compound was evaluated against Human cell line renal A498,1,Homo sapiens,Intermediate,,624.0,,9606.0,A498,,F,BAO_0000219,CHEMBL624622,5200
,80021,N,1,,,,1009,,Compound was tested for inhibition of A498 human renal cancer cell line,1,Homo sapiens,Intermediate,,624.0,,9606.0,A498,,F,BAO_0000219,CHEMBL624623,5201
,80021,N,1,,,,1043,,Growth inhibitory activity against A498 human cancer cell line,1,Homo sapiens,Intermediate,,624.0,,9606.0,A498,,F,BAO_0000219,CHEMBL874365,5202
,80021,N,1,,,,5858,,In vitro antitumor activity against human renal A498 cell line,1,Homo sapiens,Intermediate,,624.0,,9606.0,A498,,F,BAO_0000219,CHEMBL624624,5203
,80021,N,1,,,,5958,,In vitro cytotoxic activity against renal (A498) cell line,1,Homo sapiens,Intermediate,,624.0,,9606.0,A498,,F,BAO_0000219,CHEMBL624625,5204
,80021,N,1,,,,5506,,In vitro cytotoxic activity against human renal cancer (A498) cell line,1,Homo sapiens,Intermediate,,624.0,,9606.0,A498,,F,BAO_0000219,CHEMBL624626,5205
,80021,N,1,,,,12781,,Tested for cytostatic activity against renal A498 cell line,1,Homo sapiens,Intermediate,,624.0,,9606.0,A498,,F,BAO_0000219,CHEMBL624627,5206
,80021,N,1,,,,14399,,The compound was tested for the concentration to inhibit 50% of renal A498 cell lines.,1,Homo sapiens,Intermediate,,624.0,,9606.0,A498,,F,BAO_0000219,CHEMBL883157,5207
,80021,N,1,,,,5958,,In vitro cytotoxic activity against renal (A498) cell line at a concentration of 10e-5 M,1,Homo sapiens,Expert,,624.0,,9606.0,A498,,F,BAO_0000219,CHEMBL624628,5208
,22224,U,0,In vivo,,,3510,,Cmax value after 2 mpk peroral administration to beagles,1,beagle,Autocuration,,,,9615.0,,,A,BAO_0000218,CHEMBL624629,5209
,22224,U,0,In vivo,beagle,,3510,,Bioavailability,1,Canis lupus familiaris,Autocuration,,,,9615.0,,,A,BAO_0000218,CHEMBL623551,5210
,22224,U,0,In vivo,beagle,,3510,,Bioavailability after 1 mpk peroral administration to beagles,1,Canis lupus familiaris,Autocuration,,,,9615.0,,,A,BAO_0000218,CHEMBL623552,5211
,22224,U,0,In vivo,beagle,,3510,,Bioavailability after 2 mpk peroral administration to beagles,1,Canis lupus familiaris,Autocuration,,,,9615.0,,,A,BAO_0000218,CHEMBL623553,5212
,22224,U,0,,,,3085,,Specificity constant of the BSA-catalyzed deprotonation of compound at pH 9,1,Bos taurus,Autocuration,,,,9913.0,,,A,BAO_0000019,CHEMBL623554,5213
,22224,U,0,,,,3085,,Specificity constant of the bovine serum albumin catalyzed reaction expressed as (kcat/KM)/kuncat,1,Bos taurus,Autocuration,,,,9913.0,,,A,BAO_0000019,CHEMBL623555,5214
,22224,U,0,,,,3085,,Michaelis-Menten kinetics of the bovine serum albumin catalyzed reaction of the compound,1,Bos taurus,Autocuration,,,,9913.0,,,A,BAO_0000019,CHEMBL623556,5215
,22224,U,0,,,,9372,,Solubility against bovine alpha-chymotrypsin,1,Bos taurus,Autocuration,,,,9913.0,,,A,BAO_0000019,CHEMBL623557,5216
,22224,U,0,,,,3085,,Rate constant of the bovine serum albumin catalyzed reaction of the compound,1,Bos taurus,Autocuration,,,,9913.0,,,A,BAO_0000019,CHEMBL623558,5217
,22224,U,0,,,,3085,,Rate constant of the bovine serum albumin catalyzed reaction of the compound,1,Bos taurus,Autocuration,,,,9913.0,,,A,BAO_0000019,CHEMBL623559,5218
Spleen,22224,U,0,,,,1469,,Half life (t) of enzymatic phosphodiester hydrolysis of compound towards calf spleen (CS-PDE) at a concentration of 20 microg,1,Bos taurus,Autocuration,,,,9913.0,,2106.0,A,BAO_0000221,CHEMBL623560,5219
,22224,U,0,,,,4297,,Half life in culture medium containing 10% of heat inactivated foetal calf serum,1,Bos taurus,Autocuration,,,,9913.0,,,A,BAO_0000019,CHEMBL623561,5220
,22224,U,0,,,,4297,,Half life in culture medium containing 10% of heat inactivated foetal calf serum; ND=not determined,1,Bos taurus,Autocuration,,,,9913.0,,,A,BAO_0000019,CHEMBL623562,5221
,22224,U,0,,,,17585,,Ability to get deaminated by adenosine deaminase (ADA); Expressed as t1/2,1,Bos taurus,Autocuration,,,,9913.0,,,A,BAO_0000019,CHEMBL623563,5222
Spleen,22224,U,0,,,,1336,,Enzymatic stability was assessed with bovine spleen phosphodiesterase (BS PDE) exonuclase,1,Bos taurus,Autocuration,,,,9913.0,,2106.0,A,BAO_0000221,CHEMBL623564,5223
,22224,U,0,,,,3085,,Half life in presence of 2 mg/mL BSA at pH 8.8,1,Bos taurus,Autocuration,,,,9913.0,,,A,BAO_0000019,CHEMBL873806,5224
,22224,U,0,,,,2857,,Half-life in RPMI 1640 containing 10% heat inactivated fetal calf serum culture medium at step 1,1,Bos taurus,Autocuration,,,,9913.0,,,A,BAO_0000019,CHEMBL623565,5225
,22224,U,0,,,,2857,,Half-life in RPMI 1640 containing 10% heat inactivated fetal calf serum culture medium at step 2,1,Bos taurus,Autocuration,,,,9913.0,,,A,BAO_0000019,CHEMBL623566,5226
,22224,U,0,,,,2857,,Half-life in RPMI 1640 containing 10% heat inactivated fetal calf serum culture medium at step 2; Not determined,1,Bos taurus,Autocuration,,,,9913.0,,,A,BAO_0000019,CHEMBL623567,5227
,22224,U,0,,,,1540,,Half-life in the culture medium (RPMI 1640+10% fetal calf serum FCS),1,Bos taurus,Autocuration,,,,9913.0,,,A,BAO_0000019,CHEMBL623568,5228
Plasma,50588,N,1,,,,6316,,AUC (Area Under Plasma concentration-time curve) was after oral administration at 5 mg/kg,1,Canis lupus familiaris,Intermediate,,,,9615.0,,1969.0,A,BAO_0000218,CHEMBL623569,5229
Plasma,50588,N,1,,,,17594,,AUC after administration at 100 mg/kg/day in dogs,1,Canis lupus familiaris,Intermediate,,,,9615.0,,1969.0,A,BAO_0000218,CHEMBL623570,5230
Plasma,50588,N,1,,,,4953,,AUC in dog at 0-24 hr by peroral administration at 3 mpk,1,Canis lupus familiaris,Intermediate,,,,9615.0,,1969.0,A,BAO_0000218,CHEMBL624254,5231
Plasma,50588,N,1,,,,16907,,AUC value after 15 mg/kg iv dose in Dogs,1,Canis lupus familiaris,Intermediate,,,,9615.0,,1969.0,A,BAO_0000218,CHEMBL624255,5232
Plasma,50588,N,1,,,,16907,,AUC value after 30 mg/kg po dose in Dogs,1,Canis lupus familiaris,Intermediate,,,,9615.0,,1969.0,A,BAO_0000218,CHEMBL624256,5233
Plasma,50588,N,1,,,,2959,,AUC value after administration of 4 mg/Kg oral dose in dog,1,Canis lupus familiaris,Intermediate,,,,9615.0,,1969.0,A,BAO_0000218,CHEMBL624257,5234
Plasma,50588,N,1,,,,17594,,AUC0-infinity after single intravenous bolus of 1 mg/kg in dogs,1,Canis lupus familiaris,Intermediate,,,,9615.0,,1969.0,A,BAO_0000218,CHEMBL624258,5235
,50588,N,1,,,,5356,,Area Under Curve for the compound was determined in dogs at 1 mg/kg oral dosing; 25-50 ug min/mL,1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL875277,5236
,50588,N,1,,,,16807,,Area under curve (AUC) value in dogs after an intravenous dose of 0.2 mg/Kg in 0.025 M aqueous methanesulfonic acid solution with 5% mannitol at a concentration of 0.2,1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL622667,5237
,50588,N,1,,,,4527,,Area under curve by intravenous administration at a dose of 1 uM/kg in dog was determined,1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL622668,5238
,50588,N,1,,,,4527,,Area under curve by oral administration at a dose of 10 uM/kg in dog was determined,1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL622669,5239
,50588,N,1,,,,15660,,Area under curve determined in dogs after intravenous administration of 3 mg/kg,1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL622670,5240
,50588,N,1,,,,15660,,Area under curve determined in dogs after oral administration of 10 mg/kg,1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL622671,5241
,50588,N,1,,,,5802,,Area under curve of compound after both po and iv administration at a dose of 5 mg/kg and 2 mg/kg resp in dog,1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL622672,5242
,50588,N,1,,,,3598,,Area under curve of compound determined in dog after iv administration at a dose of 10 mg/kg,1,Canis lupus familiaris,Expert,,,,9615.0,,,A,BAO_0000218,CHEMBL622673,5243
,50588,N,1,,,,3598,,Area under curve of compound from zero time to infinity determined in dog after iv administration at a dose of 10 mg/kg,1,Canis lupus familiaris,Expert,,,,9615.0,,,A,BAO_0000218,CHEMBL622674,5244
,50588,N,1,,,,5944,,Area under curve determined in dog at a dose of 0 mg/kg by oral administration along with indavir (10 mg/kg),1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL622675,5245
,50588,N,1,,,,5944,,Area under curve determined in dog at a dose of 10 mg/kg by oral administration,1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL622676,5246
,50588,N,1,,,,5944,,Area under curve determined in dog at a dose of 10 mg/kg by oral administration along with indavir (10 mg/kg),1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL622677,5247
,50588,N,1,,,,5944,,Area under curve determined in dog at a dose of 5 mg/kg by oral administration,1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL622678,5248
,50588,N,1,,,,4186,,Area under curve in dog after administration of 20 mg/kg dose through peroral route,1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL622679,5249
,50588,N,1,,,,5007,,Area under curve in dogs administered perorally (5 mg/kg) and intravenously (2 mg/kg),1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL622680,5250
,50588,N,1,,,,5668,,Area under curve was determine after peroral administration at 10 mpk in dog,1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL622681,5251
,50588,N,1,,,,5668,,Area under curve was determine after peroral administration at 5 mpk in dog,1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL875278,5252
,50588,N,1,,,,5006,,Area under curve was determined,1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL622682,5253
,50588,N,1,,,,5006,,Area under curve in dogs,1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL622683,5254
,50588,N,1,,,,3771,,Area under curve in dogs at 10 mg/kg dose fo oral administration,1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL622684,5255
,50588,N,1,,,,3771,,Area under curve in dogs at 10 mg/kg dose fo oral administration (Evokes hyperglycerolemia),1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL622685,5256
,50588,N,1,,,,3771,,Area under curve in dogs at 3 mg/kg dose fo intravenous administration,1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL622686,5257
,50588,N,1,,,,1916,,Area under curve was evaluated against Beagle dog at a dose of 15 mg/kg after po administration,1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL618344,5258
,50588,N,1,,,,5302,,Area under curve value in dog at a dose of 5 mg/kg,1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL875582,5259
,50588,N,1,,,,5600,,Area under curve was determined after 0.1 mg/kg iv administration in dog,1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL618345,5260
,50588,N,1,,,,5600,,Area under curve was determined after 0.3 mg/kg po administration in dog,1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL618346,5261
,50588,N,1,,,,17764,,Area under curve was determined for compound after intravenous administration in dogs at 1.2 uM/kg,1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL618347,5262
,50588,N,1,,,,4368,,Area under curve was determined for the compound by intravenous administration of 1.2 mg/kg in dog,1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL618348,5263
,22224,U,0,,,,5318,,Tested for half life period at 37 degree Celsius in PBS buffer at 10.5 pH containing human serum esterase,1,Homo sapiens,Autocuration,,,,9606.0,,,A,BAO_0000019,CHEMBL618349,5264
,22224,U,0,,,,5318,,Tested for half life period at 37 degree Centigrade in PBS buffer at 7.3 pH containing human serum esterase,1,Homo sapiens,Autocuration,,,,9606.0,,,A,BAO_0000019,CHEMBL618350,5265
,22224,U,0,,,,5318,,Tested for half life period at 37 degree Celsius in PBS buffer at 8.0 pH containing human serum esterase,1,Homo sapiens,Autocuration,,,,9606.0,,,A,BAO_0000019,CHEMBL618351,5266
,22224,U,0,,,,5318,,Tested for half life period at 37 degree Celsius in PBS buffer at 8.8 pH containing human serum esterase,1,Homo sapiens,Autocuration,,,,9606.0,,,A,BAO_0000019,CHEMBL618352,5267
Blood,22224,U,0,,,,14518,,Time taken to reduce 50% of the concentration of compound in blood plasma,1,Homo sapiens,Autocuration,,,,9606.0,,178.0,A,BAO_0000221,CHEMBL873494,5268
Plasma,22224,U,0,,,,2209,,"Biological half life in human plasma (stability to human renal dehydropeptidase I,DHP-I).",1,Homo sapiens,Autocuration,,,,9606.0,,1969.0,A,BAO_0000366,CHEMBL618353,5269
Plasma,22224,U,0,,,,6787,,Half life in human plasma,1,Homo sapiens,Autocuration,,,,9606.0,,1969.0,A,BAO_0000366,CHEMBL618354,5270
Plasma,22224,U,0,,,,4898,,Half life in human plasma was reported,1,Homo sapiens,Autocuration,,,,9606.0,,1969.0,A,BAO_0000366,CHEMBL875583,5271
Serum,22224,U,0,,,,6072,,Half life in human serum,1,Homo sapiens,Autocuration,,,,9606.0,,1977.0,A,BAO_0000019,CHEMBL618355,5272
Plasma,22224,U,0,,,,16907,,Half life upon exposure to human plasma,1,Homo sapiens,Autocuration,,,,9606.0,,1969.0,A,BAO_0000366,CHEMBL618356,5273
,22224,U,0,In vitro,,Microsomes,5656,,t1/2 in human microsomes,1,Homo sapiens,Autocuration,,,,9606.0,,,A,BAO_0000251,CHEMBL618357,5274
Plasma,22224,U,0,,,,4755,,Half life period in 80% human plasma at 37 degree Centigrade,1,Homo sapiens,Autocuration,,,,9606.0,,1969.0,A,BAO_0000366,CHEMBL618358,5275
Zone of skin,22224,U,0,,,,17503,,Half-life for rate of hydrolysis was determined in in human skin homogenate (pH 7.4),1,Homo sapiens,Autocuration,,,,9606.0,,14.0,A,BAO_0000221,CHEMBL618359,5276
Plasma,22224,U,0,In vitro,,,12357,,Half-life measured in in vitro Cathepsin B assay in human plasma,1,Homo sapiens,Autocuration,,,,9606.0,,1969.0,A,BAO_0000366,CHEMBL618360,5277
,22224,U,0,,,,3076,,Half-life at initial concentration of 5*10e-5 M in CEM cell extract,1,Homo sapiens,Autocuration,,,,9606.0,,,A,BAO_0000019,CHEMBL618361,5278
Liver,22224,U,0,In vitro,,Microsomes,6410,,Half-life determined by human liver microsome stability assay at a concentration of 5 uM,1,Homo sapiens,Autocuration,,,,9606.0,,2107.0,A,BAO_0000251,CHEMBL618362,5279
Plasma,22224,U,0,,,,3741,,"Half-life in chemical and enzymatic hydrolysis to form L-DOPA, in 80% human plasma",1,Homo sapiens,Autocuration,,,,9606.0,,1969.0,A,BAO_0000366,CHEMBL618363,5280
Plasma,22224,U,0,,,,3741,,"Half-life in chemical and enzymatic hydrolysis to form another compound (8)*, in 80% human plasma (experiment 1)",1,Homo sapiens,Autocuration,,,,9606.0,,1969.0,A,BAO_0000366,CHEMBL618364,5281
Plasma,22224,U,0,,,,3741,,"Half-life in chemical and enzymatic hydrolysis to form another compound (8)*, in 80% human plasma (experiment 2)",1,Homo sapiens,Autocuration,,,,9606.0,,1969.0,A,BAO_0000366,CHEMBL875584,5282
,22224,U,0,,,,1540,,Half-life in the CEM cell extracts,1,Homo sapiens,Autocuration,,,,9606.0,,,A,BAO_0000019,CHEMBL618365,5283
Plasma,22224,U,0,,,,2905,,Half-life was calculated by Human plasma stability assay at 37 degree Centigrade,1,Homo sapiens,Autocuration,,,,9606.0,,1969.0,A,BAO_0000366,CHEMBL873495,5284
Plasma,22224,U,0,,,,2905,,Half-life was calculated by Human plasma stability assay at 37 degree centigrade; Not hydrolyzed,1,Homo sapiens,Autocuration,,,,9606.0,,1969.0,A,BAO_0000366,CHEMBL618366,5285
,22224,U,0,,,,5523,,Half-life was determined,1,Homo sapiens,Autocuration,,,,9606.0,,,A,BAO_0000019,CHEMBL618367,5286
Blood,22224,U,0,,,,1499,,Half-life (human blood stability),1,Homo sapiens,Autocuration,,,,9606.0,,178.0,A,BAO_0000221,CHEMBL618368,5287
Blood,22224,U,0,,,,1499,,Half-life (human blood stability); no data,1,Homo sapiens,Autocuration,,,,9606.0,,178.0,A,BAO_0000221,CHEMBL618369,5288
Plasma,22224,U,0,,,,17065,,Half-life in human plasma,1,Homo sapiens,Autocuration,,,,9606.0,,1969.0,A,BAO_0000366,CHEMBL618370,5289
,22224,U,0,,,,6861,,CYP3A4 metabolism half-life (t1/2),1,Homo sapiens,Autocuration,,,,9606.0,,,A,BAO_0000019,CHEMBL618371,5290
Blood,22224,U,0,,,,1499,,Half-life was determined; 88% of parent remained after incubation for 120 min (human blood stability),1,Homo sapiens,Autocuration,,,,9606.0,,178.0,A,BAO_0000221,CHEMBL618372,5291
Plasma,22224,U,0,In vitro,,,530,,In vitro half life in human plasma,1,Homo sapiens,Autocuration,,,,9606.0,,1969.0,A,BAO_0000366,CHEMBL618373,5292
Plasma,22224,U,0,In vitro,,,1116,,"In vitro half life at 1.5 -5.6ug/mL, 37 degree C in human plasma",1,Homo sapiens,Autocuration,,,,9606.0,,1969.0,A,BAO_0000366,CHEMBL618374,5293
Plasma,22224,U,0,In vitro,,,6695,,In vitro hydrolysis in human plasma,1,Homo sapiens,Autocuration,,,,9606.0,,1969.0,A,BAO_0000366,CHEMBL618375,5294
Plasma,22224,U,0,In vitro,,,6695,,In vitro hydrolysis in human plasma; no data,1,Homo sapiens,Autocuration,,,,9606.0,,1969.0,A,BAO_0000366,CHEMBL618376,5295
Liver,22224,U,0,In vitro,,Microsomes,10,,In vitro metabolic stability at 5 uM was determined by incubating with human liver microsomes at 37 degree C,1,Homo sapiens,Autocuration,,,,9606.0,,2107.0,A,BAO_0000251,CHEMBL618377,5296
Plasma,22224,U,0,,,,993,,Plasma half life in human,1,Homo sapiens,Autocuration,,,,9606.0,,1969.0,A,BAO_0000366,CHEMBL618378,5297
Plasma,22224,U,0,,,,15429,,Stability after incubation with human plasma (at 37 degree C),1,Homo sapiens,Autocuration,,,,9606.0,,1969.0,A,BAO_0000366,CHEMBL618379,5298
Plasma,22224,U,0,,,,1675,,T1/2 was evaluated in human plasma,1,Homo sapiens,Autocuration,,,,9606.0,,1969.0,A,BAO_0000366,CHEMBL618380,5299
Plasma,22224,U,0,,,,2209,,"Tested for Biological half life in human plasma (stability to human renal dehydropeptidase I,DHP-I).",1,Homo sapiens,Autocuration,,,,9606.0,,1969.0,A,BAO_0000366,CHEMBL618381,5300
Plasma,22224,U,0,,,,2209,,"Tested for Biological half life in human plasma (stability to human renal dehydropeptidase I,DHP-I); Not determined",1,Homo sapiens,Autocuration,,,,9606.0,,1969.0,A,BAO_0000366,CHEMBL618382,5301
,22224,U,0,,,,5318,,Tested for half life period at 37 degree Centigrade in PBS buffer at 7.3 pH containing human serum esterase,1,Homo sapiens,Autocuration,,,,9606.0,,,A,BAO_0000019,CHEMBL618383,5302
,22224,U,0,In vitro,,,2412,,Tested in vitro for the time for half reactivation against human lysosomal alpha-glucosidase,1,Homo sapiens,Autocuration,,,,9606.0,,,A,BAO_0000019,CHEMBL618384,5303
,22224,U,0,In vitro,,,2412,,Tested in vitro for the time for half reactivation against human lysosomal alpha-glucosidase; ND=Not determined,1,Homo sapiens,Autocuration,,,,9606.0,,,A,BAO_0000019,CHEMBL618385,5304
Plasma,22224,U,0,,,,2906,,The release rate of the free drug from the substrate in human plasma by human plasma stability assay,1,Homo sapiens,Autocuration,,,,9606.0,,1969.0,A,BAO_0000366,CHEMBL619099,5305
Plasma,22224,U,0,,,,2906,,The release rate of the free drug from the substrate in human plasma by human plasma stability assay; Not hydrolyzed,1,Homo sapiens,Autocuration,,,,9606.0,,1969.0,A,BAO_0000366,CHEMBL619100,5306
,22224,U,0,,,,5495,,Time taken for 50% to be consumed by serum PON1 was determined,1,Homo sapiens,Autocuration,,,,9606.0,,,A,BAO_0000019,CHEMBL619101,5307
,22224,U,0,,,,5495,,Time taken for 50% to be consumed by serum PON1; NH is Not hydrolysed,1,Homo sapiens,Autocuration,,,,9606.0,,,A,BAO_0000019,CHEMBL619102,5308
Liver,22224,U,0,,,Microsomes,4397,,Percent of the parent compound remaining after 20 mins incubation with human liver microsomes,1,Homo sapiens,Autocuration,,,,9606.0,,2107.0,A,BAO_0000251,CHEMBL619103,5309
,22224,U,0,,,,2413,,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice blood upon intraveneous administration at 2.6 gmol/mice after 1 hour,1,Mus sp.,Autocuration,,,,10095.0,,,A,BAO_0000218,CHEMBL619268,5310
,22224,U,0,,,,2413,,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice blood upon intraveneous administration at 2.6 gmol/mice after 3 hour,1,Mus sp.,Autocuration,,,,10095.0,,,A,BAO_0000218,CHEMBL619269,5311
,22224,U,0,,,,2413,,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice brain upon intraveneous administration at 2.6 gmol/mice after 1 hour,1,Mus sp.,Autocuration,,,,10095.0,,,A,BAO_0000218,CHEMBL619270,5312
,22224,U,0,,,,2413,,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice brain upon intraveneous administration at 2.6 gmol/mice after 3 hour,1,Mus sp.,Autocuration,,,,10095.0,,,A,BAO_0000218,CHEMBL619271,5313
,22224,U,0,,,,2413,,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice kidney upon intraveneous administration at 2.6 gmol/mice after 1 hour,1,Mus sp.,Autocuration,,,,10095.0,,,A,BAO_0000218,CHEMBL875585,5314
,22224,U,0,,,,2413,,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice kidney upon intraveneous administration at 2.6 gmol/mice after 24 hour,1,Mus sp.,Autocuration,,,,10095.0,,,A,BAO_0000218,CHEMBL619272,5315
,80640,N,1,,,,6058,,Compound tested for growth inhibition of renal cancer cell line 786-0,1,Homo sapiens,Intermediate,,391.0,,9606.0,786-0,,F,BAO_0000219,CHEMBL619273,5316
,80640,N,1,,,,17708,,Compound was tested for 50% growth inhibition against human renal cancer 786-0 cell line,1,Homo sapiens,Intermediate,,391.0,,9606.0,786-0,,F,BAO_0000219,CHEMBL619274,5317
,80640,N,1,,,,14017,,Concentration which reduced cell growth to 50 % of level against 786-0 renal cancer line,1,Homo sapiens,Expert,,391.0,,9606.0,786-0,,F,BAO_0000219,CHEMBL619275,5318
,80640,N,1,,,,16818,,"Percent growth of NCI cell line, renal: 786-0 exposed for 48 hr at 10e-4 concentration",1,Homo sapiens,Intermediate,,391.0,,9606.0,786-0,,F,BAO_0000219,CHEMBL619276,5319
,80640,N,1,,,,16818,,"Percent growth of NCI cell line, renal: 786-0 exposed for 48 hr at 10e-6 concentration",1,Homo sapiens,Intermediate,,391.0,,9606.0,786-0,,F,BAO_0000219,CHEMBL619277,5320
,80640,N,1,,,,16818,,"Percent growth of NCI cell line, renal: 786-0 exposed for 48 hr at 10e-8 concentration",1,Homo sapiens,Intermediate,,391.0,,9606.0,786-0,,F,BAO_0000219,CHEMBL619278,5321
,80640,N,1,,,,11970,,Tested for cytotoxicity against 786-0 cell lines in renal cancer,1,Homo sapiens,Intermediate,,391.0,,9606.0,786-0,,F,BAO_0000219,CHEMBL619279,5322
,80640,N,1,,,,12400,,Tested in vitro for cytotoxicity in 786-0 cell line of Renal cancer,1,Homo sapiens,Intermediate,,391.0,,9606.0,786-0,,F,BAO_0000219,CHEMBL858458,5323
,80640,N,1,,,,12888,,Cytotoxic effect on renal cancer line 786-0,1,Homo sapiens,Expert,,391.0,,9606.0,786-0,,F,BAO_0000219,CHEMBL619280,5324
,80640,N,1,,,,15300,,In vitro antitumor activity against Renal cancer 786-0 cell lines by 6-day assay,1,Homo sapiens,Intermediate,,391.0,,9606.0,786-0,,F,BAO_0000219,CHEMBL619281,5325
,80640,N,1,,,,14769,,Compound was evaluated for in vitro activity against 786-0 kidney cell lines (Human tumor cells ),1,Homo sapiens,Intermediate,,391.0,,9606.0,786-0,,F,BAO_0000219,CHEMBL619282,5326
,80640,N,1,,,,15895,,"Cytotoxicity against NCI tumor panel, 786-0 renal cancer cell line",1,Homo sapiens,Intermediate,,391.0,,9606.0,786-0,,F,BAO_0000219,CHEMBL619283,5327
,80640,N,1,,,,17376,,Concentration of compound that cause 50% cytotoxicity of 786-0 renal cancer cell line,1,Homo sapiens,Intermediate,,391.0,,9606.0,786-0,,F,BAO_0000219,CHEMBL619284,5328
,80640,N,1,,,,14882,,Compound was tested for antitumor activity against 786-0 renal cancer cell line(molar concentration that inhibits 50% net cell growth).,1,Homo sapiens,Intermediate,,391.0,,9606.0,786-0,,F,BAO_0000219,CHEMBL619285,5329
,80640,N,1,,,,14882,,Compound was tested for antitumor activity against 786-0 renal cancer cell line(molar concentration leading to 50% net cell death),1,Homo sapiens,Intermediate,,391.0,,9606.0,786-0,,F,BAO_0000219,CHEMBL619286,5330
,80640,N,1,,,,15176,,Growth inhibition of the 786-O Renal cancer cell line for 2-day in vitro assay.,1,Homo sapiens,Intermediate,,391.0,,9606.0,786-0,,F,BAO_0000219,CHEMBL619287,5331
,80640,N,1,,,,12696,,In vitro anti tumor activity against human tumor Renal cancer cell lines was determined,1,Homo sapiens,Intermediate,,391.0,,9606.0,786-0,,F,BAO_0000219,CHEMBL857455,5332
,80640,N,1,,,,2496,,The compound was tested in vitro for cytotoxic activity against 786-O cell line (human perirenal carcinoma),1,Homo sapiens,Intermediate,,391.0,,9606.0,786-0,,F,BAO_0000219,CHEMBL883801,5333
,80641,N,1,,,,11831,,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells having only 3-5% antigen expression,1,Homo sapiens,Intermediate,,972.0,,9606.0,791T cell line,,F,BAO_0000219,CHEMBL619288,5334
,80641,N,1,,,,11831,,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells having only 3-5% antigen expression (49% inhibition achieved at 100 micro g/mL),1,Homo sapiens,Intermediate,,972.0,,9606.0,791T cell line,,F,BAO_0000219,CHEMBL619289,5335
,80641,N,1,,,,11831,,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells having only 3-5% antigen expression; <20% inhibition achieved,1,Homo sapiens,Intermediate,,972.0,,9606.0,791T cell line,,F,BAO_0000219,CHEMBL619290,5336
,80641,N,1,,,,11831,,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells of conjugate AH1.11 (Type H1: MSR-33),1,Homo sapiens,Intermediate,,972.0,,9606.0,791T cell line,,F,BAO_0000219,CHEMBL619291,5337
,80641,N,1,,,,11831,,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells of conjugate AH1.11 (Type H2: MSR-26),1,Homo sapiens,Intermediate,,972.0,,9606.0,791T cell line,,F,BAO_0000219,CHEMBL619292,5338
,80641,N,1,,,,11831,,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells of conjugate AH1.11 (Type H3: MSR-28); <20% inhibition achieved,1,Homo sapiens,Intermediate,,972.0,,9606.0,791T cell line,,F,BAO_0000219,CHEMBL619293,5339
,80641,N,1,,,,11831,,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells of conjugate H1.11 (Type H1: MSR-33),1,Homo sapiens,Intermediate,,972.0,,9606.0,791T cell line,,F,BAO_0000219,CHEMBL619294,5340
,80641,N,1,,,,11831,,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells of conjugate H1.11 (Type H2: MSR-26),1,Homo sapiens,Intermediate,,972.0,,9606.0,791T cell line,,F,BAO_0000219,CHEMBL619295,5341
,80641,N,1,,,,11831,,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells of conjugate H1.11 (Type H2: MSR-26) (less than 20% inhibition achieved),1,Homo sapiens,Intermediate,,972.0,,9606.0,791T cell line,,F,BAO_0000219,CHEMBL619296,5342
,80641,N,1,,,,11831,,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells of conjugate H1.11 (Type H3: MSR-28); <20% inhibition achieved,1,Homo sapiens,Intermediate,,972.0,,9606.0,791T cell line,,F,BAO_0000219,CHEMBL619297,5343
,80640,N,1,,,,12782,,Growth inhibitory concentration against tumor cells in culture renal cancer 796-0 cell line,1,Homo sapiens,Intermediate,,391.0,,9606.0,786-0,,F,BAO_0000219,CHEMBL619298,5344
,22226,U,0,,,,1229,,In vitro anticancer activity against 8 NCI CNS cancer cell lines; inactive,1,,Intermediate,,,,,,,F,BAO_0000019,CHEMBL619299,5345
,80433,N,1,,,,15313,,Inhibition of cell growth in drug resistant 8226 myeloma cell line,1,Homo sapiens,Expert,,741.0,,9606.0,RPMI-8226,,F,BAO_0000219,CHEMBL619300,5346
,80433,N,1,,,,15313,,Inhibition of cell growth in drug sensitive 8226 myeloma cell line,1,Homo sapiens,Expert,,741.0,,9606.0,RPMI-8226,,F,BAO_0000219,CHEMBL619301,5347
,80433,N,1,,,,11544,,In vitro inhibition of tumor cell growth in the human myeloma 8226 system.,1,Homo sapiens,Intermediate,,741.0,,9606.0,RPMI-8226,,F,BAO_0000219,CHEMBL619302,5348
,80433,N,1,,,,9424,,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.01 ug/mL,1,Homo sapiens,Intermediate,,741.0,,9606.0,RPMI-8226,,F,BAO_0000219,CHEMBL619303,5349
,80433,N,1,,,,9424,,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.1 ug/mL,1,Homo sapiens,Intermediate,,741.0,,9606.0,RPMI-8226,,F,BAO_0000219,CHEMBL619304,5350
,80433,N,1,,,,9424,,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.1 ug/mL (*: >50% cell kill),1,Homo sapiens,Intermediate,,741.0,,9606.0,RPMI-8226,,F,BAO_0000219,CHEMBL857706,5351
,80433,N,1,,,,9424,,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.3 ug/mL (*: >50% cell kill),1,Homo sapiens,Intermediate,,741.0,,9606.0,RPMI-8226,,F,BAO_0000219,CHEMBL619305,5352
,80433,N,1,,,,9424,,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.5 ug/mL. (*: >1 log cell kill),1,Homo sapiens,Intermediate,,741.0,,9606.0,RPMI-8226,,F,BAO_0000219,CHEMBL619306,5353
,80433,N,1,,,,9424,,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 10 ug/mL (*: >1 log cell kill),1,Homo sapiens,Intermediate,,741.0,,9606.0,RPMI-8226,,F,BAO_0000219,CHEMBL619307,5354
,80433,N,1,,,,9424,,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 10 ug/mL (*: >1 log cell kill),1,Homo sapiens,Intermediate,,741.0,,9606.0,RPMI-8226,,F,BAO_0000219,CHEMBL619308,5355
,80433,N,1,,,,9424,,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 1 ug/mL. (*: >50% cell kill),1,Homo sapiens,Intermediate,,741.0,,9606.0,RPMI-8226,,F,BAO_0000219,CHEMBL619309,5356
,80433,N,1,,,,9424,,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 1 ug/mL. (*: >1 log cell kill),1,Homo sapiens,Intermediate,,741.0,,9606.0,RPMI-8226,,F,BAO_0000219,CHEMBL619310,5357
,80021,N,1,,,,14769,,Compound was evaluated for in vitro activity against A498 kidney cell lines (Human tumor cells ),1,Homo sapiens,Intermediate,,624.0,,9606.0,A498,,F,BAO_0000219,CHEMBL619311,5358
,80021,N,1,,,,15354,,Compound was tested for the growth inhibition of A498 renal tumor cell line,1,Homo sapiens,Intermediate,,624.0,,9606.0,A498,,F,BAO_0000219,CHEMBL619312,5359
,80021,N,1,,,,17445,,In vitro cytotoxicity against human tumor A498 cell line (renal cancer),1,Homo sapiens,Intermediate,,624.0,,9606.0,A498,,F,BAO_0000219,CHEMBL619313,5360
,80021,N,1,,,,4337,,In vitro inhibitory concentration against renal cancer cell line A498,1,Homo sapiens,Intermediate,,624.0,,9606.0,A498,,F,BAO_0000219,CHEMBL619314,5361
,80021,N,1,,,,15277,,Cytotoxicity against A 498 tumor cell line,1,Homo sapiens,Intermediate,,624.0,,9606.0,A498,,F,BAO_0000219,CHEMBL619959,5362
,80021,N,1,,,,4812,,In vitro antitumor activity against A498 human cancer cell line,1,Homo sapiens,Intermediate,,624.0,,9606.0,A498,,F,BAO_0000219,CHEMBL619960,5363
,80021,N,1,,,,4812,,In vitro antitumor activity against A498 human cancer cell line (Data from NCI-screening),1,Homo sapiens,Intermediate,,624.0,,9606.0,A498,,F,BAO_0000219,CHEMBL619961,5364
,80021,N,1,,,,4995,,Inhibitory dose required against A498 human tumor cell lines,1,Homo sapiens,Intermediate,,624.0,,9606.0,A498,,F,BAO_0000219,CHEMBL619962,5365
,80021,N,1,,,,5847,,Anticancer activity against one renal cancer (A498 cell line),1,Homo sapiens,Intermediate,,624.0,,9606.0,A498,,F,BAO_0000219,CHEMBL875586,5366
,80021,N,1,,,,6557,,In vitro cytotoxicity against melanoma A498 cell line,1,Homo sapiens,Intermediate,,624.0,,9606.0,A498,,F,BAO_0000219,CHEMBL619963,5367
,80021,N,1,,,,2597,,Compound was tested for growth inhibitory activity against A498 cell line,1,Homo sapiens,Intermediate,,624.0,,9606.0,A498,,F,BAO_0000219,CHEMBL619964,5368
,80021,N,1,,,,6058,,Compound tested for growth inhibition of renal cancer cell line A498,1,Homo sapiens,Intermediate,,624.0,,9606.0,A498,,F,BAO_0000219,CHEMBL620108,5369
,80021,N,1,,,,17708,,Compound was tested for 50% growth inhibition against human renal cancer A498 cell line,1,Homo sapiens,Intermediate,,624.0,,9606.0,A498,,F,BAO_0000219,CHEMBL620109,5370
,80021,N,1,,,,15176,,Growth inhibition of the A498 Renal cancer cell line for 2-day in vitro assay.,1,Homo sapiens,Intermediate,,624.0,,9606.0,A498,,F,BAO_0000219,CHEMBL620110,5371
,80021,N,1,,,,15300,,In vitro antitumor activity against Renal cancer A498 cell lines by 6-day assay,1,Homo sapiens,Intermediate,,624.0,,9606.0,A498,,F,BAO_0000219,CHEMBL620111,5372
,80021,N,1,,,,11970,,Tested for cytotoxicity against A498 cell lines in renal cancer,1,Homo sapiens,Intermediate,,624.0,,9606.0,A498,,F,BAO_0000219,CHEMBL620112,5373
,80021,N,1,,,,12400,,Tested in vitro for cytotoxicity in A498 cell line of Renal cancer,1,Homo sapiens,Intermediate,,624.0,,9606.0,A498,,F,BAO_0000219,CHEMBL620113,5374
,80021,N,1,,,,12888,,Cytotoxic effect on renal cancer lines A498,1,Homo sapiens,Expert,,624.0,,9606.0,A498,,F,BAO_0000219,CHEMBL620114,5375
,80021,N,1,,,,3030,,Antitumor activity was evaluated for reduction of growth of renal cancer (A498) cells at a concentration of 100 uM,1,Homo sapiens,Intermediate,,624.0,,9606.0,A498,,F,BAO_0000219,CHEMBL620115,5376
,80021,N,1,,,,14769,,Compound was evaluated for in vitro activity against A498 kidney cell lines (Human tumor cells ),1,Homo sapiens,Intermediate,,624.0,,9606.0,A498,,F,BAO_0000219,CHEMBL620116,5377
,80021,N,1,,,,17376,,Concentration of compound that cause 50% cytotoxicity of A498 renal cancer cell line,1,Homo sapiens,Intermediate,,624.0,,9606.0,A498,,F,BAO_0000219,CHEMBL620117,5378
,80021,N,1,,,,16558,,Growth inhibitory activity against A498-2LM human solid tumor cell line using MTT assay,1,Homo sapiens,Intermediate,,624.0,,9606.0,A498,,F,BAO_0000219,CHEMBL620118,5379
,80021,N,1,,,,5194,,Cytotoxicity against human kidney carcinoma cell lines A4982LM,1,Homo sapiens,Intermediate,,624.0,,9606.0,A498,,F,BAO_0000219,CHEMBL620119,5380
,80021,N,1,,,,10708,,Evaluated for the inhibitory concentration required to cause growth inhibition of A498Rem- renal cell line using the MTT Cytotoxicity Assay,1,Homo sapiens,Intermediate,,624.0,,9606.0,A498,,F,BAO_0000219,CHEMBL620120,5381
,80682,N,1,,,,16880,,Antiproliferative activity in vitro against A549 (human non-small lung carcinoma) cell line.,1,Homo sapiens,Expert,,646.0,,9606.0,A549,,F,BAO_0000219,CHEMBL620121,5382
,80682,N,1,,,,10196,,Antitumor activity against A549 human lung carcinoma cell line,1,Homo sapiens,Intermediate,,646.0,,9606.0,A549,,F,BAO_0000219,CHEMBL620122,5383
,80682,N,1,,,,10196,,Antitumor activity against A549 human lung carcinoma cell line in experiment 1,1,Homo sapiens,Intermediate,,646.0,,9606.0,A549,,F,BAO_0000219,CHEMBL620123,5384
,80682,N,1,,,,10196,,Antitumor activity against A549 human lung carcinoma cell line in experiment 2,1,Homo sapiens,Intermediate,,646.0,,9606.0,A549,,F,BAO_0000219,CHEMBL620124,5385
,80682,N,1,,,,12083,,"Concentration required to inhibit tumor growth in A549, human lung carcinoma (NSCLC) cell line",1,Homo sapiens,Intermediate,,646.0,,9606.0,A549,,F,BAO_0000219,CHEMBL620125,5386
,80682,N,1,,,,16464,,Cytotoxicity against A549 nonsmall lung cell line using MTT colorimetric assay,1,Homo sapiens,Expert,,646.0,,9606.0,A549,,F,BAO_0000219,CHEMBL620126,5387
,80682,N,1,,,,16464,,Cytotoxicity against A549 nonsmall lung cell line using MTT colorimetric assay; NE is no effect at 1x 10 E-5,1,Homo sapiens,Intermediate,,646.0,,9606.0,A549,,F,BAO_0000219,CHEMBL883027,5388
,80682,N,1,,,,16470,,In vitro cytotoxic activity against human lung A549 cell line,1,Homo sapiens,Expert,,646.0,,9606.0,A549,,F,BAO_0000219,CHEMBL620127,5389
,80682,N,1,,,,16470,,In vitro cytotoxic activity against human lung A549 cell line ( standard deviation in parenthesis),1,Homo sapiens,Intermediate,,646.0,,9606.0,A549,,F,BAO_0000219,CHEMBL620128,5390
,80682,N,1,,,,16470,,In vitro cytotoxic activity against human lung A549 cell line),1,Homo sapiens,Intermediate,,646.0,,9606.0,A549,,F,BAO_0000219,CHEMBL620129,5391
,80682,N,1,,,,16470,,In vitro cytotoxic activity against human lung A549 cell line;NT is not tested,1,Homo sapiens,Intermediate,,646.0,,9606.0,A549,,F,BAO_0000219,CHEMBL620130,5392
,80682,N,1,,,,16582,,In vitro cytotoxicity against human non small-cell-lung cell line A549.,1,Homo sapiens,Expert,,646.0,,9606.0,A549,,F,BAO_0000219,CHEMBL620131,5393
,80682,N,1,,,,15935,,"In vitro growth inhibition of human lung carcinoma cell line, A549 with low levels of folate receptors",1,Homo sapiens,Intermediate,,646.0,,9606.0,A549,,F,BAO_0000219,CHEMBL620132,5394
,80682,N,1,,,,15935,,"In vitro growth inhibition of human lung carcinoma cell line, A549 with low levels of folate receptors in folate deficient medium",1,Homo sapiens,Intermediate,,646.0,,9606.0,A549,,F,BAO_0000219,CHEMBL620133,5395
,80682,N,1,,,,16597,,Inhibition of A549 human lung carcinoma cell proliferation,1,Homo sapiens,Expert,,646.0,,9606.0,A549,,F,BAO_0000219,CHEMBL620134,5396
,80682,N,1,,,,17376,,Inhibitory activity against A549 lung adenocarcinoma cell line,1,Homo sapiens,Intermediate,,646.0,,9606.0,A549,,F,BAO_0000219,CHEMBL620135,5397
,80682,N,1,,,,16496,,Inhibitory concentration required to reduce A549 tumor cell growth by 50% in MTT assay,1,Homo sapiens,Intermediate,,646.0,,9606.0,A549,,F,BAO_0000219,CHEMBL620136,5398
,80682,N,1,,,,16152,,in vitro anticancer activity against cultured A549 human tumor(lung) cell line,1,Homo sapiens,Intermediate,,646.0,,9606.0,A549,,F,BAO_0000219,CHEMBL620137,5399
,80682,N,1,,,,16152,,in vitro inhibition of tumor cell growth in cultured A549 human tumor cell line,1,Homo sapiens,Intermediate,,646.0,,9606.0,A549,,F,BAO_0000219,CHEMBL620268,5400
,80682,N,1,,,,16464,,Cytotoxicity against A549 nonsmall lung cell line using MTT colorimetric assay; NE is no effect at 1x 10 E-5,1,Homo sapiens,Intermediate,,646.0,,9606.0,A549,,F,BAO_0000219,CHEMBL620269,5401
,80682,N,1,,,,2288,,Cytotoxicity was evaluated against A549 non-small cell lung carcinoma human cancer cell line,1,Homo sapiens,Intermediate,,646.0,,9606.0,A549,,F,BAO_0000219,CHEMBL620270,5402
,80682,N,1,,,,17350,,Compound was tested for antiproliferative activity against human A549 cancer cell lines using MTT assay,1,Homo sapiens,Intermediate,,646.0,,9606.0,A549,,F,BAO_0000219,CHEMBL620271,5403
,80682,N,1,,,,4090,,Inhibition of A549 cancer cell proliferation,1,Homo sapiens,Expert,,646.0,,9606.0,A549,,F,BAO_0000219,CHEMBL620272,5404
,80682,N,1,,,,4090,,Inhibition of A549 cancer cell proliferation (Not tested),1,Homo sapiens,Expert,,646.0,,9606.0,A549,,F,BAO_0000219,CHEMBL620273,5405
,80682,N,1,,,,17350,,Compound was tested for antiproliferative activity against human A549 cancer cell lines using MTT assay,1,Homo sapiens,Intermediate,,646.0,,9606.0,A549,,F,BAO_0000219,CHEMBL620274,5406
,80682,N,1,,,,4197,,In vitro inhibitory concentration required against human lung A549 carcinoma cells proliferation,1,Homo sapiens,Intermediate,,646.0,,9606.0,A549,,F,BAO_0000219,CHEMBL620275,5407
,80682,N,1,,,,17072,,Antiproliferative potency determined as inhibitory concentration against A549 cells,1,Homo sapiens,Intermediate,,646.0,,9606.0,A549,,F,BAO_0000219,CHEMBL620276,5408
,80682,N,1,,,,17072,,Percent assembly of bovine brain tubulin induced by compound at 10 uM versus that caused by 10 uM paclitaxel,1,Homo sapiens,Intermediate,,646.0,,9606.0,A549,,F,BAO_0000219,CHEMBL620277,5409
,80682,N,1,,,,5194,,Cytotoxicity against Renal cell lines A549 was determined,1,Homo sapiens,Intermediate,,646.0,,9606.0,A549,,F,BAO_0000219,CHEMBL620278,5410
,50588,N,1,,,,4257,,Area under curve was determined in dog after a 3 mg/kg of oral dose,1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL620279,5411
,50588,N,1,,,,6123,,Area under curve was determined in dog after oral administration at 1 mg/kg,1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL620280,5412
,50588,N,1,,,,1337,,Area under curve was determined in dogs after oral administration (10 mg/kg) as a 0.05 M citric acid solution.,1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL620281,5413
,50588,N,1,,,,1337,,Area under curve was determined in dogs after oral administration (8 mg/kg) as a 0.05 M citric acid solution.,1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL620282,5414
,50588,N,1,,,,8833,,Area under increased blood flow curve (AUC) at 1 microg ia at a duration of ( 0-2 mins),1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL621134,5415
,50588,N,1,,,,8833,,Area under increased blood flow curve (AUC) at 1 microg ia at a duration of ( 0-5 mins),1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL621135,5416
,50588,N,1,,,,8833,,Area under increased blood flow curve (AUC) at 1 microg ia at a duration of (0-15 mins),1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL621136,5417
,50588,N,1,,,,8833,,Area under increased blood flow curve (AUC) at 1 microg ia at a duration of( 0-120 mins),1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL621137,5418
Plasma,50588,N,1,,,,17657,,Area under plasma concentration time curve in dog upon oral administration,1,Canis lupus familiaris,Intermediate,,,,9615.0,,1969.0,A,BAO_0000218,CHEMBL621138,5419
Plasma,50588,N,1,,,,17650,,Area under plasma concentration time curve was measured in dogs after an oral dose of 10 uM/kg,1,Canis lupus familiaris,Intermediate,,,,9615.0,,1969.0,A,BAO_0000218,CHEMBL875587,5420
,50588,N,1,,,,1977,,Area under the curve for compound was evaluated in dog at a dose of 10 mg/kg.,1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL621139,5421
,50588,N,1,,,,1977,,Area under the curve for compound was evaluated in dog at a dose of 20 mg/kg.,1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL621140,5422
,50588,N,1,,,,3132,,Area under the curve for the compound was obtained when tested in dog,1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL621141,5423
,50588,N,1,,,,5473,,Area under the curve at a dose of 1 mg/kg,1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL621142,5424
,50588,N,1,,,,5474,,Area under the curve at a dose of 1 mg/kg (oral),1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL621143,5425
,50588,N,1,,,,5474,,Area under the curve at i.v. dose of 0.2 mg/kg,1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL621144,5426
,50588,N,1,,,,6062,,Area under the curve was measured in dog after an iv dose of 1 mg/kg,1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL621145,5427
,50588,N,1,,,,4709,,Bioavailability from area under the curve at time 0 to infinity after intravenous administration of 1 mg/kg in dog,1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL621146,5428
,50588,N,1,,,,2652,,Compound was evaluated for area under curve (total concentration) in dogs at a dose of 1 mpk perorally,1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL622567,5429
,50588,N,1,,,,2652,,Compound was evaluated for area under curve (total concentration) in dogs at a dose of 5 mpk perorally,1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL622568,5430
,50588,N,1,,,,2877,,Compound was evaluated for area under the curve in dog blood.,1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL622569,5431
,50588,N,1,,,,5444,,In vivo area under curve was calculated by peroral administration at 1 mg/kg in fasted dog,1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL622570,5432
Plasma,50588,N,1,,,,5130,,AUC in dog after oral dose (1 mg/kg),1,Canis lupus familiaris,Intermediate,,,,9615.0,,1969.0,A,BAO_0000218,CHEMBL622571,5433
,50588,N,1,,,,6265,,Pharmacokinetic (PK) property (AUC) was determined in dog at the single oral dose of 1 mg/kg,1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL622572,5434
,50588,N,1,,,,4657,,"Pharmacokinetic data in dogs at dose of 1 mg/kg perorally, and the area under curve (AUC) was reported.",1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL622573,5435
,50588,N,1,,,,16367,,Pharmacokinetic parameter AUC after intravenous administration to dogs,1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL622574,5436
,50588,N,1,,,,16367,,Pharmacokinetic parameter AUC after oral administration to dogs,1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL622575,5437
,50588,N,1,,,,9579,,Pharmacokinetic parameter AUC was determined in dog after oral administration of 17b,1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL622576,5438
,50588,N,1,,,,9579,,Pharmacokinetic parameter AUC was determined in dog after oral administration of 2b,1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL622577,5439
,50588,N,1,,,,5983,,Pharmacokinetic property (AUC) was measured in dog at the dose of 0.032 mg/kg p.o.,1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL622578,5440
,50588,N,1,,,,6241,,Pharmacokinetic property in dogs after oral administration at 1 mg/kg,1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL622579,5441
,50588,N,1,,,,5313,,"Tested for the pharmacokinetic data, area under the curve of concentration versus time in dog",1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL622580,5442
,50588,N,1,,,,5313,,"Tested for the pharmacokinetic data, area under the curve of concentration versus time in dog at dosage of 10 mpk",1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL622581,5443
,50588,N,1,,,,6642,,Oral AUCN in dog ( (dosed as a mixture of five compounds at 0.5 mpk each via iv only),1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL622582,5444
,50588,N,1,,,,6642,,Oral AUCN in dog (dosed as a mixture of five compounds at 0.5 mpk each via iv only),1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL622583,5445
,50588,N,1,,,,6641,,Oral AUCN in dog (dosed at 0.5 mpk iv ),1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL622584,5446
,50588,N,1,,,,6642,,Oral AUCN in dog (dosed at 0.5 mpk iv ),1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL622585,5447
,50588,N,1,,,,17791,,Compound was evaluated for oral bioavailability in dog; 90-100,1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL622586,5448
,50588,N,1,,,,17655,,Compound was tested for its cell permeability in the Madin-Darby canine kidney cell monolayer transport assay,1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL623281,5449
,50588,N,1,,,,17655,,Compound was tested for its cell permeability in the Madin-Darby canine kidney cell monolayer transport assay; Not determined,1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL623282,5450
,50588,N,1,,,,6596,,PAPP (membrane permeability) in dog kidney cell monolayer assay,1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL623283,5451
,50588,N,1,,,,3880,,Oral bioavailability in dog,1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL623284,5452
,50588,N,1,,,,16367,,Bioavailability administered orally at a dose of 10 mg/kg to dogs,1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL623285,5453
Plasma,50588,N,1,,,,17409,,Plasma protein binding towards dog plasma at 10 uM,1,Canis lupus familiaris,Intermediate,,,,9615.0,,1969.0,A,BAO_0000218,CHEMBL623463,5454
Plasma,50588,N,1,,,,17409,,Plasma protein binding towards dog plasma at 100 uM,1,Canis lupus familiaris,Intermediate,,,,9615.0,,1969.0,A,BAO_0000218,CHEMBL875952,5455
,50588,N,1,In vivo,,,2959,,Bioavailability in dog (dose 4 mg/kg p.o.),1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL621705,5456
,50588,N,1,In vivo,,,13501,,Bioavailability was determined after oral administration of compound 18 at a dose of 2 mg/kg to dog,1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL621706,5457
,50588,N,1,In vivo,,,4527,,Bioavailability by oral administration at a dose of 10 uM/kg in dog was determined,1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL621707,5458
,50588,N,1,In vivo,,,15145,,Bioavailability in dogs,1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL621708,5459
,50588,N,1,In vivo,,,4219,,Bioavailability,1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL621709,5460
,50588,N,1,In vivo,,,17538,,Oral bioavailability in dog (dose 10 mg/kg),1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL621710,5461
,50588,N,1,In vivo,,,17538,,Bioavailability in dog after po administration at a dose of 10 mg/kg; nd is not determined,1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL621711,5462
,50588,N,1,In vivo,,,1466,,Bioavailability in dog (dose 10.0 mg/kg p.o.),1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL621712,5463
,50588,N,1,In vivo,,,17650,,Bioavailability was measured in dogs after an oral dose of 10 uM/kg,1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL621713,5464
,50588,N,1,In vivo,,,3132,,Bioavailability was obtained by the comparison of AUC of intravenous dosing and AUC of oral dosing in dog,1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL621714,5465
,22224,U,0,,,,2413,,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice kidney upon intraveneous administration at 2.6 gmol/mice after 3 hour,1,Mus sp.,Autocuration,,,,10095.0,,,A,BAO_0000218,CHEMBL621715,5466
Liver,22224,U,0,,,,2413,,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice liver upon intraveneous administration at 2.6 gmol/mice after 1 hour,1,Mus sp.,Autocuration,,,,10095.0,,2107.0,A,BAO_0000218,CHEMBL623717,5467
Liver,22224,U,0,,,,2413,,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice liver upon intraveneous administration at 2.6 gmol/mice after 24 hour,1,Mus sp.,Autocuration,,,,10095.0,,2107.0,A,BAO_0000218,CHEMBL623718,5468
Liver,22224,U,0,,,,2413,,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice liver upon intraveneous administration at 2.6 gmol/mice after 3 hour,1,Mus sp.,Autocuration,,,,10095.0,,2107.0,A,BAO_0000218,CHEMBL623719,5469
,22224,U,0,,,,2413,,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice lungs upon intraveneous administration at 2.6 gmol/mice after 1 hour,1,Mus sp.,Autocuration,,,,10095.0,,,A,BAO_0000218,CHEMBL623720,5470
,22224,U,0,,,,2413,,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice lungs upon intraveneous administration at 2.6 gmol/mice after 3 hour,1,Mus sp.,Autocuration,,,,10095.0,,,A,BAO_0000218,CHEMBL623721,5471
Muscle tissue,22224,U,0,,,,2413,,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice muscle upon intraveneous administration at 2.6 gmol/mice after 1 hour,1,Mus sp.,Autocuration,,,,10095.0,,2385.0,A,BAO_0000218,CHEMBL623722,5472
Muscle tissue,22224,U,0,,,,2413,,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice muscle upon intraveneous administration at 2.6 gmol/mice after 24 hour,1,Mus sp.,Autocuration,,,,10095.0,,2385.0,A,BAO_0000218,CHEMBL623723,5473
Muscle tissue,22224,U,0,,,,2413,,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice muscle upon intraveneous administration at 2.6 gmol/mice after 3 hour,1,Mus sp.,Autocuration,,,,10095.0,,2385.0,A,BAO_0000218,CHEMBL618543,5474
Spleen,22224,U,0,,,,2413,,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice spleen upon intraveneous administration at 2.6 gmol/mice after 1 hour,1,Mus sp.,Autocuration,,,,10095.0,,2106.0,A,BAO_0000218,CHEMBL618544,5475
Spleen,22224,U,0,,,,2413,,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice spleen upon intraveneous administration at 2.6 gmol/mice after 3 hour,1,Mus sp.,Autocuration,,,,10095.0,,2106.0,A,BAO_0000218,CHEMBL875155,5476
,22224,U,0,,,,2413,,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice upon intraveneous administration at 2.6 gmol/mice after 1 hour,1,Mus sp.,Autocuration,,,,10095.0,,,A,BAO_0000218,CHEMBL618545,5477
,22224,U,0,,,,2413,,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice upon intraveneous administration at 2.6 gmol/mice after 24 hour,1,Mus sp.,Autocuration,,,,10095.0,,,A,BAO_0000218,CHEMBL618546,5478
,22224,U,0,,,,2413,,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice upon intraveneous administration at 2.6 gmol/mice after 3 hour,1,Mus sp.,Autocuration,,,,10095.0,,,A,BAO_0000218,CHEMBL623529,5479
,22224,U,0,,,,2413,,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice uvea upon intraveneous administration at 2.6 gmol/mice after 24 hour,1,Mus sp.,Autocuration,,,,10095.0,,,A,BAO_0000218,CHEMBL623530,5480
,22224,U,0,,,,2413,,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice uvea upon intraveneous administration at 2.6 gmol/mice after 3 hour,1,Mus sp.,Autocuration,,,,10095.0,,,A,BAO_0000218,CHEMBL621764,5481
,22224,U,0,,,,17827,,Compound (i.v.) was evaluated for elimination rate constants in brainstem of rhesus monkeys (Radiolabeled compound),1,Cercopithecidae,Autocuration,,,,9527.0,,,A,BAO_0000019,CHEMBL621765,5482
Cerebellum,22224,U,0,,,,17827,,Compound (i.v.) was evaluated for elimination rate constants in cerebellum of rhesus monkeys (Radiolabeled compound),1,Cercopithecidae,Autocuration,,,,9527.0,,2037.0,A,BAO_0000019,CHEMBL621766,5483
Frontal cortex,22224,U,0,,,,17827,,Compound (i.v.) was evaluated for elimination rate constants in frontal cortex of rhesus monkey (Radiolabeled compound),1,Cercopithecidae,Autocuration,,,,9527.0,,1870.0,A,BAO_0000019,CHEMBL621767,5484
,22224,U,0,,,,17827,,Compound (i.v.) was evaluated for elimination rate constants in jaw bone of rhesus monkeys; NA = not active (Radiolabeled compound),1,Cercopithecidae,Autocuration,,,,9527.0,,,A,BAO_0000019,CHEMBL621768,5485
Striatum,22224,U,0,,,,17827,,Compound (i.v.) was evaluated for elimination rate constants in striatum of rhesus monkey (Radiolabeled compound),1,Cercopithecidae,Autocuration,,,,9527.0,,2435.0,A,BAO_0000019,CHEMBL621769,5486
,22224,U,0,,,,17827,,Compound (i.v.) was evaluated for uptake rate constants in brainstem of rhesus monkeys (Radiolabeled compound),1,Cercopithecidae,Autocuration,,,,9527.0,,,A,BAO_0000019,CHEMBL621770,5487
Cerebellum,22224,U,0,,,,17827,,Compound (i.v.) was evaluated for uptake rate constants in cerebellum of rhesus monkeys (Radiolabeled compound),1,Cercopithecidae,Autocuration,,,,9527.0,,2037.0,A,BAO_0000019,CHEMBL621771,5488
Frontal cortex,22224,U,0,,,,17827,,Compound (i.v.) was evaluated for uptake rate constants in frontal cortex of rhesus monkey (Radiolabeled compound),1,Cercopithecidae,Autocuration,,,,9527.0,,1870.0,A,BAO_0000019,CHEMBL621772,5489
,22224,U,0,,,,17827,,Compound (i.v.) was evaluated for uptake rate constants in jaw bone of rhesus monkey (Radiolabeled compound),1,Cercopithecidae,Autocuration,,,,9527.0,,,A,BAO_0000019,CHEMBL621773,5490
Striatum,22224,U,0,,,,17827,,Compound (i.v.) was evaluated for uptake rate constants in striatum of rhesus monkeys (Radiolabeled compound),1,Cercopithecidae,Autocuration,,,,9527.0,,2435.0,A,BAO_0000019,CHEMBL621774,5491
,22224,U,0,,,,17791,,Compound was evaluated for oral bioavailability in rats,1,Cercopithecidae,Autocuration,,,,9527.0,,,A,BAO_0000218,CHEMBL621775,5492
Plasma,22224,U,0,In vivo,,,17667,,Maximum concentration of compound found in plasma at 5 mg/kg after oral administration,1,Cercopithecidae,Autocuration,,,,9527.0,,1969.0,A,BAO_0000218,CHEMBL621776,5493
,22224,U,0,,,,17791,,Half life period was evaluated in monkey,1,Cercopithecidae,Autocuration,,,,9527.0,,,A,BAO_0000019,CHEMBL621777,5494
,22224,U,0,In vivo,,,110,,Half-life in rhesus monkeys by intravenous administration of dose,1,Cercopithecidae,Autocuration,,,,9527.0,,,A,BAO_0000218,CHEMBL875162,5495
Plasma,50594,N,1,,,,5781,,AUC (0-6 hr) after oral administration at 30 mg/kg in ICR mouse,1,Mus musculus,Intermediate,,,,10090.0,,1969.0,A,BAO_0000218,CHEMBL621778,5496
Plasma,50594,N,1,,,,17734,,AUC after intraperitoneal administration of 100 mg/kg in mice,1,Mus musculus,Intermediate,,,,10090.0,,1969.0,A,BAO_0000218,CHEMBL621779,5497
Plasma,50594,N,1,,,,17718,,AUC value was determined after oral administration,1,Mus musculus,Intermediate,,,,10090.0,,1969.0,A,BAO_0000218,CHEMBL622479,5498
,50594,N,1,,,,4573,,Area under curve (AUC) determined at a dose 10 mg/kg administered intraperitoneally to mice,1,Mus musculus,Intermediate,,,,10090.0,,,A,BAO_0000218,CHEMBL622480,5499
,50594,N,1,,,,3277,,Area under curve (AUC) was determined in mice at a single subcutaneous administration of 40 mg/kg (n=4),1,Mus musculus,Intermediate,,,,10090.0,,,A,BAO_0000218,CHEMBL622481,5500
,50594,N,1,,,,2862,,Area under curve by ioral administration in mouse,1,Mus musculus,Intermediate,,,,10090.0,,,A,BAO_0000218,CHEMBL622482,5501
,50594,N,1,,,,2862,,Area under curve by iv administration in mouse,1,Mus musculus,Intermediate,,,,10090.0,,,A,BAO_0000218,CHEMBL622483,5502
,50594,N,1,,,,5951,,Area under curve at 0-8 hr in IRC mice after peroral administration,1,Mus musculus,Intermediate,,,,10090.0,,,A,BAO_0000218,CHEMBL622484,5503
,50594,N,1,,,,17729,,Area under curve when injected i.p. in mice at a dose of 50 mg/kg,1,Mus musculus,Intermediate,,,,10090.0,,,A,BAO_0000218,CHEMBL622641,5504
,50594,N,1,,,,17728,,Area under curve when injected intraperitoneally in BALB/C mice at a dose of 20 mg/kg,1,Mus musculus,Intermediate,,,,10090.0,,,A,BAO_0000218,CHEMBL622642,5505
,50594,N,1,,,,17728,,Area under curve when injected intravenously in BALB/C mice at a dose of 20 mg/kg,1,Mus musculus,Intermediate,,,,10090.0,,,A,BAO_0000218,CHEMBL622643,5506
,50594,N,1,,,,17729,,Area under curve when injected intravenously in mice at a dose of 20 mg/kg,1,Mus musculus,Intermediate,,,,10090.0,,,A,BAO_0000218,CHEMBL622644,5507
,80433,N,1,,,,9424,,Effect on RNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.01 ug/mL,1,Homo sapiens,Intermediate,,741.0,,9606.0,RPMI-8226,,F,BAO_0000219,CHEMBL622645,5508
,80433,N,1,,,,9424,,Effect on RNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.1 ug/mL,1,Homo sapiens,Intermediate,,741.0,,9606.0,RPMI-8226,,F,BAO_0000219,CHEMBL622646,5509
,80433,N,1,,,,9424,,Effect on RNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.1 ug/mL (*: >50% cell kill),1,Homo sapiens,Intermediate,,741.0,,9606.0,RPMI-8226,,F,BAO_0000219,CHEMBL621238,5510
,80433,N,1,,,,9424,,Effect on RNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.3 ug/mL (*: >50% cell kill),1,Homo sapiens,Intermediate,,741.0,,9606.0,RPMI-8226,,F,BAO_0000219,CHEMBL621239,5511
,80433,N,1,,,,9424,,Effect on RNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.5 ug/mL. (*: >1 log cell kill),1,Homo sapiens,Intermediate,,741.0,,9606.0,RPMI-8226,,F,BAO_0000219,CHEMBL621240,5512
,80433,N,1,,,,9424,,Effect on RNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 10 ug/mL (*: >1 log cell kill),1,Homo sapiens,Intermediate,,741.0,,9606.0,RPMI-8226,,F,BAO_0000219,CHEMBL621241,5513
,80433,N,1,,,,9424,,Effect on RNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 1 ug/mL. (*: >50% cell kill),1,Homo sapiens,Intermediate,,741.0,,9606.0,RPMI-8226,,F,BAO_0000219,CHEMBL621242,5514
,80433,N,1,,,,9424,,Effect on RNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 1 ug/mL. (*: >1 log cell kill),1,Homo sapiens,Intermediate,,741.0,,9606.0,RPMI-8226,,F,BAO_0000219,CHEMBL620350,5515
,80433,N,1,,,,9424,,Effect on protein synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.01 ug/mL,1,Homo sapiens,Intermediate,,741.0,,9606.0,RPMI-8226,,F,BAO_0000219,CHEMBL620351,5516
,80433,N,1,,,,9424,,Effect on protein synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.1 ug/mL,1,Homo sapiens,Intermediate,,741.0,,9606.0,RPMI-8226,,F,BAO_0000219,CHEMBL620352,5517
,80433,N,1,,,,9424,,Effect on protein synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.1 ug/mL (*: >50% cell kill),1,Homo sapiens,Intermediate,,741.0,,9606.0,RPMI-8226,,F,BAO_0000219,CHEMBL620353,5518
,80433,N,1,,,,9424,,Effect on protein synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.3 ug/mL (*: >50% cell kill),1,Homo sapiens,Intermediate,,741.0,,9606.0,RPMI-8226,,F,BAO_0000219,CHEMBL620354,5519
,80433,N,1,,,,9424,,Effect on protein synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.5 ug/mL. (*: >1 log cell kill),1,Homo sapiens,Intermediate,,741.0,,9606.0,RPMI-8226,,F,BAO_0000219,CHEMBL620355,5520
,80433,N,1,,,,9424,,Effect on protein synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 10 ug/mL (*: >1 log cell kill),1,Homo sapiens,Intermediate,,741.0,,9606.0,RPMI-8226,,F,BAO_0000219,CHEMBL620356,5521
,80433,N,1,,,,9424,,Effect on protein synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 1 ug/mL. (*: >50% cell kill),1,Homo sapiens,Intermediate,,741.0,,9606.0,RPMI-8226,,F,BAO_0000219,CHEMBL620357,5522
,80433,N,1,,,,9424,,Effect on protein synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 1 ug/mL. (*: >1 log cell kill),1,Homo sapiens,Intermediate,,741.0,,9606.0,RPMI-8226,,F,BAO_0000219,CHEMBL620358,5523
,80433,N,1,,,,9424,,In vitro inhibition of human 8226 myeloma tumor cell line growth.,1,Homo sapiens,Expert,,741.0,,9606.0,RPMI-8226,,F,BAO_0000219,CHEMBL620359,5524
,80433,N,1,,,,11544,,In vitro inhibition of tumor cell growth in the human myeloma 8226/ADR system.,1,Homo sapiens,Intermediate,,741.0,,9606.0,RPMI-8226,,F,BAO_0000219,CHEMBL620360,5525
,80433,N,1,,,,17378,,Cytotoxicity of compound against 8226/DOX1V cells,1,Homo sapiens,Intermediate,,741.0,,9606.0,RPMI-8226,,F,BAO_0000219,CHEMBL620361,5526
,80433,N,1,,,,17378,,Cytotoxicity of compound against 8226/S cells,1,Homo sapiens,Intermediate,,741.0,,9606.0,RPMI-8226,,F,BAO_0000219,CHEMBL620362,5527
,80433,N,1,,,,17079,,Inhibitory concentration against 8226 myeloma cancer cell line,1,Homo sapiens,Intermediate,,741.0,,9606.0,RPMI-8226,,F,BAO_0000219,CHEMBL620363,5528
,80433,N,1,,,,17079,,Inhibitory concentration against 8226/Dox40 (Dox-Re) cancer cell line,1,Homo sapiens,Intermediate,,741.0,,9606.0,RPMI-8226,,F,BAO_0000219,CHEMBL620364,5529
,80647,N,1,,,,13466,,Inhibition of cell growth was studied in human teratocarcinoma (833K).,1,Homo sapiens,Intermediate,,854.0,,9606.0,833K,,F,BAO_0000219,CHEMBL620365,5530
,80647,N,1,,,,13466,,Inhibition of cell growth was studied in human teratocarcinoma (833K); ND ='not determined',1,Homo sapiens,Intermediate,,854.0,,9606.0,833K,,F,BAO_0000219,CHEMBL620366,5531
,80647,N,1,,,,2392,,Tested in vitro for growth inhibitory activity against 833K (human teratorcarcinoma) cells,1,Homo sapiens,Expert,,854.0,,9606.0,833K,,F,BAO_0000219,CHEMBL620367,5532
,80647,N,1,,,,2392,,The compound was tested in vitro for growth inhibitory activity against 833K (human teratorcarcinoma) cells; No data,1,Homo sapiens,Intermediate,,854.0,,9606.0,833K,,F,BAO_0000219,CHEMBL620368,5533
,22226,U,0,,,,6608,,Inhibitory activity against caspase-1,1,,Autocuration,,,,,,,B,BAO_0000019,CHEMBL620369,5534
,45,H,8,,,,10199,,Percent inhibition of DAla-DAla Ligase at 10e -3 M of the compound,1,Enterococcus faecalis,Autocuration,,,,1351.0,,,B,BAO_0000357,CHEMBL620370,5535
,80648,N,1,,,,17749,,In vitro antiproliferative activity against 8701-BC human breast cancer cells at a concentration of (0-100 uM) for 72 hr using MTT assay,1,Homo sapiens,Intermediate,,705.0,,9606.0,8701-BC,,F,BAO_0000219,CHEMBL620371,5536
,80648,N,1,,,,17749,,In vitro antiproliferative activity against 8701-BC human breast cancer cells at a concentration of (0-100 uM,1,Homo sapiens,Intermediate,,705.0,,9606.0,8701-BC,,F,BAO_0000219,CHEMBL620372,5537
,22226,U,0,,,,1229,,In vitro anticancer activity against 9 NCI colon cancer cell lines; inactive,1,,Intermediate,,,,,,,F,BAO_0000019,CHEMBL876492,5538
,22226,U,0,,,,1229,,In vitro anticancer activity against 9 NCI melanoma cell lines; inactive,1,,Intermediate,,,,,,,F,BAO_0000019,CHEMBL620373,5539
,22226,U,0,,,,1229,,In vitro anticancer activity against 9 NCI renal cancer cell lines; inactive,1,,Intermediate,,,,,,,F,BAO_0000019,CHEMBL620374,5540
,22226,U,0,,,,6390,,Inhibitory activity was determined against 9-cis-epoxycarotenoid dioxygenase (NCED) expressed in Escherichia coli in presence of 9''-cis-neo-xanthin,1,,Autocuration,,,,,,,B,BAO_0000019,CHEMBL620375,5541
,22226,U,0,,,,16219,,Minimum inhibitory concentration against Streptococcus pyogenes 930MLSB,1,Streptococcus pyogenes,Autocuration,,,,1314.0,,,F,BAO_0000019,CHEMBL857902,5542
,22226,U,0,,,,16219,,Minimum inhibitory concentration against Streptococcus pyogenes 930MLSB,1,Streptococcus pyogenes,Autocuration,,,,1314.0,,,F,BAO_0000019,CHEMBL620376,5543
,11922,H,8,,,,17043,,Percent inhibition against Cdc25C phosphatase at 50 uM of compound,1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL620377,5544
,81115,N,1,,,,6929,,Tested for in vitro cytotoxic potency of compound in 9KB assay,1,Homo sapiens,Intermediate,,324.0,,9606.0,KB ,,F,BAO_0000219,CHEMBL620378,5545
,81115,N,1,,,,6929,,Tested for in vitro cytotoxic potency of compound in 9KB assay,1,Homo sapiens,Intermediate,,324.0,,9606.0,KB ,,A,BAO_0000219,CHEMBL620379,5546
,22226,U,0,,,,7083,,In vitro cytotoxicity of compound was tested against 9KB cells.,1,Homo sapiens,Autocuration,,,,9606.0,,,F,BAO_0000219,CHEMBL620380,5547
,80653,N,1,,,,12446,,Cytotoxic concentration against 9L cells was determined on day 3,1,Rattus norvegicus,Intermediate,,392.0,,10116.0,9L,,F,BAO_0000219,CHEMBL884006,5548
,80653,N,1,,,,15345,,Tested in vitro for anticancer activity against 9L cells,1,Rattus norvegicus,Expert,,392.0,,10116.0,9L,,F,BAO_0000219,CHEMBL620381,5549
,80653,N,1,,,,15345,,Tested in vitro for anticancer activity against 9L cells; Not determined,1,Rattus norvegicus,Expert,,392.0,,10116.0,9L,,F,BAO_0000219,CHEMBL620382,5550
,80682,N,1,,,,6301,,In vitro inhibitory activity against human A549 non-small cell lung tumor; Active,1,Homo sapiens,Intermediate,,646.0,,9606.0,A549,,F,BAO_0000219,CHEMBL620383,5551
,80682,N,1,,,,4833,,The compound was tested in vitro for its cytotoxicity against human A-549 cancer cell line by MTT method at 1 uM concentration; No inhibition,1,Homo sapiens,Intermediate,,646.0,,9606.0,A549,,F,BAO_0000219,CHEMBL876493,5552
,80682,N,1,,,,4833,,The compound was tested in vitro for its cytotoxicity against human A-549 cancer cell line by MTT method at 1 uM concentration; Significant inhibition,1,Homo sapiens,Intermediate,,646.0,,9606.0,A549,,F,BAO_0000219,CHEMBL620384,5553
,80682,N,1,,,,4833,,The compound was tested in vitro for its cytotoxicity against human A-549 cancer cell line by MTT method at 1 uM concentration; Slight inhibition,1,Homo sapiens,Intermediate,,646.0,,9606.0,A549,,F,BAO_0000219,CHEMBL620385,5554
,80682,N,1,,,,13330,,Cytotoxicity against human lung carcinoma A549 cell line,1,Homo sapiens,Expert,,646.0,,9606.0,A549,,F,BAO_0000219,CHEMBL620386,5555
,25,D,9,,,,17517,,Ability to induce human IL-6 assay in A549 lung carcinoma cell line.,1,Homo sapiens,Expert,,646.0,,9606.0,A549,,F,BAO_0000219,CHEMBL620387,5556
,25,D,9,,,,17517,,"Ability to induce human IL-6 assay in A549 lung carcinoma cell line; n.r.: not reported, EC50 values not reported in cases were %dex e 35%.",1,Homo sapiens,Expert,,646.0,,9606.0,A549,,F,BAO_0000219,CHEMBL621404,5557
,80682,N,1,,,,14425,,"In vitro growth inhibition of A549, lung carcinoma",1,Homo sapiens,Intermediate,,646.0,,9606.0,A549,,F,BAO_0000219,CHEMBL621405,5558
,80682,N,1,,,,14425,,"In vitro growth inhibition of A549, lung carcinoma.",1,Homo sapiens,Intermediate,,646.0,,9606.0,A549,,F,BAO_0000219,CHEMBL621406,5559
,80682,N,1,,,,5228,,In vitro cytotoxicity against A549 (human lung carcinoma) cell line.,1,Homo sapiens,Expert,,646.0,,9606.0,A549,,F,BAO_0000219,CHEMBL621407,5560
,80682,N,1,,,,5351,,Cytotoxic activity against human lung cancer A549 cell line was determined,1,Homo sapiens,Intermediate,,646.0,,9606.0,A549,,F,BAO_0000219,CHEMBL621408,5561
,80682,N,1,,,,12198,,Cytotoxicity against human solid tumor lung carcinoma A549 cell line,1,Homo sapiens,Expert,,646.0,,9606.0,A549,,F,BAO_0000219,CHEMBL885345,5562
,80682,N,1,,,,13891,,Cytotoxicity concentration against human lung carcinoma A-549 cell line,1,Homo sapiens,Intermediate,,646.0,,9606.0,A549,,F,BAO_0000219,CHEMBL621409,5563
,80682,N,1,,,,5677,,Cytotoxicity in A549 (human carcinoma) cell line.,1,Homo sapiens,Expert,,646.0,,9606.0,A549,,F,BAO_0000219,CHEMBL876034,5564
,80682,N,1,,,,13788,,Cytotoxicity on lung carcinoma (A-549) cell line,1,Homo sapiens,Intermediate,,646.0,,9606.0,A549,,F,BAO_0000219,CHEMBL621410,5565
,80682,N,1,,,,13384,,Effective dose against 50% reduction in Human lung carcinoma (A-549) cell number after 3-day incubation.,1,Homo sapiens,Expert,,646.0,,9606.0,A549,,F,BAO_0000219,CHEMBL621411,5566
,80682,N,1,,,,6726,,Effective dose of compound against replication of A549 cell line was evaluated,1,Homo sapiens,Intermediate,,646.0,,9606.0,A549,,F,BAO_0000219,CHEMBL621412,5567
,80682,N,1,,,,3455,,In vitro cytotoxic activity was determined against lung carcinoma (A549) cell line,1,Homo sapiens,Expert,,646.0,,9606.0,A549,,F,BAO_0000219,CHEMBL621413,5568
,80682,N,1,,,,5726,,In vitro cytotoxicity evaluated against human lung cancer (A549 cell line),1,Homo sapiens,Intermediate,,646.0,,9606.0,A549,,F,BAO_0000219,CHEMBL621414,5569
,80682,N,1,,,,5726,,In vitro cytotoxicity evaluated against human lung cancer (A549 cell line); NA is not active,1,Homo sapiens,Intermediate,,646.0,,9606.0,A549,,F,BAO_0000219,CHEMBL621415,5570
,80682,N,1,,,,3936,,The compound was evaluated for antiproliferative activity against A549 cell line,1,Homo sapiens,Intermediate,,646.0,,9606.0,A549,,F,BAO_0000219,CHEMBL621416,5571
,80682,N,1,,,,14991,,The compound was tested for tumor cell growth inhibitory activity against human lung carcinoma (A549) cell line.,1,Homo sapiens,Intermediate,,646.0,,9606.0,A549,,F,BAO_0000219,CHEMBL621417,5572
,80682,N,1,,,,5243,,Concentration required for growth inhibition of human lung carcinoma cell line A549,1,Homo sapiens,Intermediate,,646.0,,9606.0,A549,,F,BAO_0000219,CHEMBL621418,5573
,80682,N,1,,,,12858,,Cytotoxic activity against A549/ATCC non-small cell-lung cancer cell line,1,Homo sapiens,Intermediate,,646.0,,9606.0,A549,,F,BAO_0000219,CHEMBL621419,5574
,80682,N,1,,,,6776,,Growth inhibition against A549 cell line was evaluated,1,Homo sapiens,Intermediate,,646.0,,9606.0,A549,,F,BAO_0000219,CHEMBL621420,5575
,80682,N,1,,,,16558,,Growth inhibitory activity against A549 human solid tumor cell line using MTT assay,1,Homo sapiens,Intermediate,,646.0,,9606.0,A549,,F,BAO_0000219,CHEMBL875823,5576
,80682,N,1,,,,4583,,Inhibition of anchorage independent growth of human tumor cell line A549 K-ras-transformed in soft agar,1,Homo sapiens,Expert,,646.0,,9606.0,A549,,F,BAO_0000219,CHEMBL621421,5577
,80682,N,1,,,,13514,,Inhibitor activity against A549 (Human lung carcinoma)cell line with varying concentration of the drug for 72 hrs,1,Homo sapiens,Intermediate,,646.0,,9606.0,A549,,F,BAO_0000219,CHEMBL621422,5578
,80682,N,1,,,,15166,,Chemosensitivity against DT-diaphorase rich A549 cell lines,1,Homo sapiens,Expert,,646.0,,9606.0,A549,,F,BAO_0000219,CHEMBL884014,5579
,80682,N,1,,,,13873,,Compound tested against A549 lung carcinoma in the sulforhodamine B assay.,1,Homo sapiens,Intermediate,,646.0,,9606.0,A549,,F,BAO_0000219,CHEMBL621423,5580
,80682,N,1,,,,6447,,In vitro cytotoxicity against human A549 (lung cancer) cell line.,1,Homo sapiens,Expert,,646.0,,9606.0,A549,,F,BAO_0000219,CHEMBL621424,5581
,80682,N,1,,,,2068,,In vitro antitumor activity against A549 (lung) human tumor cell lines.,1,Homo sapiens,Intermediate,,646.0,,9606.0,A549,,F,BAO_0000219,CHEMBL621425,5582
,80682,N,1,,,,1863,,In vitro cytotoxic activity against human lung carcinoma A549 cell line,1,Homo sapiens,Expert,,646.0,,9606.0,A549,,F,BAO_0000219,CHEMBL621426,5583
,80682,N,1,,,,13873,,Compound was tested against A549 lung cancer cell line in the sulforhodamine B assay.,1,Homo sapiens,Intermediate,,646.0,,9606.0,A549,,F,BAO_0000219,CHEMBL621427,5584
,80682,N,1,,,,13873,,Compound was tested against A549 lung carcinoma cell line in the sulforhodamine B assay.,1,Homo sapiens,Intermediate,,646.0,,9606.0,A549,,F,BAO_0000219,CHEMBL621428,5585
,80682,N,1,,,,13873,,Tested against A549 lung carcinoma in the sulforhodamine B assay.,1,Homo sapiens,Expert,,646.0,,9606.0,A549,,F,BAO_0000219,CHEMBL621429,5586
,80682,N,1,,,,579,,Compound was tested for cytotoxicity on A549 lung adenocarcinoma cell line using a proliferation assay (MTT reduction),1,Homo sapiens,Intermediate,,646.0,,9606.0,A549,,F,BAO_0000219,CHEMBL621430,5587
,80682,N,1,,,,579,,Compound was tested for cytotoxicity on A549 lung adenocarcinoma cell line using a proliferation assay (MTT reduction).,1,Homo sapiens,Intermediate,,646.0,,9606.0,A549,,F,BAO_0000219,CHEMBL621431,5588
,80682,N,1,,,,4584,,Compound was tested for inhibition of growth of human lung carcinoma cell line A549 up to a conc of 10 uM; NI means no inhibition,1,Homo sapiens,Intermediate,,646.0,,9606.0,A549,,F,BAO_0000219,CHEMBL621432,5589
,80682,N,1,,,,5421,,Inhibition of NFkB (transcription factor) activation in A549 human lung carcinoma cell line,1,Homo sapiens,Expert,,646.0,,9606.0,A549,,F,BAO_0000219,CHEMBL621433,5590
,80682,N,1,,,,5421,,Compound was tested for its ability to inhibit tumor necrosis factor alpha (TNF alpha) induced apoptosis in A549 human lung carcinoma cell line,1,Homo sapiens,Intermediate,,646.0,,9606.0,A549,,F,BAO_0000219,CHEMBL875824,5591
,80682,N,1,,,,5421,,Compound was tested for its ability to inhibit tumor necrosis factor alpha (TNF alpha) induced apoptosis in A549 human lung carcinoma cell line at 20 uM concentration,1,Homo sapiens,Intermediate,,646.0,,9606.0,A549,,F,BAO_0000219,CHEMBL621434,5592
,80682,N,1,,,,5421,,Compound was tested for its ability to inhibit tumor necrosis factor alpha (TNF alpha) induced apoptosis in A549 human lung carcinoma cell line; NA=Not assayed,1,Homo sapiens,Intermediate,,646.0,,9606.0,A549,,F,BAO_0000219,CHEMBL621435,5593
,80682,N,1,,,,14188,,Compound was tested for potency against human lung A549 cells using sulforhodamine B assay.,1,Homo sapiens,Intermediate,,646.0,,9606.0,A549,,F,BAO_0000219,CHEMBL621436,5594
,80682,N,1,,,,14188,,Compound was tested for potency against human lung A549 cells using sulforhodamine B assay; UA=Potency was so low that the IC50 was unachievable.,1,Homo sapiens,Intermediate,,646.0,,9606.0,A549,,F,BAO_0000219,CHEMBL621437,5595
,80682,N,1,,,,15354,,Compound was tested for the growth inhibition of A549 lung tumor cell line,1,Homo sapiens,Intermediate,,646.0,,9606.0,A549,,F,BAO_0000219,CHEMBL621438,5596
,80682,N,1,,,,14253,,Growth inhibition of human non-small-lung carcinoma (A549) cell line,1,Homo sapiens,Expert,,646.0,,9606.0,A549,,F,BAO_0000219,CHEMBL621439,5597
,80682,N,1,,,,13873,,Compound was tested against A549 lung carcinoma cell line in the sulforhodamine B assay.,1,Homo sapiens,Intermediate,,646.0,,9606.0,A549,,F,BAO_0000219,CHEMBL621440,5598
,50588,N,1,In vivo,,,3043,,Oral bioavailability in dog (conscious),1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL621441,5599
,50588,N,1,In vivo,,,3045,,Compound was evaluated for the oral bioavailability after oral administration in dog.,1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL621442,5600
,50588,N,1,In vivo,,,3022,,Compound was tested for percent of oral bioavailability at 10 mg/ml dose in dogs,1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL621443,5601
,50588,N,1,In vivo,,,4453,,Oral bioavailability in dog,1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL621444,5602
,50588,N,1,In vivo,,,1696,,Oral bioavailability in dog,1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL625133,5603
,50588,N,1,In vivo,,,5045,,Oral bioavailability in dog,1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL625134,5604
,50588,N,1,In vivo,,,5356,,Oral bioavailability in dog (fasted),1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL625135,5605
,50588,N,1,In vivo,,,17764,,Oral bioavailability after intravenous administration in dogs at 1.2 uM/kg,1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL625136,5606
,50588,N,1,In vivo,,,6448,,Oral bioavailability in dog,1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL625137,5607
,50588,N,1,In vivo,,,1475,,Oral bioavailability in dog,1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL625138,5608
,50588,N,1,In vivo,,,3788,,Percent bioavailability in dog,1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL625139,5609
,50588,N,1,In vivo,,,3639,,Percent oral bioavailability of intravenously administered compound (6 mg/kg) was tested in dog,1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL872264,5610
,50588,N,1,In vivo,,,13397,,Oral bioavailability in dog,1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL625140,5611
,50588,N,1,In vivo,,,2137,,The compound was evaluated for bioavailability in dogs; 34-44,1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL624436,5612
,50588,N,1,In vivo,,,2959,,Bioavailability in dog (dose 4 mg/kg p.o.),1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL624437,5613
,50588,N,1,In vivo,,,6448,,Oral bioavailability in dog,1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL872261,5614
,50588,N,1,,,,6084,,8 hour trough Blood level in dog was measured after administration of compound,1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL624438,5615
Plasma,50588,N,1,In vivo,,,3639,,The compound was tested for maximum concentration ( Cmax ) in dog plasma.,1,Canis lupus familiaris,Intermediate,,,,9615.0,,1969.0,A,BAO_0000218,CHEMBL624439,5616
,50588,N,1,,,,6316,,C24 after oral administration at 5 mg/kg,1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL624440,5617
,50588,N,1,,,,5238,,Clearance after oral and iv dosing in dogs,1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL624441,5618
Plasma,50588,N,1,,,,17796,,Clearance of the drug was measured in the plasma of dog,1,Canis lupus familiaris,Intermediate,,,,9615.0,,1969.0,A,BAO_0000218,CHEMBL624442,5619
,50588,N,1,,,,2652,,Compound was evaluated for Clearance in dogs at a dose of 1 mpk intravenously,1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL624443,5620
,50588,N,1,In vivo,,,5654,,CL (clearance) of compound was determined after intravenous administration in average of two dogs at a dose of 1 mg/kg,1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL624444,5621
,50588,N,1,In vivo,,,6621,,Clearance of compound was determined in dogs,1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL624445,5622
,50588,N,1,In vivo,,,6505,,Clearance on i.v. administration of 2 mg/kg was measured in dog,1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL624446,5623
,50588,N,1,In vivo,,,5802,,Clearance of compound after both po and iv administration at a dose of 5 mg/kg and 2 mg/kg resp in dog,1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL624447,5624
,50588,N,1,In vivo,,,17267,,Plasma clearance in dog was determined,1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL624448,5625
,50588,N,1,In vivo,,,4521,,Plasma clearance in dog after 2 mg/kg by oral and 0.5 mg/kg by intravenous administration; ND is not determined,1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL624449,5626
,50588,N,1,In vivo,,,6535,,Plasma clearance in dog after administration of 0.25 mg/kg iv,1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL624450,5627
,50588,N,1,In vivo,,,6535,,Plasma clearance in dog after administration of 1 mg/kg iv,1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL875942,5628
,50588,N,1,In vivo,,,6535,,Plasma clearance in dogs,1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL624451,5629
,50588,N,1,In vivo,,,5542,,Plasma clearance by iv administration in dog at a dose of 0.3 mg/kg,1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL624452,5630
,50588,N,1,In vivo,,,5199,,Plasma clearance was determined in canine following intravenous (iv) administration of drug (1 mg/kg).,1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL624453,5631
,50588,N,1,In vivo,,,16907,,Plasma clearance after 15 mg/kg iv dose in Dogs,1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL624454,5632
,50588,N,1,In vivo,,,16907,,Plasma clearance after 30 mg/kg po dose in Dogs,1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL624455,5633
,50588,N,1,In vivo,,,16367,,Plasma administration to dogs,1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL624456,5634
,50588,N,1,In vivo,,,5505,,Plasma clearance was determined,1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL624457,5635
,50588,N,1,In vivo,,,6215,,Systemic clearance after intravenous administration (0.5 mg/kg) was determined in dog,1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL624458,5636
,50588,N,1,In vivo,,,1466,,Tested for systemic clearance upon intravenous administration of 5.0 mg/Kg dose in dog,1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL624459,5637
Liver,102164,S,2,In vitro,,Microsomes,5007,,Intrinsic clearance in human liver microsomes,1,Homo sapiens,Intermediate,,,,9606.0,,2107.0,A,BAO_0000251,CHEMBL624460,5638
Liver,102164,S,2,In vitro,,Microsomes,5007,,Intrinsic clearance in human liver microsomes,1,Homo sapiens,Intermediate,,,,9606.0,,2107.0,A,BAO_0000251,CHEMBL624461,5639
,50588,N,1,In vivo,,,16452,,Pharmacokinetic data at 0.5 mg/kg dose given to dogs intravenously.,1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL875943,5640
,50588,N,1,In vivo,,,16452,,Pharmacokinetic data at 1 mg/kg dose given to dogs intravenously,1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL624462,5641
,50588,N,1,In vivo,,,16452,,Clearance in dog (dose 1 mg/kg i.v.),1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL624463,5642
,50588,N,1,In vivo,,,6221,,Plasma clearance after oral administration (2.5 mg/kg) in dog was determined,1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL624464,5643
,50588,N,1,In vivo,,,5007,,Plasma clearance in dogs administered perorally (5 mg/kg) and intravenously (2 mg/kg),1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL624465,5644
,50588,N,1,In vivo,,,5668,,Plasma clearance after peroral administration at 10 mpk in dog,1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL624466,5645
,50588,N,1,In vivo,,,5668,,Plasma clearance after peroral administration at 5 mpk in dog,1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL624467,5646
,50588,N,1,In vivo,,,5668,,Plasma clearance after peroral administration at 5 mg/kg in dog,1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL624468,5647
,50588,N,1,In vivo,,,15660,,Plasma clearance was measured in dog,1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL624469,5648
,50588,N,1,In vivo,,,15660,,Plasma clearance was measured in dog,1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL624470,5649
,50588,N,1,In vivo,,,5983,,Pharmacokinetic property (CLtot) was measured in dog at the dose of 0.032 mg/kg i.v.,1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL624471,5650
,50588,N,1,In vivo,,,5600,,Total clearance was determined after 0.1 mg/kg iv administration in dog,1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL624472,5651
,50588,N,1,In vivo,,,17764,,Clearance of compound after intravenous administration in dogs at 1.2 uM/kg,1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL622775,5652
,50588,N,1,In vivo,,,6039,,Clearance after intravenous administration of 0.5 mg/kg in dog was determined,1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL622776,5653
,50588,N,1,In vivo,,,6039,,Clearance after intravenous administration of 1.0 mg/kg in dog was determined,1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL622777,5654
,50588,N,1,In vivo,,,6039,,Clearance after peroral administration of 0.2 mg/kg in dog was determined,1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL622778,5655
,50588,N,1,In vivo,,,4368,,Clearance by intravenous administration of 1.2 mg/kg in dog,1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL622779,5656
,50588,N,1,In vivo,,,4305,,Clearance by iv administration in dogs at a dose of 1 mg/kg,1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL622780,5657
Plasma,50588,N,1,In vivo,,,1918,,Clearance value was evaluated in dog plasma,1,Canis lupus familiaris,Intermediate,,,,9615.0,,1969.0,A,BAO_0000218,CHEMBL622781,5658
,50588,N,1,In vivo,,,6005,,Clearance was evaluated after i.v. administration in dog at a dose of 1 mg/kg,1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL622782,5659
Plasma,50588,N,1,In vivo,,,4839,,Compound was tested for plasma clearance in dog,1,Canis lupus familiaris,Intermediate,,,,9615.0,,1969.0,A,BAO_0000218,CHEMBL622783,5660
,50588,N,1,In vivo,,,4239,,Pharmacokinetic property (Plasma clearance) was measured in dog,1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL622784,5661
,50594,N,1,,,,17729,,Area under curve when injected perorally in mice at a dose of 50 mg/kg,1,Mus musculus,Intermediate,,,,10090.0,,,A,BAO_0000218,CHEMBL622785,5662
,50594,N,1,,,,17728,,Area under curve when injected perorally in BALB/C mice at a dose of 50 mg/kg,1,Mus musculus,Intermediate,,,,10090.0,,,A,BAO_0000218,CHEMBL622786,5663
,50594,N,1,,,,5302,,Area under curve value in mouse at a dose of 10 mg/kg,1,Mus musculus,Intermediate,,,,10090.0,,,A,BAO_0000218,CHEMBL622787,5664
,50594,N,1,,,,5506,,Area under curve was determined at a dose of 100 mg/kg (i.p.) in Mice,1,Mus musculus,Intermediate,,,,10090.0,,,A,BAO_0000218,CHEMBL875949,5665
,50594,N,1,,,,5506,,Area under curve was determined at a dose of 200 mg/kg (i.p.) in Mice,1,Mus musculus,Intermediate,,,,10090.0,,,A,BAO_0000218,CHEMBL622788,5666
,50594,N,1,,,,17764,,Area under curve was determined for compound after intraperitoneal administration in mice at 18 uM/kg,1,Mus musculus,Intermediate,,,,10090.0,,,F,BAO_0000218,CHEMBL622789,5667
,50594,N,1,,,,17764,,Area under curve was determined for compound after intraperitoneal administration in mice at 23 uM/kg,1,Mus musculus,Intermediate,,,,10090.0,,,F,BAO_0000218,CHEMBL622790,5668
,50594,N,1,,,,17764,,Area under curve was determined for compound after intraperitoneal administration in mice at 25 uM/kg,1,Mus musculus,Intermediate,,,,10090.0,,,F,BAO_0000218,CHEMBL622791,5669
,50594,N,1,,,,17764,,Area under curve was determined for compound after intraperitoneal administration in mice at 26 uM/kg,1,Mus musculus,Intermediate,,,,10090.0,,,F,BAO_0000218,CHEMBL622792,5670
,50594,N,1,,,,17764,,Area under curve was determined for compound after intravenous administration in mice at 24 uM/kg,1,Mus musculus,Intermediate,,,,10090.0,,,A,BAO_0000218,CHEMBL622793,5671
,50594,N,1,,,,17753,,Area under curve was determined for the compound at 24 mg/Kg,1,Mus musculus,Intermediate,,,,10090.0,,,A,BAO_0000218,CHEMBL622794,5672
,50594,N,1,,,,17753,,Area under curve was determined for the compound at 40 mg/Kg,1,Mus musculus,Intermediate,,,,10090.0,,,A,BAO_0000218,CHEMBL622795,5673
,50594,N,1,,,,17753,,Area under curve was determined for the compound at 5 mg/Kg,1,Mus musculus,Intermediate,,,,10090.0,,,A,BAO_0000218,CHEMBL621803,5674
,50594,N,1,,,,3132,,Area under the curve for the compound is obtained at dose 25 mg/kg,1,Mus musculus,Intermediate,,,,10090.0,,,A,BAO_0000218,CHEMBL621804,5675
,50594,N,1,,,,3132,,Area under the curve for the compound was obtained when tested in mouse,1,Mus musculus,Intermediate,,,,10090.0,,,A,BAO_0000218,CHEMBL621805,5676
,50594,N,1,,,,17837,,Area under the curve of compound in mouse blood following i.v. administration of 10 mg/kg,1,Mus musculus,Intermediate,,,,10090.0,,,A,BAO_0000218,CHEMBL621806,5677
,50594,N,1,,,,17837,,Area under the curve of compound in mouse blood following p.o. administration of 30 mg/kg,1,Mus musculus,Intermediate,,,,10090.0,,,A,BAO_0000218,CHEMBL621807,5678
,50594,N,1,,,,6062,,Area under the curve was measured in mouse after an iv dose of 1 mg/kg,1,Mus musculus,Intermediate,,,,10090.0,,,A,BAO_0000218,CHEMBL621808,5679
,50594,N,1,,,,4066,,Area under the curve was determined for the compound at a single subcutaneous administration of 40 mg/kg in mice,1,Mus musculus,Intermediate,,,,10090.0,,,A,BAO_0000218,CHEMBL621809,5680
,50594,N,1,,,,16597,,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for area under curve (AUCtot),1,Mus musculus,Intermediate,,,,10090.0,,,A,BAO_0000218,CHEMBL621810,5681
,50594,N,1,,,,14239,,Compound was evaluated for the area under the concentration - time curve by administering intravenously at 25 mg/kg in mice,1,Mus musculus,Intermediate,,,,10090.0,,,A,BAO_0000218,CHEMBL875164,5682
,50594,N,1,,,,14239,,Compound was evaluated for the area under the concentration - time curve by administering orally at 25 mg/kg in mice,1,Mus musculus,Intermediate,,,,10090.0,,,A,BAO_0000218,CHEMBL621811,5683
,50594,N,1,,,,4890,,"Compound was evaluated for the pharmacokinetic parameter, area under curve",1,Mus musculus,Intermediate,,,,10090.0,,,A,BAO_0000218,CHEMBL621812,5684
,50594,N,1,,,,429,,Evaluated for pharmacokinetic parameter area under curve in mouse at the dose 20 mg/kg (0-4 hr ),1,Mus musculus,Intermediate,,,,10090.0,,,A,BAO_0000218,CHEMBL621813,5685
,50594,N,1,,,,429,,Evaluated for pharmacokinetic parameter area under curve in mouse at the dose 20 mg/kg (0-4 hr),1,Mus musculus,Intermediate,,,,10090.0,,,A,BAO_0000218,CHEMBL621814,5686
,50594,N,1,,,,5969,,In vivo area under curve (AUC) was determined in murine septicemia at dose of 100 mg/kg,1,Mus musculus,Intermediate,,,,10090.0,,,A,BAO_0000218,CHEMBL621815,5687
,50594,N,1,,,,5969,,In vivo area under curve (AUC) was determined in murine septicemia at dose of 50 mg/kg,1,Mus musculus,Intermediate,,,,10090.0,,,A,BAO_0000218,CHEMBL621816,5688
,50594,N,1,,,,5969,,In vivo area under curve (AUC) was determined in murine septicemia at dose of 50 mg/kg;ND=not determined,1,Mus musculus,Intermediate,,,,10090.0,,,A,BAO_0000218,CHEMBL621817,5689
,50594,N,1,,,,6091,,Pharmacokinetic activity (AUC) in vivo after intravenous administration of 10 mg/kg in mouse,1,Mus musculus,Intermediate,,,,10090.0,,,A,BAO_0000218,CHEMBL621818,5690
,50594,N,1,,,,6091,,Pharmacokinetic activity (AUC) in vivo after intravenous administration of 10 mg/kg in mouse;ND=Not determined,1,Mus musculus,Intermediate,,,,10090.0,,,A,BAO_0000218,CHEMBL621819,5691
,50594,N,1,,,,6091,,Pharmacokinetic activity (AUC) in vivo after peroral administration of 10 mg/kg in mice,1,Mus musculus,Intermediate,,,,10090.0,,,A,BAO_0000218,CHEMBL621820,5692
,50594,N,1,,,,6091,,Pharmacokinetic activity (AUC) in vivo after peroral administration of 10 mg/kg in mice;ND=Not determined,1,Mus musculus,Intermediate,,,,10090.0,,,A,BAO_0000218,CHEMBL621821,5693
,50594,N,1,,,,6178,,Pharmacokinetic property (AUC) was determined after ip administration of 32 mg/kg in mice,1,Mus musculus,Intermediate,,,,10090.0,,,A,BAO_0000218,CHEMBL621822,5694
,50594,N,1,,,,6178,,Pharmacokinetic property (AUC) was determined after po administration of 32 mg/kg in mice,1,Mus musculus,Intermediate,,,,10090.0,,,A,BAO_0000218,CHEMBL619474,5695
,50594,N,1,,,,6619,,"Reduction in area under curve was determined in DIO mice by oral glucose tolerance test following a single i.p. dose (10 mg/kg, 30 min pre-treatment)",1,Mus musculus,Intermediate,,,,10090.0,,,A,BAO_0000218,CHEMBL619475,5696
,50594,N,1,,,,6619,,"Reduction in area under curve was determined in ob/ob mice by oral glucose tolerance test following a single i.p. dose (10 mg/kg, 30 min pre-treatment)",1,Mus musculus,Intermediate,,,,10090.0,,,A,BAO_0000218,CHEMBL619476,5697
,50594,N,1,,,,3760,,"The area under concentration-time curve(AUC) was determined at 5 mg/kg of compound dose, administered intravenously in mice",1,Mus musculus,Intermediate,,,,10090.0,,,A,BAO_0000218,CHEMBL619477,5698
,50594,N,1,,,,3760,,"The area under concentration-time curve(AUC) was determined at 5 mg/kg of compound dose, administered perorally in mice",1,Mus musculus,Intermediate,,,,10090.0,,,A,BAO_0000218,CHEMBL619478,5699
,50594,N,1,,,,3760,,"The area under concentration-time curve(AUC) was determined at 50 mg/kg of compound dose, administered intravenously in mice",1,Mus musculus,Intermediate,,,,10090.0,,,A,BAO_0000218,CHEMBL619479,5700
,50594,N,1,,,,3760,,"The area under concentration-time curve(AUC) was determined at 50 mg/kg of compound dose, administered perorally in mice",1,Mus musculus,Intermediate,,,,10090.0,,,A,BAO_0000218,CHEMBL619480,5701
,50594,N,1,,,,3192,,The area under curve in vivo in mouse blood level after oral administration at dose 50 mk/kg e-1,1,Mus musculus,Intermediate,,,,10090.0,,,A,BAO_0000218,CHEMBL619481,5702
,50594,N,1,,,,3192,,The area under curve in vivo in mouse blood level after subcutaneous administration at dose 50 mk/kg e-1,1,Mus musculus,Intermediate,,,,10090.0,,,A,BAO_0000218,CHEMBL619482,5703
,50594,N,1,,,,2675,,Area under the curve was evaluated in mice after intravenous administration,1,Mus musculus,Intermediate,,,,10090.0,,,A,BAO_0000218,CHEMBL619483,5704
,50594,N,1,,,,2675,,Area under the curve was evaluated in mice after oral administration,1,Mus musculus,Intermediate,,,,10090.0,,,A,BAO_0000218,CHEMBL619484,5705
Plasma,50594,N,1,,,,16597,,AUC total value at a dose of 10 mg/kg intravenous administration in mice.,1,Mus musculus,Intermediate,,,,10090.0,,1969.0,A,BAO_0000218,CHEMBL619485,5706
Plasma,50594,N,1,,,,16597,,AUC total value at a dose of 10 mg/kg peroral administration in mice.,1,Mus musculus,Intermediate,,,,10090.0,,1969.0,A,BAO_0000218,CHEMBL619486,5707
,50594,N,1,,,,16597,,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for area under curve (AUCtot),1,Mus musculus,Intermediate,,,,10090.0,,,A,BAO_0000218,CHEMBL619487,5708
,50594,N,1,,,,17734,,AUMC after intraperitoneal administration of 100 mg/kg in mice,1,Mus musculus,Intermediate,,,,10090.0,,,A,BAO_0000218,CHEMBL619488,5709
Blood,50594,N,1,In vivo,,,7767,,Biodistribution in blood was determined in mice after iv administration at 15 min Value expressed as percent injected dose per gram,1,Mus musculus,Intermediate,,,,10090.0,,178.0,A,BAO_0000218,CHEMBL620106,5710
,80653,N,1,,,,15345,,The compound was tested in vitro for anticancer activity against 9L cells,1,,Intermediate,,392.0,,,9L,,F,BAO_0000219,CHEMBL620107,5711
,22226,U,0,,,,2181,,Anti proliferation activity determined; Weak effect,1,Rattus norvegicus,Autocuration,,,,10116.0,,,F,BAO_0000019,CHEMBL620283,5712
,22226,U,0,,,,2181,,Inhibition of cell growth by compound at a concentration of 100 uM in 9Ltk+ cells; Completely stopped the process,1,Rattus norvegicus,Autocuration,,,,10116.0,,,F,BAO_0000219,CHEMBL875176,5713
,22226,U,0,,,,2181,,Inhibition of cell growth by compound at a concentration of 10 uM in 9Ltk+ cells,1,Rattus norvegicus,Autocuration,,,,10116.0,,,F,BAO_0000219,CHEMBL620284,5714
,22226,U,0,,,,2181,,Inhibition of cell growth by compound at a concentration of 10 uM in 9Ltk+ cells; Completely stopped the process,1,Rattus norvegicus,Autocuration,,,,10116.0,,,F,BAO_0000219,CHEMBL623515,5715
,22226,U,0,,,,10486,,The cytotoxic activity was in vitro tested by 9PS assay method,1,Mus musculus,Autocuration,,,,10090.0,,,F,BAO_0000019,CHEMBL623516,5716
,22226,U,0,,,,10486,,The cytotoxic activity was in vitro tested by 9PS assay method.,1,Mus musculus,Autocuration,,,,10090.0,,,F,BAO_0000019,CHEMBL623517,5717
,22224,U,0,,,,15508,,Partition coefficient (logD6.5),1,,Autocuration,,,,,,,A,BAO_0000019,CHEMBL857878,5718
,81034,N,1,,,,5242,,Inhibitory concentration in vitro for cytotoxic activity against A 2780 human ovarian carcinoma cells,1,Homo sapiens,Expert,,478.0,,9606.0,A2780,,F,BAO_0000219,CHEMBL623518,5719
,80018,N,1,,,,16167,,Effective concentration against A 375 cell line growth (DFMO concentration is 5.0 mM),1,Homo sapiens,Intermediate,,455.0,,9606.0,A-375,,F,BAO_0000219,CHEMBL624195,5720
,80852,N,1,,,,4782,,Inhibitory concentration required against A 431 human epidermoid carcinoma cell line,1,Homo sapiens,Expert,,500.0,,9606.0,A-431,,F,BAO_0000219,CHEMBL624196,5721
,9,D,9,,,,16093,,Inhibition of EGF-induced Tyrosine phosphorylation in A431 cells expressing EGF-R,1,Homo sapiens,Expert,,500.0,,9606.0,A-431,,F,BAO_0000219,CHEMBL624197,5722
,80021,N,1,,,,2596,,Compound was evaluated for in vitro cytotoxicity against A 498 cancer cell line,1,Homo sapiens,Intermediate,,624.0,,9606.0,A498,,F,BAO_0000219,CHEMBL624198,5723
,80021,N,1,,,,2596,,in vitro cytotoxicity against A 498 cancer cell line,1,Homo sapiens,Intermediate,,624.0,,9606.0,A498,,F,BAO_0000219,CHEMBL621287,5724
,80021,N,1,,,,3239,,In vitro cytotoxic activity against renal (A 498) cancer cell line.,1,Homo sapiens,Intermediate,,624.0,,9606.0,A498,,F,BAO_0000219,CHEMBL621288,5725
,80021,N,1,,,,1847,,Cytotoxic activity against A 498 renal cancer cell lines.,1,Homo sapiens,Intermediate,,624.0,,9606.0,A498,,F,BAO_0000219,CHEMBL876496,5726
,80021,N,1,,,,10553,,In vitro cytotoxicity was determined against A 498 human renal tumor cell line using NCI screen,1,Homo sapiens,Intermediate,,624.0,,9606.0,A498,,F,BAO_0000219,CHEMBL621289,5727
,22226,U,0,,,,16219,,Minimum inhibitory concentration against Staphylococcus aureus A 5177 MLSB-i,1,Staphylococcus aureus,Autocuration,,,,1280.0,,,F,BAO_0000019,CHEMBL621290,5728
,22226,U,0,,,,16219,,Minimum inhibitory concentration against Staphylococcus aureus A 5177 MLSB-i,1,Staphylococcus aureus,Autocuration,,,,1280.0,,,F,BAO_0000019,CHEMBL621291,5729
,22226,U,0,,,,16219,,Minimum inhibitory concentration against Staphylococcus aureus A 5278 MLSB-c,1,Staphylococcus aureus,Autocuration,,,,1280.0,,,F,BAO_0000019,CHEMBL621292,5730
,22226,U,0,,,,16219,,Minimum inhibitory concentration against Staphylococcus aureus A 5278 MLSB-c,1,Staphylococcus aureus,Autocuration,,,,1280.0,,,F,BAO_0000019,CHEMBL621293,5731
,80682,N,1,,,,4782,,Inhibitory concentration required against A 549 lung cancer cell line,1,Homo sapiens,Intermediate,,646.0,,9606.0,A549,,F,BAO_0000219,CHEMBL621294,5732
,80682,N,1,,,,11805,,Growth inhibition of A 549 cell line by MTT reduction for 3 days of incubation time,1,Homo sapiens,Intermediate,,646.0,,9606.0,A549,,F,BAO_0000219,CHEMBL621295,5733
,80682,N,1,,,,11805,,Growth inhibition of A 549 cell line by MTT reduction for 7 days of incubation time,1,Homo sapiens,Intermediate,,646.0,,9606.0,A549,,F,BAO_0000219,CHEMBL884007,5734
,80682,N,1,,,,2007,,In vitro cytotoxicity against lung cancer A 549 cell lines,1,Homo sapiens,Intermediate,,646.0,,9606.0,A549,,F,BAO_0000219,CHEMBL621296,5735
,80682,N,1,,,,4594,,Compound was tested for its cytotoxicity against A 549 cell line,1,Homo sapiens,Intermediate,,646.0,,9606.0,A549,,F,BAO_0000219,CHEMBL621297,5736
,80682,N,1,,,,6018,,"Cytotoxic activity against A 549 human lung tumor cell line, using sulforhodamine B (SRB) assay.",1,Homo sapiens,Expert,,646.0,,9606.0,A549,,F,BAO_0000219,CHEMBL839828,5737
,80682,N,1,,,,6018,,"Cytotoxic activity against A 549 human lung tumor cell line, using sulforhodamine B (SRB) assay.; No data",1,Homo sapiens,Intermediate,,646.0,,9606.0,A549,,F,BAO_0000219,CHEMBL620397,5738
,80682,N,1,,,,3599,,In vitro cytotoxic activity against A 549 (non-small cell lung) using SRB (sulforhodamine B) assay,1,Homo sapiens,Expert,,646.0,,9606.0,A549,,F,BAO_0000219,CHEMBL620398,5739
,80682,N,1,,,,2551,,Tested for in vitro cytotoxicity against A 549 (human lung) tumor cell line using sulforhodamine B (SRB) assay,1,Homo sapiens,Intermediate,,646.0,,9606.0,A549,,F,BAO_0000219,CHEMBL620399,5740
,80682,N,1,,,,16132,,In vitro inhibition of A549 (human lung cancer) cell growth.,1,Homo sapiens,Expert,,646.0,,9606.0,A549,,F,BAO_0000219,CHEMBL620400,5741
,80682,N,1,,,,16132,,Cytotoxic related antitumor activity against human cancer cell lines A 549; No data available,1,Homo sapiens,Intermediate,,646.0,,9606.0,A549,,F,BAO_0000219,CHEMBL620401,5742
,80682,N,1,,,,2551,,Tested for in vitro cytotoxicity against A 549 (human lung) tumor cell line using sulforhodamine B (SRB) assay,1,Homo sapiens,Expert,,646.0,,9606.0,A549,,F,BAO_0000219,CHEMBL620402,5743
,80682,N,1,,,,2551,,Tested for in vitro cytotoxicity against A 549 (human lung) tumor cell line using sulforhodamine B (SRB) assay; not active (> 100 uM),1,Homo sapiens,Expert,,646.0,,9606.0,A549,,F,BAO_0000219,CHEMBL620403,5744
,22226,U,0,,,,11913,,Tested against A II at (100 ng/kg iv) in Dawley rats (n=2). 24 h,1,,Autocuration,,,,,,,F,BAO_0000218,CHEMBL620404,5745
,104694,H,4,In vivo,,,12621,,The duration of action for the % peak inhibition of A II pressor response for dose of 0.1 mg/kg intravenous administration in conscious dogs.,1,,Autocuration,,,,,,,F,BAO_0000218,CHEMBL620405,5746
,104694,H,4,In vivo,,,12621,,The duration of action for the % peak inhibition of A II pressor response for dose of 1.0 mg/kg peroral administration in rhesus monkeys.,1,,Autocuration,,,,,,,F,BAO_0000218,CHEMBL620406,5747
,104694,H,4,In vivo,,,12621,,The duration of action for the % peak inhibition of angiotensin II pressor response for dose of 0.1 mg/kg peroral administration in conscious rats.,1,,Autocuration,,,,,,,F,BAO_0000218,CHEMBL620407,5748
,104694,H,4,In vivo,,,12621,,The compound was evaluated for the % peak inhibition of A II pressor response for dose of 0.3 mg/kg peroral administration in rhesus monkeys.,1,,Autocuration,,,,,,,F,BAO_0000218,CHEMBL620408,5749
,104694,H,4,In vivo,,,12621,,The compound was evaluated for the percentage of inhibition of A II pressor response in rats for peroral administration.,1,,Autocuration,,,,,,,F,BAO_0000218,CHEMBL620409,5750
,80021,N,1,,,,3600,,Inhibition of A-498 human Renal cell proliferation,1,Homo sapiens,Expert,,624.0,,9606.0,A498,,F,BAO_0000219,CHEMBL620410,5751
,22226,U,0,,,,1796,,"Membrane potential change (fluorescence-based in vitro assay using DIBAC4 as indicator) in A-10 smooth muscle cell, to estimate potassium channel opening activity at 0.1 uM",1,Rattus norvegicus,Autocuration,,,,10116.0,,,F,BAO_0000019,CHEMBL620411,5752
,22226,U,0,,,,1796,,"Membrane potential change (fluorescence-based in vitro assay using DIBAC4 as indicator) in A-10 smooth muscle cell, to estimate potassium channel opening activity at 1 uM",1,Rattus norvegicus,Autocuration,,,,10116.0,,,F,BAO_0000019,CHEMBL620412,5753
,22226,U,0,,,,1796,,"Membrane potential change (fluorescence-based in vitro assay using DIBAC4 as indicator) in A-10 smooth muscle cell, to estimate potassium channel opening activity at 10 uM",1,Rattus norvegicus,Autocuration,,,,10116.0,,,F,BAO_0000019,CHEMBL876596,5754
,80012,N,1,,,,16464,,Cytotoxicity against A-172 glioblastomas using MTT colorimetric assay,1,Homo sapiens,Expert,,622.0,,9606.0,A 172,,F,BAO_0000219,CHEMBL620413,5755
,80012,N,1,,,,16464,,Cytotoxicity against A-172 glioblastomas using MTT colorimetric assay; NE is no effect at 1x 10 E-5,1,Homo sapiens,Intermediate,,622.0,,9606.0,A 172,,F,BAO_0000219,CHEMBL620414,5756
,80012,N,1,,,,16464,,Cytotoxicity against A-172 glioblastomas using MTT colorimetric assay; NE is no effect at 1x 10 E-5,1,Homo sapiens,Intermediate,,622.0,,9606.0,A 172,,F,BAO_0000219,CHEMBL620415,5757
,80682,N,1,,,,13617,,Concentration required to inhibit growth of human tumor A549 (NSCL) cell line.,1,Homo sapiens,Expert,,646.0,,9606.0,A549,,F,BAO_0000219,CHEMBL620416,5758
,80682,N,1,,,,4584,,Concentration which produces 50% inhibition of growth of human lung carcinoma cell line A549,1,Homo sapiens,Intermediate,,646.0,,9606.0,A549,,F,BAO_0000219,CHEMBL620417,5759
,80682,N,1,,,,13799,,Cytotoxic activity evaluated against A549 tumor cells,1,Homo sapiens,Expert,,646.0,,9606.0,A549,,F,BAO_0000219,CHEMBL620418,5760
,80682,N,1,,,,16726,,Cytotoxic potentiation of Topotecan (TP) by the compound in human lung carcinoma A549 cell line,1,Homo sapiens,Intermediate,,646.0,,9606.0,A549,,F,BAO_0000219,CHEMBL620419,5761
,80682,N,1,,,,16109,,Cytotoxicity against A549 cells when the drug is exposed for a time of 1 hr,1,Homo sapiens,Intermediate,,646.0,,9606.0,A549,,F,BAO_0000219,CHEMBL620420,5762
,80682,N,1,,,,16109,,Cytotoxicity against A549 cells when the drug is exposed for a time of 96 hrs,1,Homo sapiens,Intermediate,,646.0,,9606.0,A549,,F,BAO_0000219,CHEMBL620421,5763
,80682,N,1,,,,15474,,Cytotoxicity against A549 tumor cell line determined by WST-1 assay,1,Homo sapiens,Intermediate,,646.0,,9606.0,A549,,F,BAO_0000219,CHEMBL620422,5764
,80682,N,1,,,,6851,,Cytotoxicity of compound against A549 cell line,1,Homo sapiens,Intermediate,,646.0,,9606.0,A549,,F,BAO_0000219,CHEMBL620423,5765
,80682,N,1,,,,17534,,Cytotoxicity against human lung cell carcinoma A549 cell line,1,Homo sapiens,Expert,,646.0,,9606.0,A549,,F,BAO_0000219,CHEMBL620424,5766
,80682,N,1,,,,2621,,Cytotoxicity against human lung carcinoma A549 cell line using MTT assay,1,Homo sapiens,Intermediate,,646.0,,9606.0,A549,,F,BAO_0000219,CHEMBL620425,5767
,80682,N,1,,,,830,,Cytotoxicity was evaluated in vitro against A549 (non-small cell lung carcinoma) human tumor cell lines,1,Homo sapiens,Intermediate,,646.0,,9606.0,A549,,F,BAO_0000219,CHEMBL620426,5768
,80682,N,1,,,,14255,,In vitro antitumor activity against A549 human non-small lung carcinoma cells containing 10% fetal bovine serum,1,Homo sapiens,Intermediate,,646.0,,9606.0,A549,,F,BAO_0000219,CHEMBL620427,5769
,80682,N,1,,,,14255,,In vitro antitumor activity against A549 human non-small lung carcinoma cells containing 10% fetal bovine serum; Not determined,1,Homo sapiens,Intermediate,,646.0,,9606.0,A549,,F,BAO_0000219,CHEMBL620428,5770
,80682,N,1,,,,1590,,In vitro antitumor activity against A549 human NSCLC lung carcinoma cells,1,Homo sapiens,Intermediate,,646.0,,9606.0,A549,,F,BAO_0000219,CHEMBL620429,5771
,80682,N,1,,,,6146,,In vitro concentration required to inhibit the TNF-alpha-induced RANTES production in A549 human lung epithelium cell line,1,Homo sapiens,Expert,,646.0,,9606.0,A549,,F,BAO_0000219,CHEMBL620430,5772
,80682,N,1,,,,17427,,In vitro cytotoxicity against A549 (human lung carcinoma) cell line.,1,Homo sapiens,Expert,,646.0,,9606.0,A549,,F,BAO_0000219,CHEMBL839887,5773
,80682,N,1,,,,5280,,In vitro cytotoxicity against parental and drug resistant lung human tumor cell line A549,1,Homo sapiens,Intermediate,,646.0,,9606.0,A549,,F,BAO_0000219,CHEMBL620431,5774
,80682,N,1,,,,16786,,In vitro cytotoxicity of compound against human A549 (non small cell lung) cancer cell line after 72 hr of drug exposure,1,Homo sapiens,Intermediate,,646.0,,9606.0,A549,,F,BAO_0000219,CHEMBL884010,5775
,80682,N,1,,,,5895,,In vitro cytotoxicity against A549 (human lung cancer),1,Homo sapiens,Intermediate,,646.0,,9606.0,A549,,F,BAO_0000219,CHEMBL620538,5776
,80682,N,1,,,,14297,,In vitro cytotoxicity against A-549 (human lung carcinoma) cell line.,1,Homo sapiens,Expert,,646.0,,9606.0,A549,,F,BAO_0000219,CHEMBL620539,5777
,80682,N,1,,,,17824,,In vivo antiproliferative activity against A549 cell line,1,Homo sapiens,Intermediate,,646.0,,9606.0,A549,,F,BAO_0000218,CHEMBL623373,5778
,80682,N,1,,,,14368,,Inhibition of non-small-cell lung adenocarcinoma (A549),1,Homo sapiens,Intermediate,,646.0,,9606.0,A549,,F,BAO_0000219,CHEMBL623374,5779
,80682,N,1,,,,14368,,Inhibition of non-small-cell lung adenocarcinoma (A549) after 48-h treatment,1,Homo sapiens,Intermediate,,646.0,,9606.0,A549,,F,BAO_0000219,CHEMBL623375,5780
,80682,N,1,,,,14254,,Inhibition of the growth against human non-small-lung carcinoma (A549) cell line after 72 hr exposure,1,Homo sapiens,Intermediate,,646.0,,9606.0,A549,,F,BAO_0000219,CHEMBL623376,5781
,80682,N,1,,,,15897,,Inhibitory activity against A549 cell line using MTT assay(Wild type p53),1,Homo sapiens,Intermediate,,646.0,,9606.0,A549,,F,BAO_0000219,CHEMBL623377,5782
,80682,N,1,,,,13866,,Inhibitory activity against A549 epithelial Cancer cell line at the concentration 0-30 uM for 48 hr,1,Homo sapiens,Intermediate,,646.0,,9606.0,A549,,F,BAO_0000219,CHEMBL623378,5783
,80682,N,1,,,,13370,,Inhibitory activity of compound against human A549 lung carcinoma cell line.,1,Homo sapiens,Intermediate,,646.0,,9606.0,A549,,F,BAO_0000219,CHEMBL623379,5784
,80682,N,1,,,,4862,,Inhibitory activity against A549 lung cancer cell line,1,Homo sapiens,Intermediate,,646.0,,9606.0,A549,,F,BAO_0000219,CHEMBL623380,5785
,80682,N,1,,,,4862,,Inhibitory activity against Taxol-resistant A549 lung cancer cell line,1,Homo sapiens,Intermediate,,646.0,,9606.0,A549,,F,BAO_0000219,CHEMBL623381,5786
,80682,N,1,,,,4862,,Inhibitory activity against Taxol-resistant A549 lung cancer cell line; not determined,1,Homo sapiens,Intermediate,,646.0,,9606.0,A549,,F,BAO_0000219,CHEMBL623382,5787
,80682,N,1,,,,15970,,Inhibitory concentration against A549 (lung cancer) cell line,1,Homo sapiens,Intermediate,,646.0,,9606.0,A549,,F,BAO_0000219,CHEMBL623383,5788
,80682,N,1,,,,17713,,In vitro cytotoxicity against A-549 (human lung carcinoma) cell line.,1,Homo sapiens,Expert,,646.0,,9606.0,A549,,F,BAO_0000219,CHEMBL623384,5789
,80682,N,1,,,,4833,,Tested in vitro for inhibitory effect on the growth of human A-549 cancer cell line,1,Homo sapiens,Intermediate,,646.0,,9606.0,A549,,F,BAO_0000219,CHEMBL623385,5790
,80682,N,1,,,,13736,,Activity against A549 cancer cell line.,1,Homo sapiens,Expert,,646.0,,9606.0,A549,,F,BAO_0000219,CHEMBL623386,5791
,80682,N,1,,,,4312,,The compound was evaluated for cytotoxicity against A549 cell line,1,Homo sapiens,Intermediate,,646.0,,9606.0,A549,,F,BAO_0000219,CHEMBL884105,5792
,80682,N,1,,,,5421,,The compound was examined for its ability to block tumor necrosis factor alpha (TNF alpha) induced IL-8 production in A549 human lung carcinoma cell line using an ELISA,1,Homo sapiens,Intermediate,,646.0,,9606.0,A549,,F,BAO_0000219,CHEMBL623387,5793
,80682,N,1,,,,5421,,The compound was tested for its ability to inhibit tumor necrosis factor alpha (TNF alpha) induced apoptosis in A549 human lung carcinoma cell line,1,Homo sapiens,Intermediate,,646.0,,9606.0,A549,,F,BAO_0000219,CHEMBL621568,5794
,80682,N,1,,,,14717,,Growth inhibitory activity was measured for human A549 tumor cell line.,1,Homo sapiens,Intermediate,,646.0,,9606.0,A549,,F,BAO_0000219,CHEMBL621569,5795
,80682,N,1,,,,4634,,Inhibitory activity against A549 lung cancer cell line,1,Homo sapiens,Intermediate,,646.0,,9606.0,A549,,F,BAO_0000219,CHEMBL621570,5796
,80682,N,1,,,,1149,,Inhibitory activity against A549 cell line; inactive,1,Homo sapiens,Intermediate,,646.0,,9606.0,A549,,F,BAO_0000219,CHEMBL621571,5797
,80682,N,1,,,,5421,,Inhibition of NFkB (transcription factor) activation in A549 human lung carcinoma cell line at 20 uM,1,Homo sapiens,Expert,,646.0,,9606.0,A549,,F,BAO_0000219,CHEMBL621572,5798
,80682,N,1,,,,5421,,Inhibition of NFkB (transcription factor) activation in A549 human lung carcinoma cell line at 20 uM,1,Homo sapiens,Expert,,646.0,,9606.0,A549,,F,BAO_0000219,CHEMBL621573,5799
,80682,N,1,,,,5421,,Compound was tested for its ability to inhibit tumor necrosis factor alpha (TNF alpha) induced apoptosis in A549 human lung carcinoma cell line at 20 uM concentration,1,Homo sapiens,Intermediate,,646.0,,9606.0,A549,,F,BAO_0000219,CHEMBL621574,5800
,80682,N,1,,,,3320,,In vitro cytotoxic activity against A549 tumor cell line by SRB assay at 72 hour at a concentration 10E-4 (M/L),1,Homo sapiens,Intermediate,,646.0,,9606.0,A549,,F,BAO_0000219,CHEMBL621575,5801
,80682,N,1,,,,3320,,In vitro cytotoxic activity against A549 tumor cell line by SRB assay at 72 hour at a concentration 10E-5 (M/L),1,Homo sapiens,Intermediate,,646.0,,9606.0,A549,,F,BAO_0000219,CHEMBL621576,5802
,80682,N,1,,,,3320,,In vitro cytotoxic activity against A549 tumor cell line by SRB assay at 72 hour at a concentration 10E-6 (M/L),1,Homo sapiens,Intermediate,,646.0,,9606.0,A549,,F,BAO_0000219,CHEMBL621577,5803
,80682,N,1,,,,3320,,In vitro cytotoxic activity against A549 tumor cell line by SRB assay at 72 hour at a concentration 10E-7 (M/L),1,Homo sapiens,Intermediate,,646.0,,9606.0,A549,,F,BAO_0000219,CHEMBL621578,5804
,80682,N,1,,,,3320,,In vitro cytotoxic activity against A549 tumor cell line by SRB assay at 72 hour at a concentration 10E-8 (M/L),1,Homo sapiens,Intermediate,,646.0,,9606.0,A549,,F,BAO_0000219,CHEMBL621579,5805
,80682,N,1,,,,5726,,In vitro percent inhibition evaluated against human lung cancer (A549 cell line) at >20 ug/mL,1,Homo sapiens,Intermediate,,646.0,,9606.0,A549,,F,BAO_0000219,CHEMBL621580,5806
,50588,N,1,In vivo,,,17800,,Plasma clearance (in vivo) in mongrel dogs was determined,1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL621581,5807
,50588,N,1,In vivo,,,5985,,Plasma clearance was measured in dog,1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL621582,5808
,50588,N,1,In vivo,,,5530,,Plasma clearance in vivo in dog by intravenous administration at a dose of 0.2 mg/kg,1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL621583,5809
,50588,N,1,In vivo,,,5530,,Plasma clearance in vivo in dog by intravenous administration at a dose of 1 mg/kg,1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL621584,5810
Plasma,50588,N,1,In vivo,,,4839,,Tested for plasma clearance in dog,1,Canis lupus familiaris,Intermediate,,,,9615.0,,1969.0,A,BAO_0000218,CHEMBL621585,5811
,50588,N,1,In vivo,,,3639,,The compound was tested for clearance in dog plasma.,1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL621586,5812
,50588,N,1,In vivo,,,4838,,"The pharmacokinetic parameter, clearance was reported in dog after intravenous administration",1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL875835,5813
,50588,N,1,In vivo,,,4137,,Clearance value of compound was determined after intravenous administration of 1 mg/kg/h in dog,1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL621587,5814
Plasma,50588,N,1,In vivo,,,5017,,Compound was tested for its ability of plasma clearance when administered in dog perorally (1 mg/kg) and intravenously (0.2 mg/kg),1,Canis lupus familiaris,Intermediate,,,,9615.0,,1969.0,A,BAO_0000218,CHEMBL621588,5815
Liver,50588,N,1,In vitro,,Microsomes,17538,,In vitro clearance in dog liver microsomes,1,Canis lupus familiaris,Intermediate,,,,9615.0,,2107.0,A,BAO_0000218,CHEMBL621589,5816
,50588,N,1,In vivo,,,6161,,Pharmacokinetic profile in terms of clearance was determined at a dose of 0.5 mg/kg administered intravenously in dog,1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL621590,5817
,50588,N,1,In vivo,,,6161,,Pharmacokinetic profile in terms of clearance was determined at a dose of 5 mg/kg administered intravenously in dog,1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL621591,5818
,50588,N,1,In vivo,,,1696,,Plasma clearance in dog,1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL621592,5819
,50588,N,1,In vivo,,,6762,,Clearance rate in dog,1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL621593,5820
Plasma,50588,N,1,In vivo,,,5932,,Plasma concentration in dogs after 2 hr at 30mg/kg oral dose,1,Canis lupus familiaris,Intermediate,,,,9615.0,,1969.0,A,BAO_0000218,CHEMBL621594,5821
,50588,N,1,In vivo,,,6305,,Clearance in dogs,1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL621595,5822
,50588,N,1,In vivo,,,4942,,Plasma clearance in dogs,1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL621596,5823
,50588,N,1,In vivo,,,4219,,Plasma clearance was determined,1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL621597,5824
,50588,N,1,In vivo,,,17853,,Lower clearance in dog (i.v.) at 0.5 mpk,1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL621598,5825
,50588,N,1,In vivo,,,4514,,Plasma clearance in Beagle dogs,1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL621599,5826
,50588,N,1,In vivo,,,6448,,Plasma clearance (Clp) in dog,1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL875836,5827
,50588,N,1,In vivo,,,6227,,Plasma clearance (pharmacokinetic parameter) in dog (in vivo) at a dose of 1 mg/kg,1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL621600,5828
,50588,N,1,In vivo,,,6227,,Plasma clearance (pharmacokinetic parameter) in dog was determined,1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL621601,5829
,50588,N,1,In vivo,,,6062,,Plasma clearance for the compound was measured in dog after an iv dose of 1 mg/kg,1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL618474,5830
,50588,N,1,In vivo,,,6821,,Plasma clearance of compound was determined in dog,1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL618475,5831
,50588,N,1,In vivo,,,4709,,Plasma clearance after intravenous administration of 1 mg/kg in dog,1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL624524,5832
,50588,N,1,In vivo,,,4521,,Plasma clearance in dog after 2 mg/kg by oral and 0.5 mg/kg by intravenous administration,1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL624525,5833
,50588,N,1,In vivo,,,5374,,Plasma clearance in dog was determined,1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL624526,5834
,50588,N,1,In vivo,,,6057,,Plasma clearance was calculated in dog,1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL624527,5835
,50588,N,1,In vivo,,,4727,,Plasma clearance at the dose of 2 mg/kg in dog,1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL624528,5836
,50588,N,1,In vivo,,,5145,,Plasma clearance in dog,1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL624529,5837
,50588,N,1,In vivo,,,17657,,Plasma clearance in dog,1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL624530,5838
,50588,N,1,In vivo,,,17657,,Plasma clearance in dog; Unable to calculate,1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL624531,5839
,50588,N,1,In vivo,,,5145,,Plasma clearance in rhesus monkey,1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL624532,5840
,50588,N,1,In vivo,,,6642,,Plasma clearance in dog (dosed as a mixture of five compounds at 0.5 mpk each via iv only),1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL624533,5841
,50588,N,1,In vivo,,,6641,,Plasma clearance in dog (dosed at 0.5 mpk iv and 2.0 mpk orally),1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL624534,5842
,50588,N,1,In vivo,,,6642,,Plasma clearance in dog (dosed at 0.5 mpk iv and 2.0 mpk orally),1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL624535,5843
,50588,N,1,In vivo,,,5472,,Plasma clearance was evaluated in dog,1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL624536,5844
,50588,N,1,In vivo,,,5472,,Plasma clearance was evaluated in dog; Not tested,1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL624537,5845
,50588,N,1,In vivo,,,5472,,Plasma clearance was evaluated in rhesus,1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL624538,5846
,50588,N,1,In vivo,,,5472,,Plasma clearance was evaluated in rhesus; Not tested,1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL624539,5847
,50588,N,1,In vivo,,,4257,,Plasma clearance value was determined in dog after a 3 mg/kg of iv dose,1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL624540,5848
,50588,N,1,In vivo,,,6679,,Plasma clearance was determined after 1 mg/kg (i.v.) / 2 mg/kg (p.o.) of compound administration,1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL624541,5849
,50588,N,1,In vivo,,,5546,,Plasma clearance was determined in Beagle dog at a dose of 1 mg/kg by iv administration,1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL624542,5850
,50588,N,1,In vivo,,,6348,,Plasma clearance was determined in dog after 1 mg/kg (i.v.) and 5 mg/kg (p.o.) administration,1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL624543,5851
,50588,N,1,In vivo,,,5474,,Clearance value at a dose of 0.2 mg/kg i.v.,1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL624544,5852
Plasma,50588,N,1,In vivo,,,6316,,Cmax (Maximum (Peak) plasma drug concentration) was after oral administration at 5 mg/kg,1,Canis lupus familiaris,Intermediate,,,,9615.0,,1969.0,A,BAO_0000218,CHEMBL624545,5853
,50588,N,1,In vivo,,,17594,,Cmax after oral dose of compound at 3 mg/kg in dogs,1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL624546,5854
,50588,N,1,In vivo,,,17594,,Cmax after single intravenous bolus of 1 mg/kg in dogs,1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL875957,5855
,50588,N,1,In vivo,,,5802,,Cmax of compound after both po and iv administration at a dose of 5 mg/kg and 2 mg/kg resp in dog,1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL624547,5856
,50588,N,1,In vivo,,,6535,,Cmax in dog after administration of 0.25 mg/kg iv; ND = not determined,1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL624548,5857
,50588,N,1,In vivo,,,6535,,Cmax in dog after administration of 1 mg/kg iv,1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL624549,5858
Plasma,50588,N,1,In vivo,,,1466,,Cmax in plasma was determined upon peroral administration of 10.0 mg/Kg dose in dog,1,Canis lupus familiaris,Intermediate,,,,9615.0,,1969.0,A,BAO_0000218,CHEMBL624550,5859
,50588,N,1,In vivo,,,6505,,Cmax on p.o. administration of 10 mg/kg was measured in dog,1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL621613,5860
,50588,N,1,In vivo,,,5668,,Cmax was determine after peroral administration at 10 mpk in dog,1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL621614,5861
,50588,N,1,In vivo,,,5668,,Cmax was determine after peroral administration at 5 mpk in dog,1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL623431,5862
,50588,N,1,In vivo,,,5668,,Cmax was determine after peroral administration at 5 mg/kg in dog,1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL623432,5863
,50588,N,1,In vivo,,,5600,,Cmax after 0.3 mg/kg po administration in dog,1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL623433,5864
,50588,N,1,In vivo,,,17764,,Cmax after peroral administration in dogs at 2.4 uM/kg,1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL623434,5865
,50588,N,1,In vivo,,,6123,,Cmax in dog after oral administration at 1 mg/kg,1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL623435,5866
,50588,N,1,In vivo,,,6123,,Cmax in dog after oral administration at 1 mg/kg; Below the level of quantitation,1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL623436,5867
,50588,N,1,In vivo,,,6757,,Cmax upon oral administration in male Beagle dog at 10 mg/kg,1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL875958,5868
,50588,N,1,In vivo,,,16907,,Cmax value after 15 mg/kg iv dose in Dogs,1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL623437,5869
Blood,50594,N,1,In vivo,,,7767,,Biodistribution in blood was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,1,Mus musculus,Intermediate,,,,10090.0,,178.0,A,BAO_0000218,CHEMBL623438,5870
Blood,50594,N,1,In vivo,,,7767,,Biodistribution in blood was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,1,Mus musculus,Intermediate,,,,10090.0,,178.0,A,BAO_0000218,CHEMBL623439,5871
Bone,50594,N,1,In vivo,,,7767,,Biodistribution in bone was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,1,Mus musculus,Intermediate,,,,10090.0,,10000001.0,A,BAO_0000218,CHEMBL623440,5872
Bone,50594,N,1,In vivo,,,7767,,Biodistribution in bone was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,1,Mus musculus,Intermediate,,,,10090.0,,10000001.0,A,BAO_0000218,CHEMBL623441,5873
Bone,50594,N,1,In vivo,,,7767,,Biodistribution in bone was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,1,Mus musculus,Intermediate,,,,10090.0,,10000001.0,A,BAO_0000218,CHEMBL623442,5874
,50594,N,1,In vivo,,,7767,,Biodistribution in fat and fur was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,1,Mus musculus,Intermediate,,,,10090.0,,,A,BAO_0000218,CHEMBL623469,5875
,50594,N,1,In vivo,,,7767,,Biodistribution in fat and fur was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,1,Mus musculus,Intermediate,,,,10090.0,,,A,BAO_0000218,CHEMBL623470,5876
,50594,N,1,In vivo,,,7767,,Biodistribution in fat and fur was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,1,Mus musculus,Intermediate,,,,10090.0,,,A,BAO_0000218,CHEMBL623471,5877
Heart,50594,N,1,In vivo,,,7767,,Biodistribution in heart was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,1,Mus musculus,Intermediate,,,,10090.0,,948.0,A,BAO_0000218,CHEMBL623472,5878
Heart,50594,N,1,In vivo,,,7767,,Biodistribution in heart was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,1,Mus musculus,Intermediate,,,,10090.0,,948.0,A,BAO_0000218,CHEMBL623473,5879
Heart,50594,N,1,In vivo,,,7767,,Biodistribution in heart was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,1,Mus musculus,Intermediate,,,,10090.0,,948.0,A,BAO_0000218,CHEMBL623474,5880
Kidney,50594,N,1,In vivo,,,7767,,Biodistribution in kidney was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,1,Mus musculus,Intermediate,,,,10090.0,,2113.0,A,BAO_0000218,CHEMBL623475,5881
Kidney,50594,N,1,In vivo,,,7767,,Biodistribution in kidney was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,1,Mus musculus,Intermediate,,,,10090.0,,2113.0,A,BAO_0000218,CHEMBL623476,5882
Kidney,50594,N,1,In vivo,,,7767,,Biodistribution in kidney was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,1,Mus musculus,Intermediate,,,,10090.0,,2113.0,A,BAO_0000218,CHEMBL623477,5883
Intestine,50594,N,1,In vivo,,,7767,,Biodistribution in large intestine after iv administration at 1 hr; Value expressed as percent injected dose per gram,1,Mus musculus,Intermediate,,,,10090.0,,160.0,A,BAO_0000218,CHEMBL621896,5884
Intestine,50594,N,1,In vivo,,,7767,,Biodistribution in large intestine was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,1,Mus musculus,Intermediate,,,,10090.0,,160.0,A,BAO_0000218,CHEMBL621897,5885
Intestine,50594,N,1,In vivo,,,7767,,Biodistribution in large intestine was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,1,Mus musculus,Intermediate,,,,10090.0,,160.0,A,BAO_0000218,CHEMBL621898,5886
Liver,50594,N,1,In vivo,,,7767,,Biodistribution in liver was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,1,Mus musculus,Intermediate,,,,10090.0,,2107.0,A,BAO_0000218,CHEMBL621899,5887
Liver,50594,N,1,In vivo,,,7767,,Biodistribution in liver was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,1,Mus musculus,Intermediate,,,,10090.0,,2107.0,A,BAO_0000218,CHEMBL621900,5888
Liver,50594,N,1,In vivo,,,7767,,Biodistribution in liver was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,1,Mus musculus,Intermediate,,,,10090.0,,2107.0,A,BAO_0000218,CHEMBL621901,5889
Lung,50594,N,1,In vivo,,,7767,,Biodistribution in lung was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,1,Mus musculus,Intermediate,,,,10090.0,,2048.0,A,BAO_0000218,CHEMBL621902,5890
Lung,50594,N,1,In vivo,,,7767,,Biodistribution in lung was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,1,Mus musculus,Intermediate,,,,10090.0,,2048.0,A,BAO_0000218,CHEMBL621903,5891
Lung,50594,N,1,In vivo,,,7767,,Biodistribution in lung was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,1,Mus musculus,Intermediate,,,,10090.0,,2048.0,A,BAO_0000218,CHEMBL622587,5892
Muscle tissue,50594,N,1,In vivo,,,7767,,Biodistribution in muscle was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,1,Mus musculus,Intermediate,,,,10090.0,,2385.0,A,BAO_0000218,CHEMBL620285,5893
Muscle tissue,50594,N,1,In vivo,,,7767,,Biodistribution in muscle was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,1,Mus musculus,Intermediate,,,,10090.0,,2385.0,A,BAO_0000218,CHEMBL875285,5894
Muscle tissue,50594,N,1,In vivo,,,7767,,Biodistribution in muscle was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,1,Mus musculus,Intermediate,,,,10090.0,,2385.0,A,BAO_0000218,CHEMBL620286,5895
,50594,N,1,In vivo,,,7767,,Biodistribution in pancreatic tissue was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,1,Mus musculus,Intermediate,,,,10090.0,,,A,BAO_0000218,CHEMBL620287,5896
,50594,N,1,In vivo,,,7767,,Biodistribution in pancreatic tissue was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,1,Mus musculus,Intermediate,,,,10090.0,,,A,BAO_0000218,CHEMBL620288,5897
,50594,N,1,In vivo,,,7767,,Biodistribution in pancreatic tissue was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,1,Mus musculus,Intermediate,,,,10090.0,,,A,BAO_0000218,CHEMBL620289,5898
Intestine,50594,N,1,In vivo,,,7767,,Biodistribution in small intestine was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,1,Mus musculus,Intermediate,,,,10090.0,,160.0,A,BAO_0000218,CHEMBL620290,5899
Intestine,50594,N,1,In vivo,,,7767,,Biodistribution in small intestine was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,1,Mus musculus,Intermediate,,,,10090.0,,160.0,A,BAO_0000218,CHEMBL620291,5900
Intestine,50594,N,1,In vivo,,,7767,,Biodistribution in small intestine was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,1,Mus musculus,Intermediate,,,,10090.0,,160.0,A,BAO_0000218,CHEMBL620292,5901
Spleen,50594,N,1,In vivo,,,7767,,Biodistribution in spleen was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,1,Mus musculus,Intermediate,,,,10090.0,,2106.0,A,BAO_0000218,CHEMBL620293,5902
Spleen,50594,N,1,In vivo,,,7767,,Biodistribution in spleen was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,1,Mus musculus,Intermediate,,,,10090.0,,2106.0,A,BAO_0000218,CHEMBL620294,5903
Spleen,50594,N,1,In vivo,,,7767,,Biodistribution in spleen was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,1,Mus musculus,Intermediate,,,,10090.0,,2106.0,A,BAO_0000218,CHEMBL618614,5904
Stomach,50594,N,1,In vivo,,,7767,,Biodistribution in stomach was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,1,Mus musculus,Intermediate,,,,10090.0,,945.0,A,BAO_0000218,CHEMBL618615,5905
Stomach,50594,N,1,In vivo,,,7767,,Biodistribution in stomach was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,1,Mus musculus,Intermediate,,,,10090.0,,945.0,A,BAO_0000218,CHEMBL618616,5906
,80012,N,1,,,,2036,,Cytotoxicity against A-172 human tumor cell lines,1,Homo sapiens,Expert,,622.0,,9606.0,A 172,,F,BAO_0000219,CHEMBL618617,5907
,80012,N,1,,,,2357,,Compound was evaluated for the in vitro cytotoxicity against A-172 human glioblastoma cell line,1,Homo sapiens,Intermediate,,622.0,,9606.0,A 172,,F,BAO_0000219,CHEMBL618618,5908
,80014,N,1,,,,1457,,Antiproliferative activity of compound was tested against rhabdomyosarcoma (A-204) human tumor cells,1,Homo sapiens,Intermediate,,623.0,,9606.0,A204,,F,BAO_0000219,CHEMBL618619,5909
,81034,N,1,,,,4379,,Tested for antiproliferative activity against A-2780 tumoral cell line,1,Homo sapiens,Intermediate,,478.0,,9606.0,A2780,,F,BAO_0000219,CHEMBL618620,5910
,80018,N,1,,,,1093,,Inhibitory concentration against melanoma A-375 cell line for cytotoxicity was determined,1,Homo sapiens,Intermediate,,455.0,,9606.0,A-375,,F,BAO_0000219,CHEMBL618621,5911
,80018,N,1,,,,12152,,Tested in vitro against A-375 cell line human melanoma,1,Homo sapiens,Intermediate,,455.0,,9606.0,A-375,,F,BAO_0000219,CHEMBL618622,5912
,80019,N,1,,,,16464,,Cytotoxicity against A-427 nonsmall lung cell line using MTT colorimetric assay,1,Homo sapiens,Expert,,797.0,,9606.0,A-427,,F,BAO_0000219,CHEMBL618623,5913
,80019,N,1,,,,16464,,Cytotoxicity against A-427 nonsmall lung cell line using MTT colorimetric assay; NE is no effect at 1x 10 E-5,1,Homo sapiens,Intermediate,,797.0,,9606.0,A-427,,F,BAO_0000219,CHEMBL618624,5914
,80019,N,1,,,,16582,,In vitro cytotoxicity against human non small-cell-lung cell line A-427.,1,Homo sapiens,Expert,,797.0,,9606.0,A-427,,F,BAO_0000219,CHEMBL618625,5915
,80019,N,1,,,,16464,,Cytotoxicity against A-427 nonsmall lung cell line using MTT colorimetric assay; NE is no effect at 1x 10 E-5,1,Homo sapiens,Intermediate,,797.0,,9606.0,A-427,,F,BAO_0000219,CHEMBL618626,5916
,80019,N,1,,,,10413,,Antitumor activity on A-427 lung carcinoma cell lines,1,Homo sapiens,Intermediate,,797.0,,9606.0,A-427,,F,BAO_0000219,CHEMBL618627,5917
,80019,N,1,,,,6418,,Cytotoxic activity against human A-427 lung tumor cell line,1,Homo sapiens,Intermediate,,797.0,,9606.0,A-427,,F,BAO_0000219,CHEMBL618628,5918
,80019,N,1,,,,17134,,In vitro antitumor effects against human A-427 cell lines.,1,Homo sapiens,Expert,,797.0,,9606.0,A-427,,F,BAO_0000219,CHEMBL618629,5919
,80019,N,1,,,,16132,,In vitro inhibition of A-427 (human lung cancer) cell growth.,1,Homo sapiens,Expert,,797.0,,9606.0,A-427,,F,BAO_0000219,CHEMBL618630,5920
,80019,N,1,,,,16132,,Cytotoxic related antitumor activity against human cancer cell lines A-427; No data available,1,Homo sapiens,Intermediate,,797.0,,9606.0,A-427,,F,BAO_0000219,CHEMBL618631,5921
,80019,N,1,,,,16780,,Cytotoxic activity of compound against A-427 lung human tumor cell line,1,Homo sapiens,Intermediate,,797.0,,9606.0,A-427,,F,BAO_0000219,CHEMBL618632,5922
,80852,N,1,,,,4085,,Cytotoxicity measured for the growth inhibition of A-431 Human epidermoid carcinoma cell line,1,Homo sapiens,Expert,,500.0,,9606.0,A-431,,F,BAO_0000219,CHEMBL618633,5923
,80021,N,1,,,,1276,,Cytotoxic activity was tested against human A-498 (Kidney carcinoma) cell line,1,Homo sapiens,Intermediate,,624.0,,9606.0,A498,,F,BAO_0000219,CHEMBL619315,5924
,80021,N,1,,,,3498,,Cytotoxicity against A-498 cell line in the purdue cell culture screen was determined,1,Homo sapiens,Expert,,624.0,,9606.0,A498,,F,BAO_0000219,CHEMBL619316,5925
,80021,N,1,,,,1169,,Cytotoxicity against human kidney carcinoma A-498cell lines,1,Homo sapiens,Intermediate,,624.0,,9606.0,A498,,F,BAO_0000219,CHEMBL619317,5926
,80021,N,1,,,,4450,,In vitro cytotoxic activity against A-498 (human kidney carcinoma) cell line,1,Homo sapiens,Intermediate,,624.0,,9606.0,A498,,F,BAO_0000219,CHEMBL619318,5927
,80021,N,1,,,,3311,,In vitro cytotoxicity against Renal A-498 human tumors following a 6 day exposure.,1,Homo sapiens,Intermediate,,624.0,,9606.0,A498,,F,BAO_0000219,CHEMBL619319,5928
,80021,N,1,,,,4461,,Antitumor cytotoxic activity against A-498 cell line was determined,1,Homo sapiens,Intermediate,,624.0,,9606.0,A498,,F,BAO_0000219,CHEMBL619739,5929
,80021,N,1,,,,3311,,In vitro cytotoxicity against Renal A-498 human tumors following a 2 day exposure.,1,Homo sapiens,Intermediate,,624.0,,9606.0,A498,,F,BAO_0000219,CHEMBL619740,5930
,80021,N,1,,,,3311,,In vitro cytotoxicity against Renal A-498 human tumors following a 2 day exposure; ND is no data,1,Homo sapiens,Intermediate,,624.0,,9606.0,A498,,F,BAO_0000219,CHEMBL883158,5931
,80021,N,1,,,,1457,,Antiproliferative activity of compound was tested against renal cancer (A-498) human tumor cells,1,Homo sapiens,Intermediate,,624.0,,9606.0,A498,,F,BAO_0000219,CHEMBL884012,5932
,80021,N,1,,,,3664,,In vitro inhibitory activity against A-498 ovarian cancer cell lines,1,Homo sapiens,Intermediate,,624.0,,9606.0,A498,,F,BAO_0000219,CHEMBL619741,5933
,80021,N,1,,,,15895,,"Cytotoxicity against NCI tumor panel, A-498 renal cancer cell line",1,Homo sapiens,Intermediate,,624.0,,9606.0,A498,,F,BAO_0000219,CHEMBL619742,5934
,80682,N,1,,,,11843,,Inhibition of growth lung non-small cell carcinoma A-549 cell line,1,Homo sapiens,Intermediate,,646.0,,9606.0,A549,,F,BAO_0000219,CHEMBL876610,5935
,80682,N,1,,,,11843,,Inhibition of growth of lung non-small cell carcinoma A-549 cell line,1,Homo sapiens,Intermediate,,646.0,,9606.0,A549,,F,BAO_0000219,CHEMBL619743,5936
,80682,N,1,,,,17705,,In vitro antiproliferative activity against human A-549 NSCL cell line,1,Homo sapiens,Intermediate,,646.0,,9606.0,A549,,F,BAO_0000219,CHEMBL619744,5937
,80682,N,1,,,,17705,,In vitro antiproliferative activity against human A-549 NSCL cell line; NS = Not significant,1,Homo sapiens,Intermediate,,646.0,,9606.0,A549,,F,BAO_0000219,CHEMBL619745,5938
,80682,N,1,,,,4369,,Growth inhibition of A-549 human lung adenocarcinoma at 0.01 uM compound concentration in standard MTT assay,1,Homo sapiens,Intermediate,,646.0,,9606.0,A549,,F,BAO_0000219,CHEMBL619746,5939
,80682,N,1,,,,4369,,Percent growth inhibition of A-549 human lung adenocarcinoma at 10e-6 M compound concentration in standard MTT assay,1,Homo sapiens,Intermediate,,646.0,,9606.0,A549,,F,BAO_0000219,CHEMBL619747,5940
,80682,N,1,,,,4369,,Percent growth inhibition of A-549 human lung adenocarcinoma at 10e-6 M compound concentration in standard MTT assay; ND means No data,1,Homo sapiens,Intermediate,,646.0,,9606.0,A549,,F,BAO_0000219,CHEMBL619748,5941
,80682,N,1,,,,4369,,Percent growth inhibition of A-549 human lung adenocarcinoma at 10e-7 M compound concentration in standard MTT assay,1,Homo sapiens,Intermediate,,646.0,,9606.0,A549,,F,BAO_0000219,CHEMBL619749,5942
,80682,N,1,,,,4369,,Percent growth inhibition of A-549 human lung adenocarcinoma at 10e-7 M compound concentration in standard MTT assay; ND means No data,1,Homo sapiens,Intermediate,,646.0,,9606.0,A549,,F,BAO_0000219,CHEMBL619750,5943
,80682,N,1,,,,4369,,Percent growth inhibition of A-549 human lung adenocarcinoma at 10e-8 M compound concentration in standard MTT assay,1,Homo sapiens,Intermediate,,646.0,,9606.0,A549,,F,BAO_0000219,CHEMBL624014,5944
,80682,N,1,,,,4369,,Percent growth inhibition of A-549 human lung adenocarcinoma at 10e-8 M compound concentration in standard MTT assay; ND means No data,1,Homo sapiens,Intermediate,,646.0,,9606.0,A549,,F,BAO_0000219,CHEMBL624015,5945
,80682,N,1,,,,4787,,In vitro effective concentration required to reduce the number of human lung carcinoma (A-549) after 3-day incubation,1,Homo sapiens,Expert,,646.0,,9606.0,A549,,F,BAO_0000219,CHEMBL885344,5946
,80682,N,1,,,,4787,,In vitro effective concentration required to reduce the number of human lung carcinoma cells (A-549) after 3-day incubation,1,Homo sapiens,Intermediate,,646.0,,9606.0,A549,,F,BAO_0000219,CHEMBL623224,5947
,80682,N,1,,,,6513,,Cytotoxic activity against A-549 cell line,1,Homo sapiens,Intermediate,,646.0,,9606.0,A549,,F,BAO_0000219,CHEMBL623225,5948
,80682,N,1,,,,6690,,Antitumor cytotoxicity was determined against the A-549(human lung carcinoma) cell line; Range: 0.01 to 0.03,1,Homo sapiens,Intermediate,,646.0,,9606.0,A549,,F,BAO_0000219,CHEMBL622698,5949
,80682,N,1,,,,6690,,Antitumor cytotoxicity was determined against the A-549(human lung carcinoma) cell line; Range: 10.4 to 118.1,1,Homo sapiens,Intermediate,,646.0,,9606.0,A549,,F,BAO_0000219,CHEMBL622699,5950
,80682,N,1,,,,12263,,"Cytotoxicity in vitro expressed as 50% reduction in cell number after a 3-day incubation, in human lung carcinoma A-549 cell line",1,Homo sapiens,Expert,,646.0,,9606.0,A549,,F,BAO_0000219,CHEMBL622700,5951
,80682,N,1,,,,1054,,Compound was tested for cytotoxic activity against human lung carcinoma (A-549),1,Homo sapiens,Intermediate,,646.0,,9606.0,A549,,F,BAO_0000219,CHEMBL622701,5952
,80682,N,1,,,,1359,,Compound was tested for its cytotoxic activity in MTT assay against A-549 cell line (human lung carcinoma),1,Homo sapiens,Intermediate,,646.0,,9606.0,A549,,F,BAO_0000219,CHEMBL622702,5953
,80682,N,1,,,,3547,,Cytotoxic activity against human lung carcinoma (A-549) cell line,1,Homo sapiens,Intermediate,,646.0,,9606.0,A549,,F,BAO_0000219,CHEMBL622703,5954
,80682,N,1,,,,5771,,Cytotoxic activity towards A-549 cells,1,Homo sapiens,Expert,,646.0,,9606.0,A549,,F,BAO_0000219,CHEMBL622704,5955
,80682,N,1,,,,14425,,"In vitro percent inhibition of A549, lung carcinoma.",1,Homo sapiens,Intermediate,,646.0,,9606.0,A549,,F,BAO_0000219,CHEMBL622705,5956
,80682,N,1,,,,14425,,"In vitro percent inhibition of A549, lung carcinoma",1,Homo sapiens,Intermediate,,646.0,,9606.0,A549,,F,BAO_0000219,CHEMBL622706,5957
,80682,N,1,,,,14425,,"In vitro percent inhibition of A549, lung carcinoma.",1,Homo sapiens,Intermediate,,646.0,,9606.0,A549,,F,BAO_0000219,CHEMBL622707,5958
,80682,N,1,,,,14425,,"In vitro percent inhibition of A549, lung carcinoma.; Range 18-23",1,Homo sapiens,Intermediate,,646.0,,9606.0,A549,,F,BAO_0000219,CHEMBL622708,5959
,80682,N,1,,,,5280,,Percentage inhibition against parental and drug resistant lung human tumor cell line A549 at 10 uM,1,Homo sapiens,Intermediate,,646.0,,9606.0,A549,,F,BAO_0000219,CHEMBL622709,5960
,80682,N,1,,,,15176,,Growth inhibition of the A549/ATCC non-small cell lung cancer cell line for 2-day in vitro assay.,1,Homo sapiens,Intermediate,,646.0,,9606.0,A549,,F,BAO_0000219,CHEMBL622710,5961
,80682,N,1,,,,15300,,In vitro antitumor activity against Non-small cell lung cancer A549/ATCC cell lines by 6-day assay,1,Homo sapiens,Intermediate,,646.0,,9606.0,A549,,F,BAO_0000219,CHEMBL622711,5962
,80682,N,1,,,,17824,,"Antitumor activity against A549 non small cell carcinoma at dose range of 1.56-6.25 mg/kg on day 14, 21, 28; activity expressed as maximum tolerated dose",1,Homo sapiens,Intermediate,,646.0,,9606.0,A549,,F,BAO_0000218,CHEMBL622712,5963
,80682,N,1,,,,17824,,"Antitumor activity against A549 non small cell carcinoma at dose range of 25-100 mg/kg on day 14, 21, 28; activity expressed as maximum tolerated dose",1,Homo sapiens,Intermediate,,646.0,,9606.0,A549,,F,BAO_0000218,CHEMBL622713,5964
,80682,N,1,,,,17824,,"Antitumor activity against A549 non small cell carcinoma at dose range of 3.12-12.5 mg/kg on day 14, 21, 28; activity expressed as maximum tolerated dose",1,Homo sapiens,Intermediate,,646.0,,9606.0,A549,,F,BAO_0000218,CHEMBL622714,5965
,80682,N,1,,,,17824,,"Antitumor activity against A549 non small cell carcinoma at dose range of 6.25-25 mg/kg on day 14, 21, 28; activity expressed as maximum tolerated dose",1,Homo sapiens,Intermediate,,646.0,,9606.0,A549,,F,BAO_0000218,CHEMBL622715,5966
,80682,N,1,,,,17824,,"Antitumor activity against A549 non small cell carcinoma at dose range of 70-100 mg/kg on day 14, 21, 28; activity expressed as maximum tolerated dose",1,Homo sapiens,Intermediate,,646.0,,9606.0,A549,,F,BAO_0000218,CHEMBL622716,5967
,80682,N,1,,,,17824,,"Antitumor activity against A549 non small cell carcinoma on day 14, 21, 28; activity expressed as maximum tolerated dose; NT = Not tested",1,Homo sapiens,Intermediate,,646.0,,9606.0,A549,,F,BAO_0000219,CHEMBL622717,5968
,80682,N,1,,,,17528,,Optimal dose required to inhibit human non small cell lung A549 tumor growth after subcutaneous transplantation on athymic mice at 10 mg/kg (treatment schedule: q7dX3),1,Homo sapiens,Intermediate,,646.0,,9606.0,A549,,F,BAO_0000218,CHEMBL622718,5969
,80682,N,1,,,,6870,,Cytotoxic potentiation factor of temoxolomide in human A549 tumor cell line at 0.4 uM concentration,1,Homo sapiens,Expert,,646.0,,9606.0,A549,,F,BAO_0000219,CHEMBL622719,5970
,80682,N,1,,,,6870,,Compound was evaluated for cytotoxic potentiation factor of temoxolomide in human A549 tumor cell line at 0.4 uM concentration; ND - not determined,1,Homo sapiens,Intermediate,,646.0,,9606.0,A549,,F,BAO_0000219,CHEMBL622720,5971
,80682,N,1,,,,6870,,Compound was evaluated for cytotoxic potentiation factor of topotecan in human A549 tumor cell line at 0.4 uM concentration,1,Homo sapiens,Intermediate,,646.0,,9606.0,A549,,F,BAO_0000219,CHEMBL622721,5972
,80682,N,1,,,,6870,,Compound was evaluated for cytotoxic potentiation factor of topotecan in human A549 tumor cell line at 0.4 uM concentration; ND - not determined,1,Homo sapiens,Intermediate,,646.0,,9606.0,A549,,F,BAO_0000219,CHEMBL622722,5973
,80682,N,1,,,,16726,,Cytotoxicity potentiation of Topotecan in human lung carcinoma A549 cells by the compound as potentiation factor at 50% growth inhibition,1,Homo sapiens,Intermediate,,646.0,,9606.0,A549,,F,BAO_0000219,CHEMBL876030,5974
,80682,N,1,,,,6170,,"Concentration required for 50% inhibition of proliferation of lung cancer cell line, A549 with respect to paclitaxel was tested in vitro after 72 hr of incubation",1,Homo sapiens,Intermediate,,646.0,,9606.0,A549,,F,BAO_0000219,CHEMBL620206,5975
,80682,N,1,,,,6583,,Inhibition ratio against A-549 cancer cell growth at a concentration of 10e-4 mol/L,1,Homo sapiens,Expert,,646.0,,9606.0,A549,,F,BAO_0000219,CHEMBL620207,5976
,80682,N,1,,,,6583,,Inhibition ratio against A-549 cancer cell growth at a concentration of 10e-5 mol/L,1,Homo sapiens,Expert,,646.0,,9606.0,A549,,F,BAO_0000219,CHEMBL620208,5977
,80682,N,1,,,,6583,,Inhibition ratio against A-549 cancer cell growth at a concentration of 10e-6 mol/L,1,Homo sapiens,Expert,,646.0,,9606.0,A549,,F,BAO_0000219,CHEMBL620209,5978
,80682,N,1,,,,6583,,Inhibition ratio against A-549 cancer cell growth at a concentration of 10e-7 mol/L,1,Homo sapiens,Expert,,646.0,,9606.0,A549,,F,BAO_0000219,CHEMBL620210,5979
,80682,N,1,,,,6583,,Inhibition ratio against A-549 cancer cell growth at a concentration of 10e-8 mol/L,1,Homo sapiens,Expert,,646.0,,9606.0,A549,,F,BAO_0000219,CHEMBL621639,5980
,80682,N,1,,,,17321,,Tested for cytotoxicity against human lung adenocarcinoma A549 cell line,1,Homo sapiens,Intermediate,,646.0,,9606.0,A549,,F,BAO_0000219,CHEMBL621640,5981
,80682,N,1,,,,17528,,Percentage tumor growth inhibition was calculated in respect to controls one week after the end of the treatment,1,Homo sapiens,Expert,,646.0,,9606.0,A549,,F,BAO_0000219,CHEMBL621641,5982
,80682,N,1,,,,12888,,Cytotoxic effect on non-small-cell lung cancer cell line A549/ATCC,1,Homo sapiens,Expert,,646.0,,9606.0,A549,,F,BAO_0000219,CHEMBL621642,5983
,80682,N,1,,,,4312,,Cytotoxicity of compound in synergy in 94% BCNU (10 uM) against A549 cell line,1,Homo sapiens,Intermediate,,646.0,,9606.0,A549,,F,BAO_0000219,CHEMBL621643,5984
,80682,N,1,,,,4312,,Cytotoxicity of compound in synergy in BCNU (10 uM) against A549 cell line,1,Homo sapiens,Intermediate,,646.0,,9606.0,A549,,F,BAO_0000219,CHEMBL621644,5985
,80682,N,1,,,,4312,,Cytotoxicity of compound in synergy in BCNU (10 uM) against A549 cell line; No data,1,Homo sapiens,Intermediate,,646.0,,9606.0,A549,,F,BAO_0000219,CHEMBL621645,5986
,80682,N,1,,,,17737,,In vitro antiproliferative activity against A549 cell line,1,Mus musculus,Intermediate,,646.0,,10090.0,A549,,F,BAO_0000219,CHEMBL621646,5987
,80682,N,1,,,,6630,,Synergism with indomethacin in A549 cells,1,,Intermediate,,646.0,,,A549,,F,BAO_0000219,CHEMBL621647,5988
,80682,N,1,,,,6630,,Synergism with tolmetin in A549 cells,1,,Intermediate,,646.0,,,A549,,F,BAO_0000219,CHEMBL621648,5989
,80682,N,1,,,,6630,,Synergism with sulindac in A549 cells,1,,Intermediate,,646.0,,,A549,,F,BAO_0000219,CHEMBL621649,5990
,80682,N,1,,,,6630,,Antagonism of indomethacin in A549 cells,1,,Intermediate,,646.0,,,A549,,F,BAO_0000219,CHEMBL621650,5991
,80682,N,1,,,,6630,,Antagonism of sulindac in A549 cells,1,,Intermediate,,646.0,,,A549,,F,BAO_0000219,CHEMBL621651,5992
,80682,N,1,,,,6630,,Antagonism of tolmetin in A549 cells,1,,Intermediate,,646.0,,,A549,,F,BAO_0000219,CHEMBL621652,5993
,80682,N,1,,,,6630,,Synergism with indomethacin in A549 cells,1,,Intermediate,,646.0,,,A549,,F,BAO_0000219,CHEMBL621653,5994
,80682,N,1,,,,6630,,Synergism with sulindac in A549 cells,1,,Intermediate,,646.0,,,A549,,F,BAO_0000219,CHEMBL621654,5995
,80682,N,1,,,,6630,,Drug interaction towards A549 cell line was determined in terms of combination index in presence of Tolmetin; Not available,1,,Intermediate,,646.0,,,A549,,F,BAO_0000219,CHEMBL621655,5996
,50588,N,1,In vivo,,,16907,,Cmax value after 30 mg/kg po dose in Dogs,1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL621656,5997
,50588,N,1,In vivo,,,5944,,Cmax value determined in dog at a dose of 0 mg/kg by oral administration along with indavir (10 mg/kg),1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL621657,5998
,50588,N,1,In vivo,,,5944,,Cmax value determined in dog at a dose of 10 mg/kg by oral administration,1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL621658,5999
,50588,N,1,In vivo,,,5944,,Cmax value determined in dog at a dose of 10 mg/kg by oral administration along with indavir (10 mg/kg),1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL621659,6000
,50588,N,1,In vivo,,,5944,,Cmax value determined in dog at a dose of 5 mg/kg by oral administration,1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL621660,6001
,50588,N,1,In vivo,,,2959,,Cmax value after administration of 4 mg/Kg oral dose in dog,1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL621661,6002
,50588,N,1,In vivo,,,6241,,Cmax value in dog,1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL621662,6003
,50588,N,1,In vivo,,,6241,,Cmax value in dogs after oral administration at 1 mg/kg,1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL621663,6004
,50588,N,1,In vivo,,,2652,,Bioavailability as Cmax in dogs at 5 mg/kg oral dose,1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL621664,6005
Plasma,50588,N,1,In vivo,,,1806,,Compound was evaluated for maximum observed plasma concentration at dose 27.5 mg/kg DMP323 equiv in dogs,1,Canis lupus familiaris,Intermediate,,,,9615.0,,1969.0,A,BAO_0000218,CHEMBL621665,6006
Plasma,50588,N,1,In vivo,,,1806,,Compound was evaluated for maximum observed plasma concentration at dose 7.7 mg/kg DMP323 equiv in dogs,1,Canis lupus familiaris,Intermediate,,,,9615.0,,1969.0,A,BAO_0000218,CHEMBL621666,6007
,50588,N,1,In vivo,,,1021,,Concentration maxima after oral dosing in dogs,1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL621667,6008
,50588,N,1,In vivo,,,1021,,Concentration maxima after oral dosing in dogs; not available,1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL876738,6009
,50588,N,1,In vivo,,,1021,,Concentration maxima after oral dosing in dogs; not available,1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL621668,6010
,50588,N,1,In vivo,,,5444,,In vivo maximal concentration was calculated at 0.4 mg/kg in dog; Not absorbed,1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL621669,6011
,50588,N,1,In vivo,,,5444,,In vivo maximal concentration was calculated at 0.6 mg/kg in dog; Not absorbed,1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL621670,6012
,50588,N,1,In vivo,,,5444,,In vivo maximal concentration was calculated at 1 mg/kg in dog,1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL621671,6013
,50588,N,1,In vivo,,,5444,,In vivo maximal concentration was calculated at 1 mg/kg in dog; Not absorbed,1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL622360,6014
,50588,N,1,In vivo,,,5444,,In vivo maximal concentration was calculated at 1 mg/kg in dog; Poor absorption,1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL622361,6015
Plasma,50588,N,1,In vivo,,,5130,,Cmax in dog plasma after oral dose (1 mg/kg),1,Canis lupus familiaris,Intermediate,,,,9615.0,,1969.0,A,BAO_0000218,CHEMBL622362,6016
Plasma,50588,N,1,In vivo,,,3249,,Maximal concentration (Cmax) in dog plasma at a dose of 5 mg/kg,1,Canis lupus familiaris,Intermediate,,,,9615.0,,1969.0,A,BAO_0000218,CHEMBL622363,6017
Plasma,50588,N,1,In vivo,,,5473,,Maximal plasma concentration at a dose of 1 mg/kg,1,Canis lupus familiaris,Intermediate,,,,9615.0,,1969.0,A,BAO_0000218,CHEMBL622364,6018
Plasma,50588,N,1,In vivo,,,5474,,Maximal plasma concentration at a dose of 1 mg/kg (oral),1,Canis lupus familiaris,Intermediate,,,,9615.0,,1969.0,A,BAO_0000218,CHEMBL622365,6019
Plasma,50588,N,1,In vivo,,,4657,,Maximal plasma concentration required for pharmacokinetic data in dogs at dose of 1 mg/kg perorally,1,Canis lupus familiaris,Intermediate,,,,9615.0,,1969.0,A,BAO_0000218,CHEMBL622533,6020
,50588,N,1,In vivo,,,3031,,Maximum concentration of compound in dog was evaluated.,1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL622534,6021
,50588,N,1,In vivo,,,4527,,Maximum concentration by oral administration at a dose of 10 uM/kg in dog was determined,1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL622535,6022
,50588,N,1,In vivo,,,4186,,Maximum concentration in dog after administration of 20 mg/kg dose through peroral route,1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL876739,6023
,50588,N,1,In vivo,,,5007,,Maximum concentration in dogs administered perorally (5 mg/kg) and intravenously (2 mg/kg),1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL622536,6024
Plasma,50588,N,1,In vivo,,,3132,,Maximum concentration obtained in dog plasma was determined,1,Canis lupus familiaris,Intermediate,,,,9615.0,,1969.0,A,BAO_0000218,CHEMBL622537,6025
,50588,N,1,In vivo,,,5006,,Maximum concentration was determined,1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL622538,6026
,50588,N,1,In vivo,,,4727,,Maximum concentration at the dose of 2 mg/kg in dog,1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL627867,6027
,50588,N,1,In vivo,,,1916,,Maximum concentration was evaluated against Beagle dog at a dose of 15 mg/kg after po administration,1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL627868,6028
Plasma,50588,N,1,In vivo,,,1918,,Maximum concentration was evaluated in dog plasma,1,Canis lupus familiaris,Intermediate,,,,9615.0,,1969.0,A,BAO_0000218,CHEMBL627869,6029
,50588,N,1,In vivo,,,3045,,Maximum concentration was evaluated after 75 min after administration in dog,1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL627870,6030
Plasma,50588,N,1,In vivo,,,9579,,Maximum plasma concentration determined in dog after oral administration of 17b,1,Canis lupus familiaris,Intermediate,,,,9615.0,,1969.0,A,BAO_0000218,CHEMBL627871,6031
Plasma,50588,N,1,In vivo,,,9579,,Maximum plasma concentration determined in dog after oral administration of 2b,1,Canis lupus familiaris,Intermediate,,,,9615.0,,1969.0,A,BAO_0000218,CHEMBL627872,6032
Plasma,50588,N,1,In vivo,,,933,,Maximum plasma concentration in dog,1,Canis lupus familiaris,Intermediate,,,,9615.0,,1969.0,A,BAO_0000218,CHEMBL627873,6033
Plasma,50588,N,1,In vivo,,,17839,,Maximum plasma concentration of compound in dog following p.o. administration of 0.5 mg/kg,1,Canis lupus familiaris,Intermediate,,,,9615.0,,1969.0,A,BAO_0000218,CHEMBL627874,6034
Plasma,50588,N,1,In vivo,,,17839,,Maximum plasma concentration of compound in dog following p.o. administration of 0.9 mg/kg,1,Canis lupus familiaris,Intermediate,,,,9615.0,,1969.0,A,BAO_0000218,CHEMBL627875,6035
Plasma,50588,N,1,In vivo,,,17839,,Maximum plasma concentration of compound in dog following p.o. administration of 0.95 mg/kg,1,Canis lupus familiaris,Intermediate,,,,9615.0,,1969.0,A,BAO_0000218,CHEMBL627876,6036
Plasma,50588,N,1,In vivo,,,17839,,Maximum plasma concentration of compound in dog following p.o. administration of 1 mg/kg,1,Canis lupus familiaris,Intermediate,,,,9615.0,,1969.0,A,BAO_0000218,CHEMBL627877,6037
Plasma,50588,N,1,In vivo,,,6348,,Maximum plasma concentration of compound was determined in dog after 1 mg/kg (i.v.) and 5 mg/kg (p.o.) administration,1,Canis lupus familiaris,Intermediate,,,,9615.0,,1969.0,A,BAO_0000218,CHEMBL627878,6038
Plasma,50588,N,1,In vivo,,,16367,,Maximum plasma concentration after oral administration to dogs at a dose of 10 mg/kg,1,Canis lupus familiaris,Intermediate,,,,9615.0,,1969.0,A,BAO_0000218,CHEMBL627879,6039
Plasma,50588,N,1,In vivo,,,1337,,Maximum plasma concentration in dogs after oral administration (10 mg/kg) as a 0.05 M citric acid solution.,1,Canis lupus familiaris,Intermediate,,,,9615.0,,1969.0,A,BAO_0000218,CHEMBL875355,6040
Plasma,50588,N,1,In vivo,,,1337,,Maximum plasma concentration in dogs after oral administration (8 mg/kg) as a 0.05 M citric acid solution.,1,Canis lupus familiaris,Intermediate,,,,9615.0,,1969.0,A,BAO_0000218,CHEMBL627880,6041
Plasma,50588,N,1,In vivo,,,5199,,Maximum plasma concentration at a 1 mg/kg oral dose in male and female Beagle dogs.,1,Canis lupus familiaris,Intermediate,,,,9615.0,,1969.0,A,BAO_0000218,CHEMBL627881,6042
Plasma,50588,N,1,In vivo,,,17650,,Maximum plasma concentration was measured in dogs after an oral dose of 10 uM/kg,1,Canis lupus familiaris,Intermediate,,,,9615.0,,1969.0,A,BAO_0000218,CHEMBL627882,6043
Plasma,50588,N,1,In vivo,,,6679,,Maximum plasma concentration reached by compound was determined after 2 mg/kg (p.o.) administration,1,Canis lupus familiaris,Intermediate,,,,9615.0,,1969.0,A,BAO_0000218,CHEMBL627883,6044
Plasma,50588,N,1,In vivo,,,5356,,Maximum plasma concentration was determined as in dogs at 1 mg/kg oral dosing Cmax; 0.05-0.2 ug/mL,1,Canis lupus familiaris,Intermediate,,,,9615.0,,1969.0,A,BAO_0000218,CHEMBL628526,6045
Plasma,50588,N,1,In vivo,,,5356,,Maximum plasma concentration was determined in dogs at 1 mg/kg oral dosing; 0.05-0.2 ug/mL,1,Canis lupus familiaris,Intermediate,,,,9615.0,,1969.0,A,BAO_0000218,CHEMBL628527,6046
Plasma,50588,N,1,In vivo,,,6227,,Maximum plasma concentration (Cmax) in dog (in vivo) at a dose of 1 mg/kg,1,Canis lupus familiaris,Intermediate,,,,9615.0,,1969.0,A,BAO_0000218,CHEMBL628528,6047
Plasma,50588,N,1,In vivo,,,6227,,Maximum plasma concentration (Cmax) in dog at a dose of 0.5 mg/kg,1,Canis lupus familiaris,Intermediate,,,,9615.0,,1969.0,A,BAO_0000218,CHEMBL628529,6048
Plasma,50588,N,1,In vivo,,,6227,,Maximum plasma concentration (Cmax) in dog at a dose of 0.7 mg/kg,1,Canis lupus familiaris,Intermediate,,,,9615.0,,1969.0,A,BAO_0000218,CHEMBL628530,6049
Plasma,50588,N,1,In vivo,,,6227,,Maximum plasma concentration (Cmax) in dog at a dose of 1 mg/kg,1,Canis lupus familiaris,Intermediate,,,,9615.0,,1969.0,A,BAO_0000218,CHEMBL625243,6050
Plasma,50588,N,1,In vivo,,,3598,,Maximum plasma drug concentration of compound determined in dog after iv administration at a dose of 10 mg/kg,1,Canis lupus familiaris,Expert,,,,9615.0,,1969.0,A,BAO_0000218,CHEMBL625244,6051
,50588,N,1,In vivo,,,4368,,Maximum concentration by intravenous administration of 1.2 mg/kg in dog,1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL625245,6052
,50588,N,1,In vivo,,,6265,,Pharmacokinetic (PK) property (Cmax) was determined in dog at the single dose of 1 mg/kg,1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL625246,6053
Stomach,50594,N,1,In vivo,,,7767,,Biodistribution in stomach was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,1,Mus musculus,Intermediate,,,,10090.0,,945.0,A,BAO_0000218,CHEMBL625247,6054
Urine,50594,N,1,In vivo,,,7767,,Biodistribution in urine was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,1,Mus musculus,Intermediate,,,,10090.0,,1088.0,A,BAO_0000218,CHEMBL625248,6055
Urine,50594,N,1,In vivo,,,7767,,Biodistribution in urine was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram; ND- No data,1,Mus musculus,Intermediate,,,,10090.0,,1088.0,A,BAO_0000218,CHEMBL625249,6056
Urine,50594,N,1,In vivo,,,7767,,Biodistribution in urine was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram; ND- No data,1,Mus musculus,Intermediate,,,,10090.0,,1088.0,A,BAO_0000218,CHEMBL625250,6057
,50594,N,1,,,,17811,,Compound (0.09% dose/g) was tested for accumulation in mice bone (Compound is radiolabeled) after 120 min; No increase,1,Mus musculus,Intermediate,,,,10090.0,,,A,BAO_0000218,CHEMBL625251,6058
,50594,N,1,,,,17811,,Compound (0.31% dose/g) was tested for accumulation in mice bone (Compound is radiolabeled) after 30 min; Low increase,1,Mus musculus,Intermediate,,,,10090.0,,,A,BAO_0000218,CHEMBL875356,6059
,50594,N,1,,,,17827,,Compound (i.v.) was tested for maximum activity in mice (Radiolabeled compound),1,Mus musculus,Intermediate,,,,10090.0,,,A,BAO_0000218,CHEMBL625252,6060
Blood,50594,N,1,,,,17827,,Compound was evaluated for elimination rate constants in vivo in whole blood of normal mice (Radiolabeled compound),1,Mus musculus,Intermediate,,,,10090.0,,178.0,A,BAO_0000218,CHEMBL625253,6061
,50594,N,1,,,,17827,,Compound was evaluated for rate of bone uptake after administration of radiolabeled in mice (Radiolabeled compound),1,Mus musculus,Intermediate,,,,10090.0,,,A,BAO_0000218,CHEMBL625254,6062
,50594,N,1,,,,17827,,Compound was evaluated for rate of bone uptake in mice (Radiolabeled compound),1,Mus musculus,Intermediate,,,,10090.0,,,A,BAO_0000218,CHEMBL625255,6063
,50594,N,1,,,,17827,,Compound was evaluated for rate of bone uptake in mice; NA - not active (Radiolabeled compound),1,Mus musculus,Intermediate,,,,10090.0,,,A,BAO_0000218,CHEMBL625256,6064
Blood,50594,N,1,,,,17827,,Compound was evaluated for uptake rate constants in vivo in whole blood of normal mice (Radiolabeled compound),1,Mus musculus,Intermediate,,,,10090.0,,178.0,A,BAO_0000218,CHEMBL625257,6065
Blood,50594,N,1,,,,17827,,Compound was evaluated for uptake rate constants in vivo in whole blood of normal mice; NA = not active (Radiolabeled compound),1,Mus musculus,Intermediate,,,,10090.0,,178.0,A,BAO_0000218,CHEMBL625258,6066
,50594,N,1,,,,17827,,Compound was evaluated for washout rate in mice (Radiolabeled compound),1,Mus musculus,Intermediate,,,,10090.0,,,A,BAO_0000218,CHEMBL625259,6067
,50594,N,1,,,,17827,,Compound was evaluated for washout rate in mice after radiolabeled ligand injected,1,Mus musculus,Intermediate,,,,10090.0,,,A,BAO_0000218,CHEMBL625260,6068
,50594,N,1,,,,17827,,"Maximum activity (i.v.) after in mice, expressed as [(ID%-kg)/g] (Radiolabeled compound)",1,Mus musculus,Intermediate,,,,10090.0,,,A,BAO_0000218,CHEMBL625261,6069
,50594,N,1,,,,17827,,"Maximum activity in mice, expressed as [(ID%-kg)/g] (Radiolabeled compound)",1,Mus musculus,Intermediate,,,,10090.0,,,A,BAO_0000218,CHEMBL625262,6070
,50594,N,1,,,,17827,,"Residual activity in mice at 120 minutes, expressed as [(ID%-kg)/g] (Radiolabeled compound)",1,Mus musculus,Intermediate,,,,10090.0,,,A,BAO_0000218,CHEMBL622639,6071
,50594,N,1,,,,17257,,Tested for plasma level after 90 min of 10 mg/kg dose administered in mice,1,Mus musculus,Intermediate,,,,10090.0,,,A,BAO_0000218,CHEMBL622640,6072
,50594,N,1,,,,17257,,Tested for plasma level after 90 min of 10 mg/kg dose administered in mice; Not detected.,1,Mus musculus,Intermediate,,,,10090.0,,,A,BAO_0000218,CHEMBL622812,6073
,50594,N,1,,,,17257,,Tested for plasma level after 90 min of 30 mg/kg dose administered in mice,1,Mus musculus,Intermediate,,,,10090.0,,,A,BAO_0000218,CHEMBL622813,6074
,50594,N,1,,,,17257,,Tested for plasma level after 90 min of 30 mg/kg dose administered in mice; Not determined,1,Mus musculus,Intermediate,,,,10090.0,,,A,BAO_0000218,CHEMBL622814,6075
,50594,N,1,,,,17827,,Time at maximum activity in mice (Radiolabeled compound),1,Mus musculus,Intermediate,,,,10090.0,,,A,BAO_0000218,CHEMBL622815,6076
,50594,N,1,,,,3760,,Percent oral bioavailability was determined after administration of compound at 5 mg/kg perorally in mice,1,Mus musculus,Intermediate,,,,10090.0,,,A,BAO_0000218,CHEMBL625342,6077
,50594,N,1,,,,3760,,Percent oral bioavailability was determined after administration of compound at 50 mg/kg perorally in mice,1,Mus musculus,Intermediate,,,,10090.0,,,A,BAO_0000218,CHEMBL625343,6078
,50594,N,1,,,,17409,,Binding towards mouse plasma protein at 10 uM,1,Mus musculus,Intermediate,,,,10090.0,,,A,BAO_0000218,CHEMBL877591,6079
,50594,N,1,,,,17409,,Binding towards mouse plasma protein at 100 uM,1,Mus musculus,Intermediate,,,,10090.0,,,A,BAO_0000218,CHEMBL625344,6080
,50594,N,1,In vivo,,,2675,,Bioavailability was evaluated in mice after intravenous administration,1,Mus musculus,Intermediate,,,,10090.0,,,A,BAO_0000218,CHEMBL625345,6081
,50594,N,1,In vivo,,,2675,,Bioavailability was evaluated in mice after oral administration,1,Mus musculus,Intermediate,,,,10090.0,,,A,BAO_0000218,CHEMBL625346,6082
,50594,N,1,In vivo,,,3132,,Bioavailability was obtained by the comparison of AUC of subcutaneous dosing and AUC of oral dosing in mouse,1,Mus musculus,Intermediate,,,,10090.0,,,A,BAO_0000218,CHEMBL625347,6083
,50594,N,1,In vivo,,,3132,,Bioavailability was obtained by the comparison of AUC of subcutaneous dosing and AUC of oral dosing in mouse at dose 25 mg/kg,1,Mus musculus,Intermediate,,,,10090.0,,,A,BAO_0000218,CHEMBL625348,6084
,50594,N,1,In vivo,,,16597,,Bioavailability at a dose of 10 mg/kg peroral administration in mice.,1,Mus musculus,Intermediate,,,,10090.0,,,A,BAO_0000218,CHEMBL625349,6085
,50594,N,1,In vivo,,,2862,,Oral bioavailability in mouse,1,Mus musculus,Intermediate,,,,10090.0,,,A,BAO_0000218,CHEMBL625350,6086
,50594,N,1,In vivo,,,17764,,Oral bioavailability after intravenous administration in mice at 24 uM/kg,1,Mus musculus,Intermediate,,,,10090.0,,,A,BAO_0000218,CHEMBL882952,6087
Brain,50594,N,1,In vivo,,,846,,Biodistribution of [123I]- labeled compound in mice brain was determined after 1 min of administration; expressed in percent of injected dose per gram of organ,1,Mus musculus,Intermediate,,,,10090.0,,955.0,A,BAO_0000218,CHEMBL625351,6088
Brain,50594,N,1,In vivo,,,846,,Biodistribution of [123I]- labeled compound in mice brain was determined after 10 min of administration; expressed in percent of injected dose per gram of organ,1,Mus musculus,Intermediate,,,,10090.0,,955.0,A,BAO_0000218,CHEMBL625352,6089
Brain,50594,N,1,In vivo,,,846,,Biodistribution of [123I]- labeled compound in mice brain was determined after 15 sec of administration; expressed in percent of injected dose per gram of organ,1,Mus musculus,Intermediate,,,,10090.0,,955.0,A,BAO_0000218,CHEMBL877592,6090
Brain,50594,N,1,In vivo,,,846,,Biodistribution of [123I]- labeled compound in mice brain was determined after 2 min of administration; expressed in percent of injected dose per gram of organ,1,Mus musculus,Intermediate,,,,10090.0,,955.0,A,BAO_0000218,CHEMBL625353,6091
Brain,50594,N,1,In vivo,,,846,,Biodistribution of [123I]- labeled compound in mice brain was determined after 30 sec of administration; expressed in percent of injected dose per gram of organ,1,Mus musculus,Intermediate,,,,10090.0,,955.0,A,BAO_0000218,CHEMBL625354,6092
Brain,50594,N,1,In vivo,,,846,,Biodistribution of [123I]- labeled compound in mice brain was determined after 5 min of administration; expressed in percent of injected dose per gram of organ,1,Mus musculus,Intermediate,,,,10090.0,,955.0,A,BAO_0000218,CHEMBL626019,6093
Heart,50594,N,1,In vivo,,,846,,Biodistribution of [123I]- labeled compound in mice heart was determined after 10 min of administration; expressed in percent of injected dose per gram of organ,1,Mus musculus,Intermediate,,,,10090.0,,948.0,A,BAO_0000218,CHEMBL626020,6094
Heart,50594,N,1,In vivo,,,846,,Biodistribution of [123I]- labeled compound in mice heart was determined after 15 sec of administration; expressed in percent of injected dose per gram of organ,1,Mus musculus,Intermediate,,,,10090.0,,948.0,A,BAO_0000218,CHEMBL626021,6095
Heart,50594,N,1,In vivo,,,846,,Biodistribution of [123I]- labeled compound in mice heart was determined after 1 min of administration; expressed in percent of injected dose per gram of organ,1,Mus musculus,Intermediate,,,,10090.0,,948.0,A,BAO_0000218,CHEMBL626022,6096
Heart,50594,N,1,In vivo,,,846,,Biodistribution of [123I]- labeled compound in mice heart was determined after 2 min of administration; expressed in percent of injected dose per gram of organ,1,Mus musculus,Intermediate,,,,10090.0,,948.0,A,BAO_0000218,CHEMBL626192,6097
,80682,N,1,,,,1276,,Cytotoxic activity was tested against human prostate cell line A-549 (lung carcinoma),1,Homo sapiens,Intermediate,,646.0,,9606.0,A549,,F,BAO_0000219,CHEMBL626193,6098
,80682,N,1,,,,3498,,Cytotoxicity against A-549 cell line in the purdue cell culture screen was determined,1,Homo sapiens,Expert,,646.0,,9606.0,A549,,F,BAO_0000219,CHEMBL626194,6099
,80682,N,1,,,,1169,,Cytotoxicity against human lung carcinoma A-549 cell lines,1,Homo sapiens,Intermediate,,646.0,,9606.0,A549,,F,BAO_0000219,CHEMBL626195,6100
,80682,N,1,,,,4450,,In vitro cytotoxic activity against A-549 (human lung carcinoma) cell line,1,Homo sapiens,Intermediate,,646.0,,9606.0,A549,,F,BAO_0000219,CHEMBL626196,6101
,80682,N,1,,,,358,,In vitro cytotoxicity against human lung carcinoma cell line A-549,1,Homo sapiens,Intermediate,,646.0,,9606.0,A549,,F,BAO_0000219,CHEMBL626197,6102
,80682,N,1,,,,358,,In vitro cytotoxicity against human lung carcinoma cell line A-549 at 3.6*10e-5 M,1,Homo sapiens,Intermediate,,646.0,,9606.0,A549,,F,BAO_0000219,CHEMBL626198,6103
,80682,N,1,,,,358,,In vitro cytotoxicity against human lung carcinoma cell line A-549 at 4.2*10e-5M,1,Homo sapiens,Intermediate,,646.0,,9606.0,A549,,F,BAO_0000219,CHEMBL626199,6104
,80682,N,1,,,,358,,In vitro cytotoxicity against human lung carcinoma cell line A-549 at 4.3*10e-5M,1,Homo sapiens,Intermediate,,646.0,,9606.0,A549,,F,BAO_0000219,CHEMBL626200,6105
,80682,N,1,,,,358,,In vitro cytotoxicity against human lung carcinoma cell line A-549 at 5.0*10e-5M,1,Homo sapiens,Intermediate,,646.0,,9606.0,A549,,F,BAO_0000219,CHEMBL626201,6106
,80682,N,1,,,,358,,In vitro cytotoxicity against human lung carcinoma cell line A-549 at 6.1*10e-5 M,1,Homo sapiens,Intermediate,,646.0,,9606.0,A549,,F,BAO_0000219,CHEMBL626202,6107
,80682,N,1,,,,358,,In vitro cytotoxicity against human lung carcinoma cell line A-549 at 7.4*10e-5 M,1,Homo sapiens,Intermediate,,646.0,,9606.0,A549,,F,BAO_0000219,CHEMBL626203,6108
,80682,N,1,,,,15167,,In vitro cytotoxicity against A-549 human lung cancer cells,1,Homo sapiens,Intermediate,,646.0,,9606.0,A549,,F,BAO_0000219,CHEMBL626204,6109
,80682,N,1,,,,4139,,In vitro cytotoxicity against human lung carcinoma (A-549) cell line,1,Homo sapiens,Intermediate,,646.0,,9606.0,A549,,F,BAO_0000219,CHEMBL624701,6110
,80682,N,1,,,,833,,In vitro cytotoxicity in human tumor lung carcinoma A-549 cell lines,1,Homo sapiens,Intermediate,,646.0,,9606.0,A549,,F,BAO_0000219,CHEMBL624702,6111
,80682,N,1,,,,15718,,Tested in vitro for cytotoxic activity against lung carcinoma (A-549) cell line,1,Homo sapiens,Expert,,646.0,,9606.0,A549,,F,BAO_0000219,CHEMBL624703,6112
,80682,N,1,,,,12373,,Tested in vitro for cytotoxicity against A-549 lung cancer cells,1,Homo sapiens,Intermediate,,646.0,,9606.0,A549,,F,BAO_0000219,CHEMBL624704,6113
,80682,N,1,,,,637,,The compound was tested for cytotoxicity against A-549 cell in human lung carcinoma,1,Homo sapiens,Intermediate,,646.0,,9606.0,A549,,F,BAO_0000219,CHEMBL624705,6114
,80682,N,1,,,,14867,,Cytotoxicity against human lung carcinoma cells (A-549) using SRB assay.,1,Homo sapiens,Expert,,646.0,,9606.0,A549,,F,BAO_0000219,CHEMBL624706,6115
,80682,N,1,,,,4461,,Antitumor cytotoxic activity against A-549 cell line was determined,1,Homo sapiens,Intermediate,,646.0,,9606.0,A549,,F,BAO_0000219,CHEMBL624707,6116
,80682,N,1,,,,5406,,"Tested for the cytotoxicity against the Non-small cell lung cancer cell line A-549, growth inhibition by 50% is reported",1,Homo sapiens,Intermediate,,646.0,,9606.0,A549,,F,BAO_0000219,CHEMBL624708,6117
,80682,N,1,,,,4457,,Compound was tested for cytotoxicity against A-549 human solid tumor cell line,1,Homo sapiens,Intermediate,,646.0,,9606.0,A549,,F,BAO_0000219,CHEMBL624709,6118
,80682,N,1,,,,1386,,Antineoplastic activity against A-549 (human lung carcinoma) cell line.,1,Homo sapiens,Expert,,646.0,,9606.0,A549,,F,BAO_0000219,CHEMBL884107,6119
,80682,N,1,,,,3265,,Antitumoral activity was assayed against A-549 cell line,1,Homo sapiens,Intermediate,,646.0,,9606.0,A549,,F,BAO_0000219,CHEMBL624710,6120
,80682,N,1,,,,2359,,Compound was evaluated for the cytotoxicity against A-549 tumor cell line after 3 days of incubation,1,Homo sapiens,Intermediate,,646.0,,9606.0,A549,,F,BAO_0000219,CHEMBL624711,6121
,80682,N,1,,,,4457,,Compound was tested for cytotoxicity against A-549 human solid tumor cell line,1,Homo sapiens,Intermediate,,646.0,,9606.0,A549,,F,BAO_0000219,CHEMBL624712,6122
,80682,N,1,,,,12454,,In vitro cytotoxicity against A549 (human lung carcinoma) cell line.,1,Homo sapiens,Expert,,646.0,,9606.0,A549,,F,BAO_0000219,CHEMBL624713,6123
,80682,N,1,,,,1481,,Compound was tested for inhibition of cell growth of A-549 cells,1,Homo sapiens,Intermediate,,646.0,,9606.0,A549,,F,BAO_0000219,CHEMBL624714,6124
,80682,N,1,,,,1750,,Compound was tested for its inhibitory effect on the growth of A-549 tumor cell line from lung.,1,Homo sapiens,Intermediate,,646.0,,9606.0,A549,,F,BAO_0000219,CHEMBL624715,6125
,80682,N,1,,,,5065,,Concentration required for 50% inhibition of growth in human lung carcinoma cell line was determined,1,Homo sapiens,Intermediate,,646.0,,9606.0,A549,,F,BAO_0000219,CHEMBL624716,6126
,80682,N,1,,,,808,,In vitro cytotoxicity against A549-human lung carcinoma cells.,1,Homo sapiens,Expert,,646.0,,9606.0,A549,,F,BAO_0000219,CHEMBL619505,6127
,80682,N,1,,,,16364,,Cytotoxic activity against cultured cells of A-549 human lung carcinoma.,1,Homo sapiens,Expert,,646.0,,9606.0,A549,,F,BAO_0000219,CHEMBL619506,6128
,80682,N,1,,,,1847,,Cytotoxic activity against A-549 cell lines.,1,Homo sapiens,Intermediate,,646.0,,9606.0,A549,,F,BAO_0000219,CHEMBL619507,6129
,80682,N,1,,,,1747,,Cytotoxicity was measured against neoplastic cultured A-549 cells of human lung carcinoma.,1,Homo sapiens,Expert,,646.0,,9606.0,A549,,F,BAO_0000219,CHEMBL619508,6130
,80682,N,1,,,,1003,,Cytotoxicity against human A549 non small cell lung cell lines,1,Homo sapiens,Intermediate,,646.0,,9606.0,A549,,F,BAO_0000219,CHEMBL619509,6131
,80682,N,1,,,,15313,,Inhibition of cell growth in (A-549) lung cell line,1,Homo sapiens,Expert,,646.0,,9606.0,A549,,F,BAO_0000219,CHEMBL619510,6132
,80682,N,1,,,,3122,,Growth inhibitory effect of compound was measured on A-549 human lung adenocarcinoma cancer cell line,1,Homo sapiens,Intermediate,,646.0,,9606.0,A549,,F,BAO_0000219,CHEMBL619511,6133
,80682,N,1,,,,16049,,In vitro antitumor activity against A-549 tumor cells.,1,Homo sapiens,Intermediate,,646.0,,9606.0,A549,,F,BAO_0000219,CHEMBL619512,6134
,80682,N,1,,,,17134,,In vitro antitumor effects against human A-549 cell lines.,1,Homo sapiens,Expert,,646.0,,9606.0,A549,,F,BAO_0000219,CHEMBL619513,6135
,80682,N,1,,,,6406,,In vitro cytotoxic activity of compound against A-549 cell line,1,Homo sapiens,Intermediate,,646.0,,9606.0,A549,,F,BAO_0000219,CHEMBL619514,6136
,80682,N,1,,,,627,,In vitro cytotoxicity against human lung carcinoma A-549 cell line,1,Homo sapiens,Intermediate,,646.0,,9606.0,A549,,F,BAO_0000219,CHEMBL619515,6137
,80682,N,1,,,,12307,,In vitro cytotoxicity against human non-small cell lung carcinoma A549,1,Homo sapiens,Intermediate,,646.0,,9606.0,A549,,F,BAO_0000219,CHEMBL619516,6138
,80682,N,1,,,,17861,,In vitro cytotoxicity against human A-549 cancer cell line was evaluated,1,Homo sapiens,Intermediate,,646.0,,9606.0,A549,,F,BAO_0000219,CHEMBL884005,6139
,80682,N,1,,,,6682,,In vitro cytotoxicity against the A-549 (human lung carcinoma) neoplastic cell line,1,Homo sapiens,Expert,,646.0,,9606.0,A549,,F,BAO_0000219,CHEMBL619517,6140
,80682,N,1,,,,6663,,Inhibitory concentration of compound against A-549 cell line,1,Homo sapiens,Intermediate,,646.0,,9606.0,A549,,F,BAO_0000219,CHEMBL619518,6141
,80682,N,1,,,,2454,,Tested for the cytostatic activity as inhibitory concentration against A-549 human pulmonary adenocarcinoma cells,1,Homo sapiens,Intermediate,,646.0,,9606.0,A549,,F,BAO_0000219,CHEMBL619519,6142
,80682,N,1,,,,14709,,cytotoxic activity against leukemia (A-549) cancer cell line,1,Homo sapiens,Intermediate,,646.0,,9606.0,A549,,F,BAO_0000219,CHEMBL876489,6143
,80682,N,1,,,,15718,,Tested in vitro for cytotoxic activity against lung carcinoma (A-549) cell line,1,Homo sapiens,Expert,,646.0,,9606.0,A549,,F,BAO_0000219,CHEMBL619520,6144
,80682,N,1,,,,15718,,Percent inhibition for cytotoxic activity against lung carcinoma (A-549) cell line,1,Homo sapiens,Intermediate,,646.0,,9606.0,A549,,F,BAO_0000219,CHEMBL619521,6145
,80682,N,1,,,,17130,,Cytotoxic activity of compound against A-549 cell lines at concentration of 0.1(ug/ml),1,Homo sapiens,Intermediate,,646.0,,9606.0,A549,,F,BAO_0000219,CHEMBL619522,6146
,80682,N,1,,,,17130,,Cytotoxic activity of compound against A-549 cell lines at concentration of 0.4(ug/ml),1,Homo sapiens,Intermediate,,646.0,,9606.0,A549,,F,BAO_0000219,CHEMBL619523,6147
,80682,N,1,,,,17130,,Cytotoxic activity of compound against A-549 cell lines at concentration of 1.1 (ug/ml),1,Homo sapiens,Intermediate,,646.0,,9606.0,A549,,F,BAO_0000219,CHEMBL619524,6148
,80682,N,1,,,,17130,,Cytotoxic activity of compound against A-549 cell lines at concentration of 10(ug/ml),1,Homo sapiens,Intermediate,,646.0,,9606.0,A549,,F,BAO_0000219,CHEMBL619525,6149
,80682,N,1,,,,6630,,Drug interaction towards A549 cell line was determined in terms of combination index in presence of Tometin; Not available,1,,Intermediate,,646.0,,,A549,,F,BAO_0000219,CHEMBL619526,6150
,80682,N,1,,,,16726,,Influence of PARP-1 cellular activity in human lung carcinoma A549 cells on %ADP Polymer formation at a concentration of 25 uM of the compound,1,Homo sapiens,Intermediate,,646.0,,9606.0,A549,,F,BAO_0000219,CHEMBL619527,6151
,80682,N,1,,,,17846,,Cytotoxicity against A549 cells; No cytotoxicity,1,Homo sapiens,Intermediate,,646.0,,9606.0,A549,,F,BAO_0000219,CHEMBL619528,6152
,80682,N,1,,,,3415,,Cytotoxicity against human lung carcinoma (A549) cell lines,1,Homo sapiens,Expert,,646.0,,9606.0,A549,,F,BAO_0000219,CHEMBL619529,6153
,80682,N,1,,,,3415,,Cytotoxicity against human lung carcinoma (A549) cell lines; Not active,1,Homo sapiens,Expert,,646.0,,9606.0,A549,,F,BAO_0000219,CHEMBL619530,6154
,80682,N,1,,,,5609,,In vitro anticancer activity against human lung (A549) cell line,1,Homo sapiens,Intermediate,,646.0,,9606.0,A549,,F,BAO_0000219,CHEMBL876490,6155
,80682,N,1,,,,17206,,Percent growth inhibition at 200 uM PARP inhibitor in A549 cells,1,Homo sapiens,Intermediate,,646.0,,9606.0,A549,,F,BAO_0000219,CHEMBL619531,6156
,80682,N,1,,,,17206,,Percent ADP-ribose polymer formation in presence of MNNG (25 uM) at 0..006 uM compound concentration in A549 cells,1,Homo sapiens,Intermediate,,646.0,,9606.0,A549,,F,BAO_0000219,CHEMBL619532,6157
,80682,N,1,,,,17206,,Percent ADP-ribose polymer formation in presence of MNNG (25 uM) at 0..03 uM compound concentration in A549 cells,1,Homo sapiens,Intermediate,,646.0,,9606.0,A549,,F,BAO_0000219,CHEMBL619533,6158
,80682,N,1,,,,17206,,Percent ADP-ribose polymer formation in presence of MNNG (25 uM) at 0..15 uM compound concentration in A549 cells,1,Homo sapiens,Intermediate,,646.0,,9606.0,A549,,F,BAO_0000219,CHEMBL619534,6159
,80682,N,1,,,,17206,,Percent ADP-ribose polymer formation in presence of MNNG (25 uM) at 0..4 uM compound concentration in A549 cells,1,Homo sapiens,Intermediate,,646.0,,9606.0,A549,,F,BAO_0000219,CHEMBL620164,6160
,80682,N,1,,,,17206,,Percent ADP-ribose polymer formation in presence of MNNG (25 uM) at 11 uM compound concentration in A549 cells,1,Homo sapiens,Intermediate,,646.0,,9606.0,A549,,F,BAO_0000219,CHEMBL620165,6161
,80682,N,1,,,,16295,,Inhibition of A549 human lung tumor cell proliferation,1,Homo sapiens,Expert,,646.0,,9606.0,A549,,F,BAO_0000219,CHEMBL620166,6162
,80682,N,1,,,,16825,,"Concentration required to inhibit the lung A549 cell growth by 50%,P53 status of cell line used was wild-type. ",1,Homo sapiens,Intermediate,,646.0,,9606.0,A549,,F,BAO_0000219,CHEMBL620167,6163
,80682,N,1,,,,3439,,In vitro cytotoxicity against human tumor cell line A549,1,Homo sapiens,Expert,,646.0,,9606.0,A549,,F,BAO_0000219,CHEMBL620168,6164
,80682,N,1,,,,10870,,In vitro growth inhibitory activity against A549 human nonsmall cell lung carcinoma cells. ,1,Homo sapiens,Intermediate,,646.0,,9606.0,A549,,F,BAO_0000219,CHEMBL620338,6165
,80682,N,1,,,,4845,,Inhibitory concentration of compound against proliferation of lung carcinoma A549 cell line,1,Homo sapiens,Intermediate,,646.0,,9606.0,A549,,F,BAO_0000219,CHEMBL620339,6166
,80682,N,1,,,,5822,,Inhibitory concentration (resynthesized pure material) against TNF-alpha induced apoptosis of A549 cells,1,Homo sapiens,Intermediate,,646.0,,9606.0,A549,,F,BAO_0000219,CHEMBL620340,6167
,80682,N,1,,,,5822,,Inhibitory concentration (solid phase) against TNF-alpha induced apoptosis of A549 cells,1,Homo sapiens,Intermediate,,646.0,,9606.0,A549,,F,BAO_0000219,CHEMBL620341,6168
,80682,N,1,,,,5822,,Inhibitory concentration (solid phase) against TNF-alpha induced apoptosis of A549 cells: Not tested,1,Homo sapiens,Intermediate,,646.0,,9606.0,A549,,F,BAO_0000219,CHEMBL876491,6169
,80682,N,1,,,,16381,,% inhibition against A549 cells (lung cancer) at 0.04 ug/mL,1,Homo sapiens,Intermediate,,646.0,,9606.0,A549,,F,BAO_0000219,CHEMBL620342,6170
,80682,N,1,,,,16381,,% inhibition against A549 cells (lung cancer) at 0.4 ug/mL,1,Homo sapiens,Intermediate,,646.0,,9606.0,A549,,F,BAO_0000219,CHEMBL620343,6171
,80682,N,1,,,,16381,,% inhibition against A549 cells (lung cancer) at 4 ug/mL,1,Homo sapiens,Intermediate,,646.0,,9606.0,A549,,F,BAO_0000219,CHEMBL620344,6172
,80682,N,1,,,,5609,,In vitro anticancer activity against human lung (A549) cell line,1,Homo sapiens,Intermediate,,646.0,,9606.0,A549,,F,BAO_0000219,CHEMBL620345,6173
,80682,N,1,,,,4644,,Inhibition of proliferation of A549 cells at concentration of 0.1 uM was determined,1,Homo sapiens,Intermediate,,646.0,,9606.0,A549,,F,BAO_0000219,CHEMBL620346,6174
,80682,N,1,,,,4644,,Inhibition of proliferation of A549 cells at concentration of 100 uM was determined,1,Homo sapiens,Intermediate,,646.0,,9606.0,A549,,F,BAO_0000219,CHEMBL620347,6175
,80682,N,1,,,,4644,,Inhibition of proliferation of A549 cells at concentration of 10 uM was determined,1,Homo sapiens,Intermediate,,646.0,,9606.0,A549,,F,BAO_0000219,CHEMBL620348,6176
,80682,N,1,,,,4644,,Inhibition of proliferation of A549 cells at concentration of 1 uM was determined,1,Homo sapiens,Intermediate,,646.0,,9606.0,A549,,F,BAO_0000219,CHEMBL620349,6177
,80682,N,1,,,,5822,,Inhibitory concentration (resynthesized pure material) against TNF-alpha induced apoptosis of A549 cells at 20 uM,1,Homo sapiens,Intermediate,,646.0,,9606.0,A549,,F,BAO_0000219,CHEMBL618667,6178
,80682,N,1,,,,3415,,Percentage inhibition of human lung carcinoma (A549) cell lines,1,Homo sapiens,Expert,,646.0,,9606.0,A549,,F,BAO_0000219,CHEMBL618668,6179
,80682,N,1,,,,16726,,Influence of PARP-1 cellular activity on NAD+ levels at a concentration of 25 uM of the compound,1,Homo sapiens,Intermediate,,646.0,,9606.0,A549,,F,BAO_0000219,CHEMBL876031,6180
,80682,N,1,,,,17206,,"Concentration that gives 50% growth inhibition in A549 cells, activity expressed as PF50 (TM); ND denotes not determined",1,Homo sapiens,Intermediate,,646.0,,9606.0,A549,,F,BAO_0000219,CHEMBL618759,6181
,80682,N,1,,,,17206,,Concentration that gives 50% growth inhibition (temozolomide alone/ (temozolomide + 0.4 uM of compound)) in A549 cells; ND denotes not determined,1,Homo sapiens,Intermediate,,646.0,,9606.0,A549,,F,BAO_0000219,CHEMBL618760,6182
,80682,N,1,,,,17206,,Concentration that gives 50% growth inhibition (topotecan alone/ (topotecan + 0.4 uM of compound)) in A549 cells; ND denotes not determined,1,Homo sapiens,Intermediate,,646.0,,9606.0,A549,,F,BAO_0000219,CHEMBL619000,6183
,80682,N,1,,,,17206,,"Concentration that gives 50% growth inhibition in A549 cells, activity expressed as PF50 (TM)",1,Homo sapiens,Intermediate,,646.0,,9606.0,A549,,F,BAO_0000219,CHEMBL619001,6184
,80682,N,1,,,,17206,,"Concentration that gives 50% growth inhibition in A549 cells, activity expressed as PF50 (TP) at 0.006 uM",1,Homo sapiens,Intermediate,,646.0,,9606.0,A549,,F,BAO_0000219,CHEMBL619002,6185
,80682,N,1,,,,17206,,"Concentration that gives 50% growth inhibition in A549 cells, activity expressed as PF50 (TP) at 0.03 uM",1,Homo sapiens,Intermediate,,646.0,,9606.0,A549,,F,BAO_0000219,CHEMBL619003,6186
,80682,N,1,,,,17206,,"Concentration that gives 50% growth inhibition in A549 cells, activity expressed as PF50 (TP) at 0.15 uM",1,Homo sapiens,Intermediate,,646.0,,9606.0,A549,,F,BAO_0000219,CHEMBL619597,6187
,80682,N,1,,,,17206,,"Concentration that gives 50% growth inhibition in A549 cells, activity expressed as PF50 (TP) at 0.4 uM",1,Homo sapiens,Intermediate,,646.0,,9606.0,A549,,F,BAO_0000219,CHEMBL619598,6188
,80682,N,1,,,,17206,,Concentration that gives 50% growth inhibition (temozolomide alone/ (temozolomide + 0.4 uM of compound)) in A549 cells,1,Homo sapiens,Intermediate,,646.0,,9606.0,A549,,F,BAO_0000219,CHEMBL619599,6189
,80682,N,1,,,,17206,,Concentration that gives 50% growth inhibition (topotecan alone/ (topotecan + 0.4 uM of compound)) in A549 cells,1,Homo sapiens,Intermediate,,646.0,,9606.0,A549,,F,BAO_0000219,CHEMBL619600,6190
,80682,N,1,,,,16726,,Cytotoxicity potentiation of Topotecan in human lung carcinoma A549 cells by the compound as potentiation factor at 50% growth inhibition,1,Homo sapiens,Intermediate,,646.0,,9606.0,A549,,F,BAO_0000219,CHEMBL619601,6191
,80682,N,1,,,,17206,,Effect on NAD+ depletion (% remaining versus vehicle control) in presence of MNNG (25 uM) at 0.006 uM compound concentration in A549 cells,1,Homo sapiens,Intermediate,,646.0,,9606.0,A549,,F,BAO_0000219,CHEMBL619602,6192
,80682,N,1,,,,17206,,Effect on NAD+ depletion (% remaining versus vehicle control) in presence of MNNG (25 uM) at 0.03 uM compound concentration in A549 cells,1,Homo sapiens,Intermediate,,646.0,,9606.0,A549,,F,BAO_0000219,CHEMBL619603,6193
,80682,N,1,,,,17206,,Effect on NAD+ depletion (% remaining versus vehicle control) in presence of MNNG (25 uM) at 0.15 uM compound concentration in A549 cells,1,Homo sapiens,Intermediate,,646.0,,9606.0,A549,,F,BAO_0000219,CHEMBL619604,6194
,80682,N,1,,,,17206,,Effect on NAD+ depletion (% remaining versus vehicle control) in presence of MNNG (25 uM) at 0.4 uM compound concentration in A549 cells,1,Homo sapiens,Intermediate,,646.0,,9606.0,A549,,F,BAO_0000219,CHEMBL619605,6195
,50588,N,1,In vivo,,,6084,,Pharmacokinetic activity (Cmax) (10 mg/kg) was determined in dog,1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL619606,6196
,50588,N,1,In vivo,,,6084,,Pharmacokinetic activity (Cmax) in dog,1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL876032,6197
,50588,N,1,In vivo,,,4809,,Pharmacokinetic parameter Cmax was determined in Beagle dogs after (iv) administration of a dose of 28 (uM/kg),1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL619607,6198
,50588,N,1,In vivo,,,5983,,Pharmacokinetic property (Cmax) was measured in dog at the dose of 0.032 mg/kg,1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL619608,6199
,50588,N,1,In vivo,,,6251,,Plasma clearance rate by iv administration in dog at a dose of 6 mg/kg,1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL619609,6200
Plasma,50588,N,1,In vivo,,,5932,,Cmax in dog plasma after 30mg/kg oral dose,1,Canis lupus familiaris,Intermediate,,,,9615.0,,1969.0,A,BAO_0000218,CHEMBL619610,6201
Blood,50588,N,1,In vivo,,,4273,,Tested for the peak blood level in dog,1,Canis lupus familiaris,Intermediate,,,,9615.0,,178.0,A,BAO_0000218,CHEMBL619611,6202
,50588,N,1,In vivo,,,5313,,"Tested for the pharmacokinetic data, maximum concentration (Cmax) in dog",1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL619612,6203
,50588,N,1,In vivo,,,5313,,"Tested for the pharmacokinetic data, maximum concentration (Cmax) in dog at dosage of 10 mpk",1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL619613,6204
Blood,50588,N,1,In vivo,,,6221,,The peak blood concentration after 5 hr administration (2.5 mg/kg) in dog was determined,1,Canis lupus familiaris,Intermediate,,,,9615.0,,178.0,A,BAO_0000218,CHEMBL619614,6205
,50588,N,1,,,,4709,,Concentration in the plasma after intravenous administration of 1 mg/kg in dog,1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL619615,6206
,50588,N,1,,,,167,,Compound was evaluated for Plasma levels upon oral administration at 30 mg/kg in Dog at maximum of 0.3 hours,1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL619616,6207
Plasma,50588,N,1,,,,6241,,Final plasma concentration in dogs after oral administration at 1 mg/kg,1,Canis lupus familiaris,Intermediate,,,,9615.0,,1969.0,A,BAO_0000218,CHEMBL619617,6208
,50588,N,1,,,,344,,Plasma concentration in dogs when measured 1 and 5 hours following initiation of reperfusion at 300 min,1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL619618,6209
,50588,N,1,,,,344,,Plasma concentration in dogs when measured 1 and 5 hours following initiation of reperfusion at 30 min,1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL876033,6210
,50588,N,1,,,,344,,Plasma concentration in dogs when measured 1 and 5 hours following initiation of reperfusion at 60 min,1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL619619,6211
,50588,N,1,,,,2189,,Percent of radioactive dose in urine and faeces excreted in 0-24 hr by dogs,1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL619620,6212
Urine,50588,N,1,,,,2189,,Percent of radioactive dose in urine and feces excreted by 0-24 hr in dogs,1,Canis lupus familiaris,Intermediate,,,,9615.0,,1088.0,A,BAO_0000218,CHEMBL619621,6213
Urine,50588,N,1,,,,2189,,Percent of radioactive dose in urine and feces excreted by 0-24 hr in dogs; NA is <10% inhibition at 1 uM for binding data,1,Canis lupus familiaris,Intermediate,,,,9615.0,,1088.0,A,BAO_0000218,CHEMBL619622,6214
Urine,50588,N,1,,,,2189,,Percent of radioactive dose in urine and feces excreted in 0-24 hr by dogs; NA is <10% inhibition at 1 uM for binding data,1,Canis lupus familiaris,Intermediate,,,,9615.0,,1088.0,A,BAO_0000218,CHEMBL618874,6215
,50588,N,1,In vivo,,,4257,,Absolute bioavailability was evaluated in dog,1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL618875,6216
,50588,N,1,In vivo,,,6221,,Bioavailability after oral administration (2.5 mg/kg) in dog was determined,1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL618876,6217
,50588,N,1,In vivo,,,6215,,Bioavailability after peroral administration (1 mg/kg) was determined in dog,1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL618877,6218
,50588,N,1,In vivo,,,17267,,Bioavailability in dog,1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL618878,6219
,50588,N,1,In vivo,,,6621,,Bioavailability in dog,1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL618879,6220
,50588,N,1,In vivo,,,3854,,Bioavailability after intravenous administration in dogs,1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL618880,6221
,50588,N,1,In vivo,,,3854,,Bioavailability after peroral administration in dogs,1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL618881,6222
,50588,N,1,In vivo,,,5007,,Bioavailability in dog (dose 5 mg/kg p.o. and 2 mg/kg i.v.),1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL618882,6223
,50588,N,1,In vivo,,,4333,,Bioavailability in dog (Beagle) (male) (dose 3 mg/kg i.v. and 10 mg/kg p.o.) measured from 1 to 24 hr,1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL624226,6224
Plasma,50588,N,1,In vivo,,,4333,,Bioavailability in plasma of male Beagle dogs treated with 3 mg/kg (i.v.) and 10 mg/kg (p.o.) measured from 1 to 24 hr; ND indicates not determined,1,Canis lupus familiaris,Intermediate,,,,9615.0,,1969.0,A,BAO_0000218,CHEMBL624227,6225
,50588,N,1,In vivo,,,5006,,Bioavailability,1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL624228,6226
,50588,N,1,In vivo,,,5199,,Bioavailability,1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL624229,6227
,50588,N,1,In vivo,,,4368,,Bioavailability by intravenous administration of 1.2 mg/kg in dog,1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL624230,6228
,50588,N,1,In vivo,,,3771,,Bioavailability in dog,1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL624231,6229
,50588,N,1,In vivo,,,4953,,Bioavailability in dog,1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL624232,6230
,50588,N,1,In vivo,,,5064,,Bioavailability in dog,1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL625127,6231
,50588,N,1,In vivo,,,17657,,Bioavailability in dog,1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL625128,6232
,50588,N,1,In vivo,,,17796,,Bioavailability in dog,1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL621675,6233
,50588,N,1,In vivo,,,17853,,Bioavailability in dog (p.o.) at 2.0 mpk,1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL621676,6234
,50588,N,1,In vivo,,,4521,,Bioavailability in dog (dose 2 mg/kg p.o. and 0.5 mg/kg i.v.),1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL621677,6235
,50588,N,1,In vivo,,,4521,,Bioavailability in dog after 2 mg/kg by oral and 0.5 mg/kg by intravenous administration; ND is not determined,1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL621678,6236
,50588,N,1,In vivo,,,5006,,Bioavailability in dog,1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL621679,6237
,50588,N,1,In vivo,,,16365,,Bioavailability was evaluated after oral administration in dog,1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL621680,6238
,50588,N,1,In vivo,,,1916,,Bioavailability was evaluated against Beagle dog at a dose of 15 mg/kg after po administration,1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL621681,6239
,50588,N,1,In vivo,,,1918,,Bioavailability was evaluated in dog,1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL876740,6240
,50588,N,1,In vivo,,,4239,,Bioavailability in dog,1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL621682,6241
,50588,N,1,In vivo,,,6505,,Bioavailability in dog,1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL621683,6242
,50588,N,1,In vivo,,,5334,,Bioavailability was reported after intravenous administration at a dose of 1 mg/kg in Beagle dog (male),1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL621684,6243
,50588,N,1,In vivo,,,5334,,Bioavailability was reported after oral administration at a dose of 2 mg/kg in Beagle dog (male),1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL621685,6244
,50588,N,1,In vivo,,,4809,,Bioavailability was determined in Beagle dogs after (iv) administration of a dose of 28 (uM/kg),1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL621686,6245
,50588,N,1,In vivo,,,6348,,Bioavailability was determined in dog after 1 mg/kg (i.v.) and 5 mg/kg (p.o.) administration,1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL621687,6246
,50588,N,1,In vivo,,,6005,,Bioavailability was evaluated in dog after peroral administration at a dose of 1 mg/kg,1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL621688,6247
,50588,N,1,In vivo,,,17804,,Bioavailability of compound in dog was determined after peroral administration,1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL621689,6248
,50588,N,1,In vivo,,,3184,,Oral bioavailability in dog,1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL621690,6249
,50588,N,1,In vivo,,,1806,,Compound was evaluated for oral bioavailability at different dose 27.5 mg/kg DMP323 equiv in dogs,1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL621691,6250
,50588,N,1,In vivo,,,1806,,Compound was evaluated for oral bioavailability at different dose 7.7 mg/kg DMP323 equiv in dogs,1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL875941,6251
,50588,N,1,In vivo,,,1806,,Compound was evaluated for oral bioavailability in dogs; 37-38 %,1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL621692,6252
,50588,N,1,In vivo,,,4839,,Bioavailability in dog,1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL621693,6253
,50588,N,1,In vivo,,,5017,,Oral bioavailability in dog (1 mg/kg p.o. and 0.2 mg/kg i.v.),1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL621694,6254
Heart,50594,N,1,In vivo,,,846,,Biodistribution of [123I]- labeled compound in mice heart was determined after 30 sec of administration; expressed in percent of injected dose per gram of organ,1,Mus musculus,Intermediate,,,,10090.0,,948.0,A,BAO_0000218,CHEMBL621695,6255
Heart,50594,N,1,In vivo,,,846,,Biodistribution of [123I]- labeled compound in mice heart was determined after 5 min of administration; expressed in percent of injected dose per gram of organ,1,Mus musculus,Intermediate,,,,10090.0,,948.0,A,BAO_0000218,CHEMBL621696,6256
Kidney,50594,N,1,In vivo,,,846,,Biodistribution of [123I]- labeled compound in mice kidneys was determined after 1 min of administration; expressed in percent of injected dose per gram of organ,1,Mus musculus,Intermediate,,,,10090.0,,2113.0,A,BAO_0000218,CHEMBL621697,6257
Kidney,50594,N,1,In vivo,,,846,,Biodistribution of [123I]- labeled compound in mice kidneys was determined after 10 min of administration; expressed in percent of injected dose per gram of organ,1,Mus musculus,Intermediate,,,,10090.0,,2113.0,A,BAO_0000218,CHEMBL621698,6258
Kidney,50594,N,1,In vivo,,,846,,Biodistribution of [123I]- labeled compound in mice kidneys was determined after 15 sec of administration; expressed in percent of injected dose per gram of organ,1,Mus musculus,Intermediate,,,,10090.0,,2113.0,A,BAO_0000218,CHEMBL623420,6259
Kidney,50594,N,1,In vivo,,,846,,Biodistribution of [123I]- labeled compound in mice kidneys was determined after 2 min of administration; expressed in percent of injected dose per gram of organ,1,Mus musculus,Intermediate,,,,10090.0,,2113.0,A,BAO_0000218,CHEMBL623421,6260
Kidney,50594,N,1,In vivo,,,846,,Biodistribution of [123I]- labeled compound in mice kidneys was determined after 30 sec of administration; expressed in percent of injected dose per gram of organ,1,Mus musculus,Intermediate,,,,10090.0,,2113.0,A,BAO_0000218,CHEMBL623422,6261
Kidney,50594,N,1,In vivo,,,846,,Biodistribution of [123I]- labeled compound in mice kidneys was determined after 5 min of administration; expressed in percent of injected dose per gram of organ,1,Mus musculus,Intermediate,,,,10090.0,,2113.0,A,BAO_0000218,CHEMBL623423,6262
Liver,50594,N,1,In vivo,,,846,,Biodistribution of [123I]- labeled compound in mice liver was determined after 1 min of administration; expressed in percent of injected dose per gram of organ,1,Mus musculus,Intermediate,,,,10090.0,,2107.0,A,BAO_0000218,CHEMBL623424,6263
Liver,50594,N,1,In vivo,,,846,,Biodistribution of [123I]- labeled compound in mice liver was determined after 10 min of administration; expressed in percent of injected dose per gram of organ,1,Mus musculus,Intermediate,,,,10090.0,,2107.0,A,BAO_0000218,CHEMBL623425,6264
Liver,50594,N,1,In vivo,,,846,,Biodistribution of [123I]- labeled compound in mice liver was determined after 15 sec of administration; expressed in percent of injected dose per gram of organ,1,Mus musculus,Intermediate,,,,10090.0,,2107.0,A,BAO_0000218,CHEMBL623426,6265
Liver,50594,N,1,In vivo,,,846,,Biodistribution of [123I]- labeled compound in mice liver was determined after 2 min of administration; expressed in percent of injected dose per gram of organ,1,Mus musculus,Intermediate,,,,10090.0,,2107.0,A,BAO_0000218,CHEMBL623427,6266
Liver,50594,N,1,In vivo,,,846,,Biodistribution of [123I]- labeled compound in mice liver was determined after 30 sec of administration; expressed in percent of injected dose per gram of organ,1,Mus musculus,Intermediate,,,,10090.0,,2107.0,A,BAO_0000218,CHEMBL623428,6267
Liver,50594,N,1,In vivo,,,846,,Biodistribution of [123I]- labeled compound in mice liver was determined after 5 min of administration; expressed in percent of injected dose per gram of organ,1,Mus musculus,Intermediate,,,,10090.0,,2107.0,A,BAO_0000218,CHEMBL875947,6268
Lung,50594,N,1,In vivo,,,846,,Biodistribution of [123I]- labeled compound in mice lungs was determined after 1 min of administration; expressed in percent of injected dose per gram of organ,1,Mus musculus,Intermediate,,,,10090.0,,2048.0,A,BAO_0000218,CHEMBL623429,6269
Lung,50594,N,1,In vivo,,,846,,Biodistribution of [123I]- labeled compound in mice lungs was determined after 10 min of administration; expressed in percent of injected dose per gram of organ,1,Mus musculus,Intermediate,,,,10090.0,,2048.0,A,BAO_0000218,CHEMBL623430,6270
Lung,50594,N,1,In vivo,,,846,,Biodistribution of [123I]- labeled compound in mice lungs was determined after 15 sec of administration; expressed in percent of injected dose per gram of organ,1,Mus musculus,Intermediate,,,,10090.0,,2048.0,A,BAO_0000218,CHEMBL622588,6271
Lung,50594,N,1,In vivo,,,846,,Biodistribution of [123I]- labeled compound in mice lungs was determined after 2 min of administration; expressed in percent of injected dose per gram of organ,1,Mus musculus,Intermediate,,,,10090.0,,2048.0,A,BAO_0000218,CHEMBL622589,6272
Lung,50594,N,1,In vivo,,,846,,Biodistribution of [123I]- labeled compound in mice lungs was determined after 30 sec of administration; expressed in percent of injected dose per gram of organ,1,Mus musculus,Intermediate,,,,10090.0,,2048.0,A,BAO_0000218,CHEMBL622751,6273
Lung,50594,N,1,In vivo,,,846,,Biodistribution of [123I]- labeled compound in mice lungs was determined after 5 min of administration; expressed in percent of injected dose per gram of organ,1,Mus musculus,Intermediate,,,,10090.0,,2048.0,A,BAO_0000218,CHEMBL622752,6274
,50594,N,1,,,,6599,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice blood bearing S180 tumor cell line for 1 hour,1,Mus musculus,Intermediate,,42.0,,10090.0,CCRF S-180,,A,BAO_0000218,CHEMBL622753,6275
,50594,N,1,,,,6599,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice blood bearing S180 tumor cell line for 2 hours,1,Mus musculus,Intermediate,,42.0,,10090.0,CCRF S-180,,A,BAO_0000218,CHEMBL622647,6276
,50594,N,1,,,,6599,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice blood bearing S180 tumor cell line for 30 minutes,1,Mus musculus,Intermediate,,42.0,,10090.0,CCRF S-180,,A,BAO_0000218,CHEMBL875163,6277
,50594,N,1,,,,6599,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice blood bearing S180 tumor cell line for 4 hours,1,Mus musculus,Intermediate,,42.0,,10090.0,CCRF S-180,,A,BAO_0000218,CHEMBL622648,6278
,50594,N,1,,,,6599,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice blood bearing S180 tumor cell line for 8 hours,1,Mus musculus,Intermediate,,42.0,,10090.0,CCRF S-180,,A,BAO_0000218,CHEMBL622649,6279
Brain,50594,N,1,,,,6599,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice brain bearing S180 tumor cell line for 1 hour,1,Mus musculus,Intermediate,,42.0,,10090.0,CCRF S-180,955.0,A,BAO_0000218,CHEMBL622650,6280
Brain,50594,N,1,,,,6599,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice brain bearing S180 tumor cell line for 2 hours,1,Mus musculus,Intermediate,,42.0,,10090.0,CCRF S-180,955.0,A,BAO_0000218,CHEMBL622651,6281
Brain,50594,N,1,,,,6599,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice brain bearing S180 tumor cell line for 30 minutes,1,Mus musculus,Intermediate,,42.0,,10090.0,CCRF S-180,955.0,A,BAO_0000218,CHEMBL622652,6282
Brain,50594,N,1,,,,6599,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice brain bearing S180 tumor cell line for 4 hours,1,Mus musculus,Intermediate,,42.0,,10090.0,CCRF S-180,955.0,A,BAO_0000218,CHEMBL622653,6283
Brain,50594,N,1,,,,6599,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice brain bearing S180 tumor cell line for 8 hours,1,Mus musculus,Intermediate,,42.0,,10090.0,CCRF S-180,955.0,A,BAO_0000218,CHEMBL622654,6284
Heart,50594,N,1,,,,6599,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice heart bearing S180 tumor cell line for 1 hour,1,Mus musculus,Intermediate,,42.0,,10090.0,CCRF S-180,948.0,A,BAO_0000218,CHEMBL622655,6285
Heart,50594,N,1,,,,6599,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice heart bearing S180 tumor cell line for 2 hours,1,Mus musculus,Intermediate,,42.0,,10090.0,CCRF S-180,948.0,A,BAO_0000218,CHEMBL622656,6286
Heart,50594,N,1,,,,6599,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice heart bearing S180 tumor cell line for 30 minutes,1,Mus musculus,Intermediate,,42.0,,10090.0,CCRF S-180,948.0,A,BAO_0000218,CHEMBL622657,6287
Heart,50594,N,1,,,,6599,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice heart bearing S180 tumor cell line for 4 hours,1,Mus musculus,Intermediate,,42.0,,10090.0,CCRF S-180,948.0,A,BAO_0000218,CHEMBL622658,6288
Heart,50594,N,1,,,,6599,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice heart bearing S180 tumor cell line for 8 hours,1,Mus musculus,Intermediate,,42.0,,10090.0,CCRF S-180,948.0,A,BAO_0000218,CHEMBL622659,6289
Kidney,50594,N,1,,,,6599,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice kidney bearing S180 tumor cell line for 1 hour,1,Mus musculus,Intermediate,,42.0,,10090.0,CCRF S-180,2113.0,A,BAO_0000218,CHEMBL624630,6290
Kidney,50594,N,1,,,,6599,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice kidney bearing S180 tumor cell line for 2 hours,1,Mus musculus,Intermediate,,42.0,,10090.0,CCRF S-180,2113.0,A,BAO_0000218,CHEMBL624631,6291
Kidney,50594,N,1,,,,6599,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice kidney bearing S180 tumor cell line for 30 minutes,1,Mus musculus,Intermediate,,42.0,,10090.0,CCRF S-180,2113.0,A,BAO_0000218,CHEMBL624632,6292
,80682,N,1,,,,17130,,Cytotoxic activity of compound against A-549 cell lines at concentration of 10(ug/ml) on,1,Homo sapiens,Intermediate,,646.0,,9606.0,A549,,F,BAO_0000219,CHEMBL624633,6293
,80682,N,1,,,,17130,,Cytotoxic activity of compound against A-549 cell lines at concentration of 10(ug/ml)on,1,Homo sapiens,Intermediate,,646.0,,9606.0,A549,,F,BAO_0000219,CHEMBL624634,6294
,80682,N,1,,,,17130,,Cytotoxic activity of compound against A-549 cell lines at concentration of 3.3 (ug/ml),1,Homo sapiens,Intermediate,,646.0,,9606.0,A549,,F,BAO_0000219,CHEMBL624635,6295
,80682,N,1,,,,17130,,Cytotoxic activity of compound against A-549 cell lines at concentration of 3.3 (ug/ml)),1,Homo sapiens,Intermediate,,646.0,,9606.0,A549,,F,BAO_0000219,CHEMBL624636,6296
,80682,N,1,,,,3263,,Antineoplastic activity against A-549 (human lung carcinoma) cell line.,1,Homo sapiens,Expert,,646.0,,9606.0,A549,,F,BAO_0000219,CHEMBL857055,6297
,80682,N,1,,,,6663,,In vitro rate of inhibition of A-549 tumor cell growth at 10E-4 mol/L,1,Homo sapiens,Expert,,646.0,,9606.0,A549,,F,BAO_0000219,CHEMBL624637,6298
,80682,N,1,,,,6663,,In vitro rate of inhibition of A-549 tumor cell growth at 10E-5 mol/L,1,Homo sapiens,Expert,,646.0,,9606.0,A549,,F,BAO_0000219,CHEMBL624638,6299
,80682,N,1,,,,6663,,In vitro rate of inhibition of A-549 tumor cell growth at 10E-6 mol/L,1,Homo sapiens,Expert,,646.0,,9606.0,A549,,F,BAO_0000219,CHEMBL874366,6300
,80682,N,1,,,,6663,,In vitro rate of inhibition of A-549 tumor cell growth at 10E-7 mol/L,1,Homo sapiens,Expert,,646.0,,9606.0,A549,,F,BAO_0000219,CHEMBL624639,6301
,80682,N,1,,,,6663,,In vitro rate of inhibition of A-549 tumor cell growth at 10E-8 mol/L,1,Homo sapiens,Expert,,646.0,,9606.0,A549,,F,BAO_0000219,CHEMBL624640,6302
,80682,N,1,,,,6663,,Rate of inhibition of A-549 tumor cell growth at a concentration of 0.0625 uM,1,Homo sapiens,Intermediate,,646.0,,9606.0,A549,,F,BAO_0000219,CHEMBL624641,6303
,80682,N,1,,,,6663,,Rate of inhibition of A-549 tumor cell growth at a concentration of 0.125 uM,1,Homo sapiens,Intermediate,,646.0,,9606.0,A549,,F,BAO_0000219,CHEMBL624642,6304
,80682,N,1,,,,6663,,Rate of inhibition of A-549 tumor cell growth at a concentration of 0.25 uM,1,Homo sapiens,Intermediate,,646.0,,9606.0,A549,,F,BAO_0000219,CHEMBL624643,6305
,80682,N,1,,,,6663,,Rate of inhibition of A-549 tumor cell growth at a concentration of 0.5 uM,1,Homo sapiens,Intermediate,,646.0,,9606.0,A549,,F,BAO_0000219,CHEMBL624644,6306
,80682,N,1,,,,6663,,Rate of inhibition of A-549 tumor cell growth at a concentration of 1 uM,1,Homo sapiens,Intermediate,,646.0,,9606.0,A549,,F,BAO_0000219,CHEMBL624645,6307
,80682,N,1,,,,3983,,The compound was evaluated for its cytotoxic potency against A-549 cell line,1,Homo sapiens,Intermediate,,646.0,,9606.0,A549,,F,BAO_0000219,CHEMBL619445,6308
,80682,N,1,,,,11141,,Cytotoxic concentration required to inhibit 50% cell growth in A-549 lung carcinoma cell lines,1,Homo sapiens,Expert,,646.0,,9606.0,A549,,F,BAO_0000219,CHEMBL839886,6309
,80682,N,1,,,,5076,,Cytotoxic activity of compound against A-549 tumor cell line.,1,Homo sapiens,Intermediate,,646.0,,9606.0,A549,,F,BAO_0000219,CHEMBL619446,6310
,80682,N,1,,,,3311,,In vitro cytotoxicity against Lung A-549 human tumors following a 6 day exposure.,1,Homo sapiens,Intermediate,,646.0,,9606.0,A549,,F,BAO_0000219,CHEMBL619447,6311
,80682,N,1,,,,3311,,In vitro cytotoxicity against Lung A-549 human tumors following a 2 day exposure.,1,Homo sapiens,Intermediate,,646.0,,9606.0,A549,,F,BAO_0000219,CHEMBL619448,6312
,80682,N,1,,,,3311,,In vitro cytotoxicity against Lung A-549 human tumors following a 2 day exposure; ND is no data,1,Homo sapiens,Intermediate,,646.0,,9606.0,A549,,F,BAO_0000219,CHEMBL619449,6313
,80682,N,1,,,,5076,,Cytotoxic activity of compound against A-549 tumor cell line at conc. of 20 ug/mL,1,Homo sapiens,Intermediate,,646.0,,9606.0,A549,,F,BAO_0000219,CHEMBL619450,6314
,80682,N,1,,,,4150,,Compound was tested for cytotoxic activity against A-549 human lung carcinoma (ATCC:CCL-185),1,Homo sapiens,Intermediate,,646.0,,9606.0,A549,,F,BAO_0000219,CHEMBL619451,6315
,80682,N,1,,,,2150,,In vitro inhibitory concentration against cell culture of A-549 human lung carcinoma,1,Homo sapiens,Expert,,646.0,,9606.0,A549,,F,BAO_0000219,CHEMBL619452,6316
,80682,N,1,,,,4644,,Concentration for in vitro cytotoxicity against A-549 human lung tumor cells,1,Homo sapiens,Intermediate,,646.0,,9606.0,A549,,F,BAO_0000219,CHEMBL619453,6317
,80682,N,1,,,,263,,Dose required for in vitro cytotoxic activity against A-549 lung carcinoma cells at concentration of 10 ug/ml; NA is no cytotoxicity,1,Homo sapiens,Intermediate,,646.0,,9606.0,A549,,F,BAO_0000219,CHEMBL874367,6318
,80682,N,1,,,,11333,,Cytotoxic concentration against A-549 tumor cells.,1,Homo sapiens,Intermediate,,646.0,,9606.0,A549,,F,BAO_0000219,CHEMBL619454,6319
,80682,N,1,,,,11333,,Cytotoxic concentration against A-549 tumor cells; Inactive at 10 ug/mL.,1,Homo sapiens,Intermediate,,646.0,,9606.0,A549,,F,BAO_0000219,CHEMBL619455,6320
,80682,N,1,,,,15895,,"Cytotoxicity against NCI tumor panel, A-549/ATCC non small-cell lung cancer cell line",1,Homo sapiens,Intermediate,,646.0,,9606.0,A549,,F,BAO_0000219,CHEMBL619456,6321
,50191,N,1,,,,16677,,Minimum inhibitory concentration (lowest peptide concentration) required to prevent visible bacterial growth after 18 hr of incubation at 37 C in Mueller-Hinton broth against Acinetobacter baumannii 118A,1,Acinetobacter baumannii,Expert,,,,470.0,,,F,BAO_0000218,CHEMBL619457,6322
,50192,N,1,,,,10624,,Activity against Acinetobacter calcoaceticus (AC54),1,Acinetobacter calcoaceticus,Intermediate,,,,471.0,,,F,BAO_0000218,CHEMBL619458,6323
,50274,N,1,,,,16717,,In vitro antifungal activity against Aspergillus flavus CM74,1,Aspergillus flavus,Expert,,,,5059.0,,,F,BAO_0000218,CHEMBL619459,6324
,50274,N,1,,,,16717,,In vitro antifungal activity against Aspergillus flavus CM74,1,Aspergillus flavus,Expert,,,,5059.0,,,F,BAO_0000218,CHEMBL619460,6325
,50416,N,1,,,,5513,,Inhibitory activity tested against Aspergillus fumigatus at 256 ug/mL concentration,1,Aspergillus fumigatus,Intermediate,,,,746128.0,,,F,BAO_0000218,CHEMBL619461,6326
,50416,N,1,,,,15962,,In vitro minimum fungicidal concentration required to inhibit Aspergillus fumigatus(MFC),1,Aspergillus fumigatus,Intermediate,,,,746128.0,,,F,BAO_0000218,CHEMBL619462,6327
,50416,N,1,,,,15962,,Antimicrobial activity against Aspergillus fumigatus (MIC),1,Aspergillus fumigatus,Intermediate,,,,746128.0,,,F,BAO_0000218,CHEMBL620388,6328
,50416,N,1,,,,15962,,Antimicrobial activity against Aspergillus fumigatus (MIC),1,Aspergillus fumigatus,Intermediate,,,,746128.0,,,F,BAO_0000218,CHEMBL620389,6329
,50416,N,1,,,,15962,,In vitro antimicrobial activity against Aspergillus fumigatus (MIC),1,Aspergillus fumigatus,Intermediate,,,,746128.0,,,F,BAO_0000218,CHEMBL620390,6330
,50416,N,1,,,,16717,,In vitro antifungal activity against Aspergillus fumigatus 48238E,1,Aspergillus fumigatus,Expert,,,,746128.0,,,F,BAO_0000218,CHEMBL620391,6331
,50416,N,1,,,,16717,,In vitro antifungal activity against Aspergillus fumigatus 48238E,1,Aspergillus fumigatus,Expert,,,,746128.0,,,F,BAO_0000218,CHEMBL621073,6332
,50296,N,1,,,,8117,,Compound is evaluated for plaque-bactericidal index (PBI) against Actinomyces naeslundii 631,1,Actinomyces naeslundii,Intermediate,,,,1655.0,,,F,BAO_0000218,CHEMBL621074,6333
,50366,N,1,,,,8117,,Compound is evaluated for plaque-bactericidal index (PBI) against Actinomyces viscosus M-100,1,Actinomyces viscosus,Intermediate,,,,1656.0,,,F,BAO_0000218,CHEMBL621075,6334
,50535,N,1,,,,15472,,Tested in vivo for Acanthocheilonema viteae at 200 mg/kg X 5 days(perorally),1,Acanthocheilonema viteae,Intermediate,,,,6277.0,,,F,BAO_0000218,CHEMBL619554,6335
,50535,N,1,,,,15472,,Tested in vivo for Acanthocheilonema viteae at 200 mg/kg X 5 days(perorally),1,Acanthocheilonema viteae,Intermediate,,,,6277.0,,,F,BAO_0000218,CHEMBL619555,6336
,50169,N,1,,,,16443,,Antibacterial activity determined as minimal inhibitory concentration (MIC) against Actinobacillus actinomycetecommitans ATCC 29527,1,Aggregatibacter actinomycetemcomitans,Intermediate,,,,714.0,,,F,BAO_0000218,CHEMBL619556,6337
,50169,N,1,,,,16443,,Antibacterial activity determined as minimal inhibitory concentration (MIC) against Actinobacillus actinomycetecommitans ATCC 29527; value ranges from 1-2,1,Aggregatibacter actinomycetemcomitans,Intermediate,,,,714.0,,,F,BAO_0000218,CHEMBL619557,6338
,50169,N,1,,,,16443,,Antibacterial activity determined as minimal inhibitory concentration (MIC) against Actinobacillus actinomycetecommitans ATCC 29527; value ranges from 1-2; ND is Not Determined,1,Aggregatibacter actinomycetemcomitans,Intermediate,,,,714.0,,,F,BAO_0000218,CHEMBL619558,6339
,80682,N,1,,,,17206,,Effect on NAD+ depletion (% remaining versus vehicle control) in presence of MNNG (25 uM) at 11 uM compound concentration in A549 cells,1,Homo sapiens,Intermediate,,646.0,,9606.0,A549,,F,BAO_0000219,CHEMBL619559,6340
,80682,N,1,,,,17206,,Percent ADP-ribose polymer formation at 25 uM compound concentration in A549 cells,1,Homo sapiens,Intermediate,,646.0,,9606.0,A549,,F,BAO_0000219,CHEMBL619560,6341
,80682,N,1,,,,16381,,% inhibition against A549 cells (lung cancer) at 0.04 ug/mL,1,Homo sapiens,Intermediate,,646.0,,9606.0,A549,,F,BAO_0000219,CHEMBL619561,6342
,80682,N,1,,,,16381,,% inhibition against A549 cells (lung cancer) at 0.4 ug/mL,1,Homo sapiens,Intermediate,,646.0,,9606.0,A549,,F,BAO_0000219,CHEMBL619562,6343
,80682,N,1,,,,16381,,% inhibition against A549 cells (lung cancer) at 4 ug/mL,1,Homo sapiens,Intermediate,,646.0,,9606.0,A549,,F,BAO_0000219,CHEMBL619563,6344
,80682,N,1,,,,16381,,GI values against A549 cells (lung cancer),1,Homo sapiens,Intermediate,,646.0,,9606.0,A549,,F,BAO_0000219,CHEMBL857457,6345
,80682,N,1,,,,17206,,Effect on NAD+ depletion (% remaining versus vehicle control) 25 uM compound concentration in A549 cells,1,Homo sapiens,Intermediate,,646.0,,9606.0,A549,,F,BAO_0000219,CHEMBL619564,6346
,80682,N,1,,,,16325,,Inhibitory activity against A549 human adenocarcinoma,1,Homo sapiens,Intermediate,,646.0,,9606.0,A549,,F,BAO_0000219,CHEMBL619565,6347
,80682,N,1,,,,10708,,Evaluated for the antineoplastic activity against A549 lung (nonsmall cell) tumor xenograft in nude mice after administering 3 injections (intra peritoneally) at a dose of 200 mg/kg,1,Homo sapiens,Intermediate,,646.0,,9606.0,A549,,F,BAO_0000218,CHEMBL619566,6348
,80682,N,1,,,,10708,,Evaluated for the antineoplastic activity against A549 lung (nonsmall cell) tumor xenograft in nude mice after administering 3 injections (intra peritoneally) at a dose of 100 mg/kg,1,Homo sapiens,Intermediate,,646.0,,9606.0,A549,,F,BAO_0000218,CHEMBL619567,6349
,80682,N,1,,,,17376,,Inhibitory activity against A549 lung adenocarcinoma cell line,1,Homo sapiens,Intermediate,,646.0,,9606.0,A549,,F,BAO_0000219,CHEMBL619568,6350
,80682,N,1,,,,17376,,Inhibitory activity against A549 lung adenocarcinoma cell line; not determined,1,Homo sapiens,Intermediate,,646.0,,9606.0,A549,,F,BAO_0000219,CHEMBL619569,6351
,80682,N,1,,,,17488,,Cytotoxicity against human A549 lung cells,1,Homo sapiens,Intermediate,,646.0,,9606.0,A549,,F,BAO_0000219,CHEMBL619570,6352
,80682,N,1,,,,17404,,In vivo percent inhibitory activity of intraperitoneally administered compound (50 mg/kg/day) against mice infected with A549 tumor,1,Homo sapiens,Intermediate,,646.0,,9606.0,A549,,F,BAO_0000218,CHEMBL619571,6353
,80682,N,1,,,,10958,,Growth inhibition of A549 (human lung carcinoma) cell line.,1,Homo sapiens,Expert,,646.0,,9606.0,A549,,F,BAO_0000219,CHEMBL619572,6354
,80682,N,1,,,,17099,,Effective dose required for inhibitory activity against A549 human tumor cell line.,1,Homo sapiens,Expert,,646.0,,9606.0,A549,,F,BAO_0000219,CHEMBL619573,6355
,80682,N,1,,,,17099,,Effective dose required for inhibitory activity against A549 human tumor cell line; Not active,1,Homo sapiens,Intermediate,,646.0,,9606.0,A549,,F,BAO_0000219,CHEMBL619574,6356
,80682,N,1,,,,4096,,Cytotoxicity was evaluated against A549 tumor cell lines; Inactive,1,Homo sapiens,Intermediate,,646.0,,9606.0,A549,,F,BAO_0000219,CHEMBL619575,6357
,80682,N,1,,,,4096,,Cytotoxicity evaluated against A549 tumor cell lines; significant activity,1,Homo sapiens,Expert,,646.0,,9606.0,A549,,F,BAO_0000219,CHEMBL619576,6358
,80682,N,1,,,,4096,,Cytotoxicity was evaluated against A549 tumor cell lines; Slightly active,1,Homo sapiens,Intermediate,,646.0,,9606.0,A549,,F,BAO_0000219,CHEMBL619577,6359
,80682,N,1,,,,2525,,In vitro inhibitory activity against A549 tumor cell culture,1,Homo sapiens,Intermediate,,646.0,,9606.0,A549,,F,BAO_0000219,CHEMBL619578,6360
,80682,N,1,,,,2525,,In vitro inhibitory activity against A549 tumor cell culture; IA= Inactive,1,Homo sapiens,Intermediate,,646.0,,9606.0,A549,,F,BAO_0000219,CHEMBL884009,6361
,80682,N,1,,,,5302,,Activity against human lung cancer with mutated beta-tubulin (A549-T2415),1,Homo sapiens,Intermediate,,646.0,,9606.0,A549,,F,BAO_0000219,CHEMBL619579,6362
,80682,N,1,,,,16325,,Growth inhibitory activity was determined against A549/ATCC cancer cell line of non-small cell lung cancer,1,Homo sapiens,Intermediate,,646.0,,9606.0,A549,,F,BAO_0000219,CHEMBL619580,6363
,80682,N,1,,,,16939,,Inhibition of growth of A549/ATCC nonsmall cell lung cancer cell line,1,Homo sapiens,Intermediate,,646.0,,9606.0,A549,,F,BAO_0000219,CHEMBL619581,6364
,80682,N,1,,,,17229,,In vitro antitumor activity against NSCL A549/ATCC tumor cell lines,1,Homo sapiens,Intermediate,,646.0,,9606.0,A549,,F,BAO_0000219,CHEMBL619582,6365
,80682,N,1,,,,17380,,Cytotoxicity evaluation against A549/ATCC non-small-cell lung cancer cells,1,Homo sapiens,Intermediate,,646.0,,9606.0,A549,,F,BAO_0000219,CHEMBL619583,6366
,80682,N,1,,,,17380,,Cytotoxicity evaluation against A549/ATCC non-small-cell lung cancer cells; No data,1,Homo sapiens,Intermediate,,646.0,,9606.0,A549,,F,BAO_0000219,CHEMBL876502,6367
,80682,N,1,,,,1903,,In vitro cytotoxicity against human Non-small cell lung cancer A549/ATCC cell line.,1,Homo sapiens,Intermediate,,646.0,,9606.0,A549,,F,BAO_0000219,CHEMBL619584,6368
,80682,N,1,,,,3838,,In vitro growth inhibition of compound was determined against A549/ATCC cell lines of non-small cell lung cancer,1,Homo sapiens,Intermediate,,646.0,,9606.0,A549,,F,BAO_0000219,CHEMBL619585,6369
,80682,N,1,,,,14696,,Inhibition of the growth of non-small-cell lung cancer (A549/ATCC) cell line,1,Homo sapiens,Intermediate,,646.0,,9606.0,A549,,F,BAO_0000219,CHEMBL619586,6370
,80682,N,1,,,,3838,,In vitro growth inhibition of compound was determined against A549/ATCC cell lines of non-small cell lung cancer,1,Homo sapiens,Intermediate,,646.0,,9606.0,A549,,F,BAO_0000219,CHEMBL619587,6371
,80682,N,1,,,,1522,,Tested for in vitro cytotoxicity against non-small cell lung cancer cell line A549/ATCC,1,Homo sapiens,Intermediate,,646.0,,9606.0,A549,,F,BAO_0000219,CHEMBL619588,6372
,80682,N,1,,,,12400,,Tested in vitro for cytotoxicity in A549/ATCC cell lines,1,Homo sapiens,Intermediate,,646.0,,9606.0,A549,,F,BAO_0000219,CHEMBL619589,6373
,80682,N,1,,,,14696,,inhibition of the growth of non-small-cell lung cancer (A549/ATCC) cell line,1,Homo sapiens,Intermediate,,646.0,,9606.0,A549,,F,BAO_0000219,CHEMBL619590,6374
,80682,N,1,,,,14769,,Compound was evaluated for in vitro activity against A549/ATCC lung cancer cell lines (Human tumor cells ),1,Homo sapiens,Intermediate,,646.0,,9606.0,A549,,F,BAO_0000219,CHEMBL619591,6375
,80682,N,1,,,,14696,,Inhibition of the growth of non-small-cell lung cancer (A549/ATCC) cell line at 0.01 uM,1,Homo sapiens,Intermediate,,646.0,,9606.0,A549,,F,BAO_0000219,CHEMBL619592,6376
,80682,N,1,,,,1888,,Compound was evaluated for cytotoxic activity against non-small lung cancer A549/ATCC cell lines.,1,Homo sapiens,Intermediate,,646.0,,9606.0,A549,,F,BAO_0000219,CHEMBL619593,6377
,80682,N,1,,,,12016,,Tested for cytotoxic activity against non-small cell lung cancer A549/ATCC cell line,1,Homo sapiens,Intermediate,,646.0,,9606.0,A549,,F,BAO_0000219,CHEMBL620217,6378
,80682,N,1,,,,6058,,Compound tested for growth inhibition of non-small cell lung cancer cell line A549/ATCC,1,Homo sapiens,Intermediate,,646.0,,9606.0,A549,,F,BAO_0000219,CHEMBL620218,6379
,80682,N,1,,,,17708,,Compound was tested for 50% growth inhibition against human non-small cell lung cancer A549/ATCC cell line,1,Homo sapiens,Intermediate,,646.0,,9606.0,A549,,F,BAO_0000219,CHEMBL620219,6380
,80682,N,1,,,,12301,,Antitumor activity against A549/ATCC cell line,1,Homo sapiens,Intermediate,,646.0,,9606.0,A549,,F,BAO_0000219,CHEMBL620220,6381
,80682,N,1,,,,11970,,Tested for cytotoxicity against A549/ATCC cell lines in non-small-cell lung cancer,1,Homo sapiens,Intermediate,,646.0,,9606.0,A549,,F,BAO_0000219,CHEMBL625141,6382
,80682,N,1,,,,11818,,In vitro cytotoxicity against A549/ATCC cell line.,1,Homo sapiens,Expert,,646.0,,9606.0,A549,,F,BAO_0000219,CHEMBL625142,6383
,80682,N,1,,,,12400,,Tested in vitro for cytotoxicity in A549/ATCC cell line of Non-Small Cell Lung Cancer,1,Homo sapiens,Intermediate,,646.0,,9606.0,A549,,F,BAO_0000219,CHEMBL625143,6384
,80682,N,1,,,,3381,,In vitro inhibition of Non-Small Cell Lung Cancer A549/ATCC cell lines,1,Homo sapiens,Intermediate,,646.0,,9606.0,A549,,F,BAO_0000219,CHEMBL625144,6385
,80682,N,1,,,,17376,,Concentration of compound that cause 50% cytotoxicity of A549/ATCC non small cell lung cancer cell line,1,Homo sapiens,Intermediate,,646.0,,9606.0,A549,,F,BAO_0000219,CHEMBL622474,6386
,80682,N,1,,,,10708,,Evaluated for the inhibitory concentration required to cause growth inhibition of A549Rem- cell line of lung using the MTT Cytotoxicity Assay,1,Homo sapiens,Intermediate,,646.0,,9606.0,A549,,F,BAO_0000219,CHEMBL884104,6387
,22226,U,0,,,,2964,,Cytotoxicity was evaluated against A649 human mammary carcinoma cells,1,Homo sapiens,Autocuration,,,,9606.0,,,F,BAO_0000219,CHEMBL622475,6388
,22224,U,0,In vivo,,,5005,,Compound was tested for oral bioavailability in dogs,1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL622476,6389
,50588,N,1,In vivo,,,6229,,Compound was tested for orally bioavailable in dogs with a half life of 0.7 hr,1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL875831,6390
,50588,N,1,In vivo,,,6229,,Compound was tested for orally bioavailable in dogs with a half life of 1.2h,1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL622477,6391
,50588,N,1,In vivo,,,5374,,Oral bioavailability in dog,1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL622478,6392
,50588,N,1,In vivo,,,5374,,Compound was tested for the oral bioavailability in dog; No availability,1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL623172,6393
,50588,N,1,In vivo,,,6265,,Oral bioavailability in dog (dose 5 mg/kg),1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL623173,6394
,50588,N,1,In vivo,,,5654,,Oral bioavailability (F%) of compound was determined after intravenous administration in average of two dogs at a dose of 1 mg/kg; ND=not determined,1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL623174,6395
,50588,N,1,In vivo,,,5654,,Oral bioavailability (F%) of compound was determined after intravenous administration in average of two dogs at a dose of 1 mg/kg; ND=not determined,1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL623175,6396
,50588,N,1,In vivo,,,16456,,Oral bioavailability in Beagle dogs after Per oral administration at dose of 50(mg/kg),1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL623340,6397
,50588,N,1,In vivo,,,5302,,Oral bioavailability in dog (dose 5 mg/kg),1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL623341,6398
,50588,N,1,In vivo,,,3624,,Oral bioavailability in dog (p.o. dosing of 0.05 M citric acid/0.05 M hydrochloric acid solution),1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL623342,6399
,50588,N,1,In vivo,,,16452,,Oral bioavailability of active FTIs in dogs,1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL623343,6400
,50588,N,1,In vivo,,,5802,,Oral bioavailability in dog (dose 5 mg/kg p.o. and 2 mg/kg i.v.),1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL623344,6401
,50588,N,1,In vivo,,,3598,,Oral bioavailability of compound determined in dog after iv administration at a dose of 10 mg/kg,1,Canis lupus familiaris,Expert,,,,9615.0,,,A,BAO_0000218,CHEMBL623345,6402
,50588,N,1,In vivo,,,17839,,Oral bioavailability in dog,1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL875832,6403
,50588,N,1,In vivo,,,6762,,Oral bioavailability in dog,1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL623346,6404
,50588,N,1,In vivo,,,6821,,Oral bioavailability in dog,1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL623347,6405
,50588,N,1,In vivo,,,6821,,Oral bioavailability of compound was determined in dog; Not tested,1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL623348,6406
,50588,N,1,In vivo,,,5210,,Oral bioavailability in dog,1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL623349,6407
,50588,N,1,In vivo,,,6227,,Oral bioavailability (10 mg/kg) was determined in dog,1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL623350,6408
,50588,N,1,In vivo,,,761,,Oral bioavailability,1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL623351,6409
,50588,N,1,In vivo,,,761,,Oral bioavailability in dog (dosed as neat powder in hard gelatin capsule),1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL623352,6410
,50588,N,1,In vivo,,,761,,Oral bioavailability administered in solution in rats,1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL623353,6411
,50588,N,1,In vivo,,,16907,,Oral bioavailability after 30 mg/kg po dose in Dogs,1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL875833,6412
,50588,N,1,In vivo,,,5474,,Oral bioavailability at a dose of 1 mg/kg in dogs,1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL623354,6413
,50588,N,1,In vivo,,,6535,,Oral bioavailability in dog (dose 1 mg/kg p.o.),1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL623355,6414
,50588,N,1,In vivo,,,6535,,Oral bioavailability in Dog; ND = not determined,1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL623356,6415
,50588,N,1,In vivo,,,3352,,Oral bioavailability in dog,1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL623357,6416
,50588,N,1,In vivo,,,6168,,Oral bioavailability in dog,1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL623358,6417
,50588,N,1,In vivo,,,5988,,Oral bioavailability in dog,1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL623359,6418
,50588,N,1,In vivo,,,4942,,Oral bioavailability in dog,1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL623360,6419
,50588,N,1,In vivo,,,4942,,Oral bioavailability in dogs; No data,1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL623361,6420
,50588,N,1,In vivo,,,14541,,Oral bioavailability measured in dogs,1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL623362,6421
,50588,N,1,In vivo,,,4449,,Oral bioavailability in dog,1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL623363,6422
,50588,N,1,In vivo,,,6057,,Oral bioavailability was calculated in dog,1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL623364,6423
,50588,N,1,In vivo,,,5600,,Oral bioavailability after 0.3 mg/kg po administration in dog,1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL875834,6424
,50588,N,1,In vivo,,,5542,,Oral bioavailability in dog (i.v. dosing),1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL623365,6425
,50588,N,1,In vivo,,,5542,,Oral bioavailability in dog,1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL623366,6426
,50588,N,1,In vivo,,,5546,,Oral bioavailability in Beagle dog at a dose of 2 mg/kg by po administration,1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL623367,6427
,50588,N,1,In vivo,,,4514,,Oral bioavailability in Beagle dogs,1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL623368,6428
,50588,N,1,In vivo,,,3624,,Oral bioavailability in dog,1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL623369,6429
,50588,N,1,In vivo,,,3854,,Oral bioavailability in dog,1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL623370,6430
,50588,N,1,In vivo,,,5836,,Oral bioavailability in dog,1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL623371,6431
,50588,N,1,In vivo,,,5940,,Oral bioavailability in dog,1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL623372,6432
,50588,N,1,In vivo,,,6168,,Oral bioavailability in dog,1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL621351,6433
,50588,N,1,In vivo,,,6227,,Oral bioavailability in dog,1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL621352,6434
,50588,N,1,In vivo,,,6251,,Oral bioavailability in dog,1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL621353,6435
,50588,N,1,In vivo,,,6448,,Oral bioavailability in dog,1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL621354,6436
,50588,N,1,In vivo,,,6647,,Oral bioavailability in dog,1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL621355,6437
,50588,N,1,In vivo,,,5940,,Oral bioavailability in dog,1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL621356,6438
,50588,N,1,In vivo,,,933,,Oral bioavailability in dog,1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL621357,6439
,50588,N,1,In vivo,,,5210,,Oral bioavailability in dog,1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL621358,6440
,50588,N,1,In vivo,,,6642,,Oral bioavailability in dog (dosed as a mixture of five compounds at 0.5 mg/kg each via i.v. only),1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL621359,6441
,50588,N,1,In vivo,,,6641,,Oral bioavailability in dog (dose 0.5 mg/kg i.v. and 2.0 mg/kg p.o.),1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL621360,6442
,50588,N,1,In vivo,,,6642,,Oral bioavailability in dog (dose 0.5 mg/kg i.v. and 2.0 mg/kg p.o.),1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL621361,6443
,50588,N,1,In vivo,,,5472,,Oral bioavailability in dog,1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL621362,6444
,50588,N,1,In vivo,,,5985,,Oral bioavailability in dog,1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL621363,6445
,50588,N,1,In vivo,,,15660,,Oral bioavailability in dog,1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL621364,6446
,50588,N,1,In vivo,,,5530,,Oral bioavailability in dog (dose 0.2 mg/kg i.v.),1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL621166,6447
,50588,N,1,In vivo,,,5530,,Oral bioavailability in dog (dose 1 mg/kg i.v.),1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL621167,6448
,50588,N,1,In vivo,,,6305,,Oral bioavailability (F) in dogs,1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL621168,6449
,50588,N,1,In vivo,,,5210,,Oral bioavailability in dog,1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL621169,6450
,50588,N,1,In vivo,,,5238,,Bioavailability in dog,1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL875950,6451
,50588,N,1,In vivo,,,5668,,Oral bioavailability in dog (dose 10 mg/kg),1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL621170,6452
,50588,N,1,In vivo,,,5668,,Oral bioavailability after peroral administration at 5 mpk in Dog,1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL621171,6453
,50588,N,1,In vivo,,,5668,,Oral bioavailability in dog (dose 5 mg/kg),1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL621172,6454
,50588,N,1,In vivo,,,6084,,Oral bioavailability in dog (dose 10 mg/kg),1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL621173,6455
Kidney,50594,N,1,,,,6599,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice kidney bearing S180 tumor cell line for 4 hours,1,Mus musculus,Intermediate,,42.0,,10090.0,CCRF S-180,2113.0,A,BAO_0000218,CHEMBL621174,6456
Kidney,50594,N,1,,,,6599,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice kidney bearing S180 tumor cell line for 8 hours,1,Mus musculus,Intermediate,,42.0,,10090.0,CCRF S-180,2113.0,A,BAO_0000218,CHEMBL621175,6457
Liver,50594,N,1,,,,6599,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice liver bearing S180 tumor cell line for 1 hour,1,Mus musculus,Intermediate,,42.0,,10090.0,CCRF S-180,2107.0,A,BAO_0000218,CHEMBL621176,6458
Liver,50594,N,1,,,,6599,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice liver bearing S180 tumor cell line for 2 hours,1,Mus musculus,Intermediate,,42.0,,10090.0,CCRF S-180,2107.0,A,BAO_0000218,CHEMBL621177,6459
Liver,50594,N,1,,,,6599,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice liver bearing S180 tumor cell line for 30 minutes,1,Mus musculus,Intermediate,,42.0,,10090.0,CCRF S-180,2107.0,A,BAO_0000218,CHEMBL621178,6460
Liver,50594,N,1,,,,6599,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice liver bearing S180 tumor cell line for 4 hours,1,Mus musculus,Intermediate,,42.0,,10090.0,CCRF S-180,2107.0,A,BAO_0000218,CHEMBL621179,6461
Liver,50594,N,1,,,,6599,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice liver bearing S180 tumor cell line for 8 hours,1,Mus musculus,Intermediate,,42.0,,10090.0,CCRF S-180,2107.0,A,BAO_0000218,CHEMBL621180,6462
Lung,50594,N,1,,,,6599,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice lung bearing S180 tumor cell line for 1 hour,1,Mus musculus,Intermediate,,42.0,,10090.0,CCRF S-180,2048.0,A,BAO_0000218,CHEMBL875951,6463
Lung,50594,N,1,,,,6599,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice lung bearing S180 tumor cell line for 2 hours,1,Mus musculus,Intermediate,,42.0,,10090.0,CCRF S-180,2048.0,A,BAO_0000218,CHEMBL621181,6464
Lung,50594,N,1,,,,6599,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice lung bearing S180 tumor cell line for 30 minutes,1,Mus musculus,Intermediate,,42.0,,10090.0,CCRF S-180,2048.0,A,BAO_0000218,CHEMBL621182,6465
Lung,50594,N,1,,,,6599,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice lung bearing S180 tumor cell line for 4 hours,1,Mus musculus,Intermediate,,42.0,,10090.0,CCRF S-180,2048.0,A,BAO_0000218,CHEMBL621183,6466
Lung,50594,N,1,,,,6599,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice lung bearing S180 tumor cell line for 8 hours,1,Mus musculus,Intermediate,,42.0,,10090.0,CCRF S-180,2048.0,A,BAO_0000218,CHEMBL621184,6467
,50594,N,1,,,,6599,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice muscle bearing S180 tumor cell line for 1 hour,1,Mus musculus,Intermediate,,42.0,,10090.0,CCRF S-180,,A,BAO_0000218,CHEMBL621185,6468
,50594,N,1,,,,6599,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice muscle bearing S180 tumor cell line for 2 hours,1,Mus musculus,Intermediate,,42.0,,10090.0,CCRF S-180,,A,BAO_0000218,CHEMBL621186,6469
,50594,N,1,,,,6599,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice muscle bearing S180 tumor cell line for 30 minutes,1,Mus musculus,Intermediate,,42.0,,10090.0,CCRF S-180,,A,BAO_0000218,CHEMBL621187,6470
,50594,N,1,,,,6599,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice muscle bearing S180 tumor cell line for 4 hours,1,Mus musculus,Intermediate,,42.0,,10090.0,CCRF S-180,,A,BAO_0000218,CHEMBL621188,6471
,50594,N,1,,,,6599,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice muscle bearing S180 tumor cell line for 8 hours,1,Mus musculus,Intermediate,,42.0,,10090.0,CCRF S-180,,A,BAO_0000218,CHEMBL621189,6472
Spleen,50594,N,1,,,,6599,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice spleen bearing S180 tumor cell line for 1 hour,1,Mus musculus,Intermediate,,42.0,,10090.0,CCRF S-180,2106.0,A,BAO_0000218,CHEMBL621190,6473
Spleen,50594,N,1,,,,6599,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice spleen bearing S180 tumor cell line for 2 hours,1,Mus musculus,Intermediate,,42.0,,10090.0,CCRF S-180,2106.0,A,BAO_0000218,CHEMBL618520,6474
Spleen,50594,N,1,,,,6599,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice spleen bearing S180 tumor cell line for 30 minutes,1,Mus musculus,Intermediate,,42.0,,10090.0,CCRF S-180,2106.0,A,BAO_0000218,CHEMBL621739,6475
Spleen,50594,N,1,,,,6599,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice spleen bearing S180 tumor cell line for 4 hours,1,Mus musculus,Intermediate,,42.0,,10090.0,CCRF S-180,2106.0,A,BAO_0000218,CHEMBL621740,6476
Spleen,50594,N,1,,,,6599,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice spleen bearing S180 tumor cell line for 8 hours,1,Mus musculus,Intermediate,,42.0,,10090.0,CCRF S-180,2106.0,A,BAO_0000218,CHEMBL621741,6477
,50594,N,1,,,,6599,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor bearing S180 tumor cell line for 1 hour,1,Mus musculus,Intermediate,,42.0,,10090.0,CCRF S-180,,A,BAO_0000218,CHEMBL621742,6478
,50594,N,1,,,,6599,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor bearing S180 tumor cell line for 2 hours,1,Mus musculus,Intermediate,,42.0,,10090.0,CCRF S-180,,A,BAO_0000218,CHEMBL621743,6479
,50594,N,1,,,,6599,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor bearing S180 tumor cell line for 30 minutes,1,Mus musculus,Intermediate,,42.0,,10090.0,CCRF S-180,,A,BAO_0000218,CHEMBL621744,6480
,50594,N,1,,,,6599,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor bearing S180 tumor cell line for 4 hours,1,Mus musculus,Intermediate,,42.0,,10090.0,CCRF S-180,,A,BAO_0000218,CHEMBL621745,6481
,50594,N,1,,,,6599,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor bearing S180 tumor cell line for 8 hours,1,Mus musculus,Intermediate,,42.0,,10090.0,CCRF S-180,,A,BAO_0000218,CHEMBL621746,6482
,50594,N,1,,,,6599,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/blood bearing S180 tumor cell line for 1 hour,1,Mus musculus,Intermediate,,42.0,,10090.0,CCRF S-180,,A,BAO_0000218,CHEMBL621747,6483
,50594,N,1,,,,6599,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/blood bearing S180 tumor cell line for 2 hours,1,Mus musculus,Intermediate,,42.0,,10090.0,CCRF S-180,,A,BAO_0000218,CHEMBL621748,6484
,50594,N,1,,,,6599,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/blood bearing S180 tumor cell line for 30 minutes,1,Mus musculus,Intermediate,,42.0,,10090.0,CCRF S-180,,A,BAO_0000218,CHEMBL621749,6485
,50594,N,1,,,,6599,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/blood bearing S180 tumor cell line for 4 hours,1,Mus musculus,Intermediate,,42.0,,10090.0,CCRF S-180,,A,BAO_0000218,CHEMBL621750,6486
,50594,N,1,,,,6599,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/blood bearing S180 tumor cell line for 8 hours,1,Mus musculus,Intermediate,,42.0,,10090.0,CCRF S-180,,A,BAO_0000218,CHEMBL621751,6487
Heart,50594,N,1,,,,6599,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/heart bearing S180 tumor cell line for 1 hour,1,Mus musculus,Intermediate,,42.0,,10090.0,CCRF S-180,948.0,A,BAO_0000218,CHEMBL621752,6488
Heart,50594,N,1,,,,6599,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/heart bearing S180 tumor cell line for 2 hours,1,Mus musculus,Intermediate,,42.0,,10090.0,CCRF S-180,948.0,A,BAO_0000218,CHEMBL621753,6489
Heart,50594,N,1,,,,6599,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/heart bearing S180 tumor cell line for 30 minutes,1,Mus musculus,Intermediate,,42.0,,10090.0,CCRF S-180,948.0,A,BAO_0000218,CHEMBL875955,6490
Heart,50594,N,1,,,,6599,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/heart bearing S180 tumor cell line for 4 hours,1,Mus musculus,Intermediate,,42.0,,10090.0,CCRF S-180,948.0,A,BAO_0000218,CHEMBL621754,6491
Heart,50594,N,1,,,,6599,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/heart bearing S180 tumor cell line for 8 hours,1,Mus musculus,Intermediate,,42.0,,10090.0,CCRF S-180,948.0,A,BAO_0000218,CHEMBL621755,6492
Liver,50594,N,1,,,,6599,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/liver bearing S180 tumor cell line for 1 hour,1,Mus musculus,Intermediate,,42.0,,10090.0,CCRF S-180,2107.0,A,BAO_0000218,CHEMBL621756,6493
Liver,50594,N,1,,,,6599,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/liver bearing S180 tumor cell line for 2 hours,1,Mus musculus,Intermediate,,42.0,,10090.0,CCRF S-180,2107.0,A,BAO_0000218,CHEMBL624199,6494
Liver,50594,N,1,,,,6599,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/liver bearing S180 tumor cell line for 30 minutes,1,Mus musculus,Intermediate,,42.0,,10090.0,CCRF S-180,2107.0,A,BAO_0000218,CHEMBL624200,6495
Liver,50594,N,1,,,,6599,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/liver bearing S180 tumor cell line for 4 hours,1,Mus musculus,Intermediate,,42.0,,10090.0,CCRF S-180,2107.0,A,BAO_0000218,CHEMBL624375,6496
Liver,50594,N,1,,,,6599,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/liver bearing S180 tumor cell line for 8 hours,1,Mus musculus,Intermediate,,42.0,,10090.0,CCRF S-180,2107.0,A,BAO_0000218,CHEMBL624376,6497
Lung,50594,N,1,,,,6599,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/lung bearing S180 tumor cell line for 1 hour,1,Mus musculus,Intermediate,,42.0,,10090.0,CCRF S-180,2048.0,A,BAO_0000218,CHEMBL624377,6498
Lung,50594,N,1,,,,6599,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/lung bearing S180 tumor cell line for 2 hours,1,Mus musculus,Intermediate,,42.0,,10090.0,CCRF S-180,2048.0,A,BAO_0000218,CHEMBL624378,6499
,50067,N,1,,,,12269,,Compound tested for the antimicrobial activity against Acinetobacter anitratus,1,aeinetobacter anitrotap,Intermediate,,,,107673.0,,,F,BAO_0000218,CHEMBL857901,6500
,50067,N,1,,,,12269,,Compound tested for the antimicrobial activity against Acinetobacter anitratus,1,Acinetobacter calcoaceticus subsp. anitratus,Intermediate,,,,107673.0,,,F,BAO_0000218,CHEMBL875274,6501
,50067,N,1,,,,12269,,Compound tested for the antimicrobial activity against Acinetobacter anitratus,1,Acinetobacter calcoaceticus subsp. anitratus,Intermediate,,,,107673.0,,,F,BAO_0000218,CHEMBL624379,6502
,50067,N,1,,,,12269,,Compound tested for the antimicrobial activity against Acinetobacter anitratus,1,aeinetobacter anitrotap,Intermediate,,,,107673.0,,,F,BAO_0000218,CHEMBL624380,6503
,50192,N,1,,,,10624,,Activity against Acinetobacter calcoaceticus (AC54),1,Acinetobacter calcoaceticus,Intermediate,,,,471.0,,,F,BAO_0000218,CHEMBL624381,6504
,50714,N,1,,,,17216,,Biological activity using the lizard skin (Anolis carolinensis) assay. The value indicates no prolonged biological activity,1,Anolis carolinensis,Intermediate,,,,28377.0,,,F,BAO_0000218,CHEMBL624382,6505
,50714,N,1,,,,17216,,Biological activity using the lizard skin (Anolis carolinensis) assay. The value indicates prolonged biological activity,1,Anolis carolinensis,Intermediate,,,,28377.0,,,F,BAO_0000218,CHEMBL624383,6506
,50296,N,1,,,,9560,,Chlorohexidine coefficient for Actinomyces naeslundii 631,1,Actinomyces naeslundii,Intermediate,,,,1655.0,,,F,BAO_0000218,CHEMBL624384,6507
,50296,N,1,,,,9560,,Chlorohexidine coefficient for Actinomyces naeslundii B74,1,Actinomyces naeslundii,Intermediate,,,,1655.0,,,F,BAO_0000218,CHEMBL624385,6508
,50296,N,1,,,,9560,,Chlorohexidine coefficient for Actinomyces naeslundii N/3,1,Actinomyces naeslundii,Intermediate,,,,1655.0,,,F,BAO_0000218,CHEMBL624386,6509
,50296,N,1,,,,9560,,Chlorohexidine coefficient for Actinomyces naeslundii N/9,1,Actinomyces naeslundii,Intermediate,,,,1655.0,,,F,BAO_0000218,CHEMBL624387,6510
,50296,N,1,,,,9560,,Plaque bactericidal index against Actinomyces naeslundii 631,1,Actinomyces naeslundii,Intermediate,,,,1655.0,,,F,BAO_0000218,CHEMBL624388,6511
,50296,N,1,,,,9560,,Plaque bactericidal index against Actinomyces naeslundii N/9,1,Actinomyces naeslundii,Intermediate,,,,1655.0,,,F,BAO_0000218,CHEMBL624389,6512
,50296,N,1,,,,9560,,Plaque bactericidal index against Actinomyces naeslundii B74,1,Actinomyces naeslundii,Intermediate,,,,1655.0,,,F,BAO_0000218,CHEMBL624390,6513
,50296,N,1,,,,9560,,Plaque bactericidal index against Actinomyces naeslundii N/3,1,Actinomyces naeslundii,Intermediate,,,,1655.0,,,F,BAO_0000218,CHEMBL875275,6514
,50056,N,1,,,,114,,Compound was tested for its inhibitory activity using brine shrimp (Artemia salina) immobilization assay,1,Artemia salina,Intermediate,,,,85549.0,,,F,BAO_0000218,CHEMBL624391,6515
,50056,N,1,,,,114,,"Compound was tested for its inhibitory activity using brine shrimp (Artemia salina) immobilization assay; highest level tested, showed <100% activity",1,Artemia salina,Intermediate,,,,85549.0,,,F,BAO_0000218,CHEMBL623636,6516
,50532,N,1,,,,10841,,Effect on incorporation of [32Pi] by isolated Ascaris suum mitochondria at a concentration of 0 uM,1,Ascaris suum,Intermediate,,,,6253.0,,,F,BAO_0000218,CHEMBL623637,6517
,50532,N,1,,,,10841,,Effect on incorporation of [32Pi] by isolated Ascaris suum mitochondria at a concentration of 10 uM,1,Ascaris suum,Intermediate,,,,6253.0,,,F,BAO_0000218,CHEMBL623638,6518
,50532,N,1,,,,10841,,Effect on incorporation of [32Pi] by isolated Ascaris suum mitochondria at a concentration of 200 uM,1,Ascaris suum,Intermediate,,,,6253.0,,,F,BAO_0000218,CHEMBL623639,6519
,50532,N,1,,,,10841,,Effect on incorporation of [32Pi] by isolated Ascaris suum mitochondria at a concentration of 25 uM,1,Ascaris suum,Intermediate,,,,6253.0,,,F,BAO_0000218,CHEMBL623640,6520
,50532,N,1,,,,10841,,Effect on incorporation of [32Pi] by isolated Ascaris suum mitochondria at a concentration of 3 uM,1,Ascaris suum,Intermediate,,,,6253.0,,,F,BAO_0000218,CHEMBL623641,6521
,50532,N,1,,,,10841,,Effect on incorporation of [32Pi] by isolated Ascaris suum mitochondria at a concentration of 50 uM.,1,Ascaris suum,Intermediate,,,,6253.0,,,F,BAO_0000218,CHEMBL623642,6522
,50532,N,1,,,,10841,,Effect on succinate formation by isolated Ascaris suum mitochondria at a concentration of 0 uM,1,Ascaris suum,Intermediate,,,,6253.0,,,F,BAO_0000218,CHEMBL623643,6523
,50532,N,1,,,,10841,,Effect on succinate formation by isolated Ascaris suum mitochondria at a concentration of 10 uM,1,Ascaris suum,Intermediate,,,,6253.0,,,F,BAO_0000218,CHEMBL623644,6524
,50532,N,1,,,,10841,,Effect on succinate formation by isolated Ascaris suum mitochondria at a concentration of 200 uM,1,Ascaris suum,Intermediate,,,,6253.0,,,F,BAO_0000218,CHEMBL623645,6525
,50532,N,1,,,,10841,,Effect on succinate formation by isolated Ascaris suum mitochondria at a concentration of 25 uM,1,Ascaris suum,Intermediate,,,,6253.0,,,F,BAO_0000218,CHEMBL623646,6526
,50532,N,1,,,,10841,,Effect on succinate formation by isolated Ascaris suum mitochondria at a concentration of 3 uM,1,Ascaris suum,Intermediate,,,,6253.0,,,F,BAO_0000218,CHEMBL623647,6527
,50532,N,1,,,,10841,,Effect on succinate formation by isolated Ascaris suum mitochondria at a concentration of 50 uM,1,Ascaris suum,Intermediate,,,,6253.0,,,F,BAO_0000218,CHEMBL623648,6528
,50366,N,1,,,,8117,,Compound is evaluated for minimal bactericidal concentration against plaque formation for Actinomyces viscosus,1,Actinomyces viscosus,Intermediate,,,,1656.0,,,F,BAO_0000218,CHEMBL623649,6529
,50366,N,1,,,,8117,,Compound is evaluated for minimal bactericidal concentration against plaque formation for Actinomyces viscosus,1,Actinomyces viscosus,Intermediate,,,,1656.0,,,F,BAO_0000218,CHEMBL623650,6530
,50366,N,1,,,,9560,,Chlorohexidine coefficient for Actinomyces viscosus 8A06,1,Actinomyces viscosus,Intermediate,,,,1656.0,,,F,BAO_0000218,CHEMBL623651,6531
,50366,N,1,,,,9560,,Chlorohexidine coefficient for Actinomyces viscosus M-100,1,Actinomyces viscosus,Expert,,,,1656.0,,,F,BAO_0000218,CHEMBL623652,6532
,50366,N,1,,,,9560,,Chlorohexidine coefficient for Actinomyces viscosus M-626,1,Actinomyces viscosus,Intermediate,,,,1656.0,,,F,BAO_0000218,CHEMBL623653,6533
,50366,N,1,,,,9560,,Chlorohexidine coefficient for Actinomyces viscosus T14V,1,Actinomyces viscosus,Intermediate,,,,1656.0,,,F,BAO_0000218,CHEMBL623654,6534
,50366,N,1,,,,9560,,Plaque bactericidal index against Actinomyces viscosus 8A06,1,Actinomyces viscosus,Intermediate,,,,1656.0,,,F,BAO_0000218,CHEMBL623655,6535
,50366,N,1,,,,9560,,Plaque bactericidal index against Actinomyces viscosus M-100,1,Actinomyces viscosus,Intermediate,,,,1656.0,,,F,BAO_0000218,CHEMBL623656,6536
,50366,N,1,,,,9560,,Plaque bactericidal index against Actinomyces viscosus M-100 measured as chlorohexidine coefficient,1,Actinomyces viscosus,Expert,,,,1656.0,,,F,BAO_0000218,CHEMBL623657,6537
,50366,N,1,,,,9560,,"Plaque bactericidal index against Actinomyces viscosus M-100 measured as chlorohexidine coefficient; d=Not bactericidal at highest concentration tested (0.2% w/v, 2min, 5 days)",1,Actinomyces viscosus,Intermediate,,,,1656.0,,,F,BAO_0000218,CHEMBL623658,6538
,50366,N,1,,,,9560,,"Plaque bactericidal index against Actinomyces viscosus M-100 measured as chlorohexidine coefficient; not bactericidal at highest concentration tested (0.2% w/v, 2min, 5 days)",1,Actinomyces viscosus,Intermediate,,,,1656.0,,,F,BAO_0000218,CHEMBL623659,6539
,50366,N,1,,,,9560,,Plaque bactericidal index against Actinomyces viscosus 626,1,Actinomyces viscosus,Intermediate,,,,1656.0,,,F,BAO_0000218,CHEMBL623660,6540
,50366,N,1,,,,9560,,Plaque bactericidal index against Actinomyces viscosus T14V,1,Actinomyces viscosus,Intermediate,,,,1656.0,,,F,BAO_0000218,CHEMBL623661,6541
,50535,N,1,,,,10986,,anti-filarial Activity was measured against Acanthocheilonema viteae in jirds at 1.56 mg/kg/day(5 days) dose,1,Acanthocheilonema viteae,Intermediate,,,,6277.0,,,F,BAO_0000218,CHEMBL875281,6542
,50535,N,1,,,,10986,,anti-filarial Activity was measured against Acanthocheilonema viteae in jirds at 100 mg/kg/day(5 days) dose,1,Acanthocheilonema viteae,Intermediate,,,,6277.0,,,F,BAO_0000218,CHEMBL623662,6543
,50535,N,1,,,,10986,,anti-filarial Activity was measured against Acanthocheilonema viteae in jirds at 12.5 mg/kg/day(5 days) dose,1,Acanthocheilonema viteae,Intermediate,,,,6277.0,,,F,BAO_0000218,CHEMBL623663,6544
,50535,N,1,,,,10986,,anti-filarial Activity was measured against Acanthocheilonema viteae in jirds at 200 mg/kg/day(5 days) dose,1,Acanthocheilonema viteae,Intermediate,,,,6277.0,,,F,BAO_0000218,CHEMBL623664,6545
,50535,N,1,,,,10986,,anti-filarial Activity was measured against Acanthocheilonema viteae in jirds at 25 mg/kg/day(5 days) dose,1,Acanthocheilonema viteae,Intermediate,,,,6277.0,,,F,BAO_0000218,CHEMBL623665,6546
,80023,N,1,,,,10708,,Evaluated for the inhibitory concentration required to cause growth inhibition of A673Mer+ sarcoma cell line using the MTT Cytotoxicity Assay,1,Homo sapiens,Intermediate,,165.0,,9606.0,A673,,F,BAO_0000219,CHEMBL621856,6547
,80661,N,1,,,,10708,,Evaluated for the inhibitory concentration required to cause growth inhibition of A704Rem- renal cell line using the MTT Cytotoxicity Assay,1,Homo sapiens,Intermediate,,645.0,,9606.0,A704,,F,BAO_0000219,CHEMBL620432,6548
,22226,U,0,,,,416,,Tested for inhibition of ET-1 induced phosphoinositide (PI) turnover in A7r5 smooth muscle cells,1,Rattus norvegicus,Autocuration,,,,10116.0,,,F,BAO_0000219,CHEMBL620433,6549
,80024,N,1,,,,14354,,Inhibition of Forskolin-Induced cAMP production in A9 L cells expressing m2 receptors,1,Mus musculus,Intermediate,,625.0,,10090.0,A9,,F,BAO_0000219,CHEMBL620434,6550
,80024,N,1,,,,14354,,Percent inhibition of Forskolin-Induced cAMP production in A9 L cells expressing m2 receptors,1,Mus musculus,Intermediate,,625.0,,10090.0,A9,,F,BAO_0000219,CHEMBL620435,6551
,80024,N,1,,,,5116,,Cytotoxicity against Beta- tubulin mutant expressing A9-PTX10 cell line of humans was tested,1,Homo sapiens,Intermediate,,625.0,,9606.0,A9,,F,BAO_0000219,CHEMBL620436,6552
,80024,N,1,,,,5116,,Percentage inhibition at higher concentration (100 nM) against Beta- tubulin mutant expressing A9-PTX10 cell line,1,Homo sapiens,Intermediate,,625.0,,9606.0,A9,,F,BAO_0000219,CHEMBL876597,6553
,81037,N,1,,,,15694,,Inhibition of human ovarian carcinoma (A90) FGF-R overexpressing cell proliferation,1,Homo sapiens,Expert,,874.0,,9606.0,Human ovarian carcinoma cell line,,F,BAO_0000219,CHEMBL620437,6554
,80024,N,1,,,,13038,,"Tested for stimulating PI (phosphoinositol) hydrolysis in A9L-m1 cells, activity expressed as EC50 mM.",1,Mus musculus,Expert,,625.0,,10090.0,A9,,F,BAO_0000219,CHEMBL620438,6555
,80024,N,1,,,,13038,,Stimulating PI (phosphoinositol) hydrolysis in A9L-m1 cells.,1,Mus musculus,Expert,,625.0,,10090.0,A9,,F,BAO_0000219,CHEMBL620439,6556
,80024,N,1,,,,10923,,Increase in phosphoinositide (PI) metabolism in A9L-m1 cells at 100 uM.,1,Mus musculus,Expert,,625.0,,10090.0,A9,,F,BAO_0000219,CHEMBL619657,6557
,80024,N,1,,,,10923,,The increase in phosphoinositide (PI) metabolism in A9L-m1 cells was measured at 100 uM; - = Not determined,1,Mus musculus,Intermediate,,625.0,,10090.0,A9,,F,BAO_0000219,CHEMBL619658,6558
,80024,N,1,,,,10923,,The increase in phosphoinositide (PI) metabolism in A9L-m1 cells was measured at 100 uM; i = inactive,1,Mus musculus,Intermediate,,625.0,,10090.0,A9,,F,BAO_0000219,CHEMBL619659,6559
,10649,H,8,,,,10923,,"Increase in phosphoinositide (PI) metabolism in A9L-cholinergic receptor, muscarinic 3 expressing cells was measured at 100 uMolar",1,,Expert,,,,,,,F,BAO_0000019,CHEMBL619660,6560
,80024,N,1,,,,10923,,The increase in phosphoinositide (PI) metabolism in A9L-m3 cells was measured at 100 uM; - = Not determined,1,Mus musculus,Intermediate,,625.0,,10090.0,A9,,F,BAO_0000219,CHEMBL619661,6561
,80024,N,1,,,,10923,,The increase in phosphoinositide (PI) metabolism in A9L-m3 cells was measured at 100 uM; i = inactive,1,Mus musculus,Intermediate,,625.0,,10090.0,A9,,F,BAO_0000219,CHEMBL619662,6562
,80663,N,1,,,,8158,,Ability to inhibit growth of AA-6 cells (a mutant cell line resistant to 8-azaadenine and lacks adenine phosphoryltransferase) was determined,1,Cricetulus griseus,Intermediate,,975.0,,10029.0,AA6,,F,BAO_0000219,CHEMBL619663,6563
,22226,U,0,,,,15494,,Intracellular phosphorylation (100 uM) in uninfected AA2 cells was studied after 5 hrs of Incubation.,1,Homo sapiens,Autocuration,,,,9606.0,,,F,BAO_0000219,CHEMBL619664,6564
,22226,U,0,,,,15494,,"Intracellular phosphorylation (100 uM) in uninfected AA2 cells was studied, after 5 hrs of Incubation.",1,Homo sapiens,Autocuration,,,,9606.0,,,F,BAO_0000219,CHEMBL619665,6565
,80662,N,1,,,,12348,,Anti -HIV activity was measured against AA5/HIV-1(IIIB),1,Homo sapiens,Intermediate,,974.0,,9606.0,AA5,,F,BAO_0000219,CHEMBL883244,6566
,80662,N,1,,,,12348,,Cytotoxicity was measured against AA5/HIV-1(IIIB),1,Homo sapiens,Intermediate,,974.0,,9606.0,AA5,,F,BAO_0000219,CHEMBL884011,6567
,80662,N,1,,,,2726,,Compound was evaluated for the anti-HIV activity against HIV strain IIIB in AA5 EBV-infected B-cell,1,Homo sapiens,Intermediate,,974.0,,9606.0,AA5,,F,BAO_0000219,CHEMBL619666,6568
,80566,N,1,,,,2726,,Compound was evaluated for the anti-HIV activity against HIV strain IIIB in U937 monocytic cell,1,Homo sapiens,Intermediate,,379.0,,9606.0,U-937,,F,BAO_0000219,CHEMBL619667,6569
,80578,N,1,,,,10747,,Hypersensitivity factor obtained from in vitro cytotoxicities against Chinese hamster ovary derived AA8 / UV4 cell lines,1,Cricetulus griseus,Intermediate,,274.0,,10029.0,UV4,,F,BAO_0000219,CHEMBL619668,6570
,80089,N,1,,,,11005,,"Inhibition of cell growth in culture against Chinese hamster ovary derived cell line, AA8",1,Cricetulus griseus,Expert,,185.0,,10029.0,CHO-AA8,,F,BAO_0000219,CHEMBL619669,6571
,80089,N,1,,,,12687,,Average intracellular compound concentration when the hypoxic SER=1.6,1,Cricetulus griseus,Intermediate,,185.0,,10029.0,CHO-AA8,,F,BAO_0000219,CHEMBL876608,6572
,80089,N,1,,,,12687,,Average intracellular compound concentration when the hypoxic SER=1.6.,1,Cricetulus griseus,Intermediate,,185.0,,10029.0,CHO-AA8,,F,BAO_0000219,CHEMBL619670,6573
,80089,N,1,,,,12687,,Average intracellular compound concentration where the hypoxia sensitizer enhancement ratio (SER)=1.6,1,Cricetulus griseus,Intermediate,,185.0,,10029.0,CHO-AA8,,F,BAO_0000219,CHEMBL619671,6574
,80089,N,1,,,,12687,,Average intracellular compound concentration where the sensitizer enhancement ratio (SER)=1.6 under hypoxia,1,Cricetulus griseus,Intermediate,,185.0,,10029.0,CHO-AA8,,F,BAO_0000219,CHEMBL619672,6575
,80089,N,1,,,,12687,,Compound concentration at which sensitizer enhancement ratio =1.6 under hypoxia.,1,Cricetulus griseus,Intermediate,,185.0,,10029.0,CHO-AA8,,F,BAO_0000219,CHEMBL619673,6576
,80089,N,1,,,,13436,,"Compound was tested for the concentration required to reduce cell survival under hypoxic conditions, using the cell line AA8 in the clonogenic assay.",1,Cricetulus griseus,Intermediate,,185.0,,10029.0,CHO-AA8,,F,BAO_0000219,CHEMBL619674,6577
,80089,N,1,,,,13435,,"Concentration needed to reduce cell survival to 10% of control values, using 1 hour exposure of plateau phase AA8 cells at 10e6 cells/ml",1,Cricetulus griseus,Intermediate,,185.0,,10029.0,CHO-AA8,,F,BAO_0000219,CHEMBL619675,6578
,80089,N,1,,,,13302,,Activity to reduce the surviving fraction to 10% (CT10) was used as an inverse measure of cytotoxic potency in aerobic conditions,1,Cricetulus griseus,Intermediate,,185.0,,10029.0,CHO-AA8,,F,BAO_0000219,CHEMBL619676,6579
,80089,N,1,,,,12687,,Compound concentration required to reduce cell survival to 10% of control values under hypoxic condition,1,Cricetulus griseus,Intermediate,,185.0,,10029.0,CHO-AA8,,F,BAO_0000219,CHEMBL619677,6580
,80089,N,1,,,,12687,,Compound concentration required to reduce cell survival to 10% of control values under hypoxic condition,1,Cricetulus griseus,Intermediate,,185.0,,10029.0,CHO-AA8,,A,BAO_0000219,CHEMBL619678,6581
,80089,N,1,,,,12687,,Compound concentration required to reduce cell survival to 10% of control values under hypoxic condition.,1,Cricetulus griseus,Intermediate,,185.0,,10029.0,CHO-AA8,,A,BAO_0000219,CHEMBL619679,6582
,80089,N,1,,,,12878,,Concentration x time (uM h) to reduce cell survival to 10% of control values under hypoxic conditions by clonogenic assay,1,Cricetulus griseus,Expert,,185.0,,10029.0,CHO-AA8,,A,BAO_0000219,CHEMBL619680,6583
,80089,N,1,,,,12878,,Concentration x time (uM h) to reduce cell survival to 10% of control values under hypoxic conditions by clonogenic assay. Inactive at the solubility limit,1,Cricetulus griseus,Intermediate,,185.0,,10029.0,CHO-AA8,,A,BAO_0000219,CHEMBL621457,6584
,80089,N,1,,,,14367,,Cytotoxicity under aerobic conditions determined to reduce the AA8 cell survival to 10% controls in clonogenic assay,1,Cricetulus griseus,Expert,,185.0,,10029.0,CHO-AA8,,F,BAO_0000219,CHEMBL876609,6585
,80089,N,1,,,,14367,,Cytotoxicity under aerobic conditions determined to reduce the AA8 cell survival to 10% of controls in clonogenic assay,1,Cricetulus griseus,Intermediate,,185.0,,10029.0,CHO-AA8,,F,BAO_0000219,CHEMBL621458,6586
,80089,N,1,,,,12398,,Aerobic cytotoxicity was assessed in a growth inhibition assay using log phase cultures of the chinese hamster ovary fibroblast line AA8,1,hampster,Expert,,185.0,,36483.0,CHO-AA8,,F,BAO_0000219,CHEMBL621459,6587
,80089,N,1,,,,12878,,Aerobic growth inhibition in Chinese hamster cell line AA8,1,Cricetulus griseus,Expert,,185.0,,10029.0,CHO-AA8,,F,BAO_0000219,CHEMBL621460,6588
,80089,N,1,,,,13820,,Cytotoxicity against AA8 cell and IC50 values were determined as drug concentration required to inhibit cell protein to 50%.,1,Cricetulus griseus,Expert,,185.0,,10029.0,CHO-AA8,,F,BAO_0000219,CHEMBL621461,6589
,80089,N,1,,,,13436,,Inhibition of growth under aerobic conditions in AA8 cells,1,Cricetulus griseus,Expert,,185.0,,10029.0,CHO-AA8,,F,BAO_0000219,CHEMBL621462,6590
,50588,N,1,In vivo,,,6084,,Oral bioavailability in dog (dose 10 mg/kg),1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL621463,6591
,50588,N,1,In vivo,,,5711,,Oral bioavailability in dog at 10 mg/kg of the compound,1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL621464,6592
,50588,N,1,In vivo,,,4353,,Oral bioavailability in dog (dose 5 uM/kg),1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL621465,6593
,50588,N,1,In vivo,,,4353,,Oral bioavailability in dog (dose 5 uM/kg),1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL621466,6594
,50588,N,1,In vivo,,,17800,,Oral bioavailability in dog (mongrel),1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL621467,6595
,50588,N,1,In vivo,,,3994,,Oral bioavailability in dog (dose 10 mg/kg),1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL621468,6596
,50588,N,1,In vivo,,,3994,,Oral bioavailability in dog (dose 10 mg/kg),1,Canis lupus familiaris,Intermediate,,,,9615.0,,,F,BAO_0000218,CHEMBL876734,6597
,50588,N,1,In vivo,,,5145,,Bioavailability in dog,1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL618476,6598
,50588,N,1,In vivo,,,16452,,Bioavailability in dog (dose 1 mg/kg i.v.),1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL618477,6599
,50588,N,1,In vivo,,,16452,,Pharmacokinetic data for dose given to dogs intravenously (oral PK study in parentheses),1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL618478,6600
,50588,N,1,In vivo,,,5983,,Pharmacokinetic property (F) was measured in dog at the dose of 0.032 mg/kg,1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL618479,6601
,50588,N,1,In vivo,,,4273,,Bioavailability in dog,1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL618480,6602
,50588,N,1,In vivo,,,12500,,Bioavailability in dog (dose 3-10 mg/kg),1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL618481,6603
Plasma,50588,N,1,In vivo,,,12500,,The compound was tested for bioavailability of compound in plasma of dog; Complete,1,Canis lupus familiaris,Intermediate,,,,9615.0,,1969.0,A,BAO_0000218,CHEMBL618482,6604
,50588,N,1,In vivo,,,3639,,Oral bioavailability in dog,1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL618483,6605
,50588,N,1,In vivo,,,3880,,Oral bioavailability in dog,1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL618484,6606
,50588,N,1,In vivo,,,4838,,Bioavailability in dog,1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL618485,6607
,50588,N,1,In vivo,,,15600,,oral bioavailability was measured in dogs,1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL618486,6608
,50588,N,1,,,,17248,,Compound was tested for plasma protein binding in dog; Not determined,1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL618487,6609
,50588,N,1,,,,17248,,Compound was tested for plasma protein binding of dog,1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL618488,6610
,50588,N,1,,,,17248,,Compound was tested for plasma protein binding of dog; Not determined,1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL876735,6611
,50588,N,1,,,,17443,,Concentration in dogs after oral administration at dose of 1 mg/kg after 180 min.,1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL618489,6612
,50588,N,1,In vivo,,,4186,,Apparent terminal elimination half-life in dog after administration of 20 mg/kg dose through peroral route,1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL618490,6613
,50588,N,1,,,,3749,,Half life was determined,1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL618491,6614
,50588,N,1,In vivo,,,3249,,Half life by ''Cr'' assay in dog at a dose of 5 mg/kg,1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL618492,6615
,50588,N,1,,,,3022,,Half life was evaluated in dog,1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL873354,6616
,50588,N,1,,,,3749,,Half life was determined,1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL618493,6617
,50588,N,1,In vivo,,,2517,,Biodistribution of compound was measured in bile at 2 hr post-injection in canine deep vein thrombosis model (DVT),1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL618494,6618
Heart,50588,N,1,In vivo,,,2517,,Biodistribution of compound was measured in heart at 2 hr post-injection in canine deep vein thrombosis model (DVT),1,Canis lupus familiaris,Intermediate,,,,9615.0,,948.0,A,BAO_0000218,CHEMBL618495,6619
Kidney,50588,N,1,In vivo,,,2517,,Biodistribution of compound was measured in kidney at 2 hr post-injection in canine deep vein thrombosis model (DVT),1,Canis lupus familiaris,Intermediate,,,,9615.0,,2113.0,A,BAO_0000218,CHEMBL618496,6620
Liver,50588,N,1,In vivo,,,2517,,Biodistribution of compound was measured in liver at 2 hr post-injection in canine deep vein thrombosis model (DVT),1,Canis lupus familiaris,Intermediate,,,,9615.0,,2107.0,A,BAO_0000218,CHEMBL618497,6621
Lung,50588,N,1,In vivo,,,2517,,Biodistribution of compound was measured in lung at 2 hr post-injection in canine deep vein thrombosis model (DVT),1,Canis lupus familiaris,Intermediate,,,,9615.0,,2048.0,A,BAO_0000218,CHEMBL618498,6622
Spleen,50588,N,1,In vivo,,,2517,,Biodistribution of compound was measured in spleen at 2 hr post-injection in canine deep vein thrombosis model (DVT),1,Canis lupus familiaris,Intermediate,,,,9615.0,,2106.0,A,BAO_0000218,CHEMBL618499,6623
,50588,N,1,,,,3639,,LogP in dog,1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL876736,6624
,50588,N,1,,,,6227,,Partition coefficient (logP),1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL618500,6625
,50588,N,1,,,,6227,,Partition coefficient in dog,1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL857831,6626
,50588,N,1,In vivo,,,17764,,Mean-residence time of compound after intravenous administration in dogs at 1.2 uM/kg,1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL618501,6627
,50588,N,1,In vivo,,,4809,,Pharmacokinetic parameter MRT was determined in Beagle dogs after (po) administration of a dose of 28 (uM/kg),1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL618502,6628
,50588,N,1,,,,5600,,In vitro metabolic stability determined after 30 min of incubation in dog hepatic microsomes,1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL618503,6629
,50588,N,1,,,,14294,,Metabolism of compound in dog S9 microsomes ('++''indicates 20-50% largest observed peak),1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL618504,6630
,50588,N,1,,,,14294,,Metabolism of compound in dog S9 microsomes ('++++' indicates largest observed peak),1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL618505,6631
,50588,N,1,,,,14294,,Metabolism of compound in dog S9 microsomes; Trace,1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL618506,6632
Liver,50588,N,1,,,,6251,,In vitro metabolic potential in dog liver microsomes,1,Canis lupus familiaris,Intermediate,,,,9615.0,,2107.0,A,BAO_0000218,CHEMBL618507,6633
,50588,N,1,In vivo,,,3748,,Oral bioavailability of perorally administered compound (10 mg/kg) was tested in dogs,1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL876737,6634
,50588,N,1,In vivo,,,2713,,Oral bioavailability in dog,1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL618508,6635
,50588,N,1,In vivo,,,6512,,Oral bioavailability in dog,1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL618509,6636
,50588,N,1,In vivo,,,6679,,Oral bioavailability was determined after 1 mg/kg (i.v.) / 2 mg/kg (p.o.) of compound administration,1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL618510,6637
,50588,N,1,In vivo,,,3749,,The compound was tested for bioavailability in dogs,1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL618511,6638
,50588,N,1,In vivo,,,3749,,The compound was tested for oral bioavailability in dogs,1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL618512,6639
,50588,N,1,In vivo,,,6742,,Oral bioavailability in dog,1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL618513,6640
,50588,N,1,,,,6227,,Compound was tested for percent protein binding (PB) in dog,1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL618514,6641
,50588,N,1,,,,6874,,Apparent permeability coefficient (Papp) for apical to basolateral flux was determined in MadinDarby Canine Kidney cells,1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL620052,6642
Plasma,50588,N,1,In vivo,,,2877,,Compound was evaluated for plasma clearance.,1,Canis lupus familiaris,Intermediate,,,,9615.0,,1969.0,A,BAO_0000218,CHEMBL620053,6643
Plasma,50588,N,1,In vivo,,,12500,,The compound was tested for plasma clearance in dog,1,Canis lupus familiaris,Intermediate,,,,9615.0,,1969.0,A,BAO_0000218,CHEMBL620054,6644
Plasma,50588,N,1,In vivo,,,12500,,The compound was tested for plasma clearance in dog at dose of 3-10 mgkg,1,Canis lupus familiaris,Intermediate,,,,9615.0,,1969.0,A,BAO_0000218,CHEMBL620055,6645
,50588,N,1,,,,4709,,Plasma protein binding was determined after intravenous administration of 1 mg/kg in dog,1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL620056,6646
Liver,50588,N,1,,,,5542,,In vitro relative rate of metabolism was determined in dog liver microsomes,1,Canis lupus familiaris,Intermediate,,,,9615.0,,2107.0,A,BAO_0000218,CHEMBL620057,6647
,50588,N,1,In vivo,,,17594,,Relative bioavailability after oral dose of compound at 3 mg/kg in dogs,1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL618939,6648
,50588,N,1,In vivo,,,2652,,Compound was evaluated for half-life period in dogs at a dose of 5 mpk perorally,1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL618940,6649
,50588,N,1,In vivo,,,17764,,Half life after intravenous administration in dogs at 1.2 uM/kg,1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL618941,6650
Lung,50594,N,1,,,,6599,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/lung bearing S180 tumor cell line for 30 minutes,1,Mus musculus,Intermediate,,42.0,,10090.0,CCRF S-180,2048.0,A,BAO_0000218,CHEMBL624473,6651
Lung,50594,N,1,,,,6599,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/lung bearing S180 tumor cell line for 4 hours,1,Mus musculus,Intermediate,,42.0,,10090.0,CCRF S-180,2048.0,A,BAO_0000218,CHEMBL624474,6652
Lung,50594,N,1,,,,6599,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/lung bearing S180 tumor cell line for 8 hours,1,Mus musculus,Intermediate,,42.0,,10090.0,CCRF S-180,2048.0,A,BAO_0000218,CHEMBL624475,6653
,50594,N,1,,,,6599,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/muscle bearing S180 tumor cell line for 1 hour,1,Mus musculus,Intermediate,,42.0,,10090.0,CCRF S-180,,A,BAO_0000218,CHEMBL624476,6654
,50594,N,1,,,,6599,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/muscle bearing S180 tumor cell line for 2 hours,1,Mus musculus,Intermediate,,42.0,,10090.0,CCRF S-180,,A,BAO_0000218,CHEMBL623478,6655
,50594,N,1,,,,6599,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/muscle bearing S180 tumor cell line for 30 minutes,1,Mus musculus,Intermediate,,42.0,,10090.0,CCRF S-180,,A,BAO_0000218,CHEMBL623479,6656
,50594,N,1,,,,6599,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/muscle bearing S180 tumor cell line for 4 hours,1,Mus musculus,Intermediate,,42.0,,10090.0,CCRF S-180,,A,BAO_0000218,CHEMBL623480,6657
,50594,N,1,,,,6599,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/muscle bearing S180 tumor cell line for 8 hours,1,Mus musculus,Intermediate,,42.0,,10090.0,CCRF S-180,,A,BAO_0000218,CHEMBL623481,6658
Brain,50594,N,1,,,,17641,,C2 in brain of mice at the oral dose of 50 mg/kg,1,Mus musculus,Intermediate,,,,10090.0,,955.0,A,BAO_0000218,CHEMBL623482,6659
Kidney,50594,N,1,,,,17641,,C2 in kidney of mice at the oral dose of 50 mg/kg,1,Mus musculus,Intermediate,,,,10090.0,,2113.0,A,BAO_0000218,CHEMBL623483,6660
Liver,50594,N,1,,,,17641,,C2 in liver of mice at the oral dose of 50 mg/kg,1,Mus musculus,Intermediate,,,,10090.0,,2107.0,A,BAO_0000218,CHEMBL623484,6661
Lung,50594,N,1,,,,17641,,C2 in lungs of mice at the oral dose of 50 mg/kg,1,Mus musculus,Intermediate,,,,10090.0,,2048.0,A,BAO_0000218,CHEMBL623485,6662
Spleen,50594,N,1,,,,17641,,C2 in spleen of mice at the oral dose of 50 mg/kg,1,Mus musculus,Intermediate,,,,10090.0,,2106.0,A,BAO_0000218,CHEMBL623486,6663
,50594,N,1,In vivo,,,17852,,Plasma clearance in mouse,1,Mus musculus,Intermediate,,,,10090.0,,,A,BAO_0000218,CHEMBL623487,6664
,50594,N,1,In vivo,,,17764,,Clearance of compound after intravenous administration in mice at 24 uM/kg,1,Mus musculus,Intermediate,,,,10090.0,,,A,BAO_0000218,CHEMBL623488,6665
,50594,N,1,In vivo,,,17837,,Clearance from mouse blood following i.v. administration of 10 mg/kg,1,Mus musculus,Intermediate,,,,10090.0,,,A,BAO_0000218,CHEMBL623489,6666
,50594,N,1,In vivo,,,2675,,Clearance was evaluated in mice after intravenous administration,1,Mus musculus,Intermediate,,,,10090.0,,,A,BAO_0000218,CHEMBL875157,6667
,50594,N,1,In vivo,,,2675,,Clearance was evaluated in mice after oral administration,1,Mus musculus,Intermediate,,,,10090.0,,,A,BAO_0000218,CHEMBL623490,6668
,50594,N,1,In vivo,,,4239,,Pharmacokinetic property (Plasma clearance) was measured in mouse,1,Mus musculus,Intermediate,,,,10090.0,,,A,BAO_0000218,CHEMBL623491,6669
,50594,N,1,In vivo,,,17753,,Plasma clearance of compound was determined at 40 mg/Kg,1,Mus musculus,Intermediate,,,,10090.0,,,A,BAO_0000218,CHEMBL623492,6670
,50594,N,1,In vivo,,,17753,,Plasma clearance of at 24 mg/Kg,1,Mus musculus,Intermediate,,,,10090.0,,,A,BAO_0000218,CHEMBL623493,6671
,50594,N,1,In vivo,,,17753,,Plasma clearance at 24 mg/Kg,1,Mus musculus,Intermediate,,,,10090.0,,,A,BAO_0000218,CHEMBL623494,6672
,50594,N,1,In vivo,,,17753,,Plasma clearance at 5 mg/Kg,1,Mus musculus,Intermediate,,,,10090.0,,,A,BAO_0000218,CHEMBL623495,6673
,50594,N,1,In vivo,,,5727,,Plasma clearance in mice,1,Mus musculus,Intermediate,,,,10090.0,,,A,BAO_0000218,CHEMBL623496,6674
,50594,N,1,In vivo,,,2862,,Plasma clearance value upon iv administration in mouse,1,Mus musculus,Intermediate,,,,10090.0,,,A,BAO_0000218,CHEMBL623497,6675
Plasma,50594,N,1,In vivo,,,5980,,Total plasma clearance in mice,1,Mus musculus,Intermediate,,,,10090.0,,1969.0,A,BAO_0000218,CHEMBL623498,6676
,50594,N,1,In vivo,,,17592,,Clearance in mouse,1,Mus musculus,Intermediate,,,,10090.0,,,A,BAO_0000218,CHEMBL623499,6677
,50594,N,1,In vivo,,,17718,,Clearance value was determined,1,Mus musculus,Intermediate,,,,10090.0,,,A,BAO_0000218,CHEMBL623500,6678
,50594,N,1,In vivo,,,16597,,Plasma clearance at a dose of 10 mg/kg intravenous administration in mice.,1,Mus musculus,Intermediate,,,,10090.0,,,A,BAO_0000218,CHEMBL623501,6679
,22229,U,0,,,,17384,,Calculated partition coefficient (clogP),1,,Intermediate,,,,,,,P,BAO_0000100,CHEMBL875158,6680
,50594,N,1,In vivo,,,6062,,Plasma clearance for the compound was measured in mouse after an iv dose of 1 mg/kg,1,Mus musculus,Intermediate,,,,10090.0,,,A,BAO_0000218,CHEMBL623502,6681
,50594,N,1,In vivo,,,17734,,Plasma clearance rate after intraperitoneal administration of 100 mg/kg in mice,1,Mus musculus,Intermediate,,,,10090.0,,,A,BAO_0000218,CHEMBL623503,6682
,50594,N,1,In vivo,,,6348,,Plasma clearance was determined in mouse after 5 mg/kg (i.v.) and 6 mg/kg (p.o.) administration,1,Mus musculus,Intermediate,,,,10090.0,,,A,BAO_0000218,CHEMBL623504,6683
,50594,N,1,In vivo,,,5969,,In vivo total clearance was determined in murine septicemia at dose of 100 mg/kg,1,Mus musculus,Intermediate,,,,10090.0,,,A,BAO_0000218,CHEMBL623505,6684
,50594,N,1,In vivo,,,5969,,In vivo total clearance was determined in murine septicemia at dose of 50 mg/kg,1,Mus musculus,Intermediate,,,,10090.0,,,A,BAO_0000218,CHEMBL623506,6685
,50594,N,1,In vivo,,,5969,,In vivo total clearance was determined in murine septicemia at dose of 50 mg/kg;ND=not determined,1,Mus musculus,Intermediate,,,,10090.0,,,A,BAO_0000218,CHEMBL623507,6686
,50594,N,1,In vivo,,,16597,,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for Cmax,1,Mus musculus,Intermediate,,,,10090.0,,,A,BAO_0000218,CHEMBL623508,6687
,50594,N,1,In vivo,,,5781,,Cmax after oral administration at 30 mg/kg in ICR mouse,1,Mus musculus,Intermediate,,,,10090.0,,,A,BAO_0000218,CHEMBL623509,6688
,50594,N,1,In vivo,,,17764,,Cmax after peroral administration in mice at 2.4 uM/kg,1,Mus musculus,Intermediate,,,,10090.0,,,A,BAO_0000218,CHEMBL875159,6689
Brain,50594,N,1,In vivo,,,17641,,Cmax in brain of mice at the oral dose of 50 mg/kg,1,Mus musculus,Intermediate,,,,10090.0,,955.0,A,BAO_0000218,CHEMBL623510,6690
Kidney,50594,N,1,In vivo,,,17641,,Cmax in kidney of mice at the oral dose of 50 mg/kg,1,Mus musculus,Intermediate,,,,10090.0,,2113.0,A,BAO_0000218,CHEMBL623511,6691
Liver,50594,N,1,In vivo,,,17641,,Cmax in liver of mice at the oral dose of 50 mg/kg,1,Mus musculus,Intermediate,,,,10090.0,,2107.0,A,BAO_0000218,CHEMBL623512,6692
Lung,50594,N,1,In vivo,,,17641,,Cmax in lungs of mice at the oral dose of 50 mg/kg,1,Mus musculus,Intermediate,,,,10090.0,,2048.0,A,BAO_0000218,CHEMBL623513,6693
,50594,N,1,In vivo,,,17764,,Cmax in mice at 18 uM/kg i.p. administration,1,Mus musculus,Intermediate,,,,10090.0,,,F,BAO_0000218,CHEMBL623514,6694
,50594,N,1,In vivo,,,17764,,Cmax in mice at 23 uM/kg i.v. administration,1,Mus musculus,Intermediate,,,,10090.0,,,F,BAO_0000218,CHEMBL622609,6695
,50594,N,1,In vivo,,,17764,,Cmax in mice at 24 uM/kg i.p. administration,1,Mus musculus,Intermediate,,,,10090.0,,,F,BAO_0000218,CHEMBL622610,6696
,50594,N,1,In vivo,,,17764,,Cmax in mice at 25 uM/kg i.p. administration,1,Mus musculus,Intermediate,,,,10090.0,,,F,BAO_0000218,CHEMBL621823,6697
,50594,N,1,In vivo,,,17764,,Cmax in mice at 26 uM/kg i.p. administration,1,Mus musculus,Intermediate,,,,10090.0,,,F,BAO_0000218,CHEMBL621824,6698
Spleen,50594,N,1,In vivo,,,17641,,Cmax in spleen of mice at the oral dose of 50 mg/kg,1,Mus musculus,Intermediate,,,,10090.0,,2106.0,A,BAO_0000218,CHEMBL621825,6699
,50594,N,1,In vivo,,,16597,,Cmax value at a dose of 10 mg/kg intravenous administration in mice.,1,Mus musculus,Intermediate,,,,10090.0,,,A,BAO_0000218,CHEMBL621826,6700
,50594,N,1,In vivo,,,16597,,Cmax value at a dose of 10 mg/kg peroral administration in mice.,1,Mus musculus,Intermediate,,,,10090.0,,,A,BAO_0000218,CHEMBL621827,6701
,50594,N,1,In vivo,,,5727,,Cmax value was determined,1,Mus musculus,Intermediate,,,,10090.0,,,A,BAO_0000218,CHEMBL621828,6702
,50594,N,1,In vivo,,,5951,,Cmax value in IRC mice,1,Mus musculus,Intermediate,,,,10090.0,,,A,BAO_0000218,CHEMBL621829,6703
,50594,N,1,In vivo,,,5506,,Cmax value was determined at a dose of 100 mg/kg (i.p.) in Mice,1,Mus musculus,Intermediate,,,,10090.0,,,A,BAO_0000218,CHEMBL621830,6704
,50594,N,1,In vivo,,,5506,,Cmax value was determined at a dose of 200 mg/kg (i.p.) in Mice,1,Mus musculus,Intermediate,,,,10090.0,,,A,BAO_0000218,CHEMBL621831,6705
Plasma,50594,N,1,In vivo,,,14239,,Compound was evaluated for maximum plasma concentration by administering orally at 25 mg/kg in mice,1,Mus musculus,Intermediate,,,,10090.0,,1969.0,A,BAO_0000218,CHEMBL621832,6706
Plasma,50594,N,1,In vivo,,,4890,,"Compound was evaluated for the pharmacokinetic parameter, maximum plasma concentration",1,Mus musculus,Intermediate,,,,10090.0,,1969.0,A,BAO_0000218,CHEMBL624579,6707
,50594,N,1,In vivo,,,429,,Evaluated for pharmacokinetic parameter Cmax in mouse at the dose 20 mg/kg,1,Mus musculus,Intermediate,,,,10090.0,,,A,BAO_0000218,CHEMBL624580,6708
,50535,N,1,,,,10986,,anti-filarial Activity was measured against Acanthocheilonema viteae in jirds at 50 mg/kg/day(5 days) dose,1,Acanthocheilonema viteae,Intermediate,,,,6277.0,,,F,BAO_0000218,CHEMBL624581,6709
,50535,N,1,,,,10986,,anti-filarial Activity was measured against Acanthocheilonema viteae in jirds at 6.25 mg/kg/day(5 days) dose,1,Acanthocheilonema viteae,Intermediate,,,,6277.0,,,F,BAO_0000218,CHEMBL624582,6710
,50535,N,1,,,,10986,,anti-filarial Activity was measured against Acanthocheilonema viteae in jirds at 75 mg/kg/day(5 days) dose,1,Acanthocheilonema viteae,Intermediate,,,,6277.0,,,F,BAO_0000218,CHEMBL624583,6711
,80018,N,1,,,,13227,,Inhibitory activity against human tumor cell line A0375 melanoma.,1,Homo sapiens,Intermediate,,455.0,,9606.0,A-375,,F,BAO_0000219,CHEMBL624584,6712
,12512,D,9,,,Brain membranes,4481,,Displacement of [3H]N6-PIA binding from A1 receptor in whole rat brain membranes,1,Rattus norvegicus,Expert,,,,10116.0,,,B,BAO_0000249,CHEMBL624585,6713
,114,D,9,,,,16931,,Forskolin-induced cAMP production at human A1 adenosine receptor,1,Homo sapiens,Expert,,,,9606.0,,,F,BAO_0000019,CHEMBL875165,6714
,114,H,8,,,,3850,,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 0.1; change of less than 5% of allosteric enhancement.,1,,Autocuration,,449.0,,,CHO,,F,BAO_0000219,CHEMBL619490,6715
,114,H,8,,,,3850,,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 0.1 uM; An increase of cAmp content of cells,1,,Autocuration,,449.0,,,CHO,,F,BAO_0000219,CHEMBL619491,6716
,114,H,8,,,,3850,,Percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 0.1 uM,1,,Expert,,449.0,,,CHO,,F,BAO_0000219,CHEMBL619492,6717
,114,H,8,,,,3850,,Percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 0.1 uM concentration,1,,Expert,,449.0,,,CHO,,F,BAO_0000219,CHEMBL619493,6718
,114,H,8,,,,3850,,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 0.1 uM concentration; An increase of cAmp content of cells,1,,Autocuration,,449.0,,,CHO,,F,BAO_0000219,CHEMBL619494,6719
,114,H,8,,,,3850,,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 0.1 uM concentration; change of less than 5% of allosteric enhancement,1,,Autocuration,,449.0,,,CHO,,F,BAO_0000219,CHEMBL619495,6720
,114,H,8,,,,3850,,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 0.1 uM concentration; change of less than 5% of allosteric enhancement.,1,,Autocuration,,449.0,,,CHO,,F,BAO_0000219,CHEMBL619496,6721
,114,D,9,,,,3850,,Percent response to 10 uM PD-81723 on CHO cells expressing human A1-adenosine receptor at 0.1 uM; An increase of cAmp content of cells,1,Homo sapiens,Expert,,449.0,,9606.0,CHO,,F,BAO_0000219,CHEMBL619497,6722
,114,H,8,,,,3850,,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 1 uM,1,,Autocuration,,449.0,,,CHO,,F,BAO_0000219,CHEMBL619498,6723
,114,H,8,,,,3850,,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 1 uM; change of less than 5% of allosteric enhancement.,1,,Autocuration,,449.0,,,CHO,,F,BAO_0000219,CHEMBL619499,6724
,114,H,8,,,,3850,,Percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 1 uM concentration,1,,Expert,,449.0,,,CHO,,F,BAO_0000219,CHEMBL619500,6725
,114,H,8,,,,3850,,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 1 uM concentration; change of less than 5% of allosteric enhancement.,1,,Autocuration,,449.0,,,CHO,,F,BAO_0000219,CHEMBL619501,6726
,114,H,8,,,,3850,,Percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 1 uM; An increase of cAmp content of cells,1,,Expert,,449.0,,,CHO,,F,BAO_0000219,CHEMBL619502,6727
,114,H,8,,,,3850,,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 10 uM,1,,Autocuration,,449.0,,,CHO,,F,BAO_0000219,CHEMBL619503,6728
,114,H,8,,,,3850,,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 10 uM; An increase of cAmp content of cells,1,,Autocuration,,449.0,,,CHO,,F,BAO_0000219,CHEMBL619504,6729
,114,H,8,,,,3850,,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 10 uM; change of less than 5% of allosteric enhancement.,1,,Autocuration,,449.0,,,CHO,,F,BAO_0000219,CHEMBL621298,6730
,114,H,8,,,,3850,,Percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 10 uM concentration,1,,Expert,,449.0,,,CHO,,F,BAO_0000219,CHEMBL621299,6731
,114,H,8,,,,3850,,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 10 uM concentration; An increase of cAmp content of cells,1,,Autocuration,,449.0,,,CHO,,F,BAO_0000219,CHEMBL621300,6732
,114,H,8,,,,3850,,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 10 uM concentration; change of less than 5% of allosteric enhancement.,1,,Autocuration,,449.0,,,CHO,,F,BAO_0000219,CHEMBL621301,6733
,114,H,8,,,,3850,,Percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 10 uM; An increase of cAmp content of cells,1,,Expert,,449.0,,,CHO,,F,BAO_0000219,CHEMBL621302,6734
,80013,N,1,,,,12680,,Ability to inhibit [125I]ET1 binding to vascular smooth muscle (vsm)- A10 cells,1,Oryctolagus cuniculus,Intermediate,,164.0,,9986.0,A10,,F,BAO_0000219,CHEMBL621303,6735
,22226,U,0,,,,1313,,In vitro potassium channel opening activity in A10 (smooth muscle) cells,1,Rattus norvegicus,Autocuration,,164.0,,10116.0,A10,,F,BAO_0000219,CHEMBL621304,6736
,22226,U,0,,,,1313,,In vitro potassium channel opening activity in A10 (smooth muscle) cells; Inactive,1,Rattus norvegicus,Autocuration,,164.0,,10116.0,A10,,F,BAO_0000219,CHEMBL621305,6737
,80013,N,1,,,,17567,,Effect on membrane potential of mitochondria in A10 smooth muscle cells from rats,1,Rattus norvegicus,Intermediate,,164.0,,10116.0,A10,,F,BAO_0000219,CHEMBL621306,6738
,80013,N,1,,,,17567,,Effect on membrane potential of mitochondria of A10 smooth muscle cells in rats,1,Rattus norvegicus,Intermediate,,164.0,,10116.0,A10,,F,BAO_0000219,CHEMBL618444,6739
,80013,N,1,,,,11819,,Percent decrease in fluorescence in a membrane potential assay using the A10 cell line derived from embryonic rat aorta at 0.001 uM,1,Rattus norvegicus,Intermediate,,164.0,,10116.0,A10,,F,BAO_0000219,CHEMBL618445,6740
,80089,N,1,,,,13436,,Compound was tested for aerobic growth inhibition against AA8 cells after 4 hr of exposure,1,Cricetulus griseus,Intermediate,,185.0,,10029.0,CHO-AA8,,F,BAO_0000219,CHEMBL618446,6741
,80089,N,1,,,,12687,,Concentration required to reduce AA8 cell numbers to 50% of controls in a growth inhibition microassay,1,Cricetulus griseus,Intermediate,,185.0,,10029.0,CHO-AA8,,F,BAO_0000219,CHEMBL618447,6742
,80089,N,1,,,,12651,,Concentration of the drug to inhibit chinese hamster ovary derived cell (AA8) growth in culture,1,Cricetulus griseus,Intermediate,,185.0,,10029.0,CHO-AA8,,F,BAO_0000219,CHEMBL618448,6743
,80089,N,1,,,,13300,,Cytotoxicity in a growth inhibition assay against aerobic cultures of AA8 cells was determined,1,Cricetulus griseus,Intermediate,,185.0,,10029.0,CHO-AA8,,F,BAO_0000219,CHEMBL618449,6744
,80089,N,1,,,,15296,,Cytotoxicity on AA8 cell growth (reduce cell number by 50%).,1,Cricetulus griseus,Intermediate,,185.0,,10029.0,CHO-AA8,,F,BAO_0000219,CHEMBL618637,6745
,80089,N,1,,,,15328,,"Cytotoxicity in chinese hamster ovary tumor cell line-AA8, by growth inhibition assay.",1,Cricetulus griseus,Intermediate,,185.0,,10029.0,CHO-AA8,,F,BAO_0000219,CHEMBL618638,6746
,80089,N,1,,,,13302,,Growth inhibition activity was measured in repair proficient AA8 cells under aerobic conditions (4 hours drug exposure),1,Cricetulus griseus,Intermediate,,185.0,,10029.0,CHO-AA8,,F,BAO_0000219,CHEMBL618639,6747
,80089,N,1,,,,14367,,"Growth inhibition of aerobic AA8 cells, after 18 hours exposure",1,Cricetulus griseus,Expert,,185.0,,10029.0,CHO-AA8,,F,BAO_0000219,CHEMBL618640,6748
,80089,N,1,,,,17002,,In vitro cellular toxicity against chinese hamster AA8 cell line after 4 hr of compound exposure,1,Cricetulus griseus,Expert,,185.0,,10029.0,CHO-AA8,,F,BAO_0000219,CHEMBL618641,6749
,80089,N,1,,,,13436,,Inhibitory activity against AA8 cell growth in aerobic condition after 4 hr of exposure,1,Cricetulus griseus,Intermediate,,185.0,,10029.0,CHO-AA8,,F,BAO_0000219,CHEMBL618642,6750
,80089,N,1,,,,13435,,Inhibitory activity against aerobic growth of AA8 cells.,1,Cricetulus griseus,Intermediate,,185.0,,10029.0,CHO-AA8,,F,BAO_0000219,CHEMBL618643,6751
,80089,N,1,,,,10503,,Tested for the in vitro cytotoxicity against transformed chinese hamster fibroblast line AA8,1,Cricetulus griseus,Intermediate,,185.0,,10029.0,CHO-AA8,,A,BAO_0000219,CHEMBL884013,6752
,80089,N,1,,,,10503,,In vitro cytotoxicity against transformed chinese hamster fibroblast line AA8,1,Cricetulus griseus,Expert,,185.0,,10029.0,CHO-AA8,,F,BAO_0000219,CHEMBL622723,6753
,80089,N,1,,,,10503,,Tested for the in vitro cytotoxicity against transformed chinese hamster fibroblast line AA8,1,Cricetulus griseus,Intermediate,,185.0,,10029.0,CHO-AA8,,F,BAO_0000219,CHEMBL622724,6754
,80089,N,1,,,,15090,,Tested for growth inhibition against AA8 tumor cell line(chinese hamster ovary).,1,Cricetulus griseus,Expert,,185.0,,10029.0,CHO-AA8,,F,BAO_0000219,CHEMBL622725,6755
,80089,N,1,,,,10368,,Cytotoxicity against AA8 cell line,1,Cricetulus griseus,Expert,,185.0,,10029.0,CHO-AA8,,F,BAO_0000219,CHEMBL622726,6756
,80089,N,1,,,,12651,,Hypersensitivity factor(HF) was determined as ratio of IC50(AA8) to IC50(UV4),1,Cricetulus griseus,Intermediate,,185.0,,10029.0,CHO-AA8,,F,BAO_0000219,CHEMBL622727,6757
,80089,N,1,,,,12687,,In vitro therapeutic index (aerobic IC50 / hypoxic C1.6),1,Cricetulus griseus,Intermediate,,185.0,,10029.0,CHO-AA8,,A,BAO_0000219,CHEMBL622728,6758
,80089,N,1,,,,12687,,In vitro therapeutic index (aerobic IC50 / hypoxic C1.6),1,Cricetulus griseus,Intermediate,,185.0,,10029.0,CHO-AA8,,F,BAO_0000219,CHEMBL622729,6759
,80089,N,1,,,,12687,,In vitro therapeutic index (aerobic IC50 / hypoxic C1.6),1,Cricetulus griseus,Intermediate,,185.0,,10029.0,CHO-AA8,,A,BAO_0000219,CHEMBL622730,6760
,80089,N,1,,,,1890,,Compound was evaluated for cytotoxicity against CHO AA8 cell lines for 4 hr at pH-7.4,1,Cricetulus griseus,Intermediate,,185.0,,10029.0,CHO-AA8,,F,BAO_0000219,CHEMBL622731,6761
,80089,N,1,,,,10747,,Compound was evaluated for in vitro cytotoxicities against Chinese hamster ovary derived AA8 cell lines.,1,Cricetulus griseus,Intermediate,,185.0,,10029.0,CHO-AA8,,F,BAO_0000219,CHEMBL622732,6762
,80089,N,1,,,,10747,,Compound was evaluated for in vitro cytotoxicities against Chinese hamster ovary derived AA8 cell lines.,1,Cricetulus griseus,Intermediate,,185.0,,10029.0,CHO-AA8,,F,BAO_0000219,CHEMBL622733,6763
,22224,U,0,,,,11616,,Maximum tolerated dose (MTD) in C3H/HeN mice (single ip dose),1,Cricetulus griseus,Autocuration,,,,10029.0,,,F,BAO_0000218,CHEMBL622734,6764
,80089,N,1,,,,11616,,Concentration required to increase radiation sensitivity by 1.3 when AA8 cells are exposed to drug for 30 min before and during irradiation under hypoxic condition.,1,Cricetulus griseus,Expert,,185.0,,10029.0,CHO-AA8,,F,BAO_0000219,CHEMBL622735,6765
,22224,U,0,,,,3471,,Oxygen dependence of cytotoxicity was assessed by clonogenic assay using stirred suspension cultures of AA8 cells after 1 hr under anoxic conditions,1,Cricetulus griseus,Autocuration,,185.0,,10029.0,CHO-AA8,,F,BAO_0000219,CHEMBL618746,6766
,22224,U,0,,,,3471,,Oxygen dependence of cytotoxicity was assessed by clonogenic assay using stirred suspension cultures of AA8 cells after 3h under anoxic conditions,1,Cricetulus griseus,Autocuration,,185.0,,10029.0,CHO-AA8,,F,BAO_0000219,CHEMBL618747,6767
,22224,U,0,,,,3471,,Oxygen dependence of cytotoxicity was assessed by clonogenic assay using stirred suspension cultures of AA8 cells after 4 hr under anoxic conditions,1,Cricetulus griseus,Autocuration,,185.0,,10029.0,CHO-AA8,,F,BAO_0000219,CHEMBL620540,6768
,22224,U,0,,,,3471,,Oxygen dependence of cytotoxicity was assessed by clonogenic assay using stirred suspension cultures of AA8 cells after 1 hr under aerobic conditions,1,Cricetulus griseus,Autocuration,,185.0,,10029.0,CHO-AA8,,F,BAO_0000219,CHEMBL620541,6769
,22224,U,0,,,,3471,,Oxygen dependence of cytotoxicity was assessed by clonogenic assay using stirred suspension cultures of AA8 cells after 3h under aerobic conditions,1,Cricetulus griseus,Autocuration,,185.0,,10029.0,CHO-AA8,,F,BAO_0000219,CHEMBL620542,6770
,22224,U,0,,,,3471,,Oxygen dependence of cytotoxicity was assessed by clonogenic assay using stirred suspension cultures of AA8 cells after 4 hr under aerobic conditions,1,Cricetulus griseus,Autocuration,,185.0,,10029.0,CHO-AA8,,F,BAO_0000219,CHEMBL620543,6771
,22224,U,0,,,,3471,,Ratio of oxygen dependence of cytotoxicities of AA8 cells in aerobic condition to anoxic condition,1,Cricetulus griseus,Autocuration,,185.0,,10029.0,CHO-AA8,,F,BAO_0000219,CHEMBL618832,6772
,80089,N,1,,,,11616,,Concentration required to reduce AA8 cell survival by 10%,1,Cricetulus griseus,Expert,,185.0,,10029.0,CHO-AA8,,F,BAO_0000219,CHEMBL618833,6773
,22224,U,0,,,,2656,,"Concentration required to reduce cell survival to 10% of controls under hypoxic conditions, using the AA8 (chinese hamster) aerobic cells",1,Cricetulus griseus,Autocuration,,185.0,,10029.0,CHO-AA8,,F,BAO_0000219,CHEMBL618834,6774
,22224,U,0,,,,10518,,Tested for the product of the drug concentration to the exposure time needed to reduce cell survival to 10% of controls using AA8 cells at 10 E 6 /mL in the clonogenic assay,1,Cricetulus griseus,Autocuration,,185.0,,10029.0,CHO-AA8,,F,BAO_0000219,CHEMBL618835,6775
,22224,U,0,,,,10518,,CT10 (air/N2) ratio of the product of the drug concentration to the exposure time needed to reduce cell survival to 10% of controls using AA8 cells at 10 E 6 /mL in the clonogenic assay,1,Cricetulus griseus,Autocuration,,185.0,,10029.0,CHO-AA8,,F,BAO_0000219,CHEMBL618836,6776
,22224,U,0,,,,10518,,CT10 (air/N2) ratio of the product of the drug concentration to the exposure time needed to reduce cell survival to 10% of controls using AA8 cells at 10 E 6 /mL in the clonogenic assay; range is 0.8-1.5,1,Cricetulus griseus,Autocuration,,185.0,,10029.0,CHO-AA8,,F,BAO_0000219,CHEMBL618837,6777
,22224,U,0,,,,10518,,CT10 (air/N2) ratio of the product of the drug concentration to the exposure time needed to reduce cell survival to 10% of controls using AA8 cells at 10 E 6 /mL in the clonogenic assay; range is 1-2,1,Cricetulus griseus,Autocuration,,185.0,,10029.0,CHO-AA8,,F,BAO_0000219,CHEMBL618838,6778
,22224,U,0,,,,16156,,Ability to reduce cell density of AA8 cells to 50% after 4 hr of exposure to air,1,Cricetulus griseus,Autocuration,,185.0,,10029.0,CHO-AA8,,F,BAO_0000219,CHEMBL618839,6779
,22224,U,0,,,,2656,,Aerobic cytotoxic activity was evaluated by the growth inhibition of AA8 (chinese hamster) aerobic cells,1,Cricetulus griseus,Autocuration,,185.0,,10029.0,CHO-AA8,,F,BAO_0000219,CHEMBL618840,6780
,22224,U,0,,,,11005,,"Compound was evaluated for the inhibition of cell growth in culture against Chinese hamster ovary derived cell line, AA8",1,Cricetulus griseus,Autocuration,,,,10029.0,,,F,BAO_0000019,CHEMBL618841,6781
,22224,U,0,,,,11942,,Concentration for 50% inhibition of AA8 cells growth under aerobic conditions after 18 hours exposure,1,Cricetulus griseus,Autocuration,,185.0,,10029.0,CHO-AA8,,F,BAO_0000219,CHEMBL618842,6782
,22224,U,0,,,,2128,,Concentration required for 50% inhibition of growth of AA8 cells following 4 hr drug exposure,1,Cricetulus griseus,Autocuration,,185.0,,10029.0,CHO-AA8,,F,BAO_0000219,CHEMBL618843,6783
,50588,N,1,In vivo,,,16907,,Half life period after 15 mg/kg iv dose in Dogs,1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL618844,6784
,50588,N,1,In vivo,,,16907,,Half life period after 30 mg/kg po dose in Dogs,1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL618845,6785
,50588,N,1,In vivo,,,9579,,Half life was measured after oral 2b administration (tested in 6 dogs),1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL618846,6786
,50588,N,1,In vivo,,,9579,,Half life was measured in dog after oral 17b administration,1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL618847,6787
,50588,N,1,In vivo,,,9579,,Pharmacokinetic parameter T max determined in dog after oral administration of 17b,1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL618848,6788
,50588,N,1,In vivo,,,9579,,Pharmacokinetic parameter T max determined in dog after oral administration of 2b,1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL618849,6789
,50588,N,1,In vivo,,,16907,,Tmax value after 15 mg/kg iv dose in Dogs,1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL618850,6790
,50588,N,1,In vivo,,,16907,,Tmax value after 30 mg/kg po dose in Dogs,1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL618851,6791
,50588,N,1,In vivo,,,3184,,Compound was evaluated for its half life when administered intravenously in dog,1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL873815,6792
Plasma,50588,N,1,In vivo,,,5017,,Compound was tested for plasma half life when administered in dog perorally (1 mg/kg) and intravenously (0.2 mg/kg),1,Canis lupus familiaris,Intermediate,,,,9615.0,,1969.0,A,BAO_0000218,CHEMBL618852,6793
,50588,N,1,,,,6821,,Elimination Half-life of compound was determined in dog,1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL618853,6794
,50588,N,1,In vivo,,,17839,,Half life of compound in dog following oral administration,1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL618854,6795
,50588,N,1,,,,17267,,Half life of compound was determined in dog,1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL618855,6796
Blood,50588,N,1,,,,4727,,Half life of compound was determined in dog blood,1,Canis lupus familiaris,Intermediate,,,,9615.0,,178.0,A,BAO_0000218,CHEMBL618856,6797
,50588,N,1,In vivo,,,5238,,Half life after oral and iv dosing in dogs,1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL875827,6798
,50588,N,1,,,,4942,,Half life in dogs in hours,1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL618857,6799
,50588,N,1,In vivo,,,6505,,Half life on i.v. administration of 2 mg/kg was measured in dog,1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL618858,6800
,50588,N,1,In vivo,,,5130,,t1/2 in dog after oral dose (1 mg/kg),1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL618859,6801
,50588,N,1,,,,1475,,Half life was evaluated in dog,1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL618860,6802
,50588,N,1,In vivo,,,17804,,Half life period of compound was determined after intravenous administration at 2 mg/kg,1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL618861,6803
,50588,N,1,In vivo,,,17804,,Half life period of compound was determined after peroral administration at 2 mg/kg,1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL622539,6804
,50588,N,1,In vivo,,,6084,,Half life period (10 mg/kg) was determined in dog,1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL622540,6805
,50588,N,1,In vivo,,,6084,,Half life period (10 mg/kg) was determined in dog,1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL873803,6806
,50588,N,1,In vivo,,,5542,,Half life period by iv administration in dog at a dose of 0.3 mg/kg,1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL873804,6807
,50588,N,1,In vivo,,,5542,,Half life period by po administration in dog at a dose of 0.3 mg/kg,1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL624311,6808
,50588,N,1,,,,6084,,Half life period in dog,1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL624312,6809
,50588,N,1,In vivo,,,6241,,Half life period in dogs after oral administration at 1 mg/kg,1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL624313,6810
,50588,N,1,In vivo,,,1916,,Half life period was evaluated against Beagle dog at a dose of 15 mg/kg after po administration,1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL624314,6811
,50588,N,1,,,,6621,,Half-life of compound was determined in dogs,1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL624315,6812
Plasma,50588,N,1,,,,1696,,Half-life in dog plasma,1,Canis lupus familiaris,Intermediate,,,,9615.0,,1969.0,A,BAO_0000218,CHEMBL624316,6813
,50588,N,1,,,,17800,,Half-life in mongrel dogs was determined,1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL624317,6814
,50588,N,1,In vivo,,,17657,,Half-life in dog upon oral administration,1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL624318,6815
,50588,N,1,In vivo,,,17657,,Half-life in dog upon oral administration; Unable to calculate,1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL624319,6816
,50588,N,1,,,,4239,,Half-life was measured in dog,1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL624496,6817
,50588,N,1,,,,5985,,Half-life was measured in dog,1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL624497,6818
,50588,N,1,,,,9932,,Half-recovery time (T1/2) of the vascular resistance decrease at ED30 in anesthetized dogs,1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL624498,6819
,50588,N,1,In vivo,,,5199,,Oral half life was determined,1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL624499,6820
Plasma,50588,N,1,In vivo,,,5199,,Plasma elimination half-life (08 h) was determined in canine following intravenous (iv) administration (1 mg/kg).,1,Canis lupus familiaris,Intermediate,,,,9615.0,,1969.0,A,BAO_0000218,CHEMBL624500,6821
Plasma,50588,N,1,,,,1475,,Plasma half life was evaluated,1,Canis lupus familiaris,Intermediate,,,,9615.0,,1969.0,A,BAO_0000218,CHEMBL624501,6822
Plasma,50588,N,1,,,,1475,,Plasma half life was evaluated in Dog,1,Canis lupus familiaris,Intermediate,,,,9615.0,,1969.0,A,BAO_0000218,CHEMBL623666,6823
Plasma,50588,N,1,,,,1475,,Plasma half life was evaluated in dog,1,Canis lupus familiaris,Intermediate,,,,9615.0,,1969.0,A,BAO_0000218,CHEMBL623667,6824
,50588,N,1,In vivo,,,6316,,T1/2 (Half-life) was after oral administration at 5 mg/kg,1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL623668,6825
,50588,N,1,,,,4883,,Tested for the half life value in dog,1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL623669,6826
,50588,N,1,In vivo,,,4727,,Maximum time at the dose of 2 mg/kg in dog,1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL623670,6827
,50588,N,1,In vivo,,,1916,,Maximum time was evaluated against Beagle dog at a dose of 15 mg/kg after po administration,1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL623671,6828
Blood,50588,N,1,In vivo,,,1337,,Maximum time taken to reach maximum blood concentration was determined in dogs after oral administration (10 mg/kg) as a 0.05 M citric acid solution.,1,Canis lupus familiaris,Intermediate,,,,9615.0,,178.0,A,BAO_0000218,CHEMBL875945,6829
Blood,50588,N,1,In vivo,,,1337,,Maximum time taken to reach maximum blood concentration was determined in dogs after oral administration (8 mg/kg) as a 0.05 M citric acid solution.,1,Canis lupus familiaris,Intermediate,,,,9615.0,,178.0,A,BAO_0000218,CHEMBL623672,6830
,50588,N,1,In vivo,,,6265,,Pharmacokinetic (PK) property (Tmax) was determined in dog at the single dose of 1 mg/kg,1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL623673,6831
,50588,N,1,In vivo,,,4809,,Pharmacokinetic parameter Tmax was determined in Beagle dogs after (iv) administration of a dose of 28 (uM/kg),1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL623674,6832
,50588,N,1,In vivo,,,5983,,Pharmacokinetic property (Tmax) was measured in dog at the dose of 0.032 mg/kg p.o.,1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL623675,6833
,50588,N,1,,,,5313,,"Tested for the pharmacokinetic data, time required to reach Cmax (Tmax) in dog",1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL872526,6834
,50588,N,1,In vivo,,,5313,,"Tested for the pharmacokinetic data, time required to reach Cmax (Tmax) in dog at dosage of 10 mpk",1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL623676,6835
Plasma,50588,N,1,In vivo,,,17650,,Time for maximum plasma concentration was measured in dogs after an oral dose of 10 uM/kg,1,Canis lupus familiaris,Intermediate,,,,9615.0,,1969.0,A,BAO_0000218,CHEMBL623677,6836
Plasma,50588,N,1,In vivo,,,5199,,Time taken by the compound to achieve maximum plasma concentration at a 1 mg/kg oral dose in male and female Beagle dogs.,1,Canis lupus familiaris,Intermediate,,,,9615.0,,1969.0,A,BAO_0000218,CHEMBL623678,6837
Plasma,50588,N,1,,,,933,,Time taken for maximum plasma concentration in dog,1,Canis lupus familiaris,Intermediate,,,,9615.0,,1969.0,A,BAO_0000218,CHEMBL623679,6838
,50588,N,1,In vivo,,,16367,,Time to reach Cmax after oral administration to dogs,1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL623680,6839
Plasma,50588,N,1,In vivo,,,6348,,Time to reach maximum plasma concentration was determined in dog after 1 mg/kg (i.v.) and 5 mg/kg (p.o.) administration,1,Canis lupus familiaris,Intermediate,,,,9615.0,,1969.0,A,BAO_0000218,CHEMBL623681,6840
,50588,N,1,In vivo,,,6316,,Tmax (time to reach maximum concentration) was after oral administration at 5 mg/kg,1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL623682,6841
,50588,N,1,In vivo,,,6215,,Tmax after peroral administration (1 mg/kg) was determined in dog,1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL623683,6842
,50588,N,1,In vivo,,,3598,,Tmax of compound determined in dog after iv administration at a dose of 10 mg/kg,1,Canis lupus familiaris,Expert,,,,9615.0,,,A,BAO_0000218,CHEMBL623684,6843
,50588,N,1,In vivo,,,4527,,Tmax by oral administration at a dose of 10 uM/kg in dog was determined,1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL622745,6844
,50588,N,1,In vivo,,,17764,,Tmax after peroral administration in dogs at 2.4 uM/kg,1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL622746,6845
,50594,N,1,In vivo,,,5969,,In vivo Cmax in mice at dose of 100 mg/kg,1,Mus musculus,Intermediate,,,,10090.0,,,A,BAO_0000218,CHEMBL622747,6846
,50594,N,1,In vivo,,,5969,,In vivo Cmax in mice at dose of 50 mg/kg,1,Mus musculus,Intermediate,,,,10090.0,,,A,BAO_0000218,CHEMBL622748,6847
,50594,N,1,In vivo,,,4573,,Maximal concentration determined at a dose 10 mg/kg administered intraperitoneally to mice,1,Mus musculus,Intermediate,,,,10090.0,,,A,BAO_0000218,CHEMBL622749,6848
Plasma,50594,N,1,In vivo,,,3277,,Maximum plasma concentration was determined in mice at a single subcutaneous administration of 40 mg/kg (n=4),1,Mus musculus,Intermediate,,,,10090.0,,1969.0,A,BAO_0000218,CHEMBL622750,6849
Plasma,50594,N,1,In vivo,,,17734,,Maximum concentration in plasma was determined after intraperitoneal administration of 100 mg/kg in mice,1,Mus musculus,Intermediate,,,,10090.0,,1969.0,A,BAO_0000218,CHEMBL623411,6850
Plasma,50594,N,1,In vivo,,,3132,,Maximum concentration obtained in mouse plasma was determined,1,Mus musculus,Intermediate,,,,10090.0,,1969.0,A,BAO_0000218,CHEMBL875946,6851
Plasma,50594,N,1,In vivo,,,3132,,Maximum concentration obtained in mouse plasma was determined at dose 25 mg/kg,1,Mus musculus,Intermediate,,,,10090.0,,1969.0,A,BAO_0000218,CHEMBL623412,6852
Plasma,50594,N,1,In vivo,,,6348,,Maximum plasma concentration of compound was determined in mouse after 5 mg/kg (i.v.) and 6 mg/kg (p.o.) administration,1,Mus musculus,Intermediate,,,,10090.0,,1969.0,A,BAO_0000218,CHEMBL623413,6853
Plasma,50594,N,1,In vivo,,,17729,,Maximum plasma concentration when injected i.p. in mice at a dose of 50 mg/kg,1,Mus musculus,Intermediate,,,,10090.0,,1969.0,A,BAO_0000218,CHEMBL623414,6854
Plasma,50594,N,1,In vivo,,,17729,,Maximum plasma concentration when injected intravenously in mice at a dose of 20 mg/kg,1,Mus musculus,Intermediate,,,,10090.0,,1969.0,A,BAO_0000218,CHEMBL623415,6855
Plasma,50594,N,1,In vivo,,,17729,,Maximum plasma concentration when injected perorally in mice at a dose of 50 mg/kg,1,Mus musculus,Intermediate,,,,10090.0,,1969.0,A,BAO_0000218,CHEMBL623416,6856
Plasma,50594,N,1,In vivo,,,17728,,Maximal plasma concentration in BALB/C mice after 20 mg/kg intraperitoneal dose,1,Mus musculus,Intermediate,,,,10090.0,,1969.0,A,BAO_0000218,CHEMBL623417,6857
Plasma,50594,N,1,In vivo,,,17728,,Maximal plasma concentration in BALB/C mice after 20 mg/kg intravenous dose,1,Mus musculus,Intermediate,,,,10090.0,,1969.0,A,BAO_0000218,CHEMBL623418,6858
Plasma,50594,N,1,In vivo,,,17728,,Maximal plasma concentration in BALB/C mice after 50 mg/kg oral dose,1,Mus musculus,Intermediate,,,,10090.0,,1969.0,A,BAO_0000218,CHEMBL623419,6859
,50594,N,1,In vivo,,,4066,,Peak concentration at a single subcutaneous administration of 40 mg/kg in mice,1,Mus musculus,Intermediate,,,,10090.0,,,A,BAO_0000218,CHEMBL622816,6860
,50594,N,1,In vivo,,,6178,,Pharmacokinetic property (C(max)) was determined after ip administration of 32 mg/kg in mice,1,Mus musculus,Intermediate,,,,10090.0,,,A,BAO_0000218,CHEMBL623313,6861
,50594,N,1,In vivo,,,6178,,Pharmacokinetic property (C(max)) was determined after po administration of 32 mg/kg in mice,1,Mus musculus,Intermediate,,,,10090.0,,,A,BAO_0000218,CHEMBL623314,6862
,50594,N,1,In vivo,,,3760,,Pharmacokinetic studies were carried out in vivo after administration of compound at 5 mg/kg intravenously in mice,1,Mus musculus,Intermediate,,,,10090.0,,,A,BAO_0000218,CHEMBL876788,6863
,50594,N,1,In vivo,,,3760,,Pharmacokinetic studies were carried out in vivo after administration of compound at 5 mg/kg perorally in mice,1,Mus musculus,Intermediate,,,,10090.0,,,A,BAO_0000218,CHEMBL623315,6864
,50594,N,1,In vivo,,,3760,,Pharmacokinetic studies were carried out in vivo after administration of compound at 50 mg/kg intravenously in mice,1,Mus musculus,Intermediate,,,,10090.0,,,A,BAO_0000218,CHEMBL623316,6865
,50594,N,1,In vivo,,,3760,,Pharmacokinetic studies were carried out in vivo after administration of compound at 50 mg/kg perorally in mice,1,Mus musculus,Intermediate,,,,10090.0,,,A,BAO_0000218,CHEMBL623317,6866
,50594,N,1,In vivo,,,5961,,Cmax in male mice after 2 mg/kg oral dose,1,Mus musculus,Intermediate,,,,10090.0,,,A,BAO_0000218,CHEMBL623319,6868
,50594,N,1,In vivo,,,6137,,Plasma concentration of 5-FU in HT-3 (human cervical cancer) xenograft mice at 1.38 mg/kg oral dose co-administered with 135 mg/kg Capecitabine,1,Mus musculus,Intermediate,,,,10090.0,,,A,BAO_0000218,CHEMBL623320,6869
,50594,N,1,In vivo,,,3802,,Tested for Cmax value at the dose of 10 mg/kg when administered perorally in mouse,1,Mus musculus,Intermediate,,,,10090.0,,,A,BAO_0000218,CHEMBL623321,6870
,50594,N,1,,,,3535,,Concentration in plasma (systemic) following oral dose in mouse at 0.25 hr,1,Mus musculus,Intermediate,,,,10090.0,,,A,BAO_0000218,CHEMBL623322,6871
,50594,N,1,,,,3535,,Concentration in plasma (systemic) following oral dose in mouse at 1 hr,1,Mus musculus,Intermediate,,,,10090.0,,,A,BAO_0000218,CHEMBL623323,6872
,50594,N,1,,,,3535,,Concentration in plasma (systemic) following oral dose in mouse at 24 hr,1,Mus musculus,Intermediate,,,,10090.0,,,A,BAO_0000218,CHEMBL623324,6873
,50594,N,1,,,,3535,,Concentration in plasma (systemic) following oral dose in mouse at 2 hr,1,Mus musculus,Intermediate,,,,10090.0,,,A,BAO_0000218,CHEMBL623325,6874
,50594,N,1,,,,3535,,Concentration in plasma (systemic) following oral dose in mouse at 4 hr,1,Mus musculus,Intermediate,,,,10090.0,,,A,BAO_0000218,CHEMBL623326,6875
,50594,N,1,,,,3535,,Concentration in plasma (systemic) following oral dose in mouse at 6 hr,1,Mus musculus,Intermediate,,,,10090.0,,,A,BAO_0000218,CHEMBL623327,6876
Plasma,50594,N,1,,,,2862,,Maximum concentration in plasma upon oral administration in mouse,1,Mus musculus,Intermediate,,,,10090.0,,1969.0,A,BAO_0000218,CHEMBL623328,6877
Plasma,50594,N,1,,,,2675,,Maximum plasma concentration was evaluated in mice after oral administration,1,Mus musculus,Intermediate,,,,10090.0,,1969.0,A,BAO_0000218,CHEMBL623329,6878
Plasma,50594,N,1,In vivo,,,2675,,Maximum plasma concentration was evaluated in mice after intravenous administration; Cp max Not determined,1,Mus musculus,Intermediate,,,,10090.0,,1969.0,A,BAO_0000218,CHEMBL623330,6879
,50594,N,1,,,,5399,,Dose at which the compound induced fecal excretion in mice,1,Mus musculus,Intermediate,,,,10090.0,,,A,BAO_0000218,CHEMBL876789,6880
,80013,N,1,,,,11819,,Percent decrease in fluorescence in a membrane potential assay using the A10 cell line derived from embryonic rat aorta at 0.01 uM,1,Rattus norvegicus,Expert,,164.0,,10116.0,A10,,F,BAO_0000219,CHEMBL623333,6893
,80013,N,1,,,,11819,,Percent decrease in fluorescence in a membrane potential assay using the A10 cell line derived from embryonic rat aorta at 0.1 uM,1,Rattus norvegicus,Expert,,164.0,,10116.0,A10,,F,BAO_0000219,CHEMBL623334,6894
,80013,N,1,,,,11819,,Percent decrease in fluorescence in a membrane potential assay using the A10 cell line derived from embryonic rat aorta at 1.0 uM,1,Rattus norvegicus,Expert,,164.0,,10116.0,A10,,F,BAO_0000219,CHEMBL627536,6895
,80013,N,1,,,,11819,,Percent decrease in fluorescence in a membrane potential assay using the A10 cell line derived from embryonic rat aorta at 10.0 uM,1,Rattus norvegicus,Expert,,164.0,,10116.0,A10,,F,BAO_0000219,CHEMBL627537,6896
,80013,N,1,,,,16361,,In vitro [14C]- creatine uptake (1 mM) was determined in rat A10 smooth muscle cells at a concentration of (1 mM),1,Rattus norvegicus,Intermediate,,164.0,,10116.0,A10,,F,BAO_0000219,CHEMBL627538,6897
,80655,N,1,,,,2288,,Cytotoxicity was evaluated against A121 ovarian carcinoma human cancer cell line,1,Homo sapiens,Intermediate,,393.0,,9606.0,A121,,F,BAO_0000219,CHEMBL884106,6898
,80655,N,1,,,,10404,,Anticancer activity against human ovarian carcinoma A121 cells,1,Homo sapiens,Intermediate,,393.0,,9606.0,A121,,F,BAO_0000219,CHEMBL625294,6899
,80655,N,1,,,,14790,,Cytotoxic effect (tumor cell growth inhibition) on the human cell line A121 ovarian carcinoma at the dose of of 16.6 mM,1,Homo sapiens,Intermediate,,393.0,,9606.0,A121,,F,BAO_0000219,CHEMBL625295,6900
,80655,N,1,,,,14790,,Cytotoxic effect (tumor cell growth inhibition) on the human cell line A121 ovarian carcinoma at the dose of of 83 mM,1,Homo sapiens,Intermediate,,393.0,,9606.0,A121,,F,BAO_0000219,CHEMBL625296,6901
,80655,N,1,,,,14253,,Growth inhibition of human ovarian carcinoma (A121) cell line,1,Homo sapiens,Expert,,393.0,,9606.0,A121,,F,BAO_0000219,CHEMBL625297,6902
,80655,N,1,,,,13617,,Concentration required to inhibit growth of human tumor A121 (ovarian) cell line.,1,Homo sapiens,Expert,,393.0,,9606.0,A121,,F,BAO_0000219,CHEMBL625298,6903
,80655,N,1,,,,1003,,Cytotoxicity against human A121 ovarian cells,1,Homo sapiens,Intermediate,,393.0,,9606.0,A121,,F,BAO_0000219,CHEMBL625960,6904
,80655,N,1,,,,830,,Cytotoxicity was evaluated in vitro against A121 (ovarian carcinoma) human tumor cell lines,1,Homo sapiens,Intermediate,,393.0,,9606.0,A121,,F,BAO_0000219,CHEMBL625961,6905
,80655,N,1,,,,12307,,In vitro cytotoxicity against human ovarian carcinoma A21,1,Homo sapiens,Intermediate,,393.0,,9606.0,A121,,F,BAO_0000219,CHEMBL625962,6906
,80655,N,1,,,,14254,,Inhibition of the growth against human Ovarian Carcinoma (A121) cell line after 72 hr exposure,1,Homo sapiens,Intermediate,,393.0,,9606.0,A121,,F,BAO_0000219,CHEMBL624717,6907
,80655,N,1,,,,13370,,Inhibitory activity of compound against human A121 ovarian cell line.,1,Homo sapiens,Intermediate,,393.0,,9606.0,A121,,F,BAO_0000219,CHEMBL624718,6908
,80655,N,1,,,,14790,,Dose at which compound exhibits cytotoxicity in the A121 ovarian carcinoma cell line.,1,Homo sapiens,Intermediate,,393.0,,9606.0,A121,,F,BAO_0000219,CHEMBL624719,6909
,80655,N,1,,,,3614,,Inhibition of growth of human ovarian tumor cell line (A121) after 72 hr of drug exposure,1,Homo sapiens,Intermediate,,393.0,,9606.0,A121,,F,BAO_0000219,CHEMBL624720,6910
,80012,N,1,,,,2664,,Compound was evaluated for in vitro antiproliferative activity against A172 human CNS cancer cell line,1,Homo sapiens,Intermediate,,622.0,,9606.0,A 172,,F,BAO_0000219,CHEMBL624721,6911
,80012,N,1,,,,2037,,In vitro cytotoxicity against A172 human tumor cell lines.,1,Homo sapiens,Expert,,622.0,,9606.0,A 172,,F,BAO_0000219,CHEMBL624722,6912
,80012,N,1,,,,14539,,Growth inhibition time for A172 Human Glioma cell growth at concentration 5 uM,1,Homo sapiens,Intermediate,,622.0,,9606.0,A 172,,F,BAO_0000219,CHEMBL877597,6913
,80012,N,1,,,,2836,,Compound was evaluated for cytotoxicity against human glioblastoma (A172) cell line,1,Homo sapiens,Intermediate,,622.0,,9606.0,A 172,,F,BAO_0000219,CHEMBL624723,6914
,80012,N,1,,,,10708,,Evaluated for the inhibitory concentration required to cause growth inhibition of A172Mer- cell line of central nervous system (CNS) using the MTT Cytotoxicity Assay,1,Homo sapiens,Intermediate,,622.0,,9606.0,A 172,,F,BAO_0000219,CHEMBL624724,6915
,104729,H,4,,,,8975,,Association constant against A2 adenosine receptor,1,Canis lupus familiaris,Autocuration,,,,9615.0,,,B,BAO_0000224,CHEMBL624725,6916
,80656,N,1,,,,7645,,In vitro effective dose that causes 50% inhibition of growth of A2 cell line - amelanotic melanoma,1,fish,Intermediate,,1085.0,,,A2,,F,BAO_0000219,CHEMBL624726,6917
,104713,D,5,,,,11377,,Ratio of Ki for adenosine A2 and A1 receptor binding,1,Rattus norvegicus,Autocuration,,,,10116.0,,,B,BAO_0000224,CHEMBL857535,6918
,80014,N,1,,,,13528,,In vitro cytotoxicity against A204 human rhabdomyosarcoma cancer cell line,1,Homo sapiens,Expert,,623.0,,9606.0,A204,,F,BAO_0000219,CHEMBL624727,6919
,80014,N,1,,,,10160,,In vitro antitumor activity against A204 rhabdomyosarcoma tumor cell line was determined,1,Homo sapiens,Expert,,623.0,,9606.0,A204,,F,BAO_0000219,CHEMBL624728,6920
,80015,N,1,,,,15144,,The compound was tested in vitro for antiproliferative activity against A2058 tumor cell lines,1,Homo sapiens,Intermediate,,404.0,,9606.0,A2058,,F,BAO_0000219,CHEMBL624729,6921
,80657,N,1,,,,13160,,Growth inhibition against Human squamous cell line(A 253),1,Homo sapiens,Intermediate,,973.0,,9606.0,A253 cell line,,F,BAO_0000219,CHEMBL624730,6922
,80657,N,1,,,,12898,,Growth inhibition of human squamous carcinoma cell lines following continuous (120 hours) exposure to MTX and compound A253 cell line,1,Homo sapiens,Intermediate,,973.0,,9606.0,A253 cell line,,F,BAO_0000219,CHEMBL624731,6923
,80657,N,1,,,,13069,,The compound was tested for Growth inhibition of the human squamous cell carcinoma A253 cells,1,Homo sapiens,Intermediate,,973.0,,9606.0,A253 cell line,,F,BAO_0000219,CHEMBL624732,6924
,80657,N,1,,,,15984,,Growth inhibition of A253 cell lines.,1,Homo sapiens,Intermediate,,973.0,,9606.0,A253 cell line,,F,BAO_0000219,CHEMBL883245,6925
,80657,N,1,,,,15564,,Growth inhibition of human squamous cell carcinoma A253 cells during continuous Exposure (0-12 h),1,Homo sapiens,Intermediate,,973.0,,9606.0,A253 cell line,,F,BAO_0000219,CHEMBL624733,6926
,80657,N,1,,,,15564,,Growth inhibition of human squamous cell carcinoma A253 cells during continuous Exposure (0-12 h); ND means not determined,1,Homo sapiens,Intermediate,,973.0,,9606.0,A253 cell line,,F,BAO_0000219,CHEMBL624734,6927
,80657,N,1,,,,15564,,Growth inhibition of human squamous cell carcinoma A253 cells during continuous Exposure (0-12 h); ND means not determined,1,Homo sapiens,Intermediate,,973.0,,9606.0,A253 cell line,,F,BAO_0000219,CHEMBL624735,6928
,81034,N,1,,,,4720,,In vitro cytotoxicity causing 50% growth inhibition was determined against A270 (human ovarian cancer)cell line,1,Homo sapiens,Intermediate,,478.0,,9606.0,A2780,,F,BAO_0000219,CHEMBL621780,6929
,81034,N,1,,,,16112,,Antitumor activity of compound for 96-h exposure in A2780 human ovarian cell line,1,Homo sapiens,Intermediate,,478.0,,9606.0,A2780,,F,BAO_0000219,CHEMBL877598,6930
,81034,N,1,,,,16597,,Cytotoxic activity against A2780 human ovarian carcinoma cell line,1,Homo sapiens,Expert,,478.0,,9606.0,A2780,,F,BAO_0000219,CHEMBL621781,6931
,81034,N,1,,,,16378,,Cytotoxicity against human cancer cell lines A2780 (ovarian),1,Homo sapiens,Intermediate,,478.0,,9606.0,A2780,,F,BAO_0000219,CHEMBL621782,6932
,81034,N,1,,,,16085,,Growth and colony formation inhibition of A2780 ovarian cancer cell lines,1,Homo sapiens,Expert,,478.0,,9606.0,A2780,,F,BAO_0000219,CHEMBL621783,6933
,81034,N,1,,,,16317,,Inhibition of cell growth in human ovarian carcinoma cell line (A2780) using the 96 hour continuous exposure sulforhodamine B (SRB) growth delay assay,1,Homo sapiens,Intermediate,,478.0,,9606.0,A2780,,F,BAO_0000219,CHEMBL621784,6934
,81034,N,1,,,,15748,,The compound was tested for cytotoxic activity against A2780 cell line(human ovarian carcinoma ),1,Homo sapiens,Intermediate,,478.0,,9606.0,A2780,,F,BAO_0000219,CHEMBL621785,6935
,81034,N,1,,,,16597,,Inhibition of A2780 / DDP-R human ovarian carcinoma cell proliferation,1,Homo sapiens,Expert,,478.0,,9606.0,A2780,,F,BAO_0000219,CHEMBL621968,6936
,81034,N,1,,,,16597,,Inhibition of A2780 / TAX-R human ovarian carcinoma cell proliferation,1,Homo sapiens,Expert,,478.0,,9606.0,A2780,,F,BAO_0000219,CHEMBL621969,6937
,81034,N,1,,,,16597,,Inhibition of A2780 / TAX-S human ovarian carcinoma cell proliferation,1,Homo sapiens,Expert,,478.0,,9606.0,A2780,,F,BAO_0000219,CHEMBL621970,6938
,81034,N,1,,,,15608,,cytotoxic activity toward A2780 ovarian human cell line resistant (R) to cisplatin in experiment 2,1,Homo sapiens,Intermediate,,478.0,,9606.0,A2780,,F,BAO_0000219,CHEMBL621971,6939
,81034,N,1,,,,15608,,cytotoxic activity toward A2780 ovarian human cell line resistant (R) to cisplatin in experiment 3,1,Homo sapiens,Intermediate,,478.0,,9606.0,A2780,,F,BAO_0000219,CHEMBL621972,6940
,81034,N,1,,,,15608,,cytotoxic activity toward A2780 ovarian human cell line resistant (R) to cisplatin in experiment 5,1,Homo sapiens,Intermediate,,478.0,,9606.0,A2780,,F,BAO_0000219,CHEMBL884108,6941
,22224,U,0,,,,15296,,Cytotoxicity on AA8 cell growth (reduce cell number by 50%).,1,Cricetulus griseus,Autocuration,,,,10029.0,,,F,BAO_0000019,CHEMBL623826,6942
,22224,U,0,,,,10251,,Evaluated for cytotoxicity under aerobic conditions against AA8 cells using microassay,1,Cricetulus griseus,Autocuration,,185.0,,10029.0,CHO-AA8,,A,BAO_0000219,CHEMBL623827,6943
,22224,U,0,,,,10251,,Evaluated for growth inhibition of AA8 cells under aerobic conditions,1,Cricetulus griseus,Autocuration,,185.0,,10029.0,CHO-AA8,,F,BAO_0000219,CHEMBL623828,6944
,22224,U,0,,,,10251,,Evaluated for growth inhibition of AA8 cells under aerobic or hypoxic conditions,1,Cricetulus griseus,Autocuration,,185.0,,10029.0,CHO-AA8,,F,BAO_0000219,CHEMBL623829,6945
,22224,U,0,,,,10251,,Evaluated for growth inhibition of AA8 cells under aerobic or hypoxic conditions (air/N2),1,Cricetulus griseus,Autocuration,,185.0,,10029.0,CHO-AA8,,F,BAO_0000219,CHEMBL623830,6946
,22224,U,0,,,,11858,,Growth inhibition against CHO-derived cell line AA8,1,Cricetulus griseus,Autocuration,,,,10029.0,,,F,BAO_0000019,CHEMBL623831,6947
,22224,U,0,,,,11858,,Growth inhibition against CHO-derived cell line AA8 (Non toxic at solubility limit) [RB6145 used as positive control],1,Cricetulus griseus,Autocuration,,185.0,,10029.0,CHO-AA8,,F,BAO_0000219,CHEMBL623832,6948
,80089,N,1,,,,11616,,Growth inhibition in CHO subline AA8 cells exposed for 18 hr under aerobic(air) conditions,1,hampster,Expert,,185.0,,36483.0,CHO-AA8,,F,BAO_0000219,CHEMBL623833,6949
,80089,N,1,,,,11616,,Growth inhibitory activity against CHO subline AA8 cells exposed for 18 hr under aerobic conditions,1,Cricetulus griseus,Expert,,185.0,,10029.0,CHO-AA8,,F,BAO_0000219,CHEMBL623834,6950
,22224,U,0,,,,10518,,Tested for the concentration of the drug to reduce cell numbers to 50 percent of controls against AA8 cells in the microassay,1,Cricetulus griseus,Autocuration,,185.0,,10029.0,CHO-AA8,,F,BAO_0000219,CHEMBL623835,6951
,22224,U,0,,,,11396,,Growth inhibition of aerobic chinese hamster ovary fibroblast AA8 cell line using an exposure time of 18 hours,1,Cricetulus griseus,Autocuration,,185.0,,10029.0,CHO-AA8,,F,BAO_0000219,CHEMBL623836,6952
,22224,U,0,,,,10518,,IC50 (air/N2) ratio of the drug to reduce cell numbers to 50 percent of controls using AA8 cells in the microassay,1,Cricetulus griseus,Autocuration,,185.0,,10029.0,CHO-AA8,,F,BAO_0000219,CHEMBL623837,6953
,80089,N,1,,,,11616,,In vitro therapeutic index as ratio of CT10 and C1.3 calculated for AA8 cells.,1,Cricetulus griseus,Expert,,185.0,,10029.0,CHO-AA8,,F,BAO_0000219,CHEMBL623838,6954
,12675,H,8,,,,14837,,compound was evaluated for association constant (Ka) of isolated serum protein AAG,1,,Autocuration,,,,,,,F,BAO_0000019,CHEMBL623839,6955
,12675,H,8,,,,14837,,Number of binding sites (n) of isolated serum protein AAG,1,,Autocuration,,,,,,,F,BAO_0000019,CHEMBL623840,6956
,22222,M,3,,,,16037,,Association constant for binding to AATT duplex,1,,Intermediate,,,,,,,B,BAO_0000225,CHEMBL623841,6957
,100090,N,1,,,,16597,,Inhibition of ABAE human fibroblast cell proliferation,1,Homo sapiens,Expert,,416.0,,9606.0,ABAE,,F,BAO_0000219,CHEMBL623842,6958
,80668,N,1,,,,8831,,"Compound was evaluated for the antitumor activity against AC755 breast carcinoma for ip administration and daily x 10 schedule; Number of toxic deaths over total number of mice per group (T/C), 1/7 at dose of 25 mg/kg",1,Mus musculus,Intermediate,,1064.0,,10090.0,AC755,,F,BAO_0000218,CHEMBL623843,6959
,102444,D,9,,,,13419,,Percent change in total cholesterol(TC) versus (T0)- at which drug intervention begins at a dose of 25 mg/kg in the chronic cholesterol-fed rabbit model,1,Oryctolagus cuniculus,Expert,,,,9986.0,,,F,BAO_0000218,CHEMBL618669,6960
,102444,D,9,In vivo,,,13419,,Oral bioactivity expressed as %inhibition after 4 hours of drug administration (dose 25 mg/kg) in rabbit bioassay,1,Oryctolagus cuniculus,Expert,,,,9986.0,,,F,BAO_0000218,CHEMBL618670,6961
,69,H,8,,,,15778,,Inhibitory activity against angiotensin-converting enzyme (ACE).,1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL618671,6962
,69,H,8,,,,15778,,oral activity against angiotensin -converting enzyme ( ACE) and neutral endopeptidase in mouse.,1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL618672,6963
,80669,N,1,,,,12988,,Effect against HIV-1 chronically infected promonocytic cell line ACH-2 cells,1,Homo sapiens,Intermediate,,978.0,,9606.0,ACH-2 cell line,,F,BAO_0000219,CHEMBL618673,6964
,80669,N,1,,,,12988,,Effect against HIV-1 chronically infected promonocytic cell line ACH-2 cells in the presence of PMA(phorbol 12-myristate 13-acetate),1,Homo sapiens,Intermediate,,978.0,,9606.0,ACH-2 cell line,,F,BAO_0000219,CHEMBL618674,6965
,22224,U,0,,,,12988,,Effect against HIV-1 expression in a chronically infected human T cell line ACH-2,1,Human immunodeficiency virus 1,Autocuration,,998.0,,11676.0,T cell line,,F,BAO_0000219,CHEMBL618675,6966
,22224,U,0,,,,12988,,Effect against HIV-1 expression in a chronically infected human T cell line ACH-2 in the presence of PMA(phorbol 12-myristate 13-acetate),1,Human immunodeficiency virus 1,Autocuration,,998.0,,11676.0,T cell line,,F,BAO_0000219,CHEMBL618676,6967
,22224,U,0,,,,12988,,Effect against HIV-1 expression in a chronically infected human T cell line ACH-2i n the presence of PMA(phorbol 12-myristate 13-acetate),1,Human immunodeficiency virus 1,Autocuration,,998.0,,11676.0,T cell line,,F,BAO_0000219,CHEMBL618677,6968
,80025,N,1,,,,11843,,Inhibition of growth of renal cancer ACHN cell line,1,Homo sapiens,Intermediate,,626.0,,9606.0,ACHN,,F,BAO_0000219,CHEMBL618678,6969
,80025,N,1,,,,16939,,Inhibition of growth of ACHN renal cancer cell line,1,Homo sapiens,Intermediate,,626.0,,9606.0,ACHN,,F,BAO_0000219,CHEMBL618679,6970
,80025,N,1,,,,4782,,Inhibitory concentration required against ACHN renal cancer cell line,1,Homo sapiens,Intermediate,,626.0,,9606.0,ACHN,,F,BAO_0000219,CHEMBL618680,6971
,80025,N,1,,,,6310,,Concentration required to inhibit growth of human renal (ACHN) cell line,1,Homo sapiens,Expert,,626.0,,9606.0,ACHN,,F,BAO_0000219,CHEMBL618681,6972
,80025,N,1,,,,6310,,Concentration required to inhibit growth of human renal (ACHN) cell line; nt = not tested,1,Homo sapiens,Intermediate,,626.0,,9606.0,ACHN,,F,BAO_0000219,CHEMBL618682,6973
,80025,N,1,,,,12858,,Cytotoxic activity against ACHN Renal cancer cell line,1,Homo sapiens,Intermediate,,626.0,,9606.0,ACHN,,F,BAO_0000219,CHEMBL618683,6974
,80025,N,1,,,,17380,,Cytotoxicity evaluation against ACHN renal cancer cells,1,Homo sapiens,Intermediate,,626.0,,9606.0,ACHN,,F,BAO_0000219,CHEMBL618684,6975
,80025,N,1,,,,5858,,In vitro antitumor activity against human renal ACHN cell line,1,Homo sapiens,Intermediate,,626.0,,9606.0,ACHN,,F,BAO_0000219,CHEMBL618685,6976
,80025,N,1,,,,3838,,In vitro growth inhibition of compound was determined against ACHN cell lines of Renal cancer,1,Homo sapiens,Intermediate,,626.0,,9606.0,ACHN,,F,BAO_0000219,CHEMBL876499,6977
,80025,N,1,,,,3838,,In vitro growth inhibition of compound was determined against ACHN cell lines of Renal cancer,1,Homo sapiens,Intermediate,,626.0,,9606.0,ACHN,,F,BAO_0000219,CHEMBL618686,6978
,80025,N,1,,,,5406,,"Tested for the cytotoxicity against the Renal cancer cell line ACHN, growth inhibition by 50% is reported",1,Homo sapiens,Intermediate,,626.0,,9606.0,ACHN,,F,BAO_0000219,CHEMBL618687,6979
,80025,N,1,,,,4071,,The compound was tested in vitro for cytotoxicity against human tumor cell line ACHN (renal).,1,Homo sapiens,Intermediate,,626.0,,9606.0,ACHN,,F,BAO_0000219,CHEMBL618688,6980
,80025,N,1,,,,4071,,Tested in vitro for cytotoxicity against human tumor cell line ACHN (renal).,1,Homo sapiens,Expert,,626.0,,9606.0,ACHN,,F,BAO_0000219,CHEMBL618689,6981
,80025,N,1,,,,4071,,The compound was tested in vitro for cytotoxicity against human tumor cell line ACHN (renal); Not determined,1,Homo sapiens,Intermediate,,626.0,,9606.0,ACHN,,F,BAO_0000219,CHEMBL618690,6982
,80025,N,1,,,,15002,,Antitumor activity was evaluated against human renal adenocarcinoma cell line ACHN.,1,Homo sapiens,Intermediate,,626.0,,9606.0,ACHN,,F,BAO_0000219,CHEMBL618691,6983
,80025,N,1,,,,14769,,Compound was evaluated for in vitro activity against ACHN kidney cell lines (Human tumor cells ),1,Homo sapiens,Intermediate,,626.0,,9606.0,ACHN,,F,BAO_0000219,CHEMBL619373,6984
,80025,N,1,,,,13958,,"Compound was tested for antiproliferative activity against ACHN, human renal adenocarcinoma",1,Homo sapiens,Intermediate,,626.0,,9606.0,ACHN,,F,BAO_0000219,CHEMBL884008,6985
,80025,N,1,,,,1665,,Compound was tested for its effect on the proliferation of ACHN human kidney adenocarcinoma,1,Homo sapiens,Intermediate,,626.0,,9606.0,ACHN,,F,BAO_0000219,CHEMBL619374,6986
,80025,N,1,,,,15354,,Compound was tested for the growth inhibition of ACHN renal tumor cell line,1,Homo sapiens,Intermediate,,626.0,,9606.0,ACHN,,F,BAO_0000219,CHEMBL619375,6987
,80025,N,1,,,,15354,,Compound was tested for the growth inhibition of ACHN renal tumor cell line; ND=Not determined,1,Homo sapiens,Intermediate,,626.0,,9606.0,ACHN,,F,BAO_0000219,CHEMBL619376,6988
,80025,N,1,,,,13978,,In vitro Growth Inhibitory activity against ACHN Human kidney cancer cell line,1,Homo sapiens,Intermediate,,626.0,,9606.0,ACHN,,F,BAO_0000219,CHEMBL619377,6989
,80025,N,1,,,,6798,,In vitro cytotoxicity against human renal adenocarcinoma (ACHN) tumor cell line,1,Homo sapiens,Intermediate,,626.0,,9606.0,ACHN,,F,BAO_0000219,CHEMBL619378,6990
,50588,N,1,In vivo,,,2959,,Tmax value after administration of 4 mg/Kg oral dose in dog,1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL872527,6991
,50588,N,1,,,,9932,,"Time to peak response on lowering of vascular resistance, in dogs when administered intravenously",1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL876500,6992
,50588,N,1,,,,5546,,Unbound plasma was determined in Beagle dog at a dose of 1 mg/kg by iv administration,1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL619379,6993
,50588,N,1,In vivo,,,16907,,Volume distribution after 15 mg/kg iv dose in Dogs,1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL619538,6994
,50588,N,1,In vivo,,,16907,,Volume distribution after 30 mg/kg po dose in Dogs,1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL619539,6995
,50588,N,1,In vivo,,,4257,,Volume of distribution was determined in dog after a 3 mg/kg of iv dose,1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL619540,6996
,50588,N,1,In vivo,,,4305,,Volume of distribution was determined by iv administration in dogs at a dose of 1 mg/kg,1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL619541,6997
,50588,N,1,In vivo,,,5472,,Volume of distribution was evaluated in dog,1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL619542,6998
,50588,N,1,In vivo,,,6062,,Terminal phase volume of distribution was measured in dog after an iv dose of 1 mg/kg,1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL619543,6999
,50588,N,1,,,,3598,,Apparent volume of the central plasma compartment (Vc) of compound determined in dog after iv administration at a dose of 10 mg/kg,1,Canis lupus familiaris,Expert,,,,9615.0,,,A,BAO_0000218,CHEMBL619544,7000
,50588,N,1,In vivo,,,12500,,The compound was tested for volume of distribution in dog,1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL619545,7001
,50588,N,1,In vivo,,,12500,,The compound was tested for volume of distribution in dog at dose of 3-10 mgkg,1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL619546,7002
,50588,N,1,In vivo,,,6227,,Vd (1 mg/kg) was determined in dog (in vivo),1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL619547,7003
,50588,N,1,In vivo,,,6227,,Vd in dog,1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL619548,7004
,50588,N,1,In vivo,,,4219,,Volume distribution was determined,1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL619549,7005
,50588,N,1,In vivo,,,1696,,Volume of distribution in dog,1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL619550,7006
,50588,N,1,In vivo,,,5542,,Volume of distribution by as 4 fold increase by iv administration in dogs,1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL876501,7007
,50588,N,1,In vivo,,,5199,,Volume of distribution was determined in canine following intravenous (iv) administration of drug (1 mg/kg).,1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL619551,7008
,50588,N,1,In vivo,,,6348,,Volume of distribution was determined in dog after 1 mg/kg (i.v.) and 5 mg/kg (p.o.) administration,1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL619552,7009
,50588,N,1,In vivo,,,4727,,Volume distribution at the dose of 2 mg/kg in dog,1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL619553,7010
,50588,N,1,In vivo,,,16367,,Steady state volume of distribution was determined,1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL618722,7011
,50588,N,1,In vivo,,,2652,,Bioavailability as Vdss in dogs at 1 mg/kg intravenous dose,1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL618723,7012
,50588,N,1,In vivo,,,16452,,Pharmacokinetic data at 0.5 mg/kg dose given to dogs intravenously.,1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL618724,7013
,50588,N,1,In vivo,,,16452,,Pharmacokinetic data at 1 mg/kg dose given to dogs intravenously,1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL618725,7014
,50588,N,1,In vivo,,,16452,,Bioavailability in dog (dose 1 mg/kg i.v.),1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL618726,7015
,50588,N,1,In vivo,,,5334,,Pharmacokinetic parameter volume of distribution was reported after intravenous administration at a dose of 1 mg/kg in Beagle dog (male),1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL618727,7016
,50588,N,1,In vivo,,,4239,,Pharmacokinetic property (vdss) was measured in dog,1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL624233,7017
,50588,N,1,In vivo,,,4709,,Steady state volume of distribution for the compound after intravenous administration of 1 mg/kg in dog,1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL624234,7018
,50588,N,1,In vivo,,,5600,,Vdss was determined after iv 0.1 mg/kg administration in dog,1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL624235,7019
,50588,N,1,In vivo,,,6057,,Volume displacement was calculated in dog,1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL624236,7020
,50588,N,1,In vivo,,,5654,,Volume distribution (Vdss) of compound was determined after intravenous administration in average of two dogs at a dose of 1 mg/kg,1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL624237,7021
,50588,N,1,In vivo,,,5505,,Volume distribution constant was determined,1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL624238,7022
,50588,N,1,In vivo,,,4527,,Volume distribution at a dose of 1 uM/kg in dog was determined,1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL624239,7023
,50588,N,1,In vivo,,,4521,,Volume distribution in dog after 2 mg/kg by oral and 0.5 mg/kg by intravenous administration,1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL875829,7024
,50588,N,1,In vivo,,,4521,,Volume distribution in dog after 2 mg/kg by oral and 0.5 mg/kg by intravenous administration; ND is not determined,1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL624240,7025
,50588,N,1,In vivo,,,15660,,Volume distribution (Vdss) was measured in dog,1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL624241,7026
,50588,N,1,In vivo,,,15660,,Volume distribution (Vdss) was measured in dog,1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL624242,7027
,50588,N,1,In vivo,,,6679,,Volume of distribution at steady state was determined after 1 mg/kg (i.v.) / 2 mg/kg (p.o.) of compound administration,1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL624243,7028
,50588,N,1,In vivo,,,5145,,Volume of distribution in steady state was determined in dog,1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL624244,7029
,50588,N,1,In vivo,,,6821,,Volume of distribution of compound was determined in dog,1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL624245,7030
,50588,N,1,In vivo,,,4137,,Volume of distribution after intravenous administration of 1 mg/kg/h in dog,1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL624246,7031
,50588,N,1,In vivo,,,5334,,Volume of distribution was reported after oral administration at a dose of 2 mg/kg in Beagle dog (male),1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL624247,7032
,50588,N,1,In vivo,,,15660,,Volume of distribution (Vdss) was measured in dog,1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL624248,7033
,50588,N,1,In vivo,,,6642,,Volumes of distribution in dog (dosed as a mixture of five compounds at 0.5 mpk each via iv only),1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL624249,7034
,50588,N,1,In vivo,,,6641,,Volumes of distribution in dog (dosed at 0.5 mpk iv and 2.0 mpk orally),1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL624250,7035
,50588,N,1,In vivo,,,6642,,Volumes of distribution in dog (dosed at 0.5 mpk iv and 2.0 mpk orally),1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL624251,7036
,50588,N,1,,,,11659,,Maximum rate of depolarization of the upstroke of the action potential,1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL624252,7037
,50588,N,1,In vivo,,,6448,,Steady state volume distribution in dog,1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL624253,7038
,50588,N,1,In vivo,,,5474,,Steady state volume of distribution at a dose of 0.2 mg/kg i.v.,1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL624950,7039
,50588,N,1,In vivo,,,1466,,Tested for volume of distribution at steady state upon intravenous administration of 5.0 mg/Kg dose in dog,1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL624951,7040
,50588,N,1,In vivo,,,6535,,Volume distribution in dog after administration of 0.25 mg/kg iv; ND = not determined,1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL875830,7041
,50588,N,1,In vivo,,,6535,,Volume distribution in dog after administration of 1 mg/kg iv,1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL624952,7042
,50588,N,1,In vivo,,,17764,,Volume of solubility in solution after intravenous administration in dogs at 1.2 uM/kg,1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL624953,7043
,50588,N,1,In vivo,,,6215,,Vss after intravenous administration (0.5 mg/kg) was determined in dog,1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL624954,7044
,50588,N,1,In vivo,,,6505,,Vss on i.v. administration of 2 mg/kg was measured in dog,1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL624955,7045
,50588,N,1,,,,3639,,Vss was determined,1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL624956,7046
,50588,N,1,,,,3639,,Vss in dog,1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL625129,7047
,50588,N,1,In vivo,,,6062,,Volume of distribution was measured in dog after an iv dose of 1 mg/kg,1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL625130,7048
,50588,N,1,In vivo,,,4942,,Volume distribution in dogs,1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL625131,7049
,50588,N,1,In vivo,,,17796,,Volume of distribution in dog,1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL625132,7050
,50588,N,1,In vivo,,,4883,,Tested for the oral bioavailability in dog,1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL872263,7051
,50594,N,1,In vivo,,,17837,,Bioavailability of compound in mouse blood following p.o. administration of 30 mg/kg,1,Mus musculus,Intermediate,,,,10090.0,,,A,BAO_0000218,CHEMBL624336,7060
,50594,N,1,In vivo,,,17729,,Bioavailability after i.p. administration of 50 mg/kg of dose in mice,1,Mus musculus,Intermediate,,,,10090.0,,,A,BAO_0000218,CHEMBL624337,7061
,50594,N,1,In vivo,,,17729,,Bioavailability after peroral administration of 50 mg/kg of dose in mice,1,Mus musculus,Intermediate,,,,10090.0,,,A,BAO_0000218,CHEMBL624338,7062
,50594,N,1,In vivo,,,4239,,Bioavailability was measured in mouse,1,Mus musculus,Intermediate,,,,10090.0,,,A,BAO_0000218,CHEMBL624339,7063
,50594,N,1,In vivo,,,17592,,Bioavailability in mouse,1,Mus musculus,Intermediate,,,,10090.0,,,A,BAO_0000218,CHEMBL624340,7064
,50594,N,1,In vivo,,,6348,,Bioavailability was determined in mouse after 5 mg/kg (i.v.) and 6 mg/kg (p.o.) administration,1,Mus musculus,Intermediate,,,,10090.0,,,A,BAO_0000218,CHEMBL624341,7065
,50594,N,1,In vivo,,,2801,,Bioavailability in mouse,1,Mus musculus,Intermediate,,,,10090.0,,,A,BAO_0000218,CHEMBL624342,7066
,50594,N,1,In vivo,,,2801,,Compound was evaluated for its bioavailability in mice at a dose of 1 mg/kg,1,Mus musculus,Intermediate,,,,10090.0,,,A,BAO_0000218,CHEMBL624343,7067
,50594,N,1,In vivo,,,17718,,Oral bioavailability in mouse,1,Mus musculus,Intermediate,,,,10090.0,,,A,BAO_0000218,CHEMBL624344,7068
,50594,N,1,In vivo,,,5727,,Oral availability at 50 mg/kg po in male mice,1,Mus musculus,Intermediate,,,,10090.0,,,A,BAO_0000218,CHEMBL624345,7069
,50594,N,1,In vivo,,,5302,,Oral bioavailability in mouse (dose 10 mg/kg),1,Mus musculus,Intermediate,,,,10090.0,,,A,BAO_0000218,CHEMBL624346,7070
,50594,N,1,In vivo,,,3598,,Oral bioavailability of compound determined in mouse after iv administration at a dose of 10 mg/kg,1,Mus musculus,Expert,,,,10090.0,,,A,BAO_0000218,CHEMBL624347,7071
,50594,N,1,In vivo,,,5961,,"Bioavailability in male mice, 2mg/kg oral and 1 mg/kg intravenous dose",1,Mus musculus,Intermediate,,,,10090.0,,,A,BAO_0000218,CHEMBL624348,7072
,50594,N,1,In vivo,,,6091,,Oral bioavailability in mouse,1,Mus musculus,Intermediate,,,,10090.0,,,A,BAO_0000218,CHEMBL622754,7074
,50594,N,1,In vivo,,,6091,,Oral bioavailability in vivo in mice;ND=Not determined,1,Mus musculus,Intermediate,,,,10090.0,,,A,BAO_0000218,CHEMBL622755,7075
,50594,N,1,In vivo,,,5711,,Oral bioavailability in mouse at 10 mg/kg of the compound,1,Mus musculus,Intermediate,,,,10090.0,,,A,BAO_0000218,CHEMBL622756,7076
,50594,N,1,In vivo,,,17728,,Bioavailability in mouse (BALB/C) (dose 50 mg/kg i.p.),1,Mus musculus,Intermediate,,,,10090.0,,,A,BAO_0000218,CHEMBL622757,7077
,50594,N,1,In vivo,,,17728,,Bioavailability in mouse (BALB/C) (dose 20 mg/kg i.v.),1,Mus musculus,Intermediate,,,,10090.0,,,A,BAO_0000218,CHEMBL622758,7078
,50594,N,1,In vivo,,,3802,,Tested for bioavailability of the compound,1,Mus musculus,Intermediate,,,,10090.0,,,A,BAO_0000218,CHEMBL622759,7079
,50594,N,1,In vivo,,,3802,,Tested for half life at the dose of 10 mg/kg when administered intravenously,1,Mus musculus,Intermediate,,,,10090.0,,,A,BAO_0000218,CHEMBL622760,7080
Plasma,50594,N,1,,,,14029,,The plasma half life of compound was determined on EDTA prepared by mouse plasma. ,1,Mus musculus,Intermediate,,,,10090.0,,1969.0,A,BAO_0000218,CHEMBL622761,7081
Plasma,50594,N,1,,,,14029,,The plasma half life of compound was determined on heparin prepared by human plasma. ,1,Mus musculus,Intermediate,,,,10090.0,,1969.0,A,BAO_0000218,CHEMBL622762,7082
Plasma,50594,N,1,,,,14029,,The plasma half life of compound was determined on heparin prepared by human plasma; Not degraded,1,Mus musculus,Intermediate,,,,10090.0,,1969.0,A,BAO_0000218,CHEMBL622763,7083
Plasma,50594,N,1,,,,14029,,The plasma half life of compound was determined on heparin prepared by mouse plasma. ,1,Mus musculus,Intermediate,,,,10090.0,,1969.0,A,BAO_0000218,CHEMBL622764,7084
Plasma,50594,N,1,,,,14029,,The plasma half life of compound was determined on heparin prepared by mouse plasma; Not degraded,1,Mus musculus,Intermediate,,,,10090.0,,1969.0,A,BAO_0000218,CHEMBL622765,7085
,50594,N,1,,,,17753,,Inhibitory concentration of compound was determined after intravenous administration in mice after 6 hours of exposure at 40 mg/Kg,1,Mus musculus,Intermediate,,,,10090.0,,,F,BAO_0000218,CHEMBL622766,7086
,50594,N,1,,,,17753,,Inhibitory concentration of compound was determined after intravenous administration in mice after 8 hours of exposure at 24 mg/Kg,1,Mus musculus,Intermediate,,,,10090.0,,,A,BAO_0000218,CHEMBL622767,7087
,50594,N,1,,,,17753,,Inhibitory concentration of compound was determined after intravenous administration in mice after 8 hours of exposure at 5 mg/Kg,1,Mus musculus,Intermediate,,,,10090.0,,,A,BAO_0000218,CHEMBL622768,7088
Blood,50594,N,1,In vivo,,,10107,,Biodistribution of intravenously injected [82Br]-labeled compound in blood of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,1,Mus musculus,Intermediate,,,,10090.0,,178.0,A,BAO_0000218,CHEMBL875948,7089
Blood,50594,N,1,In vivo,,,10107,,Biodistribution of intravenously injected [82Br]-labeled compound in blood of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.50 hours,1,Mus musculus,Intermediate,,,,10090.0,,178.0,A,BAO_0000218,CHEMBL622769,7090
Blood,50594,N,1,In vivo,,,10107,,Biodistribution of intravenously injected [82Br]-labeled compound in blood of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,1,Mus musculus,Intermediate,,,,10090.0,,178.0,A,BAO_0000218,CHEMBL622770,7091
Blood,50594,N,1,In vivo,,,10107,,Biodistribution of intravenously injected [82Br]-labeled compound in blood of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,1,Mus musculus,Intermediate,,,,10090.0,,178.0,A,BAO_0000218,CHEMBL622771,7092
Blood,50594,N,1,In vivo,,,10107,,Biodistribution of intravenously injected [82Br]-labeled compound in blood of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,1,Mus musculus,Intermediate,,,,10090.0,,178.0,A,BAO_0000218,CHEMBL622772,7093
Blood,50594,N,1,In vivo,,,10107,,Biodistribution of intravenously injected [82Br]-labeled compound in blood of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,1,Mus musculus,Intermediate,,,,10090.0,,178.0,A,BAO_0000218,CHEMBL622773,7094
Blood,50594,N,1,In vivo,,,10107,,Biodistribution of intravenously injected [82Br]-labeled compound in blood of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,1,Mus musculus,Intermediate,,,,10090.0,,178.0,A,BAO_0000218,CHEMBL622774,7095
Bone,50594,N,1,In vivo,,,10107,,Biodistribution of intravenously injected [82Br]-labeled compound in bone of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,1,Mus musculus,Intermediate,,,,10090.0,,10000001.0,A,BAO_0000218,CHEMBL621725,7096
Bone,50594,N,1,In vivo,,,10107,,Biodistribution of intravenously injected [82Br]-labeled compound in bone of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.5 hours,1,Mus musculus,Intermediate,,,,10090.0,,10000001.0,A,BAO_0000218,CHEMBL621726,7097
,81034,N,1,,,,15608,,cytotoxic activity toward A2780 ovarian human cell line resistant (R) to cisplatin in experiment 8,1,Homo sapiens,Intermediate,,478.0,,9606.0,A2780,,F,BAO_0000219,CHEMBL621727,7098
,81034,N,1,,,,3290,,In vitro cytotoxicity against human ovarian carcinoma cell line A2780 using sulforhodamine B (SRB) assay,1,Homo sapiens,Expert,,478.0,,9606.0,A2780,,F,BAO_0000219,CHEMBL622413,7099
,81034,N,1,,,,2859,,Compound was evaluated for cytotoxicity against A2780 cell line,1,Homo sapiens,Intermediate,,478.0,,9606.0,A2780,,F,BAO_0000219,CHEMBL622414,7100
,81034,N,1,,,,15688,,Inhibition of A2780 cell clonogenic assay,1,Homo sapiens,Expert,,478.0,,9606.0,A2780,,F,BAO_0000219,CHEMBL622415,7101
,81034,N,1,,,,5642,,Cytotoxic effect on ovarian cancer cell line (A2780),1,Homo sapiens,Expert,,478.0,,9606.0,A2780,,F,BAO_0000219,CHEMBL884001,7102
,81034,N,1,,,,6633,,Concentration required to inhibit A2780 cell growth when compared with control after incubation for 96 hr at 37 C,1,Homo sapiens,Intermediate,,478.0,,9606.0,A2780,,F,BAO_0000219,CHEMBL622416,7103
,81034,N,1,,,,3906,,"MDR-reversing activity was measured by vincristine accumulation in the multidrug resistant 2780AD, a subline of A2780 ovarian carcinoma cells at 10 mg/mL",1,Homo sapiens,Intermediate,,478.0,,9606.0,A2780,,F,BAO_0000219,CHEMBL622417,7104
,81034,N,1,,,,6788,,50% growth inhibition of A2780 (Human ovarian carcinoma) cell line compared with untreated control cells,1,Homo sapiens,Expert,,478.0,,9606.0,A2780,,F,BAO_0000219,CHEMBL622590,7105
,81034,N,1,,,,17582,,Antiproliferative activity against human A2780 cells,1,Homo sapiens,Expert,,478.0,,9606.0,A2780,,F,BAO_0000219,CHEMBL622591,7106
,81034,N,1,,,,17764,,Inhibition of human A2780 cell proliferation,1,Homo sapiens,Expert,,478.0,,9606.0,A2780,,F,BAO_0000219,CHEMBL622592,7107
,81034,N,1,,,,17764,,Antiproliferative effect against human A2780 cell line was determined in a whole cell 72 hr cytotoxicity assay,1,Homo sapiens,Expert,,478.0,,9606.0,A2780,,F,BAO_0000219,CHEMBL622593,7108
,81034,N,1,,,,17764,,Inhibition of human A2780 cell proliferation (No data),1,Homo sapiens,Expert,,478.0,,9606.0,A2780,,F,BAO_0000219,CHEMBL622594,7109
,81034,N,1,,,,2815,,Cell cytotoxicity was determined against human ovarian cancer (A2780) cell line,1,Homo sapiens,Intermediate,,478.0,,9606.0,A2780,,F,BAO_0000219,CHEMBL622595,7110
,81034,N,1,,,,16930,,Compound was evaluated against human Ovarian carcinoma cell line A2780,1,Homo sapiens,Intermediate,,478.0,,9606.0,A2780,,F,BAO_0000219,CHEMBL622596,7111
,81034,N,1,,,,17777,,Growth inhibition against A2780 wild-type ovarian cell lines,1,Homo sapiens,Expert,,478.0,,9606.0,A2780,,F,BAO_0000219,CHEMBL622597,7112
,81034,N,1,,,,17777,,Compound was evaluated for growth inhibition against A2780 wild-type ovarian cell lines; No data,1,Homo sapiens,Intermediate,,478.0,,9606.0,A2780,,F,BAO_0000219,CHEMBL622598,7113
,104766,D,5,,,,16936,,Inhibition of tubulin polymerization in human ovarian cancer cell lines,1,Homo sapiens,Autocuration,,,,9606.0,,,F,BAO_0000019,CHEMBL622599,7114
,81034,N,1,,,,13759,,Compound was tested for in vitro growth inhibition of Ovarian carcinoma cell line panel A2780,1,Homo sapiens,Intermediate,,478.0,,9606.0,A2780,,F,BAO_0000219,CHEMBL622600,7115
,81034,N,1,,,,13759,,Compound was tested for in vitro growth inhibition of Ovarian carcinoma cell line panel A2780-R,1,Homo sapiens,Intermediate,,478.0,,9606.0,A2780,,F,BAO_0000219,CHEMBL622601,7116
,81034,N,1,,,,13759,,Compound was tested for in vitro growth inhibition of Ovarian carcinoma cell line panel A2780,1,Homo sapiens,Intermediate,,478.0,,9606.0,A2780,,F,BAO_0000219,CHEMBL622602,7117
,81034,N,1,,,,13759,,Compound was tested for in vitro growth inhibition of Ovarian carcinoma cell line panel A2780-R,1,Homo sapiens,Intermediate,,478.0,,9606.0,A2780,,F,BAO_0000219,CHEMBL622603,7118
,81034,N,1,,,,15292,,Compound was tested for inhibitory activity against A2780 human ovarian carcinoma cell line; activity expressed in Mean IC50 values,1,Homo sapiens,Intermediate,,478.0,,9606.0,A2780,,F,BAO_0000219,CHEMBL622604,7119
,81034,N,1,,,,15292,,Compound was tested for inhibitory activity against A2780cisR human ovarian carcinoma cell line; activity expressed in Mean IC50 values,1,Homo sapiens,Intermediate,,478.0,,9606.0,A2780,,F,BAO_0000219,CHEMBL622605,7120
,81034,N,1,,,,15069,,In vitro inhibition of human ovarian cell line A2780,1,Homo sapiens,Expert,,478.0,,9606.0,A2780,,F,BAO_0000219,CHEMBL622606,7121
,81034,N,1,,,,15069,,"In vitro inhibition of human ovarian cell line, resistant to cisplatin (A2780cisR).",1,Homo sapiens,Expert,,478.0,,9606.0,A2780,,F,BAO_0000219,CHEMBL619463,7122
,81034,N,1,,,,14073,,Concentration of compound to inhibit the growth of human A2780 ovarian carcinoma cells(in vitro),1,Homo sapiens,Intermediate,,478.0,,9606.0,A2780,,F,BAO_0000219,CHEMBL619464,7123
,81034,N,1,,,,14553,,Concentration required to inhibit A2780-cell growth by 50%,1,Homo sapiens,Expert,,478.0,,9606.0,A2780,,F,BAO_0000219,CHEMBL619465,7124
,81034,N,1,,,,13040,,Concentration required to inhibit the cell growth by 50 % after 96 hr A2780 leukemic cells.,1,Homo sapiens,Expert,,478.0,,9606.0,A2780,,F,BAO_0000219,CHEMBL619466,7125
,81034,N,1,,,,6891,,Cytotoxic effect on human ovarian (A2780) cancer cell line,1,Homo sapiens,Expert,,478.0,,9606.0,A2780,,F,BAO_0000219,CHEMBL619467,7126
,81034,N,1,,,,15569,,Cytotoxic activity in a panel of Human ovarian tumor A2780 cell line after 96h of drug exposure,1,Homo sapiens,Intermediate,,478.0,,9606.0,A2780,,F,BAO_0000219,CHEMBL619468,7127
,81034,N,1,,,,14190,,Cytotoxic potency required to inhibit A2780 cell growth by 50% after cell drug contact for 96 hrs,1,Homo sapiens,Expert,,478.0,,9606.0,A2780,,F,BAO_0000219,CHEMBL619469,7128
,81034,N,1,,,,15014,,Cytotoxicity measured in human ovarian cell line A2780 using sulforhodamine B (SRB) assay,1,Homo sapiens,Expert,,478.0,,9606.0,A2780,,F,BAO_0000219,CHEMBL619470,7129
,81034,N,1,,,,15014,,Cytotoxicity activity of the compound was measured in human ovarian cell line A2780 using sulforhodamine B (SRB) assay,1,Homo sapiens,Intermediate,,478.0,,9606.0,A2780,,F,BAO_0000219,CHEMBL619471,7130
,81034,N,1,,,,17496,,Cytotoxicity against human ovarian carcinoma A2780 cell line,1,Homo sapiens,Intermediate,,478.0,,9606.0,A2780,,F,BAO_0000219,CHEMBL619472,7131
,81034,N,1,,,,13617,,"Cytotoxicity against A2780-C25, oxaliplatin-resistant Ovarian carcinoma cell line",1,Homo sapiens,Intermediate,,478.0,,9606.0,A2780,,F,BAO_0000219,CHEMBL619473,7132
,81034,N,1,,,,13617,,"Cytotoxicity against A2780-CP3, cisplatin-resistant Ovarian carcinoma cell line",1,Homo sapiens,Intermediate,,478.0,,9606.0,A2780,,F,BAO_0000219,CHEMBL874368,7133
,81034,N,1,,,,13617,,"Cytotoxicity against A2780-DX5, Doxorubicin-resistant Ovarian carcinoma cell line",1,Homo sapiens,Intermediate,,478.0,,9606.0,A2780,,F,BAO_0000219,CHEMBL884003,7134
,81034,N,1,,,,13617,,"Cytotoxicity against A2780-WT, human ovarian carcinoma cell line",1,Homo sapiens,Intermediate,,478.0,,9606.0,A2780,,F,BAO_0000219,CHEMBL622690,7135
,81034,N,1,,,,17672,,Cytotoxicity against ovarian carcinoma A2780 tumor cell lines,1,Homo sapiens,Intermediate,,478.0,,9606.0,A2780,,F,BAO_0000219,CHEMBL622691,7136
,81034,N,1,,,,4544,,Dose of required to inhibit growth of cisplatin resistant human ovarian carcinoma (A2780 cisR) cell line with compound free controls as measured by the sulforhodamine B growth delay assay,1,Homo sapiens,Intermediate,,478.0,,9606.0,A2780,,F,BAO_0000219,CHEMBL622692,7137
,81034,N,1,,,,4544,,Dose of required to inhibit growth of human ovarian carcinoma (A2780) cell line with compound free controls as measured by the sulforhodamine B growth delay assay,1,Homo sapiens,Intermediate,,478.0,,9606.0,A2780,,F,BAO_0000219,CHEMBL623406,7138
,81034,N,1,,,,16317,,"Growth inhibition in human ovarian carcinoma cell line (A2780cisR,cisplatin-resistant) using the 96 hour exposure sulforhodamine B (SRB) growth delay assay",1,Homo sapiens,Intermediate,,478.0,,9606.0,A2780,,F,BAO_0000219,CHEMBL884004,7139
,81034,N,1,,,,15099,,In vitro Cytotoxic activity of compound in comparison with reference compounds in human cell line A2780,1,Homo sapiens,Intermediate,,478.0,,9606.0,A2780,,F,BAO_0000219,CHEMBL623407,7140
,81034,N,1,,,,13978,,In vitro Growth Inhibitory activity against A2780 Human ovarian cancer cell line,1,Homo sapiens,Intermediate,,478.0,,9606.0,A2780,,F,BAO_0000219,CHEMBL623408,7141
,81034,N,1,,,,12989,,In vitro antitumor activity against A2780 cell line.,1,Homo sapiens,Expert,,478.0,,9606.0,A2780,,F,BAO_0000219,CHEMBL623409,7142
,81034,N,1,,,,5574,,In vitro cytotoxic activity against human tumor cell line A2780 after incubation for 96 hours,1,Homo sapiens,Intermediate,,478.0,,9606.0,A2780,,F,BAO_0000219,CHEMBL623410,7143
,81034,N,1,,,,13528,,In vitro cytotoxicity against A2780 human ovarian cancer cell line,1,Homo sapiens,Expert,,478.0,,9606.0,A2780,,F,BAO_0000219,CHEMBL623576,7144
,80025,N,1,,,,12782,,Inhibitory activity against kidney A-CHN tumor cell growth in culture,1,Homo sapiens,Intermediate,,626.0,,9606.0,ACHN,,F,BAO_0000219,CHEMBL623577,7145
,80025,N,1,,,,14255,,The IC50 value was measured on ACHN cell line in renal tumor type.,1,Homo sapiens,Intermediate,,626.0,,9606.0,ACHN,,F,BAO_0000219,CHEMBL623578,7146
,80025,N,1,,,,16364,,Concentration required for killing 50% of cells of renal ACHN cell lines was determined in vitro,1,Homo sapiens,Intermediate,,626.0,,9606.0,ACHN,,F,BAO_0000219,CHEMBL623579,7147
,80025,N,1,,,,17376,,In vitro lethal concentration against most sensitive ACHN cell line,1,Homo sapiens,Expert,,626.0,,9606.0,ACHN,,F,BAO_0000219,CHEMBL623580,7148
,80025,N,1,,,,12016,,Tested for cytotoxic activity against renal cancer ACHN cell line,1,Homo sapiens,Intermediate,,626.0,,9606.0,ACHN,,F,BAO_0000219,CHEMBL623581,7149
,80025,N,1,,,,6058,,Compound tested for growth inhibition of renal cancer cell line ACHN,1,Homo sapiens,Intermediate,,626.0,,9606.0,ACHN,,F,BAO_0000219,CHEMBL857456,7150
,80025,N,1,,,,17708,,Compound was tested for 50% growth inhibition against human renal cancer ACHN cell line,1,Homo sapiens,Intermediate,,626.0,,9606.0,ACHN,,F,BAO_0000219,CHEMBL623582,7151
,80025,N,1,,,,15176,,Growth inhibition of the ACHN Renal cancer cell line for 2-day in vitro assay.,1,Homo sapiens,Intermediate,,626.0,,9606.0,ACHN,,F,BAO_0000219,CHEMBL623583,7152
,80025,N,1,,,,2806,,In vitro anticancer activity against ACHN renal cancer cell line,1,Homo sapiens,Intermediate,,626.0,,9606.0,ACHN,,F,BAO_0000219,CHEMBL623584,7153
,80025,N,1,,,,15300,,In vitro antitumor activity against Renal cancer ACHN cell lines by 6-day assay,1,Homo sapiens,Intermediate,,626.0,,9606.0,ACHN,,F,BAO_0000219,CHEMBL623585,7154
,80025,N,1,,,,16364,,Percent selectivity was evaluated in renal ACHN cell lines,1,Homo sapiens,Intermediate,,626.0,,9606.0,ACHN,,F,BAO_0000219,CHEMBL623586,7155
,80025,N,1,,,,13859,,In vitro inhibitory activity against renal ACHN cancer cell line,1,Homo sapiens,Intermediate,,626.0,,9606.0,ACHN,,F,BAO_0000219,CHEMBL623587,7156
,80025,N,1,,,,11970,,Tested for cytotoxicity against ACHN cell lines in renal cancer,1,Homo sapiens,Intermediate,,626.0,,9606.0,ACHN,,F,BAO_0000219,CHEMBL875279,7157
,80025,N,1,,,,2450,,Tested for the in vitro cytotoxicity against ACHN renal cancer cell line,1,Homo sapiens,Intermediate,,626.0,,9606.0,ACHN,,F,BAO_0000219,CHEMBL623588,7158
,80025,N,1,,,,12696,,In vitro anti tumor activity against human tumor Renal cancer cell lines was determined,1,Homo sapiens,Intermediate,,626.0,,9606.0,ACHN,,F,BAO_0000219,CHEMBL623589,7159
,80025,N,1,,,,12400,,Tested in vitro for cytotoxicity in ACHN cell line of Renal cancer,1,Homo sapiens,Intermediate,,626.0,,9606.0,ACHN,,F,BAO_0000219,CHEMBL623590,7160
,80025,N,1,,,,12888,,Cytotoxic effect on renal cancer line ACHN,1,Homo sapiens,Expert,,626.0,,9606.0,ACHN,,F,BAO_0000219,CHEMBL623591,7161
,80025,N,1,,,,3156,,In vitro anti-cancer activity against ACHN(Renal) human tumor cell line,1,Homo sapiens,Intermediate,,626.0,,9606.0,ACHN,,F,BAO_0000219,CHEMBL623592,7162
,80025,N,1,,,,3381,,In vitro inhibition of Renal Cancer ACHN cell lines,1,Homo sapiens,Intermediate,,626.0,,9606.0,ACHN,,F,BAO_0000219,CHEMBL623593,7163
,80025,N,1,,,,16747,,Antitumor activity against human renal adenocarcinoma ACHN cells,1,Homo sapiens,Intermediate,,626.0,,9606.0,ACHN,,F,BAO_0000219,CHEMBL623594,7164
,80025,N,1,,,,16748,,Antitumor activity against human renal adenocarcinoma ACHN cells.,1,Homo sapiens,Expert,,626.0,,9606.0,ACHN,,F,BAO_0000219,CHEMBL621833,7165
,80025,N,1,,,,12062,,Inhibitory concentration required to decrease cell viability in cell growth culture against kidney cells ACHN,1,Homo sapiens,Intermediate,,626.0,,9606.0,ACHN,,F,BAO_0000219,CHEMBL621834,7166
,80025,N,1,,,,14769,,Compound was evaluated for in vitro activity against ACHN kidney cell lines (Human tumor cells ),1,Homo sapiens,Intermediate,,626.0,,9606.0,ACHN,,F,BAO_0000219,CHEMBL621835,7167
,80025,N,1,,,,15895,,"Cytotoxicity against NCI tumor panel, ACHN renal cancer cell line",1,Homo sapiens,Intermediate,,626.0,,9606.0,ACHN,,F,BAO_0000219,CHEMBL621836,7168
,80025,N,1,,,,17376,,Concentration of compound that cause 50% cytotoxicity of ACHN renal cancer cell line,1,Homo sapiens,Intermediate,,626.0,,9606.0,ACHN,,F,BAO_0000219,CHEMBL621837,7169
,80025,N,1,,,,14882,,Compound was tested for antitumor activity against ACHN renal cancer cell line(molar concentration that inhibits 50% net cell growth).,1,Homo sapiens,Intermediate,,626.0,,9606.0,ACHN,,F,BAO_0000219,CHEMBL875280,7170
,80025,N,1,,,,14882,,Compound was tested for antitumor activity against ACHN renal cancer cell line(molar concentration leading to 50% net cell death).,1,Homo sapiens,Intermediate,,626.0,,9606.0,ACHN,,F,BAO_0000219,CHEMBL621838,7171
,80025,N,1,,,,15661,,Cytotoxicity was tested against renal cancer ACHN tumor cell lines.,1,Homo sapiens,Intermediate,,626.0,,9606.0,ACHN,,F,BAO_0000219,CHEMBL621839,7172
,22224,U,0,,,,9680,,Keff is the effective biomolecular rate constant on paraxon for reactivation at pH 7.8 at 25 degree Centigrade,1,,Autocuration,,,,,,,A,BAO_0000019,CHEMBL621840,7173
,10647,H,8,,,,14579,,Compound tested for relative response using 1 uM ACh as agonist against AChM1 receptor.,1,,Autocuration,,,,,,,F,BAO_0000019,CHEMBL621841,7174
,50529,N,1,,,,17290,,Antiviral activity against AD169 strain of cytomegalovirus (CMV) in HEL (human erythroleukemia) cells.,1,Cytomegalovirus,Expert,,468.0,,10358.0,HEL,,F,BAO_0000218,CHEMBL622979,7175
,50529,N,1,,,,17290,,Antiviral activity against AD169 strain of cytomegalovirus (CMV); ND=No data,1,Cytomegalovirus,Intermediate,,,,10358.0,,,F,BAO_0000218,CHEMBL876595,7176
,12159,H,8,,,,15891,,Compound was evaluated for its inhibitory activity against calf intestinal Adenosine deaminase (ADA),1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL620221,7177
,12159,H,8,,,,15890,,Evaluated for the inhibition of calf intestinal Adenosine deaminase (ADA),1,,Autocuration,,,,,,,B,BAO_0000357,CHEMBL620222,7178
,80670,N,1,,,,3801,,Inhibitory activity against ovarian tumor cell line ADDP after 72 hr continuous exposure to compound,1,Bos taurus,Intermediate,,979.0,,9913.0,ADDP cell line,,F,BAO_0000219,CHEMBL620506,7179
,80671,N,1,,,,9222,,Tumor growth inhibition activity after subcutaneous transplanted tumor in ADJ-PC6 plasmacytoma cells,1,Mus musculus,Intermediate,,980.0,,10090.0,ADJ/PC6,,F,BAO_0000219,CHEMBL620507,7180
,80671,N,1,,,,9222,,Tumor growth inhibition activity after subcutaneously transplanted tumor in ADJ-PC6 plasmacytoma cells,1,Mus musculus,Intermediate,,980.0,,10090.0,ADJ/PC6,,F,BAO_0000219,CHEMBL620508,7181
,80671,N,1,,,,7257,,"Compound was tested for dose producing 90% reduction in tumor weight, in ADJ/PC6 mouse plasma cell tumor",1,Mus musculus,Intermediate,,980.0,,10090.0,ADJ/PC6,,F,BAO_0000219,CHEMBL620509,7182
,80671,N,1,,,,7257,,Compound was tested for inhibition against ADJ/PC6 mouse plasma cell tumor at the dose of 320 mg/Kg,1,Mus musculus,Intermediate,,980.0,,10090.0,ADJ/PC6,,F,BAO_0000219,CHEMBL620510,7183
,80671,N,1,,,,7257,,Compound was tested for dose required to kill 50 % of ADJ/PC6 mouse plasma cell tumor in a group,1,Mus musculus,Intermediate,,980.0,,10090.0,ADJ/PC6,,A,BAO_0000219,CHEMBL620511,7184
,80671,N,1,,,,8084,,In vitro incorporation of the [3H]thymidine into the ADJ/PC6 Plasmacytoma cells,1,Mus musculus,Intermediate,,980.0,,10090.0,ADJ/PC6,,F,BAO_0000219,CHEMBL620512,7185
,22224,U,0,,,,14943,,Tested for cytotoxicity against ADJ/PC6 mouse plasmacytoma,1,Mus musculus,Autocuration,,,,10090.0,,,F,BAO_0000019,CHEMBL620513,7186
,22224,U,0,,,,14943,,The compound was tested for cytotoxicity against ADJ/PC6 mouse plasmacytoma; Not determined,1,Mus musculus,Autocuration,,,,10090.0,,,F,BAO_0000019,CHEMBL620514,7187
,22224,U,0,,,,14943,,Tested for cytotoxicity against ADJ/PC6 plasmacytoma,1,Mus musculus,Autocuration,,,,10090.0,,,F,BAO_0000019,CHEMBL620515,7188
,22224,U,0,In vivo,,,10524,,Maximum concentration determined against Bacillus subtilis ATCC 6633 after oral administration in dog(25 mg/kg),1,Bacillus subtilis,Autocuration,,,,1423.0,,,A,BAO_0000218,CHEMBL620516,7189
Plasma,50588,N,1,,,,3546,,AUC value in dog after IV administration at a dose of 5 mg/kg,1,Canis lupus familiaris,Intermediate,,,,9615.0,,1969.0,A,BAO_0000218,CHEMBL620517,7190
Plasma,50588,N,1,,,,3546,,AUC value in dog after oral administration at a dose of 5 mg/kg,1,Canis lupus familiaris,Intermediate,,,,9615.0,,1969.0,A,BAO_0000218,CHEMBL620518,7191
,50588,N,1,In vivo,,,3546,,Cmax value in dog after oral administration at a dose of 5 mg/kg,1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL620519,7192
,50588,N,1,In vivo,,,3546,,Bioavailability in dog after oral administration at a dose of 5 mg/kg,1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL621386,7193
,50588,N,1,In vivo,,,3546,,Tmax value in dog after oral administration at a dose of 5 mg/kg,1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL621387,7194
,50588,N,1,In vivo,,,3184,,Compound was evaluated for its clearance when administered intravenously in dog,1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL621388,7195
,50588,N,1,In vivo,,,16456,,Plasma clearance in Beagle dogs after intravenous administration at a dose of 10 mg/kg,1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL621389,7196
,50588,N,1,In vivo,,,4809,,Plasma clearance was determined in Beagle dogs after (iv) administration of a dose of 12 (uM/kg),1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL621390,7197
,22229,U,0,,,,4219,,Calculated partition coefficient (clogP),1,,Intermediate,,,,,,,P,BAO_0000100,CHEMBL621391,7198
,50588,N,1,,,,3748,,Half life in dog,1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL621392,7199
,50588,N,1,,,,3132,,Time taken for EC90 was determined when tested in dog,1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL621393,7200
,50588,N,1,,,,4219,,Half life (iv) was determined,1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL621394,7201
Liver,50588,N,1,,,,16907,,Loss of compound (%metabolized) after 30 min exposure to human liver microsomes,1,Canis lupus familiaris,Intermediate,,,,9615.0,,2107.0,A,BAO_0000218,CHEMBL621395,7202
,50588,N,1,,,,6057,,Area under the curve was calculated in dog after iv administration,1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL621396,7203
,50588,N,1,,,,6057,,Area under the curve was calculated in dog after peroral administration,1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL621397,7204
,50588,N,1,,,,17853,,Dose-normalized area under curve in dog (p.o.) at 2.0 mpk,1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL621398,7205
,50588,N,1,,,,3639,,pKa was evaluated in dog,1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL618818,7206
,50588,N,1,,,,14541,,Compound was evaluated for pronounced GH response at 100 mg (n=6)(area under concentration curve was determined from 0-8 hr following morning and evening dosing with 25 mg of the compound,1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL618819,7207
,50588,N,1,In vivo,,,16456,,Alpha-elimination half-life in Beagle dogs after intravenous administration at a dose of 10 mg/kg,1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL618820,7208
,50588,N,1,In vivo,,,16456,,Beta-elimination half-life in Beagle dogs after intravenous administration at a dose of 10 mg/kg,1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL873810,7209
,50588,N,1,In vivo,,,2652,,Compound was evaluated for half-life period in dogs at a dose of 5 mpk perorally,1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL876606,7210
,50588,N,1,,,,3624,,Compound was evaluated for the half-life (t 1/2) in hours,1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL618821,7211
Blood,50588,N,1,In vivo,,,1337,,Half life to reach the blood concentration was determined in dogs after oral administration (10 mg/kg) as a 0.05 M citric acid solution.,1,Canis lupus familiaris,Intermediate,,,,9615.0,,178.0,A,BAO_0000218,CHEMBL618822,7212
Blood,50588,N,1,In vivo,,,1337,,Half life to reach the blood concentration was determined in dogs after oral administration (8 mg/kg) as a 0.05 M citric acid solution.,1,Canis lupus familiaris,Intermediate,,,,9615.0,,178.0,A,BAO_0000218,CHEMBL618823,7213
,50588,N,1,In vivo,,,4709,,Half life after intravenous administration of 1 mg/kg in dog,1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL618824,7214
,50588,N,1,,,,15660,,Half life was measured in dog,1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL618825,7215
,50588,N,1,In vivo,,,5302,,Half life period in dog after 5 mg/kg dose,1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL618826,7216
,50588,N,1,,,,17791,,Half life period was evaluated in dog; 4-4.8,1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL618827,7217
,50588,N,1,In vivo,,,6348,,Half life was determined in dog after 1 mg/kg (i.v.) and 5 mg/kg (p.o.) administration,1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL618828,7218
,50588,N,1,In vivo,,,4257,,Half-life was determined in dog after a3 mg/kg of iv dose,1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL618829,7219
,50588,N,1,,,,3771,,Half-life was determined,1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL618830,7220
,50588,N,1,,,,6305,,Half life in dogs,1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL618831,7221
Plasma,50588,N,1,In vivo,,,13501,,Apparent Half life was determined from the linear portion of the log plasma concentration-time profile after oral administration of compound 18 at a dose of 2 mg/kg tp dog,1,Canis lupus familiaris,Intermediate,,,,9615.0,,1969.0,A,BAO_0000218,CHEMBL619489,7222
,50588,N,1,In vivo,,,17594,,Apparent half-life after single intravenous bolus of 1 mg/kg in dogs,1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL619649,7223
,50588,N,1,In vivo,,,3045,,Compound was evaluated for the half life period after iv administration in Beagle dog.,1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL876607,7224
,50588,N,1,In vivo,,,3043,,Compound was evaluated for the half life period after oral administration in conscious dog.,1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL619650,7225
,50588,N,1,,,,4839,,Compound was tested for half life in dog,1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL619651,7226
,50588,N,1,,,,4839,,Compound was tested for its half life in dog,1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL619652,7227
,50588,N,1,In vivo,,,5802,,Half life of compound after both po and iv administration at a dose of 5 mg/kg and 2 mg/kg resp in dog,1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL619653,7228
,50588,N,1,,,,17839,,Half life of compound in dog was determined,1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL619654,7229
,50588,N,1,In vivo,,,4219,,Half life (iv) was determined,1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL619655,7230
Blood,50588,N,1,,,,13966,,Half life following administration of 70 nM in canine whole blood (dose exceeding platelet binding capacity),1,Canis lupus familiaris,Intermediate,,,,9615.0,,178.0,A,BAO_0000218,CHEMBL619656,7231
Plasma,50588,N,1,In vivo,,,3994,,Half life in Dog plasma at a dosage 5 mg/kg after intravenous administration,1,Canis lupus familiaris,Intermediate,,,,9615.0,,1969.0,A,BAO_0000218,CHEMBL873812,7232
Plasma,50588,N,1,In vivo,,,3994,,Half life in Dog plasma at a dosage 5 mg/kg after intravenous administration,1,Canis lupus familiaris,Intermediate,,,,9615.0,,1969.0,F,BAO_0000218,CHEMBL621365,7233
,50588,N,1,,,,4453,,Half life in dog,1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL621366,7234
Plasma,50588,N,1,,,,6535,,Half life in dog plasma,1,Canis lupus familiaris,Intermediate,,,,9615.0,,1969.0,A,BAO_0000218,CHEMBL621367,7235
Plasma,50588,N,1,In vivo,,,6535,,Half life in dog plasma after administration of 0.25 mg/kg iv,1,Canis lupus familiaris,Intermediate,,,,9615.0,,1969.0,A,BAO_0000218,CHEMBL621368,7236
Plasma,50588,N,1,In vivo,,,6535,,Half life in dog plasma after administration of 1 mg/kg iv,1,Canis lupus familiaris,Intermediate,,,,9615.0,,1969.0,A,BAO_0000218,CHEMBL621369,7237
Plasma,50588,N,1,In vivo,,,3132,,Half life in dog plasma was determined at dose 10 mg/kg,1,Canis lupus familiaris,Intermediate,,,,9615.0,,1969.0,A,BAO_0000218,CHEMBL621370,7238
,50588,N,1,,,,5374,,Half life in dog was determined,1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL621371,7239
,50588,N,1,In vivo,,,5007,,Half life in dogs administered perorally (5 mg/kg) and intravenously (2 mg/kg),1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL621372,7240
Plasma,50588,N,1,,,,16907,,Half life upon exposure to human plasma,1,Canis lupus familiaris,Intermediate,,,,9615.0,,1969.0,A,BAO_0000218,CHEMBL621373,7241
,50588,N,1,,,,6057,,Half life was calculated in dog,1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL621374,7242
,50588,N,1,,,,5006,,Half life was determined,1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL621375,7243
,50588,N,1,,,,5473,,Half life was determined,1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL621376,7244
,50588,N,1,In vivo,,,4368,,Half life by intravenous administration of 1.2 mg/kg in dog,1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL619624,7245
,50588,N,1,,,,6448,,Half life in dog,1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL875840,7246
,50588,N,1,,,,4353,,Half life in dog after intra venous administration of the compound,1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL619625,7247
,50588,N,1,,,,4353,,Half life in dog after intra venous administration of the compound; ND means Not determined,1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL619626,7248
,50588,N,1,In vivo,,,4353,,Half life in dog after po administration of the compound,1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL619627,7249
,50588,N,1,In vivo,,,4353,,Half life in dog after po administration of the compound; ND means Not determined,1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL873817,7250
,50588,N,1,In vivo,,,6265,,Half life in dog at the single oral dose of 1 mg/kg,1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL619628,7251
,50588,N,1,,,,5006,,Half life in dogs,1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL619629,7252
,50588,N,1,In vivo,,,5356,,Half life in dogs at 1 mg/kg oral dosing; 35-100 min,1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL619630,7253
,50588,N,1,,,,405,,Half life in rat,1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL619631,7254
,50588,N,1,In vivo,,,6642,,Half life in dog (dosed as a mixture of five compounds at 0.5 mpk each via iv only),1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL619632,7255
Bone,50594,N,1,In vivo,,,10107,,Biodistribution of intravenously injected [82Br]-labeled compound in bone of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,1,Mus musculus,Intermediate,,,,10090.0,,10000001.0,A,BAO_0000218,CHEMBL619633,7256
Bone,50594,N,1,In vivo,,,10107,,Biodistribution of intravenously injected [82Br]-labeled compound in bone of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,1,Mus musculus,Intermediate,,,,10090.0,,10000001.0,A,BAO_0000218,CHEMBL875841,7257
Bone,50594,N,1,In vivo,,,10107,,Biodistribution of intravenously injected [82Br]-labeled compound in bone of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,1,Mus musculus,Intermediate,,,,10090.0,,10000001.0,A,BAO_0000218,CHEMBL619634,7258
Bone,50594,N,1,In vivo,,,10107,,Biodistribution of intravenously injected [82Br]-labeled compound in bone of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,1,Mus musculus,Intermediate,,,,10090.0,,10000001.0,A,BAO_0000218,CHEMBL619635,7259
Bone,50594,N,1,In vivo,,,10107,,Biodistribution of intravenously injected [82Br]-labeled compound in bone of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,1,Mus musculus,Intermediate,,,,10090.0,,10000001.0,A,BAO_0000218,CHEMBL619636,7260
Gut,50594,N,1,In vivo,,,10107,,Biodistribution of intravenously injected [82Br]-labeled compound in gut of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,1,Mus musculus,Intermediate,,,,10090.0,,10000004.0,A,BAO_0000218,CHEMBL619637,7261
Gut,50594,N,1,In vivo,,,10107,,Biodistribution of intravenously injected [82Br]-labeled compound in gut of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.50 hours,1,Mus musculus,Intermediate,,,,10090.0,,10000004.0,A,BAO_0000218,CHEMBL619638,7262
Gut,50594,N,1,In vivo,,,10107,,Biodistribution of intravenously injected [82Br]-labeled compound in gut of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,1,Mus musculus,Intermediate,,,,10090.0,,10000004.0,A,BAO_0000218,CHEMBL619639,7263
Gut,50594,N,1,In vivo,,,10107,,Biodistribution of intravenously injected [82Br]-labeled compound in gut of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,1,Mus musculus,Intermediate,,,,10090.0,,10000004.0,A,BAO_0000218,CHEMBL619640,7264
Gut,50594,N,1,In vivo,,,10107,,Biodistribution of intravenously injected [82Br]-labeled compound in gut of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,1,Mus musculus,Intermediate,,,,10090.0,,10000004.0,A,BAO_0000218,CHEMBL619641,7265
Gut,50594,N,1,In vivo,,,10107,,Biodistribution of intravenously injected [82Br]-labeled compound in gut of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,1,Mus musculus,Intermediate,,,,10090.0,,10000004.0,A,BAO_0000218,CHEMBL619642,7266
Gut,50594,N,1,In vivo,,,10107,,Biodistribution of intravenously injected [82Br]-labeled compound in gut of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,1,Mus musculus,Intermediate,,,,10090.0,,10000004.0,A,BAO_0000218,CHEMBL619643,7267
Heart,50594,N,1,In vivo,,,10107,,Biodistribution of intravenously injected [82Br]-labeled compound in heart of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,1,Mus musculus,Intermediate,,,,10090.0,,948.0,A,BAO_0000218,CHEMBL619644,7268
Heart,50594,N,1,In vivo,,,10107,,Biodistribution of intravenously injected [82Br]-labeled compound in heart of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.50 hours,1,Mus musculus,Intermediate,,,,10090.0,,948.0,A,BAO_0000218,CHEMBL621112,7269
Heart,50594,N,1,In vivo,,,10107,,Biodistribution of intravenously injected [82Br]-labeled compound in heart of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,1,Mus musculus,Intermediate,,,,10090.0,,948.0,A,BAO_0000218,CHEMBL621113,7270
Heart,50594,N,1,In vivo,,,10107,,Biodistribution of intravenously injected [82Br]-labeled compound in heart of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,1,Mus musculus,Intermediate,,,,10090.0,,948.0,A,BAO_0000218,CHEMBL621114,7271
Heart,50594,N,1,In vivo,,,10107,,Biodistribution of intravenously injected [82Br]-labeled compound in heart of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,1,Mus musculus,Intermediate,,,,10090.0,,948.0,A,BAO_0000218,CHEMBL621115,7272
Heart,50594,N,1,In vivo,,,10107,,Biodistribution of intravenously injected [82Br]-labeled compound in heart of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,1,Mus musculus,Intermediate,,,,10090.0,,948.0,A,BAO_0000218,CHEMBL621116,7273
Heart,50594,N,1,In vivo,,,10107,,Biodistribution of intravenously injected [82Br]-labeled compound in heart of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,1,Mus musculus,Intermediate,,,,10090.0,,948.0,A,BAO_0000218,CHEMBL621117,7274
Kidney,50594,N,1,In vivo,,,10107,,Biodistribution of intravenously injected [82Br]-labeled compound in kidney of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,1,Mus musculus,Intermediate,,,,10090.0,,2113.0,A,BAO_0000218,CHEMBL621118,7275
Kidney,50594,N,1,In vivo,,,10107,,Biodistribution of intravenously injected [82Br]-labeled compound in kidney of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.5 hours,1,Mus musculus,Intermediate,,,,10090.0,,2113.0,A,BAO_0000218,CHEMBL621119,7276
Kidney,50594,N,1,In vivo,,,10107,,Biodistribution of intravenously injected [82Br]-labeled compound in kidney of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,1,Mus musculus,Intermediate,,,,10090.0,,2113.0,A,BAO_0000218,CHEMBL621120,7277
Kidney,50594,N,1,In vivo,,,10107,,Biodistribution of intravenously injected [82Br]-labeled compound in kidney of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,1,Mus musculus,Intermediate,,,,10090.0,,2113.0,A,BAO_0000218,CHEMBL621757,7278
Kidney,50594,N,1,In vivo,,,10107,,Biodistribution of intravenously injected [82Br]-labeled compound in kidney of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,1,Mus musculus,Intermediate,,,,10090.0,,2113.0,A,BAO_0000218,CHEMBL621758,7279
Kidney,50594,N,1,In vivo,,,10107,,Biodistribution of intravenously injected [82Br]-labeled compound in kidney of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,1,Mus musculus,Intermediate,,,,10090.0,,2113.0,A,BAO_0000218,CHEMBL621759,7280
Kidney,50594,N,1,In vivo,,,10107,,Biodistribution of intravenously injected [82Br]-labeled compound in kidney of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,1,Mus musculus,Intermediate,,,,10090.0,,2113.0,A,BAO_0000218,CHEMBL621760,7281
Liver,50594,N,1,In vivo,,,10107,,Biodistribution of intravenously injected [82Br]-labeled compound in liver of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,1,Mus musculus,Intermediate,,,,10090.0,,2107.0,A,BAO_0000218,CHEMBL621761,7282
Liver,50594,N,1,In vivo,,,10107,,Biodistribution of intravenously injected [82Br]-labeled compound in liver of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.50 hours,1,Mus musculus,Intermediate,,,,10090.0,,2107.0,A,BAO_0000218,CHEMBL621762,7283
Liver,50594,N,1,In vivo,,,10107,,Biodistribution of intravenously injected [82Br]-labeled compound in liver of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,1,Mus musculus,Intermediate,,,,10090.0,,2107.0,A,BAO_0000218,CHEMBL621763,7284
Liver,50594,N,1,In vivo,,,10107,,Biodistribution of intravenously injected [82Br]-labeled compound in liver of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,1,Mus musculus,Intermediate,,,,10090.0,,2107.0,A,BAO_0000218,CHEMBL624502,7285
Liver,50594,N,1,In vivo,,,10107,,Biodistribution of intravenously injected [82Br]-labeled compound in liver of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,1,Mus musculus,Intermediate,,,,10090.0,,2107.0,A,BAO_0000218,CHEMBL624503,7286
Liver,50594,N,1,In vivo,,,10107,,Biodistribution of intravenously injected [82Br]-labeled compound in liver of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,1,Mus musculus,Intermediate,,,,10090.0,,2107.0,A,BAO_0000218,CHEMBL624504,7287
Liver,50594,N,1,In vivo,,,10107,,Biodistribution of intravenously injected [82Br]-labeled compound in liver of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,1,Mus musculus,Intermediate,,,,10090.0,,2107.0,A,BAO_0000218,CHEMBL624505,7288
Lung,50594,N,1,In vivo,,,10107,,Biodistribution of intravenously injected [82Br]-labeled compound in lung of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,1,Mus musculus,Intermediate,,,,10090.0,,2048.0,A,BAO_0000218,CHEMBL624506,7289
,81034,N,1,,,,5895,,In vitro cytotoxicity against A2780 (human ovarian cancer),1,Homo sapiens,Intermediate,,478.0,,9606.0,A2780,,F,BAO_0000219,CHEMBL624507,7290
,81034,N,1,,,,6338,,In vitro cytotoxicity against the paclitaxel sensitive human breast carcinoma cell line A2780,1,Homo sapiens,Intermediate,,478.0,,9606.0,A2780,,F,BAO_0000219,CHEMBL624508,7291
,81034,N,1,,,,15163,,In vitro cytotoxicity against. ovarian carcinoma cell line A2780.,1,Homo sapiens,Intermediate,,478.0,,9606.0,A2780,,F,BAO_0000219,CHEMBL624509,7292
,81034,N,1,,,,15163,,In vitro cytotoxicity against. ovarian carcinoma cell line A2780cisR (cisplatin resistant counter part of A2780).,1,Homo sapiens,Intermediate,,478.0,,9606.0,A2780,,F,BAO_0000219,CHEMBL624510,7293
,81034,N,1,,,,15000,,In vitro cytotoxicity was tested against human Ovarian carcinoma A2780 cell line,1,Homo sapiens,Expert,,478.0,,9606.0,A2780,,F,BAO_0000219,CHEMBL875956,7294
,81034,N,1,,,,15000,,In vitro cytotoxicity was tested against human Ovarian carcinoma A2780 cisplatin resistant cell line,1,Homo sapiens,Expert,,478.0,,9606.0,A2780,,F,BAO_0000219,CHEMBL839885,7295
,81034,N,1,,,,14729,,In vitro cytotoxicity against A2780 ovarian cells using the sulforhodamine B(SRB) assay.,1,Homo sapiens,Expert,,478.0,,9606.0,A2780,,F,BAO_0000219,CHEMBL624511,7296
,81034,N,1,,,,17270,,In vitro cytotoxicity against A2780 cell line,1,Homo sapiens,Intermediate,,478.0,,9606.0,A2780,,F,BAO_0000219,CHEMBL624512,7297
,81034,N,1,,,,5685,,In vitro growth inhibitory activity against A2780 human ovarium carcinoma cell line was determined,1,Homo sapiens,Intermediate,,478.0,,9606.0,A2780,,F,BAO_0000219,CHEMBL624513,7298
,81034,N,1,,,,3563,,In vitro inhibitory activity against human ovarian cancer A2780 cell line,1,Homo sapiens,Intermediate,,478.0,,9606.0,A2780,,F,BAO_0000219,CHEMBL624514,7299
,81034,N,1,,,,17753,,In vivo cytotoxic concentration of compound against A2780 cell line after 72 hr exposure,1,Homo sapiens,Intermediate,,478.0,,9606.0,A2780,,F,BAO_0000218,CHEMBL618547,7300
,81034,N,1,,,,16317,,"Inhibition of cell growth in human ovarian carcinoma cell line (A2780cisR,cisplatin-resistant)using the 96 hour continuous exposure sulforhodamine B (SRB) growth delay assay",1,Homo sapiens,Intermediate,,478.0,,9606.0,A2780,,F,BAO_0000219,CHEMBL618548,7301
,81034,N,1,,,,16936,,Inhibition of tubulin polymerization in analogy of ca.,1,Homo sapiens,Intermediate,,478.0,,9606.0,A2780,,F,BAO_0000219,CHEMBL618549,7302
,81034,N,1,,,,3801,,Inhibitory activity against ovarian tumor cell line A2780 after 72 hr continuous exposure to compound,1,Homo sapiens,Intermediate,,478.0,,9606.0,A2780,,F,BAO_0000219,CHEMBL618550,7303
,81034,N,1,,,,6181,,Cytotoxic effect in ovarian cancer cell line (A2780),1,Homo sapiens,Expert,,478.0,,9606.0,A2780,,F,BAO_0000219,CHEMBL618551,7304
,81034,N,1,,,,5318,,Tested for cytotoxicity against Ovarian carcinoma parental type A2780 cell line expressing MDR-1 (-) gene,1,Homo sapiens,Intermediate,,478.0,,9606.0,A2780,,F,BAO_0000219,CHEMBL618552,7305
,81034,N,1,,,,4840,,Tested for the cytotoxicity in A2780 ovarian cell line,1,Homo sapiens,Intermediate,,478.0,,9606.0,A2780,,F,BAO_0000219,CHEMBL618553,7306
,81034,N,1,,,,15748,,The compound was tested for cytotoxic activity against A2780 cell line(human ovarian carcinoma ),1,Homo sapiens,Intermediate,,478.0,,9606.0,A2780,,F,BAO_0000219,CHEMBL618554,7307
,81034,N,1,,,,15748,,The compound was tested for cytotoxic activity against A2780/Cs cell line(human ovarian carcinoma,1,Homo sapiens,Intermediate,,478.0,,9606.0,A2780,,F,BAO_0000219,CHEMBL618555,7308
,80017,N,1,,,,15748,,The compound was tested for cytotoxic activity against A2780cisR cell line(human ovarian carcinoma,1,,Intermediate,,481.0,,,A2780cisR,,F,BAO_0000219,CHEMBL618556,7309
,80017,N,1,,,,15748,,The compound was tested for cytotoxic activity against A2780cisR cell line(human ovarian carcinoma ),1,,Intermediate,,481.0,,,A2780cisR,,F,BAO_0000219,CHEMBL618557,7310
,80017,N,1,,,,15748,,The compound was tested for cytotoxic activity against A2780cisR cell line(human ovarian carcinoma ); ND means no data,1,,Intermediate,,481.0,,,A2780cisR,,F,BAO_0000219,CHEMBL618558,7311
,80017,N,1,,,,15748,,The compound was tested for cytotoxic activity against A2780cisR cell line(human ovarian carcinoma),1,,Intermediate,,481.0,,,A2780cisR,,F,BAO_0000219,CHEMBL618559,7312
,81034,N,1,,,,17753,,In vivo log of cells killed after administration of compound in A2780 cell line,1,Homo sapiens,Intermediate,,478.0,,9606.0,A2780,,F,BAO_0000218,CHEMBL618560,7313
,81034,N,1,In vivo,,,17753,,Compound was tested in vivo for maximum tolerated dose after i.v. administration twice a day for 5 days in A2780 cell line,1,Homo sapiens,Intermediate,,478.0,,9606.0,A2780,,F,BAO_0000218,CHEMBL618561,7314
,81034,N,1,,,,16936,,Compound was tested for Tubulin polymerization inhibition by using human ovarian carcinoma cell lines.;NA means not active,1,Homo sapiens,Intermediate,,478.0,,9606.0,A2780,,F,BAO_0000219,CHEMBL618562,7315
,81034,N,1,,,,16936,,Compound was tested for colchicine binding inhibition by using human ovarian carcinoma cell lines (at 5 uM );NA means not active,1,Homo sapiens,Intermediate,,478.0,,9606.0,A2780,,F,BAO_0000219,CHEMBL618563,7316
,81034,N,1,,,,16936,,Compound was tested for Tubulin polymerization inhibition by using human ovarian carcinoma cell lines; ND means no data,1,Homo sapiens,Intermediate,,478.0,,9606.0,A2780,,F,BAO_0000219,CHEMBL618564,7317
,81034,N,1,,,,16936,,Compound was tested for colchicine binding inhibition by using human ovarian carcinoma cell lines. (at 5 uM ); ND means no data,1,Homo sapiens,Intermediate,,478.0,,9606.0,A2780,,F,BAO_0000219,CHEMBL618565,7318
,81034,N,1,,,,17528,,Optimal dose required to inhibit human ovarian A2780 tumor growth after subcutaneous transplantation on athymic mice at 10 mg/kg (treatment schedule: q4dX2),1,Homo sapiens,Intermediate,,478.0,,9606.0,A2780,,F,BAO_0000218,CHEMBL618566,7319
,81034,N,1,,,,6633,,Resistance factor was determined as IC50 cisplatin-resistant/parent for human A2780 ovarian cell line,1,Homo sapiens,Intermediate,,478.0,,9606.0,A2780,,F,BAO_0000219,CHEMBL618567,7320
,81034,N,1,,,,15000,,Resistance index is IC50 ratio of A2780 cell line and A2780cisR cell line,1,Homo sapiens,Expert,,478.0,,9606.0,A2780,,F,BAO_0000219,CHEMBL618568,7321
,81034,N,1,,,,17528,,Percentage tumor growth inhibition was calculated in respect to controls one week after the end of the treatment,1,Homo sapiens,Expert,,478.0,,9606.0,A2780,,F,BAO_0000219,CHEMBL618569,7322
,81034,N,1,,,,16936,,Compound was tested for Tubulin polymerization inhibition by using human ovarian cancer cell lines.,1,Homo sapiens,Intermediate,,478.0,,9606.0,A2780,,F,BAO_0000219,CHEMBL621857,7323
,81034,N,1,,,,16936,,Compound was tested for Tubulin polymerization inhibition by using human ovarian carcinoma cell lines.,1,Homo sapiens,Intermediate,,478.0,,9606.0,A2780,,F,BAO_0000219,CHEMBL621858,7324
,81034,N,1,,,,16936,,Percent of Tubulin polymerization inhibition by using human ovarian cancer cell lines at a concentration of 5 uM,1,Homo sapiens,Intermediate,,478.0,,9606.0,A2780,,F,BAO_0000219,CHEMBL621859,7325
,81034,N,1,,,,16936,,"Colchicine Binding Inhibition ( CBI ) by using human ovarian cancer cell lines at 5 uM, (values are mean of 9 over 4 concentrations +/- SD)",1,Homo sapiens,Intermediate,,478.0,,9606.0,A2780,,F,BAO_0000219,CHEMBL621860,7326
,81034,N,1,,,,16936,,Compound tested for colchicine Binding Inhibition by using human ovarian cancer cell line (at 5 uM ),1,Homo sapiens,Intermediate,,478.0,,9606.0,A2780,,F,BAO_0000219,CHEMBL621861,7327
,81034,N,1,,,,16936,,"Tested for colchicine binding inhibition, using human ovarian cancer cell lines (at 5 uM )",1,Homo sapiens,Expert,,478.0,,9606.0,A2780,,F,BAO_0000219,CHEMBL621862,7328
,81034,N,1,,,,16936,,Compound tested for colchicine Binding Inhibition by using human ovarian carcinoma cell line (at 5 uM ),1,Homo sapiens,Intermediate,,478.0,,9606.0,A2780,,F,BAO_0000219,CHEMBL621863,7329
,81034,N,1,,,,16936,,Compound was tested for colchicine Binding Inhibition by using human ovarian carcinoma cell line (at 5 uM ),1,Homo sapiens,Intermediate,,478.0,,9606.0,A2780,,F,BAO_0000219,CHEMBL621864,7330
,81034,N,1,,,,16936,,Compound was tested for colchicine binding inhibition by using human ovarian carcinoma cell line (at 5 uM ),1,Homo sapiens,Intermediate,,478.0,,9606.0,A2780,,F,BAO_0000219,CHEMBL621865,7331
,81034,N,1,,,,17737,,In vitro antiproliferative activity against A2780 cell line,1,Mus musculus,Intermediate,,478.0,,10090.0,A2780,,F,BAO_0000219,CHEMBL621866,7332
,81034,N,1,,,,17764,,Maximum tolerated dose in A2780 tumor in mice after intraperitoneal administration daily for 8 days,1,Mus musculus,Expert,,478.0,,10090.0,A2780,,F,BAO_0000219,CHEMBL621867,7333
,81034,N,1,,,,3830,,In vitro cytotoxicity of compound was determined against A2780 cell lines at 37 degree C after 96 hr,1,Homo sapiens,Intermediate,,478.0,,9606.0,A2780,,F,BAO_0000219,CHEMBL621868,7334
,81034,N,1,,,,3829,,In vitro cytotoxicity of compound was determined against A2780 cell lines at 37 degree C for 96 hr,1,Homo sapiens,Intermediate,,478.0,,9606.0,A2780,,F,BAO_0000219,CHEMBL875282,7335
,50588,N,1,,,,3546,,Vc value in dog after IV administration at a dose of 5 mg/kg,1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL621869,7336
,50588,N,1,In vivo,,,3546,,Half life period in dog after IV administration at a dose of 5 mg/kg,1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL621870,7337
,22224,U,0,,,,5668,,Area under curve was determine after peroral administration at 10 mpk in Rhesus,1,Cercopithecidae,Autocuration,,,,9527.0,,,A,BAO_0000019,CHEMBL621871,7338
Plasma,22224,U,0,,,,3443,,AUC (area under curve) evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,1,Cercopithecidae,Autocuration,,,,9527.0,,1969.0,A,BAO_0000218,CHEMBL621243,7339
Plasma,22224,U,0,,,,3443,,AUC (area under curve) compared to Cilastatin evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,1,Cercopithecidae,Autocuration,,,,9527.0,,1969.0,A,BAO_0000218,CHEMBL621244,7340
,22224,U,0,In vivo,,,4256,,Area under curve determined after intravenous administration at a dose of 3 mg/kg in cynomolgus monkey,1,Macaca fascicularis,Autocuration,,,,9541.0,,,A,BAO_0000218,CHEMBL621245,7341
,22224,U,0,In vivo,,,4256,,Area under curve determined after peroral administration at a dose of 10 mg/kg in cynomolgus monkey,1,Macaca fascicularis,Autocuration,,,,9541.0,,,A,BAO_0000218,CHEMBL621246,7342
,22224,U,0,In vivo,,,4256,,Area under curve determined after peroral administration at a dose of 3 mg/kg in cynomolgus monkey,1,Macaca fascicularis,Autocuration,,,,9541.0,,,A,BAO_0000218,CHEMBL621247,7343
,22224,U,0,In vivo,,,4256,,Oral Bioavailability in rat,1,Rattus norvegicus,Autocuration,,,,10116.0,,,A,BAO_0000218,CHEMBL618386,7344
,22224,U,0,,,,1916,,Area under curve was evaluated against Cynomolgus monkey at a dose of 15 mg/kg after po administration,1,Cercopithecidae,Autocuration,,,,9527.0,,,A,BAO_0000218,CHEMBL618387,7345
,22224,U,0,,,,5302,,Area under curve value in monkey at a dose of 5 mg/kg,1,Cercopithecidae,Autocuration,,,,9527.0,,,A,BAO_0000218,CHEMBL618388,7346
,22224,U,0,,,,4257,,Area under curve was determined in monkey after a 3 mg/kg of oral dose,1,Cercopithecidae,Autocuration,,,,9527.0,,,A,BAO_0000218,CHEMBL618389,7347
,22224,U,0,,,,5355,,Area under curve was determined using trapezoidal rule after intravenous administration in cynomolgus monkeys,1,Cercopithecidae,Autocuration,,,,9527.0,,,A,BAO_0000019,CHEMBL618574,7348
,22224,U,0,,,,5355,,Area under curve was determined using trapezoidal rule after oral administration in cynomolgus monkeys,1,Cercopithecidae,Autocuration,,,,9527.0,,,A,BAO_0000019,CHEMBL618575,7349
,22224,U,0,,,,5355,,Area under curve was determined using trapezoidal rule after oral administration in cynomolgus monkeys; ND means Not determined,1,Cercopithecidae,Autocuration,,,,9527.0,,,A,BAO_0000019,CHEMBL618576,7350
,22224,U,0,,,,6078,,Area under the curve for the compound calculated from 0-24 hr after intravenous administration at a dose of 10 mg/kg in monkey,1,Cercopithecidae,Autocuration,,,,9527.0,,,A,BAO_0000218,CHEMBL618577,7351
,22224,U,0,,,,6078,,Area under the curve for the compound calculated from 0-24 hr after oral administration at a dose of 10 mg/kg in monkey,1,Cercopithecidae,Autocuration,,,,9527.0,,,A,BAO_0000218,CHEMBL876487,7352
,22224,U,0,,,,6062,,Area under the curve was measured in monkey after an iv dose of 1 mg/kg,1,Cercopithecidae,Autocuration,,,,9527.0,,,A,BAO_0000218,CHEMBL618578,7353
,22224,U,0,,,,2661,,Compound was evaluated for AUC after treatment with iv dose of 1 mgkg to female cynomolgus monkey,1,Cercopithecidae,Autocuration,,,,9527.0,,,A,BAO_0000218,CHEMBL618579,7354
,22224,U,0,,,,2661,,Compound was evaluated for AUC after treatment with oral dose of 2 mgkg to female cynomolgus monkey,1,Cercopithecidae,Autocuration,,,,9527.0,,,A,BAO_0000019,CHEMBL618580,7355
,22224,U,0,,,,5394,,Pharmacokinetic parameter Cmax was measured after administration into monkey at 3 mg/kg,1,Cercopithecidae,Autocuration,,,,9527.0,,,A,BAO_0000218,CHEMBL618581,7356
,22224,U,0,,,,4397,,Pharmacokinetic property at the dose of 10 mg/kg (20% HPbetaCD) concentration in cynomolgus monkeys (0 to 24 hr) p.o.,1,Cercopithecidae,Autocuration,,,,9527.0,,,A,BAO_0000218,CHEMBL618582,7357
,22224,U,0,,,,17509,,Area under curve value 24 hr after 2 mg/kg iv administration in monkeys,1,Cercopithecidae,Autocuration,,,,9527.0,,,A,BAO_0000218,CHEMBL618583,7358
,22224,U,0,,,,17509,,Area under curve value 24 hr after 2 mg/kg oral administration in monkeys,1,Cercopithecidae,Autocuration,,,,9527.0,,,A,BAO_0000218,CHEMBL618584,7359
,22224,U,0,In vivo,,,6641,,Oral AUCN in monkey (dosed at 0.5 mpk iv ),1,Cercopithecidae,Autocuration,,,,9527.0,,,A,BAO_0000218,CHEMBL618585,7360
,22224,U,0,,,,5355,,Bioavailability was reported in cynomolgus monkeys (ratio of AUC in oral administration to that of intravenous administration),1,Cercopithecidae,Autocuration,,,,9527.0,,,A,BAO_0000218,CHEMBL618586,7361
,22224,U,0,In vivo,,,3443,,Half life compared to Cilastatin evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,1,Cercopithecidae,Autocuration,,,,9527.0,,,A,BAO_0000218,CHEMBL618587,7362
,22224,U,0,In vivo,,,3443,,Half life evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,1,Cercopithecidae,Autocuration,,,,9527.0,,,A,BAO_0000218,CHEMBL618588,7363
,22224,U,0,,,,17409,,Binding towards monkey plasma protein at 10 uM,1,Cercopithecidae,Autocuration,,,,9527.0,,,A,BAO_0000019,CHEMBL618589,7364
,22224,U,0,,,,17409,,Binding towards monkey plasma protein at 100 uM,1,Cercopithecidae,Autocuration,,,,9527.0,,,A,BAO_0000019,CHEMBL618590,7365
,22224,U,0,In vivo,,,1052,,Apparent bioavailability in squirrel monkey was determined,1,Cercopithecidae,Autocuration,,,,9527.0,,,A,BAO_0000218,CHEMBL872262,7366
,22224,U,0,In vivo,,,13501,,Bioavailability was determined after oral administration of compound 18 at a dose of 1 mg/kg to rhesus monkey,1,Cercopithecidae,Autocuration,,,,9527.0,,,A,BAO_0000218,CHEMBL618591,7367
,22224,U,0,In vivo,,,17509,,Bioavailability in monkey (dose 2 mg/kg),1,monkey,Autocuration,,,,9443.0,,,A,BAO_0000218,CHEMBL618592,7368
,22224,U,0,In vivo,,,5394,,Compound at a dose 3 mg/kg was administered to monkey and was evaluated for bioavailability after administration into monkey at 3 mg/kg,1,Cercopithecidae,Autocuration,,,,9527.0,,,A,BAO_0000218,CHEMBL876488,7369
,22224,U,0,In vivo,,,2661,,Compound was evaluated for bioavailability after treatment with oral dose of 2 mgkg to female cynomolgus monkey,1,Cercopithecidae,Autocuration,,,,9527.0,,,A,BAO_0000218,CHEMBL618593,7370
,22224,U,0,In vivo,,,11219,,Bioavailability in monkey (i.d. dosing),1,monkey,Autocuration,,,,9443.0,,,A,BAO_0000218,CHEMBL618594,7371
,22224,U,0,In vivo,,,3045,,Oral bioavailability after 5 mg/kg in cynomolgus monkey was determined,1,Cercopithecidae,Autocuration,,,,9527.0,,,A,BAO_0000218,CHEMBL618595,7372
,22224,U,0,,,,17796,,Clearance of the drug was measured in cynomolgus,1,Cercopithecidae,Autocuration,,,,9527.0,,,A,BAO_0000019,CHEMBL621469,7373
,22224,U,0,In vivo,,,1399,,Clearance was estimated in two squirrel monkeys after iv administration at 5 mg/kg,1,Cercopithecidae,Autocuration,,,,9527.0,,,A,BAO_0000218,CHEMBL621470,7374
,22224,U,0,In vivo,,,2661,,Compound was evaluated for clearance after treatment with iv dose of 1 mgkg to female cynomolgus monkey,1,Cercopithecidae,Autocuration,,,,9527.0,,,A,BAO_0000218,CHEMBL621471,7375
Plasma,22224,U,0,In vivo,,,5005,,Compound was tested for its plasma clearance rate in rhesus monkey at a dose of 0.75 mg/kg iv/ 1.5 mg/kg po,1,Macaca mulatta,Autocuration,,,,9544.0,,1969.0,A,BAO_0000218,CHEMBL621472,7376
,22224,U,0,In vivo,,,17267,,Plasma clearance in rhesus monkey was determined,1,Cercopithecidae,Autocuration,,,,9527.0,,,A,BAO_0000218,CHEMBL621473,7377
,22224,U,0,In vivo,,,6535,,Plasma clearance in monkey after administration of 1 mg/kg iv,1,Cercopithecidae,Autocuration,,,,9527.0,,,A,BAO_0000218,CHEMBL621474,7378
,22224,U,0,In vivo,,,5922,,Plasma clearance in cynomolgus monkey,1,Cercopithecidae,Autocuration,,,,9527.0,,,A,BAO_0000218,CHEMBL621475,7379
,22224,U,0,In vivo,,,6221,,Plasma clearance after oral administration (2.5 mg/kg) in monkey was determined,1,Cercopithecidae,Autocuration,,,,9527.0,,,A,BAO_0000218,CHEMBL621476,7380
,22224,U,0,In vivo,,,5668,,Plasma clearance after peroral administration at 10 mpk in Rhesus,1,Cercopithecidae,Autocuration,,,,9527.0,,,A,BAO_0000218,CHEMBL624290,7381
,22224,U,0,In vivo,,,5355,,The total clearance was determined after intravenous administration in cynomolgus monkeys,1,Cercopithecidae,Autocuration,,,,9527.0,,,A,BAO_0000218,CHEMBL624291,7382
,22224,U,0,In vivo,,,5355,,The total clearance was determined after oral administration in cynomolgus monkeys; NA means Not applicable,1,Cercopithecidae,Autocuration,,,,9527.0,,,A,BAO_0000218,CHEMBL624292,7383
,22224,U,0,In vivo,,,5355,,The total clearance was determined after oral administration in cynomolgus monkeys; NA means not applicable,1,Cercopithecidae,Autocuration,,,,9527.0,,,A,BAO_0000218,CHEMBL624293,7384
,22224,U,0,In vivo,,,4578,,Tested for Clearance upon iv administration to african green monkey,1,Cercopithecidae,Autocuration,,,,9527.0,,,A,BAO_0000218,CHEMBL624294,7385
,22224,U,0,In vivo,,,17592,,Clearance in monkey,1,Cercopithecidae,Autocuration,,,,9527.0,,,A,BAO_0000218,CHEMBL624295,7386
,50588,N,1,In vivo,,,6641,,Half life in dog (dosed at 0.5 mpk iv and 2.0 mpk orally),1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL624296,7387
,50588,N,1,In vivo,,,6642,,Half life in dog (dosed at 0.5 mpk iv and 2.0 mpk orally),1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL624297,7388
,50588,N,1,In vivo,,,16367,,Half life was evaluated after intravenous administration to dogs,1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL624298,7389
,50588,N,1,,,,5472,,Half life was evaluated in dog,1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL624299,7390
,50588,N,1,,,,5474,,Half life was evaluated in dog,1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL624300,7391
,50588,N,1,In vivo,,,5654,,Half life period (t1/2) of compound was determined after intravenous administration in average of two dogs at a dose of 1 mg/kg,1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL624301,7392
,50588,N,1,In vivo,,,6227,,Half life period after intravenous administration (1 mg/kg) was determined in dog (in vivo),1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL624302,7393
,50588,N,1,In vivo,,,6227,,Half life period after intravenous administration in dog,1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL876026,7394
,50588,N,1,In vivo,,,6221,,Half life period after oral administration (2.5 mg/kg) in dog was determined,1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL624303,7395
,50588,N,1,,,,4527,,Half life period at a dose of 1 uM/kg in dog was determined,1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL624304,7396
,50588,N,1,In vivo,,,5668,,Half life period was determine after peroral administration at 10 mpk in dog,1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL624305,7397
,50588,N,1,In vivo,,,5668,,Half life period was determine after peroral administration at 5 mpk in dog,1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL624306,7398
,50588,N,1,,,,3854,,Half life period was determined,1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL624307,7399
,50588,N,1,,,,5505,,Half life period was determined,1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL624308,7400
,50588,N,1,In vivo,,,6251,,Half life period by iv administration in dog at a dose of 6 mg/kg,1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL624309,7401
,50588,N,1,,,,1918,,Half life period was evaluated in dog,1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL624310,7402
,50588,N,1,In vivo,,,5546,,Half life period was determined in Beagle dog at a dose of 1 mg/kg by iv administration,1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL625003,7403
,50588,N,1,In vivo,,,4809,,Half life period was determined in Beagle dogs after (iv) administration of a dose of 12 (uM/kg),1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL625004,7404
,50588,N,1,In vivo,,,6215,,Half life time after intravenous administration (0.5 mg/kg) was determined in dog,1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL625005,7405
,50588,N,1,In vivo,,,4527,,Half-life period by oral administration at a dose of 10 uM/kg in dog was determined,1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL873813,7406
,50588,N,1,In vivo,,,17594,,Half-life after oral dose of compound at 3 mg/kg in dogs,1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL625006,7407
,50588,N,1,In vivo,,,17839,,Half-life of compound in dog following p.o. administration of 0.5 mg/kg,1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL625007,7408
,50588,N,1,In vivo,,,17839,,Half-life of compound in dog following p.o. administration of 0.9 mg/kg,1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL876027,7409
,50588,N,1,In vivo,,,17839,,Half-life of compound in dog following p.o. administration of 0.95 mg/kg,1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL625008,7410
,50588,N,1,In vivo,,,17839,,Half-life of compound in dog following p.o. administration of 1 mg/kg,1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL625009,7411
Plasma,50588,N,1,,,,5210,,Half-life of compound in plasma of dog was determined,1,Canis lupus familiaris,Intermediate,,,,9615.0,,1969.0,A,BAO_0000218,CHEMBL625010,7412
,50588,N,1,,,,5210,,Half-life of compound was determined in dogs,1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL625011,7413
,50588,N,1,In vivo,,,2959,,Half-life after administration of 4 mg/Kg oral dose in dog,1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL621553,7414
,50588,N,1,In vivo,,,4137,,Half-life after intravenous administration of 1 mg/kg/h in dog,1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL621554,7415
,50588,N,1,,,,5064,,Half-life in Dog,1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL621555,7416
,50588,N,1,,,,5147,,Half-life in Dog,1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL621556,7417
,50588,N,1,,,,5145,,Half-life in dog,1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL621557,7418
,50588,N,1,In vivo,,,6123,,Half-life in dog after oral administration at 1 mg/kg,1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL621558,7419
,50588,N,1,In vivo,,,6123,,Half-life in dog after oral administration at 1 mg/kg; nd is not determined,1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL621559,7420
,50588,N,1,,,,4333,,Half-life in dogs,1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL621560,7421
,50588,N,1,,,,4333,,Half-life in dogs; ND indicates not determined,1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL876028,7422
Plasma,50588,N,1,,,,12500,,Half-life in plasma of dog,1,Canis lupus familiaris,Intermediate,,,,9615.0,,1969.0,A,BAO_0000218,CHEMBL621561,7423
Plasma,50588,N,1,,,,12500,,Half-life in plasma of dog at dose of 3-10 mgkg,1,Canis lupus familiaris,Intermediate,,,,9615.0,,1969.0,A,BAO_0000218,CHEMBL621562,7424
,50588,N,1,In vivo,,,6005,,Half-life was evaluated after i.v. administration in dog at a dose of 1 mg/kg,1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL621563,7425
,50588,N,1,In vivo,,,6062,,Half-life was measured in dog after an iv dose of 1 mg/kg,1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL621564,7426
,50588,N,1,In vivo,,,17650,,Half-life was measured in dogs after an oral dose of 10 uM/kg,1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL621565,7427
,50588,N,1,In vivo,,,5530,,Half-life in vivo in dog by intravenous administration at a dose of 0.2 mg/kg,1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL621566,7428
,50588,N,1,In vivo,,,5530,,Half-life in vivo in dog by intravenous administration at a dose of 1 mg/kg,1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL621567,7429
,50588,N,1,In vivo,,,5600,,Half-life of the compound after 0.3 mg/kg po administration in dog,1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL622978,7430
,50588,N,1,In vivo,,,6039,,Half-life period after intravenous administration of 0.5 mg/kg in dog was determined,1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL873814,7431
,50588,N,1,In vivo,,,6039,,Half-life period after intravenous administration of 1.0 mg/kg in dog was determined,1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL623219,7432
,50588,N,1,In vivo,,,6039,,Half-life period after peroral administration of 0.2 mg/kg in dog was determined,1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL624477,7433
,50588,N,1,,,,6227,,t1/2 in dog,1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL624478,7434
,50588,N,1,,,,14541,,Half-life period measured in dogs,1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL624479,7435
,50588,N,1,In vivo,,,4521,,Half-life period in dog after 2 mg/kg by oral and 0.5 mg/kg by intravenous administration,1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL624480,7436
,50588,N,1,In vivo,,,4521,,Half-life period in dog after 2 mg/kg by oral and 0.5 mg/kg by intravenous administration; ND is not determined,1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL623595,7437
,50588,N,1,In vivo,,,6679,,Half-life period was determined after 1 mg/kg (i.v.) / 2 mg/kg (p.o.) of compound administration,1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL623596,7438
Plasma,50588,N,1,In vitro,,,1116,,"In vitro half life at 1.5 -5.6ug/mL, 37 degree C in dog plasma",1,Canis lupus familiaris,Intermediate,,,,9615.0,,1969.0,A,BAO_0000218,CHEMBL623597,7439
,50588,N,1,In vivo,,,5444,,In vivo half life period was calculated at 1 mg/kg in dog,1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL623598,7440
,50588,N,1,In vivo,,,5444,,In vivo half life period was calculated at 1 mg/kg in dog; ND=Not determined,1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL623599,7441
,50588,N,1,In vivo,,,17853,,Longer half-life in dog (i.v.) at 0.5 mpk,1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL623600,7442
,50588,N,1,In vivo,,,4353,,Oral bioavailability in dog (dose 5 uM/kg),1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL623601,7443
,50588,N,1,In vivo,,,16452,,Pharmacokinetic data at 0.5 mg/kg dose given to dogs intravenously.,1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL623602,7444
,50588,N,1,In vivo,,,16452,,Pharmacokinetic data at 1 mg/kg dose given to dogs intravenously,1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL623603,7445
,50588,N,1,In vivo,,,16452,,Bioavailability in dog (dose 1 mg/kg i.v.),1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL623604,7446
Lung,50594,N,1,In vivo,,,10107,,Biodistribution of intravenously injected [82Br]-labeled compound in lung of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.5 hours,1,Mus musculus,Intermediate,,,,10090.0,,2048.0,A,BAO_0000218,CHEMBL623605,7447
Lung,50594,N,1,In vivo,,,10107,,Biodistribution of intravenously injected [82Br]-labeled compound in lung of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,1,Mus musculus,Intermediate,,,,10090.0,,2048.0,A,BAO_0000218,CHEMBL623606,7448
Lung,50594,N,1,In vivo,,,10107,,Biodistribution of intravenously injected [82Br]-labeled compound in lung of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,1,Mus musculus,Intermediate,,,,10090.0,,2048.0,A,BAO_0000218,CHEMBL623607,7449
Lung,50594,N,1,In vivo,,,10107,,Biodistribution of intravenously injected [82Br]-labeled compound in lung of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,1,Mus musculus,Intermediate,,,,10090.0,,2048.0,A,BAO_0000218,CHEMBL623608,7450
Lung,50594,N,1,In vivo,,,10107,,Biodistribution of intravenously injected [82Br]-labeled compound in lung of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,1,Mus musculus,Intermediate,,,,10090.0,,2048.0,A,BAO_0000218,CHEMBL623609,7451
Lung,50594,N,1,In vivo,,,10107,,Biodistribution of intravenously injected [82Br]-labeled compound in lung of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,1,Mus musculus,Intermediate,,,,10090.0,,2048.0,A,BAO_0000218,CHEMBL623610,7452
Muscle tissue,50594,N,1,In vivo,,,10107,,Biodistribution of intravenously injected [82Br]-labeled compound in muscle of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,1,Mus musculus,Intermediate,,,,10090.0,,2385.0,A,BAO_0000218,CHEMBL623611,7453
Muscle tissue,50594,N,1,In vivo,,,10107,,Biodistribution of intravenously injected [82Br]-labeled compound in muscle of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.5 hours,1,Mus musculus,Intermediate,,,,10090.0,,2385.0,A,BAO_0000218,CHEMBL623612,7454
Muscle tissue,50594,N,1,In vivo,,,10107,,Biodistribution of intravenously injected [82Br]-labeled compound in muscle of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,1,Mus musculus,Intermediate,,,,10090.0,,2385.0,A,BAO_0000218,CHEMBL623613,7455
Muscle tissue,50594,N,1,In vivo,,,10107,,Biodistribution of intravenously injected [82Br]-labeled compound in muscle of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,1,Mus musculus,Intermediate,,,,10090.0,,2385.0,A,BAO_0000218,CHEMBL623614,7456
Muscle tissue,50594,N,1,In vivo,,,10107,,Biodistribution of intravenously injected [82Br]-labeled compound in muscle of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,1,Mus musculus,Intermediate,,,,10090.0,,2385.0,A,BAO_0000218,CHEMBL623615,7457
Muscle tissue,50594,N,1,In vivo,,,10107,,Biodistribution of intravenously injected [82Br]-labeled compound in muscle of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,1,Mus musculus,Intermediate,,,,10090.0,,2385.0,A,BAO_0000218,CHEMBL623616,7458
Muscle tissue,50594,N,1,In vivo,,,10107,,Biodistribution of intravenously injected [82Br]-labeled compound in muscle of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,1,Mus musculus,Intermediate,,,,10090.0,,2385.0,A,BAO_0000218,CHEMBL623617,7459
Zone of skin,50594,N,1,In vivo,,,10107,,Biodistribution of intravenously injected [82Br]-labeled compound in skin of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,1,Mus musculus,Intermediate,,,,10090.0,,14.0,A,BAO_0000218,CHEMBL875944,7460
Zone of skin,50594,N,1,In vivo,,,10107,,Biodistribution of intravenously injected [82Br]-labeled compound in skin of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.50 hours,1,Mus musculus,Intermediate,,,,10090.0,,14.0,A,BAO_0000218,CHEMBL623618,7461
Zone of skin,50594,N,1,In vivo,,,10107,,Biodistribution of intravenously injected [82Br]-labeled compound in skin of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,1,Mus musculus,Intermediate,,,,10090.0,,14.0,A,BAO_0000218,CHEMBL623619,7462
Zone of skin,50594,N,1,In vivo,,,10107,,Biodistribution of intravenously injected [82Br]-labeled compound in skin of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,1,Mus musculus,Intermediate,,,,10090.0,,14.0,A,BAO_0000218,CHEMBL623620,7463
Zone of skin,50594,N,1,In vivo,,,10107,,Biodistribution of intravenously injected [82Br]-labeled compound in skin of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,1,Mus musculus,Intermediate,,,,10090.0,,14.0,A,BAO_0000218,CHEMBL623621,7464
Zone of skin,50594,N,1,In vivo,,,10107,,Biodistribution of intravenously injected [82Br]-labeled compound in skin of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,1,Mus musculus,Intermediate,,,,10090.0,,14.0,A,BAO_0000218,CHEMBL623622,7465
Zone of skin,50594,N,1,In vivo,,,10107,,Biodistribution of intravenously injected [82Br]-labeled compound in skin of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,1,Mus musculus,Intermediate,,,,10090.0,,14.0,A,BAO_0000218,CHEMBL623623,7466
Spleen,50594,N,1,In vivo,,,10107,,Biodistribution of intravenously injected [82Br]-labeled compound in spleen of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,1,Mus musculus,Intermediate,,,,10090.0,,2106.0,A,BAO_0000218,CHEMBL623624,7467
Spleen,50594,N,1,In vivo,,,10107,,Biodistribution of intravenously injected [82Br]-labeled compound in spleen of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.50 hours,1,Mus musculus,Intermediate,,,,10090.0,,2106.0,A,BAO_0000218,CHEMBL618521,7468
Spleen,50594,N,1,In vivo,,,10107,,Biodistribution of intravenously injected [82Br]-labeled compound in spleen of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,1,Mus musculus,Intermediate,,,,10090.0,,2106.0,A,BAO_0000218,CHEMBL618522,7469
Spleen,50594,N,1,In vivo,,,10107,,Biodistribution of intravenously injected [82Br]-labeled compound in spleen of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,1,Mus musculus,Intermediate,,,,10090.0,,2106.0,A,BAO_0000218,CHEMBL618523,7470
Spleen,50594,N,1,In vivo,,,10107,,Biodistribution of intravenously injected [82Br]-labeled compound in spleen of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,1,Mus musculus,Intermediate,,,,10090.0,,2106.0,A,BAO_0000218,CHEMBL618524,7471
Spleen,50594,N,1,In vivo,,,10107,,Biodistribution of intravenously injected [82Br]-labeled compound in spleen of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,1,Mus musculus,Intermediate,,,,10090.0,,2106.0,A,BAO_0000218,CHEMBL618525,7472
Spleen,50594,N,1,In vivo,,,10107,,Biodistribution of intravenously injected [82Br]-labeled compound in spleen of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,1,Mus musculus,Intermediate,,,,10090.0,,2106.0,A,BAO_0000218,CHEMBL624586,7473
Stomach,50594,N,1,In vivo,,,10107,,Biodistribution of intravenously injected [82Br]-labeled compound in stomach of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,1,Mus musculus,Intermediate,,,,10090.0,,945.0,A,BAO_0000218,CHEMBL624587,7474
Stomach,50594,N,1,In vivo,,,10107,,Biodistribution of intravenously injected [82Br]-labeled compound in stomach of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.50 hours,1,Mus musculus,Intermediate,,,,10090.0,,945.0,A,BAO_0000218,CHEMBL624588,7475
Stomach,50594,N,1,In vivo,,,10107,,Biodistribution of intravenously injected [82Br]-labeled compound in stomach of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,1,Mus musculus,Intermediate,,,,10090.0,,945.0,A,BAO_0000218,CHEMBL624589,7476
Stomach,50594,N,1,In vivo,,,10107,,Biodistribution of intravenously injected [82Br]-labeled compound in stomach of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,1,Mus musculus,Intermediate,,,,10090.0,,945.0,A,BAO_0000218,CHEMBL624590,7477
Stomach,50594,N,1,In vivo,,,10107,,Biodistribution of intravenously injected [82Br]-labeled compound in stomach of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,1,Mus musculus,Intermediate,,,,10090.0,,945.0,A,BAO_0000218,CHEMBL624591,7478
Stomach,50594,N,1,In vivo,,,10107,,Biodistribution of intravenously injected [82Br]-labeled compound in stomach of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,1,Mus musculus,Intermediate,,,,10090.0,,945.0,A,BAO_0000218,CHEMBL624592,7479
Stomach,50594,N,1,In vivo,,,10107,,Biodistribution of intravenously injected [82Br]-labeled compound in stomach of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,1,Mus musculus,Intermediate,,,,10090.0,,945.0,A,BAO_0000218,CHEMBL624593,7480
,50597,N,1,In vivo,,,4689,,Oral bioavailability in rat,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL624594,7481
,50597,N,1,In vivo,,,4950,,Tested for the bioavailability in rat,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL624595,7482
,50597,N,1,In vivo,,,5328,,Bioavailability in rat (dose 1 mg/kg i.v. and 2 mg/kg p.o.),1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL624596,7483
,50597,N,1,In vivo,,,406,,Bioavailability in rat,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL624597,7484
,50597,N,1,In vivo,,,12500,,Bioavailability in rat,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL624598,7485
,50597,N,1,In vivo,,,12500,,Bioavailability in rat (dose 3-10 mg/kg),1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL624599,7486
,50597,N,1,In vivo,,,5247,,Bioavailability in rat,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL875166,7487
Plasma,50597,N,1,In vivo,,,4186,,Apparent terminal elimination half-life in rat plasma after administration of 3.5 mg/kg dose through subcutaneous route,1,Rattus norvegicus,Intermediate,,,,10116.0,,1969.0,A,BAO_0000218,CHEMBL624600,7488
Plasma,50597,N,1,In vivo,,,4186,,Apparent terminal elimination half-life in rat plasma after administration of 50 mg/kg dose through subcutaneous route,1,Rattus norvegicus,Intermediate,,,,10116.0,,1969.0,A,BAO_0000218,CHEMBL624601,7489
,50597,N,1,In vivo,,,6647,,Half life after oral administration was determined in rats at 6 mg/kg,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL624602,7490
,50597,N,1,,,,6484,,Half life was determined,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL624603,7491
,50597,N,1,In vivo,,,3249,,Half life the of compound was determined by ''Cr'' assay in rat at a dose of 10 mg/kg,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL624604,7492
Plasma,50597,N,1,In vivo,,,6281,,Plasma half life in rat at oral dose 2.8 mg/mk body weight,1,Rattus norvegicus,Intermediate,,,,10116.0,,1969.0,A,BAO_0000218,CHEMBL624605,7493
,50597,N,1,,,,3307,,Half life in rats,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL624606,7494
Blood,50597,N,1,In vivo,,,12058,,Half-lives were estimated from the elimination phase of the blood conc-time curve after oral administration,1,Rattus norvegicus,Intermediate,,,,10116.0,,178.0,A,BAO_0000218,CHEMBL624607,7495
,50597,N,1,,,,8833,,Hill coefficient of the compound,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL624608,7496
Blood,50597,N,1,,,,3193,,Compound was tested for percent hydrolysis in whole blood after a time interval of 0.5 min,1,Rattus norvegicus,Intermediate,,,,10116.0,,178.0,A,BAO_0000218,CHEMBL624609,7497
Blood,50597,N,1,,,,3193,,Compound was tested for percent hydrolysis in whole blood after a time interval of 180.0 min,1,Rattus norvegicus,Intermediate,,,,10116.0,,178.0,A,BAO_0000218,CHEMBL624610,7498
Blood,50597,N,1,,,,3193,,Compound was tested for percent hydrolysis in whole blood after a time interval of 2.0 min,1,Rattus norvegicus,Intermediate,,,,10116.0,,178.0,A,BAO_0000218,CHEMBL624611,7499
Blood,50597,N,1,,,,3193,,Compound was tested for percent hydrolysis in whole blood after a time interval of 5.0 min,1,Rattus norvegicus,Intermediate,,,,10116.0,,178.0,A,BAO_0000218,CHEMBL624612,7500
Blood,50597,N,1,,,,3193,,Compound was tested for percent hydrolysis in whole blood after a time interval of 60.0 min,1,Rattus norvegicus,Intermediate,,,,10116.0,,178.0,A,BAO_0000218,CHEMBL875167,7501
Blood,50597,N,1,,,,3193,,Compound was tested for percent hydrolysis in whole blood after a time interval of 7.0 min,1,Rattus norvegicus,Intermediate,,,,10116.0,,178.0,A,BAO_0000218,CHEMBL624613,7502
Blood,50597,N,1,,,,3193,,"Compound was tested for percent hydrolysis in whole blood, after a time interval of 15.0 min",1,Rattus norvegicus,Intermediate,,,,10116.0,,178.0,A,BAO_0000218,CHEMBL624614,7503
,50597,N,1,,,,5960,,Plasma concentration at 4 hr after 30 mg/kg post dosing in rat using HPLC/MS,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL624392,7504
Brain,50597,N,1,In vivo,,,13950,,Biodistribution of [123I]-label in rat brain was reported at 0.33 hr post injection. Value shown is %ID/organ,1,Rattus norvegicus,Intermediate,,,,10116.0,,955.0,A,BAO_0000218,CHEMBL624393,7505
Brain,50597,N,1,In vivo,,,13950,,Biodistribution of [123I]-label in rat brain was reported at 1 hr post injection. Value shown is %ID/organ,1,Rattus norvegicus,Intermediate,,,,10116.0,,955.0,A,BAO_0000218,CHEMBL624394,7506
Brain,50597,N,1,In vivo,,,13950,,Biodistribution of [123I]-label in rat brain was reported at 2 hr post injection. Value shown is %ID/organ,1,Rattus norvegicus,Intermediate,,,,10116.0,,955.0,A,BAO_0000218,CHEMBL624395,7507
Brain,50597,N,1,In vivo,,,13950,,Biodistribution of [123I]-label in rat brain was reported at 24 hr post injection. Value shown is %ID/organ,1,Rattus norvegicus,Intermediate,,,,10116.0,,955.0,A,BAO_0000218,CHEMBL624396,7508
Brain,50597,N,1,In vivo,,,13950,,Biodistribution of [123I]-label in rat brain was reported at 4 hr post injection. Value shown is %ID/organ,1,Rattus norvegicus,Intermediate,,,,10116.0,,955.0,A,BAO_0000218,CHEMBL624397,7509
Thyroid gland,50597,N,1,In vivo,,,13950,,Biodistribution of [123I]-label in rat thyroid was reported at 0.33 hr post injection. Value shown is %ID/organ,1,Rattus norvegicus,Intermediate,,,,10116.0,,2046.0,A,BAO_0000218,CHEMBL624398,7510
Thyroid gland,50597,N,1,In vivo,,,13950,,Biodistribution of [123I]-label in rat thyroid was reported at 1 hr post injection. Value shown is %ID/organ,1,Rattus norvegicus,Intermediate,,,,10116.0,,2046.0,A,BAO_0000218,CHEMBL624399,7511
Thyroid gland,50597,N,1,In vivo,,,13950,,Biodistribution of [123I]-label in rat thyroid was reported at 2 hr post injection. Value shown is %ID/organ,1,Rattus norvegicus,Intermediate,,,,10116.0,,2046.0,A,BAO_0000218,CHEMBL624400,7512
Thyroid gland,50597,N,1,In vivo,,,13950,,Biodistribution of [123I]-label in rat thyroid was reported at 24 hr post injection. Value shown is %ID/organ,1,Rattus norvegicus,Intermediate,,,,10116.0,,2046.0,A,BAO_0000218,CHEMBL624401,7513
Thyroid gland,50597,N,1,In vivo,,,13950,,Biodistribution of [123I]-label in rat thyroid was reported at 4 hr post injection. Value shown is %ID/organ,1,Rattus norvegicus,Intermediate,,,,10116.0,,2046.0,A,BAO_0000218,CHEMBL624402,7514
Blood,50597,N,1,In vivo,,,9866,,Biodistribution in normal rat blood in the presence of 0.005 M Gd/0.01 M lig at 2 hr,1,Rattus norvegicus,Intermediate,,,,10116.0,,178.0,A,BAO_0000218,CHEMBL624403,7515
Blood,50597,N,1,In vivo,,,9866,,Biodistribution in normal rat blood in the presence of 0.01 M Gd/0.05 M lig,1,Rattus norvegicus,Intermediate,,,,10116.0,,178.0,A,BAO_0000218,CHEMBL624404,7516
Blood,50597,N,1,In vivo,,,9866,,Biodistribution in normal rat blood in the presence of NAC Gd 0.01 M lig at 2 hr,1,Rattus norvegicus,Intermediate,,,,10116.0,,178.0,A,BAO_0000218,CHEMBL624405,7517
Bone,50597,N,1,In vivo,,,9866,,Biodistribution in normal rat bone in the presence of 0.005 M Gd/0.01 M lig at 2 hr,1,Rattus norvegicus,Intermediate,,,,10116.0,,10000001.0,A,BAO_0000218,CHEMBL624406,7518
Bone,50597,N,1,In vivo,,,9866,,Biodistribution in normal rat bone in the presence of 0.01 M Gd/0.05 M lig,1,Rattus norvegicus,Intermediate,,,,10116.0,,10000001.0,A,BAO_0000218,CHEMBL624407,7519
Bone,50597,N,1,In vivo,,,9866,,Biodistribution in normal rat bone in the presence of NAC Gd 0.01 M lig at 2 hr,1,Rattus norvegicus,Intermediate,,,,10116.0,,10000001.0,A,BAO_0000218,CHEMBL624408,7520
Heart,50597,N,1,In vivo,,,9866,,Biodistribution in normal rat heart in the presence of 0.005 M Gd/0.01 M lig at 2 hr,1,Rattus norvegicus,Intermediate,,,,10116.0,,948.0,A,BAO_0000218,CHEMBL618644,7521
Heart,50597,N,1,In vivo,,,9866,,Biodistribution in normal rat heart in the presence of 0.01 M Gd/0.05 M lig,1,Rattus norvegicus,Intermediate,,,,10116.0,,948.0,A,BAO_0000218,CHEMBL618645,7522
Heart,50597,N,1,In vivo,,,9866,,Biodistribution in normal rat heart in the presence of NAC Gd 0.01 M lig at 2 hr,1,Rattus norvegicus,Intermediate,,,,10116.0,,948.0,A,BAO_0000218,CHEMBL618646,7523
Kidney,50597,N,1,In vivo,,,9866,,Biodistribution in normal rat kidney in the presence of 0.005 M Gd/0.01 M lig at 2 hr,1,Rattus norvegicus,Intermediate,,,,10116.0,,2113.0,A,BAO_0000218,CHEMBL618647,7524
Kidney,50597,N,1,In vivo,,,9866,,Biodistribution in normal rat kidney in the presence of 0.01 M Gd/0.05 M lig,1,Rattus norvegicus,Intermediate,,,,10116.0,,2113.0,A,BAO_0000218,CHEMBL618648,7525
Kidney,50597,N,1,In vivo,,,9866,,Biodistribution in normal rat kidney in the presence of NAC Gd 0.01 M lig at 2 hr,1,Rattus norvegicus,Intermediate,,,,10116.0,,2113.0,A,BAO_0000218,CHEMBL618649,7526
Liver,50597,N,1,In vivo,,,9866,,Biodistribution in normal rat liver in the presence of 0.005 M Gd/0.01 M lig at 2 hr,1,Rattus norvegicus,Intermediate,,,,10116.0,,2107.0,A,BAO_0000218,CHEMBL618650,7527
Liver,50597,N,1,In vivo,,,9866,,Biodistribution in normal rat liver in the presence of 0.01 M Gd/0.05 M lig,1,Rattus norvegicus,Intermediate,,,,10116.0,,2107.0,A,BAO_0000218,CHEMBL618651,7528
Liver,50597,N,1,In vivo,,,9866,,Biodistribution in normal rat liver in the presence of NAC Gd 0.01 M lig at 2 hr,1,Rattus norvegicus,Intermediate,,,,10116.0,,2107.0,A,BAO_0000218,CHEMBL876497,7529
Lung,50597,N,1,In vivo,,,9866,,Biodistribution in normal rat lung in the presence of 0.005 M Gd/0.01 M lig at 2 hr,1,Rattus norvegicus,Intermediate,,,,10116.0,,2048.0,A,BAO_0000218,CHEMBL618652,7530
Lung,50597,N,1,In vivo,,,9866,,Biodistribution in normal rat lung in the presence of 0.01 M Gd/0.05 M lig,1,Rattus norvegicus,Intermediate,,,,10116.0,,2048.0,A,BAO_0000218,CHEMBL618653,7531
Lung,50597,N,1,In vivo,,,9866,,Biodistribution in normal rat lung in the presence of NAC Gd 0.01 M lig at 2 hr,1,Rattus norvegicus,Intermediate,,,,10116.0,,2048.0,A,BAO_0000218,CHEMBL618654,7532
,50597,N,1,,,,6351,,Recovery rate from urine and bile was determined after iv administration at 20 mg/kg in rats; Not tested,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL618655,7533
,50597,N,1,,,,1465,,Compound was tested for solubility in water,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL618656,7534
,22229,U,0,,,,5182,,Solubility in phosphate buffered saline (1% DMSO) at pH 6.5 (24 hr equilibration),1,,Intermediate,,,,,,,P,BAO_0000100,CHEMBL618657,7535
,50597,N,1,,,,17847,,Solubility was determined,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL618658,7536
,50597,N,1,,,,15339,,solubility in water (ug/mL) at 37 degree C.,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL618659,7537
,50597,N,1,,,,5202,,First pass metabolism and metabolic bioavailability using rat hepatic microsomes,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL618660,7538
,50597,N,1,,,,1088,,In vitro stability relative to (+)-AJ76 in rat hepatocyte assay,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL618661,7539
,50597,N,1,,,,3169,,Half life in rats,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL873807,7540
,50597,N,1,,,,5353,,Half life in Dawley rat,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL618662,7541
,50597,N,1,In vivo,,,2864,,Half life period after 3 mg/kg iv administration,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL618663,7542
,50597,N,1,In vivo,,,2864,,Half life period after 3 mg/kg iv administration in rat,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL618664,7543
,50597,N,1,In vivo,,,2864,,Half life period after 3 mg/kg iv administration in the rat,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL618665,7544
,50597,N,1,,,,6362,,Half life period in female Sprague-Dawley rats,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL876498,7545
,50597,N,1,,,,6249,,Half life period in rat,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL618666,7546
,50597,N,1,,,,3169,,Half-life in rats was determined,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL620440,7547
,50597,N,1,,,,3169,,Half-life in rats with metabolic oxidation,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL620441,7548
,50597,N,1,,,,3169,,Half-life in rats,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL620442,7549
,50597,N,1,In vivo,,,17260,,T 1/2 at a dose of 10 mg/Kg administered intravenously in female hanover-wistar rat,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL620443,7550
,50597,N,1,In vivo,,,17260,,T 1/2 at a dose of 10 mg/Kg administered perorally in female hanover-wistar rat,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL620444,7551
,50597,N,1,In vivo,,,17260,,T max at a dose of 10 mg/Kg administered intravenously in female hanover-wistar rat,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL620445,7552
,50597,N,1,In vivo,,,17260,,T max at a dose of 10 mg/Kg administered perorally in female hanover-wistar rat,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL620446,7553
Plasma,50597,N,1,,,,2879,,Biological half-life measured in plasma of rat,1,Rattus norvegicus,Intermediate,,,,10116.0,,1969.0,A,BAO_0000218,CHEMBL620447,7554
Plasma,50597,N,1,,,,2879,,Biological half-life measured in plasma of rat; 22-25,1,Rattus norvegicus,Intermediate,,,,10116.0,,1969.0,A,BAO_0000218,CHEMBL621129,7555
Plasma,50597,N,1,,,,2879,,Biological half-life measured in plasma of rat; 9-16,1,Rattus norvegicus,Intermediate,,,,10116.0,,1969.0,A,BAO_0000218,CHEMBL621130,7556
,50597,N,1,In vivo,,,3184,,Compound was evaluated for its half life when administered intravenously in rat,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL873808,7557
,50597,N,1,In vivo,,,4891,,Compound was evaluated for pharmacokinetic parameter percent bioavailability at 8 h,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL876598,7558
,50597,N,1,In vivo,,,429,,Evaluated for pharmacokinetic parameter half-life in rat at the dose 50 mg/kg,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL621131,7559
,50597,N,1,In vivo,,,5656,,Half life (T1/2) after oral administration in rat,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL621132,7560
,50597,N,1,In vivo,,,4413,,Half life of compound after iv administration of 20 mg/kg dose in rat,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL621133,7561
,50597,N,1,In vivo,,,3598,,Half life of compound determined in rat after iv administration at a dose of 10 mg/kg,1,Rattus norvegicus,Expert,,,,10116.0,,,A,BAO_0000218,CHEMBL621312,7562
,50597,N,1,,,,17267,,Half life of compound was determined in rat,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL621313,7563
Blood,50597,N,1,,,,4727,,Half life of compound was determined in rat blood,1,Rattus norvegicus,Intermediate,,,,10116.0,,178.0,A,BAO_0000218,CHEMBL621314,7564
,50597,N,1,In vivo,,,17651,,Half life at 1 mg/kg was determined in rat,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL621315,7565
,50597,N,1,In vivo,,,17651,,Half life at 10 mg/kg was determined in rat,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL621316,7566
,50597,N,1,,,,401,,Half life in rats,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL621317,7567
,50597,N,1,,,,4942,,Half life in rats in hours,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL621318,7568
,50597,N,1,In vivo,,,17735,,Half life following 10 mg/kg intravenous or 50 mg/kg oral dosing in rats was determined,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL621319,7569
,50597,N,1,In vivo,,,6056,,Half life was calculated at a single intravenous administration of 20 mg/kg in rat,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL621377,7570
,50597,N,1,,,,5213,,Half life was determined,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL621378,7571
,50597,N,1,In vivo,,,6616,,Half life after i.v. administration,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL876599,7572
,50597,N,1,In vivo,,,5937,,Half life in rat after intravenous administration at a concentration 0.5 mg/kg,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL621379,7573
Plasma,50597,N,1,,,,5819,,Half life in rat plasma,1,Rattus norvegicus,Intermediate,,,,10116.0,,1969.0,A,BAO_0000218,CHEMBL621380,7574
Plasma,50597,N,1,,,,5819,,Half life in rat plasma; Not detected,1,Rattus norvegicus,Intermediate,,,,10116.0,,1969.0,A,BAO_0000218,CHEMBL621381,7575
,50597,N,1,,,,6803,,Half life in rats,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL618515,7576
,50597,N,1,In vivo,,,17804,,Half life period of compound was determined after peroral administration,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL618516,7577
,50597,N,1,In vivo,,,17804,,Half life period of compound was determined at a dose of 3 mg/kg by intravenous administration,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL618517,7578
,50597,N,1,,,,5948,,Half life period in rat,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL618518,7579
,50597,N,1,In vivo,,,1916,,Half life period was evaluated against Sprague-Dawley rats at a dose of 15 mg/kg after iv administration,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL618519,7580
,50597,N,1,In vivo,,,1916,,Half life period was evaluated in Sprague-Dawley rats at a dose of 15 mg/kg after po administration,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL618698,7581
,50597,N,1,In vivo,,,1916,,Half life period was evaluated in Sprague-Dawley rats at a dose of 15 mg/kg after po administration; Not available,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL618862,7582
,50597,N,1,In vivo,,,4890,,Half life period was determined after intravenous administration at a dose 5 mg/kg to male Sprague-Dawley rats,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL618863,7583
,50597,N,1,In vivo,,,17764,,Half life period was determined for compound after intravenous administration in rats at 24 uM/kg,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL618864,7584
,50597,N,1,In vivo,,,4727,,Half life time in rat the dose of 2 mg/kg,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL618865,7585
,50597,N,1,In vivo,,,17509,,Half-life 24 hr after 10 mg/kg iv administration in rats,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL618866,7586
,50597,N,1,In vivo,,,17509,,Half-life 24 hr after 2 mg/kg iv administration in rats,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL618867,7587
,50597,N,1,,,,6597,,Half-life consistent with the observed metabolic steady state in rats,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL875828,7588
,50597,N,1,In vivo,,,17735,,Half-life following 10 mg/kg intravenous or 50 mg/kg oral dosing in rats was determined,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL618868,7589
,50597,N,1,,,,6597,,Half-life for oxidative metabolic stability was determined using male human,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL618869,7590
,50597,N,1,In vivo,,,17670,,"Half-life in fischer rats at 5 mg/kg dose, administered intravenously",1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL618870,7591
Plasma,50597,N,1,,,,1696,,Half-life in rat plasma,1,Rattus norvegicus,Intermediate,,,,10116.0,,1969.0,A,BAO_0000218,CHEMBL618871,7592
Plasma,50597,N,1,,,,1742,,Half-life in rat plasma was determined,1,Rattus norvegicus,Intermediate,,,,10116.0,,1969.0,A,BAO_0000218,CHEMBL618872,7593
,50597,N,1,,,,17800,,Half-life in rats was determined,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL873816,7594
,22224,U,0,,,,12923,,Area under curve of acid 2a was determined by HPLC at a dosage of 54.5 mg/kg administered intragastrically by gavage method in dog,1,,Autocuration,,,,,,,A,BAO_0000218,CHEMBL618873,7595
,22224,U,0,,,,11954,,Area under curve after oral dose of 0.1 mg//kg,1,,Autocuration,,,,,,,A,BAO_0000019,CHEMBL621602,7596
,22224,U,0,,,,11954,,Area under curve after oral dose of 0.3 mg/kg,1,,Autocuration,,,,,,,A,BAO_0000218,CHEMBL621603,7597
,22224,U,0,,,,11954,,Area under curve after oral dose of 1 mg/kg,1,,Autocuration,,,,,,,A,BAO_0000218,CHEMBL621604,7598
,22224,U,0,,,,11954,,Area under curve after oral dose of 10 mg/kg,1,,Autocuration,,,,,,,A,BAO_0000218,CHEMBL621605,7599
,22224,U,0,,,,11954,,Area under curve after oral dose of 23.4 mg/kg,1,,Autocuration,,,,,,,A,BAO_0000218,CHEMBL621606,7600
,22224,U,0,,,,11954,,Area under curve after oral dose of 3 mg/kg,1,,Autocuration,,,,,,,A,BAO_0000218,CHEMBL621607,7601
,22224,U,0,,,,11954,,Area under curve after oral dose of 3.87 mg/kg,1,,Autocuration,,,,,,,A,BAO_0000218,CHEMBL621608,7602
,22224,U,0,,,,5237,,Area under curve was determined,1,,Autocuration,,,,,,,A,BAO_0000019,CHEMBL621609,7603
,22224,U,0,,,,4026,,Area under curve at a dose of 10 mg/kg,1,,Autocuration,,,,,,,A,BAO_0000218,CHEMBL621610,7604
,50597,N,1,,,,5237,,Area under curve was determined; ND=No data,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL621611,7605
,50597,N,1,,,,14793,,Area under curve was evaluated in rat brain when administered intraperitoneally at a dose of 10 mg/kg for 4 or 6 hours,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL621612,7606
,50597,N,1,,,,14793,,Area under curve was evaluated in rat brain when administered intraperitoneally at a dose of 10 mg/kg for infinite hours,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL622308,7607
,50597,N,1,,,,14793,,Area under curve was evaluated in rat brain when administered intravenously at a dose of 10 mg/kg for 4 or 6 hours,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL622309,7608
,50597,N,1,,,,14793,,Area under curve was evaluated in rat brain when administered intravenously at a dose of 10 mg/kg for infinite hours,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL622310,7609
,50597,N,1,,,,14793,,Area under curve was evaluated in rat brain when administered perorally at a dose of 100 mg/kg for 4 or 6 hours,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL622311,7610
,50597,N,1,,,,14793,,Area under curve was evaluated in rat brain when administered perorally at a dose of 100 mg/kg for infinite hours; Not calculated,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL622312,7611
,50597,N,1,,,,14793,,Area under curve was evaluated in rat brain when administered perorally at a dose of 10 mg/kg for 4 or 6 hours,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL622931,7612
,50597,N,1,,,,14793,,Area under curve was evaluated in rat brain when administered perorally at a dose of 10 mg/kg for infinite hours; Not calculated,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL622932,7613
Plasma,50597,N,1,,,,14793,,Area under curve was evaluated in rat plasma when administered intraperitoneally at a dose of 10 mg/kg for 4 or 6 hours,1,Rattus norvegicus,Intermediate,,,,10116.0,,1969.0,A,BAO_0000218,CHEMBL622736,7614
Plasma,50597,N,1,,,,14793,,Area under curve was evaluated in rat plasma when administered intraperitoneally at a dose of 10 mg/kg for infinite hours,1,Rattus norvegicus,Intermediate,,,,10116.0,,1969.0,A,BAO_0000218,CHEMBL622737,7615
Plasma,50597,N,1,,,,14793,,Area under curve was evaluated in rat plasma when administered intravenously at a dose of 10 mg/kg for 4 or 6 hours,1,Rattus norvegicus,Intermediate,,,,10116.0,,1969.0,A,BAO_0000218,CHEMBL622738,7616
Plasma,50597,N,1,,,,14793,,Area under curve was evaluated in rat plasma when administered intravenously at a dose of 10 mg/kg for infinite hours,1,Rattus norvegicus,Intermediate,,,,10116.0,,1969.0,A,BAO_0000218,CHEMBL622739,7617
Plasma,50597,N,1,,,,14793,,Area under curve was evaluated in rat plasma when administered perorally at a dose of 100 mg/kg for 4 or 6 hours,1,Rattus norvegicus,Intermediate,,,,10116.0,,1969.0,A,BAO_0000218,CHEMBL622740,7618
Plasma,50597,N,1,,,,14793,,Area under curve was evaluated in rat plasma when administered perorally at a dose of 100 mg/kg for infinite hours,1,Rattus norvegicus,Intermediate,,,,10116.0,,1969.0,A,BAO_0000218,CHEMBL622741,7619
Plasma,50597,N,1,,,,14793,,Area under curve was evaluated in rat plasma when administered perorally at a dose of 10 mg/kg for 4 or 6 hours,1,Rattus norvegicus,Intermediate,,,,10116.0,,1969.0,A,BAO_0000218,CHEMBL622742,7620
Plasma,50597,N,1,,,,14793,,Area under curve was evaluated in rat plasma when administered perorally at a dose of 10 mg/kg for infinite hours,1,Rattus norvegicus,Intermediate,,,,10116.0,,1969.0,A,BAO_0000218,CHEMBL622743,7621
Plasma,50594,N,1,,,,11637,,AUC in mice,1,Mus musculus,Intermediate,,,,10090.0,,1969.0,A,BAO_0000218,CHEMBL622744,7622
,22224,U,0,,,,11149,,Area under curve was measured from the graph obtained from concentration Vs time,1,,Autocuration,,,,,,,A,BAO_0000019,CHEMBL624134,7623
,22224,U,0,,,,10016,,Area under curve value of compound per hour after oral administration,1,,Autocuration,,,,,,,A,BAO_0000019,CHEMBL624135,7624
,50597,N,1,,,,17796,,Area under curve was determined after oral administration in rats,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL624136,7625
,50597,N,1,,,,17796,,Area under curve was determined after oral administration in rats; No data,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL624137,7626
,50597,N,1,,,,17796,,Area under curve was determined after oral administration in rats;No data,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL624320,7627
,50588,N,1,,,,12923,,Area under curve was determined by HPLC at a dosage of 2.27 mg/kg administered intravenously by bolus method in dog,1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL624321,7628
,50597,N,1,,,,15372,,Area under curve was determined for the compound after iv dose of 4.74 mg/kg in rats,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL624322,7629
,50597,N,1,,,,15372,,Area under curve was determined for the compound after iv dose of 5.06 in rats,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL624323,7630
,50597,N,1,,,,15372,,Area under curve was determined for the compound after iv dose of 5.10 mg/kg in rats,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL624324,7631
,50597,N,1,,,,15372,,Area under curve was determined for the compound after po dose of 5.01 mg/kg in rats,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL624325,7632
,50597,N,1,,,,15372,,Area under curve was determined for the compound after po dose of 5.03 mg/kg in rats,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL624326,7633
,50597,N,1,,,,15372,,Area under curve was determined for the compound after po dose of 5.22 mg/kg in rats,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL624327,7634
,50597,N,1,,,,15372,,Area under curve was determined for the compound after po dose of 5.46 mg/kg in rats,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL624328,7635
,50588,N,1,,,,14169,,Area under curve was determined in Dogs after peroral administration,1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL627848,7636
,50597,N,1,,,,14169,,Area under curve was determined in Rats after peroral administration,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL627849,7637
,50597,N,1,,,,14258,,Area under curve was determined in carotid blood of rat when administered intradermally,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL627850,7638
,50597,N,1,,,,14258,,Area under curve was determined in portal blood of rat when administered intradermally,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL627851,7639
,50594,N,1,,,,15011,,Area under curve was determined using 0.4% Methyl cellulose (MC) as vehicle. Compound was administered intravenously to nude mice at a dose of 25 mg/kg,1,Mus musculus,Intermediate,,,,10090.0,,,A,BAO_0000218,CHEMBL627852,7640
,50594,N,1,,,,15011,,Area under curve was determined using 0.4% Methyl cellulose (MC) as vehicle. Compound was administered orally to nude mice at a dose of 25 mg/kg,1,Mus musculus,Intermediate,,,,10090.0,,,A,BAO_0000218,CHEMBL627853,7641
,50594,N,1,,,,15011,,Area under curve was determined using 0.4% Methyl cellulose (MC) as vehicle. Compound was administered orally to nude mice at a dose of 25 mg/kg (micronized sample),1,Mus musculus,Intermediate,,,,10090.0,,,A,BAO_0000218,CHEMBL627854,7642
,50594,N,1,,,,15011,,Area under curve was determined using 20%aqueous hydroxypropyl-beta-cyclodextrin (HPbetaCD) as vehicle. Compound was administered intravenously to nude mice at a dose of 25 mg/kg,1,Mus musculus,Intermediate,,,,10090.0,,,A,BAO_0000218,CHEMBL627855,7643
,50594,N,1,,,,15011,,Area under curve was determined using 20%aqueous hydroxypropyl-beta-cyclodextrin (HPbetaCD) as vehicle. Compound was administered intravenously to nude mice at a dose of 25 mg/kg (run time 7 hr),1,Mus musculus,Intermediate,,,,10090.0,,,A,BAO_0000218,CHEMBL627856,7644
,50594,N,1,,,,15011,,Area under curve was determined using 20%aqueous hydroxypropyl-beta-cyclodextrin (HPbetaCD) as vehicle. Compound was administered orally to nude mice at a dose of 25 mg/kg,1,Mus musculus,Intermediate,,,,10090.0,,,A,BAO_0000218,CHEMBL875339,7645
,50594,N,1,,,,15011,,Area under curve was determined using 20%aqueous hydroxypropyl-beta-cyclodextrin (HPbetaCD) as vehicle. Compound was administered orally to nude mice at a dose of 25 mg/kg (Run time = 7 hr),1,Mus musculus,Intermediate,,,,10090.0,,,A,BAO_0000218,CHEMBL627857,7646
Spleen,50597,N,1,In vivo,,,11195,,Biodistribution of the radiolabeled compound (2-5 uCi) in rat spleen 65 mins after i.v. administration,1,Rattus norvegicus,Intermediate,,,,10116.0,,2106.0,A,BAO_0000218,CHEMBL627858,7647
Blood,50597,N,1,,,,10130,,In vivo biodistribution in rats after an intravenous injection at 15 min was determined in blood; Expressed as percent dose/organ,1,Rattus norvegicus,Intermediate,,,,10116.0,,178.0,A,BAO_0000218,CHEMBL627859,7648
Brain,50597,N,1,,,,10130,,In vivo biodistribution in rats after an intravenous injection at 15 min was determined in brain; Expressed as percent dose/organ,1,Rattus norvegicus,Intermediate,,,,10116.0,,955.0,A,BAO_0000218,CHEMBL627860,7649
Heart,50597,N,1,,,,10130,,In vivo biodistribution in rats after an intravenous injection at 15 min was determined in heart; Expressed as percent dose/organ,1,Rattus norvegicus,Intermediate,,,,10116.0,,948.0,A,BAO_0000218,CHEMBL627019,7650
Liver,50597,N,1,,,,10130,,In vivo biodistribution in rats after an intravenous injection at 15 min was determined in liver; Expressed as percent dose/organ,1,Rattus norvegicus,Intermediate,,,,10116.0,,2107.0,A,BAO_0000218,CHEMBL627020,7651
Lung,50597,N,1,,,,10130,,In vivo biodistribution in rats after an intravenous injection at 15 min was determined in lung; Expressed as percent dose/organ,1,Rattus norvegicus,Intermediate,,,,10116.0,,2048.0,A,BAO_0000218,CHEMBL627021,7652
Muscle tissue,50597,N,1,,,,10130,,In vivo biodistribution in rats after an intravenous injection at 15 min was determined in muscle; Expressed as percent dose/organ,1,Rattus norvegicus,Intermediate,,,,10116.0,,2385.0,A,BAO_0000218,CHEMBL627022,7653
,50597,N,1,,,,10130,,In vivo biodistribution in rats after an intravenous injection at 15 min was determined in skin; Expressed as percent dose/organ,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL627023,7654
Spleen,50597,N,1,,,,10130,,In vivo biodistribution in rats after an intravenous injection at 15 min was determined in spleen; Expressed as percent dose/organ,1,Rattus norvegicus,Intermediate,,,,10116.0,,2106.0,A,BAO_0000218,CHEMBL627024,7655
Thyroid gland,50597,N,1,,,,10130,,In vivo biodistribution in rats after an intravenous injection at 15 min was determined in thyroid; Expressed as percent dose/organ,1,Rattus norvegicus,Intermediate,,,,10116.0,,2046.0,A,BAO_0000218,CHEMBL627025,7656
Kidney,50597,N,1,,,,10130,,In vivo biodistribution in rats after an intravenous injection at 15 min was determined in kidney; Expressed as percent dose/organ,1,Rattus norvegicus,Intermediate,,,,10116.0,,2113.0,A,BAO_0000218,CHEMBL627026,7657
Blood,50597,N,1,,,,10130,,In vivo biodistribution in rats after an intravenous injection at 2 min was determined in blood; Expressed as percent dose/organ,1,Rattus norvegicus,Intermediate,,,,10116.0,,178.0,A,BAO_0000218,CHEMBL627027,7658
Brain,50597,N,1,,,,10130,,In vivo biodistribution in rats after an intravenous injection at 2 min was determined in brain; Expressed as percent dose/organ,1,Rattus norvegicus,Intermediate,,,,10116.0,,955.0,A,BAO_0000218,CHEMBL627028,7659
Heart,50597,N,1,,,,10130,,In vivo biodistribution in rats after an intravenous injection at 2 min was determined in heart; Expressed as percent dose/organ,1,Rattus norvegicus,Intermediate,,,,10116.0,,948.0,A,BAO_0000218,CHEMBL627029,7660
Kidney,50597,N,1,,,,10130,,In vivo biodistribution in rats after an intravenous injection at 2 min was determined in kidney; Expressed as percent dose/organ,1,Rattus norvegicus,Intermediate,,,,10116.0,,2113.0,A,BAO_0000218,CHEMBL627030,7661
Liver,50597,N,1,,,,10130,,In vivo biodistribution in rats after an intravenous injection at 2 min was determined in liver; Expressed as percent dose/organ,1,Rattus norvegicus,Intermediate,,,,10116.0,,2107.0,A,BAO_0000218,CHEMBL627031,7662
Lung,50597,N,1,,,,10130,,In vivo biodistribution in rats after an intravenous injection at 2 min was determined in lung; Expressed as percent dose/organ,1,Rattus norvegicus,Intermediate,,,,10116.0,,2048.0,A,BAO_0000218,CHEMBL627032,7663
Muscle tissue,50597,N,1,,,,10130,,In vivo biodistribution in rats after an intravenous injection at 2 min was determined in muscle; Expressed as percent dose/organ,1,Rattus norvegicus,Intermediate,,,,10116.0,,2385.0,A,BAO_0000218,CHEMBL627033,7664
,50597,N,1,,,,10130,,In vivo biodistribution in rats after an intravenous injection at 2 min was determined in skin; Expressed as percent dose/organ,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL627034,7665
Spleen,50597,N,1,,,,10130,,In vivo biodistribution in rats after an intravenous injection at 2 min was determined in spleen; Expressed as percent dose/organ,1,Rattus norvegicus,Intermediate,,,,10116.0,,2106.0,A,BAO_0000218,CHEMBL627035,7666
Thyroid gland,50597,N,1,,,,10130,,In vivo biodistribution in rats after an intravenous injection at 2 min was determined in thyroid; Expressed as percent dose/organ,1,Rattus norvegicus,Intermediate,,,,10116.0,,2046.0,A,BAO_0000218,CHEMBL627036,7667
Blood,50597,N,1,,,,10130,,In vivo biodistribution in rats after an intravenous injection at 60 min was determined in blood; Expressed as percent dose/organ,1,Rattus norvegicus,Intermediate,,,,10116.0,,178.0,A,BAO_0000218,CHEMBL875340,7668
Heart,50597,N,1,,,,10130,,In vivo biodistribution in rats after an intravenous injection at 60 min was determined in heart; Expressed as percent dose/organ,1,Rattus norvegicus,Intermediate,,,,10116.0,,948.0,A,BAO_0000218,CHEMBL627037,7669
Kidney,50597,N,1,,,,10130,,In vivo biodistribution in rats after an intravenous injection at 60 min was determined in kidney; Expressed as percent dose/organ,1,Rattus norvegicus,Intermediate,,,,10116.0,,2113.0,A,BAO_0000218,CHEMBL627038,7670
Liver,50597,N,1,,,,10130,,In vivo biodistribution in rats after an intravenous injection at 60 min was determined in liver; Expressed as percent dose/organ,1,Rattus norvegicus,Intermediate,,,,10116.0,,2107.0,A,BAO_0000218,CHEMBL627039,7671
Muscle tissue,50597,N,1,,,,10130,,In vivo biodistribution in rats after an intravenous injection at 60 min was determined in muscle; Expressed as percent dose/organ,1,Rattus norvegicus,Intermediate,,,,10116.0,,2385.0,A,BAO_0000218,CHEMBL627040,7672
Spleen,50597,N,1,,,,10130,,In vivo biodistribution in rats after an intravenous injection at 60 min was determined in spleen; Expressed as percent dose/organ,1,Rattus norvegicus,Intermediate,,,,10116.0,,2106.0,A,BAO_0000218,CHEMBL624663,7673
Thyroid gland,50597,N,1,,,,10130,,In vivo biodistribution in rats after an intravenous injection at 60 min was determined in thyroid; Expressed as percent dose/organ,1,Rattus norvegicus,Intermediate,,,,10116.0,,2046.0,A,BAO_0000218,CHEMBL625963,7674
Brain,50597,N,1,,,,10130,,In vivo biodistribution in rats after an intravenous injection at 60 min was determined in brain; Expressed as percent dose/organ,1,Rattus norvegicus,Intermediate,,,,10116.0,,955.0,A,BAO_0000218,CHEMBL876799,7675
Lung,50597,N,1,,,,10130,,In vivo biodistribution in rats after an intravenous injection at 60 min was determined in lung; Expressed as percent dose/organ,1,Rattus norvegicus,Intermediate,,,,10116.0,,2048.0,A,BAO_0000218,CHEMBL626133,7676
,50597,N,1,,,,10130,,In vivo biodistribution in rats after an intravenous injection at 60 min was determined in skin; Expressed as percent dose/organ,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL626134,7677
,50597,N,1,,,,6295,,In vivo concentration in rat liver exposure 8 hour after oral administration 50 mg/kg,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL626135,7678
,50597,N,1,,,,6296,,In vivo concentration in rat liver exposure 8 hour after oral administration 50 mg/kg,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL626136,7679
,50597,N,1,,,,6296,,In vivo concentration in rat liver exposure 8 hour after oral administration 50 mg/kg; Below detection limit,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL626137,7680
,50597,N,1,,,,6295,,In vivo concentration in rat plasma exposure at 8 hour after oral administration 50 mg/kg,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL626138,7681
,50597,N,1,,,,6296,,In vivo concentration in rat plasma exposure at 8 hour after oral administration 50 mg/kg,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL626139,7682
,50597,N,1,In vivo,,,17260,,C max at a dose of 10 mg/Kg administered intravenously in female hanover-wistar rat,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL626140,7683
,50597,N,1,In vivo,,,17260,,C max at a dose of 10 mg/Kg administered perorally in female hanover-wistar rat,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL626141,7684
,50597,N,1,,,,17686,,C24h in rat p.o. at 20 mg/kg concentration,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL626142,7685
Muscle tissue,50597,N,1,In vivo,,,9866,,Biodistribution in normal rat muscle in the presence of 0.005 M Gd/0.01 M lig at 2 hr,1,Rattus norvegicus,Intermediate,,,,10116.0,,2385.0,A,BAO_0000218,CHEMBL627930,7686
Muscle tissue,50597,N,1,In vivo,,,9866,,Biodistribution in normal rat muscle in the presence of 0.01 M Gd/0.05 M lig,1,Rattus norvegicus,Intermediate,,,,10116.0,,2385.0,A,BAO_0000218,CHEMBL627931,7687
Muscle tissue,50597,N,1,In vivo,,,9866,,Biodistribution in normal rat muscle in the presence of NAC Gd 0.01 M lig at 2 hr,1,Rattus norvegicus,Intermediate,,,,10116.0,,2385.0,A,BAO_0000218,CHEMBL627932,7688
Spleen,50597,N,1,In vivo,,,9866,,Biodistribution in normal rat spleen in the presence of 0.005 M Gd/0.01 M lig at 2 hr,1,Rattus norvegicus,Intermediate,,,,10116.0,,2106.0,A,BAO_0000218,CHEMBL627933,7689
Spleen,50597,N,1,In vivo,,,9866,,Biodistribution in normal rat spleen in the presence of 0.01 M Gd/0.05 M lig,1,Rattus norvegicus,Intermediate,,,,10116.0,,2106.0,A,BAO_0000218,CHEMBL627934,7690
Spleen,50597,N,1,In vivo,,,9866,,Biodistribution in normal rat spleen in the presence of NAC Gd 0.01 M lig at 2 hr,1,Rattus norvegicus,Intermediate,,,,10116.0,,2106.0,A,BAO_0000218,CHEMBL627935,7691
Blood,50597,N,1,In vivo,,,9866,,Biodistribution in rat blood in the presence of 0.001 M/0.008 M GdDTPA-AEP,1,Rattus norvegicus,Intermediate,,,,10116.0,,178.0,A,BAO_0000218,CHEMBL627936,7692
Blood,50597,N,1,In vivo,,,9866,,Biodistribution in rat blood in the presence of 0.01 M GdDTPA-BDP,1,Rattus norvegicus,Intermediate,,,,10116.0,,178.0,A,BAO_0000218,CHEMBL627937,7693
Blood,50597,N,1,In vivo,,,9866,,Biodistribution in rat blood in the presence of 0.01 M/0.01 M GdDTPA-AEP,1,Rattus norvegicus,Intermediate,,,,10116.0,,178.0,A,BAO_0000218,CHEMBL627938,7694
Blood,50597,N,1,In vivo,,,9866,,Biodistribution in rat blood in the presence of 0.05 M Gd/0.15 M lig,1,Rattus norvegicus,Intermediate,,,,10116.0,,178.0,A,BAO_0000218,CHEMBL627939,7695
Blood,50597,N,1,In vivo,,,9866,,Biodistribution in rat blood in the presence of 0.05 M GdDTPA-BDP,1,Rattus norvegicus,Intermediate,,,,10116.0,,178.0,A,BAO_0000218,CHEMBL627940,7696
Blood,50597,N,1,In vivo,,,9866,,Biodistribution in rat blood in the presence of 0.05 M/0.05 M GdDTPA-AEP,1,Rattus norvegicus,Intermediate,,,,10116.0,,178.0,A,BAO_0000218,CHEMBL627941,7697
Blood,50597,N,1,In vivo,,,9866,,Biodistribution in rat blood in the presence of 0.05 M/0.08 M GdDTPA-HPDP,1,Rattus norvegicus,Intermediate,,,,10116.0,,178.0,A,BAO_0000218,CHEMBL876800,7698
Blood,50597,N,1,In vivo,,,9866,,Biodistribution in rat blood in the presence of 0.10 M GdDTPA-BDP,1,Rattus norvegicus,Intermediate,,,,10116.0,,178.0,A,BAO_0000218,CHEMBL627942,7699
Blood,50597,N,1,In vivo,,,9866,,Biodistribution in rat blood in the presence of 0.10 M/0.11 M GdDTPA-AEP,1,Rattus norvegicus,Intermediate,,,,10116.0,,178.0,A,BAO_0000218,CHEMBL627943,7700
Blood,50597,N,1,In vivo,,,9866,,Biodistribution in rat blood in the presence of 50 Gd/kg at 15 min,1,Rattus norvegicus,Intermediate,,,,10116.0,,178.0,A,BAO_0000218,CHEMBL627944,7701
Blood,50597,N,1,In vivo,,,9866,,Biodistribution in rat blood in the presence of 50 Gd/kg at 2 hr,1,Rattus norvegicus,Intermediate,,,,10116.0,,178.0,A,BAO_0000218,CHEMBL627945,7702
Blood,50597,N,1,In vivo,,,9866,,Biodistribution in rat blood in the presence of 50 Gd/kg at 6 hr,1,Rattus norvegicus,Intermediate,,,,10116.0,,178.0,A,BAO_0000218,CHEMBL628584,7703
Blood,50597,N,1,In vivo,,,9866,,Biodistribution in rat blood in the presence of GdDTPA at 15 min,1,Rattus norvegicus,Intermediate,,,,10116.0,,178.0,A,BAO_0000218,CHEMBL628585,7704
Blood,50597,N,1,In vivo,,,9866,,Biodistribution in rat blood in the presence of GdDTPA at 1 hr,1,Rattus norvegicus,Intermediate,,,,10116.0,,178.0,A,BAO_0000218,CHEMBL628586,7705
Blood,50597,N,1,In vivo,,,9866,,Biodistribution in rat blood in the presence of GdDTPA at 30 min,1,Rattus norvegicus,Intermediate,,,,10116.0,,178.0,A,BAO_0000218,CHEMBL628587,7706
Blood,50597,N,1,In vivo,,,9866,,Biodistribution in rat blood in the presence of GdDTPA at 4 hr,1,Rattus norvegicus,Intermediate,,,,10116.0,,178.0,A,BAO_0000218,CHEMBL628588,7707
Blood,50597,N,1,In vivo,,,9866,,Biodistribution in rat blood in the presence of GdDTPA-BDP at 15 min,1,Rattus norvegicus,Intermediate,,,,10116.0,,178.0,A,BAO_0000218,CHEMBL628589,7708
Blood,50597,N,1,In vivo,,,9866,,Biodistribution in rat blood in the presence of GdDTPA-BDP at 30 min,1,Rattus norvegicus,Intermediate,,,,10116.0,,178.0,A,BAO_0000218,CHEMBL625304,7709
Blood,50597,N,1,In vivo,,,9866,,Biodistribution in rat blood in the presence of GdDTPA-BDP at 4 hr,1,Rattus norvegicus,Intermediate,,,,10116.0,,178.0,A,BAO_0000218,CHEMBL625305,7710
Blood,50597,N,1,In vivo,,,9866,,Biodistribution in rat blood in the presence of GdDTPA-BDPat 1 hr,1,Rattus norvegicus,Intermediate,,,,10116.0,,178.0,A,BAO_0000218,CHEMBL625306,7711
Blood,50597,N,1,In vivo,,,9866,,Biodistribution in rat blood in the presence of GdDTPA-HPDP at 15 min,1,Rattus norvegicus,Intermediate,,,,10116.0,,178.0,A,BAO_0000218,CHEMBL625307,7712
Blood,50597,N,1,In vivo,,,9866,,Biodistribution in rat blood in the presence of GdDTPA-HPDP at 30 min,1,Rattus norvegicus,Intermediate,,,,10116.0,,178.0,A,BAO_0000218,CHEMBL625308,7713
Blood,50597,N,1,In vivo,,,9866,,Biodistribution in rat blood in the presence of GdDTPA-HPDP at 4 hr,1,Rattus norvegicus,Intermediate,,,,10116.0,,178.0,A,BAO_0000218,CHEMBL627740,7714
Blood,50597,N,1,In vivo,,,9866,,Biodistribution in rat blood in the presence of GdDTPA-HPDPat 1 hr,1,Rattus norvegicus,Intermediate,,,,10116.0,,178.0,A,BAO_0000218,CHEMBL627741,7715
Blood,50597,N,1,In vivo,,,9866,,Biodistribution in rat blood in the presence of NAC Gd/0.01 M GdDTPA-HPDP,1,Rattus norvegicus,Intermediate,,,,10116.0,,178.0,A,BAO_0000218,CHEMBL627742,7716
Blood,50597,N,1,In vivo,,,9866,,Biodistribution in rat blood in the presence of NCA Gd/0.01 M lip,1,Rattus norvegicus,Intermediate,,,,10116.0,,178.0,A,BAO_0000218,CHEMBL627743,7717
Blood,50597,N,1,In vivo,,,9866,,Biodistribution in rat blood in the presence of NCAGd/0.01 M lig,1,Rattus norvegicus,Intermediate,,,,10116.0,,178.0,A,BAO_0000218,CHEMBL627744,7718
Bone,50597,N,1,In vivo,,,9866,,Biodistribution in rat bone in the presence of 0.01 M GdDTPA-BDP,1,Rattus norvegicus,Intermediate,,,,10116.0,,10000001.0,A,BAO_0000218,CHEMBL627745,7719
Bone,50597,N,1,In vivo,,,9866,,Biodistribution in rat bone in the presence of 0.01 M/0.01 M GdDTPA-AEP,1,Rattus norvegicus,Intermediate,,,,10116.0,,10000001.0,A,BAO_0000218,CHEMBL627746,7720
Bone,50597,N,1,In vivo,,,9866,,Biodistribution in rat bone in the presence of 0.01 M/0.08 M GdDTPA-AEP,1,Rattus norvegicus,Intermediate,,,,10116.0,,10000001.0,A,BAO_0000218,CHEMBL627747,7721
Bone,50597,N,1,In vivo,,,9866,,Biodistribution in rat bone in the presence of 0.05 M Gd/0.15 M lig,1,Rattus norvegicus,Intermediate,,,,10116.0,,10000001.0,A,BAO_0000218,CHEMBL876810,7722
Bone,50597,N,1,In vivo,,,9866,,Biodistribution in rat bone in the presence of 0.05 M GdDTPA-BDP,1,Rattus norvegicus,Intermediate,,,,10116.0,,10000001.0,A,BAO_0000218,CHEMBL627748,7723
Bone,50597,N,1,In vivo,,,9866,,Biodistribution in rat bone in the presence of 0.05 M/0.05 M GdDTPA-AEP,1,Rattus norvegicus,Intermediate,,,,10116.0,,10000001.0,A,BAO_0000218,CHEMBL627749,7724
Bone,50597,N,1,In vivo,,,9866,,Biodistribution in rat bone in the presence of 0.05 M/0.08 M GdDTPA-HPDP,1,Rattus norvegicus,Intermediate,,,,10116.0,,10000001.0,A,BAO_0000218,CHEMBL627750,7725
Bone,50597,N,1,In vivo,,,9866,,Biodistribution in rat bone in the presence of 0.10 M GdDTPA-BDP,1,Rattus norvegicus,Intermediate,,,,10116.0,,10000001.0,A,BAO_0000218,CHEMBL618728,7726
Bone,50597,N,1,In vivo,,,9866,,Biodistribution in rat bone in the presence of 0.10 M/0.11 M GdDTPA-AEP,1,Rattus norvegicus,Intermediate,,,,10116.0,,10000001.0,A,BAO_0000218,CHEMBL618729,7727
Bone,50597,N,1,In vivo,,,9866,,Biodistribution in rat bone in the presence of GdDTPA at 15 min,1,Rattus norvegicus,Intermediate,,,,10116.0,,10000001.0,A,BAO_0000218,CHEMBL618730,7728
Bone,50597,N,1,In vivo,,,9866,,Biodistribution in rat bone in the presence of GdDTPA at 1 hr,1,Rattus norvegicus,Intermediate,,,,10116.0,,10000001.0,A,BAO_0000218,CHEMBL618731,7729
Bone,50597,N,1,In vivo,,,9866,,Biodistribution in rat bone in the presence of GdDTPA at 30 min,1,Rattus norvegicus,Intermediate,,,,10116.0,,10000001.0,A,BAO_0000218,CHEMBL618732,7730
Bone,50597,N,1,In vivo,,,9866,,Biodistribution in rat bone in the presence of GdDTPA at 4 hr,1,Rattus norvegicus,Intermediate,,,,10116.0,,10000001.0,A,BAO_0000218,CHEMBL618733,7731
Bone,50597,N,1,In vivo,,,9866,,Biodistribution in rat bone in the presence of GdDTPA-BDP at 15 min,1,Rattus norvegicus,Intermediate,,,,10116.0,,10000001.0,A,BAO_0000218,CHEMBL618734,7732
Bone,50597,N,1,In vivo,,,9866,,Biodistribution in rat bone in the presence of GdDTPA-BDP at 1 hr,1,Rattus norvegicus,Intermediate,,,,10116.0,,10000001.0,A,BAO_0000218,CHEMBL618735,7733
Bone,50597,N,1,In vivo,,,9866,,Biodistribution in rat bone in the presence of GdDTPA-BDP at 30 min,1,Rattus norvegicus,Intermediate,,,,10116.0,,10000001.0,A,BAO_0000218,CHEMBL876602,7734
Bone,50597,N,1,In vivo,,,9866,,Biodistribution in rat bone in the presence of GdDTPA-BDP at 4 hr,1,Rattus norvegicus,Intermediate,,,,10116.0,,10000001.0,A,BAO_0000218,CHEMBL618736,7735
Bone,50597,N,1,In vivo,,,9866,,Biodistribution in rat bone in the presence of GdDTPA-HPDP at 15 min,1,Rattus norvegicus,Intermediate,,,,10116.0,,10000001.0,A,BAO_0000218,CHEMBL618737,7736
Bone,50597,N,1,In vivo,,,9866,,Biodistribution in rat bone in the presence of GdDTPA-HPDP at 1 hr,1,Rattus norvegicus,Intermediate,,,,10116.0,,10000001.0,A,BAO_0000218,CHEMBL618738,7737
Bone,50597,N,1,In vivo,,,9866,,Biodistribution in rat bone in the presence of GdDTPA-HPDP at 30 min,1,Rattus norvegicus,Intermediate,,,,10116.0,,10000001.0,A,BAO_0000218,CHEMBL618739,7738
Bone,50597,N,1,In vivo,,,9866,,Biodistribution in rat bone in the presence of GdDTPA-HPDP at 4 hr,1,Rattus norvegicus,Intermediate,,,,10116.0,,10000001.0,A,BAO_0000218,CHEMBL618740,7739
Bone,50597,N,1,In vivo,,,9866,,Biodistribution in rat bone in the presence of NAC Gd/0.01 M GdDTPA-HPDP,1,Rattus norvegicus,Intermediate,,,,10116.0,,10000001.0,A,BAO_0000218,CHEMBL618741,7740
Bone,50597,N,1,In vivo,,,9866,,Biodistribution in rat bone in the presence of NCA Gd/0.01 M lip,1,Rattus norvegicus,Intermediate,,,,10116.0,,10000001.0,A,BAO_0000218,CHEMBL618742,7741
Bone,50597,N,1,In vivo,,,9866,,Biodistribution in rat bone in the presence of NCAGd/0.01 M lig,1,Rattus norvegicus,Intermediate,,,,10116.0,,10000001.0,A,BAO_0000218,CHEMBL618743,7742
Plasma,50597,N,1,In vivo,,,17752,,Half-life from rat plasma at a single oral dose of 25 mg/kg,1,Rattus norvegicus,Intermediate,,,,10116.0,,1969.0,A,BAO_0000218,CHEMBL618744,7743
,50597,N,1,,,,5610,,Half-life in male rat,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL618745,7744
,50597,N,1,In vivo,,,5939,,Half-life in rat after peroral administration at 10 mg/kg concentration,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL620479,7745
,50597,N,1,In vivo,,,5939,,Half-life in rat after peroral administration at 5 mg/kg concentration,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL620480,7746
,50597,N,1,In vivo,,,17771,,Half-life in rat at a dose of 3 mg/kg,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL620481,7747
,50597,N,1,,,,1974,,Half-life was evaluated in rats,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL620482,7748
,50597,N,1,,,,4239,,Half-life was measured in rat,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL876603,7749
,50597,N,1,In vivo,,,6681,,Half-life period for the compound was determined in rats at 50 mg/kg dose,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL620483,7750
,50597,N,1,In vivo,,,17752,,Half-life period in rats after intravenous administration at 5 mg/kg,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL620484,7751
,50597,N,1,In vivo,,,6046,,Half-life period in rat at 10 mg/kg,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL620485,7752
,50597,N,1,In vivo,,,6685,,"Half-life period was determined in rats at 10 mg/kg, p.o. dose",1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL620486,7753
,50597,N,1,In vivo,,,6685,,"Half-life period was determined in rats at 20 mg/kg, i.p. dose",1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL620487,7754
,50597,N,1,In vivo,,,6685,,"Half-life period was determined in rats at 2 mg/kg, i.v. dose",1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL620488,7755
,50597,N,1,In vivo,,,4727,,Half-life time in rat the dose of 2 mg/kg,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL620489,7756
,50597,N,1,In vivo,,,1088,,Half-life was estimated from the elimination phase of the oral [C] vs time curves in 4 rats,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL620490,7757
,50597,N,1,In vivo,,,5610,,In vivo activity against Staphylococcus aureus when administered orally for 1 hr in rat at a dose of 15 mg/kg,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL620491,7758
Plasma,50597,N,1,In vivo,,,3032,,"In vivo half life of compound in rat plasma after a oral dose of 10 mg/kg (in water, N=4)",1,Rattus norvegicus,Intermediate,,,,10116.0,,1969.0,A,BAO_0000218,CHEMBL876604,7759
,50597,N,1,In vivo,,,5199,,Oral half life was determined,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL620492,7760
,50597,N,1,In vivo,,,14941,,"Pharmacokinetic Parameter, half life period measured in Female Wistar Rats at 100 mg/kg by po administration",1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL620493,7761
,50597,N,1,In vivo,,,4408,,Pharmacokinetic property (t1/2) in rat,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL620494,7762
Plasma,50597,N,1,,,,2552,,Plasma elimination half-life was determined,1,Rattus norvegicus,Intermediate,,,,10116.0,,1969.0,A,BAO_0000218,CHEMBL620495,7763
Plasma,50597,N,1,In vivo,,,5199,,Plasma elimination half-life was determined in female Sprague-Dawley rats following intravenous (iv) administration of drug (1 mg/kg).,1,Rattus norvegicus,Intermediate,,,,10116.0,,1969.0,A,BAO_0000218,CHEMBL620496,7764
Plasma,50597,N,1,In vivo,,,15662,,Plasma half life was observed after intravenous administration in rat,1,Rattus norvegicus,Intermediate,,,,10116.0,,1969.0,A,BAO_0000218,CHEMBL620497,7765
Plasma,50597,N,1,,,,1465,,Plasma half-life was determined,1,Rattus norvegicus,Intermediate,,,,10116.0,,1969.0,A,BAO_0000218,CHEMBL620498,7766
Plasma,50597,N,1,In vivo,,,1446,,Plasma half-life following oral administration in Fisher rats,1,Rattus norvegicus,Intermediate,,,,10116.0,,1969.0,A,BAO_0000218,CHEMBL620499,7767
Plasma,50597,N,1,,,,6824,,Plasma half-life in rat,1,Rattus norvegicus,Intermediate,,,,10116.0,,1969.0,A,BAO_0000218,CHEMBL620500,7768
Plasma,50597,N,1,In vivo,,,17533,,Plasmatic Half-life after intravenous administration to rat,1,Rattus norvegicus,Intermediate,,,,10116.0,,1969.0,A,BAO_0000218,CHEMBL873809,7769
,50597,N,1,In vivo,,,5979,,T1/2 (half life) of compound after 2 hr iv infusion of 8.4 mg/kg in three rat,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL620501,7770
,50597,N,1,In vivo,,,4689,,Terminal half life after intravenous administration (1 mg/kg) in rat,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL620502,7771
,50597,N,1,In vivo,,,4689,,Terminal half life in Rat at a oral dose of 5 mg/kg,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL620503,7772
,50597,N,1,In vivo,,,2463,,Terminal phase half-life was evaluated in vivo in rat at a dose of 5 mg/kg by intra venous administration,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL620504,7773
,50597,N,1,In vivo,,,4883,,Tested for half life value after intravenous administration at dose of 0.2 mg/kg in rat,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL876605,7774
,50597,N,1,In vivo,,,4883,,Tested for half life value after oral administration at dosage of 4 mg/kg in rat,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL620505,7775
Plasma,50597,N,1,In vivo,,,15662,,plasma half life was observed after intravenous administration in rat,1,Rattus norvegicus,Intermediate,,,,10116.0,,1969.0,A,BAO_0000218,CHEMBL873811,7776
,50597,N,1,In vivo,,,3598,,Half life of compound determined in rat after iv administration at a dose of 10 mg/kg,1,Rattus norvegicus,Expert,,,,10116.0,,,A,BAO_0000218,CHEMBL624016,7777
,50597,N,1,,,,4576,,Half life of compound determined in rat,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL624017,7778
,50597,N,1,,,,4576,,Mean residence time determined in rat,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL624018,7779
,50597,N,1,,,,4576,,Plasma half life determined in rat,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL624019,7780
Brain,50597,N,1,In vivo,,,4910,,Compound was evaluated for Tmax in brain after intravenous administration in male rats,1,Rattus norvegicus,Intermediate,,,,10116.0,,955.0,A,BAO_0000218,CHEMBL624020,7781
,50597,N,1,In vivo,,,4891,,Compound was evaluated for pharmacokinetic parameter maximum time period,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL624201,7782
,50597,N,1,In vivo,,,429,,Evaluated for pharmacokinetic parameter tmax in rat at the dose 50 mg/kg,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL872528,7783
,50597,N,1,In vivo,,,5974,,In vivo Tmax was determined after intravenous administration of compound (9.13+/-0.85 mg/kg) in male Sprague-Dawley rat,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL624202,7784
,50597,N,1,In vivo,,,5974,,In vivo Tmax was determined after peroral administration of compound (158.5+/-2 mg/kg) in male Sprague-Dawley rat,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL624203,7785
,50597,N,1,In vivo,,,5974,,In vivo Tmax was determined after peroral administration of compound (19.01+/-0.31 mg/kg) in male Sprague-Dawley rat,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL624350,7786
,50597,N,1,In vivo,,,5974,,In vivo Tmax was determined after peroral administration of compound (76.4+/-2.6 mg/kg) in male Sprague-Dawley rat,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL621320,7787
,50597,N,1,In vivo,,,17582,,In vivo maximum time required for clearance of compound after oral (po) administration at a dose of 10 mg/kg was measured in rats,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL621321,7788
,50597,N,1,,,,4026,,Maximum time (Tmax) required to reach Cmax in rats,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL621322,7789
,50597,N,1,In vivo,,,4890,,Maximum time constant was determined after oral administration at a dose 10 mg/kg to male Sprague-Dawley rats,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL621323,7790
,50597,N,1,In vivo,,,6571,,Maximum time of clearance of compound in rats after peroral administration,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL621324,7791
,50597,N,1,,,,4727,,Maximum time at the dose of 2 mg/kg in rat,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL621325,7792
Plasma,50597,N,1,In vivo,,,17651,,Maximum time to achieve peak plasma concentration was determined in rat at 1 mg/kg,1,Rattus norvegicus,Intermediate,,,,10116.0,,1969.0,A,BAO_0000218,CHEMBL875837,7793
Plasma,50597,N,1,In vivo,,,17651,,Maximum time to achieve peak plasma concentration was determined in rat at 10 mg/kg,1,Rattus norvegicus,Intermediate,,,,10116.0,,1969.0,A,BAO_0000218,CHEMBL621326,7794
,50597,N,1,In vivo,,,14465,,Tmax in Guinea pig (PO dose),1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL621327,7795
,50597,N,1,In vivo,,,14941,,"Pharmacokinetic Parameter, Tmax is the time at which maximum concentration (Cmax) is reached in Female Wistar Rats at 100 mg/kg by po administration",1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL621328,7796
,50597,N,1,In vivo,,,5960,,Pharmacokinetic parameter (Tmax) in rat,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL621329,7797
,50597,N,1,In vivo,,,5022,,Pharmacokinetic parameter (Tmax) was estimated,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL621330,7798
,50597,N,1,In vivo,,,4408,,Pharmacokinetic property (Tmax) in rat,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL621331,7799
,50597,N,1,In vivo,,,5983,,Pharmacokinetic property (Tmax) was measured in rat at the dose of 0.32 mg/kg p.o.,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL621332,7800
,50597,N,1,In vivo,,,4689,,T max in Rat at a oral dose of 5 mg/kg,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL621333,7801
,50597,N,1,In vivo,,,2792,,T max was determined at 10 mg/kg po dose in rats,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL621334,7802
,50594,N,1,,,,15011,,Area under curve was determined using 20%aqueous hydroxypropyl-beta-cyclodextrin (HPbetaCD) as vehicle. Compound was administered orally to nude mice at a dose of 25 mg/kg (run time 7 hr),1,Mus musculus,Intermediate,,,,10090.0,,,A,BAO_0000218,CHEMBL621335,7803
,50588,N,1,,,,14180,,Area under curve was evaluated after intravenous injection of 1 mg/kg of compound in dogs,1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL621336,7804
,50597,N,1,,,,14180,,Area under curve was evaluated after intravenous injection of 1 mg/kg of compound in rats,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL621337,7805
,50588,N,1,,,,14599,,Area under curve was measured after i.v. administration into Beagle dog.,1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL621338,7806
,50588,N,1,,,,14599,,Area under curve was measured after iv administration into Beagle dog,1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL875838,7807
,50588,N,1,,,,14599,,Area under curve was measured after po administration into Beagle dog,1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL621339,7808
,50588,N,1,,,,14599,,Area under curve was measured after po administration into Beagle dog.,1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL621340,7809
,22224,U,0,,,,15675,,Area under curve was measured at peroral dose of 3 mg/kg,1,,Autocuration,,,,,,,A,BAO_0000218,CHEMBL621341,7810
,22224,U,0,,,,12706,,Area under curve was measured by using concentration Vs time,1,,Autocuration,,,,,,,A,BAO_0000019,CHEMBL621342,7811
,22224,U,0,,,,12706,,Area under curve was measured by using concentration Vs time; not tested,1,,Autocuration,,,,,,,A,BAO_0000019,CHEMBL621343,7812
,50594,N,1,,,,9750,,Area under curve(AUC) was measured in mice after oral administration (50 mg/kg),1,Mus musculus,Intermediate,,,,10090.0,,,A,BAO_0000218,CHEMBL621344,7813
,50594,N,1,,,,9750,,Area under curve(AUC) was measured in mice after oral administration.,1,Mus musculus,Intermediate,,,,10090.0,,,A,BAO_0000218,CHEMBL621345,7814
,22224,U,0,,,,14691,,Area under curve(AUC) value of the compound,1,,Autocuration,,,,,,,A,BAO_0000019,CHEMBL621346,7815
,22224,U,0,,,,14691,,Area under curve(AUC) value of the compound in dogs at 0.5 mg/kg dose upon oral administration,1,,Autocuration,,,,,,,A,BAO_0000218,CHEMBL621347,7816
,50588,N,1,,,,14691,,Area under curve(AUC) value of the compound in dogs at 1 mg/kg dose upon oral administration,1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL621348,7817
Blood,22224,U,0,,,,2939,,Area under curve(carotid artery) was determined by the availability in blood,1,,Autocuration,,,,,,178.0,A,BAO_0000019,CHEMBL621349,7818
Blood,22224,U,0,,,,2939,,Area under curve(carotid artery) was determined by the availability in blood; ND means no data,1,,Autocuration,,,,,,178.0,A,BAO_0000019,CHEMBL621350,7819
Blood,22224,U,0,,,,2939,,Area under curve(carotid artery) was determined by the availability in blood; No data,1,,Autocuration,,,,,,178.0,A,BAO_0000019,CHEMBL875839,7820
Blood,22224,U,0,,,,2939,,Area under curve(portal vein) was determined by the availability in blood,1,,Autocuration,,,,,,178.0,A,BAO_0000019,CHEMBL620211,7821
Blood,22224,U,0,,,,2939,,Area under curve(portal vein) was determined by the availability in blood; ND means no data,1,,Autocuration,,,,,,178.0,A,BAO_0000019,CHEMBL620212,7822
Blood,22224,U,0,,,,2939,,Area under curve(portal vein) was determined by the availability in blood; No data,1,,Autocuration,,,,,,178.0,A,BAO_0000019,CHEMBL620213,7823
Plasma,50797,N,1,,,,9552,,"Area under plasma concentration vs time curve observed in Rhesus monkeys after, iv administration of single 30 mg/kg dose",1,Macaca mulatta,Intermediate,,,,9544.0,,1969.0,A,BAO_0000218,CHEMBL620214,7824
Plasma,50797,N,1,,,,9552,,"Area under plasma concentration vs time curve observed in Rhesus monkeys after, iv administration of single 30 mg/kg dose",1,Macaca mulatta,Intermediate,,,,9544.0,,1969.0,A,BAO_0000218,CHEMBL620215,7825
Plasma,50797,N,1,,,,9552,,Area under plasma concentration vs time curve observed in Rhesus monkeys after oral administration of single 30 mg/kg dose,1,Macaca mulatta,Intermediate,,,,9544.0,,1969.0,A,BAO_0000218,CHEMBL620216,7826
Plasma,50588,N,1,,,,9552,,"Area under plasma concentration vs time curve observed in female mongrel dogs after, iv administration of single 15 mg/kg dose",1,Canis lupus familiaris,Intermediate,,,,9615.0,,1969.0,A,BAO_0000218,CHEMBL620888,7827
Plasma,50588,N,1,,,,9552,,"Area under plasma concentration vs time curve observed in female mongrel dogs after, oral administration of single 15 mg/kg dose",1,Canis lupus familiaris,Intermediate,,,,9615.0,,1969.0,A,BAO_0000218,CHEMBL620889,7828
Plasma,22224,U,0,,,,9552,,Area under plasma concentration vs time curve observed in rats for 0-3 h,1,,Autocuration,,,,,,1969.0,A,BAO_0000019,CHEMBL620890,7829
Plasma,50597,N,1,,,,11911,,Area under plasma time curve determined in male rat,1,Rattus norvegicus,Intermediate,,,,10116.0,,1969.0,A,BAO_0000218,CHEMBL620891,7830
,22224,U,0,,,,16618,,Area under the MAP curve measured over 5 min.,1,,Autocuration,,,,,,,A,BAO_0000019,CHEMBL620892,7831
,50594,N,1,,,,14387,,Area under the concentration time curve (AUC) taken for 0-24 hr was measured when administered through iv route in mice,1,Mus musculus,Intermediate,,,,10090.0,,,A,BAO_0000218,CHEMBL621079,7832
,50594,N,1,,,,14387,,Area under the concentration time curve (AUC) taken for 0-24 hr was measured when administered through oral route in mice,1,Mus musculus,Intermediate,,,,10090.0,,,A,BAO_0000218,CHEMBL621080,7833
,50588,N,1,,,,12836,,Area under the concentration vs time curve in dog at 10 mg/kg oral dose,1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL621081,7834
,100712,N,1,,,,12836,,Area under the concentration vs time curve in hamster at 10 mg/kg oral dose,1,Cricetinae,Intermediate,,,,10026.0,,,A,BAO_0000218,CHEMBL621082,7835
,50597,N,1,,,,12836,,Area under the concentration vs time curve in rat at 10 mg/kg oral dose,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL621083,7836
,50588,N,1,,,,14339,,Area under the concentration-time curve from time zero to infinity after intravenous administration of 2.5 mg/kg in dogs,1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL621084,7837
,50588,N,1,,,,14339,,Area under the concentration-time curve from time zero to infinity in oral (5 mg/kg) fasted dogs,1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL621085,7838
,50588,N,1,,,,14339,,Area under the concentration-time curve from time zero to infinity in oral (5 mg/kg) fed dogs,1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL621086,7839
,50588,N,1,,,,10524,,Area under the concentration/ time determined against Bacillus subtilis ATCC 6633 after oral administration in dog(25 mg/kg),1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL621087,7840
,50588,N,1,,,,9994,,Area under the concentration/ time in plasma after oral administration in dog (25 mg/kg),1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL622607,7841
,50588,N,1,,,,11325,,Serum AUC in marmosets (IV dose),1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL622608,7842
,22224,U,0,,,,12536,,Area under the curve after intravenous administration at a dose of 10 umol/kg,1,,Autocuration,,,,,,,A,BAO_0000019,CHEMBL624481,7843
,22224,U,0,,,,12536,,Area under the curve after intravenous administration at a dose of 2 umol/kg,1,,Autocuration,,,,,,,A,BAO_0000019,CHEMBL624482,7844
,22224,U,0,,,,12536,,Area under the curve after intravenous administration at a dose of 4 umol/kg,1,,Autocuration,,,,,,,A,BAO_0000019,CHEMBL624483,7845
,22224,U,0,,,,12536,,Area under the curve after intravenous administration at a dose of 40 umol/kg,1,,Autocuration,,,,,,,A,BAO_0000019,CHEMBL624484,7846
,22224,U,0,,,,12536,,Area under the curve after intravenous administration at a dose of 5 umol/kg,1,,Autocuration,,,,,,,A,BAO_0000019,CHEMBL624485,7847
,50597,N,1,,,,15556,,Area under the curve for fumarate salt was evaluated in F344 Rats.,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL624486,7848
,22224,U,0,,,,2809,,Area under the curve for the compound was calculated.,1,,Autocuration,,,,,,,A,BAO_0000019,CHEMBL624487,7849
,22224,U,0,,,,9511,,Area under the curve in concentration/ time,1,,Autocuration,,,,,,,A,BAO_0000019,CHEMBL624488,7850
,50597,N,1,,,,12818,,Area under the curve administered intraintestinal in rats.,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL624489,7851
,50597,N,1,,,,12818,,Area under the curve administered intravenously in rats.,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL625184,7852
,22224,U,0,,,,15118,,Area under the curve during intravenous administration,1,,Autocuration,,,,,,,A,BAO_0000019,CHEMBL625185,7853
,22224,U,0,,,,15118,,Area under the curve during intravenous administration; Not determined,1,,Autocuration,,,,,,,A,BAO_0000019,CHEMBL875954,7854
,22224,U,0,,,,15118,,Area under the curve during systemic administration,1,,Autocuration,,,,,,,A,BAO_0000019,CHEMBL625186,7855
,22224,U,0,,,,15118,,Area under the curve during systemic administration; Not determined,1,,Autocuration,,,,,,,A,BAO_0000019,CHEMBL625187,7856
,22224,U,0,,,,2632,,Area under the curve was calculated for the compound.,1,,Autocuration,,,,,,,A,BAO_0000019,CHEMBL625188,7857
,50588,N,1,,,,14346,,Area under the curve was determined after intravenous administration of 1.8 mg/kg in male Beagle dogs,1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL625189,7858
,50588,N,1,,,,14346,,Area under the curve was determined after intravenous administration of 10 mg/kg in male Beagle dogs,1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL625190,7859
,50597,N,1,,,,14346,,Area under the curve was determined after intravenous administration of 2.5 mg/kg in male Dawley rats,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL621733,7860
,50597,N,1,,,,14346,,Area under the curve was determined after intravenous administration of 2.6 mg/kg in male Dawley rats,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL621734,7861
,50597,N,1,,,,11149,,C6h was measured as concentration obtained after 6 hr of oral administration in air pouch exudate after oral administration to male F344 rats,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL621735,7862
Plasma,50597,N,1,,,,17796,,Clearance of the drug was measured in the plasma of rat; No data,1,Rattus norvegicus,Intermediate,,,,10116.0,,1969.0,A,BAO_0000218,CHEMBL621736,7863
Plasma,50597,N,1,,,,5247,,The pharmacokinetic parameter plasma clearance in vivo in rats,1,Rattus norvegicus,Intermediate,,,,10116.0,,1969.0,A,BAO_0000218,CHEMBL621737,7864
,50597,N,1,,,,4727,,Plasma clearance at the dose of 2 mg/kg in rat,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL621738,7865
,50597,N,1,In vivo,,,5654,,CL (clearance) of compound was determined as average of four rats at each dose of 5 mg/kg intravenous and 16 mg/kg peroral administration,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL622806,7866
,50597,N,1,In vivo,,,5654,,CL (clearance) of compound was determined as average of four rats at each dose of 5 mg/kg intravenous and 20 mg/kg peroral administration,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL623519,7867
,50597,N,1,In vivo,,,17260,,CL at a dose of 10 mg/Kg administered intravenously in female hanover-wistar rat,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL623520,7868
,50597,N,1,In vivo,,,17065,,Clearance measured after intravenous bolus administration of 50 mg/kg of compound to rats,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL623521,7869
,50597,N,1,In vivo,,,17671,,Clearance in male Sprague-Dawley rats following an intravenous bolus dose at 10-20 mg/kg,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL623522,7870
,50597,N,1,In vivo,,,6672,,Clearance rate in rat,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL623523,7871
,50597,N,1,In vivo,,,6673,,Clearance rate in rat,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL623690,7872
,50597,N,1,In vivo,,,5978,,Clearance (Cl) of compound (10 mg/kg) after iv administration was determined in Sprague-Dawley rat,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL623691,7873
,50597,N,1,In vivo,,,5978,,Clearance (Cl) of compound (9.83 mg/kg) after iv administration was determined in Sprague-Dawley rat,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL623692,7874
,50597,N,1,In vivo,,,5978,,Clearance (Cl) of compound (9.84 mg/kg) after iv administration was determined in Sprague-Dawley rat,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL623693,7875
,50597,N,1,In vivo,,,5978,,Clearance (Cl) of compound (9.92 mg/kg) after iv administration was determined in Sprague-Dawley rat,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL623694,7876
,50597,N,1,In vivo,,,4413,,Clearance of compound after iv administration of 20 mg/kg dose in rat,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL623695,7877
,50597,N,1,In vivo,,,2661,,Compound was evaluated for clearance after treatment with iv dose of 1 mgkg to female wistar rats,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL623696,7878
,50597,N,1,In vivo,,,2661,,Compound was evaluated for clearance after treatment with iv dose of 1 mgkg to male wistar rats,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL623697,7879
Plasma,22224,U,0,In vivo,,,5005,,Compound was tested for its plasma clearance rate in rhesus monkey at a dose of 0.75 mg/kg iv/ 1.5 mg/kg po,1,Macaca mulatta,Intermediate,,,,9544.0,,1969.0,A,BAO_0000218,CHEMBL623698,7880
Plasma,22224,U,0,In vivo,,,5005,,Compound was tested for its plasma clearance rate in Sprague Dawley rats,1,Rattus norvegicus,Intermediate,,,,10116.0,,1969.0,A,BAO_0000218,CHEMBL623699,7881
,50597,N,1,In vivo,,,15765,,Mean (%CV) PK parameters for CL(mL/min/kg).,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL623700,7882
,50597,N,1,In vivo,,,3747,,Pharmacokinetic studies were carried out to determine the clearance after administration at 20 mg/kg intravenously in rat,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL623701,7883
Plasma,50597,N,1,In vivo,,,16366,,Pharmacokinetic parameter plasma clearance was determined at when a dose of 1 mg/kg is administered,1,Rattus norvegicus,Intermediate,,,,10116.0,,1969.0,A,BAO_0000218,CHEMBL623702,7884
,50597,N,1,In vivo,,,4199,,Plasma Clearance measured at steady-state following iv infusion at 0.6 mg/kg/h in rats,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL623703,7885
,50597,N,1,In vivo,,,17267,,Plasma clearance in rat was determined,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL623704,7886
,50597,N,1,In vivo,,,6535,,Plasma clearance in rat after administration of 2 mg/kg iv,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL623705,7887
,50597,N,1,In vivo,,,6535,,Plasma clearance in rat after administration of 2 mg/kg iv,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL623706,7888
,50597,N,1,In vivo,,,5041,,Plasma clearance was determined,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL623707,7889
,50597,N,1,In vivo,,,5960,,Plasma clearance in rat,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL623708,7890
,50597,N,1,In vivo,,,5937,,Plasma clearance in rat after intravenous administration at a concentration 0.5 mg/kg,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL623709,7891
,50597,N,1,In vivo,,,5871,,Plasma clearance in rat by iv administration,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL623710,7892
,50597,N,1,In vivo,,,5874,,Plasma clearance in rat by iv administration at a dose of 3 mg/kg,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL623711,7893
,50597,N,1,In vivo,,,6504,,Plasma clearance in rat p.o.,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL623712,7894
,50597,N,1,In vivo,,,6803,,Plasma clearance in rats,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL623713,7895
,50597,N,1,In vivo,,,5041,,Plasma clearance was determined; ND denotes no data,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL623714,7896
,50597,N,1,In vivo,,,5041,,Plasma clearance was determined; ND denotes not determined,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL623715,7897
,50597,N,1,In vivo,,,1916,,Plasma clearance was evaluated in Sprague-Dawley rats at a dose of 15 mg/kg after iv administration,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL623716,7898
,50597,N,1,In vivo,,,5199,,Plasma clearance was determined in female Sprague-Dawley rats following intravenous (iv) administration of drug (1 mg/kg).,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL622980,7899
,50597,N,1,In vivo,,,16367,,Plasma administration to rats,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL622981,7900
,50597,N,1,In vivo,,,6362,,Plasma clearance of the compound in female Sprague-Dawley rats,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL622982,7901
,50597,N,1,In vivo,,,15662,,Plasma clearance was observed after intravenous administration in rat,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL622983,7902
,50597,N,1,In vivo,,,6215,,Systemic clearance after intravenous administration (5.0 mg/kg) was determined in rat,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL622984,7903
,50597,N,1,In vivo,,,1466,,Tested for systemic clearance upon intravenous administration of 5.0 mg/Kg dose in rat,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL622985,7904
Plasma,50597,N,1,In vivo,,,15662,,plasma clearance was observed after intravenous administration in rat,1,Rattus norvegicus,Intermediate,,,,10116.0,,1969.0,A,BAO_0000218,CHEMBL623631,7905
,50597,N,1,In vivo,,,4723,,In vivo CL/F determined,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL623632,7906
Plasma,50597,N,1,In vivo,,,2792,,Pharmacokinetic parameter plasma clearance was determined at 2 mg/kg i.v. dose in rats,1,Rattus norvegicus,Intermediate,,,,10116.0,,1969.0,A,BAO_0000218,CHEMBL623633,7907
Plasma,50597,N,1,In vivo,,,2792,,Pharmacokinetic parameter plasma clearance was determined at 5 mg/kg i.v. dose in rats,1,Rattus norvegicus,Intermediate,,,,10116.0,,1969.0,A,BAO_0000218,CHEMBL623634,7908
,50597,N,1,In vivo,,,5213,,Compound was tested for the lower blood clearance in rat,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL623635,7909
,50597,N,1,In vivo,,,4687,,Evaluated for the low clearance in rat (in vivo),1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL621195,7910
,50597,N,1,In vivo,,,3371,,Pharmacokinetic property (CLb)of the compound was determined in rat,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL621196,7911
,50597,N,1,In vivo,,,4690,,Rapid clearance after intravenous administration in rat was determined,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL875287,7912
,50597,N,1,In vivo,,,5702,,Clearance measured in rat,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL621197,7913
Plasma,50597,N,1,In vivo,,,740,,Compound was evaluated for plasma clearance in rat,1,Rattus norvegicus,Intermediate,,,,10116.0,,1969.0,A,BAO_0000218,CHEMBL621198,7914
Plasma,50597,N,1,In vivo,,,4853,,Low plasma clearance was calculated in rat,1,Rattus norvegicus,Intermediate,,,,10116.0,,1969.0,A,BAO_0000218,CHEMBL621199,7915
,50597,N,1,In vivo,,,5789,,Pharmacokinetic property (Clp) in rat,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL621200,7916
,50597,N,1,In vivo,,,4527,,Plasma clearance in dog at a dose of 1 uM/kg in rat was determined,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL621201,7917
,50597,N,1,In vivo,,,4527,,Plasma clearance in rat at a dose of 10 uM/kg in rat was determined,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL621202,7918
,50597,N,1,In vivo,,,6518,,Plasma clearance after IV dosing at 0.5 mg/kg in rat,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL621203,7919
,50597,N,1,In vivo,,,6518,,Plasma clearance after IV dosing at 1 mg/kg in rat,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL621204,7920
Heart,50597,N,1,In vivo,,,9866,,Biodistribution in rat heart in the presence of 0.01 M Gd/0.01 M GdDTPA-AEP,1,Rattus norvegicus,Intermediate,,,,10116.0,,948.0,A,BAO_0000218,CHEMBL621205,7921
Heart,50597,N,1,In vivo,,,9866,,Biodistribution in rat heart in the presence of 0.01 M GdDTPA-BDP,1,Rattus norvegicus,Intermediate,,,,10116.0,,948.0,A,BAO_0000218,CHEMBL621206,7922
Heart,50597,N,1,In vivo,,,9866,,Biodistribution in rat heart in the presence of 0.01 M/0.08 M GdDTPA-AEP,1,Rattus norvegicus,Intermediate,,,,10116.0,,948.0,A,BAO_0000218,CHEMBL621207,7923
Heart,50597,N,1,In vivo,,,9866,,Biodistribution in rat heart in the presence of 0.05 M /0.05 M GdDTPA-AEP,1,Rattus norvegicus,Intermediate,,,,10116.0,,948.0,A,BAO_0000218,CHEMBL621208,7924
Heart,50597,N,1,In vivo,,,9866,,Biodistribution in rat heart in the presence of 0.05 M Gd/0.15 M lig,1,Rattus norvegicus,Intermediate,,,,10116.0,,948.0,A,BAO_0000218,CHEMBL621209,7925
Heart,50597,N,1,In vivo,,,9866,,Biodistribution in rat heart in the presence of 0.05 M GdDTPA-BDP,1,Rattus norvegicus,Intermediate,,,,10116.0,,948.0,A,BAO_0000218,CHEMBL876484,7926
Heart,50597,N,1,In vivo,,,9866,,Biodistribution in rat heart in the presence of 0.05 M/0.08 M GdDTPA-HPDP,1,Rattus norvegicus,Intermediate,,,,10116.0,,948.0,A,BAO_0000218,CHEMBL621210,7927
Heart,50597,N,1,In vivo,,,9866,,Biodistribution in rat heart in the presence of 0.10 M GdDTPA-BDP,1,Rattus norvegicus,Intermediate,,,,10116.0,,948.0,A,BAO_0000218,CHEMBL621211,7928
Heart,50597,N,1,In vivo,,,9866,,Biodistribution in rat heart in the presence of 0.10 M/0.11 M GdDTPA-AEP,1,Rattus norvegicus,Intermediate,,,,10116.0,,948.0,A,BAO_0000218,CHEMBL621212,7929
Heart,50597,N,1,In vivo,,,9866,,Biodistribution in rat heart in the presence of GdDTPA at 15 min,1,Rattus norvegicus,Intermediate,,,,10116.0,,948.0,A,BAO_0000218,CHEMBL621213,7930
Heart,50597,N,1,In vivo,,,9866,,Biodistribution in rat heart in the presence of GdDTPA at 1 hr,1,Rattus norvegicus,Intermediate,,,,10116.0,,948.0,A,BAO_0000218,CHEMBL621214,7931
Heart,50597,N,1,In vivo,,,9866,,Biodistribution in rat heart in the presence of GdDTPA at 30 min,1,Rattus norvegicus,Intermediate,,,,10116.0,,948.0,A,BAO_0000218,CHEMBL621215,7932
Heart,50597,N,1,In vivo,,,9866,,Biodistribution in rat heart in the presence of GdDTPA at 4 hr,1,Rattus norvegicus,Intermediate,,,,10116.0,,948.0,A,BAO_0000218,CHEMBL621216,7933
Heart,50597,N,1,In vivo,,,9866,,Biodistribution in rat heart in the presence of GdDTPA-BDP at 1 hr,1,Rattus norvegicus,Intermediate,,,,10116.0,,948.0,A,BAO_0000218,CHEMBL621217,7934
Heart,50597,N,1,In vivo,,,9866,,Biodistribution in rat heart in the presence of GdDTPA-BDP at 30 min,1,Rattus norvegicus,Intermediate,,,,10116.0,,948.0,A,BAO_0000218,CHEMBL621218,7935
Heart,50597,N,1,In vivo,,,9866,,Biodistribution in rat heart in the presence of GdDTPA-BDP at 4 hr,1,Rattus norvegicus,Intermediate,,,,10116.0,,948.0,A,BAO_0000218,CHEMBL621219,7936
Heart,50597,N,1,In vivo,,,9866,,Biodistribution in rat heart in the presence of GdDTPA-BDPat 15 min,1,Rattus norvegicus,Intermediate,,,,10116.0,,948.0,A,BAO_0000218,CHEMBL621220,7937
Heart,50597,N,1,In vivo,,,9866,,Biodistribution in rat heart in the presence of GdDTPA-HPDP at 1 hr,1,Rattus norvegicus,Intermediate,,,,10116.0,,948.0,A,BAO_0000218,CHEMBL621221,7938
Heart,50597,N,1,In vivo,,,9866,,Biodistribution in rat heart in the presence of GdDTPA-HPDP at 30 min,1,Rattus norvegicus,Intermediate,,,,10116.0,,948.0,A,BAO_0000218,CHEMBL621222,7939
Heart,50597,N,1,In vivo,,,9866,,Biodistribution in rat heart in the presence of GdDTPA-HPDP at 4 hr,1,Rattus norvegicus,Intermediate,,,,10116.0,,948.0,A,BAO_0000218,CHEMBL621223,7940
Heart,50597,N,1,In vivo,,,9866,,Biodistribution in rat heart in the presence of GdDTPA-HPDPat 15 min,1,Rattus norvegicus,Intermediate,,,,10116.0,,948.0,A,BAO_0000218,CHEMBL876485,7941
Heart,50597,N,1,In vivo,,,9866,,Biodistribution in rat heart in the presence of NAC Gd/0.01 M GdDTPA-HPDP,1,Rattus norvegicus,Intermediate,,,,10116.0,,948.0,A,BAO_0000218,CHEMBL621224,7942
Heart,50597,N,1,In vivo,,,9866,,Biodistribution in rat heart in the presence of NCA Gd/0.01 M lip,1,Rattus norvegicus,Intermediate,,,,10116.0,,948.0,A,BAO_0000218,CHEMBL621225,7943
Heart,50597,N,1,In vivo,,,9866,,Biodistribution in rat heart in the presence of NCAGd/0.01 M lig,1,Rattus norvegicus,Intermediate,,,,10116.0,,948.0,A,BAO_0000218,CHEMBL621226,7944
Kidney,50597,N,1,In vivo,,,9866,,Biodistribution in rat kidney in the presence of 0.01 M GdDTPA-BDP,1,Rattus norvegicus,Intermediate,,,,10116.0,,2113.0,A,BAO_0000218,CHEMBL621227,7945
Kidney,50597,N,1,In vivo,,,9866,,Biodistribution in rat kidney in the presence of 0.01 M/0.01 M GdDTPA-AEP,1,Rattus norvegicus,Intermediate,,,,10116.0,,2113.0,A,BAO_0000218,CHEMBL621228,7946
Kidney,50597,N,1,In vivo,,,9866,,Biodistribution in rat kidney in the presence of 0.01 M/0.08 M GdDTPA-AEP,1,Rattus norvegicus,Intermediate,,,,10116.0,,2113.0,A,BAO_0000218,CHEMBL621229,7947
Kidney,50597,N,1,In vivo,,,9866,,Biodistribution in rat kidney in the presence of 0.05 M Gd/0.15 M lig,1,Rattus norvegicus,Intermediate,,,,10116.0,,2113.0,A,BAO_0000218,CHEMBL621230,7948
Kidney,50597,N,1,In vivo,,,9866,,Biodistribution in rat kidney in the presence of 0.05 M GdDTPA-BDP; ND=No data,1,Rattus norvegicus,Intermediate,,,,10116.0,,2113.0,A,BAO_0000218,CHEMBL621231,7949
Kidney,50597,N,1,In vivo,,,9866,,Biodistribution in rat kidney in the presence of 0.05 M/0.05 M GdDTPA-AEP,1,Rattus norvegicus,Intermediate,,,,10116.0,,2113.0,A,BAO_0000218,CHEMBL621232,7950
Kidney,50597,N,1,In vivo,,,9866,,Biodistribution in rat kidney in the presence of 0.05 M/0.08 M GdDTPA-HPDP,1,Rattus norvegicus,Intermediate,,,,10116.0,,2113.0,A,BAO_0000218,CHEMBL621233,7951
Kidney,50597,N,1,In vivo,,,9866,,Biodistribution in rat kidney in the presence of 0.10 M GdDTPA-BDP,1,Rattus norvegicus,Intermediate,,,,10116.0,,2113.0,A,BAO_0000218,CHEMBL621234,7952
Kidney,50597,N,1,In vivo,,,9866,,Biodistribution in rat kidney in the presence of 0.10 M/0.11 M GdDTPA-AEP; ND=No data,1,Rattus norvegicus,Intermediate,,,,10116.0,,2113.0,A,BAO_0000218,CHEMBL621235,7953
Kidney,50597,N,1,In vivo,,,9866,,Biodistribution in rat kidney in the presence of NAC Gd/0.01 M GdDTPA-HPDP,1,Rattus norvegicus,Intermediate,,,,10116.0,,2113.0,A,BAO_0000218,CHEMBL621236,7954
Kidney,50597,N,1,In vivo,,,9866,,Biodistribution in rat kidney in the presence of NCA Gd/0.01 M lip,1,Rattus norvegicus,Intermediate,,,,10116.0,,2113.0,A,BAO_0000218,CHEMBL621237,7955
Kidney,50597,N,1,In vivo,,,9866,,Biodistribution in rat kidney in the presence of NCAGd/0.01 M lig,1,Rattus norvegicus,Intermediate,,,,10116.0,,2113.0,A,BAO_0000218,CHEMBL876486,7956
Intestine,50597,N,1,In vivo,,,9866,,Biodistribution in rat l. intestine in the presence of 0.01 M carrier at 1 hr,1,Rattus norvegicus,Intermediate,,,,10116.0,,160.0,A,BAO_0000218,CHEMBL622436,7957
Intestine,50597,N,1,In vivo,,,9866,,Biodistribution in rat l. intestine in the presence of 50 Gd/kg at 2 hr,1,Rattus norvegicus,Intermediate,,,,10116.0,,160.0,A,BAO_0000218,CHEMBL622437,7958
Intestine,50597,N,1,In vivo,,,9866,,Biodistribution in rat l. intestine in the presence of 50 Gd/kg at 6 hr,1,Rattus norvegicus,Intermediate,,,,10116.0,,160.0,A,BAO_0000218,CHEMBL622438,7959
Liver,50597,N,1,In vivo,,,9866,,Biodistribution in rat liver by in the presence 50 Gd/kg at 15 min,1,Rattus norvegicus,Intermediate,,,,10116.0,,2107.0,A,BAO_0000218,CHEMBL622439,7960
Liver,50597,N,1,In vivo,,,9866,,Biodistribution in rat liver by in the presence of 0.05 M Gd/0.15 M lig,1,Rattus norvegicus,Intermediate,,,,10116.0,,2107.0,A,BAO_0000218,CHEMBL622440,7961
Liver,50597,N,1,In vivo,,,9866,,Biodistribution in rat liver by in the presence of NCAGd/0.01 M lig,1,Rattus norvegicus,Intermediate,,,,10116.0,,2107.0,A,BAO_0000218,CHEMBL622441,7962
Liver,50597,N,1,In vivo,,,9866,,Biodistribution in rat liver in the presence of 0.001 M/0.008 M GdDTPA-AEP,1,Rattus norvegicus,Intermediate,,,,10116.0,,2107.0,A,BAO_0000218,CHEMBL622442,7963
Liver,50597,N,1,In vivo,,,9866,,Biodistribution in rat liver in the presence of 0.01 M GdDTPA-BDP,1,Rattus norvegicus,Intermediate,,,,10116.0,,2107.0,A,BAO_0000218,CHEMBL622443,7964
Liver,50597,N,1,In vivo,,,9866,,Biodistribution in rat liver in the presence of 0.01 M/0.01 M GdDTPA-AEP,1,Rattus norvegicus,Intermediate,,,,10116.0,,2107.0,A,BAO_0000218,CHEMBL622444,7965
Liver,50597,N,1,In vivo,,,9866,,Biodistribution in rat liver in the presence of 0.05 M GdDTPA-BDP,1,Rattus norvegicus,Intermediate,,,,10116.0,,2107.0,A,BAO_0000218,CHEMBL622445,7966
Liver,50597,N,1,In vivo,,,9866,,Biodistribution in rat liver in the presence of 0.05 M/0.05 M GdDTPA-AEP,1,Rattus norvegicus,Intermediate,,,,10116.0,,2107.0,A,BAO_0000218,CHEMBL622446,7967
Liver,50597,N,1,In vivo,,,9866,,Biodistribution in rat liver in the presence of 0.05 M/0.08 M GdDTPA-HPDP,1,Rattus norvegicus,Intermediate,,,,10116.0,,2107.0,A,BAO_0000218,CHEMBL622447,7968
Liver,50597,N,1,In vivo,,,9866,,Biodistribution in rat liver in the presence of 0.10 M GdDTPA-BDP,1,Rattus norvegicus,Intermediate,,,,10116.0,,2107.0,A,BAO_0000218,CHEMBL622448,7969
Liver,50597,N,1,In vivo,,,9866,,Biodistribution in rat liver in the presence of 0.10 M/0.11 M GdDTPA-AEP; ND=No data,1,Rattus norvegicus,Intermediate,,,,10116.0,,2107.0,A,BAO_0000218,CHEMBL622449,7970
Liver,50597,N,1,In vivo,,,9866,,Biodistribution in rat liver in the presence of 50 Gd/kg at 2 hr,1,Rattus norvegicus,Intermediate,,,,10116.0,,2107.0,A,BAO_0000218,CHEMBL622450,7971
Liver,50597,N,1,In vivo,,,9866,,Biodistribution in rat liver in the presence of 50 Gd/kg at at 6 hr,1,Rattus norvegicus,Intermediate,,,,10116.0,,2107.0,A,BAO_0000218,CHEMBL622451,7972
Liver,50597,N,1,In vivo,,,9866,,Biodistribution in rat liver in the presence of GdDTPA at 15 min,1,Rattus norvegicus,Intermediate,,,,10116.0,,2107.0,A,BAO_0000218,CHEMBL622452,7973
Liver,50597,N,1,In vivo,,,9866,,Biodistribution in rat liver in the presence of GdDTPA at 1 hr,1,Rattus norvegicus,Intermediate,,,,10116.0,,2107.0,A,BAO_0000218,CHEMBL622453,7974
Liver,50597,N,1,In vivo,,,9866,,Biodistribution in rat liver in the presence of GdDTPA at 30 min,1,Rattus norvegicus,Intermediate,,,,10116.0,,2107.0,A,BAO_0000218,CHEMBL622454,7975
Liver,50597,N,1,In vivo,,,9866,,Biodistribution in rat liver in the presence of GdDTPA at 4 hr,1,Rattus norvegicus,Intermediate,,,,10116.0,,2107.0,A,BAO_0000218,CHEMBL622455,7976
Liver,50597,N,1,In vivo,,,9866,,Biodistribution in rat liver in the presence of GdDTPA-BDP at 15 min,1,Rattus norvegicus,Intermediate,,,,10116.0,,2107.0,A,BAO_0000218,CHEMBL876024,7977
,50597,N,1,In vivo,,,2792,,T max was determined at 3 mg/kg po dose in rats,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL622456,7978
,50597,N,1,In vivo,,,15078,,"The Tmax value in female wistar rat at 100 mg/kg, p.o. dose",1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL622457,7979
,50597,N,1,In vivo,,,15078,,"The Tmax value in male wistar rat at 100 mg/kg, p.o. dose",1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL622458,7980
,50597,N,1,,,,15022,,The time to reach maximum concentration of compound was measured at the dose of 100 umol/kg,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL622459,7981
,50597,N,1,,,,15022,,The time to reach maximum concentration of compound was measured at the dose of 300 umol/kg,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL873343,7982
,50597,N,1,,,,15022,,The time to reach maximum concentration of compound was measured at the dose of 30 umol/kg,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL622460,7983
Plasma,50597,N,1,,,,4576,,Time for maximum plasma concentration determined in rat,1,Rattus norvegicus,Intermediate,,,,10116.0,,1969.0,A,BAO_0000218,CHEMBL622461,7984
Plasma,50597,N,1,In vivo,,,6681,,Time for maximum plasma concentration reached by compound was determined in rats at 50 mg/kg dose,1,Rattus norvegicus,Intermediate,,,,10116.0,,1969.0,A,BAO_0000218,CHEMBL622462,7985
,50597,N,1,In vivo,,,16365,,Time of maximum concentration of the drug when administered orally a dose of 10 mg/kg to a fasting rat,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL622463,7986
,50597,N,1,In vivo,,,16365,,Time of maximum concentration of the drug when administered orally a dose of 1 mg/kg to a fasting rat,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL622464,7987
,50597,N,1,In vivo,,,16365,,Time of maximum concentration of the drug when administered orally a dose of 30 mg/kg,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL622465,7988
,50597,N,1,In vivo,,,16365,,Time of maximum concentration of the drug when administered orally a dose of 3 mg/kg to a fasting rat,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL622466,7989
,50597,N,1,In vivo,,,16365,,Time of maximum concentration of the drug when administered orally at dose of 3 mg/kg,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL622467,7990
Plasma,50597,N,1,,,,6824,,Time of maximum plasma concentration in rat,1,Rattus norvegicus,Intermediate,,,,10116.0,,1969.0,A,BAO_0000218,CHEMBL622468,7991
Plasma,50597,N,1,,,,6685,,"Time required by compound for reaching maximum plasma concentration was determined in rats at 10 mg/kg, p.o. dose",1,Rattus norvegicus,Intermediate,,,,10116.0,,1969.0,A,BAO_0000218,CHEMBL876025,7992
Plasma,50597,N,1,,,,6685,,"Time required by compound for reaching maximum plasma concentration was determined in rats at 20 mg/kg, i.p. dose",1,Rattus norvegicus,Intermediate,,,,10116.0,,1969.0,A,BAO_0000218,CHEMBL622469,7993
Plasma,50597,N,1,,,,6685,,"Time required by compound for reaching maximum plasma concentration was determined in rats at 2 mg/kg, i.v. dose; n/a: not applicable",1,Rattus norvegicus,Intermediate,,,,10116.0,,1969.0,A,BAO_0000218,CHEMBL622470,7994
,50597,N,1,In vivo,,,15662,,Time required to reach maximum concentration (Cmax) after oral administration in rat,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL622471,7995
Plasma,50597,N,1,,,,1742,,Time required to reach maximum concentration in rat plasma,1,Rattus norvegicus,Intermediate,,,,10116.0,,1969.0,A,BAO_0000218,CHEMBL622472,7996
Plasma,50597,N,1,In vivo,,,2774,,Time taken by the compound to achieve maximum concentration in rat plasma at 30 mg/Kg upon oral administration.,1,Rattus norvegicus,Intermediate,,,,10116.0,,1969.0,A,BAO_0000218,CHEMBL622473,7997
Plasma,50597,N,1,In vivo,,,5199,,Time taken by the compound to achieve maximum plasma concentration at a 1 mg/kg oral dose in female Sprague-Dawley rats,1,Rattus norvegicus,Intermediate,,,,10116.0,,1969.0,A,BAO_0000218,CHEMBL624282,7998
Plasma,50597,N,1,In vivo,,,12873,,Time taken for maximum plasma concentration for the compound in solution form (formulation) was determined in rats at peroral dose of 5 mg/kg,1,Rattus norvegicus,Intermediate,,,,10116.0,,1969.0,A,BAO_0000218,CHEMBL624283,7999
Plasma,50597,N,1,In vivo,,,12873,,Time taken for maximum plasma concentration for the compound in suspension form (formulation) was determined in rats at peroral dose of 5 mg/kg,1,Rattus norvegicus,Intermediate,,,,10116.0,,1969.0,A,BAO_0000218,CHEMBL624284,8000
Plasma,50597,N,1,In vivo,,,1916,,Time taken to reach maximum concentration in plasma was evaluated in Sprague-Dawley rats at a dose of 15 mg/kg after po administration,1,Rattus norvegicus,Intermediate,,,,10116.0,,1969.0,A,BAO_0000218,CHEMBL624285,8001
,50597,N,1,In vivo,,,16367,,Time to reach Cmax after oral administration to rats,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL624286,8002
,50597,N,1,In vivo,,,16366,,Time to reach Cmax when a dose of 1 mg/kg is administered orally,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL624287,8003
,50597,N,1,,,,216,,Time to reach maximum concentration following oral administration of 200 mg/kg in rat; value ranges from 2-4,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL624288,8004
Plasma,50597,N,1,In vivo,,,6410,,Time to reach maximum plasma concentration was evaluated at an intravenous dose of 3 mg/kg; Not applicable,1,Rattus norvegicus,Intermediate,,,,10116.0,,1969.0,A,BAO_0000218,CHEMBL624289,8005
Plasma,50597,N,1,In vivo,,,6410,,Time to reach maximum plasma concentration was evaluated at an oral dose of 30 mg/kg,1,Rattus norvegicus,Intermediate,,,,10116.0,,1969.0,A,BAO_0000218,CHEMBL873344,8006
,50597,N,1,In vivo,,,6215,,Tmax after peroral administration (10 mg/kg) was determined in rat,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL619623,8007
,50597,N,1,In vivo,,,3598,,Tmax of compound determined in rat after iv administration at a dose of 10 mg/kg,1,Rattus norvegicus,Expert,,,,10116.0,,,A,BAO_0000218,CHEMBL621399,8008
,50597,N,1,In vivo,,,4527,,Tmax by oral administration at a dose of 100 uM/kg in rat was determined,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL621400,8009
,50597,N,1,In vivo,,,17670,,"Tmax in fischer rats at 5 mg/kg dose, administered intravenously",1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL621401,8010
,50597,N,1,,,,1465,,Tmax was determined,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL621402,8011
,50597,N,1,,,,2552,,Tmax was determined,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL621403,8012
,50597,N,1,In vivo,,,5656,,Tmax after oral administration in rat,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL621121,8013
,50597,N,1,In vivo,,,17764,,Tmax after peroral administration in rats at 2.4 uM/kg,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL872525,8014
,50597,N,1,,,,5610,,Tmax in male rat,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL621122,8015
,50597,N,1,In vivo,,,6046,,Tmax in rat at 10 mg/kg,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL621123,8016
,50597,N,1,In vivo,,,5874,,Tmax in rat by po administration at a dose of 40 mg/kg,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL621124,8017
,50597,N,1,,,,17596,,Tmax in rats,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL621125,8018
,50597,N,1,In vivo,,,17804,,Tmax was measured in rats after peroral administration at 5 mg/kg,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL621126,8019
,50597,N,1,In vivo,,,1908,,Tmax value after oral dose at a dose of 10 mg/kg in rats.,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL621127,8020
,50597,N,1,In vivo,,,2959,,Tmax value after administration of 20 mg/Kg oral dose in rat,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL621128,8021
,50597,N,1,In vivo,,,6757,,Tmax value at a dose of 10 mg/kg in male SD rats,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL618263,8022
,50597,N,1,In vivo,,,6757,,Tmax value at a dose of 100 mg/kg in male SD rats,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL618264,8023
,50597,N,1,In vivo,,,6757,,Tmax value at a dose of 50 mg/kg in male SD rats,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL618265,8024
Plasma,50597,N,1,In vivo,,,4186,,Total concentration in rat plasma after administration of 3.5 mg/kg dose through subcutaneous route,1,Rattus norvegicus,Intermediate,,,,10116.0,,1969.0,A,BAO_0000218,CHEMBL618266,8025
,50597,N,1,In vivo,,,15662,,time required to reach maximum concentration (Cmax) after oral administration in rat,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL618267,8026
Urine,50597,N,1,,,,429,,Evaluated for pharmacokinetic parameter urine recovery in rat at the dose 50 mg/kg ( 0-24 hr ),1,Rattus norvegicus,Intermediate,,,,10116.0,,1088.0,A,BAO_0000218,CHEMBL618450,8027
Urine,50597,N,1,,,,429,,Evaluated for pharmacokinetic parameter urine recovery in rat at the dose 50 mg/kg (0-24 hr),1,Rattus norvegicus,Intermediate,,,,10116.0,,1088.0,A,BAO_0000218,CHEMBL618451,8028
,50597,N,1,,,,5546,,Unbound plasma was determined in Sprague-Dawley rats at a dose of 1 mg/kg by iv administration,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL618452,8029
Urine,50597,N,1,,,,3173,,Amount of urine output was measured in rat at a dose of 1 mg/kg/po,1,Rattus norvegicus,Intermediate,,,,10116.0,,1088.0,A,BAO_0000218,CHEMBL618453,8030
Urine,50597,N,1,,,,3173,,Amount of urine output was measured in rat at a dose of 10 mg/kg/po,1,Rattus norvegicus,Intermediate,,,,10116.0,,1088.0,A,BAO_0000218,CHEMBL618454,8031
Urine,50597,N,1,,,,3173,,Amount of urine output was measured in rat at a dose of 10 mg/kg/po; NT-Not tested,1,Rattus norvegicus,Intermediate,,,,10116.0,,1088.0,A,BAO_0000218,CHEMBL618455,8032
,50597,N,1,In vivo,,,4257,,Volume of distribution was determined in rat after a 3 mg/kg of iv dose,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL618456,8033
,50597,N,1,In vivo,,,6011,,Compound distribution in rat tissues was determined,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL618457,8034
,50597,N,1,In vivo,,,5472,,Volume of distribution was evaluated in rat,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL618458,8035
,50597,N,1,,,,14346,,Area under the curve was determined after intravenous administration of 2.7 mg/kg in male Dawley rats,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL618459,8036
,50597,N,1,,,,14346,,Area under the curve was determined after intravenous administration of 2.8 mg/kg in male Dawley rats,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL876733,8037
,50588,N,1,,,,14346,,Area under the curve was determined after intravenous administration of 4.9 mg/kg in male Beagle dogs,1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL618460,8038
,50597,N,1,,,,14346,,Area under the curve was determined after intravenous administration of 5.1 mg/kg in male Dawley rats,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL618461,8039
,22224,U,0,,,,15469,,Area under the curve was determined after oral administration (300 uM/Kg),1,,Autocuration,,,,,,,A,BAO_0000019,CHEMBL618462,8040
,50597,N,1,,,,14346,,Area under the curve was determined after peroral administration of 5.0 mg/kg in male Dawley rats,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL618463,8041
,50597,N,1,,,,14346,,Area under the curve was determined after peroral administration of 5.1 mg/kg in mal Dawley rats,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL618464,8042
,50597,N,1,,,,14346,,Area under the curve was determined after peroral administration of 5.1 mg/kg in male Dawley rats,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL618465,8043
,50597,N,1,,,,14346,,Area under the curve was determined after peroral administration of 5.2 mg/kg in mal Dawley rats,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL618466,8044
,50597,N,1,,,,14346,,Area under the curve was determined after peroral administration of 5.2 mg/kg in male Dawley rats,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL618467,8045
,50597,N,1,,,,15372,,Area under the curve was determined for the compound after iv dose of 4.97 mg/kg in rats,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL618468,8046
Plasma,50588,N,1,,,,12935,,Area under the plasma concentration was determined in fasted Beagle dogs after peroral administration of 100 mg/kg,1,Canis lupus familiaris,Intermediate,,,,9615.0,,1969.0,A,BAO_0000218,CHEMBL618469,8047
Plasma,50588,N,1,,,,12935,,Area under the plasma concentration was determined in fasted Beagle dogs after peroral administration of 20 mg/kg,1,Canis lupus familiaris,Intermediate,,,,9615.0,,1969.0,A,BAO_0000218,CHEMBL618470,8048
,22224,U,0,,,,14813,,Plasma drug AUC in rat (PO dose),1,,Autocuration,,,,,,,A,BAO_0000218,CHEMBL618471,8049
,50594,N,1,,,,15792,,Area under the tumor growth curve (AUC) in the B-6 Melanoma Model in C57/b1 mice at the dose of 1 mg/kg.,1,Mus musculus,Intermediate,,,,10090.0,,,A,BAO_0000218,CHEMBL618472,8050
,22224,U,0,,,,3579,,Area under was determined at a dose of 30 mg/kg,1,,Autocuration,,,,,,,A,BAO_0000218,CHEMBL618473,8051
,50506,N,1,,,,12487,,Average area under curve for compound at 1 mg/kg dose intravenous administration to Ferret,1,Mustela putorius furo,Intermediate,,,,9669.0,,,A,BAO_0000218,CHEMBL621699,8052
,50597,N,1,,,,12487,,Average area under curve for the compound at 10 mg/kg dose after intraduodenal administration to rat,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL621700,8053
,50597,N,1,,,,12487,,Average area under curve for the compound at 1 mg/kg dose after intravenous administration to rat,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL621701,8054
,50506,N,1,,,,12487,,Average area under curve at 10 mg/kg dose after intraduodenal administration to Ferret,1,Mustela putorius furo,Intermediate,,,,9669.0,,,A,BAO_0000218,CHEMBL621702,8055
,50588,N,1,,,,12487,,Average area under curve at 10 mg/kg intraduodenal administration to salt depleted dog,1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL621703,8056
,50588,N,1,,,,12487,,Average area under curve at 1 mg/kg intravenous administration to salt depleted dog,1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL621704,8057
,50597,N,1,,,,12902,,"Bioavailability in male Sprague-Dawley rats, after the iv administration at a dose of 1.0(pmol/g/h)",1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL624259,8058
,50597,N,1,,,,12902,,"Bioavailability in male Sprague-Dawley rats, after the iv administration at a dose of 2.0(pmol/g/h)",1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL624260,8059
,50597,N,1,,,,12902,,"Bioavailability in male Sprague-Dawley rats, after the iv administration at a dose of 4.0(pmol/g/h)",1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL624430,8060
,50597,N,1,,,,12902,,"Bioavailability in male Sprague-Dawley rats, after the iv administration at a dose of 5.0(pmol/g/h)",1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL624431,8061
,50597,N,1,,,,12902,,"Bioavailability in male Sprague-Dawley rats, after the iv administration at a dose of 54.0(pmol/g/h)",1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL624432,8062
,50597,N,1,,,,12902,,"Bioavailability in male Sprague-Dawley rats, after the po administration at a dose of 10.0(pmol/g/h)",1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL624433,8063
,50597,N,1,,,,12902,,"Bioavailability in male Sprague-Dawley rats, after the po administration at a dose of 20.0(pmol/g/h)",1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL624434,8064
,50597,N,1,,,,12902,,"Bioavailability in male Sprague-Dawley rats, after the po administration at a dose of 40.0(pmol/g/h)",1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL624435,8065
,50594,N,1,,,,12745,,Bioavailability in mouse brain after intravenous administration of 105.1 mg/kg of dose,1,Mus musculus,Intermediate,,,,10090.0,,,A,BAO_0000218,CHEMBL618570,8066
,50594,N,1,,,,12745,,Bioavailability in mouse brain after intravenous administration of equimolar doses of ( 2'F-ara-ddI + 2'F-ara-ddP),1,Mus musculus,Intermediate,,,,10090.0,,,A,BAO_0000218,CHEMBL618571,8067
,50594,N,1,,,,12745,,Bioavailability in mouse brain after oral administration of 100 mg/kg of dose,1,Mus musculus,Intermediate,,,,10090.0,,,A,BAO_0000218,CHEMBL618572,8068
,50594,N,1,,,,12745,,Bioavailability in mouse brain after oral administration of equimolar doses of ( 2'F-ara-ddI + 2'F-ara-ddP),1,Mus musculus,Intermediate,,,,10090.0,,,A,BAO_0000218,CHEMBL618573,8069
,50594,N,1,,,,12745,,Bioavailability in mouse serum after intravenous administration of 105.1 mg/kg of dose,1,Mus musculus,Intermediate,,,,10090.0,,,A,BAO_0000218,CHEMBL619267,8070
,50594,N,1,,,,12745,,Bioavailability in mouse serum after intravenous administration of equimolar doses of ( 2'F-ara-ddI + 2'F-ara-ddP),1,Mus musculus,Intermediate,,,,10090.0,,,A,BAO_0000218,CHEMBL619431,8071
,50594,N,1,,,,12745,,Bioavailability in mouse serum after oral administration of 100 mg/kg of dose,1,Mus musculus,Intermediate,,,,10090.0,,,A,BAO_0000218,CHEMBL619432,8072
,50594,N,1,,,,12745,,Bioavailability in mouse serum after oral administration of equimolar doses of ( 2'F-ara-ddI + 2'F-ara-ddP),1,Mus musculus,Intermediate,,,,10090.0,,,A,BAO_0000218,CHEMBL619433,8073
Plasma,22224,U,0,,,,13298,,AUC in mice after oral dose (50 mg/kg),1,,Autocuration,,,,,,1969.0,A,BAO_0000218,CHEMBL619434,8074
Serum,50594,N,1,,,,12226,,Blood level after oral administration in mice (50 mg/kg) was determined by bioassay procedure and represent total activity present in the serum,1,Mus musculus,Intermediate,,,,10090.0,,1977.0,A,BAO_0000218,CHEMBL619435,8075
Plasma,22224,U,0,,,,12634,,AUC (0-4 hr) ug/ml/h,1,,Autocuration,,,,,,1969.0,A,BAO_0000019,CHEMBL619436,8076
,50597,N,1,,,,14810,,Compound at a dose of 10 mg/kg was orally administered to rats and Area under curve was reported,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL619437,8077
,22224,U,0,,,,13889,,Compound evaluated for AUC = Area under the nucleoside serum or brain concentration versus time curve after iv administration,1,,Autocuration,,,,,,,A,BAO_0000218,CHEMBL619438,8078
,50594,N,1,,,,10018,,Compound was evaluated for Area under curve in mice,1,Mus musculus,Intermediate,,,,10090.0,,,A,BAO_0000218,CHEMBL619439,8079
,50597,N,1,,,,8758,,Compound was evaluated for area under curve doses in rat at 100 mg/kg po,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL619440,8080
,22224,U,0,,,,8758,,Compound was evaluated for area under curve doses in rat at 100 mg/kg po,1,,Autocuration,,,,,,,F,BAO_0000218,CHEMBL619441,8081
,50597,N,1,,,,8758,,Compound was evaluated for area under curve doses in rat at 50 mg/kg po,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL619442,8082
,22224,U,0,,,,2249,,Compound was evaluated for area under curve of growth hormone release after chronic oral dosing at 0.5 mpk on day 1,1,,Autocuration,,,,,,,A,BAO_0000019,CHEMBL875156,8083
,22224,U,0,,,,2249,,Compound was evaluated for area under curve of growth hormone release after chronic oral dosing at 0.5 mpk on day 4,1,,Autocuration,,,,,,,A,BAO_0000019,CHEMBL619443,8084
,22224,U,0,,,,2249,,Compound was evaluated for area under curve of growth hormone release after chronic oral dosing at 1.0 mpk on day 1,1,,Autocuration,,,,,,,A,BAO_0000019,CHEMBL619444,8085
,22224,U,0,,,,2249,,Compound was evaluated for area under curve of growth hormone release after chronic oral dosing at 1.0 mpk on day 4,1,,Autocuration,,,,,,,A,BAO_0000019,CHEMBL623464,8086
,50594,N,1,,,,15115,,Compound was evaluated for area under curve when administered through oral route in mouse,1,Mus musculus,Intermediate,,,,10090.0,,,A,BAO_0000218,CHEMBL623465,8087
,50597,N,1,In vivo,,,6518,,Plasma clearance after oral administration at a dose of 2 mg/kg in rat; no data,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL623466,8088
,50597,N,1,In vivo,,,6518,,Plasma clearance after oral administration at a dose of 4 mg/kg in rat; no data,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL623467,8089
,50597,N,1,In vivo,,,6249,,Plasma clearance in rat,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL623468,8090
,50597,N,1,In vivo,,,2463,,Plasma clearance was evaluated in vivo in rat at a dose of 5 mg/kg by intra venous administration,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL622660,8091
,50597,N,1,In vivo,,,4969,,Plasma clearance rate in Sprague-Dawley rats,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL622661,8092
,50597,N,1,In vivo,,,17720,,CLtot at a dose of 4 mg/kg in Rat Plasma after iv administration,1,Rattus norvegicus,Intermediate,,,,10116.0,,,F,BAO_0000218,CHEMBL622662,8093
,50597,N,1,In vivo,,,3457,,Pharmacokinetic property (total body clearance) in rat,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL622663,8094
,50597,N,1,In vivo,,,5983,,Pharmacokinetic property (CLtot)of the compound was measured in rat at the dose of 0.32 mg/kg i.v.,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL622664,8095
,50597,N,1,,,,6295,,In vivo concentration in rat liver exposure 0-8 hour after oral administration 50 mg/kg,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL622665,8096
,50597,N,1,,,,6296,,In vivo concentration in rat liver exposure 0-8 hour after oral administration 50 mg/kg,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL622666,8097
,50597,N,1,In vivo,,,17686,,Cl in rat i.v. at 2 mg/kg concentration,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL621615,8098
,50597,N,1,In vivo,,,17764,,Clearance of compound after intravenous administration in rats at 24 uM/kg,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL621616,8099
,50597,N,1,In vivo,,,5503,,Clearance was determined,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL621617,8100
,50597,N,1,In vivo,,,4368,,Clearance by intravenous administration of 3.4 mg/kg in rat,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL621618,8101
,50597,N,1,In vivo,,,6005,,Clearance was evaluated after i.v. administration in rat at a dose of 1 mg/kg,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL621619,8102
,50597,N,1,In vivo,,,5031,,Clearance rate after i.v. administration in rats,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL621620,8103
,50597,N,1,In vivo,,,4890,,Clearance was determined after intravenous administration at a dose 5 mg/kg to male Sprague-Dawley rats,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL621786,8104
,50597,N,1,In vivo,,,5182,,Clearance was determined by administering the compound intravenously at a dose of 1 mg/kg in male wistar rat,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL621787,8105
,50597,N,1,In vivo,,,5979,,Clearance (Cl) of compound after 2 h iv infusion of 8.4 mg/kg in three rat,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL621788,8106
,50597,N,1,In vivo,,,5656,,Clearance (Cl) after oral administration in rat,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL621789,8107
,50597,N,1,In vivo,,,17804,,Compound clearance in rats was measured after intravenous administration at 3 mg/kg,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL621790,8108
Plasma,50597,N,1,In vivo,,,4839,,Compound was tested for plasma clearance in rat,1,Rattus norvegicus,Intermediate,,,,10116.0,,1969.0,A,BAO_0000218,CHEMBL621791,8109
,50597,N,1,In vitro,,Microsomes,5041,,In vitro microsome metabolism clearance in rat was determined,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL621792,8110
,50597,N,1,In vitro,,Microsomes,5041,,In vitro microsome metabolism clearance in rat was determined; ND denotes no data,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL621793,8111
,50597,N,1,In vivo,,,5974,,In vivo Clearance (Cl) was determined after intravenous administration of compound (9.13+/-0.85 mg/kg) in male Sprague-Dawley rat,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL621794,8112
Plasma,50597,N,1,In vivo,,,5496,,In vivo plasma clearance was determined,1,Rattus norvegicus,Intermediate,,,,10116.0,,1969.0,A,BAO_0000218,CHEMBL621795,8113
,50597,N,1,In vivo,,,5739,,Pharmacokinetic property (Clearance) for the compound (5 mg/kg iv) was determined in rats,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL621796,8114
Liver,50597,N,1,In vivo,,,5676,,Pharmacokinetic property (Clearance) in rat hepatocyte i.v.,1,Rattus norvegicus,Intermediate,,401.0,,10116.0,Hepatocyte,2107.0,A,BAO_0000218,CHEMBL621797,8115
,50597,N,1,In vivo,,,4239,,Pharmacokinetic property (Plasma clearance) was measured in rat,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL621798,8116
,50597,N,1,In vivo,,,5676,,Pharmacokinetic property (clearance) in rat i.v.,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL621799,8117
,50597,N,1,In vivo,,,1918,,"Plasma Clearance was evaluated in rats, iv",1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL621800,8118
,50597,N,1,In vivo,,,17800,,Plasma clearance (in vivo) in rats was determined,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL621801,8119
,50597,N,1,In vivo,,,6056,,Plasma clearance for the compound was calculated at a single intravenous administration of 20 mg/kg in rat,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL621802,8120
,50597,N,1,In vivo,,,5496,,Plasma clearance was determined,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL618596,8121
,50597,N,1,In vivo,,,5939,,Plasma clearance in rat after peroral administration at 10 mg/kg concentration,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL618597,8122
,50597,N,1,In vivo,,,5939,,Plasma clearance in rat after peroral administration at 5 mg/kg concentration,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL618598,8123
,50597,N,1,In vivo,,,17752,,Plasma clearance in rats,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL618599,8124
,50597,N,1,In vivo,,,4576,,Plasma clearance rate determined in rat,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL618600,8125
,50597,N,1,In vivo,,,6011,,Plasma clearance was determined in rat,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL618601,8126
,50597,N,1,In vivo,,,5510,,Plasma clearance was determined,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL618602,8127
,50597,N,1,In vivo,,,5948,,Plasma clearance value in rat,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL618603,8128
Liver,50597,N,1,Ex vivo,,,6125,,Clearance rate constant using isolated perfused rat liver (IPRL) assay,1,Rattus norvegicus,Intermediate,,,,10116.0,,2107.0,A,BAO_0000218,CHEMBL618604,8129
,50597,N,1,In vivo,,,4839,,Clearance in rat,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL618605,8130
,50597,N,1,In vivo,,,17686,,Total body clearance in rat i.v. at 2 mg/kg concentration,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL618606,8131
,50597,N,1,In vivo,,,6571,,Clearance of compound in rats after intravenous administration,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL618607,8132
,50597,N,1,In vivo,,,3364,,Clearance after iv administration to rats,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL618608,8133
,50597,N,1,In vivo,,,13569,,Clearance at an iv dose of 12 mg/Kg and po dose of 23 mg/Kg,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL618609,8134
,50597,N,1,In vivo,,,13569,,Clearance at an iv dose of 14 mg/Kg and po dose of 15 mg/Kg,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL618610,8135
,50597,N,1,In vivo,,,13569,,Clearance at an iv dose of 15 mg/Kg and po dose of 30 mg/Kg,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL618611,8136
,50597,N,1,In vivo,,,13569,,Clearance at an iv dose of 15 mg/Kg and po dose of 30.2 mg/Kg,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL618612,8137
,50597,N,1,In vivo,,,13569,,Clearance at an iv dose of 15.6 mg/Kg and po dose of 31.2 mg/Kg,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL618613,8138
,50597,N,1,In vivo,,,13569,,Clearance at an iv dose of 15.7 mg/Kg and po dose of 31.4 mg/Kg,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL621076,8139
,50597,N,1,In vivo,,,13569,,Clearance at an iv dose of 16 mg/Kg and po dose of 35 mg/Kg,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL621077,8140
,50597,N,1,In vivo,,,17670,,"Clearance in fischer rats at 5 mg/kg dose, administered intravenously",1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL621078,8141
,50597,N,1,In vivo,,,5970,,Clearance in rat,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL621251,8142
,50597,N,1,In vivo,,,6495,,Clearance in rat after oral administration at 10 mg/kg,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL621252,8143
,50597,N,1,In vivo,,,4590,,Clearance in rat.,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL621253,8144
,50597,N,1,In vivo,,,6193,,Clearance rate following an oral dose of 20 mg/kg in rats,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL621254,8145
,50597,N,1,In vivo,,,2832,,Compound was evaluated for the rate of clearance in rat upon intravenous administration.,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL621255,8146
Plasma,50597,N,1,In vivo,,,1052,,Compound was tested for plasma clearance in rats after 5 mg/kg of intravenous dosing,1,Rattus norvegicus,Intermediate,,,,10116.0,,1969.0,A,BAO_0000218,CHEMBL621256,8147
Liver,50597,N,1,In vivo,,,9866,,Biodistribution in rat liver in the presence of GdDTPA-BDP at 1 hr,1,Rattus norvegicus,Intermediate,,,,10116.0,,2107.0,A,BAO_0000218,CHEMBL621257,8148
Liver,50597,N,1,In vivo,,,9866,,Biodistribution in rat liver in the presence of GdDTPA-BDP at 30 min,1,Rattus norvegicus,Intermediate,,,,10116.0,,2107.0,A,BAO_0000218,CHEMBL621258,8149
Liver,50597,N,1,In vivo,,,9866,,Biodistribution in rat liver in the presence of GdDTPA-BDP at 4 hr,1,Rattus norvegicus,Intermediate,,,,10116.0,,2107.0,A,BAO_0000218,CHEMBL621259,8150
Liver,50597,N,1,In vivo,,,9866,,Biodistribution in rat liver in the presence of GdDTPA-HPDP at 15 min,1,Rattus norvegicus,Intermediate,,,,10116.0,,2107.0,A,BAO_0000218,CHEMBL621260,8151
Liver,50597,N,1,In vivo,,,9866,,Biodistribution in rat liver in the presence of GdDTPA-HPDP at 1 hr,1,Rattus norvegicus,Intermediate,,,,10116.0,,2107.0,A,BAO_0000218,CHEMBL876494,8152
Liver,50597,N,1,In vivo,,,9866,,Biodistribution in rat liver in the presence of GdDTPA-HPDP at 30 min,1,Rattus norvegicus,Intermediate,,,,10116.0,,2107.0,A,BAO_0000218,CHEMBL621261,8153
Liver,50597,N,1,In vivo,,,9866,,Biodistribution in rat liver in the presence of GdDTPA-HPDP at 4 hr,1,Rattus norvegicus,Intermediate,,,,10116.0,,2107.0,A,BAO_0000218,CHEMBL621262,8154
Liver,50597,N,1,In vivo,,,9866,,Biodistribution in rat liver in the presence of NAC Gd/0.01 M GdDTPA-HPDP,1,Rattus norvegicus,Intermediate,,,,10116.0,,2107.0,A,BAO_0000218,CHEMBL621263,8155
Liver,50597,N,1,In vivo,,,9866,,Biodistribution in rat liver in the presence of NCA Gd/0.01 M lip,1,Rattus norvegicus,Intermediate,,,,10116.0,,2107.0,A,BAO_0000218,CHEMBL621264,8156
Muscle tissue,50597,N,1,In vivo,,,9866,,Biodistribution in rat muscle in the presence of 0.01 M GdDTPA-BDP,1,Rattus norvegicus,Intermediate,,,,10116.0,,2385.0,A,BAO_0000218,CHEMBL621265,8157
Muscle tissue,50597,N,1,In vivo,,,9866,,Biodistribution in rat muscle in the presence of 0.05 M Gd/0.15 M lig,1,Rattus norvegicus,Intermediate,,,,10116.0,,2385.0,A,BAO_0000218,CHEMBL621266,8158
Muscle tissue,50597,N,1,In vivo,,,9866,,Biodistribution in rat muscle in the presence of 0.05 M GdDTPA-BDP,1,Rattus norvegicus,Intermediate,,,,10116.0,,2385.0,A,BAO_0000218,CHEMBL621267,8159
Muscle tissue,50597,N,1,In vivo,,,9866,,Biodistribution in rat muscle in the presence of 0.10 M GdDTPA-BDP,1,Rattus norvegicus,Intermediate,,,,10116.0,,2385.0,A,BAO_0000218,CHEMBL621268,8160
Muscle tissue,50597,N,1,In vivo,,,9866,,Biodistribution in rat muscle in the presence of GdDTPA-BDP at 1 hr,1,Rattus norvegicus,Intermediate,,,,10116.0,,2385.0,A,BAO_0000218,CHEMBL621269,8161
Muscle tissue,50597,N,1,In vivo,,,9866,,Biodistribution in rat muscle in the presence of GdDTPA-BDP at 4 hr,1,Rattus norvegicus,Intermediate,,,,10116.0,,2385.0,A,BAO_0000218,CHEMBL621270,8162
Muscle tissue,50597,N,1,In vivo,,,9866,,Biodistribution in rat muscle in the presence of GdDTPA-BDPat 15 min,1,Rattus norvegicus,Intermediate,,,,10116.0,,2385.0,A,BAO_0000218,CHEMBL621271,8163
Muscle tissue,50597,N,1,In vivo,,,9866,,Biodistribution in rat muscle in the presence of GdDTPA-BDPat 30 min,1,Rattus norvegicus,Intermediate,,,,10116.0,,2385.0,A,BAO_0000218,CHEMBL621272,8164
Muscle tissue,50597,N,1,In vivo,,,9866,,Biodistribution in rat muscle in the presence of GdDTPA-HPDP at 1 hr,1,Rattus norvegicus,Intermediate,,,,10116.0,,2385.0,A,BAO_0000218,CHEMBL621273,8165
Muscle tissue,50597,N,1,In vivo,,,9866,,Biodistribution in rat muscle in the presence of GdDTPA-HPDP at 4 hr,1,Rattus norvegicus,Intermediate,,,,10116.0,,2385.0,A,BAO_0000218,CHEMBL621274,8166
Muscle tissue,50597,N,1,In vivo,,,9866,,Biodistribution in rat muscle in the presence of GdDTPA-HPDPat 15 min,1,Rattus norvegicus,Intermediate,,,,10116.0,,2385.0,A,BAO_0000218,CHEMBL876495,8167
Muscle tissue,50597,N,1,In vivo,,,9866,,Biodistribution in rat muscle in the presence of GdDTPA-HPDPat 30 min,1,Rattus norvegicus,Intermediate,,,,10116.0,,2385.0,A,BAO_0000218,CHEMBL621275,8168
Muscle tissue,50597,N,1,In vivo,,,9866,,Biodistribution in rat muscle in the presence of NCA Gd/0.01 M lip,1,Rattus norvegicus,Intermediate,,,,10116.0,,2385.0,A,BAO_0000218,CHEMBL621276,8169
Muscle tissue,50597,N,1,In vivo,,,9866,,Biodistribution in rat muscle in the presence of NCAGd/0.01 M lig,1,Rattus norvegicus,Intermediate,,,,10116.0,,2385.0,A,BAO_0000218,CHEMBL621277,8170
Intestine,50597,N,1,In vivo,,,9866,,Biodistribution in rat s. intestine in the presence of 50 Gd/kg at 2 hr,1,Rattus norvegicus,Intermediate,,,,10116.0,,160.0,A,BAO_0000218,CHEMBL621278,8171
Intestine,50597,N,1,In vivo,,,9866,,Biodistribution in rat s. intestine in the presence of 50 Gd/kg at 6 hr,1,Rattus norvegicus,Intermediate,,,,10116.0,,160.0,A,BAO_0000218,CHEMBL621279,8172
Intestine,50597,N,1,In vivo,,,9866,,Biodistribution in rat s. intestine in the presence of NCA (No carrier added),1,Rattus norvegicus,Intermediate,,,,10116.0,,160.0,A,BAO_0000218,CHEMBL621280,8173
Spleen,50597,N,1,In vivo,,,9866,,Biodistribution in rat spleen in the presence of 0.01 M GdDTPA-BDP,1,Rattus norvegicus,Intermediate,,,,10116.0,,2106.0,A,BAO_0000218,CHEMBL621281,8174
Spleen,50597,N,1,In vivo,,,9866,,Biodistribution in rat spleen in the presence of 0.05 M Gd/0.15 M lig; ND=No data,1,Rattus norvegicus,Intermediate,,,,10116.0,,2106.0,A,BAO_0000218,CHEMBL621282,8175
Spleen,50597,N,1,In vivo,,,9866,,Biodistribution in rat spleen in the presence of 0.05 M GdDTPA-BDP; ND=No data,1,Rattus norvegicus,Intermediate,,,,10116.0,,2106.0,A,BAO_0000218,CHEMBL621283,8176
Spleen,50597,N,1,In vivo,,,9866,,Biodistribution in rat spleen in the presence of 0.10 M GdDTPA-BDP,1,Rattus norvegicus,Intermediate,,,,10116.0,,2106.0,A,BAO_0000218,CHEMBL621284,8177
Spleen,50597,N,1,In vivo,,,9866,,Biodistribution in rat spleen in the presence of 50 Gd/kg at 15 min,1,Rattus norvegicus,Intermediate,,,,10116.0,,2106.0,A,BAO_0000218,CHEMBL621285,8178
Spleen,50597,N,1,In vivo,,,9866,,Biodistribution in rat spleen in the presence of 50 Gd/kg at 2 hr,1,Rattus norvegicus,Intermediate,,,,10116.0,,2106.0,A,BAO_0000218,CHEMBL621286,8179
Spleen,50597,N,1,In vivo,,,9866,,Biodistribution in rat spleen in the presence of 50 Gd/kg at 6 hr,1,Rattus norvegicus,Intermediate,,,,10116.0,,2106.0,A,BAO_0000218,CHEMBL623220,8180
Spleen,50597,N,1,In vivo,,,9866,,Biodistribution in rat spleen in the presence of NCA Gd/0.01 M lip,1,Rattus norvegicus,Intermediate,,,,10116.0,,2106.0,A,BAO_0000218,CHEMBL623221,8181
Spleen,50597,N,1,In vivo,,,9866,,Biodistribution in rat spleen in the presence of NCAGd/0.01 M lig,1,Rattus norvegicus,Intermediate,,,,10116.0,,2106.0,A,BAO_0000218,CHEMBL876029,8182
Stomach,50597,N,1,In vivo,,,9866,,Biodistribution in rat stomach in the presence of 50 Gd/kg at 15 min,1,Rattus norvegicus,Intermediate,,,,10116.0,,945.0,A,BAO_0000218,CHEMBL623222,8183
Stomach,50597,N,1,In vivo,,,9866,,Biodistribution in rat stomach in the presence of 50 Gd/kg at 2 hr,1,Rattus norvegicus,Intermediate,,,,10116.0,,945.0,A,BAO_0000218,CHEMBL623223,8184
Stomach,50597,N,1,In vivo,,,9866,,Biodistribution in rat stomach in the presence of 50 Gd/kg at 6 h; ND=No data,1,Rattus norvegicus,Intermediate,,,,10116.0,,945.0,A,BAO_0000218,CHEMBL621445,8185
Blood,50597,N,1,In vivo,,,13950,,Biodistribution of [123I]-label in rat blood was reported at 0.33 hr post injection. Value shown is %ID/g of tissue,1,Rattus norvegicus,Intermediate,,,,10116.0,,178.0,A,BAO_0000218,CHEMBL621446,8186
Blood,50597,N,1,In vivo,,,13950,,Biodistribution of [123I]-label in rat blood was reported at 1 hr post injection. Value shown is %ID/g of tissue,1,Rattus norvegicus,Intermediate,,,,10116.0,,178.0,A,BAO_0000218,CHEMBL621447,8187
Blood,50597,N,1,In vivo,,,13950,,Biodistribution of [123I]-label in rat blood was reported at 2 hr post injection. Value shown is %ID/g of tissue,1,Rattus norvegicus,Intermediate,,,,10116.0,,178.0,A,BAO_0000218,CHEMBL619681,8188
Blood,50597,N,1,In vivo,,,13950,,Biodistribution of [123I]-label in rat blood was reported at 24 hr post injection. Value shown is %ID/g of tissue,1,Rattus norvegicus,Intermediate,,,,10116.0,,178.0,A,BAO_0000218,CHEMBL619682,8189
Blood,50597,N,1,In vivo,,,13950,,Biodistribution of [123I]-label in rat blood was reported at 4 hr post injection. Value shown is %ID/g of tissue,1,Rattus norvegicus,Intermediate,,,,10116.0,,178.0,A,BAO_0000218,CHEMBL619683,8190
Brain,50597,N,1,In vivo,,,13950,,Biodistribution of [123I]-label in rat brain was reported at 0.33 hr post injection. Value shown is %ID/g of tissue,1,Rattus norvegicus,Intermediate,,,,10116.0,,955.0,A,BAO_0000218,CHEMBL619684,8191
Brain,50597,N,1,In vivo,,,13950,,Biodistribution of [123I]-label in rat brain was reported at 1 hr post injection. Value shown is %ID/g of tissue,1,Rattus norvegicus,Intermediate,,,,10116.0,,955.0,A,BAO_0000218,CHEMBL619685,8192
Brain,50597,N,1,In vivo,,,13950,,Biodistribution of [123I]-label in rat brain was reported at 2 hr post injection. Value shown is %ID/g of tissue,1,Rattus norvegicus,Intermediate,,,,10116.0,,955.0,A,BAO_0000218,CHEMBL619686,8193
Brain,50597,N,1,In vivo,,,13950,,Biodistribution of [123I]-label in rat brain was reported at 24 hr post injection. Value shown is %ID/g of tissue,1,Rattus norvegicus,Intermediate,,,,10116.0,,955.0,A,BAO_0000218,CHEMBL619687,8194
Brain,50597,N,1,In vivo,,,13950,,Biodistribution of [123I]-label in rat brain was reported at 4 hr post injection. Value shown is %ID/g of tissue,1,Rattus norvegicus,Intermediate,,,,10116.0,,955.0,A,BAO_0000218,CHEMBL619688,8195
Heart,50597,N,1,In vivo,,,13950,,Biodistribution of [123I]-label in rat heart was reported at 0.33 hr post injection. Value shown is %ID/g of tissue,1,Rattus norvegicus,Intermediate,,,,10116.0,,948.0,A,BAO_0000218,CHEMBL619689,8196
Heart,50597,N,1,In vivo,,,13950,,Biodistribution of [123I]-label in rat heart was reported at 1 hr post injection. Value shown is %ID/g of tissue,1,Rattus norvegicus,Intermediate,,,,10116.0,,948.0,A,BAO_0000218,CHEMBL619690,8197
Heart,50597,N,1,In vivo,,,13950,,Biodistribution of [123I]-label in rat heart was reported at 2 hr post injection. Value shown is %ID/g of tissue,1,Rattus norvegicus,Intermediate,,,,10116.0,,948.0,A,BAO_0000218,CHEMBL619691,8198
,50597,N,1,In vivo,,,6062,,Terminal phase volume of distribution was measured in rat after an iv dose of 1 mg/kg,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL619692,8199
,50597,N,1,,,,3598,,Apparent volume of the central plasma compartment (Vc) of compound determined in rat after iv administration at a dose of 10 mg/kg,1,Rattus norvegicus,Expert,,,,10116.0,,,A,BAO_0000218,CHEMBL619693,8200
,50597,N,1,In vivo,,,1908,,Vc value after IV dose at a dose of 5 mg/kg in rats.,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL619694,8201
,50597,N,1,In vivo,,,17596,,Apparent volume of distribution at 10 mg/kg in rat upon intravenous administration,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL619695,8202
,50597,N,1,In vivo,,,4891,,Compound was evaluated for pharmacokinetic parameter volume of distribution,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL619696,8203
,50597,N,1,In vivo,,,740,,Compound was evaluated for volume of distribution in rat,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL619697,8204
,50597,N,1,In vivo,,,16366,,Steady state volume distribution was determined; steady state(ss),1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL619698,8205
,50597,N,1,In vivo,,,3364,,Steady state volume of distribution after iv administration to rats,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL619699,8206
,50597,N,1,In vivo,,,2552,,Steady state volume of distribution dosing at 3 mg/kg iv,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL619700,8207
,50597,N,1,In vivo,,,406,,The compound was evaluated for volume of distribution in rat,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL619701,8208
,50597,N,1,In vivo,,,12500,,The compound was tested for volume of distribution in rat,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL619702,8209
,50597,N,1,In vivo,,,12500,,The compound was tested for volume of distribution in rat at dose of 3-10 mgkg,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL620335,8210
,50597,N,1,In vivo,,,5656,,Volume distribution (VD) after oral administration in rat,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL620336,8211
,50597,N,1,In vivo,,,17671,,Volume distribution of compound in male Sprague-Dawley rats following an intravenous bolus dose at 10-20 mg/kg,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL620337,8212
,50597,N,1,In vivo,,,1094,,Volume distribution in rat,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL620520,8213
,50597,N,1,In vivo,,,5833,,Volume distribution in rat,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL620521,8214
,50597,N,1,In vivo,,,5939,,Volume distribution in rat after peroral administration at 10 mg/kg,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL875825,8215
,50597,N,1,In vivo,,,5939,,Volume distribution in rat after peroral administration at 5 mg/kg,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL620522,8216
,50597,N,1,In vivo,,,6005,,Volume distribution was evaluated after i.v. administration in rat at a dose of 1 mg/kg,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL620523,8217
,50597,N,1,In vivo,,,1696,,Volume of distribution in rat.,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL620524,8218
,50597,N,1,In vivo,,,6672,,Volume of distribution in rat,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL620525,8219
,50597,N,1,In vivo,,,6673,,Volume of distribution in rat,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL620526,8220
,50597,N,1,In vivo,,,5871,,Volume of distribution in rat by iv administration,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL620527,8221
,50597,N,1,In vivo,,,6803,,Volume of distribution in rats,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL620528,8222
,50597,N,1,In vivo,,,5199,,Volume of distribution was determined in female Sprague-Dawley rats following intravenous (iv) administration of drug (1 mg/kg).,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL620529,8223
,50597,N,1,,,,4727,,Volume distribution at the dose of 2 mg/kg in rat,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL620530,8224
,50597,N,1,In vivo,,,16367,,Steady state volume of distribution was determined,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL620531,8225
,22224,U,0,In vivo,,,5005,,Compound was tested for its plasma volume distribution in rhesus monkey at a dose of 0.75 mg/kg iv/ 1.5 mg/kg po,1,Macaca mulatta,Intermediate,,,,9544.0,,,A,BAO_0000218,CHEMBL620532,8226
,22224,U,0,In vivo,,,5005,,Compound was tested for its plasma volume distribution in Sprague Dawley rats,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL620533,8227
,22224,U,0,In vivo,,,5005,,Compound was tested for its plasma volume distribution in Sprague Dawley rats; ND is not determined,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL620534,8228
,50597,N,1,In vivo,,,15765,,Mean (%CV) PK parameters for Vdss(mL/kg).,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL620535,8229
,50597,N,1,In vivo,,,2792,,Pharmacokinetic parameter Vdss was determined at 2 mg/kg i.v. dose in rats,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL875826,8230
,50597,N,1,In vivo,,,2792,,Pharmacokinetic parameter Vdss was determined at 5 mg/kg i.v. dose in rats,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL620536,8231
,50597,N,1,In vivo,,,5334,,Pharmacokinetic parameter volume of distribution was reported after intravenous administration at a dose of 1 mg/kg in Sprague-Dawley rat,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL620537,8232
,50597,N,1,In vivo,,,5334,,Pharmacokinetic parameter volume of distribution was reported in Sprague-Dawley rat; ND=Not determined,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL618526,8233
,50597,N,1,In vivo,,,5739,,Pharmacokinetic property (Vdss) for the compound (5 mg/kg iv) was determined in rats,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL618527,8234
,50597,N,1,In vivo,,,5789,,Pharmacokinetic property (Vdss) in rat,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL618528,8235
,50597,N,1,In vivo,,,4239,,Pharmacokinetic property (vdss) was measured in rat,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL618529,8236
,50597,N,1,In vivo,,,4709,,Steady state volume of distribution for the compound after intravenous administration of 1 mg/kg in rat,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL618530,8237
,50597,N,1,In vivo,,,6642,,Volume of distribution in rat,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL618531,8238
,50597,N,1,In vivo,,,5247,,The pharmacokinetic parameter volume of distribution in vivo in rats,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL618532,8239
,50597,N,1,In vivo,,,17720,,Vdss at a dose of 4 mg/kg in Rat Plasma after iv administration,1,Rattus norvegicus,Intermediate,,,,10116.0,,,F,BAO_0000218,CHEMBL618533,8240
,50597,N,1,In vivo,,,17686,,Vdss in rat i.v. at 2 mg/kg concentration,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL618534,8241
,50597,N,1,In vivo,,,4689,,Volume distribution after intravenous administration (1 mg/kg) in rat,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL618535,8242
,50597,N,1,In vivo,,,5654,,Volume distribution of compound was determined as average of four rats at each dose of 5 mg/kg intravenous and 16 mg/kg peroral administration,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL618536,8243
,50597,N,1,In vivo,,,5654,,Volume distribution of compound was determined as average of four rats at each dose of 5 mg/kg intravenous and 20 mg/kg peroral administration,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL618537,8244
,50597,N,1,In vivo,,,4527,,Volume distribution at a dose of 10 uM/kg in rat was determined,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL618538,8245
,50597,N,1,In vivo,,,4521,,Volume distribution in rat after 5 mg/kg by oral and 1 mg/kg by intravenous administration,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL618539,8246
,50597,N,1,In vivo,,,6057,,Volume distribution was calculated in rat,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL618540,8247
,50597,N,1,In vivo,,,5510,,Volume distribution was determined,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL618541,8248
,50597,N,1,In vivo,,,2938,,Volume of distribution after intravenous administration was evaluated in rat,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL618542,8249
,50597,N,1,In vivo,,,6679,,Volume of distribution at steady state was determined after 1 mg/kg (i.v.) / 2 mg/kg (p.o.) of compound administration,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL622544,8250
,50597,N,1,In vivo,,,6685,,"Volume of distribution at steady state was determined in rats at 10 mg/kg, p.o. dose; n/a: not applicable",1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL622545,8251
,50597,N,1,In vivo,,,6685,,"Volume of distribution at steady state was determined in rats at 20 mg/kg, i.p. dose; n/a: not applicable",1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL622546,8252
,50597,N,1,In vivo,,,6685,,"Volume of distribution at steady state was determined in rats at 2 mg/kg, i.v. dose",1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL622547,8253
,50597,N,1,In vivo,,,5145,,Volume of distribution in steady state was determined in rat,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL622548,8254
,50597,N,1,In vivo,,,6467,,Volume of distribution in steady state was determined in rats at the dose of 1.0 mpk by i.v. administration,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL622549,8255
,50597,N,1,In vivo,,,6467,,Volume of distribution in steady state was determined in rats at the dose of 1.0 mpk by i.v. administration; ND= not determined,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL622550,8256
,50594,N,1,,,,15115,,Compound was evaluated for area under curve when administered through oral route to mouse,1,Mus musculus,Intermediate,,,,10090.0,,,A,BAO_0000218,CHEMBL622551,8257
,50597,N,1,,,,8758,,Compound was evaluated for area under curve doses in rat at 100 mg/kg po,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL622552,8258
,50597,N,1,,,,8758,,Compound was evaluated for area under curve doses in rat at 50 mg/kg po,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL622553,8259
,22224,U,0,In vivo,,,8267,,Compound was evaluated for its bioavailability after oral administration (100 mg) to Beagle dogs,1,,Autocuration,,,,,,,F,BAO_0000218,CHEMBL622554,8260
,50588,N,1,,,,8267,,Compound was evaluated for its bioavailability after oral administration (200 mg) to Beagle dogs,1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL622555,8261
,50594,N,1,,,,14239,,Compound was evaluated for the area under the concentration - time curve by administering intravenously at 25 mg/kg in mice,1,Mus musculus,Intermediate,,,,10090.0,,,A,BAO_0000218,CHEMBL622556,8262
,50594,N,1,,,,14239,,Compound was evaluated for the area under the concentration - time curve by administering orally at 25 mg/kg in mice,1,Mus musculus,Intermediate,,,,10090.0,,,A,BAO_0000218,CHEMBL622557,8263
Blood,50594,N,1,,,,10754,,Compound was evaluated in vivo in blood samples from the orbital sinus for its concentration using Area under the time-concentration curve after 40 mg/kg intramuscular administration to mice,1,Mus musculus,Intermediate,,,,10090.0,,178.0,A,BAO_0000218,CHEMBL622558,8264
Blood,50594,N,1,,,,10754,,Compound was evaluated in vivo in blood samples from the orbital sinus for its concentration using Area under the time-concentration curve after 40 mg/kg peroral administration to mice,1,Mus musculus,Intermediate,,,,10090.0,,178.0,A,BAO_0000218,CHEMBL622559,8265
,50588,N,1,,,,10754,,Compound was evaluated in vivo in for its concentration using Area under the time-concentration curve after 40 mg/kg peroral administration to dogs.,1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL622560,8266
,50597,N,1,,,,14681,,Compound was tested for area under concentration -time curve from time 0 to time infinity in three male Wistar rats at a single 5 mg/kg oral gavage dose,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL622561,8267
,50597,N,1,,,,14681,,Compound was tested for area under concentration -time curve from time 0 to time infinity in three male Wistar rats at a single 5 mg/kg oral gavage dose. ,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL622562,8268
,50597,N,1,,,,14681,,Compound was tested for area under concentration -time curve from time 0 to time of last detectable concentration in three male Wistar rats at a single 5 mg/kg oral gavage dose,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL622563,8269
,22224,U,0,,,,13118,,Concentration of compound in Central nervous system,1,,Autocuration,,,,,,,A,BAO_0000019,CHEMBL622564,8270
,22224,U,0,,,,13118,,Concentration of compound in Central nervous system; Not detectable,1,,Autocuration,,,,,,,A,BAO_0000019,CHEMBL622565,8271
,50594,N,1,,,,13318,,"Concentration of diester in the blood, following oral administration in mice",1,Mus musculus,Intermediate,,,,10090.0,,,A,BAO_0000218,CHEMBL622566,8272
,50594,N,1,,,,13318,,"Concentration of monoester in the blood, following oral administration in mice",1,Mus musculus,Intermediate,,,,10090.0,,,A,BAO_0000218,CHEMBL624515,8273
,50594,N,1,,,,13318,,Concentration of the 9-[2-(Phosphonomethoxy)ethoxy]adenine in the blood following oral administration in mice,1,Mus musculus,Intermediate,,,,10090.0,,,A,BAO_0000218,CHEMBL624516,8274
,22224,U,0,,,,15692,,Evaluated for Pharmacokinetic property: Area under the curve,1,,Autocuration,,,,,,,A,BAO_0000019,CHEMBL624517,8275
,50594,N,1,,,,14839,,In vivo antitumor efficacy expressed as plasma area under the curve 0.4 hr after a peroral dose of 25 mg/kg in nude mice,1,Mus musculus,Intermediate,,,,10090.0,,,A,BAO_0000218,CHEMBL624518,8276
,100710,N,1,,,,14839,,In vivo antitumor efficacy expressed as plasma area under the curve 0.4 hr after iv dose of 25 mg/kg in nude mice,1,Macaca fascicularis,Intermediate,,,,9541.0,,,A,BAO_0000218,CHEMBL624519,8277
,100710,N,1,,,,14839,,In vivo antitumor efficacy in cynomolgus monkeys 0-48 hr after iv dose of 5 mg/kg expressed as Area under the curve,1,Macaca fascicularis,Intermediate,,,,9541.0,,,A,BAO_0000218,CHEMBL624520,8278
,100710,N,1,,,,14839,,In vivo antitumor efficacy in cynomolgus monkeys 0-48 hr after peroral dose of 10 mg/kg expressed as Area under the curve,1,Macaca fascicularis,Intermediate,,,,9541.0,,,A,BAO_0000218,CHEMBL624521,8279
,100710,N,1,,,,14839,,In vivo antitumor efficacy in cynomolgus monkeys 0-48 hr after peroral dose of 5 mg/kg expressed as Area under the curve,1,Macaca fascicularis,Intermediate,,,,9541.0,,,A,BAO_0000218,CHEMBL624522,8280
,100710,N,1,,,,14839,,In vivo antitumor efficacy in cynomolgus monkeys 0-8 hours after peroral dose of 25 mg/kg expressed as Area under the curve,1,Macaca fascicularis,Intermediate,,,,9541.0,,,A,BAO_0000218,CHEMBL624523,8281
,100710,N,1,,,,14839,,"In vivo antitumor efficacy in cynomolgus monkeys by injecting a dose of 10 mg/kg, as HCl salt in saline solution, perorally and the total drug exposure was determined (0-8 hr)",1,Macaca fascicularis,Intermediate,,,,9541.0,,,A,BAO_0000218,CHEMBL624409,8282
,100710,N,1,,,,14839,,"In vivo antitumor efficacy in cynomolgus monkeys by injecting a dose of 25 mg/kg, as HCl salt in saline solution, iv and the total drug exposure was determined. (0-8 hr)",1,Macaca fascicularis,Intermediate,,,,9541.0,,,A,BAO_0000218,CHEMBL624410,8283
,100710,N,1,,,,14839,,"In vivo antitumor efficacy in cynomolgus monkeys by injecting a dose of 25 mg/kg, as HCl salt in saline solution, perorally and the total drug exposure was determined (0-8 hr)",1,Macaca fascicularis,Intermediate,,,,9541.0,,,A,BAO_0000218,CHEMBL624411,8284
,100710,N,1,,,,14839,,"In vivo antitumor efficacy in cynomolgus monkeys by injecting a dose of 25 mg/kg, as the micronised free base in corn oil, iv and the total drug exposure was determined. (0-8 hr)",1,Macaca fascicularis,Intermediate,,,,9541.0,,,A,BAO_0000218,CHEMBL623531,8285
,100710,N,1,,,,14839,,"In vivo antitumor efficacy in cynomolgus monkeys by injecting a dose of 25 mg/kg, as the micronised free base in corn oil, perorally and the total drug exposure was determined (0-8 hr)",1,Macaca fascicularis,Intermediate,,,,9541.0,,,A,BAO_0000218,CHEMBL623532,8286
,100710,N,1,,,,14839,,"In vivo antitumor efficacy in cynomolgus monkeys by injecting a dose of 5 mg/kg, as HCl salt in saline solution, intravenously and the total drug exposure was determined (0-8 hr)",1,Macaca fascicularis,Intermediate,,,,9541.0,,,A,BAO_0000218,CHEMBL623533,8287
,100710,N,1,,,,14839,,"In vivo antitumor efficacy in cynomolgus monkeys by injecting a dose of 5 mg/kg, as HCl salt in saline solution, perorally and the total drug exposure was determined (0-8 hr)",1,Macaca fascicularis,Intermediate,,,,9541.0,,,A,BAO_0000218,CHEMBL623534,8288
,50594,N,1,,,,14839,,In vivo antitumor efficacy in nude mice 0-24 hr after intravenous dose of 25 mg/kg expressed as Area under the curve,1,Mus musculus,Intermediate,,,,10090.0,,,A,BAO_0000218,CHEMBL623535,8289
,50594,N,1,,,,14839,,In vivo antitumor efficacy in nude mice 0-24 hr after iperoral dose of 25 mg/kg expressed as Area under the curve,1,Mus musculus,Intermediate,,,,10090.0,,,A,BAO_0000218,CHEMBL623536,8290
,50594,N,1,,,,14839,,In vivo antitumor efficacy in nude mice 0-24 hr after iv dose of 25 mg/kg expressed as Area under the curve,1,Mus musculus,Intermediate,,,,10090.0,,,A,BAO_0000218,CHEMBL623537,8291
,50594,N,1,,,,14839,,In vivo antitumor efficacy in nude mice 0-24 hr after peroral dose of 25 mg/kg expressed as Area under the curve,1,Mus musculus,Intermediate,,,,10090.0,,,A,BAO_0000218,CHEMBL623538,8292
,50594,N,1,,,,14839,,In vivo antitumor efficacy in nude mice after peroral dose of 10 mg/kg expressed as Area under the curve,1,Mus musculus,Intermediate,,,,10090.0,,,A,BAO_0000218,CHEMBL623539,8293
,50594,N,1,,,,14839,,In vivo antitumor efficacy in nude mice after peroral dose of 25 mg/kg expressed as Area under the curve,1,Mus musculus,Intermediate,,,,10090.0,,,A,BAO_0000218,CHEMBL623540,8294
,50594,N,1,,,,14839,,"In vivo antitumor efficacy in nude mice by injecting a dose of 25 mg/kg, as HCl salt in saline solution, iv and the total drug exposure was determined.",1,Mus musculus,Intermediate,,,,10090.0,,,A,BAO_0000218,CHEMBL623541,8295
,50594,N,1,,,,14839,,"In vivo antitumor efficacy in nude mice by injecting a dose of 25 mg/kg, as HCl salt in saline solution, iv and the total drug exposure was determined. (0-24hr)",1,Mus musculus,Intermediate,,,,10090.0,,,A,BAO_0000218,CHEMBL623542,8296
,50594,N,1,,,,14839,,"In vivo antitumor efficacy in nude mice by injecting a dose of 25 mg/kg, as HCl salt in saline solution, iv and the total drug exposure was determined. (0-4 hr)",1,Mus musculus,Intermediate,,,,10090.0,,,A,BAO_0000218,CHEMBL623543,8297
,50594,N,1,,,,14839,,"In vivo antitumor efficacy in nude mice by injecting a dose of 25 mg/kg, as HCl salt in saline solution, perorally and the total drug exposure was determined",1,Mus musculus,Intermediate,,,,10090.0,,,A,BAO_0000218,CHEMBL623544,8298
,50594,N,1,,,,14839,,"In vivo antitumor efficacy in nude mice by injecting a dose of 25 mg/kg, as HCl salt in saline solution, perorally and the total drug exposure was determined (0-24hr)",1,Mus musculus,Intermediate,,,,10090.0,,,A,BAO_0000218,CHEMBL623545,8299
,50594,N,1,,,,14839,,"In vivo antitumor efficacy in nude mice by injecting a dose of 25 mg/kg, as HCl salt in saline solution, perorally and the total drug exposure was determined (0-4 hr)",1,Mus musculus,Intermediate,,,,10090.0,,,A,BAO_0000218,CHEMBL623546,8300
Plasma,50597,N,1,In vivo,,,5408,,Evaluated for plasma clearance after iv administration of 5 mg/kg to male Sprague-Dawley rats,1,Rattus norvegicus,Intermediate,,,,10116.0,,1969.0,A,BAO_0000218,CHEMBL623547,8301
,50597,N,1,In vivo,,,6827,,High i.v. clearance in Dawley rats,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL623548,8302
Liver,50597,N,1,In vitro,,Microsomes,17538,,In vitro clearance in rat liver microsomes,1,Rattus norvegicus,Intermediate,,,,10116.0,,2107.0,A,BAO_0000218,CHEMBL623549,8303
Liver,50597,N,1,In vitro,,Microsomes,6331,,Intrinsic clearance in rat liver microsomes was determined,1,Rattus norvegicus,Intermediate,,,,10116.0,,2107.0,A,BAO_0000218,CHEMBL623550,8304
Liver,50597,N,1,In vitro,,,5948,,Intrinsic clearance in rat hepatocytes was determined,1,Rattus norvegicus,Intermediate,,401.0,,10116.0,Hepatocyte,2107.0,A,BAO_0000218,CHEMBL875276,8305
,50597,N,1,In vivo,,,4026,,Plasma Clearance was determined,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL621872,8306
,50597,N,1,In vivo,,,6647,,Plasma clearance after intravenous administration of 0.4 mg/kg of dose in rats was determined,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL621873,8307
,50597,N,1,In vivo,,,1696,,Plasma clearance in rat.,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL621874,8308
,50597,N,1,In vivo,,,6597,,Plasma clearance in rats,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL621875,8309
,50597,N,1,In vivo,,,347,,Plasma clearance was estimated from the AUC after 5 mg/kg intravenous dosing in rats,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL621876,8310
,50597,N,1,In vivo,,,16423,,Plasma clearance was evaluated after 10 uM/kg of intra arterial administration,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL621877,8311
,50597,N,1,In vivo,,,2879,,Plasma clearance was measured in rat,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL621878,8312
,50597,N,1,In vivo,,,4883,,Clearance after iv administration to Sprague-Dawley rat at dosage of 0.2 mg/kg,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL621879,8313
Plasma,50597,N,1,In vivo,,,5328,,"Tested for the plasma clearance in Dawley rat at a dose of 1 mg/kg intravenous, 2 mg/kg orally",1,Rattus norvegicus,Intermediate,,,,10116.0,,1969.0,A,BAO_0000218,CHEMBL621880,8314
,50597,N,1,In vivo,,,5160,,The clearance rate in mature male rat at a intravenous dose of 3 mg/kg,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL621881,8315
,50597,N,1,In vivo,,,17582,,Total body clearance was evaluated for the compound after i.v. administration at a dose of 5 mg/kg was measured in rats,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL621882,8316
,50597,N,1,In vivo,,,17651,,Total clearance at 1 mg/kg was determined in rat,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL875283,8317
,50597,N,1,In vivo,,,17651,,Total clearance at 10 mg/kg was determined in rat,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL621883,8318
,50597,N,1,In vivo,,,6596,,Clearance in rat,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL621884,8319
,50597,N,1,In vivo,,,4796,,Plasma clearance rate determined in rats,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL621885,8320
,50597,N,1,In vivo,,,6850,,Clearance of compound in rat was evaluated,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL621886,8321
Plasma,50597,N,1,In vivo,,,5932,,Plasma concentration in rats after 7 hr at 30mg/kg oral dose,1,Rattus norvegicus,Intermediate,,,,10116.0,,1969.0,A,BAO_0000218,CHEMBL621887,8322
,50597,N,1,In vivo,,,3371,,Pharmacokinetic property (blood clearance) in rat,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL621888,8323
,50597,N,1,In vivo,,,2083,,Plasma clearance in rat,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL621889,8324
,50597,N,1,In vivo,,,4942,,Plasma clearance in rats,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL621890,8325
Liver,50597,N,1,In vitro,,Microsomes,6838,,Intrinsic clearance of compound against NADPH-fortified rat liver microsomes,1,Rattus norvegicus,Intermediate,,,,10116.0,,2107.0,A,BAO_0000218,CHEMBL621891,8326
,50597,N,1,In vivo,,,5353,,Clearance in Dawley rat,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL621892,8327
,50597,N,1,In vivo,,,6641,,Clearance rat,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL621893,8328
,50597,N,1,In vivo,,,6641,,Clearance rat (dosed at 0.5 mpk IV and 2.0 mpk po.),1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL621894,8329
,50597,N,1,In vivo,,,6641,,Clearance rat; Not determined,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL621895,8330
,50597,N,1,In vivo,,,6444,,Clearance rate was determined in rat at a dose of 1 mpk i.v.,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL875284,8331
,50597,N,1,In vivo,,,6444,,Clearance rate was determined in rat at a dose of 1 mpk i.v.; ND means not determined,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL618699,8332
,50597,N,1,In vivo,,,6444,,Clearance rate was determined in rat at a dose of 1 mpk i.v.; ND=not determined,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL618700,8333
,50597,N,1,In vivo,,,6211,,Clearance was determined by iv administration (1.5 mg/kg) in fasted male Sprague-Dawley rats,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL618701,8334
Plasma,50597,N,1,In vivo,,,12873,,"Clearance in plasma calculated from Time-Course plasma concentrations in rats at a dose of 2.5 mg/kg, iv",1,Rattus norvegicus,Intermediate,,,,10116.0,,1969.0,A,BAO_0000218,CHEMBL876600,8335
,50597,N,1,In vivo,,,6570,,Clearance of compound in rat after 1 mg/kg i.v. administration,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL618702,8336
,50597,N,1,In vivo,,,3341,,Compound was evaluated for Hepatic clearance in rat,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL618703,8337
,50597,N,1,In vivo,,,4891,,In vivo clearance after 5 mg/kg dose,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL618704,8338
Plasma,50597,N,1,In vivo,,,1094,,Compound was tested for plasma clearance in rats,1,Rattus norvegicus,Intermediate,,,,10116.0,,1969.0,A,BAO_0000218,CHEMBL618705,8339
,50597,N,1,In vivo,,,2938,,Hepatic clearance after intravenous administration was evaluated in rat,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL618706,8340
,50597,N,1,In vivo,,,17853,,Lower clearance in rat (i.v.) at 0.5 mpk,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL618707,8341
Plasma,50597,N,1,In vivo,,,6049,,Pharmacokinetic parameter expressed as plasma clearance in rat,1,Rattus norvegicus,Intermediate,,,,10116.0,,1969.0,A,BAO_0000218,CHEMBL618708,8342
,50597,N,1,In vivo,,,5789,,Pharmacokinetic property (Clp) in rat,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL618709,8343
,50597,N,1,In vivo,,,4514,,Plasma clearance in Sprague-Dawley rats,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL618710,8344
,50597,N,1,In vivo,,,6448,,Plasma clearance (Clp) in rat,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL618711,8345
,50597,N,1,In vivo,,,6062,,Plasma clearance for the compound was measured in rat after an iv dose of 1 mg/kg,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL618712,8346
,50597,N,1,In vivo,,,5710,,Plasma clearance in fasted male Sprague dawely rats on administration of 0.5 mg/Kg i.v. of the compound,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL618713,8347
,50597,N,1,In vivo,,,4709,,Plasma clearance after intravenous administration of 1 mg/kg in rat,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL618714,8348
,50597,N,1,In vivo,,,4521,,Plasma clearance in rat after 5 mg/kg by oral and 1 mg/kg by intravenous administration,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL618715,8349
,50597,N,1,In vivo,,,1742,,Plasma clearance in rat was determined,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL618716,8350
,50597,N,1,In vivo,,,6057,,Plasma clearance measured in rat,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL876601,8351
,50597,N,1,In vivo,,,6057,,Plasma clearance was calculated in rat,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL618717,8352
,50597,N,1,In vivo,,,5145,,Plasma clearance in rat,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL618718,8353
,50597,N,1,In vivo,,,5833,,Plasma clearance in rat,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL618719,8354
,50597,N,1,In vivo,,,6453,,Plasma clearance in rat,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL618720,8355
,50597,N,1,In vivo,,,6640,,Plasma clearance in rat,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL618721,8356
,50597,N,1,In vivo,,,6305,,Plasma clearance in rats,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL621477,8357
,50597,N,1,In vivo,,,6642,,Plasma clearance in rat,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL621478,8358
,50597,N,1,In vivo,,,5472,,Plasma clearance was evaluated in rat,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL621479,8359
,50597,N,1,In vivo,,,5472,,Plasma clearance was evaluated in rat; Not tested,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL621480,8360
,50597,N,1,In vivo,,,5144,,Plasma clearance rate was determined for the compound in rat,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL621481,8361
,50597,N,1,In vivo,,,6685,,"Plasma clearance rate was determined in rats at 10mg/kg, p.o. dose; n/a: not applicable",1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL621482,8362
,50597,N,1,In vivo,,,6685,,"Plasma clearance rate was determined in rats at 20 mg/kg, i.p. dose; n/a: not applicable",1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL621483,8363
,50597,N,1,In vivo,,,6685,,"Plasma clearance rate was determined in rats at 2 mg/kg, i.v. dose",1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL621484,8364
Heart,50597,N,1,In vivo,,,13950,,Biodistribution of [123I]-label in rat heart was reported at 24 hr post injection. Value shown is %ID/g of tissue,1,Rattus norvegicus,Intermediate,,,,10116.0,,948.0,A,BAO_0000218,CHEMBL621485,8365
Heart,50597,N,1,In vivo,,,13950,,Biodistribution of [123I]-label in rat heart was reported at 4 hr post injection. Value shown is %ID/g of tissue,1,Rattus norvegicus,Intermediate,,,,10116.0,,948.0,A,BAO_0000218,CHEMBL621486,8366
Intestine,50597,N,1,In vivo,,,13950,,Biodistribution of [123I]-label in rat intestine was reported at 0.33 hr post injection. Value shown is %ID/g of tissue,1,Rattus norvegicus,Intermediate,,,,10116.0,,160.0,A,BAO_0000218,CHEMBL621487,8367
Intestine,50597,N,1,In vivo,,,13950,,Biodistribution of [123I]-label in rat intestine was reported at 1 hr post injection. Value shown is %ID/g of tissue,1,Rattus norvegicus,Intermediate,,,,10116.0,,160.0,A,BAO_0000218,CHEMBL621488,8368
Intestine,50597,N,1,In vivo,,,13950,,Biodistribution of [123I]-label in rat intestine was reported at 2 hr post injection. Value shown is %ID/g of tissue,1,Rattus norvegicus,Intermediate,,,,10116.0,,160.0,A,BAO_0000218,CHEMBL621489,8369
Intestine,50597,N,1,In vivo,,,13950,,Biodistribution of [123I]-label in rat intestine was reported at 24 hr post injection. Value shown is %ID/g of tissue,1,Rattus norvegicus,Intermediate,,,,10116.0,,160.0,A,BAO_0000218,CHEMBL621490,8370
Intestine,50597,N,1,In vivo,,,13950,,Biodistribution of [123I]-label in rat intestine was reported at 4 hr post injection. Value shown is %ID/g of tissue,1,Rattus norvegicus,Intermediate,,,,10116.0,,160.0,A,BAO_0000218,CHEMBL621491,8371
Kidney,50597,N,1,In vivo,,,13950,,Biodistribution of [123I]-label in rat kidneys was reported at 0.33 hr post injection. Value shown is %ID/g of tissue,1,Rattus norvegicus,Intermediate,,,,10116.0,,2113.0,A,BAO_0000218,CHEMBL621492,8372
Kidney,50597,N,1,In vivo,,,13950,,Biodistribution of [123I]-label in rat kidneys was reported at 1 h post injection. Value shown is %ID/g of tissue,1,Rattus norvegicus,Intermediate,,,,10116.0,,2113.0,A,BAO_0000218,CHEMBL621493,8373
Kidney,50597,N,1,In vivo,,,13950,,Biodistribution of [123I]-label in rat kidneys was reported at 2 hr post injection. Value shown is %ID/g of tissue,1,Rattus norvegicus,Intermediate,,,,10116.0,,2113.0,A,BAO_0000218,CHEMBL621494,8374
Kidney,50597,N,1,In vivo,,,13950,,Biodistribution of [123I]-label in rat kidneys was reported at 24 hr post injection. Value shown is %ID/g of tissue,1,Rattus norvegicus,Intermediate,,,,10116.0,,2113.0,A,BAO_0000218,CHEMBL621495,8375
Kidney,50597,N,1,In vivo,,,13950,,Biodistribution of [123I]-label in rat kidneys was reported at 4 hr post injection. Value shown is %ID/g of tissue,1,Rattus norvegicus,Intermediate,,,,10116.0,,2113.0,A,BAO_0000218,CHEMBL621496,8376
Liver,50597,N,1,In vivo,,,13950,,Biodistribution of [123I]-label in rat liver was reported at 0.33 hr post injection. Value shown is %ID/g of tissue,1,Rattus norvegicus,Intermediate,,,,10116.0,,2107.0,A,BAO_0000218,CHEMBL621497,8377
Liver,50597,N,1,In vivo,,,13950,,Biodistribution of [123I]-label in rat liver was reported at 1 hr post injection. Value shown is %ID/g of tissue,1,Rattus norvegicus,Intermediate,,,,10116.0,,2107.0,A,BAO_0000218,CHEMBL621498,8378
Liver,50597,N,1,In vivo,,,13950,,Biodistribution of [123I]-label in rat liver was reported at 2 hr post injection. Value shown is %ID/g of tissue,1,Rattus norvegicus,Intermediate,,,,10116.0,,2107.0,A,BAO_0000218,CHEMBL621499,8379
Liver,50597,N,1,In vivo,,,13950,,Biodistribution of [123I]-label in rat liver was reported at 24 h post injection. Value shown is %ID/g of tissue,1,Rattus norvegicus,Intermediate,,,,10116.0,,2107.0,A,BAO_0000218,CHEMBL618634,8380
Liver,50597,N,1,In vivo,,,13950,,Biodistribution of [123I]-label in rat liver was reported at 4 hr post injection. Value shown is %ID/g of tissue,1,Rattus norvegicus,Intermediate,,,,10116.0,,2107.0,A,BAO_0000218,CHEMBL618635,8381
Lung,50597,N,1,In vivo,,,13950,,Biodistribution of [123I]-label in rat lung was reported at 0.33 hr post injection. Value shown is %ID/g of tissue,1,Rattus norvegicus,Intermediate,,,,10116.0,,2048.0,A,BAO_0000218,CHEMBL618636,8382
Lung,50597,N,1,In vivo,,,13950,,Biodistribution of [123I]-label in rat lung was reported at 1 hr post injection. Value shown is %ID/g of tissue,1,Rattus norvegicus,Intermediate,,,,10116.0,,2048.0,A,BAO_0000218,CHEMBL619737,8383
Lung,50597,N,1,In vivo,,,13950,,Biodistribution of [123I]-label in rat lung was reported at 2 hr post injection. Value shown is %ID/g of tissue,1,Rattus norvegicus,Intermediate,,,,10116.0,,2048.0,A,BAO_0000218,CHEMBL619738,8384
Lung,50597,N,1,In vivo,,,13950,,Biodistribution of [123I]-label in rat lung was reported at 24 hr post injection. Value shown is %ID/g of tissue,1,Rattus norvegicus,Intermediate,,,,10116.0,,2048.0,A,BAO_0000218,CHEMBL624329,8385
Lung,50597,N,1,In vivo,,,13950,,Biodistribution of [123I]-label in rat lung was reported at 4 hr post injection. Value shown is %ID/g of tissue,1,Rattus norvegicus,Intermediate,,,,10116.0,,2048.0,A,BAO_0000218,CHEMBL624330,8386
Muscle tissue,50597,N,1,In vivo,,,13950,,Biodistribution of [123I]-label in rat muscle was reported at 0.33 hr post injection. Value shown is %ID/g of tissue,1,Rattus norvegicus,Intermediate,,,,10116.0,,2385.0,A,BAO_0000218,CHEMBL624331,8387
Muscle tissue,50597,N,1,In vivo,,,13950,,Biodistribution of [123I]-label in rat muscle was reported at 1 hr post injection. Value shown is %ID/g of tissue,1,Rattus norvegicus,Intermediate,,,,10116.0,,2385.0,A,BAO_0000218,CHEMBL624332,8388
Muscle tissue,50597,N,1,In vivo,,,13950,,Biodistribution of [123I]-label in rat muscle was reported at 2 hr post injection. Value shown is %ID/g of tissue,1,Rattus norvegicus,Intermediate,,,,10116.0,,2385.0,A,BAO_0000218,CHEMBL624333,8389
Muscle tissue,50597,N,1,In vivo,,,13950,,Biodistribution of [123I]-label in rat muscle was reported at 24 hr post injection. Value shown is %ID/g of tissue,1,Rattus norvegicus,Intermediate,,,,10116.0,,2385.0,A,BAO_0000218,CHEMBL624334,8390
Muscle tissue,50597,N,1,In vivo,,,13950,,Biodistribution of [123I]-label in rat muscle was reported at 4 hr post injection. Value shown is %ID/g of tissue,1,Rattus norvegicus,Intermediate,,,,10116.0,,2385.0,A,BAO_0000218,CHEMBL624335,8391
Spleen,50597,N,1,In vivo,,,13950,,Biodistribution of [123I]-label in rat spleen was reported at 0.33 hr post injection. Value shown is %ID/g of tissue,1,Rattus norvegicus,Intermediate,,,,10116.0,,2106.0,A,BAO_0000218,CHEMBL620016,8392
Spleen,50597,N,1,In vivo,,,13950,,Biodistribution of [123I]-label in rat spleen was reported at 1 hr post injection. Value shown is %ID/g of tissue,1,Rattus norvegicus,Intermediate,,,,10116.0,,2106.0,A,BAO_0000218,CHEMBL620169,8393
Spleen,50597,N,1,In vivo,,,13950,,Biodistribution of [123I]-label in rat spleen was reported at 2 hr post injection. Value shown is %ID/g of tissue,1,Rattus norvegicus,Intermediate,,,,10116.0,,2106.0,A,BAO_0000218,CHEMBL620170,8394
Spleen,50597,N,1,In vivo,,,13950,,Biodistribution of [123I]-label in rat spleen was reported at 24 h post injection. Value shown is %ID/g of tissue,1,Rattus norvegicus,Intermediate,,,,10116.0,,2106.0,A,BAO_0000218,CHEMBL620171,8395
Spleen,50597,N,1,In vivo,,,13950,,Biodistribution of [123I]-label in rat spleen was reported at 4 hr post injection. Value shown is %ID/g of tissue,1,Rattus norvegicus,Intermediate,,,,10116.0,,2106.0,A,BAO_0000218,CHEMBL620172,8396
Stomach,50597,N,1,In vivo,,,13950,,Biodistribution of [123I]-label in rat stomach was reported at 0.33 hr post injection. Value shown is %ID/g of tissue,1,Rattus norvegicus,Intermediate,,,,10116.0,,945.0,A,BAO_0000218,CHEMBL620173,8397
Stomach,50597,N,1,In vivo,,,13950,,Biodistribution of [123I]-label in rat stomach was reported at 1 h post injection. Value shown is %ID/g of tissue,1,Rattus norvegicus,Intermediate,,,,10116.0,,945.0,A,BAO_0000218,CHEMBL620174,8398
Stomach,50597,N,1,In vivo,,,13950,,Biodistribution of [123I]-label in rat stomach was reported at 2 hr post injection. Value shown is %ID/g of tissue,1,Rattus norvegicus,Intermediate,,,,10116.0,,945.0,A,BAO_0000218,CHEMBL620175,8399
Stomach,50597,N,1,In vivo,,,13950,,Biodistribution of [123I]-label in rat stomach was reported at 24 hr post injection. Value shown is %ID/g of tissue,1,Rattus norvegicus,Intermediate,,,,10116.0,,945.0,A,BAO_0000218,CHEMBL620176,8400
Stomach,50597,N,1,In vivo,,,13950,,Biodistribution of [123I]-label in rat stomach was reported at 4 hr post injection. Value shown is %ID/g of tissue,1,Rattus norvegicus,Intermediate,,,,10116.0,,945.0,A,BAO_0000218,CHEMBL620177,8401
Cerebellum,50597,N,1,,,,13950,,Distribution of [123I]-label in rat brain (cerebellum) was reported at 20 min post injection. Value shown is %ID/g of tissue,1,Rattus norvegicus,Intermediate,,,,10116.0,,2037.0,A,BAO_0000218,CHEMBL620178,8402
Cerebellum,50597,N,1,,,,13950,,Distribution of [123I]-label in rat brain (cerebellum) was reported at 60 min post injection. Value shown is %ID/g of tissue,1,Rattus norvegicus,Intermediate,,,,10116.0,,2037.0,A,BAO_0000218,CHEMBL620179,8403
,50597,N,1,,,,13950,,Distribution of [123I]-label in rat brain (diencephalon) was reported at 20 min post injection. Value shown is %ID/g of tissue,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL620180,8404
,50597,N,1,In vivo,,,6570,,Volume of distribution of compound in rat after 1 mg/kg i.v. administration,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL620181,8405
,50597,N,1,In vivo,,,6571,,Volume of distribution of compound in rats after intravenous administration,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL620182,8406
,50597,N,1,In vivo,,,6453,,Volume of distribution in rat,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL620183,8407
,50597,N,1,In vivo,,,6444,,Volume of distribution was determined in rat at a dose of 1 mpk i.v.,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL620184,8408
,50597,N,1,In vivo,,,6444,,Volume of distribution was determined in rat at a dose of 1 mpk i.v.; ND means not determined,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL620185,8409
,50597,N,1,In vivo,,,6444,,Volume of distribution was determined in rat at a dose of 1 mpk i.v.; ND=not determined,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL620186,8410
,50597,N,1,In vivo,,,5353,,Volume of distribution was determined in Dawley rat,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL620187,8411
,50597,N,1,In vivo,,,5334,,Volume of distribution was reported after oral administration at a dose of 2 mg/kg in Sprague-Dawley rat,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL620188,8412
,50597,N,1,In vivo,,,5334,,Volume of distribution was reported in Sprague-Dawley rat,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL620189,8413
,50597,N,1,In vivo,,,6641,,Volumes of distribution in rat after peroral administration,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL620190,8414
,50597,N,1,In vivo,,,6641,,Volumes of distribution in rat after po administration,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL620191,8415
,50597,N,1,In vivo,,,6641,,Volumes of distribution in rat after po administration; Not determined,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL620192,8416
,50597,N,1,In vivo,,,5676,,Pharmacokinetic property (Volume) in rat i.v.,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL620193,8417
,50597,N,1,In vivo,,,6410,,Apparent volume of distribution when 3 mg/Kg dose was administered intravenously,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL620194,8418
,50597,N,1,In vivo,,,17670,,"Volume distribution in fischer rats at 5 mg/kg dose, administered intravenously",1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL876730,8419
,50597,N,1,In vivo,,,6495,,Volume distribution in rat after oral administration at 10 mg/kg,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL620195,8420
,50597,N,1,In vivo,,,5408,,Evaluated for Volume of distribution after iv administration of 5 mg/kg to male Sprague-Dawley rats,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL620196,8421
,50597,N,1,In vivo,,,4883,,Tested for volume of distribution after intravenous administration to Sprague-Dawley rat at dosage of 0.2 mg/kg,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL620197,8422
,50597,N,1,In vivo,,,6647,,Volume of distribution after oral administration of 6 mg/kg of dose in rats was determined,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL620198,8423
,50597,N,1,In vivo,,,6495,,Volume of distribution in rats,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL620199,8424
,50597,N,1,In vivo,,,2661,,Compound was evaluated for volume of distribution (steady state) after treatment with iv dose of 1 mgkg to female wistar rats,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL620200,8425
,50597,N,1,In vivo,,,2661,,Compound was evaluated for volume of distribution (steady state) after treatment with iv dose of 1 mgkg to male wistar rats,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL620201,8426
,50597,N,1,In vivo,,,5974,,In vivo Volume distribution (Vss) was determined after intravenous administration of compound (9.13+/-0.85 mg/kg) in male Sprague-Dawley rat,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL620202,8427
,50597,N,1,In vivo,,,5974,,In vivo Volume distribution (Vss) was determined after peroral administration of compound (158.5+/-2 mg/kg) in male Sprague-Dawley rat,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL620203,8428
,50597,N,1,In vivo,,,5974,,In vivo Volume distribution (Vss) was determined after peroral administration of compound (19.01+/-0.31 mg/kg) in male Sprague-Dawley rat;no value,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL620204,8429
,50597,N,1,In vivo,,,5974,,In vivo Volume distribution (Vss) was determined after peroral administration of compound (76.4+/-2.6 mg/kg) in male Sprague-Dawley rat,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL620205,8430
,50597,N,1,In vivo,,,5960,,Pharmacokinetic parameter (Vss) in rat,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL624664,8431
,50597,N,1,In vivo,,,5676,,Pharmacokinetic property (Volume) in rat i.v.,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL624665,8432
,50597,N,1,,,,5948,,Pharmacokinetic property (Vss) in rat,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL624666,8433
,50597,N,1,In vivo,,,5979,,Steady state volume distribution (Vss) of compound after 2 hr iv infusion of 8.4 mg/kg in three rat,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL624667,8434
,50597,N,1,In vivo,,,5978,,Steady state volume distribution (Vss) of compound after iv administration was determined in Sprague-Dawley rat,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL624668,8435
,50597,N,1,In vivo,,,5978,,Steady state volume distribution (Vss) of compound (10 mg/kg) after iv administration was determined in Sprague-Dawley rat,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL624669,8436
,50597,N,1,In vivo,,,5978,,Steady state volume distribution (Vss) of compound(9.83 mg/kg) after iv administration was determined in Sprague-Dawley rat,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL624670,8437
,50597,N,1,In vivo,,,5978,,Steady state volume distribution (Vss) of compound(9.84 mg/kg) after iv administration was determined in Sprague-Dawley rat,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL624671,8438
,50597,N,1,In vivo,,,6448,,Steady state volume distribution in rat,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL624672,8439
Plasma,50597,N,1,In vivo,,,12873,,"Steady state volume of distribution calculated from Time-Course plasma concentrations in rats at a dose of 2.5 mg/kg, iv.",1,Rattus norvegicus,Intermediate,,,,10116.0,,1969.0,A,BAO_0000218,CHEMBL624673,8440
,50597,N,1,In vivo,,,4576,,Steady state volume of distribution determined in rat,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL624674,8441
,50597,N,1,In vivo,,,17582,,Steady-state volume of distribution was evaluated for the compound after i.v. administration at a dose of 5 mg/kg was measured in rats,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL624675,8442
,50597,N,1,In vivo,,,1466,,Tested for volume of distribution at steady state upon intravenous administration of 5.0 mg/Kg dose in rat,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL621728,8443
,50597,N,1,,,,5182,,Volume at steady state distribution by administering the compound intravenously at a dose of 1 mg/kg in male wistar rat was determined,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL621729,8444
,50597,N,1,,,,5182,,Volume at steady state distribution by administering the compound intravenously at a dose of 1 mg/kg in male wistar rat was determined; NC means not calculated,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL621730,8445
,50597,N,1,In vivo,,,6535,,Volume distribution in rat after administration of 2 mg/kg iv,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL621731,8446
,50597,N,1,In vivo,,,6535,,Volume distribution in rat after administration of 2 mg/kg iv,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL621732,8447
,50597,N,1,In vivo,,,5041,,Volume in steady state distribution value was determined,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL621908,8448
,50597,N,1,In vivo,,,5041,,Volume in steady state distribution value was determined; ND denotes no data,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL875347,8449
,50597,N,1,In vivo,,,5041,,Volume in steady state distribution value was determined; ND denotes not determined,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL621909,8450
,50597,N,1,In vivo,,,17065,,Volume of distribution at a steady state measured after intravenous bolus administration of 50 mg/kg of compound to rats,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL621910,8451
,50597,N,1,In vivo,,,6597,,Volume of distribution at steady state was evaluated in rats,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL621911,8452
,50597,N,1,In vivo,,,15662,,Volume of distribution at steady state was observed after intravenous administration in rat,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL621912,8453
,50597,N,1,In vivo,,,6485,,Volume of distribution in steady state was determined in rat,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL621913,8454
,50597,N,1,In vivo,,,17655,,Volume of distribution in steady state was determined in rat,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL621914,8455
,50597,N,1,In vivo,,,6616,,Volume of distribution after i.v. administration,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL621915,8456
,50597,N,1,In vivo,,,1916,,Volume of distribution was evaluated in Sprague-Dawley rats at a dose of 15 mg/kg after iv administration,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL621916,8457
Liver,50594,N,1,In vivo,,,16438,,"Biodistribution of compound (oxidized form) in liver tissues, animals were sacrificed 60 minutes after dosing, in DMSO solution",1,Mus musculus,Intermediate,,,,10090.0,,2107.0,A,BAO_0000218,CHEMBL621917,8458
Liver,50594,N,1,In vivo,,,16438,,"Biodistribution of compound (oxidized form) in liver tissues, animals were sacrificed 60 minutes after dosing, in DMSO sol.",1,Mus musculus,Intermediate,,,,10090.0,,2107.0,A,BAO_0000218,CHEMBL621918,8459
Spleen,50594,N,1,In vivo,,,16438,,Biodistribution of compound (oxidized form) in spleen tissue,1,Mus musculus,Intermediate,,,,10090.0,,2106.0,A,BAO_0000218,CHEMBL621919,8460
Spleen,50594,N,1,In vivo,,,16438,,"Biodistribution of compound (oxidized form) in spleen tissue, animals were sacrificed 10 minutes after dosing, in DMSO sol.",1,Mus musculus,Intermediate,,,,10090.0,,2106.0,A,BAO_0000218,CHEMBL621920,8461
Spleen,50594,N,1,In vivo,,,16438,,"Biodistribution of compound (oxidized form) in spleen tissue, animals were sacrificed 10 minutes after dosing, in DMSO solution",1,Mus musculus,Intermediate,,,,10090.0,,2106.0,A,BAO_0000218,CHEMBL621921,8462
Spleen,50594,N,1,In vivo,,,16438,,"Biodistribution of compound (oxidized form) in spleen tissues, animals were sacrificed 60 minutes after dosing, in DMSO",1,Mus musculus,Intermediate,,,,10090.0,,2106.0,A,BAO_0000218,CHEMBL622401,8463
Spleen,50594,N,1,In vivo,,,16438,,"Biodistribution of compound (oxidized form) in spleen tissues, animals were sacrificed 60 minutes after dosing, in DMSO sol.",1,Mus musculus,Intermediate,,,,10090.0,,2106.0,A,BAO_0000218,CHEMBL875348,8464
Spleen,50594,N,1,In vivo,,,16438,,"Biodistribution of compound (oxidized form) in spleen tissues, animals were sacrificed 60 minutes after dosing, in DMSO solution",1,Mus musculus,Intermediate,,,,10090.0,,2106.0,A,BAO_0000218,CHEMBL622402,8465
Blood,50594,N,1,In vivo,,,16438,,Biodistribution of compound (total concentration of both oxidized and reduced forms) in blood,1,Mus musculus,Intermediate,,,,10090.0,,178.0,A,BAO_0000218,CHEMBL622403,8466
Blood,50594,N,1,In vivo,,,16438,,"Biodistribution of compound (total concentration of both oxidized and reduced forms) in blood tissues, animals were sacrificed 60 minutes after dosing, in DMSO",1,Mus musculus,Intermediate,,,,10090.0,,178.0,A,BAO_0000218,CHEMBL622404,8467
Brain,50594,N,1,In vivo,,,16438,,Biodistribution of compound (total concentration of both oxidized and reduced forms) in brain tissues,1,Mus musculus,Intermediate,,,,10090.0,,955.0,A,BAO_0000218,CHEMBL622405,8468
Brain,50594,N,1,In vivo,,,16438,,"Biodistribution of compound (total concentration of both oxidized and reduced forms) in brain tissues, animals were sacrificed 10 minutes after dosing, in DMSO",1,Mus musculus,Intermediate,,,,10090.0,,955.0,A,BAO_0000218,CHEMBL622406,8469
Brain,50594,N,1,In vivo,,,16438,,"Biodistribution of compound (total concentration of both oxidized and reduced forms) in brain tissues, animals were sacrificed 60 minutes after dosing, in DMSO",1,Mus musculus,Intermediate,,,,10090.0,,955.0,A,BAO_0000218,CHEMBL622407,8470
Heart,50594,N,1,In vivo,,,16438,,Biodistribution of compound (total concentration of both oxidized and reduced forms) in heart tissues,1,Mus musculus,Intermediate,,,,10090.0,,948.0,A,BAO_0000218,CHEMBL622408,8471
Heart,50594,N,1,In vivo,,,16438,,"Biodistribution of compound (total concentration of both oxidized and reduced forms) in heart tissues, animals were sacrificed 10 minutes after dosing, in DMSO",1,Mus musculus,Intermediate,,,,10090.0,,948.0,A,BAO_0000218,CHEMBL622409,8472
Heart,50594,N,1,In vivo,,,16438,,"Biodistribution of compound (total concentration of both oxidized and reduced forms) in heart tissues, animals were sacrificed 60 minutes after dosing, in DMSO",1,Mus musculus,Intermediate,,,,10090.0,,948.0,A,BAO_0000218,CHEMBL622410,8473
Kidney,50594,N,1,In vivo,,,16438,,Biodistribution of compound (total concentration of both oxidized and reduced forms) in kidney,1,Mus musculus,Intermediate,,,,10090.0,,2113.0,A,BAO_0000218,CHEMBL622411,8474
Kidney,50594,N,1,In vivo,,,16438,,"Biodistribution of compound (total concentration of both oxidized and reduced forms) in kidney tissues, animals were sacrificed 60 minutes after dosing in DMSO",1,Mus musculus,Intermediate,,,,10090.0,,2113.0,A,BAO_0000218,CHEMBL627864,8475
Kidney,50594,N,1,In vivo,,,16438,,"Biodistribution of compound (total concentration of both oxidized and reduced forms) in kidney tissues, animals were sacrificed 60 minutes after dosing, in DMSO",1,Mus musculus,Intermediate,,,,10090.0,,2113.0,A,BAO_0000218,CHEMBL627865,8476
Liver,50594,N,1,In vivo,,,16438,,Biodistribution of compound (total concentration of both oxidized and reduced forms) in liver,1,Mus musculus,Intermediate,,,,10090.0,,2107.0,A,BAO_0000218,CHEMBL627866,8477
Liver,50594,N,1,In vivo,,,16438,,"Biodistribution of compound (total concentration of both oxidized and reduced forms) in liver tissues, animals were sacrificed 60 minutes after dosing, in DMSO",1,Mus musculus,Intermediate,,,,10090.0,,2107.0,A,BAO_0000218,CHEMBL627751,8478
Spleen,50594,N,1,In vivo,,,16438,,Biodistribution of compound (total concentration of both oxidized and reduced forms) in spleen,1,Mus musculus,Intermediate,,,,10090.0,,2106.0,A,BAO_0000218,CHEMBL627752,8479
Spleen,50594,N,1,In vivo,,,16438,,"Biodistribution of compound (total concentration of both oxidized and reduced forms) in spleen tissues, animals were sacrificed 60 minutes after dosing in DMSO",1,Mus musculus,Intermediate,,,,10090.0,,2106.0,A,BAO_0000218,CHEMBL627753,8480
Spleen,50594,N,1,In vivo,,,16438,,"Biodistribution of compound (total concentration of both oxidized and reduced forms) in spleen tissues, animals were sacrificed 60 minutes after dosing, in DMSO",1,Mus musculus,Intermediate,,,,10090.0,,2106.0,A,BAO_0000218,CHEMBL627754,8481
,50594,N,1,,,,12467,,Cellular uptake kinetics of Porphycenes saturation cell level (cs) in SSK2 murine fibrosarcoma cells,1,Mus musculus,Intermediate,,,,10090.0,,,A,BAO_0000218,CHEMBL627755,8482
Brain,50594,N,1,In vivo,,,17208,,Biodistribution of radioactivity in normal mice (ICR) brain after 1 hour of intravenous injection of [125I]-16(IMPY),1,Mus musculus,Intermediate,,,,10090.0,,955.0,A,BAO_0000218,CHEMBL627756,8483
Brain,50594,N,1,In vivo,,,17208,,Biodistribution of radioactivity in normal mice (ICR) brain after 2 hours of intravenous injection of [125I]-16(IMPY),1,Mus musculus,Intermediate,,,,10090.0,,955.0,A,BAO_0000218,CHEMBL627757,8484
Brain,50594,N,1,In vivo,,,17208,,Biodistribution of radioactivity in normal mice (ICR) brain after 2 minutes of intravenous injection of [125I]-16(IMPY),1,Mus musculus,Intermediate,,,,10090.0,,955.0,A,BAO_0000218,CHEMBL627758,8485
Brain,50594,N,1,In vivo,,,17208,,Biodistribution of radioactivity in normal mice (ICR) brain after 24 hours of intravenous injection of [125I]-16(IMPY),1,Mus musculus,Intermediate,,,,10090.0,,955.0,A,BAO_0000218,CHEMBL627759,8486
Brain,50594,N,1,In vivo,,,17208,,Biodistribution of radioactivity in normal mice (ICR) brain after 30 minutes of intravenous injection of [125I]-16(IMPY),1,Mus musculus,Intermediate,,,,10090.0,,955.0,A,BAO_0000218,CHEMBL627760,8487
Brain,50594,N,1,In vivo,,,17208,,Biodistribution of radioactivity in normal mice (ICR) brain after 6 hours of intravenous injection of [125I]-16(IMPY),1,Mus musculus,Intermediate,,,,10090.0,,955.0,A,BAO_0000218,CHEMBL627761,8488
Heart,50594,N,1,In vivo,,,17208,,Biodistribution of radioactivity in normal mice (ICR) heart after 1 hour of intravenous injection of [125I]-16(IMPY),1,Mus musculus,Intermediate,,,,10090.0,,948.0,A,BAO_0000218,CHEMBL876811,8489
Heart,50594,N,1,In vivo,,,17208,,Biodistribution of radioactivity in normal mice (ICR) heart after 2 hours of intravenous injection of [125I]-16(IMPY),1,Mus musculus,Intermediate,,,,10090.0,,948.0,A,BAO_0000218,CHEMBL627762,8490
Heart,50594,N,1,In vivo,,,17208,,Biodistribution of radioactivity in normal mice (ICR) heart after 2 minutes of intravenous injection of [125I]-16(IMPY),1,Mus musculus,Intermediate,,,,10090.0,,948.0,A,BAO_0000218,CHEMBL627763,8491
Heart,50594,N,1,In vivo,,,17208,,Biodistribution of radioactivity in normal mice (ICR) heart after 24 hours of intravenous injection of [125I]-16(IMPY),1,Mus musculus,Intermediate,,,,10090.0,,948.0,A,BAO_0000218,CHEMBL627764,8492
Heart,50594,N,1,In vivo,,,17208,,Biodistribution of radioactivity in normal mice (ICR) heart after 30 minutes of intravenous injection of [125I]-16(IMPY),1,Mus musculus,Intermediate,,,,10090.0,,948.0,A,BAO_0000218,CHEMBL627765,8493
Heart,50594,N,1,In vivo,,,17208,,Biodistribution of radioactivity in normal mice (ICR) heart after 6 hours of intravenous injection of [125I]-16(IMPY),1,Mus musculus,Intermediate,,,,10090.0,,948.0,A,BAO_0000218,CHEMBL627766,8494
Kidney,50594,N,1,In vivo,,,17208,,Biodistribution of radioactivity in normal mice (ICR) kidney after 1 hour of intravenous injection of [125I]-16(IMPY),1,Mus musculus,Intermediate,,,,10090.0,,2113.0,A,BAO_0000218,CHEMBL627767,8495
Kidney,50594,N,1,In vivo,,,17208,,Biodistribution of radioactivity in normal mice (ICR) kidney after 2 hours of intravenous injection of [125I]-16(IMPY),1,Mus musculus,Intermediate,,,,10090.0,,2113.0,A,BAO_0000218,CHEMBL627768,8496
Kidney,50594,N,1,In vivo,,,17208,,Biodistribution of radioactivity in normal mice (ICR) kidney after 2 minutes of intravenous injection of [125I]-16(IMPY),1,Mus musculus,Intermediate,,,,10090.0,,2113.0,A,BAO_0000218,CHEMBL628422,8497
Kidney,50594,N,1,In vivo,,,17208,,Biodistribution of radioactivity in normal mice (ICR) kidney after 24 hours of intravenous injection of [125I]-16(IMPY),1,Mus musculus,Intermediate,,,,10090.0,,2113.0,A,BAO_0000218,CHEMBL628423,8498
,50597,N,1,In vivo,,,5089,,Plasma clearance value at intravenous dose of 1 mg/kg (2 mg/kg po (cassette dosing) in Dawley rat,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL628424,8499
,50597,N,1,In vivo,,,5089,,Plasma clearance value at intravenous dose of 1 mg/kg (2 mg/kg po (cassette dosing)) in Dawley rat,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL628425,8500
,50597,N,1,In vivo,,,4257,,Plasma clearance value was determined in rat after a 3 mg/kg of iv dose,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL628426,8501
,50597,N,1,In vivo,,,6679,,Plasma clearance was determined after 1 mg/kg (i.v.) / 2 mg/kg (p.o.) of compound administration,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL628427,8502
,50597,N,1,In vivo,,,5546,,Plasma clearance was determined in Sprague-Dawley rats at a dose of 1 mg/kg by iv administration,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL626938,8503
,50597,N,1,In vivo,,,6141,,Plasma clearance was evaluated at 1 mg/kg of iv administration in Sprague-Dawley rats,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL626939,8504
,50597,N,1,In vivo,,,5334,,Plasma clearance was reported after intravenous administration at a dose of 1 mg/kg in Sprague-Dawley rat,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL626940,8505
,50597,N,1,In vivo,,,5334,,Plasma clearance was reported after oral administration at a dose of 2 mg/kg in Sprague-Dawley rat,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL626941,8506
,50597,N,1,In vivo,,,5334,,Plasma clearance was reported in Sprague-Dawley rat,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL626942,8507
,50597,N,1,In vivo,,,4689,,Plasma clearance after intravenous administration (1 mg/kg) in rat,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL876812,8508
,50597,N,1,In vivo,,,6848,,Plasma clearance of compound in rats was evaluated,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL626943,8509
,50597,N,1,In vivo,,,6848,,Plasma clearance of compound in rats was evaluated; ND indicates not determined,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL626944,8510
,50597,N,1,In vivo,,,6467,,Plasma clearance in rats at the dose of 1.0 mpk by i.v. administration,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL626945,8511
,50597,N,1,In vivo,,,6467,,Plasma clearance in rats at the dose of 1.0 mpk by i.v. administration; ND= not determined,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL626946,8512
,50597,N,1,In vivo,,,4956,,Plasma clearance rate in Sprague-Dawley rats,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL626856,8513
,50597,N,1,In vivo,,,5529,,Plasma clearance was determined in rat after intravenous administration (0.5 mg/kg),1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL626857,8514
Plasma,50597,N,1,In vivo,,,406,,The compound was evaluated for plasma clearance in rat,1,Rattus norvegicus,Intermediate,,,,10116.0,,1969.0,A,BAO_0000218,CHEMBL626858,8515
Plasma,50597,N,1,In vivo,,,17655,,Total plasma clearance in rat,1,Rattus norvegicus,Intermediate,,,,10116.0,,1969.0,A,BAO_0000218,CHEMBL627018,8516
Blood,50597,N,1,In vivo,,,3293,,Absorption behavior was judged by the peak blood concentration determined after oral dose of 30 mg/kg in rats.,1,Rattus norvegicus,Intermediate,,,,10116.0,,178.0,A,BAO_0000218,CHEMBL625331,8517
Blood,50597,N,1,In vivo,,,4075,,Blood level after a 10 mg/kg oral dose in rat expressed as Cmax was determined,1,Rattus norvegicus,Intermediate,,,,10116.0,,178.0,A,BAO_0000218,CHEMBL625332,8518
,50597,N,1,In vivo,,,2792,,C max was determined at 10 mg/kg po dose in rats,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL877590,8519
,50597,N,1,In vivo,,,2792,,C max was determined at 3 mg/kg po dose in rats,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL625333,8520
,50597,N,1,In vivo,,,17594,,Cmax after repeated oral dose of compound at 1 mg/kg in rats,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL625334,8521
,50597,N,1,In vivo,,,17594,,Cmax after single intravenous bolus of 1 mg/kg in rats,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL625335,8522
,50597,N,1,In vivo,,,4762,,Cmax of compound at 5 mg/kg after po administration was determined in rat,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL625336,8523
,50597,N,1,In vivo,,,17509,,Cmax 24 hr after 10 mg/kg oral administration in rats,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL625337,8524
,50597,N,1,In vivo,,,17509,,Cmax 24 hr after 2 mg/kg oral administration in rats,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL625338,8525
Plasma,50597,N,1,In vivo,,,1466,,Cmax in plasma was determined upon peroral administration of 10.0 mg/Kg dose in rat,1,Rattus norvegicus,Intermediate,,,,10116.0,,1969.0,A,BAO_0000218,CHEMBL625339,8526
,50597,N,1,In vivo,,,6535,,Cmax in rat after administration of 2 mg/kg iv,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL625340,8527
,50597,N,1,In vivo,,,6535,,Cmax in rat after administration of 2 mg/kg iv,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL625341,8528
,50597,N,1,In vivo,,,3169,,Cmax in rats determined 6 hours after oral dosing of 20 mg/kg,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL622687,8529
Plasma,50597,N,1,In vivo,,,6515,,Cmax wa determined in rat plasma at 30 mg/kg after po administration,1,Rattus norvegicus,Intermediate,,,,10116.0,,1969.0,A,BAO_0000218,CHEMBL622688,8530
Blood,50597,N,1,In vivo,,,11149,,Cmax was calculated as maximum concentration reached in the blood after oral administration to male F344 rats,1,Rattus norvegicus,Intermediate,,,,10116.0,,178.0,A,BAO_0000218,CHEMBL622689,8531
Blood,50597,N,1,In vivo,,,11149,,Cmax was calculated as maximum concentration reached in the blood in air pouch exudate after oral administration to male F344 rats,1,Rattus norvegicus,Intermediate,,,,10116.0,,178.0,A,BAO_0000218,CHEMBL620295,8532
,50597,N,1,In vivo,,,17858,,Cmax after 10 mg/kg oral administration in rat,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL620296,8533
,50597,N,1,In vivo,,,6518,,Cmax after IV dosing at 0.5 mg/kg in rat; no data,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL620297,8534
,50597,N,1,In vivo,,,6518,,Cmax after IV dosing at 1 mg/kg in rat; no data,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL620298,8535
,50597,N,1,In vivo,,,4426,,Cmax after oral administration at 20 mpk in rats,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL620299,8536
,50597,N,1,In vivo,,,4426,,Cmax after oral administration at 20 mpk in rats; Not performed.,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL620300,8537
,50597,N,1,In vivo,,,4426,,Cmax after oral administration at 20 mpk in rats d; Not performed.,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL620301,8538
,50597,N,1,In vivo,,,5656,,Cmax after oral administration in rat,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL620302,8539
,50597,N,1,In vivo,,,6518,,Cmax after oral administration at a dose of 2 mg/kg in rat,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL620303,8540
,50597,N,1,In vivo,,,6518,,Cmax after oral administration at a dose of 4 mg/kg in rat,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL620304,8541
,50597,N,1,In vivo,,,6113,,Cmax in rats after 20 mg/kg oral dose,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL620305,8542
,50597,N,1,In vivo,,,17764,,Cmax after peroral administration in rats at 2.4 uM/kg,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL620306,8543
,50597,N,1,In vivo,,,4756,,Cmax at the dose of 2 mg/Kg administered perorally in rats,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL620307,8544
,50597,N,1,In vivo,,,4756,,Cmax at the dose of 5 mg/Kg administered perorally in rats,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL620308,8545
,50597,N,1,In vivo,,,6402,,Cmax by administering at 20 mg/kg p.o. in rats,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL620309,8546
,50597,N,1,In vivo,,,5610,,Cmax in male rat,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL620310,8547
,50597,N,1,In vivo,,,5207,,Cmax in rat,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL620311,8548
,50597,N,1,In vivo,,,6011,,Cmax in rat,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL620312,8549
,50597,N,1,In vivo,,,6504,,Cmax in rat,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL620313,8550
,50597,N,1,In vivo,,,6046,,Cmax in rat at 10 mg/kg,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL620314,8551
,50597,N,1,In vivo,,,6504,,Cmax in rat at the dose of 1 mg/kg i.v.,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL620315,8552
,50597,N,1,In vivo,,,5874,,Cmax in rat by po administration at a dose of 40 mg/kg,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL620316,8553
,50597,N,1,In vivo,,,17686,,Cmax in rat p.o. at 20 mg/kg concentration,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL620317,8554
,50597,N,1,In vivo,,,5836,,Cmax in rats,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL620318,8555
,50597,N,1,In vivo,,,17596,,Cmax in rats,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL620319,8556
,50597,N,1,In vivo,,,16423,,Cmax was evaluated after 20 uM/kg of peroral administration,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL620320,8557
,50597,N,1,In vivo,,,17804,,Cmax was measured in rats after peroral administration at 3 mg/kg,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL620321,8558
,50597,N,1,In vivo,,,1908,,Cmax value after oral dose at a dose of 10 mg/kg in rats.,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL620322,8559
,50597,N,1,,,,13950,,Distribution of [123I]-label in rat brain (diencephalon) was reported at 60 min post injection. Value shown is %ID/g of tissue,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL620323,8560
Frontal cortex,50597,N,1,,,,13950,,Distribution of [123I]-label in rat brain (frontal cortex) was reported at 20 min post injection. Value shown is %ID/g of tissue,1,Rattus norvegicus,Intermediate,,,,10116.0,,1870.0,A,BAO_0000218,CHEMBL620324,8561
Frontal cortex,50597,N,1,,,,13950,,Distribution of [123I]-label in rat brain (frontal cortex) was reported at 60 min post injection. Value shown is %ID/g of tissue,1,Rattus norvegicus,Intermediate,,,,10116.0,,1870.0,A,BAO_0000218,CHEMBL620325,8562
Hippocampus,50597,N,1,,,,13950,,Distribution of [123I]-label in rat brain (hippocampus) was reported at 20 min post injection. Value shown is %ID/g of tissue,1,Rattus norvegicus,Intermediate,,,,10116.0,,10000000.0,A,BAO_0000218,CHEMBL620326,8563
Hippocampus,50597,N,1,,,,13950,,Distribution of [123I]-label in rat brain (hippocampus) was reported at 60 min post injection. Value shown is %ID/g of tissue,1,Rattus norvegicus,Intermediate,,,,10116.0,,10000000.0,A,BAO_0000218,CHEMBL620327,8564
,50597,N,1,,,,13950,,Distribution of [123I]-label in rat brain (medulla pons) was reported at 20 min post injection. Value shown is %ID/g of tissue,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL620328,8565
,50597,N,1,,,,13950,,Distribution of [123I]-label in rat brain (medulla pons) was reported at 60 min post injection. Value shown is %ID/g of tissue,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL620329,8566
Midbrain,50597,N,1,,,,13950,,Distribution of [123I]-label in rat brain (midbrain) was reported at 20 min post injection. Value shown is %ID/g of tissue,1,Rattus norvegicus,Intermediate,,,,10116.0,,1891.0,A,BAO_0000218,CHEMBL620330,8567
Midbrain,50597,N,1,,,,13950,,Distribution of [123I]-label in rat brain (midbrain) was reported at 60 min post injection. Value shown is %ID/g of tissue,1,Rattus norvegicus,Intermediate,,,,10116.0,,1891.0,A,BAO_0000218,CHEMBL875286,8568
,50597,N,1,,,,13950,,Distribution of [123I]-label in rat brain (posterior cortex) was reported at 20 min post injection. Value shown is %ID/g of tissue,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL620331,8569
,50597,N,1,,,,13950,,Distribution of [123I]-label in rat brain (posterior cortex) was reported at 60 min post injection. Value shown is %ID/g of tissue,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL620332,8570
Striatum,50597,N,1,,,,13950,,Distribution of [123I]-label in rat brain (striatum) was reported at 20 min post injection. Value shown is %ID/g of tissue,1,Rattus norvegicus,Intermediate,,,,10116.0,,2435.0,A,BAO_0000218,CHEMBL620333,8571
Striatum,50597,N,1,,,,13950,,Distribution of [123I]-label in rat brain (striatum) was reported at 60 min post injection. Value shown is %ID/g of tissue,1,Rattus norvegicus,Intermediate,,,,10116.0,,2435.0,A,BAO_0000218,CHEMBL620334,8572
Blood,50597,N,1,,,,16434,,Radioactivity distribution in blood of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 120 min.,1,Rattus norvegicus,Intermediate,,,,10116.0,,178.0,A,BAO_0000218,CHEMBL621015,8573
Blood,50597,N,1,,,,16434,,Radioactivity distribution in blood of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 30 min.,1,Rattus norvegicus,Intermediate,,,,10116.0,,178.0,A,BAO_0000218,CHEMBL621016,8574
Blood,50597,N,1,,,,16434,,Radioactivity distribution in blood of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 5 min.,1,Rattus norvegicus,Intermediate,,,,10116.0,,178.0,A,BAO_0000218,CHEMBL621191,8575
Blood,50597,N,1,,,,16434,,Radioactivity distribution in blood of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 60 min.,1,Rattus norvegicus,Intermediate,,,,10116.0,,178.0,A,BAO_0000218,CHEMBL621192,8576
Blood,50597,N,1,,,,16434,,Radioactivity distribution in blood of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min.,1,Rattus norvegicus,Intermediate,,,,10116.0,,178.0,A,BAO_0000218,CHEMBL621193,8577
Blood,50597,N,1,,,,16434,,Radioactivity distribution in blood of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 30 min.,1,Rattus norvegicus,Intermediate,,,,10116.0,,178.0,A,BAO_0000218,CHEMBL621194,8578
Blood,50597,N,1,,,,16434,,Radioactivity distribution in blood of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min.,1,Rattus norvegicus,Intermediate,,,,10116.0,,178.0,A,BAO_0000218,CHEMBL624204,8579
Blood,50597,N,1,,,,16434,,Radioactivity distribution in blood of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min.,1,Rattus norvegicus,Intermediate,,,,10116.0,,178.0,A,BAO_0000218,CHEMBL624205,8580
Blood,50597,N,1,,,,16435,,Radioactivity distribution in blood of normal fischer rat after injection of anti-[18F]FMACBC after 120 min.,1,Rattus norvegicus,Intermediate,,,,10116.0,,178.0,A,BAO_0000218,CHEMBL624206,8581
Blood,50597,N,1,,,,16435,,Radioactivity distribution in blood of normal fischer rat after injection of anti-[18F]FMACBC after 30 min.,1,Rattus norvegicus,Intermediate,,,,10116.0,,178.0,A,BAO_0000218,CHEMBL624207,8582
Blood,50597,N,1,,,,16435,,Radioactivity distribution in blood of normal fischer rat after injection of anti-[18F]FMACBC after 5 min.,1,Rattus norvegicus,Intermediate,,,,10116.0,,178.0,A,BAO_0000218,CHEMBL624208,8583
Blood,50597,N,1,,,,16435,,Radioactivity distribution in blood of normal fischer rat after injection of anti-[18F]FMACBC after 60 min.,1,Rattus norvegicus,Intermediate,,,,10116.0,,178.0,A,BAO_0000218,CHEMBL624209,8584
Blood,50597,N,1,,,,16435,,Radioactivity distribution in blood of normal fischer rat after injection of syn-[18F]-FMACBC after 120 min.,1,Rattus norvegicus,Intermediate,,,,10116.0,,178.0,A,BAO_0000218,CHEMBL624210,8585
Blood,50597,N,1,,,,16435,,Radioactivity distribution in blood of normal fischer rat after injection of syn-[18F]-FMACBC after 30 min.,1,Rattus norvegicus,Intermediate,,,,10116.0,,178.0,A,BAO_0000218,CHEMBL624211,8586
Blood,50597,N,1,,,,16435,,Radioactivity distribution in blood of normal fischer rat after injection of syn-[18F]-FMACBC after 5 min.,1,Rattus norvegicus,Intermediate,,,,10116.0,,178.0,A,BAO_0000218,CHEMBL624212,8587
Blood,50597,N,1,,,,16435,,Radioactivity distribution in blood of normal fischer rat after injection of syn-[18F]-FMACBC after 60 min.,1,Rattus norvegicus,Intermediate,,,,10116.0,,178.0,A,BAO_0000218,CHEMBL624213,8588
Blood,50597,N,1,,,,16434,,Radioactivity distribution in blood of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min,1,Rattus norvegicus,Intermediate,,,,10116.0,,178.0,A,BAO_0000218,CHEMBL876611,8589
Blood,50597,N,1,,,,16434,,Radioactivity distribution in blood of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min,1,Rattus norvegicus,Intermediate,,,,10116.0,,178.0,A,BAO_0000218,CHEMBL624214,8590
Blood,50597,N,1,,,,16434,,Radioactivity distribution in blood of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min,1,Rattus norvegicus,Intermediate,,,,10116.0,,178.0,A,BAO_0000218,CHEMBL624215,8591
Blood,50597,N,1,,,,16435,,Radioactivity distribution in blood of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 120 min,1,Rattus norvegicus,Intermediate,,,,10116.0,,178.0,A,BAO_0000218,CHEMBL624216,8592
Blood,50597,N,1,,,,16435,,Radioactivity distribution in blood of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 5 min,1,Rattus norvegicus,Intermediate,,,,10116.0,,178.0,A,BAO_0000218,CHEMBL624217,8593
Blood,50597,N,1,,,,16435,,Radioactivity distribution in blood of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 60 min,1,Rattus norvegicus,Intermediate,,,,10116.0,,178.0,A,BAO_0000218,CHEMBL624218,8594
Blood,50597,N,1,,,,16435,,Radioactivity distribution in blood of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 120 min,1,Rattus norvegicus,Intermediate,,,,10116.0,,178.0,A,BAO_0000218,CHEMBL624219,8595
Blood,50597,N,1,,,,16435,,Radioactivity distribution in blood of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 5 min,1,Rattus norvegicus,Intermediate,,,,10116.0,,178.0,A,BAO_0000218,CHEMBL624220,8596
Blood,50597,N,1,,,,16435,,Radioactivity distribution in blood of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 60 min,1,Rattus norvegicus,Intermediate,,,,10116.0,,178.0,A,BAO_0000218,CHEMBL624221,8597
,50597,N,1,,,,16434,,Radioactivity distribution in bone of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 120 min.,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL624222,8598
,50597,N,1,,,,16434,,Radioactivity distribution in bone of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 30 min.,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL624223,8599
,50597,N,1,,,,16434,,Radioactivity distribution in bone of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 5 min.,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL624224,8600
,50597,N,1,,,,16434,,Radioactivity distribution in bone of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 60 min.,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL624225,8601
,50597,N,1,In vivo,,,17764,,Volume of solubility in solution after intravenous administration in rats at 24 uM/kg,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL622420,8602
,50597,N,1,In vivo,,,5031,,Volume of steady state distribution after i.v. administration in rats,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL622421,8603
,50597,N,1,In vivo,,,6215,,Vss after intravenous administration (5.0 mg/kg) was determined in rat,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL622422,8604
,50597,N,1,In vivo,,,17671,,Vss in male Sprague-Dawley rats following an intravenous bolus dose at 10-20 mg/kg,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL622423,8605
,50597,N,1,In vivo,,,17752,,Vss was determined,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL622424,8606
,50597,N,1,In vivo,,,6596,,Vss in rat,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL622425,8607
,50597,N,1,In vivo,,,16423,,Vss was evaluated after 10 uM/kg of intra arterial administration,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL876612,8608
,50597,N,1,In vivo,,,15662,,volume of distribution at steady state was observed after intravenous administration in rat,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL622426,8609
,50597,N,1,In vivo,,,6062,,Volume of distribution was measured in rat after an iv dose of 1 mg/kg,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL622427,8610
,50597,N,1,In vivo,,,5874,,Pharmacokinetic (PK) parameter Vz in rat,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL622428,8611
,50597,N,1,In vivo,,,4942,,Volume distribution in rats,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL622429,8612
,50597,N,1,In vivo,,,17796,,Volume of distribution in rat; No data,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL622430,8613
,50597,N,1,In vivo,,,4890,,Volume of distribution was determined after intravenous administration at a dose 5 mg/kg to male Sprague-Dawley rats,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL622431,8614
Ileum,50597,N,1,,,,15765,,% absorption predicted from in vitro rat ileum transport studies,1,Rattus norvegicus,Intermediate,,,,10116.0,,2116.0,A,BAO_0000218,CHEMBL622432,8615
,50597,N,1,In vivo,,,13569,,Bioavailability at an iv dose of 12 mg/Kg and po dose of 23 mg/Kg,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL622433,8616
,50597,N,1,In vivo,,,13569,,Bioavailability at an iv dose of 14 mg/Kg and po dose of 15 mg/Kg,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL622434,8617
,50597,N,1,In vivo,,,13569,,Bioavailability at an iv dose of 14 mg/Kg and po dose of 28 mg/Kg,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL622435,8618
,50597,N,1,In vivo,,,13569,,Bioavailability (dose 15 mg/kg i.v. and 30 mg/kg p.o.),1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL618748,8619
,50597,N,1,In vivo,,,13569,,Bioavailability at an iv dose of 15 mg/Kg and po dose of 30.2 mg/Kg,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL618749,8620
,50597,N,1,In vivo,,,13569,,Bioavailability at an iv dose of 15.6 mg/Kg and po dose of 31.2 mg/Kg,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL618750,8621
,50597,N,1,In vivo,,,13569,,Bioavailability at an iv dose of 15.7 mg/Kg and po dose of 31.4 mg/Kg,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL618751,8622
,50597,N,1,In vivo,,,13569,,Bioavailability at an iv dose of 16 mg/Kg and po dose of 35 mg/Kg,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL618752,8623
,50597,N,1,In vivo,,,4576,,Oral bioavailability in rat,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL618753,8624
Plasma,50597,N,1,In vivo,,,750,,Oral bioavailability estimated by measurement of the circulating plasma levels of BMS-183920 after intravenous and oral dosing to rats for 4 determinations,1,Rattus norvegicus,Intermediate,,,,10116.0,,1969.0,A,BAO_0000218,CHEMBL618754,8625
,50597,N,1,In vivo,,,750,,Oral bioavailability in rat,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL618755,8626
,50597,N,1,In vivo,,,4590,,Oral bioavailability in rat,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL618756,8627
,50597,N,1,In vivo,,,1716,,Oral bioavailability in rat,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL618757,8628
,50597,N,1,In vivo,,,1974,,Bioavailability in rat,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL618758,8629
,50597,N,1,In vivo,,,4502,,Oral bioavailability in rat (dose 30 mg/kg),1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL621088,8630
,50597,N,1,,,,3371,,Pharmacokinetic property (cLogP) in rat,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL621089,8631
Blood,50597,N,1,,,,9099,,Hyperglycemic activity and change in blood glucose concentration was reported 2 hours after administration of 100 mg/Kg perorally,1,Rattus norvegicus,Intermediate,,,,10116.0,,178.0,F,BAO_0000218,CHEMBL621090,8632
Blood,50597,N,1,,,,9099,,Hyperglycemic activity and change in blood glucose concentration was reported 4 hours after administration of 100 mg/Kg perorally,1,Rattus norvegicus,Intermediate,,,,10116.0,,178.0,F,BAO_0000218,CHEMBL621091,8633
,50597,N,1,In vivo,,,4590,,Clearance in rat.,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL876731,8634
,50597,N,1,In vivo,,,3184,,Compound was evaluated for its clearance when administered intravenously in rat,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL621092,8635
,50597,N,1,In vivo,,,16456,,Plasma clearance in Male Sprague-Dawley rats after intravenous administration at a dose of 10 mg/kg,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL621093,8636
,50597,N,1,,,,4199,,Blood: Brain distribution ratio is determined in rat,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL621094,8637
,50597,N,1,,,,4199,,Blood: Brain distribution ratio is determined in rat; NQ: non quantifable,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL621095,8638
,50597,N,1,,,,4199,,Blood: Brain distribution ratio is determined in rat; NQ:non quantifable,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL621096,8639
Kidney,50597,N,1,In vivo,,,8677,,"Biodistribution in Sprague-Dawley rat kidneys(2) 15 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",1,Rattus norvegicus,Intermediate,,,,10116.0,,2113.0,A,BAO_0000218,CHEMBL621097,8640
,50597,N,1,,,,7449,,Percent dose excreted in 0-48 hours administered ip to male rat,1,Rattus norvegicus,Intermediate,,,,10116.0,,,F,BAO_0000218,CHEMBL621098,8641
Cerebellum,50597,N,1,,,,11977,,Uptake of radioligand [125I]FIDA1 by cerebellum in rat after 120 minutes after an intravenous injection is given (average of 3 rats),1,Rattus norvegicus,Intermediate,,,,10116.0,,2037.0,A,BAO_0000218,CHEMBL621099,8642
Cerebellum,50597,N,1,,,,11977,,Uptake of radioligand [125I]FIDA1 by cerebellum in rat after 2 minutes after an intravenous injection is given (average of 3 rats),1,Rattus norvegicus,Intermediate,,,,10116.0,,2037.0,A,BAO_0000218,CHEMBL621100,8643
Cerebellum,50597,N,1,,,,11977,,Uptake of radioligand [125I]-FIDA1 by cerebellum in rat after 30 minutes after an intravenous injection is given (average of 2 rats),1,Rattus norvegicus,Intermediate,,,,10116.0,,2037.0,A,BAO_0000218,CHEMBL621101,8644
Cerebellum,50597,N,1,,,,11977,,Uptake of radioligand [125I]FIDA1 by cerebellum in rat after 30 minutes after an intravenous injection is given (average of 3 rats),1,Rattus norvegicus,Intermediate,,,,10116.0,,2037.0,A,BAO_0000218,CHEMBL621102,8645
Cerebellum,50597,N,1,,,,11977,,Uptake of radioligand [125I]FIDA1 by cerebellum in rat after 60 minutes after an intravenous injection is given (average of 3 rats),1,Rattus norvegicus,Intermediate,,,,10116.0,,2037.0,A,BAO_0000218,CHEMBL876732,8646
,50597,N,1,,,,11977,,Uptake of radioligand [125I]-FIDA1 by cortex in rat after 120 minutes after an intravenous injection is given (average of 3 rats),1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL621103,8647
,50597,N,1,,,,11977,,Uptake of radioligand [125I]FIDA1 by cortex in rat after 2 minutes after an intravenous injection is given (average of 3 rats),1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL621104,8648
,50597,N,1,,,,11977,,Uptake of radioligand [125I]FIDA1 by cortex in rat after 30 minutes after an intravenous injection is given (average of 2 rats),1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL621105,8649
,50597,N,1,,,,11977,,Uptake of radioligand [125I]-FIDA1 by cortex in rat after 30 minutes after an intravenous injection is given (average of 3 rats),1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL621106,8650
,50597,N,1,,,,11977,,Uptake of radioligand [125I]FIDA1 by cortex in rat after 60 minutes after an intravenous injection is given (average of 3 rats),1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL621107,8651
,50597,N,1,,,,11977,,Uptake of radioligand [125I]FIDA1 by hippo-campus in rat after 120 minutes after an intravenous injection is given (average of 3 rats),1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL621108,8652
,50597,N,1,,,,11977,,Uptake of radioligand [125I]FIDA1 by hippo-campus in rat after 2 minutes after an intravenous injection is given (average of 3 rats),1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL621109,8653
Kidney,50594,N,1,In vivo,,,17208,,Biodistribution of radioactivity in normal mice (ICR) kidney after 30 minutes of intravenous injection of [125I]-16(IMPY),1,Mus musculus,Intermediate,,,,10090.0,,2113.0,A,BAO_0000218,CHEMBL621110,8654
Kidney,50594,N,1,In vivo,,,17208,,Biodistribution of radioactivity in normal mice (ICR) kidney after 6 hours of intravenous injection of [125I]-16(IMPY),1,Mus musculus,Intermediate,,,,10090.0,,2113.0,A,BAO_0000218,CHEMBL621111,8655
Liver,50594,N,1,In vivo,,,17208,,Biodistribution of radioactivity in normal mice (ICR) liver after 1 hour of intravenous injection of [125I]-16(IMPY),1,Mus musculus,Intermediate,,,,10090.0,,2107.0,A,BAO_0000218,CHEMBL622541,8656
Liver,50594,N,1,In vivo,,,17208,,Biodistribution of radioactivity in normal mice (ICR) liver after 2 hours of intravenous injection of [125I]-16(IMPY),1,Mus musculus,Intermediate,,,,10090.0,,2107.0,A,BAO_0000218,CHEMBL622542,8657
Liver,50594,N,1,In vivo,,,17208,,Biodistribution of radioactivity in normal mice (ICR) liver after 2 minutes of intravenous injection of [125I]-16(IMPY),1,Mus musculus,Intermediate,,,,10090.0,,2107.0,A,BAO_0000218,CHEMBL622543,8658
Liver,50594,N,1,In vivo,,,17208,,Biodistribution of radioactivity in normal mice (ICR) liver after 24 hours of intravenous injection of [125I]-16(IMPY),1,Mus musculus,Intermediate,,,,10090.0,,2107.0,A,BAO_0000218,CHEMBL624412,8659
Liver,50594,N,1,In vivo,,,17208,,Biodistribution of radioactivity in normal mice (ICR) liver after 30 minutes of intravenous injection of [125I]-16(IMPY),1,Mus musculus,Intermediate,,,,10090.0,,2107.0,A,BAO_0000218,CHEMBL624413,8660
Liver,50594,N,1,In vivo,,,17208,,Biodistribution of radioactivity in normal mice (ICR) liver after 6 hours of intravenous injection of [125I]-16(IMPY),1,Mus musculus,Intermediate,,,,10090.0,,2107.0,A,BAO_0000218,CHEMBL624414,8661
Lung,50594,N,1,In vivo,,,17208,,Biodistribution of radioactivity in normal mice (ICR) lung after 1 hour of intravenous injection of [125I]-16(IMPY),1,Mus musculus,Intermediate,,,,10090.0,,2048.0,A,BAO_0000218,CHEMBL624415,8662
Lung,50594,N,1,In vivo,,,17208,,Biodistribution of radioactivity in normal mice (ICR) lung after 2 hours of intravenous injection of [125I]-16(IMPY),1,Mus musculus,Intermediate,,,,10090.0,,2048.0,A,BAO_0000218,CHEMBL624416,8663
Lung,50594,N,1,In vivo,,,17208,,Biodistribution of radioactivity in normal mice (ICR) lung after 2 minutes of intravenous injection of [125I]-16(IMPY),1,Mus musculus,Intermediate,,,,10090.0,,2048.0,A,BAO_0000218,CHEMBL624417,8664
Lung,50594,N,1,In vivo,,,17208,,Biodistribution of radioactivity in normal mice (ICR) lung after 24 hours of intravenous injection of [125I]-16(IMPY),1,Mus musculus,Intermediate,,,,10090.0,,2048.0,A,BAO_0000218,CHEMBL624418,8665
Lung,50594,N,1,In vivo,,,17208,,Biodistribution of radioactivity in normal mice (ICR) lung after 30 minutes of intravenous injection of [125I]-16(IMPY),1,Mus musculus,Intermediate,,,,10090.0,,2048.0,A,BAO_0000218,CHEMBL624419,8666
Lung,50594,N,1,In vivo,,,17208,,Biodistribution of radioactivity in normal mice (ICR) lung after 6 hours of intravenous injection of [125I]-16(IMPY),1,Mus musculus,Intermediate,,,,10090.0,,2048.0,A,BAO_0000218,CHEMBL624420,8667
Muscle tissue,50594,N,1,In vivo,,,17208,,Biodistribution of radioactivity in normal mice (ICR) muscle after 1 hr of intravenous injection of [125I]-16(IMPY),1,Mus musculus,Intermediate,,,,10090.0,,2385.0,A,BAO_0000218,CHEMBL624421,8668
Muscle tissue,50594,N,1,In vivo,,,17208,,Biodistribution of radioactivity in normal mice (ICR) muscle after 2 hours of intravenous injection of [125I]-16(IMPY),1,Mus musculus,Intermediate,,,,10090.0,,2385.0,A,BAO_0000218,CHEMBL624422,8669
Muscle tissue,50594,N,1,In vivo,,,17208,,Biodistribution of radioactivity in normal mice (ICR) muscle after 2 minutes of intravenous injection of [125I]-16(IMPY),1,Mus musculus,Intermediate,,,,10090.0,,2385.0,A,BAO_0000218,CHEMBL624423,8670
Muscle tissue,50594,N,1,In vivo,,,17208,,Biodistribution of radioactivity in normal mice (ICR) muscle after 24 hours of intravenous injection of [125I]-16(IMPY),1,Mus musculus,Intermediate,,,,10090.0,,2385.0,A,BAO_0000218,CHEMBL625123,8671
Muscle tissue,50594,N,1,In vivo,,,17208,,Biodistribution of radioactivity in normal mice (ICR) muscle after 30 minutes of intravenous injection of [125I]-16(IMPY),1,Mus musculus,Intermediate,,,,10090.0,,2385.0,A,BAO_0000218,CHEMBL625124,8672
Muscle tissue,50594,N,1,In vivo,,,17208,,Biodistribution of radioactivity in normal mice (ICR) muscle after 6 hours of intravenous injection of [125I]-16(IMPY),1,Mus musculus,Intermediate,,,,10090.0,,2385.0,A,BAO_0000218,CHEMBL625125,8673
Zone of skin,50594,N,1,In vivo,,,17208,,Biodistribution of radioactivity in normal mice (ICR) skin after 1 hour of intravenous injection of [125I]-16(IMPY),1,Mus musculus,Intermediate,,,,10090.0,,14.0,A,BAO_0000218,CHEMBL625126,8674
Zone of skin,50594,N,1,In vivo,,,17208,,Biodistribution of radioactivity in normal mice (ICR) skin after 2 hours of intravenous injection of [125I]-16(IMPY),1,Mus musculus,Intermediate,,,,10090.0,,14.0,A,BAO_0000218,CHEMBL626947,8675
Zone of skin,50594,N,1,In vivo,,,17208,,Biodistribution of radioactivity in normal mice (ICR) skin after 2 minutes of intravenous injection of [125I]-16(IMPY),1,Mus musculus,Intermediate,,,,10090.0,,14.0,A,BAO_0000218,CHEMBL626948,8676
Zone of skin,50594,N,1,In vivo,,,17208,,Biodistribution of radioactivity in normal mice (ICR) skin after 24 hours of intravenous injection of [125I]-16(IMPY),1,Mus musculus,Intermediate,,,,10090.0,,14.0,A,BAO_0000218,CHEMBL626949,8677
Zone of skin,50594,N,1,In vivo,,,17208,,Biodistribution of radioactivity in normal mice (ICR) skin after 30 minutes of intravenous injection of [125I]-16(IMPY),1,Mus musculus,Intermediate,,,,10090.0,,14.0,A,BAO_0000218,CHEMBL626950,8678
Zone of skin,50594,N,1,In vivo,,,17208,,Biodistribution of radioactivity in normal mice (ICR) skin after 6 hours of intravenous injection of [125I]-16(IMPY),1,Mus musculus,Intermediate,,,,10090.0,,14.0,A,BAO_0000218,CHEMBL626951,8679
Spleen,50594,N,1,In vivo,,,17208,,Biodistribution of radioactivity in normal mice (ICR) spleen after 1 hour of intravenous injection of [125I]-16(IMPY),1,Mus musculus,Intermediate,,,,10090.0,,2106.0,A,BAO_0000218,CHEMBL626952,8680
Spleen,50594,N,1,In vivo,,,17208,,Biodistribution of radioactivity in normal mice (ICR) spleen after 2 hours of intravenous injection of [125I]-16(IMPY),1,Mus musculus,Intermediate,,,,10090.0,,2106.0,A,BAO_0000218,CHEMBL626953,8681
Spleen,50594,N,1,In vivo,,,17208,,Biodistribution of radioactivity in normal mice (ICR) spleen after 2 minutes of intravenous injection of [125I]-16(IMPY),1,Mus musculus,Intermediate,,,,10090.0,,2106.0,A,BAO_0000218,CHEMBL626954,8682
Spleen,50594,N,1,In vivo,,,17208,,Biodistribution of radioactivity in normal mice (ICR) spleen after 24 hours of intravenous injection of [125I]-16(IMPY),1,Mus musculus,Intermediate,,,,10090.0,,2106.0,A,BAO_0000218,CHEMBL626955,8683
Spleen,50594,N,1,In vivo,,,17208,,Biodistribution of radioactivity in normal mice (ICR) spleen after 30 minutes of intravenous injection of [125I]-16(IMPY),1,Mus musculus,Intermediate,,,,10090.0,,2106.0,A,BAO_0000218,CHEMBL626956,8684
Spleen,50594,N,1,In vivo,,,17208,,Biodistribution of radioactivity in normal mice (ICR) spleen after 6 hours of intravenous injection of [125I]-16(IMPY),1,Mus musculus,Intermediate,,,,10090.0,,2106.0,A,BAO_0000218,CHEMBL626957,8685
Blood,50594,N,1,In vivo,,,17208,,Biodistribution of radioactivity in normal mice blood after 1 hour of intravenous injection of [125I]-16(IMPY),1,Mus musculus,Intermediate,,,,10090.0,,178.0,A,BAO_0000218,CHEMBL626958,8686
Blood,50594,N,1,In vivo,,,17208,,Biodistribution of radioactivity in normal mice blood after 2 hours of intravenous injection of [125I]-16(IMPY),1,Mus musculus,Intermediate,,,,10090.0,,178.0,A,BAO_0000218,CHEMBL626959,8687
Blood,50594,N,1,In vivo,,,17208,,Biodistribution of radioactivity in normal mice blood after 2 minutes of intravenous injection of [125I]-16(IMPY),1,Mus musculus,Intermediate,,,,10090.0,,178.0,A,BAO_0000218,CHEMBL626960,8688
Blood,50594,N,1,In vivo,,,17208,,Biodistribution of radioactivity in normal mice blood after 24 hours of intravenous injection of [125I]-16(IMPY),1,Mus musculus,Intermediate,,,,10090.0,,178.0,A,BAO_0000218,CHEMBL626961,8689
Blood,50594,N,1,In vivo,,,17208,,Biodistribution of radioactivity in normal mice blood after 30 minutes of intravenous injection of [125I]-16(IMPY),1,Mus musculus,Intermediate,,,,10090.0,,178.0,A,BAO_0000218,CHEMBL627589,8690
Blood,50594,N,1,In vivo,,,17208,,Biodistribution of radioactivity in normal mice blood after 6 hours of intravenous injection of [125I]-16(IMPY),1,Mus musculus,Intermediate,,,,10090.0,,178.0,A,BAO_0000218,CHEMBL627590,8691
,50594,N,1,,,,3132,,Time taken for EC90 was determined when tested in mouse,1,Mus musculus,Intermediate,,,,10090.0,,,A,BAO_0000218,CHEMBL627591,8692
,50594,N,1,,,,3132,,Time taken for EC90 was determined when tested in mouse at dose 25 mg/kg,1,Mus musculus,Intermediate,,,,10090.0,,,A,BAO_0000218,CHEMBL627592,8693
,50594,N,1,In vivo,,,16597,,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for half life (T1/2),1,Mus musculus,Intermediate,,,,10090.0,,,A,BAO_0000218,CHEMBL627593,8694
,50594,N,1,,,,5727,,Half life in mice,1,Mus musculus,Intermediate,,,,10090.0,,,A,BAO_0000218,CHEMBL627594,8695
,50594,N,1,In vivo,,,5302,,Half life period in mouse after 10 mg/Kg dose,1,Mus musculus,Intermediate,,,,10090.0,,,A,BAO_0000218,CHEMBL876813,8696
,50594,N,1,In vivo,,,5302,,Half life period in mouse after 10 mg/kg dose,1,Mus musculus,Intermediate,,,,10090.0,,,A,BAO_0000218,CHEMBL627595,8697
,50594,N,1,In vivo,,,6348,,Half life was determined in mouse after 5 mg/kg (i.v.) and 6 mg/kg (p.o.) administration,1,Mus musculus,Intermediate,,,,10090.0,,,A,BAO_0000218,CHEMBL627596,8698
,50597,N,1,In vivo,,,5964,,Cmax value at 5 mg/kg po was determined in rat,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL627597,8699
,50597,N,1,In vivo,,,6078,,Cmax value evaluated in rat,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL627598,8700
Brain,50597,N,1,In vivo,,,5206,,Cmax value was calculated by applying at a dose of 10 mg/Kg ip in rat brain,1,Rattus norvegicus,Intermediate,,,,10116.0,,955.0,A,BAO_0000218,CHEMBL627599,8701
,50597,N,1,In vivo,,,2959,,Cmax value after administration of 20 mg/Kg oral dose in rat,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL627600,8702
,50597,N,1,In vivo,,,5964,,Cmax value at 1 mg/kg po in rat,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL627601,8703
,50597,N,1,In vivo,,,5964,,Cmax value at 5 mg/kg po in rat,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL627776,8704
,50597,N,1,In vivo,,,6757,,Cmax value at a dose of 10 mg/kg in male SD rats,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL627777,8705
,50597,N,1,In vivo,,,6757,,Cmax value at a dose of 100 mg/kg in male SD rats,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL627778,8706
,50597,N,1,In vivo,,,6757,,Cmax value at a dose of 50 mg/kg in male SD rats,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL627779,8707
,50597,N,1,In vivo,,,17617,,Cmax value in rats at 10 mg/kg,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL876814,8708
,50597,N,1,In vivo,,,1445,,Cmax value was evaluated in rats at a dose of 20 mg/kg,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL627780,8709
,50597,N,1,In vivo,,,6082,,Cmax value was determined after peroral administration of 20 mg/kg in rat,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL627781,8710
,50597,N,1,In vivo,,,1446,,Cmax value was determined between 15 and 30 minutes post administration in fisher rats; value ranges from 200-500,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL627782,8711
Plasma,50597,N,1,In vivo,,,5407,,Compound was evaluated for its pharmacokinetic parameter maximum plasma concentration (Cmax) after oral administration to rats,1,Rattus norvegicus,Intermediate,,,,10116.0,,1969.0,A,BAO_0000218,CHEMBL627783,8712
Plasma,50597,N,1,In vivo,,,2690,,Compound was evaluated for maximal plasma concentration in rat upon 5 mg/kg upon oral administration,1,Rattus norvegicus,Intermediate,,,,10116.0,,1969.0,A,BAO_0000218,CHEMBL627784,8713
,50597,N,1,In vivo,,,2661,,Compound was evaluated for maximum concentration after treatment with oral dose of 2 mgkg to female wistar rats,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL627785,8714
,50597,N,1,In vivo,,,2661,,Compound was evaluated for maximum concentration after treatment with oral dose of 2 mgkg to male wistar rats,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL627786,8715
Plasma,50597,N,1,In vivo,,,4891,,Compound was evaluated for pharmacokinetic parameter maximum plasma concentration,1,Rattus norvegicus,Intermediate,,,,10116.0,,1969.0,A,BAO_0000218,CHEMBL627787,8716
Plasma,50597,N,1,In vivo,,,2807,,Compound was evaluated for plasma concentration in rats when administered at 20 mg/kg in methocel at 0.5 hr,1,Rattus norvegicus,Intermediate,,,,10116.0,,1969.0,A,BAO_0000218,CHEMBL627788,8717
Plasma,50597,N,1,In vivo,,,2807,,Compound was evaluated for plasma concentration in rats when administered at 20 mg/kg in methocel at 1 hr,1,Rattus norvegicus,Intermediate,,,,10116.0,,1969.0,A,BAO_0000218,CHEMBL626579,8718
Plasma,50597,N,1,In vivo,,,2807,,Compound was evaluated for plasma concentration in rats when administered at 20 mg/kg in methocel at 2 hr,1,Rattus norvegicus,Intermediate,,,,10116.0,,1969.0,A,BAO_0000218,CHEMBL626580,8719
,50597,N,1,In vivo,,,3634,,Compound was evaluated for the pharmacokinetic property in rats after an oral dose of 10 mg/kg,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL876815,8720
Plasma,50597,N,1,In vivo,,,1881,,Compound was tested for plasma concentration in rats when administered at 20 mg/kg in 1% methocel at 1 hr,1,Rattus norvegicus,Intermediate,,,,10116.0,,1969.0,A,BAO_0000218,CHEMBL626581,8721
Plasma,50597,N,1,In vivo,,,1881,,Compound was tested for plasma concentration in rats when administered at 20 mg/kg in 1% methocel at 2 hr,1,Rattus norvegicus,Intermediate,,,,10116.0,,1969.0,A,BAO_0000218,CHEMBL626582,8722
,50597,N,1,In vivo,,,429,,Evaluated for pharmacokinetic parameter Cmax in rat at the dose 50 mg/kg,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL626583,8723
,50597,N,1,In vivo,,,5974,,In vivo Cmax was determined after intravenous administration of compound (9.13+/-0.85 mg/kg) in male Sprague-Dawley rat,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL626205,8724
,50597,N,1,In vivo,,,5974,,In vivo Cmax was determined after peroral administration of compound (158.5+/-2 mg/kg) in male Sprague-Dawley rat,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL626206,8725
,50597,N,1,In vivo,,,5974,,In vivo Cmax was determined after peroral administration of compound (19.01+/-0.31 mg/kg) in male Sprague-Dawley rat,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL626207,8726
,50597,N,1,In vivo,,,5974,,In vivo Cmax was determined after peroral administration of compound (76.4+/-2.6 mg/kg) in male Sprague-Dawley rat,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL623882,8727
,50597,N,1,In vivo,,,17582,,Maximal concentration in male Sprague-Dawley rats after 5 mg/kg intravenous dose,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL623883,8728
,50597,N,1,In vivo,,,17582,,Maximal concentration in male Sprague-Dawley rats after 10 mg/kg oral dose,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL623884,8729
Plasma,50597,N,1,In vivo,,,3032,,"In vivo maximum concentration of compound in rat plasma after a oral dose of 10 mg/kg (in water, N=4)",1,Rattus norvegicus,Intermediate,,,,10116.0,,1969.0,A,BAO_0000218,CHEMBL623885,8730
Plasma,50597,N,1,In vivo,,,6295,,In vivo maximum concentration in rat plasma exposure after oral administration 50 mg/kg,1,Rattus norvegicus,Intermediate,,,,10116.0,,1969.0,A,BAO_0000218,CHEMBL623886,8731
,50597,N,1,In vivo,,,6619,,Maximal concentration in rat was determined,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL623887,8732
,50597,N,1,In vivo,,,6616,,Maximal concentration after i.v. administration,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL623888,8733
Plasma,50597,N,1,In vivo,,,3249,,Maximal concentration (Cmax) in the rat plasma at a dose of 10 mg/kg,1,Rattus norvegicus,Intermediate,,,,10116.0,,1969.0,A,BAO_0000218,CHEMBL623889,8734
Plasma,50597,N,1,In vivo,,,17791,,Maximal plasma concentration in rat after oral administration at 50 mg/kg,1,Rattus norvegicus,Intermediate,,,,10116.0,,1969.0,A,BAO_0000218,CHEMBL623890,8735
Plasma,50597,N,1,In vivo,,,17791,,Cmax in rat plasma after oral dose (50 mg/Kg),1,Rattus norvegicus,Intermediate,,,,10116.0,,1969.0,A,BAO_0000218,CHEMBL623891,8736
Plasma,50597,N,1,In vivo,,,1360,,Maximal plasma concentration was determined.,1,Rattus norvegicus,Intermediate,,,,10116.0,,1969.0,A,BAO_0000218,CHEMBL623892,8737
Plasma,50597,N,1,In vivo,,,2552,,Maximal plasma drug concentration was determined,1,Rattus norvegicus,Intermediate,,,,10116.0,,1969.0,A,BAO_0000218,CHEMBL623893,8738
,50597,N,1,In vivo,,,6571,,Maximal concentration in rats after peroral administration,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL877616,8739
,50597,N,1,In vivo,,,6570,,Maximum concentration in rat after 2 mg/kg peroral administration,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL623894,8740
Plasma,50597,N,1,In vivo,,,6567,,Maximum concentration in rat plasma after 5 mg/kg oral gavage,1,Rattus norvegicus,Intermediate,,,,10116.0,,1969.0,A,BAO_0000218,CHEMBL623895,8741
,50597,N,1,In vivo,,,3031,,Maximum concentration of compound in rat was evaluated.,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL623896,8742
,50597,N,1,In vivo,,,3436,,Maximum concentration at 0.5 hr by peroral administration at a dose of 20 mg/kg in rats,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL623897,8743
,50597,N,1,In vivo,,,3436,,Maximum concentration at 2 hr by peroral administration at a dose of 20 mg/kg in rats,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL623898,8744
,50597,N,1,In vivo,,,2083,,Maximum concentration at 4 hr after administration of 5 mg/kg dose peroral in rat,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL623899,8745
,50597,N,1,In vivo,,,3436,,Maximum concentration at 4 hr by peroral administration at a dose of 20 mg/kg in rats,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL623900,8746
,50597,N,1,In vivo,,,4527,,Maximum concentration by oral administration at a dose of 100 uM/kg in rat was determined,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL623901,8747
,50597,N,1,In vivo,,,1974,,Maximum concentration was evaluated in rats,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL623902,8748
Cerebrospinal fluid,50597,N,1,In vivo,,,3307,,Maximum concentration in CSF at 30 min following 24 mg/kg subcutaneous dose in rats,1,Rattus norvegicus,Intermediate,,,,10116.0,,1359.0,A,BAO_0000218,CHEMBL623903,8749
Plasma,50597,N,1,In vivo,,,3307,,Maximum concentration in plasma at 30 min following 24 mg/kg subcutaneous dose in rats,1,Rattus norvegicus,Intermediate,,,,10116.0,,1969.0,A,BAO_0000218,CHEMBL623904,8750
Plasma,50597,N,1,In vivo,,,1916,,Maximum concentration in plasma was evaluated in Sprague-Dawley rats at a dose of 15 mg/kg after po administration,1,Rattus norvegicus,Intermediate,,,,10116.0,,1969.0,A,BAO_0000218,CHEMBL877617,8751
,50597,N,1,In vivo,,,1500,,Maximum concentration in portal vein was determined at a concentration of 10 mg/kg in rats,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL623905,8752
,50597,N,1,In vivo,,,1500,,Maximum concentration in portal vein was determined at a concentration of 20 mg/kg in rats,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL623906,8753
Plasma,50597,N,1,In vivo,,,4186,,Maximum concentration in rat plasma after administration of 3.5 mg/kg dose through subcutaneous route,1,Rattus norvegicus,Intermediate,,,,10116.0,,1969.0,A,BAO_0000218,CHEMBL623907,8754
,50597,N,1,,,,16434,,Radioactivity distribution in bone of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min.,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL623908,8755
,50597,N,1,,,,16434,,Radioactivity distribution in bone of normal fischer rat after injection of [18F]-fluoro-2-methylpropanoic acid after 30 min.,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL623909,8756
,50597,N,1,,,,16434,,Radioactivity distribution in bone of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min.,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL623910,8757
,50597,N,1,,,,16434,,Radioactivity distribution in bone of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min.,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL623911,8758
,50597,N,1,,,,16435,,Radioactivity distribution in bone of normal fischer rat after injection of anti-[18F]FMACBC after 120 min.,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL623912,8759
,50597,N,1,,,,16435,,Radioactivity distribution in bone of normal fischer rat after injection of anti-[18F]FMACBC after 30 min.,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL624616,8760
,50597,N,1,,,,16435,,Radioactivity distribution in bone of normal fischer rat after injection of anti-[18F]FMACBC after 5 min.,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL624617,8761
,50597,N,1,,,,16435,,Radioactivity distribution in bone of normal fischer rat after injection of anti-[18F]FMACBC after 60 min.,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL624618,8762
,50597,N,1,,,,16435,,Radioactivity distribution in bone of normal fischer rat after injection of syn-[18F]-FMACBC after 120 min.,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL624619,8763
,50597,N,1,,,,16435,,Radioactivity distribution in bone of normal fischer rat after injection of syn-[18F]-FMACBC after 30 min.,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL624794,8764
,50597,N,1,,,,16435,,Radioactivity distribution in bone of normal fischer rat after injection of syn-[18F]-FMACBC after 5 min.,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL624795,8765
,50597,N,1,,,,16435,,Radioactivity distribution in bone of normal fischer rat after injection of syn-[18F]-FMACBC after 60 min.,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL623921,8766
,50597,N,1,,,,16434,,Radioactivity distribution in bone of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL623922,8767
,50597,N,1,,,,16434,,Radioactivity distribution in bone of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL623923,8768
,50597,N,1,,,,16434,,Radioactivity distribution in bone of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL623924,8769
,50597,N,1,,,,16435,,Radioactivity distribution in bone of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 120 min,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL623925,8770
,50597,N,1,,,,16435,,Radioactivity distribution in bone of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 5 min,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL623926,8771
,50597,N,1,,,,16435,,Radioactivity distribution in bone of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 60 min,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL623927,8772
,50597,N,1,,,,16435,,Radioactivity distribution in bone of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 120 min,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL623928,8773
,50597,N,1,,,,16435,,Radioactivity distribution in bone of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 5 min,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL623929,8774
,50597,N,1,,,,16435,,Radioactivity distribution in bone of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 60 min,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL623930,8775
Brain,50597,N,1,,,,16434,,Radioactivity distribution in brain of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 120 min.,1,Rattus norvegicus,Intermediate,,,,10116.0,,955.0,A,BAO_0000218,CHEMBL623931,8776
Brain,50597,N,1,,,,16434,,Radioactivity distribution in brain of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 30 min.,1,Rattus norvegicus,Intermediate,,,,10116.0,,955.0,A,BAO_0000218,CHEMBL622165,8777
Brain,50597,N,1,,,,16434,,Radioactivity distribution in brain of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 5 min.,1,Rattus norvegicus,Intermediate,,,,10116.0,,955.0,A,BAO_0000218,CHEMBL621249,8778
Brain,50597,N,1,,,,16434,,Radioactivity distribution in brain of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 60 min.,1,Rattus norvegicus,Intermediate,,,,10116.0,,955.0,A,BAO_0000218,CHEMBL621250,8779
Brain,50597,N,1,,,,16434,,Radioactivity distribution in brain of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min.,1,Rattus norvegicus,Intermediate,,,,10116.0,,955.0,A,BAO_0000218,CHEMBL621448,8780
Brain,50597,N,1,,,,16434,,Radioactivity distribution in brain of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 30 min.,1,Rattus norvegicus,Intermediate,,,,10116.0,,955.0,A,BAO_0000218,CHEMBL621449,8781
Brain,50597,N,1,,,,16434,,Radioactivity distribution in brain of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min.,1,Rattus norvegicus,Intermediate,,,,10116.0,,955.0,A,BAO_0000218,CHEMBL621450,8782
Brain,50597,N,1,,,,16434,,Radioactivity distribution in brain of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min.,1,Rattus norvegicus,Intermediate,,,,10116.0,,955.0,A,BAO_0000218,CHEMBL621451,8783
Brain,50597,N,1,,,,16435,,Radioactivity distribution in brain of normal fischer rat after injection of anti-[18F]FMACBC after 120 min.,1,Rattus norvegicus,Intermediate,,,,10116.0,,955.0,A,BAO_0000218,CHEMBL621452,8784
Brain,50597,N,1,,,,16435,,Radioactivity distribution in brain of normal fischer rat after injection of anti-[18F]FMACBC after 30 min.,1,Rattus norvegicus,Intermediate,,,,10116.0,,955.0,A,BAO_0000218,CHEMBL621453,8785
Brain,50597,N,1,,,,16435,,Radioactivity distribution in brain of normal fischer rat after injection of anti-[18F]FMACBC after 5 min.,1,Rattus norvegicus,Intermediate,,,,10116.0,,955.0,A,BAO_0000218,CHEMBL621454,8786
Brain,50597,N,1,,,,16435,,Radioactivity distribution in brain of normal fischer rat after injection of anti-[18F]FMACBC after 60 min.,1,Rattus norvegicus,Intermediate,,,,10116.0,,955.0,A,BAO_0000218,CHEMBL621455,8787
Brain,50597,N,1,,,,16435,,Radioactivity distribution in brain of normal fischer rat after injection of syn-[18F]-FMACBC after 120 min.,1,Rattus norvegicus,Intermediate,,,,10116.0,,955.0,A,BAO_0000218,CHEMBL621456,8788
Brain,50597,N,1,,,,16435,,Radioactivity distribution in brain of normal fischer rat after injection of syn-[18F]-FMACBC after 30 min.,1,Rattus norvegicus,Intermediate,,,,10116.0,,955.0,A,BAO_0000218,CHEMBL625145,8789
Brain,50597,N,1,,,,16435,,Radioactivity distribution in brain of normal fischer rat after injection of syn-[18F]-FMACBC after 5 min.,1,Rattus norvegicus,Intermediate,,,,10116.0,,955.0,A,BAO_0000218,CHEMBL875847,8790
Brain,50597,N,1,,,,16435,,Radioactivity distribution in brain of normal fischer rat after injection of syn-[18F]-FMACBC after 60 min.,1,Rattus norvegicus,Intermediate,,,,10116.0,,955.0,A,BAO_0000218,CHEMBL625146,8791
Brain,50597,N,1,,,,16434,,Radioactivity distribution in brain of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min,1,Rattus norvegicus,Intermediate,,,,10116.0,,955.0,A,BAO_0000218,CHEMBL625147,8792
Brain,50597,N,1,,,,16434,,Radioactivity distribution in brain of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min,1,Rattus norvegicus,Intermediate,,,,10116.0,,955.0,A,BAO_0000218,CHEMBL625148,8793
Brain,50597,N,1,,,,16434,,Radioactivity distribution in brain of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min,1,Rattus norvegicus,Intermediate,,,,10116.0,,955.0,A,BAO_0000218,CHEMBL625149,8794
Brain,50597,N,1,,,,16435,,Radioactivity distribution in brain of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 120 min,1,Rattus norvegicus,Intermediate,,,,10116.0,,955.0,A,BAO_0000218,CHEMBL625150,8795
Brain,50597,N,1,,,,16435,,Radioactivity distribution in brain of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 5 min,1,Rattus norvegicus,Intermediate,,,,10116.0,,955.0,A,BAO_0000218,CHEMBL625151,8796
Brain,50597,N,1,,,,16435,,Radioactivity distribution in brain of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 60 min,1,Rattus norvegicus,Intermediate,,,,10116.0,,955.0,A,BAO_0000218,CHEMBL625152,8797
Brain,50597,N,1,,,,16435,,Radioactivity distribution in brain of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 5 min,1,Rattus norvegicus,Intermediate,,,,10116.0,,955.0,A,BAO_0000218,CHEMBL625153,8798
Brain,50597,N,1,,,,16435,,Radioactivity distribution in brain of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 60 min,1,Rattus norvegicus,Intermediate,,,,10116.0,,955.0,A,BAO_0000218,CHEMBL625154,8799
Brain,50597,N,1,,,,16435,,Radioactivity distribution in brain of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 120 min,1,Rattus norvegicus,Intermediate,,,,10116.0,,955.0,A,BAO_0000218,CHEMBL625155,8800
,50597,N,1,,,,11977,,Uptake of radioligand [125I]FIDA1 by hippo-campus in rat after 30 minutes after an intravenous injection is given (average of 2 rats),1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL625156,8801
,50597,N,1,,,,11977,,Uptake of radioligand [125I]-FIDA1 by hippo-campus in rat after 60 minutes after an intravenous injection is given (average of 3 rats),1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL624354,8802
Hippocampus,50597,N,1,,,,11977,,Uptake of radioligand [125I]FIDA1 by hippocampus in rat after 120 minutes after an intravenous injection is given (average of 3 rats),1,Rattus norvegicus,Intermediate,,,,10116.0,,10000000.0,A,BAO_0000218,CHEMBL624355,8803
Hippocampus,50597,N,1,,,,11977,,Uptake of radioligand [125I]FIDA1 by hippocampus in rat after 2 minutes after an intravenous injection is given (average of 3 rats),1,Rattus norvegicus,Intermediate,,,,10116.0,,10000000.0,A,BAO_0000218,CHEMBL624356,8804
Hippocampus,50597,N,1,,,,11977,,Uptake of radioligand [125I]-FIDA1 by hippocampus in rat after 30 minutes after an intravenous injection is given (average of 3 rats),1,Rattus norvegicus,Intermediate,,,,10116.0,,10000000.0,A,BAO_0000218,CHEMBL624357,8805
Hippocampus,50597,N,1,,,,11977,,Uptake of radioligand [125I]FIDA1 by hippocampus in rat after 60 minutes after an intravenous injection is given (average of 3 rats),1,Rattus norvegicus,Intermediate,,,,10116.0,,10000000.0,A,BAO_0000218,CHEMBL624358,8806
Striatum,50597,N,1,,,,11977,,Uptake of radioligand [125I]FIDA1 by striatum in rat after 120 minutes after an intravenous injection is given (average of 3 rats),1,Rattus norvegicus,Intermediate,,,,10116.0,,2435.0,A,BAO_0000218,CHEMBL624359,8807
Striatum,50597,N,1,,,,11977,,Uptake of radioligand [125I]FIDA1 by striatum in rat after 2 minutes after an intravenous injection is given (average of 3 rats),1,Rattus norvegicus,Intermediate,,,,10116.0,,2435.0,A,BAO_0000218,CHEMBL624360,8808
Striatum,50597,N,1,,,,11977,,Uptake of radioligand [125I]FIDA1 by striatum in rat after 30 minutes after an intravenous injection is given (average of 2 rats),1,Rattus norvegicus,Intermediate,,,,10116.0,,2435.0,A,BAO_0000218,CHEMBL624361,8809
Striatum,50597,N,1,,,,11977,,Uptake of radioligand [125I]FIDA1 by striatum in rat after 30 minutes after an intravenous injection is given (average of 3 rats),1,Rattus norvegicus,Intermediate,,,,10116.0,,2435.0,A,BAO_0000218,CHEMBL624362,8810
Striatum,50597,N,1,,,,11977,,Uptake of radioligand [125I]FIDA1 by striatum in rat after 60 minutes after an intravenous injection is given (average of 3 rats),1,Rattus norvegicus,Intermediate,,,,10116.0,,2435.0,A,BAO_0000218,CHEMBL624363,8811
Blood,50597,N,1,In vivo,,,11977,,Biodistribution of radioligand [125I]FIDA1 in blood of rat after 120 minutes after an intravenous injection is given (average of 3 rats),1,Rattus norvegicus,Intermediate,,,,10116.0,,178.0,A,BAO_0000218,CHEMBL624364,8812
Blood,50597,N,1,In vivo,,,11977,,Biodistribution of radioligand [125I]FIDA1 in blood of rat after 2 minutes after an intravenous injection is given (average of 3 rats),1,Rattus norvegicus,Intermediate,,,,10116.0,,178.0,A,BAO_0000218,CHEMBL624365,8813
Blood,50597,N,1,In vivo,,,11977,,Biodistribution of radioligand [125I]FIDA1 in blood of rat after 30 minutes after an intravenous injection is given (average of 3 rats),1,Rattus norvegicus,Intermediate,,,,10116.0,,178.0,A,BAO_0000218,CHEMBL624366,8814
Blood,50597,N,1,In vivo,,,11977,,Biodistribution of radioligand [125I]FIDA1 in blood of rat after 60 minutes after an intravenous injection is given (average of 3 rats),1,Rattus norvegicus,Intermediate,,,,10116.0,,178.0,A,BAO_0000218,CHEMBL624367,8815
Brain,50597,N,1,In vivo,,,11977,,Biodistribution of radioligand [125I]FIDA1 in brain of rat after 120 minutes after an intravenous injection is given (average of 3 rats),1,Rattus norvegicus,Intermediate,,,,10116.0,,955.0,A,BAO_0000218,CHEMBL624368,8816
Brain,50597,N,1,In vivo,,,11977,,Biodistribution of radioligand [125I]FIDA1 in brain of rat after 2 minutes after an intravenous injection is given (average of 3 rats),1,Rattus norvegicus,Intermediate,,,,10116.0,,955.0,A,BAO_0000218,CHEMBL624369,8817
Brain,50597,N,1,In vivo,,,11977,,Biodistribution of radioligand [125I]FIDA1 in brain of rat after 30 minutes after an intravenous injection is given (average of 2 rats),1,Rattus norvegicus,Intermediate,,,,10116.0,,955.0,A,BAO_0000218,CHEMBL624370,8818
Brain,50597,N,1,In vivo,,,11977,,Biodistribution of radioligand [125I]FIDA1 in brain of rat after 30 minutes after an intravenous injection is given (average of 3 rats),1,Rattus norvegicus,Intermediate,,,,10116.0,,955.0,A,BAO_0000218,CHEMBL625069,8819
Brain,50597,N,1,In vivo,,,11977,,Biodistribution of radioligand [125I]FIDA1 in brain of rat after 60 minutes after an intravenous injection is given (average of 3 rats),1,Rattus norvegicus,Intermediate,,,,10116.0,,955.0,A,BAO_0000218,CHEMBL625070,8820
Heart,50597,N,1,In vivo,,,11977,,Biodistribution of radioligand [125I]-FIDA1 in heart of rat after 120 minutes after an intravenous injection is given (average of 3 rats),1,Rattus norvegicus,Intermediate,,,,10116.0,,948.0,A,BAO_0000218,CHEMBL626051,8821
Heart,50597,N,1,In vivo,,,11977,,Biodistribution of radioligand [125I]FIDA1 in heart of rat after 2 minutes after an intravenous injection is given (average of 3 rats),1,Rattus norvegicus,Intermediate,,,,10116.0,,948.0,A,BAO_0000218,CHEMBL626052,8822
Heart,50597,N,1,In vivo,,,11977,,Biodistribution of radioligand [125I]FIDA1 in heart of rat after 30 minutes after an intravenous injection is given (average of 2 rats),1,Rattus norvegicus,Intermediate,,,,10116.0,,948.0,A,BAO_0000218,CHEMBL626053,8823
Heart,50597,N,1,In vivo,,,11977,,Biodistribution of radioligand [125I]FIDA1 in heart of rat after 30 minutes after an intravenous injection is given (average of 3 rats),1,Rattus norvegicus,Intermediate,,,,10116.0,,948.0,A,BAO_0000218,CHEMBL626054,8824
Heart,50597,N,1,In vivo,,,11977,,Biodistribution of radioligand [125I]FIDA1 in heart of rat after 60 minutes after an intravenous injection is given (average of 3 rats),1,Rattus norvegicus,Intermediate,,,,10116.0,,948.0,A,BAO_0000218,CHEMBL626055,8825
Kidney,50597,N,1,In vivo,,,11977,,Biodistribution of radioligand [125I]FIDA1 in kidney of rat after 120 minutes after an intravenous injection is given (average of 3 rats),1,Rattus norvegicus,Intermediate,,,,10116.0,,2113.0,A,BAO_0000218,CHEMBL626056,8826
Kidney,50597,N,1,In vivo,,,11977,,Biodistribution of radioligand [125I]-FIDA1 in kidney of rat after 2 minutes after an intravenous injection is given (average of 3 rats),1,Rattus norvegicus,Intermediate,,,,10116.0,,2113.0,A,BAO_0000218,CHEMBL626057,8827
Kidney,50597,N,1,In vivo,,,11977,,Biodistribution of radioligand [125I]FIDA1 in kidney of rat after 30 minutes after an intravenous injection is given (average of 3 rats),1,Rattus norvegicus,Intermediate,,,,10116.0,,2113.0,A,BAO_0000218,CHEMBL625193,8828
Kidney,50597,N,1,In vivo,,,11977,,Biodistribution of radioligand [125I]FIDA1 in kidney of rat after 60 minutes after an intravenous injection is given (average of 3 rats),1,Rattus norvegicus,Intermediate,,,,10116.0,,2113.0,A,BAO_0000218,CHEMBL625194,8829
Liver,50597,N,1,In vivo,,,11977,,Biodistribution of radioligand [125I]FIDA1 in liver of rat after 120 minutes after an intravenous injection is given (average of 3 rats),1,Rattus norvegicus,Intermediate,,,,10116.0,,2107.0,A,BAO_0000218,CHEMBL625195,8830
Liver,50597,N,1,In vivo,,,11977,,Biodistribution of radioligand [125I]-FIDA1 in liver of rat after 2 minutes after an intravenous injection is given (average of 3 rats),1,Rattus norvegicus,Intermediate,,,,10116.0,,2107.0,A,BAO_0000218,CHEMBL625196,8831
Liver,50597,N,1,In vivo,,,11977,,Biodistribution of radioligand [125I]FIDA1 in liver of rat after 30 minutes after an intravenous injection is given (average of 2 rats),1,Rattus norvegicus,Intermediate,,,,10116.0,,2107.0,A,BAO_0000218,CHEMBL625197,8832
Liver,50597,N,1,In vivo,,,11977,,Biodistribution of radioligand [125I]FIDA1 in liver of rat after 30 minutes after an intravenous injection is given (average of 3 rats),1,Rattus norvegicus,Intermediate,,,,10116.0,,2107.0,A,BAO_0000218,CHEMBL625198,8833
Liver,50597,N,1,In vivo,,,11977,,Biodistribution of radioligand [125I]FIDA1 in liver of rat after 60 minutes after an intravenous injection is given (average of 3 rats),1,Rattus norvegicus,Intermediate,,,,10116.0,,2107.0,A,BAO_0000218,CHEMBL627929,8834
Lung,50597,N,1,In vivo,,,11977,,Biodistribution of radioligand [125I]FIDA1 in lung of rat after 120 minutes after an intravenous injection is given (average of 3 rats),1,Rattus norvegicus,Intermediate,,,,10116.0,,2048.0,A,BAO_0000218,CHEMBL627074,8835
Lung,50597,N,1,In vivo,,,11977,,Biodistribution of radioligand [125I]FIDA1 in lung of rat after 2 minutes after an intravenous injection is given (average of 3 rats),1,Rattus norvegicus,Intermediate,,,,10116.0,,2048.0,A,BAO_0000218,CHEMBL627075,8836
Lung,50597,N,1,In vivo,,,11977,,Biodistribution of radioligand [125I]FIDA1 in lung of rat after 30 minutes after an intravenous injection is given (average of 2 rats),1,Rattus norvegicus,Intermediate,,,,10116.0,,2048.0,A,BAO_0000218,CHEMBL627076,8837
Lung,50597,N,1,In vivo,,,11977,,Biodistribution of radioligand [125I]FIDA1 in lung of rat after 30 minutes after an intravenous injection is given (average of 3 rats),1,Rattus norvegicus,Intermediate,,,,10116.0,,2048.0,A,BAO_0000218,CHEMBL627077,8838
Lung,50597,N,1,In vivo,,,11977,,Biodistribution of radioligand [125I]FIDA1 in lung of rat after 60 minutes after an intravenous injection is given (average of 3 rats),1,Rattus norvegicus,Intermediate,,,,10116.0,,2048.0,A,BAO_0000218,CHEMBL627078,8839
Muscle tissue,50597,N,1,In vivo,,,11977,,Biodistribution of radioligand [125I]FIDA1 in muscle of rat after 120 minutes after an intravenous injection is given (average of 2 rats),1,Rattus norvegicus,Intermediate,,,,10116.0,,2385.0,A,BAO_0000218,CHEMBL627079,8840
,50594,N,1,In vivo,,,4573,,Half life (t1/2) determined at a dose 10 mg/kg administered intraperitoneally to mice,1,Mus musculus,Intermediate,,,,10090.0,,,A,BAO_0000218,CHEMBL873824,8841
Plasma,50594,N,1,In vivo,,,3132,,Half life in mouse plasma was determined at dose 25 mg/kg,1,Mus musculus,Intermediate,,,,10090.0,,1969.0,A,BAO_0000218,CHEMBL627080,8842
,50594,N,1,,,,17718,,Half life was determined,1,Mus musculus,Intermediate,,,,10090.0,,,A,BAO_0000218,CHEMBL627081,8843
,50594,N,1,In vivo,,,17728,,Half life in BALB/C mice at the dose of 20 mg/kg by i.v. administration,1,Mus musculus,Intermediate,,,,10090.0,,,A,BAO_0000218,CHEMBL627082,8844
,50594,N,1,In vivo,,,5961,,Half-life in male mice after 1 mg/kg intravenous dose,1,Mus musculus,Intermediate,,,,10090.0,,,A,BAO_0000218,CHEMBL627083,8845
Plasma,50594,N,1,,,,17731,,Half life in mice plasma,1,Mus musculus,Intermediate,,,,10090.0,,1969.0,A,BAO_0000218,CHEMBL627085,8847
,50594,N,1,,,,17592,,Half life in mouse,1,Mus musculus,Intermediate,,,,10090.0,,,A,BAO_0000218,CHEMBL627086,8848
Plasma,50594,N,1,In vivo,,,3132,,Half life in mouse plasma at dose 25 mg/kg,1,Mus musculus,Intermediate,,,,10090.0,,1969.0,A,BAO_0000218,CHEMBL627087,8849
,50594,N,1,In vivo,,,17729,,Half life when injected i.p. in mice at a dose of 50 mg/kg was determined,1,Mus musculus,Intermediate,,,,10090.0,,,A,BAO_0000218,CHEMBL627088,8850
,50594,N,1,In vivo,,,17729,,Half life when injected intravenously in mice at a dose of 20 mg/kg was determined,1,Mus musculus,Intermediate,,,,10090.0,,,A,BAO_0000218,CHEMBL627089,8851
,50594,N,1,In vivo,,,17729,,Half life when injected perorally in mice at a dose of 50 mg/kg was determined,1,Mus musculus,Intermediate,,,,10090.0,,,A,BAO_0000218,CHEMBL627090,8852
,50594,N,1,In vivo,,,3277,,Half life was determined in mice at a single subcutaneous administration of 40 mg/kg (n=4),1,Mus musculus,Intermediate,,,,10090.0,,,A,BAO_0000218,CHEMBL627091,8853
,50594,N,1,In vivo,,,3760,,"Half life was evaluated at 5 mg/kg of compound dose, administered perorally in mice",1,Mus musculus,Intermediate,,,,10090.0,,,A,BAO_0000218,CHEMBL627092,8854
,50594,N,1,In vivo,,,3760,,"Half life was evaluated at 50 mg/kg of compound dose, administered perorally in mice",1,Mus musculus,Intermediate,,,,10090.0,,,A,BAO_0000218,CHEMBL876785,8855
,50594,N,1,In vivo,,,2862,,Half-life by iv administration in mouse,1,Mus musculus,Intermediate,,,,10090.0,,,A,BAO_0000218,CHEMBL627093,8856
,50594,N,1,In vivo,,,2862,,Half-life by oral administration in mouse,1,Mus musculus,Intermediate,,,,10090.0,,,A,BAO_0000218,CHEMBL627094,8857
,50594,N,1,,,,5980,,Half-life in mice,1,Mus musculus,Intermediate,,,,10090.0,,,A,BAO_0000218,CHEMBL627095,8858
Brain,50594,N,1,,,,6159,,Half-life using mouse brain homogenate,1,Mus musculus,Intermediate,,,,10090.0,,955.0,A,BAO_0000218,CHEMBL627096,8859
,50594,N,1,,,,6254,,Half-life was measured in mice,1,Mus musculus,Intermediate,,,,10090.0,,,A,BAO_0000218,CHEMBL627097,8860
,50594,N,1,In vivo,,,6062,,Half-life was measured in mouse after an iv dose of 1 mg/kg,1,Mus musculus,Intermediate,,,,10090.0,,,A,BAO_0000218,CHEMBL627098,8861
Blood,50594,N,1,,,,1574,,Half-life period was determined in mouse blood,1,Mus musculus,Intermediate,,,,10090.0,,178.0,A,BAO_0000218,CHEMBL627099,8862
Brain,50594,N,1,,,,56,,"Half-times of inhibition of PEP in in an ex vivo enzyme studies, using mice brain",1,Mus musculus,Intermediate,,,,10090.0,,955.0,A,BAO_0000218,CHEMBL627100,8863
Plasma,50594,N,1,,,,993,,Plasma half life in mouse,1,Mus musculus,Intermediate,,,,10090.0,,1969.0,A,BAO_0000218,CHEMBL627101,8864
,50594,N,1,,,,6652,,Stability of the peptide in the presence of mouse serum,1,Mus musculus,Intermediate,,,,10090.0,,,A,BAO_0000218,CHEMBL627102,8865
,50594,N,1,,,,17852,,Terminal half life of compound was determined in mouse,1,Mus musculus,Intermediate,,,,10090.0,,,A,BAO_0000218,CHEMBL627103,8866
,50594,N,1,In vivo,,,2675,,Terminal half life was evaluated in mice after intravenous administration,1,Mus musculus,Intermediate,,,,10090.0,,,A,BAO_0000218,CHEMBL627104,8867
,50594,N,1,In vivo,,,2675,,Terminal half life was evaluated in mice after oral administration,1,Mus musculus,Intermediate,,,,10090.0,,,A,BAO_0000218,CHEMBL627105,8868
,50594,N,1,,,,499,,The compound was evaluated for half life (release of DOX) in mice at 37 degree Celsius at the pH 5.,1,Mus musculus,Intermediate,,,,10090.0,,,A,BAO_0000218,CHEMBL876786,8869
,50594,N,1,,,,499,,The compound was evaluated for half life (release of DOX) in mice at 37 degree Celsius at the pH 7.,1,Mus musculus,Intermediate,,,,10090.0,,,A,BAO_0000218,CHEMBL873825,8870
,50594,N,1,,,,499,,The compound was evaluated for half life (release of DOX) in mice at 37 degree Celsius at the pH 7; ND means no data,1,Mus musculus,Intermediate,,,,10090.0,,,A,BAO_0000218,CHEMBL627106,8871
,50594,N,1,In vivo,,,14239,,half life period is evaluated by administering intravenously at 25 mg/kg in mice,1,Mus musculus,Intermediate,,,,10090.0,,,A,BAO_0000218,CHEMBL626336,8872
,50594,N,1,In vivo,,,5506,,"Half life beta(2,4,6,8h) value was determined at a dose of 200 mg/kg (i.p.) in Mice",1,Mus musculus,Intermediate,,,,10090.0,,,A,BAO_0000218,CHEMBL877462,8873
,50594,N,1,In vivo,,,5506,,"Half life beta(2,4,6,8h) value was determined at a dose of 200 mg/kg (i.p.) in Mice; NC: not calculable",1,Mus musculus,Intermediate,,,,10090.0,,,A,BAO_0000218,CHEMBL626337,8874
,50594,N,1,,,,17734,,Half life after intraperitoneal administration of 100 mg/kg in mice,1,Mus musculus,Intermediate,,,,10090.0,,,A,BAO_0000218,CHEMBL626338,8875
,50594,N,1,In vivo,,,17728,,Half life in BALB/C mice at the dose of 20 mg/kg by i.p. administration,1,Mus musculus,Intermediate,,,,10090.0,,,A,BAO_0000218,CHEMBL626339,8876
,50594,N,1,In vivo,,,17728,,Half life in BALB/C mice at the dose of 20 mg/kg by i.v. administration,1,Mus musculus,Intermediate,,,,10090.0,,,A,BAO_0000218,CHEMBL626340,8877
,50594,N,1,In vivo,,,17728,,Half life in BALB/C mice at the dose of 20 mg/kg by p.o. administration,1,Mus musculus,Intermediate,,,,10090.0,,,A,BAO_0000218,CHEMBL625377,8878
,50594,N,1,In vivo,,,17728,,Half life in BALB/C mice at the dose of 50 mg/kg by i.p. administration,1,Mus musculus,Intermediate,,,,10090.0,,,A,BAO_0000218,CHEMBL625378,8879
,50594,N,1,In vivo,,,17728,,Half life in BALB/C mice at the dose of 50 mg/kg by p.o. administration,1,Mus musculus,Intermediate,,,,10090.0,,,A,BAO_0000218,CHEMBL625379,8880
,22224,U,0,,,Microsomes,14294,,Metabolism of compound in mini pig S9 microsomes ('+''indicates <20% largest observed peak),1,Sus scrofa,Autocuration,,,,9823.0,,,A,BAO_0000251,CHEMBL625380,8881
,22224,U,0,,,Microsomes,14294,,Metabolism of compound in mini pig S9 microsomes ('++++' indicates largest observed peak),1,Sus scrofa,Autocuration,,,,9823.0,,,A,BAO_0000251,CHEMBL625381,8882
,22224,U,0,,,,6056,,Stability to porcine renal DHP-I,1,Sus scrofa,Autocuration,,,,9823.0,,,A,BAO_0000019,CHEMBL625382,8883
,22224,U,0,In vivo,,,1317,,Compound was tested for its half-life period at an intravenous dose of 30 ug/kg,1,Sus scrofa,Autocuration,,,,9823.0,,,A,BAO_0000218,CHEMBL873828,8884
,22224,U,0,In vivo,,,1317,,Compound was tested for its half-life period at an intravenous dose of 3 ug/kg,1,Sus scrofa,Autocuration,,,,9823.0,,,A,BAO_0000218,CHEMBL625383,8885
,22224,U,0,,,,5229,,Half-life of the parent prodrug in porcine esterase solution,1,Sus scrofa,Autocuration,,,,9823.0,,,A,BAO_0000019,CHEMBL625384,8886
,22224,U,0,,,,4231,,"First order rate constant, k was determined in in pig liver Esterase",1,Sus scrofa,Autocuration,,,,9823.0,,,A,BAO_0000019,CHEMBL625385,8887
Liver,22224,U,0,,,,4231,,Half life of the in pig liver Esterase,1,Sus scrofa,Autocuration,,,,9823.0,,2107.0,A,BAO_0000221,CHEMBL625386,8888
Liver,22224,U,0,,,,5318,,Tested for half life period at 37 degree Celsius in PBS buffer at 11.8 pH containing porcine liver esterase,1,Sus scrofa,Autocuration,,,,9823.0,,2107.0,A,BAO_0000221,CHEMBL623571,8889
Liver,22224,U,0,,,,5318,,Tested for half life period at 37 degree Celsius in PBS buffer at 7.3 pH containing porcine liver esterase,1,Sus scrofa,Autocuration,,,,9823.0,,2107.0,A,BAO_0000221,CHEMBL623572,8890
Liver,22224,U,0,,,,5318,,Tested for half life period at 37 degree Celsius in PBS buffer at 7.3 pH in containing porcine liver esterase,1,Sus scrofa,Autocuration,,,,9823.0,,2107.0,A,BAO_0000221,CHEMBL623573,8891
Liver,22224,U,0,,,,3305,,Compound was evaluated for esterase half-life (t 1/2) period using Pig Liver Esterase (PLE) assay,1,Sus scrofa,Autocuration,,,,9823.0,,2107.0,A,BAO_0000221,CHEMBL623574,8892
Liver,22224,U,0,,,,3305,,Compound was evaluated for esterase half-life (t 1/2) period using Pig Liver Esterase (PLE) assay; ND is not determined,1,Sus scrofa,Autocuration,,,,9823.0,,2107.0,A,BAO_0000221,CHEMBL623575,8893
Liver,22224,U,0,,,,2842,,Half-life in the presence of pig liver esterase(PLE) was evaluated.,1,Sus scrofa,Autocuration,,,,9823.0,,2107.0,A,BAO_0000221,CHEMBL623749,8894
Liver,22224,U,0,,,,2842,,Half-life in the presence of pig liver esterase(PLE) was evaluated; Stable,1,Sus scrofa,Autocuration,,,,9823.0,,2107.0,A,BAO_0000221,CHEMBL623750,8895
Liver,22224,U,0,In vitro,,,889,,Half-life in vitro in pig liver,1,Sus scrofa,Autocuration,,,,9823.0,,2107.0,A,BAO_0000221,CHEMBL623751,8896
Liver,22224,U,0,,,,1904,,Half-life time was determined for esterase-catalyzed hydrolysis of the phenol ester bond in porcine liver esterase,1,Sus scrofa,Autocuration,,,,9823.0,,2107.0,A,BAO_0000221,CHEMBL623752,8897
Plasma,50597,N,1,In vivo,,,4186,,Maximum concentration in rat plasma after administration of 50 mg/kg dose through subcutaneous route,1,Rattus norvegicus,Intermediate,,,,10116.0,,1969.0,A,BAO_0000218,CHEMBL623753,8898
Plasma,50597,N,1,In vivo,,,2774,,Maximum concentration in rat plasma at 30 mg/Kg upon oral administration.,1,Rattus norvegicus,Intermediate,,,,10116.0,,1969.0,A,BAO_0000218,CHEMBL623754,8899
Plasma,50597,N,1,In vivo,,,1742,,Maximum concentration in rat plasma was determined,1,Rattus norvegicus,Intermediate,,,,10116.0,,1969.0,A,BAO_0000218,CHEMBL623755,8900
,50597,N,1,In vivo,,,3169,,Maximum concentration in rats,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL623756,8901
,50597,N,1,In vivo,,,3169,,Maximum concentration in rats at 1-2 hours,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL623757,8902
,50597,N,1,In vivo,,,2081,,Maximum concentration in rats at 1 hr was determined when dosed at 20 mg/Kg perorally,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL623758,8903
Brain,50597,N,1,In vivo,,,3307,,Maximum concentration in whole brain at 30 min following 24 mg/kg subcutaneous dose in rats,1,Rattus norvegicus,Intermediate,,,,10116.0,,955.0,A,BAO_0000218,CHEMBL623759,8904
,50597,N,1,In vivo,,,4727,,Maximum concentration at the dose of 2 mg/kg in rat,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL623760,8905
,50597,N,1,In vivo,,,6597,,Maximum concentration was evaluated in rats,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL623761,8906
Plasma,50597,N,1,In vivo,,,16365,,Maximum concentration of uncharged drug in plasma recorded in the period of 0-24 hr after administering orally a dose of 10 mg/kg to a fasting rat,1,Rattus norvegicus,Intermediate,,,,10116.0,,1969.0,A,BAO_0000218,CHEMBL623762,8907
Plasma,50597,N,1,In vivo,,,16365,,Maximum concentration of uncharged drug in plasma recorded in the period of 0-24 hr after administering orally a dose of 1 mg/kg to a fasting rat,1,Rattus norvegicus,Intermediate,,,,10116.0,,1969.0,A,BAO_0000218,CHEMBL877594,8908
Plasma,50597,N,1,In vivo,,,16365,,Maximum concentration of uncharged drug in plasma recorded in the period of 0-24 hr after administering orally a dose of 30 mg/kg,1,Rattus norvegicus,Intermediate,,,,10116.0,,1969.0,A,BAO_0000218,CHEMBL623763,8909
Plasma,50597,N,1,In vivo,,,16365,,Maximum concentration of uncharged drug in plasma recorded in the period of 0-24 hr after administering orally a dose of 3 mg/kg,1,Rattus norvegicus,Intermediate,,,,10116.0,,1969.0,A,BAO_0000218,CHEMBL623764,8910
Plasma,50597,N,1,In vivo,,,16365,,Maximum concentration of uncharged drug in plasma recorded in the period of 0-24 hr after administering orally a dose of 3 mg/kg to a fasting rat,1,Rattus norvegicus,Intermediate,,,,10116.0,,1969.0,A,BAO_0000218,CHEMBL623765,8911
Blood,50597,N,1,In vivo,,,2591,,Maximum concentration value was evaluated for high sustained blood levels in rat after 1 hr of administration,1,Rattus norvegicus,Intermediate,,,,10116.0,,178.0,A,BAO_0000218,CHEMBL623766,8912
Blood,50597,N,1,In vivo,,,2591,,Maximum concentration value was evaluated for high sustained blood levels in rat after 2 hr of administration,1,Rattus norvegicus,Intermediate,,,,10116.0,,178.0,A,BAO_0000218,CHEMBL623767,8913
Blood,50597,N,1,In vivo,,,2591,,Maximum concentration value was evaluated for high sustained blood levels in rat after 30 min of administration,1,Rattus norvegicus,Intermediate,,,,10116.0,,178.0,A,BAO_0000218,CHEMBL623768,8914
Plasma,50597,N,1,In vivo,,,5978,,Maximum plasma concentration (Cmax) of compound (19.2 mg/kg) after po administration was determined Sprague-Dawley rat,1,Rattus norvegicus,Intermediate,,,,10116.0,,1969.0,A,BAO_0000218,CHEMBL623769,8915
Plasma,50597,N,1,In vivo,,,5978,,Maximum plasma concentration (Cmax) of compound (19.76 mg/kg) after po administration was determined Sprague-Dawley rat,1,Rattus norvegicus,Intermediate,,,,10116.0,,1969.0,A,BAO_0000218,CHEMBL623770,8916
Plasma,50597,N,1,In vivo,,,5978,,Maximum plasma concentration (Cmax) of compound (20.73 mg/kg) after po administration was determined Sprague-Dawley rat,1,Rattus norvegicus,Intermediate,,,,10116.0,,1969.0,A,BAO_0000218,CHEMBL623771,8917
Plasma,50597,N,1,In vivo,,,5978,,Maximum plasma concentration (Cmax) of compound (25 mg/kg) after po administration was determined Sprague-Dawley rat,1,Rattus norvegicus,Intermediate,,,,10116.0,,1969.0,A,BAO_0000218,CHEMBL623772,8918
Plasma,50597,N,1,In vivo,,,5978,,Maximum plasma concentration (Cmax) of compound (9.83 mg/kg) after iv administration was determined Sprague-Dawley rat,1,Rattus norvegicus,Intermediate,,,,10116.0,,1969.0,A,BAO_0000218,CHEMBL623773,8919
Plasma,50597,N,1,In vivo,,,5978,,Maximum plasma concentration (Cmax) of compound (9.84 mg/kg) after iv administration was determined Sprague-Dawley rat,1,Rattus norvegicus,Intermediate,,,,10116.0,,1969.0,A,BAO_0000218,CHEMBL623774,8920
Plasma,50597,N,1,In vivo,,,5978,,Maximum plasma concentration (Cmax) of compound (9.92 mg/kg) after iv administration was determined Sprague-Dawley rat,1,Rattus norvegicus,Intermediate,,,,10116.0,,1969.0,A,BAO_0000218,CHEMBL623775,8921
,50597,N,1,In vivo,,,14465,,Cmax in rat (PO dose),1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL623776,8922
Plasma,50597,N,1,In vivo,,,4723,,Maximum plasma concentration determined after 0.3 mg/kg oral administration in potassium oxonate treated rats,1,Rattus norvegicus,Intermediate,,,,10116.0,,1969.0,A,BAO_0000218,CHEMBL622191,8923
Plasma,50597,N,1,In vivo,,,4723,,Maximum plasma concentration determined after 3 mg/kg oral administration in potassium oxonate treated rats,1,Rattus norvegicus,Intermediate,,,,10116.0,,1969.0,A,BAO_0000218,CHEMBL622192,8924
Plasma,50597,N,1,In vivo,,,4576,,Maximum plasma concentration determined in rat,1,Rattus norvegicus,Intermediate,,,,10116.0,,1969.0,A,BAO_0000218,CHEMBL622193,8925
Plasma,50597,N,1,In vivo,,,12873,,Maximum plasma concentration for the compound in solution form (formulation) was determined in rats at peroral dose of 5 mg/kg,1,Rattus norvegicus,Intermediate,,,,10116.0,,1969.0,A,BAO_0000218,CHEMBL622194,8926
Plasma,50597,N,1,In vivo,,,12873,,Maximum plasma concentration for the compound in suspension form (formulation) was determined in rats at peroral dose of 5 mg/kg,1,Rattus norvegicus,Intermediate,,,,10116.0,,1969.0,A,BAO_0000218,CHEMBL622195,8927
Plasma,50597,N,1,In vivo,,,6824,,Maximum plasma concentration in rat,1,Rattus norvegicus,Intermediate,,,,10116.0,,1969.0,A,BAO_0000218,CHEMBL622196,8928
Plasma,50597,N,1,In vivo,,,17065,,Maximum plasma concentration measured after intravenous bolus administration of 50 mg/kg of compound to rats,1,Rattus norvegicus,Intermediate,,,,10116.0,,1969.0,A,BAO_0000218,CHEMBL622197,8929
Plasma,50597,N,1,In vivo,,,2932,,Maximum plasma concentration of compound present in rats at the dose of 37 mg/kg in 15 min,1,Rattus norvegicus,Intermediate,,,,10116.0,,1969.0,A,BAO_0000218,CHEMBL622198,8930
Plasma,50597,N,1,In vivo,,,2932,,Maximum plasma concentration of compound present in rats at the dose of 38 mg/kg in 15 min,1,Rattus norvegicus,Intermediate,,,,10116.0,,1969.0,A,BAO_0000218,CHEMBL622199,8931
Plasma,50597,N,1,In vivo,,,2879,,Maximum plasma concentration of compound was measured in rat,1,Rattus norvegicus,Intermediate,,,,10116.0,,1969.0,A,BAO_0000218,CHEMBL622200,8932
Plasma,50597,N,1,In vivo,,,2864,,Maximum plasma concentration after 20 mg/kg oral administration in rat,1,Rattus norvegicus,Intermediate,,,,10116.0,,1969.0,A,BAO_0000218,CHEMBL622201,8933
Plasma,50597,N,1,In vivo,,,16367,,Maximum plasma concentration after oral administration to rats,1,Rattus norvegicus,Intermediate,,,,10116.0,,1969.0,A,BAO_0000218,CHEMBL623990,8934
Plasma,50597,N,1,In vivo,,,17717,,Maximum plasma concentration at a concentration of 15 mg/kg perorally in rats along with 100 mg/kg of compound 11,1,Rattus norvegicus,Intermediate,,,,10116.0,,1969.0,A,BAO_0000218,CHEMBL623991,8935
Plasma,50597,N,1,In vivo,,,17717,,"Maximum plasma concentration at a concentration of 3 mg/kg in rats, intravenously",1,Rattus norvegicus,Intermediate,,,,10116.0,,1969.0,A,BAO_0000218,CHEMBL623992,8936
Plasma,50597,N,1,In vivo,,,17717,,Maximum plasma concentration at a concentration of 60 mg/kg perorally in rats along with 100 mg/kg of compound 11,1,Rattus norvegicus,Intermediate,,,,10116.0,,1969.0,A,BAO_0000218,CHEMBL623993,8937
Plasma,50597,N,1,In vivo,,,17717,,Maximum plasma concentration at a concentration of 60 mg/kg perorally in rats along with control,1,Rattus norvegicus,Intermediate,,,,10116.0,,1969.0,A,BAO_0000218,CHEMBL623994,8938
Plasma,50597,N,1,In vivo,,,17720,,Maximum plasma concentration at a dose of 100 mg/kg in Rat Plasma after iv administration,1,Rattus norvegicus,Intermediate,,,,10116.0,,1969.0,F,BAO_0000218,CHEMBL623995,8939
Plasma,50597,N,1,In vivo,,,17720,,Maximum plasma concentration at a dose of 4 mg/kg in Rat Plasma after iv administration,1,Rattus norvegicus,Intermediate,,,,10116.0,,1969.0,F,BAO_0000218,CHEMBL623996,8940
Plasma,50597,N,1,In vivo,,,17720,,Maximum plasma concentration at a dose of 50 mg/kg in Rat Plasma after iv administration,1,Rattus norvegicus,Intermediate,,,,10116.0,,1969.0,F,BAO_0000218,CHEMBL623997,8941
Plasma,50597,N,1,In vivo,,,4516,,Maximum plasma concentration dosed orally in rats,1,Rattus norvegicus,Intermediate,,,,10116.0,,1969.0,A,BAO_0000218,CHEMBL623998,8942
Plasma,50597,N,1,In vivo,,,4516,,Maximum plasma concentration dosed orally in rats after 6 hours,1,Rattus norvegicus,Intermediate,,,,10116.0,,1969.0,A,BAO_0000218,CHEMBL623999,8943
Plasma,50597,N,1,In vivo,,,4516,,Maximum plasma concentration dosed orally in rats after 6 hours; ND is not detected,1,Rattus norvegicus,Intermediate,,,,10116.0,,1969.0,A,BAO_0000218,CHEMBL624000,8944
Plasma,50597,N,1,In vivo,,,5199,,Maximum plasma concentration at a 1 mg/kg oral dose in female Sprague-Dawley rats,1,Rattus norvegicus,Intermediate,,,,10116.0,,1969.0,A,BAO_0000218,CHEMBL624001,8945
Plasma,50597,N,1,In vivo,,,17538,,Maximum plasma concentration in rat after po administration,1,Rattus norvegicus,Intermediate,,,,10116.0,,1969.0,A,BAO_0000218,CHEMBL624002,8946
Plasma,50597,N,1,In vivo,,,6685,,"Maximum plasma concentration in rats at 10 mg/kg, p.o. dose",1,Rattus norvegicus,Intermediate,,,,10116.0,,1969.0,A,BAO_0000218,CHEMBL624003,8947
Plasma,50597,N,1,In vivo,,,6685,,"Maximum plasma concentration in rats at 20mg/kg, i.p. dose",1,Rattus norvegicus,Intermediate,,,,10116.0,,1969.0,A,BAO_0000218,CHEMBL624004,8948
Heart,50597,N,1,,,,16434,,Radioactivity distribution in heart of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 120 min.,1,Rattus norvegicus,Intermediate,,,,10116.0,,948.0,A,BAO_0000218,CHEMBL624005,8949
Heart,50597,N,1,,,,16434,,Radioactivity distribution in heart of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 30 min.,1,Rattus norvegicus,Intermediate,,,,10116.0,,948.0,A,BAO_0000218,CHEMBL624006,8950
Heart,50597,N,1,,,,16434,,Radioactivity distribution in heart of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 5 min.,1,Rattus norvegicus,Intermediate,,,,10116.0,,948.0,A,BAO_0000218,CHEMBL624007,8951
Heart,50597,N,1,,,,16434,,Radioactivity distribution in heart of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 60 min.,1,Rattus norvegicus,Intermediate,,,,10116.0,,948.0,A,BAO_0000218,CHEMBL624008,8952
Heart,50597,N,1,,,,16434,,Radioactivity distribution in heart of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min.,1,Rattus norvegicus,Intermediate,,,,10116.0,,948.0,A,BAO_0000218,CHEMBL624009,8953
Heart,50597,N,1,,,,16434,,Radioactivity distribution in heart of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 30 min.,1,Rattus norvegicus,Intermediate,,,,10116.0,,948.0,A,BAO_0000218,CHEMBL874387,8954
Heart,50597,N,1,,,,16434,,Radioactivity distribution in heart of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min.,1,Rattus norvegicus,Intermediate,,,,10116.0,,948.0,A,BAO_0000218,CHEMBL624010,8955
Heart,50597,N,1,,,,16434,,Radioactivity distribution in heart of normal fischer rat after injection of [18F]-fluoro-2-methylpropanoic acid after 60 min.,1,Rattus norvegicus,Intermediate,,,,10116.0,,948.0,A,BAO_0000218,CHEMBL624011,8956
Heart,50597,N,1,,,,16435,,Radioactivity distribution in heart of normal fischer rat after injection of anti-[18F]FMACBC after 120 min.,1,Rattus norvegicus,Intermediate,,,,10116.0,,948.0,A,BAO_0000218,CHEMBL624012,8957
Heart,50597,N,1,,,,16435,,Radioactivity distribution in heart of normal fischer rat after injection of anti-[18F]FMACBC after 30 min.,1,Rattus norvegicus,Intermediate,,,,10116.0,,948.0,A,BAO_0000218,CHEMBL624013,8958
Heart,50597,N,1,,,,16435,,Radioactivity distribution in heart of normal fischer rat after injection of anti-[18F]FMACBC after 5 min.,1,Rattus norvegicus,Intermediate,,,,10116.0,,948.0,A,BAO_0000218,CHEMBL624736,8959
Heart,50597,N,1,,,,16435,,Radioactivity distribution in heart of normal fischer rat after injection of anti-[18F]FMACBC after 60 min.,1,Rattus norvegicus,Intermediate,,,,10116.0,,948.0,A,BAO_0000218,CHEMBL624737,8960
Heart,50597,N,1,,,,16434,,Radioactivity distribution in heart of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min,1,Rattus norvegicus,Intermediate,,,,10116.0,,948.0,A,BAO_0000218,CHEMBL624738,8961
Heart,50597,N,1,,,,16434,,Radioactivity distribution in heart of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min,1,Rattus norvegicus,Intermediate,,,,10116.0,,948.0,A,BAO_0000218,CHEMBL624739,8962
Heart,50597,N,1,,,,16434,,Radioactivity distribution in heart of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min,1,Rattus norvegicus,Intermediate,,,,10116.0,,948.0,A,BAO_0000218,CHEMBL624740,8963
Heart,50597,N,1,,,,16435,,Radioactivity distribution in heart of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 120 min,1,Rattus norvegicus,Intermediate,,,,10116.0,,948.0,A,BAO_0000218,CHEMBL624896,8964
Heart,50597,N,1,,,,16435,,Radioactivity distribution in heart of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 5 min,1,Rattus norvegicus,Intermediate,,,,10116.0,,948.0,A,BAO_0000218,CHEMBL624897,8965
Heart,50597,N,1,,,,16435,,Radioactivity distribution in heart of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 60 min,1,Rattus norvegicus,Intermediate,,,,10116.0,,948.0,A,BAO_0000218,CHEMBL624108,8966
Heart,50597,N,1,,,,16435,,Radioactivity distribution in heart of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 120 min,1,Rattus norvegicus,Intermediate,,,,10116.0,,948.0,A,BAO_0000218,CHEMBL624109,8967
Heart,50597,N,1,,,,16435,,Radioactivity distribution in heart of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 5 min,1,Rattus norvegicus,Intermediate,,,,10116.0,,948.0,A,BAO_0000218,CHEMBL624110,8968
Heart,50597,N,1,,,,16435,,Radioactivity distribution in heart of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 60 min,1,Rattus norvegicus,Intermediate,,,,10116.0,,948.0,A,BAO_0000218,CHEMBL624111,8969
Heart,50597,N,1,,,,16435,,Radioactivity distribution in heart of normal fischer rat after injection of syn-[18F]-FMACBC after 120 min.,1,Rattus norvegicus,Intermediate,,,,10116.0,,948.0,A,BAO_0000218,CHEMBL624112,8970
Heart,50597,N,1,,,,16435,,Radioactivity distribution in heart of normal fischer rat after injection of syn-[18F]-FMACBC after 30 min.,1,Rattus norvegicus,Intermediate,,,,10116.0,,948.0,A,BAO_0000218,CHEMBL624113,8971
Heart,50597,N,1,,,,16435,,Radioactivity distribution in heart of normal fischer rat after injection of syn-[18F]-FMACBC after 5 min.,1,Rattus norvegicus,Intermediate,,,,10116.0,,948.0,A,BAO_0000218,CHEMBL619709,8972
Heart,50597,N,1,,,,16435,,Radioactivity distribution in heart of normal fischer rat after injection of syn-[18F]-FMACBC after 60 min.,1,Rattus norvegicus,Intermediate,,,,10116.0,,948.0,A,BAO_0000218,CHEMBL619710,8973
Kidney,50597,N,1,,,,16434,,Radioactivity distribution in kidney of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 120 min.,1,Rattus norvegicus,Intermediate,,,,10116.0,,2113.0,A,BAO_0000218,CHEMBL619711,8974
Kidney,50597,N,1,,,,16434,,Radioactivity distribution in kidney of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 30 min.,1,Rattus norvegicus,Intermediate,,,,10116.0,,2113.0,A,BAO_0000218,CHEMBL619712,8975
Kidney,50597,N,1,,,,16434,,Radioactivity distribution in kidney of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 5 min.,1,Rattus norvegicus,Intermediate,,,,10116.0,,2113.0,A,BAO_0000218,CHEMBL619713,8976
Kidney,50597,N,1,,,,16434,,Radioactivity distribution in kidney of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 60 min.,1,Rattus norvegicus,Intermediate,,,,10116.0,,2113.0,A,BAO_0000218,CHEMBL619714,8977
Kidney,50597,N,1,,,,16434,,Radioactivity distribution in kidney of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min.,1,Rattus norvegicus,Intermediate,,,,10116.0,,2113.0,A,BAO_0000218,CHEMBL619715,8978
Kidney,50597,N,1,,,,16434,,Radioactivity distribution in kidney of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 30 min.,1,Rattus norvegicus,Intermediate,,,,10116.0,,2113.0,A,BAO_0000218,CHEMBL619716,8979
Kidney,50597,N,1,,,,16434,,Radioactivity distribution in kidney of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min.,1,Rattus norvegicus,Intermediate,,,,10116.0,,2113.0,A,BAO_0000218,CHEMBL619717,8980
Kidney,50597,N,1,,,,16434,,Radioactivity distribution in kidney of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min.,1,Rattus norvegicus,Intermediate,,,,10116.0,,2113.0,A,BAO_0000218,CHEMBL619718,8981
Kidney,50597,N,1,,,,16435,,Radioactivity distribution in kidney of normal fischer rat after injection of anti-[18F]FMACBC after 120 min.,1,Rattus norvegicus,Intermediate,,,,10116.0,,2113.0,A,BAO_0000218,CHEMBL619719,8982
Kidney,50597,N,1,,,,16435,,Radioactivity distribution in kidney of normal fischer rat after injection of anti-[18F]FMACBC after 30 min.,1,Rattus norvegicus,Intermediate,,,,10116.0,,2113.0,A,BAO_0000218,CHEMBL875329,8983
Kidney,50597,N,1,,,,16435,,Radioactivity distribution in kidney of normal fischer rat after injection of anti-[18F]FMACBC after 5 min.,1,Rattus norvegicus,Intermediate,,,,10116.0,,2113.0,A,BAO_0000218,CHEMBL619720,8984
Kidney,50597,N,1,,,,16435,,Radioactivity distribution in kidney of normal fischer rat after injection of anti-[18F]FMACBC after 60 min.,1,Rattus norvegicus,Intermediate,,,,10116.0,,2113.0,A,BAO_0000218,CHEMBL619721,8985
Kidney,50597,N,1,,,,16435,,Radioactivity distribution in kidney of normal fischer rat after injection of syn-[18F]-FMACBC after 120 min.,1,Rattus norvegicus,Intermediate,,,,10116.0,,2113.0,A,BAO_0000218,CHEMBL619722,8986
Kidney,50597,N,1,,,,16435,,Radioactivity distribution in kidney of normal fischer rat after injection of syn-[18F]-FMACBC after 30 min.,1,Rattus norvegicus,Intermediate,,,,10116.0,,2113.0,A,BAO_0000218,CHEMBL619723,8987
Kidney,50597,N,1,,,,16435,,Radioactivity distribution in kidney of normal fischer rat after injection of syn-[18F]-FMACBC after 5 min.,1,Rattus norvegicus,Intermediate,,,,10116.0,,2113.0,A,BAO_0000218,CHEMBL619724,8988
Kidney,50597,N,1,,,,16435,,Radioactivity distribution in kidney of normal fischer rat after injection of syn-[18F]-FMACBC after 60 min.,1,Rattus norvegicus,Intermediate,,,,10116.0,,2113.0,A,BAO_0000218,CHEMBL619725,8989
Kidney,50597,N,1,,,,16434,,Radioactivity distribution in kidney of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min,1,Rattus norvegicus,Intermediate,,,,10116.0,,2113.0,A,BAO_0000218,CHEMBL619726,8990
Kidney,50597,N,1,,,,16434,,Radioactivity distribution in kidney of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min,1,Rattus norvegicus,Intermediate,,,,10116.0,,2113.0,A,BAO_0000218,CHEMBL619727,8991
Kidney,50597,N,1,,,,16434,,Radioactivity distribution in kidney of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min,1,Rattus norvegicus,Intermediate,,,,10116.0,,2113.0,A,BAO_0000218,CHEMBL619728,8992
Kidney,50597,N,1,,,,16435,,Radioactivity distribution in kidney of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 120 min,1,Rattus norvegicus,Intermediate,,,,10116.0,,2113.0,A,BAO_0000218,CHEMBL619729,8993
Muscle tissue,50597,N,1,In vivo,,,11977,,Biodistribution of radioligand [125I]FIDA1 in muscle of rat after 120 minutes after an intravenous injection is given (average of 3 rats),1,Rattus norvegicus,Intermediate,,,,10116.0,,2385.0,A,BAO_0000218,CHEMBL619730,8994
Muscle tissue,50597,N,1,In vivo,,,11977,,Biodistribution of radioligand [125I]FIDA1 in muscle of rat after 2 minutes after an intravenous injection is given (average of 3 rats),1,Rattus norvegicus,Intermediate,,,,10116.0,,2385.0,A,BAO_0000218,CHEMBL619731,8995
Muscle tissue,50597,N,1,In vivo,,,11977,,Biodistribution of radioligand [125I]FIDA1 in muscle of rat after 30 minutes after an intravenous injection is given (average of 2 rats),1,Rattus norvegicus,Intermediate,,,,10116.0,,2385.0,A,BAO_0000218,CHEMBL619732,8996
Muscle tissue,50597,N,1,In vivo,,,11977,,Biodistribution of radioligand [125I]FIDA1 in muscle of rat after 30 minutes after an intravenous injection is given (average of 3 rats),1,Rattus norvegicus,Intermediate,,,,10116.0,,2385.0,A,BAO_0000218,CHEMBL619733,8997
Muscle tissue,50597,N,1,In vivo,,,11977,,Biodistribution of radioligand [125I]FIDA1 in muscle of rat after 60 minutes after an intravenous injection is given (average of 3 rats),1,Rattus norvegicus,Intermediate,,,,10116.0,,2385.0,A,BAO_0000218,CHEMBL619734,8998
Zone of skin,50597,N,1,In vivo,,,11977,,Biodistribution of radioligand [125I]FIDA1 in skin of rat after 120 minutes after an intravenous injection is given (average of 3 rats),1,Rattus norvegicus,Intermediate,,,,10116.0,,14.0,A,BAO_0000218,CHEMBL619735,8999
Zone of skin,50597,N,1,In vivo,,,11977,,Biodistribution of radioligand [125I]FIDA1 in skin of rat after 2 minutes after an intravenous injection is given (average of 3 rats),1,Rattus norvegicus,Intermediate,,,,10116.0,,14.0,A,BAO_0000218,CHEMBL875330,9000
Zone of skin,50597,N,1,In vivo,,,11977,,Biodistribution of radioligand [125I]FIDA1 in skin of rat after 30 minutes after an intravenous injection is given (average of 2 rats),1,Rattus norvegicus,Intermediate,,,,10116.0,,14.0,A,BAO_0000218,CHEMBL628465,9001
Zone of skin,50597,N,1,In vivo,,,11977,,Biodistribution of radioligand [125I]FIDA1 in skin of rat after 30 minutes after an intravenous injection is given (average of 3 rats),1,Rattus norvegicus,Intermediate,,,,10116.0,,14.0,A,BAO_0000218,CHEMBL628466,9002
Zone of skin,50597,N,1,In vivo,,,11977,,Biodistribution of radioligand [125I]FIDA1 in skin of rat after 60 minutes after an intravenous injection is given (average of 3 rats),1,Rattus norvegicus,Intermediate,,,,10116.0,,14.0,A,BAO_0000218,CHEMBL628467,9003
Spleen,50597,N,1,In vivo,,,11977,,Biodistribution of radioligand [125I]FIDA1 in spleen of rat after 120 minutes after an intravenous injection is given (average of 3 rats),1,Rattus norvegicus,Intermediate,,,,10116.0,,2106.0,A,BAO_0000218,CHEMBL628468,9004
Spleen,50597,N,1,In vivo,,,11977,,Biodistribution of radioligand [125I]FIDA1 in spleen of rat after 2 minutes after an intravenous injection is given (average of 3 rats),1,Rattus norvegicus,Intermediate,,,,10116.0,,2106.0,A,BAO_0000218,CHEMBL628469,9005
Spleen,50597,N,1,In vivo,,,11977,,Biodistribution of radioligand [125I]FIDA1 in spleen of rat after 30 minutes after an intravenous injection is given (average of 2 rats),1,Rattus norvegicus,Intermediate,,,,10116.0,,2106.0,A,BAO_0000218,CHEMBL628470,9006
Spleen,50597,N,1,In vivo,,,11977,,Biodistribution of radioligand [125I]FIDA1 in spleen of rat after 30 minutes after an intravenous injection is given (average of 3 rats),1,Rattus norvegicus,Intermediate,,,,10116.0,,2106.0,A,BAO_0000218,CHEMBL628471,9007
Spleen,50597,N,1,In vivo,,,11977,,Biodistribution of radioligand [125I]FIDA1 in spleen of rat after 60 minutes after an intravenous injection is given (average of 3 rats),1,Rattus norvegicus,Intermediate,,,,10116.0,,2106.0,A,BAO_0000218,CHEMBL628472,9008
Thyroid gland,50597,N,1,In vivo,,,11977,,Biodistribution of radioligand [125I]FIDA1 in thyroid of rat after 120 minutes after an intravenous injection is given (average of 3 rats),1,Rattus norvegicus,Intermediate,,,,10116.0,,2046.0,A,BAO_0000218,CHEMBL625191,9009
Thyroid gland,50597,N,1,In vivo,,,11977,,Biodistribution of radioligand [125I]FIDA1 in thyroid of rat after 2 minutes after an intravenous injection is given (average of 3 rats),1,Rattus norvegicus,Intermediate,,,,10116.0,,2046.0,A,BAO_0000218,CHEMBL625192,9010
Thyroid gland,50597,N,1,In vivo,,,11977,,Biodistribution of radioligand [125I]FIDA1 in thyroid of rat after 30 minutes after an intravenous injection is given (average of 2 rats),1,Rattus norvegicus,Intermediate,,,,10116.0,,2046.0,A,BAO_0000218,CHEMBL875337,9011
Thyroid gland,50597,N,1,In vivo,,,11977,,Biodistribution of radioligand [125I]FIDA1 in thyroid of rat after 30 minutes after an intravenous injection is given (average of 3 rats),1,Rattus norvegicus,Intermediate,,,,10116.0,,2046.0,A,BAO_0000218,CHEMBL626341,9012
Thyroid gland,50597,N,1,In vivo,,,11977,,Biodistribution of radioligand [125I]FIDA1 in thyroid of rat after 60 minutes after an intravenous injection is given (average of 3 rats),1,Rattus norvegicus,Intermediate,,,,10116.0,,2046.0,A,BAO_0000218,CHEMBL626342,9013
Liver,50597,N,1,In vivo,,,11977,,Biodistribution of radioligand [125I]-FIDA1 in liver of rat after 2 minutes after an intravenous injection is given (average of 3 rats),1,Rattus norvegicus,Intermediate,,,,10116.0,,2107.0,A,BAO_0000218,CHEMBL621943,9014
,50597,N,1,,,,3748,,Half life in rats,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL621944,9015
,50597,N,1,,,,15765,,Mean percent inhibition of joint damage reduction in fasted rats at 35 mg/kg administered orally twice daily,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL621945,9016
,50597,N,1,,,,4871,,Compound was evaluated for rate of clearance by using IPRL (Isolated Perfused Rat Liver),1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL621946,9017
,50597,N,1,,,,4871,,Compound was evaluated for rate of clearance by using IPRL (Isolated Perfused Rat Liver); ND=Not determined,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL621947,9018
,50597,N,1,,,,4872,,Compound was evaluated for rate of clearance in IPRL (Isolated Perfused Rat Liver),1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL621948,9019
,50597,N,1,,,,4872,,Compound was evaluated for rate of clearance in IPRL (Isolated Perfused Rat Liver); ND=Not determined,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL621949,9020
,50597,N,1,,,,5413,,Rate constant (k) of clearance from isolated perfused rat liver (IPRL),1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL621950,9021
,50597,N,1,,,,5413,,Tested for rate of clearance from isolated perfused rat liver (IPRL) and expressed in terms of rate constant (k); not determined,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL621951,9022
Blood,50597,N,1,In vivo,,,15272,,Maximal blood concentration after oral administration of a 30 uM/kg dose of compound,1,Rattus norvegicus,Intermediate,,,,10116.0,,178.0,A,BAO_0000218,CHEMBL621952,9023
Liver,50597,N,1,,,,4689,,Stability (%) in rat liver microsomes,1,Rattus norvegicus,Intermediate,,,,10116.0,,2107.0,A,BAO_0000218,CHEMBL621953,9024
,50597,N,1,,,,6057,,Area under curve was calculated after intravenous administration,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL621954,9025
,50597,N,1,,,,6057,,Area under the curve was calculated after iv administration in rat,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL621955,9026
,50597,N,1,,,,6057,,Area under the curve was calculated in rat after peroral administration,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL621956,9027
,50597,N,1,,,,6211,,Dose-normalized AUC was determined by po administration (10 mg/kg) in fasted male Sprague-Dawley rats,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL621957,9028
,50597,N,1,,,,5710,,Dose-normalized AUC measured in fasted male Sprague dawely rats when the compound was administered at a peroral dose of 2 mg/Kg,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL621958,9029
,50597,N,1,,,,5710,,Dose-normalized AUC measured in fasted male Sprague dawely rats when the compound was administered at a peroral of 2 mg/Kg,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL621959,9030
,50597,N,1,,,,17853,,Dose-normalized area under curve in rat (i.v.) at 0.5 mpk,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL621960,9031
,50597,N,1,,,,17853,,Dose-normalized area under curve in rat (p.o.) at 2.0 mpk,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL621961,9032
,50597,N,1,,,,15765,,p value of the compound,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL621962,9033
,50597,N,1,,,,15765,,p value of the compound,1,Rattus norvegicus,Intermediate,,,,10116.0,,,F,BAO_0000218,CHEMBL876787,9034
,50597,N,1,,,,15765,,p value of the compound,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL621963,9035
Stomach,50597,N,1,,,,6175,,pH of the gastric juice (Control value = 1.42+/-0.02) of stomach content of pylorus ligated rats was measured (10 mg/kg po of the Compound was administered 1 hr before the pylorus ligation),1,Rattus norvegicus,Intermediate,,,,10116.0,,945.0,A,BAO_0000218,CHEMBL622637,9036
Stomach,50597,N,1,,,,6175,,pH of the gastric juice (Control value = 1.42+/-0.02) of stomach content of pylorus ligated rats was measured (20 mg/kg po of the Compound was administered 1 hr before the pylorus ligation),1,Rattus norvegicus,Intermediate,,,,10116.0,,945.0,A,BAO_0000218,CHEMBL622638,9037
Stomach,50597,N,1,,,,6175,,pH of the gastric juice (Control value = 1.42+/-0.02) of stomach content of pylorus ligated rats was measured (5 mg/kg po of the Compound was administered 1 hr before the pylorus ligation),1,Rattus norvegicus,Intermediate,,,,10116.0,,945.0,A,BAO_0000218,CHEMBL626561,9038
,22224,U,0,,,,7991,,Negative log of minimum effective dose (moles per kilogram) in rabbits (hypnotic),1,Oryctolagus cuniculus,Autocuration,,,,9986.0,,,F,BAO_0000019,CHEMBL626562,9039
,22224,U,0,,,,429,,Evaluated for pharmacokinetic parameter area under curve in rabbit at the dose 20 mg/kg ( 0-4 hr ),1,Oryctolagus cuniculus,Autocuration,,,,9986.0,,,A,BAO_0000218,CHEMBL626563,9040
,22224,U,0,,,,429,,Evaluated for pharmacokinetic parameter area under curve in rabbit at the dose 20 mg/kg (0-4 hr ),1,Oryctolagus cuniculus,Autocuration,,,,9986.0,,,A,BAO_0000218,CHEMBL626564,9041
,22224,U,0,In vivo,,,6253,,Clearance was measured at the concentration of 1.11 mg/kg in rabbit blood sample,1,Oryctolagus cuniculus,Autocuration,,,,9986.0,,,A,BAO_0000218,CHEMBL626565,9042
,22224,U,0,In vivo,,,6253,,Clearance was measured at the concentration of 2.0 mg/kg in rabbit blood sample,1,Oryctolagus cuniculus,Autocuration,,,,9986.0,,,A,BAO_0000218,CHEMBL626566,9043
,22224,U,0,In vivo,,,3615,,Clearance rate in rabbits,1,Oryctolagus cuniculus,Autocuration,,,,9986.0,,,A,BAO_0000218,CHEMBL626567,9044
,22224,U,0,In vivo,,,4059,,Plasma clearance was determined in rabbit at a dose of 5 mg/kg/h administered i.v.,1,Oryctolagus cuniculus,Autocuration,,,,9986.0,,,A,BAO_0000218,CHEMBL626568,9045
,22224,U,0,In vivo,,,5124,,Clearance in male New Zealand white rabbits after administration via an indwelling catheter in an ear vein at 4.9 mg/kg,1,Oryctolagus cuniculus,Autocuration,,,,9986.0,,,A,BAO_0000218,CHEMBL626569,9046
,22224,U,0,In vivo,,,5124,,Clearance in male New Zealand white rabbits after administration via an indwelling catheter in an ear vein at 5 mg/kg,1,Oryctolagus cuniculus,Autocuration,,,,9986.0,,,A,BAO_0000218,CHEMBL626570,9047
,22224,U,0,In vivo,,,5124,,Clearance in male New Zealand white rabbits after i.v. administration at 2.0 mg/kg,1,Oryctolagus cuniculus,Autocuration,,,,9986.0,,,A,BAO_0000218,CHEMBL626571,9048
,22224,U,0,In vivo,,,429,,Evaluated for pharmacokinetic parameter Cmax in rabbit at the dose 20 mg/kg,1,Oryctolagus cuniculus,Autocuration,,,,9986.0,,,A,BAO_0000218,CHEMBL626572,9049
Plasma,22224,U,0,In vivo,,,4059,,Maximum plasma concentration was determined in rabbit at a dose of 5 mg/kg/h administered i.v.,1,Oryctolagus cuniculus,Autocuration,,,,9986.0,,1969.0,A,BAO_0000218,CHEMBL626573,9050
Liver,22224,U,0,,,Microsomes,9659,,Oxidation by dutch rabbit liver microsomes in presence of NADPH/O2,1,Oryctolagus cuniculus,Autocuration,,,,9986.0,,2107.0,A,BAO_0000251,CHEMBL626574,9051
Liver,22224,U,0,,,Microsomes,9659,,Oxidation by dutch rabbit liver microsomes in presence of cumene hydroperoxide,1,Oryctolagus cuniculus,Autocuration,,,,9986.0,,2107.0,A,BAO_0000251,CHEMBL626575,9052
,22224,U,0,,,,3639,,Dose at which bioavailability of intravenously administered compound was tested in rabbit,1,Oryctolagus cuniculus,Autocuration,,,,9986.0,,,A,BAO_0000218,CHEMBL626576,9053
,22224,U,0,,,,3639,,Dose at which bioavailability of perorally administered compound was tested in rabbit,1,Oryctolagus cuniculus,Autocuration,,,,9986.0,,,A,BAO_0000218,CHEMBL626577,9054
,22224,U,0,In vivo,,,3639,,The compound was tested for its bioavailability in rabbit (by oral dosage).,1,Oryctolagus cuniculus,Autocuration,,,,9986.0,,,A,BAO_0000218,CHEMBL626578,9055
,22224,U,0,In vivo,,,5124,,Mean retention time in male New Zealand white rabbits after administration via an indwelling catheter in an ear vein at 4.9 mg/kg,1,Oryctolagus cuniculus,Autocuration,,,,9986.0,,,A,BAO_0000218,CHEMBL625263,9056
,22224,U,0,In vivo,,,5124,,Mean retention time in male New Zealand white rabbits after administration via an indwelling catheter in an ear vein at 5 mg/kg,1,Oryctolagus cuniculus,Autocuration,,,,9986.0,,,A,BAO_0000218,CHEMBL625264,9057
,22224,U,0,In vivo,,,5124,,Mean retention time in male New Zealand white rabbits after i.v. administration at 2.0 mg/kg,1,Oryctolagus cuniculus,Autocuration,,,,9986.0,,,A,BAO_0000218,CHEMBL625265,9058
,22224,U,0,,,Microsomes,14294,,Metabolism of compound in rabbit S9 microsomes ('+''indicates <20% largest observed peak),1,Oryctolagus cuniculus,Autocuration,,,,9986.0,,,A,BAO_0000251,CHEMBL625266,9059
,22224,U,0,,,Microsomes,14294,,Metabolism of compound in rabbit S9 microsomes ('++++' indicates largest observed peak),1,Oryctolagus cuniculus,Autocuration,,,,9986.0,,,A,BAO_0000251,CHEMBL876796,9060
,22224,U,0,In vivo,,,429,,Evaluated for pharmacokinetic parameter half-life in rabbit at the dose 20 mg/kg,1,Oryctolagus cuniculus,Autocuration,,,,9986.0,,,A,BAO_0000218,CHEMBL625267,9061
Plasma,22224,U,0,In vivo,,,5124,,Plasma half-life in male New Zealand white rabbits after administration via an indwelling catheter in an ear vein at 4.9 mg/kg,1,Oryctolagus cuniculus,Autocuration,,,,9986.0,,1969.0,A,BAO_0000218,CHEMBL625268,9062
Plasma,22224,U,0,In vivo,,,5124,,Plasma half-life in male New Zealand white rabbits after administration via an indwelling catheter in an ear vein at 5 mg/kg,1,Oryctolagus cuniculus,Autocuration,,,,9986.0,,1969.0,A,BAO_0000218,CHEMBL625269,9063
Plasma,22224,U,0,In vivo,,,5124,,Plasma half-life in male New Zealand white rabbits after i.v. administration at 2.0 mg/kg,1,Oryctolagus cuniculus,Autocuration,,,,9986.0,,1969.0,A,BAO_0000218,CHEMBL624689,9064
,22224,U,0,In vivo,,,429,,Evaluated for pharmacokinetic parameter tmax in rabbit at the dose 20 mg/kg,1,Oryctolagus cuniculus,Autocuration,,,,9986.0,,,A,BAO_0000218,CHEMBL624690,9065
Urine,22224,U,0,,,,429,,Evaluated for pharmacokinetic parameter urine recovery in rabbit at the dose 20 mg/kg ( 0-24 hr ),1,Oryctolagus cuniculus,Autocuration,,,,9986.0,,1088.0,A,BAO_0000218,CHEMBL624691,9066
Urine,22224,U,0,,,,429,,Evaluated for pharmacokinetic parameter urine recovery in rabbit at the dose 20 mg/kg (0-24 hr),1,Oryctolagus cuniculus,Autocuration,,,,9986.0,,1088.0,A,BAO_0000218,CHEMBL624692,9067
,22224,U,0,In vivo,,,4059,,The compound was evaluated for volume of distribution in rabbit at a dose of 5 mg/kg/h administered i.v.,1,Oryctolagus cuniculus,Autocuration,,,,9986.0,,,A,BAO_0000218,CHEMBL624693,9068
,22224,U,0,In vivo,,,4137,,Volume of distribution after intravenous administration of 1 mg/kg/h in dog,1,Oryctolagus cuniculus,Autocuration,,,,9986.0,,,A,BAO_0000218,CHEMBL624694,9069
,22224,U,0,In vitro,,,11672,,In vitro Biological half-life in crude homogenate of rabbit renal cortex,1,Oryctolagus cuniculus,Autocuration,,,,9986.0,,,A,BAO_0000221,CHEMBL877596,9070
,22224,U,0,,,,12886,,Time within which only 10% of the drug was degraded,1,Oryctolagus cuniculus,Autocuration,,,,9986.0,,,A,BAO_0000019,CHEMBL624695,9071
Liver,22224,U,0,,,,3853,,Half life period in rabbit liver homogenate,1,Oryctolagus cuniculus,Autocuration,,,,9986.0,,2107.0,A,BAO_0000221,CHEMBL624696,9072
,22224,U,0,,,,3615,,Half life value in rabbits,1,Oryctolagus cuniculus,Autocuration,,,,9986.0,,,A,BAO_0000019,CHEMBL624697,9073
Blood,22224,U,0,In vivo,,,6253,,Half-life was measured at the concentration of 1.11 mg/kg in rabbit blood sample,1,Oryctolagus cuniculus,Autocuration,,,,9986.0,,178.0,A,BAO_0000218,CHEMBL624698,9074
Blood,22224,U,0,In vivo,,,6253,,Half-life was measured at the concentration of 2.0 mg/kg in rabbit blood sample,1,Oryctolagus cuniculus,Autocuration,,,,9986.0,,178.0,A,BAO_0000218,CHEMBL624699,9075
,22224,U,0,In vivo,,,6077,,Half-life period in rabbits following intravenous administration at 2 mg/kg,1,Oryctolagus cuniculus,Autocuration,,,,9986.0,,,A,BAO_0000218,CHEMBL624700,9076
Plasma,50597,N,1,,,,17617,,AUC 0-8 hr value in rats at 10 mg/kg,1,Rattus norvegicus,Intermediate,,,,10116.0,,1969.0,A,BAO_0000218,CHEMBL622903,9077
Plasma,50597,N,1,,,,17594,,AUC after administration at 2000 mg/kg/day in rats,1,Rattus norvegicus,Intermediate,,,,10116.0,,1969.0,A,BAO_0000218,CHEMBL622904,9078
Plasma,50597,N,1,,,,6149,,AUC of compound for a 2 mpk po dose of the sodium salt in rats.,1,Rattus norvegicus,Intermediate,,,,10116.0,,1969.0,A,BAO_0000218,CHEMBL622905,9079
Plasma,50597,N,1,,,,17260,,AUC at a dose of 10 mg/Kg administered intravenously in female hanover-wistar rat,1,Rattus norvegicus,Intermediate,,,,10116.0,,1969.0,A,BAO_0000218,CHEMBL622906,9080
Plasma,50597,N,1,,,,17260,,AUC at a dose of 10 mg/Kg administered perorally in female hanover-wistar rat,1,Rattus norvegicus,Intermediate,,,,10116.0,,1969.0,A,BAO_0000218,CHEMBL622907,9081
Plasma,50597,N,1,,,,6644,,AUC in rat after oral administration at 10.5 mg/kg dose,1,Rattus norvegicus,Intermediate,,,,10116.0,,1969.0,A,BAO_0000218,CHEMBL622908,9082
Plasma,50597,N,1,,,,6644,,AUC in rat after oral administration at 11.2 mg/kg dose,1,Rattus norvegicus,Intermediate,,,,10116.0,,1969.0,A,BAO_0000218,CHEMBL622909,9083
Plasma,50597,N,1,,,,6644,,AUC in rat after oral administration at 9.7 mg/kg dose,1,Rattus norvegicus,Intermediate,,,,10116.0,,1969.0,A,BAO_0000218,CHEMBL622910,9084
Brain,50597,N,1,,,,6495,,AUC in rat brain after oral administration at 10 mg/kg,1,Rattus norvegicus,Intermediate,,,,10116.0,,955.0,A,BAO_0000218,CHEMBL622911,9085
Plasma,50597,N,1,,,,6504,,AUC in rat p.o.,1,Rattus norvegicus,Intermediate,,,,10116.0,,1969.0,A,BAO_0000218,CHEMBL622912,9086
Plasma,50597,N,1,,,,17686,,AUC in rat p.o. at 20 mg/kg concentration,1,Rattus norvegicus,Intermediate,,,,10116.0,,1969.0,A,BAO_0000218,CHEMBL622913,9087
Plasma,50597,N,1,,,,6495,,AUC in rat plasma after oral administration at 10 mg/kg,1,Rattus norvegicus,Intermediate,,,,10116.0,,1969.0,A,BAO_0000218,CHEMBL622914,9088
Plasma,50597,N,1,,,,216,,AUC in rats,1,Rattus norvegicus,Intermediate,,,,10116.0,,1969.0,A,BAO_0000218,CHEMBL622915,9089
Plasma,50597,N,1,,,,1908,,AUC value after IV dose at a dose of 5 mg/kg in rats.,1,Rattus norvegicus,Intermediate,,,,10116.0,,1969.0,A,BAO_0000218,CHEMBL622916,9090
Plasma,50597,N,1,,,,1908,,AUC value after oral dose at a dose of 10 mg/kg in rats.,1,Rattus norvegicus,Intermediate,,,,10116.0,,1969.0,A,BAO_0000218,CHEMBL622917,9091
Plasma,50597,N,1,In vivo,,,6685,,"Maximum plasma concentration in rats at 2 mg/kg, i.v. dose; n/a: not applicable",1,Rattus norvegicus,Intermediate,,,,10116.0,,1969.0,A,BAO_0000218,CHEMBL622918,9092
Plasma,50597,N,1,In vivo,,,216,,Maximum plasma concentration in rats when a oral dose of 200 mg/kg was given,1,Rattus norvegicus,Intermediate,,,,10116.0,,1969.0,A,BAO_0000218,CHEMBL622919,9093
Plasma,50597,N,1,In vivo,,,6049,,Maximum plasma concentration was evaluated in rat,1,Rattus norvegicus,Intermediate,,,,10116.0,,1969.0,A,BAO_0000218,CHEMBL622920,9094
Plasma,50597,N,1,In vivo,,,2463,,Maximum plasma concentration was evaluated in vivo in rat at a dose of 5 mg/kg by oral administration,1,Rattus norvegicus,Intermediate,,,,10116.0,,1969.0,A,BAO_0000218,CHEMBL622921,9095
Plasma,50597,N,1,In vivo,,,6679,,Maximum plasma concentration reached by compound was determined after 2 mg/kg (p.o.) administration,1,Rattus norvegicus,Intermediate,,,,10116.0,,1969.0,A,BAO_0000218,CHEMBL622922,9096
Plasma,50597,N,1,In vivo,,,6681,,Maximum plasma concentration reached by compound was determined in rats at 50 mg/kg dose,1,Rattus norvegicus,Intermediate,,,,10116.0,,1969.0,A,BAO_0000218,CHEMBL622923,9097
Plasma,50597,N,1,In vivo,,,4890,,Maximum plasma concentration was determined after oral administration at a dose 10 mg/kg to male Sprague-Dawley rats,1,Rattus norvegicus,Intermediate,,,,10116.0,,1969.0,A,BAO_0000218,CHEMBL877604,9098
Plasma,50597,N,1,In vivo,,,6410,,Maximum plasma concentration was evaluated in rats at an intravenous dose of 3 mg/kg,1,Rattus norvegicus,Intermediate,,,,10116.0,,1969.0,A,BAO_0000218,CHEMBL622924,9099
Plasma,50597,N,1,In vivo,,,6410,,Maximum plasma concentration was evaluated in rats at an oral dose of 30 mg/kg,1,Rattus norvegicus,Intermediate,,,,10116.0,,1969.0,A,BAO_0000218,CHEMBL622925,9100
Plasma,50597,N,1,In vivo,,,16366,,Maximum plasma concentration was measured when a dose of 1 mg/kg is administered orally,1,Rattus norvegicus,Intermediate,,,,10116.0,,1969.0,A,BAO_0000218,CHEMBL622926,9101
Plasma,50597,N,1,In vivo,,,6227,,Maximum plasma concentration (Cmax) in rat (in vivo) at a dose of 10 mg/kg,1,Rattus norvegicus,Intermediate,,,,10116.0,,1969.0,A,BAO_0000218,CHEMBL623625,9102
Plasma,50597,N,1,In vivo,,,3598,,Maximum plasma drug concentration of compound determined in rat after iv administration at a dose of 10 mg/kg,1,Rattus norvegicus,Expert,,,,10116.0,,1969.0,A,BAO_0000218,CHEMBL623626,9103
Plasma,50597,N,1,In vivo,,,1465,,Maximum plasma drug concentration was determined,1,Rattus norvegicus,Intermediate,,,,10116.0,,1969.0,A,BAO_0000218,CHEMBL623627,9104
,50597,N,1,In vivo,,,4368,,Maximum concentration by intravenous administration of 3.4 mg/kg in rat,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL623628,9105
Plasma,50597,N,1,In vivo,,,15662,,Mean peak plasma concentration was observed after intravenous administration in rat,1,Rattus norvegicus,Intermediate,,,,10116.0,,1969.0,A,BAO_0000218,CHEMBL623629,9106
Plasma,50597,N,1,In vivo,,,15662,,Mean peak plasma concentration was observed after oral administration in rat,1,Rattus norvegicus,Intermediate,,,,10116.0,,1969.0,A,BAO_0000218,CHEMBL623630,9107
,50597,N,1,In vivo,,,5355,,Peak concentration (Cmax) at a dose of 10 mg/kg in rats,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL623804,9108
,50597,N,1,In vivo,,,5355,,Peak concentration (Cmax) at a dose of 20 mg/kg in rats,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL623805,9109
Plasma,50597,N,1,In vivo,,,1567,,Peak oral plasma concentration was determined in rats by oral administration,1,Rattus norvegicus,Intermediate,,,,10116.0,,1969.0,A,BAO_0000218,CHEMBL623806,9110
Plasma,50597,N,1,In vivo,,,4026,,Peak plasma concentration (Cmax) was determined,1,Rattus norvegicus,Intermediate,,,,10116.0,,1969.0,A,BAO_0000218,CHEMBL623807,9111
Plasma,50597,N,1,In vivo,,,6193,,Peak plasma concentration (Cmax) following an oral dose of 20 mg/kg in rats,1,Rattus norvegicus,Intermediate,,,,10116.0,,1969.0,A,BAO_0000218,CHEMBL623808,9112
Plasma,50597,N,1,In vivo,,,4026,,Peak plasma concentration (Cmax) in rats,1,Rattus norvegicus,Intermediate,,,,10116.0,,1969.0,A,BAO_0000218,CHEMBL623809,9113
Plasma,50597,N,1,In vivo,,,6485,,Peak plasma concentration at 1 mg/kg peroral administration,1,Rattus norvegicus,Intermediate,,,,10116.0,,1969.0,A,BAO_0000218,CHEMBL623810,9114
Plasma,50597,N,1,In vivo,,,17655,,Peak plasma concentration in rat,1,Rattus norvegicus,Intermediate,,,,10116.0,,1969.0,A,BAO_0000218,CHEMBL623811,9115
Plasma,50597,N,1,In vivo,,,14941,,"Pharmacokinetic Parameter, Cmax is observed maximum plasma concentration in Female Wistar Rats at 100 mg/kg by po administration",1,Rattus norvegicus,Intermediate,,,,10116.0,,1969.0,A,BAO_0000218,CHEMBL623812,9116
,50597,N,1,In vivo,,,5394,,Pharmacokinetic parameter Cmax was measured after administration into rat at 10 mg/kg,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL877605,9117
,50597,N,1,In vivo,,,4408,,Pharmacokinetic property (Cmax) in rat,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL623813,9118
,50597,N,1,In vivo,,,5983,,Pharmacokinetic property (Cmax) was measured in rat at the dose of 0.32 mg/kg p.o.,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL623814,9119
,50597,N,1,In vivo,,,4878,,Cmax in rat after 3mg/kg oral dose,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL623815,9120
,50597,N,1,In vivo,Sprague-Dawley,,5862,,Clearance in Sprague-Dawley rats after 2mg/kg oral dose,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL623816,9121
,50597,N,1,In vivo,,,4517,,Cmax in rats after 20 mg/kg oral dose,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL623145,9122
Plasma,50597,N,1,In vivo,,,5932,,Cmax in rat plasma after 30mg/kg oral dose,1,Rattus norvegicus,Intermediate,,,,10116.0,,1969.0,A,BAO_0000218,CHEMBL623146,9123
Plasma,50597,N,1,In vivo,,,5436,,Plasma concentration after oral administration of 100 mg/kg to rats,1,Rattus norvegicus,Intermediate,,,,10116.0,,1969.0,A,BAO_0000218,CHEMBL623147,9124
Brain,50597,N,1,In vivo,,,4910,,Tested for concentration in brain after intravenous administration (4.7 mg/kg) to male rats,1,Rattus norvegicus,Intermediate,,,,10116.0,,955.0,A,BAO_0000218,CHEMBL623042,9125
,50597,N,1,In vivo,,,4950,,Tested for the Cmax in rat at 10 mg/kg per orally,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL623043,9126
,50597,N,1,In vivo,,,15078,,"The Cmax value in female wistar rat at 100 mg/kg, p.o. dose",1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL623044,9127
,50597,N,1,In vivo,,,15078,,"The Cmax value in male wistar rat at 100 mg/kg, p.o. dose",1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL623045,9128
,50597,N,1,In vivo,,,3360,,Bioavailability as oral Cmax in rats at 30 mins,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL623046,9129
,50597,N,1,In vivo,,,3360,,Bioavailability as oral Cmax in rats at 6hr,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL623226,9130
,50597,N,1,In vivo,,,15022,,The maximum concentration of compound was measured at the dose of 100 umol/kg,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL623227,9131
,50597,N,1,In vivo,,,15022,,The maximum concentration of compound was measured at the dose of 300 umol/kg,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL623228,9132
,50597,N,1,In vivo,,,15022,,The maximum concentration of compound was measured at the dose of 30 umol/kg,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL623229,9133
Plasma,50597,N,1,In vivo,,,5160,,The maximum plasma levels for the compounds were determined by LC-MS.,1,Rattus norvegicus,Intermediate,,,,10116.0,,1969.0,A,BAO_0000218,CHEMBL623230,9134
Plasma,50597,N,1,In vivo,,,15662,,mean peak plasma concentration was observed after intravenous administration in rat,1,Rattus norvegicus,Intermediate,,,,10116.0,,1969.0,A,BAO_0000218,CHEMBL623231,9135
Plasma,50597,N,1,In vivo,,,15662,,mean peak plasma concentration was observed after oral administration in rat,1,Rattus norvegicus,Intermediate,,,,10116.0,,1969.0,A,BAO_0000218,CHEMBL623232,9136
,50597,N,1,,,,4709,,Concentration in the plasma after intravenous administration of 1 mg/kg in rat,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL623233,9137
,50597,N,1,,,,3535,,Concentration in plasma (portal) following oral dose in rats at 0.25 hr,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL623234,9138
,50597,N,1,,,,3535,,Concentration in plasma (portal) following oral dose in rats at 1 hr,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL623235,9139
,50597,N,1,,,,3535,,Concentration in plasma (portal) following oral dose in rats at 2 hr,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL623236,9140
,50597,N,1,,,,3535,,Concentration in plasma (systemic) following oral dose in rats at 0.25 hr,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL623237,9141
,50597,N,1,,,,3535,,Concentration in plasma (systemic) following oral dose in rats at 1 hr,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL623238,9142
,50597,N,1,,,,3535,,Concentration in plasma (systemic) following oral dose in rats at 2 hr,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL623239,9143
Plasma,22224,U,0,In vivo,,,5005,,Compound was evaluated for the plasma concentration in rats versus time curves (AUC) in vivo,1,Rattus norvegicus,Intermediate,,,,10116.0,,1969.0,A,BAO_0000218,CHEMBL623240,9144
Hypothalamus,50597,N,1,,,,6326,,"Concentration (30 mg/kg, p.o.) in rat hypothalamus after 2 hours",1,Rattus norvegicus,Intermediate,,,,10116.0,,1898.0,A,BAO_0000218,CHEMBL623241,9145
Hypothalamus,50597,N,1,,,,6326,,"Concentration (30 mg/kg, p.o.) in rat hypothalamus after 6 hours",1,Rattus norvegicus,Intermediate,,,,10116.0,,1898.0,A,BAO_0000218,CHEMBL623242,9146
,50597,N,1,,,,6326,,"Concentration (30 mg/kg, p.o.) in rat plasma after 2 hours",1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL874394,9147
,50597,N,1,,,,6326,,"Concentration (30 mg/kg, p.o.) in rat plasma after 6 hours",1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL623243,9148
,50597,N,1,,,,17411,,Kidney concentration was determined after 5 min. of intravenous administration to rats (n=4) at dose of 20 mg/kg,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL623244,9149
Kidney,50597,N,1,,,,16435,,Radioactivity distribution in kidney of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 5 min,1,Rattus norvegicus,Intermediate,,,,10116.0,,2113.0,A,BAO_0000218,CHEMBL623245,9150
Kidney,50597,N,1,,,,16435,,Radioactivity distribution in kidney of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 60 min,1,Rattus norvegicus,Intermediate,,,,10116.0,,2113.0,A,BAO_0000218,CHEMBL623246,9151
Kidney,50597,N,1,,,,16435,,Radioactivity distribution in kidney of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 120 min,1,Rattus norvegicus,Intermediate,,,,10116.0,,2113.0,A,BAO_0000218,CHEMBL623247,9152
Kidney,50597,N,1,,,,16435,,Radioactivity distribution in kidney of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 5 min,1,Rattus norvegicus,Intermediate,,,,10116.0,,2113.0,A,BAO_0000218,CHEMBL623248,9153
Kidney,50597,N,1,,,,16435,,Radioactivity distribution in kidney of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 60 min,1,Rattus norvegicus,Intermediate,,,,10116.0,,2113.0,A,BAO_0000218,CHEMBL623249,9154
Liver,50597,N,1,,,,16434,,Radioactivity distribution in liver of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 120 min.,1,Rattus norvegicus,Intermediate,,,,10116.0,,2107.0,A,BAO_0000218,CHEMBL625072,9155
Liver,50597,N,1,,,,16434,,Radioactivity distribution in liver of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 30 min.,1,Rattus norvegicus,Intermediate,,,,10116.0,,2107.0,A,BAO_0000218,CHEMBL625073,9156
Liver,50597,N,1,,,,16434,,Radioactivity distribution in liver of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 5 min.,1,Rattus norvegicus,Intermediate,,,,10116.0,,2107.0,A,BAO_0000218,CHEMBL625074,9157
Liver,50597,N,1,,,,16434,,Radioactivity distribution in liver of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 60 min.,1,Rattus norvegicus,Intermediate,,,,10116.0,,2107.0,A,BAO_0000218,CHEMBL625075,9158
Liver,50597,N,1,,,,16434,,Radioactivity distribution in liver of normal fischer rat after injection of [18F]-fluoro-2-methylpropanoic acid after 120 min.,1,Rattus norvegicus,Intermediate,,,,10116.0,,2107.0,A,BAO_0000218,CHEMBL625076,9159
Liver,50597,N,1,,,,16434,,Radioactivity distribution in liver of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 30 min.,1,Rattus norvegicus,Intermediate,,,,10116.0,,2107.0,A,BAO_0000218,CHEMBL625077,9160
Liver,50597,N,1,,,,16434,,Radioactivity distribution in liver of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min.,1,Rattus norvegicus,Intermediate,,,,10116.0,,2107.0,A,BAO_0000218,CHEMBL625078,9161
Liver,50597,N,1,,,,16434,,Radioactivity distribution in liver of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min.,1,Rattus norvegicus,Intermediate,,,,10116.0,,2107.0,A,BAO_0000218,CHEMBL874395,9162
Liver,50597,N,1,,,,16435,,Radioactivity distribution in liver of normal fischer rat after injection of anti-[18F]FMACBC after 120 min.,1,Rattus norvegicus,Intermediate,,,,10116.0,,2107.0,A,BAO_0000218,CHEMBL625079,9163
Liver,50597,N,1,,,,16435,,Radioactivity distribution in liver of normal fischer rat after injection of anti-[18F]FMACBC after 30 min.,1,Rattus norvegicus,Intermediate,,,,10116.0,,2107.0,A,BAO_0000218,CHEMBL625080,9164
Liver,50597,N,1,,,,16435,,Radioactivity distribution in liver of normal fischer rat after injection of anti-[18F]FMACBC after 5 min.,1,Rattus norvegicus,Intermediate,,,,10116.0,,2107.0,A,BAO_0000218,CHEMBL625081,9165
Liver,50597,N,1,,,,16435,,Radioactivity distribution in liver of normal fischer rat after injection of anti-[18F]FMACBC after 60 min.,1,Rattus norvegicus,Intermediate,,,,10116.0,,2107.0,A,BAO_0000218,CHEMBL625082,9166
Liver,50597,N,1,,,,16435,,Radioactivity distribution in liver of normal fischer rat after injection of syn-[18F]-FMACBC after 30 min.,1,Rattus norvegicus,Intermediate,,,,10116.0,,2107.0,A,BAO_0000218,CHEMBL625083,9167
Liver,50597,N,1,,,,16435,,Radioactivity distribution in liver of normal fischer rat after injection of syn-[18F]-FMACBC after 5 min.,1,Rattus norvegicus,Intermediate,,,,10116.0,,2107.0,A,BAO_0000218,CHEMBL625084,9168
Liver,50597,N,1,,,,16435,,Radioactivity distribution in liver of normal fischer rat after injection of syn-[18F]-FMACBC after 60 min.,1,Rattus norvegicus,Intermediate,,,,10116.0,,2107.0,A,BAO_0000218,CHEMBL625085,9169
Liver,50597,N,1,,,,16435,,Radioactivity distribution in liver of normal fischer rat after injection of syn-[18F]-FMACBC after 120 min.,1,Rattus norvegicus,Intermediate,,,,10116.0,,2107.0,A,BAO_0000218,CHEMBL625086,9170
Liver,50597,N,1,,,,16434,,Radioactivity distribution in liver of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min,1,Rattus norvegicus,Intermediate,,,,10116.0,,2107.0,A,BAO_0000218,CHEMBL625087,9171
Liver,50597,N,1,,,,16434,,Radioactivity distribution in liver of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min,1,Rattus norvegicus,Intermediate,,,,10116.0,,2107.0,A,BAO_0000218,CHEMBL625088,9172
Liver,50597,N,1,,,,16434,,Radioactivity distribution in liver of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min,1,Rattus norvegicus,Intermediate,,,,10116.0,,2107.0,A,BAO_0000218,CHEMBL622205,9173
Liver,50597,N,1,,,,16435,,Radioactivity distribution in liver of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 120 min,1,Rattus norvegicus,Intermediate,,,,10116.0,,2107.0,A,BAO_0000218,CHEMBL622206,9174
Liver,50597,N,1,,,,16435,,Radioactivity distribution in liver of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 5 min,1,Rattus norvegicus,Intermediate,,,,10116.0,,2107.0,A,BAO_0000218,CHEMBL622207,9175
Liver,50597,N,1,,,,16435,,Radioactivity distribution in liver of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 60 min,1,Rattus norvegicus,Intermediate,,,,10116.0,,2107.0,A,BAO_0000218,CHEMBL622366,9176
Liver,50597,N,1,,,,16435,,Radioactivity distribution in liver of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 120 min,1,Rattus norvegicus,Intermediate,,,,10116.0,,2107.0,A,BAO_0000218,CHEMBL622367,9177
Liver,50597,N,1,,,,16435,,Radioactivity distribution in liver of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 5 min,1,Rattus norvegicus,Intermediate,,,,10116.0,,2107.0,A,BAO_0000218,CHEMBL875331,9178
Liver,50597,N,1,,,,16435,,Radioactivity distribution in liver of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 60 min,1,Rattus norvegicus,Intermediate,,,,10116.0,,2107.0,A,BAO_0000218,CHEMBL622368,9179
Lung,50597,N,1,,,,16434,,Radioactivity distribution in lung of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 120 min.,1,Rattus norvegicus,Intermediate,,,,10116.0,,2048.0,A,BAO_0000218,CHEMBL622369,9180
Lung,50597,N,1,,,,16434,,Radioactivity distribution in lung of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 30 min.,1,Rattus norvegicus,Intermediate,,,,10116.0,,2048.0,A,BAO_0000218,CHEMBL622370,9181
Lung,50597,N,1,,,,16434,,Radioactivity distribution in lung of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 5 min.,1,Rattus norvegicus,Intermediate,,,,10116.0,,2048.0,A,BAO_0000218,CHEMBL622371,9182
Lung,50597,N,1,,,,16434,,Radioactivity distribution in lung of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 60 min.,1,Rattus norvegicus,Intermediate,,,,10116.0,,2048.0,A,BAO_0000218,CHEMBL622372,9183
Lung,50597,N,1,,,,16434,,Radioactivity distribution in lung of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min.,1,Rattus norvegicus,Intermediate,,,,10116.0,,2048.0,A,BAO_0000218,CHEMBL622373,9184
Lung,50597,N,1,,,,16434,,Radioactivity distribution in lung of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 30 min.,1,Rattus norvegicus,Intermediate,,,,10116.0,,2048.0,A,BAO_0000218,CHEMBL622374,9185
Lung,50597,N,1,,,,16434,,Radioactivity distribution in lung of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min.,1,Rattus norvegicus,Intermediate,,,,10116.0,,2048.0,A,BAO_0000218,CHEMBL622375,9186
Lung,50597,N,1,,,,16434,,Radioactivity distribution in lung of normal fischer rat after injection of [18F]-fluoro-2-methylpropanoic acid after 60 min.,1,Rattus norvegicus,Intermediate,,,,10116.0,,2048.0,A,BAO_0000218,CHEMBL622376,9187
Lung,50597,N,1,,,,16435,,Radioactivity distribution in lung of normal fischer rat after injection of anti-[18F]FMACBC after 120 min.,1,Rattus norvegicus,Intermediate,,,,10116.0,,2048.0,A,BAO_0000218,CHEMBL622377,9188
Lung,50597,N,1,,,,16435,,Radioactivity distribution in lung of normal fischer rat after injection of anti-[18F]FMACBC after 30 min.,1,Rattus norvegicus,Intermediate,,,,10116.0,,2048.0,A,BAO_0000218,CHEMBL622378,9189
Lung,50597,N,1,,,,16435,,Radioactivity distribution in lung of normal fischer rat after injection of anti-[18F]FMACBC after 5 min.,1,Rattus norvegicus,Intermediate,,,,10116.0,,2048.0,A,BAO_0000218,CHEMBL622379,9190
Lung,50597,N,1,,,,16435,,Radioactivity distribution in lung of normal fischer rat after injection of anti-[18F]FMACBC after 60 min.,1,Rattus norvegicus,Intermediate,,,,10116.0,,2048.0,A,BAO_0000218,CHEMBL622380,9191
Lung,50597,N,1,,,,16435,,Radioactivity distribution in lung of normal fischer rat after injection of syn-[18F]-FMACBC after 120 min.,1,Rattus norvegicus,Intermediate,,,,10116.0,,2048.0,A,BAO_0000218,CHEMBL622381,9192
Lung,50597,N,1,,,,16435,,Radioactivity distribution in lung of normal fischer rat after injection of syn-[18F]-FMACBC after 60 min.,1,Rattus norvegicus,Intermediate,,,,10116.0,,2048.0,A,BAO_0000218,CHEMBL622382,9193
Lung,50597,N,1,,,,16434,,Radioactivity distribution in lung of tumor-bearing fischer rat after injection of [18F]-fluoro-2-methylpropanoic acid after 120 min,1,Rattus norvegicus,Intermediate,,,,10116.0,,2048.0,A,BAO_0000218,CHEMBL622383,9194
Stomach,50597,N,1,,,,6175,,pH of the gastric juice (Control value = 1.44+/-0.01) of stomach content of pylorus ligated rats was measured ( 5 mg/kg po of the Compound was administered 1 hr before the pylorus ligation),1,Rattus norvegicus,Intermediate,,,,10116.0,,945.0,A,BAO_0000218,CHEMBL875332,9195
Stomach,50597,N,1,,,,6175,,pH of the gastric juice (Control value = 1.44+/-0.01) of stomach content of pylorus ligated rats was measured (10 mg/kg po of the Compound was administered 1 hr before the pylorus ligation),1,Rattus norvegicus,Intermediate,,,,10116.0,,945.0,A,BAO_0000218,CHEMBL622384,9196
Stomach,50597,N,1,,,,6175,,pH of the gastric juice (control value = 1.39+/-0.02) of stomach content of pylorus ligated rats was measured (2.5 mg/kg po of the Compound was administered 1 hr before the pylorus ligation),1,Rattus norvegicus,Intermediate,,,,10116.0,,945.0,A,BAO_0000218,CHEMBL622385,9197
Stomach,50597,N,1,,,,6175,,pH of the gastric juice (control value = 1.39+/-0.02) of stomach content of pylorus ligated rats was measured (5 mg/kg po of the Compound was administered 1 hr before the pylorus ligation),1,Rattus norvegicus,Intermediate,,,,10116.0,,945.0,A,BAO_0000218,CHEMBL622386,9198
,50597,N,1,,,,10839,,The compound was tested for the plasma binding in rat,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL622387,9199
,50597,N,1,,,,16459,,"Plasma concentration after intravenous aministration at 1hr, (1 mg/kg, n=3)",1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL622388,9200
,50597,N,1,,,,16459,,"Plasma concentration after intravenous aministration at 30 min. (1 mg/kg, n=3)",1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL622389,9201
,50597,N,1,,,,16459,,"Plasma concentration after intravenous aministration at 60 min. (1 mg/kg, n=3)",1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL622390,9202
,50597,N,1,,,,16459,,Plasma concentration after oral aministration at 1 hr. (10 mg/kg),1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL622391,9203
,50597,N,1,,,,16459,,Plasma concentration after oral aministration at 2 hr. (10 mg/kg),1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL622392,9204
,50597,N,1,,,,16459,,Plasma concentration after oral aministration at 4 hr. (10 mg/kg),1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL622393,9205
,50597,N,1,,,,3278,,Plasma level at 2 hr after administration of the compound,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL622394,9206
,50597,N,1,,,,3278,,plasma level at 2 hr after administration of the compound,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL622395,9207
Serum,50597,N,1,,,,4684,,Stability in rat serum measured as % recovery at 1 min,1,Rattus norvegicus,Intermediate,,,,10116.0,,1977.0,A,BAO_0000218,CHEMBL622396,9208
Serum,50597,N,1,,,,4684,,Stability in rat serum measured as % recovery at 10 min,1,Rattus norvegicus,Intermediate,,,,10116.0,,1977.0,A,BAO_0000218,CHEMBL624894,9209
Serum,50597,N,1,,,,4684,,Stability in rat serum measured as % recovery at 10 mins,1,Rattus norvegicus,Intermediate,,,,10116.0,,1977.0,A,BAO_0000218,CHEMBL624895,9210
Serum,50597,N,1,,,,4684,,Stability in rat serum measured as % recovery at 2 hr,1,Rattus norvegicus,Intermediate,,,,10116.0,,1977.0,A,BAO_0000218,CHEMBL624058,9211
Serum,50597,N,1,,,,4684,,Stability in rat serum measured as % recovery at 3 min,1,Rattus norvegicus,Intermediate,,,,10116.0,,1977.0,A,BAO_0000218,CHEMBL624059,9212
Serum,50597,N,1,,,,4684,,Stability in rat serum measured as % recovery at 3 mins,1,Rattus norvegicus,Intermediate,,,,10116.0,,1977.0,A,BAO_0000218,CHEMBL624060,9213
Serum,50597,N,1,,,,4684,,Stability in rat serum measured as % recovery at 5 min,1,Rattus norvegicus,Intermediate,,,,10116.0,,1977.0,A,BAO_0000218,CHEMBL624061,9214
Serum,50597,N,1,,,,4684,,Stability in rat serum measured as % recovery at 5 mins,1,Rattus norvegicus,Intermediate,,,,10116.0,,1977.0,A,BAO_0000218,CHEMBL624062,9215
,50597,N,1,In vivo,,,16456,,Alpha-elimination half-life in Male Sprague-Dawley rats after intravenous administration at a dose of 10 mg/kg,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL624063,9216
,50597,N,1,In vivo,,,16456,,Beta-elimination half-life in Male Sprague-Dawley rats after intravenous administration at a dose of 10 mg/kg,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL624064,9217
Plasma,50597,N,1,,,,723,,Half life in plasma was determined against ovariectomized rats; t 1/2 (h) is short in plasma,1,Rattus norvegicus,Intermediate,,,,10116.0,,1969.0,A,BAO_0000218,CHEMBL624065,9218
Plasma,50597,N,1,,,,723,,Half life in plasma was determined against ovariectomized rats; t1/2 is longer in plasma.,1,Rattus norvegicus,Intermediate,,,,10116.0,,1969.0,A,BAO_0000218,CHEMBL624066,9219
,50597,N,1,In vivo,,,5160,,Half life tested in mature male rat at a dose of 30 mg/kg,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL877490,9220
,50597,N,1,In vivo,,,4709,,Half life after intravenous administration of 1 mg/kg in rat,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL874442,9221
,50597,N,1,In vivo,,,5633,,Half life period after administration (30 mg/kg) in rat,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL626890,9222
,50597,N,1,In vivo,,,5302,,Half life period in rat after 5 mg/Kg dose,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL626891,9223
,50597,N,1,In vivo,,,5302,,Half life period in rat after 5 mg/kg dose,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL626892,9224
,50597,N,1,,,,17791,,Half life period was determined,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL626893,9225
,50597,N,1,,,,17791,,Half life period was evaluated in rat,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL626894,9226
,50597,N,1,,,,17791,,Half life period was evaluated in rat; 0.5-1.0,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL626895,9227
,50597,N,1,,,,17791,,Half life period was evaluated in rat; 5.9-7.5,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL626896,9228
Plasma,50597,N,1,,,,14512,,Half-life in rat plasma,1,Rattus norvegicus,Intermediate,,,,10116.0,,1969.0,A,BAO_0000218,CHEMBL626897,9229
,50597,N,1,,,,6230,,Half-life time in rat was determined,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL626898,9230
,50597,N,1,In vivo,,,3364,,Terminal half-life after iv administration to rats,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL626899,9231
,50597,N,1,In vivo,,,6874,,Tested for iv terminal half-life dosed as a solution in male Han Wistar rats,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL626900,9232
,50597,N,1,,,,857,,Time required to return to 50% inhibition of pressor response after AI-challenge in normotensive rats at 0.5 umol/kg,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL626901,9233
,50597,N,1,In vivo,,,858,,Time required to return to 50% inhibition of pressor response after AI-challenge in normotensive rats at 0.5 umol/kg (iv),1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL626902,9234
,50597,N,1,In vivo,,,858,,Time required to return to 50% inhibition of pressor response after AI-challenge in normotensive rats at 5 umol/kg (iv),1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL626903,9235
,50597,N,1,In vivo,,,5355,,Time for peak concentration (tmax) at a dose of 10 mg/kg in rats,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL874443,9236
,50597,N,1,In vivo,,,5355,,Time for peak concentration (tmax) at a dose of 20 mg/kg in rats,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL626904,9237
,50597,N,1,,,,6305,,Half life in rats,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL626905,9238
Plasma,50597,N,1,In vivo,,,13501,,Apparent Half life was determined from the linear portion of the log plasma concentration-time profile after oral administration of compound 18 at a dose of 4 mg/kg to rat,1,Rattus norvegicus,Intermediate,,,,10116.0,,1969.0,A,BAO_0000218,CHEMBL873830,9239
,50597,N,1,In vivo,,,17594,,Apparent half-life after single intravenous bolus of 1 mg/kg in rats,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL626906,9240
Plasma,50597,N,1,In vivo,,,4186,,Apparent terminal elimination half-life in rat plasma after administration of 3.5 mg/kg dose through subcutaneous route,1,Rattus norvegicus,Intermediate,,,,10116.0,,1969.0,A,BAO_0000218,CHEMBL631076,9241
Plasma,50597,N,1,,,,2932,,Biological half-life was measured in plasma of rats,1,Rattus norvegicus,Intermediate,,,,10116.0,,1969.0,A,BAO_0000218,CHEMBL631077,9242
,50597,N,1,In vivo,,,17065,,Circulatory half life measured after intravenous bolus administration of 50 mg/kg of compound to rats,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL631078,9243
,50597,N,1,In vivo,,,15765,,Compound demonstarted an oral bioavailability of 6% with the half-life time as given in rats.,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL631079,9244
,50597,N,1,In vivo,,,2713,,Compound was evaluated for half life (t1/2) upon intravenous administration of 1 mg/Kg in rats,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL631080,9245
,50597,N,1,In vivo,,,2661,,Compound was evaluated for half life after treatment with iv dose of 1 mgkg to female wistar rats,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL631081,9246
,50597,N,1,In vivo,,,2661,,Compound was evaluated for half life after treatment with iv dose of 1 mgkg to male wistar rats,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL631239,9247
Plasma,50597,N,1,,,,740,,Compound was evaluated for plasma half life in rat,1,Rattus norvegicus,Intermediate,,,,10116.0,,1969.0,A,BAO_0000218,CHEMBL631240,9248
Plasma,50597,N,1,,,,6597,,AUC value at a dose of 5 mg/kg (p.o.) in rats,1,Rattus norvegicus,Intermediate,,,,10116.0,,1969.0,A,BAO_0000218,CHEMBL631241,9249
Plasma,50597,N,1,,,,2959,,AUC value after administration of 20 mg/Kg oral dose in rat,1,Rattus norvegicus,Intermediate,,,,10116.0,,1969.0,A,BAO_0000218,CHEMBL631242,9250
Plasma,50597,N,1,,,,17594,,AUC0-24 after repeated oral dose of compound at 1 mg/kg in rats,1,Rattus norvegicus,Intermediate,,,,10116.0,,1969.0,A,BAO_0000218,CHEMBL631243,9251
Plasma,50597,N,1,,,,17596,,AUC0-96 after administration at 50 mg/kg,1,Rattus norvegicus,Intermediate,,,,10116.0,,1969.0,A,BAO_0000218,CHEMBL874444,9252
Plasma,50597,N,1,,,,17594,,AUC0-infinity after single intravenous bolus of 1 mg/kg in rats,1,Rattus norvegicus,Intermediate,,,,10116.0,,1969.0,A,BAO_0000218,CHEMBL631244,9253
,50597,N,1,,,,3293,,"Absorption behavior was judged by the area under the curve, determined after oral dose of 30 mg/kg in rats.",1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL631245,9254
,50597,N,1,,,,6757,,Area under curve (0-24 hr) at a dose of 10 mg/kg in male SD rats,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL627162,9255
,50597,N,1,,,,6757,,Area under curve (0-24 hr) at a dose of 100 mg/kg in male SD rats,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL627163,9256
,50597,N,1,,,,6757,,Area under curve (0-24 hr) at a dose of 50 mg/kg in male SD rats,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL627164,9257
Kidney,50597,N,1,,,,5979,,Area under curve (AUC) at a dose 1 mg/kg was determined in rat kidney,1,Rattus norvegicus,Intermediate,,,,10116.0,,2113.0,A,BAO_0000218,CHEMBL627165,9258
,50597,N,1,,,,5979,,Area under curve (AUC) at a dose 1 mg/kg was determined in rat liver,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL627166,9259
,50597,N,1,,,,5979,,Area under curve (AUC) at a dose 1 mg/kg was determined in rat lung,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL627167,9260
,50597,N,1,,,,4026,,Area under curve (AUC) at a dose of 30 mg/kg in rats,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL627822,9261
,50597,N,1,,,,5355,,Area under curve (AUC) was calculated using trapezoidal rule at a dose of 20 mg/kg in rats,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL627823,9262
,50597,N,1,,,,5355,,Area under curve (AUC) was calculated using trapezoidal rule. at a dose of 10 mg/kg in rats,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL627824,9263
,50597,N,1,,,,5355,,Area under curve (AUC) was calculated using trapezoidal rule at a dose of 20 mg/kg in rats,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL627825,9264
,50597,N,1,,,,5633,,Area under curve (AUC0-24 h) after administration (30 mg/kg) in rat,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL627826,9265
,50597,N,1,,,,1716,,Area under curve (Pharmacokinetic property) was determined,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL627827,9266
,50597,N,1,,,,1716,,Area under curve (Pharmacokinetic property) of the compound; Not determined,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL627828,9267
,50597,N,1,,,,4689,,Area under curve after intravenous administration (1 mg/kg) in rat,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL627829,9268
,50597,N,1,,,,4527,,Area under curve by intravenous administration at a dose of 10 uM/kg in rat was determined,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL627830,9269
,50597,N,1,,,,4527,,Area under curve by oral administration at a dose of 100 uM/kg in rat was determined,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL627831,9270
,50597,N,1,,,,15662,,Area under curve in male SD rats was observed after oral administration in rat,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL627832,9271
,50597,N,1,,,,4413,,Area under curve of compound after iv administration of 20 mg/kg dose in rat,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL627833,9272
,50597,N,1,,,,3598,,Area under curve of compound determined in rat after iv administration at a dose of 10 mg/kg,1,Rattus norvegicus,Expert,,,,10116.0,,,A,BAO_0000218,CHEMBL627834,9273
,50597,N,1,,,,3598,,Area under curve of compound from zero time to infinity determined in rat after iv administration at a dose of 10 mg/kg,1,Rattus norvegicus,Expert,,,,10116.0,,,A,BAO_0000218,CHEMBL628004,9274
,50597,N,1,,,,5964,,Area under curve at 5 mg/kg po was determined in rat,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL628005,9275
,50597,N,1,,,,4689,,Area under curve in Rat at a oral dose of 5 mg/kg,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL628006,9276
,50597,N,1,,,,4186,,Area under curve in rat plasma after administration of 3.5 mg/kg dose through subcutaneous route,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL628007,9277
,50597,N,1,,,,5510,,Area under curve was determined,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL625676,9278
,50597,N,1,,,,17858,,Area under curve after 10 mg/kg oral administration in rat at 0-24 hr,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL631309,9279
,50597,N,1,,,,17804,,Area under curve after intravenous administration at 3 mg/kg,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL631310,9280
,50597,N,1,,,,6106,,Area under curve after peroral administration at 10 mg/kg in rat for 0-6 h,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL631311,9281
,50597,N,1,,,,5964,,Area under curve at 4 hr in rat,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL631312,9282
,50597,N,1,,,,4026,,Area under curve at a dose of 30 mg/kg,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL631313,9283
,50597,N,1,,,,4756,,Area under curve at the dose of 2 mg/Kg administered perorally in rats,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL631314,9284
,50597,N,1,,,,4756,,Area under curve at the dose of 5 mg/Kg administered perorally in rats,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL631315,9285
,50597,N,1,,,,5862,,Area under curve for a 2-mpk po dose in SD rats,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL631316,9286
,50597,N,1,,,,5862,,Area under curve in SD rats,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL631317,9287
,50597,N,1,,,,6644,,Area under curve in rat after oral administration at 13 mg/kg dose,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL874471,9288
,50597,N,1,,,,5871,,Area under curve in rat by po administration at 0-24 hr,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL631318,9289
Plasma,50597,N,1,,,,5919,,Area under curve in rat plasma,1,Rattus norvegicus,Intermediate,,,,10116.0,,1969.0,A,BAO_0000218,CHEMBL631319,9290
,50597,N,1,,,,5939,,Area under curve in rat plasma for 0-4 hr after peroral administration at 10 mg/kg,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL631320,9291
,50597,N,1,,,,5939,,Area under curve in rat plasma for 0-4 hr after peroral administration at 5 mg/kg,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL631321,9292
,50597,N,1,,,,10,,Area under curve was evaluated in rat at 3 mg/kg dose administered intravenously,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL631322,9293
,50597,N,1,,,,11149,,Area under curve was measured from the graph obtained from concentration Vs time after oral administration to male F344 rats,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL631323,9294
,50597,N,1,,,,5302,,Area under curve value in rat at a dose of 5 mg/kg,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL631324,9295
,50597,N,1,,,,17796,,Area under curve was determined after oral administration in rats,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL631325,9296
,50597,N,1,,,,4890,,Area under curve was determined after oral administration at a dose 10 mg/kg to male Sprague-Dawley rats,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL631326,9297
,50597,N,1,,,,6011,,Area under curve was determined after peroral administration in rat,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL631327,9298
,50597,N,1,,,,5375,,Area under curve was determined at a dose 30 mpk administered orally.,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL631328,9299
,50597,N,1,,,,17764,,Area under curve was determined for compound after intravenous administration in rats at 24 uM/kg,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL631329,9300
,50597,N,1,,,,4368,,Area under curve was determined for the compound by intravenous administration of 3.4 mg/kg in rat,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL627217,9301
,50597,N,1,,,,5610,,Area under curve was determined in male rat,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL626352,9302
,50597,N,1,,,,5833,,Area under curve was determined in rat after PO administration,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL626353,9303
,50597,N,1,,,,4257,,Area under curve was determined in rat after a 3 mg/kg of oral dose,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL626354,9304
,50597,N,1,,,,5937,,Area under curve was determined in rat after oral administration at a concentration 1 mg/kg,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL626355,9305
,50597,N,1,,,,5932,,Area under curve was determined in rat after oral administration at a concentration 30 mg/kg,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL626356,9306
,50597,N,1,,,,5932,,Area under curve was determined in rat after oral administration at a concentration 30 mg/kg; NA= Not active,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL626357,9307
,50597,N,1,,,,17411,,Liver concentration was determined after 5 min. of intravenous administration to rats (n=4) at dose of 20 mg/kg,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL626358,9308
,50597,N,1,,,,17411,,Lung concentration was determined after 5 min. of intravenous administration to rats (n=4) at dose of 20 mg/kg,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL626359,9309
Plasma,50597,N,1,,,,17771,,Peak plasma concentration in rat at a dose of 3 mg/kg,1,Rattus norvegicus,Intermediate,,,,10116.0,,1969.0,A,BAO_0000218,CHEMBL626360,9310
,50597,N,1,,,,1628,,Plasma concentration at 2 hr in rats was evaluated.,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL626361,9311
,50597,N,1,,,,1628,,Plasma concentration at 2 hr in rats was evaluated; Not available,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL626362,9312
,50597,N,1,,,,17411,,Serum concentration was determined after 5 min. of intravenous administration to rats (n=4) at dose of 20 mg/kg,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL626363,9313
,50597,N,1,,,,4910,,Tested for concentration in brain after 0.25 hrs of intravenous administration (5 mg/kg) to male rats,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL626970,9314
,50597,N,1,,,,4910,,Tested for concentration in brain after 2 hrs of intravenous administration (5 mg/kg) to male rats,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL626971,9315
Plasma,50597,N,1,,,,4910,,Tested for plasma concentration after 0.25 hrs of intravenous administration (5 mg/kg) to male rats,1,Rattus norvegicus,Intermediate,,,,10116.0,,1969.0,A,BAO_0000218,CHEMBL626972,9316
Plasma,50597,N,1,,,,4910,,Tested for plasma concentration after 2 hrs of intravenous administration (5 mg/kg) to male rats,1,Rattus norvegicus,Intermediate,,,,10116.0,,1969.0,A,BAO_0000218,CHEMBL626973,9317
Plasma,50597,N,1,,,,4910,,Tested for plasma concentration in the after 0.25 hrs of intravenous administration (5 mg/kg) to male rats,1,Rattus norvegicus,Intermediate,,,,10116.0,,1969.0,A,BAO_0000218,CHEMBL626974,9318
Plasma,50597,N,1,,,,4910,,Tested for plasma concentration in the after 2 hrs of intravenous administration (5 mg/kg) to male rats,1,Rattus norvegicus,Intermediate,,,,10116.0,,1969.0,A,BAO_0000218,CHEMBL874592,9319
,50597,N,1,,,,5510,,Percentage converted to BMS-191011 after 30 min incubation in rat plasma at 37 degree C,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL626975,9320
,50597,N,1,,,,5510,,Percentage converted to BMS-191011 after 30 min incubation in rat plasma at 37 degree C; Converted to an unknown compound,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL626976,9321
,50597,N,1,,,,5510,,Percentage converted to BMS-191011 after 30 min incubation in rat plasma at 37 degree C; Not determined,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL626977,9322
,50597,N,1,,,,5510,,Percentage converted to BMS-191011 after 30 min incubation in rat plasma at 37 degree C; Not tested,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL626978,9323
,50597,N,1,,,,16427,,PK study was carried to determine the relative absorption ranking in rat.,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL626979,9324
Plasma,50597,N,1,In vivo,,,4689,,Maximum plasma concentration in Rat at a oral dose of 5 mg/kg,1,Rattus norvegicus,Intermediate,,,,10116.0,,1969.0,A,BAO_0000218,CHEMBL626980,9325
Blood,50597,N,1,,,,11450,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in blood of unfasted rats after 30 mins of intravenous administration (10.7 uCi/animal); value ranges from 0.57-0.75 % dose/g",1,Rattus norvegicus,Intermediate,,,,10116.0,,178.0,A,BAO_0000218,CHEMBL626981,9326
Blood,50597,N,1,,,,11450,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in blood of unfasted rats after 30 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.06-0.63 % dose/g",1,Rattus norvegicus,Intermediate,,,,10116.0,,178.0,A,BAO_0000218,CHEMBL626982,9327
Blood,50597,N,1,,,,11450,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in blood of unfasted rats after 5 mins of intravenous administration (10.7 uCi/animal); value ranges from 0.40-0.55 % dose/g",1,Rattus norvegicus,Intermediate,,,,10116.0,,178.0,A,BAO_0000218,CHEMBL626983,9328
Blood,50597,N,1,,,,11450,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in blood of unfasted rats after 5 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.28-0.37% dose/g",1,Rattus norvegicus,Intermediate,,,,10116.0,,178.0,A,BAO_0000218,CHEMBL622522,9329
Blood,50597,N,1,,,,11450,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in blood of unfasted rats after 60 mins of intravenous administration (10.7 uCi/animal); value ranges from 0.56-0.74 % dose/g",1,Rattus norvegicus,Intermediate,,,,10116.0,,178.0,A,BAO_0000218,CHEMBL622523,9330
Blood,50597,N,1,,,,11450,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in blood of unfasted rats after 60 mins of intravenous administration (11.5 uCi/animal); value ranges from % dose/g",1,Rattus norvegicus,Intermediate,,,,10116.0,,178.0,A,BAO_0000218,CHEMBL622524,9331
Brain,50597,N,1,,,,11450,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in brain of unfasted rats after 30 mins of intravenous administration (10.7 uCi/animal); value ranges from 2.20-2.85 % dose/g",1,Rattus norvegicus,Intermediate,,,,10116.0,,955.0,A,BAO_0000218,CHEMBL622525,9332
Brain,50597,N,1,,,,11450,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in brain of unfasted rats after 30 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.16-1.76 % dose/g",1,Rattus norvegicus,Intermediate,,,,10116.0,,955.0,A,BAO_0000218,CHEMBL622526,9333
Brain,50597,N,1,,,,11450,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in brain of unfasted rats after 5 mins of intravenous administration (10.7 uCi/animal); value ranges from 1.96-3.72 % dose/g",1,Rattus norvegicus,Intermediate,,,,10116.0,,955.0,A,BAO_0000218,CHEMBL619849,9334
Brain,50597,N,1,,,,11450,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in brain of unfasted rats after 5 mins of intravenous administration (11.5 uCi/animal); value ranges from 2.57-3.59 % dose/g",1,Rattus norvegicus,Intermediate,,,,10116.0,,955.0,A,BAO_0000218,CHEMBL619850,9335
Brain,50597,N,1,,,,11450,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in brain of unfasted rats after 60 mins of intravenous administration (10.7 uCi/animal); value ranges from 1.36-1.53 % dose/g",1,Rattus norvegicus,Intermediate,,,,10116.0,,955.0,A,BAO_0000218,CHEMBL623864,9336
Brain,50597,N,1,,,,11450,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in brain of unfasted rats after 60 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.81-1.08 % dose/g",1,Rattus norvegicus,Intermediate,,,,10116.0,,955.0,A,BAO_0000218,CHEMBL623865,9337
Heart,50597,N,1,,,,11450,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in heart of unfasted rats after 30 mins of intravenous administration (10.7 uCi/animal); value ranges from 0.84-0.98 % dose/g",1,Rattus norvegicus,Intermediate,,,,10116.0,,948.0,A,BAO_0000218,CHEMBL623866,9338
Heart,50597,N,1,,,,11450,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in heart of unfasted rats after 30 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.06-0.53 % dose/g",1,Rattus norvegicus,Intermediate,,,,10116.0,,948.0,A,BAO_0000218,CHEMBL623867,9339
Heart,50597,N,1,,,,11450,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in heart of unfasted rats after 5 mins of intravenous administration (10.7 uCi/animal); value ranges from 1.22-1.48 % dose/g",1,Rattus norvegicus,Intermediate,,,,10116.0,,948.0,A,BAO_0000218,CHEMBL877615,9340
Heart,50597,N,1,,,,11450,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in heart of unfasted rats after 5 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.85-1.13 % dose/g",1,Rattus norvegicus,Intermediate,,,,10116.0,,948.0,A,BAO_0000218,CHEMBL623868,9341
Heart,50597,N,1,,,,11450,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in heart of unfasted rats after 60 mins of intravenous administration (10.7 uCi/animal); value ranges from 0.55-0.63 % dose/g",1,Rattus norvegicus,Intermediate,,,,10116.0,,948.0,A,BAO_0000218,CHEMBL623869,9342
Heart,50597,N,1,,,,11450,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in heart of unfasted rats after 60 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.33-0.42 % dose/g",1,Rattus norvegicus,Intermediate,,,,10116.0,,948.0,A,BAO_0000218,CHEMBL623870,9343
Lung,50597,N,1,,,,16434,,Radioactivity distribution in lung of tumor-bearing fischer rat after injection of [18F]-fluoro-2-methylpropanoic acid after 5 min,1,Rattus norvegicus,Intermediate,,,,10116.0,,2048.0,A,BAO_0000218,CHEMBL623871,9344
Lung,50597,N,1,,,,16434,,Radioactivity distribution in lung of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min,1,Rattus norvegicus,Intermediate,,,,10116.0,,2048.0,A,BAO_0000218,CHEMBL623872,9345
Lung,50597,N,1,,,,16435,,Radioactivity distribution in lung of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 120 min,1,Rattus norvegicus,Intermediate,,,,10116.0,,2048.0,A,BAO_0000218,CHEMBL622129,9346
Lung,50597,N,1,,,,16435,,Radioactivity distribution in lung of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 5 min,1,Rattus norvegicus,Intermediate,,,,10116.0,,2048.0,A,BAO_0000218,CHEMBL622130,9347
Lung,50597,N,1,,,,16435,,Radioactivity distribution in lung of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 60 min,1,Rattus norvegicus,Intermediate,,,,10116.0,,2048.0,A,BAO_0000218,CHEMBL622131,9348
Lung,50597,N,1,,,,16435,,Radioactivity distribution in lung of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 120 min,1,Rattus norvegicus,Intermediate,,,,10116.0,,2048.0,A,BAO_0000218,CHEMBL622132,9349
Lung,50597,N,1,,,,16435,,Radioactivity distribution in lung of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 5 min,1,Rattus norvegicus,Intermediate,,,,10116.0,,2048.0,A,BAO_0000218,CHEMBL622133,9350
Lung,50597,N,1,,,,16435,,Radioactivity distribution in lung of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 60 min,1,Rattus norvegicus,Intermediate,,,,10116.0,,2048.0,A,BAO_0000218,CHEMBL622134,9351
Lung,50597,N,1,,,,16435,,Radioactivity distribution in lungs of normal fischer rat after injection of syn-[18F]-FMACBC after 30 min.,1,Rattus norvegicus,Intermediate,,,,10116.0,,2048.0,A,BAO_0000218,CHEMBL622135,9352
Lung,50597,N,1,,,,16435,,Radioactivity distribution in lungs of normal fischer rat after injection of syn-[18F]-FMACBC after 5 min.,1,Rattus norvegicus,Intermediate,,,,10116.0,,2048.0,A,BAO_0000218,CHEMBL622136,9353
Muscle tissue,50597,N,1,,,,16434,,Radioactivity distribution in muscle of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 120 min.,1,Rattus norvegicus,Intermediate,,,,10116.0,,2385.0,A,BAO_0000218,CHEMBL622137,9354
Muscle tissue,50597,N,1,,,,16434,,Radioactivity distribution in muscle of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 30 min.,1,Rattus norvegicus,Intermediate,,,,10116.0,,2385.0,A,BAO_0000218,CHEMBL622138,9355
Muscle tissue,50597,N,1,,,,16434,,Radioactivity distribution in muscle of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 5 min.,1,Rattus norvegicus,Intermediate,,,,10116.0,,2385.0,A,BAO_0000218,CHEMBL623017,9356
Muscle tissue,50597,N,1,,,,16434,,Radioactivity distribution in muscle of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 60 min.,1,Rattus norvegicus,Intermediate,,,,10116.0,,2385.0,A,BAO_0000218,CHEMBL623018,9357
Muscle tissue,50597,N,1,,,,16434,,Radioactivity distribution in muscle of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min.,1,Rattus norvegicus,Intermediate,,,,10116.0,,2385.0,A,BAO_0000218,CHEMBL623019,9358
Muscle tissue,50597,N,1,,,,16434,,Radioactivity distribution in muscle of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 30 min.,1,Rattus norvegicus,Intermediate,,,,10116.0,,2385.0,A,BAO_0000218,CHEMBL623020,9359
Muscle tissue,50597,N,1,,,,16434,,Radioactivity distribution in muscle of normal fischer rat after injection of [18F]-fluoro-2-methylpropanoic acid after 5 min.,1,Rattus norvegicus,Intermediate,,,,10116.0,,2385.0,A,BAO_0000218,CHEMBL623021,9360
Muscle tissue,50597,N,1,,,,16434,,Radioactivity distribution in muscle of normal fischer rat after injection of [18F]-fluoro-2-methylpropanoic acid after 60 min.,1,Rattus norvegicus,Intermediate,,,,10116.0,,2385.0,A,BAO_0000218,CHEMBL623022,9361
Muscle tissue,50597,N,1,,,,16435,,Radioactivity distribution in muscle of normal fischer rat after injection of anti-[18F]FMACBC after 120 min.,1,Rattus norvegicus,Intermediate,,,,10116.0,,2385.0,A,BAO_0000218,CHEMBL623023,9362
Muscle tissue,50597,N,1,,,,16435,,Radioactivity distribution in muscle of normal fischer rat after injection of anti-[18F]FMACBC after 30 min.,1,Rattus norvegicus,Intermediate,,,,10116.0,,2385.0,A,BAO_0000218,CHEMBL623024,9363
Muscle tissue,50597,N,1,,,,16435,,Radioactivity distribution in muscle of normal fischer rat after injection of anti-[18F]FMACBC after 5 min.,1,Rattus norvegicus,Intermediate,,,,10116.0,,2385.0,A,BAO_0000218,CHEMBL623025,9364
Muscle tissue,50597,N,1,,,,16435,,Radioactivity distribution in muscle of normal fischer rat after injection of anti-[18F]FMACBC after 60 min.,1,Rattus norvegicus,Intermediate,,,,10116.0,,2385.0,A,BAO_0000218,CHEMBL620545,9365
Muscle tissue,50597,N,1,,,,16435,,Radioactivity distribution in muscle of normal fischer rat after injection of syn-[18F]-FMACBC after 120 min.,1,Rattus norvegicus,Intermediate,,,,10116.0,,2385.0,A,BAO_0000218,CHEMBL620546,9366
Muscle tissue,50597,N,1,,,,16435,,Radioactivity distribution in muscle of normal fischer rat after injection of syn-[18F]-FMACBC after 30 min.,1,Rattus norvegicus,Intermediate,,,,10116.0,,2385.0,A,BAO_0000218,CHEMBL620547,9367
Muscle tissue,50597,N,1,,,,16435,,Radioactivity distribution in muscle of normal fischer rat after injection of syn-[18F]-FMACBC after 5 min.,1,Rattus norvegicus,Intermediate,,,,10116.0,,2385.0,A,BAO_0000218,CHEMBL620548,9368
Muscle tissue,50597,N,1,,,,16435,,Radioactivity distribution in muscle of normal fischer rat after injection of syn-[18F]-FMACBC after 60 min.,1,Rattus norvegicus,Intermediate,,,,10116.0,,2385.0,A,BAO_0000218,CHEMBL620549,9369
Muscle tissue,50597,N,1,,,,16434,,Radioactivity distribution in muscle of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min,1,Rattus norvegicus,Intermediate,,,,10116.0,,2385.0,A,BAO_0000218,CHEMBL620550,9370
Muscle tissue,50597,N,1,,,,16434,,Radioactivity distribution in muscle of tumor-bearing fischer rat after injection of [18F]-fluoro-2-methylpropanoic acid after 5 min,1,Rattus norvegicus,Intermediate,,,,10116.0,,2385.0,A,BAO_0000218,CHEMBL620551,9371
Muscle tissue,50597,N,1,,,,16434,,Radioactivity distribution in muscle of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min,1,Rattus norvegicus,Intermediate,,,,10116.0,,2385.0,A,BAO_0000218,CHEMBL620552,9372
Muscle tissue,50597,N,1,,,,16435,,Radioactivity distribution in muscle of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 120 min,1,Rattus norvegicus,Intermediate,,,,10116.0,,2385.0,A,BAO_0000218,CHEMBL620553,9373
Muscle tissue,50597,N,1,,,,16435,,Radioactivity distribution in muscle of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 5 min,1,Rattus norvegicus,Intermediate,,,,10116.0,,2385.0,A,BAO_0000218,CHEMBL620554,9374
Muscle tissue,50597,N,1,,,,16435,,Radioactivity distribution in muscle of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 60 min,1,Rattus norvegicus,Intermediate,,,,10116.0,,2385.0,A,BAO_0000218,CHEMBL875845,9375
Muscle tissue,50597,N,1,,,,16435,,Radioactivity distribution in muscle of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 120 min,1,Rattus norvegicus,Intermediate,,,,10116.0,,2385.0,A,BAO_0000218,CHEMBL620555,9376
Muscle tissue,50597,N,1,,,,16435,,Radioactivity distribution in muscle of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 5 min,1,Rattus norvegicus,Intermediate,,,,10116.0,,2385.0,A,BAO_0000218,CHEMBL620556,9377
Muscle tissue,50597,N,1,,,,16435,,Radioactivity distribution in muscle of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 60 min,1,Rattus norvegicus,Intermediate,,,,10116.0,,2385.0,A,BAO_0000218,CHEMBL620557,9378
,50597,N,1,,,,16434,,Radioactivity distribution in pancreas of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 120 min.,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL620558,9379
,50597,N,1,,,,16434,,Radioactivity distribution in pancreas of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 30 min.,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL620559,9380
,50597,N,1,,,,16434,,Radioactivity distribution in pancreas of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 5 min.,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL622939,9381
,50597,N,1,,,,16434,,Radioactivity distribution in pancreas of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 60 min.,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL622940,9382
,50597,N,1,,,,16434,,Radioactivity distribution in pancreas of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min.,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL622941,9383
,50597,N,1,,,,16434,,Radioactivity distribution in pancreas of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 30 min.,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL622942,9384
,50597,N,1,,,,16434,,Radioactivity distribution in pancreas of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min.,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL622943,9385
,50597,N,1,,,,16434,,Radioactivity distribution in pancreas of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min.,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL622944,9386
,50597,N,1,,,,16435,,Radioactivity distribution in pancreas of normal fischer rat after injection of anti-[18F]FMACBC after 120 min.,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL622945,9387
,50597,N,1,,,,16435,,Radioactivity distribution in pancreas of normal fischer rat after injection of anti-[18F]FMACBC after 30 min.,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL622946,9388
,50597,N,1,,,,3341,,Compound was evaluated for terminal half life in rat,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL622947,9389
Plasma,50597,N,1,In vivo,,,3634,,Compound was evaluated in vivo in rat for the plasma half-life at a iv dose of 3 mg/kg and oral dose of 10 mg/kg and experiment by using concentration vs time curve,1,Rattus norvegicus,Intermediate,,,,10116.0,,1969.0,A,BAO_0000218,CHEMBL622948,9390
Plasma,50597,N,1,In vivo,,,3634,,Compound was evaluated in vivo in rat for the plasma half-life at a oral dose of 20 mg/kg experiment by using concentration vs time curve,1,Rattus norvegicus,Intermediate,,,,10116.0,,1969.0,A,BAO_0000218,CHEMBL622949,9391
,50597,N,1,,,,4839,,Compound was tested for its half life in rat,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL622950,9392
Plasma,22224,U,0,In vivo,,,5005,,Compound was tested for its plasma half life in rhesus monkey at a dose of 0.75 mg/kg iv/ 1.5 mg/kg po; ND is not determined.,1,Macaca mulatta,Intermediate,,,,9544.0,,1969.0,A,BAO_0000218,CHEMBL622951,9393
Plasma,22224,U,0,,,,5005,,Compound was tested for its plasma half life in Sprague Dawley rats,1,Rattus norvegicus,Intermediate,,,,10116.0,,1969.0,A,BAO_0000366,CHEMBL622952,9394
Plasma,22224,U,0,,,,5005,,Compound was tested for its plasma half life in Sprague Dawley rats; ND is not determined,1,Rattus norvegicus,Intermediate,,,,10116.0,,1969.0,A,BAO_0000366,CHEMBL622953,9395
Plasma,50597,N,1,,,,1094,,Compound was tested for plasma half-life period in rat,1,Rattus norvegicus,Intermediate,,,,10116.0,,1969.0,A,BAO_0000218,CHEMBL873818,9396
,50597,N,1,In vivo,,,5031,,Elimination half life after i.v. administration of compound in rats,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL622954,9397
,50597,N,1,In vivo,,,6518,,Elimination half-life after IV dosing at 0.5 mg/kg in rat,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL622955,9398
,50597,N,1,In vivo,,,6518,,Elimination half-life after IV dosing at 1 mg/kg in rat,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL875229,9399
,50597,N,1,In vivo,,,6518,,Elimination half-life after oral administration at a dose of 2 mg/kg in rat,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL622956,9400
,50597,N,1,In vivo,,,6518,,Elimination half-life after oral administration at a dose of 4 mg/kg in rat,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL622957,9401
Brain,50597,N,1,In vivo,,,5408,,Evaluated for half-life after iv administration of 1 mg/kg to male Sprague-Dawley rats in brain; not determined,1,Rattus norvegicus,Intermediate,,,,10116.0,,955.0,A,BAO_0000218,CHEMBL622958,9402
Plasma,50597,N,1,In vivo,,,5408,,Evaluated for half-life after iv administration of 1 mg/kg to male Sprague-Dawley rats in plasma,1,Rattus norvegicus,Intermediate,,,,10116.0,,1969.0,A,BAO_0000218,CHEMBL622959,9403
Brain,50597,N,1,In vivo,,,5408,,Evaluated for half-life after iv administration of 5 mg/kg to male Sprague-Dawley rats in brain,1,Rattus norvegicus,Intermediate,,,,10116.0,,955.0,A,BAO_0000218,CHEMBL622960,9404
Plasma,50597,N,1,In vivo,,,5408,,Evaluated for half-life after iv administration of 5 mg/kg to male Sprague-Dawley rats in plasma,1,Rattus norvegicus,Intermediate,,,,10116.0,,1969.0,A,BAO_0000218,CHEMBL622961,9405
,50597,N,1,In vivo,,,4687,,Evaluated for the half life in rat (in vivo),1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL622962,9406
,50597,N,1,,,,6640,,Hafl life in rat,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL622963,9407
,50597,N,1,,,,6640,,Hafl life rat,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL622964,9408
,50597,N,1,,,,6641,,Hafl life rat,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL622965,9409
,50597,N,1,,,,6640,,Hafl life rat; Not determined,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL622966,9410
,50597,N,1,,,,6641,,Hafl life rat; Not determined,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL622967,9411
Kidney,50597,N,1,In vivo,,,17411,,Half life in kidney was determined after intravenous administration to rats (n=4) at dose of 20 mg/kg,1,Rattus norvegicus,Intermediate,,,,10116.0,,2113.0,A,BAO_0000218,CHEMBL622968,9412
Liver,50597,N,1,In vivo,,,17411,,Half life in liver was determined after intravenous administration to rats (n=4) at dose of 20 mg/kg,1,Rattus norvegicus,Intermediate,,,,10116.0,,2107.0,A,BAO_0000218,CHEMBL622969,9413
Lung,50597,N,1,In vivo,,,17411,,Half life in lung was determined after intravenous administration to rats (n=4) at dose of 20 mg/kg,1,Rattus norvegicus,Intermediate,,,,10116.0,,2048.0,A,BAO_0000218,CHEMBL875327,9414
,50597,N,1,In vivo,,,6570,,Half life in rat after 1 mg/kg i.v. administration,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL628638,9415
,50597,N,1,In vivo,,,6570,,Half life in rat after 2 mg/kg peroral administration,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL628639,9416
,50597,N,1,In vivo,,,17411,,Half life in serum was determined after intravenous administration to rats (n=4) at dose of 20 mg/kg,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL625840,9417
,50597,N,1,In vivo,,,4722,,Half life of 10 mg/kg oral dose determined in rats,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL625841,9418
,50597,N,1,In vivo,,,5978,,Half life of compound (10 mg/kg) after iv administration was determined in Sprague-Dawley rat,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL625842,9419
,50597,N,1,In vivo,,,5978,,Half life of compound (19.2 mg/kg) after po administration was determined in Sprague-Dawley rat,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL625843,9420
,50597,N,1,In vivo,,,5978,,Half life of compound (20.73 mg/kg) after po administration was determined in Sprague-Dawley rat,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL625844,9421
,50597,N,1,In vivo,,,5978,,Half life of compound (25 mg/kg) after po administration was determined in Sprague-Dawley rat,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL873822,9422
,50597,N,1,In vivo,,,5978,,Half life of compound (9.83 mg/kg) after iv administration was determined in Sprague-Dawley rat,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL625845,9423
,50597,N,1,In vivo,,,5978,,Half life of compound (9.84 mg/kg) after iv administration was determined in Sprague-Dawley rat,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL627059,9424
,50597,N,1,In vivo,,,5978,,Half life of compound (9.84 mg/kg) after po administration was determined in Sprague-Dawley rat,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL627060,9425
,50597,N,1,In vivo,,,5978,,Half life of compound (9.92 mg/kg) after iv administration was determined in Sprague-Dawley rat,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL627061,9426
,50597,N,1,In vivo,,,4762,,Half life of compound at 5 mg/kg after po administration was determined in rat,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL627709,9427
,50597,N,1,In vivo,,,5327,,Half life of compound determined after intravenous administration to rat,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL627710,9428
,50597,N,1,,,,4847,,Half life of compound was determined in rat,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL627711,9429
Plasma,50597,N,1,In vivo,,,17720,,Half life at a dose of 4 mg/kg in Rat Plasma after iv administration,1,Rattus norvegicus,Intermediate,,,,10116.0,,1969.0,A,BAO_0000218,CHEMBL627712,9430
,50597,N,1,In vivo,,,4723,,Half life determined after 0.3 mg/kg oral administration in potassium oxonate treated rats,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL627713,9431
,50597,N,1,In vivo,,,4723,,Half life determined after 3 mg/kg oral administration in potassium oxonate treated rats,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL627714,9432
,22224,U,0,In vivo,,,4256,,Half life determined after intravenous administration at a dose of 3 mg/kg in cynomolgus monkey,1,Macaca fascicularis,Intermediate,,,,9541.0,,,A,BAO_0000218,CHEMBL627889,9433
,22224,U,0,In vivo,,,4256,,Half life determined in rat by intravenous administration,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL627890,9434
,50597,N,1,In vivo,,,4722,,Half life determined in rats after iv administration,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL627891,9435
Plasma,50597,N,1,In vivo,,,6535,,Half life in rat plasma after administration of 2 mg/kg iv,1,Rattus norvegicus,Intermediate,,,,10116.0,,1969.0,A,BAO_0000218,CHEMBL627892,9436
Plasma,50597,N,1,In vivo,,,6535,,Half life in rat plasma after administration of 2 mg/kg iv,1,Rattus norvegicus,Intermediate,,,,10116.0,,1969.0,A,BAO_0000218,CHEMBL627893,9437
Plasma,50597,N,1,,,,1435,,Half life in rat plasma was determined,1,Rattus norvegicus,Intermediate,,,,10116.0,,1969.0,A,BAO_0000218,CHEMBL627894,9438
Plasma,50597,N,1,,,,1435,,Half life in rat plasma was determined; NA means not applicable,1,Rattus norvegicus,Intermediate,,,,10116.0,,1969.0,A,BAO_0000218,CHEMBL627895,9439
,50597,N,1,,,,5206,,Half life in rat was tested,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL627896,9440
Plasma,50597,N,1,,,,6080,,Half life measured in rat plasma,1,Rattus norvegicus,Intermediate,,,,10116.0,,1969.0,A,BAO_0000218,CHEMBL627897,9441
,50597,N,1,,,,4449,,Half life recorded in rats,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL627898,9442
,50597,N,1,,,,6057,,Half life was calculated,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL627899,9443
,50597,N,1,,,,6057,,Half life was calculated in rat,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL873823,9444
,50597,N,1,,,,3747,,Half life was determined,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL627900,9445
,50597,N,1,In vivo,,,17858,,Half life after 10 mg/kg oral administration in rat,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL627901,9446
,50597,N,1,In vivo,,,16365,,Half life after administering orally a dose of 10 mg/kg to a fasting rat,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL627902,9447
,50597,N,1,In vivo,,,16365,,Half life after administering orally a dose of 30 mg/kg,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL627903,9448
,50597,N,1,,,,5031,,Area under the curve (Concentration) was determined for the compound as AUC with limits 0-8 after i.v. administration in rats,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL627904,9449
,50597,N,1,,,,4722,,Area under the curve determined under pharmacokinetic behavior of the 10 mg/kg oral dose of compound for 0-6 hours,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL627905,9450
,50597,N,1,,,,6078,,Area under the curve for the compound calculated from 0-24 hr after intravenous administration at a dose of 10 mg/kg in rat,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL627906,9451
,50597,N,1,,,,6078,,Area under the curve for the compound calculated from 0-24 hr after oral administration at a dose of 10 mg/kg in rat,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL627907,9452
,50597,N,1,,,,6078,,Area under the curve for the compound calculated from 0-6 hr after oral administration at a dose of 10 mg/kg,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL876783,9453
,50597,N,1,,,,6078,,Area under the curve for the compound calculated from 0-6 hr after oral administration at a dose of 10 mg/kg; activity was not determined,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL627908,9454
,50597,N,1,,,,17065,,Area under the curve measured after intravenous bolus administration of 50 mg/kg of compound to rats,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL627909,9455
,50597,N,1,,,,1353,,Area under the curve in plasma after oral administration of 30 mg/kg at 1 hr interval during 6 hrs in rats,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL627910,9456
,50597,N,1,,,,1353,,Area under the curve in plasma after oral administration of 30 mg/kg at 1 hr interval during 6 hrs in rats(0-1),1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL627911,9457
,50597,N,1,,,,1353,,Area under the curve in plasma after oral administration of 30 mg/kg at 1 hr interval during 6 hrs in rats(0-2),1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL627912,9458
,50597,N,1,,,,1353,,Area under the curve in plasma after oral administration of 30 mg/kg at 1 hr interval during 6 hrs in rats(0-5),1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL627913,9459
,50597,N,1,,,,1353,,Area under the curve in plasma after oral administration of 30 mg/kg at 1 hr interval during 6 hrs in rats(5-10),1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL627914,9460
,50597,N,1,,,,16423,,Area under the curve was evaluated after 10 uM/kg of intra arterial administration,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL627915,9461
,50597,N,1,,,,16423,,Area under the curve was evaluated after 20 uM/kg of peroral administration,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL627916,9462
,50597,N,1,,,,6062,,Area under the curve was measured in rat after an iv dose of 1 mg/kg,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL627917,9463
,50597,N,1,,,,6056,,Area under the curve was calculated for the compound at a single intravenous administration of 20 mg/kg in rat,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL627918,9464
,50597,N,1,,,,5182,,Area under the curve was determined by administering the compound at a dose of 1 mg/kg intravenously in male wistar rat,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL627919,9465
,50597,N,1,,,,6410,,Area under the curve was evaluated at an intravenous dose of 3 mg/kg,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL627920,9466
,50597,N,1,,,,6410,,Area under the curve was evaluated at an oral dose of 30 mg/kg,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL627921,9467
,50597,N,1,,,,4723,,Area under the effect time curves from time 0-24 hr determined after 0.3 mg/kg oral administration in potassium oxonate treated rats,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL627922,9468
,50597,N,1,,,,4723,,Area under the effect time curves from time 0-24 hr determined after 3 mg/kg oral administration in potassium oxonate treated rats,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL876784,9469
,50597,N,1,,,,4723,,Area under the effect time curves from time 0-6 hr determined after 0.3 mg/kg oral administration in potassium oxonate treated rats,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL627923,9470
,50597,N,1,,,,4723,,Area under the effect time curves from time 0-6 hr determined after 3 mg/kg oral administration in potassium oxonate treated rats,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL626208,9471
,50597,N,1,,,,4723,,Area under the effect time curves from time 0-infinity hr determined after 0.3 mg/kg oral administration in potassium oxonate treated rats,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL626209,9472
,50597,N,1,,,,4723,,Area under the effect time curves from time 0-infinity hr determined after 3 mg/kg oral administration in potassium oxonate treated rats,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL626210,9473
Plasma,50597,N,1,,,,2463,,Area under the plasma concentration curve was evaluated in vivo in rat at a dose of 5 mg/kg by oral administration,1,Rattus norvegicus,Intermediate,,,,10116.0,,1969.0,A,BAO_0000218,CHEMBL627994,9474
,50597,N,1,,,,4709,,Bioavailability from area under the curve at time 0 to infinity after intravenous administration of 1 mg/kg in rat,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL627995,9475
,50597,N,1,,,,4075,,Blood level after a 10 mg/kg oral dose in rat expressed as AUC was determined,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL627996,9476
,50597,N,1,,,,5394,,Compound at a dose 10 mg/kg was administered orally to rat and the pharmacokinetic parameter area under curve (AUC) was measured,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL627997,9477
,50597,N,1,,,,2661,,Compound was evaluated for AUC after treatment with iv dose of 1 mgkg to female wistar rats,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL627998,9478
,50597,N,1,,,,2661,,Compound was evaluated for AUC after treatment with iv dose of 1 mgkg to male wistar rats,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL628640,9479
,50597,N,1,,,,2661,,Compound was evaluated for AUC after treatment with oral dose of 2 mgkg to female wistar rats,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL628641,9480
,50597,N,1,,,,2661,,Compound was evaluated for AUC after treatment with oral dose of 2 mgkg to male wistar rats,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL628642,9481
,50597,N,1,,,,17791,,Compound was evaluated for area under the curve expressed as (h*ug/ml),1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL628643,9482
,50597,N,1,,,,2591,,Compound was tested for area under curve in rat,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL628644,9483
,50597,N,1,,,,6567,,Concentration in rat plasma after 5 mg/kg oral gavage for 8 hours,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL628645,9484
,50597,N,1,,,,6211,,Dose-normalized AUC was determined by po administration (10 mg/kg) in fasted male Sprague-Dawley rats,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL628646,9485
,50597,N,1,,,,5529,,Dose-normalized AUC was determined in rat after peroral administration (2 mg/kg),1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL628647,9486
,50597,N,1,,,,5408,,Evaluated for AUC after iv administration of 1 mg/kg to male Sprague-Dawley rats in brain; not determined,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL628648,9487
,50597,N,1,,,,5408,,Evaluated for AUC after iv administration of 1 mg/kg to male Sprague-Dawley rats in plasma,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL625358,9488
,50597,N,1,,,,5408,,Evaluated for AUC after iv administration of 5 mg/kg to male Sprague-Dawley rats in brain,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL625359,9489
,50597,N,1,,,,5408,,Evaluated for AUC after iv administration of 5 mg/kg to male Sprague-Dawley rats in plasma,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL625360,9490
,50597,N,1,,,,429,,Evaluated for pharmacokinetic parameter area under curve in rat at the dose 50 mg/kg ( 0-8 hr ),1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL625361,9491
,50597,N,1,,,,429,,Evaluated for pharmacokinetic parameter area under curve in rat at the dose 50 mg/kg (0-8 hr ),1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL625362,9492
,50597,N,1,,,,429,,Evaluated for pharmacokinetic parameter area under curve in rat at the dose 50 mg/kg (0-8 hr),1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL625363,9493
,50597,N,1,,,,4796,,Hepatic portal AUC was determined by pharmacokinetic study conducted in portal vein cannulated rats,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL625364,9494
,50597,N,1,,,,5974,,In vivo Area under curve (AUC) was determined after intravenous administration of compound (158.5+/-2 mg/kg) in male Sprague-Dawley rat,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL625365,9495
,50597,N,1,,,,5974,,In vivo Area under curve (AUC) was determined after intravenous administration of compound (9.13+/-0.85 mg/kg) in male Sprague-Dawley rat,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL625366,9496
,50597,N,1,,,,5974,,In vivo Area under curve (AUC) was determined after peroral administration of compound (19.01+/-0.31 mg/kg) in male Sprague-Dawley rat,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL625367,9497
Kidney,50597,N,1,,,,11450,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in kidney of unfasted rats after 30 mins of intravenous administration (10.7 uCi/animal); value ranges from 1.98-2.56 % dose/g",1,Rattus norvegicus,Intermediate,,,,10116.0,,2113.0,A,BAO_0000218,CHEMBL625368,9498
Kidney,50597,N,1,,,,11450,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in kidney of unfasted rats after 30 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.15-1.43 % dose/g",1,Rattus norvegicus,Intermediate,,,,10116.0,,2113.0,A,BAO_0000218,CHEMBL625369,9499
Kidney,50597,N,1,,,,11450,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in kidney of unfasted rats after 5 mins of intravenous administration (10.7 uCi/animal); value ranges from 3.43-4.52 % dose/g",1,Rattus norvegicus,Intermediate,,,,10116.0,,2113.0,A,BAO_0000218,CHEMBL625370,9500
Kidney,50597,N,1,,,,11450,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in kidney of unfasted rats after 5 mins of intravenous administration (11.5 uCi/animal); value ranges from 2.12-3.14 % dose/g",1,Rattus norvegicus,Intermediate,,,,10116.0,,2113.0,A,BAO_0000218,CHEMBL625371,9501
Kidney,50597,N,1,,,,11450,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in kidney of unfasted rats after 60 mins of intravenous administration (10.7 uCi/animal); value ranges from 1.40-1.60 % dose/g",1,Rattus norvegicus,Intermediate,,,,10116.0,,2113.0,A,BAO_0000218,CHEMBL625372,9502
Kidney,50597,N,1,,,,11450,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in kidney of unfasted rats after 60 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.74-0.85 % dose/g",1,Rattus norvegicus,Intermediate,,,,10116.0,,2113.0,A,BAO_0000218,CHEMBL625373,9503
Liver,50597,N,1,,,,11450,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in liver of unfasted rats after 30 mins of intravenous administration (10.7 uCi/animal); value ranges from 1.31-1.45 % dose/g",1,Rattus norvegicus,Intermediate,,,,10116.0,,2107.0,A,BAO_0000218,CHEMBL625374,9504
Liver,50597,N,1,,,,11450,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in liver of unfasted rats after 30 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.08-0.90 % dose/g",1,Rattus norvegicus,Intermediate,,,,10116.0,,2107.0,A,BAO_0000218,CHEMBL877593,9505
Liver,50597,N,1,,,,11450,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in liver of unfasted rats after 5 mins of intravenous administration (10.7 uCi/animal); value ranges from 2.02-2.78 % dose/g",1,Rattus norvegicus,Intermediate,,,,10116.0,,2107.0,A,BAO_0000218,CHEMBL625375,9506
Liver,50597,N,1,,,,11450,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in liver of unfasted rats after 5 mins of intravenous administration (11.5 uCi/animal); value ranges from 1.64-2.38 % dose/g",1,Rattus norvegicus,Intermediate,,,,10116.0,,2107.0,A,BAO_0000218,CHEMBL625376,9507
Liver,50597,N,1,,,,11450,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in liver of unfasted rats after 60 mins of intravenous administration (10.7 uCi/animal); value ranges from 0.95-1.07 % dose/g",1,Rattus norvegicus,Intermediate,,,,10116.0,,2107.0,A,BAO_0000218,CHEMBL621973,9508
Liver,50597,N,1,,,,11450,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in liver of unfasted rats after 60 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.61-0.81 % dose/g",1,Rattus norvegicus,Intermediate,,,,10116.0,,2107.0,A,BAO_0000218,CHEMBL621974,9509
Lung,50597,N,1,,,,11450,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in lungs of unfasted rats after 30 mins of intravenous administration (10.7 uCi/animal); value ranges from 5.01-7.13 % dose/g",1,Rattus norvegicus,Intermediate,,,,10116.0,,2048.0,A,BAO_0000218,CHEMBL621975,9510
Lung,50597,N,1,,,,11450,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in lungs of unfasted rats after 30 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.51-3.71 % dose/g",1,Rattus norvegicus,Intermediate,,,,10116.0,,2048.0,A,BAO_0000218,CHEMBL622166,9511
Lung,50597,N,1,,,,11450,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in lungs of unfasted rats after 5 mins of intravenous administration (10.7 uCi/animal); value ranges from 10.84-13.77 % dose/g",1,Rattus norvegicus,Intermediate,,,,10116.0,,2048.0,A,BAO_0000218,CHEMBL622167,9512
Lung,50597,N,1,,,,11450,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in lungs of unfasted rats after 5 mins of intravenous administration (11.5 uCi/animal); value ranges from 5.92-8.51% dose/g",1,Rattus norvegicus,Intermediate,,,,10116.0,,2048.0,A,BAO_0000218,CHEMBL622168,9513
Lung,50597,N,1,,,,11450,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in lungs of unfasted rats after 60 mins of intravenous administration (10.7 uCi/animal); value ranges from 3.37-3.94 % dose/g",1,Rattus norvegicus,Intermediate,,,,10116.0,,2048.0,A,BAO_0000218,CHEMBL622169,9514
Lung,50597,N,1,,,,11450,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in lungs of unfasted rats after 60 mins of intravenous administration (11.5 uCi/animal); value ranges from 1.87-2.12 % dose/g",1,Rattus norvegicus,Intermediate,,,,10116.0,,2048.0,A,BAO_0000218,CHEMBL622170,9515
Thyroid gland,50597,N,1,,,,11450,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in thyroid of unfasted rats after 30 mins of intravenous administration (10.7 uCi/animal); value ranges from 37.97-75.23 % dose/g",1,Rattus norvegicus,Intermediate,,,,10116.0,,2046.0,A,BAO_0000218,CHEMBL622171,9516
Thyroid gland,50597,N,1,,,,11450,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in thyroid of unfasted rats after 30 mins of intravenous administration (11.5 uCi/animal); value ranges from 5.03-36.88 % dose/g",1,Rattus norvegicus,Intermediate,,,,10116.0,,2046.0,A,BAO_0000218,CHEMBL622172,9517
Thyroid gland,50597,N,1,,,,11450,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in thyroid of unfasted rats after 5 mins of intravenous administration (10.7 uCi/animal); value ranges from 13.20-17.31 % dose/g",1,Rattus norvegicus,Intermediate,,,,10116.0,,2046.0,A,BAO_0000218,CHEMBL622173,9518
Thyroid gland,50597,N,1,,,,11450,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in thyroid of unfasted rats after 5 mins of intravenous administration (11.5 uCi/animal); value ranges from 7.87-16.51 % dose/g",1,Rattus norvegicus,Intermediate,,,,10116.0,,2046.0,A,BAO_0000218,CHEMBL622174,9519
Thyroid gland,50597,N,1,,,,11450,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in thyroid of unfasted rats after 60 mins of intravenous administration (10.7 uCi/animal); value ranges from 81.37-166.09 % dose/g",1,Rattus norvegicus,Intermediate,,,,10116.0,,2046.0,A,BAO_0000218,CHEMBL622175,9520
Thyroid gland,50597,N,1,,,,11450,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in thyroid of unfasted rats after 60 mins of intravenous administration (11.5 uCi/animal); value ranges from 31.90-39.98 % dose/g",1,Rattus norvegicus,Intermediate,,,,10116.0,,2046.0,A,BAO_0000218,CHEMBL622176,9521
Thyroid gland,50597,N,1,,,,11450,,"Distribution of the radioiodinated compound expressed as percent dose per organ, in thyroid of unfasted rats after 30 mins of intravenous administration (10.7 uCi/animal); value ranges from 0.41-0.83 % dose/g",1,Rattus norvegicus,Intermediate,,,,10116.0,,2046.0,A,BAO_0000218,CHEMBL622177,9522
Thyroid gland,50597,N,1,,,,11450,,"Distribution of the radioiodinated compound expressed as percent dose per organ, in thyroid of unfasted rats after 30 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.05-0.38 % dose/g",1,Rattus norvegicus,Intermediate,,,,10116.0,,2046.0,A,BAO_0000218,CHEMBL622178,9523
Thyroid gland,50597,N,1,,,,11450,,"Distribution of the radioiodinated compound expressed as percent dose per organ, in thyroid of unfasted rats after 5 mins of intravenous administration (10.7 uCi/animal); value ranges from 0.16-0.20 % dose/g",1,Rattus norvegicus,Intermediate,,,,10116.0,,2046.0,A,BAO_0000218,CHEMBL622179,9524
Thyroid gland,50597,N,1,,,,11450,,"Distribution of the radioiodinated compound expressed as percent dose per organ, in thyroid of unfasted rats after 5 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.08-0.17 % dose/g",1,Rattus norvegicus,Intermediate,,,,10116.0,,2046.0,A,BAO_0000218,CHEMBL622180,9525
,50597,N,1,,,,16435,,Radioactivity distribution in pancreas of normal fischer rat after injection of anti-[18F]FMACBC after 5 min.,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL622181,9526
,50597,N,1,,,,16435,,Radioactivity distribution in pancreas of normal fischer rat after injection of anti-[18F]FMACBC after 60 min.,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL622182,9527
,50597,N,1,,,,16435,,Radioactivity distribution in pancreas of normal fischer rat after injection of syn-[18F]-FMACBC after 120 min.,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL622183,9528
,50597,N,1,,,,16435,,Radioactivity distribution in pancreas of normal fischer rat after injection of syn-[18F]-FMACBC after 30 min.,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL622184,9529
,50597,N,1,,,,16435,,Radioactivity distribution in pancreas of normal fischer rat after injection of syn-[18F]-FMACBC after 5 min.,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL622185,9530
,50597,N,1,,,,16435,,Radioactivity distribution in pancreas of normal fischer rat after injection of syn-[18F]-FMACBC after 60 min.,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL622186,9531
,50597,N,1,,,,16434,,Radioactivity distribution in pancreas of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL622187,9532
,50597,N,1,,,,16434,,Radioactivity distribution in pancreas of tumor-bearing fischer rat after injection of [18F]-fluoro-2-methylpropanoic acid after 5 min,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL625002,9533
,50597,N,1,,,,16434,,Radioactivity distribution in pancreas of tumor-bearing fischer rat after injection of [18F]-fluoro-2-methylpropanoic acid after 60 min,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL622090,9534
,50597,N,1,,,,16435,,Radioactivity distribution in pancreas of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 120 min,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL622091,9535
,50597,N,1,,,,16435,,Radioactivity distribution in pancreas of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 5 min,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL622092,9536
,50597,N,1,,,,16435,,Radioactivity distribution in pancreas of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 60 min,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL622093,9537
,50597,N,1,,,,16435,,Radioactivity distribution in pancreas of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 120 min,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL622094,9538
,50597,N,1,,,,16435,,Radioactivity distribution in pancreas of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 5 min,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL622095,9539
,50597,N,1,,,,16435,,Radioactivity distribution in pancreas of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 60 min,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL622264,9540
Spleen,50597,N,1,,,,16434,,Radioactivity distribution in spleen of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 120 min.,1,Rattus norvegicus,Intermediate,,,,10116.0,,2106.0,A,BAO_0000218,CHEMBL622265,9541
Spleen,50597,N,1,,,,16434,,Radioactivity distribution in spleen of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 30 min.,1,Rattus norvegicus,Intermediate,,,,10116.0,,2106.0,A,BAO_0000218,CHEMBL622266,9542
Spleen,50597,N,1,,,,16434,,Radioactivity distribution in spleen of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 5 min.,1,Rattus norvegicus,Intermediate,,,,10116.0,,2106.0,A,BAO_0000218,CHEMBL622267,9543
Spleen,50597,N,1,,,,16434,,Radioactivity distribution in spleen of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 60 min.,1,Rattus norvegicus,Intermediate,,,,10116.0,,2106.0,A,BAO_0000218,CHEMBL622268,9544
Spleen,50597,N,1,,,,16434,,Radioactivity distribution in spleen of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min.,1,Rattus norvegicus,Intermediate,,,,10116.0,,2106.0,A,BAO_0000218,CHEMBL622269,9545
Spleen,50597,N,1,,,,16434,,Radioactivity distribution in spleen of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 30 min.,1,Rattus norvegicus,Intermediate,,,,10116.0,,2106.0,A,BAO_0000218,CHEMBL625071,9546
Spleen,50597,N,1,,,,16434,,Radioactivity distribution in spleen of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min.,1,Rattus norvegicus,Intermediate,,,,10116.0,,2106.0,A,BAO_0000218,CHEMBL621621,9547
Spleen,50597,N,1,,,,16434,,Radioactivity distribution in spleen of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min.,1,Rattus norvegicus,Intermediate,,,,10116.0,,2106.0,A,BAO_0000218,CHEMBL621622,9548
Spleen,50597,N,1,,,,16435,,Radioactivity distribution in spleen of normal fischer rat after injection of anti-[18F]FMACBC after 120 min.,1,Rattus norvegicus,Intermediate,,,,10116.0,,2106.0,A,BAO_0000218,CHEMBL621623,9549
Spleen,50597,N,1,,,,16435,,Radioactivity distribution in spleen of normal fischer rat after injection of anti-[18F]FMACBC after 30 min.,1,Rattus norvegicus,Intermediate,,,,10116.0,,2106.0,A,BAO_0000218,CHEMBL621624,9550
Spleen,50597,N,1,,,,16435,,Radioactivity distribution in spleen of normal fischer rat after injection of anti-[18F]FMACBC after 5 min.,1,Rattus norvegicus,Intermediate,,,,10116.0,,2106.0,A,BAO_0000218,CHEMBL621625,9551
Spleen,50597,N,1,,,,16435,,Radioactivity distribution in spleen of normal fischer rat after injection of anti-[18F]FMACBC after 60 min.,1,Rattus norvegicus,Intermediate,,,,10116.0,,2106.0,A,BAO_0000218,CHEMBL621626,9552
Spleen,50597,N,1,,,,16435,,Radioactivity distribution in spleen of normal fischer rat after injection of syn-[18F]-FMACBC after 120 min.,1,Rattus norvegicus,Intermediate,,,,10116.0,,2106.0,A,BAO_0000218,CHEMBL621627,9553
Spleen,50597,N,1,,,,16435,,Radioactivity distribution in spleen of normal fischer rat after injection of syn-[18F]-FMACBC after 30 min.,1,Rattus norvegicus,Intermediate,,,,10116.0,,2106.0,A,BAO_0000218,CHEMBL621628,9554
Spleen,50597,N,1,,,,16435,,Radioactivity distribution in spleen of normal fischer rat after injection of syn-[18F]-FMACBC after 5 min.,1,Rattus norvegicus,Intermediate,,,,10116.0,,2106.0,A,BAO_0000218,CHEMBL875328,9555
Spleen,50597,N,1,,,,16435,,Radioactivity distribution in spleen of normal fischer rat after injection of syn-[18F]-FMACBC after 60 min.,1,Rattus norvegicus,Intermediate,,,,10116.0,,2106.0,A,BAO_0000218,CHEMBL621629,9556
Spleen,50597,N,1,,,,16434,,Radioactivity distribution in spleen of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min,1,Rattus norvegicus,Intermediate,,,,10116.0,,2106.0,A,BAO_0000218,CHEMBL621630,9557
Spleen,50597,N,1,,,,16434,,Radioactivity distribution in spleen of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min,1,Rattus norvegicus,Intermediate,,,,10116.0,,2106.0,A,BAO_0000218,CHEMBL621631,9558
Spleen,50597,N,1,,,,16434,,Radioactivity distribution in spleen of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min,1,Rattus norvegicus,Intermediate,,,,10116.0,,2106.0,A,BAO_0000218,CHEMBL621632,9559
Spleen,50597,N,1,,,,16435,,Radioactivity distribution in spleen of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 120 min,1,Rattus norvegicus,Intermediate,,,,10116.0,,2106.0,A,BAO_0000218,CHEMBL621633,9560
Spleen,50597,N,1,,,,16435,,Radioactivity distribution in spleen of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 5 min,1,Rattus norvegicus,Intermediate,,,,10116.0,,2106.0,A,BAO_0000218,CHEMBL621634,9561
Spleen,50597,N,1,,,,16435,,Radioactivity distribution in spleen of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 60 min,1,Rattus norvegicus,Intermediate,,,,10116.0,,2106.0,A,BAO_0000218,CHEMBL621635,9562
Spleen,50597,N,1,,,,16435,,Radioactivity distribution in spleen of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 120 min,1,Rattus norvegicus,Intermediate,,,,10116.0,,2106.0,A,BAO_0000218,CHEMBL621636,9563
Spleen,50597,N,1,,,,16435,,Radioactivity distribution in spleen of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 5 min,1,Rattus norvegicus,Intermediate,,,,10116.0,,2106.0,A,BAO_0000218,CHEMBL621637,9564
Spleen,50597,N,1,,,,16435,,Radioactivity distribution in spleen of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 60 min,1,Rattus norvegicus,Intermediate,,,,10116.0,,2106.0,A,BAO_0000218,CHEMBL621638,9565
,50597,N,1,,,,16434,,Radioactivity distribution in testis of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 120 min.,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL618883,9566
,50597,N,1,,,,16434,,Radioactivity distribution in testis of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 30 min.,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL618884,9567
,50597,N,1,,,,16434,,Radioactivity distribution in testis of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 5 min.,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL628627,9568
,50597,N,1,,,,16434,,Radioactivity distribution in testis of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 60 min.,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL628628,9569
,50597,N,1,,,,16434,,Radioactivity distribution in testis of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min.,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL628629,9570
,50597,N,1,In vivo,,,16365,,Half life after administering orally a dose of 3 mg/kg,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL628630,9571
,50597,N,1,In vivo,,,16365,,Half life after administering orally a dose of 3 mg/kg to a fasting rat,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL628631,9572
,50597,N,1,In vivo,,,16365,,Half life after administering intravenously a dose of 1 mg/kg,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL628632,9573
,50597,N,1,In vivo,,,526,,Half life after oral dosing in rats,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL628633,9574
,50597,N,1,In vivo,,,16365,,Half life after the administered orally a dose of 1 mg/kg to a fasting rat,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL628634,9575
,50597,N,1,In vivo,,,4368,,Half life by intravenous administration of 3.4 mg/kg in rat,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL627789,9576
,50597,N,1,,,,3371,,Half life in rat,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL627790,9577
,50597,N,1,,,,6448,,Half life in rat,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL627791,9578
,50597,N,1,,,,6453,,Half life in rat,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL627792,9579
,50597,N,1,In vivo,,,4353,,Half life in rat after intravenous administration of the compound,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL627793,9580
Plasma,50597,N,1,In vivo,,,4353,,Half life in rat after intravenous administration of the compound; nf:unable to estimate plasma elimination half life,1,Rattus norvegicus,Intermediate,,,,10116.0,,1969.0,A,BAO_0000218,CHEMBL627794,9581
,50597,N,1,In vivo,,,4353,,Half life in rat after po administration of the compound,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL627795,9582
,50597,N,1,In vivo,,,4353,,Half life in rat after po administration of the compound; ND means Not determined,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL627796,9583
Plasma,50597,N,1,In vivo,,,4353,,Half life in rat after po administration of the compound; nf: unable to estimate plasma elimination half life,1,Rattus norvegicus,Intermediate,,,,10116.0,,1969.0,A,BAO_0000218,CHEMBL875335,9584
Plasma,50597,N,1,In vivo,,,4353,,Half life in rat after po administration of the compound; nf:unable to estimate plasma elimination half life,1,Rattus norvegicus,Intermediate,,,,10116.0,,1969.0,A,BAO_0000218,CHEMBL627797,9585
,50597,N,1,In vivo,,,5789,,Half life in rat i.v.,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL627798,9586
,50597,N,1,In vivo,,,17686,,Half life in rat i.v. at 2 mg/kg concentration,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL627799,9587
,50597,N,1,,,,6495,,Half life in rats,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL627800,9588
,50597,N,1,In vivo,,,484,,Half life in rats after intravenous administration,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL627801,9589
,50597,N,1,In vivo,,,6467,,Half life in rats at the dose of 1.0 mpk by i.v. administration,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL627802,9590
,50597,N,1,,,,6642,,Half life in rat,1,Rattus norvegicus,Expert,,,,10116.0,,,A,BAO_0000218,CHEMBL627803,9591
,50597,N,1,In vivo,,,16367,,Half life was evaluated after intravenous administration to rats,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL873820,9592
,50597,N,1,,,,1369,,Half life was evaluated by addition of 2 mM of 2-mercaptoethanol for inactivation of semicarbazide-sensitive amine oxidase (SSAO),1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL627804,9593
,50597,N,1,,,,5472,,Half life was evaluated in rat,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL627805,9594
,50597,N,1,,,,6049,,Half life was evaluated in rat,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL627806,9595
,50597,N,1,,,,5472,,Half life was evaluated in rat; Not tested,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL627107,9596
,50597,N,1,In vivo,,,16366,,Half life was evaluated when a dose of 1 mg/kg was administered intravenously to rats,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL627108,9597
,50597,N,1,In vivo,,,11149,,Half life was measured as time taken to reach the half of the initial dose in air pouch exudate after oral administration to male F344 rats,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL627109,9598
Blood,50597,N,1,In vivo,,,11149,,Half life was measured as time taken to reach the half of the initial dose in the blood after oral administration to male F344 rats,1,Rattus norvegicus,Intermediate,,,,10116.0,,178.0,A,BAO_0000218,CHEMBL627110,9599
,22224,U,0,In vivo,,,2891,,Half life was measured in monkey at dose of 10 mg/kg by po administration,1,Primates,Intermediate,,,,9443.0,,,A,BAO_0000218,CHEMBL627111,9600
,22224,U,0,In vivo,,,2891,,Half life was measured in monkey at dose of 10 mg/kg by po administration,1,Primates,Intermediate,,,,9443.0,,,A,BAO_0000218,CHEMBL627112,9601
,22224,U,0,In vivo,,,2891,,Half life was measured in rat at dose of 30 mg/kg by iv administration,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL627113,9602
,22224,U,0,In vivo,,,2891,,Half life was measured in rat at dose of 30 mg/kg by po administration,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL627114,9603
,50597,N,1,,,,4026,,Half life (t1/2) was determined,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL627115,9604
,50597,N,1,,,,4527,,Half life period at a dose of 10 uM/kg in rat was determined,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL627116,9605
,50597,N,1,In vivo,,,4527,,Half life period by oral administration at a dose of 100 uM/kg in rat was determined; ND is not determined,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL627117,9606
,50597,N,1,,,,5503,,Half life period was determined,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL627118,9607
,50597,N,1,In vivo,,,4426,,Half life period after intravenous administration at 20 mpk in rats,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL627119,9608
,50597,N,1,In vivo,,,4426,,Half life period after intravenous administration at 20 mpk in rats; Not performed.,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL627120,9609
,50597,N,1,In vivo,,,6109,,Half life period after intravenous administration in rat,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL626922,9610
,50597,N,1,In vivo,,,5654,,Half life period as average of four rats at each dose of 5 mg/kg intravenous and 16 mg/kg peroral administration,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL626923,9611
,50597,N,1,In vivo,,,5654,,Half life period as average of four rats at each dose of 5 mg/kg intravenous and 20 mg/kg peroral administration,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL626924,9612
Plasma,50597,N,1,,,,4755,,Half life period in 80% rat plasma at 37 degree Centigrade,1,Rattus norvegicus,Intermediate,,,,10116.0,,1969.0,A,BAO_0000218,CHEMBL626925,9613
,50597,N,1,,,,5862,,Half life period in SD rats,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL626926,9614
Plasma,50597,N,1,,,,1515,,Half life period in human plasma at 25 degree Celsius temperature (pH 7.4),1,Rattus norvegicus,Intermediate,,,,10116.0,,1969.0,A,BAO_0000218,CHEMBL626927,9615
Plasma,50597,N,1,,,,1515,,Half life period in human plasma at 37 degree Celsius temperature (pH 7.4),1,Rattus norvegicus,Intermediate,,,,10116.0,,1969.0,A,BAO_0000218,CHEMBL626928,9616
Plasma,50597,N,1,,,,1515,,Half life period in human plasma at 37 degree Celsius temperature (pH 7.4); ND means no data,1,Rattus norvegicus,Intermediate,,,,10116.0,,1969.0,A,BAO_0000218,CHEMBL626929,9617
Plasma,50597,N,1,,,,1515,,Half life period in human plasma at 37 degree Celsius temperature (pH 7.4); ND means no data,1,Rattus norvegicus,Intermediate,,,,10116.0,,1969.0,A,BAO_0000218,CHEMBL626930,9618
,50597,N,1,,,,5960,,Half life period in rat,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL626931,9619
,50597,N,1,,,,6103,,Half life period in rat,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL626932,9620
,50597,N,1,,,,6317,,Half life period in rat,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL626933,9621
,50597,N,1,In vivo,,,6644,,Half life period in rat after oral administration at 10.5 mg/kg dose,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL873826,9622
,50597,N,1,In vivo,,,6644,,Half life period in rat after oral administration at 11.2 mg/kg dose,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL626934,9623
,50597,N,1,In vivo,,,6644,,Half life period in rat after oral administration at 13 mg/kg dose,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL626935,9624
,50597,N,1,In vivo,,,6644,,Half life period in rat after oral administration at 9.7 mg/kg dose,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL626936,9625
,50597,N,1,,,,5974,,In vivo Area under curve (AUC) was determined after peroral administration of compound (76.4+/-2.6 mg/kg) in male Sprague-Dawley rat,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL626937,9626
,50597,N,1,,,,6295,,In vivo area under curve in rat plasma exposure after oral administration 50 mg/kg,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL625906,9627
,50597,N,1,,,,6296,,In vivo area under curve in rat plasma exposure after oral administration 50 mg/kg,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL625907,9628
,50597,N,1,,,,16427,,PK study was carried to determine AUC (area under curve) value in rat,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL625908,9629
,50597,N,1,,,,16367,,Pharmacokinetic parameter AUC after intravenous administration to rats,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL625909,9630
,50597,N,1,,,,16367,,Pharmacokinetic parameter AUC after oral administration to rats,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL625910,9631
,50597,N,1,,,,16365,,Pharmacokinetic parameter AUC was evaluated intravenous administration of 3 mg/kg,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL625911,9632
,50597,N,1,,,,16365,,Pharmacokinetic parameter AUC was evaluated when a dose of 10 mg/kg is administered orally to a fasting rat,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL625912,9633
,50597,N,1,,,,16365,,Pharmacokinetic parameter AUC was evaluated when a dose of 1 mg/kg is administered orally to a fasting rat,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL626538,9634
,50597,N,1,,,,16365,,Pharmacokinetic parameter AUC was evaluated when a dose of 30 mg/kg is administered orally,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL876794,9635
,50597,N,1,,,,16365,,Pharmacokinetic parameter AUC was evaluated when a dose of 3 mg/kg is administered orally,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL626539,9636
,50597,N,1,,,,16365,,Pharmacokinetic parameter AUC was evaluated when a dose of 3 mg/kg is administered orally to a fasting rat,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL626540,9637
,50597,N,1,,,,5394,,Pharmacokinetic parameter area under curve (AUC) was measured after administration into monkey at 3 mg/kg,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL626541,9638
,50597,N,1,,,,5394,,Pharmacokinetic parameter area under curve (AUC) was measured after administration into rat at 10 mg/kg,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL626542,9639
,50597,N,1,,,,2792,,Pharmacokinetic parameter area under curve was determined at 10 mg/kg po dose in rats,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL626543,9640
,50597,N,1,,,,2792,,Pharmacokinetic parameter area under curve was determined at 2 mg/kg i.v. dose in rats,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL626544,9641
,50597,N,1,,,,2792,,Pharmacokinetic parameter area under curve was determined at 3 mg/kg po dose in rats,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL626545,9642
,50597,N,1,,,,2792,,Pharmacokinetic parameter area under curve was determined at 5 mg/kg i.v. dose in rats,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL626546,9643
,50597,N,1,,,,5334,,Pharmacokinetic parameter area under curve was reported,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL626547,9644
,50597,N,1,,,,4408,,Pharmacokinetic property (AUC) in rat,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL626548,9645
,50597,N,1,,,,5983,,Pharmacokinetic property (AUC) was measured in rat at the dose of 0.32 mg/kg p.o.,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL626549,9646
,50597,N,1,,,,4397,,Pharmacokinetic property at the dose of 10 mg/kg (20% HPbetaCD) concentration in rat (0 to 6 hr) p.o.,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL626550,9647
,50597,N,1,,,,4397,,Pharmacokinetic property at the dose of 10 mg/kg (20% HPbetaCD) concentration in rat (0 to 6 hr) p.o.; Not tested,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL626551,9648
,50597,N,1,,,,5491,,Pharmacokinetic property was determined,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL623777,9649
,50597,N,1,,,,5491,,Pharmacokinetic property when administered intravenously in rat at 2 mg/kg,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL623778,9650
,50597,N,1,,,,5491,,Pharmacokinetic property when administered intravenously in rat at 2 mg/kg; Not tested,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL623779,9651
Plasma,50597,N,1,,,,4199,,Pharmacokinetic property( plasma concentration) was determined upon 10 mg/kg in 1% methylcellulose peroral administration in rats,1,Rattus norvegicus,Intermediate,,,,10116.0,,1969.0,A,BAO_0000218,CHEMBL623780,9652
Plasma,50597,N,1,,,,4199,,Pharmacokinetic property( plasma concentration) was determined upon 2 mg/kg in 1% methylcellulose peroral administration in rats,1,Rattus norvegicus,Intermediate,,,,10116.0,,1969.0,A,BAO_0000218,CHEMBL622015,9653
Plasma,50597,N,1,,,,4199,,Pharmacokinetic property( plasma concentration) was determined upon 3 mg/kg in 1% methylcellulose peroral administration in rats,1,Rattus norvegicus,Intermediate,,,,10116.0,,1969.0,A,BAO_0000218,CHEMBL622016,9654
,50597,N,1,,,,5173,,"Pharmacokinetic property, AUC determined by rapid rat PK assay observed at 0.25 h",1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL622017,9655
,50597,N,1,,,,5173,,"Pharmacokinetic property, AUC determined by rapid rat PK assay observed at 0.5 h",1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL622018,9656
,50597,N,1,,,,5173,,"Pharmacokinetic property, AUC determined by rapid rat PK assay observed at 1 h",1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL622019,9657
,50597,N,1,,,,5173,,"Pharmacokinetic property, AUC determined by rapid rat PK assay observed at 2 h",1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL622020,9658
,50597,N,1,,,,16366,,Pharmacokinetic parameter AUC was determined when a dose of 1 mg/kg was administered intravenously,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL622021,9659
,50597,N,1,,,,16366,,Pharmacokinetic parameter AUC was determined when a dose of 1 mg/kg was administered orally,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL622022,9660
,50597,N,1,,,,5327,,Plasma concentration expressed as area under curve after intravenous administration was determined in rat,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL622023,9661
,50597,N,1,,,,6681,,Plasma concentration for the compound was determined in rats at 50 mg/kg dose,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL622024,9662
,50597,N,1,,,,12873,,Plasma concentration was calculated in rats at a peroral dose of 5 mg/kg of solution (formulation of compound),1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL622693,9663
,50597,N,1,,,,12873,,Plasma concentration was calculated in rats at a peroral dose of 5 mg/kg of suspension (formulation of compound),1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL622694,9664
,50597,N,1,,,,6685,,"Plasma concentration was determined in rats at 10 mg/kg, p.o. dose",1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL622695,9665
,50597,N,1,,,,6685,,"Plasma concentration was determined in rats at 20 mg/kg, i.p. dose",1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL622696,9666
,50597,N,1,,,,6685,,"Plasma concentration was determined in rats at 2 mg/kg, i.v. dose",1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL622697,9667
,50597,N,1,,,,6619,,"Reduction in area under curve was determined in fa/fa Zucker rats by oral glucose tolerance test following a single i.p. dose (20 mg/kg, 30 min pre-treatment)",1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL622874,9668
,50597,N,1,,,,6619,,"Reduction in area under curve was determined in fa/fa Zucker rats by oral glucose tolerance test following a single i.p. dose (30 mg/kg, 30 min pre-treatment)",1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL622875,9669
,50597,N,1,,,,10363,,Suppressor cell activity was measured as area under curve(AUC) in normal rats by a splenic cell coculture assay at a dose of 30 mg/kg; Not significant,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL622876,9670
,50597,N,1,,,,4796,,Systemic AUC was determined by pharmacokinetic study conducted in portal vein cannulated rats,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL622877,9671
,50597,N,1,,,,4910,,Tested for concentration in brain after intravenous administration (4.7 mg/kg) to male rats,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL622878,9672
Plasma,50597,N,1,,,,4910,,Tested for plasma concentration after intravenous administration (4.7 mg/kg) to male rats,1,Rattus norvegicus,Intermediate,,,,10116.0,,1969.0,A,BAO_0000218,CHEMBL622879,9673
,50597,N,1,,,,4839,,Tested for the pharmacokinetic parameter in rat and expressed as area under curve,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL877602,9674
,50597,N,1,,,,15078,,"The AUC(0-infinitive) value in female wistar rat at 100 mg/kg, p.o. dose",1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL622880,9675
,50597,N,1,,,,15078,,"The AUC(0-infinitive) value in male wistar rat at 100 mg/kg, p.o. dose",1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL622881,9676
,50597,N,1,,,,15078,,"The AUC(0-t)value in female wistar rat at 100 mg/kg, p.o. dose",1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL622882,9677
,50597,N,1,,,,15078,,"The AUC(0-t)value in male wistar rat at 100 mg/kg, p.o. dose",1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL622883,9678
Thyroid gland,50597,N,1,,,,11450,,"Distribution of the radioiodinated compound expressed as percent dose per organ, in thyroid of unfasted rats after 60 mins of intravenous administration (10.7 uCi/animal); value ranges from 2.16-2.39% dose/g",1,Rattus norvegicus,Intermediate,,,,10116.0,,2046.0,A,BAO_0000218,CHEMBL622884,9679
Thyroid gland,50597,N,1,,,,11450,,"Distribution of the radioiodinated compound expressed as percent dose per organ, in thyroid of unfasted rats after 60 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.99-1.40 % dose/g",1,Rattus norvegicus,Intermediate,,,,10116.0,,2046.0,A,BAO_0000218,CHEMBL622885,9680
,50597,N,1,,,,8151,,Antidiuretic activity expressed as K(+) (potassium) excreted in milli equivalents was reported for a duration of 5 hours after administration of a dose of 100 mg/Kg.,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL622886,9681
,50597,N,1,,,,8151,,Antidiuretic activity expressed as Na+(sodium) excreted in milli equivalents was reported for a duration of 5 hours after administration of a dose of 100 mg/Kg,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL622887,9682
Urine,50597,N,1,,,,8151,,Antidiuretic activity was determined expressed as volume of urine excreted in mL was reported at a dose of 100 mg/Kg,1,Rattus norvegicus,Intermediate,,,,10116.0,,1088.0,A,BAO_0000218,CHEMBL622888,9683
Blood,50597,N,1,In vivo,,,8677,,"Biodistribution in Sprague-Dawley rat blood 15 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",1,Rattus norvegicus,Intermediate,,,,10116.0,,178.0,A,BAO_0000218,CHEMBL622889,9684
Blood,50597,N,1,In vivo,,,8677,,"Biodistribution in Sprague-Dawley rat blood 15 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",1,Rattus norvegicus,Intermediate,,,,10116.0,,178.0,A,BAO_0000218,CHEMBL622890,9685
Blood,50597,N,1,In vivo,,,8677,,"Biodistribution in Sprague-Dawley rat blood 2 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",1,Rattus norvegicus,Intermediate,,,,10116.0,,178.0,A,BAO_0000218,CHEMBL622891,9686
Blood,50597,N,1,In vivo,,,8677,,"Biodistribution in Sprague-Dawley rat blood 2 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",1,Rattus norvegicus,Intermediate,,,,10116.0,,178.0,A,BAO_0000218,CHEMBL877603,9687
Brain,50597,N,1,In vivo,,,8677,,"Biodistribution in Sprague-Dawley rat brain 15 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",1,Rattus norvegicus,Intermediate,,,,10116.0,,955.0,A,BAO_0000218,CHEMBL622892,9688
Brain,50597,N,1,In vivo,,,8677,,"Biodistribution in Sprague-Dawley rat brain 15 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",1,Rattus norvegicus,Intermediate,,,,10116.0,,955.0,A,BAO_0000218,CHEMBL622893,9689
Brain,50597,N,1,In vivo,,,8677,,"Biodistribution in Sprague-Dawley rat brain 2 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",1,Rattus norvegicus,Intermediate,,,,10116.0,,955.0,A,BAO_0000218,CHEMBL622894,9690
Brain,50597,N,1,In vivo,,,8677,,"Biodistribution in Sprague-Dawley rat brain 2 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",1,Rattus norvegicus,Intermediate,,,,10116.0,,955.0,A,BAO_0000218,CHEMBL622895,9691
Brain,50597,N,1,In vivo,,,8677,,Biodistribution in Sprague-Dawley rat brain 2 minutes after intravenous administration.,1,Rattus norvegicus,Intermediate,,,,10116.0,,955.0,A,BAO_0000218,CHEMBL622896,9692
Heart,50597,N,1,In vivo,,,8677,,"Biodistribution in Sprague-Dawley rat heart 15 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",1,Rattus norvegicus,Intermediate,,,,10116.0,,948.0,A,BAO_0000218,CHEMBL622897,9693
Heart,50597,N,1,In vivo,,,8677,,"Biodistribution in Sprague-Dawley rat heart 2 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",1,Rattus norvegicus,Intermediate,,,,10116.0,,948.0,A,BAO_0000218,CHEMBL622898,9694
Heart,50597,N,1,In vivo,,,8677,,"Biodistribution in Sprague-Dawley rat heart 2 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",1,Rattus norvegicus,Intermediate,,,,10116.0,,948.0,A,BAO_0000218,CHEMBL622899,9695
Kidney,50597,N,1,In vivo,,,8677,,"Biodistribution in Sprague-Dawley rat kidneys(2) 15 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",1,Rattus norvegicus,Intermediate,,,,10116.0,,2113.0,A,BAO_0000218,CHEMBL622900,9696
Kidney,50597,N,1,In vivo,,,8677,,"Biodistribution in Sprague-Dawley rat kidneys(2) 15 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",1,Rattus norvegicus,Intermediate,,,,10116.0,,2113.0,A,BAO_0000218,CHEMBL624114,9697
Kidney,50597,N,1,In vivo,,,8677,,"Biodistribution in Sprague-Dawley rat kidneys(2) 2 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",1,Rattus norvegicus,Intermediate,,,,10116.0,,2113.0,A,BAO_0000218,CHEMBL624115,9698
Kidney,50597,N,1,In vivo,,,8677,,"Biodistribution in Sprague-Dawley rat kidneys(2) 2 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",1,Rattus norvegicus,Intermediate,,,,10116.0,,2113.0,A,BAO_0000218,CHEMBL624116,9699
Liver,50597,N,1,In vivo,,,8677,,"Biodistribution in Sprague-Dawley rat liver 15 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",1,Rattus norvegicus,Intermediate,,,,10116.0,,2107.0,A,BAO_0000218,CHEMBL624117,9700
Liver,50597,N,1,In vivo,,,8677,,"Biodistribution in Sprague-Dawley rat liver 15 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",1,Rattus norvegicus,Intermediate,,,,10116.0,,2107.0,A,BAO_0000218,CHEMBL624118,9701
Liver,50597,N,1,In vivo,,,8677,,"Biodistribution in Sprague-Dawley rat liver 2 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",1,Rattus norvegicus,Intermediate,,,,10116.0,,2107.0,A,BAO_0000218,CHEMBL624119,9702
Liver,50597,N,1,In vivo,,,8677,,"Biodistribution in Sprague-Dawley rat liver 2 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",1,Rattus norvegicus,Intermediate,,,,10116.0,,2107.0,A,BAO_0000218,CHEMBL624120,9703
Lung,50597,N,1,In vivo,,,8677,,"Biodistribution in Sprague-Dawley rat lungs(2) 15 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",1,Rattus norvegicus,Intermediate,,,,10116.0,,2048.0,A,BAO_0000218,CHEMBL624121,9704
Lung,50597,N,1,In vivo,,,8677,,"Biodistribution in Sprague-Dawley rat lungs(2) 15 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",1,Rattus norvegicus,Intermediate,,,,10116.0,,2048.0,A,BAO_0000218,CHEMBL624122,9705
Lung,50597,N,1,In vivo,,,8677,,"Biodistribution in Sprague-Dawley rat lungs(2) 2 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",1,Rattus norvegicus,Intermediate,,,,10116.0,,2048.0,A,BAO_0000218,CHEMBL624123,9706
Lung,50597,N,1,In vivo,,,8677,,"Biodistribution in Sprague-Dawley rat lungs(2) 2 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",1,Rattus norvegicus,Intermediate,,,,10116.0,,2048.0,A,BAO_0000218,CHEMBL624124,9707
Muscle tissue,50597,N,1,In vivo,,,8677,,"Biodistribution in Sprague-Dawley rat muscle 15 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",1,Rattus norvegicus,Intermediate,,,,10116.0,,2385.0,A,BAO_0000218,CHEMBL624125,9708
Muscle tissue,50597,N,1,In vivo,,,8677,,"Biodistribution in Sprague-Dawley rat muscle 15 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",1,Rattus norvegicus,Intermediate,,,,10116.0,,2385.0,A,BAO_0000218,CHEMBL624126,9709
Muscle tissue,50597,N,1,In vivo,,,8677,,"Biodistribution in Sprague-Dawley rat muscle 2 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",1,Rattus norvegicus,Intermediate,,,,10116.0,,2385.0,A,BAO_0000218,CHEMBL624127,9710
Muscle tissue,50597,N,1,In vivo,,,8677,,"Biodistribution in Sprague-Dawley rat muscle 2 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",1,Rattus norvegicus,Intermediate,,,,10116.0,,2385.0,A,BAO_0000218,CHEMBL624128,9711
Zone of skin,50597,N,1,In vivo,,,8677,,"Biodistribution in Sprague-Dawley rat skin 15 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",1,Rattus norvegicus,Intermediate,,,,10116.0,,14.0,A,BAO_0000218,CHEMBL624129,9712
Zone of skin,50597,N,1,In vivo,,,8677,,"Biodistribution in Sprague-Dawley rat skin 15 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",1,Rattus norvegicus,Intermediate,,,,10116.0,,14.0,A,BAO_0000218,CHEMBL624130,9713
Zone of skin,50597,N,1,In vivo,,,8677,,"Biodistribution in Sprague-Dawley rat skin 2 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",1,Rattus norvegicus,Intermediate,,,,10116.0,,14.0,A,BAO_0000218,CHEMBL622340,9714
Zone of skin,50597,N,1,In vivo,,,8677,,"Biodistribution in Sprague-Dawley rat skin 2 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",1,Rattus norvegicus,Intermediate,,,,10116.0,,14.0,A,BAO_0000218,CHEMBL622341,9715
Intestine,50597,N,1,In vivo,,,8677,,"Biodistribution in Sprague-Dawley rat small intestine 15 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",1,Rattus norvegicus,Intermediate,,,,10116.0,,160.0,A,BAO_0000218,CHEMBL622342,9716
Intestine,50597,N,1,In vivo,,,8677,,"Biodistribution in Sprague-Dawley rat small intestine 15 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",1,Rattus norvegicus,Intermediate,,,,10116.0,,160.0,A,BAO_0000218,CHEMBL622343,9717
Intestine,50597,N,1,In vivo,,,8677,,"Biodistribution in Sprague-Dawley rat small intestine 2 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",1,Rattus norvegicus,Intermediate,,,,10116.0,,160.0,A,BAO_0000218,CHEMBL622344,9718
Intestine,50597,N,1,In vivo,,,8677,,"Biodistribution in Sprague-Dawley rat small intestine 2 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",1,Rattus norvegicus,Intermediate,,,,10116.0,,160.0,A,BAO_0000218,CHEMBL622345,9719
Spleen,50597,N,1,In vivo,,,8677,,"Biodistribution in Sprague-Dawley rat spleen 15 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",1,Rattus norvegicus,Intermediate,,,,10116.0,,2106.0,A,BAO_0000218,CHEMBL622346,9720
Spleen,50597,N,1,In vivo,,,8677,,"Biodistribution in Sprague-Dawley rat spleen 15 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",1,Rattus norvegicus,Intermediate,,,,10116.0,,2106.0,A,BAO_0000218,CHEMBL622347,9721
Spleen,50597,N,1,In vivo,,,8677,,"Biodistribution in Sprague-Dawley rat spleen 2 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",1,Rattus norvegicus,Intermediate,,,,10116.0,,2106.0,A,BAO_0000218,CHEMBL622348,9722
Spleen,50597,N,1,In vivo,,,8677,,"Biodistribution in Sprague-Dawley rat spleen 2 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",1,Rattus norvegicus,Intermediate,,,,10116.0,,2106.0,A,BAO_0000218,CHEMBL622349,9723
,50597,N,1,,,,16434,,Radioactivity distribution in testis of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 30 min.,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL622350,9724
,50597,N,1,,,,16434,,Radioactivity distribution in testis of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min.,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL622351,9725
,50597,N,1,,,,16434,,Radioactivity distribution in testis of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min.,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL622352,9726
,50597,N,1,,,,16435,,Radioactivity distribution in testis of normal fischer rat after injection of anti-[18F]FMACBC after 120 min.,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL622353,9727
,50597,N,1,,,,16435,,Radioactivity distribution in testis of normal fischer rat after injection of anti-[18F]FMACBC after 30 min.,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL622354,9728
,50597,N,1,,,,16435,,Radioactivity distribution in testis of normal fischer rat after injection of anti-[18F]FMACBC after 5 min.,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL622355,9729
,50597,N,1,,,,16435,,Radioactivity distribution in testis of normal fischer rat after injection of anti-[18F]FMACBC after 60 min.,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL622356,9730
,50597,N,1,,,,16435,,Radioactivity distribution in testis of normal fischer rat after injection of syn-[18F]-FMACBC after 120 min.,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL622357,9731
,50597,N,1,,,,16435,,Radioactivity distribution in testis of normal fischer rat after injection of syn-[18F]-FMACBC after 30 min.,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL622358,9732
,50597,N,1,,,,16435,,Radioactivity distribution in testis of normal fischer rat after injection of syn-[18F]-FMACBC after 5 min.,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL622359,9733
,50597,N,1,,,,16435,,Radioactivity distribution in testis of normal fischer rat after injection of syn-[18F]-FMACBC after 60 min.,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL874393,9734
,50597,N,1,,,,16434,,Radioactivity distribution in testis of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL622872,9735
,50597,N,1,,,,16434,,Radioactivity distribution in testis of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL622873,9736
,50597,N,1,,,,16434,,Radioactivity distribution in testis of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL623047,9737
,50597,N,1,,,,16435,,Radioactivity distribution in testis of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 120 min,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL623048,9738
,50597,N,1,,,,16435,,Radioactivity distribution in testis of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 5 min,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL623049,9739
,50597,N,1,,,,16435,,Radioactivity distribution in testis of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 60 min,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL623050,9740
,50597,N,1,,,,16435,,Radioactivity distribution in testis of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 120 min,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL623051,9741
,50597,N,1,,,,16435,,Radioactivity distribution in testis of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 5 min,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL623052,9742
,50597,N,1,,,,16435,,Radioactivity distribution in testis of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 60 min,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL626343,9743
,50597,N,1,,,,16434,,Radioactivity distribution in tumor of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 120 min.,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL626344,9744
,50597,N,1,,,,16434,,Radioactivity distribution in tumor of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 5 min.,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL626345,9745
,50597,N,1,,,,16434,,Radioactivity distribution in tumor of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 60 min.,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL626346,9746
,50597,N,1,,,,16434,,Radioactivity distribution in tumor of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL626347,9747
,50597,N,1,,,,16434,,Radioactivity distribution in tumor of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL626348,9748
,50597,N,1,,,,16434,,Radioactivity distribution in tumor of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL626349,9749
,50597,N,1,,,,16435,,Radioactivity distribution in tumor of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 120 min,1,Rattus norvegicus,Intermediate,,,,10116.0,,,F,BAO_0000218,CHEMBL626350,9750
,50597,N,1,,,,16435,,Radioactivity distribution in tumor of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 5 min,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL626351,9751
,50597,N,1,,,,16435,,Radioactivity distribution in tumor of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 60 min,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL627650,9752
,50597,N,1,,,,16435,,Radioactivity distribution in tumor of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 120 min,1,Rattus norvegicus,Intermediate,,,,10116.0,,,F,BAO_0000218,CHEMBL627651,9753
,50597,N,1,,,,16435,,Radioactivity distribution in tumor of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 5 min,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL627652,9754
,50597,N,1,,,,16435,,Radioactivity distribution in tumor of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 60 min,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL627653,9755
,50597,N,1,,,,13091,,Tissue biodistribution into estrogen-primed immature female rat blood at 1 hr blocked time interval,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL627654,9756
,50597,N,1,,,,13091,,Tissue biodistribution into estrogen-primed immature female rat blood at 1 hr low time interval,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL627835,9757
,50597,N,1,,,,13091,,Tissue biodistribution into estrogen-primed immature female rat blood at 1 hr time interval,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL627836,9758
,50597,N,1,,,,13091,,Tissue biodistribution into estrogen-primed immature female rat blood at 3 hr time interval,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL627837,9759
,50597,N,1,,,,13091,,Tissue biodistribution into estrogen-primed immature female rat bone at 1 hr blocked time interval,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL627838,9760
,50597,N,1,,,,13091,,Tissue biodistribution into estrogen-primed immature female rat bone at 1 hr low time interval,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL875338,9761
,50597,N,1,,,,13091,,Tissue biodistribution into estrogen-primed immature female rat bone at 1 hr time interval,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL627839,9762
,50597,N,1,,,,13091,,Tissue biodistribution into estrogen-primed immature female rat bone at 3 hr time interval,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL627840,9763
,50597,N,1,,,,13091,,Tissue biodistribution into estrogen-primed immature female rat brain at 1 hr blocked time interval,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL627841,9764
,50597,N,1,,,,13091,,Tissue biodistribution into estrogen-primed immature female rat brain at 1 hr low time interval,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL627842,9765
,50597,N,1,,,,13091,,Tissue biodistribution into estrogen-primed immature female rat brain at 1 hr time interval,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL627843,9766
,50597,N,1,,,,13091,,Tissue biodistribution into estrogen-primed immature female rat brain at 3 hr time interval,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL627844,9767
,50597,N,1,,,,13091,,Tissue biodistribution into estrogen-primed immature female rat fat at 1 hr blocked time interval,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL627845,9768
,50597,N,1,In vivo,,,5874,,Half life period in rat by iv administration at a dose of 3 mg/kg,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL627846,9769
Plasma,50597,N,1,,,,1515,,Half life period in rat plasma at 25 degree Centigrade temperature (pH 7.4),1,Rattus norvegicus,Intermediate,,,,10116.0,,1969.0,A,BAO_0000218,CHEMBL627847,9770
Plasma,50597,N,1,,,,1515,,Half life period in rat plasma at 37 degree Celsius temperature (pH 7.4),1,Rattus norvegicus,Intermediate,,,,10116.0,,1969.0,A,BAO_0000218,CHEMBL873821,9771
Plasma,50597,N,1,,,,1515,,Half life period in rat plasma at 37 degree Celsius temperature (pH 7.4); ND means no data,1,Rattus norvegicus,Intermediate,,,,10116.0,,1969.0,A,BAO_0000218,CHEMBL626079,9772
Plasma,50597,N,1,,,,1515,,Half life period in rat plasma at 37 degree Celsius temperature (pH 7.4); ND means no data,1,Rattus norvegicus,Intermediate,,,,10116.0,,1969.0,A,BAO_0000218,CHEMBL626080,9773
Plasma,50597,N,1,,,,5491,,Half life period was evaluated in rat plasma,1,Rattus norvegicus,Intermediate,,,,10116.0,,1969.0,A,BAO_0000218,CHEMBL626081,9774
Plasma,50597,N,1,,,,5491,,Half life period was evaluated in rat plasma; Not tested,1,Rattus norvegicus,Intermediate,,,,10116.0,,1969.0,A,BAO_0000218,CHEMBL875344,9775
,50597,N,1,,,,1918,,Half life period was evaluated in rats,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL626082,9776
,50597,N,1,In vivo,,,1918,,"Half life period was evaluated in rats, iv",1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL626250,9777
,50597,N,1,In vivo,,,6113,,Half life period after intravenous administration at 5 mg/kg in rat,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL626251,9778
,50597,N,1,In vivo,,,5546,,Half life period was determined in Sprague-Dawley rats at a dose of 1 mg/kg by iv administration,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL626252,9779
,50597,N,1,In vivo,,,5553,,Half life period was determined in rat after iv administration at a dose of 5 mg/kg,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL626253,9780
Plasma,50597,N,1,,,,4188,,Half life stability of compound was evaluated in rat plasma,1,Rattus norvegicus,Intermediate,,,,10116.0,,1969.0,A,BAO_0000218,CHEMBL626254,9781
,50597,N,1,In vivo,,,6215,,Half life time after intravenous administration (5.0 mg/kg) was determined in rat,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL626255,9782
,50597,N,1,In vivo,,,6141,,Half life time was evaluated at 1 mg/kg of iv administration in Sprague-Dawley rats,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL626256,9783
,50597,N,1,In vivo,,,5182,,Half life was determined by administering the compound intravenously at a dose of 1 mg/kg in male wistar rat,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL626257,9784
,50597,N,1,In vivo,,,5182,,Half life was determined by administering the compound intravenously at a dose of 1 mg/kg in male wistar rat; NC means not calculated,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL626258,9785
,50597,N,1,In vivo,,,5710,,Half life was measured in fasted male administration of compound 0.5 mg/Kg i.v.,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL626259,9786
,50597,N,1,In vivo,,,5789,,Half in rat i.v.,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL626260,9787
,50597,N,1,In vivo,,,6011,,Half period in rat after intravenous administration,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL875345,9788
,50597,N,1,In vivo,,,17594,,Half-life after repeated oral dose of compound at 1 mg/kg in rats,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL626261,9789
Liver,50597,N,1,In vitro,,,12357,,Half-life measured in in vitro Cathepsin B assay in rat liver,1,Rattus norvegicus,Intermediate,,,,10116.0,,2107.0,A,BAO_0000218,CHEMBL626262,9790
,50597,N,1,,,,5210,,Half-life of compound was determined in rats,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL626263,9791
,50597,N,1,In vivo,,,17596,,Half-life at 10 mg/kg in rat upon intravenous administration,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL625270,9792
,50597,N,1,,,,6672,,Half-life determined in rat,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL625271,9793
,50597,N,1,,,,6673,,Half-life determined in rat,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL625272,9794
Brain,50597,N,1,In vivo,,,4910,,Half-life in brain after intravenous administration (4.7 mg/kg) to male rats,1,Rattus norvegicus,Intermediate,,,,10116.0,,955.0,A,BAO_0000218,CHEMBL625273,9795
Plasma,50597,N,1,,,,3741,,"Half-life in chemical and enzymatic hydrolysis, in 80% rat plasma",1,Rattus norvegicus,Intermediate,,,,10116.0,,1969.0,A,BAO_0000218,CHEMBL625274,9796
,50597,N,1,In vivo,,,17671,,Half-life in male Sprague-Dawley rats following an intravenous bolus dose at 10-20 mg/kg,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL625275,9797
Plasma,50597,N,1,In vivo,,,4910,,Half-life in plasma after intravenous administration (4.7 mg/kg) to male rats,1,Rattus norvegicus,Intermediate,,,,10116.0,,1969.0,A,BAO_0000218,CHEMBL625276,9798
Plasma,50597,N,1,,,,17537,,Half-life in rat plasma,1,Rattus norvegicus,Intermediate,,,,10116.0,,1969.0,A,BAO_0000218,CHEMBL625277,9799
Plasma,50597,N,1,,,,4965,,Half-life in rat plasma was determined,1,Rattus norvegicus,Intermediate,,,,10116.0,,1969.0,A,BAO_0000218,CHEMBL625278,9800
Plasma,50597,N,1,,,,17537,,Half-life in rat plasma; Not tested,1,Rattus norvegicus,Intermediate,,,,10116.0,,1969.0,A,BAO_0000218,CHEMBL625279,9801
Serum,50597,N,1,,,,6124,,Half-life in rat serum,1,Rattus norvegicus,Intermediate,,,,10116.0,,1977.0,A,BAO_0000218,CHEMBL625280,9802
Serum,50597,N,1,,,,6124,,Half-life in rat serum; na is not available,1,Rattus norvegicus,Intermediate,,,,10116.0,,1977.0,A,BAO_0000218,CHEMBL876797,9803
,50597,N,1,,,,6078,,Half-life was calculated in rat,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL625281,9804
Plasma,50597,N,1,,,,17668,,Half-life was calculated in rat plasma,1,Rattus norvegicus,Intermediate,,,,10116.0,,1969.0,A,BAO_0000218,CHEMBL873827,9805
,50597,N,1,,,,3185,,Half-life was determined,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL625282,9806
,50597,N,1,,,,4883,,Half-life was determined,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL625283,9807
,50597,N,1,In vivo,,,2959,,Half-life after administration of 20 mg/Kg oral dose in rat,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL625284,9808
,50597,N,1,In vivo,,,4029,,Half-life after administration of 3.2 mg/kg intravenously in male rat,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL625285,9809
,50597,N,1,In vivo,,,4029,,Half-life after intravenous administration in female rat,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL625286,9810
,50597,N,1,In vivo,,,4029,,Half-life after intravenous administration in male rat,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL625287,9811
,50597,N,1,In vivo,,,6180,,Half-life after intravenous dose in rat,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL625288,9812
Liver,50597,N,1,,,,1557,,Half-life in a rat liver homogenate preparation,1,Rattus norvegicus,Intermediate,,,,10116.0,,2107.0,A,BAO_0000218,CHEMBL625289,9813
Plasma,50597,N,1,,,,12500,,Half-life in plasma of rat,1,Rattus norvegicus,Intermediate,,,,10116.0,,1969.0,A,BAO_0000218,CHEMBL625290,9814
Plasma,50597,N,1,,,,12500,,Half-life in plasma of rat at dose of 3-10 mgkg,1,Rattus norvegicus,Intermediate,,,,10116.0,,1969.0,A,BAO_0000218,CHEMBL876798,9815
,50597,N,1,,,,5064,,Half-life in rat,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL625291,9816
,50597,N,1,,,,5145,,Half-life in rat,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL625292,9817
,50597,N,1,,,,5147,,Half-life in rat,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL625293,9818
,50597,N,1,,,,5833,,Half-life in rat,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL622832,9819
,50597,N,1,,,,6596,,Half-life in rat,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL622833,9820
,50597,N,1,,,,17655,,Half-life in rat,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL622834,9821
,50597,N,1,In vivo,,,6495,,Half-life in rat after oral administration at 10 mg/kg,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL622835,9822
,50597,N,1,In vivo,,,17538,,Half-life in rat after po administration at a dose of 10 mg/kg,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL622836,9823
,50597,N,1,In vivo,,,17538,,Half-life in rat after po administration at a dose of 10 mg/kg; nd is not determined,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL622837,9824
,50597,N,1,In vivo,,,10,,Half-life in rat at 3 mg/kg dose administered intravenously,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL622838,9825
Brain,50597,N,1,,,,17669,,Half-life in rat brain homogenate,1,Rattus norvegicus,Intermediate,,,,10116.0,,955.0,A,BAO_0000218,CHEMBL622839,9826
Plasma,50597,N,1,,,,17065,,Half-life in rat plasma,1,Rattus norvegicus,Intermediate,,,,10116.0,,1969.0,A,BAO_0000218,CHEMBL622840,9827
,50597,N,1,,,,4333,,Half-life in rats,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL622841,9828
,50597,N,1,,,,6827,,Half-life in Dawley rats,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL622842,9829
Plasma,50597,N,1,In vitro,,,889,,Half-life in vitro in rat plasma,1,Rattus norvegicus,Intermediate,,,,10116.0,,1969.0,A,BAO_0000218,CHEMBL622843,9830
Plasma,50597,N,1,In vitro,,,889,,Half-life in vitro in rat plasma; No detectable degradation over 2 hr; no detectable degradation over 2 hours,1,Rattus norvegicus,Intermediate,,,,10116.0,,1969.0,A,BAO_0000218,CHEMBL622844,9831
,50597,N,1,,,,3747,,"The area under concentration-time curve(AUC) was determined at 20 mg/kg of compound dose, administered intravenously in rat",1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL622845,9832
,50597,N,1,,,,15022,,The area under the curve of compound was measured at the dose of 100 umol/kg,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL622846,9833
,50597,N,1,,,,15022,,The area under the curve of compound was measured at the dose of 300 umol/kg,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL622847,9834
,50597,N,1,,,,15022,,The area under the curve of compound was measured at the dose of 30 umol/kg,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL622848,9835
,50597,N,1,In vivo,,,3360,,Bioavailability as oral AUC in rats,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL622849,9836
Plasma,50597,N,1,,,,5334,,The plasma concentration versus time curve (AUC) was determined,1,Rattus norvegicus,Intermediate,,,,10116.0,,1969.0,A,BAO_0000218,CHEMBL622850,9837
,50597,N,1,,,,17411,,Total concentration in kidney was determined after 6 hr of intravenous administration to rats (n=4) at dose of 20 mg/kg,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL876807,9838
,50597,N,1,,,,17411,,Total concentration in liver was determined after 6 hr of intravenous administration to rats (n=4) at dose of 20 mg/kg,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL622851,9839
,50597,N,1,,,,17411,,Total concentration in lung was determined after 6 hr of intravenous administration to rats (n=4) at dose of 20 mg/kg,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL622852,9840
,50597,N,1,,,,6570,,Total concentration in rat after 1 mg/kg i.v. administration in 24 hours,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL622853,9841
,50597,N,1,,,,6570,,Total concentration in rat after 2 mg/kg peroral administration in 24 hours,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL622854,9842
,50597,N,1,,,,17411,,Total concentration in serum was determined after 6 hr of intravenous administration to rats (n=4) at dose of 20 mg/kg,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL622855,9843
Plasma,50597,N,1,,,,14941,,"Pharmacokinetic Parameter, AUC (0-infinity) is the area under the plasma concentration versus time curve extrapolated to infinity in Female Wistar Rats at 100 mg/kg by po administration",1,Rattus norvegicus,Intermediate,,,,10116.0,,1969.0,A,BAO_0000218,CHEMBL622856,9844
Plasma,50597,N,1,,,,14941,,"Pharmacokinetic Parameter, AUC (0-t) is the area under the plasma concentration versus time curve in Female Wistar Rats at 100 mg/kg by po administration",1,Rattus norvegicus,Intermediate,,,,10116.0,,1969.0,A,BAO_0000218,CHEMBL622857,9845
Plasma,50597,N,1,,,,17538,,AUC in rat after po administration at a dose of 10 mg/kg,1,Rattus norvegicus,Intermediate,,,,10116.0,,1969.0,A,BAO_0000218,CHEMBL622858,9846
Plasma,50597,N,1,,,,17752,,Area under the plasma concentration-time curve in rats after oral administration at 25 mg/kg,1,Rattus norvegicus,Intermediate,,,,10116.0,,1969.0,A,BAO_0000218,CHEMBL622859,9847
,50597,N,1,,,,17509,,Area under curve value 24 hr after 10 mg/kg iv administration in rats,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL622860,9848
,50597,N,1,,,,17509,,Area under curve value 24 hr after 10 mg/kg oral administration in rats,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL622861,9849
,50597,N,1,,,,17509,,Area under curve value 24 hr after 2 mg/kg iv administration in rats,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL622862,9850
,50597,N,1,,,,17509,,Area under curve value 24 hr after 2 mg/kg oral administration in rats,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL622863,9851
,50597,N,1,,,,17509,,Area under curve value 6 hr after po administration in rat,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL623817,9852
,50597,N,1,,,,17717,,Area under the curve at a concentration of 15 mg/kg perorally in rats along with 100 mg/kg of compound 11,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL623818,9853
,50597,N,1,,,,17717,,"Area under the curve at a concentration of 3 mg/kg in rats, intravenously",1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL623819,9854
,50597,N,1,,,,17717,,Area under the curve at a concentration of 60 mg/kg perorally in rats along with 100 mg/kg of compound 11,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL623820,9855
,50597,N,1,,,,17717,,Area under the curve at a concentration of 60 mg/kg perorally in rats along with control,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL623821,9856
Plasma,50597,N,1,,,,6642,,AUC normalized for dose (AUCN) in rat,1,Rattus norvegicus,Intermediate,,,,10116.0,,1969.0,A,BAO_0000218,CHEMBL623822,9857
,50597,N,1,,,,6640,,Area under curve in rat after p.o. administration,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL623823,9858
,50597,N,1,,,,6641,,Area under curve in rat after p.o. administration,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL623824,9859
,50597,N,1,,,,6641,,Area under curve in rat after p.o. administration; Not determined,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL623825,9860
,50597,N,1,,,,6641,,Area under curve in rat after peroral administration,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL622070,9861
,50597,N,1,,,,3603,,Area under curve (carotid artery) value of the compound,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL622071,9862
,50597,N,1,,,,3550,,Bioavailability expressed as the area under curve of rat carotid artery,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL622072,9863
,50597,N,1,,,,15662,,Area under curve in male SD rats was observed after intravenous administration in rat,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL622073,9864
,50597,N,1,,,,17720,,Area under curve of the compound was determined,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL622074,9865
,50597,N,1,,,,5407,,Compound was evaluated for its pharmacokinetic parameter maximum area under curve AUCmax,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL622075,9866
Plasma,50597,N,1,,,,17752,,Area under the plasma concentration-time curve in rats after oral administration at 20 mg/kg,1,Rattus norvegicus,Intermediate,,,,10116.0,,1969.0,A,BAO_0000218,CHEMBL622076,9867
Plasma,50597,N,1,,,,17752,,Area under the plasma concentration-time curve in rats following oral administration at 20 mg/kg,1,Rattus norvegicus,Intermediate,,,,10116.0,,1969.0,A,BAO_0000218,CHEMBL622077,9868
,50597,N,1,,,,3603,,Area under curve (portal vein) value of the compound,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL622078,9869
,50597,N,1,,,,3550,,Bioavailability expressed as the area under curve of rat portal vein,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL622079,9870
Plasma,50597,N,1,,,,17655,,Area Under plasma concentration time curve in rat upon peroral administration,1,Rattus norvegicus,Intermediate,,,,10116.0,,1969.0,A,BAO_0000218,CHEMBL622080,9871
,50597,N,1,,,,17582,,In vivo area under curve was determined for the compound after i.v. administration at a dose of 5 mg/kg in rats,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL877612,9872
,50597,N,1,,,,17582,,In vivo area under curve was determined for the compound after oral (po) administration at a dose of 10 mg/kg in rats,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL622081,9873
,50597,N,1,,,,17791,,Compound was evaluated for oral bioavailability in rats,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL622082,9874
,50597,N,1,,,,17791,,Compound was evaluated for oral bioavailability in rats after iv administration,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL622083,9875
,50597,N,1,,,,17791,,Compound was evaluated for oral bioavailability in rats; 30-80,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL622084,9876
,50597,N,1,,,,17791,,Compound was evaluated for oral bioavailability in rats; 50-60,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL622085,9877
,50597,N,1,,,,17791,,Compound was evaluated for oral bioavailability in rats; no data,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL622086,9878
,50597,N,1,,,,17791,,Compound was evaluated for oral bioavailability in rats; peptide,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL622087,9879
Blood,50597,N,1,,,,7768,,"Distribution of radioactivity in blood of rats at 1 day after an intravenous injection; Value expressed as mean % injected dose, Range- 0.03-0.03",1,Rattus norvegicus,Intermediate,,,,10116.0,,178.0,A,BAO_0000218,CHEMBL622088,9880
Blood,50597,N,1,,,,7768,,"Distribution of radioactivity in blood of rats at 1 hr after an intravenous injection; Value expressed as mean % injected dose, Range-0.9-1.03",1,Rattus norvegicus,Intermediate,,,,10116.0,,178.0,A,BAO_0000218,CHEMBL622089,9881
Blood,50597,N,1,,,,7768,,"Distribution of radioactivity in blood of rats at 2 mins after an intravenous injection; Value expressed as mean % injected dose, Range = 0.88-1.15",1,Rattus norvegicus,Intermediate,,,,10116.0,,178.0,A,BAO_0000218,CHEMBL623685,9882
Blood,50597,N,1,,,,7768,,"Distribution of radioactivity in blood of rats at 2 hr after an intravenous injection; Value expressed as mean % injected dose, Range = 0.71-0.87",1,Rattus norvegicus,Intermediate,,,,10116.0,,178.0,A,BAO_0000218,CHEMBL623686,9883
Stomach,50597,N,1,In vivo,,,8677,,"Biodistribution in Sprague-Dawley rat stomach 15 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",1,Rattus norvegicus,Intermediate,,,,10116.0,,945.0,A,BAO_0000218,CHEMBL623687,9884
Stomach,50597,N,1,In vivo,,,8677,,"Biodistribution in Sprague-Dawley rat stomach 15 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",1,Rattus norvegicus,Intermediate,,,,10116.0,,945.0,A,BAO_0000218,CHEMBL623688,9885
Stomach,50597,N,1,In vivo,,,8677,,"Biodistribution in Sprague-Dawley rat stomach 2 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",1,Rattus norvegicus,Intermediate,,,,10116.0,,945.0,A,BAO_0000218,CHEMBL623689,9886
Stomach,50597,N,1,In vivo,,,8677,,"Biodistribution in Sprague-Dawley rat stomach 2 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",1,Rattus norvegicus,Intermediate,,,,10116.0,,945.0,A,BAO_0000218,CHEMBL622485,9887
Thyroid gland,50597,N,1,In vivo,,,8677,,"Biodistribution in Sprague-Dawley rat thyroid 15 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",1,Rattus norvegicus,Intermediate,,,,10116.0,,2046.0,A,BAO_0000218,CHEMBL622486,9888
Thyroid gland,50597,N,1,In vivo,,,8677,,"Biodistribution in Sprague-Dawley rat thyroid 15 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",1,Rattus norvegicus,Intermediate,,,,10116.0,,2046.0,A,BAO_0000218,CHEMBL877613,9889
Thyroid gland,50597,N,1,In vivo,,,8677,,"Biodistribution in Sprague-Dawley rat thyroid 2 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",1,Rattus norvegicus,Intermediate,,,,10116.0,,2046.0,A,BAO_0000218,CHEMBL622487,9890
Thyroid gland,50597,N,1,In vivo,,,8677,,"Biodistribution in Sprague-Dawley rat thyroid 2 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",1,Rattus norvegicus,Intermediate,,,,10116.0,,2046.0,A,BAO_0000218,CHEMBL622488,9891
Heart,50597,N,1,In vivo,,,8677,,"Biodistribution in Sprague-Dawley rats heart 15 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",1,Rattus norvegicus,Intermediate,,,,10116.0,,948.0,A,BAO_0000218,CHEMBL622489,9892
Urine,50597,N,1,,,,6899,,Compound was evaluated for percent dimer tissue distribution 24 hours after a 50 mg/kg dose was administered intravenously in urine,1,Rattus norvegicus,Intermediate,,,,10116.0,,1088.0,A,BAO_0000218,CHEMBL622490,9893
Urine,50597,N,1,,,,6899,,Compound was evaluated for percent dimer tissue distribution 24 hours after a 50 mg/kg dose was administered intravenously in urine; na - not available,1,Rattus norvegicus,Intermediate,,,,10116.0,,1088.0,A,BAO_0000218,CHEMBL622491,9894
Liver,50597,N,1,,,,6899,,Compound was evaluated for percent dose tissue distribution 24 hours after a 50 mg/kg dose was administered intravenously in liver,1,Rattus norvegicus,Intermediate,,,,10116.0,,2107.0,A,BAO_0000218,CHEMBL622492,9895
Urine,50597,N,1,,,,6899,,Compound was evaluated for percent thiol tissue distribution 24 hours after a 50 mg/kg dose was administered intravenously in urine,1,Rattus norvegicus,Intermediate,,,,10116.0,,1088.0,A,BAO_0000218,CHEMBL622493,9896
Urine,50597,N,1,,,,6899,,Compound was evaluated for percent thiol tissue distribution 24 hours after a 50 mg/kg dose was administered intravenously in urine; na - not available,1,Rattus norvegicus,Intermediate,,,,10116.0,,1088.0,A,BAO_0000218,CHEMBL622494,9897
Muscle tissue,50597,N,1,,,,8677,,"Compound was evaluated for the biodistribution in Sprague-Dawley rats in muscle 15 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",1,Rattus norvegicus,Intermediate,,,,10116.0,,2385.0,A,BAO_0000218,CHEMBL622495,9898
,50597,N,1,,,,6899,,Compound was evaluated for tissue distribution 24 hours after a 50 mg/kg dose was administered intravenously in rat kidney,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL622496,9899
Urine,50597,N,1,,,,6899,,Compound was evaluated for tissue distribution 24 hours after a 50 mg/kg dose was administered intravenously in urine,1,Rattus norvegicus,Intermediate,,,,10116.0,,1088.0,A,BAO_0000218,CHEMBL622497,9900
,50597,N,1,,,,2189,,Percent of radioactive dose in urine and faeces excreted in 0-24 hr by rats,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL622498,9901
Urine,50597,N,1,,,,2189,,Percent of radioactive dose in urine and feces excreted in 0-24 hr by rats,1,Rattus norvegicus,Intermediate,,,,10116.0,,1088.0,A,BAO_0000218,CHEMBL624918,9902
Urine,50597,N,1,,,,2189,,Percent of radioactive dose in urine and feces excreted in 0-24 hr by rats; NA is <10% inhibition at 1 uM for binding data,1,Rattus norvegicus,Intermediate,,,,10116.0,,1088.0,A,BAO_0000218,CHEMBL624919,9903
Blood,50597,N,1,In vivo,,,10839,,Biodistribution of compound in rat blood after 5 min of administration,1,Rattus norvegicus,Intermediate,,,,10116.0,,178.0,A,BAO_0000218,CHEMBL624920,9904
Blood,50597,N,1,In vivo,,,10839,,Biodistribution of compound in rat blood after 5 min of administration.,1,Rattus norvegicus,Intermediate,,,,10116.0,,178.0,A,BAO_0000218,CHEMBL624921,9905
Brain,50597,N,1,In vivo,,,10839,,Biodistribution of compound in rat brain after 5 min of administration,1,Rattus norvegicus,Intermediate,,,,10116.0,,955.0,A,BAO_0000218,CHEMBL624922,9906
Heart,50597,N,1,In vivo,,,10839,,Biodistribution of compound in rat heart after 5 min of administration,1,Rattus norvegicus,Intermediate,,,,10116.0,,948.0,A,BAO_0000218,CHEMBL624923,9907
Heart,50597,N,1,In vivo,,,10839,,Biodistribution of compound in rat heart after 5 min of administration.,1,Rattus norvegicus,Intermediate,,,,10116.0,,948.0,A,BAO_0000218,CHEMBL624924,9908
Kidney,50597,N,1,In vivo,,,10839,,Biodistribution of compound in rat kidney after 5 min of administration,1,Rattus norvegicus,Intermediate,,,,10116.0,,2113.0,A,BAO_0000218,CHEMBL624925,9909
Kidney,50597,N,1,In vivo,,,10839,,Biodistribution of compound in rat kidney after 5 min of administration.,1,Rattus norvegicus,Intermediate,,,,10116.0,,2113.0,A,BAO_0000218,CHEMBL624926,9910
Liver,50597,N,1,In vivo,,,10839,,Biodistribution of compound in rat liver after 5 min of administration,1,Rattus norvegicus,Intermediate,,,,10116.0,,2107.0,A,BAO_0000218,CHEMBL624927,9911
Liver,50597,N,1,In vivo,,,10839,,Biodistribution of compound in rat liver after 5 min of administration.,1,Rattus norvegicus,Intermediate,,,,10116.0,,2107.0,A,BAO_0000218,CHEMBL874402,9912
Lung,50597,N,1,In vivo,,,10839,,Biodistribution of compound in rat lung after 5 min of administration,1,Rattus norvegicus,Intermediate,,,,10116.0,,2048.0,A,BAO_0000218,CHEMBL624928,9913
Lung,50597,N,1,In vivo,,,10839,,Biodistribution of compound in rat lung after 5 min of administration.,1,Rattus norvegicus,Intermediate,,,,10116.0,,2048.0,A,BAO_0000218,CHEMBL624929,9914
Muscle tissue,50597,N,1,In vivo,,,10839,,Biodistribution of compound in rat muscle after 5 min of administration,1,Rattus norvegicus,Intermediate,,,,10116.0,,2385.0,A,BAO_0000218,CHEMBL624930,9915
Muscle tissue,50597,N,1,In vivo,,,10839,,Biodistribution of compound in rat muscle after 5 min of administration.,1,Rattus norvegicus,Intermediate,,,,10116.0,,2385.0,A,BAO_0000218,CHEMBL624931,9916
Heart,50597,N,1,,,,4043,,In vivo heart distribution of free doxorubicin after 6 hr intravenous administration of 2.5 mg/kg of compound in rat bearing Walker 256 cells,1,Rattus norvegicus,Intermediate,,,,10116.0,,948.0,A,BAO_0000218,CHEMBL624932,9917
Heart,50597,N,1,,,,4043,,In vivo heart distribution of total doxorubicin after 6 hr intravenous administration of 2.5 mg/kg of compound in rat bearing Walker 256 cells,1,Rattus norvegicus,Intermediate,,,,10116.0,,948.0,A,BAO_0000218,CHEMBL624933,9918
Liver,50597,N,1,,,,4043,,In vivo liver distribution of free doxorubicin after 6 hr intravenous administration of 2.5 mg/kg of compound in rat bearing Walker 256 cells,1,Rattus norvegicus,Intermediate,,,,10116.0,,2107.0,A,BAO_0000218,CHEMBL624934,9919
Liver,50597,N,1,,,,4043,,In vivo liver distribution of total doxorubicin after 6 h intravenous administration of 2.5 mg/kg of compound in rat bearing Walker 256 cells,1,Rattus norvegicus,Intermediate,,,,10116.0,,2107.0,A,BAO_0000218,CHEMBL624935,9920
,50597,N,1,,,,4043,,In vivo plasma distribution of free doxorubicin after 6 h intravenous administration of 2.5 mg/kg of compound in rat bearing Walker 256 cells,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL624936,9921
,50597,N,1,,,,4043,,In vivo plasma distribution of total doxorubicin after 6 hr intravenous administration of 2.5 mg/kg of compound in rat bearing Walker 256 cells,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL624937,9922
Spleen,50597,N,1,,,,4043,,In vivo spleen distribution of free doxorubicin after 6 hr intravenous administration of 2.5 mg/kg of compound in rat bearing Walker 256 cells,1,Rattus norvegicus,Intermediate,,,,10116.0,,2106.0,A,BAO_0000218,CHEMBL624938,9923
Spleen,50597,N,1,,,,4043,,In vivo spleen distribution of total doxorubicin after 6 hr intravenous administration of 2.5 mg/kg of compound in rat bearing Walker 256 cells,1,Rattus norvegicus,Intermediate,,,,10116.0,,2106.0,A,BAO_0000218,CHEMBL624939,9924
,50597,N,1,,,,4043,,In vivo tumor distribution of free doxorubicin after 6 h intravenous administration of 2.5 mg/kg of compound in rat bearing Walker 256 cells,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL624940,9925
,50597,N,1,,,,4043,,In vivo tumor distribution of total doxorubicin after 6 hr intravenous administration of 2.5 mg/kg of compound in rat bearing Walker 256 cells,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL874403,9926
,50597,N,1,,,,1446,,Compound was tested for the duration that the plasma drug concentrations remained above the IC95,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL624941,9927
Urine,50597,N,1,,,,9971,,Dose required to lower urine osmolality to 300 mOsm/kg in rat,1,Rattus norvegicus,Intermediate,,,,10116.0,,1088.0,A,BAO_0000218,CHEMBL624942,9928
Urine,50597,N,1,,,,9971,,Dose required to lower urine osmolality to 300 mOsm/kg in rat; NT=Not tested,1,Rattus norvegicus,Intermediate,,,,10116.0,,1088.0,A,BAO_0000218,CHEMBL624943,9929
,50597,N,1,In vivo,,,5765,,% Bioavailability after 1 day of the drug administration in rats,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL624944,9930
,50597,N,1,In vivo,,,5765,,% Bioavailability after 4 day of the drug administration in rats,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL624945,9931
,50597,N,1,In vivo,,,4257,,Absolute bioavailability was evaluated in rat,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL624946,9932
,50597,N,1,,,,13091,,Tissue biodistribution into estrogen-primed immature female rat fat at 1 hr low time interval,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL624947,9933
,50597,N,1,,,,13091,,Tissue biodistribution into estrogen-primed immature female rat fat at 1 hr time interval,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL624948,9934
,50597,N,1,,,,13091,,Tissue biodistribution into estrogen-primed immature female rat fat at 3 hr time interval,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL624949,9935
Kidney,50597,N,1,,,,13091,,Tissue biodistribution into estrogen-primed immature female rat kidney at 1 hr blocked time interval,1,Rattus norvegicus,Intermediate,,,,10116.0,,2113.0,A,BAO_0000218,CHEMBL622025,9936
Kidney,50597,N,1,,,,13091,,Tissue biodistribution into estrogen-primed immature female rat kidney at 1 hr low time interval,1,Rattus norvegicus,Intermediate,,,,10116.0,,2113.0,A,BAO_0000218,CHEMBL622026,9937
Kidney,50597,N,1,,,,13091,,Tissue biodistribution into estrogen-primed immature female rat kidney at 1 hr time interval,1,Rattus norvegicus,Intermediate,,,,10116.0,,2113.0,A,BAO_0000218,CHEMBL622027,9938
Kidney,50597,N,1,,,,13091,,Tissue biodistribution into estrogen-primed immature female rat kidney at 3 hr time interval,1,Rattus norvegicus,Intermediate,,,,10116.0,,2113.0,A,BAO_0000218,CHEMBL622028,9939
Liver,50597,N,1,,,,13091,,Tissue biodistribution into estrogen-primed immature female rat liver at 1 hr blocked time interval,1,Rattus norvegicus,Intermediate,,,,10116.0,,2107.0,A,BAO_0000218,CHEMBL622029,9940
Liver,50597,N,1,,,,13091,,Tissue biodistribution into estrogen-primed immature female rat liver at 1 hr low time interval,1,Rattus norvegicus,Intermediate,,,,10116.0,,2107.0,A,BAO_0000218,CHEMBL622208,9941
Liver,50597,N,1,,,,13091,,Tissue biodistribution into estrogen-primed immature female rat liver at 1 hr time interval,1,Rattus norvegicus,Intermediate,,,,10116.0,,2107.0,A,BAO_0000218,CHEMBL622209,9942
Liver,50597,N,1,,,,13091,,Tissue biodistribution into estrogen-primed immature female rat liver at 3 hr time interval,1,Rattus norvegicus,Intermediate,,,,10116.0,,2107.0,A,BAO_0000218,CHEMBL622210,9943
,50597,N,1,,,,13091,,Tissue biodistribution into estrogen-primed immature female rat lung at 1 hr blocked time interval,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL622211,9944
,50597,N,1,,,,13091,,Tissue biodistribution into estrogen-primed immature female rat lung at 1 hr low time interval,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL622212,9945
,50597,N,1,,,,13091,,Tissue biodistribution into estrogen-primed immature female rat lung at 1 hr time interval,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL622213,9946
,50597,N,1,,,,13091,,Tissue biodistribution into estrogen-primed immature female rat lung at 3 hr time interval,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL874404,9947
Muscle tissue,50597,N,1,,,,13091,,Tissue biodistribution into estrogen-primed immature female rat muscle at 1 hr blocked time interval,1,Rattus norvegicus,Intermediate,,,,10116.0,,2385.0,A,BAO_0000218,CHEMBL620452,9948
Muscle tissue,50597,N,1,,,,13091,,Tissue biodistribution into estrogen-primed immature female rat muscle at 1 hr low time interval,1,Rattus norvegicus,Intermediate,,,,10116.0,,2385.0,A,BAO_0000218,CHEMBL620453,9949
Muscle tissue,50597,N,1,,,,13091,,Tissue biodistribution into estrogen-primed immature female rat muscle at 1 hr time interval,1,Rattus norvegicus,Intermediate,,,,10116.0,,2385.0,A,BAO_0000218,CHEMBL620454,9950
Muscle tissue,50597,N,1,,,,13091,,Tissue biodistribution into estrogen-primed immature female rat muscle at 3 hr time interval,1,Rattus norvegicus,Intermediate,,,,10116.0,,2385.0,A,BAO_0000218,CHEMBL624067,9951
,50597,N,1,,,,13091,,Tissue biodistribution into estrogen-primed immature female rat ovaries at 1 hr blocked time interval,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL624068,9952
Female gonad,50597,N,1,,,,13091,,Tissue biodistribution into estrogen-primed immature female rat ovaries at 1 hr low time interval,1,Rattus norvegicus,Intermediate,,,,10116.0,,992.0,A,BAO_0000218,CHEMBL624069,9953
Female gonad,50597,N,1,,,,13091,,Tissue biodistribution into estrogen-primed immature female rat ovaries at 1 hr time interval,1,Rattus norvegicus,Intermediate,,,,10116.0,,992.0,A,BAO_0000218,CHEMBL624070,9954
Female gonad,50597,N,1,,,,13091,,Tissue biodistribution into estrogen-primed immature female rat ovaries at 3 hr time interval,1,Rattus norvegicus,Intermediate,,,,10116.0,,992.0,A,BAO_0000218,CHEMBL624071,9955
Uterus,50597,N,1,,,,13091,,Tissue biodistribution into estrogen-primed immature female rat uterus at 1 hr blocked time interval,1,Rattus norvegicus,Intermediate,,,,10116.0,,995.0,A,BAO_0000218,CHEMBL624072,9956
Uterus,50597,N,1,,,,13091,,Tissue biodistribution into estrogen-primed immature female rat uterus at 1 hr low time interval,1,Rattus norvegicus,Intermediate,,,,10116.0,,995.0,A,BAO_0000218,CHEMBL624073,9957
Uterus,50597,N,1,,,,13091,,Tissue biodistribution into estrogen-primed immature female rat uterus at 1 hr time interval,1,Rattus norvegicus,Intermediate,,,,10116.0,,995.0,A,BAO_0000218,CHEMBL624788,9958
Uterus,50597,N,1,,,,13091,,Tissue biodistribution into estrogen-primed immature female rat uterus at 3 hr time interval,1,Rattus norvegicus,Intermediate,,,,10116.0,,995.0,A,BAO_0000218,CHEMBL624789,9959
,50597,N,1,,,,13091,,Tissue biodistribution into estrogen-primed immature female rat uterus/blood at 1 hr blocked time interval,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL624790,9960
,50597,N,1,,,,13091,,Tissue biodistribution into estrogen-primed immature female rat uterus/blood at 1 hr low time interval,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL624791,9961
,50597,N,1,,,,13091,,Tissue biodistribution into estrogen-primed immature female rat uterus/blood at 1 hr time interval,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL624792,9962
,50597,N,1,,,,13091,,Tissue biodistribution into estrogen-primed immature female rat uterus/blood at 3 hr time interval,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL624793,9963
Muscle tissue,50597,N,1,,,,13091,,Tissue biodistribution into estrogen-primed immature female rat uterus/muscle at 1 hr blocked time interval,1,Rattus norvegicus,Intermediate,,,,10116.0,,2385.0,A,BAO_0000218,CHEMBL877491,9964
Muscle tissue,50597,N,1,,,,13091,,Tissue biodistribution into estrogen-primed immature female rat uterus/muscle at 1 hr low time interval,1,Rattus norvegicus,Intermediate,,,,10116.0,,2385.0,A,BAO_0000218,CHEMBL624957,9965
Muscle tissue,50597,N,1,,,,13091,,Tissue biodistribution into estrogen-primed immature female rat uterus/muscle at 1 hr time interval,1,Rattus norvegicus,Intermediate,,,,10116.0,,2385.0,A,BAO_0000218,CHEMBL624958,9966
Muscle tissue,50597,N,1,,,,13091,,Tissue biodistribution into estrogen-primed immature female rat uterus/muscle at 3 hr time interval,1,Rattus norvegicus,Intermediate,,,,10116.0,,2385.0,A,BAO_0000218,CHEMBL624959,9967
,50597,N,1,,,,11977,,Dissociation constant was determined,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL624960,9968
,50597,N,1,,,,14941,,"Pharmacokinetic Parameter, Kel is elimination rate constant in Female Wistar Rats at 100 mg/kg by po administration",1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL624961,9969
,50597,N,1,,,,15078,,"The Kel value in female wistar rat at 100 mg/kg, p.o. dose",1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL624962,9970
,50597,N,1,,,,15078,,"The Kel value in male wistar rat at 100 mg/kg, p.o. dose",1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL624963,9971
,50597,N,1,,,,4755,,Observed rate constant in 80% rat plasma at 37 degree Centigrade,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL624964,9972
,50597,N,1,,,,589,,LogP value was evaluated in the in situ rat gut perfusion assay,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL624965,9973
,50597,N,1,In vivo,,,17582,,In vivo retention time was evaluated for the compound after i.v. administration at a dose of 5 mg/kg was measured in rats,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL624966,9974
,50597,N,1,In vivo,,,5031,,Mean residence time (Pharmacokinetic property) after i.v. administration in rats,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL624967,9975
,50597,N,1,In vivo,,,17764,,Mean-residence time of compound after intravenous administration in rats at 24 uM/kg,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL624968,9976
,50597,N,1,,,,17720,,Mean residence time at a dose of 4 mg/kg in Rat Plasma after iv administration,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL624969,9977
,50597,N,1,,,,2862,,Streptococcal cell wall-washed arthritis model in rats at 10.0 mg/kg peroral dose,1,Rattus norvegicus,Expert,,,,10116.0,,,F,BAO_0000218,CHEMBL624970,9978
,50597,N,1,,,,16423,,Half-life was evaluated after 10 uM/kg of intra arterial administration,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL624971,9979
,50597,N,1,In vivo,,,16423,,Half-life was evaluated after 20 uM/kg of peroral administration,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL624972,9980
,50597,N,1,In vivo,,,6005,,Half-life was evaluated after i.v. administration in rat at a dose of 1 mg/kg,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL624973,9981
Plasma,50597,N,1,,,,2938,,Half-life was evaluated in plasma of rat,1,Rattus norvegicus,Intermediate,,,,10116.0,,1969.0,A,BAO_0000218,CHEMBL624974,9982
,50597,N,1,In vivo,,,6410,,Half-life was evaluated in rats at an intravenous dose of 3 mg/kg,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL624975,9983
,50597,N,1,In vivo,,,6410,,Half-life was evaluated in rats at an oral dose of 30 mg/kg,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL877492,9984
,50597,N,1,In vivo,,,6062,,Half-life was measured in rat after an iv dose of 1 mg/kg,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL624976,9985
,50597,N,1,In vivo,,,6571,,Half-life period of compound in rats after peroral administration,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL624977,9986
Plasma,50597,N,1,,,,3136,,Half-life period of compound was measured in rat plasma.,1,Rattus norvegicus,Intermediate,,,,10116.0,,1969.0,A,BAO_0000218,CHEMBL626848,9987
Plasma,50597,N,1,,,,3136,,Half-life period of compound was measured in rat plasma; ND is not determined,1,Rattus norvegicus,Intermediate,,,,10116.0,,1969.0,A,BAO_0000218,CHEMBL626849,9988
Plasma,50597,N,1,,,,3136,,Half-life period of compound was measured in rat plasma; not determined,1,Rattus norvegicus,Intermediate,,,,10116.0,,1969.0,A,BAO_0000218,CHEMBL626850,9989
,50597,N,1,In vivo,,,4521,,Half-life period in rat after 5 mg/kg by oral and 1 mg/kg by intravenous administration,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL626851,9990
,50597,N,1,In vivo,,,5871,,Half-life period in rat by iv administration,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL626852,9991
,50597,N,1,In vivo,,,6077,,Half-life period in rats following intravenous administration at 2 mg/kg,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL626853,9992
,50597,N,1,In vivo,,,6679,,Half-life period was determined after 1 mg/kg (i.v.) / 2 mg/kg (p.o.) of compound administration,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL626854,9993
,50597,N,1,,,,5144,,Half-life period was determined for the compound in rat,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL627486,9994
,50597,N,1,In vivo,,,4498,,"Half-life period was evaluated in rat, after administering 1 mg/kg intravenously",1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL627487,9995
,50597,N,1,In vivo,,,4498,,"Half-life period was evaluated in rat, after administering 10 mg/kg orally",1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL627488,9996
,50597,N,1,In vivo,,,1908,,Half-life value after IV dose at a dose of 5 mg/kg in rats.,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL627489,9997
,50597,N,1,In vivo,,,6211,,Half-life was determined by iv administration (1.5 mg/kg) in fasted male Sprague-Dawley rats,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL627490,9998
,50597,N,1,In vivo,,,5529,,Half-life was determined in rat after intravenous administration (0.5 mg/kg),1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL873829,9999
,50597,N,1,In vivo,,,6444,,Half-life was determined in rat at a dose of 1 mpk i.v.,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL627655,10000
,50597,N,1,In vivo,,,6444,,Half-life was determined in rat at a dose of 1 mpk i.v.; ND means not determined,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL625994,10001
,50597,N,1,In vivo,,,6444,,Half-life was determined in rat at a dose of 1 mpk i.v.; ND=not determined,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL625995,10002
,50597,N,1,,,,5207,,Half-life in rat,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL625996,10003
Plasma,50597,N,1,In vitro,,,530,,In vitro half life in rat plasma,1,Rattus norvegicus,Intermediate,,,,10116.0,,1969.0,A,BAO_0000218,CHEMBL625850,10004
Plasma,50597,N,1,In vitro,,,1116,,"In vitro half life at 1.5 -5.6ug/mL, 37 degree C in rat plasma",1,Rattus norvegicus,Intermediate,,,,10116.0,,1969.0,A,BAO_0000218,CHEMBL625851,10005
,50597,N,1,In vitro,,,3219,,In vitro half life in rat,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL625852,10006
,50597,N,1,In vivo,,,6109,,In vivo half life period after intravenous administration in rat,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL625853,10007
,50597,N,1,In vivo,,,17582,,In vivo half-life period for compound after i.v. administration at a dose of 5 mg/kg was measured in rats,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL625854,10008
,50597,N,1,In vivo,,,17582,,In vivo half-life period for compound after oral (po) administration at a dose of 10 mg/kg was measured in rats,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL874450,10009
,50597,N,1,In vivo,,,5974,,In vivo t1/2 was determined after intravenous administration of compound (9.13+/-0.85 mg/kg) in male Sprague-Dawley rat,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL625855,10010
,50597,N,1,In vivo,,,5974,,In vivo t1/2 was determined after peroral administration of compound (158.5+/-2 mg/kg) in male Sprague-Dawley rat,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL625856,10011
,50597,N,1,In vivo,,,5974,,In vivo t1/2 was determined after peroral administration of compound (19.01+/-0.31 mg/kg) in male Sprague-Dawley rat,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL625857,10012
,50597,N,1,In vivo,,,5974,,In vivo t1/2 was determined after peroral administration of compound (76.4+/-2.6 mg/kg) in male Sprague-Dawley rat,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL873831,10013
,50597,N,1,In vivo,,,17853,,Longer half-life in rat (i.v.) at 0.5 mpk,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL625858,10014
,50597,N,1,In vivo,,,17853,,Longer half-life in rat (p.o.) at 2.0 mpk,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL625859,10015
,50597,N,1,,,,3457,,Pharmacokinetic property (half life) in rat,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL625860,10016
,50597,N,1,In vivo,,,2792,,Pharmacokinetic parameter half-life was determined at 10 mg/kg po dose in rats,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL625861,10017
,50597,N,1,In vivo,,,2792,,Pharmacokinetic parameter half-life was determined at 2 mg/kg i.v. dose in rats,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL625862,10018
,50597,N,1,In vivo,,,2792,,Pharmacokinetic parameter half-life was determined at 3 mg/kg po dose in rats,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL625863,10019
,50597,N,1,In vivo,,,2792,,Pharmacokinetic parameter half-life was determined at 5 mg/kg i.v. dose in rats,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL625864,10020
,50597,N,1,In vivo,,,5739,,Pharmacokinetic property (t1/2) for the compound (5 mg/kg iv) was determined in rats,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL625865,10021
,50597,N,1,In vivo,,,15765,,Pharmacokinetic half time was determined intravenously in rats.,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL625866,10022
Plasma,50597,N,1,In vivo,,,6567,,Plasma half life in rat after 5 mg/kg oral gavage; 6-8 hours,1,Rattus norvegicus,Intermediate,,,,10116.0,,1969.0,A,BAO_0000218,CHEMBL625867,10023
Plasma,50597,N,1,,,,2448,,Plasma half life of hydrolysis of the compound,1,Rattus norvegicus,Intermediate,,,,10116.0,,1969.0,A,BAO_0000218,CHEMBL625868,10024
Plasma,50597,N,1,In vivo,,,5423,,Plasma half life was reported after a intravenous dose of 1 mg/kg in Dawley rat,1,Rattus norvegicus,Intermediate,,,,10116.0,,1969.0,A,BAO_0000218,CHEMBL625869,10025
Plasma,50597,N,1,,,,4853,,Plasma half life period was calculated in rat,1,Rattus norvegicus,Intermediate,,,,10116.0,,1969.0,A,BAO_0000218,CHEMBL874451,10026
Plasma,50597,N,1,,,,4514,,Plasma half-life in Sprague-Dawley rats,1,Rattus norvegicus,Intermediate,,,,10116.0,,1969.0,A,BAO_0000218,CHEMBL625870,10027
Plasma,50597,N,1,,,,4514,,Plasma half-life in Sprague-Dawley rats; Not determined,1,Rattus norvegicus,Intermediate,,,,10116.0,,1969.0,A,BAO_0000218,CHEMBL625871,10028
Plasma,50597,N,1,,,,1500,,Plasma half-life in rats,1,Rattus norvegicus,Intermediate,,,,10116.0,,1969.0,A,BAO_0000218,CHEMBL625872,10029
Plasma,50597,N,1,,,,1500,,Plasma half-life in rats; <MQL,1,Rattus norvegicus,Intermediate,,,,10116.0,,1969.0,A,BAO_0000218,CHEMBL625873,10030
Plasma,50597,N,1,,,,5334,,Plasma half-life period (0-8 h) was determined,1,Rattus norvegicus,Intermediate,,,,10116.0,,1969.0,A,BAO_0000218,CHEMBL625874,10031
Plasma,50597,N,1,,,,5334,,Plasma half-life period (0-8 h) was determined in Sprague-Dawley rat,1,Rattus norvegicus,Intermediate,,,,10116.0,,1969.0,A,BAO_0000218,CHEMBL625875,10032
Plasma,50597,N,1,In vivo,,,5334,,Plasma half-life period (0-8 h) was reported after intravenous administration at a dose of 1 mg/kg in Sprague-Dawley rat,1,Rattus norvegicus,Intermediate,,,,10116.0,,1969.0,A,BAO_0000218,CHEMBL625876,10033
Plasma,50597,N,1,In vivo,,,5334,,Plasma half-life period (0-8 h) was reported after oral administration at a dose of 2 mg/kg in Sprague-Dawley rat,1,Rattus norvegicus,Intermediate,,,,10116.0,,1969.0,A,BAO_0000218,CHEMBL631258,10034
Plasma,50597,N,1,,,,4956,,Plasma half-life was determined in Sprague-Dawley rats after 0-8 h administration of the compound,1,Rattus norvegicus,Intermediate,,,,10116.0,,1969.0,A,BAO_0000218,CHEMBL631259,10035
Plasma,50597,N,1,,,,4956,,Plasma half-life was determined in Sprague-Dawley rats after 0-8 hr administration of the compound; Not determined,1,Rattus norvegicus,Intermediate,,,,10116.0,,1969.0,A,BAO_0000218,CHEMBL631260,10036
Blood,50597,N,1,,,,7768,,"Distribution of radioactivity in blood of rats at 30 mins after an intravenous injection; Value expressed as mean % injected dose, Range = 0.68-1.03",1,Rattus norvegicus,Intermediate,,,,10116.0,,178.0,A,BAO_0000218,CHEMBL631261,10037
Blood,50597,N,1,,,,7768,,"Distribution of radioactivity in blood of rats at 4 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 0.45-0.48",1,Rattus norvegicus,Intermediate,,,,10116.0,,178.0,A,BAO_0000218,CHEMBL631262,10038
Blood,50597,N,1,,,,7768,,"Distribution of radioactivity in blood of rats at 5 mins after an intravenous injection; Value expressed as mean % injected dose, Range-0.81-1",1,Rattus norvegicus,Intermediate,,,,10116.0,,178.0,A,BAO_0000218,CHEMBL631263,10039
,50597,N,1,,,,7768,,"Distribution of radioactivity in brain tissue of rats at 1 day after an intravenous injection; Value expressed as mean % injected dose, Range- 0.007-0.008",1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL631264,10040
,50597,N,1,,,,7768,,"Distribution of radioactivity in brain tissue of rats at 1 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 0.18-0.22",1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL631265,10041
,50597,N,1,,,,7768,,"Distribution of radioactivity in brain tissue of rats at 2 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 0.77-0.97",1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL631266,10042
,50597,N,1,,,,7768,,"Distribution of radioactivity in brain tissue of rats at 2 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 0.08-0.13",1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL631267,10043
,50597,N,1,,,,7768,,"Distribution of radioactivity in brain tissue of rats at 30 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 0.25-0.37",1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL631268,10044
,50597,N,1,,,,7768,,"Distribution of radioactivity in brain tissue of rats at 4 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 0.03-0.04",1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL631269,10045
,50597,N,1,,,,7768,,"Distribution of radioactivity in brain tissue of rats at 5 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 0.74-0.94",1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL631270,10046
Heart,50597,N,1,,,,7768,,"Distribution of radioactivity in heart tissue of rats at 1 day after an intravenous injection; Value expressed as mean % injected dose, Range- 0.02-0.02",1,Rattus norvegicus,Intermediate,,,,10116.0,,948.0,A,BAO_0000218,CHEMBL631271,10047
Heart,50597,N,1,,,,7768,,"Distribution of radioactivity in heart tissue of rats at 1 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 0.5-0.63",1,Rattus norvegicus,Intermediate,,,,10116.0,,948.0,A,BAO_0000218,CHEMBL631272,10048
Heart,50597,N,1,,,,7768,,"Distribution of radioactivity in heart tissue of rats at 2 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 1.35-1.55",1,Rattus norvegicus,Intermediate,,,,10116.0,,948.0,A,BAO_0000218,CHEMBL631273,10049
Heart,50597,N,1,,,,7768,,"Distribution of radioactivity in heart tissue of rats at 2 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 0.24-0.38",1,Rattus norvegicus,Intermediate,,,,10116.0,,948.0,A,BAO_0000218,CHEMBL631274,10050
Heart,50597,N,1,,,,7768,,"Distribution of radioactivity in heart tissue of rats at 30 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 0.55-0.82",1,Rattus norvegicus,Intermediate,,,,10116.0,,948.0,A,BAO_0000218,CHEMBL631275,10051
Heart,50597,N,1,,,,7768,,"Distribution of radioactivity in heart tissue of rats at 4 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 0.16-0.2",1,Rattus norvegicus,Intermediate,,,,10116.0,,948.0,A,BAO_0000218,CHEMBL626984,10052
Heart,50597,N,1,,,,7768,,"Distribution of radioactivity in heart tissue of rats at 5 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 1.13-1.29",1,Rattus norvegicus,Intermediate,,,,10116.0,,948.0,A,BAO_0000218,CHEMBL626985,10053
Liver,50597,N,1,,,,7768,,"Distribution of radioactivity in liver tissue of rats at 1 day after an intravenous injection; Value expressed as mean % injected dose, Range- 0.02-0.02",1,Rattus norvegicus,Intermediate,,,,10116.0,,2107.0,A,BAO_0000218,CHEMBL626986,10054
Liver,50597,N,1,,,,7768,,"Distribution of radioactivity in liver tissue of rats at 1 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 0.71-0.93",1,Rattus norvegicus,Intermediate,,,,10116.0,,2107.0,A,BAO_0000218,CHEMBL626987,10055
Liver,50597,N,1,,,,7768,,"Distribution of radioactivity in liver tissue of rats at 2 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 2.91-3.53",1,Rattus norvegicus,Intermediate,,,,10116.0,,2107.0,A,BAO_0000218,CHEMBL626988,10056
Liver,50597,N,1,,,,7768,,"Distribution of radioactivity in liver tissue of rats at 2 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 0.42-0.62",1,Rattus norvegicus,Intermediate,,,,10116.0,,2107.0,A,BAO_0000218,CHEMBL626989,10057
Liver,50597,N,1,,,,7768,,"Distribution of radioactivity in liver tissue of rats at 30 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 0.97-1.41",1,Rattus norvegicus,Intermediate,,,,10116.0,,2107.0,A,BAO_0000218,CHEMBL626990,10058
Liver,50597,N,1,,,,7768,,"Distribution of radioactivity in liver tissue of rats at 4 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 0.19-0.23",1,Rattus norvegicus,Intermediate,,,,10116.0,,2107.0,A,BAO_0000218,CHEMBL626991,10059
Liver,50597,N,1,,,,7768,,"Distribution of radioactivity in liver tissue of rats at 5 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 2.49-2.82",1,Rattus norvegicus,Intermediate,,,,10116.0,,2107.0,A,BAO_0000218,CHEMBL626992,10060
Lung,50597,N,1,,,,7768,,"Distribution of radioactivity in lung tissue of rats at 1 day after an intravenous injection; Value expressed as mean % injected dose, Range- 0.02-0.03",1,Rattus norvegicus,Intermediate,,,,10116.0,,2048.0,A,BAO_0000218,CHEMBL626993,10061
Lung,50597,N,1,,,,7768,,"Distribution of radioactivity in lung tissue of rats at 1 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 0.66-0.77",1,Rattus norvegicus,Intermediate,,,,10116.0,,2048.0,A,BAO_0000218,CHEMBL874593,10062
Lung,50597,N,1,,,,7768,,"Distribution of radioactivity in lung tissue of rats at 2 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 1.17-1.42",1,Rattus norvegicus,Intermediate,,,,10116.0,,2048.0,A,BAO_0000218,CHEMBL626994,10063
Lung,50597,N,1,,,,7768,,"Distribution of radioactivity in lung tissue of rats at 2 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 0.47-0.58",1,Rattus norvegicus,Intermediate,,,,10116.0,,2048.0,A,BAO_0000218,CHEMBL626995,10064
Lung,50597,N,1,,,,7768,,"Distribution of radioactivity in lung tissue of rats at 30 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 0.65-0.87",1,Rattus norvegicus,Intermediate,,,,10116.0,,2048.0,A,BAO_0000218,CHEMBL626190,10065
Lung,50597,N,1,,,,7768,,"Distribution of radioactivity in lung tissue of rats at 4 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 0.28-0.31",1,Rattus norvegicus,Intermediate,,,,10116.0,,2048.0,A,BAO_0000218,CHEMBL626191,10066
Lung,50597,N,1,,,,7768,,"Distribution of radioactivity in lung tissue of rats at 5 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 0.98-1.22",1,Rattus norvegicus,Intermediate,,,,10116.0,,2048.0,A,BAO_0000218,CHEMBL626364,10067
Thyroid gland,50597,N,1,,,,7768,,"Distribution of radioactivity in thyroid tissue of rats at 1 day after an intravenous injection; Value expressed as mean % injected dose, Range- 406-499",1,Rattus norvegicus,Intermediate,,,,10116.0,,2046.0,A,BAO_0000218,CHEMBL626365,10068
Thyroid gland,50597,N,1,,,,7768,,"Distribution of radioactivity in thyroid tissue of rats at 1 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 53.0-96",1,Rattus norvegicus,Intermediate,,,,10116.0,,2046.0,A,BAO_0000218,CHEMBL626366,10069
Thyroid gland,50597,N,1,,,,7768,,"Distribution of radioactivity in thyroid tissue of rats at 2 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 6.65-8.0.8",1,Rattus norvegicus,Intermediate,,,,10116.0,,2046.0,A,BAO_0000218,CHEMBL626367,10070
Thyroid gland,50597,N,1,,,,7768,,"Distribution of radioactivity in thyroid tissue of rats at 2 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 92-159",1,Rattus norvegicus,Intermediate,,,,10116.0,,2046.0,A,BAO_0000218,CHEMBL626368,10071
Thyroid gland,50597,N,1,,,,7768,,"Distribution of radioactivity in thyroid tissue of rats at 30 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 18.74-30.84",1,Rattus norvegicus,Intermediate,,,,10116.0,,2046.0,A,BAO_0000218,CHEMBL626369,10072
Thyroid gland,50597,N,1,,,,7768,,"Distribution of radioactivity in thyroid tissue of rats at 4 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 156-207",1,Rattus norvegicus,Intermediate,,,,10116.0,,2046.0,A,BAO_0000218,CHEMBL626370,10073
,50597,N,1,In vivo,,,4498,,"Bioavailability (F) was evaluated in rat, after administering 1 mg/kg intravenously",1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL626371,10074
,50597,N,1,In vivo,,,4498,,"Bioavailability (F) was evaluated in rat, after administering 10 mg/kg orally",1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL626372,10075
,50597,N,1,In vivo,,,3603,,Bioavailability after a dose of 10 mg/kg p.o.,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL626373,10076
,50597,N,1,In vivo,,,6215,,Bioavailability after peroral administration (10 mg/kg) was determined in rat,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL626374,10077
,50597,N,1,In vivo,,,5710,,Bioavailability in fasted male administration of 2 mg/Kg of compound p.o.,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL626375,10078
,50597,N,1,In vivo,,,5710,,Oral bioavailability in rat (Sprague-Dawley) (fasted male) (dose 2 mg/kg),1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL626376,10079
,50597,N,1,In vivo,,,5676,,Bioavailability in rat po was determined,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL626377,10080
,50597,N,1,In vivo,,,17667,,Bioavailability of compound at 10 mg/kg in rat after oral administration,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL626378,10081
,50597,N,1,In vivo,,,17667,,Bioavailability of compound at 3 mg/kg in rat after i.v. administration,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL626379,10082
,50597,N,1,In vivo,,,6848,,Bioavailability in rat (dose 1 mg/kg i.v. and 2 mg/kg p.o.),1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL626380,10083
,50597,N,1,In vivo,,,6848,,Bioavailability in rat (dose 1 mg/kg i.v. and 2 mg/kg p.o.),1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL626381,10084
,50597,N,1,In vivo,,,17267,,Bioavailability in rat,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL626382,10085
,50597,N,1,In vivo,,,6362,,Bioavailability in rat (Sprague-Dawley) (female),1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL626383,10086
,50597,N,1,In vivo,,,17671,,Bioavailability in male Sprague-Dawley rats following an intravenous bolus dose at 10-20 mg/kg,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL874652,10087
,50597,N,1,In vivo,,,17671,,Bioavailability in rat (Sprague-Dawley) (male) (dose 10-20 mg/kg),1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL626384,10088
,50597,N,1,In vivo,,,4333,,Bioavailability in rat (Sprague-Dawley) (male) (dose 1 mg/kg i.v. and 3 mg/kg p.o.) measured from 0.3 to 6 hr,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL626385,10089
,50597,N,1,In vivo,,,6077,,Bioavailability in rat at an oral dose of 2 mg/kg,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL626386,10090
,50597,N,1,In vivo,,,3278,,Bioavailability in rat,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL626387,10091
,50597,N,1,In vivo,,,5964,,Bioavailability in rat,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL626388,10092
,50597,N,1,In vivo,,,4884,,Bioavailability in rat,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL626389,10093
,50597,N,1,In vivo,,,4905,,Bioavailability in rat,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL626390,10094
,50597,N,1,In vivo,,,4884,,Bioavailability in rat was reported at the dose of 6 mg/kg in 25% PEG-300,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL626391,10095
,50597,N,1,In vivo,,,6850,,Bioavailability in rat,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL626392,10096
,50597,N,1,In vivo,,,2864,,Oral bioavailability in rat,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL626393,10097
,50597,N,1,In vivo,,,5780,,Bioavailability was determined in rat,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL623026,10098
,50597,N,1,In vivo,,,1465,,Bioavailability,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL623027,10099
,50597,N,1,In vivo,,,5199,,Bioavailability,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL623028,10100
,50597,N,1,In vivo,,,5765,,Bioavailability in rat after 1 day dosing,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL623029,10101
,50597,N,1,In vivo,,,5765,,Bioavailability in rat after 4 day dosing,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL623030,10102
,50597,N,1,In vivo,,,6518,,Bioavailability after IV dosing at 0.5 mg/kg in rat; no data,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL623031,10103
,50597,N,1,In vivo,,,6518,,Bioavailability after IV dosing at 1 mg/kg in rat; no data,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL623032,10104
,50597,N,1,In vivo,,,6518,,Bioavailability after oral administration at a dose of 2 mg/kg in rat,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL623033,10105
,50597,N,1,In vivo,,,6518,,Bioavailability after oral administration at a dose of 4 mg/kg in rat,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL623034,10106
,50597,N,1,In vivo,,,2083,,Bioavailability at 4 hr after administration of 5 mg/kg dose peroral in rat,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL623035,10107
,50597,N,1,In vivo,,,17260,,Bioavailability at a dose of 10 mg/Kg administered perorally in female hanover-wistar rat,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL623036,10108
,50597,N,1,In vivo,,,4956,,Bioavailability in rat (Sprague-Dawley) (dose 1 mg/kg i.v. and 2 mg/kg p.o.),1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL623037,10109
,50597,N,1,In vivo,,,4368,,Bioavailability by intravenous administration of 3.4 mg/kg in rat,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL623038,10110
Plasma,50597,N,1,In vivo,,,17752,,Bioavailability from rat plasma at a single oral dose of 25 mg/kg,1,Rattus norvegicus,Intermediate,,,,10116.0,,1969.0,A,BAO_0000218,CHEMBL874385,10111
,50597,N,1,In vivo,,,1446,,Bioavailability in rat (Fisher) (fasted),1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL623039,10112
,22224,U,0,In vivo,,,2891,,Bioavailability in monkey after po administration of 10 mg/kg dose,1,Primates,Intermediate,,,,9443.0,,,A,BAO_0000218,CHEMBL623040,10113
,22224,U,0,In vivo,,,2891,,Oral bioavailability in monkey (dose 10 mg/kg),1,Primates,Intermediate,,,,9443.0,,,A,BAO_0000218,CHEMBL623041,10114
,50597,N,1,In vivo,,,6672,,Bioavailability in rat,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL623741,10115
,50597,N,1,In vivo,,,6673,,Bioavailability in rat,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL623742,10116
,50597,N,1,In vivo,,,17655,,Bioavailability in rat,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL623743,10117
,50597,N,1,In vivo,,,17796,,Bioavailability in rat,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL623744,10118
,50597,N,1,In vivo,,,17853,,Bioavailability in rat (dose 2.0 mg/kg p.o.),1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL623745,10119
,50597,N,1,In vivo,,,4521,,Bioavailability in rat (dose 5 mg/kg p.o. and 1 mg/kg i.v.),1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL623746,10120
,50597,N,1,In vivo,,,4940,,Oral bioavailability in rat (dose 5 mg/kg p.o.),1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL623747,10121
,22224,U,0,In vivo,,,2891,,Bioavailability in rat after po administration of 30 mg/kg dose,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL623748,10122
,22224,U,0,In vivo,,,2891,,Bioavailability in rat after po administration of 30 mg/kg dose,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL623916,10123
,50597,N,1,In vivo,,,4521,,Bioavailability in rat after 5 mg/kg by oral and 1 mg/kg by intravenous administration,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL623917,10124
,50597,N,1,In vivo,,,17686,,Bioavailability in rat (dose 2 mg/kg i.v.),1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL623918,10125
,50597,N,1,In vivo,,,17796,,Bioavailability in rat,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL874386,10126
Plasma,50597,N,1,In vivo,,,17796,,Bioavailability in rat; Only traces detected in rat plasma,1,Rattus norvegicus,Intermediate,,,,10116.0,,1969.0,A,BAO_0000218,CHEMBL623919,10127
,50597,N,1,In vivo,,,5064,,Bioavailability in rat,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL623920,10128
,50597,N,1,In vivo,,,5147,,Bioavailability upon oral administration of compound,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL623148,10129
,50597,N,1,In vivo,,,1916,,Oral bioavailability in rat (Sprague-Dawley) (dose 15 mg/kg),1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL623149,10130
,50597,N,1,In vivo,,,6049,,Bioavailability in rat,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL623150,10131
,50597,N,1,In vivo,,,1445,,"Bioavailability was evaluated in rats at a dose of 20 mg/kg, under fasting state",1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL623151,10132
,50597,N,1,In vivo,,,1445,,"Bioavailability was evaluated in rats at a dose of 20 mg/kg, under fed state",1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL623152,10133
,50597,N,1,,,,2862,,Streptococcal cell wall-washed arthritis model in rats at 3.0 mg/kg peroral dose,1,Rattus norvegicus,Expert,,,,10116.0,,,F,BAO_0000218,CHEMBL623153,10134
,50597,N,1,,,,2862,,Streptococcal cell wall-washed arthritis model in rats at 30.0 mg/kg peroral dose,1,Rattus norvegicus,Expert,,,,10116.0,,,F,BAO_0000218,CHEMBL623154,10135
,50597,N,1,,,,4194,,In vitro and metabolic stability was determined,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL623155,10136
,50597,N,1,,,,4194,,In vitro metabolic stability in rat hepatocytes,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL623156,10137
,50597,N,1,,,,5486,,In vitro metabolic stability in rat was measured as pmol/min/mg/protein,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL623157,10138
Liver,50597,N,1,In vitro,,,17582,,Metabolic rate for compound was observed in rat hepatocytes,1,Rattus norvegicus,Intermediate,,401.0,,10116.0,Hepatocyte,2107.0,A,BAO_0000218,CHEMBL623158,10139
,50597,N,1,,,,5600,,In vitro metabolic stability determined after 30 min of incubation in rat hepatic microsomes,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL623159,10140
,50597,N,1,,,,14294,,Metabolism of compound in rat S9 microsomes ('+''indicates <20% largest observed peak),1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL874390,10141
,50597,N,1,,,,14294,,Metabolism of compound in rat S9 microsomes ('++++' indicates largest observed peak),1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL623160,10142
,50597,N,1,,,,14294,,Metabolism of compound in rat S9 microsomes; Trace,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL623161,10143
,50597,N,1,,,,17847,,Metabolism was measured as percent loss at 4 hr in rat hepatocytes,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL623162,10144
,50597,N,1,,,,11020,,Momoamine and metabolic levels observed 1 week following acute dosing at a dose of 10 mg/kg Frontal cortex 5-HIAA,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL623163,10145
,50597,N,1,,,,11020,,Momoamine and metabolic levels observed 1 week following acute dosing at a dose of 10 mg/kg Frontal cortex 5-HT,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL623164,10146
,50597,N,1,,,,11020,,Momoamine and metabolic levels observed 1 week following acute dosing at a dose of 10 mg/kg Frontal cortex DA,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL623165,10147
,50597,N,1,,,,11020,,Momoamine and metabolic levels observed 1 week following acute dosing at a dose of 10 mg/kg Frontal cortex DOPAC,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL623166,10148
,50597,N,1,,,,11020,,Momoamine and metabolic levels observed 1 week following acute dosing at a dose of 10 mg/kg Frontal cortex HVA,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL624983,10149
,50597,N,1,,,,11020,,Momoamine and metabolic levels observed 1 week following acute dosing at a dose of 10 mg/kg Frontal cortex NE,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL624984,10150
,50597,N,1,,,,11020,,Momoamine and metabolic levels observed 1 week following acute dosing at a dose of 10 mg/kg Hippocampus 5-HIAA,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL624985,10151
,50597,N,1,,,,11020,,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 10 mg/kg Hippocampus 5-HT,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL622970,10152
,50597,N,1,,,,11020,,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 10 mg/kg Hippocampus DA; below level of detection,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL622971,10153
,50597,N,1,,,,11020,,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 10 mg/kg Hippocampus DA; below the levels of detection,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL622972,10154
,50597,N,1,,,,11020,,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 10 mg/kg Hippocampus DOPAC; below level of detection,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL622973,10155
,50597,N,1,,,,11020,,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 10 mg/kg Hippocampus DOPAC; below the levels of detection,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL622974,10156
,50597,N,1,,,,11020,,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 10 mg/kg Hippocampus HVA; below level of detection,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL622975,10157
,50597,N,1,,,,11020,,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 10 mg/kg Hippocampus HVA; below the levels of detection,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL622976,10158
,50597,N,1,,,,11020,,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 10 mg/kg Hippocampus NE,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL622977,10159
,50597,N,1,,,,11020,,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Frontal cortex 5-HIAA,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL624351,10160
,50597,N,1,,,,11020,,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Frontal cortex 5-HT,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL624352,10161
,50597,N,1,,,,11020,,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Frontal cortex DA,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL624353,10162
,50597,N,1,,,,11020,,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Frontal cortex DOPAC,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL622397,10163
,50597,N,1,,,,11020,,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Frontal cortex HVA,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL622398,10164
,50597,N,1,,,,11020,,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Frontal cortex NE,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL622399,10165
,50597,N,1,,,,11020,,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Frontal cortex DA,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL622400,10166
,50597,N,1,,,,11020,,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Hippocampus 5-HIAA,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL628428,10167
,50597,N,1,,,,11020,,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Hippocampus 5-HT,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL628590,10168
,50597,N,1,,,,11020,,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Hippocampus DA; below level of detection,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL628591,10169
,50597,N,1,,,,11020,,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Hippocampus DA; below the levels of detection,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL628592,10170
,50597,N,1,,,,11020,,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Hippocampus DOPAC; below level of detection,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL628593,10171
,50597,N,1,,,,11020,,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Hippocampus DOPAC; below the levels of detection,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL875333,10172
,50597,N,1,,,,11020,,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Hippocampus HVA; below level of detection,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL628594,10173
Plasma,50597,N,1,,,,4969,,Plasma half-life was determined in Sprague-Dawley rats after 0-8 hr of administration,1,Rattus norvegicus,Intermediate,,,,10116.0,,1969.0,A,BAO_0000218,CHEMBL628595,10174
Plasma,50597,N,1,,,,6737,,Stability in rat plasma was determined,1,Rattus norvegicus,Intermediate,,,,10116.0,,1969.0,A,BAO_0000218,CHEMBL628596,10175
Plasma,50597,N,1,,,,6737,,Stability in rat plasma was determined; ND= no data,1,Rattus norvegicus,Intermediate,,,,10116.0,,1969.0,A,BAO_0000218,CHEMBL628597,10176
Plasma,50597,N,1,,,,5089,,Tested for plasma half life period in rat (0-8 hr),1,Rattus norvegicus,Intermediate,,,,10116.0,,1969.0,A,BAO_0000218,CHEMBL628598,10177
Plasma,50597,N,1,,,,5089,,Tested for plasma half life period in rat (0-8 hr); Not determined,1,Rattus norvegicus,Intermediate,,,,10116.0,,1969.0,A,BAO_0000218,CHEMBL628599,10178
,50597,N,1,In vivo,,,1466,,Tested for t1/2 upon intravenous administration of 5.0 mg/Kg dose in rat,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL628600,10179
,50597,N,1,In vivo,,,1466,,Tested for t1/2 upon peroral administration of 10.0 mg/Kg dose in rat,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL628601,10180
,50597,N,1,,,,4950,,Tested for the half life in rat,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL628602,10181
,50597,N,1,In vitro,,,2412,,Tested in vitro for the time for half reactivation against rat small intestinal glucoamylase,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL628603,10182
,50597,N,1,In vitro,,,2412,,Tested in vitro for the time for half reactivation against rat small intestinal glucoamylase; ND=Not determined,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL628604,10183
,50597,N,1,In vitro,,,2412,,Tested in vitro for the time for half reactivation against rat small intestinal isomaltase,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL628605,10184
,50597,N,1,In vitro,,,2412,,Tested in vitro for the time for half reactivation against rat small intestinal isomaltase; ND=Not determined,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL628606,10185
,50597,N,1,In vitro,,,2412,,Tested in vitro for the time for half reactivation against rat small intestinal sucrase,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL628607,10186
,50597,N,1,,,,15022,,The biological half life the compound was measured at the dose of 100 umol/kg,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL628608,10187
,50597,N,1,,,,15022,,The biological half life the compound was measured at the dose of 30 umol/kg,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL628609,10188
Plasma,50597,N,1,,,,406,,The compound was evaluated for plasma half life period in rat,1,Rattus norvegicus,Intermediate,,,,10116.0,,1969.0,A,BAO_0000218,CHEMBL628610,10189
,50597,N,1,In vivo,,,15078,,"The half life value in female wistar rat at 100 mg/kg, p.o. dose",1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL873819,10190
,50597,N,1,In vivo,,,15078,,"The half life value in male wistar rat at 100 mg/kg, p.o. dose",1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL628611,10191
,50597,N,1,In vivo,,,5247,,The pharmacokinetic parameter half-life period in vivo in rats,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL628612,10192
,50597,N,1,In vivo,,,5041,,"The pharmacokinetic property, Half-life was determined",1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL628613,10193
,50597,N,1,In vivo,,,5041,,"The pharmacokinetic property, Half-life in rat in vivo",1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL628614,10194
,50597,N,1,In vivo,,,5041,,"The pharmacokinetic property, Half-life was determined; ND denotes no data",1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL628615,10195
,50597,N,1,In vivo,,,5041,,"The pharmacokinetic property, Half-life was determined; ND denotes not determined",1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL628616,10196
Plasma,50597,N,1,,,,3918,,The plasma half life period in rats,1,Rattus norvegicus,Intermediate,,,,10116.0,,1969.0,A,BAO_0000218,CHEMBL627924,10197
Liver,50597,N,1,,,,2906,,The release rate of the free drug from the substrate in rat liver lysosomal preparation by rat liver lysosomal assay,1,Rattus norvegicus,Intermediate,,,,10116.0,,2107.0,A,BAO_0000218,CHEMBL627925,10198
,50597,N,1,In vivo,,,6467,,half life in rats at the dose of 1.0 mpk by i.v. administration; ND= not determined,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL627926,10199
,50597,N,1,,,,5510,,t1/2 (apparent elimination)of the compound was determined,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL627927,10200
,50597,N,1,,,,3788,,t1/2 value in rat,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL627928,10201
,50597,N,1,,,,17796,,Half life in rat,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL627539,10202
Plasma,50597,N,1,In vivo,,,12873,,"Half life period calculated from Time-Course plasma concentrations in rats at a dose of 2.5 mg/kg, iv",1,Rattus norvegicus,Intermediate,,,,10116.0,,1969.0,A,BAO_0000218,CHEMBL876790,10203
,50597,N,1,In vivo,,,5983,,Pharmacokinetic property (t1/2beta) was measured in rat at the dose of 0.32 mg/kg i.v.,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL858186,10204
,50597,N,1,,,,15765,,Half-life period in fasted rats,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL627540,10205
,50597,N,1,In vivo,,,2661,,Compound was evaluated for maximum time to reach Cmax after treatment with oral dose of 2 mgkg to female wistar rats,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL627541,10206
,50597,N,1,In vivo,,,2661,,Compound was evaluated for maximum time to reach Cmax after treatment with oral dose of 2 mgkg to male wistar rats,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL627715,10207
,50597,N,1,In vivo,,,429,,Evaluated for pharmacokinetic parameter tmax in rat at the dose 50 mg/kg,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL627716,10208
,50597,N,1,,,,17655,,Maximum time required to achieve Cmax was determined in rat,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL627717,10209
,50597,N,1,In vivo,,,17717,,Time calculated to reach Cmax at a concentration of 15 mg/kg perorally in rats along with 100 mg/kg of compound 11,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL627718,10210
,50597,N,1,In vivo,,,17717,,Time calculated to reach Cmax at a concentration of 60 mg/kg perorally in rats along with 100 mg/kg of compound 11,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL627719,10211
,50597,N,1,In vivo,,,17717,,Time calculated to reach Cmax at a concentration of 60 mg/kg perorally in rats along with control,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL627720,10212
,50597,N,1,In vivo,,,6570,,Time to reach maximum concentration in rat after 2 mg/kg peroral administration,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL627721,10213
,50597,N,1,In vivo,,,6570,,Time to reach maximum concentration in rat after 2 mg/kg peroral administration; 4-6,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL627722,10214
,50597,N,1,In vivo,,,5978,,Tmax of compound (19.2 mg/kg) after po administration was determined in Sprague-Dawley rat,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL627723,10215
,50597,N,1,In vivo,,,5978,,Tmax of compound (19.76 mg/kg) after po administration was determined in Sprague-Dawley rat,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL626058,10216
,50597,N,1,In vivo,,,5978,,Tmax of compound (20.73 mg/kg) after po administration was determined in Sprague-Dawley rat,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL626059,10217
,50597,N,1,In vivo,,,5978,,Tmax of compound (25 mg/kg) after po administration was determined in Sprague-Dawley rat,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL626060,10218
Plasma,50597,N,1,In vivo,,,17720,,Tmax at a dose of 4 mg/kg in Rat Plasma after iv administration,1,Rattus norvegicus,Intermediate,,,,10116.0,,1969.0,A,BAO_0000218,CHEMBL626061,10219
,50597,N,1,In vivo,,,4723,,Tmax determined after 0.3 mg/kg oral administration in potassium oxonate treated rats,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL876791,10220
,50597,N,1,In vivo,,,4723,,Tmax determined after 3 mg/kg oral administration in potassium oxonate treated rats,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL626062,10221
,50597,N,1,In vivo,,,4756,,Tmax at the dose of 2 mg/Kg administered perorally in rats,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL626063,10222
,50597,N,1,In vivo,,,4756,,Tmax at the dose of 5 mg/Kg administered perorally in rats,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL626064,10223
Plasma,50597,N,1,In vivo,,,17720,,tmax at a dose of 100 mg/kg in Rat Plasma after iv administration,1,Rattus norvegicus,Intermediate,,,,10116.0,,1969.0,A,BAO_0000218,CHEMBL626065,10224
Plasma,50597,N,1,In vivo,,,17720,,tmax at a dose of 50 mg/kg in Rat Plasma after iv administration,1,Rattus norvegicus,Intermediate,,,,10116.0,,1969.0,A,BAO_0000218,CHEMBL626066,10225
,50597,N,1,In vivo,,,1466,,tmax upon peroral administration of 10.0 mg/Kg dose in rat,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL626067,10226
,50597,N,1,,,,7449,,Percent total excretion of 3-(thiomethyl)acetaminophen glucuronide,1,Rattus norvegicus,Intermediate,,,,10116.0,,,F,BAO_0000218,CHEMBL626068,10227
,50597,N,1,,,,7449,,Percent total excretion of 3-(thiomethyl)acetaminophen sulfate,1,Rattus norvegicus,Intermediate,,,,10116.0,,,F,BAO_0000218,CHEMBL626069,10228
,50597,N,1,,,,7449,,Percent total excretion of 3-methoxyacetaminophen glucuronide,1,Rattus norvegicus,Intermediate,,,,10116.0,,,F,BAO_0000218,CHEMBL626070,10229
,50597,N,1,,,,7449,,Percent total excretion of N-methoxyacetaminophen glucuronide,1,Rattus norvegicus,Intermediate,,,,10116.0,,,F,BAO_0000218,CHEMBL626071,10230
,50597,N,1,,,,7449,,Percent total excretion of N-methoxyacetaminophen sulfate,1,Rattus norvegicus,Intermediate,,,,10116.0,,,F,BAO_0000218,CHEMBL626072,10231
,50597,N,1,,,,7449,,Percent total excretion of acetaminophen,1,Rattus norvegicus,Intermediate,,,,10116.0,,,F,BAO_0000218,CHEMBL626073,10232
Thyroid gland,50597,N,1,,,,7768,,"Distribution of radioactivity in thyroid tissue of rats at 5 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 6.19-7.22",1,Rattus norvegicus,Intermediate,,,,10116.0,,2046.0,A,BAO_0000218,CHEMBL626741,10233
,50597,N,1,,,,17655,,"Percent instability was measured by Rat S9 liver slice metabolism assay, in vitro",1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL626742,10234
,50597,N,1,,,,17735,,Plasma clearance following 10 mg/kg intravenous or 50 mg/kg oral dosing in rats,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL626743,10235
,50597,N,1,,,,5960,,Plasma concentration at 4 hr after 30 mg/kg post dosing in rat using HPLC/MS,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL876792,10236
,50597,N,1,,,,17735,,Volume of distribution following 10 mg/kg intravenous or 50 mg/kg oral dosing in rats was determined,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL626744,10237
,50597,N,1,,,,7116,,Compound was tested for antidiuretic activity in rats,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL626745,10238
Plasma,50597,N,1,In vivo,,,4878,,AUC in rat after 3mg/kg oral dose,1,Rattus norvegicus,Intermediate,,,,10116.0,,1969.0,A,BAO_0000218,CHEMBL626746,10239
,50597,N,1,,,,5939,,Ratio in brain to that of rat plasma for 2 hr after peroral administration at 10 mg/kg,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL626747,10240
,50597,N,1,,,,5939,,Ratio in brain to that of rat plasma for 2 hr after peroral administration at 5 mg/kg,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL626748,10241
,50597,N,1,,,,16367,,Bioavailability administered orally at a dose of 10 mg/kg to rats,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL626749,10242
,50597,N,1,,,,16366,,Oral Bioavailability was determined,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL626750,10243
,50597,N,1,,,,4426,,Oral bioavailability in rat,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL626751,10244
,50597,N,1,,,,4426,,Oral bioavailability in rat; Not performed.,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL626913,10245
,50597,N,1,,,,5041,,Bioavailability,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL626914,10246
,50597,N,1,,,,5041,,Bioavailability was determined; ND denotes no data,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL626915,10247
,50597,N,1,,,,1500,,Biliary excretion when administered intravenously at a dose of 2.5 mg/kg in rats,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL626916,10248
,50597,N,1,,,,1500,,Biliary excretion when administered intravenously at a dose of 5 mg/kg in rats,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL626917,10249
,50597,N,1,,,,17409,,Binding towards rat plasma protein at 10 uM,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL626918,10250
,50597,N,1,,,,17409,,Binding towards rat plasma protein at 100 uM,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL626919,10251
,50597,N,1,In vivo,,,2959,,Bioavailability in rat (dose 20 mg/kg p.o.),1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL626920,10252
,50597,N,1,In vivo,,,13501,,Bioavailability was determined after oral administration of compound 18 at a dose of 4 mg/kg to rat,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL621976,10253
,50597,N,1,In vivo,,,6567,,Bioavailability in rat after 5 mg/kg oral gavage,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL877599,10254
,50597,N,1,In vivo,,,6571,,Bioavailability in rat,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL621977,10255
,50597,N,1,In vivo,,,6715,,Bioavailability in rat (dose 1 mg/kg i.v.),1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL621978,10256
,50597,N,1,In vivo,,,6715,,Bioavailability in rat (dose 3 mg/kg p.o.),1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL621979,10257
,50597,N,1,In vivo,,,2932,,Oral bioavailability in rat,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL621980,10258
,50597,N,1,In vivo,,,4171,,Bioavailability of the compound in rats after administration of 30 mg/kg,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL621981,10259
,50597,N,1,In vivo,,,17509,,Bioavailability after administration of 10 mg/kg in rats,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL621982,10260
,50597,N,1,In vivo,,,17509,,Bioavailability after administration of 2 mg/kg in rats,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL882953,10261
,50597,N,1,In vivo,,,4527,,Bioavailability by oral administration at a dose of 100 uM/kg in rat was determined,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL621983,10262
,50597,N,1,In vivo,,,4026,,Bioavailability in dogs was determined; high,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL621984,10263
,50597,N,1,In vivo,,,6659,,Bioavailability in monkey after intravenous administration at 1 mpk,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL621985,10264
,50597,N,1,In vivo,,,6659,,Bioavailability in monkey after peroral administration at 10 mpk,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL621986,10265
,50597,N,1,In vivo,,,6659,,Bioavailability in rat after intravenous administration at 1 mpk,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL621987,10266
,50597,N,1,In vivo,,,6659,,Bioavailability in rat after intravenous administration at 2 mpk,1,Rattus norvegicus,Intermediate,,,,10116.0,,,F,BAO_0000218,CHEMBL877600,10267
,50597,N,1,In vivo,,,6659,,Bioavailability in rat after peroral administration at 30 mpk,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL621988,10268
,50597,N,1,In vivo,,,6659,,Bioavailability in rat after peroral administration at at 100 mpk,1,Rattus norvegicus,Intermediate,,,,10116.0,,,F,BAO_0000218,CHEMBL621989,10269
,50597,N,1,In vivo,,,6597,,Bioavailability in rats was evaluated,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL621990,10270
,50597,N,1,In vivo,,,1202,,Bioavailability was calculated after an intravenous dose of 0.3 mg/Kg in rats after 6 hr,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL621991,10271
,50597,N,1,In vivo,,,1202,,Bioavailability was calculated after an intravenous dose of 1 mg/Kg in rats after 6 hr,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL621992,10272
,50597,N,1,In vivo,,,1202,,Bioavailability was calculated after peroral dose of 3.0 mg/Kg in rats after 4 hr,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL621993,10273
,50597,N,1,In vivo,,,1202,,Bioavailability was calculated after peroral dose of 3.0 mg/Kg in rats after 6 hr,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL621994,10274
,50597,N,1,In vivo,,,5207,,Bioavailability in rat,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL621995,10275
,50597,N,1,In vivo,,,5970,,Bioavailability in rat,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL621996,10276
,50597,N,1,In vivo,,,17538,,Oral bioavailability in rat (dose 10 mg/kg),1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL621997,10277
,50597,N,1,In vivo,,,17538,,Bioavailability in rat after po administration at a dose of 10 mg/kg; nd is not determined,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL621998,10278
,50597,N,1,In vivo,,,1466,,Bioavailability upon peroral administration of 10.0 mg/Kg dose in rat,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL621999,10279
,50597,N,1,In vivo,,,2879,,Oral bioavailability in rat,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL622000,10280
,50597,N,1,In vivo,,,2879,,Bioavailability was measured in rat after oral administration; 2-4,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL622001,10281
,50597,N,1,In vivo,,,2879,,Bioavailability was measured in rat after oral administration; 3-7,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL622002,10282
,50597,N,1,In vivo,,,3777,,Bioavailability in rat (intraduodenal administration),1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL622003,10283
,50597,N,1,In vivo,,,3777,,Bioavailability in rat (intraduodenal administration),1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL877601,10284
,50597,N,1,In vivo,,,3777,,Oral bioavailability in rat,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL624871,10285
,50597,N,1,In vivo,,,3777,,Oral bioavailability in rat,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL622004,10286
,50597,N,1,In vivo,,,5423,,Oral bioavailability in rat (Sprague-Dawley) (dose 1 mg/kg p.o.),1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL882954,10287
,50597,N,1,In vivo,,,16365,,Bioavailability was evaluated when a dose of 3 mg/kg was administered orally,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL622005,10288
,50597,N,1,In vivo,,,16365,,Bioavailability was evaluated when a dose of 3 mg/kg was administered orally to a fasting rat,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL622006,10289
,50597,N,1,In vivo,,,4239,,Bioavailability was measured in rat,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL622007,10290
,50597,N,1,In vivo,,,5438,,Bioavailability was reported,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL622008,10291
,50597,N,1,In vivo,,,5334,,Bioavailability in rat (Sprague-Dawley) (dose 1 mg/kg i.v.),1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL622009,10292
,50597,N,1,In vivo,,,5334,,Oral bioavailability in rat (Sprague-Dawley) (dose 2 mg/kg),1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL622010,10293
,50597,N,1,In vivo,,,4199,,Bioavailability was determined upon 10 mg/kg in 1% methylcellulose peroral administration in rats,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL622011,10294
,50597,N,1,In vivo,,,4199,,Bioavailability in rat (dose 2 mg/kg in 1% methylcellulose p.o.),1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL622012,10295
,50597,N,1,In vivo,,,4199,,Bioavailability in rat (dose 3 mg/kg in 1% methylcellulose ),1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL622013,10296
,50597,N,1,In vivo,,,4890,,Bioavailability was determined after intravenous administration at a dose 5 mg/kg to male Sprague-Dawley rats,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL622014,10297
,50597,N,1,In vivo,,,2792,,Bioavailability was determined at 3 mg/kg po dose in rats,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL624749,10298
,50597,N,1,In vivo,,,5529,,Oral bioavailability in rat (dose 2 mg/kg),1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL624750,10299
,50597,N,1,In vivo,,,6685,,"Bioavailability was determined in rats at 10 mg/kg, p.o. dose",1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL624751,10300
,50597,N,1,In vivo,,,6685,,"Bioavailability was determined in rats at 20 mg/kg, i.p. dose; n/a: not applicable",1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL624752,10301
,50597,N,1,In vivo,,,6685,,"Bioavailability was determined in rats at 2 mg/kg, i.v. dose; n/a: not applicable",1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL624753,10302
,50597,N,1,In vivo,,,6005,,Bioavailability was evaluated in rat after peroral administration at a dose of 1 mg/kg,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL624754,10303
,50597,N,1,In vivo,,,6410,,Bioavailability was evaluated in rats at an intravenous dose of 3 mg/kg; Not applicable,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL624755,10304
,50597,N,1,In vivo,,,6410,,Bioavailability was evaluated in rats at an oral dose of 30 mg/kg,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL624756,10305
,50597,N,1,In vivo,,,6103,,Bioavailability in rat,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL624757,10306
,50597,N,1,In vivo,,,6410,,Bioavailability was evaluated in rats at an intravenous dose of 3 mg/kg; Not applicable,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL624758,10307
,50597,N,1,In vivo,,,6410,,Bioavailability was evaluated in rats at an oral dose of 30 mg/kg,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL622270,10308
,50597,N,1,In vivo,,,5353,,Bioavailability in rat (Sprague-Dawley),1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL622271,10309
,50597,N,1,In vivo,,,4727,,Bioavailability in rat at the dose of 2 mg/kg,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL622272,10310
,50597,N,1,In vivo,,,17804,,Oral bioavailability in rat,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL622273,10311
,50597,N,1,In vivo,,,5809,,Bioavailability in rat (cannulated) (dose 2 mg/kg),1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL622274,10312
,50597,N,1,In vivo,,,17804,,Bioavailability value of compound in rats was determined after peroral administration,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL622275,10313
,50597,N,1,In vivo,,,3634,,Oral bioavailability in rat (dose 20 mg/kg),1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL622276,10314
,50597,N,1,In vivo,,,3341,,Oral bioavailability in rat,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL622277,10315
,50597,N,1,In vivo,,,2690,,Oral bioavailability in rat (dose 5 mg/kg),1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL622278,10316
,50597,N,1,In vivo,,,3184,,Oral bioavailability in rat,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL622279,10317
,50597,N,1,In vivo,,,740,,Oral bioavailability in rat,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL622280,10318
,50597,N,1,In vivo,,,1806,,Compound was evaluated for oral bioavailability in rats; 15-27 %,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL624083,10319
,50597,N,1,In vivo,,,4891,,Compound was evaluated for pharmacokinetic parameter percent bioavailability at 18 h,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL624084,10320
,50597,N,1,In vivo,,,3634,,Compound was evaluated for pharmacokinetic property in rats after an oral dose of 10 mg/kg and the value was reported as oral bioavailability (F),1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL624085,10321
,50597,N,1,In vivo,,,64,,Compound was tested for bioavailability in rats,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL624086,10322
,50597,N,1,In vivo,,,4839,,Bioavailability in rat,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL624087,10323
,50597,N,1,In vivo,,,1094,,Oral bioavailability in rat,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL624088,10324
,22224,U,0,In vivo,,,5005,,Compound was tested for oral bioavailability in rhesus monkey at a dose of 0.75 mg/kg iv/ 1.5 mg/kg po.,1,Macaca mulatta,Intermediate,,,,9544.0,,,A,BAO_0000218,CHEMBL624089,10325
,22224,U,0,In vivo,,,5005,,Oral bioavailability in rat (Sprague-Dawley) (dose 1 mg/kg i.v. and 2 mg/kg p.o.),1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL624090,10326
,50597,N,1,In vivo,,,4687,,Evaluated for the bioavailability in rat (in vivo),1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL624091,10327
,50597,N,1,In vivo,,,17804,,F value of compound in rats was determined after peroral administration,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL624092,10328
,50597,N,1,In vivo,,,5974,,In vivo Oral bioavailability (F)was determined after intravenous administration of compound (9.13+/-0.85 mg/kg) in male Sprague-Dawley rat,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL624093,10329
,50597,N,1,In vivo,,,5974,,In vivo Oral bioavailability (F)was determined after peroral administration of compound (158.5+/-2 mg/kg) in male Sprague-Dawley rat,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL624094,10330
,50597,N,1,In vivo,,,5974,,In vivo Oral bioavailability (F)was determined after peroral administration of compound (19.01+/-0.31 mg/kg) in male Sprague-Dawley rat,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL624095,10331
,50597,N,1,In vivo,,,5974,,In vivo Oral bioavailability (F)was determined after peroral administration of compound (76.4+/-2.6 mg/kg) in male Sprague-Dawley rat,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL624096,10332
,50597,N,1,In vivo,,,1088,,"In vivo percent of absolute bioavailability obtained from blood plasma levels analyzed by means of GC/MS (dose 5 uM/kg i.v. and 40 uM/kg, p.o.)",1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL624097,10333
,50597,N,1,In vivo,,,1742,,Maximum fall in carotid flow in rat,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL624098,10334
,50597,N,1,In vivo,,,4689,,Oral Bioavailability after intravenous administration (1 mg/kg) in rat,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL874392,10335
,50597,N,1,In vivo,,,2463,,Oral bioavailability in rat (dose 5 mg/kg),1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL624099,10336
,50597,N,1,In vivo,,,5654,,Oral bioavailability (F%) of compound was determined as average of four rats at each dose of 5 mg/kg intravenous and 16 mg/kg peroral administration,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL624100,10337
,50597,N,1,In vivo,,,5654,,Oral bioavailability (F%) of compound was determined as average of four rats at each dose of 5 mg/kg intravenous and 20 mg/kg peroral administration,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL624101,10338
,50597,N,1,In vivo,,,6874,,Oral bioavailability in rat (male Wistar),1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL624102,10339
,50597,N,1,In vivo,,,5633,,Oral bioavailability after administration (30 mg/kg) in rat; good,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL624103,10340
,50597,N,1,In vivo,,,5496,,Oral bioavailability at the dose of 2 mg/kg in rat,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL624104,10341
,50597,N,1,In vivo,,,2358,,Oral bioavailability determined in rats,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL624105,10342
,50597,N,1,In vivo,,,16456,,Oral bioavailability in rat (Sprague-Dawley) (male) (dose 50 mg/kg p.o.),1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL624106,10343
,50597,N,1,In vivo,,,5302,,Oral bioavailability in rat (dose single 10 mg/kg),1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL624107,10344
,50597,N,1,In vivo,,,5302,,Oral bioavailability in rat (dose single 10 mg/kg),1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL623943,10345
,50597,N,1,In vivo,,,5302,,Oral bioavailability in rat (dose 5 mg/kg,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL623944,10346
,50597,N,1,,,,11020,,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Hippocampus HVA; below the levels of detection,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL623945,10347
,50597,N,1,,,,11020,,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Hippocampus NE,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL623946,10348
,50597,N,1,,,,11020,,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Frontal cortex 5-HIAA,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL623947,10349
,50597,N,1,,,,11020,,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Frontal cortex 5-HT,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL623948,10350
,50597,N,1,,,,11020,,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Frontal cortex DA,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL623949,10351
,50597,N,1,,,,11020,,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Frontal cortex DOPAC,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL623950,10352
,50597,N,1,,,,11020,,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Frontal cortex HVA,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL874398,10353
,50597,N,1,,,,11020,,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Frontal cortex NE,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL623951,10354
,50597,N,1,,,,11020,,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Hippocampus 5-HIAA,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL623952,10355
,50597,N,1,,,,11020,,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Hippocampus 5-HT,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL623953,10356
,50597,N,1,,,,11020,,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Hippocampus DA; below level of detection,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL623954,10357
,50597,N,1,,,,11020,,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Hippocampus DA; below the levels of detection,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL623955,10358
,50597,N,1,,,,11020,,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Hippocampus DOPAC; below level of detection,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL623956,10359
,50597,N,1,,,,11020,,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Hippocampus DOPAC; below the levels of detection,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL627807,10360
,50597,N,1,,,,11020,,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Hippocampus HVA; below level of detection,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL627808,10361
,50597,N,1,,,,11020,,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Hippocampus HVA; below the levels of detection,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL627809,10362
,50597,N,1,,,,11020,,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Hippocampus NE,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL627810,10363
,50597,N,1,,,,11020,,"Momoamine and metabolic levels observed at 3 hr postdrug against, at a dose of 20 mg/kg Frontal cortex 5-HIAA",1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL627811,10364
,50597,N,1,,,,11020,,"Momoamine and metabolic levels observed at 3 hr postdrug against, at a dose of 20 mg/kg Frontal cortex 5-HT",1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL627812,10365
,50597,N,1,,,,11020,,"Momoamine and metabolic levels observed at 3 hr postdrug against, at a dose of 20 mg/kg Frontal cortex DA",1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL627813,10366
,50597,N,1,,,,11020,,"Momoamine and metabolic levels observed at 3 hr postdrug against, at a dose of 20 mg/kg Frontal cortex DOPAC",1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL627814,10367
,50597,N,1,,,,11020,,"Momoamine and metabolic levels observed at 3 hr postdrug against, at a dose of 20 mg/kg Frontal cortex HVA",1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL875336,10368
,50597,N,1,,,,11020,,"Momoamine and metabolic levels observed at 3 hr postdrug against, at a dose of 20 mg/kg Frontal cortex NE",1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL627815,10369
,50597,N,1,,,,11020,,"Momoamine and metabolic levels observed at 3 hr postdrug against, at a dose of 20 mg/kg Hippocampus 5-HIAA",1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL627816,10370
,50597,N,1,,,,11020,,"Momoamine and metabolic levels observed at 3 h postdrug against, at a dose of 20 mg/kg Hippocampus 5-HT",1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL627817,10371
,50597,N,1,,,,11020,,"Momoamine and metabolic levels observed at 3 hr postdrug against, at a dose of 20 mg/kg Hippocampus DA; below the levels of detection",1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL627818,10372
,50597,N,1,,,,11020,,"Momoamine and metabolic levels observed at 3 hr postdrug against, at a dose of 20 mg/kg Hippocampus DOPAC; below the levels of detection",1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL627819,10373
,50597,N,1,,,,11020,,"Momoamine and metabolic levels observed at 3 hr postdrug against, at a dose of 20 mg/kg Hippocampus HVA; below the levels of detection",1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL627820,10374
,50597,N,1,,,,11020,,"Momoamine and metabolic levels observed at 3 hr postdrug against, at a dose of 20 mg/kg Hippocampus NE",1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL627821,10375
,50597,N,1,,,,11020,,Momoamine and metabolic levels observed at 3 hr postdrug against at a dose of 20 mg/kg Frontal cortex 5-HIAA,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL628464,10376
,50597,N,1,,,,11020,,Momoamine and metabolic levels observed at 3 hr postdrug against at a dose of 20 mg/kg Frontal cortex 5-HT,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL626239,10377
,50597,N,1,,,,11020,,Momoamine and metabolic levels observed at 3 hr postdrug against at a dose of 20 mg/kg Frontal cortex DA,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL626240,10378
,50597,N,1,,,,11020,,Momoamine and metabolic levels observed at 3 h postdrug against at a dose of 20 mg/kg Frontal cortex DOPAC,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL626241,10379
,50597,N,1,,,,11020,,Momoamine and metabolic levels observed at 3 hr postdrug against at a dose of 20 mg/kg Frontal cortex HVA,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL626242,10380
,50597,N,1,,,,11020,,Momoamine and metabolic levels observed at 3 hr postdrug against at a dose of 20 mg/kg Frontal cortex NE,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL626243,10381
,50597,N,1,,,,11020,,Momoamine and metabolic levels observed at 3 hr postdrug against at a dose of 20 mg/kg Hippocampus 5-HIAA,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL626244,10382
,50597,N,1,,,,11020,,Momoamine and metabolic levels observed at 3 hr postdrug against at a dose of 20 mg/kg Hippocampus 5-HT; below level of detection,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL626907,10383
,50597,N,1,,,,11020,,Momoamine and metabolic levels observed at 3 hr postdrug against at a dose of 20 mg/kg Hippocampus DA; below level of detection,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL626908,10384
,50597,N,1,,,,11020,,Momoamine and metabolic levels observed at 3 hr postdrug against at a dose of 20 mg/kg Hippocampus DOPAC; below level of detection,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL626909,10385
,50597,N,1,,,,11020,,Momoamine and metabolic levels observed at 3 hr postdrug against at a dose of 20 mg/kg Hippocampus HVA; below level of detection,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL626910,10386
,50597,N,1,,,,7449,,Percent total excretion of acetaminophen cysteine conjugate,1,Rattus norvegicus,Intermediate,,,,10116.0,,,F,BAO_0000218,CHEMBL875342,10387
,50597,N,1,,,,7449,,Percent total excretion of acetaminophen glucuronide,1,Rattus norvegicus,Intermediate,,,,10116.0,,,F,BAO_0000218,CHEMBL626911,10388
,50597,N,1,,,,7449,,Percent total excretion of acetaminophen sulfate,1,Rattus norvegicus,Intermediate,,,,10116.0,,,F,BAO_0000218,CHEMBL626912,10389
,50597,N,1,,,,7449,,Percent total excretion of acetaminophen-mercapturic acid,1,Rattus norvegicus,Intermediate,,,,10116.0,,,F,BAO_0000218,CHEMBL627065,10390
Urine,50597,N,1,,,,3172,,Amount of urine output was measured in rat at a dose of 10 mg/kg administered orally,1,Rattus norvegicus,Intermediate,,,,10116.0,,1088.0,A,BAO_0000218,CHEMBL627066,10391
,50597,N,1,In vivo,,,16456,,Volume of distribution in Male Sprague-Dawley rats after intravenous administration at a dose of 10 mg/kg,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL627067,10392
Muscle tissue,22224,U,0,In vivo,,,10839,,Biodistribution of compound in rat muscle after 5 min of administration,1,ratrat,Autocuration,,,,8656.0,,2385.0,A,BAO_0000218,CHEMBL627068,10393
Muscle tissue,22224,U,0,In vivo,,,10839,,Biodistribution of compound in rat muscle after 5 min of administration.,1,ratrat,Autocuration,,,,8656.0,,2385.0,A,BAO_0000218,CHEMBL627069,10394
,22224,U,0,In vivo,,,5334,,Plasma clearance was reported after intravenous administration at a dose of 1 mg/kg in Abraham sheep (female),1,Ovis aries,Autocuration,,,,9940.0,,,A,BAO_0000218,CHEMBL627070,10395
,22224,U,0,In vivo,,,5334,,Plasma clearance was reported after oral administration at a dose of 2 mg/kg in Abraham sheep (female),1,Ovis aries,Autocuration,,,,9940.0,,,A,BAO_0000218,CHEMBL627071,10396
,22224,U,0,In vivo,,,5334,,Bioavailability was reported after intravenous administration at a dose of 1 mg/kg in Abraham sheep (female),1,Ovis aries,Autocuration,,,,9940.0,,,A,BAO_0000218,CHEMBL627072,10397
,22224,U,0,In vivo,,,5334,,Bioavailability was reported after oral administration at a dose of 2 mg/kg in Abraham sheep (female),1,Ovis aries,Autocuration,,,,9940.0,,,A,BAO_0000218,CHEMBL627073,10398
,22224,U,0,In vivo,,,5334,,Volume of distribution was reported after intravenous administration at a dose of 1 mg/kg in Abraham sheep (female),1,Ovis aries,Autocuration,,,,9940.0,,,A,BAO_0000218,CHEMBL625387,10399
,22224,U,0,In vivo,,,5334,,Volume of distribution was reported after oral administration at a dose of 2 mg/kg in Abraham sheep (female),1,Ovis aries,Autocuration,,,,9940.0,,,A,BAO_0000218,CHEMBL625388,10400
Plasma,22224,U,0,In vivo,,,5334,,Plasma half-life period (0-8 h) was reported after intravenous administration at a dose of 1 mg/kg in Abraham sheep (female),1,Ovis aries,Autocuration,,,,9940.0,,1969.0,A,BAO_0000218,CHEMBL625389,10401
Plasma,22224,U,0,In vivo,,,5334,,Plasma half-life period (0-8 h) was reported after oral administration at a dose of 2 mg/kg in Abraham sheep (female),1,Ovis aries,Autocuration,,,,9940.0,,1969.0,A,BAO_0000218,CHEMBL875343,10402
,50497,N,1,,,,1735,,Biological half life period of compound was measured against snake venom phosphodiesterase (SVPDE),1,Serpentes,Intermediate,,,,8570.0,,,A,BAO_0000218,CHEMBL876795,10403
,50497,N,1,,,,1469,,Half life (t) of enzymatic phosphodiester hydrolysis of compound towards snake venom (SV-PDE) at a concentration of 4 microg,1,Serpentes,Intermediate,,,,8570.0,,,A,BAO_0000218,CHEMBL626552,10404
,50497,N,1,,,,1336,,Enzymatic stability was assessed with snake venom phosphodiesterase (SV PDE) exonuclase,1,Serpentes,Intermediate,,,,8570.0,,,A,BAO_0000218,CHEMBL626553,10405
Plasma,22224,U,0,,,,12403,,The human biological plasma half life of the compound,1,Homo sapiens,Autocuration,,,,9606.0,,1969.0,A,BAO_0000366,CHEMBL626554,10406
Urine,50597,N,1,,,,8151,,Antidiuretic activity was determined expressed as volume of urine excreted in mL was reported at a dose of 100 mg/Kg,1,Rattus norvegicus,Intermediate,,,,10116.0,,1088.0,A,BAO_0000218,CHEMBL626555,10407
,50597,N,1,,,,8004,,Distribution of Se-75 activity in Adrenal of female Sprague-Dawley Rat 120 min after iv administration compound,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL626556,10408
,50597,N,1,,,,8004,,Distribution of Se-75 activity in Adrenal of female Sprague-Dawley Rat 15 after iv administration of compound,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL626557,10409
,50597,N,1,,,,8004,,Distribution of Se-75 activity in Adrenal of female Sprague-Dawley Rat 240 min after iv administration compound,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL626558,10410
,50597,N,1,,,,8004,,Distribution of Se-75 activity in Adrenal of female Sprague-Dawley Rat 30 min after iv administration of compound,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL626559,10411
,50597,N,1,,,,8004,,Distribution of Se-75 activity in Adrenal of female Sprague-Dawley Rat 5 min after iv administration of compound,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL626560,10412
,50597,N,1,,,,8004,,Distribution of Se-75 activity in Adrenal of female Sprague-Dawley Rat 60 min after iv administration of compound,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL876803,10413
,50597,N,1,,,,8004,,Distribution of Se-75 activity in Heart of female Sprague-Dawley Rat 120 min after iv administration compound,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL627964,10414
,50597,N,1,,,,8004,,Distribution of Se-75 activity in Heart of female Sprague-Dawley Rat 15 min after iv administration of compound,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL627965,10415
,50597,N,1,,,,8004,,Distribution of Se-75 activity in Heart of female Sprague-Dawley Rat 240 min after iv administration compound,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL627966,10416
,50597,N,1,,,,8004,,Distribution of Se-75 activity in Heart of female Sprague-Dawley Rat 30 min after iv administration of compound,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL627967,10417
,50597,N,1,,,,8004,,Distribution of Se-75 activity in Heart of female Sprague-Dawley Rat 5 min after iv administration of compound,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL627968,10418
,50597,N,1,,,,8004,,Distribution of Se-75 activity in Heart of female Sprague-Dawley Rat 60 min after iv administration of compound,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL627969,10419
,50597,N,1,,,,8004,,Distribution of Se-75 activity in Liver of female Sprague-Dawley Rat 5 min after iv administration of compound,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL627970,10420
Blood,50597,N,1,,,,8004,,Distribution of Se-75 activity in blood of female Sprague-Dawley Rat 120 min after iv administration of compound,1,Rattus norvegicus,Intermediate,,,,10116.0,,178.0,A,BAO_0000218,CHEMBL627971,10421
Blood,50597,N,1,,,,8004,,Distribution of Se-75 activity in blood of female Sprague-Dawley Rat 240 min after iv administration of compound,1,Rattus norvegicus,Intermediate,,,,10116.0,,178.0,A,BAO_0000218,CHEMBL627972,10422
,180,D,9,,,,15917,,Dissociation constant against binding to human cyclophilin A,1,Homo sapiens,Expert,,,,9606.0,,,B,BAO_0000357,CHEMBL856029,10423
,11591,H,8,,,,12396,,Michaelis-Menten constant for inhibitory activity against bovine liver glyoxalase II,1,Bos taurus,Expert,,,,9913.0,,,B,BAO_0000019,CHEMBL627973,10424
,22224,U,0,,,,7065,,-Log C was determined by performing the electroshock minimum test,1,,Autocuration,,,,,,,A,BAO_0000019,CHEMBL627974,10425
,22224,U,0,,,,7065,,-Log C was determined by performing the foot shock test,1,,Autocuration,,,,,,,A,BAO_0000019,CHEMBL627975,10426
,22224,U,0,,,,7065,,-Log C was determined by performing the incl screen test,1,,Autocuration,,,,,,,A,BAO_0000019,CHEMBL627976,10427
,22224,U,0,,,,7065,,-Log C was determined by performing the maximum electroshock test,1,,Autocuration,,,,,,,A,BAO_0000019,CHEMBL627977,10428
,22224,U,0,,,,7065,,-Log C was determined by performing the pentylenetetrazole test,1,,Autocuration,,,,,,,A,BAO_0000019,CHEMBL627978,10429
,22224,U,0,,,,12415,,Tested for experimental arotinoid inhibitory dose,1,,Autocuration,,,,,,,A,BAO_0000019,CHEMBL627979,10430
,22224,U,0,,,,10256,,Negative log transformed activity,1,,Autocuration,,,,,,,A,BAO_0000019,CHEMBL876804,10431
,22224,U,0,,,,7991,,"Negative log of Langmuir's alpha constant (-log alpha), which is inversely proportional to the effective binding constant (protein binding)",1,,Autocuration,,,,,,,A,BAO_0000019,CHEMBL627980,10432
,50512,N,1,,,,14342,,Dissociation constant was evaluated on guinea pig bladder at M3 muscarinic receptor,1,Cavia porcellus,Intermediate,,,,10141.0,,,A,BAO_0000218,CHEMBL627981,10433
,50512,N,1,,,,14342,,Dissociation constant was evaluated on guinea pig heart (force) at M2 muscarinic receptor,1,Cavia porcellus,Intermediate,,,,10141.0,,,A,BAO_0000218,CHEMBL627982,10434
,50512,N,1,,,,14342,,Dissociation constant was evaluated on guinea pig heart (rate) at M2 muscarinic receptor,1,Cavia porcellus,Intermediate,,,,10141.0,,,A,BAO_0000218,CHEMBL627983,10435
Ileum,50512,N,1,,,,14342,,Dissociation constant was evaluated on guinea pig ileum at M3 muscarinic receptor,1,Cavia porcellus,Intermediate,,,,10141.0,,2116.0,A,BAO_0000218,CHEMBL627984,10436
,22229,U,0,,,,6047,,Solubility in water was determined; values expressed as -log,1,,Autocuration,,,,,,,P,BAO_0000100,CHEMBL627985,10437
,22224,U,0,,,,17269,,Ratio of Kcat to that of Km was determined,1,,Autocuration,,,,,,,A,BAO_0000019,CHEMBL627986,10438
,22224,U,0,,,,10026,,Observed first order rate constant,1,,Autocuration,,,,,,,A,BAO_0000019,CHEMBL627987,10439
,22224,U,0,,,,14583,,Fraction of 88Y (%) released from chelate after incubation in serum for 15 hours,1,,Autocuration,,,,,,,A,BAO_0000019,CHEMBL627988,10440
,50597,N,1,In vivo,,,2661,,Compound was evaluated for bioavailability after treatment with oral dose of 2 mgkg to female wistar rats,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL627989,10441
,50597,N,1,In vivo,,,2661,,Compound was evaluated for bioavailability after treatment with oral dose of 2 mgkg to male wistar rats,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL627990,10442
,50597,N,1,In vivo,,,4029,,Oral Bioavailability after administration of 10 mg/kg in male rat,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL876805,10443
,50597,N,1,In vivo,,,17735,,Oral bioavailability in rat (dose 10 mg/kg i.v. and 50 mg/kg p.o.),1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL627991,10444
,50597,N,1,In vivo,,,4576,,Oral bioavailability in rat,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL627992,10445
,50597,N,1,In vivo,,,17582,,Oral bioavailability after oral (po) administration at a dose of 10 mg/kg was measured in rats,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL627993,10446
,50597,N,1,In vivo,,,17651,,Oral bioavailability at 1 mg/kg was determined in rat,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL622817,10447
,50597,N,1,In vivo,,,17651,,Oral bioavailability at 10 mg/kg was determined in rat,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL622818,10448
,50597,N,1,In vivo,,,17670,,"Oral bioavailability in fischer rats at 30 mg/kg dose, administered perorally",1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL622819,10449
,50597,N,1,In vivo,,,5045,,Oral bioavailability in rat,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL872267,10450
,50597,N,1,In vivo,,,1696,,Oral bioavailability in rat,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL622820,10451
,50597,N,1,In vivo,,,17764,,Oral bioavailability after intravenous administration in rats at 24 uM/kg,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL622821,10452
,50597,N,1,In vivo,,,6448,,Oral bioavailability in rat,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL622822,10453
,50597,N,1,In vivo,,,6596,,Oral bioavailability in rat,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL622823,10454
,50597,N,1,In vivo,,,17547,,Oral bioavailability in rat,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL622824,10455
,50597,N,1,In vivo,,,17771,,Oral bioavailability in rat at a dose of 3 mg/kg,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL622825,10456
,50597,N,1,In vivo,,,6495,,Oral bioavailability in rat after oral administration at 10 mg/kg,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL622901,10457
,50597,N,1,In vivo,,,4558,,Oral bioavailability in rat,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL622902,10458
,50597,N,1,In vivo,,,17596,,Oral bioavailability in rat,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL621844,10459
,50597,N,1,In vivo,,,6827,,Oral bioavailability in Dawley rats,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL621845,10460
,50597,N,1,In vivo,,,4026,,Oral bioavailability,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL621846,10461
,50597,N,1,In vivo,,,10,,Oral bioavailability in rat (dose 30 mg/kg),1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL621847,10462
,50597,N,1,In vivo,,,17717,,Bioavailability in rat at a concentration of 15 mg/kg perorally in rat along with 100 mg/kg 11,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL877609,10463
,50597,N,1,In vivo,,,17717,,Bioavailability in rat (dose 3 mg/kg i.v.),1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL621848,10464
,50597,N,1,In vivo,,,17717,,Bioavailability in rat at a concentration of 60 mg/kg perorally in rat along with 100 mg/kg 11,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL621849,10465
,50597,N,1,In vivo,,,17717,,Oral bioavailability in rat (dose 60 mg/kg p.o.),1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL622030,10466
,50597,N,1,In vivo,,,4796,,Percent oral bioavailability determined in rats,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL622031,10467
,50597,N,1,In vivo,,,4883,,Tested for percent bioavailability after oral administration to Sprague-Dawley rat at dosage of 0.2 mg/kg,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL622032,10468
,50597,N,1,In vivo,,,2137,,The compound was evaluated for bioavailability in rats; 32-51,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL622033,10469
,50597,N,1,In vivo,,,2959,,Bioavailability in rat (dose 20 mg/kg p.o.),1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL622034,10470
,50597,N,1,In vivo,,,1361,,Oral bioavailability in rat,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL622035,10471
,50597,N,1,In vivo,,,4727,,Bioavailability percent in rat at the dose of 2 mg/kg,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL882966,10472
,50597,N,1,In vivo,,,16423,,Bioavailability was evaluated after 20 uM/kg of peroral administration,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL622036,10473
,50597,N,1,In vivo,,,5206,,Oral bioavailability in rat,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL622037,10474
,50597,N,1,In vivo,,,6448,,Oral bioavailability in rat,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL622038,10475
,50597,N,1,In vivo,,,17723,,Bioavailability in rats,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL622039,10476
Blood,50597,N,1,In vivo,,,17738,,Biodistribution of radiolabeled compound in rat blood after 24 hr postinjection activity expressed as %ID/Organ,1,Rattus norvegicus,Intermediate,,,,10116.0,,178.0,A,BAO_0000218,CHEMBL622040,10477
Blood,50597,N,1,In vivo,,,17738,,Biodistribution of radiolabeled compound in rat blood after 24 hr activity expressed as %ID/Organ,1,Rattus norvegicus,Intermediate,,,,10116.0,,178.0,A,BAO_0000218,CHEMBL622041,10478
Blood,50597,N,1,In vivo,,,17738,,Biodistribution of radiolabeled compound in rat blood after 2 hr activity expressed as %ID/Organ,1,Rattus norvegicus,Intermediate,,,,10116.0,,178.0,A,BAO_0000218,CHEMBL622042,10479
Blood,50597,N,1,In vivo,,,17738,,Biodistribution of radiolabeled compound in rat blood after 30 min activity expressed as %ID/Organ,1,Rattus norvegicus,Intermediate,,,,10116.0,,178.0,A,BAO_0000218,CHEMBL622043,10480
Blood,50597,N,1,In vivo,,,17738,,Biodistribution of radiolabeled compound in rat blood after 5 min activity expressed as %ID/Organ,1,Rattus norvegicus,Intermediate,,,,10116.0,,178.0,A,BAO_0000218,CHEMBL622044,10481
Bone,50597,N,1,In vivo,,,17738,,Biodistribution of radiolabeled compound in rat bone after 24 hr activity expressed as %ID/Organ,1,Rattus norvegicus,Intermediate,,,,10116.0,,10000001.0,A,BAO_0000218,CHEMBL622045,10482
Bone,50597,N,1,In vivo,,,17738,,Biodistribution of radiolabeled compound in rat bone after 2 hr activity expressed as %ID/Organ,1,Rattus norvegicus,Intermediate,,,,10116.0,,10000001.0,A,BAO_0000218,CHEMBL622046,10483
Bone,50597,N,1,In vivo,,,17738,,Biodistribution of radiolabeled compound in rat bone after 30 min activity expressed as %ID/Organ,1,Rattus norvegicus,Intermediate,,,,10116.0,,10000001.0,A,BAO_0000218,CHEMBL622047,10484
Bone,50597,N,1,In vivo,,,17738,,Biodistribution of radiolabeled compound in rat bone after 5 min activity expressed as %ID/Organ,1,Rattus norvegicus,Intermediate,,,,10116.0,,10000001.0,A,BAO_0000218,CHEMBL877610,10485
Brain,50597,N,1,In vivo,,,17738,,Biodistribution of radiolabeled compound in rat brain after 24 hr activity expressed as %ID/Organ,1,Rattus norvegicus,Intermediate,,,,10116.0,,955.0,A,BAO_0000218,CHEMBL622048,10486
Brain,50597,N,1,In vivo,,,17738,,Biodistribution of radiolabeled compound in rat brain after 2 hr activity expressed as %ID/Organ,1,Rattus norvegicus,Intermediate,,,,10116.0,,955.0,A,BAO_0000218,CHEMBL622049,10487
Brain,50597,N,1,In vivo,,,17738,,Biodistribution of radiolabeled compound in rat brain after 30 min activity expressed as %ID/Organ,1,Rattus norvegicus,Intermediate,,,,10116.0,,955.0,A,BAO_0000218,CHEMBL622050,10488
Brain,50597,N,1,In vivo,,,17738,,Biodistribution of radiolabeled compound in rat brain after 5 min activity expressed as %ID/Organ,1,Rattus norvegicus,Intermediate,,,,10116.0,,955.0,A,BAO_0000218,CHEMBL622051,10489
,50597,N,1,In vivo,,,17738,,Biodistribution of radiolabeled compound in rat fat after 24 hr activity expressed as %ID/Organ,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL622052,10490
,50597,N,1,In vivo,,,17738,,Biodistribution of radiolabeled compound in rat fat after 2 hr activity expressed as %ID/Organ,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL622053,10491
,50597,N,1,In vivo,,,17738,,Biodistribution of radiolabeled compound in rat fat after 30 min activity expressed as %ID/Organ,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL622054,10492
,50597,N,1,In vivo,,,17738,,Biodistribution of radiolabeled compound in rat fat after 5 min activity expressed as %ID/Organ,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL622055,10493
,50597,N,1,In vivo,,,5237,,Oral bioavailability in rats was determined; High,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL622056,10494
,50597,N,1,In vivo,,,5503,,Oral bioavailability in the rat was determined,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL622057,10495
,50597,N,1,In vivo,,,15765,,Oral bioavailability measured by the ratio of intravenous to oral area under concentration.,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL628008,10496
,50597,N,1,In vivo,,,15660,,Oral bioavailability in rat (dose 10 mg/kg p.o. and 3 mg/kg i.v.),1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL622058,10497
,50597,N,1,In vivo,,,5978,,Oral bioavailability of compound (19.2 mg/kg) after po administration was determined in Sprague-Dawley rat,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL622059,10498
,50597,N,1,In vivo,,,5978,,Oral bioavailability of compound (19.76 mg/kg) after po administration was determined in Sprague-Dawley rat,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL622060,10499
,50597,N,1,In vivo,,,5978,,Oral bioavailability of compound (20.73 mg/kg) after po administration was determined in Sprague-Dawley rat,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL622061,10500
,50597,N,1,In vivo,,,5978,,Oral bioavailability of compound (25 mg/kg) after po administration was determined in Sprague-Dawley rat,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL622062,10501
,50597,N,1,In vivo,,,5656,,Oral bioavailability of compound at a dose of 20 mg/kg was determined after oral administration in rat,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL622063,10502
,50597,N,1,In vivo,,,3598,,Oral bioavailability of compound determined in rat after iv administration at a dose of 10 mg/kg,1,Rattus norvegicus,Expert,,,,10116.0,,,A,BAO_0000218,CHEMBL877611,10503
,50597,N,1,In vivo,,,4216,,Oral bioavailability of compound in Sprague Dawley rats,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL622064,10504
,50597,N,1,In vivo,,,17839,,Oral bioavailability of compound in rat,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL622065,10505
,50597,N,1,In vivo,,,6570,,Oral bioavailability in rat (dose 2 mg/kg),1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL622066,10506
,50597,N,1,In vivo,,,5334,,Oral bioavailability of compound in rat was determined,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL622067,10507
,50597,N,1,In vivo,,,6886,,Oral bioavailability of compound in rats,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL622068,10508
,50597,N,1,In vivo,,,5210,,Oral bioavailability of compound was determined in rats,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL622069,10509
,50597,N,1,In vivo,,,4170,,Oral bioavailability at a dose of 30 mg/kg in rats,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL624796,10510
,50597,N,1,In vivo,,,6028,,Oral bioavailability in rat (dose 10 mg/kg),1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL624797,10511
,50597,N,1,In vivo,,,6028,,Oral bioavailability in rat (dose 10 mg/kg),1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL623053,10512
,50597,N,1,In vivo,,,6078,,Oral bioavailability evaluated in rat,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL623054,10513
,50597,N,1,In vivo,,,6168,,Oral bioavailability in fasted rat,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL623055,10514
,50597,N,1,In vivo,,,6168,,Oral bioavailability in fed rat,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL623056,10515
,50597,N,1,In vivo,,,5160,,Oral bioavailability in rat (mature male) (dose 30 mg/kg),1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL623057,10516
,50597,N,1,In vivo,,,6057,,Oral bioavailability in rat,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL623058,10517
,50597,N,1,In vivo,,,6535,,Oral bioavailability in rat (dose 10 mg/kg p.o.),1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL623059,10518
,50597,N,1,In vivo,,,6535,,Oral bioavailability in rat after administration of 10 mg/kg po,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL623060,10519
,50597,N,1,In vivo,,,4194,,Oral bioavailability in rat,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL623061,10520
,50597,N,1,In vivo,,,6230,,Oral bioavailability in rat,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL623062,10521
,50597,N,1,In vivo,,,6619,,Oral bioavailability in rat,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL623063,10522
,50597,N,1,In vivo,,,17607,,Oral bioavailability in rat,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL623064,10523
,50597,N,1,In vivo,,,4942,,Oral bioavailability in ratrs,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL623065,10524
,50597,N,1,In vivo,,,4942,,Oral bioavailability in rat,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL623066,10525
,50597,N,1,In vivo,,,6646,,Oral bioavailability in rat,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL623067,10526
,50597,N,1,In vivo,,,5237,,Oral bioavailability in rats was determined; High,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL623068,10527
,50597,N,1,In vivo,,,6646,,Oral bioavailability in rat,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL623069,10528
,50597,N,1,In vivo,,,4449,,Oral bioavailability in rat,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL623070,10529
,50597,N,1,In vivo,,,6057,,Oral bioavailability was calculated in rat,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL623071,10530
,50597,N,1,In vivo,,,2552,,Oral bioavailability,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL623072,10531
,50597,N,1,In vivo,,,5496,,Oral bioavailability,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL623073,10532
,50597,N,1,In vivo,,,6484,,Oral bioavailability,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL623074,10533
,50597,N,1,In vivo,,,6485,,Oral bioavailability,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL623075,10534
,50597,N,1,In vivo,,,6616,,Oral bioavailability after i.v. administration,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL623076,10535
,50597,N,1,In vivo,,,4969,,Oral bioavailability in rat (Sprague-Dawley) (dose 1 mg/kg i.v.),1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL623077,10536
,50597,N,1,In vivo,,,5862,,Oral bioavailability in rat (Sprague-Dawley),1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL623078,10537
,50597,N,1,In vivo,,,4514,,Oral bioavailability in Sprague-Dawley rats,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL623079,10538
,50597,N,1,In vivo,,,4514,,Oral bioavailability in rat (Sprague-Dawley) (dose 1 mg/kg i.v.),1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL623080,10539
,50597,N,1,In vivo,,,4514,,Oral bioavailability in rat (Sprague-Dawley) (dose 2 mg/kg),1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL623081,10540
,50597,N,1,In vivo,,,5546,,Oral bioavailability in Sprague-Dawley rats at a dose of 2 mg/kg by po administration,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL623082,10541
,50597,N,1,In vivo,,,6168,,Oral bioavailability in fasted rat,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL874400,10542
,50597,N,1,In vivo,,,6168,,Oral bioavailability in fed rat,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL623083,10543
,50597,N,1,In vivo,,,3624,,Oral bioavailability in rat,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL623084,10544
,50597,N,1,In vivo,,,5213,,Oral bioavailability in rat,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL623085,10545
,50597,N,1,In vivo,,,5496,,Oral bioavailability in rat,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL623086,10546
,50597,N,1,In vivo,,,5553,,Oral bioavailability in rat,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL623087,10547
,50597,N,1,In vivo,,,5833,,Oral bioavailability in rat,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL623088,10548
,50597,N,1,In vivo,,,5836,,Oral bioavailability in rat,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL623089,10549
,50597,N,1,In vivo,,,5865,,Oral bioavailability in rat,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL623090,10550
,50597,N,1,In vivo,,,5960,,Oral bioavailability in rat,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL623091,10551
,50597,N,1,In vivo,,,6249,,Oral bioavailability in rat,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL623092,10552
,50597,N,1,In vivo,,,6448,,Oral bioavailability in rat,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL623093,10553
,50597,N,1,In vivo,,,6453,,Oral bioavailability in rat,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL874401,10554
,50597,N,1,In vivo,,,6640,,Oral bioavailability in rat,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL623094,10555
,50597,N,1,In vivo,,,17607,,Oral bioavailability in rat,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL623095,10556
,50597,N,1,In vivo,,,5939,,Oral bioavailability in rat after peroral administration at 10 mg/kg,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL623096,10557
,50597,N,1,In vivo,,,5939,,Oral bioavailability in rat after peroral administration at 5 mg/kg,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL624913,10558
,50597,N,1,In vivo,,,6281,,Oral bioavailability in rat (dose 2.8 mg/kg p.o.),1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL624914,10559
,50597,N,1,In vivo,,,5874,,Oral bioavailability in rat by po administration at a dose of 40 mg/kg,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL624915,10560
,50597,N,1,In vivo,,,5213,,Oral bioavailability in rat; Not measured,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL624916,10561
,50597,N,1,In vivo,,,4964,,Oral bioavailability in rat,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL624917,10562
,50597,N,1,,,,11020,,Momoamine and metabolic levels observed at 3 hr postdrug against at a dose of 20 mg/kg Hippocampus NE,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL625157,10563
Liver,50597,N,1,,,,6251,,In vitro metabolic potential in rat liver microsomes,1,Rattus norvegicus,Intermediate,,,,10116.0,,2107.0,A,BAO_0000218,CHEMBL625158,10564
,50597,N,1,In vivo,,,1568,,"Oral availability was tested for plasma levels at a dose of 40 mg/kg, after 6 hr of in fed fisher rats.",1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL625159,10565
,50597,N,1,In vivo,,,3032,,"In vivo percentage mean absolute bioavailability of compound in rat after an oral dose of 10 mg/kg (in water, N=4)",1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL625160,10566
,50597,N,1,In vivo,,,3748,,Oral bioavailability of intravenously administered compound (3 mg/kg) was tested in rats,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL625161,10567
,50597,N,1,In vivo,,,401,,Oral bioavailability in rat,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL625162,10568
,50597,N,1,In vivo,,,6512,,Oral bioavailability in rat,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL625163,10569
,50597,N,1,In vivo,,,17617,,Oral bioavailability in rats at 10 mg/kg,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL625164,10570
,50597,N,1,In vivo,,,6679,,Oral bioavailability was determined after 1 mg/kg (i.v.) / 2 mg/kg (p.o.) of compound administration,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL625165,10571
,50597,N,1,In vivo,,,6742,,Oral bioavailability in rat,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL625166,10572
,50597,N,1,,,,589,,Tested for effective permeability across the rat intestinal membrane using mass balance analysis,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL625167,10573
,50597,N,1,,,,589,,Tested for effective permeability across the rat intestinal membrane using mass balance analysis at 0.01 mM concentration,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL625168,10574
,50597,N,1,In vivo,,,3185,,Plasma clearance of the compound,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL625169,10575
,50597,N,1,In vivo,,,17596,,Plasma clearance at 10 mg/kg in rat upon intravenous administration,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL626264,10576
,50597,N,1,In vivo,,,2713,,Plasma clearance upon intravenous administration of 1 mg/Kg in rats,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL626265,10577
Plasma,50597,N,1,In vivo,,,12500,,The compound was tested for plasma clearance in rat,1,Rattus norvegicus,Intermediate,,,,10116.0,,1969.0,A,BAO_0000218,CHEMBL626266,10578
Plasma,50597,N,1,In vivo,,,12500,,The compound was tested for plasma clearance in rat at dose of 3-10 mgkg,1,Rattus norvegicus,Intermediate,,,,10116.0,,1969.0,A,BAO_0000218,CHEMBL626267,10579
,50597,N,1,,,,2713,,Plasma concentration upon oral administration of 1 mg/Kg in rats,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL626268,10580
,50597,N,1,,,,1446,,Peak plasma level between 0.5 and 1.0 hour in Dawley rats; value ranges from 1021-2551,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL626269,10581
,50597,N,1,,,,6227,,Plasma level after intravenous administration in rat model of FeCl3-induced carotid thrombosis,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL626270,10582
,50597,N,1,,,,4709,,Plasma protein binding was determined after intravenous administration of 1 mg/kg in rat,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL626271,10583
,50597,N,1,,,,5510,,"Rat plasma cleavage data expressed as percentage of compound remains at 24 hr in PEG400/Water, 1:1",1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL626272,10584
,50597,N,1,,,,5510,,"Rat plasma cleavage data expressed as percentage of compound remains at 24 hr in PEG400/Water, 1:1; Not determined",1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL626273,10585
,50597,N,1,,,,5510,,"Rat plasma cleavage data expressed as percentage of compound remains at 24 hr in PEG400/Water, 1:1; Not determined",1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL875346,10586
,50597,N,1,,,,5510,,"Rat plasma cleavage data expressed as percentage of compound remains at 24 hr in PEG400/Water, 1:1; Not stable",1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL626274,10587
,50597,N,1,,,,4514,,Compound was tested for protein binding in rat plasma,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL626275,10588
,50597,N,1,,,,2713,,Compound was evaluated for absorption of radioligand following oral administration to bile duct cannulated rat. ,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL624646,10589
,50597,N,1,,,,2713,,Compound was evaluated for absorption of radioligand upon oral administration to bile duct cannulated rats,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL624647,10590
Liver,50597,N,1,,,,5340,,In vitro metabolism in rat liver microsomes was evaluated to determine diminishing of glucuronidation rate,1,Rattus norvegicus,Intermediate,,,,10116.0,,2107.0,A,BAO_0000218,CHEMBL624648,10591
,50597,N,1,,,,12058,,Area under curve ratio was determined (po/iv) in rat,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL624649,10592
,50597,N,1,,,,11195,,Blood by brain ratio of the radiolabeled compound (2-5 uCi) in rat 15 mins after i.v. administration,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL624650,10593
,50597,N,1,,,,11195,,Blood by brain ratio of the radiolabeled compound (2-5 uCi) in rat 2 mins after i.v. administration,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL624651,10594
,50597,N,1,,,,11195,,Blood by brain ratio of the radiolabeled compound (2-5 uCi) in rat 65 mins after i.v. administration,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL624652,10595
,50597,N,1,,,,6495,,Compound was tested for brain/plasma ratio after oral administration at 10 mg/kg,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL624653,10596
,50597,N,1,,,,6078,,Ratio of AUCbrain to AUCplasma,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL624654,10597
,50597,N,1,,,,5656,,Ratio of brain to plasma,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL624655,10598
,50597,N,1,,,,4910,,Ratio of the AUC values of brain and plasma after intravenous administration (4.7 mg/kg) to male rats was evaluated,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL624656,10599
,50597,N,1,,,,4910,,Ratio in brain and plasma after 0.25 hrs of intravenous administration (5 mg/kg) to male rats was evaluated,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL624657,10600
,50597,N,1,,,,4910,,Ratio in brain and plasma after 2 hrs of intravenous administration (5 mg/kg) to male rats was evaluated,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL624658,10601
,50597,N,1,,,,10130,,Selectivity ratio for biodistribution in brain and blood of rats after 15 minutes; Expressed as percent dose/gram ratio,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL624659,10602
,50597,N,1,,,,10130,,Selectivity ratio for biodistribution in brain and blood of rats after 2 minutes; Expressed as percent dose/gram ratio,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL624660,10603
,50597,N,1,,,,10130,,Selectivity ratio for biodistribution in brain and blood of rats after 60 minutes; Expressed as percent dose/gram ratio,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL624661,10604
,50597,N,1,,,,5213,,Steady state brain :blood ratio was determined,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL624662,10605
,50597,N,1,,,,4910,,Tested for ratio in brain and plasma after 0.25 hrs of intravenous administration (5 mg/kg) to male rats,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL625199,10606
,50597,N,1,,,,4910,,Tested for ratio in brain and plasma after 0.25 hrs of intravenous administration (5 mg/kg) to male rats; ND = not determined,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL625200,10607
,50597,N,1,,,,4910,,Tested for ratio in brain and plasma after 2 hrs of intravenous administration (5 mg/kg) to male rats,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL625201,10608
,50597,N,1,,,,4910,,Tested for ratio in brain and plasma after 2 hrs of intravenous administration (5 mg/kg) to male rats; ND = not determined,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL625202,10609
,50597,N,1,,,,2083,,Percentage recovery after 3h incubation with rat hapatocytes was determined,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL625203,10610
,50597,N,1,,,,2082,,Percentage recovery in rat hepatic microsomal fractions under oxidative conditions after 1 hour,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL625204,10611
,50597,N,1,,,,2082,,Percentage recovery in rhesus monkey hepatic microsomal fractions under oxidative conditions after 1 hour,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL625205,10612
,50597,N,1,,,,6351,,Recovery rate from urine and bile was determined after iv administration at 20 mg/kg in rats,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL625206,10613
,22224,U,0,,,,14583,,"Fraction of 88Y (%) released from chelate after incubation in serum for 15 hours; not measured, No site available for protein conjugation.",1,,Autocuration,,,,,,,A,BAO_0000019,CHEMBL625207,10614
,22224,U,0,,,,14583,,Fraction of 88Y (%) released from chelate after incubation in serum for 15 hours; not measured.,1,,Autocuration,,,,,,,A,BAO_0000019,CHEMBL625208,10615
,50587,N,1,,,,4608,,In vivo absorption in Caco-2 cell line monolayers was determined,1,Homo sapiens,Intermediate,,495.0,,9606.0,Caco-2,,A,BAO_0000218,CHEMBL625209,10616
,22229,U,0,,,,13668,,Calculated partition coefficient (clogP),1,,Autocuration,,,,,,,P,BAO_0000100,CHEMBL625210,10617
,50597,N,1,,,,5669,,Area under curve was determine after peroral administration at 10 mpk in Rat,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL625211,10618
,50797,N,1,,,,5669,,Area under curve was determine after peroral administration at 10 mpk in Rhesus,1,Macaca mulatta,Intermediate,,,,9544.0,,,A,BAO_0000218,CHEMBL625212,10619
,50597,N,1,,,,5669,,Area under curve was determine after peroral administration at 160 mpk in Rat,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL625213,10620
,50597,N,1,,,,5669,,Area under curve was determine after peroral administration at 20 mpk in Rat,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL625214,10621
,50597,N,1,,,,5669,,Area under curve was determine after peroral administration at 50 mpk in Rat,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL874542,10622
,22229,U,0,,,,6472,,Calculated partition coefficient (clogP) (AlogP),1,,Autocuration,,,,,,,P,BAO_0000100,CHEMBL625215,10623
,22224,U,0,,,,15106,,Activated partial thromboplastin time measured,1,,Autocuration,,,,,,,A,BAO_0000019,CHEMBL625216,10624
,22224,U,0,,,,15207,,Compound was evaluated for the aqueous solubility (AS) in mg/mL (Measured in 0.2 M phosphate buffer of pH 7.4),1,,Autocuration,,,,,,,P,BAO_0000100,CHEMBL625217,10625
,22224,U,0,,,,15207,,Compound was evaluated for the aqueous solubility (AS) in mg/mL (Measured in 0.2 M phosphate buffer of pH 7.4); ND=Not determined (AS mg/mL),1,,Autocuration,,,,,,,P,BAO_0000100,CHEMBL625218,10626
Plasma,50588,N,1,,,,13941,,AUC (Area under curve) was determined after intravenous administration at a dose 1 mg/kg in dog,1,Canis lupus familiaris,Intermediate,,,,9615.0,,1969.0,A,BAO_0000218,CHEMBL622864,10627
Plasma,50597,N,1,,,,13941,,AUC (Area under curve) was determined after intravenous administration at a dose 2 mg/kg in rat.,1,Rattus norvegicus,Intermediate,,,,10116.0,,1969.0,A,BAO_0000218,CHEMBL622865,10628
Plasma,50597,N,1,,,,13941,,AUC (Area under curve) was determined after peroral administration at a dose 10 mg/kg in rat.,1,Rattus norvegicus,Intermediate,,,,10116.0,,1969.0,A,BAO_0000218,CHEMBL622866,10629
Plasma,50588,N,1,,,,13941,,AUC (Area under curve) was determined after peroral administration at a dose 5 mg/kg in dog,1,Canis lupus familiaris,Intermediate,,,,9615.0,,1969.0,A,BAO_0000218,CHEMBL622867,10630
Plasma,50512,N,1,,,,15240,,AUC (ng h/mL) value after oral administration of 10 mg/kg in guinea pig.,1,Cavia porcellus,Intermediate,,,,10141.0,,1969.0,A,BAO_0000218,CHEMBL876808,10631
Brain,22224,U,0,,,,10655,,AUC in brain,1,,Autocuration,,,,,,955.0,A,BAO_0000019,CHEMBL627725,10632
Serum,22224,U,0,,,,10655,,AUC in serum,1,,Autocuration,,,,,,1977.0,A,BAO_0000019,CHEMBL627726,10633
Plasma,22224,U,0,,,,6504,,AUC was determined,1,,Autocuration,,,,,,1969.0,A,BAO_0000019,CHEMBL627727,10634
Plasma,22224,U,0,,,,10615,,AUC of the compound.,1,,Autocuration,,,,,,1969.0,A,BAO_0000019,CHEMBL627728,10635
Plasma,22224,U,0,,,,10353,,AUC value (0-4 hr),1,,Autocuration,,,,,,1969.0,A,BAO_0000019,CHEMBL627729,10636
Plasma,22224,U,0,,,,14907,,"AUC was measured from the graph plotted against blood plasma concentration and time at the dose of 150 uMol/kg,",1,,Autocuration,,,,,,1969.0,A,BAO_0000019,CHEMBL627730,10637
Plasma,22224,U,0,,,,14907,,AUC was measured from the graph plotted against blood plasma concentration and time at the dose of 300 uMol/kg,1,,Autocuration,,,,,,1969.0,A,BAO_0000019,CHEMBL627731,10638
Plasma,22224,U,0,,,,14907,,"AUC was measured from the graph plotted against blood plasma concentration and time at the dose of 300 uMol/kg,",1,,Autocuration,,,,,,1969.0,A,BAO_0000019,CHEMBL627732,10639
Plasma,22224,U,0,,,,14907,,"AUC was measured from the graph plotted against blood plasma concentration and time at the dose of 700 uMol/kg,",1,,Autocuration,,,,,,1969.0,A,BAO_0000019,CHEMBL627733,10640
Plasma,50597,N,1,,,,16359,,AUC(area under curve) was determined after intravenous administration in rats,1,Rattus norvegicus,Intermediate,,,,10116.0,,1969.0,A,BAO_0000218,CHEMBL627734,10641
Plasma,50597,N,1,,,,16359,,AUC(area under curve) was determined after oral administration in rats,1,Rattus norvegicus,Intermediate,,,,10116.0,,1969.0,A,BAO_0000218,CHEMBL627735,10642
Plasma,50512,N,1,,,,15240,,AUC(ng h/mL)values after oral administration of 10 mg/kg in guinea pig.,1,Cavia porcellus,Intermediate,,,,10141.0,,1969.0,A,BAO_0000218,CHEMBL627736,10643
Plasma,50597,N,1,,,,15240,,AUC(ng h/mL)values after oral administration of 10 mg/kg in rat.,1,Rattus norvegicus,Intermediate,,,,10116.0,,1969.0,A,BAO_0000218,CHEMBL876809,10644
,22224,U,0,,,,15469,,Area Under Curve after oral dosing of 100 uM/Kg,1,,Autocuration,,,,,,,A,BAO_0000019,CHEMBL627737,10645
,22224,U,0,,,,15469,,Area Under Curve after oral dosing of 30 uM/Kg,1,,Autocuration,,,,,,,A,BAO_0000019,CHEMBL627738,10646
,22224,U,0,,,,13520,,Area Under Curve was measured by ploting the graph between concentration verses time,1,,Autocuration,,,,,,,A,BAO_0000019,CHEMBL627739,10647
,50588,N,1,,,,17025,,Area under concentration-time curve of compound was determined in dog at 25 mg/kg orally,1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL626143,10648
,22224,U,0,,,,17025,,Area under concentration-time curve of compound was determined in monkey at 25 mg/kg orally,1,Simiiformes,Autocuration,,,,314293.0,,,A,BAO_0000218,CHEMBL626144,10649
,50592,N,1,,,,17025,,Area under concentration-time curve of compound was determined in rabbit at 25 mg/kg orally,1,Oryctolagus cuniculus,Intermediate,,,,9986.0,,,A,BAO_0000218,CHEMBL626145,10650
,50597,N,1,,,,17025,,Area under concentration-time curve of compound was determined in rat at 25 mg/kg orally,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL626146,10651
Blood,50597,N,1,,,,12032,,Area under curve (AUC) is the drug concentrations in blood samples of rats with arterial catheters at 5 min and 12 hr plotted against time,1,Rattus norvegicus,Intermediate,,,,10116.0,,178.0,A,BAO_0000218,CHEMBL626147,10652
,22224,U,0,,,,10291,,Area under curve (AUC) was determined,1,,Autocuration,,,,,,,A,BAO_0000019,CHEMBL626148,10653
,22224,U,0,,,,5767,,Area under curve (AUC) following ip administration at 1 mg/kg,1,,Autocuration,,,,,,,A,BAO_0000218,CHEMBL626149,10654
,22224,U,0,,,,1434,,Area under curve (AUC) was determined; ND is Not determined,1,,Autocuration,,,,,,,A,BAO_0000019,CHEMBL626150,10655
,50588,N,1,,,,14925,,Area under curve (AUC) was determined in dogs fed after intravenous administration of 25 mg/kg of the compound,1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL626151,10656
,50588,N,1,,,,14925,,Area under curve (AUC) was determined in dogs fed after oral administration of 25 mg/kg of the compound,1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL626152,10657
,50588,N,1,,,,14925,,Area under curve (AUC) was determined in fasted dogs after oral administration of 25 mg/kg of the compound,1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL626153,10658
,22224,U,0,,,,1434,,Area under curve (AUR) was determined,1,,Autocuration,,,,,,,A,BAO_0000019,CHEMBL626154,10659
,22224,U,0,,,,11883,,Area under curve at 1 uM/dg administered intravenously,1,,Autocuration,,,,,,,A,BAO_0000019,CHEMBL626155,10660
,22224,U,0,,,,11883,,Area under curve at 10 uM/dg administered perorally,1,,Autocuration,,,,,,,A,BAO_0000019,CHEMBL626156,10661
,22224,U,0,,,,11883,,Area under curve at 2 uM/dg administered intravenously,1,,Autocuration,,,,,,,A,BAO_0000019,CHEMBL626157,10662
,22224,U,0,,,,11883,,Area under curve at 20 uM/dg administered perorally,1,,Autocuration,,,,,,,A,BAO_0000019,CHEMBL626158,10663
,50588,N,1,,,,15233,,Area under curve at a peroral dose of 3 mg/kg in dog,1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL626159,10664
,50597,N,1,,,,15233,,Area under curve at a peroral dose of 3 mg/kg in rat,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL626160,10665
,50588,N,1,,,,15233,,Area under curve at an iv dose of 1 mg/kg in dog,1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL626161,10666
,50597,N,1,,,,15233,,Area under curve at an iv dose of 1 mg/kg in rat,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL626162,10667
,22224,U,0,,,,12978,,Area under curve gives the effective duration for the angiotensin II antagonist effect of the compound.,1,,Autocuration,,,,,,,A,BAO_0000019,CHEMBL626163,10668
,22224,U,0,,,,12978,,Area under curve gives the effective duration for the angiotensin II antagonist effect.,1,,Autocuration,,,,,,,A,BAO_0000019,CHEMBL626164,10669
,50594,N,1,,,,11355,,Area under curve measured as conc vs time after intravenous administration to mice.,1,Mus musculus,Intermediate,,,,10090.0,,,A,BAO_0000218,CHEMBL626165,10670
,50594,N,1,,,,11355,,Area under curve measured as conc vs time after peroral administration to mice.,1,Mus musculus,Intermediate,,,,10090.0,,,A,BAO_0000218,CHEMBL626166,10671
,50588,N,1,,,,12923,,Area under curve of acid 2a was determined by HPLC at a dosage of 2.27 mg/kg administered intravenously by bolus method in dog,1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL626167,10672
,50588,N,1,,,,12923,,Area under curve of acid 2a was determined by HPLC at a dosage of 5.45 mg/kg administered intragastrically by capsule method in dog,1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL626168,10673
,50588,N,1,,,,12923,,Area under curve of acid 2a was determined by HPLC at a dosage of 5.45 mg/kg administered intragastrically by gavage method in dog,1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL877463,10674
,50588,N,1,,,,12923,,Area under curve of acid 2a was determined by HPLC at a dosage of 54.5 mg/kg administered intragastrically by capsule method in dog,1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL626169,10675
Heart,50597,N,1,In vivo,,,17738,,Biodistribution of radiolabeled compound in rat heart after 24 hr activity expressed as %ID/Organ,1,Rattus norvegicus,Intermediate,,,,10116.0,,948.0,A,BAO_0000218,CHEMBL626170,10676
Heart,50597,N,1,In vivo,,,17738,,Biodistribution of radiolabeled compound in rat heart after 2 hr activity expressed as %ID/Organ,1,Rattus norvegicus,Intermediate,,,,10116.0,,948.0,A,BAO_0000218,CHEMBL626171,10677
Heart,50597,N,1,In vivo,,,17738,,Biodistribution of radiolabeled compound in rat heart after 30 min activity expressed as %ID/Organ,1,Rattus norvegicus,Intermediate,,,,10116.0,,948.0,A,BAO_0000218,CHEMBL626172,10678
Heart,50597,N,1,In vivo,,,17738,,Biodistribution of radiolabeled compound in rat heart after 5 min activity expressed as %ID/Organ,1,Rattus norvegicus,Intermediate,,,,10116.0,,948.0,A,BAO_0000218,CHEMBL626173,10679
Kidney,50597,N,1,In vivo,,,17738,,Biodistribution of radiolabeled compound in rat kidney after 24 hr postinjection activity expressed as %ID/Organ,1,Rattus norvegicus,Intermediate,,,,10116.0,,2113.0,A,BAO_0000218,CHEMBL626174,10680
Kidney,50597,N,1,In vivo,,,17738,,Biodistribution of radiolabeled compound in rat kidney after 24 hr activity expressed as %ID/Organ,1,Rattus norvegicus,Intermediate,,,,10116.0,,2113.0,A,BAO_0000218,CHEMBL626175,10681
Kidney,50597,N,1,In vivo,,,17738,,Biodistribution of radiolabeled compound in rat kidney after 2 hr activity expressed as %ID/Organ,1,Rattus norvegicus,Intermediate,,,,10116.0,,2113.0,A,BAO_0000218,CHEMBL626176,10682
Kidney,50597,N,1,In vivo,,,17738,,Biodistribution of radiolabeled compound in rat kidney after 30 min activity expressed as %ID/Organ,1,Rattus norvegicus,Intermediate,,,,10116.0,,2113.0,A,BAO_0000218,CHEMBL626177,10683
Kidney,50597,N,1,In vivo,,,17738,,Biodistribution of radiolabeled compound in rat kidney after 5 min activity expressed as %ID/Organ,1,Rattus norvegicus,Intermediate,,,,10116.0,,2113.0,A,BAO_0000218,CHEMBL622499,10684
Liver,50597,N,1,In vivo,,,17738,,Biodistribution of radiolabeled compound in rat liver after 24 hr postinjection activity expressed as %ID/Organ,1,Rattus norvegicus,Intermediate,,,,10116.0,,2107.0,A,BAO_0000218,CHEMBL622500,10685
Liver,50597,N,1,In vivo,,,17738,,Biodistribution of radiolabeled compound in rat liver after 24 hr activity expressed as %ID/Organ,1,Rattus norvegicus,Intermediate,,,,10116.0,,2107.0,A,BAO_0000218,CHEMBL622501,10686
Liver,50597,N,1,In vivo,,,17738,,Biodistribution of radiolabeled compound in rat liver after 2 hr activity expressed as %ID/Organ,1,Rattus norvegicus,Intermediate,,,,10116.0,,2107.0,A,BAO_0000218,CHEMBL622502,10687
Liver,50597,N,1,In vivo,,,17738,,Biodistribution of radiolabeled compound in rat liver after 30 min activity expressed as %ID/Organ,1,Rattus norvegicus,Intermediate,,,,10116.0,,2107.0,A,BAO_0000218,CHEMBL622503,10688
Liver,50597,N,1,In vivo,,,17738,,Biodistribution of radiolabeled compound in rat liver after 5 min activity expressed as %ID/Organ,1,Rattus norvegicus,Intermediate,,,,10116.0,,2107.0,A,BAO_0000218,CHEMBL877614,10689
Lung,50597,N,1,In vivo,,,17738,,Biodistribution of radiolabeled compound in rat lung after 24 hr activity expressed as %ID/Organ,1,Rattus norvegicus,Intermediate,,,,10116.0,,2048.0,A,BAO_0000218,CHEMBL624839,10690
Lung,50597,N,1,In vivo,,,17738,,Biodistribution of radiolabeled compound in rat lung after 2 hr activity expressed as %ID/Organ,1,Rattus norvegicus,Intermediate,,,,10116.0,,2048.0,A,BAO_0000218,CHEMBL624840,10691
Lung,50597,N,1,In vivo,,,17738,,Biodistribution of radiolabeled compound in rat lung after 30 min activity expressed as %ID/Organ,1,Rattus norvegicus,Intermediate,,,,10116.0,,2048.0,A,BAO_0000218,CHEMBL624841,10692
Lung,50597,N,1,In vivo,,,17738,,Biodistribution of radiolabeled compound in rat lung after 5 min activity expressed as %ID/Organ,1,Rattus norvegicus,Intermediate,,,,10116.0,,2048.0,A,BAO_0000218,CHEMBL624842,10693
Muscle tissue,50597,N,1,In vivo,,,17738,,Biodistribution of radiolabeled compound in rat muscle after 24 hr activity expressed as %ID/Organ,1,Rattus norvegicus,Intermediate,,,,10116.0,,2385.0,A,BAO_0000218,CHEMBL624843,10694
Muscle tissue,50597,N,1,In vivo,,,17738,,Biodistribution of radiolabeled compound in rat muscle after 2 hr activity expressed as %ID/Organ,1,Rattus norvegicus,Intermediate,,,,10116.0,,2385.0,A,BAO_0000218,CHEMBL624844,10695
Muscle tissue,50597,N,1,In vivo,,,17738,,Biodistribution of radiolabeled compound in rat muscle after 30 min activity expressed as %ID/Organ,1,Rattus norvegicus,Intermediate,,,,10116.0,,2385.0,A,BAO_0000218,CHEMBL624845,10696
Muscle tissue,50597,N,1,In vivo,,,17738,,Biodistribution of radiolabeled compound in rat muscle after 5 min activity expressed as %ID/Organ,1,Rattus norvegicus,Intermediate,,,,10116.0,,2385.0,A,BAO_0000218,CHEMBL621904,10697
Blood,50597,N,1,In vivo,,,11195,,Biodistribution of the radiolabeled compound (2-5 uCi) in rat blood 15 mins after i.v. administration,1,Rattus norvegicus,Intermediate,,,,10116.0,,178.0,A,BAO_0000218,CHEMBL621905,10698
Blood,50597,N,1,In vivo,,,11195,,Biodistribution of the radiolabeled compound (2-5 uCi) in rat blood 2 mins after i.v. administration,1,Rattus norvegicus,Intermediate,,,,10116.0,,178.0,A,BAO_0000218,CHEMBL874382,10699
Blood,50597,N,1,In vivo,,,11195,,Biodistribution of the radiolabeled compound (2-5 uCi) in rat blood 65 mins after i.v. administration,1,Rattus norvegicus,Intermediate,,,,10116.0,,178.0,A,BAO_0000218,CHEMBL621906,10700
Brain,50597,N,1,In vivo,,,11195,,Biodistribution of the radiolabeled compound (2-5 uCi) in rat brain 15 mins after i.v. administration,1,Rattus norvegicus,Intermediate,,,,10116.0,,955.0,A,BAO_0000218,CHEMBL621907,10701
Brain,50597,N,1,In vivo,,,11195,,Biodistribution of the radiolabeled compound (2-5 uCi) in rat brain 2 mins after i.v. administration,1,Rattus norvegicus,Intermediate,,,,10116.0,,955.0,A,BAO_0000218,CHEMBL622096,10702
Brain,50597,N,1,In vivo,,,11195,,Biodistribution of the radiolabeled compound (2-5 uCi) in rat brain 65 mins after i.v. administration,1,Rattus norvegicus,Intermediate,,,,10116.0,,955.0,A,BAO_0000218,CHEMBL622097,10703
Heart,50597,N,1,In vivo,,,11195,,Biodistribution of the radiolabeled compound (2-5 uCi) in rat heart 15 mins after i.v. administration,1,Rattus norvegicus,Intermediate,,,,10116.0,,948.0,A,BAO_0000218,CHEMBL622098,10704
Heart,50597,N,1,In vivo,,,11195,,Biodistribution of the radiolabeled compound (2-5 uCi) in rat heart 2 mins after i.v. administration,1,Rattus norvegicus,Intermediate,,,,10116.0,,948.0,A,BAO_0000218,CHEMBL622099,10705
Heart,50597,N,1,In vivo,,,11195,,Biodistribution of the radiolabeled compound (2-5 uCi) in rat heart 65 mins after i.v. administration,1,Rattus norvegicus,Intermediate,,,,10116.0,,948.0,A,BAO_0000218,CHEMBL622100,10706
Kidney,50597,N,1,In vivo,,,11195,,Biodistribution of the radiolabeled compound (2-5 uCi) in rat kidney 15 mins after i.v. administration,1,Rattus norvegicus,Intermediate,,,,10116.0,,2113.0,A,BAO_0000218,CHEMBL622101,10707
Kidney,50597,N,1,In vivo,,,11195,,Biodistribution of the radiolabeled compound (2-5 uCi) in rat kidney 2 mins after i.v. administration,1,Rattus norvegicus,Intermediate,,,,10116.0,,2113.0,A,BAO_0000218,CHEMBL622102,10708
Kidney,50597,N,1,In vivo,,,11195,,Biodistribution of the radiolabeled compound (2-5 uCi) in rat kidney 65 mins after i.v. administration,1,Rattus norvegicus,Intermediate,,,,10116.0,,2113.0,A,BAO_0000218,CHEMBL622103,10709
Liver,50597,N,1,In vivo,,,11195,,Biodistribution of the radiolabeled compound (2-5 uCi) in rat liver 15 mins after i.v. administration,1,Rattus norvegicus,Intermediate,,,,10116.0,,2107.0,A,BAO_0000218,CHEMBL622104,10710
Liver,50597,N,1,In vivo,,,11195,,Biodistribution of the radiolabeled compound (2-5 uCi) in rat liver 2 mins after i.v. administration,1,Rattus norvegicus,Intermediate,,,,10116.0,,2107.0,A,BAO_0000218,CHEMBL622105,10711
Liver,50597,N,1,In vivo,,,11195,,Biodistribution of the radiolabeled compound (2-5 uCi) in rat liver 65 mins after i.v. administration,1,Rattus norvegicus,Intermediate,,,,10116.0,,2107.0,A,BAO_0000218,CHEMBL622106,10712
Lung,50597,N,1,In vivo,,,11195,,Biodistribution of the radiolabeled compound (2-5 uCi) in rat lung 15 mins after i.v. administration,1,Rattus norvegicus,Intermediate,,,,10116.0,,2048.0,A,BAO_0000218,CHEMBL622107,10713
Lung,50597,N,1,In vivo,,,11195,,Biodistribution of the radiolabeled compound (2-5 uCi) in rat lung 2 mins after i.v. administration,1,Rattus norvegicus,Intermediate,,,,10116.0,,2048.0,A,BAO_0000218,CHEMBL622108,10714
Lung,50597,N,1,In vivo,,,11195,,Biodistribution of the radiolabeled compound (2-5 uCi) in rat lung 65 mins after i.v. administration,1,Rattus norvegicus,Intermediate,,,,10116.0,,2048.0,A,BAO_0000218,CHEMBL622109,10715
Muscle tissue,50597,N,1,In vivo,,,11195,,Biodistribution of the radiolabeled compound (2-5 uCi) in rat muscle 15 mins after i.v. administration,1,Rattus norvegicus,Intermediate,,,,10116.0,,2385.0,A,BAO_0000218,CHEMBL622110,10716
Muscle tissue,50597,N,1,In vivo,,,11195,,Biodistribution of the radiolabeled compound (2-5 uCi) in rat muscle 2 mins after i.v. administration,1,Rattus norvegicus,Intermediate,,,,10116.0,,2385.0,A,BAO_0000218,CHEMBL622111,10717
Muscle tissue,50597,N,1,In vivo,,,11195,,Biodistribution of the radiolabeled compound (2-5 uCi) in rat muscle 65 mins after i.v. administration,1,Rattus norvegicus,Intermediate,,,,10116.0,,2385.0,A,BAO_0000218,CHEMBL874383,10718
Zone of skin,50597,N,1,In vivo,,,11195,,Biodistribution of the radiolabeled compound (2-5 uCi) in rat skin 15 mins after i.v. administration,1,Rattus norvegicus,Intermediate,,,,10116.0,,14.0,A,BAO_0000218,CHEMBL622112,10719
Zone of skin,50597,N,1,In vivo,,,11195,,Biodistribution of the radiolabeled compound (2-5 uCi) in rat skin 2 mins after i.v. administration,1,Rattus norvegicus,Intermediate,,,,10116.0,,14.0,A,BAO_0000218,CHEMBL622113,10720
Zone of skin,50597,N,1,In vivo,,,11195,,Biodistribution of the radiolabeled compound (2-5 uCi) in rat skin 65 mins after i.v. administration,1,Rattus norvegicus,Intermediate,,,,10116.0,,14.0,A,BAO_0000218,CHEMBL622114,10721
Spleen,50597,N,1,In vivo,,,11195,,Biodistribution of the radiolabeled compound (2-5 uCi) in rat spleen 15 mins after i.v. administration,1,Rattus norvegicus,Intermediate,,,,10116.0,,2106.0,A,BAO_0000218,CHEMBL622115,10722
Spleen,50597,N,1,In vivo,,,11195,,Biodistribution of the radiolabeled compound (2-5 uCi) in rat spleen 2 mins after i.v. administration,1,Rattus norvegicus,Intermediate,,,,10116.0,,2106.0,A,BAO_0000218,CHEMBL622116,10723
,50597,N,1,In vivo,,,6193,,Oral bioavailability in rat,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL622117,10724
,50597,N,1,In vivo,,,6803,,Oral bioavailability in rat,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL622118,10725
,50597,N,1,In vivo,,,6647,,Oral bioavailability in rats at 6 mg/kg,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL622119,10726
,50597,N,1,In vivo,,,6647,,Oral bioavailability in rat (dose 6 mg/kg),1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL622120,10727
,50597,N,1,In vivo,,,6647,,Oral bioavailability in rats at 6 mg/kg dose; Not tested,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL622121,10728
,50597,N,1,In vivo,,,6640,,Oral bioavailability in rat,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL622122,10729
,50597,N,1,In vivo,,,6641,,Oral bioavailability in rat,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL622123,10730
,50597,N,1,In vivo,,,6641,,Oral bioavailability in rat,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL622124,10731
,50597,N,1,In vivo,,,6642,,Bioavailability in rat,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL622125,10732
,50597,N,1,In vivo,,,5472,,Oral bioavailability,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL622126,10733
,50597,N,1,In vivo,,,6141,,Oral bioavailability in rat (Sprague-Dawley) (dose 2 mg/kg),1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL620455,10734
,50597,N,1,In vivo,,,4390,,Oral bioavailability in rat,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL620456,10735
,50597,N,1,In vivo,,,5472,,Oral bioavailability in rat,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL620457,10736
,50597,N,1,In vivo,,,5472,,Oral bioavailability was evaluated; Not tested,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL620458,10737
,50597,N,1,In vivo,,,5438,,Oral bioavailability,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL620459,10738
,50597,N,1,In vivo,,,4883,,Oral bioavailability in rat by oral dosing,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL620460,10739
,50597,N,1,In vivo,,,1908,,Oral bioavailability in rat (dose 10 mg/kg p.o.),1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL620461,10740
,50597,N,1,In vivo,,,4853,,Oral bioavailability in rat (Sprague-Dawley),1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL620462,10741
,50597,N,1,In vivo,,,4853,,Oral bioavailability in rat (Sprague-Dawley) (dose 1 mg/kg i.v.),1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL620463,10742
,50597,N,1,In vivo,,,4853,,Oral bioavailability in rat (Sprague-Dawley) (dose 1 mg/kg i.v.),1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL620464,10743
,50597,N,1,In vivo,,,4853,,Oral bioavailability in rat (Sprague-Dawley) (dose 2 mg/kg),1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL620465,10744
,50597,N,1,In vivo,,,4853,,Oral bioavailability in rat (Sprague-Dawley) (dose 2 mg/kg p.o.),1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL620466,10745
,50597,N,1,In vivo,,,4853,,Oral bioavailability was calculated in Spragun Dawley rat at oral dosage of 1 mg/kg,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL620467,10746
,50597,N,1,In vivo,,,4853,,Oral bioavailability was calculated in Spragun Dawley rat at oral dosage of 2 mg/kg,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL620468,10747
,50597,N,1,In vivo,,,12873,,Oral bioavailability was calculated in rats using an average of the intravenous AUC at peroral dose of 5 mgkg in solution form,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL620469,10748
,50597,N,1,In vivo,,,12873,,Oral bioavailability was calculated in rats using an average of the intravenous AUC at peroral dose of 5 mgkg in suspension form,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL620470,10749
,50597,N,1,In vivo,,,3169,,Oral bioavailability in rat,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL620471,10750
,50597,N,1,In vivo,,,6305,,Oral bioavailability in rat,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL620472,10751
,50597,N,1,In vivo,,,4762,,Oral bioavailability of compound at 5 mg/kg after po administration was determined in rat,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL620473,10752
,50597,N,1,In vivo,,,17847,,Oral bioavailability in rat,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL620474,10753
,50597,N,1,In vivo,,,6211,,Oral bioavailability in rat (Sprague-Dawley) (fasted male) (dose 10 mg/kg),1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL620475,10754
,50597,N,1,In vivo,,,6011,,Oral bioavailability in rat,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL620476,10755
,50597,N,1,In vivo,,,6317,,Oral bioavailability in rat,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL620477,10756
,50597,N,1,In vivo,,,6644,,Oral bioavailability in rat after oral administration at 10.5 mg/kg dose,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL620478,10757
,50597,N,1,In vivo,,,6644,,Oral bioavailability in rat after oral administration at 11.2 mg/kg dose,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL618768,10758
,50597,N,1,In vivo,,,6644,,Oral bioavailability in rat after oral administration at 13 mg/kg dose,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL618769,10759
,50597,N,1,In vivo,,,6644,,Oral bioavailability in rat after oral administration at 9.7 mg/kg dose,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL618770,10760
,50597,N,1,In vivo,,,6113,,Oral bioavailability (dose 20 mg/kg p.o.),1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL618771,10761
,50597,N,1,In vivo,,,5937,,Oral bioavailability was determined in rat after oral administration at a concentration 1 mg/kg,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL618772,10762
,50597,N,1,In vivo,,,5711,,Oral bioavailability in rat at 10 mg/kg of the compound,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL618773,10763
,50597,N,1,In vivo,,,17717,,Bioavailability in rat at a concentration of 15 mg/kg perorally in rat along with 100 mg/kg 11,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL875842,10764
,50597,N,1,In vivo,,,17717,,Bioavailability in rat (dose 3 mg/kg i.v.),1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL618774,10765
,50597,N,1,In vivo,,,17717,,Bioavailability in rat at a concentration of 60 mg/kg perorally in rat along with 100 mg/kg 11,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL618775,10766
,50597,N,1,In vivo,,,17717,,Oral bioavailability in rat (dose 60 mg/kg p.o.),1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL618776,10767
,50597,N,1,In vivo,,,4722,,Percent bioavailability (F) in rats after iv administration,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL618777,10768
,50597,N,1,In vivo,,,4722,,Percent bioavailability (F) in rats after oral dose of 10 mg/kg,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL618778,10769
,50597,N,1,In vivo,,,4353,,Bioavailability in rat (dose 5 uM/kg p.o.),1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL618779,10770
,50597,N,1,In vivo,,,15662,,Oral bioavailability,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL618780,10771
,50597,N,1,In vivo,,,4756,,Bioavailability in rat (dose 2 mg/kg p.o.),1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL618781,10772
,50597,N,1,In vivo,,,4756,,Percent bioavailability at the dose of 5 mg/Kg administered perorally in rats,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL618782,10773
,50597,N,1,In vivo,,,3436,,Oral bioavailability in rat (dose 20 mg/kg),1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL618783,10774
,50597,N,1,In vivo,,,17800,,Oral bioavailability in rat,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL618784,10775
,50597,N,1,In vivo,,,15762,,Percent oral bioavailability evaluated in rat,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL618785,10776
,50597,N,1,In vivo,,,5089,,Oral bioavailability in rat,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL618786,10777
,50597,N,1,In vivo,,,5089,,Percent oral bioavailability in rat; Not determined,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL618787,10778
,50597,N,1,In vivo,,,3185,,Oral bioavailability in rat,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL618788,10779
,50597,N,1,In vivo,,,5145,,Bioavailability in rat,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL618789,10780
,50597,N,1,In vivo,,,3457,,Pharmacokinetic property (oral bioavailability) in rat (dose given as a solution),1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL618790,10781
,50597,N,1,In vivo,,,3457,,Pharmacokinetic property (oral bioavailability) in rat (dose given as a suspension),1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL618791,10782
,50597,N,1,In vivo,,,5983,,Pharmacokinetic property (F) was measured in rat at the dose of 0.32 mg/kg,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL875843,10783
,50597,N,1,In vivo,,,5739,,Oral bioavailability in rat (dose 20 mg/kg p.o.),1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL618792,10784
,50597,N,1,In vivo,,,3579,,Cmax at a dose of 30 mg/kg in rat,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL623395,10785
,22224,U,0,In vivo,,,17788,,Cmax in monkeys at a dose of 1 mg/kg,1,Simiiformes,Autocuration,,,,314293.0,,,A,BAO_0000218,CHEMBL623396,10786
,50597,N,1,In vivo,,,14956,,Cmax in rat,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL623397,10787
,50597,N,1,In vivo,,,17788,,Cmax in rats at a dose of 1 mg/kg,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL623398,10788
,50594,N,1,In vivo,,,9750,,Cmax was measured in mice after an oral dose of 50 mg/kg.,1,Mus musculus,Intermediate,,,,10090.0,,,A,BAO_0000218,CHEMBL623399,10789
,22224,U,0,In vivo,,,12767,,"Cmax value at a dose of 12.7 uM/kg, po",1,,Autocuration,,,,,,,A,BAO_0000218,CHEMBL623400,10790
,22224,U,0,In vivo,,,12767,,"Cmax value at a dose of 6.3 uM/kg, iv",1,,Autocuration,,,,,,,A,BAO_0000218,CHEMBL623401,10791
,22224,U,0,In vivo,,,12767,,"Cmax value at a dose of 7.1 uM/kg, iv",1,,Autocuration,,,,,,,A,BAO_0000218,CHEMBL623402,10792
,22224,U,0,In vivo,,,12703,,Cmax value of compound was determined after 1 hr,1,,Autocuration,,,,,,,A,BAO_0000218,CHEMBL623403,10793
,22224,U,0,In vivo,,,15778,,Cmax value of the compound,1,,Autocuration,,,,,,,A,BAO_0000218,CHEMBL623404,10794
,50597,N,1,In vivo,,,12818,,Cmax value administered intraintestinal in rats.,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL625997,10795
,50597,N,1,In vivo,,,14964,,Cmax value administered perorally was determined in rat; Not determined,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL625998,10796
,22224,U,0,In vivo,,,15808,,Cmax value at the dose of 2.3 mg/kg,1,,Autocuration,,,,,,,A,BAO_0000218,CHEMBL625999,10797
,22224,U,0,In vivo,,,15808,,Cmax value at the dose of 5 mg/kg,1,,Autocuration,,,,,,,A,BAO_0000218,CHEMBL626000,10798
,22224,U,0,In vivo,,,15778,,Cmax value in the period of 8 hr after dosing. ,1,,Autocuration,,,,,,,A,BAO_0000218,CHEMBL626001,10799
,22224,U,0,In vivo,,,3715,,Cmax value at a oral dose of 20 mg/kg; Not tested,1,,Autocuration,,,,,,,A,BAO_0000218,CHEMBL626002,10800
,22224,U,0,In vivo,,,3715,,Cmax value at a oral dose of 20 mg/kg,1,,Autocuration,,,,,,,A,BAO_0000218,CHEMBL626003,10801
,50597,N,1,In vivo,,,1446,,Cmax value was determined between 15 and 30 minutes post administration in fisher rats; value ranges from 200-500,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL626004,10802
,50512,N,1,In vivo,,,15240,,Cmax(ng /mL)values after oral administration of 10 mg/kg in guinea pig.,1,Cavia porcellus,Intermediate,,,,10141.0,,,A,BAO_0000218,CHEMBL626005,10803
,50597,N,1,In vivo,,,15240,,Cmax(ng /mL)values after oral administration of 10 mg/kg in rat.,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL626006,10804
Plasma,50597,N,1,In vivo,,,14810,,Compound at a dose of 10 mg/kg was orally administered to rats and maximum plasma concentration was reported,1,Rattus norvegicus,Intermediate,,,,10116.0,,1969.0,A,BAO_0000218,CHEMBL626007,10805
Plasma,50594,N,1,In vivo,,,14239,,Compound was evaluated for maximum plasma concentration by administering orally at 25 mg/kg in mice,1,Mus musculus,Intermediate,,,,10090.0,,1969.0,A,BAO_0000218,CHEMBL626008,10806
Liver,50588,N,1,In vivo,,,12555,,Compound was evaluated for maximum plasma concentration levels in dogs for the orally delivered compound in 0.05 M citric acid,1,Canis lupus familiaris,Intermediate,,,,9615.0,,2107.0,A,BAO_0000218,CHEMBL626009,10807
,50588,N,1,In vivo,,,10754,,Compound was evaluated in vivo for its concentration after a peroral administration 40 mg/kg in dogs.,1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL626010,10808
Blood,50594,N,1,In vivo,,,10754,,Compound was evaluated in vivo in blood samples from the orbital sinus for its concentration after a intramuscular administration 40 mg/kg in mice,1,Mus musculus,Intermediate,,,,10090.0,,178.0,A,BAO_0000218,CHEMBL626011,10809
Blood,50594,N,1,In vivo,,,10754,,Compound was evaluated in vivo in blood samples from the orbital sinus for its concentration after a peroral administration 40 mg/kg in mice,1,Mus musculus,Intermediate,,,,10090.0,,178.0,A,BAO_0000218,CHEMBL626012,10810
Blood,50594,N,1,In vivo,,,10754,,Compound was evaluated in vivo in blood samples from the orbital sinus for its concentration after a peroral administration of 40 mg/kg in mice,1,Mus musculus,Intermediate,,,,10090.0,,178.0,A,BAO_0000218,CHEMBL626013,10811
Blood,50594,N,1,In vivo,,,10754,,Compound was evaluated in vivo in blood samples from the orbital sinus for its concentration after an intramuscular administration of 40 mg/kg in mice,1,Mus musculus,Intermediate,,,,10090.0,,178.0,A,BAO_0000218,CHEMBL626014,10812
Blood,50594,N,1,In vivo,,,10754,,Compound was evaluated in vivo in blood samples from the orbital sinus for its concentration after an intramuscular administration of 40 mg/kg in mice.,1,Mus musculus,Intermediate,,,,10090.0,,178.0,A,BAO_0000218,CHEMBL877496,10813
,50588,N,1,In vivo,,,14600,,Compound was tested Growth Hormone(GH) release after 0.5 mg/kg administration (Po) in Beagle dogs,1,Canis lupus familiaris,Intermediate,,,,9615.0,,,F,BAO_0000218,CHEMBL626015,10814
,50588,N,1,In vivo,,,14600,,Compound was tested Growth Hormone(GH) release after 10 mg/kg administration (Po) in Beagle dogs,1,Canis lupus familiaris,Intermediate,,,,9615.0,,,F,BAO_0000218,CHEMBL626016,10815
,50588,N,1,In vivo,,,14600,,Compound was tested Growth Hormone(GH) release after 2.5 mg/kg administration (Po) in Beagle dogs,1,Canis lupus familiaris,Intermediate,,,,9615.0,,,F,BAO_0000218,CHEMBL626017,10816
Plasma,50588,N,1,In vivo,,,13543,,Bioavailability as maximal plasma concentration in dogs,1,Canis lupus familiaris,Intermediate,,,,9615.0,,1969.0,A,BAO_0000218,CHEMBL626018,10817
Plasma,50588,N,1,In vivo,,,13543,,Bioavailability as maximal plasma concentration in dogs,1,Canis lupus familiaris,Intermediate,,,,9615.0,,1969.0,A,BAO_0000218,CHEMBL626692,10818
Plasma,50597,N,1,In vivo,,,13543,,Bioavailability as maximal plasma concentration in rats,1,Rattus norvegicus,Intermediate,,,,10116.0,,1969.0,A,BAO_0000218,CHEMBL626693,10819
Plasma,22224,U,0,In vivo,,,13543,,Bioavailability as maximal plasma concentration in rats,1,Rattus norvegicus,Autocuration,,,,10116.0,,1969.0,A,BAO_0000218,CHEMBL626694,10820
Blood,50588,N,1,In vivo,,,14600,,Compound was tested for maximum blood concentration after 0.5 mg/kg administration (Po) in Beagle dogs; nM/L maximum blood concentration,1,Canis lupus familiaris,Intermediate,,,,9615.0,,178.0,A,BAO_0000218,CHEMBL626695,10821
Blood,50588,N,1,In vivo,,,14600,,Compound was tested for maximum blood concentration after 10 mg/kg administration (Po) in Beagle dogs; nM/L maximum blood concentration,1,Canis lupus familiaris,Intermediate,,,,9615.0,,178.0,A,BAO_0000218,CHEMBL626696,10822
Blood,50588,N,1,In vivo,,,14600,,Compound was tested for maximum blood concentration after 2.5 mg/kg administration (Po) in Beagle dogs; nM/L maximum blood concentration,1,Canis lupus familiaris,Intermediate,,,,9615.0,,178.0,A,BAO_0000218,CHEMBL626697,10823
Blood,50588,N,1,In vivo,,,14600,,Compound was tested for maximum concentration in blood after 0.5 mg/kg administration (Po) in Beagle dogs; nd = Not Detectable,1,Canis lupus familiaris,Intermediate,,,,9615.0,,178.0,A,BAO_0000218,CHEMBL626859,10824
Blood,50588,N,1,In vivo,,,14600,,Compound was tested for maximum concentration in blood after 10 mg/kg administration (Po) in Beagle dogs; nM/L maximum blood concentration,1,Canis lupus familiaris,Intermediate,,,,9615.0,,178.0,A,BAO_0000218,CHEMBL626860,10825
Blood,50588,N,1,In vivo,,,14600,,Compound was tested for maximum concentration in blood after 2.5 mg/kg administration (Po) in Beagle dogs; nM/L maximum blood concentration,1,Canis lupus familiaris,Intermediate,,,,9615.0,,178.0,A,BAO_0000218,CHEMBL626861,10826
,50597,N,1,In vivo,,,14681,,Compound was tested for maximum observed concentration in three male Wistar rats at a single 5 mg/kg oral gavage dose,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL626296,10827
,22224,U,0,In vivo,,,15905,,Compound was tested for the max. conc. when administered perorally(po) 30 mg/kg,1,,Autocuration,,,,,,,A,BAO_0000218,CHEMBL626297,10828
Plasma,22224,U,0,In vivo,,,15905,,Compound was tested for the max. plasma conc. when administered intraperitoneally (ip) 30 mg/kg.,1,,Autocuration,,,,,,1969.0,A,BAO_0000218,CHEMBL626298,10829
Plasma,50597,N,1,In vivo,,,13304,,"Drug plasma level in rat was determined on the last day of dosing at 1,2,4.8 and 24 hr and ED50 was evaluated",1,Rattus norvegicus,Intermediate,,,,10116.0,,1969.0,A,BAO_0000218,CHEMBL626299,10830
Plasma,50597,N,1,In vivo,,,15137,,Effect of ip administration of compound on plasma concentration of allo-pregnanolone (AP) in rats after 30 min.,1,Rattus norvegicus,Intermediate,,,,10116.0,,1969.0,A,BAO_0000218,CHEMBL626300,10831
Plasma,50597,N,1,In vivo,,,15137,,Effect of ip administration of compound on plasma concentration of allotetrahydrodeoxy corticosterone(THDOC) in rats after 30 min.,1,Rattus norvegicus,Intermediate,,,,10116.0,,1969.0,A,BAO_0000218,CHEMBL626301,10832
Plasma,50597,N,1,In vivo,,,15137,,Effect of ip administration of compound on plasma concentration of corticosterone (CTS) in rats after 30 min.,1,Rattus norvegicus,Intermediate,,,,10116.0,,1969.0,A,BAO_0000218,CHEMBL626962,10833
Plasma,50597,N,1,In vivo,,,15137,,Effect of ip administration of compound on plasma concentration of pregnenolone (PRE) in rats after 30 min.,1,Rattus norvegicus,Intermediate,,,,10116.0,,1969.0,A,BAO_0000218,CHEMBL626963,10834
Plasma,50597,N,1,In vivo,,,15137,,Effect of ip administration of compound on plasma concentration of progesterone (PRO) in rats after 30 min.,1,Rattus norvegicus,Intermediate,,,,10116.0,,1969.0,A,BAO_0000218,CHEMBL626964,10835
Plasma,100710,N,1,In vivo,,,14839,,In vivo antitumor efficacy expressed as maximum plasma concentration 0.4 hr after a peroral dose of 25 mg/kg in cynomolgus monkeys,1,Macaca fascicularis,Intermediate,,,,9541.0,,1969.0,A,BAO_0000218,CHEMBL626965,10836
Plasma,50594,N,1,In vivo,,,14839,,Maximal plasma concentration in nude mice after 25 mg/kg oral dose,1,Mus musculus,Intermediate,,,,10090.0,,1969.0,A,BAO_0000218,CHEMBL626966,10837
Plasma,50594,N,1,In vivo,,,14839,,Maximal plasma concentration in nude mice after 25 mg/kg oral dose,1,Mus musculus,Intermediate,,,,10090.0,,1969.0,A,BAO_0000218,CHEMBL626967,10838
Plasma,100710,N,1,In vivo,,,14839,,In vivo antitumor efficacy expressed as maximum plasma concentration after a peroral dose of 10 mg/kg in cynomolgus monkeys,1,Macaca fascicularis,Intermediate,,,,9541.0,,1969.0,A,BAO_0000218,CHEMBL626968,10839
Heart,50597,N,1,,,,8418,,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 15 min injection by intravenously; value ranges from 0.89-1.24,1,Rattus norvegicus,Intermediate,,,,10116.0,,948.0,A,BAO_0000218,CHEMBL626969,10840
Heart,50597,N,1,,,,8418,,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 15 min injection by intravenously; value ranges from 2.24-2.58,1,Rattus norvegicus,Intermediate,,,,10116.0,,948.0,A,BAO_0000218,CHEMBL627126,10841
Heart,50597,N,1,,,,8418,,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 0.24-0.28,1,Rattus norvegicus,Intermediate,,,,10116.0,,948.0,A,BAO_0000218,CHEMBL631276,10842
Heart,50597,N,1,,,,8418,,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 0.52-0.62,1,Rattus norvegicus,Intermediate,,,,10116.0,,948.0,A,BAO_0000218,CHEMBL631277,10843
Heart,50597,N,1,,,,8418,,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 0.68-0.84,1,Rattus norvegicus,Intermediate,,,,10116.0,,948.0,A,BAO_0000218,CHEMBL631278,10844
Heart,50597,N,1,,,,8418,,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 30 min injection by intravenously; value ranges from 0.75-1.03,1,Rattus norvegicus,Intermediate,,,,10116.0,,948.0,A,BAO_0000218,CHEMBL874457,10845
Heart,50597,N,1,,,,8418,,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 30 min injection by intravenously; value ranges from 1.96-2.46,1,Rattus norvegicus,Intermediate,,,,10116.0,,948.0,A,BAO_0000218,CHEMBL631279,10846
Heart,50597,N,1,,,,8418,,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 30 min injecton by intravenously; 0.36-0.42,1,Rattus norvegicus,Intermediate,,,,10116.0,,948.0,A,BAO_0000218,CHEMBL631280,10847
Heart,50597,N,1,,,,8418,,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 30 min injecton by intravenously; 0.58-0.82,1,Rattus norvegicus,Intermediate,,,,10116.0,,948.0,A,BAO_0000218,CHEMBL631281,10848
Heart,50597,N,1,,,,8418,,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 5 min injection by intravenously; value ranges from 1.24-1.46,1,Rattus norvegicus,Intermediate,,,,10116.0,,948.0,A,BAO_0000218,CHEMBL631968,10849
Heart,50597,N,1,,,,8418,,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 5 min injection by intravenously; value ranges from 2.36-3.96,1,Rattus norvegicus,Intermediate,,,,10116.0,,948.0,A,BAO_0000218,CHEMBL631969,10850
Heart,50597,N,1,,,,8418,,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 0.24-0.29,1,Rattus norvegicus,Intermediate,,,,10116.0,,948.0,A,BAO_0000218,CHEMBL631970,10851
Heart,50597,N,1,,,,8418,,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 0.39-0.74,1,Rattus norvegicus,Intermediate,,,,10116.0,,948.0,A,BAO_0000218,CHEMBL631971,10852
Heart,50597,N,1,,,,8418,,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 0.79-0.85,1,Rattus norvegicus,Intermediate,,,,10116.0,,948.0,A,BAO_0000218,CHEMBL631972,10853
Heart,50597,N,1,,,,8418,,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 60 min injection by intravenously; value ranges from 0.64-0.86,1,Rattus norvegicus,Intermediate,,,,10116.0,,948.0,A,BAO_0000218,CHEMBL630435,10854
Heart,50597,N,1,,,,8418,,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 60 min injection by intravenously; value ranges from 1.68-2.23,1,Rattus norvegicus,Intermediate,,,,10116.0,,948.0,A,BAO_0000218,CHEMBL630436,10855
Heart,50597,N,1,,,,8418,,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.19-0.23,1,Rattus norvegicus,Intermediate,,,,10116.0,,948.0,A,BAO_0000218,CHEMBL630437,10856
Heart,50597,N,1,,,,8418,,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.22-0.29,1,Rattus norvegicus,Intermediate,,,,10116.0,,948.0,A,BAO_0000218,CHEMBL630438,10857
Heart,50597,N,1,,,,8418,,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.58-0.75,1,Rattus norvegicus,Intermediate,,,,10116.0,,948.0,A,BAO_0000218,CHEMBL630439,10858
Kidney,50597,N,1,,,,8418,,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 15 min injection by intravenously; value ranges from 1.42-1.82,1,Rattus norvegicus,Intermediate,,,,10116.0,,2113.0,A,BAO_0000218,CHEMBL630440,10859
Kidney,50597,N,1,,,,8418,,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 15 min injection by intravenously; value ranges from 2.24-3.12,1,Rattus norvegicus,Intermediate,,,,10116.0,,2113.0,A,BAO_0000218,CHEMBL630441,10860
Kidney,50597,N,1,,,,8418,,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 0.62-0.92,1,Rattus norvegicus,Intermediate,,,,10116.0,,2113.0,A,BAO_0000218,CHEMBL630442,10861
Kidney,50597,N,1,,,,8418,,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 1.12-2.04,1,Rattus norvegicus,Intermediate,,,,10116.0,,2113.0,A,BAO_0000218,CHEMBL625234,10862
Kidney,50597,N,1,,,,8418,,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 1.59-2.03,1,Rattus norvegicus,Intermediate,,,,10116.0,,2113.0,A,BAO_0000218,CHEMBL625235,10863
Kidney,50597,N,1,,,,8418,,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 30 min injection by intravenously; value ranges from 1.14-1.4,1,Rattus norvegicus,Intermediate,,,,10116.0,,2113.0,A,BAO_0000218,CHEMBL625236,10864
Kidney,50597,N,1,,,,8418,,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 30 min injection by intravenously; value ranges from 1.56-1.83,1,Rattus norvegicus,Intermediate,,,,10116.0,,2113.0,A,BAO_0000218,CHEMBL625237,10865
Kidney,50597,N,1,,,,8418,,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 30 min injecton by intravenously; 0.58-0.73,1,Rattus norvegicus,Intermediate,,,,10116.0,,2113.0,A,BAO_0000218,CHEMBL626125,10866
Kidney,50597,N,1,,,,8418,,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 30 min injecton by intravenously; 1.67-2.11,1,Rattus norvegicus,Intermediate,,,,10116.0,,2113.0,A,BAO_0000218,CHEMBL626126,10867
Kidney,50597,N,1,,,,8418,,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 5 min injection by intravenously; value ranges from 1.64-3.43,1,Rattus norvegicus,Intermediate,,,,10116.0,,2113.0,A,BAO_0000218,CHEMBL626127,10868
Kidney,50597,N,1,,,,8418,,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 5 min injection by intravenously; value ranges from 3.18-4.74,1,Rattus norvegicus,Intermediate,,,,10116.0,,2113.0,A,BAO_0000218,CHEMBL626128,10869
Kidney,50597,N,1,,,,8418,,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 0.62-1.13,1,Rattus norvegicus,Intermediate,,,,10116.0,,2113.0,A,BAO_0000218,CHEMBL626129,10870
Kidney,50597,N,1,,,,8418,,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 1.73-2.64,1,Rattus norvegicus,Intermediate,,,,10116.0,,2113.0,A,BAO_0000218,CHEMBL626130,10871
Kidney,50597,N,1,,,,8418,,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 13.02-19.07,1,Rattus norvegicus,Intermediate,,,,10116.0,,2113.0,A,BAO_0000218,CHEMBL626131,10872
Kidney,50597,N,1,,,,8418,,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 60 min injection by intravenously; value ranges from 0.89-1.19,1,Rattus norvegicus,Intermediate,,,,10116.0,,2113.0,A,BAO_0000218,CHEMBL626132,10873
Kidney,50597,N,1,,,,8418,,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 60 min injection by intravenously; value ranges from 1.17-1.48,1,Rattus norvegicus,Intermediate,,,,10116.0,,2113.0,A,BAO_0000218,CHEMBL626752,10874
Kidney,50597,N,1,,,,8418,,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.48-0.72,1,Rattus norvegicus,Intermediate,,,,10116.0,,2113.0,A,BAO_0000218,CHEMBL626753,10875
Kidney,50597,N,1,,,,8418,,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.49-0.57,1,Rattus norvegicus,Intermediate,,,,10116.0,,2113.0,A,BAO_0000218,CHEMBL626754,10876
Kidney,50597,N,1,,,,8418,,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.99-1.24,1,Rattus norvegicus,Intermediate,,,,10116.0,,2113.0,A,BAO_0000218,CHEMBL626755,10877
Liver,50597,N,1,,,,8418,,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 15 min injection by intravenously; value ranges from 1.23-1.78,1,Rattus norvegicus,Intermediate,,,,10116.0,,2107.0,A,BAO_0000218,CHEMBL626756,10878
Liver,50597,N,1,,,,8418,,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 15 min injection by intravenously; value ranges from 2.43-2.92,1,Rattus norvegicus,Intermediate,,,,10116.0,,2107.0,A,BAO_0000218,CHEMBL626757,10879
Liver,50597,N,1,,,,8418,,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 0.81-1.18,1,Rattus norvegicus,Intermediate,,,,10116.0,,2107.0,A,BAO_0000218,CHEMBL626758,10880
Liver,50597,N,1,,,,8418,,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 1.37-1.74,1,Rattus norvegicus,Intermediate,,,,10116.0,,2107.0,A,BAO_0000218,CHEMBL626759,10881
Liver,50597,N,1,,,,8418,,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 4.01-4.81,1,Rattus norvegicus,Intermediate,,,,10116.0,,2107.0,A,BAO_0000218,CHEMBL626760,10882
,50588,N,1,,,,6996,,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 5.4 mg/kg after ip administration ( 0-6 hr),1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL626394,10883
,50588,N,1,,,,6996,,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 5 mg/kg after ip administration,1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL626395,10884
,50588,N,1,,,,6996,,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 5 mg/kg after ip administration (0-6 hr),1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL626396,10885
,50588,N,1,,,,6996,,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 5 mg/kg after ip administration ( 0 - 6 hr),1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL626397,10886
,50588,N,1,,,,6996,,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 5 mg/kg after ip administration ( 0-6 hr ),1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL626398,10887
,50588,N,1,,,,6996,,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 5 mg/kg after ip administration ( 0-6 hr),1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL626399,10888
,50597,N,1,,,,6996,,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 27 mg/kg after ip administration,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL874653,10889
,50597,N,1,,,,6996,,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 27 mg/kg after ip administration ( 0-5 hr),1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL626400,10890
,50597,N,1,,,,6996,,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 27 mg/kg after ip administration (0-5 hr),1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL626401,10891
,50597,N,1,,,,6996,,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 27 mg/kg after ip administration ( 0 - 5 hr),1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL626402,10892
,50597,N,1,,,,6996,,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 27 mg/kg after ip administration ( 0-5 hr ),1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL626403,10893
,50597,N,1,,,,6996,,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 27 mg/kg after ip administration ( 0-5 hr),1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL626404,10894
,50597,N,1,,,,6996,,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 3 mg/kg after ip administration,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL626405,10895
,50597,N,1,,,,6996,,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 3 mg/kg after ip administration ( 0-5 hr),1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL625529,10896
,50597,N,1,,,,6996,,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 3 mg/kg after ip administration (0-5 hr),1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL625530,10897
,50597,N,1,,,,6996,,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 3 mg/kg after ip administration ( 0 - 5 hr),1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL625531,10898
,50597,N,1,,,,6996,,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 3 mg/kg after ip administration ( 0-5 hr ),1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL625532,10899
,50597,N,1,,,,6996,,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 3 mg/kg after ip administration ( 0-5 hr),1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL625533,10900
,50597,N,1,,,,6996,,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 81 mg/kg after ip administration,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL875474,10901
,50597,N,1,,,,6996,,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 81 mg/kg after ip administration ( 0-5 hr),1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL625534,10902
,50597,N,1,,,,6996,,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 81 mg/kg after ip administration (0-5 hr),1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL625535,10903
,50597,N,1,,,,6996,,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 81 mg/kg after ip administration ( 0 - 5 hr),1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL625536,10904
,50597,N,1,,,,6996,,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 81 mg/kg after ip administration ( 0-5 hr ),1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL625537,10905
,50597,N,1,,,,6996,,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 81 mg/kg after ip administration ( 0-5 hr),1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL625538,10906
,50597,N,1,,,,6996,,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 9 mg/kg after ip administration,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL625539,10907
,50597,N,1,,,,6996,,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 9 mg/kg after ip administration ( 0-5 hr),1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL625540,10908
,50597,N,1,,,,6996,,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 9 mg/kg after ip administration (0-5 hr),1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL625541,10909
,50597,N,1,,,,6996,,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 9 mg/kg after ip administration ( 0 - 5 hr),1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL625542,10910
,50597,N,1,,,,6996,,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 9 mg/kg after ip administration ( 0-5 hr ),1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL625543,10911
,50597,N,1,,,,6996,,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 9 mg/kg after ip administration ( 0-5 hr),1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL625544,10912
,50588,N,1,,,,6996,,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 0.312 mg/kg after ip administration,1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL625545,10913
,50588,N,1,,,,6996,,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 0.3 mg/kg after ip administration (0-6 hr),1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL625546,10914
,50588,N,1,,,,6996,,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 0.625 mg/kg after ip administration,1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL625547,10915
,50588,N,1,,,,6996,,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 0.6 mg/kg after ip administration ( 0-6 hr),1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL625548,10916
,50588,N,1,,,,6996,,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 1.8 mg/kg after ip administration ( 0-6 hr),1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL625549,10917
,50588,N,1,,,,6996,,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 10 mg/kg after ip administration (0-6 hr),1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL625550,10918
,50588,N,1,,,,6996,,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 10 mg/kg after ip administration ( 0-6 hr),1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL625551,10919
,50588,N,1,,,,6996,,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 16.2 mg/kg after ip administration ( 0-6 hr),1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL875475,10920
,50588,N,1,,,,6996,,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 1 mg/kg after ip administration ( 0-6 hr),1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL625552,10921
,50588,N,1,,,,6996,,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 1 mg/kg after ip administration (0-6 hr),1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL625553,10922
,50588,N,1,,,,6996,,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 1 mg/kg after ip administration ( 0 - 6 hr),1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL625554,10923
,50588,N,1,,,,6996,,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 1 mg/kg after ip administration ( 0-6 hr ),1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL625555,10924
,50588,N,1,,,,6996,,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 20 mg/kg after ip administration ( 0-6 hr),1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL625556,10925
,50588,N,1,,,,6996,,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 2 mg/kg after ip administration,1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL624986,10926
,50588,N,1,,,,6996,,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 2 mg/kg after ip administration (0-6 hr),1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL624987,10927
,50588,N,1,,,,6996,,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 2 mg/kg after ip administration ( 0 - 6 hr),1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL624988,10928
Artery,50588,N,1,In vivo,,,9025,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 1/3 range; -2/-14,1,Canis lupus familiaris,Intermediate,,,,9615.0,,1637.0,A,BAO_0000218,CHEMBL624989,10929
Artery,50588,N,1,In vivo,,,9025,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 1/3 range; -4/-4,1,Canis lupus familiaris,Intermediate,,,,9615.0,,1637.0,A,BAO_0000218,CHEMBL624990,10930
Artery,50588,N,1,In vivo,,,9025,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 1/3 range; 4/7,1,Canis lupus familiaris,Intermediate,,,,9615.0,,1637.0,A,BAO_0000218,CHEMBL874391,10931
Artery,50588,N,1,In vivo,,,9025,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 1/3/10 range; -3/0/4,1,Canis lupus familiaris,Intermediate,,,,9615.0,,1637.0,A,BAO_0000218,CHEMBL624991,10932
Artery,50588,N,1,In vivo,,,9025,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 10/30 range; -6/0,1,Canis lupus familiaris,Intermediate,,,,9615.0,,1637.0,A,BAO_0000218,CHEMBL624992,10933
Artery,50588,N,1,In vivo,,,9025,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 10/30 range; 10/31,1,Canis lupus familiaris,Intermediate,,,,9615.0,,1637.0,A,BAO_0000218,CHEMBL624993,10934
Artery,50588,N,1,In vivo,,,9025,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 10/30 range; 11/-19,1,Canis lupus familiaris,Intermediate,,,,9615.0,,1637.0,A,BAO_0000218,CHEMBL624994,10935
Artery,50588,N,1,In vivo,,,9025,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 10/30 range; 14/6,1,Canis lupus familiaris,Intermediate,,,,9615.0,,1637.0,A,BAO_0000218,CHEMBL624995,10936
Artery,50588,N,1,In vivo,,,9025,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 10/30 range; 19/25,1,Canis lupus familiaris,Intermediate,,,,9615.0,,1637.0,A,BAO_0000218,CHEMBL624996,10937
Artery,50588,N,1,In vivo,,,9025,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 10/30 range; 19/3,1,Canis lupus familiaris,Intermediate,,,,9615.0,,1637.0,A,BAO_0000218,CHEMBL624997,10938
Artery,50588,N,1,In vivo,,,9025,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 10/30 range; 2/16,1,Canis lupus familiaris,Intermediate,,,,9615.0,,1637.0,A,BAO_0000218,CHEMBL624998,10939
Artery,50588,N,1,In vivo,,,9025,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 10/30 range; 6/2,1,Canis lupus familiaris,Intermediate,,,,9615.0,,1637.0,A,BAO_0000218,CHEMBL624999,10940
Artery,50588,N,1,In vivo,,,9025,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 10/30 range; 7/26,1,Canis lupus familiaris,Intermediate,,,,9615.0,,1637.0,A,BAO_0000218,CHEMBL882955,10941
Artery,50588,N,1,In vivo,,,9025,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 10/30 range; 8/49,1,Canis lupus familiaris,Intermediate,,,,9615.0,,1637.0,A,BAO_0000218,CHEMBL625000,10942
Artery,50588,N,1,In vivo,,,9025,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 10/30 range; 8/8,1,Canis lupus familiaris,Intermediate,,,,9615.0,,1637.0,A,BAO_0000218,CHEMBL625001,10943
Artery,50588,N,1,In vivo,,,9025,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 10/30 range; 9/-18,1,Canis lupus familiaris,Intermediate,,,,9615.0,,1637.0,A,BAO_0000218,CHEMBL625089,10944
Artery,50588,N,1,In vivo,,,9025,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 10/60 range; 13/23,1,Canis lupus familiaris,Intermediate,,,,9615.0,,1637.0,A,BAO_0000218,CHEMBL625090,10945
Artery,50588,N,1,In vivo,,,9025,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 3 range,1,Canis lupus familiaris,Intermediate,,,,9615.0,,1637.0,A,BAO_0000218,CHEMBL625091,10946
Artery,50588,N,1,In vivo,,,9025,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 3/10 range; -7/-11,1,Canis lupus familiaris,Intermediate,,,,9615.0,,1637.0,A,BAO_0000218,CHEMBL625092,10947
Artery,50588,N,1,In vivo,,,9025,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a of 1/3 dose range; 6/-7,1,Canis lupus familiaris,Intermediate,,,,9615.0,,1637.0,A,BAO_0000218,CHEMBL625093,10948
Artery,50588,N,1,In vivo,,,9025,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a of 10/30 dose range; -13/19,1,Canis lupus familiaris,Intermediate,,,,9615.0,,1637.0,A,BAO_0000218,CHEMBL625094,10949
Artery,50588,N,1,In vivo,,,9025,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a of 3/10 dose range; 30/47,1,Canis lupus familiaris,Intermediate,,,,9615.0,,1637.0,A,BAO_0000218,CHEMBL625095,10950
,50588,N,1,In vivo,,,2249,,Compound was evaluated for its bioavailability in the dogs,1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL625096,10951
,50597,N,1,In vivo,,,2249,,Compound was evaluated for its bioavailability in the rats,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL625097,10952
,22224,U,0,In vivo,,,17515,,Compound was evaluated for oral bioavailability,1,,Autocuration,,,,,,,A,BAO_0000218,CHEMBL882956,10953
,50597,N,1,In vivo,,,14541,,Compound was evaluated for percentage of Oral bioavailability in rats,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL625098,10954
,22224,U,0,In vivo,,,12797,,Bioavailability in guinea pig,1,Cavia porcellus,Autocuration,,,,10141.0,,,A,BAO_0000218,CHEMBL625099,10955
,50597,N,1,In vivo,,,12797,,Compound was evaluated for the oral bioavailability in rat,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL625100,10956
,50588,N,1,In vivo,,,12797,,Compound was evaluated for the oral bioavailability in dog,1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL625101,10957
,50597,N,1,In vivo,,,12797,,Compound was evaluated for the oral bioavailability in rat,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL874396,10958
,22224,U,0,In vivo,,,11727,,Bioavailability in dog (dosed i.v.),1,Canis lupus familiaris,Autocuration,,,,9615.0,,,F,BAO_0000218,CHEMBL625102,10959
,50588,N,1,In vivo,,,13249,,Compound was tested for in vivo bioavailability in dog,1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL625103,10960
,100712,N,1,In vivo,,,13249,,Compound was tested for in vivo bioavailability in hamsters,1,Cricetinae,Intermediate,,,,10026.0,,,A,BAO_0000218,CHEMBL625104,10961
,22224,U,0,In vivo,,,13249,,Compound was tested for in vivo bioavailability in monkey,1,Simiiformes,Autocuration,,,,314293.0,,,A,BAO_0000218,CHEMBL625105,10962
,50597,N,1,In vivo,,,13249,,Compound was tested for in vivo bioavailability in rat,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL625106,10963
,22224,U,0,In vivo,,,9552,,Oral bioavailability in mouse,1,Mus musculus,Autocuration,,,,10090.0,,,A,BAO_0000218,CHEMBL625107,10964
,50594,N,1,In vivo,,,9552,,Compound was tested for percent of oral bioavailability in mice; 56-74,1,Mus musculus,Intermediate,,,,10090.0,,,A,BAO_0000218,CHEMBL625108,10965
,22224,U,0,In vivo,,,14839,,Oral bioavailability in mouse (nude) (dose of 25 mg/kg),1,Mus musculus,Autocuration,,,,10090.0,,,A,BAO_0000218,CHEMBL625109,10966
,22224,U,0,In vivo,,,14839,,Bioavailability in cynomolgus monkey (dose 25 mg/kg i.v.),1,Macaca fascicularis,Autocuration,,,,9541.0,,,A,BAO_0000218,CHEMBL625110,10967
,22224,U,0,In vivo,,,14839,,Bioavailability in cynomolgus monkey (dose 5 mg/kg i.v.),1,Macaca fascicularis,Autocuration,,,,9541.0,,,A,BAO_0000218,CHEMBL625111,10968
,50594,N,1,In vivo,,,14839,,Oral bioavailability in mouse (nude) (dose 25 mg/kg i.v.),1,Mus musculus,Intermediate,,,,10090.0,,,A,BAO_0000218,CHEMBL625112,10969
,50594,N,1,In vivo,,,14839,,Oral bioavailability in nude mice,1,Mus musculus,Intermediate,,,,10090.0,,,A,BAO_0000218,CHEMBL875334,10970
,22224,U,0,In vivo,,,11219,,Bioavailability in monkey (i.d. dosing),1,Primates,Autocuration,,,,9443.0,,,A,BAO_0000218,CHEMBL628617,10971
,22224,U,0,In vivo,,,9552,,Bioavailability in rat,1,Rattus norvegicus,Autocuration,,,,10116.0,,,A,BAO_0000218,CHEMBL628618,10972
,22224,U,0,In vivo,,,11732,,Measure of AUCpo/AUCiv x 100% of the parent compound before (free) and after (total) beta-glucuronidase treatment; total 10%,1,,Autocuration,,,,,,,A,BAO_0000218,CHEMBL628619,10973
,22224,U,0,In vivo,,,11732,,Measure of AUCpo/AUCiv x 100% of the parent compound before (free) and after (total) beta-glucuronidase treatment; total 20%,1,,Autocuration,,,,,,,A,BAO_0000218,CHEMBL628620,10974
,100710,N,1,In vivo,,,14839,,"In vivo antitumor efficacy in cynomolgus monkeys by injecting a dose of 10 mg/kg, as HCl salt in saline solution, perorally and the maximum drug concentration was determined",1,Macaca fascicularis,Intermediate,,,,9541.0,,,A,BAO_0000218,CHEMBL628621,10975
,100710,N,1,In vivo,,,14839,,"In vivo antitumor efficacy in cynomolgus monkeys by injecting a dose of 25 mg/kg, as HCl salt in saline solution, perorally and the maximum drug concentration was determined",1,Macaca fascicularis,Intermediate,,,,9541.0,,,A,BAO_0000218,CHEMBL628622,10976
,100710,N,1,In vivo,,,14839,,"In vivo antitumor efficacy in cynomolgus monkeys by injecting a dose of 5 mg/kg, as HCl salt in saline solution, perorally and the maximum drug concentration was determined",1,Macaca fascicularis,Intermediate,,,,9541.0,,,A,BAO_0000218,CHEMBL628623,10977
Plasma,100710,N,1,In vivo,,,14839,,Maximal plasma concentration in cynomolgus monkeys after 10 mg/kg oral dose,1,Macaca fascicularis,Intermediate,,,,9541.0,,1969.0,A,BAO_0000218,CHEMBL628624,10978
Plasma,50594,N,1,In vivo,,,14839,,Maximal plasma concentration in nude mice after 25 mg/kg oral dose,1,Mus musculus,Intermediate,,,,10090.0,,1969.0,A,BAO_0000218,CHEMBL628625,10979
Plasma,100710,N,1,In vivo,,,14839,,Maximal plasma concentration in cynomolgus monkeys after 5 mg/kg oral dose,1,Macaca fascicularis,Intermediate,,,,9541.0,,1969.0,A,BAO_0000218,CHEMBL628626,10980
Plasma,50594,N,1,In vivo,,,14839,,Maximal plasma concentration in nude mice after 25 mg/kg oral dose,1,Mus musculus,Intermediate,,,,10090.0,,1969.0,A,BAO_0000218,CHEMBL627041,10981
Plasma,50594,N,1,In vivo,,,14839,,Maximal plasma concentration in nude mice after 25 mg/kg oral dose,1,Mus musculus,Intermediate,,,,10090.0,,1969.0,A,BAO_0000218,CHEMBL627042,10982
Plasma,50594,N,1,In vivo,,,14839,,Maximal plasma concentration in nude mice after 25 mg/kg oral dose,1,Mus musculus,Intermediate,,,,10090.0,,1969.0,A,BAO_0000218,CHEMBL627043,10983
Plasma,22224,U,0,In vivo,,,13932,,In vivo evaluation of maximum plasma concentration at a dose of 10 mg/kg,1,,Autocuration,,,,,,1969.0,A,BAO_0000218,CHEMBL627044,10984
Plasma,50594,N,1,In vivo,,,11637,,Cmax in mouse plasma,1,Mus musculus,Intermediate,,,,10090.0,,1969.0,A,BAO_0000218,CHEMBL627045,10985
Plasma,22224,U,0,In vivo,,,11637,,Max plasma concentration was measured by 40 mg/kg dose of peroral administration.,1,,Autocuration,,,,,,1969.0,A,BAO_0000218,CHEMBL627046,10986
Plasma,50597,N,1,In vivo,,,13960,,Maximal plasma concentration in rat,1,Rattus norvegicus,Intermediate,,,,10116.0,,1969.0,A,BAO_0000218,CHEMBL627047,10987
Plasma,50597,N,1,In vivo,,,15905,,Maximal plasma level when administered 1 mg/kg perorally (po) in rat,1,Rattus norvegicus,Intermediate,,,,10116.0,,1969.0,A,BAO_0000218,CHEMBL627048,10988
,50597,N,1,In vivo,,,14062,,Maximum concentration at an intraduodenal dose of 5.2 mg/kg in rat,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL627049,10989
,50597,N,1,In vivo,,,14062,,Maximum concentration at an intraduodenal dose of 6.6 mg/kg in rat,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL627050,10990
,50597,N,1,In vivo,,,14062,,Maximum concentration at an intravenous dose of 5.5 mg/kg in rat,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL627051,10991
,50597,N,1,In vivo,,,14062,,Maximum concentration at an intravenous dose of 6.5 mg/kg in rat,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL627052,10992
,50597,N,1,In vivo,,,14062,,Maximum concentration at an peroral dose of 6.2 mg/kg in rat,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL627053,10993
,50597,N,1,In vivo,,,14062,,Maximum concentration at an peroral dose of 6.3 mg/kg in rat,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL627054,10994
,50594,N,1,In vivo,,,15011,,Maximum concentration (Cmax) using 0.4% Methyl cellulose (MC) as vehicle. compound was administered intravenously to nude mice at a dose of 25 mg/kg,1,Mus musculus,Intermediate,,,,10090.0,,,A,BAO_0000218,CHEMBL627055,10995
,50594,N,1,In vivo,,,15011,,Maximum concentration (Cmax) using 0.4% Methyl cellulose (MC) as vehicle. compound was administered orally to nude mice at a dose of 25 mg/kg,1,Mus musculus,Intermediate,,,,10090.0,,,A,BAO_0000218,CHEMBL627056,10996
,50594,N,1,In vivo,,,15011,,Maximum concentration (Cmax) using 0.4% Methyl cellulose (MC) as vehicle. compound was administered orally to nude mice at a dose of 25 mg/kg (micronized sample),1,Mus musculus,Intermediate,,,,10090.0,,,A,BAO_0000218,CHEMBL627057,10997
,50594,N,1,In vivo,,,15011,,Maximum concentration (Cmax) using 20%aqueous hydroxypropyl-beta-cyclodextrin (HPbetaCD) as vehicle. compound was administered intravenously to nude mice at a dose of 25 mg/kg,1,Mus musculus,Intermediate,,,,10090.0,,,A,BAO_0000218,CHEMBL627058,10998
,50594,N,1,In vivo,,,15011,,Maximum concentration (Cmax) using 20%aqueous hydroxypropyl-beta-cyclodextrin (HPbetaCD) as vehicle. compound was administered orally to nude mice at a dose of 25 mg/kg,1,Mus musculus,Intermediate,,,,10090.0,,,A,BAO_0000218,CHEMBL626211,10999
,22224,U,0,In vivo,,,10291,,Maximum Concentration of the compound.,1,,Autocuration,,,,,,,A,BAO_0000218,CHEMBL626212,11000
,50588,N,1,In vivo,,,14599,,Maximum Concentration was measured after iv administration into Beagle dog,1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL626213,11001
,50588,N,1,In vivo,,,14599,,Maximum Concentration was measured after iv administration into Beagle dog.,1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL626214,11002
,50588,N,1,In vivo,,,14599,,Maximum Concentration was measured after po administration into Beagle dog,1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL626215,11003
,50588,N,1,In vivo,,,14599,,Maximum Concentration was measured after po administration into Beagle dog.,1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL626216,11004
Blood,22224,U,0,In vivo,,,12767,,Maximum blood level reached after an dose of 10.6 uM/kg intravenously,1,,Autocuration,,,,,,178.0,A,BAO_0000218,CHEMBL626217,11005
Blood,22224,U,0,In vivo,,,12767,,Maximum blood level reached after an iv dose of 12.2 uM/kg,1,,Autocuration,,,,,,178.0,A,BAO_0000218,CHEMBL626218,11006
Blood,22224,U,0,In vivo,,,12767,,Maximum blood level reached after an oral dose 14.7 uM/kg oral route,1,,Autocuration,,,,,,178.0,A,BAO_0000218,CHEMBL626219,11007
Blood,22224,U,0,In vivo,,,12767,,Maximum blood level reached after an oral dose of 14.7 uM/kg intravenous route,1,,Autocuration,,,,,,178.0,A,BAO_0000218,CHEMBL626220,11008
Blood,22224,U,0,In vivo,,,12767,,Maximum blood level reached after an oral dose of 5.0 mg/kg,1,,Autocuration,,,,,,178.0,A,BAO_0000218,CHEMBL626221,11009
Blood,22224,U,0,In vivo,,,12767,,Maximum blood level reached at dose of 10.6 uM/kg orally,1,,Autocuration,,,,,,178.0,A,BAO_0000218,CHEMBL626222,11010
,50512,N,1,In vivo,,,14706,,Maximum concentration (Cmax) in guinea pigs at 2 mg/kg after oral administration,1,Cavia porcellus,Intermediate,,,,10141.0,,,A,BAO_0000218,CHEMBL626223,11011
,50512,N,1,In vivo,,,14706,,Maximum concentration (Cmax) in guinea pigs at 3 mg/kg after oral administration,1,Cavia porcellus,Intermediate,,,,10141.0,,,A,BAO_0000218,CHEMBL626224,11012
Brain,50597,N,1,In vivo,,,14793,,Maximum concentration achieved in rat brain when administered intraperitoneally at a dose of 10 mg/kg,1,Rattus norvegicus,Intermediate,,,,10116.0,,955.0,A,BAO_0000218,CHEMBL626225,11013
Brain,50597,N,1,In vivo,,,14793,,Maximum concentration achieved in rat brain when administered intravenously at a dose of 10 mg/kg,1,Rattus norvegicus,Intermediate,,,,10116.0,,955.0,A,BAO_0000218,CHEMBL626226,11014
Brain,50597,N,1,In vivo,,,14793,,Maximum concentration achieved in rat brain when administered perorally at a dose of 100 mg/kg,1,Rattus norvegicus,Intermediate,,,,10116.0,,955.0,A,BAO_0000218,CHEMBL626227,11015
Brain,50597,N,1,In vivo,,,14793,,Maximum concentration achieved in rat brain when administered perorally at a dose of 10 mg/kg,1,Rattus norvegicus,Intermediate,,,,10116.0,,955.0,A,BAO_0000218,CHEMBL626228,11016
,50597,N,1,In vivo,,,14793,,Maximum concentration achieved in rat plasma when administered intraperitoneally at a dose of 10 mg/kg,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL626229,11017
,50597,N,1,In vivo,,,14793,,Maximum concentration achieved in rat plasma when administered intravenously at a dose of 10 mg/kg,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL626921,11018
,50597,N,1,In vivo,,,14793,,Maximum concentration achieved in rat plasma when administered perorally at a dose of 100 mg/kg,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL876793,11019
,50597,N,1,In vivo,,,14793,,Maximum concentration achieved in rat plasma when administered perorally at a dose of 10 mg/kg,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL625309,11020
,50278,N,1,In vivo,,,10524,,Maximum concentration determined against Bacillus subtilis ATCC 6633 after oral administration in dog(25 mg/kg),1,Bacillus subtilis,Intermediate,,,,1423.0,,,A,BAO_0000218,CHEMBL625310,11021
,22224,U,0,In vivo,,,11871,,Maximum concentration determined in monkeys dosed intravenously with 30 mg/kg,1,Simiiformes,Autocuration,,,,314293.0,,,A,BAO_0000218,CHEMBL625311,11022
,50597,N,1,In vivo,,,11871,,Maximum concentration determined in rats dosed intravenously with 20 mg/kg,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL625312,11023
,22224,U,0,In vivo,,,3437,,Maximum concentration for the bioavailability at a dose of 20 mg/kg administered orally,1,,Autocuration,,,,,,,A,BAO_0000218,CHEMBL625313,11024
,50594,N,1,In vivo,,,12038,,Maximum concentration in male CD-1 mice after sc administration of 20 mg/kg,1,Mus musculus,Intermediate,,,,10090.0,,,A,BAO_0000218,CHEMBL625314,11025
,50597,N,1,In vivo,,,12038,,Maximum concentration in male rats after iv administration of 20 mg/kg,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL625315,11026
Liver,50597,N,1,,,,8418,,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 30 min injection by intravenously; value ranges from 1.06-1.29,1,Rattus norvegicus,Intermediate,,,,10116.0,,2107.0,A,BAO_0000218,CHEMBL625316,11027
Liver,50597,N,1,,,,8418,,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 30 min injection by intravenously; value ranges from 1.77-2.08,1,Rattus norvegicus,Intermediate,,,,10116.0,,2107.0,A,BAO_0000218,CHEMBL625317,11028
Liver,50597,N,1,,,,8418,,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 30 min injecton by intravenously; 0.54-0.89,1,Rattus norvegicus,Intermediate,,,,10116.0,,2107.0,A,BAO_0000218,CHEMBL625318,11029
Liver,50597,N,1,,,,8418,,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 30 min injecton by intravenously; 1.57-1.66,1,Rattus norvegicus,Intermediate,,,,10116.0,,2107.0,A,BAO_0000218,CHEMBL625319,11030
Liver,50597,N,1,,,,8418,,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 5 min injection by intravenously; value ranges from 1.06-2.71,1,Rattus norvegicus,Intermediate,,,,10116.0,,2107.0,A,BAO_0000218,CHEMBL625320,11031
Liver,50597,N,1,,,,8418,,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 5 min injection by intravenously; value ranges from 2.98-3.22,1,Rattus norvegicus,Intermediate,,,,10116.0,,2107.0,A,BAO_0000218,CHEMBL625321,11032
Liver,50597,N,1,,,,8418,,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 0.73-1.45,1,Rattus norvegicus,Intermediate,,,,10116.0,,2107.0,A,BAO_0000218,CHEMBL625322,11033
Liver,50597,N,1,,,,8418,,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 1.03-1.31,1,Rattus norvegicus,Intermediate,,,,10116.0,,2107.0,A,BAO_0000218,CHEMBL876801,11034
Liver,50597,N,1,,,,8418,,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 6.76-10.44,1,Rattus norvegicus,Intermediate,,,,10116.0,,2107.0,A,BAO_0000218,CHEMBL625323,11035
Liver,50597,N,1,,,,8418,,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 60 min injection by intravenously; value ranges from 0.47-1.17,1,Rattus norvegicus,Intermediate,,,,10116.0,,2107.0,A,BAO_0000218,CHEMBL625324,11036
Liver,50597,N,1,,,,8418,,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 60 min injection by intravenously; value ranges from 1.12-1.44,1,Rattus norvegicus,Intermediate,,,,10116.0,,2107.0,A,BAO_0000218,CHEMBL625325,11037
Liver,50597,N,1,,,,8418,,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.38-0.57,1,Rattus norvegicus,Intermediate,,,,10116.0,,2107.0,A,BAO_0000218,CHEMBL625326,11038
Liver,50597,N,1,,,,8418,,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.75-1.14,1,Rattus norvegicus,Intermediate,,,,10116.0,,2107.0,A,BAO_0000218,CHEMBL625327,11039
Liver,50597,N,1,,,,8418,,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 1.36-1.74,1,Rattus norvegicus,Intermediate,,,,10116.0,,2107.0,A,BAO_0000218,CHEMBL625328,11040
Lung,50597,N,1,,,,8418,,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 15 min injection by intravenously; value ranges from 1.05-1.5,1,Rattus norvegicus,Intermediate,,,,10116.0,,2048.0,A,BAO_0000218,CHEMBL625329,11041
Lung,50597,N,1,,,,8418,,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 15 min injection by intravenously; value ranges from 3.10-3.77,1,Rattus norvegicus,Intermediate,,,,10116.0,,2048.0,A,BAO_0000218,CHEMBL625330,11042
Lung,50597,N,1,,,,8418,,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 0.4-0.54,1,Rattus norvegicus,Intermediate,,,,10116.0,,2048.0,A,BAO_0000218,CHEMBL627774,11043
Lung,50597,N,1,,,,8418,,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 0.58-0.86,1,Rattus norvegicus,Intermediate,,,,10116.0,,2048.0,A,BAO_0000218,CHEMBL627775,11044
Lung,50597,N,1,,,,8418,,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 0.77-0.86,1,Rattus norvegicus,Intermediate,,,,10116.0,,2048.0,A,BAO_0000218,CHEMBL627949,11045
Lung,50597,N,1,,,,8418,,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 30 min injection by intravenously; value ranges from 0.86-1.13,1,Rattus norvegicus,Intermediate,,,,10116.0,,2048.0,A,BAO_0000218,CHEMBL627950,11046
Lung,50597,N,1,,,,8418,,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 30 min injection by intravenously; value ranges from 2.26-2.89,1,Rattus norvegicus,Intermediate,,,,10116.0,,2048.0,A,BAO_0000218,CHEMBL627951,11047
Lung,50597,N,1,,,,8418,,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 30 min injecton by intravenously; 0.54-0.7,1,Rattus norvegicus,Intermediate,,,,10116.0,,2048.0,A,BAO_0000218,CHEMBL627952,11048
Lung,50597,N,1,,,,8418,,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 30 min injecton by intravenously; 0.6-0.66,1,Rattus norvegicus,Intermediate,,,,10116.0,,2048.0,A,BAO_0000218,CHEMBL627953,11049
Lung,50597,N,1,,,,8418,,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 5 min injection by intravenously; value ranges from 1.35-1.74,1,Rattus norvegicus,Intermediate,,,,10116.0,,2048.0,A,BAO_0000218,CHEMBL627954,11050
Lung,50597,N,1,,,,8418,,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 5 min injection by intravenously; value ranges from 3.62-7.08,1,Rattus norvegicus,Intermediate,,,,10116.0,,2048.0,A,BAO_0000218,CHEMBL627955,11051
Lung,50597,N,1,,,,8418,,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 0.47-0.56,1,Rattus norvegicus,Intermediate,,,,10116.0,,2048.0,A,BAO_0000218,CHEMBL627956,11052
Lung,50597,N,1,,,,8418,,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 0.54-1.07,1,Rattus norvegicus,Intermediate,,,,10116.0,,2048.0,A,BAO_0000218,CHEMBL876802,11053
Lung,50597,N,1,,,,8418,,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 0.76-0.91,1,Rattus norvegicus,Intermediate,,,,10116.0,,2048.0,A,BAO_0000218,CHEMBL627957,11054
Lung,50597,N,1,,,,8418,,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 60 min injection by intravenously; value ranges from 0.61-0.86,1,Rattus norvegicus,Intermediate,,,,10116.0,,2048.0,A,BAO_0000218,CHEMBL627958,11055
Lung,50597,N,1,,,,8418,,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 60 min injection by intravenously; value ranges from 2.11-3.79,1,Rattus norvegicus,Intermediate,,,,10116.0,,2048.0,A,BAO_0000218,CHEMBL627959,11056
Lung,50597,N,1,,,,8418,,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.3-0.36,1,Rattus norvegicus,Intermediate,,,,10116.0,,2048.0,A,BAO_0000218,CHEMBL627960,11057
Lung,50597,N,1,,,,8418,,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.36-0.44,1,Rattus norvegicus,Intermediate,,,,10116.0,,2048.0,A,BAO_0000218,CHEMBL627961,11058
Lung,50597,N,1,,,,8418,,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.5-0.65,1,Rattus norvegicus,Intermediate,,,,10116.0,,2048.0,A,BAO_0000218,CHEMBL627962,11059
,50597,N,1,,,,9796,,Distribution of radiolabeled compound in intestinal contents of rat 1 hr after ip administration of dose and excess 8 microg of estradiol; fmol equivalents per 100 mg,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL627963,11060
,50597,N,1,,,,9796,,Distribution of radiolabeled compound in intestinal contents of rat 1 hr after ip administration of dose; fmol equivalents per 100 mg,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL624759,11061
,50597,N,1,,,,9796,,Distribution of radiolabeled compound in intestinal contents of rat 1 hr after iv administration of dose; fmol equivalents per 100 mg,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL624760,11062
,50597,N,1,,,,9796,,Distribution of radiolabeled compound in intestinal contents of rat 4 hr after ip administration of dose; fmol equivalents per 100 mg,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL624761,11063
,50597,N,1,,,,9796,,Distribution of radiolabeled compound in intestinal contents of rat 8 hr after ip administration of dose; fmol equivalents per 100 mg,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL877607,11064
Liver,50597,N,1,,,,9796,,Distribution of radiolabeled compound in liver of rat 1 hr after ip administration of dose and excess 8 microg of estradiol; fmol equivalents per 100 mg,1,Rattus norvegicus,Intermediate,,,,10116.0,,2107.0,A,BAO_0000218,CHEMBL624762,11065
Liver,50597,N,1,,,,9796,,Distribution of radiolabeled compound in liver of rat 1 hr after ip administration of dose; fmol equivalents per 100 mg,1,Rattus norvegicus,Intermediate,,,,10116.0,,2107.0,A,BAO_0000218,CHEMBL624763,11066
Liver,50597,N,1,,,,9796,,Distribution of radiolabeled compound in liver of rat 1 hr after iv administration of dose; fmol equivalents per 100 mg,1,Rattus norvegicus,Intermediate,,,,10116.0,,2107.0,A,BAO_0000218,CHEMBL624764,11067
Liver,50597,N,1,,,,9796,,Distribution of radiolabeled compound in liver of rat 4 hr after ip administration of dose; fmol equivalents per 100 mg,1,Rattus norvegicus,Intermediate,,,,10116.0,,2107.0,A,BAO_0000218,CHEMBL624765,11068
Liver,50597,N,1,,,,9796,,Distribution of radiolabeled compound in liver of rat 8 hr after ip administration of dose; fmol equivalents per 100 mg,1,Rattus norvegicus,Intermediate,,,,10116.0,,2107.0,A,BAO_0000218,CHEMBL624766,11069
,50588,N,1,,,,6996,,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 5.4 mg/kg after ip administration ( 0-6 hr),1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL624767,11070
,50588,N,1,,,,6996,,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 5 mg/kg after ip administration,1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL624768,11071
,50588,N,1,,,,6996,,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 5 mg/kg after ip administration (0-6 hr),1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL624769,11072
,50588,N,1,,,,6996,,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 5 mg/kg after ip administration ( 0 - 6 hr),1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL624770,11073
,50588,N,1,,,,6996,,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 5 mg/kg after ip administration ( 0-6 hr ),1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL624771,11074
,50588,N,1,,,,6996,,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 5 mg/kg after ip administration ( 0-6 hr),1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL624772,11075
,50597,N,1,,,,6996,,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 27 mg/kg after ip administration,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL624773,11076
,50597,N,1,,,,6996,,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 27 mg/kg after ip administration ( 0-5 hr),1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL624774,11077
,50597,N,1,,,,6996,,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 27 mg/kg after ip administration (0-5 hr),1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL624775,11078
,50597,N,1,,,,6996,,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 27 mg/kg after ip administration ( 0 - 5 hr),1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL624776,11079
,50597,N,1,,,,6996,,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 27 mg/kg after ip administration ( 0-5 hr ),1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL624777,11080
,50597,N,1,,,,6996,,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 27 mg/kg after ip administration ( 0-5 hr),1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL624778,11081
,50597,N,1,,,,6996,,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 3 mg/kg after ip administration,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL624779,11082
,50597,N,1,,,,6996,,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 3 mg/kg after ip administration ( 0 - 5 hr),1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL624780,11083
,50597,N,1,,,,6996,,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 3 mg/kg after ip administration ( 0-5 hr ),1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL624781,11084
,50597,N,1,,,,6996,,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 3 mg/kg after ip administration ( 0-5 hr),1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL877608,11085
,50597,N,1,,,,6996,,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 3 mg/kg after ip administration (0-5 hr),1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL624782,11086
,50597,N,1,,,,6996,,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 3 mg/kg after ip administration ( 0-5 hr),1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL624783,11087
,50597,N,1,,,,6996,,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 81 mg/kg after ip administration,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL624784,11088
,50597,N,1,,,,6996,,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 81 mg/kg after ip administration ( 0-5 hr),1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL624785,11089
,50597,N,1,,,,6996,,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 81 mg/kg after ip administration (0-5 hr),1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL624786,11090
,50597,N,1,,,,6996,,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 81 mg/kg after ip administration ( 0-5 hr ),1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL624787,11091
,50597,N,1,,,,6996,,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 81 mg/kg after ip administration ( 0-5 hr),1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL628676,11092
,50597,N,1,,,,6996,,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 9 mg/kg after ip administration,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL621842,11093
,50597,N,1,,,,6996,,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 9 mg/kg after ip administration ( 0-5 hr),1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL621843,11094
,50597,N,1,,,,6996,,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 9 mg/kg after ip administration (0-5 hr),1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL623873,11095
,50597,N,1,,,,6996,,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 9 mg/kg after ip administration ( 0 - 5 hr),1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL623874,11096
,50597,N,1,,,,6996,,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 9 mg/kg after ip administration ( 0-5 hr ),1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL623875,11097
,50597,N,1,,,,6996,,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 9 mg/kg after ip administration ( 0-5 hr),1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL623876,11098
,50588,N,1,,,,6996,,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 0.312 mg/kg after ip administration,1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL623877,11099
,50588,N,1,,,,6996,,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 0.3 mg/kg after ip administration (0-6 hr),1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL623878,11100
,50588,N,1,,,,6996,,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 0.625 mg/kg after ip administration,1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL623879,11101
,50588,N,1,,,,6996,,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 0.6 mg/kg after ip administration ( 0-6 hr),1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL623880,11102
,50588,N,1,,,,6996,,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 1.8 mg/kg after ip administration ( 0-6 hr),1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL623881,11103
,50588,N,1,,,,6996,,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 10 mg/kg after ip administration (0-6 hr),1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL623957,11104
,50588,N,1,,,,6996,,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 10 mg/kg after ip administration ( 0-6 hr),1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL623958,11105
,50588,N,1,,,,6996,,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 16.2 mg/kg after ip administration ( 0-6 hr),1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL623959,11106
,50588,N,1,,,,6996,,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 1 mg/kg after ip administration ( 0-6 hr),1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL623960,11107
,50588,N,1,,,,6996,,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 1 mg/kg after ip administration (0-6 hr),1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL623961,11108
,50588,N,1,,,,6996,,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 1 mg/kg after ip administration ( 0 - 6 hr),1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL623962,11109
,50588,N,1,,,,6996,,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 1 mg/kg after ip administration ( 0-6 hr ),1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL624676,11110
,50588,N,1,,,,6996,,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 20 mg/kg after ip administration ( 0-6 hr),1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL624677,11111
,50588,N,1,,,,6996,,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 2 mg/kg after ip administration,1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL624678,11112
,50588,N,1,,,,6996,,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 2 mg/kg after ip administration (0-6 hr),1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL624679,11113
,50588,N,1,,,,6996,,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 2 mg/kg after ip administration ( 0 - 6 hr),1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL624680,11114
,22224,U,0,In vivo,,,11732,,Measure of AUCpo/AUCiv x 100% of the parent compound before (free) and after (total) beta-glucuronidase treatment; total 27%,1,,Autocuration,,,,,,,A,BAO_0000218,CHEMBL624849,11115
,22224,U,0,In vivo,,,11732,,Measure of AUCpo/AUCiv x 100% of the parent compound before (free) and after (total) beta-glucuronidase treatment; total 4%,1,,Autocuration,,,,,,,A,BAO_0000218,CHEMBL624850,11116
,22224,U,0,In vivo,,,11732,,Measure of AUCpo/AUCiv x 100% of the parent compound before (free) and after (total) beta-glucuronidase treatment; total 54%,1,,Autocuration,,,,,,,A,BAO_0000218,CHEMBL874399,11117
,22224,U,0,In vivo,,,11732,,Measure of AUCpo/AUCiv x 100% of the parent compound before (free) and after (total) beta-glucuronidase treatment; total 72%,1,,Autocuration,,,,,,,A,BAO_0000218,CHEMBL624851,11118
,22224,U,0,In vivo,,,11732,,Measure of AUCpo/AUCiv x 100% of the parent compound before (free) and after (total) beta-glucuronidase treatment; total 76%,1,,Autocuration,,,,,,,A,BAO_0000218,CHEMBL624852,11119
,22224,U,0,In vivo,,,13359,,Oral bioavailability in rat (dose 10 mg/kg),1,Rattus norvegicus,Autocuration,,,,10116.0,,,A,BAO_0000218,CHEMBL624853,11120
,22224,U,0,In vivo,,,16618,,Oral bioavailability in rat (Sprague-Dawley),1,Rattus norvegicus,Autocuration,,,,10116.0,,,A,BAO_0000218,CHEMBL624854,11121
,22224,U,0,In vivo,,,13960,,Oral bioavailability in rat,1,Rattus norvegicus,Autocuration,,,,10116.0,,,A,BAO_0000218,CHEMBL624855,11122
,22224,U,0,In vivo,,,13917,,Oral bioavailability in rats was determined in vivo,1,Rattus norvegicus,Autocuration,,,,10116.0,,,A,BAO_0000218,CHEMBL624856,11123
,22224,U,0,In vivo,,,14266,,Oral bioavailability in dog,1,Canis lupus familiaris,Autocuration,,,,9615.0,,,A,BAO_0000218,CHEMBL882957,11124
,22224,U,0,In vivo,,,12359,,Oral bioavailability of compound in monkey,1,Simiiformes,Autocuration,,,,314293.0,,,A,BAO_0000218,CHEMBL624857,11125
,50597,N,1,In vivo,,,12359,,Oral bioavailability of compound in rat,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL622202,11126
,22224,U,0,In vivo,,,12359,,Bioavailability in rat of PMEA prodrug,1,Rattus norvegicus,Autocuration,,,,10116.0,,,A,BAO_0000218,CHEMBL622203,11127
,50597,N,1,In vivo,,,12359,,Oral bioavailability of compound was evaluated relative to that of PMEA in rat; Not determined due to lack of solubility,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL625522,11128
,22224,U,0,In vivo,,,10791,,Serum conc at 3 hours following 25 mg/kg dose,1,Macaca mulatta,Autocuration,,,,9544.0,,,A,BAO_0000218,CHEMBL622868,11129
Urine,22224,U,0,In vivo,,,10791,,Urine conc 0-5 hours following 25 mg/kg dose,1,Macaca mulatta,Autocuration,,,,9544.0,,1088.0,A,BAO_0000218,CHEMBL622869,11130
Urine,22224,U,0,In vivo,,,10791,,Urine conc 0-24 hours following 25 mg/kg dose,1,Macaca mulatta,Autocuration,,,,9544.0,,1088.0,A,BAO_0000218,CHEMBL622870,11131
,22224,U,0,In vivo,,,138,,Oral bioavailability in African green monkeys; 20-25,1,Chlorocebus aethiops,Autocuration,,,,9534.0,,,A,BAO_0000218,CHEMBL622871,11132
,100710,N,1,In vivo,,,14521,,Oral bioavailability in cynomolgus monkey.,1,Macaca fascicularis,Intermediate,,,,9541.0,,,A,BAO_0000218,CHEMBL620560,11133
,22224,U,0,In vivo,,,13953,,Oral bioavailability in dog,1,Canis lupus familiaris,Autocuration,,,,9615.0,,,A,BAO_0000218,CHEMBL620561,11134
,50588,N,1,In vivo,,,12836,,Oral bioavailability in dog at 10 mg/kg oral dose,1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL620562,11135
,100712,N,1,In vivo,,,12836,,Oral bioavailability in hamster at 10 mg/kg oral dose,1,Cricetinae,Intermediate,,,,10026.0,,,A,BAO_0000218,CHEMBL620563,11136
,50597,N,1,In vivo,,,12836,,Oral bioavailability in rat at 10 mg/kg oral dose,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL620564,11137
,22224,U,0,In vivo,,,14521,,Oral bioavailability in rat,1,Rattus norvegicus,Autocuration,,,,10116.0,,,A,BAO_0000218,CHEMBL872265,11138
,22224,U,0,In vivo,,,13953,,Oral bioavailability in rat,1,Rattus norvegicus,Autocuration,,,,10116.0,,,A,BAO_0000218,CHEMBL620565,11139
,22224,U,0,In vivo,,,6799,,Oral bioavailability,1,Eutheria,Autocuration,,,,9347.0,,,A,BAO_0000218,CHEMBL620566,11140
,22224,U,0,In vivo,,,11311,,Oral bioavailability was determined; range 49-102%,1,,Autocuration,,,,,,,A,BAO_0000218,CHEMBL620567,11141
,50588,N,1,In vivo,,,4013,,Oral bioavailability was determined in dogs,1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL620568,11142
,22224,U,0,In vivo,,,4013,,Oral bioavailability in rat,1,Rattus norvegicus,Autocuration,,,,10116.0,,,A,BAO_0000218,CHEMBL620569,11143
,22224,U,0,In vivo,,,17591,,Oral bioavailability,1,Eutheria,Autocuration,,,,9347.0,,,A,BAO_0000218,CHEMBL620570,11144
,22224,U,0,In vivo,,,17591,,Oral bioavailability was determined; Not orally available,1,,Autocuration,,,,,,,A,BAO_0000218,CHEMBL620571,11145
,50594,N,1,In vivo,,,15011,,Percent bioavailability was administered by using 0.4% Methyl cellulose (MC) as vehicle to nude mice at a dose of 25 mg/kg (micronized sample),1,Mus musculus,Intermediate,,,,10090.0,,,A,BAO_0000218,CHEMBL620572,11146
,22224,U,0,In vivo,,,15011,,Bioavailability in mouse (nude) (dose 0.4% Methylcellulose (MC) as vehicle 25 mg/kg),1,Mus musculus,Autocuration,,,,10090.0,,,A,BAO_0000218,CHEMBL620573,11147
,22224,U,0,In vivo,,,15011,,Bioavailability in mouse (nude) using 20% aqueous hydroxypropyl-beta-cyclodextrin (HPbetaCD) as vehicle 25 mg/kg,1,Mus musculus,Autocuration,,,,10090.0,,,A,BAO_0000218,CHEMBL620574,11148
,22224,U,0,In vivo,,,9552,,Oral bioavailability in Rhesus monkey,1,Macaca mulatta,Autocuration,,,,9544.0,,,A,BAO_0000218,CHEMBL620575,11149
,22224,U,0,In vivo,,,9552,,Oral bioavailability in dog (female mongrel),1,Canis lupus familiaris,Autocuration,,,,9615.0,,,A,BAO_0000218,CHEMBL620576,11150
,22224,U,0,In vivo,,,3639,,Percent oral bioavailability of perorally administered compound (30 mg/kg) was tested,1,,Autocuration,,,,,,,A,BAO_0000218,CHEMBL875846,11151
,22224,U,0,In vivo,,,13397,,Oral bioavailability in dog,1,Canis lupus familiaris,Autocuration,,,,9615.0,,,A,BAO_0000218,CHEMBL620577,11152
,22224,U,0,In vivo,,,3031,,Percentage Bioavailability was evaluated.,1,,Autocuration,,,,,,,A,BAO_0000218,CHEMBL620578,11153
,22224,U,0,In vivo,,,12818,,Bioavailability in rat administered i.d.,1,Rattus norvegicus,Autocuration,,,,10116.0,,,A,BAO_0000218,CHEMBL620579,11154
,22224,U,0,In vivo,,,4847,,Bioavailability,1,Eutheria,Autocuration,,,,9347.0,,,A,BAO_0000218,CHEMBL621248,11155
,22224,U,0,In vivo,,,12421,,Bioavailability in dog (male Beagle) i.v. administration,1,Canis lupus familiaris,Autocuration,,,,9615.0,,,A,BAO_0000218,CHEMBL625390,11156
,22224,U,0,In vivo,,,11966,,"Bioavailability in rat (dose 20 mg/kg p.o. in 1% methocel, and 5 mg/kg i.v. in PEG400)",1,Rattus norvegicus,Autocuration,,,,10116.0,,,A,BAO_0000218,CHEMBL625391,11157
,22224,U,0,In vivo,,,11218,,Bioavailability in monkey (dose 10 mg/kg i.d. or 0.3 mg/kg i.v.),1,Primates,Autocuration,,,,9443.0,,,A,BAO_0000218,CHEMBL872266,11158
,22224,U,0,In vivo,,,13129,,Oral bioavailability in rat (Sprague-Dawley) (male),1,Rattus norvegicus,Autocuration,,,,10116.0,,,A,BAO_0000218,CHEMBL625392,11159
,50597,N,1,In vivo,,,12350,,The oral bioavailability was measured on rats after oral administration,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL625393,11160
,50597,N,1,In vivo,,,2231,,Bioavailability was evaluated in rat at an intravenous dose of 3 mg/kg and peroral dose of 5 mg/kg,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL625394,11161
,50797,N,1,In vivo,,,2231,,Bioavailability was evaluated in rhesus monkey at an intravenous dose of 1 mg/kg and peroral dose of 1 mg/kg,1,Macaca mulatta,Intermediate,,,,9544.0,,,A,BAO_0000218,CHEMBL625395,11162
,22224,U,0,In vivo,,,12187,,Bioavailability in rat (dose 10 mg/kg i.d.),1,Rattus norvegicus,Autocuration,,,,10116.0,,,A,BAO_0000218,CHEMBL625396,11163
,22224,U,0,In vivo,,,12421,,Bioavailability in dog (male Beagle) i.v. administration,1,Canis lupus familiaris,Autocuration,,,,9615.0,,,A,BAO_0000218,CHEMBL625397,11164
,50594,N,1,In vivo,,,13256,,Biodistribution in CD-1 mice was determined after 1 minute in Striatum(expressed as percent injected dose per gram normalized to a 25 g mouse),1,Mus musculus,Intermediate,,,,10090.0,,,A,BAO_0000218,CHEMBL625398,11165
Blood,50594,N,1,In vivo,,,13256,,Biodistribution in CD-1 mice was determined after 1 minute in blood(expressed as percent injected dose per gram normalized to a 25 g mouse),1,Mus musculus,Intermediate,,,,10090.0,,178.0,A,BAO_0000218,CHEMBL625399,11166
Cerebellum,50594,N,1,In vivo,,,13256,,Biodistribution in CD-1 mice was determined after 1 minute in cerebellum(expressed as percent injected dose per gram normalized to a 25 g mouse),1,Mus musculus,Intermediate,,,,10090.0,,2037.0,A,BAO_0000218,CHEMBL626074,11167
,50594,N,1,In vivo,,,13256,,Biodistribution in CD-1 mice was determined after 1 minute in cortex(expressed as percent injected dose per gram normalized to a 25 g mouse),1,Mus musculus,Intermediate,,,,10090.0,,,A,BAO_0000218,CHEMBL626075,11168
Plasma,50597,N,1,In vivo,,,2231,,Maximum concentration in plasma (Cmax) was evaluated in rat at an intravenous dose of 3 mg/kg and peroral dose of 5 mg/kg,1,Rattus norvegicus,Intermediate,,,,10116.0,,1969.0,A,BAO_0000218,CHEMBL626076,11169
Plasma,50797,N,1,In vivo,,,2231,,Maximum concentration in plasma (Cmax) was evaluated in rhesus monkey at an intravenous dose of 1 mg/kg and peroral dose of 1 mg/kg,1,Macaca mulatta,Intermediate,,,,9544.0,,1969.0,A,BAO_0000218,CHEMBL626077,11170
Blood,50597,N,1,In vivo,,,12178,,Maximum concentration in whole blood recorded in the period 0-24 hr postdose of 1 mg/kg in rat (normalized to a 1 mg/kg dose),1,Rattus norvegicus,Intermediate,,,,10116.0,,178.0,A,BAO_0000218,CHEMBL626078,11171
Blood,22224,U,0,In vivo,,,12178,,Maximum concentration in whole blood recorded in the period 0-24 hr postdose of 2.5 mg/kg in rat (normalized to a 1 mg/kg dose),1,,Autocuration,,,,,,178.0,A,BAO_0000218,CHEMBL625846,11172
Blood,22224,U,0,In vivo,,,12178,,Maximum concentration in whole blood recorded in the period 0-24 hr postdose of 5.0 mg/kg GP (normalized to a 1 mg/kg dose),1,,Autocuration,,,,,,178.0,A,BAO_0000218,CHEMBL625847,11173
,50597,N,1,In vivo,,,15633,,Maximum concentration observed in rats at an oral dose of 50 mg/kg,1,Rattus norvegicus,Expert,,,,10116.0,,,A,BAO_0000218,CHEMBL625848,11174
Plasma,50597,N,1,In vivo,,,14258,,Maximum concentration of compound in plasma administered orally to rats,1,Rattus norvegicus,Intermediate,,,,10116.0,,1969.0,A,BAO_0000218,CHEMBL625849,11175
Plasma,50588,N,1,In vivo,,,14224,,"Maximum concentration (10 mg/kg, orally) in plasma of dogs",1,Canis lupus familiaris,Intermediate,,,,9615.0,,1969.0,A,BAO_0000218,CHEMBL626023,11176
Plasma,50588,N,1,In vivo,,,14224,,"Maximum concentration (10 mg/kg, perorally) in plasma of dogs",1,Canis lupus familiaris,Intermediate,,,,9615.0,,1969.0,A,BAO_0000218,CHEMBL626024,11177
Plasma,50588,N,1,In vivo,,,14224,,"Maximum concentration (5 mg/kg, intravenously) in plasma of dogs",1,Canis lupus familiaris,Intermediate,,,,9615.0,,1969.0,A,BAO_0000218,CHEMBL626025,11178
,22224,U,0,In vivo,,,5566,,Maximum concentration after 10 mg/kg by oral administration,1,,Autocuration,,,,,,,A,BAO_0000218,CHEMBL626026,11179
,22224,U,0,In vivo,,,16935,,Maximum concentration at a dose of 1.5 mg/kg,1,,Autocuration,,,,,,,A,BAO_0000218,CHEMBL626027,11180
,22224,U,0,In vivo,,,16935,,Maximum concentration at a dose of 2.0 mg/kg,1,,Autocuration,,,,,,,A,BAO_0000218,CHEMBL626028,11181
Plasma,50588,N,1,In vivo,,,14224,,Maximum concentration in dog plasma,1,Canis lupus familiaris,Intermediate,,,,9615.0,,1969.0,A,BAO_0000218,CHEMBL626029,11182
Plasma,22224,U,0,In vivo,,,12536,,Maximum concentration in plasma after administration of 10 umol/kg dose perorally,1,,Autocuration,,,,,,1969.0,A,BAO_0000218,CHEMBL626030,11183
Plasma,22224,U,0,In vivo,,,12536,,Maximum concentration in plasma after administration of 2 umol/kg dose intravenously,1,,Autocuration,,,,,,1969.0,A,BAO_0000218,CHEMBL626031,11184
Plasma,22224,U,0,In vivo,,,12536,,Maximum concentration in plasma after administration of 4 umol/kg dose intravenously,1,,Autocuration,,,,,,1969.0,A,BAO_0000218,CHEMBL626032,11185
Plasma,22224,U,0,In vivo,,,12536,,Maximum concentration in plasma after administration of 40 umol/kg dose perorally,1,,Autocuration,,,,,,1969.0,A,BAO_0000218,CHEMBL626033,11186
Plasma,22224,U,0,In vivo,,,12536,,Maximum concentration in plasma after administration of 5 umol/kg dose intravenously,1,,Autocuration,,,,,,1969.0,A,BAO_0000218,CHEMBL626034,11187
Plasma,50588,N,1,In vivo,,,9994,,Maximum concentration in plasma after oral administration in dog (25 mg/kg),1,Canis lupus familiaris,Intermediate,,,,9615.0,,1969.0,A,BAO_0000218,CHEMBL626035,11188
Plasma,22224,U,0,In vivo,,,1434,,Maximum concentration in plasma at Tmax,1,,Autocuration,,,,,,1969.0,A,BAO_0000218,CHEMBL626036,11189
Plasma,50588,N,1,In vivo,,,12836,,Maximum concentration in plasma recorded 0-6 hr post dose in dog at 10 mg/kg oral dose,1,Canis lupus familiaris,Expert,,,,9615.0,,1969.0,A,BAO_0000218,CHEMBL626037,11190
Plasma,100712,N,1,In vivo,,,12836,,Maximum concentration in plasma recorded in the period 0-6 hr post dose in hamster at 10 mg/kg oral dose,1,Cricetinae,Intermediate,,,,10026.0,,1969.0,A,BAO_0000218,CHEMBL626038,11191
Plasma,50597,N,1,In vivo,,,12836,,Maximum concentration in plasma recorded in the period 0-6 hr post dose in rat at 10 mg/kg oral dose,1,Rattus norvegicus,Intermediate,,,,10116.0,,1969.0,A,BAO_0000218,CHEMBL626039,11192
Plasma,50597,N,1,In vivo,,,12545,,Maximum concentration in plasma was determined by oral administration to rats at 20 mg/kg,1,Rattus norvegicus,Intermediate,,,,10116.0,,1969.0,A,BAO_0000218,CHEMBL626040,11193
Plasma,50592,N,1,In vivo,,,13856,,Maximum concentration present in the rabbit plasma following peroral administration of 10 mg/kg,1,Oryctolagus cuniculus,Intermediate,,,,9986.0,,1969.0,A,BAO_0000218,CHEMBL626041,11194
,22224,U,0,In vivo,,,3550,,Maximum concentration was calculated,1,,Autocuration,,,,,,,A,BAO_0000218,CHEMBL626042,11195
,22224,U,0,In vivo,,,2632,,Maximum concentration was calculated.,1,,Autocuration,,,,,,,A,BAO_0000218,CHEMBL626043,11196
,22224,U,0,In vivo,,,5566,,Maximum concentration at a peroral dose of 10 mg/kg,1,,Autocuration,,,,,,,A,BAO_0000218,CHEMBL626044,11197
,22224,U,0,In vivo,,,11883,,Maximum concentration of the drug at 10 uM/dg administered perorally,1,,Autocuration,,,,,,,A,BAO_0000218,CHEMBL626045,11198
,22224,U,0,In vivo,,,11883,,Maximum concentration of the drug at 2 uM/dg administered intravenously,1,,Autocuration,,,,,,,A,BAO_0000218,CHEMBL626046,11199
Plasma,50588,N,1,In vivo,,,14122,,"Maximum concentration of the unchanged compound in dog plasma, recorded in the period 0-6 hr post dose.",1,Canis lupus familiaris,Intermediate,,,,9615.0,,1969.0,A,BAO_0000218,CHEMBL626047,11200
Plasma,100712,N,1,In vivo,,,14122,,"Maximum concentration of the unchanged compound in hamster plasma, recorded in the period 0-6 hr post dose.",1,Cricetinae,Intermediate,,,,10026.0,,1969.0,A,BAO_0000218,CHEMBL626048,11201
Plasma,50597,N,1,In vivo,,,14122,,"Maximum concentration of the unchanged compound in rat plasma, recorded in the period 0-6 hr post dose.",1,Rattus norvegicus,Intermediate,,,,10116.0,,1969.0,A,BAO_0000218,CHEMBL626049,11202
Plasma,50597,N,1,In vivo,,,12542,,Maximum concentration of unchanged drug in plasma recorded in the period 0-6 hr of postdose in anesthetized rat at 60 mg/kg oral dose,1,Rattus norvegicus,Intermediate,,,,10116.0,,1969.0,A,BAO_0000218,CHEMBL626050,11203
Plasma,50588,N,1,In vivo,,,12542,,Maximum concentration of unchanged drug in plasma recorded in the period 0-6 hr of postdose in dog at 5 mg/kg oral dose,1,Canis lupus familiaris,Intermediate,,,,9615.0,,1969.0,A,BAO_0000218,CHEMBL874541,11204
Plasma,100712,N,1,In vivo,,,12542,,Maximum concentration of unchanged drug in plasma recorded in the period 0-6 hr of postdose in hamster at 40 mg/kg oral dose,1,Cricetinae,Intermediate,,,,10026.0,,1969.0,A,BAO_0000218,CHEMBL622826,11205
Plasma,100712,N,1,In vivo,,,12542,,Maximum concentration of unchanged drug in plasma recorded in the period 0-6 hr of postdose to hamster at 40 mg/kg oral dose,1,Cricetinae,Intermediate,,,,10026.0,,1969.0,A,BAO_0000218,CHEMBL622827,11206
Plasma,50597,N,1,In vivo,,,12542,,Maximum concentration of unchanged drug in plasma recorded in the period 0-6 hr of postdose in anesthetized rat at 25 mg/kg oral dose,1,Rattus norvegicus,Intermediate,,,,10116.0,,1969.0,A,BAO_0000218,CHEMBL622828,11207
Plasma,50597,N,1,In vivo,,,14080,,Maximum concentration of unchanged drug in rat plasma in the period 0-24 hr after dosing,1,Rattus norvegicus,Intermediate,,,,10116.0,,1969.0,A,BAO_0000218,CHEMBL622829,11208
,50597,N,1,In vivo,,,11911,,Maximum concentration reached following intravenous administration in male rat,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL876806,11209
,50588,N,1,In vivo,,,13204,,Maximum concentration was determined in an aqueous sodium hydroxide solution adjusted to pH 10 at 10 mg/kg dosage administered perorally in dog,1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL622830,11210
,50597,N,1,In vivo,,,13204,,Maximum concentration was determined in an aqueous sodium hydroxide solution adjusted to pH 10 at 5 mg/kg dosage administered perorally in rats,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL622831,11211
,50588,N,1,In vivo,,,14346,,Maximum concentration was measured after peroral administration of 10 mg/kg of drug in male Beagle dogs,1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL626794,11212
,50597,N,1,In vivo,,,14346,,Maximum concentration was measured after peroral administration of 5.0 mg/kg of drug in male Dawley rats,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL626795,11213
,50597,N,1,In vivo,,,14346,,Maximum concentration was measured after peroral administration of 5.1 mg/kg of drug in male Dawley rats,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL626796,11214
,50597,N,1,In vivo,,,14346,,Maximum concentration was measured after peroral administration of 5.2 mg/kg of drug in male Dawley rats,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL626797,11215
,50597,N,1,In vivo,,,14127,,Maximum drug concentration is determined after oral dosing in rats.,1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL626798,11216
,50588,N,1,In vivo,,,14339,,Maximum observed concentration in oral (5 mg/kg) fasted dogs,1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL626799,11217
,50588,N,1,In vivo,,,14339,,Maximum observed concentration in oral (5 mg/kg) fed dogs,1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL626800,11218
Plasma,22224,U,0,In vivo,,,13494,,Maximum plasma concentration,1,,Autocuration,,,,,,1969.0,A,BAO_0000218,CHEMBL626801,11219
Plasma,50597,N,1,In vivo,,,14925,,Maximum plasma concentration (Cmax) was determined in rats after intraduodenal administration of the drug,1,Rattus norvegicus,Intermediate,,,,10116.0,,1969.0,A,BAO_0000218,CHEMBL876816,11220
Plasma,50597,N,1,In vivo,,,14474,,Maximum plasma concentration following oral administration of 26.3 mg/kg in rats,1,Rattus norvegicus,Intermediate,,,,10116.0,,1969.0,A,BAO_0000218,CHEMBL626802,11221
Plasma,50588,N,1,In vivo,,,14474,,Maximum plasma concentration following oral administration of 3.8 mg/kg in Beagle dog,1,Canis lupus familiaris,Intermediate,,,,9615.0,,1969.0,A,BAO_0000218,CHEMBL626803,11222
Plasma,22224,U,0,In vivo,,,13917,,Maximum plasma concentration following oral administration of 30 umol/kg,1,,Autocuration,,,,,,1969.0,A,BAO_0000218,CHEMBL626804,11223
Plasma,50597,N,1,,,,9796,,Distribution of radiolabeled compound in plasma of rat 1 hr after ip administration of dose,1,Rattus norvegicus,Intermediate,,,,10116.0,,1969.0,A,BAO_0000218,CHEMBL626805,11224
Plasma,50597,N,1,,,,9796,,Distribution of radiolabeled compound in plasma of rat 1 hr after ip administration of dose and excess 8 microg of estradiol; fmol equivalents per 100 mg,1,Rattus norvegicus,Intermediate,,,,10116.0,,1969.0,A,BAO_0000218,CHEMBL626309,11225
Plasma,50597,N,1,,,,9796,,Distribution of radiolabeled compound in plasma of rat 1 hr after iv administration of dose; fmol equivalents per 100 mg,1,Rattus norvegicus,Intermediate,,,,10116.0,,1969.0,A,BAO_0000218,CHEMBL626310,11226
Plasma,50597,N,1,,,,9796,,Distribution of radiolabeled compound in plasma of rat 4 hr after ip administration of dose; fmol equivalents per 100 mg,1,Rattus norvegicus,Intermediate,,,,10116.0,,1969.0,A,BAO_0000218,CHEMBL626311,11227
Plasma,50597,N,1,,,,9796,,Distribution of radiolabeled compound in plasma of rat 8 hr after ip administration of dose; fmol equivalents per 100 mg,1,Rattus norvegicus,Intermediate,,,,10116.0,,1969.0,A,BAO_0000218,CHEMBL626312,11228
Uterus,50597,N,1,,,,9796,,Distribution of radiolabeled compound in uterus of rat 1 hr after ip administration of dose; fmol equivalents per 100 mg,1,Rattus norvegicus,Intermediate,,,,10116.0,,995.0,A,BAO_0000218,CHEMBL626313,11229
Uterus,50597,N,1,,,,9796,,Distribution of radiolabeled compound in uterus of rat 1 hr after ip administration of dose and excess 8 microg of estradiol; fmol equivalents per 100 mg,1,Rattus norvegicus,Intermediate,,,,10116.0,,995.0,A,BAO_0000218,CHEMBL626314,11230
Uterus,50597,N,1,,,,9796,,Distribution of radiolabeled compound in uterus of rat 1 hr after iv administration of dose; fmol equivalents per 100 mg,1,Rattus norvegicus,Intermediate,,,,10116.0,,995.0,A,BAO_0000218,CHEMBL626315,11231
Uterus,50597,N,1,,,,9796,,Distribution of radiolabeled compound in uterus of rat 4 hr after ip administration of dose; fmol equivalents per 100 mg,1,Rattus norvegicus,Intermediate,,,,10116.0,,995.0,A,BAO_0000218,CHEMBL626316,11232
Uterus,50597,N,1,,,,9796,,Distribution of radiolabeled compound in uterus of rat 8 hr after ip administration of dose; fmol equivalents per 100 mg,1,Rattus norvegicus,Intermediate,,,,10116.0,,995.0,A,BAO_0000218,CHEMBL626317,11233
,50597,N,1,,,,8363,,Distribution of rat erythrocytes for tube 2 on rate of aging in 2 mL of cell suspension; Minus (-),1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL626318,11234
,50597,N,1,,,,8363,,Distribution of rat erythrocytes for tube 2 on rate of aging in 2 mL of cell suspension; Plus (+),1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL626319,11235
,50597,N,1,,,,8363,,Distribution of rat erythrocytes for tube 3 on rate of aging in 2 mL of cell suspension; Minus (-),1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL626320,11236
,50597,N,1,,,,8363,,Distribution of rat erythrocytes for tube 3 on rate of aging in 2 mL of cell suspension; Plus (+),1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL875053,11237
,50597,N,1,,,,8363,,Distribution of rat erythrocytes for tube 4 on rate of aging in 2 mL of cell suspension; Minus (-),1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL626321,11238
,50597,N,1,,,,8363,,Distribution of rat erythrocytes for tube 4 on rate of aging in 2 mL of cell suspension; Plus (+),1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL626322,11239
,50597,N,1,,,,8363,,Distribution of rat erythrocytes for tube 5 on rate of aging in 2 mL of cell suspension; Minus (-),1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL626323,11240
,50597,N,1,,,,8363,,Distribution of rat erythrocytes for tube 5 on rate of aging in 2 mL of cell suspension; Plus (+),1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL626324,11241
,50597,N,1,,,,8363,,Distribution of rat erythrocytes for tube 6 on rate of aging in 2 mL of cell suspension; Minus (-),1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL626325,11242
,50597,N,1,,,,8363,,Distribution of rat erythrocytes for tube 6 on rate of aging in 2 mL of cell suspension; Plus (+),1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL626326,11243
,50597,N,1,,,,8363,,Distribution of rat erythrocytes for tube 7 on rate of aging in 2 mL of cell suspension; Plus (+),1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL626327,11244
,50597,N,1,,,,8363,,Distribution of rat erythrocytes for tube 1 on rate of aging in 2 mL of cell suspension; Minus (-),1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL626328,11245
Blood,50597,N,1,,,,8684,,"Distribution in blood of rat 5 min after intravenous administration, injected dose/gm",1,Rattus norvegicus,Intermediate,,,,10116.0,,178.0,A,BAO_0000218,CHEMBL626329,11246
Blood,50597,N,1,,,,8684,,"Distribution in blood of rat, 15 min after intravenous administration, injected dose/gm",1,Rattus norvegicus,Intermediate,,,,10116.0,,178.0,A,BAO_0000218,CHEMBL626330,11247
Blood,50597,N,1,,,,8684,,"Distribution in blood of rat, 1 hr after intravenous administration, injected dose/gm",1,Rattus norvegicus,Intermediate,,,,10116.0,,178.0,A,BAO_0000218,CHEMBL626331,11248
Blood,50597,N,1,,,,8684,,"Distribution in blood of rat, 2 hr after intravenous administration, injected dose/gm",1,Rattus norvegicus,Intermediate,,,,10116.0,,178.0,A,BAO_0000218,CHEMBL626332,11249
Blood,50597,N,1,,,,8684,,"Distribution in blood of rat, 30 min after intravenous administration, injected dose/gm",1,Rattus norvegicus,Intermediate,,,,10116.0,,178.0,A,BAO_0000218,CHEMBL626333,11250
Blood,50597,N,1,,,,8684,,"Distribution in blood of rat, 4 hr after intravenous administration, injected dose/gm",1,Rattus norvegicus,Intermediate,,,,10116.0,,178.0,A,BAO_0000218,CHEMBL626334,11251
Blood,50597,N,1,,,,8684,,"Distribution in blood of rat, 6 hr after intravenous administration, injected dose/gm",1,Rattus norvegicus,Intermediate,,,,10116.0,,178.0,A,BAO_0000218,CHEMBL626335,11252
Blood,50597,N,1,,,,8684,,"Distribution in blood of rat, 8 hr after intravenous administration, injected dose/gm",1,Rattus norvegicus,Intermediate,,,,10116.0,,178.0,A,BAO_0000218,CHEMBL624798,11253
Brain,50597,N,1,,,,8684,,"Distribution in brain of rat, 15 min after intravenous administered, injected dose/gm",1,Rattus norvegicus,Intermediate,,,,10116.0,,955.0,A,BAO_0000218,CHEMBL624799,11254
Brain,50597,N,1,,,,8684,,"Distribution in brain of rat, 1 hr after intravenous administered, injected dose/gm",1,Rattus norvegicus,Intermediate,,,,10116.0,,955.0,A,BAO_0000218,CHEMBL624800,11255
Brain,50597,N,1,,,,8684,,"Distribution in brain of rat, 2 hr after intravenous administered, injected dose/gm",1,Rattus norvegicus,Intermediate,,,,10116.0,,955.0,A,BAO_0000218,CHEMBL624801,11256
Brain,50597,N,1,,,,8684,,"Distribution in brain of rat, 30 min after intravenous administered, injected dose/gm",1,Rattus norvegicus,Intermediate,,,,10116.0,,955.0,A,BAO_0000218,CHEMBL624802,11257
Brain,50597,N,1,,,,8684,,"Distribution in brain of rat, 4 hr after intravenous administered, injected dose/gm",1,Rattus norvegicus,Intermediate,,,,10116.0,,955.0,A,BAO_0000218,CHEMBL624803,11258
Brain,50597,N,1,,,,8684,,"Distribution in brain of rat, 5 min after intravenous administered, injected dose/gm",1,Rattus norvegicus,Intermediate,,,,10116.0,,955.0,A,BAO_0000218,CHEMBL624804,11259
Brain,50597,N,1,,,,8684,,"Distribution in brain of rat, 6 hr after intravenous administered, injected dose/gm",1,Rattus norvegicus,Intermediate,,,,10116.0,,955.0,A,BAO_0000218,CHEMBL624805,11260
Brain,50597,N,1,,,,8684,,"Distribution in brain of rat, 8 hr after intravenous administered, injected dose/gm",1,Rattus norvegicus,Intermediate,,,,10116.0,,955.0,A,BAO_0000218,CHEMBL624806,11261
,50597,N,1,,,,8684,,"Distribution in rat fat 15 min after intravenous administration, injected dose/gm",1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL624807,11262
,50597,N,1,,,,8684,,"Distribution in rat fat 1 hr after intravenous administration, injected dose/gm",1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL624808,11263
,50597,N,1,,,,8684,,"Distribution in rat fat 2 hr after intravenous administration, injected dose/gm",1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL624809,11264
,50597,N,1,,,,8684,,"Distribution in rat fat 30 min after intravenous administration, injected dose/gm",1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL624810,11265
,50597,N,1,,,,8684,,"Distribution in rat fat 4 hr after intravenous administration, injected dose/gm",1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL877618,11266
,50597,N,1,,,,8684,,"Distribution in rat fat 5 min after intravenous administration, injected dose/gm",1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL624811,11267
,50597,N,1,,,,8684,,"Distribution in rat fat 6 hr after intravenous administration, injected dose/gm",1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL624812,11268
,50597,N,1,,,,8684,,"Distribution in rat fat 8 hr after intravenous administration, injected dose/gm",1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL624813,11269
,50597,N,1,,,,8684,,"Distribution in rat heart 15 min after intravenous administration, injected dose/gm",1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL624814,11270
,50597,N,1,,,,8684,,"Distribution in rat heart 1 hr after intravenous administration, injected dose/gm",1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL624815,11271
,50597,N,1,,,,8684,,"Distribution in rat heart 2 hr after intravenous administration, injected dose/gm",1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL624816,11272
,50597,N,1,,,,8684,,"Distribution in rat heart 30 min after intravenous administration, injected dose/gm",1,Rattus norvegicus,Intermediate,,,,10116.0,,,A,BAO_0000218,CHEMBL624817,11273
,50588,N,1,,,,6996,,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 5.4 mg/kg after ip administration ( 0-6 hr),1,Canis lupus familiaris,Intermediate,,,,9615.0,,,A,BAO_0000218,CHEMBL624818,11274
